PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Marin, JM; Carrizo, SJ; Garcia, R; Ejea, MV				Marin, JM; Carrizo, SJ; Garcia, R; Ejea, MV			Effects of nedocromil sodium in steroid-resistant asthma: A randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						steroid-resistant asthma; asthma; treatment; nedocromil sodium	GLUCOCORTICOID RECEPTOR CHARACTERISTICS; BRONCHIAL-ASTHMA; INHALED CORTICOSTEROIDS; DRUG-THERAPY; DOUBLE-BLIND; INVITRO; CYCLOSPORINE; EFFICACY	Background: Some patients with asthma respond poorly to corticosteroids and have persistent airway inflammation and daily clinical symptoms. The aim of this study was to investigate the effects of nedocromil sodium (NS), a nonsteroidal antinflamatory drug, in the treatment of steroid-resistant asthma. Methods: Steroid-resistant asthma was diagnosed in any patient who demonstrated 20% improvement in FEV(1) after treatment with inhaled salbutamol with failure of FEV(1) to improve by at least 15% after a 2-week trial of prednisolone, 30 mg daily. In a double-blind placebo-controlled trial, the patients received either 4 mg of inhaled NS (n = 13) or placebo (n = 13), 4 times daily for 3 months. Results: NS brit not placebo resulted in a mean increase in FEV(1) of 11.4% after 12 weeks of therapy (p = 0.05) and of 12.4% (p = 0.04) and 15% (0.02) in morning peak expiratory flow after 8 and 12 weeks of treatment, respectively. Changes in FEV(1) at 4 and 8 weeks and in peak expiratory flow at 4 weeks of NS therapy were not significant. NS was also effective in reducing valiability of peak expiratory flow (p = 0.02) and use of salbutamol (p = 0.005) and in improving quality of life (p = 0.007) by the trial end. Six of the 12 patients treated with NS who completed the treatment period showed a ''good response,'' defined by a reduction in salbutamol use of more than 50% and an increase in morning peak expiratory flow of more than 20% from baseline; there were no clinical predictors of this response. Two patients were withdrawn from the study because of severe asthma exacerbation (one from each treatment group). Conclusion: Inhaled NS improved pulmonary function and decreased asthma severity in steroid-resistant asthma, but its effectiveness is not homogeneous and cannot be predicted from baseline clinical data.	UNIV ZARAGOZA,DEPT FARMACOL,ZARAGOZA,SPAIN; HOSP GEN SAN JORGE,UNIDAD ALERGIA,HUESCA,SPAIN	University of Zaragoza; Hospital Universidad San Jorge	Marin, JM (corresponding author), HOSP MIGUEL SERVET,SERV NEUMOL,AVDA ISABEL LA CATOLICA 1-3,E-50006 ZARAGOZA,SPAIN.		CARRIZO SIERRA, SANTIAGO/AAO-1780-2021					ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; ALVAREZ J, 1992, J ALLERGY CLIN IMMUN, V89, P714, DOI 10.1016/0091-6749(92)90379-G; BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BEL EH, 1990, AM REV RESPIR DIS, V141, P21, DOI 10.1164/ajrccm/141.1.21; BONE MF, 1989, THORAX, V44, P654, DOI 10.1136/thx.44.8.654; BROWN PH, 1991, LANCET, V337, P576, DOI 10.1016/0140-6736(91)91639-C; CALLAGHAN B, 1992, CHEST, V101, P787, DOI 10.1378/chest.101.3.787; CARMICHAEL J, 1981, BRIT MED J, V282, P1419, DOI 10.1136/bmj.282.6274.1419; CHERNIACK R M, 1990, Chest, V97, P1299; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; CYPCAR D, 1993, J ALLERGY CLIN IMMUN, V92, P362, DOI 10.1016/0091-6749(93)90114-U; DEJONG JW, 1994, AM J RESP CRIT CARE, V149, P91, DOI 10.1164/ajrccm.149.1.8111606; FINK JN, 1994, J ALLERGY CLIN IMMUN, V94, P473, DOI 10.1016/0091-6749(94)90203-8; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; LAL S, 1993, CHEST, V104, P438, DOI 10.1378/chest.104.2.438; LANE SJ, 1993, AM REV RESPIR DIS, V147, P690, DOI 10.1164/ajrccm/147.3.690; LANE SJ, 1991, AM REV RESPIR DIS, V143, P1020, DOI 10.1164/ajrccm/143.5_Pt_1.1020; MEKORI YA, 1993, J ALLERGY CLIN IMMUN, V91, P817, DOI 10.1016/0091-6749(93)90202-Q; OKRET S, 1991, BIOCHIMIE, V73, P51, DOI 10.1016/0300-9084(91)90074-B; POZNANSKY MC, 1985, CLIN EXP IMMUNOL, V61, P135; REBUCK AS, 1990, J ALLERGY CLIN IMMUN, V85, P612, DOI 10.1016/0091-6749(90)90101-9; SHINER RJ, 1990, LANCET, V336, P136; THOMSON NC, 1989, RESP MED, V83, P269, DOI 10.1016/S0954-6111(89)80195-7; WILKINSON JRW, 1989, J CLIN INVEST, V84, P1930, DOI 10.1172/JCI114381; 1991, PUBLICATION NIH NAT; 1987, AM REV RESPIR DIS, V136, P224; 1990, BRIT MED J, V301, P651	29	14	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1996	97	2					602	610		10.1016/S0091-6749(96)70305-6	http://dx.doi.org/10.1016/S0091-6749(96)70305-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW087	8621845				2022-12-18	WOS:A1996TW08700005
J	Baraniuk, JN				Baraniuk, JN			Molecular actions of glucocorticoids: An introduction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											Baraniuk, JN (corresponding author), GEORGETOWN UNIV,MED CTR,DIV RHEUMATOL, IMMUNOL, & ALLERGY,3800 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.			Baraniuk, James Nicholas/0000-0002-1866-4177					0	14	14	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	2	S			141	142		10.1016/S0091-6749(96)80213-2	http://dx.doi.org/10.1016/S0091-6749(96)80213-2			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TT805	8568144	hybrid			2022-12-18	WOS:A1996TT80500006
J	Wasserfallen, JB; Baraniuk, JN				Wasserfallen, JB; Baraniuk, JN			Clinical use of inhaled corticosteroids in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							NEWLY DIAGNOSED ASTHMA; BECLOMETHASONE DIPROPIONATE; AIRWAY RESPONSIVENESS; CONTROLLED TRIAL; BUDESONIDE; INFLAMMATION; MODERATE; CHILDREN; REGIMEN; THERAPY		GEORGETOWN UNIV,MED CTR,CLIN ECONOM RES UNIT,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DIV RHEUMATOL ALLERGY & IMMUNOL,WASHINGTON,DC 20007	Georgetown University; Georgetown University				Baraniuk, James Nicholas/0000-0002-1866-4177				ADELROTH E, 1988, LANCET, V1, P476; BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; BARNES PJ, 1988, AM J MED, V85, P64, DOI 10.1016/0002-9343(88)90245-8; BARNES PJ, 1990, AM REV RESPIR DIS, V141, pS70; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOE J, 1989, ALLERGY, V44, P349, DOI 10.1111/j.1398-9995.1989.tb00457.x; Bregenzer T, 1990, Pneumologie, V44, P960; CAMPBELL LM, 1993, BR J MED EC, V6, P67; CAPEWELL S, 1990, BRIT MED J, V300, P1548, DOI 10.1136/bmj.300.6739.1548; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; CONNETT GJ, 1993, BR J MED EC, V6, P127; DAHL R, 1982, EUR J RESPIR S122, V62, pS167; DDOULL IJ, 1995, AM J RESP CRIT CARE, V151, P1715; DUKES MNG, 1994, CLIN EXP ALLERGY, V24, P160, DOI 10.1111/j.1365-2222.1994.tb00214.x; EBDEN P, 1986, THORAX, V41, P869, DOI 10.1136/thx.41.11.869; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; FABBRI L, 1993, THORAX, V48, P817, DOI 10.1136/thx.48.8.817; GERDTHAM UG, 1993, IMPACT INHALED CORTI; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; JUNIPER EF, 1990, EUR RESPIR J, V3, P1122; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; KRUSZYNSKA YT, 1987, THORAX, V42, P881, DOI 10.1136/thx.42.11.881; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; LEBLANC P, 1994, ALLERGY, V49, P380, DOI 10.1111/j.1398-9995.1994.tb02286.x; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; MAK VHF, 1992, EUR RESPIR J, V5, P1068; MALO JL, 1989, AM REV RESPIR DIS, V140, P624, DOI 10.1164/ajrccm/140.3.624; MANN M, 1992, CHEST, V101, P496, DOI 10.1378/chest.101.2.496; MAWHINNEY H, 1991, ANN ALLERGY, V66, P294; PADFIELD PL, 1993, EUR RESPIR REV, V3, P494; PEDERSEN S, 1993, AM REV RESPIR DIS, V147, pA265; RUTTENVANMOLKEN MPMH, 1993, PHARMACOECONOMICS, V4, P257, DOI 10.2165/00019053-199304040-00004; RUTTENVANMOLKEN MPMH, 1995, AM J RESP CRIT CARE, V151, P975; SCHLEIMER RP, 1990, AM REV RESPIR DIS, V141, pS59; TOOGOOD JH, 1993, J ALLERGY CLIN IMMUN, V91, P571, DOI 10.1016/0091-6749(93)90263-F; TOOGOOD JH, 1984, EUR J RESPIR DIS, V65, P35; TOOGOOD JH, 1995, J ALLERGY CLIN IMMUN, V96, P157, DOI 10.1016/S0091-6749(95)70003-X; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317, DOI 10.1164/ajrccm/143.6.1317; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; 1992, NIH923091 NAT HEART	41	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	2	S			177	182		10.1016/S0091-6749(96)80218-1	http://dx.doi.org/10.1016/S0091-6749(96)80218-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TT805	8568149	Bronze			2022-12-18	WOS:A1996TT80500005
J	OLIVA, A; QUINTI, I; SCALA, E; FANALESBELASIO, E; RAINALDI, L; PIERDOMINICI, M; GIOVANNETTI, A; PAGANELLI, R; AIUTI, F; PANDOLFI, F				OLIVA, A; QUINTI, I; SCALA, E; FANALESBELASIO, E; RAINALDI, L; PIERDOMINICI, M; GIOVANNETTI, A; PAGANELLI, R; AIUTI, F; PANDOLFI, F			IMMUNODEFICIENCY WITH HYPERIMMUNOGLOBULINEMIA-M IN 2 FEMALE-PATIENTS IS NOT ASSOCIATED WITH ABNORMALITIES OF CD40 OR CD40 LIGAND EXPRESSION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IMMUNODEFICIENCY; IMMUNOGLOBULINS HYPERIMMUNOGLOBULINEMIA M; HEPATITIS C VIRUS; CD40; CD40 LIGAND	COMMON VARIABLE IMMUNODEFICIENCY; X-LINKED IMMUNODEFICIENCY; HYPER-IGM SYNDROME; IMMUNOGLOBULIN DEFICIENCY; DEFECTIVE EXPRESSION; SELECTIVE DEFICIENCY; B-CELLS; CYTOMEGALOVIRUS; LYMPHOCYTES; INFECTION	The immunologic defect in X-linked immunodeficiency and hyperimmunoglobulinemia M (HIM) ms related to defective expression of the CD40 ligand (CD40L). We have studied two female patients with HIM to evaluate the role of CD40/CD40L in the pathogenesis of impaired immunoglobulin switching. In addition to recurrent infections characteristic of humoral immunodeficiencies, the two patients had chronic hepatitis caused by type C virus. Phenotypic characterization of peripheral blood mononuclear cells showed a similar picture in both patients with a reduction in the absolute numbers of CD4 cells and increased numbers of CD8 and CD3/DR DR cells, B cells (CD19+) were reduced in one patient, but CD40 was expressed on all CD19+ cells in both patients. The expression of CD40L was normal on peripheral blood mononuclear cells from the two patients with HIM on both resting and stimulated cells. The combination of anti-CD40 and cytokines (interleukin-2, interleukin-4 and interleukin-10) was able to restore proliferative capacity to anti-IgM Peripheral blood mononuclear cells from the two patients with HIM showed a high spontaneous production of IgM in vitro and no production of IgG or IgE. Our data suggest that the defect of isotype switching in female patients with HIM is not related to defective expression of the CD40/CD40L receptor system. A possible role for chronic hepatitis C virus infection in the pathogenesis of the disease is suggested by the detection of specific production of anti-hepatitis C virus IgM.	UNIV ROMA LA SAPIENZA, DEPT ALLERGY & CLIN IMMUNOL, I-00185 ROME, ITALY; UNIV ROME, ROME, ITALY	Sapienza University Rome; Sapienza University Rome			BELASIO, EMANUELE FANALES/C-7718-2016; Giovannetti, Antonello/E-7736-2012; Pandolfi, Franco/D-3025-2011; Scala, Enrico/H-6997-2012; Paganelli, Roberto/AAF-5712-2020; Pierdominici, Marina/J-6436-2016	BELASIO, EMANUELE FANALES/0000-0003-2369-9996; Scala, Enrico/0000-0002-9391-9168; Pandolfi, Franco/0000-0003-3516-3961; Pierdominici, Marina/0000-0002-6372-3754				AMADORI A, 1989, J IMMUNOL, V143, P2146; BEALL GN, 1980, J ALLERGY CLIN IMMUN, V65, P471, DOI 10.1016/0091-6749(80)90242-0; BRAHMI Z, 1983, J CLIN IMMUNOL, V3, P127, DOI 10.1007/BF00915483; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; DOCKE WD, 1991, LANCET, V338, P1597, DOI 10.1016/0140-6736(91)92422-X; DURANDY A, 1993, EUR J IMMUNOL, V23, P2294, DOI 10.1002/eji.1830230936; FIORILLI M, 1986, CLIN IMMUNOL IMMUNOP, V38, P256, DOI 10.1016/0090-1229(86)90143-1; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; GALAMA JMD, 1991, J INFECTION, V23, P175, DOI 10.1016/0163-4453(91)92161-W; Goddard E A, 1991, J Clin Lab Immunol, V35, P183; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; HINZ CF, 1963, NEW ENGL J MED, V269, P1329, DOI 10.1056/NEJM196312192692501; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; MARODI L, 1988, EUR J PEDIATR, V148, P215, DOI 10.1007/BF00441406; MITSUYA H, 1979, J CLIN LAB IMMUNOL, V2, P337; NONOYAMA S, 1993, J CLIN INVEST, V92, P1282, DOI 10.1172/JCI116701; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; NOTARANGELO LD, 1991, HUM GENET, V88, P130; OHNO T, 1987, CLIN IMMUNOL IMMUNOP, V45, P471, DOI 10.1016/0090-1229(87)90098-5; PAGANELLI R, 1991, CLIN EXP IMMUNOL, V84, P28; PANDOLFI F, 1992, CLIN EXP IMMUNOL, V89, P198; PANDOLFI F, 1991, CLIN IMMUNOL IMMUNOP, V60, P371, DOI 10.1016/0090-1229(91)90094-Q; PANDOLFI F, 1993, CLIN EXP IMMUNOL, V92, P239; QUINTI I, 1994, BRIT MED J, V308, P856, DOI 10.1136/bmj.308.6932.856a; RADIUZZIN S, 1989, EUR J IMMUNOL, V19, P469; ROSEN FS, 1963, NEW ENGL J MED, V269, P1336, DOI 10.1056/NEJM196312192692502; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; SOOTHILL JF, 1966, LANCET, V1, P1385	28	14	14	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1995	96	3					403	410		10.1016/S0091-6749(95)70060-9	http://dx.doi.org/10.1016/S0091-6749(95)70060-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RU660	7560643	Green Published			2022-12-18	WOS:A1995RU66000013
J	ARRIGHI, HM; MAIER, WC; REDDING, GJ; MORRAY, BH; LLEWELLYN, CE				ARRIGHI, HM; MAIER, WC; REDDING, GJ; MORRAY, BH; LLEWELLYN, CE			THE IMPACT OF ALLERGIC RHINITIS IN SEATTLE SCHOOL-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	14	15	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	2				192	192						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QE854					2022-12-18	WOS:A1995QE85400208
J	LOCKEY, RF; LAVINS, BJ; SNADER, L				LOCKEY, RF; LAVINS, BJ; SNADER, L			EFFECTS OF 13 WEEKS OF TREATMENT WITH ICI-204,219 (ACCOLATE(TM)) IN PATIENTS WITH MILD-TO-MODERATE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	2				350	350						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QE854					2022-12-18	WOS:A1995QE85400837
J	NGUYEN, MT; HOFFMAN, DR				NGUYEN, MT; HOFFMAN, DR			ANAPHYLAXIS TO LAMINARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							BOVINE SERUM-ALBUMIN; INSEMINATION		E CAROLINA UNIV,SCH MED,DEPT PATHOL & LAB MED,GREENVILLE,NC 27858; PERMANENTE MED GRP INC,DEPT ALLERGY,OAKLAND,CA	University of North Carolina; East Carolina University; Permanente Medical Groups								HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; SONENTHAL KR, 1992, J ALLERGY CLIN IMMUN, V89, P351; STUBBLEFIELD PG, 1986, CLIN OBSTET GYNAECOL, V13, P53; STUBBLEFIELD PG, 1980, DILATATION UTERINE C, P335; TOMB R, 1992, J ALLERGY CLIN IMMUN, V89, P351	5	14	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				138	139		10.1016/S0091-6749(95)70164-8	http://dx.doi.org/10.1016/S0091-6749(95)70164-8			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7822657	Bronze			2022-12-18	WOS:A1995QC31200020
J	SCHOENHOFF, M; BATES, D; RUPPEL, J; FEI, D; FOX, JA; THOMAS, D; JARDIEU, P				SCHOENHOFF, M; BATES, D; RUPPEL, J; FEI, D; FOX, JA; THOMAS, D; JARDIEU, P			PHARMACOKINETICS/DYNAMICS FOLLOWING ADMINISTRATION OF A RECOMBINANT HUMANIZED MONOCLONAL ANTI IGE ANTIBODY IN THE CYNOMOLGUS MONKEY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									GENENTECH INC,S SAN FRANCISCO,CA	Roche Holding; Genentech									0	14	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	2				356	356						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QE854					2022-12-18	WOS:A1995QE85400862
J	BERNSTEIN, DI; BERNSTEIN, IL; GAINES, WG; STAUDER, T; WILSON, ER				BERNSTEIN, DI; BERNSTEIN, IL; GAINES, WG; STAUDER, T; WILSON, ER			CHARACTERIZATION OF SKIN PRICK TESTING RESPONSES FOR DETECTING SENSITIZATION TO DETERGENT ENZYMES AT EXTREME DILUTIONS - INABILITY OF THE RAST TO DETECT LIGHTLY SENSITIZED INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ENZYME ALCALASE; ALPHA-AMYLASE; SAVINASE; PRICK TESTING; RAST	RADIOALLERGOSORBENT TEST; ANTIBODIES; DIAGNOSIS; ALCALASE; ASSAY; OLD	We observed that a group of detergent enzyme workers with known exposure to the subtilisin enzyme, Alcalase (Novo Industries, Bagsvaerde, Denmark), exhibited percutaneous sensitivity to Savinase (Novo Industries), a microbial protease, to which there was no previous occupational exposure. This was attributed to either cross-reactivity between these enzymes or to foreign enzyme contaminants contained in the Savinase antigen. The aims of this study were to determine the range of concentrations eliciting percutaneous responses to Alcalase and to another enzyme, Rapidase (an alpha-amylase) (Gist Brocades, Belgie, Netherlands); to compare the sensitivity of RAST and skin prick testing; and to characterize the relationship between wheal site and antigen concentration. Prick resting was conducted over six log(10) antigen dilutions of Alcalase and Rapidase in 30 workers with previous exposure and skin reactivity to enzymes (group 1) and compared to nonexposed control groups, which included 60 atopic subjects (group 2) and 30 nonatopic subjects (group 3). The RAST was performed with Alcalase and Rapidase antigens. The percutaneous threshold concentrations in group 1 subjects varied widely from 10(3) to 10(-3) mu g of protein per milliliter. Of 19 group 1 workers with skin test reactivity to Alcalase, 84% had positive RAST results; 83% of 24 workers who were reactive to Rapidase had positive RAST results. It was concluded that skin prick testing is preferred over in vitro methods for longitudinal monitoring of human sensitization to workplace allergens. In addition, the data predicted that based on a known Alcalase level of 0.07% in Savinase, 26% of Alcalase-sensitized subjects could react to Savinase. An excellent correlation (r > 0.97) was found between log concentration of antigen and wheal size parameters, with the log diameter and log area performing equally as well (r > 0.98). Analysis of variance revealed that more than 60% of intragroup variation represented human variability in wheal parameters at each concentration tested whereas at least 95% of intergroup variation was due to regression. The excellent correlations of both wheal diameter and area with antigen concentrations were attributed to the very small changes observed between test concentrations.	PROCTER & GAMBLE CO,CINCINNATI,OH 45239	Procter & Gamble	BERNSTEIN, DI (corresponding author), UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL ML 563,231 BETHESDA AVE,CINCINNATI,OH 45267, USA.							ARLIAN LG, 1990, INT ARCH ALLER A IMM, V91, P278, DOI 10.1159/000235128; BECKER EL, 1948, J ALLERGY, V19, P317, DOI 10.1016/0021-8707(48)90112-9; BELIN LGA, 1977, CLIN ALLERGY, V7, P55, DOI 10.1111/j.1365-2222.1977.tb01425.x; BERNSTEIN IL, 1988, J ALLERGY CLIN IMMUN, V82, P487, DOI 10.1016/0091-6749(88)90958-X; BJORKSTEN F, 1984, J ALLERGY CLIN IMMUN, V73, P324, DOI 10.1016/0091-6749(84)90404-4; BRIGHTON WD, 1979, CLIN ALLERGY, V9, P591, DOI 10.1111/j.1365-2222.1979.tb00484.x; DOR PJ, 1986, J ALLERGY CLIN IMMUN, V78, P877, DOI 10.1016/0091-6749(86)90234-4; DORFMAN R. I., 1938, JOUR ALLERGY, V9, P464, DOI 10.1016/S0021-8707(38)90552-0; GALLAGHER JS, 1989, J ALLERGY CLIN IMMUN, V83, P261; HORDLE DA, 1984, J IMMUNOL METHODS, V75, P369, DOI 10.1016/0022-1759(84)90121-2; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; MILLER HYMAN, 1941, JOUR ALLERGY, V12, P335, DOI 10.1016/S0021-8707(41)90261-7; NIEROP G, 1981, ANN ALLERGY, V46, P105; Ottesen M., 1970, METHOD ENZYMOL, P199, DOI [10.1016/0076-6879(70)19014-8, DOI 10.1016/0076-6879(70)19014-8]; OWENBY DR, 1982, J ALLERGY CLIN IMMUN, V69, P536; Pepys J., 1975, BR J HOSP MED, V14, P412; SARLO K, 1990, J ALLERGY CLIN IMMUN, V86, P393, DOI 10.1016/S0091-6749(05)80103-4; SKASSABROCIEK W, 1987, J ALLERGY CLIN IMMUN, V80, P711, DOI 10.1016/0091-6749(87)90292-2; Sokal RR., 1973, INTRO BIOSTATISTICS, V2; SQUIRE JR, 1950, CLIN SCI, V9, P127; VOORHORST R, 1975, ANN ALLERGY, V34, P77; 1976, THORAX, V31, P621	22	14	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	1				498	507		10.1016/0091-6749(94)90206-2	http://dx.doi.org/10.1016/0091-6749(94)90206-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG907	8083455				2022-12-18	WOS:A1994PG90700009
J	BITTLEMAN, DB; STAPLETON, J; CASALE, TB				BITTLEMAN, DB; STAPLETON, J; CASALE, TB			REPORT OF SUCCESSFUL DESENSITIZATION TO ITRACONAZOLE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242; VET ADM MED CTR,IOWA CITY,IA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377	NIEHS NIH HHS [P30 ES05605-12] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		GRAYBILL JR, 1990, AM J MED, V89, P282, DOI 10.1016/0002-9343(90)90339-F; LYMAN CA, 1992, DRUGS, V44, P9, DOI 10.2165/00003495-199244010-00002; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P275, DOI 10.1016/S0091-6749(82)80004-3; Tucker R M, 1988, Ann N Y Acad Sci, V544, P451, DOI 10.1111/j.1749-6632.1988.tb40443.x	4	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2					270	271		10.1016/0091-6749(94)90054-X	http://dx.doi.org/10.1016/0091-6749(94)90054-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC926	8064084	Bronze			2022-12-18	WOS:A1994PC92600023
J	MONTGOMERY, MR; REASOR, MJ				MONTGOMERY, MR; REASOR, MJ			A TOXICOLOGIC APPROACH FOR EVALUATING CASES OF SICK BUILDING SYNDROME OR MULTIPLE CHEMICAL-SENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Symposium on Building-Related and Home-Related Complaints and Illnesses: Sick Building Syndrome	DEC 03-05, 1992	LAKE BUENA VISTA, FL			SICK BUILDING SYNDROME; MULTIPLE CHEMICAL SENSITIVITY; TOXICOLOGY		The nonspecificity of symptoms and exposures commonly reported as ''sick building syndrome'' is very similar to that reported for the condition termed ''multiple chemical sensitivity (MCS).'' In many instances health care practitioners are divided on the reality of the latter. As in all scientific cases of possible cause-and-effect relationships, an organized, dispassionate approach should be used to evaluate each claim of MCS. Most obviously known medical conditions must be ruled out before chemical ''sensitivity'' is proposed. Also several questions on the toxicology of the chemical exposure must be addressed. Although temporality may be apparent (toxicity followed exposure), the time frame for the appearance of symptoms must be appropriate to the exposure conditions and chemical(s) involved. The chemical(s) must have known or reasonable inferred properties to cause the claimed effect. The dose(s) received must be evaluated thoroughly, that is, are there other more logical explanations for the symptoms? In contrast to single-chemical exposures, exposure to mixtures of chemicals, as commonly found in sick buildings, is very difficult to evaluate. However a rational, scientific approach to cause-and-effect questions will help avoid erroneous and subjective decision making.	UNIV S FLORIDA,COLL PUBL HLTH,TAMPA,FL 33620; W VIRGINIA UNIV,HLTH SCI CTR,DEPT PHARMACOL & TOXICOL,MORGANTOWN,WV 26506	State University System of Florida; University of South Florida; West Virginia University	MONTGOMERY, MR (corresponding author), JAMES A HALEY VET ADM MED CTR,MAIL CODE 151,13000 BRUCE B DOWNS BLVD,TAMPA,FL 33612, USA.							BARDANA EJ, 1989, J RESPIR DIS, V10, P32; CULLEN MR, 1992, TOXICOL IND HEALTH, V8, P15; CULLEN MR, 1987, OCCUP MED, V2, P655; HILEMAN B, 1991, CHEM ENG NEWS   0722, P26; REST KM, 1992, TOXICOL IND HEALTH, V8, P1; SAFRAN C, 1992, GOOD HOUSEKEEPING, V214, P176; SAMET JM, 1987, J ALLERGY CLIN IMMUN, V79, P685, DOI 10.1016/0091-6749(87)90197-7; 1989, ANN INTERN MED, V111, P168	8	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2	2				371	375						5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG770	8077592				2022-12-18	WOS:A1994PG77000014
J	MAJCHEL, AM; BAROODY, F; KAGEYSOBOTKA, A; LICHTENSTEIN, LM; NACLERIO, RM				MAJCHEL, AM; BAROODY, F; KAGEYSOBOTKA, A; LICHTENSTEIN, LM; NACLERIO, RM			EFFECT OF OXYMETAZOLINE ON THE EARLY RESPONSE TO NASAL CHALLENGE WITH ANTIGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							BLOOD-FLOW		JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,BALTIMORE,MD 21205	Johns Hopkins University	MAJCHEL, AM (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205, USA.				NIAID NIH HHS [AI 08270, AI 31335] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031335, R01AI008270, R37AI008270] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENDE M, 1983, ACTA OTO-LARYNGOL, V96, P277, DOI 10.3109/00016488309132900; CHURCH MK, 1982, J IMMUNOL, V129, P2116; DRUCE HM, 1984, J APPL PHYSIOL, V57, P1276, DOI 10.1152/jappl.1984.57.4.1276; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; WATASE T, 1986, Rhinology (Utrecht), V24, P181; WEINER N, 1985, PHARMACOL BASIS THER, P145; 1985, PHYSICIANS DESK REFE, P524	7	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					767	770		10.1016/0091-6749(93)90021-7	http://dx.doi.org/10.1016/0091-6749(93)90021-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	7693785				2022-12-18	WOS:A1993MG98200019
J	HORNER, WE; LEVETIN, E; LEHRER, SB				HORNER, WE; LEVETIN, E; LEHRER, SB			BASIDIOSPORE ALLERGEN RELEASE - ELUTION FROM INTACT SPORES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FUNGAL ALLERGENS; FUNGI; BASIDIOMYCETE; SPORE WALL; ALLERGEN EXTRACTION	IGE ANTIBODIES; REACTIVITY; INHIBITION; EXTRACTS	Background: We sought to test the hypothesis that allergens are readily released by intact basidiospores in vitro and that different species release allergens in different patterns that are related to spore wall structure. Methods: To assess basidiospore allergen releasability basidiospore allergens were extracted from disrupted spores and eluted from intact spores, and the allergens potency of the extracts and eluates was compared in Calvatia cyathiformis, Psilocybe cubensis, Lentinus edodes, and Pleurotus ostreatus. Results: There was a significant species difference, on the basis of dry weight, the yield of extract and eluates from Pl. ostreatus greatly exceeded the yield from C. cyathiformis extract and eluates. As measured by RAST inhibition; the allergenic potency of Pl. ostreatus and L. edodes spore eluates reached the potency of disrupted spore extract in less than 4 hours. Allergen potency of Ps. cubensis and C. cyathiformis eluate approached the potency of disrupted spore extract only after 8 and 24 hours. Allergen staining intensity in sodium dodecyl sulfate polyacrylamide gel electrophoresis IgE immunoblot correlated with RAST activity. C. cyathiformis and Ps. cubensis spores have thick walls, whereas P1. ostreatus and L. edodes spore walls are thin and hyaline (nonpigmented). Thus spore allergen release may relate to spore wall characteristics. Conclusions: These studies indicate that intact basidiospores of all four species release allergens, but the release patterns differ by species, and these differences may be clinically significant.	UNIV TULSA,DEPT BIOL SCI,TULSA,OK 74104	University of Tulsa	HORNER, WE (corresponding author), TULANE UNIV,MED CTR,CLIN IMMUNOL SECT,1700 PERDIDO ST,NEW ORLEANS,LA 70112, USA.			Levetin, Estelle/0000-0002-2409-5142	NIAID NIH HHS [AI 20331] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020331] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTNICK.S, 1968, ANNU REV MICROBIOL, V22, P87, DOI 10.1146/annurev.mi.22.100168.000511; BOUZIANE H, 1989, INT ARCH ALLER A IMM, V88, P261, DOI 10.1159/000234804; Bozzola J. J., 1992, ELECT MICROSCOPY PRI, P542; BUTCHER BT, 1987, J ALLERGY CLIN IMMUN, V80, P803, DOI 10.1016/S0091-6749(87)80269-5; CLEMENCON H, 1986, AGARICALES MODERN TA, P83; DEMEULEMESTER C, 1987, ELECTROPHORESIS, V8, P71, DOI 10.1002/elps.1150080113; DEZUBIRIA A, 1990, J ALLERGY CLIN IMMUN, V86, P26, DOI 10.1016/S0091-6749(05)80119-8; GRIFFEN DH, 1981, FUNGAL PHYSL, P351; HORNER WE, 1989, J ALLERGY CLIN IMMUN, V83, P784, DOI 10.1016/0091-6749(89)90015-8; HUNSLEY D, 1970, J GEN MICROBIOL, V62, P203, DOI 10.1099/00221287-62-2-203; IBANEZ MD, 1988, J ALLERGY CLIN IMMUN, V82, P787, DOI 10.1016/0091-6749(88)90080-2; KARR RM, 1981, J ALLERGY CLIN IMMUN, V67, P194, DOI 10.1016/0091-6749(81)90061-0; KYSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SB, 1986, J ALLERGY CLIN IMMUN, V78, P478, DOI 10.1016/0091-6749(86)90036-9; LOPEZ M, 1989, J ALLERGY CLIN IMMUN, V84, P242, DOI 10.1016/0091-6749(89)90331-X; MILLER OK, 1981, MUSHROOMS N AM, P354; MIMS CW, 1977, CAN J BOT, V55, P2319, DOI 10.1139/b77-263; ONEIL CE, 1988, INT ARCH ALLER A IMM, V85, P161, DOI 10.1159/000234496; PEGLER DN, 1971, NOVA HEDWIGIA S, V35, P1; REIJULA KE, 1991, J ALLERGY CLIN IMMUN, V87, P683, DOI 10.1016/0091-6749(91)90389-6; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; SWEENEY M, 1985, J ALLERGY CLIN IMMUN, V75, P118, DOI 10.1016/0091-6749(85)90188-5; WANNER A, 1988, ALLERGY PRINCIPLES P, V1, P541; WEISSMAN DN, 1985, ANN ALLERGY, V55, P279	25	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1993	92	2					306	312		10.1016/0091-6749(93)90174-E	http://dx.doi.org/10.1016/0091-6749(93)90174-E			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LT469	8349941				2022-12-18	WOS:A1993LT46900011
J	LIEBERS, V; RAULF, M; MAZUR, G; MODROW, S; BAUR, X				LIEBERS, V; RAULF, M; MAZUR, G; MODROW, S; BAUR, X			EPITOPE MAPPING WITH PEPTIDES OF CHI-T-I COMPONENT-III AND IMMUNOMODULATION OF THE CHI-T IMMUNE-RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGEN; T-CELL EPITOPE; CHI-T-I COMPONENT-III; IMMUNOMODULATION	CELL EPITOPES; ANTIGEN; HEMOGLOBIN; SEQUENCE; ERYTHROCRUORIN; RECOGNITION; COMPETITION; ALLERGENS; MOLECULES; PROTEINS	Background: Hemoglobins of the Diptera family are known as aggressive inhalant allergens. Methods: The whole sequence of the insect allergen Chi t I component III was studied for T-cell epitope activity in cell cultures of 15 sensitized patients with a panel of 17 overlapping synthetic peptides and 12 peptides obtained by tryptic cleavage. Results: All but one of the peptides tested were found to be immunogenic. The nonstimulatory sequence 102-109 and two other tryptic peptides (69-90 and 110-135) were used in inhibition experiments. The Chi t I-induced proliferation was downregulated by all tested peptides when compared with stimulation with Chi t I alone. Conclusions: Because stimulation with phytohemagglutinin or tetanus toxoid was not influenced by the above-mentioned peptides, this mechanism seems to be specific for the antigen. Specific immunomodulation with nonstimulating peptides may offer new therapy approaches.	KLINIKUM GROBHADERN,MUNICH,GERMANY; INST MED MIKROBIOL & HYG,REGENSBURG,GERMANY		LIEBERS, V (corresponding author), BGFA,GILSINGSTR 14,W-4630 BOCHUM 1,GERMANY.							ADORINI L, 1990, IMMUNOL TODAY, V11, P21; ADORINI L, 1988, NATURE, V334, P623, DOI 10.1038/334623a0; ATASSI MZ, 1989, BIOCHEM J, V259, P731, DOI 10.1042/bj2590731; BAUR X, 1992, INT ARCH OCC ENV HEA, V64, P185, DOI 10.1007/BF00380907; BAUR X, 1986, ASTHMA ALVEOLITIS AS; BAUR X, 1986, SCIENCE, V223, P351; BUSE G, 1979, H-S Z PHYSIOL CHEM, V360, P89, DOI 10.1515/bchm2.1979.360.1.89; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; FAITH A, 1991, IMMUNOLOGY, V74, P1; FERRARI C, 1991, J CLIN INVEST, V88, P214, DOI 10.1172/JCI115280; HAIST S, 1992, IN PRESS AIDS RES HU; HUANG SK, 1991, IMMUNOLOGY, V73, P363; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; LAL RB, 1991, AIDS RES HUM RETROV, V7, P663, DOI 10.1089/aid.1991.7.663; LIEBERS V, 1991, INT ARCH ALLER A IMM, V95, P163, DOI 10.1159/000235423; LIEBERS V, 1992, IN PRESS INT S WORKS; MARGALIT H, 1987, J IMMUNOL, V138, P2213; OHEHIR RE, 1991, J ALLERGY CLIN IMMUN, V87, P1120, DOI 10.1016/0091-6749(91)92158-W; OSMULSKI PA, 1986, COMP BIOCHEM PHYS B, V85, P701, DOI 10.1016/0305-0491(86)90166-5; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; STEIGEMANN W, 1979, J MOL BIOL, V127, P309, DOI 10.1016/0022-2836(79)90332-2; TAUTZ C, 1990, Journal of Allergy and Clinical Immunology, V85, P201; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0	26	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1993	92	2					334	339		10.1016/0091-6749(93)90177-H	http://dx.doi.org/10.1016/0091-6749(93)90177-H			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LT469	7688779				2022-12-18	WOS:A1993LT46900014
J	DONNELLY, A; CASALE, TB				DONNELLY, A; CASALE, TB			NEDOCROMIL SODIUM IS RAPIDLY EFFECTIVE IN THE THERAPY OF SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NEDOCROMIL SODIUM; ALLERGIC RHINITIS; RAGWEED POLLEN	1-PERCENT NASAL SOLUTION; BECLOMETHASONE DIPROPIONATE; DISODIUM-CROMOGLYCATE; INDUCED CHEMOTAXIS; MEDIATOR RELEASE; CROMOLYN SODIUM; MAST-CELLS; GUINEA-PIG; INHIBITION; CHALLENGE	Background: Nedocromil sodium has proven to be efficacious in prophylactic and long-term therapy for the treatment of seasonal allergic rhinitis. We examined the speed of onset of intranasal nedocromil sodium (1%) for relief of symptoms due to ragweed allergic rhinitis. Methods: In a double-blind, placebo-controlled trial, 104 patients received either nedocromil sodium or placebo four times daily. Patients spent 10 hours per day for 2 consecutive days in Iowa City Park during the peak of ragweed season. Only patients who had significant symptoms during 3 hourly baseline assessments received drug. Symptom scores for stuffy nose, runny nose, itchy nose, and sneezing and global symptom summary scores were recorded at 19 hourly time points during the 2 days. In the evening patients recorded symptom scores for the postexposure period. Results: In comparison with placebo, nedocromil significantly improved rhinitis symptoms as evidenced by lower symptom summary scores within 2 hours (p = 0.016). Further, this reduction in rhinitis symptoms was maintained throughout the 2-day pollen exposure period. After patients left the study site, postexposure symptom summary scores were also significantly lower in patients treated with nedocromil compared with those treated with placebo (p < 0.007). Conclusions: Nedocromil significantly relieved preexisting seasonal a allergic rhinitis symptoms during peak pollen exposures within 2 hours of the first dose, and the therapeutic benefits were maintained on a dosing regimen of four times a day.	UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA	University of Iowa			Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377				BARNES PJ, 1989, DRUGS, V37, P94, DOI 10.2165/00003495-198900371-00017; BARNES PJ, 1990, JUN P ASTHM S MONTR, P14; BELLIONI P, 1988, Rhinology (Utrecht), V26, P281; BRUIJNZEEL PLB, 1990, BRIT J PHARMACOL, V99, P798, DOI 10.1111/j.1476-5381.1990.tb13009.x; BRUIJNZEEL PLB, 1989, BRIT J PHARMACOL, V97, P1251, DOI 10.1111/j.1476-5381.1989.tb12586.x; BUSSE WW, 1989, DRUGS, V137, P1; CHURCH MK, 1989, DRUGS, V37, P101, DOI 10.2165/00003495-198900371-00018; CORRADO OJ, 1987, J ALLERGY CLIN IMMUN, V80, P218, DOI 10.1016/0091-6749(87)90132-1; DRUCE HM, 1990, ANN ALLERGY, V65, P212; EADY RP, 1986, EUR J RESPIR DIS, V69, P112; HANDELMAN NI, 1977, J ALLERGY CLIN IMMUN, V59, P237, DOI 10.1016/0091-6749(77)90156-7; KAULBACH HC, 1992, J ALLERGY CLIN IMMUN, V89, P599, DOI 10.1016/0091-6749(92)90328-Y; LOZEWICZ S, 1990, J ALLERGY CLIN IMMUN, V85, P125, DOI 10.1016/0091-6749(90)90233-T; MOQBEL R, 1989, DRUGS, V37, P19, DOI 10.2165/00003495-198900371-00005; MOQBEL R, 1988, ALLERGY, V43, P268, DOI 10.1111/j.1398-9995.1988.tb00899.x; OSTUKA H, 1986, J ALLERGY CLIN IMMUN, V78, P365; PELIKAN Z, 1982, ANN ALLERGY, V49, P200; PELIKAN Z, 1982, ANN ALLERGY, V49, P283; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; RUHNO J, 1988, J ALLERGY CLIN IMMUN, V81, P557, DOI 10.1016/0091-6749(88)90196-0; SCHULLER DE, 1990, J ALLERGY CLIN IMMUN, V86, P554, DOI 10.1016/S0091-6749(05)80212-X; SCHWARTZ HJ, 1987, J ALLERGY CLIN IMMUN, V79, P186; TOGIAS A, 1985, AM J MED, V79, P26, DOI 10.1016/0002-9343(85)90084-1; VERLEDEN GM, 1991, AM REV RESPIR DIS, V143, P114, DOI 10.1164/ajrccm/143.1.114; VIEGAS M, 1987, BRIT MED J, V294, P414, DOI 10.1136/bmj.294.6569.414; WALDEN SM, 1988, J ALLERGY CLIN IMMUN, V81, P940, DOI 10.1016/0091-6749(88)90157-1; 1990, CHEST, V97, P1299	27	14	15	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1993	91	5					997	1004		10.1016/0091-6749(93)90212-X	http://dx.doi.org/10.1016/0091-6749(93)90212-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LC978	8388007	Bronze			2022-12-18	WOS:A1993LC97800006
J	BOND, JF; SEGAL, DB; YU, XB; THERIAULT, KA; POLLOCK, J; YEUNG, H				BOND, JF; SEGAL, DB; YU, XB; THERIAULT, KA; POLLOCK, J; YEUNG, H			HUMAN IGE REACTIVITY TO PURIFIED RECOMBINANT AND NATIVE GRASS ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	2				339	339						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK431					2022-12-18	WOS:A1993KK43100792
J	NIELSON, CP; CROWLEY, JJ; VESTAL, RE; CONNOLLY, MJ				NIELSON, CP; CROWLEY, JJ; VESTAL, RE; CONNOLLY, MJ			IMPAIRED BETA-ADRENOCEPTOR FUNCTION, INCREASED LEUKOCYTE RESPIRATORY BURST, AND BRONCHIAL HYPERRESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LEUKOCYTE; BETA-ADRENOCEPTOR; BRONCHIAL HYPERRESPONSIVENESS; RESPIRATORY BURST	EXERCISE-INDUCED ASTHMA; NEUTROPHIL CHEMOTACTIC ACTIVITY; PLATELET-ACTIVATING FACTOR; AIRWAY RESPONSIVENESS; BRONCHOALVEOLAR LAVAGE; ADRENERGIC RECEPTORS; CALCIUM IONOPHORE; CELLS; DESENSITIZATION; LEUKOTRIENE-B4	Inflammatory processes have potential importance in the pathogenesis of bronchial hyperresponsiveness and asthma. Because beta-adrenoceptor function may be impaired in asthma, we studied regulation of the leukocyte respiratory burst using blood samples from subjects with bronchial hyperresponsiveness to methacholine. Leukocytes from hyperresponsive subjects were less responsive to the beta-agonist isoproterenol than were leukocytes from healthy control subjects. The magnitude of the respiratory burst was increased in cells from hyperresponsive subjects and correlated with the degree of methacholine responsiveness. These results demonstrate that peripheral leukocytes reflect a functional impairment in beta-adrenergic responsiveness that parallels airway hyperresponsiveness. Because untreated subjects demonstrated a reduction in beta-adrenergic response, the impairment in beta-adrenoceptor function was not a result of drug therapy and may be associated with the pathogenesis of asthma.	DEPT VET AFFAIRS MED CTR,PULM MED SECT,BOISE,ID; DEPT VET AFFAIRS MED CTR,CLIN PHARMACOL & GERONTOL RES UNIT,BOISE,ID; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; ARM JP, 1988, AM REV RESPIR DIS, V138, P47, DOI 10.1164/ajrccm/138.1.47; BELCHER NG, 1988, J ALLERGY CLIN IMMUN, V81, P100, DOI 10.1016/0091-6749(88)90227-8; BRUSASCO V, 1990, J APPL PHYSIOL, V69, P2209, DOI 10.1152/jappl.1990.69.6.2209; BUCHANAN DR, 1987, AM REV RESPIR DIS, V136, P1397, DOI 10.1164/ajrccm/136.6.1397; CHUNG KF, 1989, THORAX, V44, P108, DOI 10.1136/thx.44.2.108; Connolly M J, 1988, Pulm Pharmacol, V1, P53, DOI 10.1016/0952-0600(88)90011-7; CONOLLY ME, 1980, J CLIN INVEST, V65, P577; DAVIS PB, 1986, J ALLERGY CLIN IMMUN, V77, P871, DOI 10.1016/0091-6749(86)90386-6; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; GREENACRE JK, 1978, BRIT J CLIN PHARMACO, V5, P199, DOI 10.1111/j.1365-2125.1978.tb01624.x; HIRSHMAN CA, 1987, J ALLERGY CLIN IMMUN, V79, P46, DOI 10.1016/S0091-6749(87)80015-5; KARIMAN K, 1980, LUNG, V158, P41, DOI 10.1007/BF02713701; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; LARSEN GL, 1987, FASEB J, V46, P105; MACK JA, 1986, BRIT J PHARMACOL, V88, P417, DOI 10.1111/j.1476-5381.1986.tb10219.x; MARTINSSON A, 1985, CHEST, V88, P594, DOI 10.1378/chest.88.4.594; MOTOJIMA S, 1989, ALLERGY, V44, P66, DOI 10.1111/j.1398-9995.1989.tb00448.x; MUELLER H, 1988, MOL PHARMACOL, V34, P347; NIELSON CP, 1987, J IMMUNOL, V139, P2392; O'BRYNE P M, 1985, Journal of Applied Physiology, V59, P1941; OKAYAMA H, 1989, AM REV RESPIR DIS, V139, P725, DOI 10.1164/ajrccm/139.3.725; PAUWELS R, 1989, CLIN EXP ALLERGY, V19, P395, DOI 10.1111/j.1365-2222.1989.tb02404.x; SANO Y, 1983, J ALLERGY CLIN IMMUN, V72, P495, DOI 10.1016/0091-6749(83)90587-0; SCHUSTER A, 1991, EUR J PEDIATR, V150, P209, DOI 10.1007/BF01963569; SHELHAMER JH, 1983, J ALLERGY CLIN IMMUN, V71, P57, DOI 10.1016/0091-6749(83)90547-X; TOWNLEY RG, 1989, J ALLERGY CLIN IMMUN, V83, P997, DOI 10.1016/0091-6749(89)90437-5; WEISS EB, 1985, J ALLERGY CLIN IMMUN, V75, P692, DOI 10.1016/0091-6749(85)90095-8; WILKINSON JRW, 1989, J CLIN INVEST, V84, P1930, DOI 10.1172/JCI114381	29	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1992	90	5					825	832		10.1016/0091-6749(92)90108-E	http://dx.doi.org/10.1016/0091-6749(92)90108-E			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ319	1331219				2022-12-18	WOS:A1992JZ31900014
J	REISMAN, RE				REISMAN, RE			SHOULD ROUTINE MEASUREMENTS OF SERUM VENOM-SPECIFIC IGG BE A STANDARD OF PRACTICE IN PATIENTS RECEIVING VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							DIAGNOSTIC METHODS; STING CHALLENGE; BEE VENOM; INSECT; HYPERSENSITIVITY; ANAPHYLAXIS; ALLERGY		SUNY BUFFALO,SCH MED,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V79, P947, DOI 10.1016/0091-6749(87)90245-4; GOLDEN DBK, 1992, J ALLERGY CLIN IMMUN, V90, P386, DOI 10.1016/S0091-6749(05)80019-3; HAUGAARD L, 1991, J ALLERGY CLIN IMMUN, V87, P699, DOI 10.1016/0091-6749(91)90391-Z; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; LANTNER R, 1989, J ALLERGY CLIN IMMUN, V84, P900, DOI 10.1016/0091-6749(89)90387-4; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; LIGHT W C, 1975, Clinical Allergy, V5, P389, DOI 10.1111/j.1365-2222.1975.tb01878.x; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; REISMAN RE, IN PRESS J ALLERGY C; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, P1189; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X	15	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				282	284		10.1016/S0091-6749(05)80004-1	http://dx.doi.org/10.1016/S0091-6749(05)80004-1			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1527312				2022-12-18	WOS:A1992JP52000002
J	ARLIAN, LG; VYSZENSKIMOHER, DAL; LAWRENCE, AT; SCHROTEL, KR; RITZ, HL				ARLIAN, LG; VYSZENSKIMOHER, DAL; LAWRENCE, AT; SCHROTEL, KR; RITZ, HL			ANTIGENIC AND ALLERGENIC ANALYSIS OF PSYLLIUM SEED COMPONENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PSYLLIUM; PSYLLIUM HUSK; ALLERGENICITY; LAXATIVES; CEREALS; FIBER	MITE TYROPHAGUS-PUTRESCENTIAE; HOUSE DUST MITES; DERMATOPHAGOIDES-FARINAE; MODERATE HYPERCHOLESTEROLEMIA; OCCUPATIONAL ASTHMA; CROSS-ANTIGENICITY; PRUDENT DIET; NURSES; SENSITIZATION; PTERONYSSINUS	The outer portions (husk) of psyllium seeds are a concentrated source of natural fiber used in some bulk-fiber laxatives and cereals. They are known to elicit respiratory allergic reactions after inhalation or ingestion among sensitized individuals. Antigenic and allergenic characterization of three psyllium-seed fractions (husk, endosperm, and embryo) was conducted with crossed immunoelectrophoresis (CIE), crossed radioimmunoelectrophoresis, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis to determine the source of psyllium allergenicity. Homologous CIE demonstrated psyllium endosperm and embryo extracts contained seven and four antigens, respectively. Husk extracts were too gelatinous to react by CIE. However, heterologous CIE profiles of endosperm or embryo extracts, reacted with antihusk antibodies, resulted in antigen-antibody precipitin peaks that matched the heavy staining precipitin lines of homologous reactions for endosperm and embryo, respectively. These results indicated that commercial-grade husk, endosperm, and embryo contained similar antigens. Extracts of all three seed components contained antigens that bound IgE antibodies in the sera of 11 psyllium RAST-positive individuals, as determined by crossed radioimmunoelectrophoresis. The few prominent husk protein/peptide bands resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis were common in either embryo or endosperm. Immunoblots revealed common IgE reactive bands in all three seed fractions. Microscopic examination of the powdered commercial-grade psyllium (95% pure) revealed it contained endosperm and embryo particles. These immunologic, biochemical, and microscopic findings suggest that other contaminating seed components are primarily responsible for the allergenicity of commercial-grade psyllium-husk powder rather than the husk itself.	PROCTER & GAMBLE CO,CINCINNATI,OH 45239	Procter & Gamble	ARLIAN, LG (corresponding author), WRIGHT STATE UNIV,DEPT BIOL SCI,DAYTON,OH 45435, USA.							ALARIE JP, 1985, CHEST, V88, P313, DOI 10.1378/chest.88.2.313b; ANDERSON JW, 1988, ARCH INTERN MED, V148, P292, DOI 10.1001/archinte.148.2.292; ARLIAN LG, 1988, J MED ENTOMOL, V25, P240, DOI 10.1093/jmedent/25.4.240; ARLIAN LG, 1990, INT ARCH ALLER A IMM, V91, P278, DOI 10.1159/000235128; ARLIAN LG, 1984, J ALLERGY CLIN IMMUN, V74, P172, DOI 10.1016/0091-6749(84)90282-3; ARLIAN LG, 1984, J ALLERGY CLIN IMMUN, V74, P166, DOI 10.1016/0091-6749(84)90281-1; ARLIAN LG, 1987, J MED ENTOMOL, V24, P252, DOI 10.1093/jmedent/24.2.252; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P457, DOI 10.1016/0091-6749(87)90363-0; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P467, DOI 10.1016/0091-6749(87)90364-2; BELL LP, 1989, JAMA-J AM MED ASSOC, V261, P3419, DOI 10.1001/jama.261.23.3419; Bernton H S, 1970, Med Ann Dist Columbia, V39, ppassim; CARTIER A, 1987, CLIN ALLERGY, V17, P1, DOI 10.1111/j.1365-2222.1987.tb02313.x; GAUSS WF, 1985, ALLERGY, V40, P73, DOI 10.1111/j.1398-9995.1985.tb04158.x; GAUSS WF, 1985, ALLERGY, V40, P535, DOI 10.1111/j.1398-9995.1985.tb00263.x; GORANSSON K, 1979, SCAND J WORK ENV HEA, V5, P257; GROSS R, 1979, JAMA-J AM MED ASSOC, V214, P1573; JAMES JM, 1991, J ALLERGY CLIN IMMUN, V88, P402, DOI 10.1016/0091-6749(91)90104-V; LANTNER RR, 1990, JAMA-J AM MED ASSOC, V264, P2534, DOI 10.1001/jama.264.19.2534; LEVIN EG, 1990, ARCH INTERN MED, V150, P1822, DOI 10.1001/archinte.150.9.1822; MACHADO L, 1979, ALLERGY, V34, P51, DOI 10.1111/j.1398-9995.1979.tb02000.x; MALO JL, 1990, AM REV RESPIR DIS, V142, P1359, DOI 10.1164/ajrccm/142.6_Pt_1.1359; MANTELL CL, 1947, WATER SOLUBLE GUMS, P133; MCCONNOCHIE K, 1990, CLIN EXP ALLERGY, V20, P199, DOI 10.1111/j.1365-2222.1990.tb02668.x; NEAL GW, 1990, SOUTH MED J, V83, P1131, DOI 10.1097/00007611-199010000-00005; NELSON WL, 1987, J OCCUP ENVIRON MED, V29, P497; POZNER LH, 1986, ANN ALLERGY, V56, P14; ROSENBERG S, 1982, ANN ALLERGY, V48, P294; SCHOENWETTER WF, 1985, ANN INTERN MED, V103, P642, DOI 10.7326/0003-4819-103-4-642; SUSSMAN GL, 1990, ALLERGY PROC, V11, P241, DOI 10.2500/108854190778879828	29	14	15	1	10	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1992	89	4					866	876		10.1016/0091-6749(92)90443-6	http://dx.doi.org/10.1016/0091-6749(92)90443-6			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN860	1560169				2022-12-18	WOS:A1992HN86000013
J	DAUL, CB; SLATTERY, M; MORGAN, JE; LEHRER, SB				DAUL, CB; SLATTERY, M; MORGAN, JE; LEHRER, SB			IDENTIFICATION OF A COMMON MAJOR CRUSTACEA ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	2				194	194						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HB760					2022-12-18	WOS:A1992HB76000152
J	ADELMAN, DC; YEN, TY; CUMBERLAND, WG; SIDELL, N; SAXON, A				ADELMAN, DC; YEN, TY; CUMBERLAND, WG; SIDELL, N; SAXON, A			13-CIS RETINOIC ACID ENHANCES INVIVO LYMPHOCYTE-B DIFFERENTIATION IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						13-CIS RETINOIC ACID; COMMON VARIABLE IMMUNODEFICIENCY; LYMPHOCYTE-B DIFFERENTIATION; LEU-8	BOOSTER IMMUNIZATION; CELL DEFECTS; IMMUNOLOGICAL ASPECTS; VITAMIN-A; HUMAN T; RESPONSES; HYPOGAMMAGLOBULINEMIA; SUPPRESSOR; RECEPTOR; HELPER	Retinoic acid (RA) has been demonstrated to drive both phenotypic and functional in vitro differentiation of B cell hybridomas from patients with common variable immunodeficiency (CVI) who manifest an "intrinsic" defect in terminal B cell differentiation (J Exp Med 1988;168: 55-71). Therefore, we conducted an open trial to determine the effects of oral 13-cis RA (0.5 mg/kg/day; 12 weeks receiving and 12 weeks without drug) on in vivo B cell differentiation in subjects with CVI. At various times before, during, and after drug administration, patients' B cells were tested for changes in cell-surface phenotype and in vitro immunoglobulin production in response to recombinant cytokines. Before 13-cis RA, all patients had decreased Leu-8 coexpression on CD20+ cells. Seven of eight subjects demonstrated "normalization" of this phenotype after 8 to 16 weeks of 13-cis RA administration. Patients whose B cells demonstrated more than normal CD20 display also had a fall toward normal in this parameter. These effects persisted for 6 to 12 weeks after drug was stopped. It appears that 13-cis RA drives B cells of patients with CVI to express a more differentiated cell-surface phenotype and may promote functional differentiation in some patients.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV CLIN IMMUNOL & ALLERGY,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT BIOSTAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	ADELMAN, DC (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,DIV ALLERGY & IMMUNOL,SAN FRANCISCO,CA 94143, USA.				NATIONAL CANCER INSTITUTE [P01CA012800, R01CA030515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI015332] Funding Source: NIH RePORTER; NCI NIH HHS [CA-30515, CA-12800] Funding Source: Medline; NIAID NIH HHS [AI-15332] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRAUN J, 1991, IMMUNOL LETT, V27, P205, DOI 10.1016/0165-2478(91)90152-Z; BUTCHER EC, 1986, CURR TOP MICROBIOL, V128, P85; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; COHEN BE, 1973, J IMMUNOL, V111, P1376; DEGAST GC, 1980, CLIN EXP IMMUNOL, V42, P535; DENNERT G, 1984, RETINOIDS, V2, P373; GEHA RS, 1974, NEW ENGL J MED, V291, P1, DOI 10.1056/NEJM197407042910101; GEOFFROY JS, 1989, J CELL BIOL, V109, P2463, DOI 10.1083/jcb.109.5.2463; GIORGI JV, 1987, J CLIN IMMUNOL, V7, P140, DOI 10.1007/BF00916008; HOF H, 1979, ANN INST PASTEUR IMM, VC130, P587; HOLLANDER M, 1973, NONPARAMETRIC STATIS; JONES BM, 1984, CLIN IMMUNOL IMMUNOP, V32, P41, DOI 10.1016/0090-1229(84)90041-2; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; PECK GL, 1979, NEW ENGL J MED, V300, P329, DOI 10.1056/NEJM197902153000701; SAIKI O, 1982, P NATL ACAD SCI-BIOL, V79, P6008, DOI 10.1073/pnas.79.19.6008; SAXON A, 1989, J ALLERGY CLIN IMMUN, V84, P44, DOI 10.1016/0091-6749(89)90177-2; SAXON A, 1986, J CLIN INVEST, V78, P959, DOI 10.1172/JCI112686; SAXON A, 1976, J IMMUNOL METHODS, V12, P285, DOI 10.1016/0022-1759(76)90050-8; SHERR E, 1988, J EXP MED, V168, P55, DOI 10.1084/jem.168.1.55; SIDELL N, 1984, CELL IMMUNOL, V87, P118, DOI 10.1016/0008-8749(84)90136-9; SIDELL N, 1984, CELL IMMUNOL, V88, P374, DOI 10.1016/0008-8749(84)90170-9; SIDELL N, 1990, J INVEST DERMATOL, V95, P597, DOI 10.1111/1523-1747.ep12505593; SIDELL N, 1988, CELL IMMUNOL, V115, P299, DOI 10.1016/0008-8749(88)90183-9; SIEGAL FP, 1978, NEW ENGL J MED, V299, P172, DOI 10.1056/NEJM197807272990404; SKINNIDER LF, 1979, CANCER RES, V39, P3332; SNELLER MC, 1990, J IMMUNOL, V144, P3762; STEVENS RH, 1978, J CLIN INVEST, V62, P1154, DOI 10.1172/JCI109234; STEVENS RH, 1979, J IMMUNOL, V122, P2498; STEVENS RH, 1980, CLIN IMMUNOL IMMUNOP, V16, P336, DOI 10.1016/0090-1229(80)90139-7	30	14	16	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1991	88	5					705	712		10.1016/0091-6749(91)90176-O	http://dx.doi.org/10.1016/0091-6749(91)90176-O			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GQ452	1720149				2022-12-18	WOS:A1991GQ45200004
J	HUDSON, TJ; NEWKIRK, M; GERVAIS, F; SHUSTER, J				HUDSON, TJ; NEWKIRK, M; GERVAIS, F; SHUSTER, J			ADVERSE REACTION TO THE RECOMBINANT HEPATITIS-B VACCINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							PROTEINS		MCGILL UNIV,MONTREAL GEN HOSP,DEPT MED,DIV CLIN IMMUNOL & ALLERGY,1650 CEDAR AVE,ROOM 7135,MONTREAL H3G 1A4,QUEBEC,CANADA	McGill University				Hudson, Thomas/0000-0002-1376-4849				ANDRE FE, 1987, POSTGRAD MED J, V63, P169; COX NH, 1988, CONTACT DERMATITIS, V18, P229, DOI 10.1111/j.1600-0536.1988.tb02809.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIEDERMANN G, 1987, POSTGRAD MED J, V63, P109	5	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1991	88	5					821	822		10.1016/0091-6749(91)90194-S	http://dx.doi.org/10.1016/0091-6749(91)90194-S			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GQ452	1835467				2022-12-18	WOS:A1991GQ45200022
J	PAGANELLI, R; FANALESBELASIO, E; SCALA, E; CARMINI, D; MEZZAROMA, I; PINTER, E; AIUTI, F				PAGANELLI, R; FANALESBELASIO, E; SCALA, E; CARMINI, D; MEZZAROMA, I; PINTER, E; AIUTI, F			SERUM EOSINOPHIL CATIONIC PROTEIN (ECP) IN HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							INTERFERON; GAMMA; IGE				PAGANELLI, R (corresponding author), UNIV ROME LA SAPIENZA,CATTEDRA ALLERGOL & IMMUNOL CLIN,VIALE UNIV 37,I-00185 ROME,ITALY.		Paganelli, Roberto/AAF-5712-2020; Scala, Enrico/H-6997-2012; BELASIO, EMANUELE FANALES/C-7718-2016	Scala, Enrico/0000-0002-9391-9168; BELASIO, EMANUELE FANALES/0000-0003-2369-9996				BREEN EC, 1990, J IMMUNOL, V144, P480; FREW AJ, 1990, J ALLERGY CLIN IMMUN, V85, P533, DOI 10.1016/0091-6749(90)90090-Q; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LIN RY, 1988, ANN ALLERGY, V61, P269; LUCEY DR, 1989, J EXP MED, V169, P327, DOI 10.1084/jem.169.1.327; LUCEY DR, 1990, AIDS RES HUM RETROV, V6, P427, DOI 10.1089/aid.1990.6.427; MURRAY HW, 1984, NEW ENGL J MED, V310, P883, DOI 10.1056/NEJM198404053101404; PARKIN JM, 1987, BRIT MED J, V294, P1185, DOI 10.1136/bmj.294.6581.1185; VENGE P, 1987, INT ARCH ALLER A IMM, V82, P333, DOI 10.1159/000234219; VENGE P, 1978, BRIT J HAEMATOL, V38, P475, DOI 10.1111/j.1365-2141.1978.tb01072.x; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P445, DOI 10.1016/0091-6749(90)90154-V; 1986, MMWR, V20, P334	14	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1991	88	3	1				416	418		10.1016/0091-6749(91)90107-Y	http://dx.doi.org/10.1016/0091-6749(91)90107-Y			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GG126	1890272				2022-12-18	WOS:A1991GG12600039
J	CALKHOVEN, PG; AALBERS, M; SCHILTE, PPM; YNTEMA, BJL; GRIFFIOEN, RW; VANNIEROP, JC; ORANJE, AP; AALBERSE, RC				CALKHOVEN, PG; AALBERS, M; SCHILTE, PPM; YNTEMA, BJL; GRIFFIOEN, RW; VANNIEROP, JC; ORANJE, AP; AALBERSE, RC			NEWLY GENERATED IGE ANTIBODIES TO DERMATOPHAGOIDES-PTERONYSSINUS IN CHILDREN ARE DIRECTED AGAINST COMPONENTS DISTINCT FROM DER-P-I AND DER-P-II	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HOUSE DUST MITE; DERMATOPHAGOIDES PTERONYSSINUS; IGE-MEDIATED ALLERGY; DER-P-I; DER-P-II	MAJOR ALLERGEN; FARINAE MITE; PURIFICATION; EXTRACTS; ANTIGENS; BODY; CULTURE; SKIN	The specificity of newly generated IgE antibodies (Abs) to the house dust mite, Dermatophagoides pteronyssinus, in longitudinal serum samples from 18 young children with an increased risk for IgE-mediated allergy was studied. The first IgE Ab response to house dust mite was detected early in life (mean age, 32 months; range, 11 to 60 months). For 83% of the children, more than half of the newly generated IgE Ab response to house dust mite was directed against components distinct from the major allergens, Der p I (P1) and Der p II (DpX). These results suggest that the early IgE Ab response to house dust mite is induced by components distinct from the major allergens, Der P I and Der p II.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,POB 9406,1006 AK AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL,AMSTERDAM,NETHERLANDS; MED CTR ALKMAAR,ALKMAAR,NETHERLANDS; EMMA CHILDRENS HOSP,AMSTERDAM,NETHERLANDS; UNIV HOSP ROTTERDAM,SOPHIA CHILDRENS HOSP,ROTTERDAM,NETHERLANDS	University of Amsterdam; Medical Center Of Alkmaar; Emma Children's Hospital; University of Amsterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital								AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; AALBERSE RC, 1973, IMMUNOCHEMISTRY, V10, P295, DOI 10.1016/0019-2791(73)90025-6; ARLIAN LG, 1987, J MED ENTOMOL, V24, P252, DOI 10.1093/jmedent/24.2.252; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P467, DOI 10.1016/0091-6749(87)90364-2; CALKHOVEN PG, 1991, CLIN EXP ALLERGY, V21, P91, DOI 10.1111/j.1365-2222.1991.tb00809.x; CALKHOVEN PG, 1991, CLIN EXP ALLERGY, V21, P99, DOI 10.1111/j.1365-2222.1991.tb00810.x; CARSWELL F, 1986, LANCET, V2, P13, DOI 10.1016/S0140-6736(86)92560-2; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; DANDEU JP, 1982, IMMUNOLOGY, V46, P679; KRILIS S, 1984, J ALLERGY CLIN IMMUN, V74, P132, DOI 10.1016/0091-6749(84)90275-6; LEMAO J, 1981, IMMUNOLOGY, V44, P239; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; THOMPSON SJ, 1988, IMMUNOLOGY, V64, P311; TOVEY ER, 1987, J ALLERGY CLIN IMMUN, V79, P93, DOI 10.1016/S0091-6749(87)80022-2; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214, DOI 10.1159/000234137	17	14	14	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1991	88	2					265	271		10.1016/0091-6749(91)90337-N	http://dx.doi.org/10.1016/0091-6749(91)90337-N			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB225	1880326				2022-12-18	WOS:A1991GB22500016
J	MAZER, BD; RENZ, H; GELFAND, EW				MAZER, BD; RENZ, H; GELFAND, EW			AN ELISA SPOT ASSAY FOR QUANTITATION OF HUMAN IMMUNOGLOBULIN-SECRETING CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ANTIBODY-SECRETING CELLS; ISOTYPE DETECTION; ELISA SPOT ASSAY	SOLID-PHASE; B-CELLS; IMMUNE-RESPONSE; IGE PRODUCTION; T-CELL; ENUMERATION; ANTIBODY; LEVEL	The elucidation of changes in populations of immunoglobulin-secreting cells has been a cumbersome process. We present a simplified method for the enumeration of human immunoglobulin-secreting cells with an ELISA spot assay (ESA). This method is specific, will detect all isotypes, including IgE, and is sensitive, detecting as little as 10 pg of antibody secreted. In this article, we describe the methodology for performing the ESA, demonstrate the kinetics for optimal use in both B-lymphoblastoid lines and fresh B cells, and determine the correlation between the ESA and immunoglobulin secretion under various experimental conditions. This assay permits an estimate of the level of immunoglobulin secreted per cell, thus distinguishing expansion of immunoglobulin-secreting cell populations from increases in average (per cell) immunoglobulin production. The combination of ESA and quantitation of immunoglobulin in supernatants of cultured cells provides an easy and reliable means for studying the regulation of immunoglobulin secretion.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206; RAYMOND & BEVERLY SACKLER FDN,DENVER,CO	National Jewish Health					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029704, R01AI026490] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26490, AI-29704] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CZERKINSKY C, 1988, J IMMUNOL METHODS, V110, P29, DOI 10.1016/0022-1759(88)90079-8; CZERKINSKY C, 1988, J IMMUNOL METHODS, V115, P31, DOI 10.1016/0022-1759(88)90306-7; CZERKINSKY CC, 1983, J IMMUNOL METHODS, V65, P109, DOI 10.1016/0022-1759(83)90308-3; HOLT PG, 1984, CLIN IMMUNOL IMMUNOP, V30, P159, DOI 10.1016/0090-1229(84)90017-5; HOLT PG, 1984, J IMMUNOL METHODS, V74, P1, DOI 10.1016/0022-1759(84)90360-0; Jackson A. L., 1986, MANUAL CLIN LABORATO, P226; JERNE NK, 1963, SCIENCE, V140, P405, DOI 10.1126/science.140.3565.405; KEHRL JH, 1984, IMMUNOL REV, V78, P75, DOI 10.1111/j.1600-065X.1984.tb00477.x; KING CL, 1990, J IMMUNOL METHODS, V132, P37, DOI 10.1016/0022-1759(90)90395-C; KLINMAN DM, 1987, J IMMUNOL METHODS, V102, P157, DOI 10.1016/0022-1759(87)90072-X; LEFKOVITS I, 1984, IMMUNOL TODAY, V5, P265, DOI 10.1016/0167-5699(84)90137-3; LOGTENBERG T, 1985, IMMUNOL LETT, V9, P343, DOI 10.1016/0165-2478(85)90060-4; MAZER B, 1990, J IMMUNOL, V145, P2602; RENZ H, 1990, J IMMUNOL, V145, P3641; SEDGWICK JD, 1983, J IMMUNOL METHODS, V57, P301, DOI 10.1016/0022-1759(83)90091-1; SKIDMORE BJ, 1989, EUR J IMMUNOL, V19, P1591, DOI 10.1002/eji.1830190911; STEIN LD, 1986, EUR J IMMUNOL, V16, P1167, DOI 10.1002/eji.1830160922; VERSTEEGEN JMT, 1988, J IMMUNOL METHODS, V111, P25, DOI 10.1016/0022-1759(88)90055-5; VOS Q, 1990, J IMMUNOL METHODS, V126, P89, DOI 10.1016/0022-1759(90)90015-N; WISMANS PJ, 1989, CLIN EXP IMMUNOL, V78, P75; ZIGTERMAN GJWJ, 1988, J IMMUNOL METHODS, V106, P101, DOI 10.1016/0022-1759(88)90277-3	21	14	16	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1991	88	2					235	243		10.1016/0091-6749(91)90334-K	http://dx.doi.org/10.1016/0091-6749(91)90334-K			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB225	1880324				2022-12-18	WOS:A1991GB22500013
J	SLAVIN, RG				SLAVIN, RG			MEDICAL-MANAGEMENT OF NASAL POLYPS AND SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							FUNGAL SINUSITIS; RHINOSINUSITIS				SLAVIN, RG (corresponding author), ST LOUIS UNIV, SCH MED, DEPT INTERNAL MED & MICROBIOL, 1402 S GRAND ST, R209, ST LOUIS, MO 63104 USA.							AFZELIUS B A, 1976, Science (Washington D C), V193, P317; AUST R, 1976, Rhinology (Utrecht), V14, P43; AUST R, 1976, ACTA OTO-LARYNGOL, V81, P468, DOI 10.3109/00016487609107502; AUST R, 1974, Rhinology (Utrecht), V12, P25; CAPLAN ES, 1982, JAMA-J AM MED ASSOC, V247, P639, DOI 10.1001/jama.247.5.639; CARENFELT C, 1978, ACTA OTO-LARYNGOL, V85, P116, DOI 10.3109/00016487809121431; CARENFELT C, 1977, ACTA OTO-LARYNGOL, V84, P138, DOI 10.3109/00016487709123952; DRETTNER B, 1980, CLIN OTOLARYNGOL, V5, P277, DOI 10.1111/j.1365-2273.1980.tb01658.x; Drettner B., 1965, ACTA OTO-LARYNGOL, V60, P304; ELVERLAND HH, 1979, ACTA OTO-LARYNGOL, V360, P219; GUNTERT VG, 1963, HNO, V11, P77; LILDHOLDT T, 1988, ACTA OTO-LARYNGOL, V105, P140, DOI 10.3109/00016488809119457; LINDEN BE, 1988, ARCH OTOLARYNGOL, V114, P860; MELEN I, 1986, ACTA OTO-LARYNGOL, V101, P494, DOI 10.3109/00016488609108636; MORGAN MA, 1984, AM J CLIN PATHOL, V82, P597, DOI 10.1093/ajcp/82.5.597; MYGIND N, 1976, ACTA OTO-LARYNGOL, V82, P252, DOI 10.3109/00016487609120897; REINER A, 1978, ACTA OTO-LARYNGOL, V355, P1; SETTIPANE GA, 1987, IMMUNOL ALLERGY CLIN, V7, P105; SETTIPANE GA, 1984, RHINITIS, P133; SIEGEL JD, 1987, J AM GERIATR SOC, V35, P685, DOI 10.1111/j.1532-5415.1987.tb04347.x; SLAVIN RG, 1988, ALLERGY PRINCIPLES P, V2, P1291; SORENSEN H, 1976, ACTA OTO-LARYNGOL, V3, P802; STIEHM ER, 1980, IMMUNOLOGIC DISORDER, P183; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P; SYKES DA, 1986, LANCET, V2, P359; WASHBURN RG, 1988, MEDICINE, V67, P231, DOI 10.1097/00005792-198807000-00004	26	14	14	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1991	88	2					141	146		10.1016/0091-6749(91)90322-F	http://dx.doi.org/10.1016/0091-6749(91)90322-F			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB225	1880314				2022-12-18	WOS:A1991GB22500001
J	SPEELBERG, B; PANIS, EAH; BIJL, D; VANHERWAARDEN, CLA; BRUYNZEEL, PLB				SPEELBERG, B; PANIS, EAH; BIJL, D; VANHERWAARDEN, CLA; BRUYNZEEL, PLB			LATE ASTHMATIC RESPONSES AFTER EXERCISE CHALLENGE ARE REPRODUCIBLE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BRONCHIAL-ASTHMA; FLOW; IMMEDIATE	In this study the reproducibility of a late asthmatic reaction (LAR) after exercise challenge (EC) has been documented. Eighty-three hospitalized patients with asthma were challenged with exercise. The patients were examined according to a standardized protocol that comprised 8 minutes of bicycling at 90% of predicted heart rate. An LAR after EC was considered to have occurred when there was a fall in peak expiratory flow rate greater-than-or-equal-to 20% on three or more time points on the exercise day compared to corresponding clock time on a control day. According to these criteria, 11 patients (13.3%) experienced an LAR. Those patients were rechallenged 21 to 150 days after the first EC, without changing the therapy regimen of the patients, to study its reproducibility. Eight patients (73%) demonstrated a reproducible LAR after EC based on the criteria for a positive LAR. Although the LAR after EC was reproducible, the time points at which the LAR took place after the second EC differed from LARs after the first EC. Our results indicate that the LAR after EC occurs in a considerable number of patients with bronchial asthma and is quite reproducible.	CATHOLIC UNIV NIJMEGEN,MED CTR,DEPT PULM DIS,NIJMEGEN,NETHERLANDS; SWISS INST ALLERGY & ASTHMA RES,DAVOS,SWITZERLAND	Radboud University Nijmegen; Swiss Institute of Allergy & Asthma Research	SPEELBERG, B (corresponding author), DUTCH ASTHMA CTR,DAVOS SYMONDSTR 11,7270 DAVOS PL,DAVOS,SWITZERLAND.							ARMITAGE P, 1985, STATISTICAL METHODS; BIERMAN CW, 1984, J ALLERGY CLIN IMMUN, V73, P654, DOI 10.1016/0091-6749(84)90300-2; BIERMAN CW, 1984, J ALLERGY CLIN IMMUN, V74, P701, DOI 10.1016/0091-6749(84)90233-1; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BOULET LP, 1987, J ALLERGY CLIN IMMUN, V80, P655, DOI 10.1016/0091-6749(87)90284-3; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; FORESI A, 1986, J ALLERGY CLIN IMMUN, V78, P1130, DOI 10.1016/0091-6749(86)90262-9; HARGREAVE FE, 1985, CHEST, V87, P2025; HETZEL MR, 1979, LANCET, V1, P597; IIKURA Y, 1985, J ALLERGY CLIN IMMUN, V75, P285, DOI 10.1016/0091-6749(85)90059-4; KELLY CA, 1988, THORAX, V43, P335, DOI 10.1136/thx.43.4.335; LEE TH, 1983, LANCET, V1, P520; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PERKS WH, 1979, THORAX, V34, P79, DOI 10.1136/thx.34.1.79; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; RUBINSTEIN I, 1987, NEW ENGL J MED, V317, P482, DOI 10.1056/NEJM198708203170805; SCHERRER M, 1983, SCHWEIZ MED WOCHENSC, V112, P1695; SPEELBERG B, 1989, EUR RESPIR J, V2, P402; SPEELBERG B, 1990, American Review of Respiratory Disease, V141, pA759; VERHOEFF NPLG, 1990, CHEST, V98, P1194, DOI 10.1378/chest.98.5.1194; ZAWADSKI DK, 1988, AM REV RESPIR DIS, V137, P837, DOI 10.1164/ajrccm/137.4.837; 1987, AM REV RESPIR DIS, V136, P225	23	14	15	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1991	87	6					1128	1137		10.1016/0091-6749(91)92159-X	http://dx.doi.org/10.1016/0091-6749(91)92159-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR066	2045617				2022-12-18	WOS:A1991FR06600013
J	TAMAOKI, J; SAKAI, N; ISONO, K; KANEMURA, T; YAMAWAKI, I; TAKIZAWA, T				TAMAOKI, J; SAKAI, N; ISONO, K; KANEMURA, T; YAMAWAKI, I; TAKIZAWA, T			EFFECTS OF PLATELET-ACTIVATING-FACTOR ON BIOELECTRIC PROPERTIES OF CULTURED TRACHEAL AND BRONCHIAL EPITHELIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							FACTOR STIMULATES SECRETION; ION-TRANSPORT; FACTOR PAF; CHLORIDE SECRETION; CALCIUM-IONOPHORE; RELEASE; PROSTAGLANDINS; PRODUCTS; INVITRO; AIRWAYS	To elucidate the effect of platelet-activating factor (PAF) on ion transport function of airway epithelial cells, we studied bioelectric properties of cultured tracheal and bronchial epithelia from dogs under short-circuit conditions in vitro. Addition of PAF (10(-5) mol/L) to mucosal solution of Ussing chamber increased short-circuit current of tracheal epithelium from 3.3 +/- 0.7 to 8.5 +/- 1.2-mu-A/cm2 (p < 0.001). This effect was dose dependent, and there was a corresponding increase in transepithelial potential difference. In contrast, PAF was without effect when it was added to the submucosal side. Electrical properties of bronchial epithelium remained unchanged by PAF. The PAF-induced increase in short-circuit current was not affected by amiloride but abolished by diphenylamine-2-carboxylate, bumetanide, or Cl-free medium. The effects of PAF were not altered by AA-861 or U-60257, but attenuated by indomethacin and piroxicam, and dose-dependently blocked by CV 6209 and WEB 2086. Mucosal, but not submucosal, addition of PAF increased the rate of prostaglandin release from tracheal epithelium. These results suggest that PAF selectively stimulates Cl secretion across tracheal epithelium, probably through activation of its specific receptors and the subsequent production of prostaglandins.	TOKYO WOMENS MED COLL,DEPT MED 1,DIV PULM,8-1 KAWADA CHO,SHINJUKU KU,TOKYO 162,JAPAN	Tokyo Women's Medical University								ADLER KB, 1987, EXP LUNG RES, V13, P25, DOI 10.3109/01902148709064307; ALBAZZAZ F, 1981, AM J PHYSIOL, V240, pF101, DOI 10.1152/ajprenal.1981.240.2.F101; ALBAZZAZ FJ, 1984, LUNG, V162, P357, DOI 10.1007/BF02715668; BOUCHER RC, 1979, AM J PHYSIOL, V47, P397; BRAQUET P, 1987, PHARMACOL REV, V39, P97; CASALSSTENZEL J, 1987, N-S ARCH PHARMACOL, V335, P351; CHRISTMAN BW, 1987, AM REV RESPIR DIS, V135, P1267; DISTEFANO A, 1985, PFLUG ARCH EUR J PHY, V405, pS95, DOI 10.1007/BF00581787; GOSWAMI SK, 1989, J ALLERGY CLIN IMMUN, V84, P726, DOI 10.1016/0091-6749(89)90301-1; HAMASAKI Y, 1984, AM REV RESPIR DIS, V129, P742, DOI 10.1164/arrd.1984.129.5.742; HANGLOW AC, 1989, AM J PHYSIOL, V257, pG845, DOI 10.1152/ajpgi.1989.257.5.G845; LEE TC, 1982, BIOCHEM BIOPH RES CO, V105, P1303, DOI 10.1016/0006-291X(82)90928-7; LEIKAUF GD, 1986, AM J PHYSIOL, V250, pF47, DOI 10.1152/ajprenal.1986.250.1.F47; LEIKAUF GD, 1985, FED PROC, V44, P1920; LEIKAUF GD, 1985, AM J PHYSIOL, V248, pF48, DOI 10.1152/ajprenal.1985.248.1.F48; MENCIAHUERTA JM, 1979, EUR J IMMUNOL, V9, P409, DOI 10.1002/eji.1830090512; MENCIAHUERTA JM, 1983, J IMMUNOL, V131, P2958; ODONNELL SR, 1987, EUR J PHARMACOL, V138, P385, DOI 10.1016/0014-2999(87)90477-8; POPOVICH KJ, 1988, J APPL PHYSIOL, V65, P914, DOI 10.1152/jappl.1988.65.2.914; SALARI H, 1990, EUR J PHARMACOL, V175, P253, DOI 10.1016/0014-2999(90)90562-K; SCHULZ R, 1986, BIOCHEM PHARMACOL, V35, P183, DOI 10.1016/0006-2952(86)90512-5; SMITH PL, 1982, J MEMBRANE BIOL, V70, P217, DOI 10.1007/BF01870564; STIMLER NP, 1983, AM J PATHOL, V113, P75; TERASHITA Z, 1986, 2ND INT C PLAT ACT F, P29; WELSH MJ, 1980, J APPL PHYSIOL, V49, P905, DOI 10.1152/jappl.1980.49.5.905; WIDDICOMBE JH, 1980, AM J PHYSIOL, V239, pC112, DOI 10.1152/ajpcell.1980.239.3.C112; WIDDICOMBE JH, 1983, AM J PHYSIOL, V245, pC388, DOI 10.1152/ajpcell.1983.245.5.C388; YAMAGUCHI T, 1976, AM J PHYSIOL, V230, P1737, DOI 10.1152/ajplegacy.1976.230.6.1737	28	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1991	87	6					1042	1049		10.1016/0091-6749(91)92148-T	http://dx.doi.org/10.1016/0091-6749(91)92148-T			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR066	2045609				2022-12-18	WOS:A1991FR06600002
J	TAYLOR, RJ				TAYLOR, RJ			HYPERSENSITIVITY VASCULITIS OCCURRING IN A PATIENT RECEIVING IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							HYPOSENSITIZATION		SO ILLINOIS UNIV,SCH MED,SPRINGFIELD,IL 62708	Southern Illinois University System; Southern Illinois University								LEVINSON AI, 1978, J ALLERGY CLIN IMMUN, V62, P109, DOI 10.1016/0091-6749(78)90087-8; LOCKEY R, 1989, J ALLERGY CLIN IMMUN, V84, P1032; PHANUPHAK P, 1980, AM J MED, V68, P479, DOI 10.1016/0002-9343(80)90285-5; RAPHAEL SA, 1976, J ALLERGY CLIN IMMUN, V57, P231; STEIN MR, 1978, J ALLERGY CLIN IMMUN, V62, P211, DOI 10.1016/0091-6749(78)90209-9	5	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					889	890		10.1016/0091-6749(91)90139-F	http://dx.doi.org/10.1016/0091-6749(91)90139-F			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	1826508				2022-12-18	WOS:A1991FG05900021
J	KAISER, HB				KAISER, HB			H1-RECEPTOR ANTAGONIST TREATMENT OF SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	CONF ON ADVANCEMENTS IN ANTIALLERGIC THERAPY : BEYOND CONVENTIONAL ANTIHISTAMINES	OCT 12-15, 1989	NAPLES, FL	PFIZER LAB			HAY-FEVER; TERFENADINE; TRIAL	H-1-receptor antagonists are usually first-line treatment given for seasonal allergic rhinitis. However, many patients suffer with symptoms of allergic rhinitis rather than tolerate the sedative and anticholinergic side effects of the first-generation H-1-receptor antagonists. Researchers have sought to replace these older H-1-receptor antagonists with a new generation of H-1-receptor antagonists that approach the optimal therapy: clinically effective, safe, free of side effects, and convenient for the patient. Among the new second-generation H-1-receptor antagonists are terfenadine and astemizole (already marketed) and loratadine and cetirizine, which are expected to be approved soon. All four demonstrate efficacy, convenience, and minimal side effects on the central nervous system. In this review of the current treatment of seasonal allergic rhinitis, the clinical studies that compare these four new second-generation H-1-receptor antagonists are discussed.			KAISER, HB (corresponding author), ALLERGY & ASTHMA SPECIALISTS PA,1149 MED ARTS BLDG,MINNEAPOLIS,MN 55402, USA.							BUCKLEY CE, 1988, ANN ALLERGY, V60, P123; BUSSCHE G V, 1987, Annals of Allergy, V58, P184; DAVIES BH, 1989, CLIN TRIALS J, V26, P100; DOCKHORN RJ, 1987, ANN ALLERGY, V58, P407; GROSSMAN J, 1989, ANN ALLERGY, V62, P250; HOWARTH PH, 1984, THORAX, V39, P668, DOI 10.1136/thx.39.9.668; KEMP JP, 1985, ANN ALLERGY, V54, P502; ROHR AS, IMMUNOL ALLERGY PRAC, V8, P17; SIMONS FER, 1988, J ALLERGY CLIN IMMUN, V81, P975, DOI 10.1016/0091-6749(88)90164-9; NDA SAR1 PFIZ INC PF	10	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	2	S			1000	1003		10.1016/S0091-6749(05)80243-X	http://dx.doi.org/10.1016/S0091-6749(05)80243-X			4	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER131	1979793				2022-12-18	WOS:A1990ER13100002
J	DAVE, NK; HOPP, RJ; BIVEN, RE; DEGAN, J; BEWTRA, AK; TOWNLEY, RG				DAVE, NK; HOPP, RJ; BIVEN, RE; DEGAN, J; BEWTRA, AK; TOWNLEY, RG			PERSISTENCE OF INCREASED NONSPECIFIC BRONCHIAL REACTIVITY IN ALLERGIC CHILDREN AND ADOLESCENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV, SCH MED, CTR ALLERG DIS, 2500 CALIF ST, OMAHA, NE 68178 USA	Creighton University			Hopp, Russell/K-4578-2019					ALPER B, 1982, AM REV RESPIR DIS, V125, P73; BAHOUS J, 1984, AM REV RESPIR DIS, V129, P216; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CLIFFORD RD, 1987, ARCH DIS CHILD, V62, P66, DOI 10.1136/adc.62.1.66; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; GURWITZ D, 1981, J PEDIATR-US, V98, P551, DOI 10.1016/S0022-3476(81)80758-5; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; HAGY GW, 1976, J ALLERGY CLIN IMMUN, V58, P330, DOI 10.1016/0091-6749(76)90139-1; HOPP RJ, 1987, J ALLERGY CLIN IMMUN, V80, P821, DOI 10.1016/S0091-6749(87)80272-5; HOPP RJ, 1986, AM REV RESPIR DIS, V134, P994, DOI 10.1164/arrd.1986.134.5.994; HOPP RJ, 1985, J ALLERGY CLIN IMMUN, V76, P609, DOI 10.1016/0091-6749(85)90783-3; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V74, P154, DOI 10.1016/0091-6749(84)90279-3; HOPP RJ, 1987, PEDIATR ASTHMA ALLER, V1, P103; ITKIN IH, 1967, J ALLERGY, V40, P245, DOI 10.1016/0021-8707(67)90087-1; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KONIG P, 1973, ARCH DIS CHILD, V48, P513, DOI 10.1136/adc.48.7.513; LONGO G, 1987, AM J DIS CHILD, V141, P331, DOI 10.1001/archpedi.1987.04460030109037; MALO JL, 1982, J APPL PHYSIOL, V52, P1464, DOI 10.1152/jappl.1982.52.6.1464; MITCHELL I, 1978, J PEDIATR-US, V93, P744, DOI 10.1016/S0022-3476(78)81070-1; MOTOYAMA EK, 1986, 90TH ROSS LAB C PED; OREHEK J, 1977, AM REV RESPIR DIS, V115, P937; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; PHELAN PS, 1988, IMMUNOL ALLERGY PRAC, V10, P334; REDLINE S, 1989, AM REV RESPIR DIS, V140, P172, DOI 10.1164/ajrccm/140.1.172; SPECTOR SL, 1975, J ALLERGY CLIN IMMUN, V56, P308, DOI 10.1016/0091-6749(75)90105-0; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; 1971, 1ST P NAT HEART LUNG	34	14	14	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1990	86	2					147	153		10.1016/S0091-6749(05)80059-4	http://dx.doi.org/10.1016/S0091-6749(05)80059-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DV316	2200819	Bronze			2022-12-18	WOS:A1990DV31600002
J	POLOSA, R; FINNERTY, JP; HOLGATE, ST				POLOSA, R; FINNERTY, JP; HOLGATE, ST			TACHYPHYLAXIS TO INHALED HISTAMINE IN ASTHMA - ITS SIGNIFICANCE AND RELATIONSHIP TO BASAL AIRWAY RESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											POLOSA, R (corresponding author), SOUTHAMPTON GEN HOSP,DEPT IMMUNOPHARMACOL,MED 1,LEVEL D,CTR BLOCK,TREMONA RD,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BOULET LP, 1987, RESPIRATION, V52, P237, DOI 10.1159/000195332; BRINK C, 1982, J PHARM PHARMACOL, V34, P199, DOI 10.1111/j.2042-7158.1982.tb04224.x; CARPENTIERE G, 1988, CHEST, V93, P933, DOI 10.1378/chest.93.5.933; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V77, P570, DOI 10.1016/0091-6749(86)90347-7; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CONNOLLY MJ, 1989, THORAX, V44, P146, DOI 10.1136/thx.44.2.146; DAXUN Z, 1989, J ALLERGY CLIN IMMUN, V83, P152, DOI 10.1016/0091-6749(89)90490-9; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; FISH JE, 1984, AM REV RESPIR DIS, V130, P571; GERRITSEN J, 1987, CLIN ALLERGY, V17, P119, DOI 10.1111/j.1365-2222.1987.tb02329.x; HAHN AG, 1984, THORAX, V39, P919, DOI 10.1136/thx.39.12.919; HOLTZMAN MJ, 1980, AM REV RESPIR DIS, V122, P17; JACKSON PJ, 1988, AM REV RESPIR DIS, V138, P784, DOI 10.1164/ajrccm/138.4.784; JENKINS JR, 1989, J ALLERGY CLIN IMMUN, V83, P282; LEMIRE I, 1984, J ALLERGY CLIN IMMUN, V73, P234, DOI 10.1016/S0091-6749(84)80013-5; LEWIS RA, 1984, DRUGS LUNG, P63; MACHIN D, 1987, STATISTICAL TABLES D; MANNING PJ, 1988, AM REV RESPIR DIS, V137, P1323, DOI 10.1164/ajrccm/137.6.1323; MANNING PJ, 1987, J APPL PHYSIOL, V63, P1572, DOI 10.1152/jappl.1987.63.4.1572; PHILLIPS GD, 1989, AM REV RESPIR DIS, V140, P321, DOI 10.1164/ajrccm/140.2.321; RUFFIN RE, 1981, J ALLERGY CLIN IMMUN, V67, P285, DOI 10.1016/0091-6749(81)90023-3; SCHOEFFEL RE, 1980, THORAX, V35, P164, DOI 10.1136/thx.35.3.164; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SHORE S, 1985, J APPL PHYSIOL, V59, P1355, DOI 10.1152/jappl.1985.59.5.1355; STEEL L, 1979, J ALLERGY CLIN IMMUN, V64, P287, DOI 10.1016/0091-6749(79)90146-5	27	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1990	86	2					265	271		10.1016/S0091-6749(05)80075-2	http://dx.doi.org/10.1016/S0091-6749(05)80075-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DV316	2384654				2022-12-18	WOS:A1990DV31600019
J	SCHROECKENSTEIN, DC; MEIERDAVIS, S; YUNGINGER, JW; BUSH, RK				SCHROECKENSTEIN, DC; MEIERDAVIS, S; YUNGINGER, JW; BUSH, RK			ALLERGENS INVOLVED IN OCCUPATIONAL ASTHMA CAUSED BY BABY BREATH (GYPSOPHILA-PANICULATA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WILLIAM S MIDDLETON MEM VET ADM MED CTR,ALLERGY SECT,2500 OVERLOOK TERRACE,MADISON,WI 53705; UNIV WISCONSIN,DEPT MED,ALLERGY CLIN IMMUNOL SECT,MADISON,WI 53706; MAYO CLIN & MAYO FDN,ALLERGY RES LABS,ROCHESTER,MN 55905	US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison; Mayo Clinic								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS SM, 1985, CHEST, V87, pS218, DOI 10.1378/chest.87.5_Supplement.218S; BUTCHER BT, 1986, J ALLERGY CLIN IMMUN, V78, P547, DOI 10.1016/0091-6749(86)90068-0; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; DAVIES RJ, 1983, ALLERGY PRINCIPLES P, P1037; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; KROUTIL LA, 1987, J ALLERGY CLIN IMMUN, V80, P170, DOI 10.1016/0091-6749(87)90126-6; MORRIS W, 1981, AM HERITAGE DICT ENG, P96; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; PETRY RW, 1985, J ALLERGY CLIN IMMUN, V75, P268, DOI 10.1016/0091-6749(85)90056-9; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN, V69, P474, DOI 10.1016/0091-6749(82)90124-5; WIDE L, 1967, LANCET, V2, P1105	12	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1990	86	2					189	193		10.1016/S0091-6749(05)80065-X	http://dx.doi.org/10.1016/S0091-6749(05)80065-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DV316	2384649				2022-12-18	WOS:A1990DV31600008
J	FRIERI, M; LINN, N; SCHWEITZER, M; ANGADI, C; PARDANANI, B				FRIERI, M; LINN, N; SCHWEITZER, M; ANGADI, C; PARDANANI, B			LYMPHADENOPATHIC MASTOCYTOSIS WITH EOSINOPHILIA AND BICLONAL GAMMOPATHY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Discussion									NASSAU CTY MED CTR,DEPT MED,E MEADOW,NY 11554; NASSAU CTY MED CTR,DEPT RADIOL,E MEADOW,NY 11554		FRIERI, M (corresponding author), SUNY STONY BROOK,NASSAU CTY MED CTR,DEPT PATHOL & LABS,2201 HEMPSTEAD TURNPIKE,E MEADOW,NY 11554, USA.							BRUNNING RD, 1983, AM J SURG PATHOL, V7, P425, DOI 10.1097/00000478-198307000-00005; CAPRON JP, 1978, GASTROENTEROLOGY, V74, P595; FRIERI M, 1982, ANN INTERN MED, V97, P220, DOI 10.7326/0003-4819-97-2-220; FRIERI M, 1983, J IMMUNOL, V131, P1942; FRIERI M, 1985, AM J MED, V78, P9, DOI 10.1016/0002-9343(85)90454-1; FRIERI M, 1990, ANN ALLERGY, V64, P345; GAGNON JH, 1975, CAN MED ASSOC J, V112, P1329; HYUN BH, 1983, DIFFERENTIAL DIAGNOS; KLATT EC, 1983, CANCER, V51, P1119, DOI 10.1002/1097-0142(19830315)51:6<1119::AID-CNCR2820510624>3.0.CO;2-M; KYLE RA, 1981, AM J MED, V71, P999, DOI 10.1016/0002-9343(81)90326-0; LENNERT K, 1979, HISTOPATHOLOGY, V3, P349, DOI 10.1111/j.1365-2559.1979.tb03017.x; LEWIS RA, 1984, J ALLERGY CLIN IMMUN, V74, P755, DOI 10.1016/0091-6749(84)90172-6; MEGGS WJ, 1985, ANN INTERN MED, V103, P894, DOI 10.7326/0003-4819-103-6-894; NADER HB, 1980, BIOCHIM BIOPHYS ACTA, V627, P40, DOI 10.1016/0304-4165(80)90121-X; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; SAGHER F, 1967, MASTOCYTOSIS MAST CE; SUN T, 1979, AM J CLIN PATHOL, V72, P5; TRAVIS WD, 1988, MEDICINE, V67, P345, DOI 10.1097/00005792-198811000-00001; WEBB TA, 1982, CANCER, V49, P927, DOI 10.1002/1097-0142(19820301)49:5<927::AID-CNCR2820490517>3.0.CO;2-B; WELLS VJ, 1987, BASIC CLIN IMMUNOLOG	20	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					126	132		10.1016/S0091-6749(05)80132-0	http://dx.doi.org/10.1016/S0091-6749(05)80132-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	2115055				2022-12-18	WOS:A1990DQ68800018
J	CLARK, AR; RACHELEFSKY, G; MASON, PL; GOLDENHERSH, MJ; HOLLINGWORTH, A				CLARK, AR; RACHELEFSKY, G; MASON, PL; GOLDENHERSH, MJ; HOLLINGWORTH, A			THE USE OF RESERVOIR DEVICES FOR THE SIMULTANEOUS DELIVERY OF 2 METERED-DOSE AEROSOLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FISONS PHARMACEUT,RES & DEV LABS,LOUGHBOROUGH,ENGLAND; ALLERGY RES FDN,LOS ANGELES,CA									BELL J H, 1973, Journal of Pharmacy and Pharmacology, V25, P32; CORR D, 1982, J AEROSOL SCI, V13, P1, DOI 10.1016/0021-8502(82)90002-7; CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P101; DOLOVICH M, 1983, CHEST, V84, P36, DOI 10.1378/chest.84.1.36; EPSTEIN SW, 1979, CAN MED ASSOC J, V120, P813; KONIG P, 1985, CHEST, V88, P276, DOI 10.1378/chest.88.2.276; MAY KR, 1968, BACTERIOL REV, V30, P559; MAY KR, 1973, AEROSOL SCI, V4, P235; NEWMAN SP, 1981, THORAX, V36, P52, DOI 10.1136/thx.36.1.52; NEWMAN SP, 1986, CHEST, V89, P551, DOI 10.1378/chest.89.4.551; NEWMAN SP, 1989, THORAX, V44, P706, DOI 10.1136/thx.44.9.706; NEWMAN SP, 1984, THORAX, V39, P936; OREHEK J, 1976, BRIT MED J, V1, P76, DOI 10.1136/bmj.1.6001.76; SAUNDERS KB, 1965, BRIT MED J, V1, P1037, DOI 10.1136/bmj.1.5441.1037; TOBIN MJ, 1982, AM REV RESPIR DIS, V126, P670; WEEKE ER, 1982, EUR J RESPIR DIS, V63, P105	16	14	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				75	79		10.1016/0091-6749(90)90224-R	http://dx.doi.org/10.1016/0091-6749(90)90224-R			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2105348				2022-12-18	WOS:A1990CM37800012
J	GRAMMER, LC; PATTERSON, R; ZEISS, CR				GRAMMER, LC; PATTERSON, R; ZEISS, CR			GUIDELINES FOR THE IMMUNOLOGICAL EVALUATION OF OCCUPATIONAL LUNG-DISEASE - REPORT OF THE SUBCOMMITTEE-ON-IMMUNOLOGIC-EVALUATION-OF-OCCUPATIONAL-IMMUNOLOGIC-LUNG-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University	GRAMMER, LC (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,OCCUPAT MED SECT,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.			Grammer, Leslie/0000-0001-6860-2014	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adkinson NF, 1986, MANUAL CLIN LABORATO, P664; ALANKO K, 1978, CLIN ALLERGY, V8, P25, DOI 10.1111/j.1365-2222.1978.tb00444.x; BALDO BA, 1978, CLIN ALLERGY, V8, P109, DOI 10.1111/j.1365-2222.1978.tb00456.x; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BAUR X, 1979, CLIN ALLERGY, V9, P443, DOI 10.1111/j.1365-2222.1979.tb02507.x; BERNSTEIN DI, 1982, J ALLERGY CLIN IMMUN, V69, P311, DOI 10.1016/S0091-6749(82)80009-2; BERNSTEIN DI, 1983, J ALLERGY CLIN IMMUN, V72, P475, DOI 10.1016/0091-6749(83)90584-5; BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P24, DOI 10.1016/0091-6749(82)90197-X; BLOCK G, 1983, CLIN ALLERGY, V13, P359, DOI 10.1111/j.1365-2222.1983.tb02610.x; BLOCK GT, 1982, JAMA-J AM MED ASSOC, V247, P1600, DOI 10.1001/jama.247.11.1600; BOHNER CB, 1940, J ALLERGY, V12, P290; BURGE PS, 1979, CLIN ALLERGY, V9, P185, DOI 10.1111/j.1365-2222.1979.tb01540.x; BURGE PS, 1980, CLIN ALLERGY, V10, P355, DOI 10.1111/j.1365-2222.1980.tb02119.x; BUTCHER BT, 1977, J ALLERGY CLIN IMMUN, V59, P223, DOI 10.1016/0091-6749(77)90153-1; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; BUTCHER BT, 1977, AM REV RESPIR DIS, V116, P411, DOI 10.1164/arrd.1977.116.3.411; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P146, DOI 10.1016/0091-6749(79)90049-6; Card WI, 1935, LANCET, V2, P1348; CHANYEUNG M, 1987, AM REV RESPIR DIS, V135, P950, DOI 10.1164/arrd.1987.135.4.950; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; CHANYEUNG M, 1986, AM REV RESPIR DIS, V133, P666; COCKCROFT A, 1981, LANCET, V1, P827; COCKCROFT DW, 1980, J ALLERGY CLIN IMMUN, V66, P458, DOI 10.1016/0091-6749(80)90006-8; COLTEN HR, 1975, NEW ENGL J MED, V292, P1050, DOI 10.1056/NEJM197505152922003; CROMWELL O, 1979, CLIN ALLERGY, V9, P109, DOI 10.1111/j.1365-2222.1979.tb01529.x; CURRAN WS, 1961, ANN INTERN MED, V55, P777, DOI 10.7326/0003-4819-55-5-777; DALES RE, 1987, AM REV RESPIR DIS, V135, P817, DOI 10.1164/arrd.1987.135.4.817; DAVIES RJ, 1976, AM REV RESPIR DIS, V114, P1011; DAVIES RJ, 1977, J ALLERGY CLIN IMMUN, V60, P223, DOI 10.1016/0091-6749(77)90134-8; DAVIES RJ, 1974, CLIN ALLERGY, V4, P227; DAVIES RJ, 1984, SEMIN RESPIR MED, V5, P229, DOI 10.1055/s-2007-1011457; DAVIES RJ, 1975, CLIN ALLERGY, V1, P99; DOPICO GA, 1987, CHEST, V73, P3; FALLERONI AE, 1981, J ALLERGY CLIN IMMUN, V68, P156, DOI 10.1016/0091-6749(81)90173-1; FEINBERG SM, 1945, J ALLERGY, V16, P209, DOI 10.1016/0021-8707(45)90001-3; Figley KD, 1928, J AMER MED ASSOC, V90, P79, DOI 10.1001/jama.1928.02690290009003; FINK JN, 1983, ALLERGY PRINCIPLES P, P1085; FINK JN, 1975, INT ARCH ALLER A IMM, V49, P83; FRANKLAND AW, 1965, BRIT J IND MED, V22, P157; GELFAND HH, 1983, J ALLERGY, V34, P374; GLEICH GJ, 1980, NEW ENGL J MED, V302, P617, DOI 10.1056/NEJM198003133021107; GRAMMER LC, 1985, ALLERGIC DISEASES DI, P691; GRAMMER LC, 1987, J OCCUP MED, V29, P206; GRAMMER LC, 1986, INTERNAL MED, P686; GREENBERG M, 1970, BMJ-BRIT MED J, V2, P629, DOI 10.1136/bmj.2.5710.629; HAGY GW, 1966, J ALLERGY, V37, P107; HANSEN PJ, 1974, INT ARCH ALLER A IMM, V47, P498, DOI 10.1159/000231244; HILL D, 1975, MED J AUSTRALIA, V2, P553, DOI 10.5694/j.1326-5377.1975.tb106057.x; JOHANSSON SGO, 1978, ALLERGY PRINCIPLES P, P551; JOHNSON AM, 1986, MANUAL CLIN LABORATO, P14; KARR RM, 1978, J ALLERGY CLIN IMMUN, V62, P143, DOI 10.1016/0091-6749(78)90098-2; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; LUTSKY I, 1984, J ALLERGY CLIN IMMUN, V73, P56, DOI 10.1016/0091-6749(84)90484-6; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; MALO JL, 1982, J ALLERGY CLIN IMMUN, V69, P55, DOI 10.1016/0091-6749(82)90088-4; MCCONNELL LH, 1973, ANN INTERN MED, V78, P888, DOI 10.7326/0003-4819-78-6-888; MEHL VS, 1986, MANUAL CLIN LABORATO, P126; MOLLER DR, 1985, J ALLERGY CLIN IMMUN, V75, P663, DOI 10.1016/0091-6749(85)90091-0; NOVEY HS, 1983, J ALLERGY CLIN IMMUN, V72, P407, DOI 10.1016/0091-6749(83)90507-9; NOVEY HS, 1980, CLIN ALLERGY, V10, P721, DOI 10.1111/j.1365-2222.1980.tb02157.x; PARKES WR, 1982, OCCUPATIONAL LUNG DI, P359; PATTERSON R, 1987, J ALLERGY CLIN IMMUN, V79, P705, DOI 10.1016/0091-6749(87)90199-0; PATTERSON R, 1987, INT ARCH ALLER A IMM, V84, P93, DOI 10.1159/000234404; Pepys J, 1972, Clin Allergy, V2, P391, DOI 10.1111/j.1365-2222.1972.tb01303.x; PEPYS J, 1973, Clinical Allergy, V3, P143, DOI 10.1111/j.1365-2222.1973.tb01318.x; PEPYS J, 1965, THORAX, V20, P21, DOI 10.1136/thx.20.1.21; PEPYS J, 1979, CLIN ALLERGY, V9, P99, DOI 10.1111/j.1365-2222.1979.tb01528.x; PERLMAN F, 1976, ANN ALLERGY, V36, P302; PICKERING CAC, 1972, P ROY SOC MED, V65, P2; REYNOLDS HY, 1977, J CLIN INVEST, V59, P165, DOI 10.1172/JCI108615; SCHUYLER MR, 1978, ANN INTERN MED, V88, P355, DOI 10.7326/0003-4819-88-3-355; SEATON A, 1984, OCCUPATIONAL LUNG DI, P564; SLAVIN RG, 1971, J ALLERGY CLIN IMMUN, V48, P262, DOI 10.1016/0091-6749(71)90026-1; SLOVAK AJM, 1981, THORAX, V36, P906, DOI 10.1136/thx.36.12.906; STANKUS RP, 1982, CRC CR REV TOXICOL, V11, P15, DOI 10.3109/10408448209089847; SUTTON R, 1984, CLIN ALLERGY, V14, P93, DOI 10.1111/j.1365-2222.1984.tb02196.x; SYMINGTON IS, 1981, CLIN ALLERGY, V11, P43, DOI 10.1111/j.1365-2222.1981.tb01564.x; TAYLOR RN, 1986, MANUAL CLIN LABORATO, P951; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN, V69, P474, DOI 10.1016/0091-6749(82)90124-5; VALLIERES M, 1977, AM REV RESPIR DIS, V115, P867; Voller A, 1986, MANUAL CLIN LABORATO, P99; WIDE L, 1967, LANCET, V2, P1105; WILSON MR, 1981, OCCUPATIONAL LUNG DI, P125; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1983, 11 INT C ALL LOND, P219	86	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	2	S			805	814		10.1016/0091-6749(89)90343-6	http://dx.doi.org/10.1016/0091-6749(89)90343-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CC527	2681334				2022-12-18	WOS:A1989CC52700003
J	WIGGINS, CA; DYKEWICZ, MS; PATTERSON, R				WIGGINS, CA; DYKEWICZ, MS; PATTERSON, R			CORTICOSTEROID-DEPENDENT IDIOPATHIC ANAPHYLAXIS - A REPORT OF 5 CASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV, SCH MED,DEPT MED,ALLERGY IMMUNOL SECT, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA	Northwestern University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOXER M, 1987, ARCH INTERN MED, V147, P269, DOI 10.1001/archinte.147.2.269; BOXER MB, 1989, ANN ALLERGY, V62, P201; DAERON M, 1982, J IMMUNOL, V129, P1212; DANON A, 1978, NATURE, V273, P552, DOI 10.1038/273552a0; FLOWER RJ, 1979, NATURE, V278, P456, DOI 10.1038/278456a0; HEIMAN AS, 1984, PROSTAGLANDINS, V27, P335, DOI 10.1016/0090-6980(84)90084-4; KALINER MA, 1984, NER ALLERGY P, V5, P324; KING SJ, 1985, P NATL ACAD SCI USA, V82, P1214, DOI 10.1073/pnas.82.4.1214; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PIPKORN U, 1987, INT ARCH ALLER A IMM, V84, P123, DOI 10.1159/000234410; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHLEIMER RP, 1982, J IMMUNOL, V129, P1632; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P227, DOI 10.1016/0091-6749(85)90048-X; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2; WIGGINS CA, 1988, J ALLERGY CLIN IMMUN, V82, P849, DOI 10.1016/0091-6749(88)90089-9; WOLF B, 1988, J ALLERGY CLIN IMMUN, V81, P238, DOI 10.1016/0091-6749(88)90516-7	16	14	15	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1989	84	3					311	315		10.1016/0091-6749(89)90413-2	http://dx.doi.org/10.1016/0091-6749(89)90413-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AR199	2778237				2022-12-18	WOS:A1989AR19900006
J	WEISS, ME; TRENT, P; FISHER, R; NORMAN, PS; WATERBURY, WE; ADKINSON, NF				WEISS, ME; TRENT, P; FISHER, R; NORMAN, PS; WATERBURY, WE; ADKINSON, NF			RABBIT F(AB')2 ANTIHUMAN IGE IS A UNIVERSAL SKIN-TEST REAGENT IN THE EVALUATION OF SKIN MAST-CELL DE-GRANULATION INVIVO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DIV CLIN IMMUNOL,5601 LOCH RAVEN BLVD,BALTIMORE,MD 21239	Johns Hopkins University								Adkinson NF, 1986, MANUAL CLIN LABORATO, P664; BERNSTEIN DI, 1988, J ALLERGY CLIN IMMUN, V81, P6, DOI 10.1016/0091-6749(88)90213-8; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; CAPRON A, 1986, IMMUNOL TODAY, V7, P15, DOI 10.1016/0167-5699(86)90184-2; COHEN RW, 1986, J ALLERGY CLIN IMMUN, V77, P802, DOI 10.1016/0091-6749(86)90377-5; CONROY MC, 1977, FED PROC, V36, P1216; CONROY MC, 1977, J IMMUNOL, V118, P1317; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DUNBAR WP, 1917, J HYG CAMB, V13, P105; GALLI SJ, 1988, ALLERGY PRINCIPLES P, P106; GRONNEBERG R, 1985, ALLERGY, V40, P36, DOI 10.1111/j.1398-9995.1985.tb04152.x; ISHIZAKA K, 1968, J IMMUNOL, V100, P554; ISHIZAKA K, 1969, J IMMUNOL, V103, P588; KUNKEL HG, 1961, J CLIN INVEST, V40, P117, DOI 10.1172/JCI104224; LAI CKW, 1988, J ALLERGY CLIN IMMUN, V81, P231, DOI 10.1016/0091-6749(88)90486-1; LICHTENSTEIN LM, 1970, IMMUNOLOGY, V19, P831; MACGLASHAN D, 1983, J IMMUNOL, V130, P2330; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; NEWCOMB RW, 1969, J ALLERGY, V43, P292, DOI 10.1016/0021-8707(69)90150-6; NGUYEN K, 1988, FASEB J, V2, pA1251; Norman P, 1986, MANUAL CLIN LABORATO, P660; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; SCHROHENLOHER RE, 1966, J CLIN INVEST, V45, P501, DOI 10.1172/JCI105364; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; TAKAISHI T, 1984, J ALLERGY CLIN IMMUN, V74, P297; TRIGGIANI M, IN PRESS INT ARCH AL; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; WARNER JA, 1986, J IMMUNOL, V136, P2583	30	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1989	83	6					1040	1048		10.1016/0091-6749(89)90445-4	http://dx.doi.org/10.1016/0091-6749(89)90445-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC235	2471717				2022-12-18	WOS:A1989AC23500006
J	JAGGI, KS; EKRAMODDOULLAH, AKM; KISIL, FT; DZUBAFISCHER, JMM; RECTOR, ES; SEHON, AH				JAGGI, KS; EKRAMODDOULLAH, AKM; KISIL, FT; DZUBAFISCHER, JMM; RECTOR, ES; SEHON, AH			IDENTIFICATION OF 2 DISTINCT ALLERGENIC SITES ON RYEGRASS-POLLEN ALLERGEN, LOL-P-IV	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,DEPT IMMUNOL,MRC,ALLERGY RES GRP,WINNIPEG R3E 0W3,MANITOBA,CANADA	University of Manitoba								BOSE R, 1988, IMMUNOLOGY, V63, P579; BOSE R, 1986, IMMUNOLOGY, V59, P309; CHAPMAN MD, 1987, J IMMUNOL, V139, P1479; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; EKRAMODDOULLAH AKM, 1984, MOL IMMUNOL, V21, P375, DOI 10.1016/0161-5890(84)90034-8; EKRAMODDOULLAH AKM, 1986, MOL IMMUNOL, V23, P111, DOI 10.1016/0161-5890(86)90031-3; EKRAMODDOULLAH AKM, 1987, J IMMUNOL, V138, P1739; EKRAMODDOULLAH AKM, 1983, MOL IMMUNOL, V20, P465, DOI 10.1016/0161-5890(83)90027-5; ESCH RE, 1987, J ALLERGY CLIN IMMUN, V79, P489, DOI 10.1016/0091-6749(87)90367-8; FORD SA, 1986, INT ARCH ALLER A IMM, V81, P193, DOI 10.1159/000234134; HEYNINGEN VV, 1983, J IMMUNOL METHODS, V62, P147; HOWLETT BJ, 1981, BIOCHEM J, V197, P695, DOI 10.1042/bj1970695; JACKSON DC, 1982, INFECT IMMUN, V37, P912, DOI 10.1128/IAI.37.3.912-918.1982; KAHN CR, 1986, MOL IMMUNOL, V23, P1281, DOI 10.1016/0161-5890(86)90013-1; KLINMAN NR, 1969, CLIN EXP IMMUNOL, V4, P473; LIU FT, 1984, HYBRIDOMA, V3, P277, DOI 10.1089/hyb.1984.3.277; MARSH DG, 1987, J ALLERGY CLIN IMMUN, V80, P639, DOI 10.1016/0091-6749(87)90282-X; MARSH DG, 1975, ANTIGENS, V3, P271; MAZUR G, 1987, J ALLERGY CLIN IMMUN, V80, P876, DOI 10.1016/S0091-6749(87)80280-4; OLSON JR, 1986, J IMMUNOL, V136, P2109; REIMER CB, 1984, HYBRIDOMA, V3, P263, DOI 10.1089/hyb.1984.3.263; UNDERWOOD PA, 1984, MOL IMMUNOL, V21, P663, DOI 10.1016/0161-5890(84)90052-X	23	14	15	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					845	852		10.1016/0091-6749(89)90024-9	http://dx.doi.org/10.1016/0091-6749(89)90024-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2708744	Bronze			2022-12-18	WOS:A1989U342000021
J	OHICKEY, SP; ARM, JP; REES, PJ; LEE, TH				OHICKEY, SP; ARM, JP; REES, PJ; LEE, TH			AIRWAY RESPONSIVENESS TO METHACHOLINE AFTER INHALATION OF NEBULIZED HYPERTONIC SALINE IN BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT ALLERGY & ALLIED RESP DISORDERS,LONDON SE1 9RT,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT THORAC MED,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059				ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; BASCOM R, 1986, AM REV RESPIR DIS, V134, P248; BELCHER NG, 1988, J ALLERGY CLIN IMMUN, V81, P100, DOI 10.1016/0091-6749(88)90227-8; BELCHER NG, 1987, AM REV RESPIR DIS, V135, P822, DOI 10.1164/arrd.1987.135.4.822; BELCHER NG, 1988, AM REV RESPIR DIS, V137, P1026, DOI 10.1164/ajrccm/137.5.1026; CHOWIENCZYK PJ, 1981, J APPL PHYSIOL, V50, P672, DOI 10.1152/jappl.1981.50.3.672; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; EISER NM, 1980, CLIN SCI, V58, P537, DOI 10.1042/cs0580537; FORESI A, 1986, CHEST, V90, P822, DOI 10.1378/chest.90.6.822; HAHN AG, 1984, THORAX, V39, P919, DOI 10.1136/thx.39.12.919; HOLTZMAN MJ, 1980, AM REV RESPIR DIS, V122, P17; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; MAGNUSSEN H, 1986, THORAX, V41, P667, DOI 10.1136/thx.41.9.667; MALO JL, 1986, B EUR PHYSIOPATH RES, V22, P473; MATTOLI S, 1987, J ALLERGY CLIN IMMUN, V79, P678, DOI 10.1016/S0091-6749(87)80165-3; MATTOLI S, 1987, ANN ALLERGY, V58, P134; OBYRNE PM, 1986, AM REV RESPIR DIS, V134, P69; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285, DOI 10.1136/bmj.283.6302.1285; SMITH CM, 1987, J ALLERGY CLIN IMMUN, V79, P85, DOI 10.1016/S0091-6749(87)80021-0; STEARNS DR, 1981, J APPL PHYSIOL, V50, P503, DOI 10.1152/jappl.1981.50.3.503; SUZUKI S, 1985, ANN ALLERGY, V54, P136	22	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	1				472	476		10.1016/0091-6749(89)90136-X	http://dx.doi.org/10.1016/0091-6749(89)90136-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4489	2645345				2022-12-18	WOS:A1989T448900017
J	BERNSTEIN, IL; BERNSTEIN, DI				BERNSTEIN, IL; BERNSTEIN, DI			REACTIVE AIRWAYS DISEASE SYNDROME (RADS) AFTER EXPOSURE TO TOXIC AMMONIA FUMES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	14	15	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					173	173						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419					2022-12-18	WOS:A1989T041900031
J	JIN, ZW; CLEVELAND, RP; KAUFMAN, DB				JIN, ZW; CLEVELAND, RP; KAUFMAN, DB			IMMUNODEFICIENCY IN PATIENTS WITH HEMOPHILIA - AN UNDERLYING DEFICIENCY AND LACK OF CORRELATION WITH FACTOR REPLACEMENT THERAPY OR EXPOSURE TO HUMAN IMMUNODEFICIENCY VIRUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MICHIGAN STATE UNIV,DEPT PEDIAT & HUMAN DEV,B338 LIFE SCI BLDG,E LANSING,MI 48824	Michigan State University			Kaufman, Dixon B/E-4524-2016					ABO T, 1981, J IMMUNOL, V127, P1024; BRIEVA JA, 1985, CLIN EXP IMMUNOL, V59, P491; DESHAZO RD, 1983, ANN INTERN MED, V99, P159, DOI 10.7326/0003-4819-99-2-159; ENGVALL E, 1972, J IMMUNOL, V109, P127; GILL JC, 1986, J PEDIATR-US, V108, P511, DOI 10.1016/S0022-3476(86)80824-1; GJERSET GF, 1985, BLOOD, V66, P718; GORSKI A, 1986, CLIN IMMUNOL IMMUNOP, V40, P447, DOI 10.1016/0090-1229(86)90189-3; JIN Z, 1984, Pediatric Research, V18, p257A; KREISS JK, 1986, AM J MED, V80, P345, DOI 10.1016/0002-9343(86)90704-7; LANDAY A, 1983, J CLIN INVEST, V71, P1500, DOI 10.1172/JCI110904; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LEDERMAN MM, 1985, ANN INTERN MED, V102, P753, DOI 10.7326/0003-4819-102-6-753; LEDERMAN MM, 1983, NEW ENGL J MED, V308, P79, DOI 10.1056/NEJM198301133080205; LEE CA, 1983, LANCET, V2, P158; MENITOVE JE, 1983, NEW ENGL J MED, V308, P83, DOI 10.1056/NEJM198301133080206; PAHWA S, 1985, P NATL ACAD SCI USA, V82, P8198, DOI 10.1073/pnas.82.23.8198; PAHWA S, 1986, P NATL ACAD SCI USA, V83, P9124, DOI 10.1073/pnas.83.23.9124; PORZSOLT F, 1984, BLUT, V49, P61, DOI 10.1007/BF00320385; SEKI H, 1985, CLIN IMMUNOL IMMUNOP, V34, P27, DOI 10.1016/0090-1229(85)90004-2; SHANNON BT, 1986, J CLIN IMMUNOL, V6, P121, DOI 10.1007/BF00918744; STEIN SF, 1985, BLOOD, V66, P973; SULLIVAN JL, 1986, J PEDIATR-US, V108, P504, DOI 10.1016/S0022-3476(86)80823-X; WEINTRUB PS, 1983, J PEDIATR-US, V103, P692, DOI 10.1016/S0022-3476(83)80459-4; 1985, MMWR, V34, P241; 1986, MMWR, V35, P171	25	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					165	170		10.1016/0091-6749(89)90492-2	http://dx.doi.org/10.1016/0091-6749(89)90492-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419	2913135				2022-12-18	WOS:A1989T041900023
J	MROWIETZ, U; KONTER, U; TRAUT, R; SCHRODER, JM; CHRISTOPHERS, E				MROWIETZ, U; KONTER, U; TRAUT, R; SCHRODER, JM; CHRISTOPHERS, E			ATOPIC-DERMATITIS - INFLUENCE OF BACTERIAL-INFECTIONS ON HUMAN MONOCYTE AND NEUTROPHIL GRANULOCYTE FUNCTIONAL ACTIVITIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MROWIETZ, U (corresponding author), UNIV KIEL,DEPT DERMATOL,SCHITTENHELMSTR 7,D-2300 KIEL 1,FED REP GER.		Schroeder, Jens M/B-3994-2009; Mrowietz, U/B-1645-2010	Mrowietz, U/0000-0002-9539-0712				ALTHAUS D, 1980, INT ARCH ALLER A IMM, V61, P321, DOI 10.1159/000232454; BOYUM A, 1968, SCAND J CLIN LAB INV, V21, P17; BRIHEIM G, 1987, BIOL PHAGOCYTES HLTH, P89; CHRISTOPHERS E, 1987, ARCH DERMATOL RES, V279, pS48, DOI 10.1007/BF00585919; DAHL MV, 1976, ARCH DERMATOL, V112, P1387, DOI 10.1001/archderm.112.10.1387; DAHL MV, 1978, ARCH DERMATOL, V114, P544, DOI 10.1001/archderm.114.4.544; DESHAZO RD, 1982, J ALLERGY CLIN IMMUN, V69, P429, DOI 10.1016/0091-6749(82)90117-8; ENGLISH D, 1981, J IMMUNOL, V126, P165; FERNANDEZ HN, 1976, J IMMUNOL, V117, P1688; FREUNDLICH B, 1983, J IMMUNOL METHODS, V62, P31, DOI 10.1016/0022-1759(83)90107-2; FURUKAWA CT, 1978, J ALLERGY CLIN IMMUN, V61, P288, DOI 10.1016/0091-6749(78)90049-0; GALLI E, 1983, ALLERGOL IMMUNOPATH, V11, P189; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; HANIFIN JM, 1986, J ALLERGY CLIN IMMUN, V78, P563, DOI 10.1016/0091-6749(86)90071-0; HANIFIN JM, 1977, ARCH DERMATOL, V113, P1383, DOI 10.1001/archderm.113.10.1383; HILL HR, 1974, J CLIN INVEST, V53, P996, DOI 10.1172/JCI107666; HILL HR, 1974, LANCET, P183; HUBER H, 1968, SCIENCE, V162, P1281, DOI 10.1126/science.162.3859.1281; LINK AS, 1979, J INFECT DIS, V140, P517, DOI 10.1093/infdis/140.4.517; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; MOWAT AG, 1971, BRIT MED J, V3, P617, DOI 10.1136/bmj.3.5775.617; MROWIETZ U, 1988, SCAND J IMMUNOL, V28, P139, DOI 10.1111/j.1365-3083.1988.tb02425.x; MROWIETZ U, 1987, IMMUNOBIOLOGY, V174, P460, DOI 10.1016/S0171-2985(87)80018-9; MROWIETZ U, 1987, ACTA PATHOL MIC SC, V94, P1; RASANEN L, 1987, ARCH DERMATOL RES, V279, P215, DOI 10.1007/BF00417317; RING J, 1983, J AM ACAD DERMATOL, V8, P378, DOI 10.1016/S0190-9622(83)70043-5; ROGGE JL, 1976, ARCH DERMATOL, V112, P1391, DOI 10.1001/archderm.112.10.1391; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; SCHRODER JM, 1985, J INVEST DERMATOL, V85, P194, DOI 10.1111/1523-1747.ep12276664; SETSUKO I, 1983, CLIN EXP IMMUNOL, V51, P407; SNYDERMAN R, 1977, J ALLERGY CLIN IMMUN, V60, P121, DOI 10.1016/0091-6749(77)90037-9; SOLOMKIN JS, 1981, SURGERY, V90, P319; TERNOWITZ T, 1986, ARCH DERMATOL RES, V278, P454, DOI 10.1007/BF00455163	33	14	15	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					1027	1036		10.1016/0091-6749(88)90140-6	http://dx.doi.org/10.1016/0091-6749(88)90140-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	2849616	Bronze			2022-12-18	WOS:A1988R631100011
J	NAIR, MPN; SCHWARTZ, SA				NAIR, MPN; SCHWARTZ, SA			IMMUNOREGULATION OF HUMAN NATURAL-KILLER CELLS (NK) BY CORTICOSTEROIDS - INHIBITORY EFFECT OF CULTURE SUPERNATANTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,DEPT EPIDEMIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	NAIR, MPN (corresponding author), UNIV MICHIGAN,DEPT PEDIAT,109 S OBSERV,RM 2039 SPH-1,ANN ARBOR,MI 48109, USA.				NCI NIH HHS [R0I CA 35922] Funding Source: Medline; NIAAA NIH HHS [P50AA07378] Funding Source: Medline; PHSPO CDC HHS [SO7 R405383] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007378] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); PHSPO CDC HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BOWEN DL, 1984, J IMMUNOL, V133, P1885; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADLEY TP, 1982, J IMMUNOL, V129, P2260; CUDKOWICZ G, 1979, IMMUNOL REV, V44, P13, DOI 10.1111/j.1600-065X.1979.tb00266.x; CUDKOWICZ G, 1979, DEV IMMUNOBIOL, P1; DAMORE PJ, 1985, J IMMUNOL, V134, P272; FAUCI AS, 1975, BLOOD, V46, P235; GERRARD TL, 1984, CELL IMMUNOL, V85, P330, DOI 10.1016/0008-8749(84)90247-8; HALL TJ, 1983, CLIN EXP IMMUNOL, V54, P493; HEBERT J, 1980, CELL IMMUNOL, V54, P49, DOI 10.1016/0008-8749(80)90188-4; Herberman R B, 1978, Adv Cancer Res, V27, P305; HOCHMAN PS, 1979, J IMMUNOL, V123, P968; HOLBROOK NJ, 1983, CANCER RES, V43, P4019; KADISH AS, 1981, J IMMUNOL, V127, P1817; LANGHOFF E, 1986, LANCET, V1, P1296; LIPSMEYER EA, 1972, ARTHRITIS RHEUM-US, V15, P183, DOI 10.1002/art.1780150207; LOMNITZER R, 1983, CLIN IMMUNOL IMMUNOP, V27, P378, DOI 10.1016/0090-1229(83)90090-9; MAGE M, 1981, EUR J IMMUNOL, V11, P228, DOI 10.1002/eji.1830110312; MARDER P, 1983, IMMUNOPHARMACOLOGY, V6, P155, DOI 10.1016/0162-3109(83)90008-5; MCADAM L, 1974, ARTHRITIS RHEUM, V17, P92, DOI 10.1002/art.1780170114; MORETTA L, 1981, J EXP MED, V154, P569, DOI 10.1084/jem.154.2.569; MUUL LM, 1984, J IMMUNOL, V132, P1202; NAIR MPN, 1981, J IMMUNOL, V126, P2221; NAIR MPN, 1984, J IMMUNOL, V132, P2876; NAIR MPN, 1981, CELL IMMUNOL, V58, P9, DOI 10.1016/0008-8749(81)90144-1; NAIR MPN, 1982, J IMMUNOL, V129, P2511; NAIR MPN, 1983, CLIN RES, V31, P349; NAIR PNM, 1980, INT J CANCER, V25, P667, DOI 10.1002/ijc.2910250518; OTOOLE C, 1974, J EXP MED, V139, P457, DOI 10.1084/jem.139.3.457; POLLACK SB, 1979, J IMMUNOL, V122, P718; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; ROCKLIN RE, 1978, CELL IMMUNOL, V37, P162, DOI 10.1016/0008-8749(78)90184-3; SHARMA SD, 1984, CELL IMMUNOL, V85, P125, DOI 10.1016/0008-8749(84)90284-3; SLADE JD, 1983, J LAB CLIN MED, V101, P479; TAKAHASHI K, 1985, J CANCER RES CLIN, V109, P78, DOI 10.1007/BF01884259; TIMONEN T, 1980, J IMMUNOL METHODS, V36, P285, DOI 10.1016/0022-1759(80)90133-7	36	14	15	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					1089	1097		10.1016/0091-6749(88)90148-0	http://dx.doi.org/10.1016/0091-6749(88)90148-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	3204252				2022-12-18	WOS:A1988R631100019
J	FREUDENBERGER, T; GRIZZANTI, JN; ROSENSTREICH, DL				FREUDENBERGER, T; GRIZZANTI, JN; ROSENSTREICH, DL			NATURAL IMMUNITY TO DUST MITES IN PATIENTS WITH CHRONIC RHINOSINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT ALLERGY & IMMUNOL,CHANIN 628,1300 MORRIS PK AVE,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023169, R01AI017934] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI-17934, R01 AI-23169] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; BACHOFEN H, 1967, DEUT MED WOCHENSCHR, V92, P1597, DOI 10.1055/s-0028-1106011; BERMAN SZ, 1974, J ALLERGY CLIN IMMUN, V53, P311, DOI 10.1016/0091-6749(74)90111-0; BULLEN SS, 1932, J ALLERGY, V4, P402; BURR ML, 1980, THORAX, V35, P513, DOI 10.1136/thx.35.7.513; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; HOMBURGER HA, 1986, J ALLERGY CLIN IMMUN, V77, P427, DOI 10.1016/0091-6749(86)90176-4; HONG R, 1974, PROGR CLIN IMMUNOLOG, V2, P14; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; MAUNSELL K, 1968, LANCET, V1, P1267; MIDDLETON E, 1983, ALLERGY PRINCIPLES P, P1229; MITCHELL EB, 1985, CLIN ALLERGY, V15, P235, DOI 10.1111/j.1365-2222.1985.tb02280.x; MORITA Y, 1975, ANN ALLERGY, V35, P361; PEPYS J, 1978, IMMUNOLOGICAL DISEAS, P692; PHIPATAN.CS, 1974, ARCH OTOLARYNGOL, V100, P109; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P505, DOI 10.1016/0091-6749(87)90369-1; SLAVIN RG, 1982, ANN ALLERGY, V49, P76; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; SOLIMAN MY, 1986, AM REV RESPIR DIS, V134, P962, DOI 10.1164/arrd.1986.134.5.962; Spieksma F. Th. M., 1967, Acarologia, V9, P226; TAYLOR G, 1971, Clinical Allergy, V1, P63, DOI 10.1111/j.1365-2222.1971.tb02448.x; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; WALSHAW MJ, 1986, Q J MED, V58, P199; Zar J.H, 1999, BIOSTAT ANAL, V4th; 1971, DIGEST HLTH STATISTI	27	14	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				855	862		10.1016/0091-6749(88)90090-5	http://dx.doi.org/10.1016/0091-6749(88)90090-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	3192869				2022-12-18	WOS:A1988R170800021
J	DOLOVICH, J; RUHNO, J; SAUDER, DN; AHLSTEDT, S; HARGREAVE, FE				DOLOVICH, J; RUHNO, J; SAUDER, DN; AHLSTEDT, S; HARGREAVE, FE			ISOLATED LATE CUTANEOUS SKIN-TEST RESPONSE TO AMPICILLIN - A DISTINCT ENTITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											DOLOVICH, J (corresponding author), MCMASTER UNIV,MED CTR,DEPT PEDIAT,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA.							ASKENASE PW, 1976, J CLIN INVEST, V58, P1145, DOI 10.1172/JCI108567; BUTTAR K, 1981, ANN ALLERGY, V46, P183; DEHAAN P, 1986, ALLERGY, V41, P75; DESHAZO RD, 1982, J ALLERGY CLIN IMMUN, V69, P229, DOI 10.1016/0091-6749(82)90104-X; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1972, J ALLERGY CLIN IMMUN, V49, P43, DOI 10.1016/0091-6749(72)90122-4; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289, DOI 10.1111/apm.1966.66.3.289; FELLNER MJ, 1969, J AMER MED ASSOC, V210, P2061, DOI 10.1001/jama.1969.03160370045008; KOHLER PF, 1983, ALLERGY PRINCIPLES P, P176; KOPONEN M, 1986, J ALLERGY CLIN IMMUN, V78, P645, DOI 10.1016/0091-6749(86)90083-7; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; PELIKAN Z, 1983, ALLERGY, V38, P209; REDMOND AP, 1967, J ALLERGY, V39, P51, DOI 10.1016/0021-8707(67)90127-X; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TAGAMI H, 1983, ARCH DERMATOL, V119, P910, DOI 10.1001/archderm.119.11.910; WARREN CPW, 1977, CLIN ALLERGY, V7, P303, DOI 10.1111/j.1365-2222.1977.tb01458.x; ZETTERSTROM O, 1978, CLIN ALLERGY, V8, P77, DOI 10.1111/j.1365-2222.1978.tb00452.x	18	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					676	679		10.1016/0091-6749(88)90982-7	http://dx.doi.org/10.1016/0091-6749(88)90982-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	3171007				2022-12-18	WOS:A1988Q639900022
J	BRUMMUND, W; KURUP, VP; RESNICK, A; MILSON, TJ; FINK, JN				BRUMMUND, W; KURUP, VP; RESNICK, A; MILSON, TJ; FINK, JN			IMMUNOLOGICAL RESPONSE TO FAENIA-RECTIVIRGULA (MICROPOLYSPORA-FAENI) IN A DAIRY FARM FAMILY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CLEMENT J ZABLOCKI VET ADM MED CTR,RES SERV 151,MILWAUKEE,WI 53295; MED COLL WISCONSIN,DEPT MED,ALLERGY IMMUNOL SECT,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT SURG,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023071] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 23071] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBORIAK JJ, 1965, J LAB CLIN MED, V65, P600; CORBAZ R, 1974, ASPERGILLOSIS FARMER, P12; CORMIER Y, 1984, AM REV RESPIR DIS, V130, P1046; FINK JN, 1984, J ALLERGY CLIN IMMUN, V74, P1, DOI 10.1016/0091-6749(84)90077-0; FLAHERTY DK, 1976, AM REV RESPIR DIS, V114, P1093; HOLLICK GE, 1983, LAB MED, V14, P39; KURUP VP, 1979, SABOURAUDIA, V17, P163; KURUP VP, 1975, J CLIN MICROBIOL, V2, P55; KURUP VP, 1986, ZBL BAKT-INT J MED M, V261, P509; KURUP VP, 1977, INFECT IMMUN, V15, P608, DOI 10.1128/IAI.15.2.608-613.1977; KURUP VP, 1976, MYCOLOGIA, V68, P662, DOI 10.2307/3758987; KURUP VP, 1984, MOL IMMUNOL, V21, P215, DOI 10.1016/0161-5890(84)90076-2; KURUP VP, 1978, MICROBIOS, V19, P191; LACEY J, 1974, ASPERGILLOSIS FARMER, P16; LEATHERMAN JW, 1984, ANN INTERN MED, V100, P390, DOI 10.7326/0003-4819-100-3-390; MARX J J JR, 1973, Clinical Research, V21, P852; MCSHARRY C, 1983, CLIN EXP IMMUNOL, V54, P282; MILSON TJ, 1986, J IMMUNOL METHODS, V87, P155, DOI 10.1016/0022-1759(86)90525-9; MILSON TJ, 1982, J CLIN LAB IMMUNOL, V7, P205; MORNEX JF, 1984, J ALLERGY CLIN IMMUN, V74, P719, DOI 10.1016/0091-6749(84)90236-7; OUCHTERLONY O, 1953, ACTA PATHOL MIC SC, V32, P231; PEPYS J, 1969, MONOGRAPHS ALLERGY, V4; TREUHAFT MW, 1981, J ALLERGY CLIN IMMUN, V67, P375, DOI 10.1016/0091-6749(81)90083-X; VANSELOW NA, 1967, MANUAL CLIN ALLERGY, P59; WENZEL FJ, 1974, AM REV RESPIR DIS, V109, P464; YOCUM MW, 1976, AM J MED, V61, P939, DOI 10.1016/0002-9343(76)90419-8	26	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					190	195		10.1016/0091-6749(88)90998-0	http://dx.doi.org/10.1016/0091-6749(88)90998-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	3042838				2022-12-18	WOS:A1988P874100008
J	PIENKOWSKI, MM; KAZMIER, WJ; ADKINSON, NF				PIENKOWSKI, MM; KAZMIER, WJ; ADKINSON, NF			BASOPHIL HISTAMINE-RELEASE REMAINS UNAFFECTED BY CLINICAL DESENSITIZATION TO PENICILLIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, GOOD SAMARITAN HOSP,SCH MED,DEPT MED, DIV CLIN IMMUNOL,5601 LOCH RAVEN BLVD, BALTIMORE, MD 21239 USA	Johns Hopkins University								ADKINSON NF, 1971, NEW ENGL J MED, V285, P22, DOI 10.1056/NEJM197107012850104; ADKINSON NF, 1979, J IMMUNOL, V122, P965; BOLTON AE, 1973, BIOCHIM BIOPHYS ACTA, V329, P318, DOI 10.1016/0304-4165(73)90296-1; BROWN LA, 1982, J ALLERGY CLIN IMMUN, V69, P51, DOI 10.1016/0091-6749(82)90087-2; DAVID B, 1976, CR ACAD SCI D NAT, V283, P1811; de Weck A L, 1972, Int Arch Allergy Appl Immunol, V42, P798; DEMBO M, 1979, J IMMUNOL, V123, P1864; FELLNER MJ, 1970, J ALLERGY, V45, P55, DOI 10.1016/0021-8707(70)90017-1; GOREVIC PD, 1981, J ALLERGY CLIN IMMUN, V68, P267, DOI 10.1016/0091-6749(81)90150-0; GRAYBILL JR, 1974, SOUTH MED J, V67, P62, DOI 10.1097/00007611-197401000-00017; KAZIMIERCZAK W, 1984, AM REV RESPIR DIS, V129, P592; KIMURA I, 1985, CLIN ALLERGY, V15, P1, DOI 10.1111/j.1365-2222.1985.tb02248.x; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MACGLASHAN D, 1983, J IMMUNOL, V130, P2330; MATTSON JR, 1975, ARCH INTERN MED, V135, P818, DOI 10.1001/archinte.135.6.818; MENDOZA GR, 1982, INT ARCH ALLER A IMM, V68, P101, DOI 10.1159/000233076; MENDOZA GR, 1982, INT ARCH ALLER A IMM, V69, P282, DOI 10.1159/000233185; NACLERIO R, 1983, J ALLERGY CLIN IMMUN, V71, P294, DOI 10.1016/0091-6749(83)90083-0; OSTERBALLE O, 1982, ALLERGY, V37, P491, DOI 10.1111/j.1398-9995.1982.tb02332.x; PEDERSEN.J, 1969, ACTA ALLERGOL, V24, P333, DOI 10.1111/j.1398-9995.1969.tb03748.x; REISMAN RE, 1962, J ALLERGY, V33, P178, DOI 10.1016/0021-8707(62)90007-2; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SOBOTKA AK, 1979, J IMMUNOL, V122, P511; STAHLSKOV P, 1977, CLIN EXP IMMUNOL, V27, P432; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P500, DOI 10.1016/0091-6749(82)90174-9; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P275, DOI 10.1016/S0091-6749(82)80004-3; VANARSDEL P, 1961, J ALLERGY, V32, P348, DOI 10.1016/0021-8707(61)90103-4	28	14	14	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					171	178		10.1016/0091-6749(88)90996-7	http://dx.doi.org/10.1016/0091-6749(88)90996-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	2457040	Bronze			2022-12-18	WOS:A1988P874100006
J	AHMED, T; KIM, CS; DANTA, I				AHMED, T; KIM, CS; DANTA, I			INHIBITION OF ANTIGEN-INDUCED BRONCHOCONSTRICTION BY A NEW CALCIUM-ANTAGONIST, GALLOPAMIL - COMPARISON WITH CROMOLYN SODIUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											AHMED, T (corresponding author), UNIV MIAMI,MT SINAI MED CTR,SCH MED,DIV PULM DIS,4300 ALTON RD,MIAMI BEACH,FL 33140, USA.							AHMED T, 1985, CHEST, V88, P176, DOI 10.1378/chest.88.2.176; AHMED T, 1985, CHEST, V88, pS142; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; CARPENTER N, 1986, AM REV RESPIR DIS, V133, pA14; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Conover WJ, 1980, PRACTICAL NONPARAMET, P299; COX J S G, 1971, British Journal of Diseases of the Chest, V65, P189, DOI 10.1016/0007-0971(71)90028-3; D'BROT J, 1987, American Review of Respiratory Disease, V135, pA312; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; FLECKENSTEIN A, 1977, ANNU REV PHARMACOL, V17, P149, DOI 10.1146/annurev.pa.17.040177.001053; FLECKENSTEINGRU.C, 1984, GALLOPAMIL PHARM CLI, P33; FOREMAN JC, 1977, J PHYSIOL-LONDON, V271, P193, DOI 10.1113/jphysiol.1977.sp011996; GOODMAN FR, 1981, NEW PERSPECTIVES CAL, P217; HENDERSON AF, 1983, AM REV RESPIR DIS, V127, P549, DOI 10.1164/arrd.1983.127.5.549; HEYDER J, 1980, GENERATION AEROSOLS, P65; HIMORI N, 1980, BRIT J PHARMACOL, V68, P595, DOI 10.1111/j.1476-5381.1980.tb10848.x; ISHIZAKA T, 1979, P NATL ACAD SCI USA, V76, P5858, DOI 10.1073/pnas.76.11.5858; KIM C S, 1984, American Review of Respiratory Disease, V129, pA110; MIDDLETON E, 1980, J PHARM SCI-US, V69, P243, DOI 10.1002/jps.2600690244; NEUSS H, 1984, GALLOPAMIL PHARM CLI, P99; PATEL KR, 1983, CLIN ALLERGY, V13, P119, DOI 10.1111/j.1365-2222.1983.tb02578.x; POPA VT, 1984, AM REV RESPIR DIS, V130, P1006; ROSENTHAL RR, 1975, J ALLERGY CLIN IMMUN, V56, P338, DOI 10.1016/0091-6749(75)90127-X; RUSSI EW, 1983, AM REV RESPIR DIS, V127, P675; RUSSI EW, 1984, CHEST, V86, P475, DOI 10.1378/chest.86.3.475; RUSSI EW, 1985, CHEST, V88, P74, DOI 10.1378/chest.88.1.74; SO SY, 1982, CLIN ALLERGY, V12, P595, DOI 10.1111/j.1365-2222.1982.tb02558.x; SOLWAY J, 1985, AM REV RESPIR DIS, V132, P666; YU CP, 1983, J AEROSOL SCI, V14, P599, DOI 10.1016/0021-8502(83)90065-4	32	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	1				852	858		10.1016/0091-6749(88)90942-6	http://dx.doi.org/10.1016/0091-6749(88)90942-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7036	3131404				2022-12-18	WOS:A1988N703600014
J	HIRSHMAN, CA; AUSTIN, DR; KETTELKAMP, NS				HIRSHMAN, CA; AUSTIN, DR; KETTELKAMP, NS			ENHANCED BRONCHOALVEOLAR LAVAGE MAST-CELLS HISTAMINE RELEASABILITY IN ALLERGIC DOGS WITH AND WITHOUT AIRWAY HYPERRESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									OREGON HLTH SCI UNIV,DEPT ANESTHESIOL,PORTLAND,OR 97201	Oregon Health & Science University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025831] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 25831] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEFUS AD, 1982, J IMMUNOL, V128, P2475; BIENENSTOCK J, 1983, MONOGR ALLERGY, V18, P124; BIENENSTOCK J, 1985, INT ARCH ALLER A IMM, V77, P126, DOI 10.1159/000233766; CONROY MC, 1977, J IMMUNOL, V118, P1317; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289, DOI 10.1111/apm.1966.66.3.289; ENNIS M, 1982, AGENTS ACTIONS, V12, P60, DOI 10.1007/BF01965108; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; GLANTZ SA, 1981, PRIMER BIOSTATISTICS, P87; GODARD P, 1981, NOUV PRESSE MED, V10, P3141; HIRSHMAN CA, 1984, J APPL PHYSIOL, V56, P1272, DOI 10.1152/jappl.1984.56.5.1272; HIRSHMAN CA, 1987, J ALLERGY CLIN IMMUN, V79, P46, DOI 10.1016/S0091-6749(87)80015-5; HIRSHMAN CA, 1986, AM REV RESPIR DIS, V133, P482; HIRSHMAN CA, 1980, J APPL PHYSIOL, V49, P953, DOI 10.1152/jappl.1980.49.6.953; HIRSHMAN CA, 1986, RESPIR PHYSL, V63, P334; HOLGATE ST, 1985, INT ARCH ALLER A IMM, V77, P47, DOI 10.1159/000233752; HOOK WA, 1975, J IMMUNOL, V114, P1185; HOOK WA, 1976, J IMMUNOL, V117, P594; Hugli TE, 1987, ADV IMMUNOL, V26, P1; JOHNSON AR, 1975, IMMUNOLOGY, V28, P1067; LICHTENSTEIN LM, 1986, J ALLERGY CLIN IMMUN, V77, P291, DOI 10.1016/S0091-6749(86)80106-3; LUNA LG, 1968, MANUAL HISTOLOGIC ST, P164; NORTH FC, 1987, ANESTHESIOLOGY, V66, P543, DOI 10.1097/00000542-198704000-00016; PATERSON NAM, 1976, J IMMUNOL, V117, P1356; PATTERSON R, 1980, J ALLERGY CLIN IMMUN, V65, P278, DOI 10.1016/0091-6749(80)90156-6; PATTERSON R, 1977, J CLIN INVEST, V59, P217, DOI 10.1172/JCI108631; PATTERSON R, 1974, CLIN EXP IMMUNOL, V16, P223; SCHULMAN ES, 1983, J IMMUNOL, V131, P1936; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; TSAO C, 1976, INT ARCH ALLER A IMM, V52, P315, DOI 10.1159/000231697; TUNG R, 1982, J IMMUNOL, V128, P2067; WILLEMSE A, 1984, INVESTIGATIONS CANIN	33	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	1				829	835		10.1016/0091-6749(88)90938-4	http://dx.doi.org/10.1016/0091-6749(88)90938-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7036	2453543	Bronze			2022-12-18	WOS:A1988N703600010
J	SHAPIRO, PA				SHAPIRO, PA			EFFECTS OF NASAL OBSTRUCTION ON FACIAL DEVELOPMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SHAPIRO, PA (corresponding author), UNIV WASHINGTON,SCH DENT,DEPT ORTHODONT,SM-46,SEATTLE,WA 98195, USA.							BRESOLIN D, 1984, PEDIATRICS, V73, P622; BRESOLIN D, 1983, AM J ORTHOD DENTOFAC, V83, P334, DOI 10.1016/0002-9416(83)90229-4; DUNN GF, 1973, ANGLE ORTHOD, V43, P129; GURLEY WH, 1982, AM J ORTHOD DENTOFAC, V82, P33, DOI 10.1016/0002-9416(82)90543-7; HANDELMAN CS, 1976, ANGLE ORTHOD, V46, P243; HANNUKSELA A, 1981, EUR J ORTHODONT, V3, P187, DOI 10.1093/ejo/3.3.187; HARVOLD EP, 1981, AM J ORTHOD DENTOFAC, V79, P359, DOI 10.1016/0002-9416(81)90379-1; HARVOLD EP, 1973, AM J ORTHOD DENTOFAC, V63, P494, DOI 10.1016/0002-9416(73)90162-0; KEALL CL, 1987, AM J ORTHOD DENTOFAC, V19, P207; KOSKI K, 1975, AM J ORTHOD DENTOFAC, V68, P660, DOI 10.1016/0002-9416(75)90100-1; Linder-Aronson S, 1974, AM J ORTHOD DENTOFAC, V65, P1, DOI 10.1016/0002-9416(74)90153-5; Linder-Aronson S, 1960, ODONTOL REVY, V2, P343; Linder-Aronson S, 1970, ACTA OTO-LARYNGOL, V265, P5; LINDERARONSON S, 1986, AM J ORTHOD DENTOFAC, V89, P273, DOI 10.1016/0002-9416(86)90049-7; LINDERARONSON S, 1979, NASORESPIRATORY FUNC, P120; MARKS MB, 1965, J ALLERGY, V36, P293, DOI 10.1016/0021-8707(65)90088-2; MILLER AJ, 1982, AM J ORTHOD DENTOFAC, V81, P99, DOI 10.1016/0002-9416(82)90033-1; OPHIR D, 1985, ARCH OTOLARYNGOL, V111, P93; SASSOUNI V, 1985, ANN ALLERGY, V54, P493; TOMER BS, 1982, AM J ORTHOD DENTOFAC, V82, P114, DOI 10.1016/0002-9416(82)90490-0; TRASK GM, 1987, AM J ORTHOD DENTOFAC, V92, P286, DOI 10.1016/0889-5406(87)90328-3; VIG PS, 1981, AM J ORTHOD DENTOFAC, V79, P263, DOI 10.1016/0002-9416(81)90074-9; WARREN DW, 1986, AM J ORTHOD DENTOFAC, V89, P480, DOI 10.1016/0002-9416(86)90005-9; WARREN DW, 1987, AM J ORTHOD DENTOFAC, V91, P111, DOI 10.1016/0889-5406(87)90467-7; WOODSIDE D G, 1979, European Journal of Orthodontics, V1, P25	25	14	15	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	2	S			967	971		10.1016/0091-6749(88)90162-5	http://dx.doi.org/10.1016/0091-6749(88)90162-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7037	3286736				2022-12-18	WOS:A1988N703700007
J	PAUWELS, R; VANDERSTRAETEN, M				PAUWELS, R; VANDERSTRAETEN, M			THE EFFECT OF KETOTIFEN ON BRONCHIAL BETA-ADRENERGIC TACHYPHYLAXIS IN NORMAL HUMAN VOLUNTEERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV GHENT HOSP,DEPT RESP DIS,B-9000 GHENT,BELGIUM	Ghent University; Ghent University Hospital								BRETZ U, 1983, EUR J PHARM, V86, P21; BRODDE OE, 1985, J CLIN INVEST, V76, P1096, DOI 10.1172/JCI112063; CONOLLY ME, 1982, J ALLERGY CLIN IMMUN, V70, P423, DOI 10.1016/0091-6749(82)90004-5; CRAPS LP, 1984, RESPIRATION, V45, P411, DOI 10.1159/000194648; ELIASSON O, 1985, AM REV RESPIR DIS, V132, P858; ELLULMICALLEF R, 1975, LANCET, V2, P269; FREEDMAN BJ, 1972, BR J DIS CHEST, V76, P341; HARVEY JE, 1982, THORAX, V37, P280, DOI 10.1136/thx.37.4.280; HOLGATE ST, 1977, LANCET, V2, P375; HOLGATE ST, 1980, CLIN SCI, V59, P155, DOI 10.1042/cs0590155; JENNE JW, 1982, J ALLERGY CLIN IMMUN, V70, P413, DOI 10.1016/0091-6749(82)90002-1; LARSSON S, 1977, J ALLERGY CLIN IMMUN, V59, P93, DOI 10.1016/0091-6749(77)90209-3; MORLEY J, 1985, TRIANGLE, V24, P59; NEWMAN SP, 1985, AEROSOLS MED PRINCIP, P289; PERSSON CGA, 1982, ANN NY ACAD SCI, V384, P544, DOI 10.1111/j.1749-6632.1982.tb21399.x; Snedecor G.W., 1980, STAT METHODS, V7; STERK PJ, 1983, B EUR PHYSIOPATH RES, V19, P27; TASHKIN DP, 1985, BRONCHIAL ASTHMA MEC, P604; TINKELMAN DG, 1985, J ALLERGY CLIN IMMUN, V76, P487, DOI 10.1016/0091-6749(85)90732-8; WANNER A, 1977, AM REV RESPIR DIS, V116, P73; WEBER RW, 1982, J ALLERGY CLIN IMMUN, V70, P417, DOI 10.1016/0091-6749(82)90003-3; WILSON AF, 1976, J ALLERGY CLIN IMMUN, V58, P204, DOI 10.1016/0091-6749(76)90156-1	22	14	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1988	81	4					674	680		10.1016/0091-6749(88)91037-8	http://dx.doi.org/10.1016/0091-6749(88)91037-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N0650	3281997	Bronze			2022-12-18	WOS:A1988N065000006
J	ANSARI, AA; KILLORAN, EA; MARSH, DG				ANSARI, AA; KILLORAN, EA; MARSH, DG			AN INVESTIGATION OF HUMAN IMMUNE-RESPONSE TO PERENNIAL RYEGRASS (LOLIUM-PERENNE) POLLEN CYTOCHROME-C (LOL P X)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ANSARI, AA (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019727, R01AI020059, R55AI019727] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-19727, AI-20059] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANSARI AA, 1986, FASEB J, V45, P490; Brautigan D L, 1978, Methods Enzymol, V53, P128; CHAKRABARTY S, 1981, INT ARCH ALLER A IMM, V66, P142, DOI 10.1159/000232813; EKRAMODDOULLAH AKM, 1984, MOL IMMUNOL, V21, P375, DOI 10.1016/0161-5890(84)90034-8; EKRAMODDOULLAH AKM, 1981, INT ARCH ALLER A IMM, V65, P367, DOI 10.1159/000232778; EKRAMODDOULLAH AKM, 1982, MOL IMMUNOL, V19, P1527, DOI 10.1016/0161-5890(82)90263-2; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; FREIDHOFF LR, 1983, J ALLERGY CLIN IMMUN, V72, P274, DOI 10.1016/0091-6749(83)90032-5; GOODFRIEND L, 1979, FED PROC, V38, P1415; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HANNUM CH, 1985, J IMMUNOL, V135, P3303; HANNUM CH, 1985, J IMMUNOL, V135, P3314; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARGOLIASH E, 1966, ADV PROTEIN CHEM, V21, P14; MARSH DG, 1980, J ALLERGY CLIN IMMUN, V65, P322, DOI 10.1016/0091-6749(80)90208-0; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1986, B WORLD HEALTH ORGAN, V64, P767; MARSH DG, 1977, IMMUNOGENETICS, V5, P235, DOI 10.1007/BF01570479; MARSH DG, 1975, ANTIGENS, V3, P271; Reichlin M, 1975, Adv Immunol, V20, P71, DOI 10.1016/S0065-2776(08)60207-2; ROEBBER M, 1982, J IMMUNOL, V129, P120; SCHWARTZ RH, 1985, J IMMUNOL, V135, P2598; URBANSKI GJ, 1977, IMMUNOCHEMISTRY ENZY, P203	23	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1987	80	2					229	235		10.1016/0091-6749(87)90134-5	http://dx.doi.org/10.1016/0091-6749(87)90134-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J6575	3038988				2022-12-18	WOS:A1987J657500016
J	PANUSKA, JR; KING, TR; KORENBLAT, PE; WEDNER, HJ				PANUSKA, JR; KING, TR; KORENBLAT, PE; WEDNER, HJ			HYPERSENSITIVITY REACTION TO DESIPRAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV ALLERGY & IMMUNOL,ST LOUIS,MO 63110	Washington University (WUSTL)								CESKA M, 1983, METHODS ENZYMOL, V73, P646; DESWARTE RD, 1984, J ALLERGY CLIN IMMUN, V74, P209, DOI 10.1016/0091-6749(84)90246-X; DEVANE CL, 1981, EUR J CLIN PHARMACOL, V19, P61, DOI 10.1007/BF00558386; ERIKSOO E, 1970, ARZNEI-FORSCHUNG, V20, P1561; FARR RS, 1971, METHODS IMMUNOLOGY I, V3, P66; FECSIK AI, 1964, J EXP MED, V120, P1041, DOI 10.1084/jem.120.6.1041; HUBBARD JW, 1978, J PHARM SCI, V67, P1571, DOI 10.1002/jps.2600671119; JONES DR, 1980, AM J PSYCHIAT, V137, P115; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KRAUS RP, 1984, CAN J PSYCHIAT, V29, P142, DOI 10.1177/070674378402900212; MIDHA KK, 1978, J ANAL TOXICOL, V2, P185, DOI 10.1093/jat/2.5.185; MIDHA KK, 1980, J ANAL TOXICOL, V4, P237, DOI 10.1093/jat/4.5.237; MUTNICK A, 1982, DRUG INTEL CLIN PHAR, V16, P966, DOI 10.1177/106002808201601215; NELSON JC, 1983, CLIN PHARMACOL THER, V33, P183, DOI 10.1038/clpt.1983.28; PARKER CW, 1980, CLIN IMMUNOLOGY, V2, P1219; POWELL WJ, 1968, J AMER MED ASSOC, V206, P642, DOI 10.1001/jama.206.3.642; SPECTOR S, 1975, PSYCHOPHARMACOL COMM, V1, P421	17	14	15	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1987	80	1					18	23		10.1016/S0091-6749(87)80185-9	http://dx.doi.org/10.1016/S0091-6749(87)80185-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J2194	3598027				2022-12-18	WOS:A1987J219400003
J	ILIOPOULOS, O; PROUD, D; LICHTENSTEIN, LM; KAGEYSOBOTKA, A; CRETICOS, PS; ADKINSON, NF; MACDONALD, SM; NORMAN, PS; NACLERIO, RM				ILIOPOULOS, O; PROUD, D; LICHTENSTEIN, LM; KAGEYSOBOTKA, A; CRETICOS, PS; ADKINSON, NF; MACDONALD, SM; NORMAN, PS; NACLERIO, RM			RELATIONSHIPS BETWEEN EARLY (ER), LATE (LPR) AND RECHALLENGE (RCR) RESPONSES TO NASAL CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					253	253						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810					2022-12-18	WOS:A1987F881000537
J	ONEIL, CE; MCCANTS, ML; SALVAGGIO, JE; LEHRER, SB				ONEIL, CE; MCCANTS, ML; SALVAGGIO, JE; LEHRER, SB			FUSARIUM-SOLANI - PREVALENCE OF SKIN REACTIVITY AND ANTIGENIC ALLERGENIC ANALYSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,DEPT MED,NEW ORLEANS,LA 70118	Tulane University					NHLBI NIH HHS [HL 32621] Funding Source: Medline; NIAID NIH HHS [AI20331] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL032621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020331] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUKRUST L, 1977, SCAND J IMMUNOL, V6, P1093; AUKRUST L, 1980, ALLERGY, V35, P206, DOI 10.1111/j.1398-9995.1980.tb01747.x; AUKRUST L, 1978, SCAND J IMMUNOL, V8, P421, DOI 10.1111/j.1365-3083.1978.tb00537.x; AUKRUST L, 1979, INT ARCH ALLER A IMM, V60, P68, DOI 10.1159/000232324; AUKRUST L, 1979, INT ARCH ALLER A IMM, V58, P371; AUKRUST L, 1981, 14TH P NORD C ALL GO; BONIL.O, 1961, J ALLERGY, V32, P246, DOI 10.1016/0021-8707(61)90055-7; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; HARBOE NMG, 1983, SCAND J IMMUNOL S10, V17, P107; HOWARD WA, 1984, MOULD ALLERGY, P147; KARR RM, 1981, J ALLERGY CLIN IMMUN, V67, P194, DOI 10.1016/0091-6749(81)90061-0; KAUFFMAN HF, 1980, INT ARCH ALLER A IMM, V62, P252, DOI 10.1159/000232521; KIM SJ, 1978, AM REV RESPIR DIS, V118, P547; KIM SJ, 1978, AM REV RESPIR DIS, V118, P553; KIM SJ, 1979, AM REV RESPIR DIS, V120, P1297; KIM SJ, 1979, AM REV RESPIR DIS, V120, P1305; KRAMER C. L., 1960, TRANS KANSAS ACAD SCI, V63, P228, DOI 10.2307/3626900; LEHRER SB, 1983, CLIN CHEST MED, P23; MARSH DG, 1975, ANTIGENS, V3, P271; O'NEIL C E, 1984, Journal of Allergy and Clinical Immunology, V73, P152; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P82, DOI 10.1016/0091-6749(71)90090-X; SANTILLI J, 1985, J ALLERGY CLIN IMMUN, V75, P118, DOI 10.1016/0091-6749(85)90191-5; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; STERNBERGER LA, 1956, J ALLERGY, V27, P16, DOI 10.1016/0021-8707(56)90034-X; VIJAY HM, 1985, J ALLERGY CLIN IMMUN, V75, P117, DOI 10.1016/0091-6749(85)90184-8; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V57, P293, DOI 10.1016/0091-6749(76)90085-3	30	14	15	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1986	77	6					842	849		10.1016/0091-6749(86)90382-9	http://dx.doi.org/10.1016/0091-6749(86)90382-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C8694	3711551				2022-12-18	WOS:A1986C869400009
J	MULFINGER, LM; BENTON, AW; GURALNICK, MW; WILSON, RA				MULFINGER, LM; BENTON, AW; GURALNICK, MW; WILSON, RA			A QUALITATIVE AND QUANTITATIVE-ANALYSIS OF PROTEINS FOUND IN VESPID VENOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									PENN STATE UNIV,DEPT VET SCI,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	MULFINGER, LM (corresponding author), VESPA LABS,RD 1,SPRING MILLS,PA 16875, USA.			Mulfinger, Lorraine/0000-0003-4765-1081				BAER H, 1981, MONOGR INSECT ALLERG, V11; BROWN H, 1970, ARCH INTERN MED, V125, P665, DOI 10.1001/archinte.125.4.665; GURALNICK MW, FOLIA ALLERGOL IMMUN; HABERMANN E, 1972, ANAL BIOCHEM, V50, P163, DOI 10.1016/0003-2697(72)90495-2; HOFFMAN DR, 1982, ANN ALLERGY, V48, P78; HOFFMAN DR, 1981, ANN ALLERGY, V47, P23; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KERN F, 1976, J ALLERGY CLIN IMMUN, V57, P554, DOI 10.1016/0091-6749(76)90006-3; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1983, MOL IMMUNOL, V20, P297, DOI 10.1016/0161-5890(83)90069-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAIR BC, 1976, J ALLERGY CLIN IMMUN, V58, P101, DOI 10.1016/0091-6749(76)90111-1; REISNER AH, 1975, ANAL BIOCHEM, V64, P509, DOI 10.1016/0003-2697(75)90461-3; RICHMAN PG, 1980, ANAL BIOCHEM, V109, P376, DOI 10.1016/0003-2697(80)90663-6; SCHWARTZ HJ, 1965, J AMER MED ASSOC, V194, P703, DOI 10.1001/jama.194.7.703; SCHWARTZ HJ, 1981, J ALLERGY CLIN IMMUN, V67, P81, DOI 10.1016/0091-6749(81)90051-8; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; WICHER K, 1980, J ALLERGY CLIN IMMUN, V66, P244, DOI 10.1016/0091-6749(80)90047-0; WYPYCH JI, 1979, J ALLERGY CLIN IMMUN, V63, P267, DOI 10.1016/0091-6749(79)90111-8	19	14	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1986	77	5					681	686		10.1016/0091-6749(86)90409-4	http://dx.doi.org/10.1016/0091-6749(86)90409-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C3903	3700891				2022-12-18	WOS:A1986C390300007
J	MASSICOT, JG; ISHIZAKA, K				MASSICOT, JG; ISHIZAKA, K			WORKSHOP ON MEASUREMENT OF INVITRO IGE SYNTHESIS AND REGULATION OF IGE SYNTHESIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED & MICROBIOL,BALTIMORE,MD 21205	Johns Hopkins University	MASSICOT, JG (corresponding author), NIAID,ASTHMA & ALLERGY BRANCH,ROOM 752,BETHESDA,MD 20892, USA.							CHEN PP, 1984, J IMMUNOL, V133, P1909; DELESPESSE G, UNPUB IGE RECEPTORS; HASSNER A, 1984, J IMMUNOL, V132, P2844; HELM RM, 1985, J ALLERGY CLIN IMMUN, V75, P138, DOI 10.1016/0091-6749(85)90268-4; HEMADY Z, 1983, J ALLERGY CLIN IMMUN, V71, P324, DOI 10.1016/0091-6749(83)90087-8; HEMADY Z, 1985, CLIN IMMUNOL IMMUNOP, V35, P156, DOI 10.1016/0090-1229(85)90062-5; HUFF TF, 1984, P NATL ACAD SCI-BIOL, V81, P1514, DOI 10.1073/pnas.81.5.1514; ISHIZAKA K, 1984, ANNU REV IMMUNOL, V2, P159, DOI 10.1146/annurev.immunol.2.1.159; ISHIZAKA K, 1985, J IMMUNOL, V135, P1; KANOWITHKLEIN S, 1985, J CLIN IMMUNOL, V5, P38, DOI 10.1007/BF00915167; KATZ DH, 1985, INT ARCH ALLER A IMM, V77, P21, DOI 10.1159/000233747; KATZ DH, 1984, ALLERGY, V39, P81, DOI 10.1111/j.1398-9995.1984.tb01940.x; MARTENS CL, 1985, P NATL ACAD SCI USA, V82, P2460, DOI 10.1073/pnas.82.8.2460; MCNEIL D, 1985, J ALLERGY CLIN IMMUN, V75, P139, DOI 10.1016/0091-6749(85)90272-6; NAKAJIMA T, UNPUB IGE RECEPTORS; RECTOR E, 1985, IMMUNOLOGY, V55, P481; RICCI M, 1985, INT ARCH ALLER A IMM, V77, P32, DOI 10.1159/000233749; ROMAGNANI S, 1983, CLIN EXP IMMUNOL, V52, P85; ROMAGNANI S, 1980, CLIN EXP IMMUNOL, V42, P579; SAMPSON HA, 1981, J IMMUNOL, V127, P829; SARFATI M, UNPUB RADIOIMMUNOASS; SARYAN JA, 1983, J IMMUNOL, V130, P242; SAXON A, 1980, J CLIN INVEST, V65, P1457, DOI 10.1172/JCI109810; SPIEGELBERG HL, 1983, J IMMUNOL, V131, P3001; TAMIR R, UNPUB GENERATION SUP; THOMPSON LF, 1985, CLIN EXP IMMUNOL, V59, P77; TURNER KJ, 1983, CLIN EXP IMMUNOL, V51, P387; UMETSU DT, 1985, J EXP MED, V162, P202, DOI 10.1084/jem.162.1.202; YOUNG MC, 1984, EUR J IMMUNOL, V14, P871, DOI 10.1002/eji.1830141003	29	14	15	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1986	77	4					544	554		10.1016/0091-6749(86)90343-X	http://dx.doi.org/10.1016/0091-6749(86)90343-X			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A9381	2937830				2022-12-18	WOS:A1986A938100003
J	KOPP, DE; ESSER, B; TASHOFF, T; GOLDMAN, DW; GOETZL, EJ; LEMANSKE, RF				KOPP, DE; ESSER, B; TASHOFF, T; GOLDMAN, DW; GOETZL, EJ; LEMANSKE, RF			INVIVO AND INVITRO ASSESSMENT OF THE ROLE OF LEUKOTRIENE B4 AS A MEDIATOR OF RAT CUTANEOUS LATE-PHASE REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO,MED CTR,HOWARD HUGHES MED INST LABS,SAN FRANCISCO,CA 94143; UNIV WISCONSIN,SCH MED,DEPT PEDIAT,MADISON,WI 53792; UNIV WISCONSIN,SCH MED,DEPT MED,600 HIGHLAND AVE,H6-367,MADISON,WI 53792	University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL001147, R01HL031809] Funding Source: NIH RePORTER; NHLBI NIH HHS [1 K08 HL01147-01, HL 31809] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAY MA, 1981, BRIT J PHARMACOL, V72, P483, DOI 10.1111/j.1476-5381.1981.tb11000.x; BRAY MA, 1981, PROSTAGLANDINS, V22, P213, DOI 10.1016/0090-6980(81)90036-8; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FLOWER RT, 1976, BR J PHARM, V56, P224; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FORDHUTCHINSON AW, 1982, BRIT J PHARMACOL, V76, P215, DOI 10.1111/j.1476-5381.1982.tb09209.x; FORDHUTCHINSON AW, 1981, J PHARM PHARMACOL, V33, P332, DOI 10.1111/j.2042-7158.1981.tb13794.x; GOETZL EJ, 1972, J EXP MED, V136, P1564, DOI 10.1084/jem.136.6.1564; GOETZL EJ, 1981, J EXP MED, V153, P482, DOI 10.1084/jem.153.2.482; GOLDMAN DW, 1982, J IMMUNOL, V129, P1600; GOLDMAN DW, 1984, J EXP MED, V159, P1027, DOI 10.1084/jem.159.4.1027; JUHLIN L, 1983, PROSTA LEUKOTR MED, V11, P381, DOI 10.1016/0262-1746(83)90090-2; KRELL RD, 1981, PROSTAG OTH LIPID M, V22, P387, DOI 10.1016/0090-6980(81)90101-5; LEMANSKE R, 1982, CRC CRIT REV IMMUNOL, V1, P547; LEMANSKE RF, 1983, J ALLERGY CLIN IMMUN, V72, P94, DOI 10.1016/0091-6749(83)90058-1; LEMANSKE RF, 1983, J IMMUNOL, V130, P1881; LEMANSKE RF, 1983, J IMMUNOL, V131, P929; LEMANSKE RF, 1982, IMMUNOLOGY, V45, P561; LEMANSKE RF, 1983, J IMMUNOL, V130, P2837; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN TR, 1984, AM REV RESPIR DIS, V129, P106; MENCIAHUERTA JM, 1983, J IMMUNOL, V130, P1885; OERTEL HL, 1981, J IMMUNOL, V127, P1398; PALMER RMJ, 1980, PROSTAGLANDINS, V20, P411, DOI 10.1016/S0090-6980(80)80058-X; PETERS SP, 1984, J IMMUNOL, V132, P1972; PHILLIPS MJ, 1983, J IMMUNOL, V131, P906; RAPHAEL GD, 1978, EXP CELL RES, V115, P428, DOI 10.1016/0014-4827(78)90300-2; SIROIS P, 1981, PROSTAG LEUKOTR ESS, V7, P327, DOI 10.1016/0161-4630(81)90137-3; SMITH MJH, 1980, J PHARM PHARMACOL, V32, P517, DOI 10.1111/j.2042-7158.1980.tb12985.x; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; SULLIVAN TJ, 1975, J IMMUNOL, V114, P1473; TANNENBAUM S, 1980, J IMMUNOL, V125, P325; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0	36	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1986	77	2					302	308		10.1016/S0091-6749(86)80108-7	http://dx.doi.org/10.1016/S0091-6749(86)80108-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A0899	3003177				2022-12-18	WOS:A1986A089900006
J	EISENBREY, AB; AGARWAL, MK; OFFORD, KP; ADOLPHSON, CR; YUNGINGER, JW; GLEICH, GJ				EISENBREY, AB; AGARWAL, MK; OFFORD, KP; ADOLPHSON, CR; YUNGINGER, JW; GLEICH, GJ			SEASONAL-VARIATION OF INVITRO LYMPHOCYTE PROLIFERATIVE RESPONSE TO RAGWEED ANTIGEN-E	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO MED SCH,DEPT IMMUNOL,ALLERG DIS RES LAB,ROCHESTER,MN 55901; MAYO MED SCH,DEPT MED,ROCHESTER,MN 55901; MAYO MED SCH,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO MED SCH,DEPT MED STAT & EPIDEMIOL,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic					NIAID NIH HHS [AI 07047, AI 11483] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; BUCKLEY RH, 1977, J ALLERGY CLIN IMMUN, V59, P70, DOI 10.1016/0091-6749(77)90180-4; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GATIEN JG, 1975, CLIN IMMUNOL IMMUNOP, V4, P32, DOI 10.1016/0090-1229(75)90036-7; GEHA RS, 1975, J CLIN INVEST, V56, P386, DOI 10.1172/JCI108103; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GRAMMER L, 1981, INT ARCH ALLER A IMM, V66, P179, DOI 10.1159/000232817; HENGARTNER H, 1981, IMMUNOLOGICAL METHOD, V2, P277; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; Oppenheim J. J., 1976, MANUAL CLIN IMMUNOLO, P81; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; ROCKLIN RE, 1974, J CLIN INVEST, V53, P735, DOI 10.1172/JCI107612; SAXON A, 1980, J CLIN INVEST, V65, P1457, DOI 10.1172/JCI109810; STANGHELLINI V, 1983, GASTROENTEROLOGY, V85, P83; YUNGINGER JW, 1973, J ALLERGY CLIN IMMUN, V51, P174, DOI 10.1016/0091-6749(73)90022-5; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294; ZURAW BL, 1981, J IMMUNOL, V127, P1169	18	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					84	90						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABF26	3968332				2022-12-18	WOS:A1985ABF2600013
J	HENDELES, L; WEINBERGER, M				HENDELES, L; WEINBERGER, M			THEOPHYLLINE PRODUCT AND DOSING INTERVAL SELECTION FOR CHRONIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV FLORIDA,DEPT PEDIAT,GAINESVILLE,FL 32610	State University System of Florida; University of Florida	HENDELES, L (corresponding author), UNIV FLORIDA,COLL PHARM,DIV CLIN PHARMACOKINET,BOX J-4,GAINESVILLE,FL 32610, USA.							BELL T, 1978, PEDIATRICS, V62, P352; FAGERSTROM PO, 1983, INT J CLIN PHARM TH, V21, P359; GINCHANSKY E, 1977, J PEDIATR-US, V91, P655, DOI 10.1016/S0022-3476(77)80527-1; GONZALEZ MA, 1984, 36TH ANN M AM PHARM, V14, P108; HENDELES L, 1985, CHEST, V87, P758, DOI 10.1378/chest.87.6.758; HENDELES L, 1984, CLIN PHARMACOKINET, V9, P95, DOI 10.2165/00003088-198409020-00001; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; KARIM A, 1984, 3RD ANN C CURR CONC; LAGAS M, 1983, EUR J CLIN PHARMACOL, V24, P761, DOI 10.1007/BF00607084; LEEDS NH, 1982, J CLIN PHARMACOL, V22, P196, DOI 10.1002/j.1552-4604.1982.tb02162.x; MYHRE KI, 1983, BRIT J CLIN PHARMACO, V15, P683, DOI 10.1111/j.1365-2125.1983.tb01550.x; OSMAN MA, 1983, BIOPHARM DRUG DISPOS, V4, P63, DOI 10.1002/bdd.2510040109; PEDERSEN S, 1982, ALLERGY, V37, P531, DOI 10.1111/j.1398-9995.1982.tb02336.x; PEDERSEN S, 1984, PEDIATRICS, V74, P534; PURKISS R, 1984, ALLERGY, V39, P634, DOI 10.1111/j.1398-9995.1984.tb01985.x; ROGERS RJ, 1985, J PEDIATR-US, V106, P496, DOI 10.1016/S0022-3476(85)80690-9; SCOTT PH, 1981, J PEDIATR-US, V99, P476, DOI 10.1016/S0022-3476(81)80354-X; SHARGEL L, 1981, J PHARM SCI, V70, P599, DOI 10.1002/jps.2600700606; SIPS AP, 1984, EUR J CLIN PHARMACOL, V26, P405, DOI 10.1007/BF00548776; SPANGLER DL, 1980, ANN ALLERGY, V45, P355; SPANGLER DL, 1978, ANN ALLERGY, V40, P6; TABACHNIK E, 1982, J PEDIATR-US, V100, P489, DOI 10.1016/S0022-3476(82)80467-8; UPTON RA, 1980, J PHARMACOKINET BIOP, V8, P131, DOI 10.1007/BF01065189; WEINBERGER M, 1981, J PEDIATR-US, V99, P145, DOI 10.1016/S0022-3476(81)80982-1; WEINBERGER M, 1983, NEW ENGL J MED, V308, P760, DOI 10.1056/NEJM198303313081306; WEINBERGER M, 1978, NEW ENGL J MED, V299, P852, DOI 10.1056/NEJM197810192991603; WEINBERGER MM, 1984, PHARMACOTHERAPY, V4, P181	27	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					285	291		10.1016/0091-6749(85)90643-8	http://dx.doi.org/10.1016/0091-6749(85)90643-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	4019956				2022-12-18	WOS:A1985APE8900007
J	LUTSKY, I; FINK, JN; KIDD, J; DAHLBERG, MJE; YUNGINGER, JW				LUTSKY, I; FINK, JN; KIDD, J; DAHLBERG, MJE; YUNGINGER, JW			ALLERGENIC PROPERTIES OF RAT URINE AND PELT EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM MED CTR,RES SERV,WOOD,WI 53193; MED COLL WISCONSIN,DEPT MED,ALLERGY IMMUNOL SECT,MILWAUKEE,WI 53226; MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901	US Department of Veterans Affairs; Veterans Health Administration (VHA); Medical College of Wisconsin; Mayo Clinic	LUTSKY, I (corresponding author), HEBREW UNIV JERUSALEM,SCH MED,DEPT COMPARAT MED,POB 1172,IL-91010 JERUSALEM,ISRAEL.				NHLBI NIH HHS [HL 29319] Funding Source: Medline; NIAID NIH HHS [AI 11483, AI 19104] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI019104, P50AI011483] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; DIXON WJ, 1969, INTRO STATISTICAL AN, P222; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; LONGBOTTOM JL, 1980, ADV ALLERGOLOGY APPL, P483; LUTSKY I, 1980, CLIN ALLERGY, V10, P331, DOI 10.1111/j.1365-2222.1980.tb02115.x; LUTSKY II, 1975, ANN ALLERGY, V35, P201; LUTSKY II, 1983, J OCCUP ENVIRON MED, V25, P372; NEWMANTAYLOR A, 1977, LANCET, V2, P847; PEPYS J, 1964, CLIN ASPECTS IMMUNOL, P55; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; SCHUMACHER MJ, 1980, MOL IMMUNOL, V17, P1087, DOI 10.1016/0161-5890(80)90105-4; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Yunginger J. W., 1980, MANUAL CLIN IMMUNOLO, P778; 1981, OCCUPATIONAL ASTHMA, P1	15	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	2					279	284		10.1016/0091-6749(85)90058-2	http://dx.doi.org/10.1016/0091-6749(85)90058-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABZ05	3871448				2022-12-18	WOS:A1985ABZ0500008
J	MANN, JS; CLEMENT, P; SHERIDAN, AQ; SORYAL, I; FAIRFAX, AJ; HOLGATE, ST				MANN, JS; CLEMENT, P; SHERIDAN, AQ; SORYAL, I; FAIRFAX, AJ; HOLGATE, ST			INHALED IODOXAMIDE TROMETHAMINE IN THE TREATMENT OF PERENNIAL ASTHMA - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STAFFORDSHIRE GEN INFIRM,STAFFORD,ENGLAND		MANN, JS (corresponding author), SOUTHAMPTON GEN HOSP,MED 1,LEVEL D,CTR BLOCK,TREMONA RD,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							ALTOUNYAN RE, 1967, ACTA ALLERGOL, V22, P487; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; BASOMBA A, 1976, CLIN ALLERGY, V6, P269, DOI 10.1111/j.1365-2222.1976.tb01907.x; BERNSTEIN IL, 1981, J ALLERGY CLIN IMMUN, V68, P247; BIENENSTOCK J, 1982, J ALLERGY CLIN IMMUN, V70, P407, DOI 10.1016/0091-6749(82)90001-X; BROOKS CD, 1979, J ALLERGY CLIN IMMUN, V63, P161; CASE RL, 1982, JAMA-J AM MED ASSOC, V247, P661, DOI 10.1001/jama.247.5.661; CHURCH MK, 1982, J IMMUNOL, V129, P2116; CHURCH MK, 1983, BRIT J PHARMACOL, V78, P671, DOI 10.1111/j.1476-5381.1983.tb09419.x; CHURCH MK, 1978, MED ACT DRUGS TODAY, V14, P281; COLLIER JG, 1983, BRIT J CLIN PHARMACO, V16, P639, DOI 10.1111/j.1365-2125.1983.tb02234.x; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; DEVRIES K, 1976, B INT UNION TUBERC, V51, P617; DIXON M, 1980, BRIT J PHARMACOL, V70, P11, DOI 10.1111/j.1476-5381.1980.tb10898.x; EDWARDS JG, 1979, BRIT J PSYCHIAT, V134, P624, DOI 10.1192/bjp.134.6.624; FORD L, 1980, J ALLERGY CLIN IMMUN, V65, P183; FULLER RW, 1983, CLIN SCI, V64, P13; GARLAND LG, 1973, BRIT J PHARMACOL, V49, P128, DOI 10.1111/j.1476-5381.1973.tb08275.x; GRIBBIN HR, 1979, BRIT MED J, V1, P92, DOI 10.1136/bmj.1.6156.92; HOLGATE ST, 1983, ADV MED, V19, P287; HOWARTH PH, 1984, THORAX, V39, P225; HOWARTH PH, 1983, THORAX, V38, P705; JOHNSON HG, 1978, INT ARCH ALLER A IMM, V56, P481, DOI 10.1159/000232062; JOHNSON HG, 1978, INT ARCH ALLER A IMM, V56, P416, DOI 10.1159/000232051; KATCHER ML, 1980, J ALLERGY CLIN IMMUN, V66, P223, DOI 10.1016/0091-6749(80)90043-3; KOETER GH, 1982, ALLERGY, V37, P587, DOI 10.1111/j.1398-9995.1982.tb02344.x; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; OLLIER S, 1982, CLIN ALLERGY, V12, P587, DOI 10.1111/j.1365-2222.1982.tb02557.x; PARRISH RW, 1983, THORAX, V38, P458, DOI 10.1136/thx.38.6.458; PEARCE FL, 1980, AGENTS ACTIONS, V10, P124, DOI 10.1007/BF02024193; SHEARD P, 1967, NATURE, V216, P283, DOI 10.1038/216283a0; STOKES TC, 1981, BRIT J DIS CHEST, V75, P1, DOI 10.1016/S0007-0971(81)80002-2; UNGERER RG, 1981, J ALLERGY CLIN IMMUN, V68, P471, DOI 10.1016/0091-6749(81)90201-3; WATT GD, 1980, J ALLERGY CLIN IMMUN, V66, P286, DOI 10.1016/0091-6749(80)90023-8; WOENNE R, 1979, AM REV RESPIR DIS, V119, P927; 1972, BR MED J, V4, P383	36	14	14	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	1					83	90		10.1016/0091-6749(85)90808-5	http://dx.doi.org/10.1016/0091-6749(85)90808-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AMV84	4008815				2022-12-18	WOS:A1985AMV8400011
J	NALL, TM				NALL, TM			ANALYSIS OF 677 DEATH CERTIFICATES AND 168 AUTOPSIES OF STINGING INSECT DEATHS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					207	207		10.1016/0091-6749(85)90545-7	http://dx.doi.org/10.1016/0091-6749(85)90545-7			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ACF22					2022-12-18	WOS:A1985ACF2200410
J	SILBER, G; NACLERIO, R; EGGLESTON, P; PROUD, D; TOGIAS, A; LICHTENSTEIN, L; NORMAN, P				SILBER, G; NACLERIO, R; EGGLESTON, P; PROUD, D; TOGIAS, A; LICHTENSTEIN, L; NORMAN, P			INVIVO RELEASE OF HISTAMINE BY HYPEROSMOLAR STIMULI	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					176	176		10.1016/0091-6749(85)90420-8	http://dx.doi.org/10.1016/0091-6749(85)90420-8			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ACF22					2022-12-18	WOS:A1985ACF2200285
J	WELLER, FR; KALLENBERG, CGM; JANSEN, HM; TORENSMA, R; KLAASSEN, RJL; WELLER, HH; ORIE, NGM; THE, TH				WELLER, FR; KALLENBERG, CGM; JANSEN, HM; TORENSMA, R; KLAASSEN, RJL; WELLER, HH; ORIE, NGM; THE, TH			THE PRIMARY IMMUNE-RESPONSE IN BRONCHIAL-ASTHMA .1. A KINETIC-STUDY OF HELIX-POMATIA HEMOCYANIN-SPECIFIC IGE, IGG, IGA, AND IGM ANTIBODY-RESPONSES IN PATIENTS WITH ASTHMA AND IN MATCHED CONTROLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV GRONINGEN HOSP,DEPT PULMONOL,9713 EZ GRONINGEN,NETHERLANDS; UNIV AMSTERDAM,DEPT PULMONOL,AMSTERDAM,NETHERLANDS; ST ELISABETH GROOTE GASTHUIS,HAARLEM,NETHERLANDS	University of Groningen; University of Amsterdam	WELLER, FR (corresponding author), STATE UNIV GRONINGEN HOSP,DEPT CLIN IMMUNOL,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS.		Torensma, Ruurd/C-2853-2009	Torensma, Ruurd/0000-0002-0555-7903				BERRENS L, 1977, LANCET, V2, P92; BRETTING H, 1983, COMP BIOCHEM PHYS B, V75, P269, DOI 10.1016/0305-0491(83)90326-7; BRUYNZEEL PLB, 1979, INT ARCH ALLER A IMM, V58, P344, DOI 10.1159/000232211; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; BURKE GP, 1977, J ALLERGY CLIN IMMUN, V59, P303; CHAPMAN MD, 1983, J ALLERGY CLIN IMMUN, V72, P27, DOI 10.1016/0091-6749(83)90048-9; CHAPMAN MD, 1978, CLIN EXP IMMUNOL, V34, P126; CHING YC, 1966, J CLIN INVEST, V45, P1593, DOI 10.1172/JCI105465; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DOLOVICH J, 1981, THORAX, V36, P641, DOI 10.1136/thx.36.9.614; GREENBURY CL, 1963, IMMUNOLOGY, V6, P421; HSIEH KH, 1980, ANN ALLERGY, V45, P104; IIO A, 1978, J IMMUNOL, V120, P1696; ISHIZAKA K, 1978, IMMUNOL REV, V41, P109; JANSEN HM, 1978, THORAX, V33, P755, DOI 10.1136/thx.33.6.755; KALLENBERG CGM, 1984, RECENT DEV CLIN IMMU, P1; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARTINEZ JD, 1979, J ALLERGY CLIN IMMUN, V64, P485, DOI 10.1016/0091-6749(79)90057-5; MOROZ LA, 1973, IMMUNOLOGY, V25, P441; NAGEL JE, 1979, J ALLERGY CLIN IMMUN, V63, P308, DOI 10.1016/0091-6749(79)90124-6; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; SALVAGGIO J, 1969, J ALLERGY, V6, P421; WALDMANN TA, 1969, PROG ALLERGY, V13, P1, DOI 10.1159/000287491; WALDMANN TA, 1976, J IMMUNOL, V117, P1139; WELLER FR, THESIS	25	14	15	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	1					29	34		10.1016/0091-6749(85)90800-0	http://dx.doi.org/10.1016/0091-6749(85)90800-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AMV84	4008812				2022-12-18	WOS:A1985AMV8400003
J	GOODMAN, MG; WEIGLE, WO				GOODMAN, MG; WEIGLE, WO			REGULATION OF LYMPHOCYTE-B PROLIFERATIVE RESPONSES BY ARACHIDONATE METABOLITES - EFFECTS ON MEMBRANE-DIRECTED VERSUS INTRACELLULAR ACTIVATORS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GOODMAN, MG (corresponding author), SCRIPPS CLIN & RES FDN,DEPT IMMUNOL,10666 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015284] Funding Source: NIH RePORTER; NCRR NIH HHS [RRO-5514] Funding Source: Medline; NIAID NIH HHS [AI07007, AI15284] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACH MK, 1980, J IMMUNOL, V125, P115; FULTON AM, 1981, CELL IMMUNOL, V59, P54, DOI 10.1016/0008-8749(81)90433-0; GOODMAN MG, 1980, J IMMUNOL, V125, P593; GOODMAN MG, 1978, J IMMUNOL, V121, P1905; GOODMAN MG, 1982, J IMMUNOL, V128, P2399; GOODMAN MG, 1981, P NATL ACAD SCI-BIOL, V78, P7604, DOI 10.1073/pnas.78.12.7604; GOODMAN MG, 1984, P NATL ACAD SCI-BIOL, V81, P862, DOI 10.1073/pnas.81.3.862; GOODMAN MG, 1982, J IMMUNOL, V129, P2715; GOODWIN JS, 1977, J EXP MED, V146, P1719, DOI 10.1084/jem.146.6.1719; HARWELL L, 1980, J EXP MED, V152, P893, DOI 10.1084/jem.152.4.893; HSUEH W, 1981, NATURE, V290, P710, DOI 10.1038/290710a0; OSUNDWA V, 1983, FED PROC, V42, P409; RANKIN JA, 1982, NATURE, V297, P329, DOI 10.1038/297329a0; ROUZER CA, 1982, J EXP MED, V156, P1077, DOI 10.1084/jem.156.4.1077; SIEGEL MI, 1980, P NATL ACAD SCI-BIOL, V77, P308, DOI 10.1073/pnas.77.1.308; WEBB DR, 1978, CELL IMMUNOL, V41, P72, DOI 10.1016/S0008-8749(78)80029-X	16	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					418	425		10.1016/0091-6749(84)90141-6	http://dx.doi.org/10.1016/0091-6749(84)90141-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6432883				2022-12-18	WOS:A1984TQ63300021
J	KAUFFMAN, HF; BEAUMONT, F; DEMONCHY, JGR; SLUITER, HJ; DEVRIES, K				KAUFFMAN, HF; BEAUMONT, F; DEMONCHY, JGR; SLUITER, HJ; DEVRIES, K			IMMUNOLOGICAL STUDIES IN BRONCHOALVEOLAR FLUID IN A PATIENT WITH ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV GRONINGEN HOSP,INTERNAL MED CLIN,DEPT PULMONOL,9713 EZ GRONINGEN,NETHERLANDS	University of Groningen	KAUFFMAN, HF (corresponding author), STATE UNIV GRONINGEN HOSP,INTERNAL MED CLIN,DEPT ALLERGOL,9713 EZ GRONINGEN,NETHERLANDS.							BEAUMONT F, ALLERGY; BERNARD J, 1980, THORAX, V35, P1; CRIMI E, 1983, ALLERGY, V38, P553, DOI 10.1111/j.1398-9995.1983.tb04139.x; DELACROIX DL, 1982, J IMMUNOL METHODS, V51, P49, DOI 10.1016/0022-1759(82)90381-7; DEUTSCHL H, 1974, CLIN EXP IMMUNOL, V16, P401; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; HAYEM A, 1979, NOUV PRESSE MED, V8, P2119; KAUFFMAN HF, 1983, J ALLERGY CLIN IMMUN, V72, P255, DOI 10.1016/0091-6749(83)90029-5; KAUFFMAN HF, J ALLERGY CLIN IMMUN; KAUFFMAN JF, 1984, J ALLERGY CLIN IMMUN, V73, P567; KAUFFMANN HF, 1980, INT ARCH ALLER A IMM, V62, P265, DOI 10.1159/000232522; MERRILL WW, 1980, J LAB CLIN MED, V96, P494; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; REYNOLDS HY, 1977, J CLIN INVEST, V59, P165, DOI 10.1172/JCI108615; SCHAFFNER A, 1982, J CLIN INVEST, V69, P617, DOI 10.1172/JCI110489; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; STALLMAN PJ, 1977, INT ARCH ALLER A IMM, V54, P9, DOI 10.1159/000231803	17	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	6					835	840		10.1016/0091-6749(84)90187-8	http://dx.doi.org/10.1016/0091-6749(84)90187-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW418	6334111				2022-12-18	WOS:A1984TW41800012
J	PAYAN, DG; GOETZL, EJ				PAYAN, DG; GOETZL, EJ			RECOGNITION OF LEUKOTRIENE-B4 BY A UNIQUE SUBSET OF HUMAN LYMPHOCYTES-T	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO,MED CTR,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	PAYAN, DG (corresponding author), UNIV CALIF SAN FRANCISCO,MED CTR,HOWARD HUGHES MED INST LABS,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019784] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 21809] Funding Source: Medline; NIAID NIH HHS [AI 19784] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORGEAT P, 1979, J BIOL CHEM, V254, P7865; BORGEAT P, 1979, J BIOL CHEM, V254, P2643; FEINMARK SJ, 1981, FEBS LETT, V136, P141, DOI 10.1016/0014-5793(81)81233-1; FELS AOS, 1982, P NATL ACAD SCI-BIOL, V79, P7866, DOI 10.1073/pnas.79.24.7866; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GOETZL EJ, 1983, IMMUNOLOGY, V50, P35; GOETZL EJ, 1981, J EXP MED, V153, P482, DOI 10.1084/jem.153.2.482; GOETZL EJ, 1980, J IMMUNOL, V125, P1789; GOLDMAN DW, 1982, J IMMUNOL, V129, P1600; HOLTZMAN MJ, 1983, BIOCHEM BIOPH RES CO, V114, P1071, DOI 10.1016/0006-291X(83)90671-X; LEWIS RA, 1982, P NATL ACAD SCI-BIOL, V79, P7904, DOI 10.1073/pnas.79.24.7904; LEWIS RA, 1981, J EXP MED, V154, P1243, DOI 10.1084/jem.154.4.1243; LOBITZ WC, 1972, BRIT J DERMATOL, V86, P317, DOI 10.1111/j.1365-2133.1972.tb05045.x; NAGY L, 1982, CLIN EXP IMMUNOL, V47, P541; OFLAHERTY JT, 1981, BIOCHEM BIOPH RES CO, V103, P552, DOI 10.1016/0006-291X(81)90487-3; OFLAHERTY JT, 1981, AM J PATHOL, V105, P264; PALMER RMJ, 1980, PROSTAGLANDINS, V20, P411, DOI 10.1016/S0090-6980(80)80058-X; PAWLOWSKI NA, 1983, J EXP MED, V158, P393, DOI 10.1084/jem.158.2.393; PAYAN DG, 1982, J EXP MED, V156, P756, DOI 10.1084/jem.156.3.756; PAYAN DG, 1983, J IMMUNOL, V131, P551; PAYAN DG, 1984, P NATL ACAD SCI USA, V81, P3105; PAYAN DG, CHEM BIOL LEUKOTRIEN; PHILLIPS MJ, 1983, J IMMUNOL, V131, P906; RAE SA, 1981, J PHARM PHARMACOL, V33, P616, DOI 10.1111/j.2042-7158.1981.tb13884.x; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; ROLAPLESZCZYNSKI M, 1983, BIOCHEM BIOPH RES CO, V113, P531, DOI 10.1016/0006-291X(83)91758-8; ROLAPLESZCZYNSKI M, 1982, BIOCHEM BIOPH RES CO, V108, P1531, DOI 10.1016/S0006-291X(82)80081-8; SAMUELSSON B, 1983, ADV PROSTAG THROMB L, V11, P1; WEBB DR, 1982, BIOCHEM BIOPH RES CO, V104, P1617, DOI 10.1016/0006-291X(82)91438-3	29	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					403	406		10.1016/0091-6749(84)90138-6	http://dx.doi.org/10.1016/0091-6749(84)90138-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6206107				2022-12-18	WOS:A1984TQ63300018
J	TAKAISHI, T; MORITA, Y; KUDO, K; MIYAMOTO, T				TAKAISHI, T; MORITA, Y; KUDO, K; MIYAMOTO, T			AURANOFIN, AN ORAL CHRYSOTHERAPEUTIC AGENT, INHIBITS HISTAMINE-RELEASE FROM HUMAN BASOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TOKYO,FAC MED,DEPT MED & PHYS THERAPY,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								American Rheumatism Association, 1973, ARTHRITIS RHEUM, V16, P353; BERGLOF FE, 1978, J RHEUMATOL, V5, P68; CALIN A, 1982, J RHEUMATOL, V9, P146; CHAMPION GD, 1982, J RHEUMATOL, V9, P137; DAVIS P, 1982, Journal of Rheumatology, V9, P1; FINKELSTEIN AE, 1976, ANN RHEUM DIS, V35, P251, DOI 10.1136/ard.35.3.251; FINKELSTEIN AE, 1977, J RHEUMATOL, V4, P245; Forestier J, 1932, LANCET, V1, P441; FRASER TN, 1945, ANN RHEUM DIS, V4, P71, DOI 10.1136/ard.4.4.71; MARONE G, 1979, J IMMUNOL, V123, P1669; METCALFE DD, 1981, CELLULAR FUNCTIONS I, P301; MORITA Y, 1983, ALLERGY, V38, P413, DOI 10.1111/j.1398-9995.1983.tb05084.x; MURANAKA M, 1978, ANN ALLERGY, V40, P132; SIRAGANIAN RP, 1980, MANUAL CLIN IMMUNOLO, P808; SIRAGANIAN RP, 1981, CELLULAR FUNCTIONS I, P323; SUZUKI S, 1983, J ALLERGY CLIN IMMUN, V72, P469, DOI 10.1016/0091-6749(83)90583-3; WALZ DT, 1982, J RHEUMATOL, V9, P54; WALZ DT, 1976, J PHARMACOL EXP THER, V197, P142; 1961, ANN RHEUM DIS, V20, P315	19	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					296	301		10.1016/0091-6749(84)90261-6	http://dx.doi.org/10.1016/0091-6749(84)90261-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TJ808	6206106				2022-12-18	WOS:A1984TJ80800013
J	COCKCROFT, DW; BERSCHEID, BA; RAMSHAW, IA; DOLOVICH, J				COCKCROFT, DW; BERSCHEID, BA; RAMSHAW, IA; DOLOVICH, J			SPOROBOLOMYCES - A POSSIBLE CAUSE OF EXTRINSIC ALLERGIC ALVEOLITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SASKATCHEWAN HOSP,DEPT MED,SASKATOON S7N 0W8,SASKATCHEWAN,CANADA; UNIV SASKATCHEWAN HOSP,DEPT MICROBIOL,SASKATOON S7N 0W8,SASKATCHEWAN,CANADA; ST JOSEPHS HOSP,REG CHEST & ALLERGY UNIT,HAMILTON L8N 1Y4,ONTARIO,CANADA	University of Saskatchewan; University of Saskatchewan; McGill University; McMaster University								BISBY GR, 1929, FUNGI MANITOBA, P80; BRUCE RA, 1963, INT ARCH ALLER A IMM, V22, P294, DOI 10.1159/000229372; BULLER AH, 1958, RES FUNGI, V5, P171; CALDWELL JR, 1973, J ALLERGY CLIN IMMUN, V52, P225, DOI 10.1016/0091-6749(73)90060-2; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; EIDINGER D, 1977, CELL IMMUNOL, V30, P82, DOI 10.1016/0008-8749(77)90049-1; EVANS RG, 1965, ACTA ALLERGOL, V20, P197, DOI 10.1111/j.1398-9995.1965.tb03370.x; FINK JN, 1972, CHEST, V62, P277, DOI 10.1378/chest.62.3.277; HANSEN PJ, 1974, INT ARCH ALLER A IMM, V47, P498, DOI 10.1159/000231244; LAST FT, 1956, REV APPL MYCOLOGY, V35, P430; MOORE VL, 1974, J ALLERGY CLIN IMMUN, V53, P319, DOI 10.1016/0091-6749(74)90115-8; MUIR DCF, 1972, CLIN ASPECTS INHALED, P54; MUNOZ J, 1971, METHODS IMMUNOLOGY I, V3, P146; RICHERSON HB, 1980, PULMONARY DISEASES D, P691; SCHATZ M, 1977, J ALLERGY CLIN IMMUN, V60, P27, DOI 10.1016/0091-6749(77)90079-3; SKINNER CE, 1947, HENRICIS MOLDS YEAST, P300	16	14	15	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	3					305	309		10.1016/0091-6749(83)90036-2	http://dx.doi.org/10.1016/0091-6749(83)90036-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RH938	6684133	Bronze			2022-12-18	WOS:A1983RH93800012
J	HAYDIK, IB				HAYDIK, IB			HISTAMINE DETERMINATION BY RADIOIMMUNOASSAY (RIA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	14	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					152	152		10.1016/0091-6749(83)90380-9	http://dx.doi.org/10.1016/0091-6749(83)90380-9			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ462					2022-12-18	WOS:A1983PZ46200257
J	HERMAN, JJ				HERMAN, JJ			INTRACTABLE SNEEZING DUE TO IGE-MEDIATED TRIETHANOLAMINE SENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HERMAN, JJ (corresponding author), NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DEPT PEDIAT,DIV ALLERGY,CHICAGO,IL 60614, USA.							BOOTH BH, 1980, DIAGNOSIS IMMEDIATE, P88; Brubaker AP, 1919, J AMER MED ASSOC, V73, P585, DOI 10.1001/jama.1919.02610340017004; CASTELAIN PYM, 1967, SOC FRANC DERM SYPH, V74, P562; CO S, 1979, ARCH NEUROL-CHICAGO, V36, P111, DOI 10.1001/archneur.1979.00500380081012; EVERETT HC, 1964, NEUROLOGY, V14, P483, DOI 10.1212/WNL.14.5.483; FISHER AA, 1971, ARCH DERMATOL, V104, P286, DOI 10.1001/archderm.104.3.286; JUNGALWALA FB, 1975, BIOCHEM J, V145, P517, DOI 10.1042/bj1450517; KAPLAN MJ, 1970, ANN ALLERGY, V28, P24; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; PATTERSON R, 1978, J IMMUNOL, V120, P66; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182	12	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	3					339	344		10.1016/0091-6749(83)90089-1	http://dx.doi.org/10.1016/0091-6749(83)90089-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH188	6186715				2022-12-18	WOS:A1983QH18800011
J	KRZANOWSKI, JJ; SZENTIVANYI, A				KRZANOWSKI, JJ; SZENTIVANYI, A			REFLECTIONS ON SOME ASPECTS OF CURRENT RESEARCH IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											KRZANOWSKI, JJ (corresponding author), UNIV S FLORIDA,COLL MED,DEPT PHARMACOL & THERAPEUT,TAMPA,FL 33612, USA.							ABRAMSKY O, 1975, CLIN EXP IMMUNOL, V19, P11; AHLQUIST RP, 1977, FED PROC, V36, P2572; ALMON RR, 1974, SCIENCE, V186, P55, DOI 10.1126/science.186.4158.55; APOLD J, 1977, J ALLERGY CLIN IMMUN, V59, P343, DOI 10.1016/0091-6749(77)90015-X; BENFEY BG, 1975, NATURE, V256, P745, DOI 10.1038/256745a0; BENFEY BG, 1978, FED PROC, V37, P686; BENFEY BG, 1977, FED PROC, V36, P2575; BENFEY BG, 1979, TRENDS AUTONOMIC PHA, V1, P289; BENFREY BG, 1976, NATURE, V259, P252; BHATIA SP, 1975, BRIT J CLIN PHARMACO, V2, P463, DOI 10.1111/j.1365-2125.1975.tb00557.x; BISHOPRIC NH, 1980, J ALLERGY CLIN IMMUN, V65, P29, DOI 10.1016/0091-6749(80)90173-6; BROOKS SM, 1979, J ALLERGY CLIN IMMUN, V63, P401, DOI 10.1016/0091-6749(79)90213-6; BUSSE WW, 1976, J ALLERGY CLIN IMMUN, V58, P586, DOI 10.1016/0091-6749(76)90205-0; BUSSE WW, 1979, AM REV RESPIR DIS, V119, P561; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; CHAN TM, 1979, J BIOL CHEM, V254, P2428; COOPER KD, 1982, CLIN RES, V30, P27; CORWIN EJ, 1982, AM J PHYSL, V243, P23; CSEUZ R, 1973, ENDOCRINOLOGY, V93, P752, DOI 10.1210/endo-93-3-752; DRACHMAN DB, 1978, NEW ENGL J MED, V298, P1116, DOI 10.1056/NEJM197805182982004; EYRE P, 1982, PHARM HISTAMINE RECE, P289; FLIER JS, 1975, SCIENCE, V190, P63, DOI 10.1126/science.170678; FRASER CM, 1980, P NATL ACAD SCI-BIOL, V77, P7034, DOI 10.1073/pnas.77.12.7034; FRASER CM, 1981, NEW ENGL J MED, V305, P1165, DOI 10.1056/NEJM198111123052001; FRASER CM, J CELL BIOCH; GALANT SP, 1979, J INVEST DERMATOL, V72, P330, DOI 10.1111/1523-1747.ep12531768; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; GALANT SP, 1980, J CLIN INVEST, V65, P577, DOI 10.1172/JCI109702; GIANNETTI A, 1979, P INT S ATOPIC DERMA; GREENACRE JK, 1978, BRIT J CLIN PHARMACO, V5, P199, DOI 10.1111/j.1365-2125.1978.tb01624.x; GUELLAEN G, 1978, J BIOL CHEM, V253, P1114; HARRISON LC, 1978, GENETIC CONTROL AUTO, P61; HARVEY JE, 1982, THORAX, V37, P280, DOI 10.1136/thx.37.4.280; HASEGAWA M, 1983, J ALLERGY CLIN IMMUN, V71, P230, DOI 10.1016/0091-6749(83)90104-5; HOLGATE ST, 1977, LANCET, V2, P375; HOLGATE ST, 1980, CLIN SCI, V59, P155, DOI 10.1042/cs0590155; HOMCY CJ, 1980, J CLIN INVEST, V65, P1111, DOI 10.1172/JCI109764; JENNE JW, 1982, J ALLERGY CLIN IMMUN, V70, P413, DOI 10.1016/0091-6749(82)90002-1; JENNE JW, 1978, J ALLERGY CLIN IMMUN, V60, P346; KAHN CR, 1976, NEW ENGL J MED, V294, P739, DOI 10.1056/NEJM197604012941401; KALISKER A, 1977, J ALLERGY CLIN IMMUN, V60, P259, DOI 10.1016/0091-6749(77)90141-5; KARIMAN K, 1980, LUNG, V158, P41, DOI 10.1007/BF02713701; KARIMAN K, 1977, CLIN RES, V25, P503; KEIGHLEY JF, 1966, ANN INTERN MED, V65, P985, DOI 10.7326/0003-4819-65-5-985; KRALL JF, 1980, J PHARMACOL EXP THER, V214, P554; KRZANOWSKI JJ, 1979, CLIN EXP PHARMACOL P, V6, P111, DOI 10.1111/j.1440-1681.1979.tb00013.x; KUNOS G, 1978, ANNU REV PHARMACOL, V18, P291, DOI 10.1146/annurev.pa.18.040178.001451; KUNOS G, 1968, NATURE, V217, P1077, DOI 10.1038/2171077a0; KUNOS G, 1980, TRENDS PHARMACOL SCI, V1, P282, DOI 10.1016/0165-6147(80)90023-1; KUNOS G, 1983, J BIOL CHEM, V258, P326; KUNOS G, 1981, ADRENOCEPTORS CATECH, P297; LANG P, 1978, J ALLERGY CLIN IMMUN, V61, P248, DOI 10.1016/0091-6749(78)90199-9; LARSSON S, 1977, J ALLERGY CLIN IMMUN, V59, P93, DOI 10.1016/0091-6749(77)90209-3; LINDSTROM JM, 1976, NEUROLOGY, V26, P1054, DOI 10.1212/WNL.26.11.1054; MAKINO S, 1977, J ALLERGY CLIN IMMUN, V59, P348, DOI 10.1016/0091-6749(77)90016-1; MANLEY SW, 1974, J ENDOCRINOL, V61, P437, DOI 10.1677/joe.0.0610437; MENDELSOHN J, 1979, J CLIN INVEST, V63, P1124, DOI 10.1172/JCI109405; MORRIS HG, 1977, CLIN PHARMACOL THER, V22, P352; MOTULSKY HJ, 1982, NEW ENGL J MED, V307, P18, DOI 10.1056/NEJM198207013070104; MOTULSKY HJ, BIOCH PHARM; NELSON HS, 1975, J ALLERGY CLIN IMMUN, V55, P299, DOI 10.1016/0091-6749(75)90002-0; NIAUDET P, 1976, EUR J IMMUNOL, V6, P834, DOI 10.1002/eji.1830061117; NICKERSON M, 1977, FED PROC, V36, P2580; OKAJIMA F, 1982, ARCH BIOCHEM BIOPHYS, V213, P658, DOI 10.1016/0003-9861(82)90596-3; PAGE ED, 1978, BIOCHEM PHARMACOL, V27, P953, DOI 10.1016/0006-2952(78)90424-0; PARKER C W, 1972, Clinical Research, V20, P418; PARKER CW, 1977, J INVEST DERMATOL, V68, P302, DOI 10.1111/1523-1747.ep12494569; PATRICK J, 1973, P NATL ACAD SCI USA, V70, P3334, DOI 10.1073/pnas.70.12.3334; PLUMMER AL, 1978, CHEST, V73, P949, DOI 10.1378/chest.73.6.949; POLSON JB, 1982, ALLERGOL IMMUNOPATH, V10, P101; POPOVIC WJ, 1979, J CLIN INVEST, V64, P56, DOI 10.1172/JCI109463; PREIKSAITIS HG, 1979, LIFE SCI, V24, P35, DOI 10.1016/0024-3205(79)90277-7; PREIKSAITIS HG, 1982, J BIOL CHEM, V257, P4321; REED CE, 1976, J INVEST DERMATOL, V67, P333, DOI 10.1111/1523-1747.ep12514494; ROBERTS JM, 1977, NATURE, V270, P624, DOI 10.1038/270624a0; RUOHO AE, 1980, J ALLERGY CLIN IMMUN, V66, P46, DOI 10.1016/0091-6749(80)90137-2; SAFKO MJ, 1981, J ALLERGY CLIN IMMUN, V68, P218, DOI 10.1016/0091-6749(81)90187-1; SANO Y, 1981, CLIN RES, V29, P172; SANO Y, 1983, J ALLERGY CLIN IMMUN; SANO Y, 1979, CLIN RES, V27, P403; SCHULZ V, 1972, INT J CLIN PHARM S, V4, P167; SHARMA VK, 1978, J BIOL CHEM, V253, P5277; SHEPPARD JR, 1977, NATURE, V269, P693, DOI 10.1038/269693a0; SIMI WW, 1977, J ALLERGY CLIN IMMUN, V59, P178, DOI 10.1016/0091-6749(77)90222-6; SIMONSSON BG, 1972, SCAND J RESPIR DIS, V53, P227; SMITH BR, 1974, LANCET, V2, P427; SNAVELY MD, 1982, CLIN EXP HYPERTENS, V4, P829, DOI 10.3109/10641968209061616; STERNBERG J, 1952, ARCH DERMATOL, V65, P392; SVEDMYR NLV, 1976, CHEST, V69, P479, DOI 10.1378/chest.69.4.479; SZENTIVANYI A, 1980, J ALLERGY CLIN IMMUN, V65, P5, DOI 10.1016/0091-6749(80)90170-0; Szentivanyi A, 1979, Triangle, V18, P109; Szentivanyi A, 1979, Ann N Y Acad Sci, V332, P295, DOI 10.1111/j.1749-6632.1979.tb47123.x; SZENTIVANYI A, 1979, REV FR ALLERGOL, V19, P205, DOI 10.1016/S0335-7457(79)80006-4; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; SZENTIVANYI A, 1983, ADV IMMUNOPHARMACOL, V2, P269; SZENTIVANYI A, 1983, P INT S RECEPTORS CH, P38; SZENTIVANYI A, 1982, P C EUROPEAN ACADEMY, P104; Szentivanyi A, 1980, ACTA DERM-VENEREOL, VS92, P19; Szentivanyi A, 1980, ADV ALLERGOLOGY CLIN, P301; Szentivanyi A, 1971, TXB IMMUNOLOGICAL DI, P356; Szentivanyi A, 1978, ALLERGY PRINCIPLES P, P256; Szentivanyi A, 1980, PATHOMECHANISMUS PAT, P460; Szentivanyi A, 1980, ALLERGIC DISEASES IN, P173; SZENTIVANYI A, 1982, ADRENERGIC CHOLINERG, P16; Szentivanyi A, 1980, PATHOMECHANISMUS PAT, P511; SZENTIVANYI A, 1983, ALLERGY PRINCIPLES P, pCH12; SZENTIVANYI A, 1982, P INT C NETHERLANDS, P38; SZENTIVANYI M, 1973, NATURE-NEW BIOL, V243, P276, DOI 10.1038/newbio243276a0; SZENTIVANYI M, 1970, American Journal of Physiology, V218, P869; SZENTIVANYI M, 1978, 7TH P INT C PHARM OX, P271; TASHKIN DP, 1982, AM REV RESPIR DIS, V125, P185; TERPSTRA GK, 1983, 5TH P INT C CYCL NUC, P117; TOHMEH JF, 1980, J CLIN INVEST, V65, P836, DOI 10.1172/JCI109735; UPRICHARD DC, 1977, J BIOL CHEM, V252, P6450; VENTER JC, 1980, SCIENCE, V207, P1361, DOI 10.1126/science.6153472; VENTER JC, 1983, TRENDS PHARMACOL SCI, V4, P256; VENTER JC, 1980, SCIENCE, V207, P1316; VENTER JC, 1981, MONOCLONAL ANTIBODIE, P119; VERTESI C, 1978, 7TH P INT C PHARM OX, P271; WILLIAMS LT, 1976, J CLIN INVEST, V57, P149, DOI 10.1172/JCI108254; WILLIAMS LT, 1978, RECEPTOR BINDING STU, P127; WILLIAMS RS, 1981, J APPL PHYSIOL, V51, P1232, DOI 10.1152/jappl.1981.51.5.1232; WILSON AF, 1976, J ALLERGY CLIN IMMUN, V58, P204, DOI 10.1016/0091-6749(76)90156-1	123	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	5					433	442		10.1016/0091-6749(83)90578-X	http://dx.doi.org/10.1016/0091-6749(83)90578-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RR916	6313790				2022-12-18	WOS:A1983RR91600002
J	THOMSON, NC; OBYRNE, P; HARGREAVE, FE				THOMSON, NC; OBYRNE, P; HARGREAVE, FE			PROLONGED ASTHMATIC RESPONSES TO INHALED METHACHOLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP,DEPT MED,HAMILTON L8N 1Y4,ONTARIO,CANADA; MCMASTER UNIV,HAMILTON L8S 4L8,ONTARIO,CANADA	McGill University; McMaster University; McMaster University				Thomson, Neil/0000-0003-1632-6630; O'Byrne, Paul/0000-0003-0979-281X				ADKINSON NF, 1980, AM REV RESPIR DIS, V121, P911; BANDOUVAKIS J, 1981, BRIT J DIS CHEST, V75, P295, DOI 10.1016/0007-0971(81)90009-7; BEGIN P, 1982, Journal of Allergy and Clinical Immunology, V69, P105; BRINK C, 1980, BRIT J PHARMACOL, V69, P383, DOI 10.1111/j.1476-5381.1980.tb07026.x; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COLTON T, 1974, STAT MED, P219; FANTOZZI R, 1978, NATURE, V273, P473, DOI 10.1038/273473a0; FOREMAN JC, 1981, ANNU REV PHARMACOL, V21, P63, DOI 10.1146/annurev.pa.21.040181.000431; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; NADEL JA, 1981, J ALLERGY CLIN IMMUN, V67, P417; OBYRNE PM, UNPUB PROTECTIVE EFF; OREHEK J, 1975, J PHARMACOL EXP THER, V194, P554; OREHEK J, 1973, NATURE-NEW BIOL, V245, P84, DOI 10.1038/newbio245084a0; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; STEEL L, 1979, J ALLERGY CLIN IMMUN, V64, P287, DOI 10.1016/0091-6749(79)90146-5; SWEATMAN WJ, 1968, NATURE, V217, P69, DOI 10.1038/217069a0; TAYLOR P, 1980, PHARMACOL BASIS THER, P92; THOMSON NC, UNPUB ROLE AIRWAY SM; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9	22	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	4					357	362		10.1016/0091-6749(83)90062-3	http://dx.doi.org/10.1016/0091-6749(83)90062-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QL121	6833676				2022-12-18	WOS:A1983QL12100001
J	DAVIS, PB; LIEBERMAN, P				DAVIS, PB; LIEBERMAN, P			NORMAL ALPHA-2-ADRENERGIC RESPONSES IN PLATELETS FROM PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TENNESSEE,CTR HLTH SCI,DEPT MED,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center								ALEXANDER RW, 1978, J CLIN INVEST, V61, P1136, DOI 10.1172/JCI109028; BLAISS M, 1981, J ALLERGY CLIN IMMUN, V67, P5; BROWN BL, 1971, BIOCHEM J, V121, P562; BROWN J K, 1981, American Review of Respiratory Disease, V123, P51; HARRIS DM, 1975, POSTGRAD MED J, V51, P20; HARWELL WB, 1973, J ALLERGY CLIN IMMUN, V51, P274, DOI 10.1016/0091-6749(73)90129-2; HASEGAWA M, 1981, J ALLERGY CLIN IMMUN, V67, P59; HENDERSON WR, 1979, NEW ENGL J MED, V300, P642, DOI 10.1056/NEJM197903223001203; HOFFMAN BB, 1980, NEW ENGL J MED, V302, P1390, DOI 10.1056/NEJM198006193022504; HSU CY, 1979, J PHARMACOL EXP THER, V208, P366; INSEL PA, 1978, BIOCHEMISTRY, V17, P5261; KAFKA MS, 1977, LIFE SCI, V21, P1429, DOI 10.1016/0024-3205(77)90197-7; LEE K, 1981, J ALLERGY CLIN IMMUN, V67, P59; MACCIA CA, 1977, J ALLERGY CLIN IMMUN, V59, P101, DOI 10.1016/0091-6749(77)90210-X; NEWMAN KD, 1978, J CLIN INVEST, V61, P395, DOI 10.1172/JCI108950; SANO J, 1981, J ALLERGY CLIN IMMUN, V67, P59; SCHUYLER MR, 1981, J ALLERGY CLIN IMMUN, V68, P72, DOI 10.1016/0091-6749(81)90126-3; Szentivanyi A, 1979, Triangle, V18, P109; Williams LT, 1978, RECEPTOR BINDING STU	19	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	1					35	38		10.1016/0091-6749(82)90084-7	http://dx.doi.org/10.1016/0091-6749(82)90084-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ377	6119331				2022-12-18	WOS:A1982MZ37700006
J	WEISSBERGER, D; OLIVER, W; ABRAHAM, WM; WANNER, A				WEISSBERGER, D; OLIVER, W; ABRAHAM, WM; WANNER, A			IMPAIRED TRACHEAL MUCUS TRANSPORT IN ALLERGIC BRONCHOCONSTRICTION - EFFECT OF TERBUTALINE PRETREATMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MT SINAI MED CTR,DEPT MED,DIV PULM DIS,MIAMI BEACH,FL 33140	Mount Sinai Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL020989] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-20989] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMED T, 1980, American Review of Respiratory Disease, V121, P106; BALFRE K, 1980, FED PROC, V39, P835; BONE JF, 1962, AM J VET RES, V23, P1113; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COOK CD, 1957, J CLIN INVEST, V36, P440, DOI 10.1172/JCI103441; CRUZ RS, 1974, AM REV RESPIR DIS, V109, P458; DAIN D, 1975, J APPL PHYSIOL, V38, P96, DOI 10.1152/jappl.1975.38.1.96; FRIEDMAN M, 1977, AM REV RESPIR DIS, V115, P67; KALINER M, 1975, ANNU REV PHARMACOL, V15, P177, DOI 10.1146/annurev.pa.15.040175.001141; MEZEY RJ, 1978, AM REV RESPIR DIS, V118, P677, DOI 10.1164/arrd.1978.118.4.677; MOSSBERG B, 1976, SCAND J RESPIR DIS, V57, P119; MOSSBERG B, 1977, SCAND J RESP DIS   S, V101, P71; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; SACKNER MA, 1975, CHEST, V68, P774, DOI 10.1378/chest.68.6.774; SACKNER MA, 1979, B EUR PHYSIOPATH RES, V15, P505; WANNER A, 1977, AM REV RESPIR DIS, V116, P73; WANNER A, 1975, J APPL PHYSIOL, V39, P950, DOI 10.1152/jappl.1975.39.6.950; WANNER A, 1979, J APPL PHYSIOL, V47, P917, DOI 10.1152/jappl.1979.47.5.917	18	14	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	5					357	362		10.1016/0091-6749(81)90080-4	http://dx.doi.org/10.1016/0091-6749(81)90080-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ563	7229224				2022-12-18	WOS:A1981LQ56300005
J	DOLOVICH, M; OBMINSKI, G; COCKCROFT, DW; HARGREAVE, FE; NEWHOUSE, MT				DOLOVICH, M; OBMINSKI, G; COCKCROFT, DW; HARGREAVE, FE; NEWHOUSE, MT			STANDARDIZATION OF INHALATION TESTS - INFLUENCE OF METHOD OF AEROSOL GENERATION AND INHALATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	3					165	165						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GN274					2022-12-18	WOS:A1979GN27400101
J	FAIRSHTER, RD; NOVEY, HS; MARCHIOLI, LE; WILSON, AF				FAIRSHTER, RD; NOVEY, HS; MARCHIOLI, LE; WILSON, AF			LARGE AIRWAY CONSTRICTION IN ALLERGIC RHINITIS - RESPONSE TO INHALATION OF HELIUM-OXYGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FAIRSHTER, RD (corresponding author), UNIV CALIF IRVINE,DEPT MED,ORANGE,CA 92668, USA.							ANTIC R, 1976, AM REV RESPIR DIS, V114, P851; BENETAR SR, 1975, AM REV RESPIR DIS, V111, P126; BOREN HG, 1966, AM J MED, V41, P96, DOI 10.1016/0002-9343(66)90008-8; BUIST AS, 1973, AM REV RESPIR DIS, V108, P1078; BUIST AS, 1973, AM REV RESPIR DIS, V107, P744; DESPAS PJ, 1972, J CLIN INVEST, V51, P3235, DOI 10.1172/JCI107150; DOGGETT W E, 1976, American Review of Respiratory Disease, V113, P158; DOSMAN J, 1975, J CLIN INVEST, V55, P1090, DOI 10.1172/JCI108010; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; FAIRSHTER RD, 1977, J ALLERGY CLIN IMMUN, V59, P243, DOI 10.1016/0091-6749(77)90157-9; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; GROSSMAN J, 1975, J ALLERGY CLIN IMMUN, V55, P49, DOI 10.1016/S0091-6749(75)80007-8; HOWARD PF, 1976, CHEST, V70, P429; INGRAM RH, 1966, AM REV RESPIR DIS, V94, P56; INGRAM RH, 1977, NEW ENGL J MED, V297, P596; INGRAM RH, 1977, J CLIN INVEST, V59, P696, DOI 10.1172/JCI108688; KORY RC, 1961, AM J MED, V30, P243, DOI 10.1016/0002-9343(61)90096-1; MACKLEM PT, 1967, J APPL PHYSIOL, V22, P395, DOI 10.1152/jappl.1967.22.3.395; MORGAN EJ, 1976, THORAX, V31, P80, DOI 10.1136/thx.31.1.80; MORRIS JF, 1975, AM REV RESPIR DIS, V111, P755; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; OGILVIE CM, 1957, J CLIN INVEST, V36, P1, DOI 10.1172/JCI103402; RONCORONI AJ, 1975, ACTA ALLERGOL, V30, P375, DOI 10.1111/j.1398-9995.1975.tb01673.x; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; WELLMAN JJ, 1976, J APPL PHYSIOL, V41, P153, DOI 10.1152/jappl.1976.41.2.153	25	14	14	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	1					39	46		10.1016/0091-6749(79)90160-X	http://dx.doi.org/10.1016/0091-6749(79)90160-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GE110	758340				2022-12-18	WOS:A1979GE11000006
J	GRAFFLONNEVIG, V				GRAFFLONNEVIG, V			DIURNAL EXPIRATORY FLOW AFTER INHALATION OF FREONS AND FENOTEROL IN CHILDHOOD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV HOSP,KAROLINSKA INST,DEPT PEDIAT,HUDDINGE,SWEDEN	Karolinska Institutet								BACKLUND L, 1968, SCAND J RESPIR DIS, V49, P284; BJURE J, 1963, ACTA PAEDIATR, V52, P232, DOI 10.1111/j.1651-2227.1963.tb03775.x; CLARK TJH, 1977, BRIT J DIS CHEST, V71, P87, DOI 10.1016/0007-0971(77)90087-0; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DOLLERY CT, 1970, LANCET, V2, P1164; GRAFFLONNEVIG V, 1976, ACTA ALLERGOL, V31, P463, DOI 10.1111/j.1398-9995.1976.tb01496.x; HETZEL MR, 1977, THORAX, V32, P418, DOI 10.1136/thx.32.4.418; JACK D, 1971, BRIT MED J, V2, P708, DOI 10.1136/bmj.2.5763.708-b; KALES A, 1970, J ALLERGY, V46, P300, DOI 10.1016/0021-8707(70)90070-5; MACDONALD JB, 1976, BRIT MED J, V1, P1493, DOI 10.1136/bmj.1.6024.1493; MCCLURE DA, 1972, TOXICOL APPL PHARM, V22, P221, DOI 10.1016/0041-008X(72)90172-X; MINETTE A, 1972, INT J CLIN PHARMAC S, V4, P120; MORGAN A, 1972, INT J APPL RADIAT IS, V23, P285, DOI 10.1016/0020-708X(72)90076-2; PENNOCK BE, 1977, CHEST, V72, P731, DOI 10.1378/chest.72.6.731; REINBERG A, 1972, B PHYSIO-PATHOL RESP, V8, P663; SILVERGLADE A, 1972, J AMER MED ASSOC, V222, P827, DOI 10.1001/jama.222.7.827; SOUTAR CA, 1975, THORAX, V30, P436, DOI 10.1136/thx.30.4.436; STERLING GM, 1969, THORAX, V24, P228, DOI 10.1136/thx.24.2.228; TAYLOR GJ, 1970, J AMER MED ASSOC, V214, P81, DOI 10.1001/jama.214.1.81; TURNERWARWICK M, 1977, BRIT J DIS CHEST, V71, P73, DOI 10.1016/0007-0971(77)90086-9; VALIC F, 1977, BRIT J IND MED, V34, P130; 1977, LANCET, V2, P912	22	14	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					534	538		10.1016/0091-6749(79)90064-2	http://dx.doi.org/10.1016/0091-6749(79)90064-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX840	574523	Bronze			2022-12-18	WOS:A1979HX84000010
J	WASSERMAN, SI; CENTER, DM				WASSERMAN, SI; CENTER, DM			RELEVANCE OF NEUTROPHIL CHEMOTACTIC FACTORS TO ALLERGIC DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											WASSERMAN, SI (corresponding author), UNIV CALIF SAN DIEGO HOSP,SCH MED,SAN DIEGO,CA 92103, USA.			Center, David/0000-0002-5879-7978					0	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	4					231	234		10.1016/0091-6749(79)90137-4	http://dx.doi.org/10.1016/0091-6749(79)90137-4			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HQ469	479473				2022-12-18	WOS:A1979HQ46900001
J	NEIBURGER, RG; NEIBURGER, JB; DOCKHORN, RJ				NEIBURGER, RG; NEIBURGER, JB; DOCKHORN, RJ			DISTRIBUTION OF PERIPHERAL BLOOD-T AND BLOOD-B LYMPHOCYTE MARKERS IN ATOPIC CHILDREN AND CHANGES DURING IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NEIBURGER, RG (corresponding author), CHILDRENS MERCY HOSP,ALLERGY IMMUNOL SECT,KANSAS CITY,MO 64108, USA.							ABDOU NI, 1973, CLIN EXP IMMUNOL, V13, P45; ABDOU NI, 1973, J CLIN INVEST, V52, P2218, DOI 10.1172/JCI107407; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CORMANE RH, 1974, BRIT J DERMATOL, V90, P597, DOI 10.1111/j.1365-2133.1974.tb06687.x; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GREY HM, 1971, J CLIN INVEST, V50, P2368, DOI 10.1172/JCI106735; JONDAL M, 1972, J EXP MED, V136, P207, DOI 10.1084/jem.136.2.207; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LIN MS, 1977, J PEDIATR-US, V91, P222, DOI 10.1016/S0022-3476(77)80816-0; NEIBURGER JB, 1976, INFECT IMMUN, V14, P118, DOI 10.1128/IAI.14.1.118-121.1976; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; PRUZANSKY JJ, 1968, J AMER MED ASSOC, V203, P805, DOI 10.1001/jama.203.9.805; RABELLINO E, 1971, J EXP MED, V133, P156, DOI 10.1084/jem.133.1.156; RAFF MC, 1970, IMMUNOLOGY, V19, P637; REISMAN RE, 1975, INT ARCH ALLER A IMM, V48, P721, DOI 10.1159/000231360; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; WYBRAN J, 1972, J CLIN INVEST, V51, P2537, DOI 10.1172/JCI107069	19	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	2					88	92		10.1016/0091-6749(78)90230-0	http://dx.doi.org/10.1016/0091-6749(78)90230-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EL413	304454				2022-12-18	WOS:A1978EL41300004
J	PETTY, TL				PETTY, TL			CHRONIC-BRONCHITIS VERSUS ASTHMA - OR WHATS IN A NAME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											PETTY, TL (corresponding author), UNIV COLORADO, MED CTR, DENVER, CO 80262 USA.							BATES DV, 1973, AM REV RESPIR DIS, V108, P1043; BURROWS B, 1978, COURSE PROGNOSIS ADV; FLETCHER C, 1976, NATURAL HISTORY CHRO; KANNER RE, 1978, CHEST, V74, P241, DOI 10.1378/chest.74.3.241; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MITCHELL RS, 1976, AM REV RESPIR DIS, V114, P137; PETTY TL, 1973, CHEST, V64, P146, DOI 10.1378/chest.64.1.146; PETTY TL, 1970, CHEST, V57, P204, DOI 10.1378/chest.57.2.204; PETTY TL, 1976, AM REV RESPIR DIS, V114, P881; REED CE, 1974, MED CLIN N AM, V58, P55, DOI 10.1016/S0025-7125(16)32176-9; SIMPSON DL, 1978, AM REV RESPIR DIS, V117, P449; SPECTOR S, 1975, NEW DIRECTIONS ASTHM, pCH18; THURLBECK WM, 1977, CHEST, V72, P341, DOI 10.1378/chest.72.3.341; 1971, IDENTIFICATION ASTHM	14	14	14	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	6					323	324		10.1016/0091-6749(78)90130-6	http://dx.doi.org/10.1016/0091-6749(78)90130-6			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GA292	712017	Bronze			2022-12-18	WOS:A1978GA29200001
J	NEWMAN, S; GLOVSKY, MM; GHEKIERE, L; ALENTY, A				NEWMAN, S; GLOVSKY, MM; GHEKIERE, L; ALENTY, A			QUANTITATIVE REQUIREMENTS FOR C3 TO INDUCE FORSSMAN SYSTEMIC SHOCK AND CUTANEOUS HEMORRHAGIC VASCULITIS IN GUINEA-PIGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SO CALIF PERMANENTE MED GRP,DEPT ALLERGY & CLIN IMMUNOL,LOS ANGELES,CA 90027; KAISER FDN HOSP,LOS ANGELES,CA 90027	Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; Kaiser Permanente								BOKISCH VA, 1973, NEW ENGL J MED, V289, P996, DOI 10.1056/NEJM197311082891902; BORSOS T, 1967, J IMMUNOL, V99, P263; CHARLESWORTH JA, 1974, J CLIN INVEST, V53, P1578, DOI 10.1172/JCI107708; COCHRANE CG, 1970, J IMMUNOL, V105, P55; FRIEDBERGER E, 1910, Z IMMUNITATSFORSCH, V6, P179; GLOVSKY M, 1970, J IMMUNOL, V104, P1072; GLOVSKY MM, 1968, J IMMUNOL, V100, P979; GLOVSKY MM, 1976, J ALLERGY CLIN IMMUN, V57, P134, DOI 10.1016/0091-6749(76)90032-4; GLOVSKY MM, 1969, J IMMUNOL, V102, P1; HENSON PM, 1976, J EXP MED, V143, P937, DOI 10.1084/jem.143.4.937; HUMPHREY JF, 1954, IMMUNOLOGY, V2, P31; Hyde RR, 1927, AM J HYG, V7, P614, DOI 10.1093/oxfordjournals.aje.a120434; Hyde RR, 1927, AM J HYG, V7, P619, DOI 10.1093/oxfordjournals.aje.a120435; ISHIZAKA K, 1971, Clinical Allergy, V1, P9, DOI 10.1111/j.1365-2222.1971.tb02444.x; JENSEN JA, 1969, J EXP MED, V130, P217, DOI 10.1084/jem.130.2.217; JOHNSON AR, 1975, IMMUNOLOGY, V28, P1067; Kallos Paul, 1942, SCHXREIZ ZCITSCHR ALLG PATH U BAKT, V5, P97; KELLY JF, 1974, JAMA-J AM MED ASSOC, V227, P1431, DOI 10.1001/jama.1974.03230250055038; MAY JE, 1972, J IMMUNOL, V108, P1517; NELSON RA, 1965, INFLAMMATORY PROCESS, P819; Redfern WW, 1926, AM J HYG, V6, P276, DOI 10.1093/oxfordjournals.aje.a120015; RUDDY S, 1967, J IMMUNOL, V99, P1162; SPEAR GS, 1955, B JOHNS HOPKINS HOSP, V96, P199; TANAKA N, 1956, J IMMUNOL, V77, P198; TANNENBAUM H, 1975, J ALLERGY CLIN IMMUN, V56, P226, DOI 10.1016/0091-6749(75)90094-9; TSAI CC, 1973, AM J PATHOL, V72, P179; VYAS GN, 1968, LANCET, V2, P312	27	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	4					327	333		10.1016/0091-6749(77)90055-0	http://dx.doi.org/10.1016/0091-6749(77)90055-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DB886	850022				2022-12-18	WOS:A1977DB88600009
J	SIMI, WW; MILLER, WC				SIMI, WW; MILLER, WC			CLINICAL INVESTIGATION OF FENOTEROL, A NEW BRONCHODILATOR, IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									UNIV TEXAS, SCH MED, DEPT MED, DIV PULM, HOUSTON, TX 77025 USA	University of Texas System								BEARDSHAW J, 1974, CHEST, V65, P507, DOI 10.1378/chest.65.5.507; BERGNER RK, 1976, JAMA-J AM MED ASSOC, V235, P288, DOI 10.1001/jama.235.3.288; DACOSTA JL, 1973, MED J AUSTRALIA, V2, P588; EPSTEIN SW, 1973, AM REV RESPIR DIS, V108, P1367; FUNAHASHI A, 1976, AM REV RESPIR DIS, V113, P398; GILES RE, 1973, J PHARMACOL EXP THER, V186, P472; KAIK G, 1975, RESPIRATION, V32, P62, DOI 10.1159/000193636; LANDS AM, 1967, NATURE, V214, P597, DOI 10.1038/214597a0; LEIFER KN, 1975, ANN ALLERGY, V35, P69; MARSDEN CD, 1968, J PHYSIOL-LONDON, V194, pP70; MILLER J, 1967, J CLIN PHARMACOL N D, V7, P34, DOI 10.1002/j.1552-4604.1967.tb00027.x; MINETTE A, 1970, RESPIRATION, V27, P276, DOI 10.1159/000192688; NEWBALL HH, 1975, CHEST, V67, P311, DOI 10.1378/chest.67.3.311; ODONNELL SR, 1970, EUR J PHARMACOL, V12, P35, DOI 10.1016/0014-2999(70)90026-9; SVEDMYR NLV, 1976, CHEST, V69, P479, DOI 10.1378/chest.69.4.479; TASHKIN DP, 1975, CHEST, V68, P155, DOI 10.1378/chest.68.2.155; 1972, INT J PHARMACOL   S4, P129	17	14	14	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	2					178	181		10.1016/0091-6749(77)90222-6	http://dx.doi.org/10.1016/0091-6749(77)90222-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CV622	319143				2022-12-18	WOS:A1977CV62200014
J	ALLEGRA, J; TRAUTLEIN, J; DEMERS, L; FIELD, J; GILLIN, M				ALLEGRA, J; TRAUTLEIN, J; DEMERS, L; FIELD, J; GILLIN, M			PERIPHERAL PLASMA DETERMINATIONS OF PROSTAGLANDIN-E IN ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT MED,DIV INTERN MED & CLIN PATHOL,HERSHEY,PA 17033; PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT PATHOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health								DEMERS LM, 1974, PROSTAG OTH LIPID M, V5, P513, DOI 10.1016/S0090-6980(74)80026-2; FISHBURNE JI, 1972, OBSTET GYNECOL, V39, P892; MATHE AA, 1973, BRIT MED J, V1, P193, DOI 10.1136/bmj.1.5847.193; OKAZAKI T, 1974, J ALLERGY CLIN IMMUN, V53, P75; PARKER CW, 1973, ANN INTERN MED, V78, P963, DOI 10.7326/0003-4819-78-6-963; PARKER CW, 1973, J CLIN INVEST, V52, P1336, DOI 10.1172/JCI107305; SHAW JO, 1975, CHEST, V68, P75, DOI 10.1378/chest.68.1.75; SMITH AP, 1972, BRIT MED J, V3, P212, DOI 10.1136/bmj.3.5820.212	8	14	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	5					546	550		10.1016/0091-6749(76)90200-1	http://dx.doi.org/10.1016/0091-6749(76)90200-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CL088	977861				2022-12-18	WOS:A1976CL08800002
J	BAKER, J; HONG, R; DICK, E; REED, C				BAKER, J; HONG, R; DICK, E; REED, C			ASTHMA, IGA DEFICIENCY, AND RESPIRATORY-INFECTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ASTHMA & ALLERGIC DIS CTR, MADISON, WI USA; UNIV WISCONSIN, SCH MED, DEPT PEDIAT, MADISON, WI 53706 USA; UNIV WISCONSIN, SCH MED, DEPT PREVENT MED, MADISON, WI 53706 USA; UNIV WISCONSIN, SCH MED, DEPT MED, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								AMMANN AJ, 1971, MEDICINE, V50, P223, DOI 10.1097/00005792-197105000-00004; BARRETTC.E, 1971, AM REV RESPIR DIS, V103, P845; BARRY AL, 1972, APPL MICROBIOL, V24, P31, DOI 10.1128/AEM.24.1.31-33.1972; BUCKLEY RH, 1969, NEW ENGL J MED, V281, P465, DOI 10.1056/NEJM196908282810903; BUCKLEY RH, 1975, CLINICAL IMMUNOLOGIC, P134; CHANOCK ROBERT M., 1961, PERSPECTIVES IN VIROL, V2, P126; DICK EC, 1966, ARCH ENVIRON HEALTH, V13, P450, DOI 10.1080/00039896.1966.10664594; DORFF GJ, 1973, AM J MED SCI, V266, P349, DOI 10.1097/00000441-197311000-00002; GLEZEN WP, 1971, J PEDIATR-US, V78, P397, DOI 10.1016/S0022-3476(71)80218-4; HALL CB, 1975, J INFECT DIS, V131, P1, DOI 10.1093/infdis/131.1.1; HARVEY HS, 1961, NEW ENGL J MED, V264, P684, DOI 10.1056/NEJM196104062641402; HOPESIMPSON RE, 1969, PROGR MEDICAL VIROLO, V2, P354; HORN MEC, 1973, CHEST, V63, pS44; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MINOR TE, 1974, J PEDIATR-US, V85, P472, DOI 10.1016/S0022-3476(74)80447-6; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; PIRTLE JK, 1969, AM REV RESPIR DIS, V100, P831; SALVAGGIO J E, 1973, Clinical Allergy, V3, P43, DOI 10.1111/j.1365-2222.1973.tb01308.x; STOKES CR, 1974, LANCET, V2, P485; TAGER I, 1975, NEW ENGL J MED, V292, P563, DOI 10.1056/NEJM197503132921105; TAYLOR B, 1973, LANCET, V2, P111; TSE KS, 1973, J ALLERGY CLIN IMMUN, V51, P208, DOI 10.1016/0091-6749(73)90140-1; VASSALLO CL, 1970, AM REV RESPIR DIS, V101, P245; VYAS GN, 1968, LANCET, V2, P312	24	14	14	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	6					713	721		10.1016/0091-6749(76)90182-2	http://dx.doi.org/10.1016/0091-6749(76)90182-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP077	993484				2022-12-18	WOS:A1976CP07700009
J	MATSUMURA, Y; TAN, EM; VAUGHAN, JH				MATSUMURA, Y; TAN, EM; VAUGHAN, JH			HISTAMINE HYPERSENSITIVITY IN MICE INDUCED BY BORDETELLA-PERTUSSIS OR PHARMACOLOGIC BETA-ADRENERGIC BLOCKADE - EFFECTS OF ADRENERGIC, CHOLINERGIC, AND OTHER DRUGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN,DIV ALLERGY & IMMUNOL,LA JOLLA,CA 92037	Scripps Research Institute								BALL JH, 1972, J CLIN INVEST, V51, P2124, DOI 10.1172/JCI107019; BERGMAN RK, 1965, NATURE, V205, P910, DOI 10.1038/205910a0; BERGMAN RK, 1966, P SOC EXP BIOL MED, V122, P428; BOURNE HR, 1972, J IMMUNOL, V108, P685; FISHEL CW, 1963, J ALLERGY, V34, P439, DOI 10.1016/0021-8707(63)90009-1; FISHEL CW, 1962, J IMMUNOL, V89, P8; FISHER RA, 1936, STATISTICAL METHODS, P100; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; KIND LS, 1954, J ALLERGY, V25, P33, DOI 10.1016/0021-8707(54)90046-5; KIND LS, 1958, BACTERIOL REV, V22, P173, DOI 10.1128/MMBR.22.3.173-182.1958; LEE TP, 1972, P NATL ACAD SCI USA, V69, P3287, DOI 10.1073/pnas.69.11.3287; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; MALKIEL S, 1956, J ALLERGY, V27, P445, DOI 10.1016/0021-8707(56)90104-6; MATSUMURA Y, 1976, J ALLERGY CLIN IMMUN, V58, P387, DOI 10.1016/0091-6749(76)90119-6; MATSUMURA Y, 1974, J ALLERGY CLIN IMMUN, V54, P191, DOI 10.1016/0091-6749(74)90061-X; MATSUMURA Y, IN PRESS; PERPER RJ, 1972, INT ARCH ALLER A IMM, V43, P837, DOI 10.1159/000230901; PIERONI RE, 1967, J ALLERGY, V39, P25, DOI 10.1016/0021-8707(67)90123-2; POLSON JB, 1974, J ALLERGY CLIN IMMUN, V53, P100; REED CE, 1970, J ALLERGY, V46, P90, DOI 10.1016/0021-8707(70)90076-6; TAUBER AI, 1973, J IMMUNOL, V111, P27; TOWNLEY RG, 1970, J ALLERGY, V45, P71; TOWNLEY RG, 1967, J ALLERGY, V39, P177, DOI 10.1016/0021-8707(67)90036-6; ZURIER RB, 1974, J CLIN INVEST, V53, P297, DOI 10.1172/JCI107550	24	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	3					395	404		10.1016/0091-6749(76)90120-2	http://dx.doi.org/10.1016/0091-6749(76)90120-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD454	9437				2022-12-18	WOS:A1976CD45400006
J	MCGEADY, S; SARACLAR, Y; MANSMANN, HC				MCGEADY, S; SARACLAR, Y; MANSMANN, HC			NORMAL T-CELL NUMBERS FOUND IN ATOPIC CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	3					194	194						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BJ240					2022-12-18	WOS:A1976BJ24000013
J	TOMAR, RH; KNIGHT, R; STERN, M				TOMAR, RH; KNIGHT, R; STERN, M			TRANSFER-FACTOR - HYPOXANTHINE IS A MAJOR COMPONENT OF A FRACTION WITH INVIVO ACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY, UPSTATE MED CTR,DEPT MED,SYRACUSE,NY 13210; SUNY, UPSTATE MED CTR,DIV CLIN PATHOL,DEPT PATHOL,SYRACUSE,NY 13210	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; SUNY Maritime College; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; SUNY Maritime College								BARAM P, 1966, J IMMUNOL, V97, P407; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; GALLIN JI, 1974, P NATL ACAD SCI USA, V71, P498, DOI 10.1073/pnas.71.2.498; GOTTLIEB AA, 1974, PROGR IMMUNOLOGY, V5, P375; HOPKINSON DA, 1969, ANN HUM GENET, V32, P361, DOI 10.1111/j.1469-1809.1969.tb00087.x; KIRKPATRICK CH, 1974, ONCOLOGY-BASEL, V29, P46, DOI 10.1159/000224888; KIRKPATRICK CH, 1975, J ALLERGY CLIN IMMUN, V55, P411, DOI 10.1016/0091-6749(75)90080-9; Lawrence H S, 1969, Adv Immunol, V11, P195, DOI 10.1016/S0065-2776(08)60480-0; MENDES NF, 1973, J IMMUNOL, V111, P860; NEIDHART JA, 1973, CELL IMMUNOL, V9, P319, DOI 10.1016/0008-8749(73)90083-X; SCHNEIDER WC, 1957, METHOD ENZYMOL, V3, P99; STAHL E, 1969, THIN LAYER CHROMATOG, P734; 1971, AII9370W TECHN IND S	13	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					190	197		10.1016/0091-6749(76)90154-8	http://dx.doi.org/10.1016/0091-6749(76)90154-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX744	956555				2022-12-18	WOS:A1976BX74400008
J	YOCUM, MW; STRONG, DM; LAKIN, JD				YOCUM, MW; STRONG, DM; LAKIN, JD			COMPETENT CELLULAR IMMUNITY IN ALLERGIC RHINITIS PATIENTS WITH ELEVATED IGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									USN NATL NAVAL MED CTR,DEPT MED,BETHESDA,MD; USN NAVAL MED RES INST,DEPT CLIN & EXPTL IMMUNOL,BETHESDA,MD	Walter Reed National Military Medical Center; Naval Medical Research Center (NMRC)								AMOS B, 1971, PROGR IMMUNOLOGY; BRANCH LB, 1975, J ALLERGY CLIN IMMUN, V55, P113; DUPREE E, 1975, J ALLERGY CLIN IMMUN, V55, P102; FRANZ ML, 1975, J ALLERGY CLIN IMMUN, V55, P113; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GROVE DI, 1975, J ALLERGY CLIN IMMUN, V55, P152, DOI 10.1016/0091-6749(75)90011-1; GUPTA S, 1975, J ALLERGY CLIN IMMUN, V55, P99; ISHIZAKA K, 1973, MECHANISMS ALLERGY R, P63; JOHNSON EE, 1974, J ALLERGY CLIN IMMUN, V54, P94, DOI 10.1016/0091-6749(74)90037-2; LAKIN JD, 1975, ANN INTERN MED, V83, P204, DOI 10.7326/0003-4819-83-2-204; LAKIN JD, TO BE PUBLISHED; LOBITZ WC, 1972, BRIT J DERMATOL, V86, P317, DOI 10.1111/j.1365-2133.1972.tb05045.x; LUCKASEN JR, 1974, ARCH DERMATOL, V110, P375, DOI 10.1001/archderm.110.3.375; LUCKASEN JR, 1974, CLIN EXP IMMUNOL, V16, P535; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; PALACIOS J, 1966, J INVEST DERMATOL, V47, P484, DOI 10.1038/jid.1966.172; PATTERSON R, 1975, AM J MED, V58, P553, DOI 10.1016/0002-9343(75)90130-8; POLMAR SH, 1972, AM J PATHOL, V69, P499; ROCKLIN RE, 1974, J CLIN INVEST, V53, P735, DOI 10.1172/JCI107612; STRONG DM, 1975, CLIN EXP IMMUNOL, V21, P442; TADA T, 1973, MECHANISMS ALLERGY, P43; VANSELOW NA, 1967, MANUAL CLIN ALLERGY, pCH4	22	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	4					384	388		10.1016/0091-6749(76)90096-8	http://dx.doi.org/10.1016/0091-6749(76)90096-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BM689	1262612				2022-12-18	WOS:A1976BM68900013
J	SCHUMACHER, MJ; MCCLATCHY, JK; FARR, RS; MINDEN, P				SCHUMACHER, MJ; MCCLATCHY, JK; FARR, RS; MINDEN, P			PRIMARY INTERACTION BETWEEN ANTIBODY AND COMPONENTS OF ALTERNARIA .1. IMMUNOLOGICAL AND CHEMICAL CHARACTERISTICS OF LABELED ANTIGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,DEPT ALLERGY & CLIN IMMUNOL,DENVER,CO	National Jewish Health								AAS K, 1970, ARCH DIS CHILD, V45, P221, DOI 10.1136/adc.45.240.221; BARDANA EJ, 1972, J ALLERGY CLIN IMMUN, V50, P208, DOI 10.1016/0091-6749(72)90015-2; BONIL.O, 1961, J ALLERGY, V32, P246, DOI 10.1016/0021-8707(61)90055-7; BONILLAS.O, 1969, J ALLERGY, V43, P125, DOI 10.1016/S0021-8707(69)80003-1; BRONSKY EA, 1969, PEDIATR CLIN N AM, V16, P85; Brown G.T., 1936, J ALLERGY, V7, P455, DOI [10.1016/S0021-8707(36)80004-5, DOI 10.1016/S0021-8707(36)80004-5]; DURHAM O. C., 1937, Journal of Allergy, V8, P480, DOI 10.1016/S0021-8707(37)90405-2; FARR RS, 1958, J INFECT DIS, V103, P239, DOI 10.1093/infdis/103.3.239; Feinberg SM, 1936, J AMER MED ASSOC, V107, P1861, DOI 10.1001/jama.1936.02770490015006; FEINBERG SM, 1935, WISC MED J, V34, P254; FERRARI A, 1960, ANN NY ACAD SCI, V87, P792, DOI 10.1111/j.1749-6632.1960.tb23236.x; FORSGREN A, 1967, J IMMUNOL, V99, P19; Fraenkel EM, 1938, BMJ-BRIT MED J, V2, P68, DOI 10.1136/bmj.2.4044.68; FREY D., 1963, MYCOPATHOL ET MYCOL APPL, V19, P83, DOI 10.1007/BF02049016; FREY D, 1962, Mycopathol Mycol Appl, V16, P295, DOI 10.1007/BF02135821; GILMAN JC, 1957, MANUAL SOIL FUNGI, P347; HEREMANS JF, 1959, NATURE, V183, P1606, DOI 10.1038/1831606a0; Hopkins JG, 1930, J AMER MED ASSOC, V94, P6, DOI 10.1001/jama.1930.02710270008002; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MINDEN P, 1969, J EXP MED, V130, P931, DOI 10.1084/jem.130.5.931; MINDEN P, 1972, SCIENCE, V176, P57, DOI 10.1126/science.176.4030.57; MINDEN P, 1967, J IMMUNOL, V99, P304; MINDEN P, 1971, INFECT IMMUN, V3, P524, DOI 10.1128/IAI.3.4.524-529.1971; MINDEN P, 1969, J IMMUNOL, V102, P832; MINDEN P, 1973, HDB EPXT IMMUNOLOGY, pCH15; MINDEN P, 1971, IMMUNOLOGICAL DISEAS, P179; NISSONOFF A, 1964, METH MED RES, V10, P134; REED CE, 1973, J ALLERGY CLIN IMMUN, V51, P84, DOI 10.1016/S0091-6749(73)80017-X; SCHONWALD PHILIPP, 1938, JOUR ALLERGY, V9, P175, DOI 10.1016/S0021-8707(38)90512-X; SCHUMACHER MJ, 1975, J ALLERGY CLIN IMMUN, V56, P54, DOI 10.1016/0091-6749(75)90034-2; SCOTT J. E., 1965, METHOD CARBOHYD CHEM, V5, P38; SEELIGER H. P. R., 1960, TRANS BRIT MYCOL SOC, V43, P543; SOBER HA, 1956, J AM CHEM SOC, V78, P756, DOI 10.1021/ja01585a017; STERNBERGER LA, 1956, J ALLERGY, V27, P16, DOI 10.1016/0021-8707(56)90034-X; TALMAGE DW, 1953, J INFECT DIS, V92, P288, DOI 10.1093/infdis/92.3.288; WAWRZYN B, 1971, STATISTICAL REPORT P; Wolfrom M. L., 1963, METHODS CARBOHYDR CH, V2, P65; WRIGHT GL, 1971, CLIN CHIM ACTA, V32, P285, DOI 10.1016/0009-8981(71)90345-7	38	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	1					39	53		10.1016/0091-6749(75)90033-0	http://dx.doi.org/10.1016/0091-6749(75)90033-0			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AH615	48526				2022-12-18	WOS:A1975AH61500005
J	WILBUR, RD; EVANS, R				WILBUR, RD; EVANS, R			IMMUNOLOGICAL EVALUATION OF DEERFLY HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	14	15	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	2					72	73						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V5498					2022-12-18	WOS:A1975V549800010
J	ZAVALA, DC; RHODES, ML; RICHERSON, HB; OSKVIG, R				ZAVALA, DC; RHODES, ML; RICHERSON, HB; OSKVIG, R			LIGHT AND IMMUNOFLUORESCENT STUDY OF ARTHUS REACTION IN RABBIT LUNG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,COLL MED,DEPT MED,PULM DIV,IOWA CITY,IA 52240; UNIV IOWA,COLL MED,DEPT MED,ALLERGY IMMUNOL DIV,IOWA CITY,IA 52240	University of Iowa; University of Iowa								BENSCH KG, 1967, SCIENCE, V157, P1204, DOI 10.1126/science.157.3793.1204; BEUTNER EH, 1971, DEFINED IMMUNOFLUORE; Cannon PR, 1941, AM J PATHOL, V17, P777; CHURG J, 1951, AM J PATHOL, V27, P277; CLAMAN HN, 1974, J ALLERGY CLIN IMMUN, V54, P54, DOI 10.1016/S0091-6749(74)80008-4; Fried BM, 1933, J EXP MED, V57, P111, DOI 10.1084/jem.57.1.111; HAGADORN JE, 1969, AM J PATHOL, V57, P17; Liebow AA., 1968, LUNG, P332; NAGAYA H, 1965, AM REV RESPIR DIS, V91, P375, DOI 10.1164/arrd.1965.91.3.375; Opie EL, 1924, J IMMUNOL, V9, P231; OUCHTERLONY O, 1962, PROG ALLERGY, V6, P30, DOI 10.1159/000313795; READ J, 1958, J PATHOL BACTERIOL, V76, P403, DOI 10.1002/path.1700760209; REDDY PA, 1970, CHEST, V58, P319, DOI 10.1378/chest.58.4.319; RICHERSO.HB, 1974, J ALLERGY CLIN IMMUN, V53, P87; RICHERSON HB, 1971, AM REV RESPIR DIS, V104, P568; RICHERSON HB, 1974, ANN NY ACAD SCI, V221, P340, DOI 10.1111/j.1749-6632.1974.tb28236.x; WILLOUGHBY WF, 1970, J IMMUNOL, V104, P28; ZAVALA DC, 1973, P SOC EXP BIOL MED, V144, P509, DOI 10.3181/00379727-144-37624	18	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	6					450	463		10.1016/0091-6749(75)90063-9	http://dx.doi.org/10.1016/0091-6749(75)90063-9			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZ301	128566				2022-12-18	WOS:A1975AZ30100004
J	MCGEADY, SJ; BUCKLEY, RH				MCGEADY, SJ; BUCKLEY, RH			STUDIES OF CELL-MEDIATED IMMUNE FUNCTION IN ATOPIC ECZEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract													Buckley, Rebecca/AAB-1578-2019						0	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	2					72	73						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S0380					2022-12-18	WOS:A1974S038000019
J	HOBDAY, JD; TOWNLEY, RG				HOBDAY, JD; TOWNLEY, RG			DEPOSITION OF INHALED POLLEN GRAINS IN LOWER RESPIRATORY TRACT OF GUINEA PIG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter																		COMROE JH, 1965, PHYSIOLOGY RESPIRATI; HOEHNE J, 1971, J ALLERGY, V47, P108; WILSON AF, 1971, J ALLERGY, V47, P107	3	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	4					254	&		10.1016/0091-6749(71)90075-3	http://dx.doi.org/10.1016/0091-6749(71)90075-3			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K5566	5285775	Bronze			2022-12-18	WOS:A1971K556600011
J	MAY, CD; ADUNA, N				MAY, CD; ADUNA, N			LOSS AND RECOVERY OF LEUKOCYTE SENSITIVITY TO ANTIGENIC HISTAMINE RELEASE DURING INTENSIVE INJECTION THERAPY WITH ALLERGEN EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note																		LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1967, J ALLERGY, V40, P160, DOI 10.1016/0021-8707(67)90005-6; LYMAN M, 1971, J ALLERGY, V47, P119; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MAY CD, 1970, J ALLERGY, V46, P73, DOI 10.1016/0021-8707(70)90075-4; MELAM HL, 1970, J ALLERGY, V46, P292, DOI 10.1016/0021-8707(70)90069-9; OSGOOD E E, 1954, Rev Hematol, V9, P543; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; PRUZANSKY JJ, 1968, JAMA-J AM MED ASSOC, V203, P289; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SHERMAN WB, 1968, HYPERSENSITIVITY, P70	11	14	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	5					313	&		10.1016/0091-6749(71)90033-9	http://dx.doi.org/10.1016/0091-6749(71)90033-9			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K7978	4106085				2022-12-18	WOS:A1971K797800009
J	Oykhman, P; Paramo, FA; Bousquet, J; Kennedy, DW; Brignardello-Petersen, R; Chu, DK				Oykhman, Paul; Paramo, Fernando Aleman; Bousquet, Jean; Kennedy, David W.; Brignardello-Petersen, Romina; Chu, Derek K.			Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Dupilumab; omalizumab; mepolizumab; reslizumab; benralizumab; etokimab; AK001; aspirin desensitization; chronic rhinosinusitis with nasal polyposis (CRSwNP); biologics	QUALITY-OF-LIFE; EXACERBATED RESPIRATORY-DISEASE; DOUBLE-BLIND; EOSINOPHILIC ASTHMA; MEPOLIZUMAB; PREVALENCE; BIOLOGICS; DUPILUMAB; MULTICENTER; RESLIZUMAB	Background: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is an inflammatory condition of the upper airways. Optimal management is unclear. Objective: We compared the effects of mAbs and aspirin desensitization (ASA-D) for treatment of CRSwNP. Methods: We searched the Medline, Embase, Cochrane Central Register of Controlled Trials, International Clinical Trials Registry Platform, US Food and Drug Administration, and the European Medicines Agency databases from inception to August 4, 2021, for randomized controlled trials comparing the effects of mAbs and ASA-D for CRSwNP. We conducted network meta-analysis of sinusitis symptoms, heath-related quality of life, rescue oral corticosteroids and surgery, endoscopic and radiologic scores, and adverse events. We used the Grades of Recommendation Assessment, Development and Evaluation (GRADE) approach to assess certainty of evidence. PROSPERO CRD42020177334. Results: Twenty-nine randomized controlled trials evaluating 8 treatments (n = 3461) were included in the network meta-analysis. Compared to placebo, moderate to high certainty evidence showed that health-related quality of life (SNOT-22) improved with dupilumab (mean difference [MD] -19.91 [95% confidence interval (CI) -22.50, -17.32]), omalizumab (MD -16.09 [95% CI -19.88, -12.30]), mepolizumab (MD -12.89 [95% CI -16.58, -9.19], ASA-D (MD -10.61 [95% CI -14.51, -6.71]), and benralizumab (MD -7.68 [95% CI -12.09, -3.27]). The risk of rescue nasal polyp surgery likely decreased with dupilumab (risk difference [RD] -16.35% [95% CI -18.13, -13.48]), omalizumab (RD -7.40% [95% CI -11.04, -2.43]), mepolizumab (RD -12.33% [95% CI -15.56, -7.22]), and ASA-D (RD -16.00% [95% CI -19.79, 0.21]; all moderate certainty). Comparisons among agents show with moderate to high certainty that dupilumab ranks among the most beneficial for 7 of 7 outcomes, omalizumab for 2 of 7, mepolizumab for 1 of 7, and ASA-D for 1 of 7. Conclusions: Multiple biologics and ASA-D credibly improve patient-important outcomes, with clinically important differences in effects among agents; dupilumab uniquely ranks among the most beneficial for all outcomes studied.	[Oykhman, Paul; Paramo, Fernando Aleman; Chu, Derek K.] McMaster Univ, Dept Med, Div Clin Immunol & Allergy, Hamilton, ON, Canada; [Brignardello-Petersen, Romina; Chu, Derek K.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Chu, Derek K.] Res Inst St Joes Hamilton, Hamilton, ON, Canada; [Bousquet, Jean] Charite Univ Med Berlin, Berlin, Germany; [Bousquet, Jean] Humboldt Univ, Berlin, Germany; [Bousquet, Jean] Berlin Inst Hlth, Comprehens Allergy Ctr, Dept Dermatol & Allergy, Berlin, Germany; [Bousquet, Jean] CHU, Montpellier, France; [Bousquet, Jean] MACVIA France, Montpellier, France; [Kennedy, David W.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA	McMaster University; McMaster University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Berlin Institute of Health; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; University of Pennsylvania	Chu, DK (corresponding author), McMaster Univ, Div Clin Immunol & Allergy, Dept Med, Med Ctr, Rm 3V51,1280 Main St W, Hamilton, ON L8S 4K1, Canada.; Chu, DK (corresponding author), McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Med Ctr, Rm 3V51,1280 Main St W, Hamilton, ON L8S 4K1, Canada.	chudk@mcmaster.ca		Chu, Derek/0000-0001-8269-4496				Agache I, 2021, ALLERGY, V76, P2337, DOI 10.1111/all.14809; Akl EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057132; Bachert C, 2020, ANN ALLERG ASTHMA IM, V125, pS47; Bachert C, 2020, J ALLER CL IMM-PRACT, V8, P1514, DOI 10.1016/j.jaip.2020.03.007; Bachert C, 2019, LANCET, V394, P1638, DOI 10.1016/S0140-6736(19)31881-1; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Bachert C, 2017, J ALLERGY CLIN IMMUN, V140, P1024, DOI 10.1016/j.jaci.2017.05.044; Bachert C, 2016, J ALLER CL IMM-PRACT, V4, P621, DOI 10.1016/j.jaip.2016.05.004; Brignardello-Petersen R, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3900; Brignardello-Petersen R, 2019, J CLIN EPIDEMIOL, V105, P60, DOI 10.1016/j.jclinepi.2018.08.022; Busse W, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.congress-2018.PA1125; Canonica GW, 2022, ALLERGY, V77, P150, DOI 10.1111/all.14902; Castro M, 2018, NEW ENGL J MED, V378, P2486, DOI 10.1056/NEJMoa1804092; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; Chen S, 2020, CURR MED RES OPIN, V36, P1897, DOI 10.1080/03007995.2020.1815682; Chong LY, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013513.pub2; Chu DK, 2019, INT FORUM ALLERGY RH, V9, P1409, DOI 10.1002/alr.22428; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Chupp GL, 2017, LANCET RESP MED, V5, P390, DOI 10.1016/S2213-2600(17)30125-X; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; Ebrahim S, 2013, J CLIN EPIDEMIOL, V66, P1014, DOI 10.1016/j.jclinepi.2013.03.014; Esmaeilzadeh H, 2015, CLIN IMMUNOL, V160, P349, DOI 10.1016/j.clim.2015.05.012; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Fruth K, 2013, ALLERGY, V68, P659, DOI 10.1111/all.12131; Gevaert P, 2008, J ALLERGY CLIN IMMUN, V121, P797, DOI 10.1016/j.jaci.2008.01.062; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Gevaert P, 2020, J ALLERGY CLIN IMMUN, V146, P595, DOI 10.1016/j.jaci.2020.05.032; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Han JK, 2021, LANCET RESP MED, V9, P1141, DOI 10.1016/S2213-2600(21)00097-7; Harrison TW, 2021, LANCET RESP MED, V9, P260, DOI 10.1016/S2213-2600(20)30414-8; Hayashi H, 2020, AM J RESP CRIT CARE, V201, P1488, DOI 10.1164/rccm.201906-1215OC; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; Iqbal IZ, 2020, INT FORUM ALLERGY RH, V10, P165, DOI 10.1002/alr.22473; Johansson L, 2003, ANN OTO RHINOL LARYN, V112, P625, DOI 10.1177/000348940311200709; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.1136/bmj.l4898, 10.4084/MJHID.2010.005]; Klossek JM, 2005, ALLERGY, V60, P233, DOI 10.1111/j.1398-9995.2005.00688.x; Laidlaw TM, 2021, ANN ALLERG ASTHMA IM, V126, P584, DOI 10.1016/j.anai.2021.01.012; Laidlaw TM, 2021, ANN ALLERG ASTHMA IM, V126, P118, DOI 10.1016/j.anai.2020.08.008; Laidlaw TM, 2019, J ALLER CL IMM-PRACT, V7, P2462, DOI 10.1016/j.jaip.2019.03.044; Lang DM, 2018, ANN ALLERG ASTHMA IM, V121, P98, DOI 10.1016/j.anai.2018.05.007; Lee S, 2021, J ALLERGY CLIN IMMUN, V147, pAB125; Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006; Mortazavi N, 2017, IRAN J PHARM RES, V16, P1639; Mostafa BE, 2020, EUR ARCH OTO-RHINO-L, V277, P121, DOI 10.1007/s00405-019-05650-y; Mullol J, 2018, ALLERGY, V73, P203; Mullol J, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.congress-2019.RCT3783; Nelsen L, 2017, EUR RESPIR J, V50, DOI 10.1183/1393003.congress-2017.PA3583; Nsouli S, 2020, ANN ALLERG ASTHMA IM, V125, pS49; Nsouli S, 2018, ANN ALLERG ASTHMA IM, V121, pS40, DOI 10.1016/j.anai.2018.09.129; Peters AT, 2021, J ALLER CL IMM-PRACT, V9, P2461, DOI 10.1016/j.jaip.2021.01.031; Peters AT, 2014, ANN ALLERG ASTHMA IM, V113, P347, DOI 10.1016/j.anai.2014.07.025; Pinto JM, 2010, RHINOLOGY, V48, P318, DOI [10.4193/Rhin09.144, 10.4193/Rhino09.144]; Rabe KF, 2018, NEW ENGL J MED, V378, P2475, DOI 10.1056/NEJMoa1804093; Rajan JP, 2015, J ALLERGY CLIN IMMUN, V135, P676, DOI 10.1016/j.jaci.2014.08.020; Rudmik L, 2011, CURR ALLERGY ASTHM R, V11, P247, DOI 10.1007/s11882-010-0175-2; Santesso N, 2020, J CLIN EPIDEMIOL, V119, P126, DOI 10.1016/j.jclinepi.2019.10.014; Schandelmaier S, 2020, CAN MED ASSOC J, V192, pE901, DOI 10.1503/cmaj.200077; Schlosser RJ, 2016, AM J RHINOL ALLERGY, V30, P250, DOI 10.2500/ajra.2016.30.4343; Schunemann H, 2013, GRADE HDB; Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; Swierczynska-Krepa M, 2014, J ALLERGY CLIN IMMUN, V134, P883, DOI 10.1016/j.jaci.2014.02.041; Takabayashi T, 2021, AM J RHINOL ALLERGY, V35, P861, DOI 10.1177/19458924211009429; Thorlund K, 2011, RES SYNTH METHODS, V2, P188, DOI 10.1002/jrsm.46; Tversky J, 2021, CLIN EXP ALLERGY, V51, P836, DOI 10.1111/cea.13852; Wahba AA, 2019, EGYPT J OTOLARYNGOL, V35, P269, DOI 10.4103/ejo.ejo_19_19; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; Wilkes SR, 2016, J INVEST DERMATOL, V136, P1944, DOI 10.1016/j.jid.2016.05.104; Workman Alan D, 2020, World J Otorhinolaryngol Head Neck Surg, V6, P230, DOI 10.1016/j.wjorl.2020.06.002	71	13	13	2	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2022	149	4					1286	1295						10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	3T5RO	34543652	hybrid			2022-12-18	WOS:000840331500021
J	[Anonymous]				[Anonymous]			Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material														Chu, Derek/0000-0001-8269-4496					0	13	13	2	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2022	149	4					1195	1200		10.1016/j.jaci.2021.09.009	http://dx.doi.org/10.1016/j.jaci.2021.09.009			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	3T5RO	34543652	hybrid			2022-12-18	WOS:000840331500005
J	Alkon, N; Bauer, WM; Krausgruber, T; Goh, I; Griss, J; Nguyen, V; Reininger, B; Bangert, C; Staud, C; Brunner, PM; Bock, C; Haniffa, M; Stingl, G				Alkon, Natalia; Bauer, Wolfgang M.; Krausgruber, Thomas; Goh, Issac; Griss, Johannes; Nguyen, Vy; Reininger, Baerbel; Bangert, Christine; Staud, Clement; Brunner, Patrick M.; Bock, Christoph; Haniffa, Muzlifah; Stingl, Georg			Single-cell analysis reveals innate lymphoid cell lineage infidelity in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate lymphoid cells; atopic dermatitis; human skin; single-cell RNA sequencing	T-CELLS; HUMAN SKIN; EXPRESSION; IL-33; INFLAMMATION; PROVIDE; TISSUE; IL-25	Background: Although ample knowledge exists about phenotype and function of cutaneous T lymphocytes, much less is known about the lymphocytic components of the skin's innate immune system. Objective: To better understand the biologic role of cutaneous innate lymphoid cells (ILCs), we investigated their phenotypic and molecular features under physiologic (normal human skin [NHS]) and pathologic (lesional skin of patients with atopic dermatitis [AD]) conditions. Methods: Skin punch biopsies and reduction sheets as well as blood specimens were obtained from either patients with AD or healthy individuals. Cell and/or tissue samples were analyzed by flow cytometry, immunohistochemistry, and single-cell RNA sequencing or subjected to in vitro/ex vivo culture. Results: Notwithstanding substantial quantitative differences between NHS and AD skin, we found that the vast majority of cutaneous ILCs belong to the CRTH2(+) subset and reside in the upper skin layers. Single-cell RNA sequencing of cutaneous ILC-enriched cell samples confirmed the predominance of biologically heterogeneous group 2 ILCs and, for the first time, demonstrated considerable ILC lineage infidelity (coexpression of genes typical of either type 2 [GATA3 and IL13] or type 3/17 [RORC, IL22, and IL26] immunity within individual cells) in lesional AD skin, and to a much lesser extent, in NHS. Similar events were demonstrated in ILCs from skin explant cultures and in vitro expanded ILCs from the peripheral blood. Conclusion: These findings support the concept that instead of being a stable entity with well-defined components, the skin immune system consists of a network of highly flexible cellular players that are capable of adjusting their function to the needs and challenges of the environment.	[Alkon, Natalia; Bauer, Wolfgang M.; Griss, Johannes; Nguyen, Vy; Reininger, Baerbel; Bangert, Christine; Brunner, Patrick M.; Stingl, Georg] Med Univ Vienna, Dept Dermatol, Vienna, Austria; [Staud, Clement] Med Univ Vienna, Dept Surg, Div Plast & Reconstruct Surg, Vienna, Austria; [Bock, Christoph] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Inst Artificial Intelligence & Decis Support, Vienna, Austria; [Krausgruber, Thomas; Bock, Christoph] Austrian Acad Sci, Res Ctr Mol Med, Vienna, Austria; [Goh, Issac; Haniffa, Muzlifah] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Haniffa, Muzlifah] Newcastle Hosp NHS Fdn Trust, Dept Dermatol, Newcastle Upon Tyne, Tyne & Wear, England; [Haniffa, Muzlifah] Newcastle Hosp NHS Fdn Trust, NIHR Newcastle Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England; [Haniffa, Muzlifah] Wellcome Sanger Inst, Wellcome Genome Campus, Cambridge, England	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Austrian Academy of Sciences; Newcastle University - UK; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Wellcome Trust Sanger Institute	Alkon, N (corresponding author), Med Univ Vienna, Dept Dermatol, Gen Hosp AKH, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	natalia.alkon@meduniwien.ac.at	Krausgruber, Thomas/H-8490-2018; Bock, Christoph/AAE-7618-2019	Krausgruber, Thomas/0000-0002-1374-0329; Bock, Christoph/0000-0001-6091-3088; Brunner, Patrick/0000-0002-3488-3345; Bangert, Christine/0000-0003-3392-6590; Bauer, Wolfgang/0000-0002-0155-1176; Nguyen, Thi-Tuong-Vy/0000-0003-3436-3662; Alkon, Natalia/0000-0002-0336-5318; Goh, Issac/0000-0002-6397-3518	Austrian Science Fund (FWF) [DK W 1248-B30]; Medical University of Vienna; Austrian Academy of Sciences [IF_2017_29]; Medical Scientific Fund of the Mayor of the City of Vienna [18130]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Medical University of Vienna; Austrian Academy of Sciences; Medical Scientific Fund of the Mayor of the City of Vienna	Supported by grants from the Austrian Science Fund (FWF; DK W 1248-B30) and the Medical University of Vienna, as well as by grant IF_2017_29 from the innovation fund of the Austrian Academy of Sciences (to G.S.) and, in part, by grant 18130 from the Medical Scientific Fund of the Mayor of the City of Vienna (to G.S.).	Bernink JH, 2019, NAT IMMUNOL, V20, P992, DOI 10.1038/s41590-019-0423-0; Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019; Bjorklund AK, 2016, NAT IMMUNOL, V17, P451, DOI 10.1038/ni.3368; Bruggen MC, 2016, J INVEST DERMATOL, V136, P2396, DOI 10.1016/j.jid.2016.07.017; Brunner PM, 2019, J AM ACAD DERMATOL, V81, P510, DOI 10.1016/j.jaad.2019.04.036; Camelo A, 2017, BLOOD ADV, V1, P577, DOI 10.1182/bloodadvances.2016002352; Cardoso V, 2017, NATURE, V549, P277, DOI 10.1038/nature23469; Dambacher J, 2009, GUT, V58, P1207, DOI 10.1136/gut.2007.130112; de Boer OJ, 2020, J HISTOCHEM CYTOCHEM, V68, P127, DOI 10.1369/0022155419897257; Dyring-Andersen B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19383-8; Ebert LM, 2006, J IMMUNOL, V176, P4331, DOI 10.4049/jimmunol.176.7.4331; Fabre T, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar7754; Ferran Marta, 2010, World Allergy Organ J, V3, P44, DOI 10.1097/WOX.0b013e3181d675f8; Forkel M, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0652-3; Gober MD, 2008, J INVEST DERMATOL, V128, P1460, DOI 10.1038/sj.jid.5701199; Godinho-Silva C, 2019, NATURE, V574, P254, DOI 10.1038/s41586-019-1579-3; Golebski K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09883-7; Griss J, MOL CELL PROTEOMICS; Hams E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00597; Hazenberg MD, 2014, BLOOD, V124, P700, DOI 10.1182/blood-2013-11-427781; Imai Y, 2019, J INVEST DERMATOL, V139, P2185, DOI 10.1016/j.jid.2019.04.016; Imai Y, 2013, P NATL ACAD SCI USA, V110, P13921, DOI 10.1073/pnas.1307321110; Jin SQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21246-9; Kim BS, 2014, J IMMUNOL, V193, P3717, DOI 10.4049/jimmunol.1401307; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Klose CSN, 2020, CELL RES, V30, P475, DOI 10.1038/s41422-020-0323-8; Kobayashi T, 2020, TRENDS IMMUNOL, V41, P100, DOI 10.1016/j.it.2019.12.004; Kobayashi T, 2019, CELL, V176, P982, DOI 10.1016/j.cell.2018.12.031; Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592-019-0619-0; Kurioka A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00486; Lanier LL, 2019, J EXP MED, V216, P1726, DOI 10.1084/jem.20191183; Li Jian, 2016, Inflamm Cell Signal, V3, DOI 10.14800/ics.1404; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Lim AI, 2017, CELL, V168, P1086, DOI 10.1016/j.cell.2017.02.021; Mjosberg J, 2016, J ALLERGY CLIN IMMUN, V138, P1265, DOI 10.1016/j.jaci.2016.09.009; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Nagasawa M, 2019, J EXP MED, V216, P1762, DOI 10.1084/jem.20190490; Nihal M, 2000, J MOL DIAGN, V2, P5, DOI 10.1016/S1525-1578(10)60609-5; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nomura T, 2020, J ALLER CL IMM-PRACT, V8, P1840, DOI 10.1016/j.jaip.2020.02.022; Popescu DM, 2019, NATURE, V574, P365, DOI 10.1038/s41586-019-1652-y; Rai AK, 2011, INT J PARASITOL, V41, P1069, DOI 10.1016/j.ijpara.2011.05.010; Rak GD, 2016, J INVEST DERMATOL, V136, P487, DOI 10.1038/JID.2015.406; Rendeiro AF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14081-6; Reynolds G, 2021, SCIENCE, V371, P364, DOI 10.1126/science.aba6500; Roediger B, 2015, J ALLERGY CLIN IMMUN, V136, P1653, DOI 10.1016/j.jaci.2015.03.043; Roediger B, 2013, NAT IMMUNOL, V14, P564, DOI 10.1038/ni.2584; Rojahn TB, 2020, J ALLERGY CLIN IMMUN, V146, P1056, DOI 10.1016/j.jaci.2020.03.041; Salimi M, 2016, J IMMUNOL, V196, P45, DOI 10.4049/jimmunol.1501102; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Sarker G, 2020, NAT IMMUNOL, V21, P106, DOI 10.1038/s41590-019-0580-1; Seillet C, 2020, NAT IMMUNOL, V21, P168, DOI 10.1038/s41590-019-0567-y; Szabo PA, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aas9673; Takahashi T, 2006, J IMMUNOL, V176, P211, DOI 10.4049/jimmunol.176.1.211; Teunissen MBM, 2014, J INVEST DERMATOL, V134, P2351, DOI 10.1038/jid.2014.146; Tubo NJ, 2011, AM J PATHOL, V178, P2496, DOI 10.1016/j.ajpath.2011.02.031; Vacca P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00170; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Villanova F, 2014, J INVEST DERMATOL, V134, P984, DOI 10.1038/jid.2013.477; von Moltke J, 2017, J EXP MED, V214, P27, DOI 10.1084/jem.20161274; Werfel T, 1996, J INVEST DERMATOL, V107, P871, DOI 10.1111/1523-1747.ep12331164; Wolf FA, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1663-x; Wolf FA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-017-1382-0; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963; Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049	66	13	13	14	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2022	149	2					624	639		10.1016/j.jaci.2021.07.025	http://dx.doi.org/10.1016/j.jaci.2021.07.025			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YV3IA	34363841	hybrid, Green Published			2022-12-18	WOS:000752623200021
J	Conrado, AB; Patel, N; Turner, PJ				Conrado, Alessia Baseggio; Patel, Nandinee; Turner, Paul J.			Global patterns in anaphylaxis due to specific foods: A systematic review	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen labeling; anaphylaxis; Codex; epidemiology; food allergy; prevalence	EMERGENCY-DEPARTMENT VISITS; HOSPITAL PRESENTATIONS; PEDIATRIC ANAPHYLAXIS; ALLERGIC REACTIONS; CLINICAL-FEATURES; PREVALENCE; CHILDREN; TRIGGERS; SENSITIZATION; ADULTS	Background: There are increasing global data relating to prevalence of food allergy and food-induced anaphylaxis; however, this is often based on surrogate measures of sensitization rather than objective symptoms at food challenge. In terms of protecting food-allergic consumers from reactions, to our knowledge, there has been no global survey assessing geographic differences in the proportion of anaphylaxis triggered by specific foods. Objective: We sought to identify common triggers for food induced anaphylaxis and how these vary from country to country. Methods: Systematic review of relevant reports published between January 2010 and November 2020. Results were reported following PRISMA guidelines. Publications were screened and data extracted by 2 independent reviewers, and the risk of bias was assessed. Results: Sixty-five studies (encompassing 41 countries and all 6 regions as defined by the Food and Agriculture Organization of the United Nations) were included. Significant regional variations in the most common triggers of food anaphylaxis were seen; however, in general, there was good agreement between local legislative requirements for allergen disclosure and the most common allergens for each region or nation. Conclusions: Local legislation for allergen disclosure generally reflects those allergens commonly responsible for food anaphylaxis. Cow's milk and crustaceans appear to cause a higher proportion of anaphylaxis compared to peanut in some regions. (J Allergy Clin Immunol 2021;148:1515-25.)	[Conrado, Alessia Baseggio; Patel, Nandinee; Turner, Paul J.] Imperial Coll London, Natl Heart & Lung Inst, Norfolk Pl, London W2 1PG, England; [Turner, Paul J.] Univ Sydney, Dept Paediat & Child Hlth, Sydney, NSW, Australia	Imperial College London; University of Sydney	Turner, PJ (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, Norfolk Pl, London W2 1PG, England.	p.turner@imperial.ac.uk		Turner, Paul/0000-0001-9862-5161	UK Medical Research Council [MR/K010468/1]; National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust; Imperial College London	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust; Imperial College London(General Electric)	Funded by a UK Medical Research Council Clinician Scientist award to P. J. Turner (reference MR/K010468/1). P. J. Turner is supported through the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London.	Abunada T, 2018, WORLD ALLERGY ORGAN, V11, DOI 10.1186/s40413-018-0200-9; Ahanchian H, 2018, MED GAS RES, V8, P129, DOI 10.4103/2045-9912.248262; Alkanhal R, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011582; Allen KJ, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-10; Alvarez-Perea A, 2017, J ALLER CL IMM-PRACT, V5, P1256, DOI 10.1016/j.jaip.2017.02.011; Andrew E, 2018, PREHOSP EMERG CARE, V22, P445, DOI 10.1080/10903127.2017.1402110; Asai Y, 2014, INT ARCH ALLERGY IMM, V164, P246, DOI 10.1159/000365631; Aurich S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00750; Barzegar Saeideh, 2010, World Allergy Organ J, V3, P9, DOI 10.1097/WOX.0b013e3181c82128; Bedolla-Barajas M, 2014, ALLERGY ASTHMA IMMUN, V6, P511, DOI 10.4168/aair.2014.6.6.511; Brown SGA, 2013, J ALLERGY CLIN IMMUN, V132, P1141, DOI 10.1016/j.jaci.2013.06.015; Carlson G, 2019, ANN ALLERG ASTHMA IM, V123, P359, DOI 10.1016/j.anai.2019.07.022; Chan CF, 2014, PEDIATR NEONATOL, V55, P275, DOI 10.1016/j.pedneo.2013.11.006; Charatsi A, 2014, CLIN TRANSL ALLERGY, V4, P87; Chippendale S., 2018, SEVERE ALLERGIC REAC; Cho H, 2019, MEDICINE, V98, DOI [10.1097/MD.0000000000014114, 10.1097/md.0000000000014114]; Civelek E, 2017, ASIAN PAC J ALLERGY, V35, P212, DOI 10.12932/AP0752; Clarke AE, 2020, J ALLER CL IMM-PRACT, V8, P1428, DOI 10.1016/j.jaip.2019.10.021; Cohen N, 2019, J ALLER CL IMM-PRACT, V7, P2882, DOI 10.1016/j.jaip.2019.04.038; Conrado AB, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n251; Corriger J, 2019, J INVEST ALLERG CLIN, V29, P357, DOI 10.18176/jiaci.0348; de Silva NR, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0295-0; De Vera MJ, 2020, ASIA PAC ALLERGY, V10, DOI 10.5415/apallergy.2020.10.e1; Deng S, 2019, ALLERGY ASTHMA IMMUN, V11, P116, DOI 10.4168/aair.2019.11.1.116; Dyer AA, 2015, ANN ALLERG ASTHMA IM, V115, P56, DOI 10.1016/j.anai.2015.05.006; Esakova NV, 2015, AM J PUBLIC HLTH RES, V3, P187, DOI 10.12691/ajphr-3-5-2; Feuerhake T, 2018, REV CHIL PEDIATR-CHI, V89, P448, DOI 10.4067/S0370-41062018005000403; Food and Agriculture Organization of the United Nations; World Health Organization; Codex Alimentarius Commission, 1985, GEN STAND LAB PRE PA; Gabrielli S, 2019, J ALLER CL IMM-PRACT, V7, P2232, DOI 10.1016/j.jaip.2019.04.018; Gaspar A, 2022, J INVEST ALLERG CLIN, V32, P23, DOI 10.18176/jiaci.0515; Ghazali Hanen, 2017, Tunis Med, V95, P45; Goh SH, 2018, INT ARCH ALLERGY IMM, V175, P91, DOI 10.1159/000485127; Gonzalez-Estrada A, 2017, ANN ALLERG ASTHMA IM, V118, P80, DOI 10.1016/j.anai.2016.10.025; Grabenhenrich LB, 2016, J ALLERGY CLIN IMMUN, V137, P1128, DOI 10.1016/j.jaci.2015.11.015; Gupta RS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.5630; Gupta RS, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-1235; Hoy D, 2012, J CLIN EPIDEMIOL, V65, P934, DOI 10.1016/j.jclinepi.2011.11.014; Huang F, 2012, J ALLERGY CLIN IMMUN, V129, P162, DOI 10.1016/j.jaci.2011.09.018; Imamura T, 2008, PEDIAT ALLERG IMM-UK, V19, P270, DOI 10.1111/j.1399-3038.2007.00621.x; Jeong K, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2020.100449; Jiang NN, 2016, ALLERGY ASTHMA IMMUN, V8, P353, DOI 10.4168/aair.2016.8.4.353; Khan NU, 2013, QJM-INT J MED, V106, P1095, DOI 10.1093/qjmed/hct179; Kim M, 2017, ALLERGY ASTHMA IMMUN, V9, P410, DOI [10.4168/aair.2017.9.5.410, 10.4168/aair.2017.9.6.483]; Kool B, 2016, POSTGRAD MED J, V92, P640, DOI 10.1136/postgradmedj-2015-133530; Lacombe-Barrios J, 2019, J INVEST ALLERG CLIN, V29, P222, DOI 10.18176/jiaci.0313; Lao-araya M, 2012, PEDIATR INT, V54, P238, DOI 10.1111/j.1442-200X.2011.03544.x; Lee AJ, 2013, ASIA PAC ALLERGY, V3, P3, DOI 10.5415/apallergy.2013.3.1.3; Lee SY, 2016, ALLERGY ASTHMA IMMUN, V8, P535, DOI 10.4168/aair.2016.8.6.535; Li J, 2020, J ALLER CL IMM-PRACT, V8, P1349, DOI 10.1016/j.jaip.2019.11.042; Li PH, 2020, CLIN TRANSL ALLERGY, V10, DOI 10.1186/s13601-020-00355-6; Lin LF, 2020, HEALTH SCI REP-US, V3, DOI 10.1002/hsr2.178; Lyons SA, 2020, J ALLER CL IMM-PRACT, V8, P2736, DOI 10.1016/j.jaip.2020.04.020; Lyons SA, 2019, J ALLER CL IMM-PRACT, V7, P1920, DOI 10.1016/j.jaip.2019.02.044; Mahesh PA, 2016, ALLERGY, V71, P1010, DOI 10.1111/all.12868; Manuyakorn W, 2015, ASIAN PAC J ALLERGY, V33, P281, DOI 10.12932/AP0610.33.4.2015; Maris I, 2015, CLIN TRANSL ALLERGY, V5, pP102; McWilliam VL, 2018, J ALLERGY CLIN IMMUN, V141, P982, DOI 10.1016/j.jaci.2017.09.012; Moher D, 2009, PLOS MED; Moro MM, 2011, J INVEST ALLERG CLIN, V21, P142; Motosue MS, 2018, PEDIAT ALLERG IMM-UK, V29, P538, DOI 10.1111/pai.12908; Mullins RJ, 2016, CLIN EXP ALLERGY, V46, P1099, DOI 10.1111/cea.12748; Muramatsu K, 2022, J EPIDEMIOL, V32, P163, DOI 10.2188/jea.JE20200309; Nabavi M, 2017, IRAN J ALLERGY ASTHM, V16, P480; Noimark L, 2012, CLIN EXP ALLERGY, V42, P284, DOI 10.1111/j.1365-2222.2011.03912.x; Nwaru BI, 2014, ALLERGY, V69, P992, DOI 10.1111/all.12423; Ontiveros N, 2016, ALLERGOL IMMUNOPATH, V44, P563, DOI 10.1016/j.aller.2016.03.003; Oropeza AR, 2017, SCAND J TRAUMA RESUS, V25, DOI 10.1186/s13049-017-0402-0; Ouahidi I, 2010, REV FR ALLERGOL, V50, P15, DOI 10.1016/j.reval.2009.08.008; Poirot E, 2020, J PUBLIC HEALTH MAN, V26, P548, DOI 10.1097/PHH.0000000000001137; Pouessel G, 2018, ALLERGY, V73, P1902, DOI 10.1111/all.13483; Pouessel G, 2019, ALLERGY, V74, P1193, DOI 10.1111/all.13717; Poziomkowska-Gesicka I, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082787; Prescott SL, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-21; Ramsey NB, 2019, J ALLER CL IMM-PRACT, V7, P2241, DOI 10.1016/j.jaip.2019.04.025; Rangkakulnuwat P, 2020, ASIAN PAC J ALLERGY, V38, P31, DOI 10.12932/AP-210318-0284; Renaudin JM, 2017, REV FR ALLERGOL, V57, pE3, DOI 10.1016/j.reval.2017.10.005; Rolla G, 2013, INTERN EMERG MED, V8, P615, DOI 10.1007/s11739-013-0978-y; Santadusit Sathit, 2005, J Med Assoc Thai, V88 Suppl 8, pS27; Sasaki M, 2018, J ALLERGY CLIN IMMUN, V141, P391, DOI 10.1016/j.jaci.2017.05.041; Schwarzer G, 2019, RES SYNTH METHODS, V10, P476, DOI 10.1002/jrsm.1348; Sole D, 2012, ALLERGOL IMMUNOPATH, V40, P331, DOI 10.1016/j.aller.2011.09.008; Speakman S, 2018, J PAEDIATR CHILD H, V54, P254, DOI 10.1111/jpc.13705; Turner PJ, 2014, CLIN EXP ALLERGY, V44, P1458, DOI 10.1111/cea.12425; Turner PJ, 2016, CURR OPIN ALLERGY CL, V16, P441, DOI 10.1097/ACI.0000000000000305; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021; Vetander M, 2012, CLIN EXP ALLERGY, V42, P568, DOI 10.1111/j.1365-2222.2011.03954.x; Vezir E, 2013, ALLERGY ASTHMA PROC, V34, P239, DOI 10.2500/aap.2013.34.3654; Wang YC, 2019, ALLERGY, V74, P1063, DOI 10.1111/all.13732; Worm M, 2014, ALLERGY, V69, P1397, DOI 10.1111/all.12475; Wu TC, 2012, INTERN MED J, V42, P1310, DOI 10.1111/j.1445-5994.2012.02820.x; Xu YS, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-38; Yamamoto-Hanada K, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2020.100479	92	13	13	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2021	148	6					1515	+		10.1016/j.jaci.2021.03.048	http://dx.doi.org/10.1016/j.jaci.2021.03.048		DEC 2021	14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XM1ZO	33940057	Green Published, hybrid			2022-12-18	WOS:000728634000018
J	Pacheco, SE; Guidos-Fogelbach, G; Annesi-Maesano, I; Pawankar, R; D' Amato, G; Latour-Staffeld, P; Urrutia-Pereira, M; Kesic, MJ; Hernandez, ML				Pacheco, Susan E.; Guidos-Fogelbach, Guillermo; Annesi-Maesano, Isabella; Pawankar, Ruby; D' Amato, Gennaro; Latour-Staffeld, Patricia; Urrutia-Pereira, Marylin; Kesic, Matthew J.; Hernandez, Michelle L.		Amer Acad Allergy; Amer Acad Allergy Asthma Immunolog	Climate change and global issues in allergy and immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Climate change; global warming; human health; allergy; asthma; vulnerable populations; air pollution; greenhouse gases; heat waves; wildfires; dust storms; tropical storms; thunderstorms	AMBIENT AIR-POLLUTION; WILDLAND FIRE SMOKE; LUNG-FUNCTION; WOOD SMOKE; EXPOSURE; ASTHMA; HEALTH; CHILDHOOD; POLLEN; RISK	The steady increase in global temperatures, resulting from the combustion of fossil fuels and the accumulation of greenhouse gases (GHGs), continues to destabilize all ecosystems worldwide. Although annual emissions must be halved by 2030 and reach net zero by 2050 to limit some of the most catastrophic impacts associated with a warming planet, the world's efforts to curb GHG emissions fall short of the commitments made in the 2015 Paris Agreement. To this effect, July 2021 was recently declared the hottest month ever recorded in 142 years. The ramifications of these changes for global temperatures are complex and further promote outdoor air pollution, pollen exposure, and extreme weather events. Besides worsening respiratory health, air pollution promotes atopy and susceptibility to infections. The effects of GHGs on pollen affect the frequency and severity of asthma and allergic rhinitis. Changes in temperature, air pollution, and extreme weather events exert adverse multisystemic health effects and disproportionally affect disadvantaged and vulnerable populations. This review article is an update for allergists and immunologists about the health impacts of climate change that are already evident in our daily practices. It is also a call to action and advocacy, including to integrate climate change-related mitigation, education, and adaptation measures to protect our patients and avert further injury to our planet. (J Allergy Clin Immunol 2021;148:1366-77.)	[Pacheco, Susan E.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA; [Guidos-Fogelbach, Guillermo] Inst Politecn Nacl, ENM H SEPI, Mexico City, DF, Mexico; [Annesi-Maesano, Isabella] INSERM, Inst Desbrest Epidemiol & Publ Hlth, Montpellier, France; [Annesi-Maesano, Isabella] Montpellier Univ, Montpellier, France; [Pawankar, Ruby] Nippon Med Sch, Dept Pediat, Div Allergy, Tokyo, Japan; [D' Amato, Gennaro] High Specialty Hosp A Cardarelli, Chairman Comm World Allergy Org Aerobi Ology Clim, Div Resp Dis & Allergy, Naples, Italy; [D' Amato, Gennaro] Univ Naples Federico II, Sch Specializat Resp Dis, Naples, Italy; [Latour-Staffeld, Patricia] Univ Nacl Pedro Henriquez Urena, Ctr Avanzado Alergia & Asma Santo Domingo, Santo Domingo, Dominican Rep; [Latour-Staffeld, Patricia] Univ Nacl Pedro Henriquez Urena, Sch Med, Santo Domingo, Dominican Rep; [Urrutia-Pereira, Marylin] Fed Univ Pampa, Pediat Dept, Bage, Brazil; [Kesic, Matthew J.] Campbell Univ, Coll Pharm & Hlth Sci, Phys Assistant Program, Buies Creek, NC 27506 USA; [Hernandez, Michelle L.] Univ N Carolina, Sch Med, Clin Res Unit, Childrens Res Inst, Chapel Hill, NC 27515 USA	University of Texas System; University of Texas Health Science Center Houston; Instituto Politecnico Nacional - Mexico; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Nippon Medical School; Antonio Cardarelli Hospital; University of Naples Federico II; Universidad Nacional Pedro Henriquez Urena; Universidad Nacional Pedro Henriquez Urena; Universidade Federal do Pampa; Campbell University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Pacheco, SE (corresponding author), Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Pediat, Houston, TX 77030 USA.	Susan.E.Pacheco@uth.tmc.edu		Guidos Fogelbach, Guillermo/0000-0003-1675-3894				Acevedo N, 2019, ALLERGY ASTHMA IMMUN, V11, P450, DOI 10.4168/aair.2019.11.4.450; Adetona O, 2016, INHAL TOXICOL, V28, P95, DOI 10.3109/08958378.2016.1145771; Administration NASA, DUST PLUM REM; Agency UR, DAT REV IMP CLIM EM; Aghababaeian Hamidreza, 2021, Environ Health Insights, V15, p11786302211018390, DOI 10.1177/11786302211018390; Aguilera R, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2020-027128; Ahn K, 2014, J ALLERGY CLIN IMMUN, V134, P993, DOI 10.1016/j.jaci.2014.09.023; Akerlof KL, 2015, INT J ENV RES PUB HE, V12, P15419, DOI 10.3390/ijerph121214994; American Lung Association, 2021, STAT AIR; Anderegg WRL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2013284118; Annesi-Maesano I, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.02981-2020; [Anonymous], 2016, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, V109; [Anonymous], 2018, SPECIAL REPORT GLOBA; [Anonymous], 2021, OVERVIEW WEATHER GLO; [Anonymous], GREENHOUSE GASES; [Anonymous], 1994, UN FRAMEWORK CONVENT; [Anonymous], 2021, MORE NEAR RECORDWARM; [Anonymous], LANCET COUNTDOWN HLT; [Anonymous], POPULATIONS CONCERN; [Anonymous], 2021, WASH POST; [Anonymous], 2017, MENTAL HLTH OUR CHAN; [Anonymous], 2021, 2020 TIED WARMEST YE; [Anonymous], NATL EMISSIONS INVEN; Arnetz BB, 2020, J ASTHMA, V57, P28, DOI 10.1080/02770903.2018.1545856; Balsari S, 2020, CURR ENV HLTH REP, V7, P404, DOI 10.1007/s40572-020-00291-4; Bekkar B, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8243; Bergougnan C, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2020.100109; Huynh BT, 2010, PRIM CARE RESP J, V19, P254, DOI 10.4104/pcrj.2010.00027; Bowe B, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.15834; Brandt EB, 2015, J ALLERGY CLIN IMMUN, V136, P295, DOI 10.1016/j.jaci.2014.11.043; Brunst KJ, 2013, J ALLERGY CLIN IMMUN, V131, P592, DOI 10.1016/j.jaci.2012.10.042; Burbank AJ, 2019, J ALLERGY CLIN IMMUN, V143, P2299, DOI 10.1016/j.jaci.2019.02.006; Burbank AJ, 2017, J ALLERGY CLIN IMMUN, V140, P1, DOI 10.1016/j.jaci.2017.05.010; Burke SEL, 2018, CURR PSYCHIAT REP, V20, DOI 10.1007/s11920-018-0896-9; Buters J, 2015, J ALLERGY CLIN IMMUN, V136, P87, DOI 10.1016/j.jaci.2015.01.049; Case MJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205677; Cecchi L, 2018, J ALLERGY CLIN IMMUN, V141, P846, DOI 10.1016/j.jaci.2018.01.016; Chen J, 2021, SCI TOTAL ENVIRON, V761, DOI 10.1016/j.scitotenv.2020.143218; Chiu YHM, 2014, J ALLERGY CLIN IMMUN, V133, P713, DOI 10.1016/j.jaci.2013.09.023; Codispoti CD, 2015, ANN ALLERG ASTHMA IM, V114, P126, DOI 10.1016/j.anai.2014.10.020; Cohen AJ, 2017, LANCET, V389, P1907, DOI [10.1016/S0140-6736(17)30505-6, 10.1016/s0140-6736(17)30505-6]; Collins TW, 2019, ENVIRON RES, V179, DOI 10.1016/j.envres.2019.108772; Council Environm Hlth, 2015, PEDIATRICS, V136, P992, DOI 10.1542/peds.2015-3232; Croft DP, 2017, ENVIRON RES, V154, P352, DOI 10.1016/j.envres.2017.01.027; Custovic A, 2015, CLIN EXP ALLERGY, V45, P54, DOI 10.1111/cea.12450; D'Amato G, 2017, J ALLERGY CLIN IMMUN, V139, P1786, DOI 10.1016/j.jaci.2017.03.003; D'Amato G, 2016, ALLERGY ASTHMA IMMUN, V8, P391, DOI 10.4168/aair.2016.8.5.391; D'Amato G, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0073-0; D'Amato G, 2013, MULTIDISCIP RESP MED, V8, DOI 10.1186/2049-6958-8-12; D'Amato G, 2011, MULTIDISCIP RESP MED, V6, P28, DOI 10.1186/2049-6958-6-1-28; D'Amato M, 2018, J INVEST ALLERG CLIN, V28, P91, DOI 10.18176/jiaci.0228; Damialis A, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2019034118; Dannenberg AL, 2019, CLIMATIC CHANGE, V153, P1, DOI 10.1007/s10584-019-02382-0; Data OWi, EN POV IND AIR POLL; Davies JM., 2019, ENCY ENV HLTH, V2nd edn, P300; De Roos AJ, 2020, ENVIRON INT, V145, DOI 10.1016/j.envint.2020.106138; Domingo JL, 2020, ENVIRON RES, V187, DOI 10.1016/j.envres.2020.109650; Du WJ, 2021, CHEMOSPHERE, V267, DOI 10.1016/j.chemosphere.2020.128905; Duarte PA, 2020, BJAI, V4, P423; Edenhofer O., 2015, CLIMATE CHANGE 2014; Ellwanger JH, 2020, AN ACAD BRAS CIENC, V92, DOI 10.1590/0001-3765202020191375; Filippidou E. C., 2011, Progress in Health Sciences, V1, P144; Fisk WJ, 2007, INDOOR AIR, V17, P284, DOI 10.1111/j.1600-0668.2007.00475.x; Forster P, 2021, CRITICAL ISSUES CLIM, DOI [DOI 10.5281/ZENODO.4570334, 10.5281/zenodo.4570334]; Ghio AJ, 2012, OCCUP ENVIRON MED, V69, P170, DOI 10.1136/oem.2011.065276; Nguyen GH, 2019, INT J DERMATOL, V58, P279, DOI 10.1111/ijd.14016; Gilles S, 2020, ALLERGY, V75, P576, DOI 10.1111/all.14047; Gilliland FD, 2009, PEDIATRICS, V123, pS168, DOI 10.1542/peds.2008-2233G; Glass GE, 2018, US GLOBAL CHANGE RES; Glick S, 2021, SCI TOTAL ENVIRON, V781, DOI 10.1016/j.scitotenv.2021.146382; Group NWC, DIX FIR; Gruzieva O, 2017, ENVIRON HEALTH PERSP, V125, P104, DOI 10.1289/EHP36; Gutierrez MP, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082496; Heft-Neal S, 2020, NAT SUSTAIN, V3, P863, DOI 10.1038/s41893-020-0562-1; HelpAge International, 2015, CLIM CHANG AG WORLD; Ho SM, 2010, J ALLERGY CLIN IMMUN, V126, P453, DOI 10.1016/j.jaci.2010.07.030; Hsu HHL, 2015, AM J RESP CRIT CARE, V192, P1052, DOI 10.1164/rccm.201504-0658OC; Hulin M, 2013, INT J HYG ENVIR HEAL, V216, P155, DOI 10.1016/j.ijheh.2012.02.011; Hurteau MD, 2014, ENVIRON SCI TECHNOL, V48, P2298, DOI 10.1021/es4050133; Institute for Economics and Peace, ON BILL PEOPL THREAT; Khomenko S, 2021, LANCET PLANET HEALTH, V5, pE121, DOI 10.1016/S2542-5196(20)30272-2; Kim H, 2021, AM J RESP CRIT CARE, V204, P97, DOI 10.1164/rccm.202010-3844LE; Kingsley SL, 2014, J EXPO SCI ENV EPID, V24, P253, DOI 10.1038/jes.2014.5; Kinney PL, 2018, CURR ENV HLTH REP, V5, P179, DOI 10.1007/s40572-018-0188-x; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Kodgule R, 2012, CURR OPIN ALLERGY CL, V12, P82, DOI 10.1097/ACI.0b013e32834ecb65; Korten I, 2017, PAEDIATR RESPIR REV, V21, P38, DOI 10.1016/j.prrv.2016.08.008; Kotsyfakis M, 2019, INT J OCCUP MED ENV, V32, P749, DOI 10.13075/ijomeh.1896.01466; Kurganskiy A, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd7658; Kurganskiy A, 2020, ATMOS CHEM PHYS, V20, P2099, DOI 10.5194/acp-20-2099-2020; Landrigan PJ, 2018, LANCET, V391, P462, DOI 10.1016/S0140-6736(17)32345-0; LIU D, 1992, AM REV RESPIR DIS, V146, P1469, DOI 10.1164/ajrccm/146.6.1469; Liu GT, 2016, ENVIRON RES, V150, P1, DOI 10.1016/j.envres.2016.04.039; Liu YW, 2019, AM J RESP CRIT CARE, V200, P24, DOI 10.1164/rccm.201810-1823OC; Mallett LH, 2018, DISASTERS, V42, P432, DOI 10.1111/disa.12256; Manoli G, 2019, NATURE, V573, P55, DOI 10.1038/s41586-019-1512-9; Mathiarasan S, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020795; Maupin CR, 2021, NAT GEOSCI, V14, P396, DOI 10.1038/s41561-021-00729-w; Monteil MA, 2008, ENVIRON GEOCHEM HLTH, V30, P339, DOI 10.1007/s10653-008-9162-0; Morales E, 2015, THORAX, V70, P64, DOI 10.1136/thoraxjnl-2014-205413; Movassagh, SCI REP-UK, V11, P4067; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Nelin TD, 2012, TOXICOL LETT, V208, P293, DOI 10.1016/j.toxlet.2011.11.008; Nishimura KK, 2016, J ALLERGY CLIN IMMUN, V138, P1703, DOI 10.1016/j.jaci.2016.03.058; OXFAM International, CARB EM RICH 1 PERC; Paller AS, 2019, J ALLERGY CLIN IMMUN, V143, P46, DOI 10.1016/j.jaci.2018.11.006; Paudel B, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92178-z; Po JYT, 2011, THORAX, V66, P232, DOI 10.1136/thx.2010.147884; Poole JA, 2019, J ALLERGY CLIN IMMUN, V143, P1702, DOI 10.1016/j.jaci.2019.02.018; Potestio M., 2021, TORONTO STAR; Ramirez, 2018, HOUSTON CHRONICLE; Reid CE, 2016, ENVIRON HEALTH PERSP, V124, P1334, DOI 10.1289/ehp.1409277; Rice MB, 2021, ANN AM THORAC SOC, V18, P921, DOI 10.1513/AnnalsATS.202102-148ST; Robichaud A, 2020, J AIR WASTE MANAGE, V70, P341, DOI 10.1080/10962247.2020.1723738; Robine JM, 2008, CR BIOL, V331, P171, DOI 10.1016/j.crvi.2007.12.001; Romanello M, 2021, LANCET, V398, P1619, DOI 10.1016/S0140-6736(21)01787-6; Roseboom TJ, 2011, MATURITAS, V70, P141, DOI 10.1016/j.maturitas.2011.06.017; Sakhamuri S, 2019, LANCET PLANET HEALTH, V3, pE242, DOI 10.1016/S2542-5196(19)30088-9; Sbihi H, 2015, ENVIRON HEALTH PERSP, V123, P902, DOI 10.1289/ehp.1408700; Schei MA, 2004, J EXPO ANAL ENV EPID, V14, pS110, DOI 10.1038/sj.jea.7500365; Schiavoni G, 2017, ANN ALLERG ASTHMA IM, V118, P269, DOI 10.1016/j.anai.2016.12.019; Schmidt CW, 2016, ENVIRON HEALTH PERSP, V124, pA70, DOI 10.1289/ehp.124-A70; Schramm PJ, 2020, HEALTH AFFAIR, V39, P2153, DOI 10.1377/hlthaff.2020.00997; Schraufnagel DE, 2019, ANN AM THORAC SOC, V16, P1478, DOI 10.1513/AnnalsATS.201907-538CME; Shang L, 2021, ENVIRON SCI POLLUT R, V28, P3296, DOI 10.1007/s11356-020-10705-3; Shin HH, 2021, SCI TOTAL ENVIRON, V755, DOI 10.1016/j.scitotenv.2020.143135; Shukla P.R., 2019, INTERGOVERNMENTAL PA; Stefanovic N, 2021, CURR TREAT OPTION AL, V8, P222, DOI 10.1007/s40521-021-00289-9; Tager IB, 2005, EPIDEMIOLOGY, V16, P751, DOI 10.1097/01.ede.0000183166.68809.b0; Takaro TK, 2013, EXPERT REV RESP MED, V7, P349, DOI 10.1586/17476348.2013.814367; The Lancet Planetary Health, 2020, LANCET PLANET HEALTH, V4; Thien F, 2018, RESPIROLOGY, V23, P976, DOI 10.1111/resp.13410; Union of Concerned Scientists, 2019, KILL HEAT US CLIM CH; United Nations Department of Economic and Social Affairs Population Division, 2020, WORLD POPULATION AGE; Urrutia-Pereira M, 2020, ALLERGOL IMMUNOPATH, V48, P496, DOI 10.1016/j.aller.2020.05.004; US Environmental Protection Agency, GREENH GAS WHAT TREN; US Environmental Protection Agency, GLOB GREENH EM DAT; USGCRP, 2018, IMP RISKS AD US 4 N, VII; Vicedo-Cabrera AM, 2021, NAT CLIM CHANGE, V11, P492, DOI 10.1038/s41558-021-01058-x; Vinik D., 2018, POLITICO; Watts N, 2021, LANCET, V397, P129, DOI 10.1016/S0140-6736(20)32290-X; WHO, 2021, AIR POLLUTION; WHO (World Health Organization), AMB OUTD AIR POLL; Willison CE, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-001191; Woodby B, 2021, ANN NY ACAD SCI, V1486, P15, DOI 10.1111/nyas.14512; Wooldridge G, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00472; World Health Organization, AIR POLL CHILD HLTH; World Health Organization Regional Office for Europe, 2013, REV EV HLTH ASP AIR; World Health Organization (WHO), NEW WHO GLOB AIR QUA; Yang Song-I, 2019, Korean J Pediatr, V62, P22, DOI 10.3345/kjp.2018.07045; Zhang WJ, 2019, J AM HEART ASSOC, V8, DOI [10.1161/jaha.118.010995, 10.1161/JAHA.118.010995]; Zhang XL, 2016, ATMOSPHERE-BASEL, V7, DOI 10.3390/atmos7120158; Zheng XY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138146; Ziska LH, 2019, LANCET PLANET HEALTH, V3, pE124, DOI 10.1016/S2542-5196(19)30015-4	154	13	13	11	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2021	148	6					1366	1377		10.1016/j.jaci.2021.10.011	http://dx.doi.org/10.1016/j.jaci.2021.10.011		DEC 2021	12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XM1ZO	34688774	Bronze			2022-12-18	WOS:000728634000002
J	Altman, MC; Calatroni, A; Ramratnam, S; Jackson, DJ; Presnell, S; Rosasco, MG; Gergen, PJ; Bacharier, LB; O'Connor, GT; Sandel, MT; Kattan, M; Wood, RA; Visness, CM; Gern, JE				Altman, Matthew C.; Calatroni, Agustin; Ramratnam, Sima; Jackson, Daniel J.; Presnell, Scott; Rosasco, Mario G.; Gergen, Peter J.; Bacharier, Leonard B.; O'Connor, George T.; Sandel, Megan T.; Kattan, Meyer; Wood, Robert A.; Visness, Cynthia M.; Gern, James E.		Inner City Asthma Consortium	Endotype of allergic asthma with airway obstruction in urban children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma; endotypes; phenotypes; environmental exposures; transcriptomics	WHEEZING PHENOTYPES; ATOPY; SENSITIZATION; RHINOVIRUS; CHILDHOOD; RESPONSES; SUSCEPTIBILITY; SUBPHENOTYPES; TRAJECTORIES; EXPOSURE	Background: Black and Hispanic children growing up in disadvantaged urban neighborhoods have the highest rates of asthma and related morbidity in the United States. Objectives: This study sought to identify specific respiratory phenotypes of health and disease in this population, associations with early life exposures, and molecular patterns of gene expression in nasal epithelial cells that underlie clinical disease. Methods: The study population consisted of 442 high-risk urban children who had repeated assessments of wheezing, allergen specific IgE, and lung function through 10 years of age. Phenotypes were identified by developing temporal trajectories for these data, and then compared to early life exposures and patterns of nasal epithelial gene expression at 11 years of age. Results: Of the 6 identified respiratory phenotypes, a high wheeze, high atopy, low lung function group had the greatest respiratory morbidity. In early life, this group had low exposure to common allergens and high exposure to ergosterol in house dust. While all high-atopy groups were associated with increased expression of a type-2 inflammation gene module in nasal epithelial samples, an epithelium IL-13 response module tracked closely with impaired lung function, and a MUC5AC hypersecretion module was uniquely upregulated in the high wheeze, high atopy, low lung function group. In contrast, a medium wheeze, low atopy group showed altered expression of modules of epithelial integrity, epithelial injury, and antioxidant pathways. Conclusions: In the first decade of life, high-risk urban children develop distinct phenotypes of respiratory health versus disease that link early life environmental exposures to childhood allergic sensitization and asthma. Moreover, unique patterns of airway gene expression demonstrate how specific molecular pathways underlie distinct respiratory phenotypes, including allergic and nonallergic asthma. (J Allergy Clin Immunol 2021;148:1198-209.)	[Altman, Matthew C.; Presnell, Scott; Rosasco, Mario G.] Univ Washington, Benaroya Res Inst Syst, Immunol Div, Seattle, WA 98195 USA; [Altman, Matthew C.] Univ Washington, Dept Med, Seattle, WA USA; [Calatroni, Agustin; Visness, Cynthia M.] Rho Fed Syst Div Inc, Durham, NC USA; [Ramratnam, Sima; Jackson, Daniel J.; Gern, James E.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA; [Gergen, Peter J.] NIAID, Rockville, MD USA; [Bacharier, Leonard B.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Bacharier, Leonard B.] St Louis Childrens Hosp, St Louis, MO 63178 USA; [O'Connor, George T.; Sandel, Megan T.] Boston Univ, Sch Med, Dept Med, Boston, MA 02215 USA; [Kattan, Meyer] Columbia Univ, Dept Pediat, Irving Med Ctr, New York, NY 10027 USA; [Wood, Robert A.] Johns Hopkins Univ, Med Ctr, Dept Pediat, Baltimore, MD 21218 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Boston University; Columbia University; NewYork-Presbyterian Hospital; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Altman, MC (corresponding author), 1201 Ninth Ave, Seattle, WA 98101 USA.	maltman@benaroyaresearch.org		Calatroni, Agustin/0000-0002-1738-5176	National Institute of Allergy and Infectious Diseases (NIAID) , National Institutes of Health (NIH) [1UM1AI114271-01, UM2AI117870]; National Center for Research Resources, NIH [UL1TR001079]	National Institute of Allergy and Infectious Diseases (NIAID) , National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID) , National Institutes of Health (NIH) , under contracts 1UM1AI114271-01 and UM2AI117870. Additional support was provided by the National Center for Research Resources, NIH, under grant NCRR: UL1TR001079.	Altman MC, 2019, NAT IMMUNOL, V20, P637, DOI 10.1038/s41590-019-0347-8; Altman MC, 2018, J ALLERGY CLIN IMMUN, V142, P1856, DOI 10.1016/j.jaci.2018.02.019; Bacharier LB, 2019, AM J RESP CRIT CARE, V199, P71, DOI 10.1164/rccm.201801-0190OC; Belgrave DCM, 2014, AM J RESP CRIT CARE, V189, P1101, DOI 10.1164/rccm.201309-1700OC; Belgrave DCM, 2013, J ALLERGY CLIN IMMUN, V132, P575, DOI 10.1016/j.jaci.2013.05.041; Bonser LR, 2017, J CLIN MED, V6, DOI 10.3390/jcm6120112; Bonser LR, 2016, J CLIN INVEST, V126, P2367, DOI 10.1172/JCI84910; Boucher RC, 2019, NEW ENGL J MED, V380, P1941, DOI 10.1056/NEJMra1813799; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P529, DOI 10.1016/j.jaci.2010.01.036; Chen G, 2009, J CLIN INVEST, V119, P2914, DOI 10.1172/JCI39731; Chen QX, 2012, ANN ALLERG ASTHMA IM, V108, P311, DOI 10.1016/j.anai.2012.02.016; Evans CM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7281; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Granell R, 2016, J ALLERGY CLIN IMMUN, V138, P1060, DOI 10.1016/j.jaci.2016.01.046; Havstad S, 2014, J ALLERGY CLIN IMMUN, V134, P722, DOI 10.1016/j.jaci.2014.01.022; Iosifidis T, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133125; Jackson DJ, 2018, J ALLERGY CLIN IMMUN, V141, pAB114, DOI 10.1016/j.jaci.2017.12.362; Jackson DJ, 2017, J ALLERGY CLIN IMMUN, V139, P379, DOI 10.1016/j.jaci.2016.12.941; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Karvonen AM, 2015, PEDIATRICS, V135, pE598, DOI 10.1542/peds.2014-1239; Kicic A, 2016, CLIN EXP ALLERGY, V46, P1441, DOI 10.1111/cea.12767; Kicic A, 2020, J ALLERGY CLIN IMMUN, V145, P1562, DOI 10.1016/j.jaci.2020.02.018; Kurebayashi Y, 2012, CELL REP, V1, P360, DOI 10.1016/j.celrep.2012.02.007; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Larson D, 2020, J ALLERGY CLIN IMMUN, V145, P1585, DOI 10.1016/j.jaci.2020.02.024; Looi K, 2018, CLIN EXP ALLERGY, V48, P513, DOI 10.1111/cea.13097; Lopez-Guisa JM, 2012, J ALLERGY CLIN IMMUN, V129, P990, DOI 10.1016/j.jaci.2011.11.035; Loss GJ, 2016, AM J RESP CRIT CARE, V193, P889, DOI 10.1164/rccm.201507-1493OC; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mendell MJ, 2011, ENVIRON HEALTH PERSP, V119, P748, DOI 10.1289/ehp.1002410; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Nagai S, 2013, ANN NY ACAD SCI, V1280, P30, DOI 10.1111/nyas.12059; O'Connor GT, 2018, J ALLERGY CLIN IMMUN, V141, P1468, DOI 10.1016/j.jaci.2017.06.040; Oksel C, 2019, ANN AM THORAC SOC, V16, P868, DOI 10.1513/AnnalsATS.201811-837OC; Okuda K, 2019, AM J RESP CRIT CARE, V199, P715, DOI 10.1164/rccm.201804-0734OC; Platts-Mills TAE, 2015, J ALLERGY CLIN IMMUN, V136, P3, DOI 10.1016/j.jaci.2015.03.048; Poole A, 2014, J ALLERGY CLIN IMMUN, V133, P670, DOI 10.1016/j.jaci.2013.11.025; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rubner FJ, 2017, J ALLERGY CLIN IMMUN, V139, P501, DOI 10.1016/j.jaci.2016.03.049; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Sbihi H, 2017, AM J RESP CRIT CARE, V195, P607, DOI 10.1164/rccm.201601-0164OC; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Stein RT, 1997, THORAX, V52, P946, DOI 10.1136/thx.52.11.946; Taupin D, 2003, NAT REV MOL CELL BIO, V4, P721, DOI 10.1038/nrm1203; Thysen AH, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw0258; Wills-Karp M, 2012, J EXP MED, V209, P607, DOI 10.1084/jem.20110079; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yang LM, 2018, PEDIAT ALLERG IMM-UK, V29, P606, DOI 10.1111/pai.12917; Yuan S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010525; Zahran HS, 2018, MMWR-MORBID MORTAL W, V67, P149, DOI 10.15585/mmwr.mm6705e1; Zhang YL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04826-y	55	13	13	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2021	148	5					1198	1209		10.1016/j.jaci.2021.02.040	http://dx.doi.org/10.1016/j.jaci.2021.02.040		NOV 2021	12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WV7LX	33713771	Green Accepted			2022-12-18	WOS:000717415000019
J	Braithwaite, IE; Cai, F; Tom, JA; Galanter, JM; Owen, RP; Zhu, R; Williams, M; McGregor, AG; Eliahu, A; Durk, MR; Dengler, HS; Zak, M; Kenny, JR; Wilson, ME; Beasley, R; Chen, HB				Braithwaite, Irene E.; Cai, Fang; Tom, Jennifer A.; Galanter, Joshua M.; Owen, Ryan P.; Zhu, Rui; Williams, Mathew; McGregor, Anna G.; Eliahu, Avi; Durk, Matthew R.; Dengler, Hart S.; Zak, Mark; Kenny, Jane R.; Wilson, Maria E.; Beasley, Richard; Chen, Hubert			Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						JAK inhibitor; airway inflammation; clinical trial	DOUBLE-BLIND; SAFETY; ADULTS; REPRODUCIBILITY; HEALTHY	Background: The Janus kinase (JAK) pathway mediates the activity of many asthma-relevant cytokines, including IL-4 and IL-13. GDC-0214 is a potent, inhaled, small-molecule JAK inhibitor being developed for the treatment of asthma. Objective: We sought to determine whether GDC-0214 reduces fractional exhaled nitric oxide (FENO), a JAK1-dependent biomarker of airway inflammation, in patients with mild asthma. Methods: We conducted a double-blind, randomized, placebo controlled, phase 1 proof-of-activity study in adults with mild asthma and FENO higher than 40 parts per billion (ppb). Subjects were randomized 2:1 (GDC-0214:placebo) into 4 sequential ascending-dose cohorts (1 mg once daily [QD], 4 mg QD, 15 mg QD, or 15 mg twice daily). All subjects received 4 days of blinded placebo, then 10 days of either active drug or placebo. The primary outcome was placebo-corrected percent reduction in FENO from baseline to day 14. Baseline was defined as the average FENO during the blinded placebo period. Pharmacokinetics, safety, and tolerability were also assessed. Results: Thirty-six subjects (mean age, 28 years; 54% females) were enrolled. Mean FENO at baseline across all subjects was 93 +/- 43 ppb. At day 14, placebo-corrected difference in FENO was -23% (95% CI, -37.3 to -9) for 15 mg QD and -42% (95% CI, -57 to -27.4) for 15 mg twice daily. Higher plasma exposure was associated with greater FENO reduction. No dose-limiting adverse events, serious adverse events, or treatment discontinuations occurred. There were no major imbalances in adverse events or laboratory findings, or evidence of systemic JAK inhibition. Conclusions: GDC-0214, an inhaled JAK inhibitor, caused dose-dependent reductions in FENO in mild asthma and was well tolerated without evidence of systemic toxicity.	[Braithwaite, Irene E.; Williams, Mathew; Beasley, Richard] Med Res Inst New Zealand, Private Bag 7902, Wellington 6242, New Zealand; [Cai, Fang; Tom, Jennifer A.; Galanter, Joshua M.; Owen, Ryan P.; Zhu, Rui; McGregor, Anna G.; Eliahu, Avi; Durk, Matthew R.; Dengler, Hart S.; Zak, Mark; Kenny, Jane R.; Wilson, Maria E.; Chen, Hubert] Genentech Inc, San Francisco, CA USA	Medical Research Institute Of New Zealand; Roche Holding; Genentech	Braithwaite, IE (corresponding author), Med Res Inst New Zealand, Private Bag 7902, Wellington 6242, New Zealand.	irene.braithwaite@mrinz.ac.nz		McGregor, Anna/0000-0001-6240-763X	Genentech, Inc	Genentech, Inc(Roche HoldingGenentech)	This work was supported by Genentech, Inc, which participated in the study design, the collection, analysis, and interpretation of data, the writing of the report, and the deci-sion to submit the report for publication.	[Anonymous], 2019, XELJANZ; Burgess G, 2018, EBIOMEDICINE, V35, P67, DOI 10.1016/j.ebiom.2018.07.035; Calbet M, 2019, J PHARMACOL EXP THER, V370, P137, DOI 10.1124/jpet.119.256263; Castro M, 2018, NEW ENGL J MED, V378, P2486, DOI 10.1056/NEJMoa1804092; Clark JD, 2014, J MED CHEM, V57, P5023, DOI 10.1021/jm401490p; Cooper AE, 2012, CURR DRUG METAB, V13, P457; Corren J, 2017, NEW ENGL J MED, V377, P936, DOI 10.1056/NEJMoa1704064; Dengler HS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao2151; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Erin EM, 2008, CHEST, V134, P740, DOI 10.1378/chest.07-2575; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Food and Drug Administration, BIOAN METH VAL GUID; Gabay C, 2013, LANCET, V381, P1541, DOI 10.1016/S0140-6736(13)60250-0; Gelman A, 2008, ANN APPL STAT, V2, P1360, DOI 10.1214/08-AOAS191; Haan C, 2006, BIOCHEM PHARMACOL, V72, P1538, DOI 10.1016/j.bcp.2006.04.013; Harrington D, 2019, NEW ENGL J MED, V381, P285, DOI 10.1056/NEJMe1906559; Hashizume M, 2011, CYTOKINE, V54, P92, DOI 10.1016/j.cyto.2011.01.007; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Jones SL, 2002, EUR RESPIR J, V20, P601, DOI 10.1183/09031936.02.00285302; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903a; Kharitonov SA, 2002, THORAX, V57, P889, DOI 10.1136/thorax.57.10.889; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; O'Connor BJ, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-60; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Owen R, 2020, J ALLERGY CLIN IMMUN, V145, pAB17; Pavord ID, 2018, LANCET, V391, P350, DOI 10.1016/S0140-6736(17)30879-6; Pernis AB, 2002, J CLIN INVEST, V109, P1279, DOI 10.1172/JCI200215786; Peters MC, 2020, LANCET, V395, P371, DOI 10.1016/S0140-6736(19)33005-3; SATTERTHWAITE FE, 1946, BIOMETRICS BULL, V2, P110, DOI 10.2307/3002019; Silkoff PE, 2001, CHEST, V119, P1322, DOI 10.1378/chest.119.5.1322; Suresh V, 2007, AM J RESP CELL MOL, V37, P97, DOI 10.1165/rcmb.2006-0419OC; Travers J, 2007, AM J RESP CRIT CARE, V176, P238, DOI 10.1164/rccm.200609-1346OC; Wenzel S, 2016, LANCET, V388, P31, DOI 10.1016/S0140-6736(16)30307-5; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Winthrop KL, 2017, NAT REV RHEUMATOL, V13, P234, DOI 10.1038/nrrheum.2017.23; Zak M, 2019, BIOORG MED CHEM LETT, V29, DOI 10.1016/j.bmcl.2019.126658	38	13	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2021	148	3					783	789		10.1016/j.jaci.2021.02.042	http://dx.doi.org/10.1016/j.jaci.2021.02.042		SEP 2021	7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UP2VR	33744327	hybrid			2022-12-18	WOS:000695242900027
J	Wolf, K; Kuhn, H; Boehm, F; Gebhardt, L; Glaudo, M; Agelopoulos, K; Stander, S; Ectors, P; Zahn, D; Riedel, YK; Thimm, D; Muller, CE; Kretschmann, S; Kremer, AN; Chien, D; Limjunyawong, N; Peng, Q; Dong, XZ; Kolkhir, P; Scheffel, J; Sogaard, ML; Weigmann, B; Neurath, MF; Hawro, T; Metz, M; Fischer, MJM; Kremer, AE				Wolf, Katharina; Kuehn, Helen; Boehm, Felicitas; Gebhardt, Lisa; Glaudo, Markus; Agelopoulos, Konstantin; Staender, Sonja; Ectors, Philipp; Zahn, Dirk; Riedel, Yvonne K.; Thimm, Dominik; Mueller, Christa E.; Kretschmann, Sascha; Kremer, Anita N.; Chien, Daphne; Limjunyawong, Nathachit; Peng, Qi; Dong, Xinzhong; Kolkhir, Pavel; Scheffel, Joerg; Sogaard, Mia Lykke; Weigmann, Benno; Neurath, Markus F.; Hawro, Tomasz; Metz, Martin; Fischer, Michael J. M.; Kremer, Andreas E.			A group of cationic amphiphilic drugs activates MRGPRX2 and induces scratching behavior in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mas gene-related G protein-coupled receptors; &nbsp; mast cells; &nbsp; pseudoallergic drug reactions; (drug-induced) pruritus	PROTEIN-COUPLED RECEPTORS; MAST-CELL; INDUCED PRURITUS; SUBSTANCE-P; HISTAMINE; HYPERSENSITIVITY; PAROXETINE; ITCH; ANTIHISTAMINES; MRGX2	Background: Mas gene-related G protein-coupled receptors (MRGPRs) are a G protein-coupled receptor family responsive to various exogenous and endogenous agonists, playing a fundamental role in pain and itch sensation. The primate specific family member MRGPRX2 and its murine orthologue MRGPRB2 are expressed by mast cells mediating IgEindependent signaling and pseudoallergic drug reactions. Objectives: Our aim was to increase knowledge about the function and regulation of MRGPRX2/MRGPRB2, which is of major importance in prevention of drug hypersensitivity reactions and drug-induced pruritus. Methods: To identify novel MRGPR (ant)agonists, we screened a library of pharmacologically active compounds by utilizing a high-throughput calcium mobilization assay. The identified hit compounds were analyzed for their pseudoallergic and pruritogenic effects in mice and human. Results: We found a class of commonly used drugs activating MRGPRX2 that, to a large extent, consists of antidepressants, antiallergic drugs, and antipsychotics. Three-dimensional pharmacophore modeling revealed structural similarities of the identified agonists, classifying them as cationic amphiphilic drugs. Mast cell activation was investigated by using the 3 representatively selected antidepressants clomipramine, paroxetine, and desipramine. Indeed, we were able to show a concentration-dependent activation and MRGPRX2-dependent degranulation of the human mast cell line LAD2 (Laboratory of Allergic Diseases-2). Furthermore, clomipramine, paroxetine, and desipramine were able to induce degranulation of human skin and murine peritoneal mast cells. These substances elicited dose-dependent scratching behavior following intradermal injection into C57BL/6 mice but less so in MRGPRB2-mutant mice, as well as wheal-and-flare reactions following intradermal injections in humans. Conclusion: Our results contribute to the characterization of structure-activity relationships and functionality of MRGPRX2 ligands and facilitate prediction of adverse reactions such as drug-induced pruritus to prevent severe drug hypersensitivity reactions. (J Allergy Clin Immunol 2021;148:506-22.)	[Wolf, Katharina; Kuehn, Helen; Boehm, Felicitas; Gebhardt, Lisa; Glaudo, Markus; Sogaard, Mia Lykke; Weigmann, Benno; Neurath, Markus F.; Kremer, Andreas E.] Univ Hosp Erlangen, Dept Med 1, Ulmenweg 18, D-91054 Erlangen, Germany; [Wolf, Katharina; Kuehn, Helen; Boehm, Felicitas; Gebhardt, Lisa; Glaudo, Markus; Sogaard, Mia Lykke; Weigmann, Benno; Neurath, Markus F.; Kremer, Andreas E.] Friedrich Alexander Univ Erlangen Nurnberg, Erlangen, Germany; [Agelopoulos, Konstantin; Staender, Sonja] Univ Munster, Ctr Chron Pruritus, Dept Dermatol, Munster, Germany; [Ectors, Philipp; Zahn, Dirk] Friedrich Alexander Univ Erlangen Nurnberg, Comp Chem Ctr, Erlangen, Germany; [Riedel, Yvonne K.; Thimm, Dominik; Mueller, Christa E.] Univ Bonn, PharmaCtr Bonn, Pharmaceut Inst, Pharmaceut & Med Chem, Bonn, Germany; [Kretschmann, Sascha; Kremer, Anita N.] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 5, Erlangen, Germany; [Chien, Daphne; Limjunyawong, Nathachit; Peng, Qi; Dong, Xinzhong] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD USA; [Kolkhir, Pavel] IM Sechenov First Moscow State Med Univ, Sechenov Univ, Div Immune Mediated Skin Dis, Moscow, Russia; [Kolkhir, Pavel; Scheffel, Joerg; Hawro, Tomasz; Metz, Martin] Charite Univ Med Berlin, Dermatol Allergol, Allergie Ctr Charite, Dept Dermatol & Allergol, Berlin, Germany; [Kolkhir, Pavel; Scheffel, Joerg; Hawro, Tomasz; Metz, Martin] Free Univ Berlin, Berlin, Germany; [Kolkhir, Pavel; Scheffel, Joerg; Hawro, Tomasz; Metz, Martin] Humboldt Univ, Berlin, Germany; [Kolkhir, Pavel; Scheffel, Joerg; Hawro, Tomasz; Metz, Martin] Berlin Inst Hlth, Berlin, Germany; [Neurath, Markus F.] Deutsch Zentrum Immuntherapie DZI, German Ctr Immunotherapy, Erlangen, Germany; [Fischer, Michael J. M.] Univ Vienna, Ctr Physiol & Pharmacol, Vienna, Austria	University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Munster; University of Erlangen Nuremberg; University of Bonn; University of Erlangen Nuremberg; Johns Hopkins University; Sechenov First Moscow State Medical University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; University of Vienna	Kremer, AE (corresponding author), Univ Hosp Erlangen, Dept Med 1, Ulmenweg 18, D-91054 Erlangen, Germany.; Wolf, K (corresponding author), Univ Hosp Erlangen, Dept Med TRC 1, Schwabachanlage 12, D-91054 Erlangen, Germany.	katharina.b.wolf@fau.de; andreas.kremer@uk-erlangen.de	Metz, Martin/B-8799-2009; Limjunyawong, Nathachit/GVS-1517-2022; Maurer, Marcus/ABG-2174-2020	Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X; Wolf, Katharina/0000-0001-7931-6056; /0000-0001-8168-7542; Zahn, Dirk/0000-0002-4303-3422	German Research Foundation [AG 271/1-1, FOR2690, STA 1159/4-1, KR3618/3-1]; Interdisciplinary Center for Clinical Research (at the Friedrich-Alexander-University of Erlangen-Nurnberg); Russian Academic Excellence Project 5-100; GA2LEN fellowship; Bavarian Equal Opportunities Sponsorship (Realization Equal Opportunities forWomen in Research and Teaching); DFG [GRK1873]	German Research Foundation(German Research Foundation (DFG)); Interdisciplinary Center for Clinical Research (at the Friedrich-Alexander-University of Erlangen-Nurnberg); Russian Academic Excellence Project 5-100(Ministry of Education and Science, Russian FederationProject 5-100, Ministry of Education and Science, Russian Federation); GA2LEN fellowship; Bavarian Equal Opportunities Sponsorship (Realization Equal Opportunities forWomen in Research and Teaching); DFG(German Research Foundation (DFG))	Financially supported by grants from the German Research Foundation to K.A. (AG 271/1-1, FOR2690), S.S.T. (STA 1159/4-1, FOR2690), and A.E.K. (KR3618/3-1, FOR2690). Additional funding was provided by the Interdisciplinary Center for Clinical Research (at the Friedrich-Alexander-University of Erlangen-N_urnberg) within grant E20 to A.E.K. and within grant E27 to A.E.K. and M.J.M.F. P.K. was supported by the Russian Academic Excellence Project 5-100 and a GA2LEN fellowship. K.W. was supported by a Bavarian Equal Opportunities Sponsorship (Realization Equal Opportunities forWomen in Research and Teaching). C.E.M. is grateful for support by the DFG for the International Research Training Group GRK1873, which is dedicated to research on G protein-coupled receptors.	Amin K, 2012, RESP MED, V106, P9, DOI 10.1016/j.rmed.2011.09.007; Azimi E, 2017, J ALLERGY CLIN IMMUN, V140, P447, DOI 10.1016/j.jaci.2016.12.980; Azimi E, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89362; Bautista DM, 2014, NAT NEUROSCI, V17, P175, DOI 10.1038/nn.3619; Beckmann N, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00331; Berroa F, 2015, ANESTH ANALG, V121, P117, DOI 10.1213/ANE.0000000000000776; Bohm R, 2018, DTSCH ARZTEBL INT, V115, P501, DOI 10.3238/arztebl.2018.0501; Boozalis E, 2021, J DERMATOL TREAT, V32, P124, DOI 10.1080/09546634.2019.1623369; Bourin M, 2001, CNS DRUG REV, V7, P25; Bulfone-Paus S, 2017, TRENDS IMMUNOL, V38, P657, DOI 10.1016/j.it.2017.01.008; CALKIN JM, 1993, CONTACT DERMATITIS, V29, P223; Dhand A, 2014, BRAIN, V137, P313, DOI 10.1093/brain/awt158; Dittert I, 1998, J NEUROSCI METH, V82, P195, DOI 10.1016/S0165-0270(98)00051-X; Dong XT, 2018, NEURON, V98, P482, DOI 10.1016/j.neuron.2018.03.023; Dong XZ, 2001, CELL, V106, P619, DOI 10.1016/S0092-8674(01)00483-4; EISER N, 1991, RESP MED, V85, P393, DOI 10.1016/S0954-6111(06)80184-8; Engels B, 2003, HUM GENE THER, V14, P1155, DOI 10.1089/104303403322167993; Espino SS, 2018, TOXICON, V154, P28, DOI 10.1016/j.toxicon.2018.09.002; Evans H, 2014, J VIS EXP, P1; Ferry X, 2002, PEPTIDES, V23, P1507, DOI 10.1016/S0196-9781(02)00090-6; Finkelman FD, 2016, J ALLERGY CLIN IMMUN, V137, P1674, DOI 10.1016/j.jaci.2016.02.015; Flegel C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128951; Folks D G, 2001, Curr Psychiatry Rep, V3, P219, DOI 10.1007/s11920-001-0057-3; Gonzalez-Estrada A, 2015, J ALLER CL IMM-PRACT, V3, P101, DOI 10.1016/j.jaip.2014.11.005; Goosens A, 1998, CONTACT DERMATITIS, V39, P38, DOI 10.1111/j.1600-0536.1998.tb05817.x; GREENBERG JH, 1995, CONTACT DERMATITIS, V33, P281, DOI 10.1111/j.1600-0536.1995.tb00494.x; Greil W, 2019, EUR NEUROPSYCHOPHARM, V29, P111, DOI 10.1016/j.euroneuro.2018.10.010; Griffioen M, 2008, HAEMATOL-HEMATOL J, V93, P1535, DOI 10.3324/haematol.13067; Grimes J, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.547; Guhl S, 2011, BIOSCI BIOTECH BIOCH, V75, P382, DOI 10.1271/bbb.100745; Gupta K, 2018, IMMUNOL REV, V282, P168, DOI 10.1111/imr.12622; Hautmann G, 2003, J EUR ACAD DERMATOL, V17, P383, DOI 10.1046/j.1468-3083.2003.00749.x; Hou YJ, 2019, MOL IMMUNOL, V111, P118, DOI 10.1016/j.molimm.2019.04.008; Ikoma A, 2006, NAT REV NEUROSCI, V7, P535, DOI 10.1038/nrn1950; Iversen L, 2013, EUR J PHARMACOL, V700, P147, DOI 10.1016/j.ejphar.2012.12.006; JOZAKI K, 1990, J IMMUNOL, V145, P4252; Kaur R, 2018, EUR NEUROPSYCHOPHARM, V28, P341, DOI 10.1016/j.euroneuro.2018.01.007; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Kobayashi H, 1996, EUR J PHARMACOL, V311, P29, DOI 10.1016/0014-2999(96)00402-5; Kornhuber Johannes, 2013, Handb Exp Pharmacol, P169, DOI 10.1007/978-3-7091-1368-4_9; Kremer AE, 2014, BBA-MOL BASIS DIS, V1842, P869, DOI 10.1016/j.bbadis.2014.02.007; Kremer AE, 2010, GASTROENTEROLOGY, V139, P1008, DOI 10.1053/j.gastro.2010.05.009; Kroeze WK, 2003, NEUROPSYCHOPHARMACOL, V28, P519, DOI 10.1038/sj.npp.1300027; Kuhn H, 2021, J ALLERGY CLIN IMMUN, V147, P456, DOI 10.1016/j.jaci.2020.08.027; Kuhn H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59092-2; Kushnir-Sukhov NM, 2006, J IMMUNOL, V177, P6422, DOI 10.4049/jimmunol.177.9.6422; Lansu K, 2017, NAT CHEM BIOL, V13, P529, DOI [10.1038/NCHEMBIO.2334, 10.1038/nchembio.2334]; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Lay M, 2020, ANNU REV NEUROSCI, V43, P187, DOI 10.1146/annurev-neuro-083019-024537; Lee SH, 2018, J ALLERGY CLIN IMMUN, V142, P1349, DOI 10.1016/j.jaci.2018.05.031; Lehmann S, 2020, SKIN PHARMACOL PHYS, V33, P244, DOI 10.1159/000508795; Li HK, 2019, NEW ENGL J MED, V380, P425, DOI 10.1056/NEJMoa1710926; Liu Q, 2009, CELL, V139, P1353, DOI 10.1016/j.cell.2009.11.034; MARTINEZMIR MI, 1992, BRIT J PHARMACOL, V107, P528, DOI 10.1111/j.1476-5381.1992.tb12778.x; Mayorga C, 2019, ALLERGY, V74, P2368, DOI 10.1111/all.14061; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; MCQUADE RD, 1990, DRUG DEVELOP RES, V20, P301, DOI 10.1002/ddr.430200305; Meixiong J, 2017, ANNU REV GENET, V51, P103, DOI 10.1146/annurev-genet-120116-024723; Mestres J, 2011, CLIN PHARMACOL THER, V90, P662, DOI 10.1038/clpt.2011.177; Micallef L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101717; Mousavizadeh K, 2002, J UROLOGY, V168, P2716, DOI 10.1016/S0022-5347(05)64250-4; Murphy Jennifer Leontine, 2016, Hosp Pediatr, V6, P330, DOI 10.1542/hpeds.2015-0069; Obara I, 2015, PAIN, V156, P1519, DOI 10.1097/j.pain.0000000000000197; OSIFO NG, 1984, ARCH DERMATOL, V120, P80, DOI 10.1001/archderm.120.1.80; Owens MJ, 2001, BIOL PSYCHIAT, V50, P345, DOI 10.1016/S0006-3223(01)01145-3; PATON WDM, 1951, BRIT J PHARM CHEMOTH, V6, P499, DOI 10.1111/j.1476-5381.1951.tb00661.x; Peng L, 2014, CURR NEUROPHARMACOL, V12, P365, DOI 10.2174/1570159X12666140828221720; Pichler WJ, 2016, INT ARCH ALLERGY IMM, V171, P166, DOI 10.1159/000453265; Porebski G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03027; Reddy VB, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8864; Reich A, 2009, ACTA DERM-VENEREOL, V89, P236, DOI 10.2340/00015555-0650; Ribeiro-Vaz I, 2013, EUR J CLIN PHARMACOL, V69, P673, DOI 10.1007/s00228-012-1376-5; Robas N, 2003, J BIOL CHEM, V278, P44400, DOI 10.1074/jbc.M302456200; Robering JW, 2019, GLIA, V67, P999, DOI 10.1002/glia.23585; del Rio PR, 2009, J INVEST ALLERG CLIN, V19, P317; Rossbach K, 2011, NEUROSCIENCE, V190, P89, DOI 10.1016/j.neuroscience.2011.06.002; Roth B, 2020, PSYCHOACTIVE DRUG SC; Roth BL, 2004, NAT REV DRUG DISCOV, V3, P353, DOI 10.1038/nrd1346; Roy S, 2019, J IMMUNOL, V202, P1229, DOI 10.4049/jimmunol.1801227; Sachs B, 2019, PHARMACOEPIDEM DR S, V28, P377, DOI 10.1002/pds.4726; Seifert R, 2015, N-S ARCH PHARMACOL, V388, P279, DOI 10.1007/s00210-015-1093-6; Shinohara T, 2004, J BIOL CHEM, V279, P23559, DOI 10.1074/jbc.M314240200; Shtessel M, 2021, J INVEST DERMATOL, V141, P678, DOI 10.1016/j.jid.2020.06.030; SIMONE DA, 1987, SOMATOSENS MOT RES, V5, P81, DOI 10.3109/07367228709144620; Simons FER, 2004, NEW ENGL J MED, V351, P2203, DOI 10.1056/NEJMra033121; Spoerl D, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061223; Stander S, 2009, ACTA DERM-VENEREOL, V89, P45, DOI 10.2340/00015555-0553; Steinhoff M, 2018, IMMUNOL REV, V282, P248, DOI 10.1111/imr.12635; Subramanian H, 2012, J BIOL CHEM; Subramanian H, 2016, J ALLERGY CLIN IMMUN, V138, P700, DOI 10.1016/j.jaci.2016.04.051; Subramanian H, 2013, J IMMUNOL, V191, P345, DOI 10.4049/jimmunol.1300023; Subramanian H, 2011, MOL PHARMACOL, V79, P1005, DOI 10.1124/mol.111.071472; TASAKA K, 1986, ANN ALLERGY, V56, P464; Tatemoto K, 2006, BIOCHEM BIOPH RES CO, V349, P1322, DOI 10.1016/j.bbrc.2006.08.177; Tatsumi M, 1997, EUR J PHARMACOL, V340, P249, DOI 10.1016/S0014-2999(97)01393-9; Varricchi G, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00299; Warnock Julia K, 2002, Am J Clin Dermatol, V3, P329, DOI 10.2165/00128071-200203050-00005; Weisshaar E, 2012, ACTA DERM-VENEREOL, V92, P563, DOI 10.2340/00015555-1400; Wernersson S, 2014, NAT REV IMMUNOL, V14, P478, DOI 10.1038/nri3690; Yang S, 2005, GENE, V352, P30, DOI 10.1016/j.gene.2005.03.001; Yaris E, 2003, PHARMACOL RES, V48, P335, DOI 10.1016/S1043-6618(03)00157-9; Yosipovitch G, 2013, NEW ENGL J MED, V368, P1625, DOI 10.1056/NEJMcp1208814; Zhang B, 2018, PHARMACOLOGY, V101, P104, DOI 10.1159/000479878; Zhang L, 2005, MOL BRAIN RES, V133, P187, DOI 10.1016/j.molbrainres.2004.10.007; Zylicz Z, 2003, J PAIN SYMPTOM MANAG, V26, P1105, DOI 10.1016/j.jpainsymman.2003.05.004; Zylka MJ, 2003, P NATL ACAD SCI USA, V100, P10043, DOI 10.1073/pnas.1732949100	107	13	13	3	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2021	148	2					506	+		10.1016/j.jaci.2020.12.655	http://dx.doi.org/10.1016/j.jaci.2020.12.655		AUG 2021	25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UD3IW	33617860				2022-12-18	WOS:000687104900004
J	Garcia, E; Rice, MB; Gold, DR				Garcia, Erika; Rice, Mary B.; Gold, Diane R.			Air pollution and lung function in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Children; lung function; FEV1; FVC; air pollution; wildfire; gas stoves; biomass	VOLATILE ORGANIC-COMPOUNDS; NITROGEN-DIOXIDE EXPOSURE; PRIMARY-SCHOOL CHILDREN; EMERGENCY-ROOM VISITS; EARLY-LIFE EXPOSURE; RESPIRATORY SYMPTOMS; PULMONARY-FUNCTION; PARTICULATE MATTER; POSTNATAL EXPOSURE; FUNCTION GROWTH	In this narrative review, we summarize the literature and provide updates on recent studies of air pollution exposures and child lung function and lung function growth. We include exposures to outdoor air pollutants that are monitored and regulated through air quality standards, and air pollutants that are not routinely monitored or directly regulated, including wildfires, indoor biomass and coal burning, gas and wood stove use, and volatile organic compounds. Included is a more systematic review of the recent literature on long-term air pollution and child lung function because this is an indicator of future adult respiratory health and exposure assessment tools have improved dramatically in recent years. We present "summary observations" and "knowledge gaps." We end by discussing what is known about what can be done at the individual/household, local/regional, and national levels to overcome structural impediments, reduce air pollution exposures, and improve child lung function. We found a large literature on adverse air pollution effects on children's lung function level and growth; however, many questions remain. Important areas needing further research include whether early-life effects are fixed or reversible; and what are windows of increased susceptibility, long-term effects of repeated wildfire events, and effects of air quality interventions.	[Garcia, Erika] Univ Southern Calif, Dept Prevent Med, Los Angeles, CA 90007 USA; [Rice, Mary B.] Harvard Med Sch, Div Pulm & Crit Care Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Gold, Diane R.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Gold, Diane R.] Harvard Med Sch, Channing Div Network Med, Brigham & Womens Hosp, Boston, MA 02115 USA	University of Southern California; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Garcia, E (corresponding author), Keck Sch Med USC, Dept Prevent Med, 2001 N Soto St,SSB1 Rm 225F MC 9237, Los Angeles, CA 90089 USA.	garc991@usc.edu			National Institute of Environmental Health Sciences [P30 ES00002, P30 ES007048]	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported in part by the National Institute of Environmental Health Sciences (grant no. P30 ES00002 to D.R.G. and M.B.R. and grant no. P30 ES007048 to E.G.).	Adar SD, 2015, AM J RESP CRIT CARE, V191, P1413, DOI 10.1164/rccm.201410-1924OC; Adar Sara D, 2014, Curr Environ Health Rep, V1, P258; Altug H, 2014, SCI TOTAL ENVIRON, V479, P201, DOI 10.1016/j.scitotenv.2014.01.127; [Anonymous], WHAT ARE VOLATILE OR; Avdalovic MV, 2012, ANAT REC, V295, P1707, DOI 10.1002/ar.22545; Balmes JR, 2018, NEW ENGL J MED, V378, P881, DOI 10.1056/NEJMp1716846; Bateson TF, 2008, J TOXICOL ENV HEAL A, V71, P238, DOI 10.1080/15287390701598234; Batterman S, 2007, ENVIRON RES, V104, P224, DOI 10.1016/j.envres.2007.01.008; Belanger K, 2006, AM J RESP CRIT CARE, V173, P297, DOI 10.1164/rccm.200408-1123OC; Bergstra AD, 2018, ENVIRON HEALTH-GLOB, V17, DOI 10.1186/s12940-018-0373-2; Billionnet C, 2011, ENVIRON RES, V111, P425, DOI 10.1016/j.envres.2011.02.008; Black C, 2017, AM J RESP CELL MOL, V56, P657, DOI 10.1165/rcmb.2016-0380OC; Bose S, 2018, ENVIRON RES, V167, P591, DOI 10.1016/j.envres.2018.08.019; Bougas N, 2018, ANN AM THORAC SOC, V15, P599, DOI 10.1513/AnnalsATS.201711-900OC; Breton CV, 2011, AM J RESP CRIT CARE, V183, P243, DOI 10.1164/rccm.201006-0849OC; Brown SK., 1999, ORGANIC INDOOR AIR P, P170; BRUNEKREEF B, 1990, J AIR WASTE MANAGE, V40, P1252, DOI 10.1080/10473289.1990.10466779; BRUNEKREEF B, 1993, J EXPO ANAL ENV EPID, V3, P117; Cai YT, 2020, AM J RESP CRIT CARE, V202, P112, DOI 10.1164/rccm.201902-0286OC; Cakmak S, 2014, ENVIRON POLLUT, V194, P145, DOI 10.1016/j.envpol.2014.07.020; CASTILLEJOS M, 1992, AM REV RESPIR DIS, V145, P276, DOI 10.1164/ajrccm/145.2_Pt_1.276; CASTILLEJOS M, 1995, AM J RESP CRIT CARE, V152, P1501, DOI 10.1164/ajrccm.152.5.7582284; Chang YK, 2012, CHEMOSPHERE, V87, P26, DOI 10.1016/j.chemosphere.2011.11.048; Chen C, 2018, SCI TOTAL ENVIRON, V645, P1014, DOI 10.1016/j.scitotenv.2018.07.154; Chen CH, 2015, ENVIRON RES, V137, P40, DOI 10.1016/j.envres.2014.11.021; Cloutier MM, 2020, J ALLERGY CLIN IMMUN, V146, P1217, DOI 10.1016/j.jaci.2020.10.003; Cui XX, 2018, ENVIRON INT, V114, P27, DOI 10.1016/j.envint.2018.02.010; Cusick Daniel, 2020, SCI AM; Deflorio-Barker S, 2019, ENVIRON HEALTH PERSP, V127, DOI [10.1289/ehp3860, 10.1289/EHP3860]; Delfino RJ, 2009, OCCUP ENVIRON MED, V66, P189, DOI 10.1136/oem.2008.041376; Department of Environmental Quality, WHAT YOU CAN RED AIR; Diez U, 2000, INT J HYG ENVIR HEAL, V203, P23, DOI 10.1078/S1438-4639(04)70004-8; EPA US., 2016, INT SCI ASS OX NITR, Vvol 24, P810, DOI [10.1177/1073191115625800, DOI 10.1177/1073191115625800]; Fanucchi MV, 2006, AM J PHYSIOL-LUNG C, V291, pL644, DOI 10.1152/ajplung.00027.2006; Finlayson-Pitts B.J., 2000, CHEM UP LOW ATMOS, P844, DOI [10.1016/B978-012257060-5/50017-4, DOI 10.1016/B978-012257060-5/50017-4]; Frye C, 2003, ENVIRON HEALTH PERSP, V111, P383, DOI 10.1289/ehp.5355; Garrett MH, 1998, AM J RESP CRIT CARE, V158, P891, DOI 10.1164/ajrccm.158.3.9701084; Gauderman WJ, 2007, LANCET, V369, P571, DOI 10.1016/S0140-6736(07)60037-3; Gauderman WJ, 2015, NEW ENGL J MED, V372, P905, DOI 10.1056/NEJMoa1414123; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gehring U, 2013, ENVIRON HEALTH PERSP, V121, P1357, DOI 10.1289/ehp.1306770; Gibson EA, 2019, CURR ENV HLTH REP, V6, P53, DOI 10.1007/s40572-019-00229-5; Gilliland F, 2017, Res Rep Health Eff Inst, P1; Glazener A, 2019, CURR ENV HLTH REP, V6, P22, DOI 10.1007/s40572-019-0228-1; Gold DR, 2020, J ALLER CL IMM-PRACT, V8, P1272, DOI 10.1016/j.jaip.2020.01.043; Gold DR, 1996, NEW ENGL J MED, V335, P931, DOI 10.1056/NEJM199609263351304; Gold DR, 1999, EPIDEMIOLOGY, V10, P8, DOI 10.1097/00001648-199901000-00004; Good N, 2016, J EXPO SCI ENV EPID, V26, P397, DOI 10.1038/jes.2015.68; Gray D, 2017, THORAX, V72, P445, DOI 10.1136/thoraxjnl-2015-207401; GUNESER S, 1994, J TROP PEDIATRICS, V40, P114, DOI 10.1093/tropej/40.2.114; Gutierrez-Delgado RI, 2020, PEDIATR PULM, V55, P2142, DOI 10.1002/ppul.24889; He BT, 2019, ENVIRON INT, V123, P444, DOI 10.1016/j.envint.2018.11.073; Heinzerling AP, 2016, THORAX, V71, P421, DOI 10.1136/thoraxjnl-2015-207783; Hesterberg TW, 2009, CRIT REV TOXICOL, V39, P743, DOI 10.3109/10408440903294945; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; Jedrychowski W, 2005, PUBLIC HEALTH, V119, P535, DOI 10.1016/j.puhe.2004.10.016; Kile ML, 2014, ENVIRON HEALTH-GLOB, V13, DOI 10.1186/1476-069X-13-71; KOUTRAKIS P, 2017, P NATL ACAD SCI USA, V114, pE3880; Krieger N, 2020, AM J PUBLIC HEALTH, V110, P1046, DOI 10.2105/AJPH.2020.305656; Lee D, 2011, INHAL TOXICOL, V23, P520, DOI 10.3109/08958378.2011.591447; Lee D, 2010, J APPL PHYSIOL, V109, P1115, DOI 10.1152/japplphysiol.00295.2010; Li SS, 2012, J ASTHMA, V49, P895, DOI 10.3109/02770903.2012.724129; Linn WS, 1996, J EXPO ANAL ENV EPID, V6, P449; MacNeill SJ, 2009, THORAX, V64, P651, DOI 10.1136/thx.2008.101360; McClure CD, 2018, P NATL ACAD SCI USA, V115, P7901, DOI 10.1073/pnas.1804353115; McDonald E, 2002, CHEST, V122, P1535, DOI 10.1378/chest.122.5.1535; McGeachie MJ, 2016, NEW ENGL J MED, V374, P1842, DOI 10.1056/NEJMoa1513737; Mendell MJ, 2007, INDOOR AIR, V17, P259, DOI 10.1111/j.1600-0668.2007.00478.x; Mentz G, 2019, THORAX, V74, P1055, DOI 10.1136/thoraxjnl-2017-211458; Milanzi EB, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00218-2018; Mirabelli MC, 2009, EPIDEMIOLOGY, V20, P451, DOI 10.1097/EDE.0b013e31819d128d; Morales E, 2015, THORAX, V70, P64, DOI 10.1136/thoraxjnl-2014-205413; Moreno-Macias H, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-14; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; Moshammer H, 2006, EUR RESPIR J, V27, P1138, DOI 10.1183/09031936.06.00089605; Moshammer H, 2010, EUR RESPIR J, V36, P249, DOI 10.1183/09031936.00102409; Mudway IS, 2019, LANCET PUBLIC HEALTH, V4, pE28, DOI 10.1016/S2468-2667(18)30202-0; Na K, 2008, ENVIRON RES, V108, P7, DOI 10.1016/j.envres.2008.04.004; Nardone A, 2020, LANCET PLANET HEALTH, V4, pE24, DOI 10.1016/S2542-5196(19)30241-4; Neophytou AM, 2016, AM J RESP CRIT CARE, V193, P1271, DOI 10.1164/rccm.201508-1706OC; Nicole W, 2014, ENVIRON HEALTH PERSP, V122, pA27, DOI 10.1289/ehp.122-A27; Noonan CW, 2015, ENVIRON HEALTH PERSP, V123, pA30, DOI 10.1289/ehp.1409136; O'Connor GT, 2008, J ALLERGY CLIN IMMUN, V121, P1133, DOI 10.1016/j.jaci.2008.02.020; Qian Z, 2007, INDOOR AIR, V17, P135, DOI 10.1111/j.1600-0668.2006.00463.x; Qiu L, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16081465; RAIZENNE ME, 1989, ENVIRON HEALTH PERSP, V79, P179, DOI 10.2307/3430547; Rinne ST, 2006, RESP MED, V100, P1208, DOI 10.1016/j.rmed.2005.10.020; Rodrigues PF, 2020, ENVIRON POLLUT, V258, DOI 10.1016/j.envpol.2019.113745; Rojas-Martinez R, 2007, AM J RESP CRIT CARE, V176, P377, DOI 10.1164/rccm.200510-1678OC; Rojas-Rueda D, 2013, PREV MED, V57, P573, DOI 10.1016/j.ypmed.2013.07.021; Rokoff LB, 2017, CURR PROB PEDIATR AD, V47, P123, DOI 10.1016/j.cppeds.2017.04.001; Roy A, 2012, INDOOR AIR, V22, P3, DOI 10.1111/j.1600-0668.2011.00748.x; Rumchev K, 2004, THORAX, V59, P746, DOI 10.1136/thx.2003.013680; Saleh S, 2020, INT J TUBERC LUNG D, V24, P150, DOI 10.5588/ijtld.19.0417; Scarlett JF, 1996, THORAX, V51, P1109, DOI 10.1136/thx.51.11.1109; Schelegle ES, 2003, TOXICOL APPL PHARM, V191, P74, DOI 10.1016/S0041-008X(03)00218-7; Schultz ES, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0709-y; Schultzl ES, 2016, AM J RESP CRIT CARE, V193, P171, DOI 10.1164/rccm.201505-0928OC; Schwartz J, 2004, PEDIATRICS, V113, P1037; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; Shao JY, 2020, RESPIROLOGY, V25, P198, DOI 10.1111/resp.13617; Shen S, 1992, Biomed Environ Sci, V5, P136; Shore SA, 2002, J APPL PHYSIOL, V92, P1019, DOI 10.1152/japplphysiol.00381.2001; Shore SA, 2009, J APPL PHYSIOL, V107, P1445, DOI 10.1152/japplphysiol.00456.2009; Singer BC., 2014, POLLUTANT EXPOSURES; Sordillo JE, 2019, J ALLERGY CLIN IMMUN, V144, P1534, DOI 10.1016/j.jaci.2019.07.044; Speizer F E, 1979, Epidemiol Rev, V1, P124; SPEKTOR DM, 1988, AM REV RESPIR DIS, V137, P313, DOI 10.1164/ajrccm/137.2.313; Stafoggia Massimo, 2017, Curr Environ Health Rep, V4, P481, DOI 10.1007/s40572-017-0162-z; Strickland MJ, 2018, AM J RESP CRIT CARE, V197, P697, DOI 10.1164/rccm.201712-2434ED; Sugiri D, 2006, ENVIRON HEALTH PERSP, V114, P282, DOI 10.1289/ehp.8180; Tasmin S, 2019, EPIDEMIOLOGY, V30, pS15, DOI [10.1097/EDE.0000000000001012, 10.1097/ede.0000000000001012]; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654, DOI 10.1164/ajrccm.155.2.9032209; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798, DOI 10.1093/oxfordjournals.aje.a010280; Transport for London, 2017, HLTH STREETS LOND PR; Tsui HC, 2018, ENVIRON POLLUT, V236, P953, DOI 10.1016/j.envpol.2017.10.092; U.S. Environmental Protection Agency, INT SCI ASS ISAS; U.S. EPA, 2020, INT SCI ASS OZ REL P; Underhill LJ, 2018, INDOOR AIR, V28, P459, DOI 10.1111/ina.12446; United States Environmental Protection Agency, REP ENV PART MATT EM; Urman R, 2014, THORAX, V69, P540, DOI 10.1136/thoraxjnl-2012-203159; US EPA, 2019, EPA600R19188; Usemann J, 2019, ENVIRON INT, V126, P682, DOI 10.1016/j.envint.2018.12.019; Jacobson LDV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104177; Jacobson LDV, 2012, ENVIRON RES, V117, P27, DOI 10.1016/j.envres.2012.05.006; WHO (World Health Organization), AMB OUTD AIR POLL; Xu DD, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61003-4; Zanobetti A, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.016935; Zhang JJ, 2007, ENVIRON HEALTH PERSP, V115, P848, DOI 10.1289/ehp.9479; Zhong J, 2017, P NATL ACAD SCI USA, V114, P3503, DOI 10.1073/pnas.1618545114	131	13	13	16	34	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2021	148	1					1	14		10.1016/j.jaci.2021.05.006	http://dx.doi.org/10.1016/j.jaci.2021.05.006		JUL 2021	14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE3IE	34238501	Green Accepted			2022-12-18	WOS:000669906700001
J	Srivastava, A; Luo, LL; Lohcharoenkal, W; Meisgen, F; Pasquali, L; Pivarcsi, A; Sonkoly, E				Srivastava, Ankit; Luo, Longlong; Lohcharoenkal, Warangkana; Meisgen, Florian; Pasquali, Lorenzo; Pivarcsi, Andor; Sonkoly, Eniko			Cross-talk between IFN-gamma and TWEAK through miR-149 amplifies skin inflammation in psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Psoriasis; skin inflammation; keratinocytes; microRNAs; cytokines; IFN-gamma; IFN-gamma-mediated priming; TWEAK/TWEAKR pathway	KERATINOCYTE PROLIFERATION; INTERFERON-GAMMA; SUPPRESSES; DISEASE; MICRORNAS; CYTOKINE; PATHOGENESIS; ACTIVATION; EXPRESSION; PATHWAY	Background: Psoriasis is a chronic inflammatory skin disease with disturbed interplay between immune cells and keratinocytes. A strong IFN-gamma signature is characteristic for psoriasis skin, but the role of IFN-gamma has been elusive. MicroRNAs are short RNAs regulating gene expression. Objective: Our aim was to investigate the role of miR-149 in psoriasis and in the inflammatory responses of keratinocytes. Methods: miR-149 expression was measured by quantitative RT-PCR in keratinocytes isolated from healthy skin and lesional and nonlesional psoriasis skin. Synthetic miR-149 was injected intradermally into the back skin of mice, and imiquimod was applied to induce psoriasis-like skin inflammation, which was then evaluated at the morphologic, histologic, and molecular levels. miR-149 was transiently overexpressed or inhibited in keratinocytes in combination with IFN-gamma- and/or TNF-related weak inducer of apoptosis (TWEAK)-treatment. Results: Here we report a microRNA-mediated mechanism by which IFN-gamma primes keratinocytes to inflammatory stimuli. Treatment with IFN-gamma results in a rapid and long-lasting suppression of miR-149 in keratinocytes. Depletion of miR-149 in keratinocytes leads to widespread transcriptomic changes and induction of inflammatory mediators with enrichment of the TWEAK pathway. We show that IFN-gamma-mediated suppression of miR-149 leads to amplified inflammatory responses to TWEAK. TWEAK receptor (TWEAKR/Fn14) is identified as a novel direct target of miR-149. The in vivo relevance of this pathway is supported by decreased miR-149 expression in psoriasis keratinocytes, as well as by the protective effect of synthetic miR-149 in the imiquimod-induced mouse model of psoriasis. Conclusion: Our data define a new mechanism, in which IFN-gamma primes keratinocytes for TWEAK-induced inflammatory responses through suppression of miR-149, promoting skin inflammation.	[Srivastava, Ankit; Luo, Longlong; Lohcharoenkal, Warangkana; Meisgen, Florian; Pasquali, Lorenzo; Pivarcsi, Andor; Sonkoly, Eniko] Karolinska Inst, Dept Med Solna, Dermatol & Venereol Div, CMM L8 02, S-17176 Stockholm, Sweden; [Pivarcsi, Andor] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden; [Sonkoly, Eniko] Karolinska Univ Hosp, Unit Dermatol, Stockholm, Sweden	Karolinska Institutet; Uppsala University; Karolinska Institutet; Karolinska University Hospital	Sonkoly, E (corresponding author), Karolinska Inst, Dept Med Solna, Dermatol & Venereol Div, CMM L8 02, S-17176 Stockholm, Sweden.	eniko.sonkoly@ki.se		Srivastava, Ankit/0000-0001-5328-7509; Lohcharoenkal, Warangkana/0000-0001-6541-1693	Stockholm County Council; Swedish Medical Research Council (Vetenskapsradet); Swedish Psoriasis Association (Psoriasisfonden); Swedish Cancer Foundation (Cancerfonden); Finsen Foundation/Hudfonden (Skin Foundation); National Psoriasis Foundation; Welander Foundation/Hudfonden (Skin Foundation)	Stockholm County Council(Stockholm County Council); Swedish Medical Research Council (Vetenskapsradet)(Swedish Medical Research Council (SMRC)Swedish Research Council); Swedish Psoriasis Association (Psoriasisfonden); Swedish Cancer Foundation (Cancerfonden)(Swedish Cancer Society); Finsen Foundation/Hudfonden (Skin Foundation); National Psoriasis Foundation; Welander Foundation/Hudfonden (Skin Foundation)	Supported by the Stockholm County Council, the Swedish Medical Research Council (Vetenskapsradet), the Swedish Psoriasis Association (Psoriasisfonden), the Swedish Cancer Foundation (Cancerfonden), Welander and Finsen Foundations/Hudfonden (Skin Foundation), and the National Psoriasis Foundation.	Abdallah MA, 2009, CUTIS, V84, P163; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Best JL, 2004, P NATL ACAD SCI USA, V101, P17622, DOI 10.1073/pnas.0406374101; Burkly LC, 2011, IMMUNOL REV, V244, P99, DOI 10.1111/j.1600-065X.2011.01054.x; Chen QJ, 2018, BIOMED PHARMACOTHER, V101, P763, DOI 10.1016/j.biopha.2018.02.133; Cheng H, 2016, EXP DERMATOL, V25, P32, DOI 10.1111/exd.12820; Doerner JL, 2015, J INVEST DERMATOL, V135, P1986, DOI 10.1038/jid.2015.124; Greb JE, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.82; Hermann H, 2017, J INVEST DERMATOL, V137, P1945, DOI 10.1016/j.jid.2017.05.012; Hile GA, 2020, CYTOKINE, V132, DOI 10.1016/j.cyto.2018.11.022; Hu XY, 2006, IMMUNITY, V24, P563, DOI 10.1016/j.immuni.2006.02.014; Johansen C, 2005, BRIT J DERMATOL, V152, P37, DOI 10.1111/J.1365-2133.2004.06304.X; Johansen C, 2010, BRIT J DERMATOL, V163, P1194, DOI 10.1111/j.1365-2133.2010.10036.x; Johnson-Huang LM, 2012, J INVEST DERMATOL, V132, P1177, DOI 10.1038/jid.2011.458; Kurtovic Nermina Ovcina, 2018, Med Arch, V72, P410, DOI 10.5455/medarh.2018.72.410-413; Lang HX, 2017, MOL MED REP, V16, P2156, DOI 10.3892/mmr.2017.6796; Lerman G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020916; Li BS, 2014, J INVEST DERMATOL, V134, P1828, DOI 10.1038/jid.2014.28; Li P, 2015, CELL RES, V25, P588, DOI 10.1038/cr.2015.51; Liu J, 2019, J INVEST DERMATOL, V139, P224, DOI 10.1016/j.jid.2018.05.036; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Mehta NN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14365-1; Meisgen F, 2012, EXP DERMATOL, V21, P312, DOI 10.1111/j.1600-0625.2012.01462.x; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Pasquali L, 2019, ACTA DERM-VENEREOL, V99, P196, DOI 10.2340/00015555-3066; Peng L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0820-6; Perera GK, 2012, ANNU REV PATHOL-MECH, V7, P385, DOI 10.1146/annurev-pathol-011811-132448; Qiao Y, 2013, IMMUNITY, V39, P454, DOI 10.1016/j.immuni.2013.08.009; Ronholt K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112297; Sakurai K, 2019, J ALLERGY CLIN IMMUN, V144, P1036, DOI 10.1016/j.jaci.2019.06.019; Shao S, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav7561; Sidler D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15395; Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610; Sonkoly E, 2010, J INVEST DERMATOL, V130, P124, DOI 10.1038/jid.2009.294; Sonkoly E, 2009, INT REV IMMUNOL, V28, P535, DOI 10.3109/08830180903208303; Srivastava A, 2019, J INVEST DERMATOL, V139, P2547, DOI 10.1016/j.jid.2019.05.019; Srivastava A, 2018, ACTA DERM-VENEREOL, V98, P772, DOI 10.2340/00015555-2960; Srivastava A, 2017, J ALLERGY CLIN IMMUN, V139, P550, DOI 10.1016/j.jaci.2016.07.025; Strittmatter GE, 2016, J INVEST DERMATOL, V136, P610, DOI 10.1016/j.jid.2015.12.022; Sweeney BA, 2019, NUCLEIC ACIDS RES, V47, pD221, DOI [10.1093/nar/gky1034, 10.1093/nar/gky1206]; Swindell WR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079253; Swindell WR, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-527; Xu GX, 2014, J CELL BIOCHEM, V115, P919, DOI 10.1002/jcb.24734; Xu N, 2013, J IMMUNOL, V190, P678, DOI 10.4049/jimmunol.1202695; Xu N, 2011, J INVEST DERMATOL, V131, P1521, DOI 10.1038/jid.2011.55	46	13	13	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2021	147	6					2225	2235		10.1016/j.jaci.2020.12.657	http://dx.doi.org/10.1016/j.jaci.2020.12.657		JUN 2021	11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM7MD	33705829	Green Published, hybrid			2022-12-18	WOS:000657783800003
J	Warren, C; Lei, D; Sicherer, S; Schleimer, R; Gupta, R				Warren, Christopher; Lei, Dawn; Sicherer, Scott; Schleimer, Robert; Gupta, Ruchi			Prevalence and characteristics of peanut allergy in US adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; atopy; peanut allergy; prevalence; adult-onset food allergy	TREE NUT ALLERGY; NATURAL-HISTORY; FOOD ALLERGY; EPIDEMIOLOGY; UPDATE	Background: Peanut allergy (PA) is the leading pediatric food allergy and a common cause of anaphylaxis. Little is known, however, on the prevalence and characteristics of PA in the adult population and whether phenotypic differences exist between adult-onset and childhood-onset PA. Objectives: This study describes the current US population -level burden of adult PA. Methods: A cross-sectional food allergy survey was administered via phone and web in 2015 and 2016, resulting in nationally representative complex-survey weighted data for 40,443 adults. Reported food allergies were considered "convincing" if symptoms to specific allergens were consistent with an IgE-mediated reaction. Results: The prevalence of current self-reported PA was 2.9% among US adults, with 1.8% having convincing PA. Over 17% of adults with peanut allergy reported onset of their PA in adulthood. In adults with childhood-onset PA, 75.4% reported physician-diagnosed PA, compared with only 58.9% of adult- onset PA. Despite a similar frequency of food allergy-related emergency department visits within the past year (approximately 1 in 5 adults with PA allergy), adults with childhood-onset PA were significantly more likely to have a current epinephrine prescription compared with those with adult-onset PA (56% vs 44% respectively; P = .02) and were more likely to use an epinephrine autoinjector (48% vs 35%, P = .01). Conclusions: Approximately 4.6 million US adults have PA-over 800,000 of whom appear to have developed their PA after age 18 years. Further examination of phenotypic differences between childhood-onset and adult-onset PA may improve understanding and management of adult PA. (J Allergy Clin Immunol 2021;147:2263-70.)	[Warren, Christopher; Gupta, Ruchi] Northwestern Univ, Feinberg Sch Med, Ctr Food Allergy & Asthma Res, Chicago, IL 60611 USA; [Lei, Dawn; Schleimer, Robert] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Dept Med, Chicago, IL 60611 USA; [Lei, Dawn; Gupta, Ruchi] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Warren, Christopher] Stanford Univ, Sch Med, Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA 94305 USA; [Sicherer, Scott] Mt Sinai Sch Med, Dept Pediat, Div Allergy, Elliot & Roslyn Jaffe Food Allergy Inst, New York, NY USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Stanford University; Icahn School of Medicine at Mount Sinai	Gupta, R (corresponding author), 750 N Lake Shore Dr,Suite 680, Chicago, IL 60611 USA.	r-gupta@northwestern.edu			National Institute of Allergy and Infectious Diseases [R21AI135702-PI]; National Institutes of Health [AI135705, AI130348, AI138907]; Rho Inc; Stanford Sean N. Parker Center for Allergy Research; UnitedHealth Group; Thermo Fisher Scientific; Genentech; National Confectioners Association; National Institutes of Health	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rho Inc; Stanford Sean N. Parker Center for Allergy Research; UnitedHealth Group; Thermo Fisher Scientific; Genentech(Roche HoldingGenentech); National Confectioners Association; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by grant R21AI135702-PI from the National Institute of Allergy and Infectious Diseases. Disclosure of potential conflict of interest: R. S. Gupta reports receiving grants from the National Institutes of Health (grants R21 ID# AI135705, R01 ID# AI130348, and U01 ID# AI138907) , Rho Inc, Stanford Sean N. Parker Center for Allergy Research, UnitedHealth Group, Thermo Fisher Scientific, Genentech, and the National Confectioners Association; and serves as a medical consultant/advisor for Before Brands, Kale?o Inc, Genentech, Institute for Clinical and Economic Review, Food Allergy Research and Education, Aimmune Therapeutics, and DBV Technologies. S. Sicherer reports royalty payments from UpToDate and from Johns Hopkins University Press; grants to his institution from the National Institute of Allergy and Infectious Diseases, from Food Allergy Research and Education, and from HAL Allergy; and personal fees from the American Academy of Allergy, Asthma and Immunology, outside of the submitted work. S. Sicherer was the American Academy of Pediatrics representative to the National Institute of Allergy and Infectious Diseases Expert Panel for peanut allergy guidelines and also coauthor of American Academy of Pediatrics Clinical Reports regarding atopy prevention. R. Schleimer reports National Institutes of Health grant money paid to the institution and to himself, and consulting fees and/or stock ownership from Intersect ENT, GlaxoSmithKline, Allakos, Aurasense, Merck, BioMarck, Sanofi, AstraZeneca/Medimmune, Genetech, Exicure, Otsuka, Aqualung Therapeutics Corp, Actobio Therapeutics, Lyra Therapeutics, Astellas Pharm Inc, and Genzyme/Sanofi Corp; and has Siglec8 and Siglec8 ligandrelated patents licensed to Allakos Inc. The rest of the authors declare that they have no relevant conflicts of interest.	Acker WW, 2017, J ALLERGY CLIN IMMUN, V140, P1587, DOI 10.1016/j.jaci.2017.04.006; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; Chaudhry RQ, 2012, CURR ALLERGY ASTHM R, V12, P311, DOI 10.1007/s11882-012-0266-3; Cianferoni A, 2012, IMMUNOL ALLERGY CLIN, V32, P165, DOI 10.1016/j.iac.2011.10.002; Dyer AA, 2015, ALLERGY ASTHMA PROC, V36, P58, DOI 10.2500/aap.2015.36.3819; Fleischer DM, 2007, CURR ALLERGY ASTHM R, V7, P175, DOI 10.1007/s11882-007-0018-y; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Gupta RS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.5630; Gupta RS, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-1235; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Ho MHK, 2008, J ALLERGY CLIN IMMUN, V121, P731, DOI 10.1016/j.jaci.2007.11.024; Jones SM, 2017, NEW ENGL J MED, V377, P1168, DOI 10.1056/NEJMcp1611971; Kamdar TA, 2015, J ALLER CL IMM-PRACT, V3, P114, DOI 10.1016/j.jaip.2014.07.007; Kelly Caleb, 2009, J Allergy (Cairo), V2009, P159845, DOI 10.1155/2009/159845; Kuwayama SP, 2002, NEW ENGL J MED, V347, P1534; Leickly FE, 2018, J PEDIATR-US, V192, P223, DOI 10.1016/j.jpeds.2017.09.026; Pali-Scholl I, 2019, CURR OPIN ALLERGY CL, V19, P249, DOI 10.1097/ACI.0000000000000529; Peters RL, 2015, J ALLERGY CLIN IMMUN, V135, P1257, DOI 10.1016/j.jaci.2015.01.002; Sampson HA, 2014, J ALLERGY CLIN IMMUN, V134, P1016, DOI 10.1016/j.jaci.2014.05.013; Sicherer SH, 2018, J ALLERGY CLIN IMMUN, V141, P41, DOI 10.1016/j.jaci.2017.11.003; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Spergel JM, 2001, CURR OPIN PEDIATR, V13, P517, DOI 10.1097/00008480-200112000-00004; Turner PJ, 2017, J ALLER CL IMM-PRACT, V5, P1169, DOI 10.1016/j.jaip.2017.06.031; Vickery BP, 2018, NEW ENGL J MED, V379, P1991, DOI 10.1056/NEJMoa1812856; Warren CM, 2020, CURR ALLERGY ASTHM R, V20, DOI 10.1007/s11882-020-0898-7; Warren CM, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0614-9; Woods RK, 2002, EUR J CLIN NUTR, V56, P31, DOI 10.1038/sj.ejcn.1601306; Xu YS, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-38	34	13	13	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2021	147	6					2263	+		10.1016/j.jaci.2020.11.046	http://dx.doi.org/10.1016/j.jaci.2020.11.046		JUN 2021	13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM7MD	33579526				2022-12-18	WOS:000657783800006
J	Bartemes, KR; Kita, H				Bartemes, Kathleen R.; Kita, Hirohito			Roles of innate lymphoid cells (ILCs) in allergic diseases: The 10-year anniversary for ILC2s	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Innate lymphoid cells; group 2 innate lymphoid cells; asthma; allergic rhinitis; chronic rhinosinusitis; atopic dermatitis; eosinophilic esophagitis	CD4(+) T-CELLS; TRANSCRIPTION FACTOR GATA3; TYPE-2 IMMUNE-RESPONSE; AIRWAY INFLAMMATION; CRITICAL REGULATOR; PERIPHERAL-BLOOD; IL-13 PRODUCTION; NASAL POLYPS; TISSUE; PLASTICITY	In the 12 years since the discovery of innate lymphoid cells (ILCs), our knowledge of their immunobiology has expanded rapidly. Group 2 ILCs (ILC2s) respond rapidly to allergen exposure and environmental insults in mucosal organs, producing type 2 cytokines. Early studies showed that epithelium-derived cytokines activate ILC2s, resulting in eosinophilia, mucus hypersecretion, and remodeling of mucosal tissues. We now know that ILC2s are regulated by other cytokines, eicosanoids, and neuropeptides as well, and interact with both immune and stromal cells. Furthermore, ILC2s exhibit plasticity by adjusting their functions depending on their tissue environment and may consist of several heterogeneous subpopulations. Clinical studies show that ILC2s are involved in asthma, allergic rhinitis, chronic rhinosinusitis, food allergy, and eosinophilic esophagitis. However, much remains unknown about the immunologic mechanisms involved. Beneficial functions of ILCs in maintenance or restoration of tissue wellbeing and human health also need to be clarified. As our understanding of the crucial functions ILCs play in both homeostasis and disease pathology expands, we are poised to make tremendous strides in diagnostic and therapeutic options for patients with allergic diseases. This review summarizes discoveries in immunobiology of ILCs and their roles in allergic diseases in the past 5 years, discusses controversies and gaps in our knowledge, and suggests future research directions. (J Allergy Clin Immunol 2021;147:1531-47.)	[Bartemes, Kathleen R.] Mayo Clin, Div Allerg Dis, Rochester, MN USA; [Bartemes, Kathleen R.] Mayo Clin, Dept Med, Rochester, MN USA; [Bartemes, Kathleen R.] Mayo Clin, Dept Otolaryngol Head & Neck Surg, Rochester, MN USA; [Kita, Hirohito] Mayo Clin, Dept Immunol, Rochester, MN USA; [Kita, Hirohito] Mayo Clin, Div Allergy Asthma & Immunol, Scottsdale, AZ 85259 USA; [Kita, Hirohito] Mayo Clin, Dept Med, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Kita, H (corresponding author), Mayo Clin, Dept Med, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.; Kita, H (corresponding author), Mayo Clin, Div Allerg Dis, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	kita.hirohito@mayo.edu		Kita, Hirohito/0000-0002-6854-2936; Bartemes, Kathleen/0000-0003-4561-3233	National Institutes of Health [R37AI71106, R01HL117823, R01AI128729]; Mayo Foundation	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation	This work was supported by the National Institutes of Health (grant nos. R37AI71106, R01HL117823, and R01AI128729), and by the Mayo Foundation.	[Anonymous], 2013, IMMUN INFLAMM DIS; [Anonymous], 2018, AM J RESP CRIT CARE; [Anonymous], 2018, P NATL ACAD SCI USA; [Anonymous], 2013, SCI IMMUNOL; [Anonymous], 2016, PLOS PATHOG; [Anonymous], 2003, MUCOSAL IMMUNOL; [Anonymous], 2018, SCIENCE; [Anonymous], 2019, NAT IMMUNOL; [Anonymous], 2013, BLOOD; [Anonymous], 2017, J ALLERGY CLIN IMMUN; [Anonymous], 2017, ALLERGY ASTHMA IMMUN; [Anonymous], 2013, J ALLERGY CLIN IMMUN; [Anonymous], 2018, GASTROENTEROLOGY; [Anonymous], 2016, J ALLERGY CLIN IMMUN; [Anonymous], 2013, J ALLERGY CLIN IMMUN; [Anonymous], 2018, P NATL ACAD SCI USA; Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Bankova LG, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat9453; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Bartemes K, 2018, J IMMUNOL, V200, P229, DOI 10.4049/jimmunol.1602085; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Bernink JH, 2019, NAT IMMUNOL, V20, P992, DOI 10.1038/s41590-019-0423-0; Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019; Beuraud C, 2019, ALLERGY, V74, P933, DOI 10.1111/all.13679; Boonpiyathad T, J ALLERGY CLIN IMMUN; Boonpiyathad T, 2019, SEMIN IMMUNOL, V46, DOI 10.1016/j.smim.2019.101333; Brestoff JR, 2015, NATURE, V519, P242, DOI 10.1038/nature14115; Bruggen MC, 2016, J INVEST DERMATOL, V136, P2396, DOI 10.1016/j.jid.2016.07.017; Cai T, 2019, J ALLERGY CLIN IMMUN, V143, P229, DOI 10.1016/j.jaci.2018.03.007; Califano D, 2015, IMMUNITY, V43, P354, DOI 10.1016/j.immuni.2015.07.005; Cao YJ, 2019, IMMUNOLOGY, V156, P402, DOI 10.1111/imm.13040; Cardoso V, 2017, NATURE, V549, P277, DOI 10.1038/nature23469; Cavagnero KJ, 2019, J ALLERGY CLIN IMMUN, V144, P1432, DOI 10.1016/j.jaci.2019.07.018; Cephus JY, 2017, CELL REP, V21, P2487, DOI 10.1016/j.celrep.2017.10.110; Chang JE, 2014, J ALLERGY CLIN IMMUN, V133, P899, DOI 10.1016/j.jaci.2013.09.020; Chen RC, 2017, AM J RESP CRIT CARE, V196, P700, DOI 10.1164/rccm.201612-2427OC; Chen YL, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax2945; Chinthrajah S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131347; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Corrigan C, 2005, J ALLERGY CLIN IMMUN, V115, P316, DOI 10.1016/j.jaci.2004.10.051; Djuretic IM, 2007, NAT IMMUNOL, V8, P145, DOI 10.1038/ni1424; Doherty TA, 2015, J ALLERGY CLIN IMMUN, V136, P792, DOI 10.1016/j.jaci.2015.05.048; Doherty TA, 2014, J ALLERGY CLIN IMMUN, V133, P1203, DOI 10.1016/j.jaci.2013.12.1086; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Drake LY, 2014, ALLERGY, V69, P1300, DOI 10.1111/all.12446; Eastman JJ, 2017, J ALLERGY CLIN IMMUN, V140, P101, DOI 10.1016/j.jaci.2016.11.023; Eberl G, 2004, NAT IMMUNOL, V5, P64, DOI 10.1038/ni1022; Entwistle LJ, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03114; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Fan DC, 2016, ALLERGY ASTHMA IMMUN, V8, P216, DOI 10.4168/aair.2016.8.3.216; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Germain RN, 2019, CURR OPIN IMMUNOL, V56, P76, DOI 10.1016/j.coi.2018.11.001; Golebski K, 2021, IMMUNITY, V54, P291, DOI 10.1016/j.immuni.2020.12.013; Golebski K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09883-7; Gury-BenAri M, 2016, CELL, V166, P1231, DOI 10.1016/j.cell.2016.07.043; Halim TYF, 2018, IMMUNITY, V48, P1195, DOI 10.1016/j.immuni.2018.05.003; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hams E, 2014, P NATL ACAD SCI USA, V111, P367, DOI 10.1073/pnas.1315854111; He J, 2019, CELL REP, V29, P2718, DOI 10.1016/j.celrep.2019.10.077; He YT, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/7024905; Helou DG, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17813-1; Ho J, 2015, CLIN EXP ALLERGY, V45, P394, DOI 10.1111/cea.12462; Hochdorfer T, 2019, EUR J IMMUNOL, V49, P884, DOI 10.1002/eji.201848006; Howard E, J ALLERGY CLIN IMMUN; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Huang YF, 2018, SCIENCE, V359, P114, DOI 10.1126/science.aam5809; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Imai Y, 2013, P NATL ACAD SCI USA, V110, P13921, DOI 10.1073/pnas.1307321110; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Jia Y, 2016, AM J RESP CELL MOL, V55, P675, DOI 10.1165/rcmb.2016-0099OC; Johansson K, 2017, J ALLERGY CLIN IMMUN, V139, P1007, DOI 10.1016/j.jaci.2016.06.035; Judd LM, 2016, AM J PHYSIOL-GASTR L, V310, pG13, DOI 10.1152/ajpgi.00290.2015; Kabata H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3675; Karta MR, 2019, J ALLERGY CLIN IMMUN, V144, P1112, DOI 10.1016/j.jaci.2019.06.001; Karta MR, 2018, J ALLERGY CLIN IMMUN, V141, P329, DOI 10.1016/j.jaci.2017.03.010; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Klingler AI, 2021, J ALLERGY CLIN IMMUN, V147, P1306, DOI 10.1016/j.jaci.2020.11.037; Klose CSN, 2017, NATURE, V549, P282, DOI 10.1038/nature23676; Knolle MD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02232; Komine O, 2003, J EXP MED, V198, P51, DOI 10.1084/jem.20021200; Kramer B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006373; Krempski JW, 2020, J IMMUNOL, V204, P3086, DOI 10.4049/jimmunol.2000029; Krohn IK, 2018, ALLERGY, V73, P837, DOI 10.1111/all.13340; Kudo F, 2018, CELL IMMUNOL, V323, P33, DOI 10.1016/j.cellimm.2017.10.010; Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826; Lao-Araya M, 2014, J ALLERGY CLIN IMMUN, V134, P1193, DOI 10.1016/j.jaci.2014.07.029; Lau CM, 2018, NAT IMMUNOL, V19, P963, DOI 10.1038/s41590-018-0176-1; Lee HS, 2019, J MOL MED, V97, P937, DOI 10.1007/s00109-019-01768-y; Lee JB, 2016, J ALLERGY CLIN IMMUN, V137, P1216, DOI 10.1016/j.jaci.2015.09.019; Lee MW, 2015, CELL, V160, P74, DOI 10.1016/j.cell.2014.12.011; Leyva-Castillo JM, 2020, J ALLERGY CLIN IMMUN, V145, P1606, DOI 10.1016/j.jaci.2020.02.026; Lim AWY, 2015, GENES IMMUN, V16, P177, DOI 10.1038/gene.2014.83; Lim AI, 2016, J EXP MED, V213, P569, DOI 10.1084/jem.20151750; Liu SC, 2020, J ALLERGY CLIN IMMUN, V146, P390, DOI 10.1016/j.jaci.2020.01.038; Liu SC, 2018, J ALLERGY CLIN IMMUN, V141, P257, DOI 10.1016/j.jaci.2017.03.032; Liu T, 2015, RESP MED, V109, P1391, DOI 10.1016/j.rmed.2015.09.016; Lombardi V, 2016, J ALLERGY CLIN IMMUN, V138, P305, DOI 10.1016/j.jaci.2015.12.1325; Lund SJ, 2017, J IMMUNOL, V199, P1096, DOI 10.4049/jimmunol.1601569; Luu M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01225; Maazi H, 2018, J ALLERGY CLIN IMMUN, V141, P893, DOI 10.1016/j.jaci.2017.04.043; Maier E, 2012, EUR J IMMUNOL, V42, P2827, DOI 10.1002/eji.201242433; Malhotra N, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao6923; Maric J, 2019, J ALLERGY CLIN IMMUN, V143, P2202, DOI 10.1016/j.jaci.2018.10.069; Maric J, 2018, J ALLERGY CLIN IMMUN, V141, P1761, DOI 10.1016/j.jaci.2017.09.050; Martinez-Gonzalez I, 2016, IMMUNITY, V45, P198, DOI 10.1016/j.immuni.2016.06.017; Matha L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214286; Mchedlidze T, 2013, IMMUNITY, V39, P357, DOI 10.1016/j.immuni.2013.07.018; Meininger I, 2020, TRENDS IMMUNOL, V41, P902, DOI 10.1016/j.it.2020.08.009; Miljkovic D, 2014, ALLERGY, V69, P1154, DOI 10.1111/all.12440; Mirchandani AS, 2014, J IMMUNOL, V192, P2442, DOI 10.4049/jimmunol.1300974; Miyamoto C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08365-0; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Morita H, 2019, J ALLERGY CLIN IMMUN, V143, P2190, DOI 10.1016/j.jaci.2018.12.1018; Morita H, 2016, J ALLERGY CLIN IMMUN, V138, P1253, DOI 10.1016/j.jaci.2016.09.011; Moriyama S, 2018, SCIENCE, V359, P1056, DOI 10.1126/science.aan4829; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Mortha A, 2014, SCIENCE, V343, P1477, DOI 10.1126/science.1249288; Nadjsombati MS, 2018, IMMUNITY, V49, P33, DOI 10.1016/j.immuni.2018.06.016; Nagakumar P, 2016, J ALLERGY CLIN IMMUN, V137, P624, DOI 10.1016/j.jaci.2015.06.038; Natoli G, 2019, NAT IMMUNOL, V20, P783, DOI [10.1038/s41590-019-0399-9, 10.1038/S41590-019-0399-9]; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Ogasawara N, 2020, MUCOSAL IMMUNOL, V13, P86, DOI 10.1038/s41385-019-0215-8; Ohne Y, 2016, NAT IMMUNOL, V17, P646, DOI 10.1038/ni.3447; Oliphant CJ, 2014, IMMUNITY, V41, P283, DOI 10.1016/j.immuni.2014.06.016; Pasha MA, 2019, ALLERGY ASTHMA PROC, V40, P138, DOI 10.2500/aap.2019.40.4217; Patel DF, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aax7006; Peng YQ, 2020, J ALLERGY CLIN IMMUN, V145, P855, DOI 10.1016/j.jaci.2019.11.029; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Pulendran B, 2012, SCIENCE, V337, P431, DOI 10.1126/science.1221064; Ricardo-Gonzalez RR, 2018, NAT IMMUNOL, V19, P1093, DOI 10.1038/s41590-018-0201-4; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P801, DOI 10.1016/j.jaci.2016.02.030; Robinette ML, 2015, NAT IMMUNOL, V16, P306, DOI 10.1038/ni.3094; Salimi M, 2017, J ALLERGY CLIN IMMUN, V140, P1090, DOI 10.1016/j.jaci.2016.12.958; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Samuchiwal SK, 2018, J ALLERGY CLIN IMMUN, V141, P1182, DOI 10.1016/j.jaci.2018.02.006; Satoh-Takayama N, 2020, IMMUNITY, V52, P635, DOI 10.1016/j.immuni.2020.03.002; Saunders SP, 2016, J ALLERGY CLIN IMMUN, V137, P482, DOI 10.1016/j.jaci.2015.06.045; Schneider C, 2019, NAT REV IMMUNOL, V19, P584, DOI 10.1038/s41577-019-0176-x; Schneider C, 2019, IMMUNITY, V50, P1425, DOI 10.1016/j.immuni.2019.04.019; Seehus CR, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02023-z; Shen XF, 2019, J IMMUNOL, V202, P1669, DOI 10.4049/jimmunol.1800852; Shih HY, 2016, CELL, V165, P1120, DOI 10.1016/j.cell.2016.04.029; Silver JS, 2016, NAT IMMUNOL, V17, P626, DOI 10.1038/ni.3443; Simoni Y, 2017, IMMUNITY, V46, P148, DOI 10.1016/j.immuni.2016.11.005; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Spooner CJ, 2013, NAT IMMUNOL, V14, P1229, DOI 10.1038/ni.2743; Stevens WW, 2021, ANN ALLERG ASTHMA IM, V126, P110, DOI 10.1016/j.anai.2020.08.001; Stier MT, 2016, J ALLERGY CLIN IMMUN, V138, P814, DOI 10.1016/j.jaci.2016.01.050; Sugita K, 2018, J ALLERGY CLIN IMMUN, V141, P300, DOI 10.1016/j.jaci.2017.02.038; Sui PF, 2018, SCIENCE, V360, P1086, DOI 10.1126/science.aan8546; Talbot S, 2015, NEURON, V87, P341, DOI 10.1016/j.neuron.2015.06.007; Thio CLP, 2019, J ALLERGY CLIN IMMUN, V144, P682, DOI 10.1016/j.jaci.2019.03.008; Thio CLP, 2018, J ALLERGY CLIN IMMUN, V142, P1867, DOI 10.1016/j.jaci.2018.02.032; Tojima I, 2016, CLIN IMMUNOL, V170, P1, DOI 10.1016/j.clim.2016.07.010; Toki S, 2018, J ALLERGY CLIN IMMUN, V142, P1515, DOI 10.1016/j.jaci.2017.11.043; Townsend EA, 2012, ENDOCR REV, V33, P1, DOI 10.1210/er.2010-0031; Ualiyeva S, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aax7224; Uchida M, 2017, ALLERGY, V72, P1521, DOI 10.1111/all.13158; Van Crombruggen K, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00742-2018; Verma M, 2018, J ALLERGY CLIN IMMUN, V142, P793, DOI 10.1016/j.jaci.2017.10.020; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; von Moltke J, 2017, J EXP MED, V214, P27, DOI 10.1084/jem.20161274; von Moltke J, 2016, NATURE, V529, P221, DOI 10.1038/nature16161; Walford HH, 2014, CLIN IMMUNOL, V155, P126, DOI 10.1016/j.clim.2014.09.007; Wallrapp A, 2019, IMMUNITY, V51, P709, DOI 10.1016/j.immuni.2019.09.005; Wallrapp A, 2017, NATURE, V549, P351, DOI 10.1038/nature24029; Wang S, 2017, CELL, V171, P201, DOI 10.1016/j.cell.2017.07.027; Winkler C, 2019, J ALLERGY CLIN IMMUN, V144, P61, DOI 10.1016/j.jaci.2019.01.027; Wojno EDT, 2015, MUCOSAL IMMUNOL, V8, P1313, DOI 10.1038/mi.2015.21; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Xiong N, 2012, PROTEIN CELL, V3, P571, DOI 10.1007/s13238-012-2927-3; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Yu QN, 2018, ALLERGY, V73, P1860, DOI 10.1111/all.13438; Yu QN, 2018, INT ARCH ALLERGY IMM, V176, P124, DOI 10.1159/000488050; Zeis P, 2020, IMMUNITY, V53, P775, DOI 10.1016/j.immuni.2020.09.002; Zhang KN, 2017, J IMMUNOL, V198, P1798, DOI 10.4049/jimmunol.1601421; Zhou WS, 2020, J IMMUNOL, V205, P1157, DOI 10.4049/jimmunol.1901544; Zhou Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00501	184	13	14	4	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2021	147	5					1531	1547		10.1016/j.jaci.2021.03.015	http://dx.doi.org/10.1016/j.jaci.2021.03.015		MAY 2021	17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RY1MN	33965091	Green Accepted			2022-12-18	WOS:000647680800001
J	Rochman, M; Xie, YM; Mack, L; Caldwell, JM; Klingler, AM; Osswald, GA; Azouz, NP; Rothenberg, ME				Rochman, Mark; Xie, Yong Mei; Mack, Lydia; Caldwell, Julie M.; Klingler, Andrea M.; Osswald, Garrett A.; Azouz, Nurit P.; Rothenberg, Marc E.			Broad transcriptional response of the human esophageal epithelium to proton pump inhibitors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Proton pump inhibitors; omeprazole; esomeprazole; eosinophilic esophagitis; epithelium; IL-13; aryl hydrocarbon receptor	EXPRESSION; OMEPRAZOLE; INFLAMMATION; EOSINOPHILIA; CHILDREN; CELLS	Background: Proton pump inhibitors (PPIs) have been recognized as a primary treatment of eosinophilic esophagitis (EoE), an allergic inflammatory disease of the esophageal mucosa. The mechanisms underlying esophageal epithelial responses to PPIs remain poorly understood. Objective: We hypothesized that PPIs can counteract IL-13-mediated esophageal epithelial responses that are germane for EoE pathogenesis. Methods: Transcriptional responses of human esophageal cells to IL-13 and the PPIs omeprazole and esomeprazole were assessed by RT-PCR and RNA sequencing. Cytokine secretion was measured by multiplex analysis and ELISA. Results: Human esophageal epithelial cells robustly responded to PPI stimulation by inducing a set of 479 core genes common between omeprazole and esomeprazole treatments. The transcriptional response to PPIs was partially mediated through the aryl hydrocarbon receptor signaling pathway, as the aryl hydrocarbon receptor antagonist GNF-351 modified approximately 200 genes, particularly those enriched in metabolic processes and regulation of cell death. PPI treatment reversed approximately 20% of the IL-13 transcriptome. Functional analysis of the PPI-responsive, upregulated genes revealed enrichment in metabolic and oxidation processes, and the unfolded protein response. In contrast, downregulated genes were overrepresented in functional terms related to cell division and cytoskeletal organization, which were also enriched for the genes in the EoE transcriptome reversed by PPIs. Furthermore, PPI treatment decreased the IL-13-induced proliferative response of esophageal epithelial cells. Conclusions: These results demonstrate broad effects of PPIs on esophageal epithelium, including their ability to curtail transcriptomic processes involved in cellular proliferation and IL-13-induced responses, and they highlight the importance of AHR signaling in mediating these responses. (J Allergy Clin Immunol 2021;147:1924-35.)	[Rochman, Mark; Xie, Yong Mei; Mack, Lydia; Caldwell, Julie M.; Klingler, Andrea M.; Osswald, Garrett A.; Azouz, Nurit P.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave,MLC 7028, Cincinnati, OH 45229 USA; [Azouz, Nurit P.; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Xie, Yong Mei] Sichuan Univ, West China Univ Hosp 2, Dept Pediat, Chengdu, Sichuan, Peoples R China; [Xie, Yong Mei] Sichuan Univ, Minist Educ, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Sichuan, Peoples R China	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Sichuan University; Sichuan University	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave,MLC 7028, Cincinnati, OH 45229 USA.	Marc.Rothenberg@cchmc.org			National Institutes of Health [R37 AI045898, R01 AI124355, U19 AI070235, P30 DK078392]; Campaign Urging Research for Eosinophilic Disease (CURED); Buckeye Foundation; Sunshine Charitable Foundation; Key Research and Development Project of Sichuan Provincial Science and Technology Program, China [2019YFG0165]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Campaign Urging Research for Eosinophilic Disease (CURED); Buckeye Foundation; Sunshine Charitable Foundation; Key Research and Development Project of Sichuan Provincial Science and Technology Program, China	Supported by the National Institutes of Health (grants R37 AI045898, R01 AI124355, U19 AI070235, and P30 DK078392 [Gene and Protein Expression Core]); the Campaign Urging Research for Eosinophilic Disease (CURED) (M.E.R.); the Buckeye Foundation (M.E.R.); the Sunshine Charitable Foundation and its supporters Denise A. Bunning and David G. Bunning (M.E.R.); and the Key Research and Development Project of Sichuan Provincial Science and Technology Program, China (grant 2019YFG0165, Y.-M. X.).	Azouz NP, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aap9736; Balza E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.218; Biswas K, 2003, J BIOL CHEM, V278, P10993, DOI 10.1074/jbc.M210328200; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Cheng E, 2013, GUT, V62, P824, DOI 10.1136/gutjnl-2012-302250; Collins MH, 2014, DIGEST DIS, V32, P68, DOI 10.1159/000357012; Cortes JR, 2009, J ALLERGY CLIN IMMUN, V124, P607, DOI 10.1016/j.jaci.2009.06.023; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Ghebremariam YT, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0614-x; Gutierrez-Junquera C, 2016, J PEDIATR GASTR NUTR, V62, P704, DOI 10.1097/MPG.0000000000001019; Hammond CL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222779; Handa O, 2006, INFLAMM RES, V55, P476, DOI 10.1007/s00011-006-6056-4; Hirano I, 2019, GASTROENTEROLOGY, V156, P592, DOI 10.1053/j.gastro.2018.10.051; Ishizaki T, 1999, ALIMENT PHARM THERAP, V13, P27; Jensen ET, 2013, J PEDIATR GASTR NUTR, V57, P67, DOI 10.1097/MPG.0b013e318290d15a; Jyonouchi S, 2014, CLIN EXP ALLERGY, V44, P58, DOI 10.1111/cea.12201; Kanagaratham C., 2020, J ALLERGY CLIN IMMUN; Kedika RR, 2009, DIGEST DIS SCI, V54, P2312, DOI 10.1007/s10620-009-0951-9; Kiran KC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127755; Kodama T, 2000, J ALLERGY CLIN IMMUN, V105, P45, DOI 10.1016/S0091-6749(00)90176-3; Matsui MS, 2015, J INVEST DERMATOL, V135, P834, DOI 10.1038/jid.2014.461; Miller DE, 2019, G3-GENES GENOM GENET, V9, P729, DOI 10.1534/g3.118.200901; Min JY, 2017, J ALLERGY CLIN IMMUN, V139, P130, DOI 10.1016/j.jaci.2016.07.020; Mitre E, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2018.0315; Molina-Infante J, 2011, CLIN GASTROENTEROL H, V9, P110, DOI 10.1016/j.cgh.2010.09.019; Niranjan R, 2015, CLIN IMMUNOL, V157, P103, DOI 10.1016/j.clim.2015.01.007; Rochman M, 2015, MUCOSAL IMMUNOL, V8, P785, DOI 10.1038/mi.2014.109; Sherrill JD, 2014, GENES IMMUN, V15, P361, DOI 10.1038/gene.2014.27; Sherrill JD, 2014, MUCOSAL IMMUNOL, V7, P718, DOI 10.1038/mi.2013.90; Simon WA, 2006, BIOCHEM PHARMACOL, V71, P1337, DOI 10.1016/j.bcp.2006.01.009; Smith KJ, 2011, J PHARMACOL EXP THER, V338, P318, DOI 10.1124/jpet.110.178392; Strand DS, 2017, GUT LIVER, V11, P27, DOI 10.5009/gnl15502; van Rhijn BD, 2014, CLIN GASTROENTEROL H, V12, P1815, DOI 10.1016/j.cgh.2014.02.037; Vanoni S, 2020, J ALLERGY CLIN IMMUN, V145, P239, DOI 10.1016/j.jaci.2019.07.049; Vignesh KS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102197; Yoshinari K, 2008, BIOCHEM PHARMACOL, V76, P139, DOI 10.1016/j.bcp.2008.04.005; Zhang X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050037	37	13	13	2	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2021	147	5					1924	1935		10.1016/j.jaci.2020.09.039	http://dx.doi.org/10.1016/j.jaci.2020.09.039		MAY 2021	12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SD7ZE	33289661	Green Accepted			2022-12-18	WOS:000651594000001
J	Bruhns, P; Chollet-Martin, S				Bruhns, Pierre; Chollet-Martin, Sylvie			Mechanisms of human drug-induced anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; drugs; IgE; IgG; MRGPRX2; histamine; serotonin; mast cells; basophils; neutro-phils; platelets; Platelet-activating factor	PLATELET-ACTIVATING-FACTOR; HUMAN MAST-CELLS; SYSTEMIC-ANAPHYLAXIS; PAF ACETYLHYDROLASE; FATAL ANAPHYLAXIS; TRYPTASE LEVELS; IGE; ANTIBODIES; SUGAMMADEX; HISTAMINE	Drug-induced anaphylaxis is a hyperacute reaction affecting multiple organs that can be of fatal consequence. Its incidence is increasing, consistent with a global increased sensitization to various allergens and drugs in the population. Few risk factors and mechanisms have been identified from human studies due to the rarity of anaphylactic events and their unpredictability. This systemic reaction is caused by the rapid release of a large range of functionally diverse mediators, including histamine and platelet-activating factor as the main drivers identified. Mechanisms defined from models of experimental anaphylaxis identify drug-specific antibodies of the IgE and IgG class that link the drug to antibody receptors on multiple cell types, causing their activation and mediator release. In the case of drugs with peculiar chemical structures, antibodies may not be necessary because drug-binding receptors, such as Mas-related G protein-coupled receptor member X2, have been identified. This review describes the complex reaction leading to drug induced anaphylaxis that can involve various antibody classes, various cell types-including mast cells, neutrophils, platelets, basophils, macrophages, and monocytes-and their mediators and receptors that, importantly, can be activated alone or in association to participate in the severity of the reaction	[Bruhns, Pierre] Inst Pasteur, INSERM, UMR 1222, Unit Antibodies Therapy & Pathol, Paris, France; [Bruhns, Pierre] Univ Paris Diderot Paris 7, DHU FIRE, Labex Inflamex, Paris, France; [Chollet-Martin, Sylvie] Hop Bichat Claude Bernard, AP HP, DMU BioGeM, Dept Autoimmun & Hypersensibilites, Paris, France; [Chollet-Martin, Sylvie] Univ Paris Saclay, Fac Pharm, UMR 996, Inflammat Microbiome & Immunosurveillance,INSERM, Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Bruhns, P (corresponding author), Inst Pasteur, INSERM, UMR 1222, Unit Antibodies Therapy & Pathol,Dept Immunol, 25 Rue Docteur Roux, F-75015 Paris, France.; Chollet-Martin, S (corresponding author), Univ Paris Saclay, Fac Pharm, INSERM, Inflammat Chimiokines & Immunopathol,UMR S996, F-92290 Chatenay Malabry, France.	bruhns@pasteur.fr; sylvie.chollet-martin@universite-paris-saclay.fr	Bruhns, Pierre/F-5567-2013	Bruhns, Pierre/0000-0002-4709-8936	Institut Pasteur; Institut National de la Sante et de la RechercheMedicale (INSERM); European Research Council (ERC)-Seventh Frame-work Program [ERC-2013-CoG 616050]	Institut Pasteur(European Commission); Institut National de la Sante et de la RechercheMedicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); European Research Council (ERC)-Seventh Frame-work Program(European Research Council (ERC))	This work was supported by the Institut Pasteur, the Institut National de la Sante et de la RechercheMedicale (INSERM), and the European Research Council (ERC)-Seventh Frame-work Program (ERC-2013-CoG 616050) and a Contrat Local d'Interface to P.B. of the Assistance Publique des Hopitaux de Paris.	Alkanfari I, 2018, J IMMUNOL, V201, P343, DOI 10.4049/jimmunol.1701793; Anderson J, 2020, BRIT J ANAESTH, V125, pE450, DOI 10.1016/j.bja.2020.05.049; Ansotegui IJ, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2019.100080; Arias K, 2009, J ALLERGY CLIN IMMUN, V124, P307, DOI 10.1016/j.jaci.2009.03.012; Asrat S, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aav8402; Balbino B, 2017, J ALLERGY CLIN IMMUN, V139, P584, DOI 10.1016/j.jaci.2016.05.047; BALDO BA, 1983, NATURE, V306, P262, DOI 10.1038/306262a0; Banerji A, 2021, J ALLER CL IMM-PRACT, V9, P1980, DOI 10.1016/j.jaip.2020.11.025; Banerji A, 2014, J ALLER CL IMM-PRACT, V2, P46, DOI 10.1016/j.jaip.2013.08.012; BASRAN GS, 1984, CLIN ALLERGY, V14, P75, DOI 10.1111/j.1365-2222.1984.tb02193.x; Beutier H, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aan5997; Beutier H, 2017, J ALLERGY CLIN IMMUN, V139, P269, DOI 10.1016/j.jaci.2016.03.028; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Boni Elisa, 2016, Clin Mol Allergy, V14, P14; Broyles AD, 2020, J ALLER CL IMM-PRACT, V8, pS16, DOI 10.1016/j.jaip.2020.08.006; Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121; Cardona V, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2020.100472; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; Clark S, 2014, J ALLERGY CLIN IMMUN, V134, P1125, DOI 10.1016/j.jaci.2014.05.018; Cloutier N, 2018, P NATL ACAD SCI USA, V115, pE1550, DOI 10.1073/pnas.1720553115; Croote D, 2018, SCIENCE, V362, P1306, DOI 10.1126/science.aau2599; CUSS FM, 1986, LANCET, V2, P189; Daguet A, 2011, MABS-AUSTIN, V3, P417, DOI 10.4161/mabs.3.5.17485; Davies JM, 2013, J ALLERGY CLIN IMMUN, V131, P972, DOI 10.1016/j.jaci.2012.12.1569; Dewachter P, 2018, J ALLER CL IMM-PRACT, V6, P1681, DOI 10.1016/j.jaip.2017.12.037; Ebo DG, 2021, J ALLERGY CLIN IMMUN, V147, P1143, DOI 10.1016/j.jaci.2020.10.027; Ebo DG, 2021, BRIT J ANAESTH, V126, pE27, DOI 10.1016/j.bja.2020.10.006; Ebo DG, 2020, J ALLER CL IMM-PRACT, V8, P1410, DOI 10.1016/j.jaip.2019.11.018; Elst J, 2020, BRIT J ANAESTH, V125, pE448, DOI 10.1016/j.bja.2020.08.035; Elst Jessy, 2020, Methods Mol Biol, V2163, P219, DOI 10.1007/978-1-0716-0696-4_18; Epelman S, 2014, IMMUNITY, V41, P21, DOI 10.1016/j.immuni.2014.06.013; Fernandez J, 2020, CURR OPIN ALLERGY CL, V20, P333, DOI 10.1097/ACI.0000000000000648; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Finkelman FD, 2016, J ALLERGY CLIN IMMUN, V137, P1674, DOI 10.1016/j.jaci.2016.02.015; Gao Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71083-x; Gillis C. M., 2015, COMPENDIUM INFLAMMAT, DOI [10.1007/978-3-7643-8550-7_115, DOI 10.1007/978-3-7643-8550-7_115]; Gillis CM, 2017, J ALLERGY CLIN IMMUN, V139, P1253, DOI 10.1016/j.jaci.2016.06.058; Goyard S, 2020, ALLERGY, V75, P2952, DOI 10.1111/all.14365; Granger V, 2020, ALLERGY, V75, P699, DOI 10.1111/all.14059; He S, 1998, J PHARMACOL EXP THER, V286, P289; Hogwood J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193482; Hoh RA, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aay4209; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; ISHIZAKA K, 1966, J ALLERGY, V37, P135, DOI 10.1016/0021-8707(66)90088-8; Janssens AS, 2005, J CLIN PATHOL, V58, P285, DOI 10.1136/jcp.2004.017210; Jerschow E, 2014, J ALLERGY CLIN IMMUN, V134, P1318, DOI 10.1016/j.jaci.2014.08.018; Jonsson F, 2012, BLOOD, V119, P2533, DOI 10.1182/blood-2011-07-367334; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; Jonsson F, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat1479; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; Khan F, 2009, BLOOD, V113, P279, DOI 10.1182/blood-2008-01-128686; Khodoun M, 2009, J ALLERGY CLIN IMMUN, V123, P342, DOI 10.1016/j.jaci.2008.11.004; Khodoun MV, 2011, P NATL ACAD SCI USA, V108, P12413, DOI 10.1073/pnas.1105695108; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kucuk ZY, 2012, J ALLERGY CLIN IMMUN, V129, P1343, DOI 10.1016/j.jaci.2012.03.004; Kuruvilla M, 2015, IMMUNOL ALLERGY CLIN, V35, P303, DOI 10.1016/j.iac.2015.01.008; LAGUNOFF D, 1983, ANNU REV PHARMACOL, V23, P331, DOI 10.1146/annurev.pa.23.040183.001555; Lansu K, 2017, NAT CHEM BIOL, V13, P529, DOI [10.1038/NCHEMBIO.2334, 10.1038/nchembio.2334]; Laroche D, 2011, ANESTHESIOLOGY, V114, P91, DOI 10.1097/ALN.0b013e31820164d2; Leysen J, 2011, ANAESTHESIA, V66, P526, DOI 10.1111/j.1365-2044.2011.06729.x; Liu E, 2002, J CLIN INVEST, V110, P1021, DOI 10.1172/JCI200215488; Looney TJ, 2016, J ALLERGY CLIN IMMUN, V137, P579, DOI 10.1016/j.jaci.2015.07.014; MacGinnitie AJ, 2017, J ALLERGY CLIN IMMUN, V139, P873, DOI 10.1016/j.jaci.2016.08.010; McDonnell NJ, 2011, BRIT J ANAESTH, V106, P199, DOI 10.1093/bja/aeq366; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Mencarelli A, 2020, J LEUKOCYTE BIOL, V107, P797, DOI 10.1002/JLB.3MA1219-210RR; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; Nadeau KC, 2012, IMMUNOL ALLERGY CLIN, V32, P111, DOI 10.1016/j.iac.2011.11.004; Orengo JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03636-8; Orihara M, 2020, BRIT J ANAESTH, V124, P154, DOI 10.1016/j.bja.2019.10.016; Payne V, 2004, ANAESTHESIA, V59, P695, DOI 10.1111/j.1365-2044.2004.03757.x; Pichler WJ, 2021, ALLERGY, V76, P1340, DOI 10.1111/all.14554; Platts-Mills TAE, 2016, J ALLERGY CLIN IMMUN, V137, P1662, DOI 10.1016/j.jaci.2016.04.010; Pravettoni V, 2014, J ALLERGY CLIN IMMUN, V133, P1218, DOI 10.1016/j.jaci.2013.10.033; Raft J, 2012, ANN FR ANESTH, V31, P158, DOI 10.1016/j.annfar.2011.10.023; Reber LL, 2017, J ALLERGY CLIN IMMUN, V140, P335, DOI 10.1016/j.jaci.2017.06.003; Sanchez-Lopez J, 2021, ALLERGY, V76, P1480, DOI 10.1111/all.14689; Savic L, 2014, ANAESTH INTENS CARE, V42, P7, DOI 10.1177/0310057X1404200102; Savvatianos S, 2011, ALLERGY, V66, P983, DOI 10.1111/j.1398-9995.2011.02566.x; Schuch A, 2017, IMMUNOL ALLERGY CLIN, V37, P153, DOI 10.1016/j.iac.2016.08.017; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; Sellaturay P, 2021, J ALLER CL IMM-PRACT, V9, P670, DOI 10.1016/j.jaip.2020.09.029; Spoerl D, 2016, INT ARCH ALLERGY IMM, V169, P256, DOI 10.1159/000446182; Steinke JW, 2015, J ALLERGY CLIN IMMUN, V135, P589, DOI 10.1016/j.jaci.2014.12.1947; Strait RT, 2015, NATURE, V517, P501, DOI 10.1038/nature13868; Strait RT, 2011, J ALLERGY CLIN IMMUN, V127, P982, DOI 10.1016/j.jaci.2011.01.034; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Tacquard C, 2017, ACTA ANAESTH SCAND, V61, P290, DOI 10.1111/aas.12855; Tanno LK, 2021, CURR OPIN ALLERGY CL, V21, P168, DOI 10.1097/ACI.0000000000000722; Tatemoto K, 2006, BIOCHEM BIOPH RES CO, V349, P1322, DOI 10.1016/j.bbrc.2006.08.177; Turner PJ, 2017, J ALLER CL IMM-PRACT, V5, P1169, DOI 10.1016/j.jaip.2017.06.031; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Vadas P, 2013, J ALLERGY CLIN IMMUN, V131, P144, DOI 10.1016/j.jaci.2012.08.016; Van der Poorten MLM, 2020, BRIT J ANAESTH, V125, pE443, DOI 10.1016/j.bja.2020.05.032; van der Poorten MLM, 2020, CLIN CHIM ACTA, V504, P119, DOI 10.1016/j.cca.2020.02.005; Varricchi G, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00299; VIGORITO C, 1983, J CARDIOVASC PHARM, V5, P531, DOI 10.1097/00005344-198307000-00004; Vitte J, 2019, ALLERGY, V74, P1157, DOI 10.1111/all.13752; Vultaggio A, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.590991; WALKER SA, 1986, CLIN EXP IMMUNOL, V66, P633; Wenande E, 2016, CLIN EXP ALLERGY, V46, P907, DOI 10.1111/cea.12760; Yu RJ, 2021, J ALLER CL IMM-PRACT, V9, P819, DOI 10.1016/j.jaip.2020.09.021; Zhou ZH, 2021, J ALLER CL IMM-PRACT, V9, P1731, DOI 10.1016/j.jaip.2020.11.011	104	13	13	3	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1133	1142		10.1016/j.jaci.2021.02.013	http://dx.doi.org/10.1016/j.jaci.2021.02.013		APR 2021	10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RJ1NP	33832695	Green Submitted			2022-12-18	WOS:000637368900002
J	Gonzalez-Gil, A; Li, TA; Porell, RN; Fernandes, SM; Tarbox, HE; Lee, HS; Aoki, K; Tiemeyer, M; Kim, J; Schnaar, RL				Gonzalez-Gil, Anabel; Li, T. August; Porell, Ryan N.; Fernandes, Steve M.; Tarbox, Haley E.; Lee, Hyun Sil; Aoki, Kazuhiro; Tiemeyer, Michael; Kim, Jean; Schnaar, Ronald L.			Isolation, identification, and characterization of the human airway ligand for the eosinophil and mast cell immunoinhibitory receptor Siglec-8	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Siglec-8; upper airway; mucus layer; nasal lavage; DMBT1; GP340; SALSA; sialic acid; keratan sulfate; submucosal gland	GLYCOPROTEINS; RECOGNITION	Background: The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation. Siglec-8 ligands were found on postmortem human trachea and bronchi and on upper airways in 2 compartments, cartilage and submucosal glands, but they were surprisingly absent from the epithelium. We hypothesized that Siglec-8 ligands in submucosal glands and ducts are normally transported to the airway mucus layer, which is lost during tissue preparation. Objective: Our aim was to identify the major Siglec-8 sialoglycan ligand on the mucus layer of human airways. Methods: Human upper airway mucus layer proteins were recovered during presurgical nasal lavage of patients at a sinus clinic. Proteins were resolved by gel electrophoresis and blotted, and Siglec-8 ligands detected. Ligands were purified by size exclusion and affinity chromatography, identified by proteomic mass spectrometry, and validated by electrophoretic and histochemical colocalization. The affinity of Siglec-8 binding to purified human airway ligand was determined by inhibition of glycan binding. Results: A Siglec-8-ligand with a molecular weight of approximately 1000 kDa was found in all patient nasal lavage samples. Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats. Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8). Quantitative inhibition revealed that DMBT1S8 has picomolar affinity for Siglec-8. Conclusion: A distinct DMBT1 isoform, DMBT1S8, is the major high-avidity ligand for Siglec-8 on human airways.	[Gonzalez-Gil, Anabel; Li, T. August; Porell, Ryan N.; Fernandes, Steve M.; Tarbox, Haley E.; Schnaar, Ronald L.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA; [Lee, Hyun Sil; Kim, Jean] Johns Hopkins Univ, Sch Med, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD 21205 USA; [Kim, Jean] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; [Aoki, Kazuhiro; Tiemeyer, Michael] Univ Georgia, Complex Carbohydrate Res Ctr, 220 Riverbend Rd, Athens, GA 30602 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University System of Georgia; University of Georgia	Schnaar, RL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.	schnaar@jhu.edu		Alvarenga, Anabel/0000-0002-1618-8920; Porell, Ryan/0000-0003-3332-6819	National Institutes of Health [U19-AI136443, K12-HL141952, T32-GM008763, T32-GM080189]; Flight Attendant Medical Research Institute	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Flight Attendant Medical Research Institute	Supported by the National Institutes of Health (grants U19-AI136443 [to R.L.S.], K12-HL141952 [to A.G.G. and J.K.], T32-GM008763 [to T.A.L.], and T32-GM080189 [to R.N.P. and H.T.]), the Flight Attendant Medical Research Institute, and a research gift from the Carl and Kara Pittinger Family (to H.L. and J.K.).	Barnig C, 2018, PHARMACOL THERAPEUT, V186, P98, DOI 10.1016/j.pharmthera.2018.01.004; Braga FAV, 2019, NAT MED, V25, P1153, DOI 10.1038/s41591-019-0468-5; Carroll DJ, 2018, J ALLERGY CLIN IMMUN, V141, P2196, DOI 10.1016/j.jaci.2017.08.013; Duan ST, 2020, ANNU REV IMMUNOL, V38, P365, DOI 10.1146/annurev-immunol-102419-035900; Gonzalez-Gil A, 2018, GLYCOBIOLOGY, V28, P786, DOI 10.1093/glycob/cwy057; Holmskov U, 1997, J BIOL CHEM, V272, P13743, DOI 10.1074/jbc.272.21.13743; Jia Y, 2015, J ALLERGY CLIN IMMUN, V135, P799, DOI 10.1016/j.jaci.2015.01.004; Johansson MW, 2018, INT ARCH ALLERGY IMM, V177, P16, DOI 10.1159/000488951; Kerr SC, 2020, CLIN EXP ALLERGY, V50, P904, DOI 10.1111/cea.13681; Kikly KK, 2000, J ALLERGY CLIN IMMUN, V105, P1093, DOI 10.1067/mai.2000.107127; Laubli H, 2020, CELL MOL LIFE SCI, V77, P593, DOI 10.1007/s00018-019-03288-x; Lee HS, 2009, AM J RESP CRIT CARE, V180, P1056, DOI 10.1164/rccm.200905-0740OC; Madsen J, 2010, INNATE IMMUN-LONDON, V16, P160, DOI 10.1177/1753425910368447; Meiers J, 2019, CURR OPIN CHEM BIOL, V53, P51, DOI 10.1016/j.cbpa.2019.07.005; Moustafa I, 2004, J BIOL CHEM, V279, P40819, DOI 10.1074/jbc.M404965200; Nexoe AB, 2020, J HISTOCHEM CYTOCHEM, V68, P377, DOI 10.1369/0022155420927109; O'Sullivan JA, 2020, J LEUKOCYTE BIOL, V108, P73, DOI 10.1002/JLB.2MR0120-352RR; Propster JM, 2016, P NATL ACAD SCI USA, V113, pE4170, DOI 10.1073/pnas.1602214113; Reichhardt MP, 2017, MOL IMMUNOL, V89, P100, DOI 10.1016/j.molimm.2017.05.029; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schulz BL, 2002, ANAL CHEM, V74, P6088, DOI 10.1021/ac025890a; Schulz BL, 2002, BIOCHEM J, V366, P511, DOI 10.1042/BJ20011876; Steentoft C, 2013, EMBO J, V32, P1478, DOI 10.1038/emboj.2013.79; Steward M, 2015, CLIN BIOCHEM, V48, P796, DOI 10.1016/j.clinbiochem.2015.03.024; Taylor ME, ESSENTIALS GLYCOBIOL, V3rd; Wang HS, 2017, GLYCOCONJUGATE J, V34, P643, DOI 10.1007/s10719-017-9786-3; Yu HF, 2017, GLYCOBIOLOGY, V27, P657, DOI 10.1093/glycob/cwx026	27	13	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1442	1452		10.1016/j.jaci.2020.08.001	http://dx.doi.org/10.1016/j.jaci.2020.08.001		APR 2021	11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RX3VK	32791164	Green Accepted			2022-12-18	WOS:000647154500009
J	Carter, MC; Maric, I; Brittain, EH; Bai, Y; Lumbard, K; Bolan, H; Cantave, D; Scott, LM; Metcalfe, DD				Carter, Melody C.; Maric, Irina; Brittain, Erica H.; Bai, Yun; Lumbard, Keith; Bolan, Hyejeong; Cantave, Daly; Scott, Linda M.; Metcalfe, Dean D.			A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Idiopathic anaphylaxis; omalizumab; randomized; therapy		Background: Idiopathic anaphylaxis (IA) is a diagnosis of exclusion, thus taking away the option of therapeutic management focused on eliminating the inciting agent. Epinephrine and antihistamines followed by systemic corticosteroids are the mainstays of therapy for acute events. There is no prophylactic therapy that reliably prevents anaphylaxis. Objective: We sought to determine the efficacy of omalizumab in the management of patients with frequent episodes of IA in a double-blind, placebo-controlled trial. Methods: We prospectively enrolled 19 patients with frequent IA (>_6 episodes/y) who then underwent a medical evaluation that included a serum tryptase determination, mutational analysis for KIT D816V, and bone marrow evaluation to rule out a clonal mast cell disorder. Computer-generated random numbers were provided by the study pharmacist. The primary end point was anaphylactic events in the 6 months after baseline. Sixteen patients completed the primary trial. Results: No statistically significant difference was demonstrated between the placebo and treated groups. There was a trend for efficacy in the treatment group, particularly after 60 days. Overall, the safety profile was favorable without long-term side effects. Conclusions: Omalizumab was safely administered to a difficult to-treat patient population with IA. The efficacy results trended modestly in favor of the treatment group, but no statistically significant differences were detected. (J Allergy Clin Immunol 2021;147:1004-10.) <comment>Superscript/Subscript Available</comment	[Carter, Melody C.; Bai, Yun; Bolan, Hyejeong; Scott, Linda M.; Metcalfe, Dean D.] NIAID, Mast Cell Biol Sect, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Maric, Irina] NIH, Hematol Sect, Dept Lab Med, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA; [Brittain, Erica H.] NIAID, Biostat Res Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Lumbard, Keith] Frederick Natl Lab Canc Res, Clin Monitoring Res Program Directorate, Frederick, MD USA; [Cantave, Daly] NIH, Dept Nursing, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Carter, MC (corresponding author), Bldg 10-11C207,10 Ctr Dr,MSC 1881, Bethesda, MD 20892 USA.	mcarter@niaid.nih.gov			Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; National Cancer Institute, National Institutes of Health [75N91019D00024, 75N91019F00130]	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. This project has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health (under contract no. 75N91019D00024, task order no. 75N91019F00130). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government.	BOXER M, 1987, ARCH INTERN MED, V147, P269, DOI 10.1001/archinte.147.2.269; Carter MC, 2018, ALLERGY, V73, P1131, DOI 10.1111/all.13366; Carter MC, 2018, J ALLERGY CLIN IMMUN, V141, P180, DOI 10.1016/j.jaci.2017.05.036; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Constantine GM, 2019, J ALLER CL IMM-PRACT, V7, P1314, DOI 10.1016/j.jaip.2018.07.041; Demirturk M, 2012, J DERMATOL, V39, P552, DOI 10.1111/j.1346-8138.2012.01520.x; Ditto AM, 1996, ANN ALLERG ASTHMA IM, V77, P285, DOI 10.1016/S1081-1206(10)63322-4; Enck P, 2019, HANDB EXP PHARMACOL, V260, P399, DOI 10.1007/164_2019_269; Fenny N, 2015, IMMUNOL ALLERGY CLIN, V35, P349, DOI 10.1016/j.iac.2015.01.004; Foroughi S, 2007, J ALLERGY CLIN IMMUN, V120, P594, DOI 10.1016/j.jaci.2007.06.015; Greenberger PA, 2007, IMMUNOL ALLERGY CLIN, V27, P273, DOI 10.1016/j.iac.2007.03.009; Jagdis A, 2014, ANN ALLERG ASTHMA IM, V113, P115, DOI 10.1016/j.anai.2014.05.001; Jones JD, 2008, ANN ALLERG ASTHMA IM, V101, P550, DOI 10.1016/S1081-1206(10)60296-7; Kaplan AP, 2017, ALLERGY, V72, P519, DOI 10.1111/all.13083; KHAN DA, 1994, ANN ALLERGY, V73, P370; Kibsgaard L, 2014, ACTA DERM-VENEREOL, V94, P363, DOI 10.2340/00015555-1687; Kristensen T, 2011, J MOL DIAGN, V13, P180, DOI 10.1016/j.jmoldx.2010.10.004; Lee J, 2014, ASIA PAC ALLERGY, V4, P126, DOI 10.5415/apallergy.2014.4.2.126; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Lieberman P., 1998, ANAPHYLAXIS ANAPHYLA, V5th; Lieberman P, 2015, ANN ALLERG ASTHMA IM, V115, P341, DOI 10.1016/j.anai.2015.07.019; Lieberman PL, 2017, J ALLERGY CLIN IMMUN, V140, P1734, DOI 10.1016/j.jaci.2017.07.013; Maric I, 2007, J ALLERGY CLIN IMMUN, V120, P680, DOI 10.1016/j.jaci.2007.05.024; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Neugut AI, 2001, ARCH INTERN MED, V161, P15, DOI 10.1001/archinte.161.1.15; Ozdemir O, 2017, TURK PEDIATR ARSIVI, V52, P105, DOI 10.5152/TurkPediatriArs.2017.2262; Pitt TJ, 2010, J ALLERGY CLIN IMMUN, V126, P415, DOI 10.1016/j.jaci.2010.05.043; Plum T, 2020, IMMUNITY, V52, P404, DOI 10.1016/j.immuni.2020.01.012; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sanchez-Valenzuela MC, 2019, ANN ALLERG ASTHMA IM, V123, P612, DOI 10.1016/j.anai.2019.09.020; Soar J, 2008, RESUSCITATION, V77, P157, DOI 10.1016/j.resuscitation.2008.02.001; Warrier P, 2009, ANN ALLERG ASTHMA IM, V102, P257, DOI 10.1016/S1081-1206(10)60091-9; Webb LM, 2006, ANN ALLERG ASTHMA IM, V97, P39, DOI 10.1016/S1081-1206(10)61367-1; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084; WONG S, 1990, ARCH INTERN MED, V150, P1323, DOI 10.1001/archinte.150.6.1323; Wood RA, 2014, J ALLERGY CLIN IMMUN, V133, P461, DOI 10.1016/j.jaci.2013.08.016	36	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					1004	+		10.1016/j.jaci.2020.11.005	http://dx.doi.org/10.1016/j.jaci.2020.11.005		MAR 2021	9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RG4QF	33220353				2022-12-18	WOS:000635524300005
J	Krueger, JG; Murrell, DF; Garcet, S; Navrazhina, K; Lee, PC; Muscianisi, E; Blauvelt, A				Krueger, James G.; Murrell, Dedee F.; Garcet, Sandra; Navrazhina, Kristina; Lee, Patricia C.; Muscianisi, Elisa; Blauvelt, Andrew			Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Krueger, James G.; Garcet, Sandra; Navrazhina, Kristina] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA; [Murrell, Dedee F.] Univ New South Wales, Dept Dermatol, St George Hosp, Sydney, NSW, Australia; [Lee, Patricia C.] Ctr Clin Studies, Webster, TX USA; [Muscianisi, Elisa] Novartis Pharmaceut, E Hanover, NJ USA; [Blauvelt, Andrew] Oregon Med Res Ctr, Portland, OR USA	Rockefeller University; St George Hospital; University of New South Wales Sydney; Novartis	Krueger, JG (corresponding author), Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA.	kruegej@mail.rockefeller.edu		Garcet, Sandra/0000-0002-4465-8547	Novartis Pharmaceuticals Corporation, East Hanover, NJ	Novartis Pharmaceuticals Corporation, East Hanover, NJ	This study was sponsored by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Medical writing support was provided by the study sponsor.	American Academy of Dermatology Association, 2020, GUID US IMM SUPPR AG; Bashyam AM, 2020, J DERMATOL TREAT, V31, P317, DOI 10.1080/09546634.2020.1742438; Damiani G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13475; Gisondi P, 2020, BRIT J DERMATOL, V183, P373, DOI 10.1111/bjd.19158; Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Krueger JG, 2020, AM AC DERM ANN M MAR; Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031; Suarez-Farinas M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-294; Tang Y, 2011, CLIN EXP IMMUNOL, V166, P281, DOI 10.1111/j.1365-2249.2011.04471.x; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683	12	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					1107	+		10.1016/j.jaci.2020.09.021	http://dx.doi.org/10.1016/j.jaci.2020.09.021		MAR 2021	6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RG4QF	33002515	hybrid, Green Published			2022-12-18	WOS:000635524300019
J	Rachid, R; Stephen-Victor, E; Chatila, TA				Rachid, Rima; Stephen-Victor, Emmanuel; Chatila, Talal A.			The microbial origins of food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; IgA; IgE; microbiota; microbiome; fecal microbiota transplantation; dysbiosis; regulatory T cells; ROR gamma t(+) Treg	GUT MICROBIOME; ORAL TOLERANCE; T-CELLS; INFANTS; DIETARY; RISK; CHILDHOOD; DIAGNOSIS; DELIVERY; IMMUNITY	Food allergy (FA) is a significant public health issue, propelled by its rapidly increasing prevalence. Its sharp rise into prominence has focused attention on causative environmental factors and their interplay with the immune system in disease pathogenesis. In that regard, there is now substantial evidence that alterations in the gut microbiome early in life imprint the host gut mucosal immunity and may play a critical role in precipitating FA. These changes may impact key steps in the development of the infant gut microbiome, including its shaping by maternal factors and upon the introduction of solid food (the weaning reaction). These early-life changes may have long-range effects on host immunity that manifest later in time as disease pathology. Experimental studies have shown that resetting the host intestinal immune responses by treatment with either a healthy fecal microbiota transplantation or defined commensal bacterial taxa can prevent or treat FA. The mechanisms by which these interventions suppress FA include restoration of gut immune regulatory checkpoints, notably the retinoic orphan receptor gamma T+ regulatory T cells, the epithelial barrier, and healthy immunoglobulin A responses to the gut commensals. These findings inform human studies currently in progress that evaluate the role of microbial therapies in FA.	[Rachid, Rima; Stephen-Victor, Emmanuel; Chatila, Talal A.] Boston Childrens Hosp, Div Immunol, Karp Family Res Bldg,Rm 10-214-B, Boston, MA 02115 USA; [Rachid, Rima; Stephen-Victor, Emmanuel; Chatila, Talal A.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Chatila, TA (corresponding author), Boston Childrens Hosp, Div Immunol, Karp Family Res Bldg,Rm 10-214-B, Boston, MA 02115 USA.	Talal.chatila@childrens.harvard.edu	Stephen Victor, Emmanuel/HDN-0252-2022	Stephen Victor, Emmanuel/0000-0001-5049-7017	National Institutes of Health [R01 AI126915, R21 AI132843]; Bunning Food Allergy Fund; Jasmine and Paul Mashikian Fund	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bunning Food Allergy Fund; Jasmine and Paul Mashikian Fund	This work was supported by the National Institutes of Health (grant nos. R01 AI126915 and R21 AI132843 to T.A.C.) , the Bunning Food Allergy Fund, and the Jasmine and Paul Mashikian Fund.	Abdel-Gadir A, 2018, CLIN EXP ALLERGY, V48, P825, DOI 10.1111/cea.13161; Abdel-Gadir A, 2019, NAT MED, V25, P1164, DOI 10.1038/s41591-019-0461-z; Al Nabhani Z, 2019, IMMUNITY, V50, P1276, DOI 10.1016/j.immuni.2019.02.014; Amoah AS, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0733-y; Amoah AS, 2013, J ALLERGY CLIN IMMUN, V132, P639, DOI 10.1016/j.jaci.2013.04.023; Anvari S, 2017, JAMA PEDIATR, V171, P77, DOI 10.1001/jamapediatrics.2016.2552; Arkestal K, 2011, J ALLERGY CLIN IMMUN, V127, P1024, DOI 10.1016/j.jaci.2011.01.033; Bunyavanich S, 2019, J ALLERGY CLIN IMMUN, V144, P1468, DOI 10.1016/j.jaci.2019.10.019; Bunyavanich S, 2016, J ALLERGY CLIN IMMUN, V138, P1122, DOI 10.1016/j.jaci.2016.03.041; Crestani E, 2020, J ALLERGY CLIN IMMUN, V145, P897, DOI 10.1016/j.jaci.2019.10.014; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Dzidic M, 2017, J ALLERGY CLIN IMMUN, V139, P1017, DOI 10.1016/j.jaci.2016.06.047; Eggesbo M, 2003, J ALLERGY CLIN IMMUN, V112, P420, DOI 10.1067/mai.2003.1610; Feehley T, 2019, NAT MED, V25, P448, DOI 10.1038/s41591-018-0324-z; Ganal-Vonarburg SC, 2020, SCIENCE, V368, P604, DOI 10.1126/science.aba0478; Gowthaman U, 2019, SCIENCE, V365, P883, DOI 10.1126/science.aaw6433; Gupta RS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.5630; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Henrick BM, BIFIDOBACTERIA MEDIA, DOI 10.24.353250; Hong SW, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw1507; Keir ME, 2020, J EXP MED, V217, DOI 10.1084/jem.20192195; Kim KS, 2016, SCIENCE, V351, P858, DOI 10.1126/science.aac5560; Knoop KA, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aao1314; Kukkonen K, 2010, PEDIAT ALLERG IMM-UK, V21, P67, DOI 10.1111/j.1399-3038.2009.00907.x; Lathrop SK, 2011, NATURE, V478, P250, DOI 10.1038/nature10434; Macpherson AJ, 2018, ANNU REV IMMUNOL, V36, P359, DOI 10.1146/annurev-immunol-042617-053238; Mitselou N, 2018, J ALLERGY CLIN IMMUN, V142, P1510, DOI 10.1016/j.jaci.2018.06.044; Ohnmacht C, 2015, SCIENCE, V349, P989, DOI 10.1126/science.aac4263; OMahony L, MICROBIOME ALLERGIC; Pannaraj PS, 2017, JAMA PEDIATR, V171, P647, DOI 10.1001/jamapediatrics.2017.0378; PRACTALL document of the American Academy of Allergy Asthma & Immunology and the European Academy of Allergy and Clinical Immunology, 2017, J ALLERGY CLIN IMMUN, V139, P1099; Rachid R, 2016, CURR OPIN PEDIATR, V28, P748, DOI 10.1097/MOP.0000000000000427; Ramanan D, 2020, CELL, V181, P1276, DOI 10.1016/j.cell.2020.04.030; Reinhardt RL, 2009, NAT IMMUNOL, V10, P385, DOI 10.1038/ni.1715; Renz H, 2021, NAT REV IMMUNOL, V21, P177, DOI 10.1038/s41577-020-00420-y; Rivas MN, 2015, IMMUNITY, V42, P512, DOI 10.1016/j.immuni.2015.02.004; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Robertson RC, 2019, TRENDS MICROBIOL, V27, P131, DOI 10.1016/j.tim.2018.09.008; Sandin A, 2011, PEDIAT ALLERG IMM-UK, V22, P477, DOI 10.1111/j.1399-3038.2010.01106.x; Sela DA, 2008, P NATL ACAD SCI USA, V105, P18964, DOI 10.1073/pnas.0809584105; Sicherer SH, 2018, J ALLERGY CLIN IMMUN, V141, P41, DOI 10.1016/j.jaci.2017.11.003; Song XY, 2020, NATURE, V577, P410, DOI 10.1038/s41586-019-1865-0; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Stephen-Victor E, 2020, IMMUNITY, V53, P277, DOI 10.1016/j.immuni.2020.07.025; Stephen-Victor E, 2019, CURR OPIN IMMUNOL, V60, P141, DOI 10.1016/j.coi.2019.06.001; Stewart CJ, 2018, NATURE, V562, P583, DOI 10.1038/s41586-018-0617-x; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Tan J, 2016, CELL REP, V15, P2809, DOI 10.1016/j.celrep.2016.05.047; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; Turner JA, 2020, IMMUNITY, V53, P1202, DOI [10.1016/j.immuni.2020.10.002, 10.1016/j.immuni.2020.11.011]; Verma R, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat6975; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; Zhou L, 2019, NATURE, V568, P405, DOI 10.1038/s41586-019-1082-x	54	13	13	8	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					808	813		10.1016/j.jaci.2020.12.624	http://dx.doi.org/10.1016/j.jaci.2020.12.624		MAR 2021	6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RA9TV	33347905	Green Accepted			2022-12-18	WOS:000631762400003
J	Fournier, B; Tusseau, M; Villard, M; Malcus, C; Chopin, E; Martin, E; Cordeiro, DJ; Fabien, N; Fusaro, M; Gauthier, A; Garnier, N; Goncalves, D; Lounis, S; Lenoir, C; Mathieu, AL; Moreews, M; Perret, M; Picard, C; Picard, C; Poitevin, F; Viel, S; Bertrand, Y; Walzer, T; Belot, A; Latour, S				Fournier, Benjamin; Tusseau, Maud; Villard, Marine; Malcus, Christophe; Chopin, Emilie; Martin, Emmanuel; Cordeiro, Debora Jorge; Fabien, Nicole; Fusaro, Mathieu; Gauthier, Alexandra; Garnier, Nathalie; Goncalves, David; Lounis, Sonia; Lenoir, Christelle; Mathieu, Anne-Laure; Moreews, Marion; Perret, Magali; Picard, Capucine; Picard, Cecile; Poitevin, Francoise; Viel, Sebastien; Bertrand, Yves; Walzer, Thierry; Belot, Alexandre; Latour, Sylvain			DEF6 deficiency, a mendelian susceptibility to EBV infection, lymphoma, and autoimmunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Fournier, Benjamin; Martin, Emmanuel; Cordeiro, Debora Jorge; Fusaro, Mathieu; Lounis, Sonia; Lenoir, Christelle; Picard, Capucine; Latour, Sylvain] Inst Natl Sante & Rech Med Inserm, UMR 1163, Lab Lymphocyte Activat & Susceptibil EBV Infect, F-75015 Paris, France; [Fournier, Benjamin; Martin, Emmanuel; Cordeiro, Debora Jorge; Lounis, Sonia; Lenoir, Christelle; Picard, Capucine; Latour, Sylvain] Univ Paris, Imagine Inst, F-75015 Paris, France; [Tusseau, Maud; Mathieu, Anne-Laure; Moreews, Marion; Viel, Sebastien; Bertrand, Yves; Walzer, Thierry; Belot, Alexandre] Univ Lyon 1, Ecole Normale Super Lyon, Int Ctr Infectiol Res, Inserm,U1111,CNRS,UMR5308, Lyon, France; [Villard, Marine; Fabien, Nicole; Goncalves, David; Perret, Magali; Viel, Sebastien] Lyon 1 Univ, Ctr Hosp Lyon Sud, Immunol Dept, Lyon, France; [Malcus, Christophe; Poitevin, Francoise] Hosp Civils Lyon, Hop Edouard Herriot, Immunol Lab, Lyon, France; [Chopin, Emilie] Hosp Civils Lyon, Ctr Biol & Pathol Est, Ctr Biotechnol Cellulaire, Bron, France; [Fusaro, Mathieu; Picard, Capucine] Necker Enfants Malad Hosp, AP HP, Study Ctr Primary Immunodeficiencies, F-75015 Paris, France; [Gauthier, Alexandra; Garnier, Nathalie; Bertrand, Yves] Hosp Civils Lyon, Inst Hematol & Oncol Pediat, Lyon, France; [Picard, Cecile] UCBL Lyon 1 Univ, Hosp Civils Lyon, Grp Hosp Est, Inst Pathol Multisite, Lyon, France; [Belot, Alexandre] Natl Referee Ctr Rheumat & AutoImmune & Syst Dis, Lyon, France; [Belot, Alexandre] Univ Lyon 1, Hosp Civils Lyon, Hop Femme Mere Enfant, Dermatol Unit,Pediat Nephrol,Rheumatol, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; CHU Lyon; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); CHU Lyon; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Latour, S (corresponding author), Inst Natl Sante & Rech Med Inserm, UMR 1163, Lab Lymphocyte Activat & Susceptibil EBV Infect, F-75015 Paris, France.; Latour, S (corresponding author), Univ Paris, Imagine Inst, F-75015 Paris, France.; Belot, A (corresponding author), Univ Lyon 1, Ecole Normale Super Lyon, Int Ctr Infectiol Res, Inserm,U1111,CNRS,UMR5308, Lyon, France.; Belot, A (corresponding author), Natl Referee Ctr Rheumat & AutoImmune & Syst Dis, Lyon, France.; Belot, A (corresponding author), Univ Lyon 1, Hosp Civils Lyon, Hop Femme Mere Enfant, Dermatol Unit,Pediat Nephrol,Rheumatol, Lyon, France.	alexandre.belot@chu-lyon.fr; sylvain.latour@inserm.fr	Viel, Sebastien/A-7258-2016; Belot, Alexandre/C-7378-2013; Walzer, Thierry/L-9418-2014; Martin, Emmanuel/F-9743-2016	Viel, Sebastien/0000-0002-5085-443X; Belot, Alexandre/0000-0003-4902-5332; Walzer, Thierry/0000-0002-0857-8179; Martin, Emmanuel/0000-0003-4211-7373; VILLARD, Marine/0000-0002-3905-8993	Ligue Contre le Cancer-Equipe Labellisee (France); INSERM (France); Rare Diseases Foundation (France) [ANR-14-CE14-0028-01, ANR 18-CE15-0025-01]; ''Investissements d'avenir'' program (Imagine Institute) [ANR-10-IAHU-01]; Societe Francaise Societe Francaise de Lutte contre les Cancers et Leucemies de l'Enfant et de l'Adolescent, AREMIG (France); Federation Enfants et Sante (France); Fondation pour la Recherche Medicale fellowship (France) [FDM20170638301]; Imagine Institute PhD program - Fondation Bettencourt Schueller	Ligue Contre le Cancer-Equipe Labellisee (France); INSERM (France)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Rare Diseases Foundation (France); ''Investissements d'avenir'' program (Imagine Institute)(French National Research Agency (ANR)); Societe Francaise Societe Francaise de Lutte contre les Cancers et Leucemies de l'Enfant et de l'Adolescent, AREMIG (France); Federation Enfants et Sante (France); Fondation pour la Recherche Medicale fellowship (France); Imagine Institute PhD program - Fondation Bettencourt Schueller	This study was funded by the Ligue Contre le Cancer-Equipe Labellisee (France) (to S.L.), INSERM (France), Rare Diseases Foundation (to S.L.) (France), ANR-14CE14-0028-01 (to S.L.), ANR 18-CE15-0025-01 (to S.L.), ''Investissements d'avenir'' program ANR-10-IAHU-01 (Imagine Institute), the Societe Francaise Societe Francaise de Lutte contre les Cancers et Leucemies de l'Enfant et de l'Adolescent, AREMIG (France), Federation Enfants et Sante (to S.L.) (France). B.F. is the recipient of a Fondation pour la Recherche Medicale fellowship (FDM20170638301) (France). D.J.C. was supported by the Imagine Institute PhD program funded by the Fondation Bettencourt Schueller. S.L. is a senior scientist at the Centre National de la Recherche Scientifique-CNRS (France).	Fanzo JC, 2006, J CLIN INVEST, V116, P703, DOI 10.1172/JCI24096; Fos C, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005565; Hey F, 2012, J BIOL CHEM, V287, P31073, DOI 10.1074/jbc.M112.346767; Horwitz DA, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2894; Schuster M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01583; Serwas NK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10812-x; Tangye SG, 2020, BLOOD, V135, P644, DOI 10.1182/blood.2019000928; Vely F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01036; Yi W, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00348-3	9	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					740	+		10.1016/j.jaci.2020.05.052	http://dx.doi.org/10.1016/j.jaci.2020.05.052		FEB 2021	10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	32562707	Green Submitted, Bronze			2022-12-18	WOS:000616665800038
J	Platt, CD; Zaman, F; Bainter, W; Stafstrom, K; Almutairi, A; Reigle, M; Weeks, S; Geha, RS; Chou, J				Platt, Craig D.; Zaman, Fatima; Bainter, Wayne; Stafstrom, Kelsey; Almutairi, Abuarahman; Reigle, Margot; Weeks, Sabrina; Geha, Raif S.; Chou, Janet		Int Consortium Immunodeficiencies	Efficacy and economics of targeted panel versus whole-exome sequencing in 878 patients with suspected primary immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Next-generation sequencing; targeted panel; whole-exome sequencing; primary immunodeficiency; genomics		Background: Next-generation sequencing has become a first-line tool for the diagnosis of primary immunodeficiency. However, patient access remains limited because of restricted insurance coverage and a lack of guidelines addressing the use of targeted panels versus whole-exome sequencing (WES). Objectives: We sought to compare targeted next-generation sequencing with WES in a global population of patients with primary immunodeficiency. Methods: This was a longitudinal study of 878 patients with likely primary immunodeficiency sequenced between 2010 and 2020. Most patients (n = 780) were first sequenced using a 264 gene panel. This was followed by WES in selected cases if a candidate gene was not found. A subset of patients (n = 98) were selected for a WES-only pipeline if the history was atypical for genes within the targeted panel. Results: Disease-causing variants were identified in 498 of the 878 probands (56%), encompassing 152 distinct monogenic disorders. Sixteen patients had disorders that were novel at the time of sequencing (1.8%). Diagnostic yield in patients sequenced by targeted panel was 56% (433 of 780 patients), with subsequent WES leading to an additional 18 diagnoses (overall diagnostic yield 58%, 451 of 780 patients). The WES-only approach had a diagnostic yield of 45% (45 of 98 patients), reflecting that these cases had less common clinical and laboratory phenotypes. Cost analysis, based on current commercial WES and targeted panel prices, demonstrated savings ranging from $300 to $950 with a WES-only approach, depending on diagnostic yield. Conclusions: Advantages of WES over targeted next-generation sequencing include simplified workflow, reduced overall cost, and the potential for identification of novel diseases.	[Platt, Craig D.; Zaman, Fatima; Bainter, Wayne; Stafstrom, Kelsey; Almutairi, Abuarahman; Reigle, Margot; Weeks, Sabrina; Geha, Raif S.; Chou, Janet; Int Consortium Immunodeficiencies] Harvard Med Sch, Div Immunol, Boston Childrens Hosp, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	Geha, RS; Chou, J (corresponding author), 1 Blackfan Circle,Karp Bldg,10th Floor, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu; janet.chou@childrens.harvard.edu			National Institutes of Health (NIH) [1K08AI116979-01]; Eleanor and Miles Shore 50th Anniversary Fellowship Award; NIH [1R01AI139633-01]; Samara Turkel Foundation; Perkin Fund	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Eleanor and Miles Shore 50th Anniversary Fellowship Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Samara Turkel Foundation; Perkin Fund	This study was supported by National Institutes of Health (NIH) grant number 1K08AI116979-01 (J.C.), Eleanor and Miles Shore 50th Anniversary Fellowship Award (C.D.P.), NIH grant number 1R01AI139633-01 (R.S.G.), the Samara Turkel Foundation (R.S.G.), and the Perkin Fund (R.S.G.).	Chinn IK, 2020, J ALLERGY CLIN IMMUN, V145, P46, DOI 10.1016/j.jaci.2019.09.009; Cifaldi C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01184; Dillon OJ, 2018, EUR J HUM GENET, V26, P644, DOI 10.1038/s41431-018-0099-1; Heimall J, 2019, J ALLER CL IMM-PRACT, V7, P833, DOI 10.1016/j.jaip.2018.12.022; LaDuca H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170843; Marson A, 2015, J CLIN INVEST, V125, P2234, DOI 10.1172/JCI78086; Modell V, 2014, IMMUNOL RES, V60, P132, DOI 10.1007/s12026-014-8498-z; Mortaz E, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00365; Reuter CM, 2019, J GENET COUNS, V28, P1107, DOI 10.1002/jgc4.1161; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Rudilla F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02325; Tan TY, 2017, JAMA PEDIATR, V171, P855, DOI 10.1001/jamapediatrics.2017.1755; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x	13	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					723	726		10.1016/j.jaci.2020.08.022	http://dx.doi.org/10.1016/j.jaci.2020.08.022		FEB 2021	4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	32888943	Green Accepted			2022-12-18	WOS:000616665800034
J	Wilson, JM; Keshavarz, B; Retterer, M; Workman, LJ; Schuyler, AJ; McGowan, EC; Lane, C; Kandeel, A; Purser, J; Ronmark, E; LaRussa, J; Commins, SP; Merritt, T; Platts-Mills, TAE				Wilson, Jeffrey M.; Keshavarz, Behnam; Retterer, Maya; Workman, Lisa J.; Schuyler, Alexander J.; McGowan, Emily C.; Lane, Charles; Kandeel, Alaaddin; Purser, Jane; Ronmark, Eva; LaRussa, Joseph; Commins, Scott P.; Merritt, Tina; Platts-Mills, Thomas A. E.			A dynamic relationship between two regional causes of IgE-mediated anaphylaxis: alpha-Gal syndrome and imported fire ant	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Tick; galactose-alpha-1,3-galactose; mammalian meat allergy; alpha-Gal syndrome; IgE; anaphylaxis; imported fire ant		Background: A syndrome of mammalian meat allergy relating to IgE specific for galactose-alpha-1,3-galactose (alpha-Gal) was first reported 10 years ago in the southeastern United States and has been related to bites of the lone star tick (Amblyomma americanum). Objective: Here we investigated the epidemiology of the "alpha-Gal syndrome'' in the United States and sought additional evidence for the connection to tick bites. Methods: A survey of allergists was conducted by using a snowball approach. A second tier of the survey included questions about anaphylaxis to imported fire ants (IFAs). History of tick bites and tick-related febrile illness were assessed as part of a case-control study in Virginia. Antibody assays were conducted on sera from subjects reporting allergic reactions to mammalian meat or IFA. Results: In North America the alpha-Gal syndrome is recognized across the Southeast, Midwest, and Atlantic Coast, with many providers in this area managing more than 100 patients each. The distribution of cases generally conformed to the reported range of A americanum, although within this range there was an inverse relationship between alpha-Gal cases and cases of IFA anaphylaxis that were closely related to the territory of IFA. The connection between tick bites and alpha-Gal sensitization was further supported by patients' responses to a questionnaire and the results of serologic tests. Conclusions: The alpha-Gal syndrome is commonly acquired in adulthood as a consequence of tick bites and has a regional distribution that largely conforms to the territory of the lone star tick. The epidemiology of the syndrome is expected to be dynamic and shifting north because of climate change and ecologic competition from IFA.	[Wilson, Jeffrey M.; Keshavarz, Behnam; Retterer, Maya; Workman, Lisa J.; Schuyler, Alexander J.; McGowan, Emily C.; Platts-Mills, Thomas A. E.] Univ Virginia, Div Allergy & Clin Immunol, POB 801355, Charlottesville, VA 22908 USA; [Lane, Charles] Allergy Partners Lynchburg, Lynchburg, VA USA; [Kandeel, Alaaddin] Essentia Hlth, Duluth, MN USA; [Purser, Jane] Allergy Clin Tulsa, Tulsa, OK USA; [Ronmark, Eva] Umea Univ, Dept Publ Hlth & Clin Med, OLIN Unit, Umea, Sweden; [LaRussa, Joseph] Pediat & Adult Asthma & Allergy, Birmingham, AL USA; [Commins, Scott P.] Univ N Carolina, Div Rheumatol Allergy & Immunol, Chapel Hill, NC 27515 USA; [Merritt, Tina] Allergy & Asthma Clin Northwest Arkansas, Bentonville, AR USA	University of Virginia; Umea University; University of North Carolina; University of North Carolina Chapel Hill	Platts-Mills, TAE (corresponding author), Univ Virginia, Div Allergy & Clin Immunol, POB 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu	K, B/Q-7874-2016; Wilson, JM/AAD-6421-2020	K, B/0000-0001-5121-6950; Wilson, JM/0000-0002-5975-1760; Platts-Mills, Thomas/0000-0002-1263-329X	National Institutes of Health [NIH R37 AI-20565]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by the National Institutes of Health (grant NIH R37 AI-20565 [to T.P.M.]).	Apostolovic D, 2018, ALLERGY, V73, P1525, DOI 10.1111/all.13400; Apostolovic D, 2020, ALLERGY, V75, P217, DOI 10.1111/all.13978; Apostolovic D, 2016, ALLERGO J, V25, P29, DOI 10.1007/s15007-016-1044-7; Araujo RN, 2016, INT J PARASITOL, V46, P213, DOI 10.1016/j.ijpara.2015.12.005; BROWN LL, 1972, SOUTHERN MED J, V65, P273, DOI 10.1097/00007611-197203000-00003; BURNS EC, 1977, J MED ENTOMOL, V14, P247, DOI 10.1093/jmedent/14.2.247; Cabezas-Cruz A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01210; Castellanos AA, 2016, BIOL LETTERS, V12, DOI 10.1098/rsbl.2016.0463; Chandrasekhar JL, 2019, J IMMUNOL, V203, P813, DOI 10.4049/jimmunol.1801156; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Crispell G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01056; Dahlgren FS, 2016, AM J TROP MED HYG, V94, P35, DOI 10.4269/ajtmh.15-0580; Diuk-Wasser MA, 2006, J MED ENTOMOL, V43, P166, DOI 10.1603/0022-2585(2006)043[0166:SPOHIS]2.0.CO;2; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Gaines DN, 2014, VECTOR-BORNE ZOONOT, V14, P307, DOI 10.1089/vbz.2013.1509; Gonzalez-Quintela A, 2014, CLIN EXP ALLERGY, V44, P1061, DOI 10.1111/cea.12326; Hamsten C, 2013, ALLERGY, V68, P549, DOI 10.1111/all.12128; Hamsten C, 2013, J ALLERGY CLIN IMMUN, V132, P1431, DOI 10.1016/j.jaci.2013.07.050; HARRIS W G, 1972, Environmental Entomology, V1, P362; Hashizume H, 2018, J AM ACAD DERMATOL, V78, P1135, DOI 10.1016/j.jaad.2017.12.028; Heckathorn DD, 2011, SOCIOL METHODOL, V41, P355, DOI 10.1111/j.1467-9531.2011.01244.x; Hoffman DR, 2005, J ALLERGY CLIN IMMUN, V115, P611, DOI 10.1016/j.jaci.2004.11.020; HOFFMAN DR, 1995, ALLERGY, V50, P535, DOI 10.1111/j.1398-9995.1995.tb01196.x; Homann A, 2017, J ALLERGY CLIN IMMUN, V140, P356, DOI 10.1016/j.jaci.2017.04.019; Jaenson TGT, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-8; Karpathy SE, 2016, INT J SYST EVOL MICR, V66, P5236, DOI 10.1099/ijsem.0.001502; Kemp SF, 2000, J ALLERGY CLIN IMMUN, V105, P683, DOI 10.1067/mai.2000.105707; Kim MS, 2020, J ALLER CL IMM-PRACT, V8, P364, DOI 10.1016/j.jaip.2019.08.045; Kirchherr J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201710; Mabelane T, 2018, PEDIAT ALLERG IMM-UK, V29, P841, DOI 10.1111/pai.12969; Molaei G, 2019, NEW ENGL J MED, V381, P2189, DOI 10.1056/NEJMp1911661; Needleman RK, 2018, WILD ENVIRON MED, V29, P226, DOI 10.1016/j.wem.2017.11.004; Nieto NC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199644; O'Neil BH, 2007, J CLIN ONCOL, V25, P3644, DOI 10.1200/JCO.2007.11.7812; Park Y, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010018; Perzanowski MS, 2016, J ALLERGY CLIN IMMUN, V138, P1582, DOI 10.1016/j.jaci.2016.05.017; Platts-Mills TAE, 2020, J ALLERGY CLIN IMMUN, V145, P1061, DOI 10.1016/j.jaci.2020.01.047; Qian J, 2007, ANAL BIOCHEM, V364, P8, DOI 10.1016/j.ab.2007.01.023; Raghavan RK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209082; RHOADES RB, 1989, J ALLERGY CLIN IMMUN, V84, P159, DOI 10.1016/0091-6749(89)90319-9; SEAGROATT V, 1981, J BIOL STAND, V9, P431, DOI 10.1016/S0092-1157(81)80034-0; Showler AT, 2019, ENVIRON ENTOMOL, V48, P1063, DOI 10.1093/ee/nvz097; Springer YP, 2015, AM J TROP MED HYG, V93, P875, DOI 10.4269/ajtmh.15-0330; Springer YP, 2014, J MED ENTOMOL, V51, P342, DOI 10.1603/ME13115; Stoltz LP, 2019, J ALLER CL IMM-PRACT, V7, P664, DOI 10.1016/j.jaip.2018.07.014; Stromdahl EY, 2008, VECTOR-BORNE ZOONOT, V8, P15, DOI 10.1089/vbz.2007.0138; van Nunen SA, 2018, MED J AUSTRALIA, V208, P316, DOI 10.5694/mja17.00591; Van Nunen SA, 2009, MED J AUSTRALIA, V190, P510, DOI 10.5694/j.1326-5377.2009.tb02533.x; Wilson JM, 2019, J ALLER CL IMM-PRACT, V7, P2348, DOI 10.1016/j.jaip.2019.03.031; Wilson JM, 2018, MOL IMMUNOL, V100, P107, DOI 10.1016/j.molimm.2018.03.018; Wilson JM, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0672-7	53	13	13	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					643	+		10.1016/j.jaci.2020.05.034	http://dx.doi.org/10.1016/j.jaci.2020.05.034		FEB 2021	17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	32522461	Green Accepted, Bronze			2022-12-18	WOS:000616665800026
J	Azzano, P; Paquin, M; Langlois, A; Morin, C; Parizeault, G; Lacombe-Barrios, J; Samaan, K; Graham, F; Paradis, L; Des Roches, A; Begin, P				Azzano, Pauline; Paquin, Maxime; Langlois, Alexandra; Morin, Charles; Parizeault, Guy; Lacombe-Barrios, Jonathan; Samaan, Kathryn; Graham, Francois; Paradis, Louis; Des Roches, Anne; Begin, Philippe			Determinants of omalizumab dose-related efficacy in oral immunotherapy: Evidence from a cohort of 181 patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Continued consumption; desensitization; dosage; food allergy; OIT; omalizumab; oral immunotherapy; pharmacokinetics; pharmacokinetics and pharmacodynamics	IGE-ASSISTED DESENSITIZATION; ANTI-IGE; COWS MILK; MONOCLONAL-ANTIBODY; CHALLENGE RESPONSES; HUMAN BASOPHILS; SERUM IGE; PHARMACOKINETICS; PHARMACODYNAMICS; SENSITIVITY	Background: Omalizumab has been shown to improve the safety and feasibility of oral immunotherapy (OIT), but the optimal dosage strategy is unknown. Objective: Our aim was to identify determinants of omalizumab dose-related efficacy in the context of OIT. Methods: The study sample consisted of a clinical cohort of 181 patients treated with omalizumab-enabled oral immunotherapy at 3 centers. Patients received omalizumab for at least 2 months before an initial food escalation (IFE) with a mix of up to 6 allergens. Progression through IFE steps was assessed with survival analysis. Continued food dose tolerance with omalizumab weaning was also documented. Results: Omalizumab dosage per weight alone was strongly associated with progression through the IFE (chi(2) = 28.18; P<.0001), whereas the standard dosage per weight and total IgE level used for asthma was not (chi(2) = 0.001; P = .97). When the values at time of IFE were estimated through pharmacokinetics and pharmacodynamics simulation, IFE outcome was best predicted by a model that includes levels of free allergen-specific IgE and their interaction with blocking omalizumab-IgE complexes and free omalizumab levels in serum (chi(2) = 65.84; degrees of freedom [df] = 2; P<.0005). The occurrence of immediate-type reactions to food dosing subsequent to weaning of omalizumab was associated with a greater ratio of specific IgE level to total IgE level at baseline (geometric mean 0.39 vs 0.16 in those without symptom; P<.0001). Conclusion: In the context of OIT and IgE-mediated disease, omalizumab dosages should be adjusted for body weight alone, independently of total IgE level. The fraction of allergen-specific/total IgE may be useful to predict patients at greater risk of food dosing reactions subsequent to weaning.	[Azzano, Pauline; Langlois, Alexandra; Lacombe-Barrios, Jonathan; Samaan, Kathryn; Paradis, Louis; Des Roches, Anne; Begin, Philippe] Ctr Hosp Univ St Justine, Sect Allergy & Clin Immunol, Dept Pediat, Montreal, PQ, Canada; [Paquin, Maxime; Graham, Francois; Paradis, Louis; Begin, Philippe] Ctr Hosp Univ Montreal, Dept Med, Sect Allergy & Clin Immunol, Montreal, PQ, Canada; [Morin, Charles; Parizeault, Guy; Begin, Philippe] Hop Chicoutimi, Dept Pediat, Saguenay, PQ, Canada	Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal	Begin, P (corresponding author), Ctr Hosp Univ St Justine, Dept Pediat, Serv Allergy & Clin Immunol, 3175 Chemin Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	philippe.begin@umontreal.ca	Bégin, Philippe/AAU-9126-2021		Canadian Institutes of Health Research [420365]; Fonds de Recherche du Quebec en Sante [281662]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Fonds de Recherche du Quebec en Sante(Fonds de la Recherche en Sante du Quebec)	P. Begin was supported by a Project Grant from the Canadian Institutes of Health Research (420365) and a Clinical Research Scholar grant from the Fonds de Recherche du Quebec en Sante (281662).	Andorf S, 2018, LANCET GASTROENTEROL, V3, P85, DOI 10.1016/S2468-1253(17)30392-8; Ankerst J, 2010, INT ARCH ALLERGY IMM, V152, P71, DOI 10.1159/000260086; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Begin P, 2020, ALLERGY ASTHMA CL IM, V16, DOI 10.1186/s13223-020-0413-7; Begin P, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-1; Begin P, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-7; Bousquet J, 2007, RESP MED, V101, P1483, DOI 10.1016/j.rmed.2007.01.011; Boyano-Martinez T, 2012, J INVEST ALLERG CLIN, V22, P109; Brandstrom J, 2017, CLIN EXP ALLERGY, V47, P540, DOI 10.1111/cea.12862; Brandstrom J, 2019, CLIN EXP ALLERGY, V49, P1328, DOI 10.1111/cea.13469; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Di Lorenzo G, 2009, J ALLERGY CLIN IMMUN, V123, P1103, DOI 10.1016/j.jaci.2009.02.012; Eggel A, 2014, J ALLERGY CLIN IMMUN, V133, P1709, DOI 10.1016/j.jaci.2014.02.005; Fiocchi A, 2017, CURR OPIN ALLERGY CL, V17, P232, DOI 10.1097/ACI.0000000000000357; Frischmeyer-Guerrerio PA, 2017, J ALLERGY CLIN IMMUN, V140, P1043, DOI 10.1016/j.jaci.2017.03.028; Gasser P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13815-w; Gupta RS, 2014, J ALLER CL IMM-PRACT, V2, P300, DOI 10.1016/j.jaip.2013.12.006; Hamilton RG, 2006, J ALLERGY CLIN IMMUN, V117, P759, DOI 10.1016/j.jaci.2006.01.012; Honma W, 2016, DRUG METAB PHARMACOK, V31, P173, DOI 10.1016/j.dmpk.2015.12.003; Hsu CL, 2010, INT IMMUNOPHARMACOL, V10, P533, DOI 10.1016/j.intimp.2010.02.001; Johansson SGO, 2009, ALLERGY, V64, P1472, DOI 10.1111/j.1398-9995.2009.02051.x; Korn S, 2012, RESP MED, V106, P1494, DOI 10.1016/j.rmed.2012.07.010; Labrosse R, 2017, ARCH IMMUNOL THER EX, V65, P189, DOI 10.1007/s00005-016-0420-z; Lafuente I, 2014, PEDIAT ALLERG IMM-UK, V25, P717, DOI 10.1111/pai.12259; Langlois A, 2020, ALLERGY ASTHMA CL IM, V16, DOI 10.1186/s13223-020-00419-z; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Lin C, 2017, PEDIAT ALLERG IMM-UK, V28, P619, DOI 10.1111/pai.12767; Loh WY, 2018, IMMUNOL ALLERGY CLIN, V38, P89, DOI 10.1016/j.iac.2017.09.008; Lowe PJ, 2009, BRIT J CLIN PHARMACO, V68, P61, DOI 10.1111/j.1365-2125.2009.03401.x; MacGinnitie AJ, 2017, J ALLERGY CLIN IMMUN, V139, P873, DOI 10.1016/j.jaci.2016.08.010; MacGlashan D, 2019, J ALLERGY CLIN IMMUN, V144, P1177, DOI 10.1016/j.jaci.2019.09.024; MacGlashan D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179734; MacGlashan DW, 2013, J ALLERGY CLIN IMMUN, V132, P906, DOI 10.1016/j.jaci.2013.04.056; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Martorell-Calatayud C, 2016, PEDIAT ALLERG IMM-UK, V27, P544, DOI 10.1111/pai.12567; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Odajima H, 2017, ALLERGOL INT, V66, P106, DOI 10.1016/j.alit.2016.06.004; Paterniti M, 2011, CLIN EXP ALLERGY, V41, P963, DOI 10.1111/j.1365-2222.2011.03719.x; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Sampson HA, 2011, J ALLERGY CLIN IMMUN, V127, P1309, DOI 10.1016/j.jaci.2011.01.051; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P1123, DOI 10.1016/j.jaci.2012.05.039; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Takahashi M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16730-6; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P1103, DOI 10.1016/j.jaci.2015.10.005; Zheng L, 2008, BIOCHEM BIOPH RES CO, V375, P619, DOI 10.1016/j.bbrc.2008.08.055	46	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					233	243		10.1016/j.jaci.2020.08.039	http://dx.doi.org/10.1016/j.jaci.2020.08.039		JAN 2021	11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	32980425				2022-12-18	WOS:000613645900027
J	Fischer-Riepe, L; Daber, N; Schulte-Schrepping, J; De Carvalho, BCV; Russo, A; Pohlen, M; Fischer, J; Chasan, AI; Wolf, M; Ulas, T; Glander, S; Schulz, C; Skryabin, B; Andreas Wollbrink, DI; Steingraeber, N; Stremmel, C; Koehle, M; Gartner, F; Vettorazzi, S; Holzinger, D; Gross, J; Rosenbauer, F; Stoll, M; Niemann, S; Tuckermann, J; Schultze, JL; Roth, J; Barczyk-Kahlert, K				Fischer-Riepe, Lena; Daber, Niklas; Schulte-Schrepping, Jonas; De Carvalho, Brune Caroline Veras; Russo, Antonella; Pohlen, Michele; Fischer, Josephine; Chasan, Achmet Imam; Wolf, Marc; Ulas, Thomas; Glander, Shirin; Schulz, Christian; Skryabin, Boris; Andreas Wollbrink, Dipl-Ing; Steingraeber, Nadine; Stremmel, Christopher; Koehle, Megan; Gaertner, Florian; Vettorazzi, Sabine; Holzinger, Dirk; Gross, Joachim; Rosenbauer, Frank; Stoll, Monika; Niemann, Silke; Tuckermann, Jan; Schultze, Joachim L.; Roth, Johannes; Barczyk-Kahlert, Katarzyna			CD163 expression defines specific, IRF8-dependent, immune-modulatory macrophages in the bone marrow	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Resident bone marrow macrophages; scavenger receptor CD163; IFN regulatory factor 8; sterile and systemic inflammation	SCAVENGER RECEPTOR CD163; GLUCOCORTICOID-INDUCIBLE MEMBER; HUMAN MONOCYTES; STAPHYLOCOCCUS-AUREUS; IN-VIVO; DIFFERENTIATION; ANTIGEN; BINDING; HETEROGENEITY; RECOGNITION	Background: Scavenger receptor CD163 is exclusively expressed on monocytes/macrophages and is widely used as a marker for alternatively activated macrophages. However, the role of CD163 is not yet clear. Objectives: We sought to examine the function of CD163 in steady-state as well as in sterile and infectious inflammation. Methods: Expression of CD163 was analyzed under normal and inflammatory conditions in mice. Functional relevance of CD163 was investigated in models of inflammation in wild-type and CD163(-/-) mice. Results: We describe a subpopulation of bone marrow-resident macrophages (BMRMs) characterized by a high expression of CD163 and functionally distinct from classical bone marrow-derived macrophages. Development of CD163(+) BMRMs is strictly dependent on IFN regulatory factor-8. CD163(+) BMRMs show a specific transcriptome and cytokine secretion pattern demonstrating a specific immunomodulatory profile of these cells. Accordingly, CD163(-/-) mice show a stronger inflammation in allergic contact dermatitis, indicating a regulatory role of CD163. However, CD163(-/-) mice are highly susceptible to S aureus infections, demonstrating the relevance of CD163 for antimicrobial defense as well. Conclusions: Our data indicate that anti-inflammatory and immunosuppressive mechanisms are not necessarily associated with a decreased antimicrobial activity. In contrast, our data define a novel macrophage population that controls overwhelming inflammation on one hand but is also necessary for an effective control of infections on the other hand.	[Fischer-Riepe, Lena; Daber, Niklas; De Carvalho, Brune Caroline Veras; Russo, Antonella; Pohlen, Michele; Chasan, Achmet Imam; Wolf, Marc; Holzinger, Dirk; Roth, Johannes; Barczyk-Kahlert, Katarzyna] Univ Munster, Inst Immunol, Roentgenstr 21, D-48149 Munster, Germany; [Schulte-Schrepping, Jonas; Ulas, Thomas; Schultze, Joachim L.] Univ Bonn, Genom & Immunoregulat Life & Med Sci Inst, Bonn, Germany; [Pohlen, Michele] Univ Hosp Muenster, Dept Med Hematol & Oncol A, Munster, Germany; [Fischer, Josephine; Rosenbauer, Frank] Univ Hosp Muenster, Inst Mol Tumor Biol, Munster, Germany; [Glander, Shirin; Stoll, Monika] Univ Hosp Muenster, Inst Human Genet, Genet Epidemiol, Munster, Germany; [Schulz, Christian; Stremmel, Christopher; Koehle, Megan; Gaertner, Florian] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Med Klin & Poliklin 1, Munich, Germany; [Schulz, Christian] DZHK German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, Munich, Germany; [Skryabin, Boris] Univ Munster, Dept Med Transgen Anim & Genet Engn Models, Munster, Germany; [Andreas Wollbrink, Dipl-Ing; Steingraeber, Nadine; Gross, Joachim] Univ Munster, Inst Biomagnetism & Biosignalanal, Munster, Germany; [Vettorazzi, Sabine; Tuckermann, Jan] Univ Ulm, Inst Comparat Mol Endocrinol CME, Ulm, Germany; [Niemann, Silke] Univ Hosp Muenster, Inst Med Microbiol, Munster, Germany; [Schultze, Joachim L.] DZNE, Platform Single Cell Genom & Epigenom PRECISE, Bonn, Germany; [Schultze, Joachim L.] Univ Bonn, Bonn, Germany; [Roth, Johannes] Univ Munster, Interdisciplinary Ctr Clin Res, Munster, Germany	University of Munster; University of Bonn; University of Munster; University of Munster; University of Munster; University of Munich; German Centre for Cardiovascular Research; Munich Heart Alliance; University of Munster; University of Munster; Ulm University; University of Munster; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Bonn; University of Munster	Barczyk-Kahlert, K (corresponding author), Univ Munster, Inst Immunol, Roentgenstr 21, D-48149 Munster, Germany.	bar@uni-muenster.de	Gaertner, Florian/AAY-1420-2021; Gaertner, Florian/GXG-7213-2022; Stremmel, Christopher/ABH-5416-2020; Schultze, Joachim L./ABA-8176-2020; Skryabin, Boris/AAL-3100-2020	Gaertner, Florian/0000-0001-6120-3723; Schultze, Joachim L./0000-0003-2812-9853; Skryabin, Boris/0000-0002-4392-185X; de Carvalho, Bruna Caroline/0000-0002-3123-7479; Vettorazzi, Dr. Sabine/0000-0001-8667-9488; Imam Chasan, Achmet/0000-0001-5137-6890	Interdisciplinary Center of Clinical Research at the University of Muenster [Ro2/003/15]; German Research Foundation (Deutsche Forschungsgmeinschaft; DFG) Collaborative Research Center (CRC) [1009, CRC Transregio 34, C13(N), DFG CRU 342 P3]; Excellence Cluster ImmunoSensation; Excellence Cluster "Cells in Motion''; CRC [914]; Deutsches Zentrum fur Herz-Kreislauf-Forschung (DZHK; German Centre for Cardiovascular Research, High Risk High Volume); BMBF (Bundesministerium fur Bildung und Forschung; German Ministry of Education and Research)	Interdisciplinary Center of Clinical Research at the University of Muenster; German Research Foundation (Deutsche Forschungsgmeinschaft; DFG) Collaborative Research Center (CRC); Excellence Cluster ImmunoSensation; Excellence Cluster "Cells in Motion''; CRC(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); Deutsches Zentrum fur Herz-Kreislauf-Forschung (DZHK; German Centre for Cardiovascular Research, High Risk High Volume); BMBF (Bundesministerium fur Bildung und Forschung; German Ministry of Education and Research)	This work was supported by grants of the Interdisciplinary Center of Clinical Research at the University of Muenster (grant no. Ro2/003/15 to J.R.) and the German Research Foundation (Deutsche Forschungsgmeinschaft; DFG) Collaborative Research Center (CRC) 1009 B1, B9, and Z2 to S.N. and J.R., CRC Transregio 34, C13(N), DFG CRU 342 P3, and Mye-EUNITER to K.B-K. and J.R., the Excellence Cluster ImmunoSensation to J.L.S., the Excellence Cluster "Cells in Motion'' to J.R., and the CRC 914 (A10) as well as the Deutsches Zentrum fur Herz-Kreislauf-Forschung (DZHK; German Centre for Cardiovascular Research, High Risk High Volume) and the BMBF (Bundesministerium fur Bildung und Forschung; German Ministry of Education and Research) to C.Sch. C.Str. was supported by a Gerok position of the CRC 914.	Buechler C, 2000, J LEUKOCYTE BIOL, V67, P97, DOI 10.1002/jlb.67.1.97; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Dreschers S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09359-8; Ehrchen J, 2007, BLOOD, V109, P1265, DOI 10.1182/blood-2006-02-001115; Ehrchen JM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000871; Fabriek BO, 2007, BLOOD, V109, P5223, DOI 10.1182/blood-2006-08-036467; Fabriek BO, 2005, GLIA, V51, P297, DOI 10.1002/glia.20208; Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419; Guilliams M, 2018, IMMUNITY, V49, P595, DOI 10.1016/j.immuni.2018.10.005; Hagemeyer N, 2016, EMBO J, V35, P1730, DOI 10.15252/embj.201693801; Heming M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00893; Hogger P, 1998, J IMMUNOL, V161, P1883; Hume DA, 2008, MUCOSAL IMMUNOL, V1, P432, DOI 10.1038/mi.2008.36; Kneidl J, 2014, CELL MICROBIOL, V16, P364, DOI 10.1111/cmi.12225; Kneidl J, 2012, CELL MICROBIOL, V14, P914, DOI 10.1111/j.1462-5822.2012.01766.x; Lavin Y, 2015, NAT REV IMMUNOL, V15, P731, DOI 10.1038/nri3920; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; Mass E, 2016, SCIENCE, V353, DOI 10.1126/science.aaf4238; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nippe N, 2011, J INVEST DERMATOL, V131, P125, DOI 10.1038/jid.2010.282; Oesper L, 2011, SOURCE CODE BIOL MED, V6, DOI 10.1186/1751-0473-6-7; Perdiguero EG, 2015, NATURE, V518, P547, DOI 10.1038/nature13989; Petersen B, 2013, EMBO J, V32, P100, DOI 10.1038/emboj.2012.309; Philippidis P, 2004, CIRC RES, V94, P119, DOI 10.1161/01.RES.0000109414.78907.F9; Polfliet MMJ, 2006, IMMUNOBIOLOGY, V211, P419, DOI 10.1016/j.imbio.2006.05.015; Polfliet MMJ, 2002, J NEUROIMMUNOL, V122, P1, DOI 10.1016/S0165-5728(01)00445-3; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rothlin CV, 2015, ANNU REV IMMUNOL, V33, P355, DOI 10.1146/annurev-immunol-032414-112103; Schaer DJ, 2001, IMMUNOGENETICS, V53, P170, DOI 10.1007/s002510100304; Schonheit J, 2013, CELL REP, V3, P1617, DOI 10.1016/j.celrep.2013.04.007; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sulahian TH, 2000, CYTOKINE, V12, P1312, DOI 10.1006/cyto.2000.0720; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; Tuckermann JP, 2007, J CLIN INVEST, V117, P1381, DOI 10.1172/JCI28034; Ulas T, 2017, NAT IMMUNOL, V18, P622, DOI 10.1038/ni.3745; VERSCHURE PJ, 1989, SCAND J IMMUNOL, V29, P371, DOI 10.1111/j.1365-3083.1989.tb01136.x; Vogl T, 2018, J CLIN INVEST, V128, P1852, DOI 10.1172/JCI89867; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; ZWADLO G, 1987, EXP CELL BIOL, V55, P295	41	13	13	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2020	146	5					1137	1151		10.1016/j.jaci.2020.02.034	http://dx.doi.org/10.1016/j.jaci.2020.02.034			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OP5VH	32199911				2022-12-18	WOS:000588153700017
J	Rajput, C; Han, MY; Ishikawa, T; Lei, J; Jazaeri, S; Bentley, JK; Hershenson, MB				Rajput, Charu; Han, Mingyuan; Ishikawa, Tomoko; Lei, Jing; Jazaeri, Seyedehzarifeh; Bentley, J. Kelley; Hershenson, Marc B.			Early-life heterologous rhinovirus infections induce an exaggerated asthma-like phenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; childhood; early-life; IL-13; rhinovirus; RV-A1B; RV-A2; trained immunity; type 2 innate lymphoid cell; ILC2	INNATE LYMPHOID-CELLS; RESPIRATORY-SYNCYTIAL-VIRUS; AIRWAY INFLAMMATION; MUCOUS METAPLASIA; TYPE-2 IMMUNITY; T-CELLS; AGE; RISK; ALLERGY; HYPERRESPONSIVENESS	Background: Early-life wheezing-associated respiratory tract infection by rhinovirus (RV) is a risk factor for asthma development. Infants are infected with many different RV strains per year. Objective: We previously showed that RV infection of 6-day-old BALB/c mice induces a mucous metaplasia phenotype that is dependent on type 2 innate lymphoid cells (ILC2s). We hypothesized that early-life RV infection alters the response to subsequent heterologous infection, inducing an exaggerated asthma-like phenotype. Methods: Wild-type BALB/c mice and Rora(fl/fl)Il7r(cre) mice lacking ILC2s were treated as follows: (1) sham on day 6 of life plus sham on day 13 of life, (2) RV-A1B on day 6 plus sham on day 13, (3) sham on day 6 plus RV-A2 on day 13, and (4) RV-A1B on day 6 plus RV-A2 on day 13. Results: Mice infected with RV-A1B at day 6 and sham at day 13 showed an increased number of bronchoalveolar lavage eosinophils and increased expression of IL-13 mRNA but not expression of IFN-gamma mRNA (which is indicative of a type 2 immune response), whereas mice infected with sham on day 6 and RV-A2 on day 13 of life demonstrated increased IFN-gamma expression (which is a mature antiviral response). In contrast, mice infected with RV-A1B on day 6 before RV-A2 infection on day 13 showed increased expression of IL-13, IL-5, GobS, Muc5b, and Muc5ac mRNA; increased numbers of eosinophils and IL-13-producing ILC2s; and exaggerated mucus metaplasia and airway hyperresponsiveness. Compared with Rora(fl/fl) mice, Rora(fl/fl)Il7r(cre) mice showed complete suppression of bronchoalveolar lavage eosinophils and mucous metaplasia. Conclusion: Early-life RV infection alters the response to subsequent heterologous infection, inducing an intensified asthma-like phenotype that is dependent on ILC2s.	[Rajput, Charu; Han, Mingyuan; Ishikawa, Tomoko; Lei, Jing; Jazaeri, Seyedehzarifeh; Bentley, J. Kelley; Hershenson, Marc B.] Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI USA; [Hershenson, Marc B.] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hershenson, MB (corresponding author), Med Sci Res Bldg 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	mhershen@umich.edu	Han, Mingyuan/O-5065-2019	Han, Mingyuan/0000-0002-2970-6715	National Institutes of Health [R01 AI120526]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health (grant R01 AI120526 [to M.B.H.]).	Bouchery T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7970; Culley FJ, 2002, J EXP MED, V196, P1381, DOI 10.1084/jem.20020943; Dakhama A, 2005, J IMMUNOL, V175, P1876, DOI 10.4049/jimmunol.175.3.1876; Dowling DJ, 2014, TRENDS IMMUNOL, V35, P299, DOI 10.1016/j.it.2014.04.007; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; Halim TYF, 2018, IMMUNITY, V48, P1195, DOI 10.1016/j.immuni.2018.05.003; Halim TYF, 2016, NAT IMMUNOL, V17, P57, DOI 10.1038/ni.3294; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Han MY, 2017, J IMMUNOL, V199, P1308, DOI 10.4049/jimmunol.1700216; Han MY, 2017, AM J RESP CELL MOL, V56, P242, DOI 10.1165/rcmb.2016-0056OC; Hong JY, 2014, J ALLERGY CLIN IMMUN, V134, P429, DOI 10.1016/j.jaci.2014.04.020; Hong JY, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-63; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kim J, 2019, J ALLERGY CLIN IMMUN, V143, P1769, DOI 10.1016/j.jaci.2018.10.040; KleinJan A, 2014, J IMMUNOL, V192, P1385, DOI 10.4049/jimmunol.1301888; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Lee BH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035812; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lewin G, 2017, BIRTH DEFECTS RES, V109, P1519, DOI 10.1002/bdr2.1089; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; MINOR TE, 1974, INFECT IMMUN, V10, P1192, DOI 10.1128/IAI.10.5.1192-1193.1974; Moraes TJ, 2018, THORAX, V73, P105, DOI 10.1136/thoraxjnl-2017-211104; Newcomb DC, 2008, AM J RESP CRIT CARE, V177, P1111, DOI 10.1164/rccm.200708-1243OC; Nussbaum JC, 2013, NATURE, V502, P245, DOI 10.1038/nature12526; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Oliphant CJ, 2014, IMMUNITY, V41, P283, DOI 10.1016/j.immuni.2014.06.016; Pelly VS, 2016, MUCOSAL IMMUNOL, V9, P1407, DOI 10.1038/mi.2016.4; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P801, DOI 10.1016/j.jaci.2016.02.030; ROSENBAUM MJ, 1971, AM J EPIDEMIOL, V93, P183, DOI 10.1093/oxfordjournals.aje.a121245; Rubner FJ, 2017, J ALLERGY CLIN IMMUN, V139, P501, DOI 10.1016/j.jaci.2016.03.049; Schneider C, 2019, IMMUNITY, V50, P1425, DOI 10.1016/j.immuni.2019.04.019; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Tsai WC, 2004, AM J RESP CRIT CARE, V170, P1331, DOI 10.1164/rccm.200402-200OC; Tuthill TJ, 2003, J GEN VIROL, V84, P2829, DOI 10.1099/vir.0.19109-0; van Meel ER, 2018, THORAX, V73, P167, DOI 10.1136/thoraxjnl-2017-210149; Wolterink RGJK, 2013, P NATL ACAD SCI USA, V110, P10240, DOI 10.1073/pnas.1217158110; Yang ZM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068433	41	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2020	146	3					571	+		10.1016/j.jaci.2020.03.039	http://dx.doi.org/10.1016/j.jaci.2020.03.039			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NO0HS	32344055	Bronze, Green Accepted			2022-12-18	WOS:000569168900010
J	Talbot, S; Doyle, B; Huang, JW; Wang, JC; Ahmadi, M; Roberson, DP; Yekkirala, A; Foster, SL; Browne, LE; Bean, BP; Levy, BD; Woolf, CJ				Talbot, Sebastien; Doyle, Benjamin; Huang, Junwei; Wang, Jo-Chiao; Ahmadi, Maryam; Roberson, David P.; Yekkirala, Ajay; Foster, Simmie L.; Browne, Liam E.; Bean, Bruce P.; Levy, Bruce D.; Woolf, Clifford J.			Vagal sensory neurons drive mucous cell metaplasia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							AIRWAY; INFLAMMATION; MUCUS		[Talbot, Sebastien; Doyle, Benjamin; Huang, Junwei; Roberson, David P.; Yekkirala, Ajay; Foster, Simmie L.; Browne, Liam E.; Woolf, Clifford J.] Childrens Hosp Boston, FM Kirby Neurobiol Ctr, Boston, MA USA; [Talbot, Sebastien; Doyle, Benjamin; Huang, Junwei; Roberson, David P.; Yekkirala, Ajay; Foster, Simmie L.; Browne, Liam E.; Bean, Bruce P.; Woolf, Clifford J.] Harvard Med Sch, Dept Neurobiol, Boston, MA 02115 USA; [Wang, Jo-Chiao; Ahmadi, Maryam] Univ Montreal, Dept Pharmacol & Physiol, Montreal, PQ, Canada; [Browne, Liam E.] UCL, Wolfson Inst Biomed Res, London, England; [Levy, Bruce D.] Harvard Med Sch, Brigham & Womens Hosp, Dept Internal Med, Pulm & Crit Care Med Div, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Universite de Montreal; University of London; University College London; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Talbot, S (corresponding author), Childrens Hosp Boston, FM Kirby Neurobiol Ctr, Boston, MA USA.; Talbot, S (corresponding author), Harvard Med Sch, Dept Neurobiol, Boston, MA 02115 USA.	sebastien.talbot@umontreal.ca; clifford.woolf@childrens.harvard.edu		Browne, Liam/0000-0002-5693-7703	National Institute of Health [PO1NS072040, HL122531]; Canadian Institutes of Health Research [407016]; Canadian Foundation for Innovation [37439]; Canada Research Chair program [950-231859]; Natural Sciences and Engineering Research Council of Canada [RGPIN-2019-06824]; Brain Canada Foundation; Azrieli Foundation; European Commission fellowship [329202]; Wellcome Trust [109372/Z/15/Z]; Royal Society [109372/Z/15/Z]; Bastable-Potts Graduate research award from Asthma Canada; Canadian Allergy, Asthma and Immunology Foundation; Health Canada	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Innovation(Canada Foundation for Innovation); Canada Research Chair program(Canada Research Chairs); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Brain Canada Foundation; Azrieli Foundation; European Commission fellowship; Wellcome Trust(Wellcome Trust); Royal Society(Royal Society of London); Bastable-Potts Graduate research award from Asthma Canada; Canadian Allergy, Asthma and Immunology Foundation; Health Canada	This work was partially supported by the National Institute of Health (grants PO1NS072040 to C.J.W. and B.P.B. and HL122531 to B.D.L.); the Canadian Institutes of Health Research (S.T., 407016), the Canadian Foundation for Innovation (S.T., 37439), Canada Research Chair program (S.T., 950-231859), Natural Sciences and Engineering Research Council of Canada (S.T.; RGPIN-2019-06824) and the Brain Canada Foundation, Health Canada and the Azrieli Foundation (S.T.); and a European Commission fellowship (L.E.B.; 329202) and a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (L.E.B.; 109372/Z/15/Z). JCW received a Bastable-Potts Graduate research award from Asthma Canada and the Canadian Allergy, Asthma and Immunology Foundation.	Bando H, 2007, J NEUROSCI, V27, P4359, DOI 10.1523/JNEUROSCI.4131-06.2007; BARNES PJ, 1992, J ASTHMA, V29, P165, DOI 10.3109/02770909209099025; Binshtok AM, 2007, NATURE, V449, P607, DOI 10.1038/nature06191; Browne LE, 2017, CELL REP, V20, P89, DOI 10.1016/j.celrep.2017.06.024; Chang RB, 2015, CELL, V161, P622, DOI 10.1016/j.cell.2015.03.022; Chen G, 2019, J CLIN INVEST, V129, P4433, DOI 10.1172/JCI125669; Ehre C, 2012, P NATL ACAD SCI USA, V109, P16528, DOI 10.1073/pnas.1206552109; Evans CM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7281; Fahy JV, 2010, NEW ENGL J MED, V363, P2233, DOI 10.1056/NEJMra0910061; Gu WJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40398; Han S, 2019, CELL STEM CELL, V25, P342, DOI 10.1016/j.stem.2019.07.008; Haworth O, 2008, NAT IMMUNOL, V9, P873, DOI 10.1038/ni.1627; Herberth G, 2006, CLIN EXP ALLERGY, V36, P1408, DOI 10.1111/j.1365-2222.2006.02576.x; Ianowski JP, 2008, PFLUG ARCH EUR J PHY, V457, P529, DOI 10.1007/s00424-008-0527-0; Krause T, 2017, MABS-AUSTIN, V9, P333, DOI 10.1080/19420862.2016.1264551; Rogers DF, 2001, RESP PHYSIOL, V125, P129, DOI 10.1016/S0034-5687(00)00209-7; Roy MG, 2014, NATURE, V505, P412, DOI 10.1038/nature12807; Talbot S, 2015, NEURON, V87, P341, DOI 10.1016/j.neuron.2015.06.007; Talbot S, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-36; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; TOMAKI M, 1995, AM J RESP CRIT CARE, V151, P613; Voynow JA, 2009, CHEST, V135, P505, DOI 10.1378/chest.08-0412; Zhou Y, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819875168	23	13	13	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1693	+		10.1016/j.jaci.2020.01.003	http://dx.doi.org/10.1016/j.jaci.2020.01.003			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	31954778	Green Published, Green Accepted, Bronze			2022-12-18	WOS:000539157800026
J	Hoppe, A; Katsoulis-Dimitriou, K; Edler, HJ; Dudeck, J; Drube, S; Dudeck, A				Hoppe, Anja; Katsoulis-Dimitriou, Konstantinos; Edler, Hanna J.; Dudeck, Jan; Drube, Sebastian; Dudeck, Anne			Mast cells initiate the vascular response to contact allergens by sensing cell stress	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							T-CELLS; RECEPTOR; IL-33		[Hoppe, Anja] Tech Univ Dresden, Med Fac Carl Gustav Cams, Inst Immunol, Dresden, Germany; [Katsoulis-Dimitriou, Konstantinos; Edler, Hanna J.; Dudeck, Jan; Dudeck, Anne] Otto von Guericke Univ, Inst Mol & Clin Immunol, Med Fac, Magdeburg, Germany; [Dudeck, Jan; Dudeck, Anne] Otto von Guericke Univ, Hlth Campus Immunol Infectiol & Inflammat, Magdeburg, Germany; [Drube, Sebastian] Jena Univ Hosp, Inst Immunol, Jena, Germany	Technische Universitat Dresden; Otto von Guericke University; Otto von Guericke University; Friedrich Schiller University of Jena	Dudeck, A (corresponding author), Otto von Guericke Univ, Inst Mol & Clin Immunol, Med Fac, Magdeburg, Germany.; Dudeck, A (corresponding author), Otto von Guericke Univ, Hlth Campus Immunol Infectiol & Inflammat, Magdeburg, Germany.	anne.dudeck@med.ovgu.de	Dudeck, Anne/ABB-3498-2020	Dudeck, Anne/0000-0002-1311-9620	German Research Foundation (DFG) [DUl172/2, DUl172/3]; CRC854 [97850925, DR1 113/1-1]	German Research Foundation (DFG)(German Research Foundation (DFG)); CRC854	This work was supported by grants from the German Research Foundation (DFG; grant nos. DUl172/2 [Priority Program 1468], DUl172/3 [Priority Program 1394], and CRC854/A28N [Project-ID 97850925]) to A.D., and grant number DR1 113/1-1 to S.D.	Bruhs A, 2018, J INVEST DERMATOL, V138, P570, DOI 10.1016/j.jid.2017.09.032; Drube S, 2016, J IMMUNOL, V197, P3662, DOI 10.4049/jimmunol.1600658; Drube S, 2010, BLOOD, V115, P3899, DOI 10.1182/blood-2009-10-247411; Dudeck A, 2019, J ALLERGY CLIN IMMUN, V144, pS4, DOI 10.1016/j.jaci.2018.10.054; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Dudeck A, 2011, EUR J IMMUNOL, V41, P1883, DOI 10.1002/eji.201040994; Dudeck J, 2019, J ALLERGY CLIN IMMUN, V143, P1849, DOI 10.1016/j.jaci.2018.08.052; Dudeck J, 2015, CELL REP, V13, P399, DOI 10.1016/j.celrep.2015.08.078; Fu AKY, 2016, P NATL ACAD SCI USA, V113, pE2705, DOI 10.1073/pnas.1604032113; Imai Y, 2014, J DERMATOL SCI, V74, P159, DOI 10.1016/j.jdermsci.2014.01.009; Martin SF, 2008, J EXP MED, V205, P2151, DOI 10.1084/jem.20070509; Renert Yuval Y, 2020, ANN ALLERG ASTHMA IM, V124, P28; Savinko T, 2012, J INVEST DERMATOL, V132, P1392, DOI 10.1038/jid.2011.446; Scholten J, 2008, TRANSGENIC RES, V17, P307, DOI 10.1007/s11248-007-9153-4; Stachon P, 2017, CIRCULATION, V135, P2524, DOI 10.1161/CIRCULATIONAHA.117.027400; Voehringer D, 2008, J IMMUNOL, V180, P4742, DOI 10.4049/jimmunol.180.7.4742; Weber FC, 2010, J EXP MED, V207, P2609, DOI 10.1084/jem.20092489	17	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2020	145	5					1476	+		10.1016/j.jaci.2020.01.036	http://dx.doi.org/10.1016/j.jaci.2020.01.036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LK7TB	32018029	hybrid			2022-12-18	WOS:000531063400022
J	Su, KW; Patil, SU; Stockbridge, JL; Martin, VM; Virkud, YV; Huang, JL; Shreffler, WG; Yuan, Q				Su, Kuan-Wen; Patil, Sarita U.; Stockbridge, Jennifer L.; Martin, Victoria M.; Virkud, Yamini V.; Huang, Jing-Long; Shreffler, Wayne G.; Yuan, Qian			Food aversion and poor weight gain in food protein-induced enterocolitis syndrome: A retrospective study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food protein-induced enterocolitis syndrome; food aversion; poor body weight gain	ALLERGY; PREVALENCE; MANAGEMENT; DIAGNOSIS; DISEASE	Background: Food protein-induced enterocolitis syndrome (FPIES) is a form of non-IgE-mediated gastrointestinal food allergy. Insufficient data exist in regard to gastrointestinal history and outcome, particularly comorbidity, family history, food aversion, and poor body weight gain. Objective: We sought to identify the gastrointestinal outcomes and related risk factors in FPIES. Methods: We analyzed the clinical features and gastrointestinal outcomes of patients with FPIES retrospectively at 4 hospitals in Boston. Results: Two hundred three patients with FPIES were identified, including 180 only with acute FPIES, 8 with chronic FPIES, and 15 with both. Oat (34.5%), rice (29.6%), and cow's milk (19.2%) were the most common food triggers. The prevalence rates of personal history with allergic proctocolitis (23.2%) and family history with inflammatory bowel diseases (9.4%) and celiac disease (7.3%) were higher than those in the general population. Compared with patients with FPIES with 1 or 2 food triggers, the risk of developing food aversion increased in cases triggered by 3 or more foods (adjusted odds ratio, 3.07; 95% CI, 1.38-6.82; P = .006). The risk of poor body weight gain increased in FPIES triggered by cow's milk (adjusted odds ratio, 3.41; 95% CI, 1.21-9.63; P = .02) and banana (adjusted odds ratio, 7.63; 95% CI, 2.10-27.80; P = .002). Conclusions: Gastrointestinal comorbidities and family history were common in patients with FPIES. Patients with FPIES with 3 or more triggers were at risk of food aversion. Patients with FPIES with cow's milk and banana as triggers were at risk of poor body weight gain.	[Su, Kuan-Wen; Patil, Sarita U.; Stockbridge, Jennifer L.; Martin, Victoria M.; Virkud, Yamini V.; Shreffler, Wayne G.; Yuan, Qian] Massachusetts Gen Hosp, Food Allergy Ctr, Boston, MA 02114 USA; [Su, Kuan-Wen; Patil, Sarita U.; Stockbridge, Jennifer L.; Virkud, Yamini V.; Shreffler, Wayne G.] Massachusetts Gen Hosp, Div Pediat Allergy & Immunol, Boston, MA 02114 USA; [Su, Kuan-Wen] Keelung Chang Gung Mem Hosp, Dept Pediat, Keelung, Taiwan; [Su, Kuan-Wen] Chang Gung Univ, Grad Inst Clin Med Sci, Taoyuan, Taiwan; [Patil, Sarita U.; Martin, Victoria M.; Virkud, Yamini V.; Shreffler, Wayne G.; Yuan, Qian] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Patil, Sarita U.; Virkud, Yamini V.; Shreffler, Wayne G.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Martin, Victoria M.; Yuan, Qian] Massachusetts Gen Hosp, Div Pediat Gastroenterol Hepatol & Nutr, Boston, MA 02114 USA; [Huang, Jing-Long] Chang Gung Mem Hosp, Dept Pediat, Div Allergy Asthma & Rheumatol, Taoyuan, Taiwan; [Huang, Jing-Long] Chang Gung Univ, Coll Med, Taoyuan, Taiwan	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Chang Gung Memorial Hospital; Chang Gung University; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Chang Gung Memorial Hospital; Chang Gung University	Yuan, Q (corresponding author), Massachusetts Gen Hosp, Food Allergy Ctr, 55 Fruit St,CPZS 553, Boston, MA 02114 USA.; Yuan, Q (corresponding author), Massachusetts Gen Hosp, Div Pediat Gastroenterol Hepatol & Nutr, 55 Fruit St,CPZS 553, Boston, MA 02114 USA.; Huang, JL (corresponding author), 5 Fu Hsin St, Taoyuan 333, Taiwan.	long@adm.cgmh.org.tw; qyuan@mgh.harvard.edu		Su, Kuan-Wen/0000-0001-8841-0108; Huang, Jing-Long/0000-0002-3530-7753; Martin, Victoria/0000-0002-4322-9564	Demarest Lloyd Jr Foundation [230465]; Food Allergy Science Initiative [229711]; Chang Gung Memorial Hospital; Ministry of Science and Technology, Taiwan [107-2917-I-182-001]; National Institutes of Health, National Institute of Allergy and Infectious Diseases [K23AI121491, K23AI130408]	Demarest Lloyd Jr Foundation; Food Allergy Science Initiative; Chang Gung Memorial Hospital(Chang Gung Memorial Hospital); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); National Institutes of Health, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the Demarest Lloyd Jr Foundation (grant no. 230465) and the Food Allergy Science Initiative (grant no. 229711). K.W.S. was supported by grants from Chang Gung Memorial Hospital and from the Ministry of Science and Technology, Taiwan (grant no. 107-2917-I-182-001). S.U.P. and Y.V.V. were supported by the National Institutes of Health, National Institute of Allergy and Infectious Diseases (grant no. K23AI121491 to S.U.P. and grant no. K23AI130408 to Y.V.V.).	Blackman AC, 2019, ANN ALLERG ASTHMA IM, V122, P407, DOI 10.1016/j.anai.2019.01.022; Caubet JC, 2014, J ALLERGY CLIN IMMUN, V134, P382, DOI 10.1016/j.jaci.2014.04.008; Du Y, 2018, ANN ALLERG ASTHMA IM, V121, P736; Elizur A, 2012, PEDIAT ALLERG IMM-UK, V23, P766, DOI 10.1111/pai.12009; Fasano A, 2003, ARCH INTERN MED, V163, P286, DOI 10.1001/archinte.163.3.286; Fiocchi A, 2010, J ALLERGY CLIN IMMUN, V126, P1119, DOI 10.1016/j.jaci.2010.10.011; Ji Q, 2013, INT J DEV BIOL, V57, P495, DOI 10.1387/ijdb.130244kw; Mehr S, 2017, J ALLERGY CLIN IMMUN, V140, P1323, DOI 10.1016/j.jaci.2017.03.027; Mehr S, 2009, PEDIATRICS, V123, pe459, DOI 10.1542/peds.2008-2029; Ng SC, 2017, LANCET, V390, P2769, DOI 10.1016/S0140-6736(17)32448-0; Noimark L, 2008, PEDIAT ALLERG IMM-UK, V19, P188, DOI 10.1111/j.1399-3038.2007.00700.x; Nowak-Wegrzyn A, 2017, J ALLERGY CLIN IMMUN, V139, P1111, DOI 10.1016/j.jaci.2016.12.966; Ruffner MA, 2013, J ALLER CL IMM-PRACT, V1, P343, DOI 10.1016/j.jaip.2013.05.011; Su KW, 2019, J ALLERGY CLIN IMMUN, V143, pAB157, DOI 10.1016/j.jaci.2018.12.477; Tan JA, 2014, J ALLER CL IMM-PRACT, V2, P355, DOI 10.1016/j.jaip.2014.02.002; Venter C, 2014, CURR OPIN ALLERGY CL, V14, P255, DOI 10.1097/ACI.0000000000000054; Wei T., 2021, R PACKAGECORRPLOTVIS	17	13	13	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2020	145	5					1430	+		10.1016/j.jaci.2020.01.001	http://dx.doi.org/10.1016/j.jaci.2020.01.001			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LK7TB	31940468	Green Accepted, Bronze			2022-12-18	WOS:000531063400015
J	Westman, M; Aberg, K; Apostolovic, D; Lupinek, C; Gattinger, P; Mittermann, I; Andersson, N; Melen, E; Bergstrom, A; Anto, JM; Bousquet, J; Valenta, R; Wickman, M; van Hage, M				Westman, Marit; Aberg, Karin; Apostolovic, Danijela; Lupinek, Christian; Gattinger, Pia; Mittermann, Irene; Andersson, Niklas; Melen, Erik; Bergstrom, Anna; Anto, Josep M.; Bousquet, Jean; Valenta, Rudolf; Wickman, Magnus; van Hage, Marianne		Mechanisms Dev Allergies MeDALL	Sensitization to grass pollen allergen molecules in a birth cohort-natural Phl p 4 as an early indicator of grass pollen allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen molecules; allergic rhinitis; BAMSE; grass pollen; cohort; IgE; MeDALL; microarray; Phl p 4	IMMUNOLOGICAL CHARACTERIZATION; IGE SENSITIZATION; PRATENSE; PROFILES; RHINITIS; CHILDHOOD; EVOLUTION; IMMUNOTHERAPY; PREVALENCE; REACTIVITY	Background: Grass pollen allergy is one of the most common allergies worldwide. Objective: The aim of this study was to evaluate the usefulness of grass pollen allergen molecules for prediction of grass pollen allergy during childhood and up to adolescence. Method: Questionnaire data and sera obtained from the study subjects at the ages of 4, 8, and 16 years from the population-based Barn/Children Allergy Milieu Stockholm Epidemiology birth cohort were used. Sera from 763 representative subjects with serum samples available at all 3 ages were analyzed for IgE reactivity to 8 Phleum pratense (Phl p) allergens (MeDALL [Mechanisms for the Development of Allergies] chip) and to timothy grass extract (ImmunoCAP). Allergic rhinitis to grass pollen (ARg) was defined as upper airway symptoms during grass pollen exposure. Results: The prevalence of sensitization to any Phl p molecule was higher compared with that to timothy extract at all 3 ages: at the age of 4 years, 9.7% versus 6.8%; at the age of 8 years, 28.4% versus 15.3%; and at the age of 16 years, 37.1% versus 27.1%. General estimating equations analyses revealed that among children sensitized at the age of 4 years, the overall odds ratio (OR) of later ARg (up to 16 years) was increased only for IgE reactivity to Phl p 1 (OR = 4.9) and natural Phl p 4 (OR = 6.9). The likelihood of later symptoms increased with the number of allergen molecules; at the age of 4 years, 2 or more molecules predicted ARg to 78% and 3 or more molecules predicted ARg to 95%. A positive test result for timothy extract predicted ARg to 70%. Conclusions: Natural Phl p 4 is a hitherto unrecognized early indicator of grass pollen allergy, in addition to Phl p 1. To identify grass pollen sensitization and predict later ARg, allergen molecules are of added value to timothy extract alone and may help clinicians improve prediction of grass pollen allergy.	[Westman, Marit; Apostolovic, Danijela; van Hage, Marianne] Karolinska Inst, Dept Med Solna, Immunol & Allergy Unit, Stockholm, Sweden; [Westman, Marit; Apostolovic, Danijela; van Hage, Marianne] Univ Hosp, Stockholm, Sweden; [Westman, Marit; Aberg, Karin] Karolinska Univ Hosp, Dept Ear Nose & Throat Dis, Stockholm, Sweden; [Aberg, Karin] Karolinska Inst, Div Ear Nose & Throat Dis, Dept Clin Sci Intervent & Technol, Stockholm, Sweden; [Lupinek, Christian; Gattinger, Pia; Mittermann, Irene; Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria; [Andersson, Niklas; Melen, Erik; Bergstrom, Anna; Wickman, Magnus] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Melen, Erik] Sachs Childrens Hosp, Stockholm, Sweden; [Melen, Erik] Soder Sjukhuset, Dept Clin Sci & Educ, Stockholm, Sweden; [Bergstrom, Anna] Ctr Occupat & Environm Med, Stockholm, Region Stockhol, Sweden; [Anto, Josep M.] Ctr Res Environm Epidemiol, Barcelona, Spain; [Anto, Josep M.] Hosp del Mar Res Inst, Barcelona, Spain; [Anto, Josep M.] Univ Pompeu Fabra, Barcelona, Spain; [Anto, Josep M.] CIBER Epidemiol & Salud Publ, Barcelona, Spain; [Bousquet, Jean] Univ Hosp Montpellier, Hop Arnaud Villeneuve, Inst Natl Sante & Rech Med 1018, Villejuif, France; [Valenta, Rudolf] Fed Med Biol Agcy Russia, Natl Res Ctr Inst Immunol, Moscow, Russia; [Valenta, Rudolf] Sechenov First Moscow State Med Univ, Dept Clin Immunol & Allergy, Lab Immunopathol, Moscow, Russia	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Medical University of Vienna; Karolinska Institutet; Sodersjukhuset Hospital; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; NRC Institute of Immunology FMBA of Russia; Sechenov First Moscow State Medical University	Westman, M (corresponding author), Astma & Allergimottagningen St Gorans Sjukhus, S-11281 Stockholm, Sweden.	marit.westman@ki.se	Apostolovic, Danijela/J-6089-2019; Lupinek, Christian/I-3311-2019; Andersson, Niklas/AAN-1633-2020; Anto, J M/H-2676-2014	Apostolovic, Danijela/0000-0001-8388-6916; Lupinek, Christian/0000-0002-8612-8245; Andersson, Niklas/0000-0001-9785-7462; Anto, J M/0000-0002-4736-8529; Westman, Marit/0000-0003-0041-4249; Bousquet, Jean/0000-0002-4061-4766; Gattinger, Pia/0000-0001-6724-8543; Valenta, Rudolf/0000-0001-5944-3365	Acta Oto-Laryngologica Foundation; Stockholm County Council; Swedish Asthma and Allergy Research Foundation; Swedish Heart-Lung Foundation; Swedish Research Council; European Commissions Seventh Framework 29 Program MeDALL [261357]	Acta Oto-Laryngologica Foundation; Stockholm County Council(Stockholm County Council); Swedish Asthma and Allergy Research Foundation; Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission); European Commissions Seventh Framework 29 Program MeDALL	Supported by the Acta Oto-Laryngologica Foundation, the Stockholm County Council, the Swedish Asthma and Allergy Research Foundation, the Swedish Heart-Lung Foundation, the Swedish Research Council, and the European Commissions Seventh Framework 29 Program MeDALL under grant agreement No. 261357.	Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Asarnoj A, 2016, J ALLERGY CLIN IMMUN, V137, P813, DOI 10.1016/j.jaci.2015.09.052; Beitia JM, 2014, INT ARCH ALLERGY IMM, V165, P9, DOI 10.1159/000365866; Bodtger U, 2006, ALLERGY, V61, P712, DOI 10.1111/j.1398-9995.2006.01140.x; Bousquet PJ, 2007, ALLERGY, V62, P301, DOI 10.1111/j.1398-9995.2006.01293.x; Cabauatan CR, 2014, J ALLERGY CLIN IMMUN, V133, P910, DOI 10.1016/j.jaci.2013.10.004; Cipriani F, 2018, ALLERGY, V73, P673, DOI 10.1111/all.13338; Custovic A, 2015, J ALLERGY CLIN IMMUN, V136, P1645, DOI 10.1016/j.jaci.2015.03.041; Darsow U, 2014, CLIN EXP ALLERGY, V44, P778, DOI 10.1111/cea.12303; DeWitt AM, 2002, CLIN EXP ALLERGY, V32, P1329, DOI 10.1046/j.1365-2222.2002.01467.x; Gangl K, 2013, CLIN EXP ALLERGY, V43, P1202, DOI 10.1111/cea.12128; Gattinger P, 2019, EBIOMEDICINE, V39, P33, DOI 10.1016/j.ebiom.2018.12.002; Gobl C, 2017, J ALLERGY CLIN IMMUN, V140, P1187, DOI 10.1016/j.jaci.2017.05.005; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; Kilpelainen M, 2001, ALLERGY, V56, P377, DOI 10.1034/j.1398-9995.2001.056005377.x; Laffer S, 1996, J ALLERGY CLIN IMMUN, V98, P652, DOI 10.1016/S0091-6749(96)70099-4; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Mari A, 2003, CLIN EXP ALLERGY, V33, P43, DOI 10.1046/j.1365-2222.2003.01569.x; Matricardi PM, 2016, PEDIAT ALLERG IMM-UK, V27, P1, DOI 10.1111/pai.12563; Micallef L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101717; Panzner P, 2014, INT ARCH ALLERGY IMM, V164, P74, DOI 10.1159/000362760; Scala E, 2010, CLIN EXP ALLERGY, V40, P911, DOI 10.1111/j.1365-2222.2010.03470.x; Scaparrotta A, 2013, MULTIDISCIP RESP MED, V8, DOI 10.1186/2049-6958-8-17; Stemeseder T, 2017, ALLERGY, V72, P754, DOI 10.1111/all.13071; Tillander H, 2014, J ALLERGY CLIN IMMUN, V133, P580, DOI 10.1016/j.jaci.2013.09.009; Tripodi S, 2012, J ALLERGY CLIN IMMUN, V129, P834, DOI 10.1016/j.jaci.2011.10.045; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Westman M, 2017, SEMIN IMMUNOL, V30, P61, DOI 10.1016/j.smim.2017.07.005; Westman M, 2015, J ALLERGY CLIN IMMUN, V135, P1199, DOI 10.1016/j.jaci.2014.10.042; Westman M, 2012, J ALLERGY CLIN IMMUN, V129, P403, DOI 10.1016/j.jaci.2011.09.036; Westritschnig K, 2008, EUR J CLIN INVEST, V38, P260, DOI 10.1111/j.1365-2362.2008.01938.x; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Zafred D, 2013, J ALLERGY CLIN IMMUN, V132, P696, DOI 10.1016/j.jaci.2013.03.021	33	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2020	145	4					1174	+		10.1016/j.jaci.2020.01.006	http://dx.doi.org/10.1016/j.jaci.2020.01.006			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LA0FR	31954777	Bronze			2022-12-18	WOS:000523633400014
J	Messinger, AI; Luo, G; Deterding, RR				Messinger, Amanda I.; Luo, Gang; Deterding, Robin R.			The doctor will see you now: How machine learning and artificial intelligence can extend our understanding and treatment of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; machine learning; artificial intelligence; digital health			[Messinger, Amanda I.; Deterding, Robin R.] Univ Colorado, Sch Med, Childrens Hosp Colorado, Dept Pediat,Breathing Inst, Aurora, CO USA; [Luo, Gang] Univ Washington, Dept Biomed Informat & Med Educ, Seattle, WA 98195 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Washington; University of Washington Seattle	Messinger, AI (corresponding author), Childrens Hosp Colorado, 13123,East 16th Ave,Box 395, Aurora, CO 80045 USA.	amanda.messinger@childrenscolorado.org			National Heart, Lung, and Blood Institute (NHLBI) [2T32HL007670-26]; NHLBI of the NIH [R01HL142503]	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	A. I. Messinger was funded by the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI) (Abman T-32 training grant no. 2T32HL007670-26). G. Luo was partially supported by the NHLBI of the NIH (award no. R01HL142503). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. R. R. Deterding is cofounder and board member of Triple Endoscopy, Inc (Patent Nasal Endoscopy Scope); is on the Pediatric Interstitial Lung Disease Advisory Board for Boehringer Ingelheim; is cofounder and board member of Now Vitals, Inc; has the patents (1) Computing Systems for Determining Vital Information and (2) Personalized Health CareWearable Sensor System; and receives support from Colorado Advanced Industries Accelerator (AIA).	Buhl R, 2016, RESP MED, V115, P7, DOI 10.1016/j.rmed.2016.04.001; Finkelstein J, 2017, ANN NY ACAD SCI, V1387, P153, DOI 10.1111/nyas.13218; Haider S., 2019, EMJ, V3, P82; Luo G, 2020, JMIR MED INF, V8, P79, DOI 10.2196/16080; Mohktar MS, 2015, ARTIF INTELL MED, V63, P51, DOI 10.1016/j.artmed.2014.12.003; Rajkomar A, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0029-1; Ram S, 2015, IEEE J BIOMED HEALTH, V19, P1216, DOI 10.1109/JBHI.2015.2404829; Saglani S, 2019, AM J RESP CRIT CARE, V199, P414, DOI 10.1164/rccm.201810-1956CI; Slob EM, 2019, CURR OPIN ALLERGY CL, V19, P141, DOI 10.1097/ACI.0000000000000517; Szefler SJ, 2018, J ALLERGY CLIN IMMUN, V142, P773, DOI 10.1016/j.jaci.2018.03.010	10	13	14	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2020	145	2					476	478		10.1016/j.jaci.2019.12.898	http://dx.doi.org/10.1016/j.jaci.2019.12.898			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK6ZG	31883444	Green Accepted, Bronze			2022-12-18	WOS:000512887400004
J	Wu, QW; Chen, JN; Deng, HY; Ren, Y; Sun, YQ; Wang, WH; Yuan, LX; Hong, HY; Zheng, R; Kong, WF; Huang, XK; Huang, GF; Wang, LJ; Zhang, YN; Han, LQ; Yang, QT				Wu, Qingwu; Chen, Jianning; Deng, Huiyi; Ren, Yong; Sun, Yueqi; Wang, Weihao; Yuan, Lianxiong; Hong, Haiyu; Zheng, Rui; Kong, Weifeng; Huang, Xuekun; Huang, Guifang; Wang, Lunji; Zhang, Yana; Han, Lanqing; Yang, Qintai			Expert-level diagnosis of nasal polyps using deep learning on whole-slide imaging	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHRONIC RHINOSINUSITIS		[Wu, Qingwu; Deng, Huiyi; Wang, Weihao; Zheng, Rui; Kong, Weifeng; Huang, Xuekun; Yang, Qintai] Sun Yat Sen Univ, Dept Otorhinolaryngol Head & Neck Surg, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China; [Chen, Jianning] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Ren, Yong; Huang, Guifang; Wang, Lunji; Han, Lanqing] Res Inst Tsinghua, Artificial Intelligence Innovat Ctr, Guangzhou, Guangdong, Peoples R China; [Sun, Yueqi] Sun Yat Sen Univ, Otorhinolaryngol Hosp, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Yuan, Lianxiong] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Sci & Res, Guangzhou, Guangdong, Peoples R China; [Hong, Haiyu] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Otolaryngol Head & Neck Surg, Zhuhai, Peoples R China; [Zhang, Yana] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Northwestern University; Feinberg School of Medicine	Han, LQ (corresponding author), Res Inst Tsinghua, Artificial Intelligence Innovat Ctr, Guangzhou, Guangdong, Peoples R China.	hanlance@tsinghua-gd.org; yang.qt@163.com	Wu, Qingwu/AAQ-4190-2020; ren, yong/GQP-8426-2022	Wu, Qingwu/0000-0003-0943-2558; Yang, Qintai/0000-0003-3377-737X	National Natural Science Foundation of China [81670912, 81870704]; Industry-Academic Cooperation Foundation of Guangzhou [201704030046]; Sun Yat-sen University Clinical Research 5010 Program [2019006]; Third Affiliated Hospital of Sun Yat-Sen University, Clinical Research Program [QHJH201901]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Industry-Academic Cooperation Foundation of Guangzhou; Sun Yat-sen University Clinical Research 5010 Program; Third Affiliated Hospital of Sun Yat-Sen University, Clinical Research Program	This work was supported by the National Natural Science Foundation of China (grants 81670912 and 81870704), the Industry-Academic Cooperation Foundation of Guangzhou (grant 201704030046), Sun Yat-sen University Clinical Research 5010 Program (grant 2019006), and The Third Affiliated Hospital of Sun Yat-Sen University, Clinical Research Program (grant QHJH201901).	Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Ikeda K, 2013, LARYNGOSCOPE, V123, pE1, DOI 10.1002/lary.24154; Lin HT, 2019, ECLINICALMEDICINE, V9, P52, DOI 10.1016/j.eclinm.2019.03.001; Long EP, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551-016-0024; Luo HY, 2019, LANCET ONCOL, V20, P1645, DOI 10.1016/S1470-2045(19)30637-0; Mahdavinia M, 2015, J ALLERGY CLIN IMMUN, V135, P576, DOI 10.1016/j.jaci.2014.08.031; Snidvongs K, 2012, INT FORUM ALLERGY RH, V2, P376, DOI 10.1002/alr.21032; Wen WP, 2012, J ALLERGY CLIN IMMUN, V129, P1522, DOI 10.1016/j.jaci.2012.01.079	9	13	18	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2020	145	2					698	+		10.1016/j.jaci.2019.12.002	http://dx.doi.org/10.1016/j.jaci.2019.12.002			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK6ZG	31830490	Bronze			2022-12-18	WOS:000512887400030
J	Bertelsen, T; Ljungberg, C; Litman, T; Huppertz, C; Hennze, R; Ronholt, K; Iversen, L; Johansen, C				Bertelsen, Trine; Ljungberg, Christine; Litman, Thomas; Huppertz, Christine; Hennze, Robert; Ronholt, Kirsten; Iversen, Lars; Johansen, Claus			I kappa B zeta is a key player in the antipsoriatic effects of secukinumab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Secukinumab; psoriasis; IL-17A; NFKBIZ; I kappa B zeta; keratinocytes; c-Jun; NF-kappa B activator 1; p38 mitogen-activated protein kinase; nuclear factor kappa B	PSORIASIS; GENES; RECEPTOR; PROTEIN; SKIN; EXPRESSION; IL-17; PATHOGENESIS; BRODALUMAB; INDUCTION	Background: I kappa B zeta plays a key role in psoriasis by mediating IL-17A-driven effects, but the molecular mechanism by which IL-17A regulates I kappa B zeta expression is not clarified. Objective: We sought to explore the molecular transformation in patients with psoriasis during anti-IL-17A (secukinumab) treatment with a focus on I kappa B zeta. Methods: The study was an open-label, single-arm, single-center secukinumab treatment study that included 14 patients with plaque psoriasis. Skin biopsy specimens and blood samples were collected on days 0, 4,14, 42, and 84 and processed for microarray gene expression analysis. Furthermore, in vitro experiments with human keratinocytes and synovial fibroblasts were conducted. Results: Secukinumab improved clinical scores and histologic psoriasis features. Moreover, secukinumab altered the skin transcriptome. The major transcriptional shift appeared between day 14 and day 42 after treatment initiation, although 80 genes were differentially expressed already at day 4. Expression of nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor (I kappa B) zeta (NFKBIZ, the gene encoding I kappa B zeta) was reduced already after 4 days of treatment in the skin. NFKBIZ expression correlated to Psoriasis Area and Severity Index score, and NFKBIZ mRNA levels in the skin decreased during anti-IL-17A treatment. Moreover, specific NFKBIZ signature genes were significantly altered during antiIL-17A treatment. Finally, we identified NF-kappa B activator 1 (Act1), p38 mitogen-activated protein kinase (MAPK), Jun NH2-terminal kinase (JNK), and nuclear factor kappa-light- chain-enhancer of activated B cells (NF-kappa B) as key signaling pathways in NFKBIZ/I kappa B zeta regulation. Conclusion: Our results define a crucial role for I kappa B zeta in the antipsoriatic effect of secukinumab. Because I kappa B zeta signature genes were regulated already after 4 days of treatment, this strongly indicates that I kappa B zeta plays a crucial role in the antipsoriatic effects mediated by anti-IL-17A treatment.	[Bertelsen, Trine; Ljungberg, Christine; Ronholt, Kirsten; Iversen, Lars; Johansen, Claus] Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark; [Litman, Thomas] Univ Copenhagen, Dept Immunol & Microbiol, Copenhagen, Denmark; [Huppertz, Christine; Hennze, Robert] Novartis Pharma AG, Novartis Inst BioMed Res, Basel, Switzerland	Aarhus University; University of Copenhagen; Novartis	Bertelsen, T (corresponding author), Palle Juul Jensen Blvd 9, DK-8200 Aarhus N, Denmark.	bertelsen.trine@gmail.com		Johansen, Claus/0000-0002-5665-5212; Bertelsen, Trine/0000-0002-4777-1991; Iversen, Lars/0000-0003-1816-4508; Litman, Thomas/0000-0002-6068-901X	Novartis; Danish Psoriasis Research Society; A.P. Moeller Foundation; Aage Bang foundation; Wehnerts Foundation	Novartis(Novartis); Danish Psoriasis Research Society; A.P. Moeller Foundation; Aage Bang foundation; Wehnerts Foundation	Supported by Novartis, the Danish Psoriasis Research Society, the A.P. Moeller Foundation, the Aage Bang foundation, and the Wehnerts Foundation.	Bertelsen T, 2018, EXP DERMATOL, V27, P1048, DOI 10.1111/exd.13722; Bertelsen T, 2017, EXP DERMATOL, V26, P234, DOI 10.1111/exd.13182; Bowcock AM, 2005, NAT REV IMMUNOL, V5, P699, DOI 10.1038/nri1689; Capon F, 2007, HUM GENET, V122, P201, DOI 10.1007/s00439-007-0397-0; Chang SH, 2006, J BIOL CHEM, V281, P35603, DOI 10.1074/jbc.C600256200; Chapman A, 2017, COMORBIDITY RHEUM DI, V7, P81; Chen Y, 2011, MOL VIS, V17, P3072; Chyou S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032828; Coimbra S, 2012, INT J DERMATOL, V51, P389, DOI 10.1111/j.1365-4632.2011.05154.x; Gaffen SL, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa8398; Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707; Johansen C, 2005, BRIT J DERMATOL, V152, P37, DOI 10.1111/J.1365-2133.2004.06304.X; Johansen C, 2009, BRIT J DERMATOL, V160, P319, DOI 10.1111/j.1365-2133.2008.08902.x; Johansen C, 2015, P NATL ACAD SCI USA, V112, pE5825, DOI 10.1073/pnas.1509971112; Kim J, 2015, DERMATOL CLIN, V33, P13, DOI 10.1016/j.det.2014.09.002; Kitamura H, 2000, FEBS LETT, V485, P53, DOI 10.1016/S0014-5793(00)02185-2; Kolbinger F, 2017, J ALLERGY CLIN IMMUN, V139, P923, DOI 10.1016/j.jaci.2016.06.038; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Krueger JG, 2019, J ALLERGY CLIN IMMUN, V144, P750, DOI 10.1016/j.jaci.2019.04.029; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Liu CN, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000382; Loesche C, 2016, ADV PRECIS MED, V1, P66; Lowes MA, 2008, J INVEST DERMATOL, V128, P1207, DOI 10.1038/sj.jid.5701213; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Martin DA, 2013, J INVEST DERMATOL, V133, P17, DOI 10.1038/jid.2012.194; Muller A, 2018, P NATL ACAD SCI USA, V115, P10088, DOI 10.1073/pnas.1801377115; Muromoto R, 2016, INT IMMUNOL, V28, P443, DOI 10.1093/intimm/dxw011; Papp KA, 2016, BRIT J DERMATOL, V175, P273, DOI 10.1111/bjd.14493; Pasquali L, 2019, ACTA DERM-VENEREOL, V99, P196, DOI 10.2340/00015555-3066; Qian YC, 2007, NAT IMMUNOL, V8, P247, DOI 10.1038/ni1439; Reich K, 2015, EXP DERMATOL, V24, P529, DOI 10.1111/exd.12710; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Russell CB, 2014, J IMMUNOL, V192, P3828, DOI 10.4049/jimmunol.1301737; Shirley M, 2016, DRUGS, V76, P1135, DOI 10.1007/s40265-016-0602-3; Smale ST, 2011, NAT IMMUNOL, V12, P689, DOI 10.1038/ni.2070; Sylvester J, 2004, CELL SIGNAL, V16, P469, DOI 10.1016/j.cellsig.2003.09.008; Toy D, 2006, J IMMUNOL, V177, P36, DOI 10.4049/jimmunol.177.1.36; Tsoi LC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8001; Visvanathan S, 2019, J ALLERGY CLIN IMMUN, V143, P2158, DOI 10.1016/j.jaci.2018.11.042; Wang CQF, 2014, J INVEST DERMATOL, V134, P2990, DOI 10.1038/jid.2014.268; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; Yamazaki S, 2005, J BIOL CHEM, V280, P1678, DOI 10.1074/jbc.M409983200; Zaba LC, 2009, J ALLERGY CLIN IMMUN, V124, P1022, DOI 10.1016/j.jaci.2009.08.046; Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963	44	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					379	390		10.1016/j.jaci.2019.09.029	http://dx.doi.org/10.1016/j.jaci.2019.09.029			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31622687	Green Published, hybrid			2022-12-18	WOS:000505590800041
J	Cavagnero, KJ; Badrani, JH; Naji, LH; Amadeo, MB; Shah, VS; Gasparian, S; Pham, A; Wang, AW; Seumois, G; Croft, M; Broide, DH; Doherty, TA				Cavagnero, Kellen J.; Badrani, Jana H.; Naji, Luay H.; Amadeo, Michael B.; Shah, Veranca S.; Gasparian, Suzanna; Alexa Pham; Wang, Alice W.; Seumois, Gregory; Croft, Michael; Broide, David H.; Doherty, Taylor A.			Unconventional ST2-and CD127-negative lung ILC2 populations are induced by the fungal allergen Alternaria alternata	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							LYMPHOID-CELLS; INFLAMMATION		[Cavagnero, Kellen J.; Badrani, Jana H.; Naji, Luay H.; Amadeo, Michael B.; Shah, Veranca S.; Gasparian, Suzanna; Alexa Pham; Croft, Michael; Broide, David H.; Doherty, Taylor A.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Wang, Alice W.; Seumois, Gregory; Croft, Michael] La Jolla Inst Allergy & Immunol, La Jolla, CA USA	University of California System; University of California San Diego; La Jolla Institute for Immunology	Doherty, TA (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	tdoherty@ucsd.edu	Badrani, Jana/GVR-9659-2022	Broide, David/0000-0001-8405-9090; Shah, Veranca/0000-0001-8795-6846; Seumois, Gregory/0000-0002-8164-6852; Cavagnero, Kellen J/0000-0003-4160-6394	NIH [AI 114585, AI 070535, AI 107779, AI 242236]; National Institutes of Health [S10OD016262, P30CA23100]; NATIONAL CANCER INSTITUTE [P30CA023100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070535, R01AI114585, R01AI107779] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	T.A.D. is supported by NIH grants AI 114585 and AI 070535, D.H.B. is supported by NIH grants AI 070535, AI 107779, and AI 242236, and M.C. is supported by NIH grant AI 070535. We thank Cody Fine and Jesus Olvera of the UCSD Human Embryonic Stem Cell Core for help with cell sorting, the LJI RNA Sequencing Core for help with RNA sequencing (National Institutes of Health Sequencer grant no. S10OD016262), the Histology Core at the University of California,San Diego Moores Cancer Center for help with lung sectioning and staining (National Institutes of Health grant no. P30CA23100), and Karina N. Roman for help with mouse work.	Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Cheng RYS, 2014, ENVIRON MOL MUTAGEN, V55, P244, DOI 10.1002/em.21851; Doherty TA, 2019, ALLERGOL INT, V68, P9, DOI 10.1016/j.alit.2018.11.001; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Doherty TA, 2012, J IMMUNOL, V188, P2622, DOI 10.4049/jimmunol.1101632; HANTOS Z, 1992, J APPL PHYSIOL, V73, P427, DOI 10.1152/jappl.1992.73.2.427; Hollingsworth JW, 2010, AM J RESP CELL MOL, V43, P269, DOI 10.1165/rcmb.2009-0198OC; Irvin CG, 2003, RESPIR RES, V4, DOI 10.1186/rr199; Jurak LM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01895; Lin R, 2012, BRIT J PHARMACOL, V165, P2365, DOI 10.1111/j.1476-5381.2011.01725.x; Ohne Y, 2016, NAT IMMUNOL, V17, P646, DOI 10.1038/ni.3447; Silver JS, 2016, NAT IMMUNOL, V17, P626, DOI 10.1038/ni.3443; Wojno EDT, 2016, J EXP MED, V213, P2229, DOI 10.1084/jem.20160525	14	13	13	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1432	+		10.1016/j.jaci.2019.07.018	http://dx.doi.org/10.1016/j.jaci.2019.07.018			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31369800	Bronze, Green Accepted			2022-12-18	WOS:000495004700038
J	Boyce, JA				Boyce, Joshua A.			Aspirin sensitivity: Lessons in the regulation (and dysregulation) of mast cell function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Aspirin; asthma; leukotrienes; mast cells; prostaglandins	EXACERBATED RESPIRATORY-DISEASE; E-PROSTANOID 2; PROSTAGLANDIN E-2; NASAL POLYPS; INDUCED BRONCHOCONSTRICTION; CYSTEINYL LEUKOTRIENES; RECEPTOR EXPRESSION; ASTHMATIC-PATIENTS; HYPERSENSITIVITY; 5-LIPOXYGENASE	The idiosyncratic activation of mast cells (MCs) in response to administration of nonselective COX inhibitors is a cardinal feature of aspirin-exacerbated respiratory disease (AERD). Older studies using MC-stabilizing drugs support a critical role for MCs and their products in driving the severe eosinophilic inflammation and respiratory dysfunction that is typical of AERD. Because patients with AERD react to all nonselective COX inhibitors regardless of their chemical structure, the mechanism of MC activation is not caused by classical, antigen-induced cross-linking of IgE receptors. Recent studies in both human subjects and animal models have revealed a complex and multifactorial process culminating in dysregulation of MC function and an aberrant dependency on COX-1-derived prostaglandin E-2 to maintain a tenuous homeostasis. This article reviews the factors most likely to contribute to MC dysregulation in patients with AERD and the potential diagnostic and therapeutic implications.	[Boyce, Joshua A.] Brigham & Womens Hosp, Div Allergy & Clin Immunol, Hale Bldg Transformat Med,60 Fenwood Rd, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Boyce, JA (corresponding author), Brigham & Womens Hosp, Div Allergy & Clin Immunol, Hale Bldg Transformat Med,60 Fenwood Rd, Boston, MA 02115 USA.	jboyce@rics.bwh.harvard.edu			NHLBI NIH HHS [R01 HL136209, P01 HL036110] Funding Source: Medline; NIAID NIH HHS [U19 AI095219, R01 AI136041, R01 AI078908, R37 AI052353, R01 AI052353] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adamjee J, 2006, J PATHOL, V209, P392, DOI 10.1002/path.1979; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Amayasu H, 2001, ANN ALLERG ASTHMA IM, V87, P146, DOI 10.1016/S1081-1206(10)62210-7; ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; Bankova LG, 2018, SCI IMMUNOL, P3; Berges-Gimeno MP, 2003, J ALLERGY CLIN IMMUN, V111, P180, DOI 10.1067/mai.2003.7; Bochenek G, 1996, ALLERGY, V51, P16, DOI 10.1111/j.1398-9995.1996.tb00004.x; Bochenek G, 2014, J ALLERGY CLIN IMMUN, V133, P98, DOI 10.1016/j.jaci.2013.07.004; Buchheit KM, 2016, J ALLERGY CLIN IMMUN, V137, P1566, DOI 10.1016/j.jaci.2015.10.020; Cahill KN, 2019, AM J RESP CRIT CARE, V200, P704, DOI 10.1164/rccm.201809-1755OC; Cahill KN, 2019, J ALLERGY CLIN IMMUN, V143, P799, DOI 10.1016/j.jaci.2018.10.007; Cahill KN, 2017, NEW ENGL J MED, V376, P1911, DOI 10.1056/NEJMoa1613125; Cahill KN, 2016, AM J RESP CELL MOL, V54, P34, DOI 10.1165/rcmb.2014-0486OC; Cahill KN, 2015, J ALLERGY CLIN IMMUN, V135, P245, DOI 10.1016/j.jaci.2014.07.031; Cheong HS, 2011, ALLERGY, V66, P637, DOI 10.1111/j.1398-9995.2010.02514.x; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Corrigan CJ, 2012, J ALLERGY CLIN IMMUN, V129, P1636, DOI 10.1016/j.jaci.2012.02.007; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Feng CL, 2006, BLOOD, V107, P3243, DOI 10.1182/blood-2005-07-2772; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; Gevaert P, 2005, ALLERGY, V60, P71, DOI 10.1111/j.1398-9995.2004.00621.x; Hayashi H, 2016, J ALLERGY CLIN IMMUN, V137, P1585, DOI 10.1016/j.jaci.2015.09.034; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Imokawa Shiro, 1992, Japanese Journal of Allergology, V41, P1515; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; Johns CB, 2014, AM J RHINOL ALLERGY, V28, P287, DOI 10.2500/ajra.2014.28.4054; Kay LJ, 2006, BRIT J PHARMACOL, V147, P707, DOI 10.1038/sj.bjp.0706664; Krystel-Whittemore M, 2016, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00620; Laidlaw TM, 2016, NEW ENGL J MED, V374, P484, DOI 10.1056/NEJMcibr1514013; Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826; Lang DM, 2018, ANN ALLERG ASTHMA IM, V121, P98, DOI 10.1016/j.anai.2018.05.007; Lazarinis N, 2018, J ALLERGY CLIN IMMUN, V142, P1080, DOI 10.1016/j.jaci.2018.02.024; Lewis R A, 1981, Kroc Found Ser, V14, P239; Liu T, 2019, MUCOSAL IMMUNOL, V12, P679, DOI 10.1038/s41385-019-0134-8; Liu T, 2018, J IMMUNOL, V200, P915, DOI 10.4049/jimmunol.1700603; Liu T, 2015, J IMMUNOL, V195, P3537, DOI 10.4049/jimmunol.1500905; Liu T, 2013, P NATL ACAD SCI USA, V110, P16987, DOI 10.1073/pnas.1313185110; Machado-Carvalho L, 2016, J ALLERGY CLIN IMMUN, V137, P99, DOI 10.1016/j.jaci.2015.09.028; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; Mellor EA, 2002, J EXP MED, V195, P583, DOI 10.1084/jem.20020044; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Nasser SMS, 1996, AM J RESP CRIT CARE, V153, P90, DOI 10.1164/ajrccm.153.1.8542168; Ordovas-Montanes J, 2018, NATURE, V560, P649, DOI 10.1038/s41586-018-0449-8; Pan DX, 2019, J ALLERGY CLIN IMMUN, V143, P1047, DOI 10.1016/j.jaci.2018.06.033; Paruchuri S, 2008, J BIOL CHEM, V283, P16477, DOI 10.1074/jbc.M705822200; Pushparaj PN, 2009, P NATL ACAD SCI USA, V106, P9773, DOI 10.1073/pnas.0901206106; Rajan JP, 2015, J ALLERGY CLIN IMMUN, V135, P676, DOI 10.1016/j.jaci.2014.08.020; Robuschi M, 1997, AM J RESP CRIT CARE, V155, P1461, DOI 10.1164/ajrccm.155.4.9105094; Roca-Ferrer J, 2013, RESPIROLOGY, V18, P711, DOI 10.1111/resp.12076; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; SLADEK K, 1993, EUR RESPIR J, V6, P391; Smith WL, 1997, ADV EXP MED BIOL, V400, P189; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Tan BK, 2011, J ALLERGY CLIN IMMUN, V128, P1198, DOI 10.1016/j.jaci.2011.08.037; Weiss J W, 1982, Trans Assoc Am Physicians, V95, P30; Ying S, 2006, J ALLERGY CLIN IMMUN, V117, P312, DOI 10.1016/j.jaci.2005.10.037; Yoshida S, 1998, ANN ALLERG ASTHMA IM, V80, P171, DOI 10.1016/S1081-1206(10)62951-1; Yoshida S, 1998, INT ARCH ALLERGY IMM, V117, P146, DOI 10.1159/000024002; Yoshimura Tsuyoshi, 2008, Allergol Int, V57, P429, DOI 10.2332 allergolint.O-08-545	61	13	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2019	144	4					875	881		10.1016/j.jaci.2019.08.022	http://dx.doi.org/10.1016/j.jaci.2019.08.022			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB8FZ	31587797	Green Accepted			2022-12-18	WOS:000488803900001
J	Kyogoku, Y; Sugiura, H; Ichikawa, T; Numakura, T; Koarai, A; Yamada, M; Fujino, N; Tojo, Y; Onodera, K; Tanaka, R; Sato, K; Sano, H; Yamanaka, S; Itakura, K; Mitsune, A; Tamada, T; Akaike, T; Ichinose, M				Kyogoku, Yorihiko; Sugiura, Hisatoshi; Ichikawa, Tomohiro; Numakura, Tadahisa; Koarai, Akira; Yamada, Mitsuhiro; Fujino, Naoya; Tojo, Yutaka; Onodera, Katsuhiro; Tanaka, Rie; Sato, Kei; Sano, Hirohito; Yamanaka, Shun; Itakura, Koji; Mitsune, Ayumi; Tamada, Tsutomu; Akaike, Takaaki; Ichinose, Masakazu			Nitrosative stress in patients with asthma-chronic obstructive pulmonary disease overlap	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nitrosative stress; 3-nitrotyrosine; reactive persulfides and polysulfides; cystathionine beta-synthase; cystathionine gamma-lyase	NITRIC-OXIDE SYNTHASE; NITRATIVE STRESS; OXIDATIVE STRESS; MATRIX METALLOPROTEINASES; CHEMICAL BIOLOGY; INDUCED SPUTUM; PEROXYNITRITE; COPD; HYDROPERSULFIDES; BIOCHEMISTRY	Background: Asthma-chronic obstructive pulmonary disease overlap (ACO) has frequent exacerbations and a poor quality of life and prognosis compared with those of chronic obstructive pulmonary disease alone. However, the pathogenesis of ACO has not been fully elucidated yet. Objectives: The aim of this study was to investigate nitrosative stress, which causes a redox imbalance and tissue inflammation in the airways of patients with ACO, and to evaluate the relationship between nitrosative stress and the clinical course in study subjects. Methods: Thirty healthy subjects and 56 asthmatic patients participated in this study. The asthmatic patients were divided into 33 asthmatic patients and 23 patients with ACO. The study subjects had been followed prospectively for 2 years to evaluate the clinical course. Nitrosative stress was evaluated based on the production of 3-nitrotyrosine (3-NT) in sputum cells. Results: Production of 3-NT was significantly enhanced in patients with ACO compared with that in asthmatic patients. Amounts of reactive persulfides and polysulfides, newly identified powerful antioxidants, were significantly decreased in the ACO group. Baseline levels of 3-NT were significantly correlated with the frequency of exacerbations and decrease in FEV1 adjusted by age, smoking history, and blood eosinophil count. The 3-NT-positive cells were also significantly correlated with amounts of proinflammatory chemokines and cytokines. Conclusions: These findings suggested that greater nitrosative stress occurred in the airways of patients with ACO, and the degree of nitrosative stress was correlated with an impairment in the clinical course. Nitrosative stress might be related to the pathogenesis of ACO.	[Kyogoku, Yorihiko; Sugiura, Hisatoshi; Ichikawa, Tomohiro; Numakura, Tadahisa; Koarai, Akira; Yamada, Mitsuhiro; Fujino, Naoya; Tojo, Yutaka; Onodera, Katsuhiro; Tanaka, Rie; Sato, Kei; Sano, Hirohito; Yamanaka, Shun; Itakura, Koji; Mitsune, Ayumi; Tamada, Tsutomu; Ichinose, Masakazu] Tohoku Univ, Grad Sch Med, Dept Resp Med, Sendai, Miyagi, Japan; [Akaike, Takaaki] Tohoku Univ, Grad Sch Med, Dept Environm Med & Mol Toxicol, Sendai, Miyagi, Japan	Tohoku University; Tohoku University	Sugiura, H (corresponding author), Tohoku Univ, Grad Sch Med, Dept Resp Med, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	sugiura@rm.med.tohoku.ac.jp	koarai, akira/T-6382-2019; YAMADA, MITSUHIRO/Q-8003-2016	YAMADA, MITSUHIRO/0000-0002-0832-1939; NUMAKURA, TADAHISA/0000-0001-9877-6250	Japan Society for the Promotion of Science [16K15453, 16H05307, 17H04180]; Practical Research Project for Allergic Diseases and Immunology from Japan Agency for Medical Research and Development, AMED [16ek0410018h0002, 16ek040036h0001, 17ek0410036h0002, 18ek0410036h0003]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Practical Research Project for Allergic Diseases and Immunology from Japan Agency for Medical Research and Development, AMED(Japan Agency for Medical Research and Development (AMED))	Supported by grants from the Japan Society for the Promotion of Science (grants #16K15453, #16H05307, and #17H04180) and a grant from the Practical Research Project for Allergic Diseases and Immunology from Japan Agency for Medical Research and Development, AMED (grants #16ek0410018h0002, #16ek040036h0001, #17ek0410036h0002, and #18ek0410036h0003).	Abe K, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0322-y; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Anglada JM, 2018, PHYS CHEM CHEM PHYS, V20, P4793, DOI 10.1039/c7cp07570g; Barnes PJ, 2005, EUR RESPIR J, V25, P1084, DOI 10.1183/09031936.05.00139104; Bartesaghi S, 2018, REDOX BIOL, V14, P618, DOI 10.1016/j.redox.2017.09.009; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bellocq A, 1999, AM J RESP CELL MOL, V21, P128, DOI 10.1165/ajrcmb.21.1.3379; Celano L, 2009, ARCH BIOCHEM BIOPHYS, V491, P96, DOI 10.1016/j.abb.2009.08.022; Chibana K, 2008, CLIN EXP ALLERGY, V38, P936, DOI 10.1111/j.1365-2222.2008.02969.x; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; Global initiative for asthma, DIAGN IN TREATM ASTH; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Greiner R, 2013, ANTIOXID REDOX SIGN, V19, P1749, DOI 10.1089/ars.2012.5041; Gunaydin H, 2009, CHEM RES TOXICOL, V22, P894, DOI 10.1021/tx800463y; Hargreave FE, 1999, AM J RESP CRIT CARE, V160, pS53, DOI 10.1164/ajrccm.160.supplement_1.14; Ichikawa T, 2008, AM J PHYSIOL-LUNG C, V295, pL800, DOI 10.1152/ajplung.90264.2008; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701, DOI 10.1164/ajrccm.162.2.9908132; Ida T, 2014, P NATL ACAD SCI USA, V111, P7606, DOI 10.1073/pnas.1321232111; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Iwamoto H, 2014, EUR RESPIR J, V43, P421, DOI 10.1183/09031936.00024313; Kauppi P, 2011, J ASTHMA, V48, P279, DOI 10.3109/02770903.2011.555576; Kimura H, 2015, ANTIOXID REDOX SIGN, V22, P362, DOI 10.1089/ars.2014.5869; Lane C, 2004, THORAX, V59, P757, DOI 10.1136/thx.2003.014894; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Menezes AMB, 2014, CHEST, V145, P297, DOI 10.1378/chest.13-0622; Millikin R, 2016, FREE RADICAL BIO MED, V97, P136, DOI 10.1016/j.freeradbiomed.2016.05.013; Nishida M, 2012, NAT CHEM BIOL, V8, P714, DOI [10.1038/nchembio.1018, 10.1038/NCHEMBIO.1018]; Numakura T, 2017, THORAX, V72, P1074, DOI 10.1136/thoraxjnl-2016-209359; Okamoto T, 2001, J BIOL CHEM, V276, P29596, DOI 10.1074/jbc.M102417200; Ono K, 2014, FREE RADICAL BIO MED, V77, P82, DOI 10.1016/j.freeradbiomed.2014.09.007; Paul BD, 2012, NAT REV MOL CELL BIO, V13, P499, DOI 10.1038/nrm3391; Pizzichini MMM, 1996, AM J RESP CRIT CARE, V154, P866, DOI 10.1164/ajrccm.154.4.8887576; Postma DS, 2015, NEW ENGL J MED, V373, P1241, DOI 10.1056/NEJMra1411863; Rahman I, 2006, EUR RESPIR J, V28, P219, DOI 10.1183/09031936.06.00053805; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Ricciardolo FLM, 2005, J ALLERGY CLIN IMMUN, V116, P1028, DOI 10.1016/j.jaci.2005.06.034; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Shi XL, 2000, MOL CELL BIOCHEM, V206, P125, DOI 10.1023/A:1007012403691; Sin DD, 2016, EUR RESPIR J, V48, P664, DOI 10.1183/13993003.00436-2016; Soriano JB, 2003, CHEST, V124, P474, DOI 10.1378/chest.124.2.474; Sugiura H, 1999, AM J RESP CRIT CARE, V160, P663, DOI 10.1164/ajrccm.160.2.9807160; Sugiura H, 2006, AM J RESP CELL MOL, V34, P592, DOI 10.1165/rcmb.2005-0339OC; Sugiura H, 2008, J ALLERGY CLIN IMMUN, V121, P355, DOI 10.1016/j.jaci.2007.11.009; Sugiura H, 2008, ANTIOXID REDOX SIGN, V10, P785, DOI 10.1089/ars.2007.1937; Sugiura H, 2012, AM J PHYSIOL-LUNG C, V302, pL764, DOI 10.1152/ajplung.00342.2011; Sugiura H, 2011, NITRIC OXIDE-BIOL CH, V25, P138, DOI 10.1016/j.niox.2011.03.079; Sugiura H, 2009, AM J RESP CELL MOL, V40, P654, DOI 10.1165/rcmb.2008-0371OC; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222; Tommola M, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02383-2016; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; Verrills NM, 2011, AM J RESP CRIT CARE, V183, P1633, DOI 10.1164/rccm.201010-1623OC; Yates DH, 1996, AM J RESP CRIT CARE, V154, P247, DOI 10.1164/ajrccm.154.1.8680689	55	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2019	144	4					972	+		10.1016/j.jaci.2019.04.023	http://dx.doi.org/10.1016/j.jaci.2019.04.023			26	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB8FZ	31077687	Bronze			2022-12-18	WOS:000488803900013
J	Maurer, M; Taube, C; Schroder, NWJ; Ebmeyer, J; Siebenhaar, F; Geldmacher, A; Schubert, N; Roers, A				Maurer, Marcus; Taube, Christian; Schroeder, Nicolas W. J.; Ebmeyer, Joerg; Siebenhaar, Frank; Geldmacher, Astrid; Schubert, Nadja; Roers, Axel			Mast cells drive IgE-mediated disease but might be bystanders in many other inflammatory and neoplastic conditions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; inflammation; pathogenesis	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; BRONCHOALVEOLAR LAVAGE FLUID; COLLAGEN-INDUCED ARTHRITIS; TYPE-1 DIABETES-MELLITUS; NECROSIS-FACTOR-ALPHA; MYELIN BASIC-PROTEIN; FC-EPSILON-RI; C-KIT; AIRWAY HYPERRESPONSIVENESS; CHRONIC RHINOSINUSITIS	Mast cells (MCs) are capable of executing powerful inflammatory response programs triggered by surface IgE cross-linking or through pattern recognition receptors. The question of how MCs contribute to human disease has been intensely investigated and stimulated much controversy. Correlative evidence comes from human studies, pointing to pathogenetic or protective MC functions in patients with atopic conditions, autoimmune disorders, type 2 diabetes, chronic urticaria, mastocytosis, and cancer. Experiments in MC-deficient mice underpinned key roles for MCs in patients with IgE-mediated allergic conditions. Important pathogenetic MC contributions to other inflammatory and neoplastic conditions were suggested by studies in traditional KIT mutant MC-deficient mouse strains. However, many of these findings were not reproduced in more recently developed improved mouse models of MC deficiency, largely ruling out roles for MCs in mouse models for autoimmune disease, diabetes, and cancer. We discuss limitations of studies in mice and human subjects and provide suggestions for how they can be overcome, such as through the development of specific and selective MC-targeted treatments.	[Maurer, Marcus; Schroeder, Nicolas W. J.; Siebenhaar, Frank; Geldmacher, Astrid] Charite Univ Med Berlin, Dept Dermatol & Allergy, Charitepl 1, D-10117 Berlin, Germany; [Schubert, Nadja] Charite Univ Med Berlin, Inst Biochem, Berlin, Germany; [Taube, Christian] Univ Hosp Essen Ruhrlandklin, Dept Pulm Med, Essen, Germany; [Schroeder, Nicolas W. J.] Med Fak Magdeburg, Dept Pathol, Magdeburg, Germany; [Ebmeyer, Joerg] Klinikum Bremerhaven Reinkenheide, Dept Otorhinolaryngol Head & Neck Surg, Bremerhaven, Germany; [Schubert, Nadja; Roers, Axel] Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Immunol, Fetscherstr 74, D-01307 Dresden, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Maurer, M (corresponding author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Charitepl 1, D-10117 Berlin, Germany.; Roers, A (corresponding author), Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Immunol, Fetscherstr 74, D-01307 Dresden, Germany.	marcus.maurer@charite.de; axel.roers@tu-dresden.de	Maurer, Marcus/ABG-2174-2020	Maurer, Marcus/0000-0002-4121-481X; Siebenhaar, Frank/0000-0003-4532-1644; Taube, Christian/0000-0002-3546-1398	Priority Programme of the Deutsche Forschungsgemeinschaft (DFG) SPP 1394: Mast cells - promoters of health and modulators of disease	Priority Programme of the Deutsche Forschungsgemeinschaft (DFG) SPP 1394: Mast cells - promoters of health and modulators of disease(German Research Foundation (DFG))	This article was published as part of a supplement sponsored by the members of the Priority Programme of the Deutsche Forschungsgemeinschaft (DFG) SPP 1394: Mast cells - promoters of health and modulators of disease.	Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Akahoshi M, 2011, J CLIN INVEST, V121, P4180, DOI 10.1172/JCI46139; Akin C, 2000, EXP HEMATOL, V28, P140, DOI 10.1016/S0301-472X(99)00145-9; Altrichter S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014794; Anderson E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01532; Ando T, 2013, J INVEST DERMATOL, V133, P2695, DOI 10.1038/jid.2013.250; Antsiferova M, 2013, J IMMUNOL, V191, P6147, DOI 10.4049/jimmunol.1301350; Ashina K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132367; Bachert C, 2017, J ALLER CL IMM-PRACT, V5, P1512, DOI 10.1016/j.jaip.2017.04.024; Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC; Banuelos-Cabrera I, 2014, ARCH MED RES, V45, P677, DOI 10.1016/j.arcmed.2014.11.010; Bennett JL, 2009, J IMMUNOL, V182, P5507, DOI 10.4049/jimmunol.0801485; Benoist C, 2002, NATURE, V420, P875, DOI 10.1038/nature01324; Bergot AS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004466; Bidder T, 2018, RHINOLOGY, V56, P42, DOI [10.4193/Rhin17.139, 10.4193/Rhino17.139]; Bieber K, 2017, EXP DERMATOL, V26, P1248, DOI 10.1111/exd.13382; Bischoff SC, 1999, P NATL ACAD SCI USA, V96, P8080, DOI 10.1073/pnas.96.14.8080; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Bowatte G, 2015, ACTA PAEDIATR, V104, P85, DOI 10.1111/apa.13151; Braunstahl GJ, 2001, AM J RESP CRIT CARE, V164, P858, DOI 10.1164/ajrccm.164.5.2006082; BRENNER T, 1994, J NEUROL SCI, V122, P210, DOI 10.1016/0022-510X(94)90300-X; Broesby-Olsen S, 2018, ALLERGY, V73, P230, DOI 10.1111/all.13237; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Buckley MG, 1997, CLIN SCI, V93, P363, DOI 10.1042/cs0930363; Cahill KN, 2017, NEW ENGL J MED, V376, P1911, DOI 10.1056/NEJMoa1613125; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; Cerny-Reiterer S, 2015, ONCOTARGET, V6, P3071, DOI 10.18632/oncotarget.3074; Cervera R, 2015, ANN RHEUM DIS, V74, P1011, DOI 10.1136/annrheumdis-2013-204838; Chaaban MR, 2013, AM J RHINOL ALLERGY, V27, P473, DOI 10.2500/ajra.2013.27.3981; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Chai OH, 2011, EXP MOL MED, V43, P35, DOI 10.3858/emm.2011.43.1.004; Chen RY, 2002, J IMMUNOL, V169, P3987, DOI 10.4049/jimmunol.169.7.3987; Chen RY, 2001, J CLIN INVEST, V108, P1151, DOI 10.1172/jci11494; CHERVENI.PA, 1969, J CELL PHYSIOL, V73, P25, DOI 10.1002/jcp.1040730104; Chmelar J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00524; Cho YG, 2007, AUTOIMMUN REV, V7, P65, DOI 10.1016/j.autrev.2007.08.001; Choi HW, 2016, IMMUNITY, V45, P1258, DOI 10.1016/j.immuni.2016.11.003; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COURTENAY JS, 1980, NATURE, V283, P666, DOI 10.1038/283666a0; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; CRISP AJ, 1984, ARTHRITIS RHEUM, V27, P845, DOI 10.1002/art.1780270802; Cunin P, 2017, J CLIN INVEST, V127, P1714, DOI 10.1172/JCI84598; D'Auria L, 2000, EXP DERMATOL, V9, P131, DOI 10.1034/j.1600-0625.2000.009002131.x; Dalton DK, 2012, CANCER IMMUNOL IMMUN, V61, P1511, DOI 10.1007/s00262-012-1246-0; de Lange-Brokaar BJE, 2016, OSTEOARTHR CARTILAGE, V24, P664, DOI 10.1016/j.joca.2015.11.011; de Vries VC, 2010, CURR OPIN IMMUNOL, V22, P643, DOI 10.1016/j.coi.2010.08.015; Di Lorenzo G, 2001, INT ARCH ALLERGY IMM, V125, P164, DOI 10.1159/000053811; DIETSCH GN, 1989, J IMMUNOL, V142, P1476; Dimitriadou V, 1997, ANTICANCER RES, V17, P1541; Dimson OG, 2003, J INVEST DERMATOL, V120, P784, DOI 10.1046/j.1523-1747.2003.12146.x; Divoux A, 2012, J CLIN ENDOCR METAB, V97, pE1677, DOI 10.1210/jc.2012-1532; DOLECEK R, 1981, PHARMATHERAPEUTICA, V2, P568; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Dudeck A, 2011, EUR J IMMUNOL, V41, P1883, DOI 10.1002/eji.201040994; Dufour C, 2012, BRIT J DERMATOL, V166, P1140, DOI 10.1111/j.1365-2133.2011.10748.x; El-Haggar SM, 2015, J DIABETES COMPLICAT, V29, P427, DOI 10.1016/j.jdiacomp.2015.01.013; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Fairley JA, 2009, J ALLERGY CLIN IMMUN, V123, P704, DOI 10.1016/j.jaci.2008.11.035; Fang H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00407; Ferrer M, 2010, CLIN EXP ALLERGY, V40, P1760, DOI 10.1111/j.1365-2222.2010.03582.x; Feyerabend TB, 2016, CELL METAB, V24, P1, DOI 10.1016/j.cmet.2016.06.019; Feyerabend TB, 2011, IMMUNITY, V35, P832, DOI 10.1016/j.immuni.2011.09.015; Fletcher L, 2019, CURR OPIN HEMATOL, V26, P112, DOI 10.1097/MOH.0000000000000486; Forster A, 2015, J ALLERGY CLIN IMMUN, V135, P1077, DOI 10.1016/j.jaci.2014.10.005; Freire PC, 2017, BRIT J DERMATOL, V177, P1644, DOI 10.1111/bjd.15924; Galinsky DST, 2008, CRIT REV ONCOL HEMAT, V68, P115, DOI 10.1016/j.critrevonc.2008.06.001; Galli SJ, 2016, ALLERGOL INT, V65, P3, DOI 10.1016/j.alit.2015.09.002; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gauthier M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94580; Gebhardt T, 2002, EUR J IMMUNOL, V32, P2308, DOI 10.1002/1521-4141(200208)32:8<2308::AID-IMMU2308>3.0.CO;2-X; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Gentek R, 2018, IMMUNITY, V48, P1160, DOI 10.1016/j.immuni.2018.04.025; Geoffrey R, 2006, J IMMUNOL, V177, P7275, DOI 10.4049/jimmunol.177.10.7275; Gericke J, 2017, J ALLERGY CLIN IMMUN, V139, P1059, DOI 10.1016/j.jaci.2016.07.047; Ghouse SM, 2018, CELL REP, V22, P27, DOI 10.1016/j.celrep.2017.12.010; Gomez-Pinilla PJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085304; Gonzalez-Gay MA, 2006, CLIN EXP RHEUMATOL, V24, P83; Gotis-Graham I, 1998, ANN RHEUM DIS, V57, P664, DOI 10.1136/ard.57.11.664; GotisGraham I, 1997, ARTHRITIS RHEUM, V40, P479, DOI 10.1002/art.1780400314; Gotlib J, 2016, NEW ENGL J MED, V374, P2530, DOI 10.1056/NEJMoa1513098; Gounaris E, 2007, P NATL ACAD SCI USA, V104, P19977, DOI 10.1073/pnas.0704620104; GRAHAM HT, 1955, BLOOD, V10, P467, DOI 10.1182/blood.V10.5.467.467; Gutierrez DA, 2015, CELL METAB, V21, P678, DOI 10.1016/j.cmet.2015.04.013; Gutierrez DA, 2014, DIABETES, V63, P3827, DOI 10.2337/db14-0372; Hakim-Rad K, 2009, CURR OPIN ALLERGY CL, V9, P427, DOI 10.1097/ACI.0b013e32832e9af1; Heger K, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001762; Heger K, 2014, EUR J IMMUNOL, V44, P296, DOI 10.1002/eji.201343731; Heimbach L, 2011, J BIOL CHEM, V286, P15003, DOI 10.1074/jbc.M111.221036; Hessner MJ, 2004, J IMMUNOL, V173, P6993, DOI 10.4049/jimmunol.173.11.6993; Holmdahl R, 2002, AGEING RES REV, V1, P135, DOI 10.1016/S0047-6374(01)00371-2; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hubner MP, 2011, CLIN IMMUNOL, V141, P205, DOI 10.1016/j.clim.2011.08.004; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; Ibrahim MZM, 1996, J NEUROIMMUNOL, V70, P131, DOI 10.1016/S0165-5728(96)00102-6; Inglis JJ, 2008, NAT PROTOC, V3, P612, DOI 10.1038/nprot.2008.19; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; Jawhar M, 2015, LEUKEMIA, V29, P1115, DOI 10.1038/leu.2015.4; Kakizoe E, 1999, INFLAMM RES, V48, P318, DOI 10.1007/s000110050467; Kallweit U, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-19; Kashem SW, 2011, EUR J PHARMACOL, V668, P299, DOI 10.1016/j.ejphar.2011.06.027; Kasperkiewicz M, 2007, CLIN REV ALLERG IMMU, V33, P67, DOI 10.1007/s12016-007-0030-y; Katz HR, 2011, IMMUNITY, V35, P668, DOI 10.1016/j.immuni.2011.11.004; Khazaie K, 2011, CANCER METAST REV, V30, P45, DOI 10.1007/s10555-011-9286-z; Kim YS, 2007, EUR J IMMUNOL, V37, P1107, DOI 10.1002/eji.200636612; Kiortsis DN, 2005, ANN RHEUM DIS, V64, P765, DOI 10.1136/ard.2004.026534; KITAMURA Y, 1978, BLOOD, V52, P447; Knight PA, 2000, J EXP MED, V192, P1849, DOI 10.1084/jem.192.12.1849; Kobayashi T, 2000, J IMMUNOL, V164, P3855, DOI 10.4049/jimmunol.164.7.3855; Kohlgruber A, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892-015-0670-x; Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074-7613(00)80045-X; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; Krathen RA, 2005, J AM ACAD DERMATOL, V53, P338, DOI 10.1016/j.jaad.2005.02.014; Lafaille JJ, 1997, J EXP MED, V186, P307, DOI 10.1084/jem.186.2.307; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lane JE, 2006, J AM ACAD DERMATOL, V54, P68, DOI 10.1016/j.jaad.2005.09.030; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; Li HM, 2011, J IMMUNOL, V187, P274, DOI 10.4049/jimmunol.1003603; Lilla JN, 2011, BLOOD, V118, P6930, DOI 10.1182/blood-2011-03-343962; Lim KH, 2009, BLOOD, V113, P5727, DOI 10.1182/blood-2009-02-205237; Lin L, 2011, J BIOL CHEM, V286, P37358, DOI 10.1074/jbc.M111.272401; Liu J, 2009, NAT MED, V15, P940, DOI 10.1038/nm.1994; LIU Z, 1995, J CLIN INVEST, V95, P1539, DOI 10.1172/JCI117826; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; London VA, 2012, ARCH DERMATOL, V148, P1241, DOI 10.1001/archdermatol.2012.1604; Magnusson SE, 2009, FASEB J, V23, P875, DOI 10.1096/fj.08-120394; Malik ST, 2018, J CLIN PATHOL, V71, P840, DOI 10.1136/jclinpath-2017-204881; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marichal T, 2013, CANCER IMMUNOL RES, V1, P269, DOI 10.1158/2326-6066.CIR-13-0119; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Mashiko S, 2015, J ALLERGY CLIN IMMUN, V136, P351, DOI 10.1016/j.jaci.2015.01.033; Masuda T, 2003, CLIN EXP ALLERGY, V33, P705, DOI 10.1046/j.1365-2222.2003.01588.x; Masure D, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002588; Matsumoto I, 1999, SCIENCE, V286, P1732, DOI 10.1126/science.286.5445.1732; McDermott JR, 2003, P NATL ACAD SCI USA, V100, P7761, DOI 10.1073/pnas.1231488100; MCKEAN PG, 1989, PARASITE IMMUNOL, V11, P293, DOI 10.1111/j.1365-3024.1989.tb00667.x; McNelis JC, 2014, IMMUNITY, V41, P36, DOI 10.1016/j.immuni.2014.05.010; Messingham KAN, 2014, IMMUNOL RES, V59, P273, DOI 10.1007/s12026-014-8547-7; Metcalfe DD, 2017, ANNU REV PATHOL-MECH, V12, P487, DOI 10.1146/annurev-pathol-052016-100312; Metz M, 2006, SCIENCE, V313, P526, DOI 10.1126/science.1128877; Metz M, 2014, J INVEST DERMATOL, V134, P2833, DOI 10.1038/jid.2014.226; Metz M, 2014, J DERMATOL SCI, V73, P57, DOI 10.1016/j.jdermsci.2013.08.011; Modena BD, 2016, TRANSL RES, V174, P98, DOI 10.1016/j.trsl.2016.02.011; Moniaga CS, 2010, AM J PATHOL, V176, P2385, DOI 10.2353/ajpath.2010.090957; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; Nakae S, 2007, J ALLERGY CLIN IMMUN, V120, P48, DOI 10.1016/j.jaci.2007.02.046; Nigrovic PA, 2007, P NATL ACAD SCI USA, V104, P2325, DOI 10.1073/pnas.0610852103; Nigrovic PA, 2008, AM J PATHOL, V173, P1693, DOI 10.2353/ajpath.2008.080407; Noordenbos T, 2012, ARTHRITIS RHEUM-US, V64, P99, DOI 10.1002/art.33396; O'Mahony L, 2011, J ALLERGY CLIN IMMUN, V128, P1153, DOI 10.1016/j.jaci.2011.06.051; Ohrviki H, 2016, ONCOTARGET, V7, P68990, DOI 10.18632/oncotarget.11837; Oiwa M, 2008, CLIN EXP ALLERGY, V38, P1357, DOI 10.1111/j.1365-2222.2008.03007.x; Olsson N, 2001, ANN RHEUM DIS, V60, P187, DOI 10.1136/ard.60.3.187; ORMEROD AD, 1988, J ALLERGY CLIN IMMUN, V82, P586, DOI 10.1016/0091-6749(88)90968-2; Otsuka A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025538; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Paul C, 2016, EUR J IMMUNOL, V46, P114, DOI 10.1002/eji.201545613; Pedotti R, 2003, TRENDS IMMUNOL, V24, P479, DOI 10.1016/S1471-4906(03)00233-3; Pejler G, 2007, ADV IMMUNOL, V95, P167, DOI 10.1016/S0065-2776(07)95006-3; Peschke K, 2014, CELL REP, V8, P1300, DOI 10.1016/j.celrep.2014.07.046; Piconese S, 2011, LAB INVEST, V91, P627, DOI 10.1038/labinvest.2011.3; Pitman N, 2011, ANN RHEUM DIS, V70, P1170, DOI 10.1136/ard.2010.134528; Pittoni P, 2011, CANCER RES, V71, P5987, DOI 10.1158/0008-5472.CAN-11-1637; PUDDINGTON L, 1994, IMMUNITY, V1, P733, DOI 10.1016/S1074-7613(94)80015-4; Rabenhorst A, 2012, BLOOD, V120, P2042, DOI 10.1182/blood-2012-03-415638; Ramirez J, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-0970-9; Reber LL, 2012, TRENDS IMMUNOL, V33, P613, DOI 10.1016/j.it.2012.09.008; Reitz M, 2017, MUCOSAL IMMUNOL, V10, P481, DOI 10.1038/mi.2016.56; Reuter S, 2008, EUR RESPIR J, V31, P773, DOI 10.1183/09031936.00058907; Rivero A, 2017, ANN OTO RHINOL LARYN, V126, P739, DOI 10.1177/0003489417731782; Rodewald HR, 2012, IMMUNITY, V37, P13, DOI 10.1016/j.immuni.2012.07.007; Roy A, 2014, J BIOL CHEM, V289, P237, DOI 10.1074/jbc.M112.435156; RUHNO J, 1990, ALLERGY, V45, P370, DOI 10.1111/j.1398-9995.1990.tb00513.x; Russi AE, 2015, TRANSL RES, V165, P255, DOI 10.1016/j.trsl.2014.08.005; Sawaguchi M, 2012, J IMMUNOL, V188, P1809, DOI 10.4049/jimmunol.1101746; Sawai N, 1999, BLOOD, V93, P3703, DOI 10.1182/blood.V93.11.3703.411a21_3703_3712; Sayed BA, 2008, ANNU REV IMMUNOL, V26, P705, DOI 10.1146/annurev.immunol.26.021607.090320; Sayed BA, 2011, J IMMUNOL, V186, P3294, DOI 10.4049/jimmunol.1003574; Schmetzer O, 2018, J ALLERGY CLIN IMMUN, V142, P876, DOI 10.1016/j.jaci.2017.10.035; Schneider LA, 2007, J EXP MED, V204, P2629, DOI 10.1084/jem.20071262; Schonhuber N, 2014, NAT MED, V20, P1340, DOI 10.1038/nm.3646; Scholten J, 2008, TRANSGENIC RES, V17, P307, DOI 10.1007/s11248-007-9153-4; Schubert N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01870; Schubert N, 2015, ARTHRITIS RHEUMATOL, V67, P903, DOI 10.1002/art.38996; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; Sehra S, 2016, J INVEST DERMATOL, V136, P1429, DOI 10.1016/j.jid.2016.03.019; Shimokawa C, 2017, IMMUNITY, V46, P863, DOI 10.1016/j.immuni.2017.04.017; Shin K, 2006, ARTHRITIS RHEUM-US, V54, P2863, DOI 10.1002/art.22058; Siebenhaar F, 2018, ALLERGY, V73, P1489, DOI 10.1111/all.13425; Siebenhaar F, 2016, ALLERGY, V71, P869, DOI 10.1111/all.12842; Siebenhaar F, 2018, TRENDS IMMUNOL, V39, P151, DOI 10.1016/j.it.2017.10.005; Siebenhaar F, 2014, EXP DERMATOL, V23, P159, DOI 10.1111/exd.12328; Slats AM, 2007, AM J RESP CRIT CARE, V176, P121, DOI 10.1164/rccm.200612-1814OC; Soucek L, 2007, NAT MED, V13, P1211, DOI 10.1038/nm1649; St John AL, 2013, J IMMUNOL, V190, P4458, DOI 10.4049/jimmunol.1203420; STARKEY JR, 1988, INT J CANCER, V42, P48, DOI 10.1002/ijc.2910420110; Stelekati E, 2009, IMMUNITY, V31, P665, DOI 10.1016/j.immuni.2009.08.022; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; Sulcova J, 2015, AM J PATHOL, V185, P1575, DOI 10.1016/j.ajpath.2015.02.005; Suurmond J, 2016, J ALLERGY CLIN IMMUN, V138, P869, DOI 10.1016/j.jaci.2016.01.017; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Tanaka A, 2011, AM J PHYSIOL-CELL PH, V301, pC1360, DOI 10.1152/ajpcell.00514.2010; Taube C, 2004, J IMMUNOL, V172, P6398, DOI 10.4049/jimmunol.172.10.6398; Theoharides TC, 2004, TRENDS IMMUNOL, V25, P235, DOI 10.1016/j.it.2004.02.013; TOMS R, 1990, J NEUROIMMUNOL, V30, P169, DOI 10.1016/0165-5728(90)90101-R; Tunon-de-Lara J, 2002, NEW ENGL J MED, V347, P1040; VALENT P, 1990, J IMMUNOL, V145, P3432; VALENT P, 1990, J IMMUNOL, V145, P1885; van Buul AR, 2015, EXPERT OPIN BIOL TH, V15, P1713, DOI 10.1517/14712598.2015.1084283; Van Crombruggen K, 2011, J ALLERGY CLIN IMMUN, V128, P728, DOI 10.1016/j.jaci.2011.07.049; Voehringer D, 2008, J IMMUNOL, V180, P4742, DOI 10.4049/jimmunol.180.7.4742; Waern I, 2009, J IMMUNOL, V183, P6369, DOI 10.4049/jimmunol.0900180; Wasiuk A, 2012, CANCER IMMUNOL IMMUN, V61, P2273, DOI 10.1007/s00262-012-1276-7; Wedemeyer J, 2005, LAB INVEST, V85, P388, DOI 10.1038/labinvest.3700232; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; Willenborg S, 2014, J INVEST DERMATOL, V134, P2005, DOI 10.1038/jid.2014.12; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; WINTROUB BU, 1978, NEW ENGL J MED, V298, P417, DOI 10.1056/NEJM197802232980803; Yavuz AS, 2002, BLOOD, V100, P661, DOI 10.1182/blood-2002-01-0203; Yu KK, 2014, J AM ACAD DERMATOL, V71, P468, DOI 10.1016/j.jaad.2014.04.053; Yu M, 2006, J CLIN INVEST, V116, P1633, DOI 10.1172/JCI25702; Yu YX, 2016, EUR J PHARMACOL, V778, P33, DOI 10.1016/j.ejphar.2015.07.017; Zebrowska A, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/936545; Zhou JS, 2007, J EXP MED, V204, P2797, DOI 10.1084/jem.20071391; Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313	225	13	13	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2019	144	4		S	SI		S19	S30		10.1016/j.jaci.2019.07.017	http://dx.doi.org/10.1016/j.jaci.2019.07.017			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB8GI	31369803	Bronze			2022-12-18	WOS:000488805000003
J	Inda, ME; Mimee, M; Lu, TK				Inda, Maria Eugenia; Mimee, Mark; Lu, Timothy K.			Cell-based biosensors for immunology, inflammation, and allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Synthetic biology; biotechnology; biosensor; gene circuit; biomedical applications; diagnosis; treatment	RESPOND		[Inda, Maria Eugenia; Mimee, Mark; Lu, Timothy K.] MIT, MIT Synthet Biol Ctr, Cambridge, MA 02139 USA; [Inda, Maria Eugenia; Mimee, Mark; Lu, Timothy K.] MIT, Res Lab Elect, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA; [Lu, Timothy K.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Mimee, M; Lu, TK (corresponding author), MIT, 500 Technol Sq,Rm NE47-221, Cambridge, MA 02139 USA.	mimee@mit.edu; timlu@mit.edu		/0000-0002-3083-2671; Mimee, Mark/0000-0002-0749-8054; Inda, Maria Eugenia/0000-0002-3840-7370	American Heart Association [229460]; Amyotrophic Lateral Sclerosis Association [18-IIA-403]; Army Research Office [W911NF-17-20077]; ARO-ISN UARC [W911NF-13-D-0001 T.O.8]; Breast Cancer Alliance; Defense Advanced Research Projects Agency (DARPA) [152304.5106735.0006, HR0011-15-C-0084]; Defense Threat Reduction Agency (DTRA) [E2045481, HDTRA1-15-10050, HDTRA1 14 1 0007]; Human Frontier Science Program [LT000595/2017-L]; National Institutes of Health (NIH) [4R33-AI121669-04]; National Science Foundation (NSF) [CCF-1521925, DMR-1419807]; Office of Naval Research [107215392]; Pew Charitable Trusts [00030623]; Pfizer [8500437439]; Naval Warfare Systems Center [N66001 -13-G4025]; Leona M. and Harry B. Helmsley Charitable Trust [W81XWH 16 1-0565, W81XWH17 1 0159, W81XWH 18 1 0513]; United States -Israel Binational Science Foundation [2017189]	American Heart Association(American Heart Association); Amyotrophic Lateral Sclerosis Association; Army Research Office; ARO-ISN UARC; Breast Cancer Alliance; Defense Advanced Research Projects Agency (DARPA)(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); Defense Threat Reduction Agency (DTRA)(United States Department of DefenseDefense Threat Reduction Agency); Human Frontier Science Program(Human Frontier Science Program); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation (NSF)(National Science Foundation (NSF)); Office of Naval Research(Office of Naval Research); Pew Charitable Trusts; Pfizer(Pfizer); Naval Warfare Systems Center; Leona M. and Harry B. Helmsley Charitable Trust; United States -Israel Binational Science Foundation(US-Israel Binational Science Foundation)	The Lu laboratory acknowledges financial support from the American Heart Association (229460); the Amyotrophic Lateral Sclerosis Association (18-IIA-403); the Army Research Office (W911NF-17-20077); ARO-ISN UARC (W911NF-13-D-0001 T.O.8); the Breast Cancer Alliance; the Defense Advanced Research Projects Agency (DARPA; 152304.5106735.0006 and HR0011-15-C-0084); the Defense Threat Reduction Agency (DTRA; E2045481 via George Mason University, and HDTRA1-15-10050 and HDTRA1 14 1 0007); the Human Frontier Science Program (LT000595/2017-L); the National Institutes of Health (NIH; 229825 via Massachusetts General Hospital and 4R33-AI121669-04); the National Science Foundation (NSF; CCF-1521925 and DMR-1419807); the Office of Naval Research (ONR; 107215392); the Pew Charitable Trusts (00030623); Pfizer (8500437439); the Singapore -MIT Alliance for Research and Technology (S.M.A.R.T.), Space and Naval Warfare Systems Center (N66001 -13-G4025); the Leona M. and Harry B. Helmsley Charitable Trust (3239); the US Army Medical Research and Material Command (W81XWH 16 1-0565, W81XWH17 1 0159, and W81XWH 18 1 0513), and the United States -Israel Binational Science Foundation (2017189).	Archer EJ, 2012, ACS SYNTH BIOL, V1, P451, DOI 10.1021/sb3000595; Auslander D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5408; Chassin H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01211-1; Daeffler KNM, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20167416; Isabella VM, 2018, NAT BIOTECHNOL, V36, P857, DOI 10.1038/nbt.4222; Lim B, 2017, CELL, V169, P547, DOI 10.1016/j.cell.2017.03.045; Mimee M, 2018, SCIENCE, V360, P915, DOI 10.1126/science.aas9315; Mimee M, 2015, CELL SYST, V1, P62, DOI 10.1016/j.cels.2015.06.001; Riglar DT, 2017, NAT BIOTECHNOL, V35, P653, DOI 10.1038/nbt.3879; Schukur L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4964	10	13	13	2	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					645	647		10.1016/j.jaci.2019.07.024	http://dx.doi.org/10.1016/j.jaci.2019.07.024			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IW8CV	31376406	Bronze			2022-12-18	WOS:000485222300003
J	Alosaimi, MF; Maciag, MC; Platt, CD; Geha, RS; Chou, J; Bartnikas, LM				Alosaimi, Mohammed F.; Maciag, Michelle C.; Platt, Craig D.; Geha, Raif S.; Chou, Janet; Bartnikas, Lisa M.			A novel variant in STAT2 presenting with hemophagocytic lymphohistiocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DEFICIENCY; TRANSCRIPTION		[Alosaimi, Mohammed F.; Maciag, Michelle C.; Platt, Craig D.; Geha, Raif S.; Chou, Janet; Bartnikas, Lisa M.] Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Alosaimi, Mohammed F.; Maciag, Michelle C.; Platt, Craig D.; Geha, Raif S.; Chou, Janet; Bartnikas, Lisa M.] Harvard Med Sch, Boston, MA 02115 USA; [Alosaimi, Mohammed F.] King Saud Univ, Dept Pediat, Riyadh, Saudi Arabia	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; King Saud University	Bartnikas, LM (corresponding author), Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA.; Bartnikas, LM (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	lisa.bartnikas@childrens.harvard.edu	Alosaimi, Mohammed F/AAY-5814-2021	Alosaimi, Mohammed F/0000-0002-8025-3491	Perkin Foundation [T32AI007512, 1R01AI139633-01];  [5K08AI116979-04];  [K23AI143962-01]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI116979, T32AI007512, K23AI143962, R01AI139633] Funding Source: NIH RePORTER	Perkin Foundation; ; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by T32AI007512 (to M.C.M.), 1R01AI139633-01 (to R.S.G.), the Perkin Foundation (to R.S.G.), 5K08AI116979-04 (to J.C.), and K23AI143962-01 (to L.M.B.).	Bode SFN, 2015, HAEMATOLOGICA, V100, P978, DOI 10.3324/haematol.2014.121608; Hambleton S, 2013, P NATL ACAD SCI USA, V110, P3053, DOI 10.1073/pnas.1220098110; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Hui-Yuen J, 2011, J VIS EXP, V57; Moens L, 2017, J ALLERGY CLIN IMMUN, V139, P1995, DOI 10.1016/j.jaci.2016.10.033; Naqvi, 2014, LYMPHOSIGN J, V1, P87, DOI DOI 10.14785/LPSN-2014-0004; Shahni R, 2015, BRAIN, V138, P2834, DOI 10.1093/brain/awv182; Tesi B, 2015, J ALLERGY CLIN IMMUN, V135, P1638, DOI 10.1016/j.jaci.2014.11.030; Zhang J, 2006, J BIOL CHEM, V281, P9163; Zhang LW, 2004, VIROLOGY, V323, P141, DOI 10.1016/j.virol.2004.03.007	10	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					611	+		10.1016/j.jaci.2019.05.008	http://dx.doi.org/10.1016/j.jaci.2019.05.008			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	31102697	Bronze, Green Accepted			2022-12-18	WOS:000478789300032
J	Kellner, ES; Krupski, C; Kuehn, HS; Rosenzweig, SD; Yoshida, N; Kojima, S; Boutboul, D; Latour, S; Barlogis, V; Galambrun, C; Stray-Pedersen, A; Erichsen, HC; Marsh, RA				Kellner, Erinn S.; Krupski, Christa; Kuehn, Hye Sun; Rosenzweig, Sergio D.; Yoshida, Nao; Kojima, Seiji; Boutboul, David; Latour, Sylvain; Barlogis, Vincent; Galambrun, Claire; Stray-Pedersen, Asbjorg; Erichsen, Hans Christian; Marsh, Rebecca A.			Allogeneic hematopoietic stem cell transplant outcomes for patients with dominant negative IKZF1/IKAROS mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IKAROS		[Kellner, Erinn S.; Krupski, Christa; Marsh, Rebecca A.] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45229 USA; [Kellner, Erinn S.; Krupski, Christa; Marsh, Rebecca A.] Univ Cincinnati, Cincinnati, OH 45221 USA; [Kuehn, Hye Sun; Rosenzweig, Sergio D.] NIH, Serv Immunol, Dept Lab Med, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA; [Yoshida, Nao] Japanese Red Cross Nagoya First Hosp, Childrens Med Ctr, Dept Hematol & Oncol, Nagoya, Aichi, Japan; [Kojima, Seiji] Nagoya Univ, Grad Sch Med, Dept Pediat, Nagoya, Aichi, Japan; [Boutboul, David; Latour, Sylvain] INSERM, UMR 1163, Lab Lymphocyte Activat & Susceptibil EBV Infect, Paris, France; [Boutboul, David] Univ Paris Diderot, Hop St Louis, AP HP, Dept Clin Immunol, Paris, France; [Latour, Sylvain] Univ Paris 05, Sorbonne Paris Cite, Imagine Inst, Paris, France; [Barlogis, Vincent] La Timone Hosp, Dept Pediat Immunol, Marseille, France; [Galambrun, Claire] Timone Enfants Hosp, Dept Pediat Hematol & Oncol, Marseille, France; [Galambrun, Claire] Aix Marseille Univ, Marseille, France; [Stray-Pedersen, Asbjorg] Oslo Univ Hosp, Norwegian Natl Unit Newborn Screening, Oslo, Norway; [Erichsen, Hans Christian] Oslo Univ Hosp, Rigshosp, Sect Specialized Pediat Med, Oslo, Norway	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Red Cross Nagoya Daiichi Hospital; Nagoya University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; University of Oslo; University of Oslo; National Hospital Norway	Kellner, ES (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45229 USA.; Kellner, ES (corresponding author), Univ Cincinnati, Cincinnati, OH 45221 USA.	erinn.kellner@cchmc.org	; Latour, Sylvain/H-3652-2017	Stray-Pedersen, Asbjorg/0000-0002-9168-0878; Latour, Sylvain/0000-0001-8238-4391	Intramural Research Program, National Institutes of Health Clinical Center; Jeffrey Modell Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001122] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL010304] Funding Source: NIH RePORTER	Intramural Research Program, National Institutes of Health Clinical Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jeffrey Modell Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER	Supported by the Intramural Research Program, National Institutes of Health Clinical Center (to H.S.K. and S.D.R.), and the Jeffrey Modell Foundation (salary support for E.S.K)	Boutboul D, 2018, J CLIN INVEST, V128, P3071, DOI 10.1172/JCI98164; Churchman ML, 2018, CANCER CELL, V33, P937, DOI 10.1016/j.ccell.2018.03.021; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Goldman FD, 2012, PEDIATR BLOOD CANCER, V58, P591, DOI 10.1002/pbc.23160; Kuehn HS, 2016, NEW ENGL J MED, V374, P1032, DOI 10.1056/NEJMoa1512234; Olsson L, 2015, BRIT J HAEMATOL, V169, P479, DOI 10.1111/bjh.13342; Toubai T, 2011, BLOOD, V118, P192, DOI 10.1182/blood-2010-12-324616; Yoshida N, 2017, LEUKEMIA, V31, P1221, DOI 10.1038/leu.2017.25; Yoshida T, 2014, INT J HEMATOL, V100, P220, DOI 10.1007/s12185-014-1644-5	9	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					339	342		10.1016/j.jaci.2019.03.025	http://dx.doi.org/10.1016/j.jaci.2019.03.025			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30965037	Bronze			2022-12-18	WOS:000473432800043
J	Krishnan, U; Chan, LJ; Andrew, GJ; Rothenberg, ME; Wen, T				Krishnan, Usha; Chan Lijuan; Andrew, Gifford J.; Rothenberg, Marc E.; Wen, Ting			Analysis of eosinophilic esophagitis in children with repaired congenital esophageal atresia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophils; T(H)2 inflammation; EoE transcriptome; GERD	INTERSTITIAL-CELLS; SLOW WAVES; PREVALENCE; CAJAL; ANO1; COMPLICATIONS; DIAGNOSIS; DISEASE; ADULTS	Background: A high prevalence of eosinophilic esophagitis (EoE) has been preliminarily reported in patients after repair of esophageal atresia (EA), but the basis of this association is unknown. Objectives: We aimed to (1) characterize theEoEtranscriptome in patients with EA, (2) compare the EoE transcriptome in patients with EoE and EAwith that in patients with EoE alone, and (3) identify transcripts that could predispose patients with EA to EoE. Methods: This single-center, population-based, retrospective study identified 4 EoE study cohorts: healthy control subjects, patients with EA and EoE (EA+EoE+), patients with EA without EoE (EA+EoE-), and patients with EoE without EA (EA-EoE+). Molecular signatures were assessed by using the EoE diagnostic panel, a 94-gene expression quantitative PCR array. Results: In a cohort of 110 pediatric patients with surgically repaired EA, 20 (18%) patients were given a diagnosis of EoE, representing a 364-fold enrichment of EoE in patients with EA compared with the general pediatric population. EoE diagnostic panel analyses revealed a major overlap between the EA+EoE+ and EA-EoE+ cohorts. A proportion (approximately 25%) of EoE signature genes were dysregulated in patients with EA+EoE- compared with healthy control subjects, including those involved in epithelial barrier function and type 2-associated inflammatory responses. Patients with EA+EoE+ exhibit a more severe EoE clinical phenotype than those with EA-EoE+ in terms of dysphagia and dilation need. Conclusions: Patients with EA have increased risk of EoE. Patients with EoE with EA have a similar molecular profile compared with that of patients with EoE without EA. Dysregulated baseline epithelial barrier and type 2-associated genes in EA monomorbidity might explain the higher EoE prevalence in patients with EA.	[Rothenberg, Marc E.; Wen, Ting] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Krishnan, Usha; Chan Lijuan; Andrew, Gifford J.] Univ New South Wales, Discipline Paediat, Sch Womens & Childrens Hlth, Fac Med, Sydney, NSW, Australia; [Krishnan, Usha] Sydney Childrens Hosp, Dept Paediat Gastroenterol, Randwick, NSW, Australia; [Andrew, Gifford J.] Prince Wales Hosp, Dept Anat Pathol SEALS, Sydney, NSW, Australia	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of New South Wales Sydney	Wen, T (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA.	ting.wen@cchmc.org		Chan, Jasmine/0000-0002-0526-1643; Gifford, Andrew/0000-0002-4092-2347	National Institutes of Health [P30 DK078392, R37 AI045898, R01 AI124355, U19 AI070235]; Campaign Urging Research for Eosinophilic Disease (CURED); Buckeye Foundation; Sunshine Charitable Foundation; Clinical and Translational Science Award of the University of Cincinnati [UL1 TR001425]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI124355, U19AI070235, R37AI045898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Campaign Urging Research for Eosinophilic Disease (CURED); Buckeye Foundation; Sunshine Charitable Foundation; Clinical and Translational Science Award of the University of Cincinnati; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported in part by National Institutes of Health grants P30 DK078392, R37 AI045898, R01 AI124355, and U19 AI070235; the Campaign Urging Research for Eosinophilic Disease (CURED); the Buckeye Foundation; the Sunshine Charitable Foundation and its supporters, Denise A. Bunning and David G. Bunning; and the Clinical and Translational Science Award of the University of Cincinnati (UL1 TR001425).	Abonia JP, 2013, J ALLERGY CLIN IMMUN, V132, P378, DOI 10.1016/j.jaci.2013.02.030; Aceves SS, 2014, CLIN GASTROENTEROL H, V12, P1216, DOI 10.1016/j.cgh.2013.09.007; Arias A, 2016, ALIMENT PHARM THER, V43, P3, DOI 10.1111/apt.13441; Batres LA, 2002, J PEDIATR GASTR NUTR, V35, P224, DOI 10.1097/00005176-200208000-00024; Bin LH, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-016-0158-5; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Chan LJ, 2016, DIS ESOPHAGUS, V29, P563, DOI 10.1111/dote.12368; CHETCUTI P, 1993, ARCH DIS CHILD, V68, P167, DOI 10.1136/adc.68.2.167; Cobine CA, 2017, J PHYSIOL-LONDON, V595, P2021, DOI 10.1113/JP273618; Damera G, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-39; Davis BP, 2016, ANNU REV PATHOL-MECH, V11, P365, DOI 10.1146/annurev-pathol-012615-044241; Dellon ES, 2014, CLIN GASTROENTEROL H, V12, P589, DOI 10.1016/j.cgh.2013.09.008; Dhaliwal J, 2014, DIS ESOPHAGUS, V27, P340, DOI 10.1111/dote.12119; Gatzinsky V, 2014, J PEDIATR SURG, V49, P1347, DOI 10.1016/j.jpedsurg.2013.12.027; Gomez-Pinilla PJ, 2009, AM J PHYSIOL-GASTR L, V296, pG1370, DOI 10.1152/ajpgi.00074.2009; Gorter RR, 2012, J PEDIATR SURG, V47, pE9, DOI 10.1016/j.jpedsurg.2012.01.079; Henderson CJ, 2014, J PEDIATR GASTR NUTR, V58, P553, DOI 10.1097/MPG.0000000000000253; Hill CA, 2013, JAMA OTOLARYNGOL, V139, P903, DOI 10.1001/jamaoto.2013.4171; Kassabian S, 2014, WORLD J GASTROENTERO, V20, P18038, DOI 10.3748/wjg.v20.i47.18038; Kovesi T, 2013, DIS ESOPHAGUS, V26, P413, DOI 10.1111/dote.12061; Krishnan U, 2016, J PEDIATR GASTR NUTR, V63, P550, DOI 10.1097/MPG.0000000000001401; Krishnan U, 2015, EUR J PEDIATR SURG, V25, P336, DOI 10.1055/s-0035-1559815; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lucendo AJ, 2015, BEST PRACT RES CL GA, V29, P759, DOI 10.1016/j.bpg.2015.06.010; Malysz J, 2017, AM J PHYSIOL-GASTR L, V312, pG228, DOI 10.1152/ajpgi.00363.2016; Otiveira C, 2008, J PEDIATR SURG, V43, P810, DOI 10.1016/j.jpedsurg.2007.12.018; Patria MF, 2017, INT J ENV RES PUBLIC, V14; Pedersen RN, 2012, ARCH DIS CHILD, V97, P227, DOI 10.1136/archdischild-2011-300597; Sfeir R, 2013, J PEDIATR SURG, V48, P1664, DOI 10.1016/j.jpedsurg.2013.03.075; Shang L, 2016, ONCOTARGET, V7, P24374, DOI 10.18632/oncotarget.8223; Soon IS, 2013, J PEDIATR GASTR NUTR, V57, P72, DOI 10.1097/MPG.0b013e318291fee2; Wen T, 2015, J ALLERGY CLIN IMMUN, V135, P187, DOI 10.1016/j.jaci.2014.08.043; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046; Yamada Y, 2013, INT ARCH ALLERGY IMM, V161, P159, DOI 10.1159/000350400	34	13	14	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1455	+		10.1016/j.jaci.2018.08.040	http://dx.doi.org/10.1016/j.jaci.2018.08.040			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30527929	Green Accepted, Bronze			2022-12-18	WOS:000463348900021
J	Hasegawa-Ishii, S; Shimada, A; Imamura, F				Hasegawa-Ishii, Sanae; Shimada, Atsuyoshi; Imamura, Fumiaki			Neuroplastic changes in the olfactory bulb associated with nasal inflammation in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; olfactory system; nasal inflammation; brain plasticity; LPS	CHRONIC RHINOSINUSITIS; TUFTED CELLS; GRANULE CELLS; ODOR MAPS; BRAIN; SINUSITIS; NEURONS; VOLUME; MODEL; NEUROINFLAMMATION	Background: Rhinitis and rhinosinusitis are olfactory disorders caused by inflammation of the nasal passage and paranasal sinuses. Although patients with chronic rhinosinusitis have smaller olfactory bulbs (OBs), there is limited knowledge regarding the influence of chronic nasal inflammation on OB neurons. Objective: Repeated intranasal administration of LPS that induced persistent nasal inflammation in mice caused a loss of olfactory sensory neurons (OSNs) and gliosis and synaptic loss in the OBs within 3 weeks. The present study aimed to clarify the effects of long-term LPS treatment on the OB neurocircuit. Methods: LPS was repeatedly administered into a mouse nostril for up to 24 weeks. For the recovery analyses, the mice received LPS for 10 weeks and were subsequently maintained without additional treatment for another 10 weeks. The effects of these treatments on the OBs were examined histologically. Three or more mice were analyzed per group. Results: Long-term repeated LPS administration caused OB atrophy, particularly in the layers along which OSN axons travel and in the superficial external plexiform layer, in which tufted cells form synapses with interneurons. Interestingly, the OBs recovered from atrophy after cessation of LPS administration: OB volume and superficial external plexiform layer thickness returned to pretreatment levels after the nontreatment period. In contrast, OSN regeneration was incomplete. Conclusion: These results suggest that chronic nasal inflammation induces structural changes in a specific OB circuit related to tufted cells, whereas tufted cells retain a high degree of plasticity that enables recovery from structural damages after inflammation subsides.	[Hasegawa-Ishii, Sanae; Imamura, Fumiaki] Penn State Coll Med, Dept Pharmacol, 500 Univ Dr, Hershey, PA 17033 USA; [Hasegawa-Ishii, Sanae; Shimada, Atsuyoshi] Kyorin Univ, Fac Hlth Sci, Tokyo, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Kyorin University	Imamura, F (corresponding author), Penn State Coll Med, Dept Pharmacol, 500 Univ Dr, Hershey, PA 17033 USA.	fui1@psu.edu			Japan Society for the Promotion of Science, Japan [25290020]	Japan Society for the Promotion of Science, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	Supported by Grants-in Aid for Scientific Research from Japan Society for the Promotion of Science, Japan (contract grant no. 25290020 to A.S.).	Ahmad N, 2008, OTOLARYNG CLIN N AM, V41, P267, DOI 10.1016/j.otc.2007.11.010; Alarabawy RA, 2016, EGYPT J RADIOL NUC M, V47, P487, DOI 10.1016/j.ejrnm.2016.02.011; Benninger MS, 2003, OTOLARYNG HEAD NECK, V129, pS1, DOI 10.1016/S0194-5998(03)01397-4; Bergmann O, 2012, NEURON, V74, P634, DOI 10.1016/j.neuron.2012.03.030; Burton SD, 2014, J PHYSIOL-LONDON, V592, P2097, DOI 10.1113/jphysiol.2013.269886; Chamanza R, 2015, J COMP PATHOL, V153, P287, DOI 10.1016/j.jcpa.2015.08.009; Coussens M, 2008, PLOS ONE, V3, DOI [10.1371/journal.pone.0001571, 10.1371/journal.pone.0002640]; Dalton P, 2004, CURR ALLERGY ASTHM R, V4, P230, DOI 10.1007/s11882-004-0031-3; DeConde AS, 2016, AM J RHINOL ALLERGY, V30, P134, DOI 10.2500/ajra.2016.30.4297; Doty RL, 2001, LARYNGOSCOPE, V111, P409, DOI 10.1097/00005537-200103000-00008; Finegold SM, 2002, CLIN INFECT DIS, V35, P428, DOI 10.1086/341899; Fujiwara N, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00337; Fukunaga I, 2012, NEURON, V75, P320, DOI 10.1016/j.neuron.2012.05.017; Gire DH, 2012, J NEUROSCI, V32, P2964, DOI 10.1523/JNEUROSCI.5580-11.2012; Gudziol V, 2009, BRAIN, V132, P3096, DOI 10.1093/brain/awp243; Gussing F, 2004, EUR J NEUROSCI, V19, P2511, DOI 10.1111/j.0953-816X.2004.03331.x; Ha KR, 2007, AM J RHINOL, V21, P339, DOI 10.2500/ajr.2007.21.3032; Haddad R, 2013, NAT NEUROSCI, V16, P949, DOI 10.1038/nn.3407; Hasegawa-Ishii S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10229-w; Hooten KG, 2015, NEUROTHERAPEUTICS, V12, P364, DOI 10.1007/s13311-014-0329-3; Hummel T, 2011, EXP BRAIN RES, V214, P285, DOI 10.1007/s00221-011-2832-7; Igarashi KM, 2012, J NEUROSCI, V32, P7970, DOI 10.1523/JNEUROSCI.0154-12.2012; Imamura F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00475; Imamura F, 2011, NAT NEUROSCI, V14, P331, DOI 10.1038/nn.2754; Jacob A, 2001, ARCH OTOLARYNGOL, V127, P657, DOI 10.1001/archotol.127.6.657; Kanaya K, 2014, CELL TISSUE RES, V357, P279, DOI 10.1007/s00441-014-1848-2; Kavoi BM, 2011, INT J MORPHOL, V29, P939, DOI 10.4067/S0717-95022011000300047; Kern RC, 2000, LARYNGOSCOPE, V110, P1071, DOI 10.1097/00005537-200007000-00001; Kikuta S, 2013, NEURON, V77, P1122, DOI 10.1016/j.neuron.2013.01.022; Koleske AJ, 2013, NAT REV NEUROSCI, V14, P536, DOI 10.1038/nrn3486; KOLTAI PJ, 1985, LARYNGOSCOPE, V95, P34; Lane AP, 2010, J NEUROSCI, V30, P2324, DOI 10.1523/JNEUROSCI.4507-09.2010; Lindsay R, 2006, OTOLARYNG HEAD NECK, V134, P724, DOI 10.1016/j.otohns.2005.11.048; Litvack JR, 2008, LARYNGOSCOPE, V118, P2225, DOI 10.1097/MLG.0b013e318184e216; Ma Y, 2005, NEUROSCIENCE, V135, P1203, DOI 10.1016/j.neuroscience.2005.07.014; Ma Y, 2008, FRONT NEUROANAT, V2, DOI 10.3389/neuro.05.001.2008; Malnic B, 2004, P NATL ACAD SCI USA, V101, P2584, DOI 10.1073/pnas.0307882100; Mandairon N, 2006, NEUROSCIENCE, V141, P443, DOI 10.1016/j.neuroscience.2006.03.066; McEwen BS, 2016, NEUROPSYCHOPHARMACOL, V41, P3, DOI 10.1038/npp.2015.171; McEwen BS, 2013, NEURON, V79, P16, DOI 10.1016/j.neuron.2013.06.028; Mitsui Sachiko, 2011, Neural Syst Circuits, V1, P5, DOI 10.1186/2042-1001-1-5; MORI K, 1983, J COMP NEUROL, V219, P339, DOI 10.1002/cne.902190308; Mottahedin A, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00190; Mueller A, 2005, J NEURAL TRANSM, V112, P1363, DOI 10.1007/s00702-005-0280-x; Murai A, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0242-16.2016; Nagayama S, 2004, J NEUROPHYSIOL, V91, P2532, DOI 10.1152/jn.01266.2003; Nagayama S, 2014, FRONT NEURAL CIRCUIT, V8, DOI 10.3389/fncir.2014.00098; Nagayama S, 2010, FRONT NEURAL CIRCUIT, V4, DOI 10.3389/fncir.2010.00120; Olivenza R, 2000, J NEUROCHEM, V74, P785, DOI 10.1046/j.1471-4159.2000.740785.x; ORONA E, 1984, J COMP NEUROL, V226, P346, DOI 10.1002/cne.902260305; Phillips JE, 2009, CAN J VET RES, V73, P205; Richard MB, 2010, P NATL ACAD SCI USA, V107, P15613, DOI 10.1073/pnas.1007931107; Rombaux P, 2009, RHINOLOGY, V47, P3; Rombaux P, 2008, AM J RHINOL, V22, P598, DOI 10.2500/ajr.2008.22.3237; Rosenfeld RM, 2015, OTOLARYNG HEAD NECK, V152, P598, DOI 10.1177/0194599815574247; Sanai N, 2011, NATURE, V478, P382, DOI 10.1038/nature10487; Shin HW, 2016, LARYNSCOPE INVESTIG, V1, P116, DOI 10.1002/lio2.29; Takahashi YK, 2004, J NEUROSCI, V24, P8690, DOI 10.1523/JNEUROSCI.2510-04.2004; Thomann PA, 2009, NEUROBIOL AGING, V30, P838, DOI 10.1016/j.neurobiolaging.2007.08.001; Vedin V, 2009, J COMP NEUROL, V513, P375, DOI 10.1002/cne.21973; Wang J, 2011, AM J NEURORADIOL, V32, P677, DOI 10.3174/ajnr.A2350; Wang SB, 2017, EXP THER MED, V14, P5275, DOI 10.3892/etm.2017.5208; Weisbecker V, 2012, BRAIN STRUCT FUNCT, V217, P677, DOI 10.1007/s00429-011-0366-1; Wolfensberger M, 2002, CHEM SENSES, V27, P617, DOI 10.1093/chemse/27.7.617; Yamaguchi M, 2005, P NATL ACAD SCI USA, V102, P9697, DOI 10.1073/pnas.0406082102; Yee KK, 2009, ANN NY ACAD SCI, V1170, P590, DOI 10.1111/j.1749-6632.2009.04364.x; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800	67	13	15	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					978	+		10.1016/j.jaci.2018.09.028	http://dx.doi.org/10.1016/j.jaci.2018.09.028			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30315829	Bronze			2022-12-18	WOS:000460272900018
J	Pan, DX; Buchheit, KM; Samuchiwal, SK; Liu, T; Cirka, H; Raff, H; Boyce, JA				Pan, Dingxin; Buchheit, Kathleen M.; Samuchiwal, Sachin K.; Liu, Tao; Cirka, Haley; Raff, Hannah; Boyce, Joshua A.			COX-1 mediates IL-33-induced extracellular signal-regulated kinase activation in mast cells: Implications for aspirin sensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eicosanoids; mast cells; IL-33; aspirin-exacerbated respiratory disease; cyclooxygenase asthma	INNATE LYMPHOID-CELLS; EXACERBATED RESPIRATORY-DISEASE; CYSTEINYL LEUKOTRIENE RECEPTOR; CYTOSOLIC PHOSPHOLIPASE A(2); AIRWAY SMOOTH-MUSCLE; PROSTAGLANDIN D-2; CHRONIC RHINOSINUSITIS; CYTOKINE PRODUCTION; ALLERGEN CHALLENGE; ARACHIDONIC-ACID	Background: Classical Fc epsilon RI-induced mast cell (MC) activation causes synthesis of arachidonic acid (AA)-derived eicosanoids (leukotriene [LT] C-4, prostaglandin [PG] D-2, and thromboxane A(2)), which mediate vascular leak, bronchoconstriction, and effector cell chemotaxis. Little is known about the significance and regulation of eicosanoid generation in response to nonclassical MC activation mechanisms. Objectives: We sought to determine the regulation and significance of MC-derived eicosanoids synthesized in response to IL-33, a cytokine critical to innate type 2 immunity. Methods: We used an ex vivo model of mouse bone marrow-derived mast cells and an IL-33-dependent in vivo model of aspirin-exacerbated respiratory disease (AERD). Results: IL-33 potently liberates AA and elicits LTC4, PGD(2), and thromboxane A(2) production by bone marrow-derived mast cells. Unexpectedly, the constitutive function of COX-1 is required for IL-33 to activate group IVa cytosolic phospholipase A2 with consequent AA release for synthesis of all eicosanoids, including CysLTs. In contrast, COX-1 was dispensable for FceRI-driven CysLT production. Inhibition of COX-1 prevented IL-33-induced phosphorylation of extracellular signal-related kinase, an upstream effector of cytosolic phospholipase A(2), which was restored by exogenous PGH2, implying that the effects of COX-1 required its catalytic function. Administration of a COX-1-selective antagonist to mice completely prevented the generation of both PGD(2) and LTC4 in a model of AERD in which MC activation is IL-33 driven. Conclusions: MC-intrinsic COX-1 amplifies IL-33-induced activation in the setting of innate type 2 immunity and might help explain the phenomenon of therapeutic desensitization to aspirin by nonselective COX inhibitors in patients with AERD.	[Pan, Dingxin; Buchheit, Kathleen M.; Samuchiwal, Sachin K.; Liu, Tao; Boyce, Joshua A.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Pan, Dingxin; Buchheit, Kathleen M.; Samuchiwal, Sachin K.; Liu, Tao; Cirka, Haley; Raff, Hannah; Boyce, Joshua A.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Boyce, JA (corresponding author), Brigham & Womens Hosp, 60 Fenwood Dr,Bldg Transformat Med, Boston, MA 02115 USA.	jboyce@rics.bwh.harvard.edu	Samuchiwal, Sachin/AAL-2904-2021; Pan, Dingxin/AAE-1205-2021		National Institutes of Health [R37AI052353, R01AI13601, R01HL136209, U19AI095219, R01AI078908, T32AI007306]; Kaye Family; Vinik Family; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL136209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI095219, T32AI007306, R01AI136041, R01AI078908, R37AI052353] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Kaye Family; Vinik Family; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants R37AI052353, R01AI13601, R01HL136209, U19AI095219, R01AI078908, R01AI078908, and T32AI007306 and generous contributions from the Vinik Family and the Kaye Family.	Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Baba S, 2014, LARYNGOSCOPE, V124, pE115, DOI 10.1002/lary.24462; Baothman BK, 2018, EUR J PHARMACOL, V819, P225, DOI 10.1016/j.ejphar.2017.12.005; Berges-Gimeno MP, 2003, J ALLERGY CLIN IMMUN, V111, P180, DOI 10.1067/mai.2003.7; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Buchheit KM, 2016, J ALLERGY CLIN IMMUN, V137, P1566, DOI 10.1016/j.jaci.2015.10.020; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Enoksson M, 2011, J IMMUNOL, V186, P2523, DOI 10.4049/jimmunol.1003383; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Hamilton A, 1998, J ALLERGY CLIN IMMUN, V102, P177, DOI 10.1016/S0091-6749(98)70083-1; Hartert TV, 2000, AM J RESP CRIT CARE, V162, P637, DOI 10.1164/ajrccm.162.2.9904038; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hepworth MR, 2012, P NATL ACAD SCI USA, V109, P6644, DOI 10.1073/pnas.1112268109; Higaki T, 2012, CLIN EXP ALLERGY, V42, P1217, DOI 10.1111/j.1365-2222.2012.04015.x; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; HOLGATE ST, 1984, J IMMUNOL, V133, P2138; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Ishizuka T, 1998, CLIN EXP IMMUNOL, V112, P464; Ishizuka T, 1996, EUR J PHARMACOL, V312, P367, DOI 10.1016/0014-2999(96)00478-5; Israel E, 2002, J ALLERGY CLIN IMMUN, V110, P847, DOI 10.1067/mai.2002.129413; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Kanaoka Y, 2013, J BIOL CHEM, V288, P10967, DOI 10.1074/jbc.C113.453704; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Laidlaw TM, 2013, IMMUNOL ALLERGY CLIN, V33, P195, DOI 10.1016/j.iac.2012.11.006; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; Lewis R A, 1981, Kroc Found Ser, V14, P239; Liu T, 2015, J IMMUNOL, V195, P3537, DOI 10.4049/jimmunol.1500905; Liu T, 2013, P NATL ACAD SCI USA, V110, P16987, DOI 10.1073/pnas.1313185110; Lorentz A, 2001, IMMUNOL REV, V179, P57, DOI 10.1034/j.1600-065X.2001.790106.x; Lynch KR, 1999, NATURE, V399, P789; MALAVIYA R, 1993, J BIOL CHEM, V268, P4939; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; Mellor EA, 2002, J EXP MED, V195, P583, DOI 10.1084/jem.20020044; Miyahara N, 2005, J IMMUNOL, V174, P4979, DOI 10.4049/jimmunol.174.8.4979; Moulin D, 2007, CYTOKINE, V40, P216, DOI 10.1016/j.cyto.2007.09.013; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; NASSER SMS, 1995, AM J RESP CRIT CARE, V151, P1326, DOI 10.1164/ajrccm.151.5.7735581; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Oskeritzian CA, 2005, J ALLERGY CLIN IMMUN, V115, P1162, DOI 10.1016/j.jaci.2005.02.022; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Rao PNP, 2008, J PHARM PHARM SCI, V11, P81, DOI 10.18433/J3T886; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; Shaw JL, 2012, INT FORUM ALLERGY RH, V2, P233, DOI 10.1002/alr.21021; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; Tsuchiya H, 2015, VET IMMUNOL IMMUNOP, V168, P223, DOI 10.1016/j.vetimm.2015.10.003; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WENZEL SE, 1991, J ALLERGY CLIN IMMUN, V87, P540, DOI 10.1016/0091-6749(91)90013-E; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002; Woessner KM, 2002, ARTHRITIS RHEUM, V46, P2201, DOI 10.1002/art.10426; Wojno EDT, 2015, MUCOSAL IMMUNOL, V8, P1313, DOI 10.1038/mi.2015.21; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Xue LZ, 2005, J IMMUNOL, V175, P6531, DOI 10.4049/jimmunol.175.10.6531; Yasuda K, 2012, P NATL ACAD SCI USA, V109, P3451, DOI 10.1073/pnas.1201042109; Yu CK, 2003, J IMMUNOL, V171, P3808, DOI 10.4049/jimmunol.171.7.3808	63	13	13	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1047	+		10.1016/j.jaci.2018.06.033	http://dx.doi.org/10.1016/j.jaci.2018.06.033			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30017554	Green Accepted, Bronze			2022-12-18	WOS:000460272900025
J	Akiyama, M				Akiyama, Masashi			Early-onset generalized pustular psoriasis is representative of autoinflammatory keratinization diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Akiyama, Masashi] Nagoya Univ, Grad Sch Med, Dept Dermatol, Nagoya, Aichi, Japan	Nagoya University	Akiyama, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Dermatol, Nagoya, Aichi, Japan.	makiyama@med.nagoya-u.ac.jp	Akiyama, Masashi/I-1122-2012	Akiyama, Masashi/0000-0001-5863-9315				Akiyama M, 2017, J ALLERGY CLIN IMMUN, V140, P1545, DOI 10.1016/j.jaci.2017.05.019; Hussain S, 2015, J ALLERGY CLIN IMMUN, V135, P1067, DOI 10.1016/j.jaci.2014.09.043; Li ZT, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000011741, 10.1097/md.0000000000011741]; Mossner R, 2018, BRIT J DERMATOL, V178, P740, DOI 10.1111/bjd.15867; Setta-Kaffetzi N, 2013, J INVEST DERMATOL, V133, P1366, DOI 10.1038/jid.2012.490; Sugiura K, 2013, J INVEST DERMATOL, V133, P2514, DOI 10.1038/jid.2013.230; Twelves S, 2019, J ALLERGY CLIN IMMUN, V143, P1021, DOI 10.1016/j.jaci.2018.06.038	7	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					809	810		10.1016/j.jaci.2018.11.009	http://dx.doi.org/10.1016/j.jaci.2018.11.009			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	30606494	Bronze			2022-12-18	WOS:000457718700051
J	Chuang, YT; Leung, K; Chang, YJ; DeKruyff, RH; Savage, PB; Cruse, R; Benoit, C; Elewaut, D; Baumgarth, N; Umetsu, DT				Chuang, Ya-Ting; Leung, Krystle; Chang, Ya-Jen; DeKruyff, Rosemarie H.; Savage, Paul B.; Cruse, Richard; Benoit, Christophe; Elewaut, Dirk; Baumgarth, Nicole; Umetsu, Dale T.			A natural killer T-cell subset that protects against airway hyperreactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Natural killer T subset; asthma; airway hyperreactivity; hygiene hypothesis; influenza; CD38	NKT CELLS; ALPHA-GALACTOSYLCERAMIDE; BONE-MARROW; EARLY-LIFE; ASTHMA; INNATE; EXPOSURE; LIGAND; ACTIVATION; MICE	Background: Infection of suckling mice with influenza virus expands a CD4(-)CD8(-) double-negative (DN) natural killer T (NKT) cell subpopulation that protects the mice as adults against allergen-induced airway hyperreactivity (AHR). However, this NKT cell subset has not been characterized, and the underlying mechanisms of protection remain unknown. Objective: We characterized this specific NKT cell subpopulation that developed during influenza infection in neonatal mice and that suppressed the subsequent development of AHR. Methods: A cell-surface marker was identified by comparing the mRNA expression profile of wild-type CD4+ NKT cells with that of suppressive V alpha 14 DN NKT cells. The marker-enriched NKT cell subset was then analyzed for its cytokine profile and its suppressive in vitro and in vivo abilities. Results: We showed that DN NKT cells with high CD38 expression produced IFN-gamma, but not IL-17, IL-4, or IL-13, and inhibited development of AHR through contact-dependent suppression of helper CD4 T-cell proliferation. The NKT subset expanded in the lungs of neonatal mice after infection with influenza and also after treatment of neonatal mice with Nu-alpha-GalCer, which effectively increased DN CD38(hi) NKT cell numbers. Conclusion: These results suggest that early/neonatal exposure to infection or antigen challenge affects subsequent lung immunity by altering the cellular composition of cells in the lung and that some subsets of NKT cells suppress AHR. These results provide a possible mechanism by which prior infections can protect against the development of allergic asthma and might be further explored as a protective measure for young children.	[Chuang, Ya-Ting; Leung, Krystle; Chang, Ya-Jen; DeKruyff, Rosemarie H.; Umetsu, Dale T.] Harvard Med Sch, Boston Childrens Hosp, Dept Pediat, Boston, MA USA; [Chuang, Ya-Ting] Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan; [Leung, Krystle] Harvard Med Sch, Dept Med, Boston, MA USA; [Chang, Ya-Jen] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [DeKruyff, Rosemarie H.] Stanford Univ, Dept Med, Stanford, CA 94305 USA; [Savage, Paul B.] Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA; [Cruse, Richard; Benoit, Christophe] Harvard Med Sch, Div Immunol, Dept Microbiol & Immunobiol, Boston, MA USA; [Elewaut, Dirk] Univ Ghent, Dept Rheumatol, Fac Med & Hlth Sci, Ghent, Belgium; [Elewaut, Dirk] Univ Ghent, Unit Mol Immunol & Inflammat, VIB Inflammat Res Ctr, Ghent, Belgium; [Baumgarth, Nicole] Univ Calif Davis, Dept Pathol Microbiol & Immunol, Sch Vet Med, Davis, CA 95616 USA; [Umetsu, Dale T.] Genentech Inc, San Francisco, CA 94080 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; National Taiwan University; National Taiwan University Hospital; Harvard University; Harvard Medical School; Academia Sinica - Taiwan; Stanford University; Brigham Young University; Harvard University; Harvard Medical School; Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; University of California System; University of California Davis; Roche Holding; Genentech	Umetsu, DT (corresponding author), Genentech Inc, San Francisco, CA 94080 USA.; Umetsu, DT (corresponding author), 1 DNA Way,MS 453b, San Francisco, CA 94080 USA.	dale.umetsu@gmail.com	Savage, Paul B/HGB-3414-2022; Chang, Ya-Jen/O-1584-2018; Baumgarth, Nicole/AAI-6949-2020; Savage, Paul B/E-1448-2011	Savage, Paul B/0000-0002-4642-6109; Chang, Ya-Jen/0000-0003-1377-6142; Savage, Paul B/0000-0002-4642-6109; Elewaut, Dirk/0000-0002-7468-974X	National Institutes of Health [RO1 AI26322, RC1 HL099839, PO1AI054456]; Ministry of Science and Technology (MOST) of Taiwan [105-2628-B-002-016-MY2]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC1HL099839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026322, P01AI054456] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Science and Technology (MOST) of Taiwan(Ministry of Science and Technology, Taiwan); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants RO1 AI26322, RC1 HL099839, and PO1AI054456 and Ministry of Science and Technology (MOST) of Taiwan grant 105-2628-B-002-016-MY2.	Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Aspeslagh S, 2011, EMBO J, V30, P2294, DOI 10.1038/emboj.2011.145; AVITAL A, 1991, AM REV RESPIR DIS, V144, P36, DOI 10.1164/ajrccm/144.1.36; Beasley R, 2015, LANCET, V386, P1075, DOI 10.1016/S0140-6736(15)00156-7; Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711; Beura LK, 2016, NATURE, V532, P512, DOI 10.1038/nature17655; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Brennan PJ, 2013, NAT REV IMMUNOL, V13, P101, DOI 10.1038/nri3369; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Chang YJ, 2011, J CLIN INVEST, V121, P57, DOI 10.1172/JCI44845; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; Gray J, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf9412; Hachem P, 2005, EUR J IMMUNOL, V35, P2793, DOI 10.1002/eji.200535268; Holgate ST, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.25; Hong S, 2001, NAT MED, V7, P1052, DOI 10.1038/nm0901-1052; Hongo D, 2012, BLOOD, V119, P1581, DOI 10.1182/blood-2011-08-371948; Ikehara Y, 2000, J CLIN INVEST, V105, P1761, DOI 10.1172/JCI8922; Jiang X, 2007, AM J TRANSPLANT, V7, P1482, DOI 10.1111/j.1600-6143.2007.01827.x; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; Kawano T, 1999, CANCER RES, V59, P5102; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kim HY, 2014, NAT MED, V20, P54, DOI 10.1038/nm.3423; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Lehuen A, 1998, J EXP MED, V188, P1831, DOI 10.1084/jem.188.10.1831; Lynch L, 2015, NAT IMMUNOL, V16, P85, DOI 10.1038/ni.3047; Lynch L, 2012, IMMUNITY, V37, P574, DOI 10.1016/j.immuni.2012.06.016; Matangkasombut P, 2009, MUCOSAL IMMUNOL, V2, P383, DOI 10.1038/mi.2009.96; Matsuda H, 2005, AM J RESP CELL MOL, V33, P22, DOI 10.1165/rcmb.2004-0010OC; Metelitsa LS, 2001, J IMMUNOL, V167, P3114, DOI 10.4049/jimmunol.167.6.3114; Monteiro M, 2010, J IMMUNOL, V185, P2157, DOI 10.4049/jimmunol.1000359; Morishima Y, 2005, EUR J IMMUNOL, V35, P2803, DOI 10.1002/eji.200525994; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; PALATHUMPAT V, 1992, J IMMUNOL, V149, P808; Patton DT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017359; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Randall TD, 2010, ADV IMMUNOL, V107, P187, DOI [10.1016/S0065-2776(10)07002-1, 10.1016/B978-0-12-381300-8.00007-1]; Read S, 1998, EUR J IMMUNOL, V28, P3435, DOI 10.1002/(SICI)1521-4141(199811)28:11<3435::AID-IMMU3435>3.3.CO;2-G; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Sag D, 2014, J CLIN INVEST, V124, P3725, DOI 10.1172/JCI72308; Seino K, 2001, P NATL ACAD SCI USA, V98, P2577, DOI 10.1073/pnas.041608298; Sharif S, 2001, NAT MED, V7, P1057, DOI 10.1038/nm0901-1057; Shimizu K, 2014, P NATL ACAD SCI USA, V111, P12474, DOI 10.1073/pnas.1406240111; Sonoda KH, 2002, J IMMUNOL, V168, P2028, DOI 10.4049/jimmunol.168.4.2028; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Taniguchi M, 2000, SEMIN IMMUNOL, V12, P543, DOI 10.1006/smim.2000.0270; Trappeniers M, 2008, J AM CHEM SOC, V130, P16468, DOI 10.1021/ja8064182; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; von Mutius E, 2016, J ALLERGY CLIN IMMUN, V137, P680, DOI 10.1016/j.jaci.2015.12.1301; Wenzel S, 2012, CLIN EXP ALLERGY, V42, P650, DOI 10.1111/j.1365-2222.2011.03929.x; Yu AX, 2009, IMMUNITY, V30, P204, DOI 10.1016/j.immuni.2008.11.014; Zeng DF, 1999, J EXP MED, V189, P1073, DOI 10.1084/jem.189.7.1073	55	13	14	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					565	576		10.1016/j.jaci.2018.03.022	http://dx.doi.org/10.1016/j.jaci.2018.03.022			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	29852257	Bronze			2022-12-18	WOS:000457718700017
J	Delmonte, OM; Fleisher, TA				Delmonte, Ottavia M.; Fleisher, Thomas A.			Flow cytometry: Surface markers and beyond	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunophenotype; flow cytometry; primary immunodeficiency; immune function testing	LINKED LYMPHOPROLIFERATIVE DISEASE; COMMON VARIABLE IMMUNODEFICIENCY; CHRONIC GRANULOMATOUS-DISEASE; ANTIBODY-DEFICIENCY SYNDROME; IMMUNE DYSREGULATION; RECOMBINATION ACTIVITY; GERMLINE MUTATIONS; MASS CYTOMETRY; CELL-FUNCTION; DIAGNOSIS	Flow cytometry is a routinely available laboratory method to study cells in suspension from a variety of human sources. Application of this technology as a clinical laboratory method has evolved from the identification of cell-surface proteins to characterizing intracellular proteins and providing multiple different techniques to assess specific features of adaptive and innate immune function. This expanded menu of flow cytometric testing approaches has increased the utility of this platform in characterizing and diagnosing disorders of immune function.	[Delmonte, Ottavia M.] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Fleisher, Thomas A.] NIH, Immunol Serv, Dept Lab Med, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Delmonte, OM (corresponding author), NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	ottavia.delmonte@nih.gov			Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.	Agematsu K, 1998, J CLIN INVEST, V102, P853, DOI 10.1172/JCI3409; Alangari A, 2012, J ALLERGY CLIN IMMUN, V130, P481, DOI 10.1016/j.jaci.2012.05.043; Allsopp Catherine E M, 2002, Methods Mol Med, V72, P409, DOI 10.1385/1-59259-271-6:409; Aluri J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00188; BERLINER N, 1986, BLOOD, V67, P80; Bjornson ZB, 2013, CURR OPIN IMMUNOL, V25, P484, DOI 10.1016/j.coi.2013.07.004; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Brown SD, 2017, BIOINFORMATICS, V33, P1111, DOI 10.1093/bioinformatics/btw810; Bryceson YT, 2012, BLOOD, V119, P2754, DOI 10.1182/blood-2011-08-374199; Cols M, 2016, J ALLERGY CLIN IMMUN, V137, P1206, DOI 10.1016/j.jaci.2015.09.013; Cote M, 2009, J CLIN INVEST, V119, P3765, DOI 10.1172/JCI40732; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; d'Hennezel E, 2012, J MED GENET, V49, P291, DOI 10.1136/jmedgenet-2012-100759; El Hawary R, 2016, J CLIN IMMUNOL, V36, P610, DOI 10.1007/s10875-016-0297-y; Etzioni A, 2010, CLIN REV ALLERG IMMU, V38, P54, DOI 10.1007/s12016-009-8132-3; Ferrari S, 2001, P NATL ACAD SCI USA, V98, P12614, DOI 10.1073/pnas.221456898; Flanagan SE, 2014, NAT GENET, V46, P812, DOI 10.1038/ng.3040; Foster Barbara, 2007, Curr Protoc Immunol, VChapter 6, DOI 10.1002/0471142735.im0624s78; Gamez-Diaz L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00720; Gifford CE, 2014, CYTOM PART B-CLIN CY, V86, P263, DOI 10.1002/cyto.b.21166; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Gulino AV, 2003, CURR OPIN RHEUMATOL, V15, P422, DOI 10.1097/00002281-200307000-00009; Hanna S, 2014, J ALLERGY CLIN IMMUN, V134, P269, DOI 10.1016/j.jaci.2014.06.001; Hsieh EWY, 2016, CURR OPIN ALLERGY CL, V16, P549, DOI 10.1097/ACI.0000000000000319; Janssen E, 2014, CLIN IMMUNOL, V150, P220, DOI 10.1016/j.clim.2013.12.006; Jirapongsananuruk O, 2003, J ALLERGY CLIN IMMUN, V111, P374, DOI 10.1067/mai.2003.58; Johnson TS, 2011, J IMMUNOL METHODS, V364, P1, DOI 10.1016/j.jim.2010.11.006; Kanegane H, 2001, J ALLERGY CLIN IMMUN, V108, P1012, DOI 10.1067/mai.2001.120133; Kanegane H, 2018, ALLERGOL INT, V67, P43, DOI 10.1016/j.alit.2017.06.003; Kawai S, 2002, J IMMUNOL METHODS, V260, P195, DOI 10.1016/S0022-1759(01)00549-X; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Kuhns DB, 2010, NEW ENGL J MED, V363, P2600, DOI 10.1056/NEJMoa1007097; Lanzi G, 2012, J EXP MED, V209, P29, DOI 10.1084/jem.20110896; Lee WI, 2005, BLOOD, V105, P1881, DOI 10.1182/blood-2003-12-4420; Lee YN, 2014, J ALLERGY CLIN IMMUN, V133, P1099, DOI 10.1016/j.jaci.2013.10.007; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Lucas CL, 2016, NAT REV IMMUNOL, V16, P702, DOI 10.1038/nri.2016.93; Lucas CL, 2014, J EXP MED, V211, P2537, DOI 10.1084/jem.20141759; Marcenaro S, 2006, BLOOD, V108, P2316, DOI 10.1182/blood-2006-04-015693; Marciano BE, 2018, J ALLERGY CLIN IMMUN, V141, P365, DOI 10.1016/j.jaci.2017.04.035; Marsh RA, 2009, CYTOM PART B-CLIN CY, V76B, P334, DOI 10.1002/cyto.b.20473; Mei HE, 2015, J IMMUNOL, V194, P2022, DOI 10.4049/jimmunol.1402661; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; Nakajima M, 2009, EUR J HAEMATOL, V82, P223, DOI 10.1111/j.1600-0609.2008.01180.x; Notarangelo LD, 2008, CURR OPIN HEMATOL, V15, P30, DOI 10.1097/MOH.0b013e3282f30448; Oliveira JB, 2010, BLOOD, V116, pE35, DOI 10.1182/blood-2010-04-280347; Oliveira JB, 2008, CURR OPIN ALLERGY CL, V8, P499, DOI 10.1097/ACI.0b013e328312c790; Ornatsky O, 2010, J IMMUNOL METHODS, V361, P1, DOI 10.1016/j.jim.2010.07.002; Ottou FG, 2014, BRIT J HAEMATOL, V166, P50, DOI 10.1111/bjh.12839; Pai SY, 2014, J ALLERGY CLIN IMMUN, V134, P221, DOI 10.1016/j.jaci.2014.02.023; Picard C, 2011, CLIN MICROBIOL REV, V24, P490, DOI 10.1128/CMR.00001-11; Pilch H, 2002, CLIN DIAGN LAB IMMUN, V9, P257, DOI 10.1128/CDLI.9.2.257-266.2002; Poujol F, 2014, J IMMUNOL METHODS, V415, P71, DOI 10.1016/j.jim.2014.10.006; Rosel AL, 2015, J ALLERGY CLIN IMMUN, V135, P198, DOI 10.1016/j.jaci.2014.06.022; Rubin TS, 2017, BLOOD, V129, P2993, DOI 10.1182/blood-2016-12-753830; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Schwab C, 2018, J ALLERGY CLIN IMMUN, V142, P1932, DOI 10.1016/j.jaci.2018.02.055; Seyama K, 1998, BLOOD, V92, P2421, DOI 10.1182/blood.V92.7.2421.2421_2421_2434; Shinozaki K, 2002, INT IMMUNOL, V14, P1215, DOI 10.1093/intimm/dxf084; SOTTINI A, 1995, BLOOD, V85, P2105, DOI 10.1182/blood.V85.8.2105.bloodjournal8582105; Spitzer MH, 2016, CELL, V165, P780, DOI 10.1016/j.cell.2016.04.019; SUTHERLAND DR, 1994, EXP HEMATOL, V22, P1003; Tirosh I, 2019, J ALLERGY CLIN IMMUN, V143, P726, DOI 10.1016/j.jaci.2018.04.027; van de Vijver E, 2013, HEMATOL ONCOL CLIN N, V27, P101, DOI 10.1016/j.hoc.2012.10.001; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Villa A, 2008, J ALLERGY CLIN IMMUN, V122, P1082, DOI 10.1016/j.jaci.2008.09.037; von Bernuth H, 2006, PEDIATRICS, V118, P2498, DOI 10.1542/peds.2006-1845; Wada T, 2001, P NATL ACAD SCI USA, V98, P8697, DOI 10.1073/pnas.151260498; Wang Lili, 2017, Curr Protoc Cytom, V79, DOI 10.1002/cpcy.14; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Warnatz K, 2008, CYTOM PART B-CLIN CY, V74B, P261, DOI 10.1002/cyto.b.20432; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Wu D, 2016, AM J CLIN PATHOL, V145, P467, DOI 10.1093/ajcp/aqw015; Yamaguchi K, 2002, BLOOD, V100, P1208, DOI 10.1182/blood-2002-01-0211	79	13	13	3	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					528	537		10.1016/j.jaci.2018.08.011	http://dx.doi.org/10.1016/j.jaci.2018.08.011			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	30170120	Bronze			2022-12-18	WOS:000457718700007
J	Ballas, ZK				Ballas, Zuhair K.			The 2018 Nobel Prize in Physiology or Medicine: An exemplar of bench to bedside in immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Nobel Prize; immune checkpoint; cytotoxic T lymphocyte-associated antigen 4; CD28; cancer; immunotherapy; checkpoint blockade	CTLA-4; PD-1		[Ballas, Zuhair K.] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA; [Ballas, Zuhair K.] Iowa City VA Med Ctr, Iowa City, IA USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Ballas, ZK (corresponding author), Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA.; Ballas, ZK (corresponding author), Univ Iowa Hosp & Clin, Internal Med, C42-E13 GH,200 Hawkins Dr, Iowa City, IA 52242 USA.	ballasz@uiowa.edu		Ballas, Zuhair/0000-0001-5569-1230; Knaack, Aaron/0000-0001-7712-1415				Gettinger SN, 2015, J CLIN ONCOL, V33, P2004, DOI 10.1200/JCO.2014.58.3708; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Sharpe AH, 2009, IMMUNOL REV, V229, P5, DOI 10.1111/j.1600-065X.2009.00784.x; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Wieder T, 2018, J ALLERGY CLIN IMMUN, V142, P1403, DOI 10.1016/j.jaci.2018.02.042	10	13	15	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1752	1753		10.1016/j.jaci.2018.10.021	http://dx.doi.org/10.1016/j.jaci.2018.10.021			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	30539724	Bronze			2022-12-18	WOS:000452315800007
J	Yamani, A; Wu, D; Waggoner, L; Noah, T; Koleske, AJ; Finkelman, F; Hogan, SP				Yamani, Amnah; Wu, David; Waggoner, Lisa; Noah, Taeko; Koleske, Anthony J.; Finkelman, Fred; Hogan, Simon P.			The vascular endothelial specific IL-4 receptor alpha-ABL1 kinase signaling axis regulates the severity of IgE-mediated anaphylactic reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-4 receptor alpha chain; hypovolemic shock; IgE and mast cells; food-induced anaphylaxis; histamine; vascular endothelial barrier dysfunction; ABL1 kinase	LIGHT-CHAIN KINASE; VE-CADHERIN; MAST-CELLS; LINEAGE ANALYSIS; INHIBITION; PERMEABILITY; ASTHMA; BASOPHILS; HISTAMINE; ALLERGY	Background: Severe IgE-mediated, food-induced anaphylactic reactions are characterizedby pulmonaryvenous vasodilatation and fluid extravasation, which are thought to lead to the life-threatening anaphylactic phenotype. The underlying immunologic and cellular processes involved in driving fluid extravasation and the severe anaphylactic phenotype are not fully elucidated. Objective: We sought to define the interaction and requirement of IL-4 and vascular endothelial (VE) IL-4 receptor alpha chain (IL-4R alpha) signaling in histamine-abelson murine leukemia viral oncogene homology 1 (ABL1)-mediated VE dysfunction and fluid extravasation in the severity of IgE-mediated anaphylactic reactions in mice. Methods: Mice deficient in VE IL-4R alpha and models of passive and active oral antigen- and IgE-induced anaphylaxis were used to define the requirements of the VE IL-4R alpha and ABL1 pathway in severe anaphylactic reactions. The human VE cell line (EA. hy926 cells) and pharmacologic (imatinib) and genetic (short hairpin RNA knockdown of IL4RA and ABL1) approaches were used to define the requirement of this pathway in VE barrier dysfunction. Results: IL-4 exacerbation of histamine-induced hypovolemic shock in mice was dependent on VE expression of IL-4R alpha. IL-4- and histamine-induced ABL1 activation in human VE cells and VE barrier dysfunction was ABL1-dependent. Development of severe IgE-mediated hypovolemia and shock required VE-restricted ABL1 expression. Treatment of mice with a history of food-induced anaphylaxis with the ABL kinase inhibitor imatinib protected the mice from severe IgE-mediated anaphylaxis. Conclusion: IL-4 amplifies IgE- and histamine-induced VE dysfunction, fluid extravasation, and the severity of anaphylaxis through a VE IL-4R alpha/ABL1-dependent mechanism. These studies implicate an important contribution by the VE compartment in the severity of anaphylaxis and identify a new pathway for therapeutic intervention of IgE-mediated reactions.	[Yamani, Amnah; Wu, David; Waggoner, Lisa; Noah, Taeko; Hogan, Simon P.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol,Dept Pediat, Cincinnati, OH 45221 USA; [Finkelman, Fred] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Immunobiol,Dept Pediat, Cincinnati, OH 45221 USA; [Koleske, Anthony J.] Yale Univ, Dept Biol & Biomed Sci, New Haven, CT USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Yale University	Hogan, SP (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, MLC 7028,3333 Burnet Ave, Cincinnati, OH 45229 USA.	simon.hogan@cchmc.org		Hogan, Simon/0000-0001-5793-4304	National Institutes of Health [R01 AI073553, R01 AI 112626, R01 DK090119, P30DK078392, U19A1070235]; Food Allergy Research Education Award; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI112626, R01AI073553, U19AI070235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK090119, P30DK078392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH115939] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS089662, R01NS105640] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy Research Education Award; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by National Institutes of Health grants R01 AI073553, R01 AI 112626, R01 DK090119 (to S.P.H.), P30DK078392, and U19A1070235 and a Food Allergy Research Education Award (to S.P.H.).	Ahrens R, 2012, AM J PATHOL, V180, P1535, DOI 10.1016/j.ajpath.2011.12.036; Alcaide P, 2012, AM J PHYSIOL-CELL PH, V303, pC385, DOI 10.1152/ajpcell.00126.2012; Alva JA, 2006, DEV DYNAM, V235, P759, DOI 10.1002/dvdy.20643; Aman J, 2012, CIRCULATION, V126, P2728, DOI 10.1161/CIRCULATIONAHA.112.134304; Andriopoulou P, 1999, ARTERIOSCL THROM VAS, V19, P2286, DOI 10.1161/01.ATV.19.10.2286; BANIYASH M, 1984, EUR J IMMUNOL, V14, P799, DOI 10.1002/eji.1830140907; BEAUPRE PN, 1984, ANESTHESIOLOGY, V60, P482, DOI 10.1097/00000542-198405000-00017; BERGMAN RK, 1965, J IMMUNOL, V95, P1; Bhasin M, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-342; Black JH, 1937, AM J CLIN PATHOL, V7, P300; Blaeser F, 2003, J EXP MED, V198, P1189, DOI 10.1084/jem.20030471; Bouis Diane, 2001, Angiogenesis, V4, P91, DOI 10.1023/A:1012259529167; Brandt EB, 2009, J ALLERGY CLIN IMMUN, V123, P53, DOI 10.1016/j.jaci.2008.10.001; Brown SGA, 2007, IMMUNOL ALLERGY CLIN, V27, P165, DOI 10.1016/j.iac.2007.03.003; Brown SGA, 2013, J ALLERGY CLIN IMMUN, V132, P1141, DOI 10.1016/j.jaci.2013.06.015; Burton OT, 2013, MUCOSAL IMMUNOL, V6, P740, DOI 10.1038/mi.2012.112; Cahill KN, 2017, NEW ENGL J MED, V376, P1911, DOI 10.1056/NEJMoa1613125; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Cerny-Reiterer S, 2015, ONCOTARGET, V6, P3071, DOI 10.18632/oncotarget.3074; Chalubinski M, 2015, VASC PHARMACOL, V73, P57, DOI 10.1016/j.vph.2015.07.012; Chen CY, 2015, IMMUNITY, V43, P788, DOI 10.1016/j.immuni.2015.08.020; Cheng LE, 2015, J EXP MED, V212, P513, DOI 10.1084/jem.20141671; Chislock EM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085231; Crosby CV, 2005, BLOOD, V105, P2771, DOI 10.1182/blood-2004-06-2244; Dudek SM, 2010, MOL BIOL CELL, V21, P4042, DOI 10.1091/mbc.E09-10-0876; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Faffe DS, 2003, AM J PHYSIOL-LUNG C, V285, pL907, DOI 10.1152/ajplung.00120.2003; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; FISHER M, 1977, BRIT J ANAESTH, V49, P1023, DOI 10.1093/bja/49.10.1023; FISHER MM, 1986, ANAESTH INTENS CARE, V14, P17, DOI 10.1177/0310057X8601400105; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; FULTON JD, 1957, P SOC EXP BIOL MED, V95, P625, DOI 10.3181/00379727-95-23309; Gavard Julie, 2014, Cell Adh Migr, V8, P158; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Ikezoe T, 2017, BONE MARROW TRANSPL, V52, P245, DOI 10.1038/bmt.2016.241; Iwaki S, 2005, J BIOL CHEM, V280, P40261, DOI 10.1074/jbc.M506063200; Jabbour E, 2015, CL LYMPH MYELOM LEUK, V15, P323, DOI 10.1016/j.clml.2015.03.006; Khodoun MV, 2004, J EXP MED, V200, P857, DOI 10.1084/jem.20040598; Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106; Kotowicz K, 2004, CLIN EXP ALLERGY, V34, P445, DOI 10.1111/j.1365-2222.2004.01902.x; Lee JB, 2016, J ALLERGY CLIN IMMUN, V137, P1216, DOI 10.1016/j.jaci.2015.09.019; LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223; Lyseng-Williamson K, 2001, DRUGS, V61, P1765, DOI 10.2165/00003495-200161120-00007; Mathias CB, 2011, J ALLERGY CLIN IMMUN, V127, P795, DOI 10.1016/j.jaci.2010.11.009; Mikelis CM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7725; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Moresco EMY, 2005, J NEUROSCI, V25, P6105, DOI 10.1523/JNEUROSCI.1432-05.2005; MUNOZ J, 1965, NATURE, V205, P199, DOI 10.1038/205199b0; Noah TK, 2010, EXP CELL RES, V316, P452, DOI 10.1016/j.yexcr.2009.09.020; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; Ogawa Y, 2007, IMMUNOL ALLERGY CLIN, V27, P249, DOI 10.1016/j.iac.2007.03.013; Osher E, 2006, MOL CELL ENDOCRINOL, V252, P201, DOI 10.1016/j.mce.2006.03.038; Osterfeld H, 2010, J ALLERGY CLIN IMMUN, V125, P469, DOI 10.1016/j.jaci.2009.09.054; Radeva MY, 2018, ACTA PHYSIOL, V222, DOI 10.1111/apha.12860; Risma KA, 2002, J IMMUNOL, V169, P1604, DOI 10.4049/jimmunol.169.3.1604; Rudders SA, 2014, J ALLERGY CLIN IMMUN, V134, P960, DOI 10.1016/j.jaci.2014.06.018; Sampath V, 2017, ANN ALLERG ASTHMA IM, V118, P21, DOI 10.1016/j.anai.2016.10.017; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sampson Hugh A, 2004, Novartis Found Symp, V257, P161; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135, DOI 10.1067/mai.2000.107926; Shen QA, 2010, CARDIOVASC RES, V87, P272, DOI 10.1093/cvr/cvq144; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; SILVERMAN HJ, 1984, AM J MED, V77, P341, DOI 10.1016/0002-9343(84)90717-4; Skaria T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156002; Sledd J, 2015, IMMUN INFLAMM DIS, V3, P420, DOI 10.1002/iid3.80; SONIN L, 1983, ANN INTERN MED, V99, P634, DOI 10.7326/0003-4819-99-5-634; Stone SF, 2009, J ALLERGY CLIN IMMUN, V124, P786, DOI 10.1016/j.jaci.2009.07.055; Strait Richard, 2004, Novartis Found Symp, V257, P80; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Sullivan BM, 2011, NAT IMMUNOL, V12, P527, DOI 10.1038/ni.2036; Tachdjian R, 2010, J ALLERGY CLIN IMMUN, V125, P1128, DOI 10.1016/j.jaci.2010.01.054; Tachdjian R, 2009, J EXP MED, V206, P2191, DOI 10.1084/jem.20091480; Tordesillas L, 2017, IMMUNITY, V47, P32, DOI 10.1016/j.immuni.2017.07.004; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Wechsler JB, 2013, ALLERGY, V68, P1338, DOI 10.1111/all.12227; Wenzel SE, 2007, AM J RESP CRIT CARE, V175, P570, DOI 10.1164/rccm.200607-909OC; WILLIAMS TJ, 1973, NATURE, V246, P215, DOI 10.1038/246215a0; Wu D, 2011, J BIOL CHEM, V286, P13357, DOI 10.1074/jbc.M110.214965; Zhang JM, 2010, NATURE, V463, P501, DOI 10.1038/nature08675; Zhang WJ, 2017, MICROCIRCULATION, V24, DOI 10.1111/micc.12358	85	13	13	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1159	+		10.1016/j.jaci.2017.08.046	http://dx.doi.org/10.1016/j.jaci.2017.08.046			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29157947	Green Accepted, Bronze			2022-12-18	WOS:000446327300016
J	Castellano, G; Divella, C; Sallustio, F; Montinaro, V; Curci, C; Zanichelli, A; Bonanni, E; Suffritti, C; Caccia, S; Bossi, F; Gallone, A; Schena, FP; Gesualdo, L; Cicardi, M				Castellano, Giuseppe; Divella, Chiara; Sallustio, Fabio; Montinaro, Vincenzo; Curci, Claudia; Zanichelli, Andrea; Bonanni, Erika; Suffritti, Chiara; Caccia, Sonia; Bossi, Fleur; Gallone, Anna; Schena, Francesco Paolo; Gesualdo, Loreto; Cicardi, Marco			A transcriptomics study of hereditary angioedema attacks	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hereditary angioedema; Cl inhibitor deficiency; peripheral blood mononuclear cells; genes; acute attacks; vascular permeability; plasmin	ESTERASE INHIBITOR DEFICIENCY; MOLECULAR-WEIGHT KININOGEN; COMPLEMENT FACTOR-H; C1 INHIBITOR; ENDOTHELIAL-CELLS; PLASMINOGEN ACTIVATION; VASCULAR-PERMEABILITY; BINDING-PROTEIN; HUMAN ADRENOMEDULLIN; ANGIONEUROTIC-EDEMA	Background: Hereditary angioedema (HAE) caused by Cl-inhibitor deficiency is a lifelong illness characterized by recurrent acute attacks of localized skin or mucosal edema. Activation of the kallikrein/bradykinin pathway at the endothelial cell level has a relevant pathogenetic role in acute HAE attacks. Moreover, other pathways are involved given the variable clinical expression of the disease in different patients. Objective: We sought to explore the involvement of other putative genes in edema formation. Methods: We performed a PBMC microarray gene expression analysis on RNA isolated from patients with HAE during an acute attack and compared them with the transcriptomic profile of the same patients in the remission phase. Results: Gene expression analysis identified 23 genes significantly modulated during acute attacks that are involved primarily in the natural killer cell signaling and leukocyte extravasation signaling pathways. Gene set enrichment analysis showed a significant activation of relevant biological processes, such as response to external stimuli and protein processing (q < 0.05), suggesting involvement of PBMCs during acute HAE attacks. Upregulation of 2 genes, those encoding adrenomedullin and cellular receptor for urokinase plasminogen activator (uPAR), which occurs during an acute attack, was confirmed in PBMCs of 20 additional patients with HAE by using real-time PCR. Finally, in vitro studies demonstrated the involvement of uPAR in the generation of bradykinin and endothelial leakage. Conclusions: Our study demonstrates the increase in levels of adrenomedullin and uPAR in PBMCs during an acute HAE attack. Activation of these genes usually involved in regulation of vascular tone and in inflammatory response might have a pathogenic role by amplifying bradykinin production and edema formation in patients with HAE.	[Castellano, Giuseppe; Divella, Chiara; Sallustio, Fabio; Montinaro, Vincenzo; Curci, Claudia; Gesualdo, Loreto] Univ Aldo Moro, Nephrol Unit, Dept Emergency & Organ Transplantat, Piazza G Cesare 11, I-70124 Bari, Italy; [Castellano, Giuseppe; Divella, Chiara; Sallustio, Fabio; Montinaro, Vincenzo; Curci, Claudia; Gesualdo, Loreto] Ctr Diag & Treatment Hereditary Angioedema, Bari, Italy; [Sallustio, Fabio; Gallone, Anna] Univ Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy; [Zanichelli, Andrea; Bonanni, Erika; Suffritti, Chiara; Caccia, Sonia; Cicardi, Marco] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci, Milan, Italy; [Bossi, Fleur] IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, Trieste, Italy; [Schena, Francesco Paolo] Univ Bari, Bari, Italy; [Schena, Francesco Paolo] Fdn Schena, Bari, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; University of Milan; Luigi Sacco Hospital; IRCCS Burlo Garofolo; Universita degli Studi di Bari Aldo Moro	Castellano, G (corresponding author), Univ Aldo Moro, Nephrol Unit, Dept Emergency & Organ Transplantat, Piazza G Cesare 11, I-70124 Bari, Italy.	giuseppe.castellano@uniba.it	Castellano, Giuseppe/H-1626-2012; Sallustio, Fabio/D-2326-2011; Gesualdo, Loreto/K-7751-2016; Caccia, Sonia/G-5938-2014; montinaro, vincenzo/H-3674-2019; Sallustio, Fabio/AFP-7212-2022; Divella, Chiara/K-2783-2016; Curci, Claudia/A-6918-2013; Gallone, Anna/K-5384-2018; Suffritti, Chiara/AAE-2940-2020; cicardi, marco/K-9219-2016	Castellano, Giuseppe/0000-0002-0153-3795; Sallustio, Fabio/0000-0002-5132-6532; Gesualdo, Loreto/0000-0002-4861-0911; Caccia, Sonia/0000-0003-0829-5379; Sallustio, Fabio/0000-0002-5132-6532; Divella, Chiara/0000-0003-2717-3158; Curci, Claudia/0000-0003-2055-7837; Gallone, Anna/0000-0002-2252-9584; Suffritti, Chiara/0000-0002-8872-8842; cicardi, marco/0000-0003-1251-225X; zanichelli, andrea/0000-0002-7512-4644; montinaro, vincenzo/0000-0003-4018-0221	Telethon Foundation [GGP08223]	Telethon Foundation(Fondazione Telethon)	Supported by the Telethon Foundation (Telethon grant no. GGP08223; to G.C., S.C., and M.C.).	Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Arcoleo F, 2014, CLIN CHEM LAB MED, V52, pE91, DOI 10.1515/cclm-2013-1008; Bafunno V, 2018, J ALLERGY CLIN IMMUN, V141, P1009, DOI 10.1016/j.jaci.2017.05.020; Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1; Bossi F, 2009, J ALLERGY CLIN IMMUN, V124, P1303, DOI 10.1016/j.jaci.2009.08.007; Caccia S, 2014, PEDIAT ALLER IMM PUL, V27, P159, DOI 10.1089/ped.2014.0425; Cedzynski M, 2008, ARCH IMMUNOL THER EX, V56, P69, DOI 10.1007/s00005-008-0004-7; Chaung WW, 2011, MOL MED, V17, P1075, DOI 10.2119/molmed.2010.00104; Cheung BMY, 2000, RHEUMATOLOGY, V39, P804, DOI 10.1093/rheumatology/39.7.804; Cicardi M, 2014, ALLERGY, V69, P602, DOI 10.1111/all.12380; Cicardi M, 2012, ACTA HAEMATOL-BASEL, V127, P208, DOI 10.1159/000336590; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Davis AE, 2005, CLIN IMMUNOL, V114, P3, DOI 10.1016/j.clim.2004.05.007; Davis AE, 2006, IMMUNOL ALLERGY CLIN, V26, P633, DOI 10.1016/j.iac.2006.08.003; Davis AE, 2008, MOL IMMUNOL, V45, P4057, DOI 10.1016/j.molimm.2008.06.028; de Maat S, 2014, SEMIN THROMB HEMOST, V40, P887, DOI 10.1055/s-0034-1395159; Del Rosso M, 2008, FRONT BIOSCI-LANDMRK, V13, P4667, DOI 10.2741/3032; Del Rosso M, 2011, CURR PHARM DESIGN, V17, P1924; Dewald G, 2006, BIOCHEM BIOPH RES CO, V343, P1286, DOI 10.1016/j.bbrc.2006.03.092; Ellis V, 2003, CURR TOP DEV BIOL, V54, P263, DOI 10.1016/S0070-2153(03)54012-1; Ferreira VP, 2010, MOL IMMUNOL, V47, P2187, DOI 10.1016/j.molimm.2010.05.007; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; Frank MM, 2010, J ALLERGY CLIN IMMUN, V125, pS262, DOI 10.1016/j.jaci.2009.10.063; Fuhrman B, 2012, ATHEROSCLEROSIS, V222, P8, DOI 10.1016/j.atherosclerosis.2011.10.044; Gonzalez-Rey E, 2007, AM J PATHOL, V170, P263, DOI 10.2353/ajpath.2007.060596; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; Hay DL, 2001, PEPTIDES, V22, P1753, DOI 10.1016/S0196-9781(01)00532-0; Hofman Z, 2016, CLIN REV ALLERG IMMU, V51, P152, DOI 10.1007/s12016-016-8540-0; Ishimitsu T, 1998, BIOCHEM BIOPH RES CO, V243, P463, DOI 10.1006/bbrc.1998.8110; Joseph K, 2017, J ALLERGY CLIN IMMUN, V140, P170, DOI 10.1016/j.jaci.2016.09.032; Joseph K, 2016, J ALLERGY CLIN IMMUN, V137, P1822, DOI 10.1016/j.jaci.2015.07.041; Kajdacsi E, 2016, J CLIN IMMUNOL, V36, P160, DOI 10.1007/s10875-016-0239-8; Kalmar L, 2005, HUM MUTAT, V25, P1, DOI 10.1002/humu.20112; Kaplan AP, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00206; Kaplan AP, 2016, CLIN REV ALLERG IMMU, V51, P207, DOI 10.1007/s12016-016-8555-6; Kaplan AP, 2014, ADV IMMUNOL, V121, P41, DOI 10.1016/B978-0-12-800100-4.00002-7; Kaplan AP, 2011, WORLD ALLERGY ORGAN, V4, P73, DOI 10.1097/WOX.0b013e318216b7b2; Kaplan AP, 2010, J ALLERGY CLIN IMMUN, V126, P918, DOI 10.1016/j.jaci.2010.08.012; Kaplan AP, 2010, MOL IMMUNOL, V47, P2161, DOI 10.1016/j.molimm.2010.05.010; KAPLAN AP, 1971, J EXP MED, V133, P696, DOI 10.1084/jem.133.4.696; KLEMPERER MR, 1968, J CLIN INVEST, V47, P604, DOI 10.1172/JCI105756; Longhurst H, 2012, LANCET, V379, P474, DOI 10.1016/S0140-6736(11)60935-5; Lopez-Lera A, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-77; Mahdi F, 2002, BLOOD, V99, P3585, DOI 10.1182/blood.V99.10.3585; Maurer M, 2011, ALLERGY, V66, P1397, DOI 10.1111/j.1398-9995.2011.02686.x; Mondino A, 2004, TRENDS IMMUNOL, V25, P450, DOI 10.1016/j.it.2004.06.004; Navaratna D, 2008, FASEB J, V22, P3310, DOI 10.1096/fj.08-110155; Pappalardo E, 2004, J ALLERGY CLIN IMMUN, V114, P638, DOI 10.1016/j.jaci.2004.06.021; Pio R, 2001, J BIOL CHEM, V276, P12292, DOI 10.1074/jbc.M007822200; SHOEMAKER LR, 1994, CLIN EXP IMMUNOL, V95, P22; Sim RB, 2015, MOL IMMUNOL, V68, P45, DOI 10.1016/j.molimm.2015.06.006; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Theodorou G, 2016, J DAIRY RES, V83, P360, DOI 10.1017/S0022029916000418; Tosi M, 1998, IMMUNOBIOLOGY, V199, P358, DOI 10.1016/S0171-2985(98)80040-5; Trimarchi Hernan, 2013, World J Nephrol, V2, P103, DOI 10.5527/wjn.v2.i4.103; Xie ZH, 2018, J LEUKOCYTE BIOL, V103, P749, DOI 10.1002/JLB.5A0817-324R; Zeerleder S, 2011, SEMIN THROMB HEMOST, V37, P362, DOI 10.1055/s-0031-1276585; Zhou M, 2007, MOL MED, V13, P488, DOI 10.2119/2007-00113.Zhou	59	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					883	891		10.1016/j.jaci.2018.03.016	http://dx.doi.org/10.1016/j.jaci.2018.03.016			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29729940	Green Published, Green Submitted, Bronze			2022-12-18	WOS:000443726500021
J	Natarajan, M; Hsu, AP; Weinreich, MA; Zhang, Y; Niemela, JE; Butman, JA; Pittaluga, S; Sugui, J; Collar, AL; Lim, JK; Zangeneh, T; Carr, T; Oler, AJ; Similuk, M; Rosen, LB; Desai, JV; Freeman, AF; Holland, SM; Kwon-Chung, KJ; Milner, JD; Lionakis, MS				Natarajan, Mukil; Hsu, Amy P.; Weinreich, Michael A.; Zhang, Yuan; Niemela, Julie E.; Butman, John A.; Pittaluga, Stefania; Sugui, Janyce; Collar, Amanda L.; Lim, Jean K.; Zangeneh, Tirdad; Carr, Tara; Oler, Andrew J.; Similuk, Morgan; Rosen, Lindsey B.; Desai, Jigar V.; Freeman, Alexandra F.; Holland, Steven M.; Kwon-Chung, Kyung J.; Milner, Joshua D.; Lionakis, Michail S.			Aspergillosis, eosinophilic esophagitis, and allergic rhinitis in signal transducer and activator of transcription 3 haploinsufficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MUTATIONS; STAT3		[Natarajan, Mukil; Hsu, Amy P.; Sugui, Janyce; Collar, Amanda L.; Similuk, Morgan; Rosen, Lindsey B.; Desai, Jigar V.; Freeman, Alexandra F.; Holland, Steven M.; Kwon-Chung, Kyung J.; Lionakis, Michail S.] NIAID, Lab Clin Immunol & Microbiol, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Weinreich, Michael A.; Zhang, Yuan; Milner, Joshua D.] NIAID, Lab Allerg Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Niemela, Julie E.] NCI, Dept Lab Med, Ctr Clin, NIH, Bethesda, MD 20892 USA; [Butman, John A.] NCI, Radiol & Imaging Sci, CC, NIH, Bethesda, MD 20892 USA; [Pittaluga, Stefania] NCI, Pathol Lab, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA; [Lim, Jean K.] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA; [Zangeneh, Tirdad; Carr, Tara] Univ Arizona, Coll Med, Dept Med, Tucson, AZ USA; [Oler, Andrew J.] NIAID, Bioinformat & Computat Biosci Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Icahn School of Medicine at Mount Sinai; University of Arizona; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lionakis, MS (corresponding author), NIAID, Lab Clin Immunol & Microbiol, 9000 Rockville Pike, Bethesda, MD 20892 USA.	lionakism@mail.nih.gov	Lionakis, Michail/J-8840-2017; Butman, John A/A-2694-2008; Butman, John/J-2780-2013; Desai, Jigar V/I-3109-2019; Zhang, Yuan/C-7777-2018	Lionakis, Michail/0000-0003-4994-9500; Butman, John/0000-0002-1547-9195; Zhang, Yuan/0000-0001-9932-917X; Carr, Tara/0000-0002-6397-5396; Natarajan, Mukil/0000-0001-8908-7306; Collar, Amanda/0000-0003-3214-1898; Hsu, Amy/0000-0001-6841-2122	Intramural Research Program of the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Intramural Research through the Clinical Center Genomics Opportunity; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000657, ZIAAI001247, ZIAAI001175, ZIAAI001183, ZIAAI000646, ZIAAI001098] Funding Source: NIH RePORTER	Intramural Research Program of the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Intramural Research through the Clinical Center Genomics Opportunity; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the Intramural Research Program of the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health and by the Deputy Director of Intramural Research through the Clinical Center Genomics Opportunity.	Anolik Robert, 2009, Dermatol Online J, V15, P16; Arora M, 2017, J CLIN IMMUNOL, V37, P695, DOI 10.1007/s10875-017-0429-z; Carroll RJ, 2014, BIOINFORMATICS, V30, P2375, DOI 10.1093/bioinformatics/btu197; Denny JC, 2010, BIOINFORMATICS, V26, P1205, DOI 10.1093/bioinformatics/btq126; Guo Y, 2014, NAT PROTOC, V9, P2643, DOI 10.1038/nprot.2014.174; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Hsu AP, 2013, J ALLERGY CLIN IMMUN, V131, P1586, DOI 10.1016/j.jaci.2013.02.038; Lionakis MS, 2014, COLD SPRING HARB PER, V4; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Woellner C, 2010, J ALLERGY CLIN IMMUN, V125, P424, DOI 10.1016/j.jaci.2009.10.059	12	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					993	+		10.1016/j.jaci.2018.05.009	http://dx.doi.org/10.1016/j.jaci.2018.05.009			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29803798	Bronze			2022-12-18	WOS:000443726500036
J	Gendrin, C; Shubin, NJ; Boldenow, E; Merillat, S; Clauson, M; Power, D; Doran, KS; Abrink, M; Pejler, G; Rajagopal, L; Piliponsky, AM				Gendrin, Claire; Shubin, Nicholas J.; Boldenow, Erica; Merillat, Sean; Clauson, Morgan; Power, Danial; Doran, Kelly S.; Abrink, Magnus; Pejler, Gunnar; Rajagopal, Lakshmi; Piliponsky, Adrian M.			Mast cell chymase decreases the severity of group B Streptococcus infections	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Group B Streptococcus; mast cells; proteases; mouse mast cell protease 4; chymase; fibronectin	AGALACTIAE; DISEASE; FIBRONECTIN; EXPRESSION; PROTEASES; PROTEIN; FAMILY; MODEL; MICE; RAT	Background: Group B Streptococcus (GBS) or Streptococcus agalactiae are beta-hemolytic gram-positive bacteria that colonize the lower genital tracts of women and are frequently associated with infections during pregnancy. Innate immune defenses are critical for controlling GBS dissemination and systemic infection. Mast cells are resident sentinel cells that come into contact with pathogens early during colonization and infection. Objective: We aimed to investigate the contribution of chymase to systemic GBS infection and rates of preterm birth. Methods: Pharmacologic and genetic approaches using mice deficient in mast cell protease (MCPT) 4, the mouse functional homologue of human chymase, were used. Results: Our studies show that mast cells release a protease with chymotrypsin-like cleavage specificity in response to GBS. Additionally, increased GBS systemic infection and preterm births were observed in MCPT4-deficient mice versus MCPT4-sufficient mice. Furthermore, we observed that proteolytic cleavage of the host extracellular matrix protein fibronectin by peritoneal cell-derived mast cell lysates diminished GBS adherence. Consistent with this observation, the increase in GBS dissemination and preterm births observed in MCPT4-deficient mice was abolished when GBS was deficient in expression of the fibronectin-binding protein SfbA. Conclusions: Taken together, our results suggest that the protective effect of MCPT4 against GBS dissemination and preterm labor can be attributed in part to MCPT4-mediated proteolysis of fibronectin. Our studies reveal a novel role of mast cells in defense against bacterial infections.	[Gendrin, Claire; Rajagopal, Lakshmi; Piliponsky, Adrian M.] Univ Washington, Dept Pediat Infect Dis, Seattle, WA 98195 USA; [Rajagopal, Lakshmi] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Gendrin, Claire; Shubin, Nicholas J.; Boldenow, Erica; Merillat, Sean; Clauson, Morgan; Power, Danial; Rajagopal, Lakshmi; Piliponsky, Adrian M.] Seattle Childrens Res Inst, Seattle, WA USA; [Doran, Kelly S.] San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; [Doran, Kelly S.] San Diego State Univ, Ctr Microbial Sci, San Diego, CA 92182 USA; [Doran, Kelly S.] Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA; [Abrink, Magnus] Swedish Univ Agr Sci, Dept Biomed Sci & Vet Publ Hlth, Uppsala, Sweden; [Pejler, Gunnar] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden; [Pejler, Gunnar] Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, Uppsala, Sweden	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Seattle Children's Hospital; California State University System; San Diego State University; California State University System; San Diego State University; University of California System; University of California San Diego; Swedish University of Agricultural Sciences; Uppsala University; Swedish University of Agricultural Sciences	Piliponsky, AM (corresponding author), Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, 1900 9th Ave,Rm 721, Seattle, WA 98122 USA.; Rajagopal, L (corresponding author), Seattle Childrens Res Inst, Ctr Global Infect Dis Res, 1900 9th Ave,Rm 826, Seattle, WA 98122 USA.	lakshmi.rajagopal@seattlechildrens.org; adrian.piliponsky@seattlechildrens.org	Åbrink, Magnus/AAK-8346-2020	Gendrin, Claire/0000-0002-4517-6136; Abrink, Magnus/0000-0002-1335-3927	National Institutes of Health (NIH) [R01AI100989, R21AI109222, R01AI112619, R01HL113351, R01NS051247]; NIH [T32 HD007233]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007233] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL113351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI100989, R21AI109222, R01AI112619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051247] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by funding from the National Institutes of Health (NIH): grants R01AI100989, R21AI109222, and R01AI112619 (to L.R.); grant R01HL113351 to (A.M.P.), and Grant R01NS051247 (to K.S.D.). NIH training grant T32 HD007233 (Principal Investigator: Lisa Frenkel; supported E.B.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Boldenow E, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah4576; Choi HW, 2016, IMMUNITY, V45, P1258, DOI 10.1016/j.immuni.2016.11.003; CHRISTENSEN RD, 1980, PEDIATR RES, V14, P1147, DOI 10.1203/00006450-198010000-00013; COMBS JW, 1965, J CELL BIOL, V25, P577, DOI 10.1083/jcb.25.3.577; Currie AJ, 2011, INFECT IMMUN, V79, P1588, DOI 10.1128/IAI.00535-10; Edmond KM, 2012, LANCET, V379, P547, DOI 10.1016/S0140-6736(11)61651-6; Elovitz MA, 2003, AM J PATHOL, V163, P2103, DOI 10.1016/S0002-9440(10)63567-5; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Galli SJ, 2010, EUR J IMMUNOL, V40, P1843, DOI 10.1002/eji.201040559; Gela A, 2015, ALLERGY, V70, P161, DOI 10.1111/all.12542; Gendrin C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1400225; Groschwitz KR, 2009, P NATL ACAD SCI USA, V106, P22381, DOI 10.1073/pnas.0906372106; Hellman L, 2014, BIOL CHEM, V395, P15, DOI 10.1515/hsz-2013-0211; HIRSCH E, 1995, AM J OBSTET GYNECOL, V172, P1598, DOI 10.1016/0002-9378(95)90503-0; Jacobsson K, 2003, VET MICROBIOL, V96, P103, DOI 10.1016/S0378-1135(03)00206-2; Jiang SM, 2014, INFECT IMMUN, V82, P1007, DOI 10.1128/IAI.01014-13; Johnzon CF, 2016, AM J PATHOL, V186, P4, DOI 10.1016/j.ajpath.2015.06.024; Kalin A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007976; Ledger WJ, 2008, CURR OPIN OBSTET GYN, V20, P120, DOI 10.1097/GCO.0b013e3282f734db; Lembo A, 2010, MOL MICROBIOL, V77, P431, DOI 10.1111/j.1365-2958.2010.07215.x; LeVine AM, 1999, J CLIN INVEST, V103, P563, DOI 10.1172/JCI5212; Lind T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167964; Malbec O, 2007, J IMMUNOL, V178, P6465, DOI 10.4049/jimmunol.178.10.6465; MARTIN TR, 1988, J INFECT DIS, V157, P91, DOI 10.1093/infdis/157.1.91; Maurer M, 2004, NATURE, V432, P512, DOI 10.1038/nature03085; Metz M, 2006, SCIENCE, V313, P526, DOI 10.1126/science.1128877; Mu R, 2014, INFECT IMMUN, V82, P2276, DOI 10.1128/IAI.01559-13; MUSSER JM, 1989, P NATL ACAD SCI USA, V86, P4731, DOI 10.1073/pnas.86.12.4731; Okumura K, 2004, CLIN CHIM ACTA, V347, P223, DOI 10.1016/j.cccn.2004.04.019; Orinska Z, 2007, NAT MED, V13, P927, DOI 10.1038/nm1615; Patras KA, 2013, CELL MICROBIOL, V15, P1154, DOI 10.1111/cmi.12105; Pejler G, 2010, BLOOD, V115, P4981, DOI 10.1182/blood-2010-01-257287; Pritzlaff CA, 2001, MOL MICROBIOL, V39, P236, DOI 10.1046/j.1365-2958.2001.02211.x; Rajagopal L, 2006, MOL MICROBIOL, V62, P941, DOI 10.1111/j.1365-2958.2006.05431.x; Reimer JM, 2008, MOL IMMUNOL, V45, P2116, DOI 10.1016/j.molimm.2007.10.015; Schubert A, 2002, MOL MICROBIOL, V46, P557, DOI 10.1046/j.1365-2958.2002.03177.x; SCHWARTZ LB, 1981, J IMMUNOL, V126, P2071; SCUDAMORE CL, 1995, GUT, V37, P235, DOI 10.1136/gut.37.2.235; Spellerberg B, 1999, INFECT IMMUN, V67, P871, DOI 10.1128/IAI.67.2.871-878.1999; Tani K, 2000, J LEUKOCYTE BIOL, V67, P585, DOI 10.1002/jlb.67.4.585; Tchougounova E, 2003, J EXP MED, V198, P423, DOI 10.1084/jem.20030671; Theoharides TC, 2015, TRANSL ANDROL UROL, V4, P579, DOI 10.3978/j.issn.2223-4683.2015.10.04; Verani Jennifer R., 2010, Morbidity and Mortality Weekly Report, V59, P1; Vornhagen J, 2017, TRENDS MICROBIOL; Wastling JM, 1997, IMMUNOLOGY, V90, P308, DOI 10.1046/j.1365-2567.1997.00155.x; Weston EJ, 2011, PEDIATR INFECT DIS J, V30, P937, DOI 10.1097/INF.0b013e318223bad2; Whidbey C, 2015, EMBO MOL MED, V7, P488, DOI 10.15252/emmm.201404883; Whidbey C, 2013, J EXP MED, V210, P1265, DOI 10.1084/jem.20122753; Wong GW, 2014, BIOCHEM BIOPH RES CO, V451, P314, DOI 10.1016/j.bbrc.2014.07.124	49	13	14	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					120	+		10.1016/j.jaci.2017.07.042	http://dx.doi.org/10.1016/j.jaci.2017.07.042			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	28916188	Green Accepted, Bronze			2022-12-18	WOS:000437837500016
J	Bin, LH; Li, XZ; Richers, B; Streib, JE; Hu, JW; Taylor, P; Leung, DYM				Bin, Lianghua; Li, Xiaozhao; Richers, Brittany; Streib, Joanne E.; Hu, Jack W.; Taylor, Patricia; Leung, Donald Y. M.			Ankyrin repeat domain 1 regulates innate immune responses against herpes simplex virus 1: A potential role in eczema herpeticum	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Herpes simplex virus; ankyrin repeat domain 1; innate immunity; atopic dermatitis; eczema herpeticum; interferon regulatory 3; nuclear factor kB1; IFN-beta 1; IL-29	ATOPIC-DERMATITIS; DILATED CARDIOMYOPATHY; TRANSCRIPTIONAL REPRESSOR; CYTOKINE MILIEU; OVARIAN-CANCER; IFN-LAMBDA; IN-VIVO; PROTEIN; ANKRD1; EXPRESSION	Background: Atopic dermatitis (AD) is a common inflammatory skin disease. A subset of patients with AD are susceptible to disseminated herpes simplex virus (HSV) infection, a complication termed eczema herpeticum (ADEH1). The immune mechanisms causing ADEH1 remain elusive. Using RNA sequencing, we recently found that ankyrin repeat domain 1 (ANKRD1) was significantly induced in human PBMCs upon HSV-1 stimulation, and its induction in patients with ADEH1 was significantly reduced compared with that seen in AD patients without a history of eczema herpeticum (ADEH2). Objective: We sought to validate ANKRD1 gene expression in nonatopic (NA) subjects, patients with ADEH2, and patients with ADEH1 and to delineate the biological function of ANKRD1 and the signaling pathway or pathways involved. Methods: Purification of human PBMCs, monocytes, B cells, dendritic cells, T cells, and natural killer cells; RNA extraction and quantitative RT-PCR; small interfering RNA technique; coimmunoprecipitation; and Western blot assays were used. Results: ANKRD1 expression was significantly reduced in PBMCs from patients with ADEH1 after HSV-1 stimulation compared with PBMCs from patients with ADEH2. We found that the induction of ANKRD1 by HSV-1 and multiple pattern recognition receptor agonists are mediated by inflammatory cytokines. Silencing ANKRD1 gene expression in antigenpresenting cells led to increased viral load and reduced IFNB1 and IL29 production. Using co-immunoprecipitation methods, we demonstrated that ANKRD1 formed protein complexes with interferon regulatory factor (IRF) 3 and IRF7, which are important transcription factors regulating signaling transduction of pattern recognition receptors. Overexpression of ANKRD1 enhanced the IRF3-mediated signaling pathways. Conclusion: ANKRD1 is involved in IRF3-mediated antiviral innate immune signaling pathways. Its reduced expression in patients with ADEH1 might contribute to the pathogenesis of ADEH1.	[Bin, Lianghua; Li, Xiaozhao; Richers, Brittany; Streib, Joanne E.; Taylor, Patricia; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, 1400 Jackson St,Rm K926i, Denver, CO 80206 USA; [Bin, Lianghua] Jinan Univ, Affiliated Hosp 1, Biomed Translat Res Inst, Int Immunol Ctr, Guangzhou, Guangdong, Peoples R China; [Bin, Lianghua] Jinan Univ, Key Lab Antibody Engn Guangdong Prov, Guangzhou, Guangdong, Peoples R China; [Hu, Jack W.] Rho, Chapel Hill, NC USA; [Leung, Donald Y. M.] Univ Colorado, Sch Med, Aurora, CO USA	National Jewish Health; Jinan University; Jinan University; Rho; University of Colorado System; University of Colorado Anschutz Medical Campus	Leung, DYM (corresponding author), Natl Jewish Hlth, Dept Pediat, 1400 Jackson St,Rm K926i, Denver, CO 80206 USA.	leungd@njhealth.org		Bin, Lianghua/0000-0002-3786-0106	National Institutes of Health/National Institute of Allergy and Infectious Diseases through the Atopic Dermatitis Research Network [U19 AI117673]; National Natural Science Foundation of China [81371716]; 111 project [B16021]; Colorado Clinical and Translational Science Award/Colorado Clinical & Translational Sciences Institute from National Center for Research Resources/National Institutes of Health (NIH) [UL1 RR025780]; NIH/National Center for Advancing Translational Sciences [UL1 TR0001082]; Edelstein Family Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI117673] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases through the Atopic Dermatitis Research Network; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 111 project(Ministry of Education, China - 111 Project); Colorado Clinical and Translational Science Award/Colorado Clinical & Translational Sciences Institute from National Center for Research Resources/National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/National Center for Advancing Translational Sciences; Edelstein Family Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health/National Institute of Allergy and Infectious Diseases through the Atopic Dermatitis Research Network (U19 AI117673). L.B. is also supported by National Natural Science Foundation of China (no. 81371716) and 111 project (B16021). The CTRC is supported in part by the Colorado Clinical and Translational Science Award/Colorado Clinical & Translational Sciences Institute grant UL1 RR025780 from National Center for Research Resources/National Institutes of Health (NIH) and UL1 TR0001082 from the NIH/National Center for Advancing Translational Sciences. Additionally, the authors wish to acknowledge the Edelstein Family Foundation for their generous support of our work.	Aihara Y, 2000, HYPERTENSION, V36, P48, DOI 10.1161/01.HYP.36.1.48; Almodovar-Garcia K, 2014, MOL CELL BIOL, V34, P1500, DOI 10.1128/MCB.01357-13; Ank N, 2006, J VIROL, V80, P4501, DOI 10.1128/JVI.80.9.4501-4509.2006; Aravalli RN, 2005, J IMMUNOL, V175, P4189, DOI 10.4049/jimmunol.175.7.4189; Bang ML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093638; Bang ML, 2001, J CELL BIOL, V153, P413, DOI 10.1083/jcb.153.2.413; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Bin L, 2011, J ALLERGY CLIN IMMUN, V127, pAB148, DOI 10.1016/j.jaci.2010.12.587; Bin LH, 2014, J ALLERGY CLIN IMMUN, V134, P848, DOI 10.1016/j.jaci.2014.07.018; Bin LH, 2011, J ALLERGY CLIN IMMUN, V127, P430, DOI 10.1016/j.jaci.2010.11.013; CHU W, 1995, J BIOL CHEM, V270, P10236, DOI 10.1074/jbc.270.17.10236; Deonarain R, 2000, J VIROL, V74, P3404, DOI 10.1128/JVI.74.7.3404-3409.2000; Duboscq-Bidot L, 2009, EUR HEART J, V30, P2128, DOI 10.1093/eurheartj/ehp225; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Jeyaseelan R, 1997, J BIOL CHEM, V272, P22800, DOI 10.1074/jbc.272.36.22800; Kaczkowski B, 2012, SCI REP-UK, V2, DOI 10.1038/srep00515; Kojic S, 2010, ARCH BIOCHEM BIOPHYS, V502, P60, DOI 10.1016/j.abb.2010.06.029; Labbe E, 2007, CANCER RES, V67, P75, DOI 10.1158/0008-5472.CAN-06-2559; Lei Y, 2015, ONCOGENE, V34, P485, DOI 10.1038/onc.2013.566; Leib DA, 1999, J EXP MED, V189, P663, DOI 10.1084/jem.189.4.663; Leung DYM, 2013, ANTIVIR RES, V98, P153, DOI 10.1016/j.antiviral.2013.02.010; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Leung DY, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Ling SSM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071362; Liu XH, 2015, BIOCHEM BIOPH RES CO, V464, P208, DOI 10.1016/j.bbrc.2015.06.118; Matsuura K, 2007, HUM PATHOL, V38, P410, DOI 10.1016/j.humpath.2006.09.006; Miller MK, 2003, J MOL BIOL, V333, P951, DOI 10.1016/j.jmb.2003.09.012; Moulik M, 2009, J AM COLL CARDIOL, V54, P325, DOI 10.1016/j.jacc.2009.02.076; Nagueh SF, 2004, CIRCULATION, V110, P155, DOI 10.1161/01.CIR.0000135591.37759.AF; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Rasmussen SB, 2007, J VIROL, V81, P13315, DOI 10.1128/JVI.01167-07; Samaras SE, 2015, AM J PATHOL, V185, P96, DOI 10.1016/j.ajpath.2014.09.018; Scurr LL, 2008, CLIN CANCER RES, V14, P6924, DOI 10.1158/1078-0432.CCR-07-5189; Shi Y, 2005, AM J PATHOL, V166, P303, DOI 10.1016/S0002-9440(10)62254-7; Sun LJ, 2010, CELL, V140, P436, DOI 10.1016/j.cell.2010.01.041; Takaoka A, 2007, NATURE, V448, P501, DOI 10.1038/nature06013; Than TT, 2016, SCI REP-UK, V6, DOI 10.1038/srep20819; Thompson MR, 2011, VIRUSES-BASEL, V3, P920, DOI 10.3390/v3060920; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Wollenberg A, 2003, J AM ACAD DERMATOL, V49, P198, DOI 10.1067/S0190-9622(03)00896-X; Wu Y, 2013, BIOCHEM BIOPH RES CO, V437, P355, DOI 10.1016/j.bbrc.2013.06.079; Zhang SY, 2008, IMMUNOL REV, V226, P29, DOI 10.1111/j.1600-065X.2008.00698.x; Zhou Q, 2014, CELL HOST MICROBE, V16, P450, DOI 10.1016/j.chom.2014.09.006; Zolk O, 2003, CARDIOVASC RES, V59, P563, DOI 10.1016/S0008-6363(03)00476-0; Zou YM, 1997, DEVELOPMENT, V124, P793	46	13	13	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2085	+		10.1016/j.jaci.2018.01.001	http://dx.doi.org/10.1016/j.jaci.2018.01.001			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29371118	Green Accepted, Bronze			2022-12-18	WOS:000434701600015
J	Jhamnani, RD; Levin, S; Rasooly, M; Stone, KD; Milner, JD; Nelson, C; DiMaggio, T; Jones, N; Guerrerio, AL; Frischmeyer-Guerrerio, PA				Jhamnani, Rekha D.; Levin, Samara; Rasooly, Marjohn; Stone, Kelly D.; Milner, Joshua D.; Nelson, Celeste; DiMaggio, Tom; Jones, Nina; Guerrerio, Anthony L.; Frischmeyer-Guerrerio, Pamela A.			Impact of food allergy on the growth of children with moderate-severe atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							NATURAL-HISTORY; MILK ALLERGY; ASSOCIATION; ECZEMA		[Jhamnani, Rekha D.; Levin, Samara; Rasooly, Marjohn; Stone, Kelly D.; Milner, Joshua D.; Nelson, Celeste; DiMaggio, Tom; Frischmeyer-Guerrerio, Pamela A.] NIAID, Lab Allerg Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Jones, Nina] Leidos Biomed Res Inc, Clin Monitoring Res Program, Clin Res Directorate, Frederick, MD USA; [Guerrerio, Anthony L.] Johns Hopkins Univ, Div Gastroenterol Hepatol & Nutr, Dept Pediat, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Frischmeyer-Guerrerio, PA (corresponding author), NIAID, Lab Allerg Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA.	pamela.guerrerio@nih.gov	Guerrerio, Pamela/S-9360-2019; Guerrerio, Anthony/T-2632-2019	Guerrerio, Anthony/0000-0003-2458-7160	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases [1K08DK106463]; National Cancer Institute, National Institutes of Health [HHSN261200800001E]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK106463] Funding Source: NIH RePORTER	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Financial support was provided by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases. A.L.G. was supported by KO8 grant 1K08DK106463 from the National Institute of Diabetes and Digestive and Kidney Diseases. N.J. was funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract no. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government.	Breuer K, 2004, CLIN EXP ALLERGY, V34, P817, DOI 10.1111/j.1365-2222.2004.1953.x; Cho HN, 2011, ALLERGY ASTHMA IMMUN, V3, P53, DOI 10.4168/aair.2011.3.1.53; Fleischer DM, 2011, J PEDIATR-US, V158, P578, DOI 10.1016/j.jpeds.2010.09.027; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; Hobbs CB, 2015, J ALLER CL IMM-PRACT, V3, P133, DOI 10.1016/j.jaip.2014.11.004; Robbins KA, 2014, J ALLERGY CLIN IMMUN, V134, P1466, DOI 10.1016/j.jaci.2014.08.037; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P492, DOI 10.1016/j.jaci.2013.12.1041; Silverberg JI, 2015, J INVEST DERMATOL, V135, P56, DOI 10.1038/jid.2014.325; Silverberg JI, 2011, J ALLERGY CLIN IMMUN, V127, P1180, DOI 10.1016/j.jaci.2011.01.063; Spergel JM, 2015, PEDIATRICS, V136, pE1530, DOI 10.1542/peds.2015-1444; Wood RA, 2013, J ALLERGY CLIN IMMUN, V131, P805, DOI 10.1016/j.jaci.2012.10.060; Zhang A, 2015, J AM ACAD DERMATOL, V72, P606, DOI 10.1016/j.jaad.2014.12.013	12	13	14	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1526	+		10.1016/j.jaci.2017.11.056	http://dx.doi.org/10.1016/j.jaci.2017.11.056			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29378286	Green Accepted, Bronze			2022-12-18	WOS:000429197800049
J	Sallis, BF; Erkert, L; Monino-Romero, S; Acar, U; Wu, R; Konnikova, L; Lexmond, WS; Hamilton, MJ; Dunn, WA; Szepfalusi, Z; Vanderhoof, JA; Snapper, SB; Turner, JR; Goldsmith, JD; Spencer, LA; Nurko, S; Fiebiger, E				Sallis, Benjamin F.; Erkert, Lena; Monino-Romero, Sherezade; Acar, Utkucan; Wu, Rina; Konnikova, Liza; Lexmond, Willem S.; Hamilton, Matthew J.; Dunn, W. Augustine; Szepfalusi, Zsolt; Vanderhoof, Jon A.; Snapper, Scott B.; Turner, Jerrold R.; Goldsmith, Jeffrey D.; Spencer, Lisa A.; Nurko, Samuel; Fiebiger, Edda			An algorithm for the classification of mRNA patterns in eosinophilic esophagitis: Integration of machine learning	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy diagnosis; eosinophils; eosinophilic esophagitis; chronic allergic inflammation; IgE; machine learning; medical algorithm	FC-EPSILON-RI; GENE-EXPRESSION; GASTROINTESTINAL DISORDERS; FOOD ALLERGY; DIAGNOSIS; IGE; DISEASE; INFLAMMATION; PERSPECTIVE; THERAPY	Background: Diagnostic evaluation of eosinophilic esophagitis (EoE) remains difficult, particularly the assessment of the patient's allergic status. Objective: This study sought to establish an automated medical algorithm to assist in the evaluation of EoE. Methods: Machine learning techniques were used to establish a diagnostic probability score for EoE, p(EoE), based on esophageal mRNA transcript patterns from biopsies of patients with EoE, gastroesophageal reflux disease and controls. Dimensionality reduction in the training set established weighted factors, which were confirmed by immunohistochemistry. Following weighted factor analysis, p(EoE) was determined by random forest classification. Accuracy was tested in an external test set, and predictive power was assessed with equivocal patients. Esophageal IgE production was quantified with epsilon germ line (IGHE) transcripts and correlated with serum IgE and the T(H)2-type mRNA profile to establish an IGHE score for tissue allergy. Results: In the primary analysis, a 3-class statistical model generated a p(EoE) score based on common characteristics of the inflammatory EoE profile. A p(EoE) >= 25 successfully identified EoE with high accuracy (sensitivity: 90.9%, specificity: 93.2%, area under the curve: 0.985) and improved diagnosis of equivocal cases by 84.6%. The p(EoE) changed in response to therapy. A secondary analysis loop in EoE patients defined an IGHE score of >= 37.5 for a patient subpopulation with increased esophageal allergic inflammation. Conclusions: The development of intelligent data analysis from a machine learning perspective provides exciting opportunities to improve diagnostic precision and improve patient care in EoE. The p(EoE) and the IGHE score are steps toward the development of decision trees to define EoE subpopulations and, consequently, will facilitate individualized therapy.	[Sallis, Benjamin F.; Erkert, Lena; Monino-Romero, Sherezade; Acar, Utkucan; Wu, Rina; Konnikova, Liza; Lexmond, Willem S.; Dunn, W. Augustine; Vanderhoof, Jon A.; Snapper, Scott B.; Nurko, Samuel; Fiebiger, Edda] Boston Childrens Hosp, Dept Pediat, Div Gastroenterol Hepatol & Nutr, Boston, MA USA; [Goldsmith, Jeffrey D.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA; [Sallis, Benjamin F.; Acar, Utkucan; Konnikova, Liza; Lexmond, Willem S.; Hamilton, Matthew J.; Dunn, W. Augustine; Snapper, Scott B.; Spencer, Lisa A.; Nurko, Samuel; Fiebiger, Edda] Harvard Med Sch, Dept Med, Boston, MA USA; [Hamilton, Matthew J.; Turner, Jerrold R.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Hamilton, Matthew J.; Turner, Jerrold R.] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, 75 Francis St, Boston, MA 02115 USA; [Spencer, Lisa A.] Beth Israel Deaconess Med Ctr, Dept Med, Div Allergy & Inflammat, Boston, MA 02215 USA; [Monino-Romero, Sherezade; Szepfalusi, Zsolt] Med Univ Vienna, Dept Pediat & Adolescent Med, Vienna, Austria	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Medical University of Vienna	Fiebiger, E (corresponding author), 300 Longwood Ave,EN630, Boston, MA 02115 USA.	edda.fiebiger@childrens.harvard.edu	Turner, Jerrold/H-1502-2019; Moñino-Romero, Sherezade/K-3118-2019	Moñino-Romero, Sherezade/0000-0003-3775-2989; Nurko, Samuel/0000-0003-0936-4807; Szepfalusi, Zsolt/0000-0003-4852-3102; Sallis, Benjamin Fidelius/0000-0001-7572-7210; Konnikova, Yelizaveta/0000-0003-4804-5497	Research Council of Boston Children's Hospital; Food Allergy Research Education; Crohn's and Colitis Foundation; Fonds zur Forderung der wissenschaftlichen Forschung [DK W1248]; Helmsley Charitable Trust through the Very Early Onset Inflammatory Bowel Disease Consortium; National Institutes of Health (NIH) [NIHDK094971]; NIH [R01DK61931, R01DK68271, R24DK099803, R01AI121186]; NIH grant of the Harvard Digestive Diseases Center [P30DK034854]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI121186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061931, R24DK099803, P30DK034854, R01DK068271] Funding Source: NIH RePORTER	Research Council of Boston Children's Hospital; Food Allergy Research Education; Crohn's and Colitis Foundation; Fonds zur Forderung der wissenschaftlichen Forschung(Austrian Science Fund (FWF)); Helmsley Charitable Trust through the Very Early Onset Inflammatory Bowel Disease Consortium; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH grant of the Harvard Digestive Diseases Center; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	E.F. is supported by a Bridge Grant from the Research Council of Boston Children's Hospital, an Emerging Investigator Award from Food Allergy Research & Education, a Senior Research Award from the Crohn's and Colitis Foundation, and an unrestricted gift from the Mead Johnson Nutrition Company. S.M.-R. was supported by the Fonds zur Forderung der wissenschaftlichen Forschung grant DK W1248. W.A.D. is supported by a grant from The Helmsley Charitable Trust through the Very Early Onset Inflammatory Bowel Disease Consortium. M.J.H. is supported by National Institutes of Health (NIH) grant NIHDK094971. J.R.T. is supported by NIH grants R01DK61931, R01DK68271, and R24DK099803 as well as a Senior Research Award from the Crohn's and Colitis Foundation. L.A.S. is supported by NIH grant R01AI121186. This work was further supported by an NIH grant of the Harvard Digestive Diseases Center (P30DK034854, Cores B and C).	Abe Y, 2017, CLIN J GASTROENTEROL, V10, P87, DOI 10.1007/s12328-017-0725-4; Abonia JP, 2017, J ALLER CL IMM-PRACT, V5, P951, DOI 10.1016/j.jaip.2017.02.004; Aceves Seema S, 2016, Gastroenterol Hepatol (N Y), V12, P516; Aceves SS, 2015, IMMUNOL ALLERGY CLIN, V35, P145, DOI 10.1016/j.iac.2014.09.007; Atkins D, 2017, PEDIAT ALLERG IMM-UK, V28, P312, DOI 10.1111/pai.12715; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2017, J INTERN MED, V281, P448, DOI 10.1111/joim.12568; Blanchard C, 2006, J ALLERGY CLIN IMMUN, V118, P1054, DOI 10.1016/j.jaci.2006.07.038; Cianferoni A, 2016, CLIN REV ALLERG IMMU, V50, P159, DOI 10.1007/s12016-015-8501-z; Cianferoni A, 2015, EXPERT REV GASTROENT, V9, P1501, DOI 10.1586/17474124.2015.1094372; Cianferoni A, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0558-5; Clayton F, 2014, GASTROENTEROLOGY, V147, P602, DOI 10.1053/j.gastro.2014.05.036; Collins MH, 2017, DIS ESOPHAGUS, V30, DOI 10.1111/dote.12470; Dehlink E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012204; Dehlink E, 2009, IMMUNOL ALLERGY CLIN, V29, P159, DOI 10.1016/j.iac.2008.09.004; Dellon ES, 2017, NAT REV GASTRO HEPAT, V14, P479, DOI 10.1038/nrgastro.2017.56; Dellon ES, 2017, CLIN TRANSL GASTROEN, V8, DOI 10.1038/ctg.2017.2; Dellon ES, 2014, CLIN GASTROENTEROL H, V12, P2015, DOI 10.1016/j.cgh.2014.06.019; Dellon ES, 2014, GASTROENTEROL CLIN N, V43, P201, DOI 10.1016/j.gtc.2014.02.002; Dellon ES, 2014, CLIN GASTROENTEROL H, V12, P589, DOI 10.1016/j.cgh.2013.09.008; Dellon ES, 2014, DIGEST DIS, V32, P48, DOI 10.1159/000357009; Fahey LM, 2017, PEDIATR CLIN N AM, V64, P475, DOI 10.1016/j.pcl.2017.01.009; Furuta GT, 2008, J PEDIATR GASTR NUTR, V47, P234, DOI 10.1097/MPG.0b013e318181b1c3; Furuta GT, 2015, NEW ENGL J MED, V373, P1640, DOI 10.1056/NEJMra1502863; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Hommel KA, 2012, J PEDIATR PSYCHOL, V37, P533, DOI 10.1093/jpepsy/jsr090; Kononenko I, 2001, ARTIF INTELL MED, V23, P89, DOI 10.1016/S0933-3657(01)00077-X; Kottyan LC, 2017, MUCOSAL IMMUNOL, V10, P580, DOI 10.1038/mi.2017.4; Lexmond WS, 2015, CLIN EXP ALLERGY, V45, P1317, DOI 10.1111/cea.12523; Lexmond WS, 2014, AM J GASTROENTEROL, V109, P646, DOI 10.1038/ajg.2014.12; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Loizou D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0113483; Lopez-Alonso V, 2013, STUD HEALTH TECHNOL, V192, P942, DOI 10.3233/978-1-61499-289-9-942; Martin LJ, 2015, J ALLERGY CLIN IMMUN, V135, P1519, DOI 10.1016/j.jaci.2015.03.004; Molina-Infante J, 2017, CURR OPIN GASTROEN, V33, P285, DOI 10.1097/MOG.0000000000000371; Mudde ACA, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0114-3; Pelz BJ, 2016, CLIN EXP ALLERGY, V46, P1431, DOI 10.1111/cea.12776; Platts-Mills TAE, 2016, J ALLERGY CLIN IMMUN, V137, P1662, DOI 10.1016/j.jaci.2016.04.010; Rocha R, 2011, EUR J PEDIATR, V170, P1471, DOI 10.1007/s00431-011-1540-4; Rochman M, 2017, J ALLERGY CLIN IMMUN, V140, P738, DOI 10.1016/j.jaci.2016.11.042; Sarkar IN, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-22; Simon D, 2016, ALLERGY, V71, P611, DOI 10.1111/all.12846; Spergel JM, 2015, BEST PRACT RES CL GA, V29, P771, DOI 10.1016/j.bpg.2015.06.011; Wen T, 2015, J ALLERGY CLIN IMMUN, V135, P187, DOI 10.1016/j.jaci.2014.08.043; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046; Wu LC, 2014, NAT REV IMMUNOL, V14, P247, DOI 10.1038/nri3632; Yen EH, 2010, J PEDIATR GASTR NUTR, V51, P584, DOI 10.1097/MPG.0b013e3181de7685	47	13	13	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1354	+		10.1016/j.jaci.2017.11.027	http://dx.doi.org/10.1016/j.jaci.2017.11.027			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29273402	Green Accepted			2022-12-18	WOS:000429197800021
J	Amoah, AS; Asuming-Brempong, EK; Obeng, BB; Versteeg, SA; Larbi, IA; Aryeetey, Y; Platts-Mills, TAE; Mari, A; Brzezicka, K; Gyan, BA; Mutocheluh, M; Boakye, DA; Reichardt, NC; van Ree, R; Hokke, CH; van Diepen, A; Yazdanbakhsh, M				Amoah, Abena S.; Asuming-Brempong, Elias K.; Obeng, Benedicta B.; Versteeg, Serge A.; Larbi, Irene A.; Aryeetey, Yvonne; Platts-Mills, Thomas A. E.; Mari, Adriano; Brzezicka, Katarzyna; Gyan, Ben A.; Mutocheluh, Mohamed; Boakye, Daniel A.; Reichardt, Niels-Christian; van Ree, Ronald; Hokke, Cornelis H.; van Diepen, Angela; Yazdanbakhsh, Maria			Identification of dominant anti-glycan IgE responses in school children by glycan microarray	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							NUCLEOTIDE-BINDING DOMAIN; PARTICULATE MATTER; EPITHELIAL-CELLS; CARBOHYDRATE; EXPRESSION; ANTIBODIES; EXPOSURE		[Amoah, Abena S.; Asuming-Brempong, Elias K.; Obeng, Benedicta B.; Larbi, Irene A.; Aryeetey, Yvonne; Boakye, Daniel A.] Univ Ghana, Coll Hlth Sci, Noguchi Mem Inst Med Res, Dept Parasitol, Accra, Ghana; [Amoah, Abena S.; Obeng, Benedicta B.; Hokke, Cornelis H.; van Diepen, Angela; Yazdanbakhsh, Maria] Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands; [Versteeg, Serge A.; van Ree, Ronald] Acad Med Ctr, Dept Expt Immunol, Amsterdam, Netherlands; [Platts-Mills, Thomas A. E.] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; [Mari, Adriano] Associated Centers Mol Allergol, Rome, Italy; [Brzezicka, Katarzyna; Reichardt, Niels-Christian] CIC BiomaGUNE, Glycotechnol Lab, San Sebastian, Spain; [Gyan, Ben A.] Univ Ghana, Coll Hlth Sci, Noguchi Mem Inst Med Res, Dept Immunol, Accra, Ghana; [Mutocheluh, Mohamed] Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Dept Clin Microbiol, Kumasi, Ghana; [Reichardt, Niels-Christian] CIBER BBN, San Sebastian, Spain; [van Ree, Ronald] Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands	University of Ghana; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; University of Virginia; CIC biomaGUNE; University of Ghana; Kwame Nkrumah University Science & Technology; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN; University of Amsterdam; Academic Medical Center Amsterdam	Amoah, AS (corresponding author), Univ Ghana, Coll Hlth Sci, Noguchi Mem Inst Med Res, Dept Parasitol, Accra, Ghana.; Amoah, AS (corresponding author), Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands.	a.s.amoah@lumc.nl	Yazdanbakhsh, Maria/AAI-3996-2020; Asuming-Brempong, Elias/GQH-4379-2022; Hokke, Cornelis Hendrik/AAQ-4712-2021	Yazdanbakhsh, Maria/0000-0002-7666-1441; Asuming-Brempong, Elias/0000-0001-7038-8184; Hokke, Cornelis Hendrik/0000-0003-3545-7804; Mutocheluh, Mohamed/0000-0002-1396-5085; Ashong, Yvonne Aryeetey/0000-0003-3305-223X; Platts-Mills, Thomas/0000-0002-1263-329X; Amoah, Abena/0000-0003-2270-1871	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, R37AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI020565, R37 AI020565] Funding Source: Medline; Wellcome Trust [075791/Z/04/Z] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		Altmann F, 2007, INT ARCH ALLERGY IMM, V142, P99, DOI 10.1159/000096114; Amoah AS, 2013, J ALLERGY CLIN IMMUN, V132, P639, DOI 10.1016/j.jaci.2013.04.023; Brzezicka K, 2015, ACS CHEM BIOL, V10, P1290, DOI 10.1021/cb501023u; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Gold MJ, 2016, MUCOSAL IMMUNOL, V9, P809, DOI 10.1038/mi.2015.104; Hamid F, 2015, CURR TOP MICROBIOL, V388, P91, DOI 10.1007/978-3-319-13725-4_5; Hirota JA, 2015, EXP LUNG RES, V41, P353, DOI 10.3109/01902148.2015.1040528; Hirota JA, 2015, AM J RESP CELL MOL, V52, P96, DOI 10.1165/rcmb.2014-0158OC; Hirota JA, 2012, J ALLERGY CLIN IMMUN, V129, P1116, DOI 10.1016/j.jaci.2011.11.033; Holden NS, 2011, P NATL ACAD SCI USA, V108, P19713, DOI 10.1073/pnas.1110226108; Macher BA, 2008, BBA-GEN SUBJECTS, V1780, P75, DOI 10.1016/j.bbagen.2007.11.003; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Rider CF, 2013, EUR J PHARMACOL, V708, P60, DOI 10.1016/j.ejphar.2013.02.056; Rider CF, 2011, J PHARMACOL EXP THER, V338, P860, DOI 10.1124/jpet.111.181016; Smit CH, 2015, MOL CELL PROTEOMICS, V14, P1750, DOI 10.1074/mcp.M115.048280; Wuhrer M, 2003, GLYCOBIOLOGY, V13, P129, DOI 10.1093/glycob/cwg005; Yang YYM, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005339	17	13	13	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1130	+		10.1016/j.jaci.2017.09.040	http://dx.doi.org/10.1016/j.jaci.2017.09.040			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29128671	Green Accepted, Bronze			2022-12-18	WOS:000426974800036
J	Petersheim, D; Massaad, MJ; Lee, S; Scarselli, A; Cancrini, C; Moriya, K; Sasahara, Y; Lankester, AC; Dorsey, M; Di Giovanni, D; Bezrodnik, L; Ohnishi, H; Nishikomori, R; Tanita, K; Kanegane, H; Morio, T; Gelfand, EW; Jain, A; Secord, E; Picard, C; Casanova, JL; Albert, MH; Torgerson, TR; Geha, RS				Petersheim, Daniel; Massaad, Michel J.; Lee, Saetbyul; Scarselli, Alessia; Cancrini, Caterina; Moriya, Kunihiko; Sasahara, Yoji; Lankester, Arjan C.; Dorsey, Morna; Di Giovanni, Daniela; Bezrodnik, Liliana; Ohnishi, Hidenori; Nishikomori, Ryuta; Tanita, Kay; Kanegane, Hirokazu; Morio, Tomohiro; Gelfand, Erwin W.; Jain, Ashish; Secord, Elizabeth; Picard, Capucine; Casanova, Jean-Laurent; Albert, Michael H.; Torgerson, Troy R.; Geha, Raif S.			Mechanisms of genotype-phenotype correlation in autosomal dominant anhidrotic ectodermal dysplasia with immune deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ectodermal dysplasia with immune deficiency; NF-kappa B inhibitor alpha; canonical nuclear factor kappa B pathway; noncanonical nuclear factor kappa B pathway; lymphorganogenesis; hematopoietic stem cell transplantation	NF-KAPPA-B; LYMPHOTOXIN-BETA-RECEPTOR; SECONDARY LYMPHOID-TISSUES; GENE-EXPRESSION; MICE DEFICIENT; ALPHA MUTATION; SPLENIC MICROARCHITECTURE; ABNORMAL-DEVELOPMENT; IMMUNODEFICIENCY; ORGANOGENESIS	Background: Autosomal dominant anhidrotic ectodermal dysplasia with immune deficiency (AD EDA-ID) is caused by heterozygous point mutations at or close to serine 32 and serine 36 or N-terminal truncations in I kappa B alpha that impair its phosphorylation and degradation and thus activation of the canonical nuclear factor kappa light chain enhancer of activated B cells (NF-kappa B) pathway. The outcome of hematopoietic stem cell transplantation is poor in patients with AD EDA-ID despite achievement of chimerism. Mice heterozygous for the serine 32I mutation in I kappa B alpha have impaired noncanonical NF-kappa B activity and defective lymphorganogenesis. Objective: We sought to establish genotype-phenotype correlation in patients with AD EDA-ID. Methods: A disease severity scoring system was devised. Stability of I kappa B alpha mutants was examined in transfected cells. Immunologic, biochemical, and gene expression analyses were performed to evaluate canonical and noncanonical NF-kappa B signaling in skin-derived fibroblasts. Results: Disease severity was greater in patients with IkBa point mutations than in those with truncation mutations. IkBa point mutants were expressed at significantly higher levels in transfectants compared with truncation mutants. Canonical NF-kappa B-dependent IL-6 secretion and upregulation of the NF-kappa B subunit 2/p100 and RELB proto-oncogene, NF-kappa B subunit (RelB) components of the noncanonical NF-kappa B pathway were diminished significantly more in patients with point mutations compared with those with truncations. Noncanonical NF-kappa B-driven generation of the transcriptionally active p100 cleavage product p52 and upregulation of CCL20, intercellular adhesion molecule 1 (ICAM1), and vascular cell adhesion molecule 1 (VCAM1), which are important for lymphorganogenesis, were diminished significantly more in LPS plus alpha-lymphotoxin beta receptor-stimulated fibroblasts from patients with point mutations compared with those with truncations. Conclusions: I kappa B alpha point mutants accumulate at higher levels compared with truncation mutants and are associated with more severe disease and greater impairment of canonical and noncanonical NF-kappa B activity in patients with AD EDA-ID.	[Petersheim, Daniel; Massaad, Michel J.; Lee, Saetbyul; Geha, Raif S.] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Scarselli, Alessia; Cancrini, Caterina] Bambino Gesu Pediat Hosp, Dept Pediat, Div Immunol & Infect Dis, Rome, Italy; [Scarselli, Alessia; Cancrini, Caterina] Univ Roma Tor Vergata, Rome, Italy; [Moriya, Kunihiko; Sasahara, Yoji] Tohoku Univ, Dept Pediat, Sendai, Miyagi, Japan; [Lankester, Arjan C.] Leiden Univ, Med Ctr, Dept Pediat, Leiden, Netherlands; [Dorsey, Morna] Univ Calif San Francisco, Div Allergy Immunol & Bone Marrow Transplantat, San Francisco, CA 94143 USA; [Di Giovanni, Daniela; Bezrodnik, Liliana] Ricardo Gutierrez Childrens Hosp, Serv Immunol, Buenos Aires, DF, Argentina; [Ohnishi, Hidenori] Gifu Univ, Dept Pediat, Gifu, Japan; [Nishikomori, Ryuta] Kyoto Univ, Dept Pediat, Kyoto, Japan; [Tanita, Kay; Kanegane, Hirokazu; Morio, Tomohiro] Tokyo Med & Dent Univ, Dept Pediat, Tokyo, Japan; [Gelfand, Erwin W.] Natl Jewish Hlth, Dept Pediat, Immunodeficiency Diag & Treatment Program, Denver, CO USA; [Jain, Ashish] Merck Res Labs Boston, Boston, MA USA; [Secord, Elizabeth] Childrens Hosp Michigan, Div Allergy Asthma & Immunol, Detroit, MI 48201 USA; [Picard, Capucine; Casanova, Jean-Laurent] Paris Descartes Univ, Necker Hosp, Pediat Hematol Immunol & Rheumatol Unit, Paris, France; [Casanova, Jean-Laurent] Rockefeller Univ, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, 1230 York Ave, New York, NY 10021 USA; [Albert, Michael H.] Ludwig Maximilians Univ Munchen, Dr von Hauner Univ Childrens Hosp, Dept Pediat Hematol & Oncol, Munich, Germany; [Torgerson, Troy R.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Petersheim, Daniel] Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Dept Pediat, Munich, Germany	Harvard University; Boston Children's Hospital; Harvard Medical School; IRCCS Bambino Gesu; University of Rome Tor Vergata; Tohoku University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of California System; University of California San Francisco; Hospital de Ninos Doctor Ricardo Gutierrez; Instituto Nacional de Saude Dr. Ricardo Jorge; University of Buenos Aires; Gifu University; Kyoto University; Tokyo Medical & Dental University (TMDU); National Jewish Health; Merck & Company; Children's Hospital of Michigan; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Rockefeller University; University of Munich; University of Washington; University of Washington Seattle; University of Munich	Geha, RS (corresponding author), One Blackfan Circle, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Petersheim, Daniel Roman/AAE-2298-2020; Dorsey, Morna/V-7270-2018; Nishikomori, Ryuta/N-4039-2018; scarselli, alessia/AAB-5815-2020; Petersheim, Daniel/U-4530-2017; Nishikomori, Ryuta/AAM-5771-2020	Petersheim, Daniel Roman/0000-0003-1121-8745; Dorsey, Morna/0000-0002-9432-3542; Nishikomori, Ryuta/0000-0002-9407-6158; Petersheim, Daniel/0000-0003-1121-8745; Nishikomori, Ryuta/0000-0002-9407-6158; Morio, Tomohiro/0000-0002-9259-1025	DAAD Thematic Network "Research for Rare Diseases and Personalized Medicine"; Bayer Foundations; USPHS [1R21AI124101-01]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI061093, R21AI124101] Funding Source: NIH RePORTER	DAAD Thematic Network "Research for Rare Diseases and Personalized Medicine"; Bayer Foundations; USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by a scholarship from the DAAD Thematic Network "Research for Rare Diseases and Personalized Medicine" and a Carl Duisberg scholarship from Bayer Foundations (to D.P.) and USPHS grant 1R21AI124101-01 (to R.S.G).	Alimzhanov MB, 1997, P NATL ACAD SCI USA, V94, P9302, DOI 10.1073/pnas.94.17.9302; BANKS TA, 1995, J IMMUNOL, V155, P1685; Boisson B, 2017, J CLIN IMMUNOL; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bousfiha A, 2015, J CLIN IMMUNOL, V35, P727, DOI 10.1007/s10875-015-0198-5; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Cildir G, 2016, TRENDS MOL MED, V22, P414, DOI 10.1016/j.molmed.2016.03.002; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Dupuis-Girod S, 2006, PEDIATRICS, V118, pE205, DOI 10.1542/peds.2005-2661; Fish JD, 2009, BONE MARROW TRANSPL, V43, P217, DOI 10.1038/bmt.2008.308; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giancane G, 2013, J ALLERGY CLIN IMMUN, V132, P1451, DOI 10.1016/j.jaci.2013.05.034; Granados EL, 2008, HUM MUTAT, V29, P861, DOI 10.1002/humu.20740; Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Hoorweg K, 2015, J IMMUNOL, V195, P4257, DOI 10.4049/jimmunol.1402584; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Janssen R, 2004, J EXP MED, V200, P559, DOI 10.1084/jem.20040773; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Koike R, 1996, EUR J IMMUNOL, V26, P669, DOI 10.1002/eji.1830260324; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Krappmann D, 2004, MOL CELL BIOL, V24, P6488, DOI 10.1128/MCB.24.14.6488-6500.2004; Kuprash DV, 1999, J IMMUNOL, V163, P6575; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; Lee AJ, 2016, J CLIN IMMUNOL, V36, P12, DOI 10.1007/s10875-015-0223-8; Lee PPW, 2010, J CLIN IMMUNOL, V30, P121, DOI 10.1007/s10875-009-9341-5; Lee YN, 2014, J ALLERGY CLIN IMMUN, V133, P1099, DOI 10.1016/j.jaci.2013.10.007; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; Lo JC, 2006, BLOOD, V107, P1048, DOI 10.1182/blood-2005-06-2452; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; McDonald DR, 2007, J ALLERGY CLIN IMMUN, V120, P900, DOI 10.1016/j.jaci.2007.08.035; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; Mooster JL, 2015, J EXP MED, V212, P185, DOI 10.1084/jem.20140979; Moratto Daniele, 2007, Expert Rev Clin Immunol, V3, P813, DOI 10.1586/1744666X.3.5.813; Ohnishi H, 2012, J ALLERGY CLIN IMMUN, V129, P578, DOI 10.1016/j.jaci.2011.09.042; Paxian S, 2002, GASTROENTEROLOGY, V122, P1853, DOI 10.1053/gast.2002.33651; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Picard C, 2011, CLIN MICROBIOL REV, V24, P490, DOI 10.1128/CMR.00001-11; Rumbo M, 2004, GASTROENTEROLOGY, V127, P213, DOI 10.1053/j.gastro.2004.04.018; Schimke LF, 2013, J CLIN IMMUNOL, V33, P1088, DOI 10.1007/s10875-013-9906-1; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shih VFS, 2011, CELL RES, V21, P86, DOI 10.1038/cr.2010.161; Spinner MA, 2014, BLOOD, V123, P809, DOI 10.1182/blood-2013-07-515528; Staples E, 2017, J CLIN IMMUNOL, V37, P415, DOI 10.1007/s10875-017-0390-x; Sun SC, 2012, IMMUNOL REV, V246, P125, DOI 10.1111/j.1600-065X.2011.01088.x; van de Pavert SA, 2010, NAT REV IMMUNOL, V10, P664, DOI 10.1038/nri2832; Weemaes CMR, 2013, EUR J HUM GENET, V21, P1219, DOI 10.1038/ejhg.2013.40; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Williams IR, 2006, ANN NY ACAD SCI, V1072, P52, DOI 10.1196/annals.1326.036; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Yoshioka T, 2013, J CLIN IMMUNOL, V33, P1165, DOI 10.1007/s10875-013-9924-z	60	13	14	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1060	+		10.1016/j.jaci.2017.05.030	http://dx.doi.org/10.1016/j.jaci.2017.05.030			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	28629746	Green Accepted, Bronze			2022-12-18	WOS:000426974800026
J	Yanase, Y; Morioke, S; Iwamoto, K; Takahagi, S; Uchida, K; Kawaguchi, T; Ishii, K; Hide, I; Hide, M				Yanase, Yuhki; Morioke, Satoshi; Iwamoto, Kazumasa; Takahagi, Shunsuke; Uchida, Kazue; Kawaguchi, Tomoko; Ishii, Kaori; Hide, Izumi; Hide, Michihiro			Histamine and Toll-like receptor ligands synergistically induce endothelial cell gap formation by the extrinsic coagulating pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Yanase, Yuhki; Morioke, Satoshi; Iwamoto, Kazumasa; Takahagi, Shunsuke; Uchida, Kazue; Kawaguchi, Tomoko; Ishii, Kaori; Hide, Michihiro] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Dermatol, Hiroshima, Japan; [Hide, Izumi] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Mol & Pharmacol Neurosci, Hiroshima, Japan	Hiroshima University; Hiroshima University	Yanase, Y (corresponding author), Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Dermatol, Hiroshima, Japan.	edlh-wlde-road@hiroshima-u.ac.jp	Yanase, Yuhki/U-6082-2017; Hide, Michihiro/H-2519-2019	Hide, Michihiro/0000-0002-1569-6034; Iwamoto, Kazumasa/0000-0001-6183-6467				Asero R, 2015, J ALLERGY CLIN IMMUN, V135, P1401, DOI 10.1016/j.jaci.2014.11.016; Chen XL, 2012, DEV CELL, V22, P146, DOI 10.1016/j.devcel.2011.11.002; Cugno M, 2016, J INVEST ALLERG CLIN, V26, P310, DOI 10.18176/jiaci.0051; Harvima IT, 2014, J ALLERGY CLIN IMMUN, V134, P530, DOI 10.1016/j.jaci.2014.03.007; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Kaplan AP, 2009, CLIN EXP ALLERGY, V39, P777, DOI 10.1111/j.1365-2222.2009.03256.x; Moormann C, 2006, J INVEST DERMATOL, V126, P746, DOI 10.1038/sj.jid.5700169; Wedi B, 2004, CURR OPIN ALLERGY CL, V4, P387, DOI 10.1097/00130832-200410000-00010; Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313	9	13	13	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1115	1118		10.1016/j.jaci.2017.07.026	http://dx.doi.org/10.1016/j.jaci.2017.07.026			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	28859973	Bronze			2022-12-18	WOS:000426974800031
J	Roekevisch, E; Schram, ME; Leeflang, MMG; Brouwer, MWD; Gerbens, LAA; Bos, JD; Spuls, PI				Roekevisch, Evelien; Schram, Mandy Elvira; Leeflang, Mariska Maria Geertruida; Brouwer, Marijke Willemijn Dorothee; Gerbens, Louise Anna Andrea; Bos, Jan Dositheus; Spuls, Phyllis Ira			Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							SEVERITY		[Roekevisch, Evelien; Schram, Mandy Elvira; Brouwer, Marijke Willemijn Dorothee; Gerbens, Louise Anna Andrea; Bos, Jan Dositheus; Spuls, Phyllis Ira] Acad Med Ctr, Dept Dermatol, Amsterdam, Netherlands; [Leeflang, Mariska Maria Geertruida; Bos, Jan Dositheus] Acad Med Ctr, Amsterdam Publ Hlth Res Inst, Dept Clin Epidemiol Biostat & Bioinformat, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Roekevisch, E (corresponding author), Acad Med Ctr, Dept Dermatol, Amsterdam, Netherlands.	e.roekevisch@amc.uva.nl	Leeflang, Mariska/AAF-8199-2019; Gerbens, Louise/ABD-1648-2021	Leeflang, Mariska/0000-0001-5960-0471; Gerbens, Louise/0000-0002-5244-5058; Spuls, Phyllis/0000-0002-6035-2863				Brenninkmeijer EEA, 2008, BRIT J DERMATOL, V158, P754, DOI 10.1111/j.1365-2133.2007.08412.x; Charman CR, 2004, ARCH DERMATOL, V140, P1513, DOI 10.1001/archderm.140.12.1513; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; National Cancer Institute (U.S.), 2009, COMM TERM CRIT ADV E; Nijsten TEC, 2006, J INVEST DERMATOL, V126, P1244, DOI 10.1038/sj.jid.5700212; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Roekevisch E., 2016, BR J DERMATOL; Schram ME, 2011, J ALLERGY CLIN IMMUN, V128, P353, DOI 10.1016/j.jaci.2011.03.024; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298	9	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					825	+		10.1016/j.jaci.2017.09.033	http://dx.doi.org/10.1016/j.jaci.2017.09.033			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	29111215	Bronze			2022-12-18	WOS:000424410800053
J	Wang, MQ; Yang, IV; Davidson, EJ; Joetham, A; Takeda, K; O'Connor, BP; Gelfand, EW				Wang, Meiqin; Yang, Ivana V.; Davidson, Elizabeth J.; Joetham, Anthony; Takeda, Katsuyuki; O'Connor, Brian P.; Gelfand, Erwin W.			Forkhead box protein 3 demethylation is associated with tolerance induction in peanut-induced intestinal allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DNA methylation; regulatory T cells; forkhead box protein 3; tolerance; peanut allergy	REGULATORY T-CELLS; ORAL TOLERANCE; DENDRITIC CELLS; CIS-ELEMENT; FOXP3 GENE; IMMUNOTHERAPY; MODULATION; POPULATION; EXPRESSION; RESPONSES	Background: Regulatory T (Treg) cells play an essential role in the maintenance of immune homeostasis in allergic diseases. Objectives: We sought to define the mechanisms underlying induction of tolerance to peanut protein and prevention of the development of peanut allergy. Methods: High or low doses of peanut extract were administered to pups every day for 2 weeks before peanut sensitization and challenge. After challenge, symptoms, Treg cell numbers, and forkhead box protein 3 (Foxp3), T(H)2 and T(H)17 cytokine, and Tgf beta expression in mesenteric lymph node (MLN) CD4(+) T cells and jejunum were monitored. Treg cell suppressive activity and Foxp3 methylation in MLN CD4(+) T cells were assayed. Results: Feeding high but not low doses of peanut before sensitization induced tolerance, as demonstrated by prevention of diarrhea and peanut-specific IgE responses, increases in the percentage of CD4(+)CD25(+)FoxP3(+) cells in MLNs, and Foxp3 mRNA and protein expression in CD4(+) cells from MLNs or jejunum. Feeding high doses of peanut before sensitization decreased percentages of CD3(+)CD4(+)IL-13(+) and CD3(+)CD4(+)IL-17(+) cells in MLNs and decreased Il13 and Il17a and increased Tgf beta mRNA expression in the jejunum; numbers of CD103(+) dendritic cells in MLNs were significantly increased. Treg cell suppression was shown to be antigen specific. Foxp3 methylation was increased in peanut extract-sensitized and challenged mice, whereas in tolerized mice levels were significantly reduced. Conclusions: Feeding high doses of peanut to pups induced tolerance to peanut protein. Foxp3 demethylation was associated with tolerance induction, indicating that Treg cells play an important role in the regulation of peanut sensitivity and maintenance of immune homeostasis.	[Wang, Meiqin; Joetham, Anthony; Takeda, Katsuyuki; O'Connor, Brian P.; Gelfand, Erwin W.] Natl Jewish Hlth, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA; [Yang, Ivana V.; Davidson, Elizabeth J.] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA; [Yang, Ivana V.; O'Connor, Brian P.] Natl Jewish Hlth, Ctr Genes Environm & Hlth, 1400 Jackson St, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njhealth.org	Yang, Ivana V/P-3059-2018	Yang, Ivana V/0000-0002-1018-489X	National Institutes of Health [HL-36577, AI-77609]; Joanne Siegel Fund; Eugene F. and Easton M. Crawford Charitable Lead Unitrust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077609, R56AI077609] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Joanne Siegel Fund; Eugene F. and Easton M. Crawford Charitable Lead Unitrust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants HL-36577 and AI-77609 (to E.W.G.), the Joanne Siegel Fund, and the Eugene F. and Easton M. Crawford Charitable Lead Unitrust. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health.	Ashino S, 2010, INT IMMUNOL, V22, P503, DOI 10.1093/intimm/dxq034; Bacchetta R, 2007, J ALLERGY CLIN IMMUN, V120, P227, DOI 10.1016/j.jaci.2007.06.023; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Berin MC, 2013, J ALLERGY CLIN IMMUN, V131, P14, DOI 10.1016/j.jaci.2012.10.058; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; de Lafaille MAC, 2008, IMMUNITY, V29, P114, DOI 10.1016/j.immuni.2008.05.010; de Lafaille MAC, 2009, IMMUNITY, V30, P626, DOI 10.1016/j.immuni.2009.05.002; Du Toit G, 2016, NEW ENGL J MED, V374, P1435, DOI 10.1056/NEJMoa1514209; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Dubois B, 2003, BLOOD, V102, P3295, DOI 10.1182/blood-2003-03-0727; Dutta S, 2016, LIFE SCI, V152, P244, DOI 10.1016/j.lfs.2015.10.025; Faria AMC, 2006, CLIN DEV IMMUNOL, V13, P143, DOI 10.1080/17402520600876804; Feng YQ, 2014, CELL, V158, P749, DOI 10.1016/j.cell.2014.07.031; Hara M, 2001, J IMMUNOL, V166, P3789, DOI 10.4049/jimmunol.166.6.3789; Hinz D, 2012, ALLERGY, V67, P380, DOI 10.1111/j.1398-9995.2011.02767.x; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Hong XM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7304; Hong XM, 2012, SEMIN IMMUNOPATHOL, V34, P655, DOI 10.1007/s00281-012-0323-y; Hong XM, 2009, CURR OPIN PEDIATR, V21, P770, DOI 10.1097/MOP.0b013e32833252dc; Joetham A, 2017, J ALLERGY CLIN IMMUN, V139, P1331, DOI 10.1016/j.jaci.2016.06.051; Jones SM, 2016, J ALLERGY CLIN IMMUN, V137, P1258, DOI 10.1016/j.jaci.2016.01.008; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Koenecke C, 2009, EUR J IMMUNOL, V39, P3091, DOI 10.1002/eji.200939432; Kotz D, 2011, J ALLERGY CLIN IMMUN, V127, P623, DOI 10.1016/j.jaci.2010.11.021; Li MO, 2016, NAT REV IMMUNOL, V16, P220, DOI 10.1038/nri.2016.26; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XD, 2014, CELL, V158, P734, DOI 10.1016/j.cell.2014.07.030; Liang DC, 2012, J IMMUNOL, V188, P5785, DOI 10.4049/jimmunol.1200109; Lim E, 2014, J IMMUNOL, V192, P466, DOI 10.4049/jimmunol.1302454; Lin W, 2005, J ALLERGY CLIN IMMUN, V116, P1106, DOI 10.1016/j.jaci.2005.08.046; Lluis A, 2014, J ALLERGY CLIN IMMUN, V133, P551, DOI 10.1016/j.jaci.2013.06.034; LOWENTHAL JW, 1985, J IMMUNOL, V135, P3988; Mayer CT, 2014, EUR J IMMUNOL, V44, P2990, DOI 10.1002/eji.201344315; McHugh RS, 2002, J IMMUNOL, V168, P5979, DOI 10.4049/jimmunol.168.12.5979; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Oshiba A, 1997, J IMMUNOL, V159, P4056; Pabst O, 2012, MUCOSAL IMMUNOL, V5, P232, DOI 10.1038/mi.2012.4; Park KS, 2009, MOD RHEUMATOL, V19, P581, DOI 10.1007/s10165-009-0210-0; Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105; Pons L, 2004, J ALLERGY CLIN IMMUN, V114, P915, DOI 10.1016/j.jaci.2004.06.049; Postlethwaite AE, 2008, ARTHRITIS RHEUM-US, V58, P1810, DOI 10.1002/art.23501; Roesner LM, 2015, ALLERGY, V70, P1656, DOI 10.1111/all.12712; Ruane DT, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00025; Rubtsov YP, 2010, SCIENCE, V329, P1667, DOI 10.1126/science.1191996; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Smit JJ, 2011, CLIN EXP ALLERGY, V41, P890, DOI 10.1111/j.1365-2222.2011.03738.x; Suarez-Alvarez B, 2013, EPIGENETICS-US, V8, P694, DOI 10.4161/epi.25201; Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Tanoue T, 2016, NAT REV IMMUNOL, V16, P295, DOI 10.1038/nri.2016.36; Verhasselt V, 2010, MUCOSAL IMMUNOL, V3, P326, DOI 10.1038/mi.2010.25; Wang MQ, 2013, J ALLERGY CLIN IMMUN, V132, P1174, DOI 10.1016/j.jaci.2013.05.027; Wang MQ, 2012, J ALLERGY CLIN IMMUN, V130, P932, DOI 10.1016/j.jaci.2012.07.032; Wang MQ, 2010, J ALLERGY CLIN IMMUN, V126, P306, DOI 10.1016/j.jaci.2010.05.017; Weiner HL, 2011, IMMUNOL REV, V241, P241, DOI 10.1111/j.1600-065X.2011.01017.x; Worbs T, 2006, J EXP MED, V203, P519, DOI 10.1084/jem.20052016; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750	64	13	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					659	+		10.1016/j.jaci.2017.04.020	http://dx.doi.org/10.1016/j.jaci.2017.04.020			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28479331	Green Accepted, Bronze			2022-12-18	WOS:000424410800023
J	Basu, T; Seyedmousavi, S; Sugui, JA; Balenga, N; Zhao, M; Chung, KJK; Biardel, S; Laviolette, M; Druey, KM				Basu, Trisha; Seyedmousavi, Seyedmojtaba; Sugui, Janyce A.; Balenga, Nariman; Zhao, Ming; Chung, Kyung Joo Kwon; Biardel, Sabrina; Laviolette, Michel; Druey, Kirk M.			Aspergillus fumigatus alkaline protease 1 (Alp1/Asp f13) in the airways correlates with asthma severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Basu, Trisha; Balenga, Nariman; Druey, Kirk M.] NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Seyedmousavi, Seyedmojtaba; Sugui, Janyce A.; Chung, Kyung Joo Kwon] NIAID, Mol Microbiol Sect, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Zhao, Ming] NIAID, Prot Chem, Res Technol Branch, NIH, Rockville, MD USA; [Biardel, Sabrina; Laviolette, Michel] Laval Univ, Inst Univ Cardiol & Pneumol Quebec, Dept Multidisciplinaire Pneumol & Chirurg Thorac, Quebec City, PQ, Canada; [Balenga, Nariman] Univ Maryland, Sch Med, Dept Surg, Div Gen & Oncol Surg,Marlene & Stewart Greenebaum, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Laval University; University System of Maryland; University of Maryland Baltimore	Druey, KM (corresponding author), NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	kdruey@niaid.nih.gov	Seyedmousavi, Seyedmojtaba/O-9267-2016; Balenga, Nariman/A-5895-2011	Seyedmousavi, Seyedmojtaba/0000-0002-6194-7447; Balenga, Nariman/0000-0002-2741-9595	Intramural Research Program of the National Institute of Allergy and Infectious Diseases/National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZICAI001051, ZIAAI000939] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases/National Institutes of Health.	Agarwal R, 2011, CURR ALLERGY ASTHM R, V11, P403, DOI 10.1007/s11882-011-0217-4; Balenga NA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7763; Behnsen J, 2010, INFECT IMMUN, V78, P3585, DOI 10.1128/IAI.01353-09; Borger P, 1999, J INFECT DIS, V180, P1267, DOI 10.1086/315027; Castanhinha S, 2015, J ALLERGY CLIN IMMUN, V136, P312, DOI 10.1016/j.jaci.2015.01.016; Denning DW, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-14; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; Millien VO, 2013, SCIENCE, V341, P792, DOI 10.1126/science.1240342; Namvar S, 2015, CLIN EXP ALLERGY, V45, P982, DOI 10.1111/cea.12426	9	13	13	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					423	+		10.1016/j.jaci.2017.07.034	http://dx.doi.org/10.1016/j.jaci.2017.07.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28882610	Bronze, Green Accepted			2022-12-18	WOS:000419312200053
J	Hacini-Rachinel, F; de Aguero, MG; Kanjarawi, R; Moro-Sibilot, L; Le Luduec, JB; Macari, C; Boschetti, G; Bardel, E; Langella, P; Dubois, B; Kaiserlian, D				Hacini-Rachinel, Feriel; de Aguero, Mercedes Gomez; Kanjarawi, Reem; Moro-Sibilot, Ludovic; Le Luduec, Jean-Benoit; Macari, Claire; Boschetti, Gilles; Bardel, Emilie; Langella, Philippe; Dubois, Bertrand; Kaiserlian, Dominique			Intestinal dendritic cell licensing through Toll-like receptor 4 is required for oral tolerance in allergic contact dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Oral tolerance; contact dermatitis; Toll-like receptor 4; microbiota; dendritic cells	REGULATORY T-CELLS; RETINOIC-ACID; SKIN INFLAMMATION; INNATE IMMUNITY; IN-VIVO; INDUCTION; ACTIVATION; ANTIGEN; BETA; HYPERSENSITIVITY	Background: Induction of oral tolerance to haptens is an efficient way to prevent allergic contact dermatitis (ACD) in mice. Toll-like receptor (TLR)-mediated sensing of the microbiota contributes to gut homeostasis, yet whether it contributes to induction of oral tolerance has not been documented. Objective: We examined whether oral tolerance to the contact sensitizer 2,4-dinitro-fluorobenzene (DNFB) depends on microbiota/TLRs and evaluated the role of TLR4 on the tolerogenic function of intestinal dendritic cells (DCs). Methods: Oral tolerance was induced by DNFB gavage in germfree and mice deficient in several TLRs. Tolerance was assessed by means of suppression of contact hypersensitivity and hapten-specific IFN-gamma-producing effector T cells. The tolerogenic function of intestinal DCs was tested by adoptive transfer experiments, ex vivo hapten presentation, and forkhead box p3 regulatory T-cell conversion. Results: Oral tolerance induced by DNFB gavage was impaired in germ-free mice and TLR4-deficient mice. Bone marrow chimeras revealed that TLR4 expression on hematopoietic cells was necessary for oral tolerance induction. TLR4 appeared to be essential for the ability of intestinal dendritic cells from DNFB-fed mice to inhibit ACD on adoptive transfer. Indeed, TLR4 conditioned the in vivo mobilization to mesenteric lymph nodes of intestinal migratory CD103(+) DCs carrying oral DNFB, especially the CD103(+) CD11b(+) DC subset expressing the vitamin A-converting enzyme retinaldehyde dehydrogenase and specialized in forkhead box p3-positive regulatory T-cell conversion. Conclusions: Our data demonstrate that TLR4 conditions induction of oral tolerance to DNFB through licensing tolerogenic gut DCs. Oral biotherapy with TLR4 ligands might be useful to potentiate oral tolerance to haptens and alleviate ACD in human subjects.	[Hacini-Rachinel, Feriel; de Aguero, Mercedes Gomez; Kanjarawi, Reem; Moro-Sibilot, Ludovic; Le Luduec, Jean-Benoit; Macari, Claire; Boschetti, Gilles; Bardel, Emilie; Dubois, Bertrand; Kaiserlian, Dominique] Univ Claude Bernard Lyon 1, Mucosal Immun Vaccinat & Biotherapies Lab, CNRS INSERMU1111 UMR5308, Ecole Normale Super Lyon, Lyon, France; [Langella, Philippe] Micalis Inst, INRA, Commensal & Probiot Host Interact Lab UMR1319, Jouy En Josas, France; [Dubois, Bertrand] Univ Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Ctr Rech Cancerol Lyon, Lyon, France; [Kaiserlian, Dominique] Batiment IMBL, INSERM CarMeN Lab U1060, Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; AgroParisTech; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard	Kaiserlian, D (corresponding author), Batiment IMBL, INSERM U1060, 15 Ave Jean Capelle, F-69621 Villeurbanne, France.	dominique.kaiserlian@inserm.fr	Boschetti, Gilles/X-5406-2019; KAISERLIAN, Dominique/G-3325-2013; Dubois, Bertrand/D-4446-2013; Langella, Philippe/N-8368-2017	Boschetti, Gilles/0000-0003-4039-7607; KAISERLIAN, Dominique/0000-0001-6252-4916; Dubois, Bertrand/0000-0002-7859-4975; Langella, Philippe/0000-0001-5960-4341; Gomez de Aguero, Mercedes/0000-0002-7132-290X; LE LUDUEC, Jean-Benoit/0000-0002-1046-2941	INSERM; Leonardo Da Vinci Program; Fondation pour la Recherche Medicale; ITMO IHP	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Leonardo Da Vinci Program; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); ITMO IHP	F.H.-R. was a recipient of an INSERM grant during her thesis. M.G.A. and L.M.-S. had fellowships from the Leonardo Da Vinci Program and "Fondation pour la Recherche Medicale.'' This work has benefited from an INSERM grant from ITMO IHP.	Bashir MEH, 2004, J IMMUNOL, V172, P6978, DOI 10.4049/jimmunol.172.11.6978; Bogunovic M, 2009, IMMUNITY, V31, P513, DOI 10.1016/j.immuni.2009.08.010; Chapat L, 2004, EUR J IMMUNOL, V34, P2520, DOI 10.1002/eji.200425139; Chieppa M, 2006, J EXP MED, V203, P2841, DOI 10.1084/jem.20061884; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; de Aguero MG, 2012, J CLIN INVEST, V122, P1700, DOI 10.1172/JCI59725; Desvignes C, 2000, J IMMUNOL, V164, P2515, DOI 10.4049/jimmunol.164.5.2515; Dubois B, 2003, BLOOD, V102, P3295, DOI 10.1182/blood-2003-03-0727; Dubois B, 2009, GASTROENTEROLOGY, V137, P1019, DOI 10.1053/j.gastro.2009.03.055; Goubier A, 2008, IMMUNITY, V29, P464, DOI 10.1016/j.immuni.2008.06.017; Guilliams M, 2010, BLOOD, V115, P1958, DOI 10.1182/blood-2009-09-245274; Hacini-Rachinel F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004903; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Honda K, 2016, NATURE, V535, P75, DOI 10.1038/nature18848; HUSBY S, 1994, J IMMUNOL, V152, P4663; Jaensson E, 2008, J EXP MED, V205, P2139, DOI 10.1084/jem.20080414; Kehren J, 1999, J EXP MED, V189, P779, DOI 10.1084/jem.189.5.779; LOWNEY ED, 1973, J INVEST DERMATOL, V61, P90, DOI 10.1111/1523-1747.ep12675416; MACPHERSON GG, 1995, J IMMUNOL, V154, P1317; Martin SF, 2011, ALLERGY, V66, P1152, DOI 10.1111/j.1398-9995.2011.02652.x; Martin SF, 2008, J EXP MED, V205, P2151, DOI 10.1084/jem.20070509; Martin SF, 2015, CURR OPIN ALLERGY CL, V15, P124, DOI 10.1097/ACI.0000000000000142; Matteoli G, 2010, GUT, V59, P595, DOI 10.1136/gut.2009.185108; Mazzini E, 2014, IMMUNITY, V40, P248, DOI 10.1016/j.immuni.2013.12.012; MOREAU MC, 1988, INFECT IMMUN, V56, P2766, DOI 10.1128/IAI.56.10.2766-2768.1988; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; Ortega-Cava CF, 2003, J IMMUNOL, V170, P3977, DOI 10.4049/jimmunol.170.8.3977; Pabst O, 2012, MUCOSAL IMMUNOL, V5, P232, DOI 10.1038/mi.2012.4; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Sudo N, 1997, J IMMUNOL, V159, P1739; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Thaiss CA, 2016, NATURE, V535, P65, DOI 10.1038/nature18847; Travis MA, 2014, ANNU REV IMMUNOL, V32, P51, DOI 10.1146/annurev-immunol-032713-120257; Turnbull EL, 2005, J IMMUNOL, V174, P1374, DOI 10.4049/jimmunol.174.3.1374; van Helden SFG, 2010, J IMMUNOL, V184, P1280, DOI 10.4049/jimmunol.0900764; Von Bubnoff D, 2011, J IMMUNOL, V186, P6701, DOI 10.4049/jimmunol.1003151; Worbs T, 2006, J EXP MED, V203, P519, DOI 10.1084/jem.20052016; Worthington JJ, 2011, GASTROENTEROLOGY, V141, P1802, DOI 10.1053/j.gastro.2011.06.057; Zheng L, 2009, GASTROENTEROLOGY, V137, P2041, DOI 10.1053/j.gastro.2009.08.055	40	13	14	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					163	170		10.1016/j.jaci.2017.02.022	http://dx.doi.org/10.1016/j.jaci.2017.02.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28342908	Bronze			2022-12-18	WOS:000419312200022
J	Kaler, M; Barochia, AV; Weir, NA; Cuento, RA; Stylianou, M; Roth, MJ; Filie, AC; Vaughey, EC; Nathan, SD; Levine, SJ				Kaler, Maryann; Barochia, Amisha V.; Weir, Nargues A.; Cuento, Rosemarie A.; Stylianou, Mario; Roth, Mark J.; Filie, Armando C.; Vaughey, Ellen C.; Nathan, Steven D.; Levine, Stewart J.			A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GAMMA AGONIST ROSIGLITAZONE		[Kaler, Maryann; Barochia, Amisha V.; Weir, Nargues A.; Cuento, Rosemarie A.; Levine, Stewart J.] NHLBI, Lab Asthma & Lung Inflammat, Cardiovasc & Pulm Branch, NIH, Bldg 10, Bethesda, MD 20892 USA; [Stylianou, Mario] NHLBI, Off Biostat Res, NIH, Bldg 10, Bethesda, MD 20892 USA; [Roth, Mark J.; Filie, Armando C.] NCI, Pathol Lab, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA; [Weir, Nargues A.; Nathan, Steven D.] Inova Fairfax Hosp, Adv Lung Dis & Lung Transplant Clin, Falls Church, VA USA; [Vaughey, Ellen C.] Northern Virginia Pulm & Crit Care Associates, Annandale, VA USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Inova Fairfax Hospital	Levine, SJ (corresponding author), NHLBI, Lab Asthma & Lung Inflammat, Cardiovasc & Pulm Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.	levines@nhlbi.nih.gov	Barochia, Amisha/R-6964-2019		Division of Intramural Research at the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md; NATIONAL CANCER INSTITUTE [ZICBC011052] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002547] Funding Source: NIH RePORTER	Division of Intramural Research at the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research was funded by the Division of Intramural Research at the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.	Anderson JR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160257; Belvisi MG, 2006, EUR J PHARMACOL, V533, P101, DOI 10.1016/j.ejphar.2005.12.048; Dixon AE, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0303-6; Richards DB, 2010, RESP MED, V104, P668, DOI 10.1016/j.rmed.2009.11.006; Rinne ST, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-34; Sandhu MS, 2012, ANN ALLERG ASTHMA IM, V109, P75, DOI 10.1016/j.anai.2012.05.001; Spears M, 2009, CLIN PHARMACOL THER, V86, P49, DOI 10.1038/clpt.2009.41; Straus DS, 2007, TRENDS IMMUNOL, V28, P551, DOI 10.1016/j.it.2007.09.003; Ward JE, 2007, PPAR RES, V2007, DOI 10.1155/2007/14983	9	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1716	1718		10.1016/j.jaci.2017.05.033	http://dx.doi.org/10.1016/j.jaci.2017.05.033			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28625806	Bronze, Green Accepted			2022-12-18	WOS:000417206000031
J	Aubert, G; Strauss, KA; Lansdorp, PM; Rider, NL				Aubert, Geraldine; Strauss, Kevin A.; Lansdorp, Peter M.; Rider, Nicholas L.			Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immune deficiency; telomere length; cartilagehair hypoplasia; mitochondrial RNA processing endoribonuclease; lymphocyte	RNASE-MRP; MUTATIONS; ABNORMALITIES; CANCER; LENGTH; CELLS; AMISH; CYCLE	Background: Mutations in the long noncoding RNA RNase component of the mitochondrial RNA processing endoribonuclease (RMRP) give rise to the autosomal recessive condition cartilage-hair hypoplasia (CHH). The CHH disease phenotype has some overlap with dyskeratosis congenita, a wellknown "telomere disorder.'' RMRP binds the telomerase reverse transcriptase (catalytic subunit) in some cell lines, raising the possibility that RMRP might play a role in telomere biology. Objective: We sought to determine whether a telomere phenotype is present in immune cells from patients with CHH and explore mechanisms underlying these observations. Methods: We assessed proliferative capacity and telomere length using flow-fluorescence in situ hybridization (in situ hybridization and flow cytometry) of primary lymphocytes from patients with CHH, carrier relatives, and control subjects. The role of telomerase holoenzyme components in gene expression and activity were assessed by using quantitative PCR and the telomere repeat amplification protocol from PBMCs and enriched lymphocyte cultures. Results: Lymphocyte cultures from patients with CHH display growth defects in vitro, which is consistent with an immune deficiency cellular phenotype. Here we show that telomere length and telomerase activity are impaired in primary lymphocyte subsets from patients with CHH. Notably, telomerase activity is affected in a gene dose-dependent manner when comparing heterozygote RMRP carriers with patients with CHH. Telomerase deficiency in patients with CHH is not mediated by abnormal telomerase gene transcript levels relative to those of endogenous genes. Conclusion: These findings suggest that telomere deficiency is implicated in the CHH disease phenotype through an as yet unidentified mechanism.	[Aubert, Geraldine; Lansdorp, Peter M.] BC Canc Agcy, Terry Fox Lab, Vancouver, BC, Canada; [Strauss, Kevin A.] Clin Special Children, Strasburg, PA USA; [Lansdorp, Peter M.] Univ British Columbia, Div Hematol, Dept Med, Vancouver, BC, Canada; [Lansdorp, Peter M.] Univ Groningen, Univ Med Ctr Groningen, European Res Inst Biol Aging, Groningen, Netherlands; [Rider, Nicholas L.] Texas Childrens Hosp, Baylor Coll Med, Sect Immunol Allergy & Rheumatol, Suite 330,1102 Bates Ave, Houston, TX 77030 USA	British Columbia Cancer Agency; University of British Columbia; University of Groningen; Baylor College of Medicine	Rider, NL (corresponding author), Texas Childrens Hosp, Baylor Coll Med, Sect Immunol Allergy & Rheumatol, Suite 330,1102 Bates Ave, Houston, TX 77030 USA.; Lansdorp, PM (corresponding author), Univ British Columbia, Dept Med, Terry Fox Lab, BC Canc Res Ctr, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	plansdor@bccrc.ca; nlrider@bcm.edu		Lansdorp, Peter/0000-0001-7435-1071	Canadian Institutes of Health Research [MOP38075, GMH79042]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Work in the Lansdorp laboratory is supported by grants from the Canadian Institutes of Health Research (MOP38075 and GMH79042). N.L.R. worked at the Clinic for Special Children, Strasburg, Pennsylvania, during the majority of this work.	Akbar AN, 2011, NAT REV IMMUNOL, V11, P289, DOI 10.1038/nri2959; Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Alter BP, 2009, BLOOD, V113, P6549, DOI 10.1182/blood-2008-12-192880; Aubert G, 2008, PHYSIOL REV, V88, P557, DOI 10.1152/physrev.00026.2007; Aubert G, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002696; Aubert G, 2012, MUTAT RES-FUND MOL M, V730, P59, DOI 10.1016/j.mrfmmm.2011.04.003; Baerlocher GM, 2006, NAT PROTOC, V1, P2365, DOI 10.1038/nprot.2006.263; Bordon V, 2010, BLOOD, V116, P27, DOI 10.1182/blood-2010-01-259168; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; Chambers J.M., 1992, STAT MODELS, V1st; Cohen SB, 2007, SCIENCE, V315, P1850, DOI 10.1126/science.1138596; de la Fuente MA, 2011, J ALLERGY CLIN IMMUN, V128, P139, DOI 10.1016/j.jaci.2011.03.042; Gadalla SM, 2013, BIOL BLOOD MARROW TR, V19, P1238, DOI 10.1016/j.bbmt.2013.05.021; Graf SA, 2007, CLIN GENET, V71, P468, DOI 10.1111/j.1399-0004.2007.00776.x; Hermanns P, 2005, HUM MOL GENET, V14, P3723, DOI 10.1093/hmg/ddi403; Knudson M, 2005, BLOOD, V105, P682, DOI 10.1182/blood-2004-04-1673; Lopez-Verges S, 2010, BLOOD, V116, P3865, DOI 10.1182/blood-2010-04-282301; Maida Y, 2009, NATURE, V461, P230, DOI 10.1038/nature08283; Makitie O, 1999, J PEDIATR-US, V134, P315, DOI 10.1016/S0022-3476(99)70456-7; MCKUSICK VA, 1965, B JOHNS HOPKINS HOSP, V116, P285; Mukherjee S, 2011, P NATL ACAD SCI USA, V108, pE1363, DOI 10.1073/pnas.1112414108; Nakashima E, 2007, AM J MED GENET A, V143A, P2675, DOI 10.1002/ajmg.a.32053; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; Rider NL, 2009, CLIN IMMUNOL, V131, P119, DOI 10.1016/j.clim.2008.11.001; Rogler LE, 2014, HUM MOL GENET, V23, P368, DOI 10.1093/hmg/ddt427; Rosenbluh J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026270; Roth A, 2003, BLOOD, V102, P849, DOI 10.1182/blood-2002-07-2015; Sahin E, 2010, NATURE, V464, P520, DOI 10.1038/nature08982; Savage Sharon A, 2009, Pediatr Blood Cancer, V53, P520, DOI 10.1002/pbc.22061; Sharma NK, 2012, NUCLEIC ACIDS RES, V40, P712, DOI 10.1093/nar/gkr758; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; SULISALO T, 1993, NAT GENET, V3, P338, DOI 10.1038/ng0493-338; Taskinen M, 2008, AM J MED GENET A, V146A, P2370, DOI 10.1002/ajmg.a.32478; Thiel CT, 2007, AM J HUM GENET, V81, P519, DOI 10.1086/521034; Thiel CT, 2011, BEST PRACT RES CL EN, V25, P131, DOI 10.1016/j.beem.2010.08.004; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; Williams MS, 2005, AM J MED GENET A, V138A, P35, DOI 10.1002/ajmg.a.30902	38	13	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1120	+		10.1016/j.jaci.2016.11.051	http://dx.doi.org/10.1016/j.jaci.2016.11.051			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28126377				2022-12-18	WOS:000412172900023
J	Burbank, AJ; Duran, CG; Almond, M; Wells, H; Jenkins, S; Jiang, Q; Yang, C; Wang, T; Zhou, HB; Hernandez, ML; Peden, DB				Burbank, Allison J.; Duran, Charity G.; Almond, Martha; Wells, Heather; Jenkins, Sha'Leema; Jiang, Qing; Yang, Chao; Wang, Ting; Zhou, Haibo; Hernandez, Michelle L.; Peden, David B.			A short course of gamma tocopherol mitigates LPS-induced inflammatory responses in humans ex vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							VITAMIN-E; AIRWAY NEUTROPHIL; IN-VIVO; SUPPLEMENTATION; RATS; RECRUITMENT; STRESS		[Burbank, Allison J.; Duran, Charity G.; Almond, Martha; Wells, Heather; Jenkins, Sha'Leema; Hernandez, Michelle L.; Peden, David B.] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA; [Burbank, Allison J.; Hernandez, Michelle L.; Peden, David B.] Univ N Carolina, Dept Pediat, Div Allergy Immunol & Rheumatol, Chapel Hill, NC 27599 USA; [Jiang, Qing; Yang, Chao] Purdue Univ, Dept Nutr Sci, W Lafayette, IN 47907 USA; [Wang, Ting; Zhou, Haibo] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of North Carolina; University of North Carolina Chapel Hill	Burbank, AJ (corresponding author), Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA.; Burbank, AJ (corresponding author), Univ N Carolina, Dept Pediat, Div Allergy Immunol & Rheumatol, Chapel Hill, NC 27599 USA.	allison_burbank@med.unc.edu	ZHOU, Haibo/M-7373-2017	Peden, David/0000-0003-4526-4627	US EPA [CR 83578501];  [R01ES023349];  [P30ES010126];  [2T32GM086330];  [5T32ES007126-33];  [R01ES021900]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES021900, T32ES007126, R01ES023349, P30ES010126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM086330] Funding Source: NIH RePORTER	US EPA(United States Environmental Protection Agency); ; ; ; ; ; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grant numbers R01ES023349, P30ES010126, and US EPA CR 83578501. A.J.B. is supported by grant number 2T32GM086330. C.G.D. is supported by grant number 5T32ES007126-33. H.Z. and T.W. are supported by grant number R01ES021900. The views expressed in this article are those of the authors and do not necessarily reflect the views or policies of the US Environmental Protection Agency.	Berdnikovs S, 2009, J IMMUNOL, V182, P4395, DOI 10.4049/jimmunol.0803659; Hernandez ML, 2013, FREE RADICAL BIO MED, V60, P56, DOI 10.1016/j.freeradbiomed.2013.02.001; Hoskins A, 2012, ALLERGY, V67, P676, DOI 10.1111/j.1398-9995.2012.02810.x; Jiang Q, 2003, FASEB J, V17, P816, DOI 10.1096/fj.02-0877com; Marchese ME, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-31; Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110; Patel A, 2007, J ORG CHEM, V72, P6504, DOI 10.1021/jo0706832; Wagner JG, 2014, FREE RADICAL BIO MED, V68, P101, DOI 10.1016/j.freeradbiomed.2013.11.024; Wiser J, 2008, FREE RADICAL BIO MED, V45, P40, DOI 10.1016/j.freeradbiomed.2008.03.002	9	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1179	+		10.1016/j.jaci.2017.04.030	http://dx.doi.org/10.1016/j.jaci.2017.04.030			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28506847	Green Accepted, Bronze			2022-12-18	WOS:000412172900038
J	Shearer, WT; Jacobson, DL; Yu, W; Siberry, GK; Purswani, M; Siminski, S; Butler, L; Leister, E; Scott, G; Van Dyke, RB; Yogev, R; Paul, ME; Puga, A; Colin, AA; Kattan, M				Shearer, William T.; Jacobson, Denise L.; Yu, Wendy; Siberry, George K.; Purswani, Murli; Siminski, Suzanne; Butler, Laurie; Leister, Erin; Scott, Gwendolyn; Van Dyke, Russell B.; Yogev, Ram; Paul, Mary E.; Puga, Ana; Colin, Andrew A.; Kattan, Meyer		Pediat HIV AIDS Cohort Study	Long-term pulmonary complications in perinatally HIV-infected youth	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pediatric HIV infection; pulmonary complications of HIV infection; asthma; pulmonary function testing; obstructive and restrictive pulmonary disease; reversibility of obstructive air flow with bronchodilators; chronic obstructive pulmonary disease; asthma-COPD overlap syndrome; immune imbalance (T(H)2 shift)	HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY ERA; BRONCHODILATOR RESPONSE; CHILDHOOD ASTHMA; B-CELLS; DIAGNOSTIC-ACCURACY; OVERLAP SYNDROME; LUNG-FUNCTION; IGE ANTIBODY; SERUM IGE	Background: Increased incidence and prevalence of asthma have been documented for perinatally HIV-infected youth 10 to 21 years of age compared with HIV-exposed uninfected (HEU) youth. Objective: We sought to perform objective pulmonary function tests (PFTs) in HIV-infected and HEU youth with and without diagnosed asthma. Method: Asthma was determined in 370 participants (218 HIV-infected and 152 HEU participants) by means of chart review and self-report at 13 sites. Interpretable PFTs (188 HIV-infected and 132 HEU participants) were classified as obstructive, restrictive, or normal, and reversibility was determined after bronchodilator inhalation. Values forHIV-1RNA, CD4andCD8Tcells, eosinophils, total IgE, allergen-specific IgE, and urinary cotinine were measured. Adjusted prevalence ratios (PRs) of asthma and PFT outcomes were determined for HIV-infected participants relative to HEU participants, controlling for age, race/ethnicity, and sex. Results: Current asthma was identified in 75 (34%) of 218 HIV-infected participants and 38 (25%) of 152 HEU participants (adjusted PR, 1.33; P = .11). The prevalence of obstructive disease did not differ by HIV status. Reversibility was less likely in HIV-infected youth than in HEU youth (17/183 [9%] vs 21/126 [17%]; adjusted PR, 0.47; P = .020) overall and among just those with obstructive PFT results (adjusted PR, 0.46; P = .016). Among HIV-infected youth with current asthma, serum IgE levels were inversely correlated with CD8 T-cell counts and positively correlated with eosinophil counts and not associated with CD4 T-cell counts. HIV-infected youth had lower association of specific IgE levels to several inhalant and food allergens compared with HEU participants and significantly lower CD4/CD8 T-cell ratios (suggesting immune imbalance). Conclusion: Compared with HEU youth, HIV-infected youth demonstrated decreased reversibility of obstructive lung disease, which is atypical of asthma. This might indicate an early stage of chronic obstructive pulmonary disease. Follow-up into adulthood is warranted to further define their pulmonary outcomes.	[Shearer, William T.; Paul, Mary E.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Shearer, William T.] Texas Childrens Hosp, Dept Allergy & Immunol, Houston, TX 77030 USA; [Jacobson, Denise L.; Yu, Wendy; Leister, Erin] Harvard TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res, Dept Biostat, Boston, MA USA; [Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal Pediat Infect Dis Branch, NIH, Bethesda, MD USA; [Purswani, Murli] Bronx Lebanon Hosp Ctr, New York, NY USA; [Siminski, Suzanne; Butler, Laurie] Frontier Sci & Technol Res Fdn Inc, Amherst, NY USA; [Scott, Gwendolyn] Univ Miami, Miller Sch Med, Div Clin Res, Dept Pediat, Miami, FL 33136 USA; [Van Dyke, Russell B.] Tulane Univ Med Ctr Hosp & Clin, Dept Pediat, Sect Infect Dis, New Orleans, LA USA; [Yogev, Ram] Northwestern Univ, Feinberg Sch Med, Pediat Infect Dis, Chicago, IL 60611 USA; [Paul, Mary E.] Texas Childrens Hosp, Dept Retrovirol, Houston, TX 77030 USA; [Puga, Ana] Childrens Diagnost & Treatment Ctr, Pediat Infect Dis, Ft Lauderdale, FL USA; [Colin, Andrew A.] Batchelor Res Inst, Div Pediat Pulm, Miami, FL USA; [Kattan, Meyer] Columbia Univ, Med Ctr, Div Pediat Pulmonol, New York, NY USA	Baylor College of Medicine; Baylor College of Medicine; Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); BronxCare Health System; Frontier Science Foundation; University of Miami; Tulane University; Northwestern University; Feinberg School of Medicine; Baylor College of Medicine; Columbia University	Shearer, WT (corresponding author), Texas Childrens Hosp, Baylor Coll Med, Sect Pediat Immunol Allergy & Rheumatol, 1102 Bates St,Suite 330, Houston, TX 77030 USA.	wtsheare@texaschildrens.org	Paul, Mary/AAA-2722-2021; Purswani, Murli/L-9954-2019	Purswani, Murli/0000-0001-6902-7779; Yu, Wendy/0000-0001-5967-2352; Shearer, William/0000-0002-2483-2130	Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute of Allergy and Infectious Diseases; Office of AIDS Research; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Institute on Deafness and Other Communication Disorders; National Heart, Lung, and Blood Institute; National Institute of Dental and Craniofacial Research; National Institute on Alcohol Abuse and Alcoholism; Harvard T.H. Chan School of Public Health [HD052102]; Tulane University School of Medicine [HD052104]; Baylor College of Medicine-University of Texas Center for AIDS Research [AI 36211]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U01HD052104, U01HD052102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Office of AIDS Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute on Deafness and Other Communication Disorders(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); National Institute on Alcohol Abuse and Alcoholism(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Harvard T.H. Chan School of Public Health; Tulane University School of Medicine; Baylor College of Medicine-University of Texas Center for AIDS Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development with cofunding from the National Institute on Drug Abuse; the National Institute of Allergy and Infectious Diseases; the Office of AIDS Research; the National Institute of Mental Health; the National Institute of Neurological Disorders and Stroke; the National Institute on Deafness and Other Communication Disorders; the National Heart, Lung, and Blood Institute; the National Institute of Dental and Craniofacial Research; and the National Institute on Alcohol Abuse and Alcoholism through cooperative agreements with the Harvard T.H. Chan School of Public Health (HD052102; Principal Investigator: George Seage; Project Director: Julie Alperen) and the Tulane University School of Medicine (HD052104; Principal Investigator: Russell Van Dyke; Co-Principal Investigators: Kenneth Rich, Ellen Chadwick; Project Director: Patrick Davis). Data management services were provided by Frontier Science and Technology Research Foundation (Principal Investigator: Suzanne Siminski), and regulatory services and logistical support were provided by Westat (Principal Investigator: Julie Davidson). In addition, the Baylor College of Medicine-University of Texas Center for AIDS Research (AI 36211; Principal Investigator: Janet S. Butel) supported this study. The following institutions, clinical site investigators, and staff participated in conducting Pediatric HIV/AIDS Cohort Study (PHACS) Adolescent Master Protocol (AMP) and AMP Up in 2015 in alphabetical order: Ann & Robert H. Lurie Children's Hospital of Chicago-Ram Yogev, Margaret Ann Sanders, Kathleen Malee, and Scott Hunter; Baylor College of Medicine-William Shearer, Mary Paul, Norma Cooper, and Lynnette Harris; Bronx Lebanon Hospital Center: Murli Purswani, Mahboobullah Baig, and Anna Cintron; Children's Diagnostic & Treatment Center-Ana Puga, Sandra Navarro, Patricia A. Garvie, and James Blood; Children's Hospital, Boston-Sandra K. Burchett, Nancy Karthas, and Betsy Kammerer; Jacobi Medical Center-Andrew Wiznia, Marlene Burey, and Molly Nozyce; Rutgers-New Jersey Medical School-Arry Dieudonne, Linda Bettica; St Christopher's Hospital for Children-Janet S. Chen, Maria Garcia Bulkley, Latreaca Ivey, and Mitzie Grant; St Jude Children's Research Hospital-Katherine Knapp, Kim Allison, and Megan Wilkins; San Juan Hospital/Department of Pediatrics-Midnela Acevedo-Flores, Heida Rios, and Vivian Olivera; Tulane University School of Medicine-Margarita Silio, Medea Gabriel, and Patricia Sirois; University of California, San Diego Stephen A. Spector, Kim Norris, and Sharon Nichols; University of Colorado Denver Health Sciences Center-Elizabeth McFarland, Juliana Darrow, Emily Barr, and Paul Harding; University of Miami-Gwendolyn Scott, Grace Alvarez, and Anai Cuadra. Note: The conclusions and opinions expressed in this article are those of the authors and do not necessarily reflect those of the National Institutes of Health or US Department of Health and Human Services.	[Anonymous], 2003, NHANES RESP DIS SYMP; [Anonymous], 1978, REC RESP DIS QUEST U, P48; [Anonymous], 2015, IMMUNO CAP IGE; Bacot BK, 1997, J ALLERGY CLIN IMMUN, V100, P707, DOI 10.1016/S0091-6749(97)70177-5; Barnes PJ, 2015, J ALLERGY CLIN IMMUN, V136, P531, DOI 10.1016/j.jaci.2015.05.052; Bolton CE, 2015, THORAX, V70, P574, DOI 10.1136/thoraxjnl-2014-206590; Bunupuradah T, 2015, CLIN IMMUNOL, V157, P26, DOI 10.1016/j.clim.2014.12.006; Clausen E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112237; Colin AA, 2001, AM J RESP CRIT CARE, V163, P865, DOI 10.1164/ajrccm.163.4.9901040; Cui Q, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-6; Linhar LD, 2013, EUR ANN ALLERGY CLIN, V45, P155; Dolen WK, 2003, ALLERGY, V58, P717, DOI 10.1034/j.1398-9995.2003.00281.x; Drummond MB, 2015, AIDS, V29, P1691, DOI 10.1097/QAD.0000000000000750; Drummond MB, 2012, THORAX, V67, P309, DOI 10.1136/thoraxjnl-2011-200702; Dundas I, 2005, THORAX, V60, P13, DOI 10.1136/thx.2004.029934; Fitzpatrick ME, 2014, AIDS, V28, P2505, DOI 10.1097/QAD.0000000000000471; Foster SB, 2008, J ALLERGY CLIN IMMUN, V122, P159, DOI 10.1016/j.jaci.2008.04.043; Foster SB, 2007, J ALLERGY CLIN IMMUN, V119, P750, DOI 10.1016/j.jaci.2007.01.002; Foster SB, 2010, AIDS, V24, P2133, DOI 10.1097/QAD.0b013e32833cba08; French MA, 2007, HIV MED, V8, P148, DOI 10.1111/j.1468-1293.2007.00445.x; Galant SP, 2007, J PEDIATR-US, V151, P457, DOI 10.1016/j.jpeds.2007.05.004; Gelb AF, 2015, J ALLERGY CLIN IMMUN, V136, P553, DOI 10.1016/j.jaci.2015.06.013; George MP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006328; Gingo MR, 2013, CLIN CHEST MED, V34, P273, DOI 10.1016/j.ccm.2013.02.002; Gingo MR, 2013, CURR HIV-AIDS REP, V10, P42, DOI 10.1007/s11904-012-0140-x; Gingo MR, 2012, J ALLERGY CLIN IMMUN, V129, P708, DOI 10.1016/j.jaci.2011.11.015; Gingo MR, 2010, AM J RESP CRIT CARE, V182, P790, DOI 10.1164/rccm.200912-1858OC; GRIECO MH, 1989, J ALLERGY CLIN IMMUN, V84, P1, DOI 10.1016/0091-6749(89)90170-X; Gutin F, 2009, ANN ALLERG ASTHMA IM, V102, P438, DOI 10.1016/S1081-1206(10)60518-2; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hausmann Oliver, 2014, Allergo J Int, V23, P261; ISRAELBIET D, 1992, J ALLERGY CLIN IMMUN, V89, P68, DOI 10.1016/S0091-6749(05)80042-9; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Keet CA, 2015, J ALLERGY CLIN IMMUN, V135, P655, DOI 10.1016/j.jaci.2014.11.022; Kristoffersen US, 2012, CLIN PHYSIOL FUNCT I, V32, P288, DOI 10.1111/j.1475-097X.2012.01124.x; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Marone G, 2001, J ALLERGY CLIN IMMUN, V107, P22, DOI 10.1067/mai.2001.111589; MAZZA DS, 1995, ANN ALLERG ASTHMA IM, V74, P411; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Morris A, 2012, AIDS, V26, P731, DOI 10.1097/QAD.0b013e32835099ae; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Ozcan E, 2008, J ALLERGY CLIN IMMUN, V122, P1054, DOI 10.1016/j.jaci.2008.10.023; Poirier CD, 2001, AM J RESP CRIT CARE, V164, P542, DOI 10.1164/ajrccm.164.4.2010019; Postma DS, 2015, NEW ENGL J MED, V373, P1241, DOI 10.1056/NEJMra1411863; Postma DS, 2015, J ALLERGY CLIN IMMUN, V136, P521, DOI 10.1016/j.jaci.2015.06.018; Postma DS, 2015, LANCET, V385, P899, DOI 10.1016/S0140-6736(14)60446-3; Reddel HK, 2015, J ALLERGY CLIN IMMUN, V136, P546, DOI 10.1016/j.jaci.2015.06.043; Rodriguez C, 1996, CLIN IMMUNOL IMMUNOP, V81, P191, DOI 10.1006/clin.1996.0176; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Shearer WT, 2015, C RETR OPP INF CROI; SHORPOSNER G, 1995, J ALLERGY CLIN IMMUN, V95, P886, DOI 10.1016/S0091-6749(95)70133-8; Siberry GK, 2012, CLIN IMMUNOL, V142, P201, DOI 10.1016/j.clim.2011.10.005; Sly PD, 2016, AM J RESP CRIT CARE, V193, P1, DOI 10.1164/rccm.201509-1801ED; SMALL CB, 1993, J INFECT DIS, V167, P283, DOI 10.1093/infdis/167.2.283; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; Svanes C, 2010, THORAX, V65, P14, DOI 10.1136/thx.2008.112136; Tai A, 2014, J ALLERGY CLIN IMMUN, V133, P1572, DOI 10.1016/j.jaci.2013.12.1033; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V135, P1465, DOI 10.1016/j.jaci.2014.12.1942; Tse SM, 2013, J ALLERGY CLIN IMMUN, V132, P554, DOI 10.1016/j.jaci.2013.03.031; Wesemann DR, 2011, J EXP MED, V208, P2733, DOI 10.1084/jem.20111155; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P445, DOI 10.1016/0091-6749(90)90154-V; Yunginger JW, 2000, J ALLERGY CLIN IMMUN, V105, P1077, DOI 10.1067/mai.2000.107041; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	63	13	13	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1101	+		10.1016/j.jaci.2017.01.031	http://dx.doi.org/10.1016/j.jaci.2017.01.031			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28279683	Bronze, Green Accepted			2022-12-18	WOS:000412172900021
J	Stukus, DR				Stukus, David R.			Peanut-free schools: What does it really mean, and are they necessary?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Peanut allergy; food allergy; anaphylaxis; school; epinephrine	FOOD ALLERGY		[Stukus, David R.] Nationwide Childrens Hosp, Div Allergy & Immunol, 700 Childrens Dr, Columbus, OH 43205 USA; [Stukus, David R.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University	Stukus, DR (corresponding author), Nationwide Childrens Hosp, Div Allergy & Immunol, 700 Childrens Dr, Columbus, OH 43205 USA.	david.stukus@nationwidechildrens.org			American College of Allergy, Asthma Immunology	American College of Allergy, Asthma Immunology	D. R. Stukus has an unpaid volunteer position on the board of directors for the Asthma and Allergy Foundation of America; has had consultant arrangements with Aimmune Therapeutics; is employed by Nationwide Children's Hospital and the Ohio State University College of Medicine; and has received payment for lectures from the American College of Allergy, Asthma & Immunology.	[Anonymous], 2016, DSD; Bartnikas LM, 2017, J ALLERGY CLIN IMMUN, V140, P465, DOI 10.1016/j.jaci.2017.01.040; Centers for Disease Control and Prevention, 2013, VOL GUID MAN FOOD AL; Gupta RS, 2014, PEDIATRICS, V134, P729, DOI 10.1542/peds.2014-0402; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; NEA Research, 2014, RANK STAT 2013 EST S; Portnoy JM, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0467-z; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; White MV, 2015, ALLERGY ASTHMA PROC, V36, P306, DOI 10.2500/aap.2015.36.3859	9	13	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					391	392		10.1016/j.jaci.2017.03.037	http://dx.doi.org/10.1016/j.jaci.2017.03.037			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28454741				2022-12-18	WOS:000406855500010
J	Berings, M; Arasi, S; De Ruyck, N; Perna, S; Resch, Y; Lupinek, C; Chen, KW; Vrtala, S; Pajno, GB; Bachert, C; Lambrecht, BN; Dullaers, M; Valenta, R; Matricardi, PM; Gevaert, P				Berings, Margot; Arasi, Stefania; De Ruyck, Natalie; Perna, Serena; Resch, Yvonne; Lupinek, Christian; Chen, Kuan-Wei; Vrtala, Susanne; Pajno, Giovanni Battista; Bachert, Claus; Lambrecht, Bart N.; Dullaers, Melissa; Valenta, Rudolf; Matricardi, Paolo Maria; Gevaert, Philippe			Reliable mite-specific IgE testing in nasal secretions by means of allergen microarray	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LOCAL PRODUCTION; ANTIBODIES		[Berings, Margot; De Ruyck, Natalie; Bachert, Claus; Gevaert, Philippe] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium; [Berings, Margot; Lambrecht, Bart N.; Dullaers, Melissa] Univ Ghent, Immunoregulat Lab, VIB Inflammat Res Ctr, Ghent, Belgium; [Lambrecht, Bart N.; Dullaers, Melissa] Univ Ghent, Dept Internal Med, Ghent, Belgium; [Arasi, Stefania; Perna, Serena; Matricardi, Paolo Maria] Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany; [Arasi, Stefania; Pajno, Giovanni Battista] Univ Messina, Dept Pediat, Allergy Unit, Messina, Italy; [Resch, Yvonne; Lupinek, Christian; Chen, Kuan-Wei; Vrtala, Susanne; Valenta, Rudolf] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Divis Immunopathol, Vienna, Austria; [Vrtala, Susanne] Med Univ Vienna, Christian Doppler Lab Dev Allergen Chips, Vienna, Austria; [Dullaers, Melissa] Ghent Univ Hosp, Dept Resp Med, Clin Immunol Res Lab, Ghent, Belgium	Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Messina; Medical University of Vienna; Medical University of Vienna; Ghent University; Ghent University Hospital	Berings, M (corresponding author), Univ Ghent, Upper Airways Res Lab, Ghent, Belgium.; Berings, M (corresponding author), Univ Ghent, Immunoregulat Lab, VIB Inflammat Res Ctr, Ghent, Belgium.	margot.berings@ugent.be	Gevaert, Philippe/ABA-4588-2021; Lupinek, Christian/I-3311-2019; Lambrecht, Bart N/K-2484-2014; Bachert, Claus/J-8825-2012; Arasi, Stefania/K-2858-2018; Gevaert, Philippe/AAP-1892-2020	Lupinek, Christian/0000-0002-8612-8245; Lambrecht, Bart N/0000-0003-4376-6834; Arasi, Stefania/0000-0002-8135-0568; Gevaert, Philippe/0000-0002-1629-8468; Dullaers, Melissa/0000-0003-0223-230X; Chen, Kuan-Wei/0000-0001-5899-5766; Resch, Yvonne/0000-0002-7933-2547; Vrtala, Susanne/0000-0003-4250-8243; Valenta, Rudolf/0000-0001-5944-3365	Flemish Scientific Research Foundation; Austrian Science Fund; Christian Doppler Research Association; Austrian Science Fund (Der Wissenschaftsfonds [FWF]); ThermoFisher	Flemish Scientific Research Foundation; Austrian Science Fund(Austrian Science Fund (FWF)); Christian Doppler Research Association; Austrian Science Fund (Der Wissenschaftsfonds [FWF]); ThermoFisher	M. Berings receives grant support from Flemish Scientific Research Foundation. C. Lupinek receives payment for lectures from ThermoFisher. S. Vrtala receives grant support from Austrian Science Fund and Christian Doppler Research Association. R. Valenta receives grant support from the Austrian Science Fund (Der Wissenschaftsfonds [FWF]) and Christian Doppler Research Association and serves as a consultant for Biomay AG, Thermo Fisher Scientific, and Fresenius Medical Care. P. M. Matricardi receives materials and agents from ThermoFisher Scientific; serves as a consultant for ThermoFisher Scientific and Eutoimmun AG; and receives grant support from ThermoFisher. P. Gevaert receives grant support from the Flemish Scientific Research Foundation. The rest of the authors declare that they have no relevant conflicts of interest.	Dullaers M, 2012, J ALLERGY CLIN IMMUN, V129, P635, DOI 10.1016/j.jaci.2011.10.029; Howarth Peter H, 2005, J Allergy Clin Immunol, V115, pS414, DOI 10.1016/j.jaci.2004.12.1134; HUGGINS KG, 1975, LANCET, V2, P148; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; Reisacher WR, 2013, INT FORUM ALLERGY RH, V3, P399, DOI 10.1002/alr.21111; Rondon C, 2012, J ALLERGY CLIN IMMUN, V129, P1460, DOI 10.1016/j.jaci.2012.02.032; Sakaida H, 2014, ALLERGOL INT, V63, P467, DOI 10.2332/allergolint.13-OA-0668; Scadding Glenis, 2011, Clin Transl Allergy, V1, P2, DOI 10.1186/2045-7022-1-2	9	13	13	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					301	303		10.1016/j.jaci.2016.11.047	http://dx.doi.org/10.1016/j.jaci.2016.11.047			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28238352	Bronze			2022-12-18	WOS:000404542000039
J	Mortari, EP; Baban, A; Cantarutti, N; Bocci, C; Adorisio, R; Carsetti, R				Mortari, Eva Piano; Baban, Anwar; Cantarutti, Nicoletta; Bocci, Chiara; Adorisio, Rachele; Carsetti, Rita			Heterotaxy syndrome with and without spleen: Different infection risk and management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MEMORY B-CELLS; ASPLENIA; HYPOSPLENIA; CHILDREN		[Mortari, Eva Piano; Bocci, Chiara; Carsetti, Rita] Bambino Gesu Children Hosp, Cell Physiopathol Unit B, Immunol Res Area, Rome, Italy; [Baban, Anwar; Cantarutti, Nicoletta; Adorisio, Rachele] Bambino Gesu Children Hosp, Med & Surg Dept Paedriat Cardiol, Rome, Italy	IRCCS Bambino Gesu; IRCCS Bambino Gesu	Mortari, EP (corresponding author), Bambino Gesu Children Hosp, Cell Physiopathol Unit B, Immunol Res Area, Rome, Italy.	eva.pianomortari@gmail.com	Adorisio, Rachele/AAA-7306-2020; Piano Mortari, Eva/Q-9402-2016; Cantarutti, Nicoletta/AAA-6226-2020; carsetti, rita/K-7616-2016	Piano Mortari, Eva/0000-0002-0054-4732; Cantarutti, Nicoletta/0000-0001-9888-2395; Adorisio, Rachele/0000-0002-9577-2155; Bocci, Chiara/0000-0001-5954-9135; carsetti, rita/0000-0002-2632-1078; Baban, Anwar/0000-0002-9428-4934				Burton EC, 2014, PEDIATR DEVEL PATHOL, V17, P250, DOI 10.2350/13-11-1406-OA.1; Capolunghi F, 2013, IMMUNOL LETT, V152, P114, DOI 10.1016/j.imlet.2013.04.007; Chiu SN, 2016, PEDIATR RES, V79, P271, DOI 10.1038/pr.2015.221; Chiu SN, 2014, J PEDIATR-US, V164, P99, DOI 10.1016/j.jpeds.2013.08.051; Kruetzmann S, 2003, J EXP MED, V197, P939, DOI 10.1084/jem.20022020; Loomba RS, 2016, CONGENIT HEAR D 0718; Luoto TT, 2016, SURGERY, V159, P1583, DOI 10.1016/j.surg.2015.12.014; Price VE, 2007, INFECT DIS CLIN N AM, V21, P697, DOI 10.1016/j.idc.2007.07.002; Salvadori MI, 2014, PAED CHILD HEALT-CAN, V19, P271, DOI 10.1093/pch/19.5.271; Weller S, 2004, BLOOD, V104, P3647, DOI 10.1182/blood-2004-01-0346	10	13	13	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1981	+		10.1016/j.jaci.2016.10.014	http://dx.doi.org/10.1016/j.jaci.2016.10.014			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27864025	hybrid			2022-12-18	WOS:000402724600029
J	Spohn, G; Arenas-Ramirez, N; Bouchaud, G; Boyman, O				Spohn, Gunther; Arenas-Ramirez, Natalia; Bouchaud, Gregory; Boyman, Onur			Endogenous polyclonal anti-IL-1 antibody responses potentiate IL-1 activity during pathogenic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cytokine; IL-1 beta; antibody; autoantibody; inflammation; inflammatory disease; autoinflammatory disease	CHRONIC MUCOCUTANEOUS CANDIDIASIS; COLONY-STIMULATING FACTOR; B-CELL TOLERANCE; BIOLOGICAL-ACTIVITY; IFN-GAMMA; IN-VIVO; AUTOANTIBODIES; RECEPTOR; CYTOKINE; ALPHA	Background: Particular neutralizing mAbs to certain cytokines act as agonists in vivo through protection of the cytokine's active site and prolongation of its half-life. Although this principle might be useful for targeted immunotherapy, its role in the pathogenesis of inflammation and autoimmunity is unclear. Objective: We sought to determine whether slight, structurally nonrelevant modifications of the prototypic proinflammatory cytokine IL-1 beta during an immune response could elicit polyclonal anti-IL-1 beta antibody responses that modulated IL-1 beta's in vivo activity. Methods: We engineered 2 different IL-1 beta variants, thereby mimicking the process of cytokine modification occurring during inflammation, and conjugated them to virus-like particles, followed by immunization of mice. The resulting polyclonal anti-IL-1 beta antibody responses were assessed by using in vitro and in vivo assays, as well as 2 relevant (auto-)inflammatory murine models. Results: Although antibody responses generated to one variant were potently inhibiting IL-1 beta, antibody responses induced by the other variant even potentiated the in vivo effects of IL-1 beta; the latter led to enhanced morbidity in 2 different IL-1 beta-mediated mouse models, including a model of inflammatory bowel disease and an inflammatory arthritis model. Conclusion: These data demonstrate that endogenous polyclonal anti-cytokine antibody responses can enhance the cytokine's activity in inflammatory and autoimmune diseases.	[Spohn, Gunther] Cytos Biotechnol, Wagistr 25, CH-8952 Schlieren, Switzerland; [Arenas-Ramirez, Natalia; Bouchaud, Gregory; Boyman, Onur] Univ Zurich, Univ Zurich Hosp, Dept Immunol, Gloriastr 23, CH-8091 Zurich, Switzerland; [Bouchaud, Gregory] INRA, Nantes, France	University of Zurich; University Zurich Hospital; INRAE	Spohn, G (corresponding author), Cytos Biotechnol, Wagistr 25, CH-8952 Schlieren, Switzerland.; Boyman, O (corresponding author), Univ Zurich, Univ Zurich Hosp, Dept Immunol, Gloriastr 23, CH-8091 Zurich, Switzerland.	cri.gunther@bluewin.ch; onur.boyman@uzh.ch	Bouchaud, Gregory/AAC-4596-2020	Bouchaud, Gregory/0000-0002-3794-7287; Arenas-Ramirez, Natalia/0000-0003-4415-5605; Boyman, Onur/0000-0001-8279-5545	Swiss National Science Foundation [PP00P3-128421, PP00P3-150751]; Zurich Integrative Human Physiology (ZIHP) cooperative project grant; Stiftung fuer wissenschaftliche Forschung of University of Zurich; Novartis Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Zurich Integrative Human Physiology (ZIHP) cooperative project grant; Stiftung fuer wissenschaftliche Forschung of University of Zurich; Novartis Foundation(Novartis)	Supported by Swiss National Science Foundation grants PP00P3-128421 and PP00P3-150751, a Zurich Integrative Human Physiology (ZIHP) cooperative project grant, a grant of the Stiftung fuer wissenschaftliche Forschung of University of Zurich, and a grant of the Novartis Foundation (all to O.B.).	Arenas-Ramirez N, 2015, TRENDS IMMUNOL, V36, P763, DOI 10.1016/j.it.2015.10.003; AURON PE, 1992, BIOCHEMISTRY-US, V31, P6632, DOI 10.1021/bi00144a002; Basten A, 2010, CURR OPIN IMMUNOL, V22, P566, DOI 10.1016/j.coi.2010.08.001; Bendtzen K, 1998, IMMUNOL TODAY, V19, P209, DOI 10.1016/S0167-5699(98)01252-3; BHOL K, 1994, DERMATOLOGY, V189, P85, DOI 10.1159/000246938; BOST KL, 1988, IMMUNOLOGY, V65, P611; Bouchaud G, 2013, J EXP MED, V210, P2105, DOI 10.1084/jem.20130291; Boyman O, 2006, SCIENCE, V311, P1924, DOI 10.1126/science.1122927; Boyman O, 2008, J IMMUNOL, V180, P7265, DOI 10.4049/jimmunol.180.11.7265; Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Browne SK, 2014, ANNU REV IMMUNOL, V32, P635, DOI 10.1146/annurev-immunol-032713-120222; Browne SK, 2012, NEW ENGL J MED, V367, P725, DOI 10.1056/NEJMoa1111160; Browne SK, 2010, LANCET INFECT DIS, V10, P875, DOI 10.1016/S1473-3099(10)70196-1; CARUSO A, 1990, J IMMUNOL, V144, P685; Casadevall N, 2002, NEW ENGL J MED, V346, P469, DOI 10.1056/NEJMoa011931; Casadevall N, 1996, NEW ENGL J MED, V334, P630, DOI 10.1056/NEJM199603073341004; Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417; Doffinger R, 2004, CLIN INFECT DIS, V38, pE10, DOI 10.1086/380453; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; FOMSGAARD A, 1989, SCAND J IMMUNOL, V30, P219, DOI 10.1111/j.1365-3083.1989.tb01204.x; GEHRKE L, 1990, J BIOL CHEM, V265, P5922; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; Halverson R, 2004, NAT IMMUNOL, V5, P645, DOI 10.1038/ni1076; HANSEN MB, 1991, SCAND J IMMUNOL, V33, P777, DOI 10.1111/j.1365-3083.1991.tb02552.x; Hellmich B, 2002, ARTHRITIS RHEUM, V46, P2384, DOI 10.1002/art.10497; Hoflich C, 2004, BLOOD, V103, P673, DOI 10.1182/blood-2003-04-1065; Jegerlehner A, 2002, VACCINE, V20, P3104, DOI 10.1016/S0264-410X(02)00266-9; Jouvenne P, 1997, SCAND J IMMUNOL, V46, P413, DOI 10.1046/j.1365-3083.1997.d01-139.x; JU G, 1991, P NATL ACAD SCI USA, V88, P2658, DOI 10.1073/pnas.88.7.2658; Kampmann B, 2005, J CLIN INVEST, V115, P2480, DOI 10.1172/JCI19316; Kim JJ, 2012, JOVE-J VIS EXP, DOI 10.3791/3678; Kisand K, 2010, J EXP MED, V207, P299, DOI 10.1084/jem.20091669; Kitamura T, 1999, J EXP MED, V190, P875, DOI 10.1084/jem.190.6.875; Kitamura T, 2000, AM J RESP CRIT CARE, V162, P658, DOI 10.1164/ajrccm.162.2.9910032; KLEIN B, 1995, IMMUNOL TODAY, V16, P216, DOI 10.1016/0167-5699(95)80161-8; Letourneau S, 2010, P NATL ACAD SCI USA, V107, P2171, DOI 10.1073/pnas.0909384107; Liu S, 2005, J IMMUNOL, V175, P5067, DOI 10.4049/jimmunol.175.8.5067; MAY LT, 1993, J IMMUNOL, V151, P3225; Owyang AM, 2011, MABS-AUSTIN, V3, P49, DOI 10.4161/mabs.3.1.13989; Patel SY, 2005, J IMMUNOL, V175, P4769, DOI 10.4049/jimmunol.175.7.4769; POZZETTO B, 1984, J INFECT DIS, V150, P707, DOI 10.1093/infdis/150.5.707; Puel A, 2008, J IMMUNOL, V180, P647, DOI 10.4049/jimmunol.180.1.647; Puel A, 2010, J EXP MED, V207, P291, DOI 10.1084/jem.20091983; Rosen LB, 2013, J IMMUNOL, V190, P3959, DOI 10.4049/jimmunol.1202526; ROSS C, 1990, CLIN EXP IMMUNOL, V82, P57; SATO TA, 1993, J IMMUNOL, V150, P2717; Spohn G, 2008, EUR J IMMUNOL, V38, P877, DOI 10.1002/eji.200737989; Spohn G, 2007, J IMMUNOL, V178, P7450, DOI 10.4049/jimmunol.178.11.7450; Spohn G, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.48; Spohn G, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-146; TIBERIO L, 1993, SCAND J IMMUNOL, V38, P472, DOI 10.1111/j.1365-3083.1993.tb02590.x; Uchida K, 2009, BLOOD, V113, P2547, DOI [10.1182/blood-2008-05-155689, 10.1182/blood-2009-05-155689]; Van den Steen P, 1998, ADV EXP MED BIOL, V435, P133; Wang DL, 2010, NAT IMMUNOL, V11, P905, DOI 10.1038/ni.1925; Wildbaum G, 2003, IMMUNITY, V19, P679, DOI 10.1016/S1074-7613(03)00291-7; Woytschak J, 2016, IMMUNITY, V45, P172, DOI 10.1016/j.immuni.2016.06.025	56	13	13	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1957	+		10.1016/j.jaci.2016.09.033	http://dx.doi.org/10.1016/j.jaci.2016.09.033			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27833025	Bronze			2022-12-18	WOS:000402724600026
J	Barlogis, V; Mahlaoui, N; Auquier, P; Pellier, I; Fouyssac, F; Vercasson, C; Allouche, M; De Azevedo, CB; Suarez, F; Moshous, D; Neven, B; Pasquet, M; Jeziorski, E; Aladjidi, N; Schleinitz, N; Thomas, C; Gandemer, V; Mazingue, F; Lutz, P; Hermine, O; Picard, C; Blanche, S; Michel, G; Fischer, A				Barlogis, Vincent; Mahlaoui, Nizar; Auquier, Pascal; Pellier, Isabelle; Fouyssac, Fanny; Vercasson, Camille; Allouche, Maya; De Azevedo, Carolina Brito; Suarez, Felipe; Moshous, Despina; Neven, Benedicte; Pasquet, Marlene; Jeziorski, Eric; Aladjidi, Nathalie; Schleinitz, Nicolas; Thomas, Caroline; Gandemer, Virginie; Mazingue, Francoise; Lutz, Patrick; Hermine, Olivier; Picard, Capucine; Blanche, Stephane; Michel, Gerard; Fischer, Alain			Physical health conditions and quality of life in adults with primary immunodeficiency diagnosed during childhood: A French Reference Center for PIDs (CEREDIH) study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; childhood; young adults; health status; quality of life	STEM-CELL TRANSPLANTATION; DEFICIENCY; THERAPY; COHORT	Background: Most children with primary immunodeficiencies (PIDs) now reach adulthood. However, few studies have evaluated their health status and health-related quality of life (HRQoL). Objective: To investigate long-term morbidity, the French Reference Center for PIDs initiated a prospective multicenter cohort: the French Childhood Immune Deficiency Long-term Cohort. The data collected were used to assess the physical health condition of patients who reached adulthood and the effect on their quality of life. Methods: Patients were asked to complete health status questionnaires. A severity score (grade 1 [mild] to grade 4 [life-threatening]) was assigned to each health condition. The HRQoL of patients was compared with age-and sex-matched French normal values by using the 36-item Short-Form Survey (SF-36) HRQoL questionnaire. Results: Among 329 participants, the mean age at evaluation was 27.6 years, with a 21-year mean follow-up after diagnosis; 43% reported at least 1 grade 4 health condition, and 86% reported at least 1 grade 3 (severe) or 4 health condition. Twenty-five (7.6%) patients had been treated for cancer. Compared with the French normal values, adults with PIDs scored significantly lower for all HRQoL domains. HRQoL was strongly associated with the burden of health conditions. The association with grade 4 or grade 3-4 health conditions was highly significant for all physical and mental domains. Conclusion: Adults with PIDs diagnosed during childhood experienced a heavy burden of health conditions, which affected their HRQoL. Our results emphasize the need to closely monitor this vulnerable population.	[Barlogis, Vincent; Allouche, Maya; Michel, Gerard] Assistance Publ Hop Marseille, Dept Pediat Hematol Oncol, Marseille, France; [Barlogis, Vincent; Mahlaoui, Nizar; Pellier, Isabelle; Fouyssac, Fanny; De Azevedo, Carolina Brito; Suarez, Felipe; Moshous, Despina; Neven, Benedicte; Pasquet, Marlene; Jeziorski, Eric; Aladjidi, Nathalie; Schleinitz, Nicolas; Thomas, Caroline; Gandemer, Virginie; Mazingue, Francoise; Lutz, Patrick; Hermine, Olivier; Picard, Capucine; Blanche, Stephane; Michel, Gerard; Fischer, Alain] Necker Enfants Malades Univ Hosp, AP HP, French Natl Reference Ctr Primary Immune Deficien, Paris, France; [Barlogis, Vincent; Auquier, Pascal; Vercasson, Camille; Michel, Gerard] Aix Marseille Univ, Univ Hosp Marseille, Dept Publ Hlth, EA 3279,Res Unit, Marseille, France; [Mahlaoui, Nizar; Moshous, Despina; Neven, Benedicte; Picard, Capucine; Blanche, Stephane; Fischer, Alain] Necker Enfants Malades Univ Hosp, AP HP, Pediat Immunohaematol & Rheumatol Unit, Paris, France; [Mahlaoui, Nizar; Suarez, Felipe; Moshous, Despina; Neven, Benedicte; Hermine, Olivier; Picard, Capucine; Blanche, Stephane; Fischer, Alain] Univ Paris 05, Necker Med Sch, Sorbonne Paris Cite, INSERM,UMR1163,Imagine Inst, Paris, France; [Pellier, Isabelle] Univ Hosp Angers, Dept Pediat Oncohematol, Angers, France; [Fouyssac, Fanny] Univ Hosp Nancy, Dept Pediat Hematol Oncol, Nancy, France; [Suarez, Felipe; Hermine, Olivier] Univ Paris 05, Necker Univ Hosp, APHP, Adult Hematol Unit, Paris, France; [Suarez, Felipe] Univ Paris 05, Necker Med Sch, Sorbonne Paris Cite, CNRS,ERL8254,Imagine Inst, Paris, France; [Pasquet, Marlene] Ctr Hosp Univ Toulouse Purpan, Dept Hematol, Toulouse, France; [Pasquet, Marlene] IUCT Oncopole, CRCT, INSERM, Toulouse, France; [Jeziorski, Eric] Montpellier Univ Hosp, Hop Arnaud de Villeneuve, Serv Pediat Gen & Infectiol & Immunol Clin, Montpellier, France; [Aladjidi, Nathalie] Univ Hosp Bordeaux, Dept Pediat Hematol, Bordeaux, France; [Aladjidi, Nathalie] Univ Hosp Bordeaux, INSERM CICP, CIC 0005, Bordeaux, France; [Schleinitz, Nicolas] CHU Timone, Assistance Publ Hop Marseille, Dept Internal Med, Marseille, France; [Thomas, Caroline] Univ Hosp Nantes, Hop Mere Enfant, Pediat Hematol Oncol Unit, Nantes, France; [Gandemer, Virginie] Univ Hosp Rennes, Dept Pediat Hematol Oncol, Rennes, France; [Mazingue, Francoise] Univ Hosp Lille, Hop Jeanne de Flandre, Dept Pediat, Lille, France; [Lutz, Patrick] EA3430, Pediat Hematol Oncol, Strasbourg, France; [Fischer, Alain] Coll France, Paris, France	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU de Nancy; Universite de Lorraine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Montpellier; CHU de Montpellier; CHU Bordeaux; CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Nantes Universite; CHU de Nantes; CHU Rennes; Universite de Rennes; Universite de Lille - ISITE; CHU Lille; UDICE-French Research Universities; PSL Research University Paris; College de France	Barlogis, V (corresponding author), Hop Enfants La Timone, Dept Pediat Hematol Oncol, Marseille, France.; Barlogis, V (corresponding author), Univ Aix Marseille, Marseille, France.	vincent.barlogis@ap-hm.fr	MAHLAOUI, Nizar/AAH-6103-2020; Moshous, Despina/B-7507-2017; Mahlaoui, Nizar/J-7928-2017; Hermine, Olivier/Q-7072-2018; schleinitz, nicolas/AAL-6751-2020; Jeziorski, Eric/AAI-3530-2021; pasquet, marlene/W-8568-2019	MAHLAOUI, Nizar/0000-0002-0030-8094; Moshous, Despina/0000-0001-6719-3693; Mahlaoui, Nizar/0000-0002-0030-8094; schleinitz, nicolas/0000-0001-9449-3392; Jeziorski, Eric/0000-0003-0318-3044; Hermine, Olivier/0000-0003-2574-3874	French National Program for Clinical Research (PHRC) [2012-A0033-35]	French National Program for Clinical Research (PHRC)	Supported by the French National Program for Clinical Research (PHRC; EudraCT trial no. 2012-A0033-35, Ministry of Health).	Abbott J, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007418; Abdou NI, 2009, INT ARCH ALLERGY IMM, V149, P267, DOI 10.1159/000199723; Aguilar C, 2014, CLIN INFECT DIS, V59, P1462, DOI 10.1093/cid/ciu646; Beaute J, 2010, CLIN IMMUNOL, V135, P264, DOI 10.1016/j.clim.2010.02.021; Bertilsson L, 2013, J RHEUMATOL, V40, P715, DOI 10.3899/jrheum.120602; Chapel H, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00627; Cole T, 2013, J ALLERGY CLIN IMMUN, V132, P1150, DOI 10.1016/j.jaci.2013.05.031; Dill EJ, 2013, CHEST, V144, P981, DOI 10.1378/chest.12-1404; Espanol T, 2014, PATIENT PREFER ADHER, V8, P621, DOI [10.2147/PPA.S60771, 10.2147/PPA.S.60771]; Fischer A, 2015, CLIN GENET, V88, P507, DOI 10.1111/cge.12576; Forte GC, 2015, RESP CARE, V60, P1459, DOI 10.4187/respcare.03665; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; Griffith LM, 2014, J ALLERGY CLIN IMMUN, V133, P335, DOI 10.1016/j.jaci.2013.07.052; Grimbacher B, 2014, CLIN EXP IMMUNOL, V178, P18, DOI 10.1111/cei.12496; Hanna KM, 2014, RES NURS HEALTH, V37, P399, DOI 10.1002/nur.21620; Howard V, 2006, CLIN IMMUNOL, V118, P201, DOI 10.1016/j.clim.2005.11.002; Jiang FD, 2015, ALLERGY ASTHMA CL IM, V11, DOI 10.1186/s13223-015-0092-y; Kang E, 2014, HEMATOL ONCOL CLIN N, V28, P1157, DOI 10.1016/j.hoc.2014.08.006; Kuburovic NB, 2014, PATIENT PREFER ADHER, V8, P323, DOI 10.2147/PPA.S58040; Leplege A, 1998, J CLIN EPIDEMIOL, V51, P1013, DOI 10.1016/S0895-4356(98)00093-6; Louie AD, 2000, BONE MARROW TRANSPL, V25, P1191, DOI 10.1038/sj.bmt.1702419; National Institutes of Health/ National Cancer Institute, 2009, CANC THER EV PROGR C; Neven B, 2009, BLOOD, V113, P4114, DOI 10.1182/blood-2008-09-177923; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Perneger, 2001, QUESTIONNAIRE MOS SF; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Raab A, 2013, CLIN EXP RHEUMATOL, V31, P796; Seeborg FO, 2015, J CLIN IMMUNOL, V35, P638, DOI 10.1007/s10875-015-0196-7	28	13	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1275	+		10.1016/j.jaci.2016.08.027	http://dx.doi.org/10.1016/j.jaci.2016.08.027			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27697497	Bronze			2022-12-18	WOS:000398771800022
J	Ahuja, SK; Manoharan, MS; Harper, NL; Jimenez, F; Hobson, BD; Martinez, H; Ingale, P; Liu, YG; Carrillo, A; Lou, Z; Kellog, DL; Ahuja, SS; Rather, CG; Esch, RE; Ramirez, DA; Clark, RA; Nadeau, K; Andrews, CP; Jacobs, RL; He, WJ				Ahuja, Sunil K.; Manoharan, Muthu Saravanan; Harper, Nathan L.; Jimenez, Fabio; Hobson, Benjamin D.; Martinez, Hernan; Ingale, Puraskar; Liu, Ya-Guang; Carrillo, Andrew; Lou, Zheng; Kellog, Dean L.; Ahuja, Seema S.; Rather, Cynthia G.; Esch, Robert E.; Ramirez, Daniel A.; Clark, Robert A.; Nadeau, Kari; Andrews, Charles P.; Jacobs, Robert L.; He, Weijing			Preservation of epithelial cell barrier function and muted inflammation in resistance to allergic rhinoconjunctivitis from house dust mite challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen challenge chamber; house dust mites; rhino-conjunctivitis; RNA sequencing; epithelial barrier	GENOME-WIDE ASSOCIATION; LARGE GENE LISTS; ATOPIC-DERMATITIS; SUSCEPTIBILITY LOCI; SKIN BARRIER; SENSITIZATION; EXPOSURE; FILAGGRIN; CHAMBER; POLLEN	Background: An emerging paradigm holds that resistance to the development of allergic diseases, including allergic rhinoconjunctivitis, relates to an intact epithelial/epidermal barrier during early childhood. Conceivably, the immunologic and genomic footprint of this resistance is preserved in nonatopic, nonallergic adults and is unmasked during exposure to an aeroallergen. Objective: The aim of this study was to obtain direct support of the epithelial/epidermal barrier model for allergic rhinoconjunctivitis. Methods: Twenty-three adults allergic to house dust mites (HDMs) (M+) and 15 nonsensitive, nonallergic (M-) participants completed 3-hour exposures to aerosolized HDM (Dermatophagoides pteronyssinus) powder on 4 consecutive days in an allergen challenge chamber. We analyzed: (1) peripheral blood leukocyte levels and immune responses; and (2) RNA sequencing-derived expression profiles of nasal cells, before and after HDM exposure. Results: On HDM challenge: (1) onlyM+ persons developed allergic rhinoconjunctivitis symptoms; and (2) peripheral blood leukocyte levels/responses and gene expression patterns in nasal cells were largely concordant between M+ and M- participants; gross differences in these parameters were not observed at baseline (pre-exposure). Two key differences were observed. First, peripheral blood CD4(+) and CD8(+) T-cell activation levels initially decreased in M- participants versus increased in M+ participants. Second, in M-compared with M+ participants, genes that promoted epidermal/epithelial barrier function (eg, filament- aggregating protein [filaggrin]) versus inflammation (eg, chemokines) and innate immunity (interferon) were upregulated versus muted, respectively. Conclusion: An imprint of resistance to HDM challenge in nonatopic, nonallergic adults was muted T-cell activation in the peripheral blood and inflammatory response in the nasal compartment, coupled with upregulation of genes that promote epidermal/epithelial cell barrier function.	[Ahuja, Sunil K.; Manoharan, Muthu Saravanan; Harper, Nathan L.; Jimenez, Fabio; Martinez, Hernan; Ingale, Puraskar; Liu, Ya-Guang; Carrillo, Andrew; Lou, Zheng; Ahuja, Seema S.; Clark, Robert A.; He, Weijing] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA; [Ahuja, Sunil K.; Manoharan, Muthu Saravanan; Harper, Nathan L.; Jimenez, Fabio; Martinez, Hernan; Ingale, Puraskar; Liu, Ya-Guang; Carrillo, Andrew; Lou, Zheng; Kellog, Dean L.; Ahuja, Seema S.; Clark, Robert A.; He, Weijing] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA; [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA; [Harper, Nathan L.; Jimenez, Fabio; Martinez, Hernan] Fdn Advancing Vet Hlth Res, San Antonio, TX USA; [Hobson, Benjamin D.; Nadeau, Kari] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; [Hobson, Benjamin D.; Nadeau, Kari] Stanford Univ, Sch Med, Sean N Parker Ctr Allergy Res, Stanford, CA USA; [Rather, Cynthia G.; Ramirez, Daniel A.; Andrews, Charles P.; Jacobs, Robert L.] Biogen Res Chamber, San Antonio, TX USA; [Esch, Robert E.] Lenoir Rhyne Univ, Sch Nat Sci, Hickory, NC USA; [Nadeau, Kari] Stanford Hosp, Lucile Packard Childrens Hosp, Div Allergy Immunol & Rheumatol, Stanford, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Stanford University; Stanford University; Lucile Packard Children's Hospital (LPCH); Stanford University	Ahuja, SK (corresponding author), 7400 Merton Minter Blvd,Room W200, San Antonio, TX 78229 USA.	ahujas@uthscsa.edu	Clark, Robert/Q-6764-2019; Manoharan, Muthu Saravanan/L-4851-2019	Clark, Robert/0000-0002-4892-3619; Andrews, Charles/0000-0002-8944-8404; Ingale, Puraskar/0000-0003-2769-878X; Hobson, Benjamin/0000-0002-2745-5318	Doris Duke Distinguished Clinical Scientist Award; Burroughs Wellcome Clinical Scientist in Transitional Research Award; Max and Minnie Tomerlin Senior Scholar Voelcker Award; Center for Personalized Medicine South Texas Veterans Health Care System [CX00875-01A1]; National Institutes of Health Clinical and Translational Science Award [UL1-TR001120]; Sean N. Parker Center for Food Allergy Research; Veterans Affairs [IP1CX000875] Funding Source: NIH RePORTER	Doris Duke Distinguished Clinical Scientist Award(Doris Duke Charitable Foundation (DDCF)); Burroughs Wellcome Clinical Scientist in Transitional Research Award; Max and Minnie Tomerlin Senior Scholar Voelcker Award; Center for Personalized Medicine South Texas Veterans Health Care System; National Institutes of Health Clinical and Translational Science Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sean N. Parker Center for Food Allergy Research; Veterans Affairs(US Department of Veterans Affairs)	Supported by a the Doris Duke Distinguished Clinical Scientist Award, a Burroughs Wellcome Clinical Scientist in Transitional Research Award, a Max and Minnie Tomerlin Senior Scholar Voelcker Award, and a grant from the Center for Personalized Medicine (CX00875-01A1) at the South Texas Veterans Health Care System (S.K.A.); by a National Institutes of Health Clinical and Translational Science Award (UL1-TR001120; R.A.C.); and by the Sean N. Parker Center for Food Allergy Research (K.N.).	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bendall SC, 2012, TRENDS IMMUNOL, V33, P323, DOI 10.1016/j.it.2012.02.010; Bonnelykke K, 2015, CURR OPIN IMMUNOL, V36, P115, DOI 10.1016/j.coi.2015.08.002; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393; Chaussabel D, 2014, NAT REV IMMUNOL, V14, P271, DOI 10.1038/nri3642; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; De Benedetto A, 2012, J INVEST DERMATOL, V132, P949, DOI 10.1038/jid.2011.435; de Koning HD, 2012, BRIT J DERMATOL, V166, P1245, DOI 10.1111/j.1365-2133.2012.10885.x; De Marchi F, 2015, ALLERGY ASTHMA PROC, V36, pE127, DOI 10.2500/aap.2015.36.3872; Dharmage SC, 2014, ALLERGY, V69, P17, DOI 10.1111/all.12268; Ellis AK, 2013, ANN ALLERG ASTHMA IM, V111, P323, DOI 10.1016/j.anai.2013.07.019; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Hashida R, 2007, J HUM GENET, V52, P13, DOI 10.1007/s10038-006-0085-2; He WJ, 2015, J ALLERGY CLIN IMMUN, V136, P658, DOI 10.1016/j.jaci.2015.02.041; Hinds DA, 2013, NAT GENET, V45, P907, DOI 10.1038/ng.2686; Hovnanian A, 2013, CELL TISSUE RES, V351, P289, DOI 10.1007/s00441-013-1558-1; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Hubiche T, 2007, ACTA DERM-VENEREOL, V87, P499, DOI 10.2340/00015555-0329; Jacobs RL, 2014, J ALLERGY CLIN IMMUN, V133, pe1; Jacobs RL, 2015, J ALLERGY CLIN IMMUN, V135, P1071, DOI 10.1016/j.jaci.2014.09.047; Jacobs RL, 2014, J ALLERGY CLIN IMMUN, V133, P1340, DOI 10.1016/j.jaci.2013.09.051; Jacobs RL, 2012, J ALLERGY CLIN IMMUN, V130, P122, DOI 10.1016/j.jaci.2012.03.031; Jin HL, 2009, J INVEST DERMATOL, V129, P31, DOI 10.1038/jid.2008.106; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kukurba Kimberly R, 2015, Cold Spring Harb Protoc, V2015, P951, DOI 10.1101/pdb.top084970; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Leung DYM, 2013, ALLERGOL INT, V62, P151, DOI 10.2332/allergolint.13-RAI-0564; Li W, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0218-2; Marenholz I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9804; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Moniuszko M, 2009, CLIN IMMUNOL, V130, P338, DOI 10.1016/j.clim.2008.09.011; O'Regan GM, 2010, CLIN EXP ALLERGY, V40, P965, DOI 10.1111/j.1365-2222.2010.03522.x; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Platts-Mills TAE, 2015, J ALLERGY CLIN IMMUN, V136, P3, DOI 10.1016/j.jaci.2015.03.048; Portelli MA, 2015, CLIN EXP ALLERGY, V45, P21, DOI 10.1111/cea.12327; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Spergel JM, 2010, ANN ALLERG ASTHMA IM, V105, P99, DOI 10.1016/j.anai.2009.10.002; Tang HY, 2014, NAT GENET, V46, P45, DOI 10.1038/ng.2827; Wong KL, 2012, IMMUNOL RES, V53, P41, DOI 10.1007/s12026-012-8297-3	43	13	13	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					844	854		10.1016/j.jaci.2016.08.019	http://dx.doi.org/10.1016/j.jaci.2016.08.019			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27658763	Bronze			2022-12-18	WOS:000397295800017
J	van Schie, KA; Kruithof, S; van Schouwenburg, PA; Vennegoor, A; Killestein, J; Wolbink, G; Rispens, T				van Schie, Karin A.; Kruithof, Simone; van Schouwenburg, Pauline A.; Vennegoor, Anke; Killestein, Joep; Wolbink, Gertjan; Rispens, Theo			Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFLIXIMAB		[van Schie, Karin A.; Kruithof, Simone; van Schouwenburg, Pauline A.; Wolbink, Gertjan; Rispens, Theo] Univ Amsterdam, Acad Med Ctr, Dept Immunopathol Sanquin Res, NL-1012 WX Amsterdam, Netherlands; [van Schie, Karin A.; Kruithof, Simone; van Schouwenburg, Pauline A.; Wolbink, Gertjan; Rispens, Theo] Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1012 WX Amsterdam, Netherlands; [Vennegoor, Anke; Killestein, Joep] Vrije Univ Amsterdam Med Ctr, VUmc MS Ctr Amsterdam, Dept Neurol Amsterdam Neurosci, Amsterdam, Netherlands; [Wolbink, Gertjan] Jan Van Breemen Res Inst, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Rispens, T (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Immunopathol Sanquin Res, NL-1012 WX Amsterdam, Netherlands.; Rispens, T (corresponding author), Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1012 WX Amsterdam, Netherlands.	T.Rispens@sanquin.nl		van Schouwenburg, Pauline/0000-0003-2779-1415; Killestein, Joep/0000-0002-6347-5957; Wolbink, Gerrit Jan/0000-0003-1924-7460	Pfizer; TEVA; Blogen Idec; Novartis; Bayer Schering Pharma; GlaxoSmithKline; Merck-Serono; AbbVie; UCB; Genmab; Reneneron; Biogen-Idec; Roche	Pfizer(Pfizer); TEVA(Teva Pharmaceutical Industries); Blogen Idec; Novartis(Novartis); Bayer Schering Pharma(Bayer AG); GlaxoSmithKline(GlaxoSmithKline); Merck-Serono(Merck & Company); AbbVie(AbbVie); UCB(UCB Pharma SA); Genmab(Genmab); Reneneron; Biogen-Idec(Biogen); Roche(Roche Holding)	K.A. van Schie receives grant support from Pfizer. S. Kruithof receives grant support from Pfizer. A. Vennegoor receives payments for lectures from TEVA. J. Killestein serves as a consultant for Blogen Idec, Roche, Novartis, Merck-Serono, TEVA, and Genzyme and grant support from Blogen Idec, Novartis, TEVA, Bayer Schering Pharma, GlaxoSmithKline, and Merck-Serono. G. Wolbink receives grant support from Pfizer and payments for lectures from Pfizer, AbbVie, and UCB. T. Rispens receives grant support from Pfizer and Genmab; serves as a consultant for Genmab; and receives payments for lectures from Pfizer, Abbvie, and Reneneron. VUmc MS Center Amsterdam has received financial support for research activities from Bayer Schering Pharma, Biogen-Idec, GlaxoSmithKline, Merck-Serono, Novartis, Genzyme, Roche, and Teva. The rest of the authors declare that they have no relevant conflicts of interest.	Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Brugnara C., 2003, NATHAN OSKIS HEMATOL, P1848; Calabresi PA, 2007, NEUROLOGY, V69, P1391, DOI 10.1212/01.wnl.0000277457.17420.b5; Homann A, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0706-7; Kjeldsberg C., 2006, PRACTICAL DIAGNOSIS, P408; Kosmac M, 2011, PEDIATR RES, V69, P243, DOI 10.1203/PDR.0b013e318208451d; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; van Schie KA, 2015, ANN RHEUM DIS, V74, P311, DOI 10.1136/annrheumdis-2014-206237; van Schie KA, 2015, MABS-AUSTIN, V7, P662, DOI 10.1080/19420862.2015.1048411; van Schouwenburg PA, 2014, J BIOL CHEM, V289, P34482, DOI 10.1074/jbc.M114.615500; Vennegoor A, 2013, MULT SCLER J, V19, P593, DOI 10.1177/1352458512460604; Yu YM, 2013, J BIOL CHEM, V288, P32314, DOI 10.1074/jbc.M113.501668	12	13	14	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					1035	1037		10.1016/j.jaci.2016.09.014	http://dx.doi.org/10.1016/j.jaci.2016.09.014			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27717666				2022-12-18	WOS:000397295800037
J	Anderson, HM; Lemanske, RF; Evans, MD; Gangnon, RE; Pappas, T; Grindle, K; Bochkov, YA; Gern, JE; Jackson, DJ				Anderson, Halie M.; Lemanske, Robert F., Jr.; Evans, Michael D.; Gangnon, Ronald E.; Pappas, Tressa; Grindle, Kris; Bochkov, Yury A.; Gern, James E.; Jackson, Daniel J.			Assessment of wheezing frequency and viral etiology on childhood and adolescent asthma risk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							COMBINED IMMUNODEFICIENCY; RHINOVIRUS ILLNESSES; CHILDREN		[Anderson, Halie M.; Lemanske, Robert F., Jr.; Pappas, Tressa; Grindle, Kris; Bochkov, Yury A.; Gern, James E.; Jackson, Daniel J.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Div Allergy Immunol & Rheumatol, Madison, WI 53706 USA; [Evans, Michael D.; Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Anderson, HM (corresponding author), Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Div Allergy Immunol & Rheumatol, Madison, WI 53706 USA.	Handerson@pediatrics.wisc.edu		Gangnon, Ronald/0000-0003-2587-6714; Evans, Michael/0000-0001-7449-3993; Bochkov, Yury/0000-0003-2618-4496	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI104317, T32AI007635] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR003186] Funding Source: Medline; NHLBI NIH HHS [P01 HL070831] Funding Source: Medline; NIAID NIH HHS [T32 AI007635, U19 AI104317] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Herz W, 2013, J ALLERGY CLIN IMMUN, V131, P658, DOI 10.1016/j.jaci.2012.11.033; Bochkov YA, 2014, J CLIN MICROBIOL, V52, P2461, DOI 10.1128/JCM.00075-14; Bonnelykke K, 2015, J ALLERGY CLIN IMMUN, V136, P81, DOI 10.1016/j.jaci.2015.02.024; Coonrod EM, 2014, BIOTECHNIQUES, V57, P204, DOI 10.2144/000114217; Hastie T, 1995, Stat Methods Med Res, V4, P187, DOI 10.1177/096228029500400302; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Lee WM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000966; Lee WM, 2007, J CLIN MICROBIOL, V45, P2626, DOI 10.1128/JCM.02501-06; Lee WM, 2012, AM J RESP CRIT CARE, V186, P886, DOI 10.1164/rccm.201202-0330OC; Lee YN, 2014, J ALLERGY CLIN IMMUN, V133, P1099, DOI 10.1016/j.jaci.2013.10.007; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Spann KM, 2014, THORAX, V69, P918, DOI 10.1136/thoraxjnl-2013-204908; Yin FF, 2009, NAT STRUCT MOL BIOL, V16, P499, DOI 10.1038/nsmb.1593	15	13	13	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					692	694		10.1016/j.jaci.2016.07.031	http://dx.doi.org/10.1016/j.jaci.2016.07.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27609657	Bronze, Green Published, Green Accepted			2022-12-18	WOS:000397002400038
J	Ramirez-Carrozzi, V; Sambandam, A; Zhou, MJ; Yan, DH; Kang, J; Wu, XM; Suto, E; Baca, M; Austin, C; Xu, M; Lee, W; Pappu, R				Ramirez-Carrozzi, Vladimir; Sambandam, Arivazhagan; Zhou, Meijuan; Yan, Donghong; Kang, Jing; Wu, Xiumin; Suto, Eric; Baca, Miriam; Austin, Cary; Xu, Min; Lee, Wyne; Pappu, Rajita			Combined blockade of the IL-13 and IL-33 pathways leads to a greater inhibition of type 2 inflammation over inhibition of either pathway alone	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA		[Ramirez-Carrozzi, Vladimir; Sambandam, Arivazhagan; Pappu, Rajita] Genentech Inc, Dept Immunol Discovery, San Francisco, CA 94080 USA; [Zhou, Meijuan; Yan, Donghong; Kang, Jing; Wu, Xiumin; Suto, Eric; Xu, Min; Lee, Wyne] Genentech Inc, Dept Transplantat Immunol, San Francisco, CA USA; [Baca, Miriam; Austin, Cary] Genentech Inc, Dept Pathol, San Francisco, CA USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Pappu, R (corresponding author), Genentech Inc, Dept Immunol Discovery, San Francisco, CA 94080 USA.	rajitap@gene.com			Genentech	Genentech(Roche HoldingGenentech)	V. Ramirez-Carrozzi is employed by Genentech; has 1 or more patents (pending) with Genentech and Roche; and owns stock/stock options in Roche. A. Sambandam is employed by Genentech; has 1 or more patents (planned) with Genentech and Roche; and owns stock/stock options in Roche. D. Yan is employed by Genentech; has 1 or more patents (pending) with Genentech and Roche; and owns stock/stock options in Roche. M. Zhou was employed by Genentech; has 1 or more patents (pending) with Genentech and Roche; and owns stock/stock options in Roche. J. Kang is employed by Genentech; has 1 or more patents (planned) with Genentech and Roche; and owns stock/stock options in Roche. X. Wu is employed by Genentech; has 1 or more patents (pending) with Genentech and Roche; and owns stock/stock options in Roche. E. Suto is employed by Genentech; has 1 or more patents (planned) with Genentech and Roche; and owns stock/stock options in Roche. M. Baca is employed by Genentech; has 1 or more patents (planned) with Genentech and Roche; and owns stock/stock options in Roche. C. Austin is employed by Genentech; has 1 or more patents (planned) with Genentech and Roche; owns stock/stock options in Roche; and has received paid travel expenses from Genentech. M. Xu is employed by Genentech; has 1 or more patents (pending) with Genentech and Roche; owns stock/stock options in Roche; and has been paid for writing/reviewing manuscripts by Genentech. W. Lee is employed by Genentech; has 1 or more patents (pending) with Genentech and Roche; and owns stock/stock options in Roche. R. Pappu is employed by Genentech; has 1 or more patents (pending) with Genentech and Roche; and owns stock/stock options in Roche.	Evans CM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7281; Gauthier M, 2015, AM J RESP CRIT CARE, V192, P660, DOI 10.1164/rccm.201504-0763PP; Harvie M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00074; Katelaris C, 2009, OMALIZUMAB RECOMMEND; Lee HY, 2014, EXP LUNG RES, V40, P66, DOI 10.3109/01902148.2013.870261; MOLOFSKY AB, 2015, IMMUNITY, V42, P1005, DOI [DOI 10.1016/j.immuni.2015.06.006, DOI 10.1016/J.IMMUNI.2015.06.006]; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482	10	13	13	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					705	+		10.1016/j.jaci.2016.08.026	http://dx.doi.org/10.1016/j.jaci.2016.08.026			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27697499	Bronze			2022-12-18	WOS:000397002400043
J	Lougaris, V; Moratto, D; Baronio, M; Tampella, G; van der Meer, JWM; Badolato, R; Fliegauf, M; Plebani, A				Lougaris, Vassilios; Moratto, Daniele; Baronio, Manuela; Tampella, Giacomo; van der Meer, Jos W. M.; Badolato, Raffaele; Fliegauf, Manfred; Plebani, Alessandro			Early and late B-cell developmental impairment in nuclear factor kappa B, subunit 1-mutated common variable immunodeficiency disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							KNOCKOUT; DEFECTS; PATHWAY; P50		[Lougaris, Vassilios; Baronio, Manuela; Tampella, Giacomo; Badolato, Raffaele; Plebani, Alessandro] Univ Brescia, Dept Clin & Expt Sci, Pediat Clin, Spedali Civili Brescia, I-25121 Brescia, Italy; [Lougaris, Vassilios; Moratto, Daniele; Baronio, Manuela; Tampella, Giacomo; Badolato, Raffaele; Plebani, Alessandro] Univ Brescia, Inst Mol Med A Nocivelli, Spedali Civili Brescia, I-25121 Brescia, Italy; [Moratto, Daniele] Univ Brescia, Dept Pathol, Spedali Civili Brescia, Lab Genet Disorders Childhood,Dept Mol & Translat, I-25121 Brescia, Italy; [van der Meer, Jos W. M.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands; [Fliegauf, Manfred] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Fliegauf, Manfred] Univ Freiburg, Freiburg, Germany	University of Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Brescia; Radboud University Nijmegen; University of Freiburg; University of Freiburg	Lougaris, V (corresponding author), Univ Brescia, Dept Clin & Expt Sci, Pediat Clin, Spedali Civili Brescia, I-25121 Brescia, Italy.; Lougaris, V (corresponding author), Univ Brescia, Inst Mol Med A Nocivelli, Spedali Civili Brescia, I-25121 Brescia, Italy.	vlougarisbs@yahoo.com	Badolato, Raffaele/A-8081-2010; van der Meer, Jos W.M./C-8521-2013	Badolato, Raffaele/0000-0001-7375-5410; van der Meer, Jos W.M./0000-0001-5120-3690	European Community [201549 (EURO-PADnet HEALTH-F2-2008-201549)]; Italian Ministerial Grant [GR-2010-2315762]; "Fondazione C. Golgi,'' Brescia, Italy; Jeffrey Modell Foundation; German Federal Ministry of Education and Research [BMBF 01EO1303]; E-Rare EURO-CMC [01GM1502]	European Community(European Commission); Italian Ministerial Grant; "Fondazione C. Golgi,'' Brescia, Italy; Jeffrey Modell Foundation; German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); E-Rare EURO-CMC	The research leading to these results has received funding from the European Community's Seventh Framework Programme FP7/2007-2013 under grant agreement no. 201549 (EURO-PADnet HEALTH-F2-2008-201549) and from the Italian Ministerial Grant GR-2010-2315762. The research leading to these results also received funding from the "Fondazione C. Golgi,'' Brescia, Italy, and the Jeffrey Modell Foundation. This study was supported by the German Federal Ministry of Education and Research (grant no. BMBF 01EO1303) and by E-Rare EURO-CMC (grant no. 01GM1502).	Chen K, 2013, AM J HUM GENET, V93, P812, DOI 10.1016/j.ajhg.2013.09.009; Claudio E, 2009, J IMMUNOL, V182, P3406, DOI 10.4049/jimmunol.0803360; Fliegauf M, 2015, AM J HUM GENET, V97, P389, DOI 10.1016/j.ajhg.2015.07.008; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; Gerondakis S, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000182; Lougaris V, 2015, J ALLERGY CLIN IMMUN, V135, P1641, DOI 10.1016/j.jaci.2014.11.038; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Snapper CM, 1996, J IMMUNOL, V156, P183; Wehr C, 2004, CLIN IMMUNOL, V113, P161, DOI 10.1016/j.clim.2004.05.010; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744	10	13	14	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					349	+		10.1016/j.jaci.2016.05.045	http://dx.doi.org/10.1016/j.jaci.2016.05.045			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27555455				2022-12-18	WOS:000393996800036
J	Kramer, CB; LeRoy, L; Donahue, S; Apter, AJ; Bryant-Stephens, T; Elder, JP; Hamilton, WJ; Krishnan, JA; Shelef, DQ; Stout, JW; Sumino, K; Teach, SJ; Federman, AD				Kramer, C. Bradley; LeRoy, Lisa; Donahue, Sara; Apter, Andrea J.; Bryant-Stephens, Tyra; Elder, John P.; Hamilton, Winifred J.; Krishnan, Jerry A.; Shelef, Deborah Q.; Stout, James W.; Sumino, Kaharu; Teach, Stephen J.; Federman, Alex D.			Enrolling African-American and Latino patients with asthma in comparative effectiveness research: Lessons learned from 8 patient-centered studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Comparative effectiveness research; patient-centered outcomes research; asthma; study recruitment; vulnerable populations	HEALTH; RECRUITMENT; STRATEGIES; ADULTS	Background: African-American and Latino patients are often difficult to recruit for asthma studies. This challenge is a barrier to improving asthma care and outcomes for these populations. Objectives: We sought to examine the recruitment experiences of 8 asthma comparative effectiveness studies that specifically targeted African-American and Latino patients, and identify the solutions they developed to improve recruitment. Methods: Case report methodology was used to gather and evaluate information on study design, recruitment procedures and outcomes from study protocols and annual reports, and in-depth interviews with each research team. Data were analyzed for themes, commonalities, and differences. Results: There were 4 domains of recruitment challenges: individual participant, institutional, research team, and study intervention. Participants had competing demands for time and some did not believe they had asthma. Institutional challenges included organizational policies governing monetary incentives and staff hiring. Research team challenges included ongoing training needs of recruitment staff, and intervention designs often were unappealing to participants because of inconveniences. Teams identified a host of strategies to address these challenges, most importantly engagement of patients and other stakeholders in study design and troubleshooting, and flexibility in data collection and intervention application to meet the varied needs of patients. Conclusions: Asthma researchers may have greater success with recruitment by addressing uncertainty among patients about asthma diagnosis, engaging stakeholders in all aspects of study design and implementation, and maximizing flexibility of study and intervention protocols. However, even with such efforts, engagement of African-American and Latino patients in asthma research may remain low. Greater investment in research on engaging these populations in asthma research may ultimately be needed to improve their asthma care and outcomes.	[Kramer, C. Bradley] Publ Hlth Seattle & King Cty, Seattle, WA USA; [LeRoy, Lisa; Donahue, Sara] Abt Associates Inc, Cambridge, MA USA; [Apter, Andrea J.] Univ Penn, Dept Med, Perelman Sch Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA; [Bryant-Stephens, Tyra] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Bryant-Stephens, Tyra] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Elder, John P.] San Diego State Univ, Sch Publ Hlth, Inst Behav & Community Hlth, San Diego, CA 92182 USA; [Hamilton, Winifred J.] Baylor Coll Med, Environm Hlth Sect, Chron Dis Prevent & Control Res Ctr, Houston, TX 77030 USA; [Krishnan, Jerry A.] Univ Illinois, Coll Med, Dept Med, Div Pulm Crit Care Sleep & Allergy, Chicago, IL USA; [Krishnan, Jerry A.] Univ Illinois Hosp & Hlth Sci Syst, Populat Hlth Sci Program, Chicago, IL USA; [Shelef, Deborah Q.] Childrens Natl Hlth Syst, Washington, DC USA; [Stout, James W.] Univ Washington, Dept Pediat & Hlth Serv, Seattle, WA 98195 USA; [Sumino, Kaharu] Washington Univ, Sch Med, Div Pulm & Crit Care Med, St Louis, MO 63130 USA; [Teach, Stephen J.] Childrens Natl Hlth Syst, Div Emergency Med, Washington, DC USA; [Teach, Stephen J.] Childrens Natl Hlth Syst, Dept Pediat, Washington, DC USA; [Federman, Alex D.] Icahn Sch Med Mt Sinai, Div Gen Internal Med, 1 Gustave Levy Pl,Box 1087, New York, NY 10029 USA	ABT Associates; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; California State University System; San Diego State University; Baylor College of Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Children's National Health System; University of Washington; University of Washington Seattle; Washington University (WUSTL); Children's National Health System; Children's National Health System; Icahn School of Medicine at Mount Sinai	Federman, AD (corresponding author), Icahn Sch Med Mt Sinai, Div Gen Internal Med, 1 Gustave Levy Pl,Box 1087, New York, NY 10029 USA.	alex.federman@mssm.edu	Sumino, Kaharu/AAA-2028-2021	Sumino, Kaharu/0000-0002-6214-2966	Patient-Centered Outcomes Research Institute (PCORI) [2000-50-30-20 AD0004, AS-1307-05218, AS-1308-05876, AS-1307-05584, AS-1308-05887, AS-1307-05498, AS 1307-05420, AS-1307-05588, AS-1307-05284]	Patient-Centered Outcomes Research Institute (PCORI)(Patient-Centered Outcomes Research Institute - PCORI)	Research reported in this article was funded through Patient-Centered Outcomes Research Institute (PCORI) awards (2000-50-30-20 AD0004 to Abt; AS-1307-05218 to A.J.A.; AS-1308-05876 to J.E.; AS-1307-05584 to A.D.F.; AS-1308-05887 to W.H.; AS-1307-05498 to J.W.S.; AS 1307-05420 to J.A.K.; AS-1307-05588 to K.S.; and AS-1307-05284 to S.T.). The views, statements, and opinions in this article are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its Board of Governors, or the Methodology Committee.	Ahmed SM, 2016, PROG COMM HLTH PARTN, V10, P51, DOI 10.1353/cpr.2016.0019; Beck AF, 2016, JAMA PEDIATR, V170, P695, DOI 10.1001/jamapediatrics.2016.0269; Bonevski B, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-42; Ejiogu N, 2011, GERONTOLOGIST, V51, pS33, DOI 10.1093/geront/gnr027; Ellinger A. E., 2005, RES ORG FDN METHODS, P327; Federman AD, 2013, PATIENT EDUC COUNS, V92, P273, DOI 10.1016/j.pec.2013.02.013; Forno E, 2009, CURR OPIN ALLERGY CL, V9, P154, DOI 10.1097/ACI.0b013e3283292207; Halm EA, 2006, CHEST, V129, P573, DOI 10.1378/chest.129.3.573; Huffman LE, 2016, ETHNIC DIS, V26, P295, DOI 10.18865/ed.26.3.295; Karasz HN, 2013, AM J PUBLIC HEALTH, V103, P617, DOI 10.2105/AJPH.2012.300999; Kok MC, 2016, GLOB PUBLIC HEALTH, V11, P1; [National Institutes of Health Biennial report of the Director], BIENN REP DIR NAT I; Patient-Centered Outcomes Research Institute, 2014, PCORI ENG RUBR; Patient-Centered Outcomes Research Institute, 2013, PCORI FUND ANN TREAT; Patient-Centered Outcomes Research Institute, 2013, PCORI METH STAND; Riden Heather E, 2012, BMC Res Notes, V5, P624, DOI 10.1186/1756-0500-5-624; Sofianou A, 2013, J GEN INTERN MED, V28, P67, DOI 10.1007/s11606-012-2160-z; Ulin PR, 2005, QUALITATIVE METHODS; Wendler D, 2006, PLOS MED, V3, P201, DOI 10.1371/journal.pmed.0030019; Yin R., 1994, CASE STUDY RES DESIG	20	13	13	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1600	1607		10.1016/j.jaci.2016.10.011	http://dx.doi.org/10.1016/j.jaci.2016.10.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	EF0MK	27789250	Bronze			2022-12-18	WOS:000390019300016
J	Wood, RA				Wood, Robert A.			Advances in food allergy in 2015	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; peanut allergy; immunotherapy; diagnosis; IgE testing; basophil activation test; allergy prevention	COMPONENT-RESOLVED DIAGNOSTICS; PEANUT ORAL IMMUNOTHERAPY; EARLY ATOPIC-DERMATITIS; RISK INFANTS; IMMUNOACTIVE PREBIOTICS; CLINICAL REACTIVITY; INDUCED ANAPHYLAXIS; HAZELNUT ALLERGY; RANDOMIZED-TRIAL; NATURAL-HISTORY	This review highlights research advances in food allergy that were published in the Journal in 2015. The world of food allergy research continues to rapidly accelerate, with increasing numbers of outstanding submissions to the Journal. In 2015, important studies on the epidemiology of food allergy were published, suggesting differential rates of food allergy in specific racial and ethnic groups. Even more importantly, studies were published identifying specific risk factors for the development of peanut allergy, as well as specific prevention strategies. We also saw new studies on the diagnosis of food allergy and potential approaches to the treatment of food allergy, as well as novel mechanistic studies helping to explain the immunologic correlates of food allergy and food desensitization.	[Wood, Robert A.] Johns Hopkins Univ, Sch Med, Div Allergy & Immunol, Baltimore, MD USA	Johns Hopkins University	Wood, RA (corresponding author), Johns Hopkins Med Ctr, Dept Pediat, 600 N Wolfe St, Baltimore, MD 21287 USA.	rwood@jhmi.edu			National Institute of Allergy and Infectious Diseases; DBV; Aimmune; Astellas; HAL Allergy	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); DBV; Aimmune; Astellas(Astellas Pharmaceuticals); HAL Allergy(HAL Allergy Group)	R. A. Wood is an employee of Johns Hopkins University; receives grant support from the National Institute of Allergy and Infectious Diseases, DBV, Aimmune, Astellas, and HAL Allergy; and receives royalties from UpToDate.	Ballmer-Weber BK, 2015, J ALLERGY CLIN IMMUN, V135, P964, DOI 10.1016/j.jaci.2014.10.047; Bartnikas LM, 2013, J ALLERGY CLIN IMMUN, V131, P451, DOI 10.1016/j.jaci.2012.11.032; Bauer RN, 2015, J ALLERGY CLIN IMMUN, V135, P312, DOI 10.1016/j.jaci.2014.12.1908; Begin P, 2015, J ALLERGY CLIN IMMUN, V135, P1636, DOI 10.1016/j.jaci.2015.03.010; Bernard H, 2015, J ALLERGY CLIN IMMUN, V135, P1267, DOI 10.1016/j.jaci.2014.10.025; Brandstrom J, 2015, CLIN EXP ALLERGY, V45, P1412, DOI 10.1111/cea.12515; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Branum Amy M, 2008, NCHS Data Brief, P1; Brockow K, 2015, J ALLERGY CLIN IMMUN, V135, P977, DOI 10.1016/j.jaci.2014.08.024; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P630, DOI 10.1016/j.jaci.2013.02.034; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P623, DOI 10.1016/j.jaci.2013.02.035; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, P1240, DOI 10.1016/j.jaci.2014.12.1917; Cuello-Garcia CA, 2015, J ALLERGY CLIN IMMUN, V136, P952, DOI [10.1016/j.jaci.2015.07.021, 10.1016/j.jaci.2015.04.031]; Datema MR, 2015, J ALLERGY CLIN IMMUN, V136, P382, DOI 10.1016/j.jaci.2014.12.1949; Dias RP, 2008, PEDIATR ALLERGY IMMU, V19, P86, DOI 10.1111/j.1399-3038.2007.00582.x; Du Toit G, 2016, ALLERGOL INT, V65, P370, DOI 10.1016/j.alit.2016.08.001; du Toit G, 2016, J ALLERGY CLIN IMMUN, V137, P998, DOI 10.1016/j.jaci.2016.02.005; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Fleischer DM, 2016, PEDIATR DERMATOL, V33, P102, DOI 10.1111/pde.12685; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Fox AT, 2015, J ALLERGY CLIN IMMUN, V135, P580, DOI 10.1016/j.jaci.2014.09.022; Gern JE, 2015, J ALLERGY CLIN IMMUN, V136, P23, DOI 10.1016/j.jaci.2015.05.017; Gill P, 2015, J ALLERGY CLIN IMMUN, V135, P1424, DOI 10.1016/j.jaci.2015.04.019; Goldberg MR, 2015, J ALLERGY CLIN IMMUN, V136, P1601, DOI 10.1016/j.jaci.2015.05.040; Gorelik M, 2015, J ALLERGY CLIN IMMUN, V135, P1283, DOI 10.1016/j.jaci.2014.11.010; Green PHR, 2015, J ALLERGY CLIN IMMUN, V135, P1099, DOI 10.1016/j.jaci.2015.01.044; Gruber C, 2015, J ALLERGY CLIN IMMUN, V136, P1696, DOI 10.1016/j.jaci.2015.07.049; Gruber C, 2010, J ALLERGY CLIN IMMUN, V126, P791, DOI 10.1016/j.jaci.2010.07.022; Holt PG, 2015, J ALLERGY CLIN IMMUN, V136, P15, DOI 10.1016/j.jaci.2015.05.011; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; Kattan JD, 2014, J ALLER CL IMM-PRACT, V2, P633, DOI 10.1016/j.jaip.2014.03.013; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Leonard SA, 2015, J ALLER CL IMM-PRACT, V3, P13, DOI 10.1016/j.jaip.2014.10.001; Liu AH, 2015, J ALLERGY CLIN IMMUN, V136, P860, DOI 10.1016/j.jaci.2015.08.012; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Martino D, 2015, J ALLERGY CLIN IMMUN, V135, P1319, DOI 10.1016/j.jaci.2014.12.1933; McGowan EC, 2015, J ALLERGY CLIN IMMUN, V135, P171, DOI 10.1016/j.jaci.2014.06.033; Mondoulet L, 2015, J ALLERGY CLIN IMMUN, V135, P1546, DOI 10.1016/j.jaci.2014.11.028; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135; Nowak-Wegrzyn A, 2015, J ALLERGY CLIN IMMUN, V135, P1114, DOI 10.1016/j.jaci.2015.03.025; Patil SU, 2015, J ALLERGY CLIN IMMUN, V136, P125, DOI 10.1016/j.jaci.2015.03.026; Peters RL, 2015, J ALLERGY CLIN IMMUN, V135, P1257, DOI 10.1016/j.jaci.2015.01.002; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P179, DOI 10.1016/j.jaci.2014.09.001; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Sato S, 2015, J ALLERGY CLIN IMMUN, V136, P1131, DOI 10.1016/j.jaci.2015.07.019; Sato S, 2014, INT ARCH ALLERGY IMM, V164, P1, DOI 10.1159/000361025; Savvatianos S, 2015, J ALLERGY CLIN IMMUN, V136, P192, DOI 10.1016/j.jaci.2015.03.037; Sicherer SH, 2013, J ALLER CL IMM-PRACT, V1, P1, DOI 10.1016/j.jaip.2012.10.004; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Steinke JW, 2015, J ALLERGY CLIN IMMUN, V135, P589, DOI 10.1016/j.jaci.2014.12.1947; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Strid J, 2004, IMMUNOLOGY, V113, P293, DOI 10.1111/j.1365-2567.2004.01989.x; Tang MLK, 2015, J ALLERGY CLIN IMMUN, V135, P737, DOI 10.1016/j.jaci.2014.11.034; Tripathi A, 2015, J ALLERGY CLIN IMMUN, V135, P985, DOI 10.1016/j.jaci.2014.11.032; Tuano KS, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0534-0; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V136, P376, DOI 10.1016/j.jaci.2014.12.1925; Van Overtvelt L, 2010, VACCINE, V28, P2986, DOI 10.1016/j.vaccine.2010.02.009; Wang J, 2015, J ALLERGY CLIN IMMUN, V136, P962, DOI 10.1016/j.jaci.2015.04.029; Wang JL, 2012, CURR ALLERGY ASTHM R, V12, P332, DOI 10.1007/s11882-012-0265-4; West CE, 2015, J ALLERGY CLIN IMMUN, V135, P3, DOI 10.1016/j.jaci.2014.11.012; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P973, DOI 10.1016/j.jaci.2016.01.001	65	13	13	5	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1541	1547		10.1016/j.jaci.2016.10.002	http://dx.doi.org/10.1016/j.jaci.2016.10.002			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27931535	Bronze			2022-12-18	WOS:000390019300006
J	Kane, A; Lau, A; Brink, R; Tangye, SG; Deenick, EK				Kane, Alisa; Lau, Anthony; Brink, Robert; Tangye, Stuart G.; Deenick, Elissa K.			B-cell-specific STAT3 deficiency: Insight into the molecular basis of autosomal-dominant hyper-IgE syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RESPONSES; IL-21		[Kane, Alisa; Lau, Anthony; Brink, Robert; Tangye, Stuart G.; Deenick, Elissa K.] Garvan Inst Med Res, Div Immunol, Darlinghurst, NSW, Australia; [Kane, Alisa; Brink, Robert; Tangye, Stuart G.; Deenick, Elissa K.] UNSW Australia, St Vincents Clin Sch, Darlinghurst, NSW, Australia; [Lau, Anthony] Univ Bath, Bath BA2 7AY, Avon, England	Garvan Institute of Medical Research; University of New South Wales Sydney; University of Bath	Deenick, EK (corresponding author), Garvan Inst Med Res, Div Immunol, Darlinghurst, NSW, Australia.; Deenick, EK (corresponding author), UNSW Australia, St Vincents Clin Sch, Darlinghurst, NSW, Australia.	e.deenick@garvan.org.au	Tangye, Stuart G/H-4023-2014; Deenick, Elissa/AAY-8998-2020; Brink, Robert/B-7910-2010	Tangye, Stuart G/0000-0002-5360-5180; Deenick, Elissa/0000-0002-9271-0004; Brink, Robert/0000-0002-9586-3655; Lau, Anthony/0000-0002-7338-7176				Avery DT, 2010, J EXP MED, V207, P155, DOI 10.1084/jem.20091706; Colley T, 2016, J ALLERGY CLIN IMMUN, V137, P1595, DOI 10.1016/j.jaci.2015.10.013; Durant L, 2010, IMMUNITY, V32, P605, DOI 10.1016/j.immuni.2010.05.003; Fornek JL, 2006, BLOOD, V107, P1085, DOI 10.1182/blood-2005-07-2871; Kane A, 2014, CURR OPIN IMMUNOL, V28, P49, DOI 10.1016/j.coi.2014.01.015; Kim SR, 2013, J ALLERGY CLIN IMMUN, V132, P1397, DOI 10.1016/j.jaci.2013.08.041; Lee HS, 2013, ARTHRITIS RHEUM-US, V65, P1776, DOI 10.1002/art.37963; Lee JH, 2009, DIABETES, V58, P344, DOI 10.2337/db07-1795; Lindblad EB, 2004, IMMUNOL CELL BIOL, V82, P497, DOI 10.1111/j.0818-9641.2004.01286.x; Ma CS, 2012, BLOOD, V119, P3997, DOI 10.1182/blood-2011-11-392985; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Phan TG, 2006, J EXP MED, V203, P2419, DOI 10.1084/jem.20061254; Ray JP, 2014, IMMUNITY, V40, P367, DOI 10.1016/j.immuni.2014.02.005; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79	14	13	15	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1455	+		10.1016/j.jaci.2016.05.018	http://dx.doi.org/10.1016/j.jaci.2016.05.018			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27423495	Bronze			2022-12-18	WOS:000389542700031
J	Pelham, SJ; Lenthall, HC; Deenick, EK; Tangye, SG				Pelham, Simon J.; Lenthall, Helen C.; Deenick, Elissa K.; Tangye, Stuart G.			Elucidating the effects of disease-causing mutations on STAT3 function in autosomal-dominant hyper-IgE syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CELLS		[Pelham, Simon J.; Deenick, Elissa K.; Tangye, Stuart G.] Garvan Inst Med Res, Immunol Res Program, Darlinghurst, NSW, Australia; [Pelham, Simon J.; Lenthall, Helen C.; Deenick, Elissa K.; Tangye, Stuart G.] Univ New South Wales Australia, St Vincents Clin Sch, Darlinghurst, NSW, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney	Deenick, EK (corresponding author), Garvan Inst Med Res, Immunol Res Program, Darlinghurst, NSW, Australia.; Deenick, EK (corresponding author), Univ New South Wales Australia, St Vincents Clin Sch, Darlinghurst, NSW, Australia.	e.deenick@garvan.org.au; s.tangye@garvan.org.au	Deenick, Elissa/AAY-8998-2020; Tangye, Stuart G/H-4023-2014	Deenick, Elissa/0000-0002-9271-0004; Tangye, Stuart G/0000-0002-5360-5180				Avery DT, 2010, J EXP MED, V207, P155, DOI 10.1084/jem.20091706; Bhattacharya S, 2003, J CLIN INVEST, V111, P553, DOI 10.1172/JCI200315372; Deenick EK, 2013, J EXP MED, V210, P2739, DOI 10.1084/jem.20130323; Giacomelli M, 2011, EUR J IMMUNOL, V41, P3075, DOI 10.1002/eji.201141721; He JX, 2012, J BIOSCIENCES, V37, P243, DOI 10.1007/s12038-012-9202-x; Heimall J, 2011, CLIN IMMUNOL, V139, P75, DOI 10.1016/j.clim.2011.01.001; Kane A, 2014, CURR OPIN IMMUNOL, V28, P49, DOI 10.1016/j.coi.2014.01.015; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Ma CS, 2015, J ALLERGY CLIN IMMUN, V136, P993, DOI 10.1016/j.jaci.2015.05.036; Ma CS, 2012, BLOOD, V119, P3997, DOI 10.1182/blood-2011-11-392985; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Vogel TP, 2015, J CLIN IMMUNOL, V35, P615, DOI 10.1007/s10875-015-0187-8; Woellner C, 2010, J ALLERGY CLIN IMMUN, V125, P424, DOI 10.1016/j.jaci.2009.10.059	16	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1210	1213		10.1016/j.jaci.2016.04.020	http://dx.doi.org/10.1016/j.jaci.2016.04.020			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27315770				2022-12-18	WOS:000385499400033
J	De Schryver, E; Calus, L; Bonte, H; Natalie, D; Gould, H; Donovan, E; Elewaut, D; Valenta, R; Mittermann, I; Gutermuth, J; Seher, T; Schleimer, RP; Tan, BK; Derycke, L; Van Zele, T; Bachert, C; Gevaert, P				De Schryver, Els; Calus, Lien; Bonte, Henryk; Natalie, De Ruyck; Gould, Hannah; Donovan, Erin; Elewaut, Dirk; Valenta, Rudolf; Mittermann, Irene; Gutermuth, Jan; Seher, Tanja; Schleimer, Robert P.; Tan, Bruce K.; Derycke, Lara; Van Zele, Thibaut; Bachert, Claus; Gevaert, Philippe			The quest for autoreactive antibodies in nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SERUM SKIN-TEST; CHRONIC RHINOSINUSITIS; MOLECULAR MIMICRY; AUTOANTIBODIES; ACTIVATION; RECEPTOR; VIRUS; IGE		[De Schryver, Els; Calus, Lien; Bonte, Henryk; Derycke, Lara; Van Zele, Thibaut; Bachert, Claus; Gevaert, Philippe] Ghent Univ Hosp, Upper Airways Res Lab, Ghent, Belgium; [Natalie, De Ruyck] Ghent Univ Hosp, Dept Otorhinolaryngol, Ghent, Belgium; [Gould, Hannah] Randall Div Cell & Mol Biophys, London, England; [Gould, Hannah] Div Allergy Asthma & Lung Biol, London, England; [Donovan, Erin; Elewaut, Dirk] Ghent Univ Hosp, GE01, Div Rheumatol, Dept Internal Med, Ghent, Belgium; [Elewaut, Dirk] VIB, Inflammat Res Ctr, Unit Mol Immunol & Inflammat, Ghent, Belgium; [Valenta, Rudolf; Mittermann, Irene] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria; [Gutermuth, Jan] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Dept Dermatol, Brussels, Belgium; [Gutermuth, Jan; Seher, Tanja] Tech Univ Munich, Ctr Allergy & Environm ZAUM, Munich, Germany; [Gutermuth, Jan; Seher, Tanja] German Ctr Lung Res DZL, Helmholtz Ctr Munich, German Res Ctr Environm Hlth, Munich, Germany; [Schleimer, Robert P.; Tan, Bruce K.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Bachert, Claus] Karolinska Inst, Div ENT Dis, Stockholm, Sweden	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; University of London; King's College London; Ghent University; Ghent University Hospital; Flanders Institute for Biotechnology (VIB); Medical University of Vienna; University Hospital Brussels; Vrije Universiteit Brussel; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Northwestern University; Feinberg School of Medicine; Karolinska Institutet	Gevaert, P (corresponding author), Ghent Univ Hosp, Upper Airways Res Lab, Ghent, Belgium.	philippe.gevaert@UGent.be	Gevaert, Philippe/ABA-4588-2021; Bachert, Claus/J-8825-2012; Gevaert, Philippe/AAP-1892-2020	Gevaert, Philippe/0000-0002-1629-8468; Van Zele, Thibaut/0000-0002-6031-4293; Valenta, Rudolf/0000-0001-5944-3365; Mittermann, Irene/0000-0002-6240-6730; Elewaut, Dirk/0000-0002-7468-974X	NHLBI NIH HHS [R37 HL068546] Funding Source: Medline; NIAID NIH HHS [U19 AI106683] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI106683] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bachert Claus, 2007, Clin Allergy Immunol, V20, P163; Blank M, 2007, CLIN REV ALLERG IMMU, V32, P111; Chan YC, 2014, J ALLERGY CLIN IMMUN, V134, P1394, DOI 10.1016/j.jaci.2014.06.029; FREDRIKSEN K, 1993, SCAND J IMMUNOL, V38, P401, DOI 10.1111/j.1365-3083.1993.tb01744.x; Gevaert P, 2013, ALLERGY, V68, P55, DOI 10.1111/all.12054; Hansen KE, 1998, SEMIN ARTHRITIS RHEU, V27, P263, DOI 10.1016/S0049-0172(98)80047-4; Hulse KE, 2013, J ALLERGY CLIN IMMUN, V131, P1075, DOI 10.1016/j.jaci.2013.01.043; Konstantinou GN, 2009, ALLERGY, V64, P1256, DOI 10.1111/j.1398-9995.2009.02132.x; Kuo IH, 2013, J INVEST DERMATOL, V133, P988, DOI 10.1038/jid.2012.437; MANOUSSAKIS MN, 1987, CLIN EXP IMMUNOL, V69, P557; Poole BD, 2006, AUTOIMMUNITY, V39, P63, DOI 10.1080/08916930500484849; Sokolowska M, 2015, J IMMUNOL, V194, P5472, DOI 10.4049/jimmunol.1401343; Tan BK, 2011, J ALLERGY CLIN IMMUN, V128, P1198, DOI 10.1016/j.jaci.2011.08.037; Van Zele T, 2007, CLIN EXP ALLERGY, V37, P1840, DOI 10.1111/j.1365-2222.2007.02838.x; Zambetti G, 2010, INT J IMMUNOPATH PH, V23, P641, DOI 10.1177/039463201002300228	15	13	13	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					893	+		10.1016/j.jaci.2016.03.040	http://dx.doi.org/10.1016/j.jaci.2016.03.040			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27283383	Green Accepted, Bronze			2022-12-18	WOS:000385496000026
J	Liu, XD; Lao, XQ; Wong, CCY; Tan, LX; Zhang, ZL; Wong, TW; Tse, LA; Lau, APS; Yu, ITS				Liu, Xudong; Lao, Xiang Qian; Wong, Claudie Chiu-Yi; Tan, Lixing; Zhang, Zilong; Wong, Tze Wai; Tse, Lap-ah; Lau, Arthur P. S.; Yu, Ignatius T. S.			Frequent use of household cleaning products is associated with rhinitis in Chinese children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinitis; household cleaning products; school-age children	LUNG-FUNCTION; DOMESTIC USE; ASTHMA; PREVALENCE; SYMPTOMS; EXPOSURE; INFECTIONS; ALLERGIES; BLEACH; SPRAYS	Background: Despite the popular use of household cleaning products worldwide, there is no published study investigating the health effects of these products on rhinitis in children. Objective: We sought to investigate the household use of cleaning products and rhinitis patterns in Chinese children. Methods: A total of 2299 children were recruited from 21 primary schools with wide geographic coverage in Hong Kong. Self-administered questionnaires were completed by parents/guardians to collect detailed information on respiratory symptoms and household use of 14 types of chemical cleaning products, as well as clean water. Students were categorized into 4 mutually exclusive rhinitis patterns (never, occasional, frequent, and persistent). The total chemical burden (TCB) score was used as the exposure indicator by calculating the total time of exposure to the 14 cleaning products. Multinomial logistic regression was used to assess the relationship between rhinitis patterns and the use of household cleaning products. Results: Every 10-unit increment of TCB score was associated with an increase in the odds of occasional (odds ratio [OR], 1.21; 95% CI, 1.05-1.41), frequent (OR, 1.36; 95% CI, 1.13-1.60), and persistent (OR, 1.21; 95% CI, 1.01-1.56) rhinitis after adjustment for a wide range of potential confounders. Compared with the children within the lowest tertile of TCB scores, the adjusted ORs of occasional, frequent, and persistent rhinitis in children within the highest tertile were 1.29 (95% CI, 1.01-1.65), 1.97 (95% CI, 1.40-2.76), and 1.67 (95% CI, 1.10-2.54), respectively. Conclusion: Frequent use of chemical cleaning products at home is associated with an increase in the odds of rhinitis in Chinese primary school children.	[Liu, Xudong; Lao, Xiang Qian; Wong, Claudie Chiu-Yi; Tan, Lixing; Zhang, Zilong; Wong, Tze Wai; Tse, Lap-ah; Yu, Ignatius T. S.] Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Shatin, Hong Kong, Peoples R China; [Lau, Arthur P. S.] Hong Kong Univ Sci & Technol, Div Environm, Clear Water Bay, Hong Kong, Peoples R China; [Yu, Ignatius T. S.] Hong Kong Occupat & Environm Hlth Acad, Tsimshatsui, Hong Kong, Peoples R China	Chinese University of Hong Kong; Hong Kong University of Science & Technology	Lao, XQ (corresponding author), Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Prince Wales Hosp, Sch Publ Hlth 4 F, Shatin, Hong Kong, Peoples R China.	xqlao@cuhk.edu.hk	Yu, Ignatius Tak Sun/A-9936-2008; Lao, Xiang Qian/M-5817-2017	Lao, Xiang Qian/0000-0002-2645-0128; Lau, Arthur/0000-0002-7445-051X; Tse, Lap Ah/0000-0003-0355-6218; Zhang, Zilong/0000-0002-7003-6565	Health Medical Research Fund [11121101]; Hong Kong General Research Fund [CU11688]	Health Medical Research Fund; Hong Kong General Research Fund	Supported by the Health Medical Research Fund (no. 11121101) and the Hong Kong General Research Fund (no. CU11688).	Ait-Khaled N, 2009, ALLERGY, V64, P123, DOI 10.1111/j.1398-9995.2008.01884.x; Araki A, 2010, SCI TOTAL ENVIRON, V408, P2208, DOI 10.1016/j.scitotenv.2010.02.012; Asher MI, 1998, EUR RESPIR J, V12, P315; Bernstein JA, 2009, ANN ALLERG ASTHMA IM, V102, P41, DOI 10.1016/S1081-1206(10)60106-8; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Casas L, 2015, OCCUP ENVIRON MED, V72, P602, DOI 10.1136/oemed-2014-102701; Casas L, 2013, EUR RESPIR J, V42, P1415, DOI 10.1183/09031936.00066313; Casas L, 2013, INT J PUBLIC HEALTH, V58, P757, DOI 10.1007/s00038-012-0417-2; Chaudhuri N, 2005, CHILDRENS HLTH ENV G; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Field Z., 2012, DISCOVERING STAT USI; Folletti I, 2014, J ASTHMA, V51, P18, DOI 10.3109/02770903.2013.833217; Hardjojo A, 2011, ASIA PAC ALLERGY, V1, P115, DOI 10.5415/apallergy.2011.1.3.115; Henderson J, 2008, EUR RESPIR J, V31, P547, DOI 10.1183/09031936.00086807; Herr M, 2012, CLIN EXP ALLERGY, V42, P275, DOI 10.1111/j.1365-2222.2011.03933.x; Hong Soyoung, 2014, Environ Health Toxicol, V29, pe2014017, DOI 10.5620/eht.e2014017; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Johnson RA, 2007, APPL MULTIVARIATE ST; Lao XQ, 2014, IND AIR 2014 13 INT, P687; Le Moual N, 2012, EUR RESPIR J, V40, P1381, DOI 10.1183/09031936.00197611; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; Montefort S, 2009, PEDIAT ALLERG IMM-UK, V20, P67, DOI 10.1111/j.1399-3038.2008.00746.x; Nazaroff WW, 2004, ATMOS ENVIRON, V38, P2841, DOI 10.1016/j.atmosenv.2004.02.040; Nickmilder M, 2007, PEDIAT ALLERG IMM-UK, V18, P27, DOI 10.1111/j.1399-3038.2006.00487.x; Nitsch C, 2010, ULLMANNS ENCY IND CH; Ott WR, 1998, SCI AM, V278, P86, DOI 10.1038/scientificamerican0298-86; Sergeant ESG, 2018, EPITOOLS EPIDEMIOLOG; Sherriff A, 2005, THORAX, V60, P45, DOI 10.1136/thx.2004.021154; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Wieslander G, 2001, OCCUP ENVIRON MED, V58, P649, DOI 10.1136/oem.58.10.649; Wolkoff P, 1998, SCI TOTAL ENVIRON, V215, P135, DOI 10.1016/S0048-9697(98)00110-7; Wong CCY, 2014, ISEE ANN C LOC GLOB; Zock JP, 2007, AM J RESP CRIT CARE, V176, P735, DOI 10.1164/rccm.200612-1793OC; Zock JP, 2009, J ALLERGY CLIN IMMUN, V124, P731, DOI 10.1016/j.jaci.2009.06.007	35	13	14	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					754	+		10.1016/j.jaci.2016.03.038	http://dx.doi.org/10.1016/j.jaci.2016.03.038			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27262743	hybrid			2022-12-18	WOS:000385496000011
J	Morris, DW; Stucke, EM; Martin, LJ; Abonia, JP; Mukkada, VA; Putnam, PE; Rothenberg, ME; Fulkerson, PC				Morris, David W.; Stucke, Emily M.; Martin, Lisa J.; Abonia, J. Pablo; Mukkada, Vincent A.; Putnam, Philip E.; Rothenberg, Marc E.; Fulkerson, Patricia C.			Eosinophil progenitor levels are increased in patients with active pediatric eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CELLS; ASTHMA; BLOOD		[Morris, David W.; Stucke, Emily M.; Abonia, J. Pablo; Rothenberg, Marc E.; Fulkerson, Patricia C.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Coll Med, Div Allergy & Immunol,Dept Pediat, Cincinnati, OH 45220 USA; [Martin, Lisa J.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Coll Med, Div Human Genet,Dept Pediat, Cincinnati, OH USA; [Mukkada, Vincent A.; Putnam, Philip E.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Coll Med, Dept Pediat,Div Gastroenterol Hepatol & Nutr, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Fulkerson, PC (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Coll Med, Div Allergy & Immunol,Dept Pediat, Cincinnati, OH 45220 USA.	Patricia.Fulkerson@cchmc.org	Martin, Lisa/E-2425-2016; Mukkada, Vincent/AAF-6995-2019	Martin, Lisa/0000-0001-8702-9946; Mukkada, Vincent/0000-0003-4225-5506	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI117804, T32AI060515, K08AI093673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR001425] Funding Source: Medline; NIAID NIH HHS [K08 AI093673, U54 AI117804, T32 AI060515] Funding Source: Medline; NIDDK NIH HHS [P30 DK078392] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, P208, DOI 10.1016/j.jaci.2010.10.039; Bullock JZ, 2007, J PEDIATR GASTR NUTR, V45, P22, DOI 10.1097/MPG.0b013e318043c097; Henderson CJ, 2012, J ALLERGY CLIN IMMUN, V129, P1570, DOI 10.1016/j.jaci.2012.03.023; Konikoff MR, 2006, CLIN GASTROENTEROL H, V4, P1328, DOI 10.1016/j.cgh.2006.08.013; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Makowska JS, 2008, ANN ALLERG ASTHMA IM, V101, P402, DOI 10.1016/S1081-1206(10)60317-1; Martin LJ, 2015, J ALLERGY CLIN IMMUN, V135, P1519, DOI 10.1016/j.jaci.2015.03.004; Mori Y, 2009, J EXP MED, V206, P183, DOI 10.1084/jem.20081756; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645, DOI 10.1165/ajrcmb.15.5.8918371; Smith SG, 2015, J ALLERGY CLIN IMMUN, V135, P1594, DOI 10.1016/j.jaci.2014.12.1918	11	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					915	+		10.1016/j.jaci.2016.03.027	http://dx.doi.org/10.1016/j.jaci.2016.03.027			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27199214	Green Accepted, Bronze			2022-12-18	WOS:000385496000035
J	Suurmond, J; Habets, KLL; Tatum, Z; Schonkeren, JJ; 't Hoen, PAC; Huizinga, TWJ; Laros, JFJ; Toes, REM; Kurreeman, F				Suurmond, Jolien; Habets, Kim L. L.; Tatum, Zuotian; Schonkeren, Joris J.; 't Hoen, Peter A. C.; Huizinga, Tom W. J.; Laros, Jeroen F. J.; Toes, Rene E. M.; Kurreeman, Fina			Repeated Fc epsilon RI triggering reveals modified mast cell function related to chronic allergic responses in tissue	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; IgE; chronic allergy; transcriptome; chronic rhinosinusitis; atopic dermatitis; atopic asthma	GENE-EXPRESSION DATA; CD4(+) T-CELLS; AIRWAY HYPERRESPONSIVENESS; DEFICIENT MICE; ASTHMA MODEL; C/EBP-ALPHA; INFLAMMATION; RECEPTOR; BINDING; IDENTIFICATION	Background: Activation of mast cells through Fc epsilon RI plays an important role in acute allergic reactions. However, little is known about the function of mast cells in patients with chronic allergic inflammation or the effect of repeated Fc epsilon RI triggering occurring in such responses. Objective: We aimed to identify changes in mast cell function after repeated Fc epsilon RI triggering and to correlate these changes to chronic allergic responses in tissue. Methods: Human cord blood-derived mast cells were treated for 2 weeks with anti-IgE. The function of naive or treated mast cells was analyzed by means of RNA sequencing, quantitative RT-PCR, flow cytometry, and functional assays. Protein secretion was measured with ELISAs and multiplex assays. Results: We observed several changes in mast cell function after repeated anti-IgE triggering. Although the acute response was dampened, we identified 289 genes significantly upregulated after repeated anti-IgE. Most of these genes (84%) were not upregulated after a single anti-IgE stimulus, indicating a significantly different response mode characterized by increased antigen presentation, response to bacteria, and chemotaxis. Changes in mast cell function were related to changes in expression of the transcription factors RXRA and BATF and others. Importantly, we found a substantial overlap between genes upregulated after repeated anti-IgE triggering and genes upregulated in tissue from patients with chronic allergy, in particular those of patients with chronic rhinosinusitis. Conclusion: Our study provides evidence for intrinsic modulation of mast cell function on repeated Fc epsilon RI-mediated activation. The overlap with gene expression in tissues is suggestive of a direct link between repeated IgE-mediated activation of mast cells and chronic allergy.	[Suurmond, Jolien; Habets, Kim L. L.; Tatum, Zuotian; Schonkeren, Joris J.; Huizinga, Tom W. J.; Toes, Rene E. M.; Kurreeman, Fina] Leiden Univ, Med Ctr, Dept Rheumatol, C1-R,Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands; [Tatum, Zuotian; 't Hoen, Peter A. C.; Laros, Jeroen F. J.] Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Kurreeman, F (corresponding author), Leiden Univ, Med Ctr, Dept Rheumatol, C1-R,Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands.	b.a.s.kurreeman@lumc.nl	Hoen, Peter A 't/D-3950-2018	Hoen, Peter A 't/0000-0003-4450-3112; Suurmond, Jolien/0000-0002-4092-8925; Toes, Rene/0000-0002-9618-6414; Laros, Jeroen F.J./0000-0002-8715-7371	Dutch Organization for Scientific Research; Research Foundation Sole Mio; Leiden Research Foundation (STROL); Centre for Medical Systems Biology (CMSB) within Netherlands Genomics Initiative (NGI); Leiden University Medical Center (LUMC) fellowship; IMI JU [115142]; European Union [223404]; Dutch Arthritis Foundation; ReumaFonds [LLP-5] Funding Source: researchfish	Dutch Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Research Foundation Sole Mio; Leiden Research Foundation (STROL); Centre for Medical Systems Biology (CMSB) within Netherlands Genomics Initiative (NGI); Leiden University Medical Center (LUMC) fellowship; IMI JU; European Union(European Commission); Dutch Arthritis Foundation; ReumaFonds	Supported by the Dutch Arthritis Foundation, the Dutch Organization for Scientific Research (Vici grants), the Research Foundation Sole Mio, the Leiden Research Foundation (STROL), the Centre for Medical Systems Biology (CMSB) within the framework of the Netherlands Genomics Initiative (NGI), a Leiden University Medical Center (LUMC) fellowship, the IMI JU funded project BeTheCure (contract no. 115142-2), and the European Union (Seventh Framework Programme integrated project Masterswitch; grant no. 223404).	Ando T, 2014, CELL REP, V6, P366, DOI 10.1016/j.celrep.2013.12.029; Ando T, 2013, J INVEST DERMATOL, V133, P2695, DOI 10.1038/jid.2013.250; Arinobu Y, 2005, P NATL ACAD SCI USA, V102, P18105, DOI 10.1073/pnas.0509148102; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324; Feuser K, 2012, CYTOKINE, V58, P178, DOI 10.1016/j.cyto.2012.01.001; Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gaudenzio N, 2013, J ALLERGY CLIN IMMUN, V131, P1400, DOI 10.1016/j.jaci.2013.01.029; Hjertson M, 2003, J INVEST DERMATOL, V120, P239, DOI 10.1046/j.1523-1747.2003.12030.x; Holgate ST, 2006, J ALLERGY CLIN IMMUN, V117, P496, DOI 10.1016/j.jaci.2006.01.039; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hulsen T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-488; Islam SA, 2013, J EXP MED, V210, P1889, DOI 10.1084/jem.20130240; Kambayashi T, 2014, NAT REV IMMUNOL, V14, P719, DOI 10.1038/nri3754; Kasakura K, 2014, FEBS LETT, V588, P4645, DOI 10.1016/j.febslet.2014.10.036; Kato A, 2009, J IMMUNOL, V182, P7233, DOI 10.4049/jimmunol.0801375; Kearley J, 2011, AM J RESP CRIT CARE, V183, P865, DOI 10.1164/rccm.200909-1462OC; Kobayashi T, 2000, J IMMUNOL, V164, P3855, DOI 10.4049/jimmunol.164.7.3855; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Lebbink RJ, 2007, MOL IMMUNOL, V44, P2153, DOI 10.1016/j.molimm.2006.11.014; Lebbink RJ, 2009, MATRIX BIOL, V28, P202, DOI 10.1016/j.matbio.2009.03.005; Masuda A, 2007, J EXP MED, V204, P907, DOI 10.1084/jem.20060631; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Motakis E, 2014, BLOOD, V123, pE58, DOI 10.1182/blood-2013-02-483792; Nagai H, 1996, CLIN EXP ALLERGY, V26, P642, DOI 10.1046/j.1365-2222.1996.993357.x; Nigo YI, 2006, P NATL ACAD SCI USA, V103, P2286, DOI 10.1073/pnas.0510685103; Okumura S, 2005, J ALLERGY CLIN IMMUN, V115, P272, DOI 10.1016/j.jaci.2004.10.004; PADAWER J, 1974, EXP MOL PATHOL, V20, P269, DOI 10.1016/0014-4800(74)90059-8; Peterson S, 2012, J ALLERGY CLIN IMMUN, V129, P119, DOI 10.1016/j.jaci.2011.08.021; Price MM, 2013, J ALLERGY CLIN IMMUN, V131, P501, DOI 10.1016/j.jaci.2012.07.014; Qi XP, 2013, IMMUNITY, V39, P97, DOI 10.1016/j.immuni.2013.06.012; Qiao HH, 2006, BLOOD, V107, P610, DOI 10.1182/blood-2005-06-2271; Reber LL, 2013, J ALLERGY CLIN IMMUN, V132, P881, DOI 10.1016/j.jaci.2013.06.008; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Suurmond J, 2015, CLIN EXP ALLERGY, V45, P788, DOI 10.1111/cea.12509; Suurmond J, 2014, EUR J IMMUNOL, V44, P386, DOI 10.1002/eji.201343617; Suurmond J, 2013, EUR J IMMUNOL, V43, P1758, DOI 10.1002/eji.201243058; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Williams KL, 2001, EUR J IMMUNOL, V31, P1620, DOI 10.1002/1521-4141(200105)31:5<1620::AID-IMMU1620>3.0.CO;2-3; Yu M, 2006, J CLIN INVEST, V116, P1633, DOI 10.1172/JCI25702; Zambelli F, 2012, NUCLEIC ACIDS RES, V40, pW510, DOI 10.1093/nar/gks483; Zambelli F, 2009, NUCLEIC ACIDS RES, V37, pW247, DOI 10.1093/nar/gkp464	47	13	13	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					869	880		10.1016/j.jaci.2016.01.017	http://dx.doi.org/10.1016/j.jaci.2016.01.017			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27033170	Bronze			2022-12-18	WOS:000385496000023
J	Koch, S; Graser, A; Mirzakhani, H; Zimmermann, T; Melichar, VO; Wolfel, M; Croteau-Chonka, DC; Raby, BA; Weiss, ST; Finotto, S				Koch, Sonja; Graser, Anna; Mirzakhani, Hooman; Zimmermann, Theodor; Melichar, Volker O.; Woelfel, Marco; Croteau-Chonka, Damien C.; Raby, Benjamin A.; Weiss, Scott T.; Finotto, Susetta			Increased expression of nuclear factor of activated T cells 1 drives IL-9-mediated allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TRANSCRIPTION FACTOR; LYMPHOCYTE; DEDICATOR; DOCK8		[Koch, Sonja; Graser, Anna; Finotto, Susetta] Univ Klinikum Erlangen, Dept Mol Pneumol, Lab Cellular & Mol Lung Immunol, Erlangen, Germany; [Zimmermann, Theodor; Melichar, Volker O.; Woelfel, Marco] Univ Klinikum Erlangen, Dept Pediat & Adolescent Med, Pediat Pneumology Allergol, Erlangen, Germany; [Mirzakhani, Hooman; Croteau-Chonka, Damien C.; Raby, Benjamin A.; Weiss, Scott T.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Mirzakhani, Hooman; Croteau-Chonka, Damien C.; Raby, Benjamin A.; Weiss, Scott T.] Harvard Univ, Sch Med, Boston, MA USA	University of Erlangen Nuremberg; University of Erlangen Nuremberg; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Finotto, S (corresponding author), Univ Klinikum Erlangen, Dept Mol Pneumol, Lab Cellular & Mol Lung Immunol, Erlangen, Germany.	susetta.finotto@uk-erlangen.de	Raby, Benjamin/AAK-3866-2021; Finotto, Susetta/H-2753-2019	Mirzakhani, Hooman/0000-0002-2290-4436	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC2HL101543, T32HL007427] Funding Source: NIH RePORTER; NHLBI NIH HHS [RC2 HL101543, L30 HL129467, T32 HL007427] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074-7613(02)00329-1; Cuellar-Rodriguez J, 2015, BIOL BLOOD MARROW TR, V21, P1037, DOI 10.1016/j.bbmt.2015.01.022; De Silva NS, 2012, IMMUNOL REV, V247, P73, DOI 10.1111/j.1600-065X.2012.01113.x; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Glasmacher E, 2012, SCIENCE, V338, P975, DOI 10.1126/science.1228309; Jing H, 2014, J ALLERGY CLIN IMMUN, V133, P1667, DOI 10.1016/j.jaci.2014.03.025; Koch S, 2015, CLIN EXP ALLERGY, V45, P1356, DOI 10.1111/cea.12493; Muller MR, 2010, NAT REV IMMUNOL, V10, P645, DOI 10.1038/nri2818; Raby B, 2011, AM J RESP CRIT CARE, V183; Sharma S, 2014, J ALLERGY CLIN IMMUN, V134, P1153, DOI 10.1016/j.jaci.2014.04.011; Staudt V, 2010, IMMUNITY, V33, P192, DOI 10.1016/j.immuni.2010.07.014; Ubel C, 2014, J ALLERGY CLIN IMMUN, V133, P198, DOI 10.1016/j.jaci.2013.09.049	12	13	15	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1898	+		10.1016/j.jaci.2015.11.047	http://dx.doi.org/10.1016/j.jaci.2015.11.047			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26993036	Green Published, hybrid			2022-12-18	WOS:000377527200037
J	Garcia-Boyano, M; Pedrosa, M; Quirce, S; Boyano-Martinez, T				Garcia-Boyano, Miguel; Pedrosa, Maria; Quirce, Santiago; Boyano-Martinez, Teresa			Household almond and peanut consumption is related to the development of sensitization in young children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGY; EXPOSURE; RISK; INFANTS; TRIAL		[Garcia-Boyano, Miguel] Univ Complutense, Fac Med, E-28040 Madrid, Spain; [Pedrosa, Maria; Quirce, Santiago; Boyano-Martinez, Teresa] Hosp Univ La Paz, Dept Allergol, Madrid, Spain; [Pedrosa, Maria; Quirce, Santiago; Boyano-Martinez, Teresa] Hosp Univ La Paz, Inst Hlth Res IdiPaz, Madrid, Spain	Complutense University of Madrid; Hospital Universitario La Paz; Hospital Universitario La Paz	Garcia-Boyano, M (corresponding author), Univ Complutense, Fac Med, E-28040 Madrid, Spain.	mboyano.hulp@salud.madrid.org	s, q/AAD-7171-2020	Pedrosa, Maria/0000-0002-5295-870X; Garcia-Boyano, Miguel/0000-0002-3717-4819				Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2012, J ALLERGY CLIN IMMUN, V129, P1187, DOI 10.1016/j.jaci.2012.02.036; Palmer DJ, 2013, J ALLERGY CLIN IMMUN, V132, P387, DOI 10.1016/j.jaci.2013.05.002	9	13	13	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1248	+		10.1016/j.jaci.2015.09.006	http://dx.doi.org/10.1016/j.jaci.2015.09.006			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26521041	Bronze			2022-12-18	WOS:000373351200034
J	Greenhawt, M; Schultz, F; DunnGalvin, A				Greenhawt, Matthew; Schultz, Fallon; DunnGalvin, Audrey			A validated index to measure health-related quality of life in patients with food protein-induced enterocolitis syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CLINICAL-FEATURES; ONDANSETRON; EXPERIENCE; MANAGEMENT; CHALLENGE		[Greenhawt, Matthew] Univ Michigan, Sch Med, Dept Internal Med, Div Allergy & Clin Immunol, Ann Arbor, MI USA; [Greenhawt, Matthew] Univ Michigan, Sch Med, Dept Pediat, Child Hlth Evaluat & Res Unit, Ann Arbor, MI USA; [Schultz, Fallon] Int FPIES Assoc I FPIES, Point Pleasant Beach, NJ USA; [DunnGalvin, Audrey] Natl Univ Ireland Univ Coll Cork, Dept Pediat & Child Hlth, Cork, Ireland; [Greenhawt, Matthew] Univ Colorado Denver, Sch Med, Childrens Hosp Colorado, Allergy Sect, Aurora, CO USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University College Cork; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Greenhawt, M (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Allergy & Clin Immunol, Ann Arbor, MI USA.; Greenhawt, M (corresponding author), Univ Michigan, Sch Med, Dept Pediat, Child Hlth Evaluat & Res Unit, Ann Arbor, MI USA.; Greenhawt, M (corresponding author), Univ Colorado Denver, Sch Med, Childrens Hosp Colorado, Allergy Sect, Aurora, CO USA.	Matthew.Greenhawt@childrenscolorado.org	DunnGalvin, Audrey/G-1741-2012		NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000433, KL2TR000434] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024986] Funding Source: NIH RePORTER; NCATS NIH HHS [KL2 TR000434, 2UL1TR000433, #2KL2TR000434] Funding Source: Medline; NCRR NIH HHS [UL1RR024986] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Caubet JC, 2014, J ALLERGY CLIN IMMUN, V134, P382, DOI 10.1016/j.jaci.2014.04.008; GRYBOSKI JD, 1967, PEDIATRICS, V40, P354; Holbrook T, 2013, J ALLERGY CLIN IMMUN, V132, P1219, DOI 10.1016/j.jaci.2013.06.021; Hwang JB, 2008, J KOREAN MED SCI, V23, P251, DOI 10.3346/jkms.2008.23.2.251; Jarvinen KM, 2013, J ALLER CL IMM-PRACT, V1, P317, DOI 10.1016/j.jaip.2013.04.004; Leonard SA, 2011, ANN ALLERG ASTHMA IM, V107; Leonard SA, 2011, ANN ALLERG ASTHMA IM, V107, P101; Leonard SA, 2011, ANN ALLERG ASTHMA IM, V107, P95, DOI 10.1016/j.anai.2011.06.004; Mehr S, 2009, PEDIATRICS, V123, pe459, DOI 10.1542/peds.2008-2029; POWELL GK, 1978, J PEDIATR-US, V93, P553, DOI 10.1016/S0022-3476(78)80887-7; Sicherer SH, 1998, J PEDIATR-US, V133, P214, DOI 10.1016/S0022-3476(98)70222-7; Sopo SM, 2014, INT ARCH ALLERGY IMM, V164, P137, DOI 10.1159/000363384; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298	13	13	14	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1251	+		10.1016/j.jaci.2015.09.056	http://dx.doi.org/10.1016/j.jaci.2015.09.056			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26714413	Bronze			2022-12-18	WOS:000373351200035
J	Barreto-Luis, A; Pino-Yanes, M; Corrales, A; Campo, P; Callero, A; Acosta-Herrera, M; Cumplido, J; Ma, SF; Martinez-Tadeo, J; Villar, J; Garcia, JGN; Carrillo, T; Carracedo, A; Blanca, M; Flores, C				Barreto-Luis, Amalia; Pino-Yanes, Maria; Corrales, Almudena; Campo, Paloma; Callero, Ariel; Acosta-Herrera, Marialbert; Cumplido, Jose; Ma, Shwu-Fan; Martinez-Tadeo, Juan; Villar, Jesus; Garcia, Joe G. N.; Carrillo, Teresa; Carracedo, Angel; Blanca, Miguel; Flores, Carlos			Genome-wide association study in Spanish identifies ADAM metallopeptidase with thrombospondin type 1 motif, 9 (ADAMTS9), as a novel asthma susceptibility gene	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							METAANALYSIS		[Barreto-Luis, Amalia; Pino-Yanes, Maria; Corrales, Almudena; Acosta-Herrera, Marialbert; Flores, Carlos] Hosp Univ NS de Candelaria, Res Unit, Tenerife, Spain; [Callero, Ariel; Martinez-Tadeo, Juan] Hosp Univ NS de Candelaria, Allergy Unit, Tenerife, Spain; [Barreto-Luis, Amalia; Flores, Carlos] Univ La Laguna, Inst Univ Enfermedades Trop & Salud Publ Canarias, Genet Lab, G2A, Tenerife, Spain; [Pino-Yanes, Maria; Corrales, Almudena; Flores, Carlos] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain; [Campo, Paloma; Blanca, Miguel] Reg Univ Hosp Malaga IBIMA, UGC Allergy, Malaga, Spain; [Acosta-Herrera, Marialbert; Villar, Jesus] Hosp Univ Dr Negrin, MODERN, Res Unit, Gran Canaria, Spain; [Cumplido, Jose; Carrillo, Teresa] Hosp Univ Dr Negrin, Allergy Unit, Gran Canaria, Spain; [Ma, Shwu-Fan] Univ Chicago, Sect Pulm & Crit Care Med, Chicago, IL 60637 USA; [Garcia, Joe G. N.] Univ Arizona, Arizona Hlth Sci Ctr, Tucson, AZ USA; [Carracedo, Angel] Univ Santiago de Compostela, Fdn Galega Med Xen SERGAS, CIBERER, Grp Med Xen, Santiago De Compostela, Spain	Universidad de la Laguna; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; Universidad de Malaga; University of Chicago; University of Arizona; University of Arizona Health Sciences; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Universidade de Santiago de Compostela	Flores, C (corresponding author), Hosp Univ NS de Candelaria, Res Unit, Tenerife, Spain.; Flores, C (corresponding author), Univ La Laguna, Inst Univ Enfermedades Trop & Salud Publ Canarias, Genet Lab, G2A, Tenerife, Spain.; Flores, C (corresponding author), Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.	cflores@ull.edu.es	Corrales, Almudena/G-5391-2017; Carracedo, Angel/D-4257-2012; Flores, Carlos/R-1159-2019; Villar, Jesús/R-4526-2019; Pino-Yanes, Maria/C-8498-2017	Corrales, Almudena/0000-0002-2207-5463; Carracedo, Angel/0000-0003-1085-8986; Villar, Jesús/0000-0001-5687-3562; Pino-Yanes, Maria/0000-0003-0332-437X; Flores, Carlos/0000-0001-5352-069X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL091889] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Shawwa B, 2006, J ASTHMA, V43, P231, DOI 10.1080/02770900600567056; Chiappara G, 2001, CURR OPIN ALLERGY CL, V1, P85, DOI 10.1097/00130832-200102000-00015; Dong CZ, 2014, GENE, V539, P30, DOI 10.1016/j.gene.2014.02.001; Ferreira MAR, 2014, J ALLERGY CLIN IMMUN, V133, P1564, DOI 10.1016/j.jaci.2013.10.030; Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578; Heid IM, 2010, NAT GENET, V42, P949, DOI 10.1038/ng.685; Liu CT, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003681; Meyers DA, 2014, LANCET RESP MED, V2, P405, DOI 10.1016/S2213-2600(14)70012-8; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Nihlberg K, 2010, THORAX, V65, P670, DOI 10.1136/thx.2009.129320; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Visness CM, 2010, J ASTHMA, V47, P822, DOI 10.3109/02770903.2010.489388; Weitoft M, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-67	13	13	13	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					964	966		10.1016/j.jaci.2015.09.051	http://dx.doi.org/10.1016/j.jaci.2015.09.051			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26620591	Bronze			2022-12-18	WOS:000371897500052
J	Ducharme, FM; Jensen, ME; Mendelson, MJ; Parkin, PC; Desplats, E; Zhang, X; Platt, R				Ducharme, Francine M.; Jensen, Megan E.; Mendelson, Morton J.; Parkin, Patricia C.; Desplats, Eve; Zhang, Xun; Platt, Robert			Asthma Flare-up Diary for Young Children to monitor the severity of exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; discrimination; preschool child; questionnaire design; randomized controlled trial; reliability and validity	QUALITY-OF-LIFE; GENERIC CORE SCALES; COMMUNICATION INSTRUMENT; PRESCHOOL-CHILDREN; CHILDHOOD ASTHMA; VALIDATION; QUESTIONNAIRE; RELIABILITY; VALIDITY; MONTELUKAST	Background: Few instruments exist to ascertain the severity of a preschool-aged child's asthma exacerbations managed at home. Objective: We sought to develop and validate a functional status instrument to assess asthma exacerbation severity in preschoolers. Methods: The parent-completed Asthma Flare-up Diary for Young Children (ADYC), which was developed systematically, comprises 17 items, each scored from 1 (best) to 7 (worst). The ADYC was completed daily from the onset of an upper respiratory tract infection (URTI) until asthma symptom resolution; the cumulative daily score was reported. The ADYC was examined for key psychometric properties in a randomized placebo-controlled trial of pre-emptive high-dose fluticasone in preschoolers with URTI-induced asthma. Results: In 121 children aged 2.7 +/- 1.1 years (59.5% male), the ADYC's internal consistency (Cronbach alpha = .97), feasibility (97% completion), and test-retest reliability (r = 0.71; 95% CI, 0.59-0.80) were demonstrated. The ADYC was responsive to change between 2 consecutive days (Guyatt statistic = 0.77) with a minimal important difference of 0.22 (0.17-0.27). Of 871 episodes, the cumulative ADYC score was significantly higher during exacerbations than during URTIs (mean difference [MD], 7.6; 95% CI, 6.4-8.9) and for exacerbations with an acute-care visit (MD, 9.1; 95% CI, 7.6-10.7), systemic corticosteroids (MD, 10.1; 95% CI, 8.3-12.0), and hospitalization (MD, 6.8; 95% CI, 2.9-10.7) versus those without. In children receiving fluticasone, the ADYC score was significantly lower versus that in the placebo group (MD, 5.1; 95% CI, 1.8-8.3). Conclusions: The 17-item ADYC proved feasible, responsive to day-to-day changes, and discriminative across exacerbations of different severities. In a trial testing effective therapy in preschoolers, it identified a significant reduction in asthma exacerbation severity.	[Ducharme, Francine M.] Univ Montreal, St Justine Univ Hlth Ctr, Dept Pediat, Montreal, PQ, Canada; [Ducharme, Francine M.] Univ Montreal, St Justine Univ Hlth Ctr, Dept Social & Prevent Med, Montreal, PQ, Canada; [Ducharme, Francine M.; Jensen, Megan E.] Univ Montreal, St Justine Univ Hlth Ctr, Clin Res & Knowledge Transfer Unit Childhood Asth, Res Ctr, Montreal, PQ, Canada; [Desplats, Eve] Univ Montreal, St Justine Univ Hlth Ctr, Res Ctr, Unite Rech Clin Appl, Montreal, PQ, Canada; [Mendelson, Morton J.] McGill Univ, Dept Psychol, Montreal, PQ, Canada; [Parkin, Patricia C.] Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; [Zhang, Xun] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada; [Platt, Robert] McGill Univ, Ctr Hlth, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Platt, Robert] McGill Univ, Ctr Hlth, Dept Pediat, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; McGill University; McGill University	Ducharme, FM (corresponding author), St Justine Univ, Ctr Hlth, 3175 Cote St Catherine,Rm 7939, Montreal, PQ H3T 1C5, Canada.	Francine.m.ducharme@umontreal.ca	Zhang, Xun/HHM-9059-2022; Ducharme, Francine/N-8332-2013	Zhang, Xun/0000-0001-5411-2727; Ducharme, Francine/0000-0001-5096-0614; Desplats, Eve/0000-0002-8781-3615; Platt, Robert/0000-0002-5981-8443	George Hogg Family Foundation; Fonds de la recherche en sante du Quebec; Bourse de Chercheur National (National Scholarship) of the FRSQ	George Hogg Family Foundation; Fonds de la recherche en sante du Quebec(Fonds de la Recherche en Sante du Quebec); Bourse de Chercheur National (National Scholarship) of the FRSQ	We acknowledge the support of the funds from George Hogg Family Foundation and the Fonds de la recherche en sante du Quebec for the infrastructure support provided to the Research Centre of the participating centers, namely the Centre hospitalier universitaire Ste-Justine (CHU Sainte-Justine), McGill University Health Centre (MUHC), Centre hospitalier universitaire de Sherbrooke (CHUS), and the Hopital Maisonneuve-Rosemont. F. M. D. and R. P. were awarded the Bourse de Chercheur National (National Scholarship) of the FRSQ.	Asthma G., 2020, GLOB STRAT ASTHM MAN; Barrett A, 2013, EUR RESPIR J, V42, P513, DOI 10.1183/09031936.00052112; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Burks ML, 2013, ANN ALLERG ASTHMA IM, V111, P14, DOI 10.1016/j.anai.2013.05.008; Chan KS, 2005, MED CARE, V43, P256, DOI 10.1097/00005650-200503000-00008; Chipps B, 2011, PEDIATRICS, V127, pE737, DOI 10.1542/peds.2010-1465; Clayton K, 2012, ANN ALLERG ASTHMA IM, V109, P416, DOI 10.1016/j.anai.2012.09.013; Ducharme FM, 2009, NEW ENGL J MED, V360, P339, DOI 10.1056/NEJMoa0808907; Garbutt J, 2009, ANN ALLERG ASTHMA IM, V103, P469, DOI 10.1016/S1081-1206(10)60262-1; Garbutt JM, 2009, ANN ALLERG ASTHMA IM, V102, P504, DOI 10.1016/S1081-1206(10)60125-1; GUILLEMIN F, 1993, J CLIN EPIDEMIOL, V46, P1417, DOI 10.1016/0895-4356(93)90142-N; GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; Juniper EF, 1997, J CLIN EPIDEMIOL, V50, P233, DOI 10.1016/S0895-4356(96)00377-0; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0; Knorr B, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.3.e48; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Lougheed MD, 2009, CHEST, V135, P724, DOI 10.1378/chest.08-0371; Murphy KR, 2009, J ALLERGY CLIN IMMUN, V123, P833, DOI 10.1016/j.jaci.2009.01.058; Nkoy FL, 2013, PEDIATRICS, V132, pE1554, DOI 10.1542/peds.2013-1389; Okelo SO, 2014, J ALLER CL IMM-PRACT, V2, P186, DOI 10.1016/j.jaip.2013.10.005; Okelo SO, 2013, J ALLERGY CLIN IMMUN, V132, P55, DOI 10.1016/j.jaci.2013.01.007; Papi A, 2009, ALLERGY, V64, P1463, DOI 10.1111/j.1398-9995.2009.02134.x; Perez-Yarza EG, 2009, PEDIATR PULM, V44, P54, DOI 10.1002/ppul.20929; Santanello NC, 2000, J ALLERGY CLIN IMMUN, V106, P861, DOI 10.1067/mai.2000.110478; Seid M, 2010, J ASTHMA, V47, P170, DOI 10.3109/02770900903533966; Self TH, 2010, J ASTHMA, V47, P1123, DOI 10.3109/02770903.2010.514641; Sorkness CA, 2007, AM J RESP CRIT CARE, V175, pA782; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Topal E, 2014, ANN ALLERG ASTHMA IM, V112, P361, DOI 10.1016/j.anai.2014.01.025; van Bragt S, 2014, QUAL LIFE RES, V23, P927, DOI 10.1007/s11136-013-0533-3; Zeiger RS, 2011, NEW ENGL J MED, V365, P1990, DOI 10.1056/NEJMoa1104647; Zorc JJ, 2006, J ASTHMA, V43, P753, DOI 10.1080/02770900601031615	33	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					744	+		10.1016/j.jaci.2015.07.028	http://dx.doi.org/10.1016/j.jaci.2015.07.028			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26341275	Bronze			2022-12-18	WOS:000371897500016
J	Okura, Y; Kobayashi, I; Yamada, M; Sasaki, S; Yamada, Y; Kamioka, I; Kanai, R; Takahashi, Y; Ariga, T				Okura, Yuka; Kobayashi, Ichiro; Yamada, Masafumi; Sasaki, Satoshi; Yamada, Yutaka; Kamioka, Ichiro; Kanai, Rie; Takahashi, Yutaka; Ariga, Tadashi			Clinical characteristics and genotype-phenotype correlations in C3 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							COMPOUND HETEROZYGOUS MUTATIONS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CIRCULATING IMMUNE-COMPLEXES; INHERITED C-3 DEFICIENCY; COMPLEMENT COMPONENT C3; 3RD COMPONENT; HEREDITARY-DEFICIENCY; COMPLETE ABSENCE; RECURRENT MENINGITIS; REPEATED INFECTIONS		[Okura, Yuka; Kobayashi, Ichiro; Yamada, Masafumi; Sasaki, Satoshi; Ariga, Tadashi] Hokkaido Univ, Grad Sch Med, Dept Pediat, Sapporo, Hokkaido, Japan; [Okura, Yuka; Takahashi, Yutaka] KKR Sapporo Med Ctr, Dept Pediat, Sapporo, Hokkaido, Japan; [Sasaki, Satoshi; Yamada, Yutaka] Hakodate Cent Gen Hosp, Dept Pediat, Hakodate, Hokkaido, Japan; [Kamioka, Ichiro] Kakogawa West City Hosp, Dept Pediat, Kakogawa, Hyogo, Japan; [Kanai, Rie] Shimane Univ, Fac Med, Dept Pediat, Izumo, Shimane, Japan	Hokkaido University; Shimane University	Okura, Y (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Pediat, Sapporo, Hokkaido, Japan.; Okura, Y (corresponding author), KKR Sapporo Med Ctr, Dept Pediat, Sapporo, Hokkaido, Japan.	okura@med.hokudai.ac.jp						ALPER CA, 1972, LANCET, V2, P1179; ALPER CA, 1976, J CLIN INVEST, V57, P222, DOI 10.1172/JCI108263; BALLOW M, 1975, J CLIN INVEST, V56, P703, DOI 10.1172/JCI108141; BERGER M, 1983, NEW ENGL J MED, V308, P1009, DOI 10.1056/NEJM198304283081706; Bhide SS, 2006, INDIAN PEDIATR, V43, P269; BORZY MS, 1985, AM J KIDNEY DIS, V5, P54, DOI 10.1016/S0272-6386(85)80137-2; BORZY MS, 1988, AM J DIS CHILD, V142, P79, DOI 10.1001/archpedi.1988.02150010089032; BOTTO M, 1990, J CLIN INVEST, V86, P1158, DOI 10.1172/JCI114821; BOTTO M, 1992, P NATL ACAD SCI USA, V89, P4957, DOI 10.1073/pnas.89.11.4957; COZMA G, 1987, CLIN NEPHROL, V27, P269; DAVIS AE, 1977, CLIN IMMUNOL IMMUNOP, V8, P543, DOI 10.1016/0090-1229(77)90019-8; Fujioka H, 2005, AM J MED GENET A, V138A, P399, DOI 10.1002/ajmg.a.30964; Ghannam A, 2008, J IMMUNOL, V181, P5158, DOI 10.4049/jimmunol.181.7.5158; Goldberg M, 2011, MOL IMMUNOL, V48, P1926, DOI 10.1016/j.molimm.2011.05.020; GRACE HJ, 1976, S AFR MED J, V50, P139; GRUMACH AS, 1988, BRAZ J MED BIOL RES, V21, P247; HSIEH KH, 1981, CLIN IMMUNOL IMMUNOP, V20, P305, DOI 10.1016/0090-1229(81)90140-9; HUANG JL, 1994, CLIN IMMUNOL IMMUNOP, V73, P267, DOI 10.1006/clin.1994.1197; Hyodo Y, 1981, RINSHO MENEKI, V13, P23; IMAI K, 1991, NEPHRON, V59, P148, DOI 10.1159/000186535; Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005; KATZ Y, 1995, IMMUNOLOGY, V84, P5; Kida M, 2008, BLOOD CELL MOL DIS, V40, P410, DOI 10.1016/j.bcmd.2007.11.002; Matsuyama W, 2001, INTERNAL MED, V40, P1254, DOI 10.2169/internalmedicine.40.1254; Okura Y, 2012, SCAND J RHEUMATOL, V41, P405, DOI 10.3109/03009742.2012.698302; Okura Y, 2011, PEDIATR INT, V53, pe16, DOI 10.1111/j.1442-200X.2010.03259.x; OSOFSKY SG, 1977, J PEDIATR-US, V90, P180, DOI 10.1016/S0022-3476(77)80626-4; PELEG D, 1992, PEDIATR INFECT DIS J, V11, P401, DOI 10.1097/00006454-199205000-00011; PUSSELL BA, 1980, LANCET, V1, P675, DOI 10.1016/S0140-6736(80)92827-5; Reis ED, 2002, J CLIN IMMUNOL, V22, P321, DOI 10.1023/A:1020665614139; Reis ES, 2006, SCAND J IMMUNOL, V63, P155, DOI 10.1111/j.1365-3083.2006.01729.x; Reis ES, 2004, IMMUNOGENETICS, V55, P667, DOI 10.1007/s00251-003-0624-3; ROORD JJ, 1983, PEDIATRICS, V71, P81; SANAL O, 1992, EUR J PEDIATR, V151, P676; SANO Y, 1981, ARTHRITIS RHEUM-US, V24, P1255, DOI 10.1002/art.1780241005; Santos-Valente E, 2013, J CLIN IMMUNOL, V33, P127, DOI 10.1007/s10875-012-9775-z; SINGER L, 1994, J BIOL CHEM, V269, P28494; Singer L, 1996, CLIN IMMUNOL IMMUNOP, V81, P244, DOI 10.1006/clin.1996.0185; Singh DK, 2009, INDIAN J PEDIATR, V76, P95, DOI 10.1007/s12098-009-0036-y; Totan Mehmet, 2002, Indian Journal of Pediatrics, V69, P625, DOI 10.1007/BF02722692; Tsukamoto H, 2005, BIOCHEM BIOPH RES CO, V330, P298, DOI 10.1016/j.bbrc.2005.02.159; Tuerlinckx D, 2004, PEDIATR INFECT DIS J, V23, P371, DOI 10.1097/00006454-200404000-00025; Ulbrich AG, 2001, SCAND J IMMUNOL, V53, P622, DOI 10.1046/j.1365-3083.2001.00934.x; van Hess C L, 1992, Arch Dermatol, V128, P700, DOI 10.1001/archderm.128.5.700; WEISS RM, 1989, BRIT J DERMATOL, V121, P413, DOI 10.1111/j.1365-2133.1989.tb01441.x	45	13	13	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					640	+		10.1016/j.jaci.2015.08.017	http://dx.doi.org/10.1016/j.jaci.2015.08.017			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26435005	Bronze			2022-12-18	WOS:000369235500044
J	Shorter, C; Taubel, M; Pierse, N; Douwes, J; Howden-Chapman, P; Hyvarinen, A; Crane, J				Shorter, Caroline; Taubel, Martin; Pierse, Nevil; Douwes, Jeroen; Howden-Chapman, Philippa; Hyvarinen, Anne; Crane, Julian			Objective assessment of domestic mold contamination using quantitative PCR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Shorter, Caroline; Crane, Julian] Univ Otago, Dept Med, Wellington Asthma Res Grp, Wellington, New Zealand; [Taubel, Martin; Hyvarinen, Anne] Natl Inst Hlth & Welf THL, Dept Hlth Protect, Kuopio, Finland; [Pierse, Nevil; Howden-Chapman, Philippa] Univ Otago, He Kainga Oranga Housing & Hlth Res Grp, Dept Publ Hlth, Wellington, New Zealand; [Douwes, Jeroen] Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand	University of Otago; Finland National Institute for Health & Welfare; University of Otago; Massey University	Shorter, C (corresponding author), Univ Otago, Dept Med, Wellington Asthma Res Grp, Wellington, New Zealand.	caroline.shorter@otago.ac.nz	Täubel, Martin/P-7059-2019	Täubel, Martin/0000-0001-8082-1041; Douwes, Jeroen/0000-0003-3599-4036; Hyvarinen, Anne/0000-0002-2823-0866				Frankel M, 2012, INDOOR AIR, V22, P405, DOI 10.1111/j.1600-0668.2012.00770.x; Haugland R.A., 2002, U.S. Patent, Patent No. [6,387,652, 6387652]; Hyvarinen A, 2001, AEROSOL SCI TECH, V35, P688, DOI 10.1080/02786820117763; Jaakkola MS, 2013, AM J RESP CRIT CARE, V187; Jaakkola MS, 2013, J ALLERGY CLIN IMMUN, V132, P1099, DOI 10.1016/j.jaci.2013.07.028; Karkkainen PM, 2010, J ENVIRON MONITOR, V12, P759, DOI 10.1039/b917937b; Mendell MJ, 2011, ENVIRON HEALTH PERSP, V119, P748, DOI 10.1289/ehp.1002410; Noss I, 2008, APPL ENVIRON MICROB, V74, P5621, DOI 10.1128/AEM.00619-08; Portnoy JM, 2004, J ALLERGY CLIN IMMUN, V113, P189, DOI 10.1016/j.jaci.2003.11.021	9	13	13	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					622	+		10.1016/j.jaci.2015.06.039	http://dx.doi.org/10.1016/j.jaci.2015.06.039			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26277598	Bronze			2022-12-18	WOS:000369235500036
J	Bittner, C; Peters, U; Frenzel, K; Musken, H; Brettschneider, R				Bittner, Cordula; Peters, Ulrike; Frenzel, Karsten; Muesken, Horst; Brettschneider, Reinhold			New wheat allergens related to baker's asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IGE		[Bittner, Cordula] Univ Med Ctr Hamburg Eppendorf, Inst Occupat Med & Maritime Med ZfAM, Hamburg, Germany; [Muesken, Horst] Practice Musken, Bad Lippspringe, Germany; [Peters, Ulrike; Frenzel, Karsten; Brettschneider, Reinhold] Univ Hamburg, Bioctr Klein Flottbek & Bot Garden, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg	Bittner, C (corresponding author), Univ Med Ctr Hamburg Eppendorf, Inst Occupat Med & Maritime Med ZfAM, Hamburg, Germany.	cordula.bittner@bgv.hamburg.de						Bittner C, 2008, J ALLERGY CLIN IMMUN, V121, P744, DOI 10.1016/j.jaci.2007.09.051; Brisman J, 2002, OCCUP ENVIRON MED, V59, P498, DOI 10.1136/oem.59.7.498; Crameri R, 2002, Methods Mol Biol, V185, P461; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Olivieri M, 2013, OCCUP ENVIRON MED, V70, P617, DOI 10.1136/oemed-2012-101112; Pahr S, 2012, CLIN EXP ALLERGY, V42, P597, DOI 10.1111/j.1365-2222.2012.03961.x; Sander I, 2011, ALLERGY, V66, P1208, DOI 10.1111/j.1398-9995.2011.02636.x; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Wiszniewska M, 2011, ALLERGY ASTHMA PROC, V32, P111, DOI 10.2500/aap.2011.32.3422	9	13	14	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1416	1418		10.1016/j.jaci.2015.05.010	http://dx.doi.org/10.1016/j.jaci.2015.05.010			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26100087	Bronze			2022-12-18	WOS:000364787200038
J	Sullivan, PW; Campbell, JD; Globe, G; Ghushchyan, VH; Bender, B; Schatz, M; Chon, Y; Woolley, JM; Magid, DJ				Sullivan, Patrick W.; Campbell, Jonathan D.; Globe, Gary; Ghushchyan, Vahram H.; Bender, Bruce; Schatz, Michael; Chon, Yun; Woolley, J. Michael; Magid, David J.			Measuring the effect of asthma control on exacerbations and health resource use	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							UNITED-STATES; PATTERNS; BURDEN		[Sullivan, Patrick W.] Regis Univ, Sch Pharm, Denver, CO 80221 USA; [Magid, David J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA; [Campbell, Jonathan D.; Ghushchyan, Vahram H.] Univ Colorado, Dept Clin Pharm, Ctr Pharmaceut Outcomes Res, Aurora, CO USA; [Globe, Gary; Chon, Yun; Woolley, J. Michael] Amgen Inc, Thousand Oaks, CA USA; [Ghushchyan, Vahram H.] Amer Univ Armenia, Yerevan, Armenia; [Bender, Bruce] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Schatz, Michael] Kaiser Permanente, Med Ctr, San Diego, CA USA	Regis University; Kaiser Permanente; University of Colorado System; University of Colorado Anschutz Medical Campus; Amgen; American University of Armenia; National Jewish Health; Kaiser Permanente	Sullivan, PW (corresponding author), Regis Univ, Sch Pharm, Denver, CO 80221 USA.	psulliva@regis.edu						Campbell JD, 2008, ALLERGY, V63, P1581, DOI 10.1111/j.1398-9995.2008.01888.x; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Meltzer EO, 2011, J ALLERGY CLIN IMMUN, V127, P167, DOI 10.1016/j.jaci.2010.08.042; Stempel DA, 2005, J ALLERGY CLIN IMMUN, V115, P935, DOI 10.1016/j.jaci.2005.01.054; Sullivan PW, 2014, J ASTHMA, V51, P769, DOI 10.3109/02770903.2014.906607; Sullivan PW, 2011, J ALLERGY CLIN IMMUN, V127, P363, DOI 10.1016/j.jaci.2010.10.042; Sullivan SD, 2007, ALLERGY, V62, P126, DOI 10.1111/j.1398-9995.2006.01254.x; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127	8	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1409	1411		10.1016/j.jaci.2015.04.046	http://dx.doi.org/10.1016/j.jaci.2015.04.046			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26073753				2022-12-18	WOS:000364787200035
J	Oyoshi, MK; Beaupre, J; Venturelli, N; Lewis, CN; Iwakura, Y; Geha, RS				Oyoshi, Michiko K.; Beaupre, Jacqueline; Venturelli, Nicholas; Lewis, Christopher N.; Iwakura, Yoichiro; Geha, Raif S.			Filaggrin deficiency promotes the dissemination of cutaneously inoculated vaccinia virus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vaccinia virus; filaggrin; IL-17A	HUMAN ATOPIC-DERMATITIS; IMMUNE-RESPONSE; EPICUTANEOUS SENSITIZATION; SKIN INFLAMMATION; FLAKY TAIL; BARRIER; MOUSE; GENE; VACCINATION; MUTATIONS	Background: Eczema vaccinatum is a life-threatening complication of smallpox vaccination in patients with atopic dermatitis (AD) characterized by dissemination of vaccinia virus (VV) in the skin and internal organs. Mutations in the filaggrin (FLG) gene, the most common genetic risk factor for AD, confer a greater risk for eczema herpeticum in patients with AD, suggesting that it impairs the response to cutaneous viral infections. Objective: We sought to determine the effects of FLG deficiency on the response of mice to cutaneous VV inoculation. Methods: VV was inoculated by means of scarification of unsensitized skin or skin topically sensitized with ovalbumin in FLG-deficient flaky tail (ft/ft) mice or wild-type (WT) control mice. The sizes of primary and satellite skin lesions were measured, and hematoxylin and eosin staining was performed. VV genome copy numbers and cytokine mRNA levels were measured by using quantitative PCR. Results: VV inoculation in unsensitized skin of ft/ft mice, independent of the matted hair mutation, resulted in larger primary lesions, more abundant satellite lesions, heavier viral loads in internal organs, greater epidermal thickness, dermal cellular infiltration, and higher local Il17a, Il4, Il13, and Ifng mRNA levels than in WT control mice. VV inoculation at sites of topical ovalbumin application amplified all of these features in ft/ft mice but had no detectable effect in WT control mice. The number of satellite lesions and the viral loads in internal organs after cutaneous VV inoculation were significantly reduced in both unsensitized and topically sensitized ft/ft mice. Conclusion: FLG deficiency predisposes to eczema vaccinatum. This is mediated primarily through production of IL-17A.	[Oyoshi, Michiko K.; Beaupre, Jacqueline; Venturelli, Nicholas; Lewis, Christopher N.; Geha, Raif S.] Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Oyoshi, Michiko K.; Beaupre, Jacqueline; Venturelli, Nicholas; Lewis, Christopher N.; Geha, Raif S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Iwakura, Yoichiro] Tokyo Univ Sci, Res Inst Biomed Sci, Chiba, Japan	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Tokyo University of Science	Oyoshi, MK (corresponding author), Boston Childrens Hosp, Div Immunol, Karp 10,300 Longwood Ave, Boston, MA 02115 USA.	michiko.oyoshi@childrens.harvard.edu	Iwakura, Yoichiro/E-5457-2011	Iwakura, Yoichiro/0000-0002-9934-5775; Oyoshi, Michiko/0000-0002-0931-3949; Lewis, Holly/0000-0002-5238-3774	National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIAID) [HHSN272201000020C]; Boston Children's Hospital Faculty Career Development Fellowship; Children's Hospital Pediatric Associates Award; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI117673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Boston Children's Hospital Faculty Career Development Fellowship; Children's Hospital Pediatric Associates Award; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIAID) contract no. HHSN272201000020C (to R.S.G.). M.K.O. was supported by the Boston Children's Hospital Faculty Career Development Fellowship and the Children's Hospital Pediatric Associates Award.	Basu R, 2013, IMMUNOL REV, V252, P89, DOI 10.1111/imr.12035; Bin LH, 2014, J ALLERGY CLIN IMMUN, V134, P848, DOI 10.1016/j.jaci.2014.07.018; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Combadiere B, 2004, J EXP MED, V199, P1585, DOI 10.1084/jem.20032083; Cooney LA, 2013, CRIT REV IMMUNOL, V33, P379, DOI 10.1615/CritRevImmunol.2013007096; Engler RJM, 2002, J ALLERGY CLIN IMMUN, V110, P357, DOI 10.1067/mai.2002.128052; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Freyschmidt EJ, 2007, J ALLERGY CLIN IMMUN, V119, P671, DOI 10.1016/j.jaci.2006.12.645; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Harper EG, 2009, J INVEST DERMATOL, V129, P2175, DOI 10.1038/jid.2009.65; He R, 2008, P NATL ACAD SCI USA, V105, P11875, DOI 10.1073/pnas.0801532105; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Irvine AD, 2006, J INVEST DERMATOL, V126, P1200, DOI 10.1038/sj.jid.5700365; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jin HL, 2009, J ALLERGY CLIN IMMUN, V123, P875, DOI 10.1016/j.jaci.2009.02.007; Jin HL, 2009, J CLIN INVEST, V119, P47, DOI 10.1172/JCI32310; Kanda N, 2005, J ALLERGY CLIN IMMUN, V116, P1144, DOI 10.1016/j.jaci.2005.08.014; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kuo IH, 2013, J ALLERGY CLIN IMMUN, V131, P266, DOI 10.1016/j.jaci.2012.12.1563; LANE PW, 1972, J HERED, V63, P135, DOI 10.1093/oxfordjournals.jhered.a108252; Laouini D, 2003, J ALLERGY CLIN IMMUN, V112, P981, DOI 10.1016/j.jaci.2003.07.007; Laouini D, 2003, J CLIN INVEST, V112, P1058, DOI 10.1172/JCI200318246; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449; Moniaga CS, 2010, AM J PATHOL, V176, P2385, DOI 10.2353/ajpath.2010.090957; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Oyoshi MK, 2009, P NATL ACAD SCI USA, V106, P14954, DOI 10.1073/pnas.0904021106; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Reed JL, 2012, CLIN INFECT DIS, V54, P832, DOI 10.1093/cid/cir952; Saunders SP, 2013, J ALLERGY CLIN IMMUN, V132, P1121, DOI 10.1016/j.jaci.2013.08.046; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Scott JE, 2007, J ALLERGY CLIN IMMUN, V120, P1382, DOI 10.1016/j.jaci.2007.08.004; Silverberg JI, 2014, J ALLERGY CLIN IMMUN, V133, P1041, DOI 10.1016/j.jaci.2013.08.012; Slifka MK, 2014, J ALLERGY CLIN IMMUN, V133, P439, DOI 10.1016/j.jaci.2013.10.037; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014; Tian T, 2009, J INVEST DERMATOL, V129, P70, DOI 10.1038/jid.2008.191; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Wollenberg A, 2003, J ALLERGY CLIN IMMUN, V112, P667, DOI 10.1016/j.jaci.2003.07.001; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010	45	13	14	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1511	U188		10.1016/j.jaci.2014.12.1923	http://dx.doi.org/10.1016/j.jaci.2014.12.1923			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25649082	Green Accepted, Bronze			2022-12-18	WOS:000355933400014
J	Cagnoni, EF; Ferreira, DS; da Silva, LFF; Petry, ALNC; dos Santos, ABG; Medeiros, MCR; Dolhnikoff, M; Rabe, KF; Mauad, T				Cagnoni, Erika Feltrini; Ferreira, Diogenes Seraphim; Ferraz da Silva, Luiz Fernando; Nicoletti Carvalho Petry, Ana Laura; Gomes dos Santos, Angela Batista; Rodrigues Medeiros, Maria Cristina; Dolhnikoff, Marisa; Rabe, Klaus F.; Mauad, Thais			Bronchopulmonary lymph nodes and large airway cell trafficking in patients with fatal asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; bronchopulmonary lymph nodes; dendritic cells; eosinophils; antigen presenting cell	CD8(+) T-LYMPHOCYTES; DENDRITIC CELLS; EOSINOPHILS; ANTIGEN; EXPRESSION; MONOCYTE; LUNG	Background: Immune responses in asthmatic patients involve coordinated cellular responses in the airways and lymph nodes (LNs). However, no studies have described the composition of different cell populations in the bronchopulmonary LNs of asthmatic patients. Objective: We sought to investigate the expression of dendritic cells (DCs) and costimulatory molecules, B cells, T cells, T(H)2-related cytokines, eosinophils, and vascular cell adhesion molecule in the bronchopulmonary LNs and large airways of asthmatic patients. Methods: Using histochemistry, immunohistochemistry, and image analysis, we investigated the expression of Factor XIIIa(+), CD1a(+), CD83(+), and CD207(+) DCs; CD4(+) and CD8(+) T cells; CD20(+) B cells; CD23(+) (Fc epsilon RII) cells; IL-4; IL-5; eosinophils, and vascular cell adhesion molecule 1 in the large airways and bronchopulmonary LNs of 11 nonsmokers who died from an asthma exacerbation (fatal asthma [FA]) in comparison with 8 nonasthmatic control subjects. In selected cases of FA, we analyzed the coexpression of HLA-DR, CD40, and CD80 in lung and LN eosinophils. Results: The LNs of asthmatic patients exhibited increased density of eosinophils. No other cells were expressed differently in the LNs of patients with FA. The large airways of patients with FA had increased expression of eosinophils in all layers and increased expression of Factor XIIIa(+) cells, CD4(+) and CD8(+) T cells, CD20(+) B cells, and CD23(+) cells in the outer layer. There was colocalization of HLA-DR, CD40, and CD80 in the eosinophils at both sites. Conclusions: FA is associated with the increased presence of eosinophils in the LNs and large airways, which express HLA-DR and costimulatory molecules. The expression of Factor XIIIa(+) monocyte-derived DCs, CD4(+) and CD8(+) T cells, CD20(+) B cells, and CD23(+) cells was increased in the large airways without a corresponding increase in the expression of these cells in the bronchopulmonary LNs. These findings support the concept that eosinophils might act as antigen-presenting cells in patients with FA.	[Cagnoni, Erika Feltrini; Ferreira, Diogenes Seraphim; Ferraz da Silva, Luiz Fernando; Nicoletti Carvalho Petry, Ana Laura; Gomes dos Santos, Angela Batista; Rodrigues Medeiros, Maria Cristina; Dolhnikoff, Marisa; Mauad, Thais] Univ Sao Paulo, Sch Med, Dept Pathol, BR-01246903 Sao Paulo, SP, Brazil; [Rabe, Klaus F.] LungenClin Grosshansdorf, Grosshansdorf, Germany	Universidade de Sao Paulo; Grosshansdorf Hospital	Cagnoni, EF (corresponding author), Univ Sao Paulo, Sch Med, Dept Pathol, Av Dr Arnaldo 455,Room 1155, BR-01246903 Sao Paulo, SP, Brazil.	erikafeltrini@yahoo.com.br	Silva, Luiz/D-2760-2012; Rabe, Klaus F./AAW-6296-2021; Dolhnikoff, Marisa/B-9019-2013; Ferreira, Diogenes Seraphim/AAB-2486-2020	Silva, Luiz/0000-0002-0181-6357; Rabe, Klaus F./0000-0002-7020-1401; Dolhnikoff, Marisa/0000-0002-9073-9989; Ferreira, Diogenes/0000-0002-6086-835X	Brazilian Research Council (CNPq) [302828/2010-9]; Coordination for the Improvement of Higher Level Personnel (Capes)	Brazilian Research Council (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordination for the Improvement of Higher Level Personnel (Capes)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	Supported by the Brazilian Research Council (CNPq; grant no. 302828/2010-9) and Coordination for the Improvement of Higher Level Personnel (Capes).	Amsen Derk, 2009, V511, P107, DOI 10.1007/978-1-59745-447-6_5; Araujo BB, 2008, EUR RESPIR J, V32, P61, DOI 10.1183/09031936.00147807; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BAI A, 1994, J APPL PHYSIOL, V77, P1011, DOI 10.1152/jappl.1994.77.2.1011; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Condon TV, 2011, J LEUKOCYTE BIOL, V90, P883, DOI 10.1189/jlb.0311134; Dahlin JS, 2012, J IMMUNOL, V189, P3869, DOI 10.4049/jimmunol.1201200; den Otter I, 2010, CLIN EXP ALLERGY, V40, P1473, DOI 10.1111/j.1365-2222.2010.03576.x; Denning KL, 2009, ARCH PATHOL LAB MED, V133, P643, DOI 10.1043/1543-2165-133.4.643; Duez C, 2004, J ALLERGY CLIN IMMUN, V114, P820, DOI 10.1016/j.jaci.2004.08.011; Duperrier K, 2000, J IMMUNOL METHODS, V238, P119, DOI 10.1016/S0022-1759(00)00147-2; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; GROULS V, 1981, STAIN TECHNOL, V56, P323, DOI 10.3109/10520298109067335; Holt PG, 2000, ALLERGY, V55, P688, DOI 10.1034/j.1398-9995.2000.00118.x; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Jeffery Peter K, 2004, Proc Am Thorac Soc, V1, P176, DOI 10.1513/pats.200402-009MS; Kelly MM, 2010, J ALLERGY CLIN IMMUN, V125, P349, DOI 10.1016/j.jaci.2009.09.011; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lipscomb MF, 2002, PHYSIOL REV, V82, P97, DOI 10.1152/physrev.00023.2001; Liu LY, 2006, ALLERGY, V61, P589, DOI 10.1111/j.1398-9995.2006.01060.x; MacKenzie JR, 2001, J IMMUNOL, V167, P3146, DOI 10.4049/jimmunol.167.6.3146; Masten BJ, 2006, J IMMUNOL, V177, P7784, DOI 10.4049/jimmunol.177.11.7784; Mauad T, 2008, REV PANAM SALUD PUBL, V23, P418, DOI 10.1590/S1020-49892008000600007; Mesnil C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053242; NESTLE FO, 1993, J IMMUNOL, V151, P6535; O'Sullivan S, 2001, AM J RESP CRIT CARE, V164, P560, DOI 10.1164/ajrccm.164.4.2102018; Oda H, 2014, ANN ALLERG ASTHMA IM, V112, P23, DOI 10.1016/j.anai.2013.09.004; Ohtani O, 2008, ARCH HISTOL CYTOL, V71, P69, DOI 10.1679/aohc.71.69; Padigel UM, 2006, INFECT IMMUN, V74, P3232, DOI 10.1128/IAI.02067-05; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; PUMP KK, 1972, CHEST, V62, P447, DOI 10.1378/chest.62.4.447; Saetta M, 2003, SARCOIDOSIS VASC DIF, V20, P28; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; Shi HZ, 2004, J LEUKOCYTE BIOL, V76, P520, DOI 10.1189/jlb.0404228; Simoes SD, 2005, CLIN EXP ALLERGY, V35, P602, DOI 10.1111/j.1365-2222.2005.02235.x; Tager AM, 1999, J LEUKOCYTE BIOL, V66, P901, DOI 10.1002/jlb.66.6.901; Thornton EE, 2012, J EXP MED, V209, P1183, DOI 10.1084/jem.20112667; Traister RS, 2014, ANN ALLERG ASTHMA IM, V112, P4, DOI 10.1016/j.anai.2013.11.011; Tschernig Thomas, 2009, BMC Pulm Med, V9, P39, DOI 10.1186/1471-2466-9-39; Van der Valk P, 1992, HISTOLOGY PATHOLOGIS; van Rijt LS, 2003, J IMMUNOL, V171, P3372, DOI 10.4049/jimmunol.171.7.3372; Zaba LC, 2009, J INVEST DERMATOL, V129, P302, DOI 10.1038/jid.2008.225	43	13	13	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1352	U399		10.1016/j.jaci.2014.08.021	http://dx.doi.org/10.1016/j.jaci.2014.08.021			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25262462	Green Published			2022-12-18	WOS:000353980700029
J	dos Santos-Pinto, JRA; dos Santos, LD; Arcuri, HA; Menegasso, ARD; Pego, PN; Santos, KS; Castro, FM; Kalil, JE; De-Simone, SG; Palma, MS				Aparecido dos Santos-Pinto, Jose Roberto; dos Santos, Lucilene Delazari; Arcuri, Helen Andrade; da Silva Menegasso, Anally Ribeiro; Pego, Paloma Napoleao; Santos, Keity Souza; Castro, Fabio Morato; Kalil, Jorge Elias; De-Simone, Salvatore Giovanni; Palma, Mario Sergio			B-cell linear epitopes mapping of antigen-5 allergen from Polybia paulista wasp venom	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HYMENOPTERA VENOM; IGE		[Aparecido dos Santos-Pinto, Jose Roberto; da Silva Menegasso, Anally Ribeiro; Palma, Mario Sergio] Univ Sao Paulo State, UNESP, Inst Biosci Rio Claro, Rio Claro, Brazil; [Pego, Paloma Napoleao; De-Simone, Salvatore Giovanni] Fiocruz MS, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil; [dos Santos, Lucilene Delazari] Univ Sao Paulo State, UNESP, CEVAP, Botucatu, SP, Brazil; [Aparecido dos Santos-Pinto, Jose Roberto; dos Santos, Lucilene Delazari; Arcuri, Helen Andrade; da Silva Menegasso, Anally Ribeiro; Santos, Keity Souza; Castro, Fabio Morato; Kalil, Jorge Elias; Palma, Mario Sergio] INCT, Sao Paulo, Brazil; [Arcuri, Helen Andrade; Santos, Keity Souza; Castro, Fabio Morato; Kalil, Jorge Elias] Discipline Allergy & Immunol HC Incor FMUSP, Sao Paulo, Brazil	Universidade Estadual Paulista; Fundacao Oswaldo Cruz; Universidade Estadual Paulista	dos Santos-Pinto, JRA (corresponding author), Univ Sao Paulo State, UNESP, Inst Biosci Rio Claro, Rio Claro, Brazil.	mspalma@rc.unesp.br	Santos, Keity Souza/Q-5704-2019; De-Simone, Salvatore/I-2989-2013; Palma, Mario Sergio/E-7800-2012; Souza, Keity/AEX-0817-2022; Fapesp, Biota/F-8655-2017; Castro, Fabio FM/C-1082-2017; Palma, Mario/N-3903-2019; Santos, Keity/M-9401-2015; Castro, Fabio/AAP-5433-2020; KALIL, JORGE/C-8029-2012; Santos-Pinto, José Roberto Aparecido dos/V-8745-2019	Santos, Keity Souza/0000-0001-5271-4011; De-Simone, Salvatore/0000-0002-2172-656X; Palma, Mario Sergio/0000-0002-7363-8211; Souza, Keity/0000-0001-5271-4011; Fapesp, Biota/0000-0002-9887-8449; Castro, Fabio FM/0000-0002-6211-5773; KALIL, JORGE/0000-0001-8415-4274; Santos-Pinto, José Roberto Aparecido dos/0000-0003-3172-0097; Pego, Paloma/0000-0001-8781-9067				dos Santos-Pinto JRA, 2014, J PROTEOME RES, V13, P855, DOI 10.1021/pr4008927; Castro FFM, 2009, ALERGIA VENENOS INSE; De-Simone SG, 2014, TOXICON, V78, P83, DOI 10.1016/j.toxicon.2013.12.001; dos Santos LD, 2010, J PROTEOME RES, V9, P3867, DOI 10.1021/pr1000829; Pinto JRAD, 2012, J PROTEOME RES, V11, P4643, DOI 10.1021/pr300451g; Hoffman DR, 2006, CLIN REV ALLERG IMMU, V30, P109, DOI 10.1385/CRIAI:30:2:109; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P606, DOI 10.1016/0091-6749(85)90037-5; Mittermann I, 2010, J ALLERGY CLIN IMMUN, V125, P1300, DOI 10.1016/j.jaci.2010.03.017; Muller UR, 2009, ALLERGY, V64, P543, DOI 10.1111/j.1398-9995.2008.01794.x; Winkler B, 2003, IMMUNOLOGY, V110, P376, DOI 10.1046/j.1365-2567.2003.01751.x	10	13	13	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					264	U404		10.1016/j.jaci.2014.07.006	http://dx.doi.org/10.1016/j.jaci.2014.07.006			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25129676	Green Published			2022-12-18	WOS:000347298200033
J	Pellerin, L; Paul, C; Schmitt, AM; Serre, G; Simon, M				Pellerin, Laurence; Paul, Carle; Schmitt, Anne-Marie; Serre, Guy; Simon, Michel			Bleomycin hydrolase downregulation in lesional skin of adult atopic dermatitis patients is independent of FLG gene mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FILAGGRIN; DEFECTS; BARRIER		[Pellerin, Laurence; Paul, Carle; Serre, Guy; Simon, Michel] CNRS, UMR5165, F-75700 Paris, France; [Pellerin, Laurence; Paul, Carle; Serre, Guy; Simon, Michel] INSERM, U1056, F-75654 Paris 13, France; [Pellerin, Laurence; Paul, Carle; Serre, Guy; Simon, Michel] Univ Toulouse, Toulouse, France; [Paul, Carle] Toulouse Univ Hosp, Dept Dermatol, Toulouse, France; [Schmitt, Anne-Marie] Pierre Fabre Dermo Cosmet, CERPER, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; CHU de Toulouse	Pellerin, L (corresponding author), CNRS, UMR5165, F-75700 Paris, France.	michel.simon@udear.cnrs.fr	Pellerin, Laurence/AAH-3424-2020; Simon, Michel/B-7308-2011	Simon, Michel/0000-0003-3655-6329; Paul, Carle/0000-0003-0165-5263				Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393; Chattopadhyay PK, 2005, NAT MED, V11, P1113, DOI 10.1038/nm1293; DALE BA, 1985, ANN NY ACAD SCI, V455, P330, DOI 10.1111/j.1749-6632.1985.tb50420.x; Kamata Y, 2011, J BIOL CHEM, V286, P8204, DOI 10.1074/jbc.M110.169292; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kezic S, 2014, FRONT BIOSCI-LANDMRK, V19, P541, DOI 10.2741/4225; Novak EJ, 2001, J IMMUNOL, V166, P6665, DOI 10.4049/jimmunol.166.11.6665; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Pendaries V, 2014, J INVEST DERMATOL, V134, P2938, DOI 10.1038/jid.2014.259; SIMON M, 1995, J INVEST DERMATOL, V105, P432, DOI 10.1111/1523-1747.ep12321148; Tan SP, 2012, BRIT J DERMATOL, V166, P1137, DOI 10.1111/j.1365-2133.2011.10750.x; Yamamoto M, 2011, J DERMATOL SCI, V61, P110, DOI 10.1016/j.jdermsci.2010.11.018	12	13	13	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1459	+		10.1016/j.jaci.2014.07.056	http://dx.doi.org/10.1016/j.jaci.2014.07.056			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25240784				2022-12-18	WOS:000346075400034
J	Sabato, V; Boita, M; Shubber, S; Bridts, CH; Shibuya, A; De Clerck, LS; Falcone, FH; Ebo, DG				Sabato, Vito; Boita, Monica; Shubber, Saif; Bridts, Chris H.; Shibuya, Akira; De Clerck, Luc S.; Falcone, Franco H.; Ebo, Didier G.			Mechanism of phosphatidylserine inhibition of IgE/Fc epsilon RI-dependent anaphylactic human basophil degranulation via CD300a	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IDENTIFICATION; PIECEMEAL; MARKERS		[Sabato, Vito; Bridts, Chris H.; De Clerck, Luc S.; Ebo, Didier G.] Univ Antwerp, Fac Med & Hlth Sci, Dept Immunol Allergol Rheumatol, B-2020 Antwerp, Belgium; [Sabato, Vito; Bridts, Chris H.; De Clerck, Luc S.; Ebo, Didier G.] Univ Antwerp Hosp, Antwerp, Belgium; [Boita, Monica] Univ Turin, Turin, Italy; [Shubber, Saif] Univ Nottingham, Sch Pharm, Div Drug Delivery & Tissue Engn, Nottingham NG7 2RD, England; [Shibuya, Akira] Univ Tsukuba, Fac Med, Dept Immunol, Div Biomed Sci, Tsukuba, Ibaraki, Japan; [Falcone, Franco H.] Univ Nottingham, Sch Pharm, Div Mol & Cellular Sci, Nottingham NG7 2RD, England	University of Antwerp; University of Antwerp; University of Turin; University of Nottingham; University of Tsukuba; University of Nottingham	Sabato, V (corresponding author), Univ Antwerp, Fac Med & Hlth Sci, Dept Immunol Allergol Rheumatol, B-2020 Antwerp, Belgium.	immuno@uantwerpen.be	Sabato, Vito/B-6479-2017; BRIDTS, Chris HM/M-7933-2016; EBO, Didier/H-4894-2016; Falcone, Franco H/F-9210-2013; Falcone, Franco/AAE-8026-2021	Sabato, Vito/0000-0002-1321-314X; BRIDTS, Chris HM/0000-0002-3324-7320; EBO, Didier/0000-0003-0672-7529; Falcone, Franco H/0000-0002-1732-9932; Falcone, Franco/0000-0002-1732-9932				Bussmann C, 2010, ALLERGY, V65, P1558, DOI 10.1111/j.1398-9995.2010.02430.x; DVORAK AM, 1992, INT ARCH ALLERGY IMM, V99, P74, DOI 10.1159/000236338; Gibbs BF, 2008, CLIN EXP ALLERGY, V38, P480, DOI 10.1111/j.1365-2222.2007.02919.x; Hennersdorf F, 2005, CELL RES, V15, P325, DOI 10.1038/sj.cr.7290301; Karra L, 2011, ADV EXP MED BIOL, V716, P143, DOI 10.1007/978-1-4419-9533-9_9; MacGlashan D, 2010, CLIN EXP ALLERGY, V40, P1365, DOI 10.1111/j.1365-2222.2010.03572.x; Martin S, 2000, INT ARCH ALLERGY IMM, V123, P249, DOI 10.1159/000024451; Nakahashi-Oda C, 2012, BIOCHEM BIOPH RES CO, V417, P646, DOI 10.1016/j.bbrc.2011.12.025; Sabato V, 2012, CYTOM PART B-CLIN CY, V82B, P132, DOI 10.1002/cyto.b.21003	9	13	15	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					734	737		10.1016/j.jaci.2014.03.029	http://dx.doi.org/10.1016/j.jaci.2014.03.029			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24815424	Green Submitted			2022-12-18	WOS:000341372400031
J	Zhou, WS; Goleniewska, K; Zhang, J; Dulek, DE; Toki, S; Lotz, MT; Newcomb, DC; Boswell, MG; Polosukhin, VV; Milne, GL; Wu, PS; Moore, ML; FitzGerald, GA; Peebles, RS				Zhou, Weisong; Goleniewska, Kasia; Zhang, Jian; Dulek, Daniel E.; Toki, Shinji; Lotz, Matthew T.; Newcomb, Dawn C.; Boswell, Madison G.; Polosukhin, Vasiliy V.; Milne, Ginger L.; Wu, Pingsheng; Moore, Martin L.; FitzGerald, Garret A.; Peebles, R. Stokes, Jr.			Cyclooxygenase inhibition abrogates aeroallergen-induced immune tolerance by suppressing prostaglandin I-2 receptor signaling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PGI(2); allergy; immune tolerance	REGULATORY T-CELLS; BOUND TGF-BETA; ALLERGIC INFLAMMATION; AIRWAY HYPERRESPONSIVENESS; CYTOKINE PRODUCTION; DEFICIENT MICE; ASTHMA; INCREASES; SENSITIZATION; CHALLENGE	Background: The prevalence of allergic diseases has doubled in developed countries in the past several decades. Cyclooxygenase (COX)-inhibiting drugs augmented allergic diseases in mice by increasing allergic sensitization and memory immune responses. However, whether COX inhibition can promote allergic airway diseases by inhibiting immune tolerance is not known. Objective: To determine the role of the COX pathway and prostaglandin I-2 (PGI(2)) signaling through the PGI(2) receptor (IP) in aeroallergen-induced immune tolerance. Methods: Wild-type (WT) BALB/c mice and IP knockout mice were aerosolized with ovalbumin (OVA) to induce immune tolerance prior to immune sensitization with an intraperitoneal injection of OVA/alum. The COX inhibitor indomethacin or vehicle was administered in drinking water to inhibit enzyme activity during the sensitization phase. Two weeks after sensitization, the mice were challenged with OVA aerosols. Mouse bronchoalveolar lavage fluid was harvested for cell counts and T(H)2 cytokine measurements. Results: WT mice treated with indomethacin had greater numbers of total cells, eosinophils, and lymphocytes, and increased IL-5 and IL-13 protein expression in BAL fluid compared to vehicle-treated mice. Similarly, IP knockout mice had augmented inflammation and T(H)2 cytokine responses compared to WT mice. In contrast, the PGI(2) analog cicaprost attenuated the anti-tolerance effect of COX inhibition. Conclusion: COX inhibition abrogated immune tolerance by suppressing PGI(2) IP signaling, suggesting that PGI(2) signaling promotes immune tolerance and that clinical use of COX-inhibiting drugs may increase the risk of developing allergic diseases.	[Zhou, Weisong; Goleniewska, Kasia; Zhang, Jian; Dulek, Daniel E.; Toki, Shinji; Lotz, Matthew T.; Newcomb, Dawn C.; Boswell, Madison G.; Polosukhin, Vasiliy V.; Wu, Pingsheng; Peebles, R. Stokes, Jr.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; [Milne, Ginger L.] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37232 USA; [Moore, Martin L.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; [FitzGerald, Garret A.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	Vanderbilt University; Vanderbilt University; Emory University; University of Pennsylvania	Zhou, WS (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, T 1217 MCN,21st Ave S, Nashville, TN 37232 USA.	weisong.zhou@vanderbilt.edu	Milne, Ginger/D-7648-2014	Milne, Ginger/0000-0003-3890-151X; Dulek, Daniel/0000-0002-1821-6657	National Institutes of Health [R01 AI 111820, 2I01BX000624, U19 AI 095227-02, R01 HL 090664-04, R56 AI076411]; US Department of Veterans Affairs [2I01BX000624]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD043483] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL069765, R01HL090664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI111820, R01AI054660, R56AI076411, U19AI095227] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000624] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Veterans Affairs(US Department of Veterans Affairs); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by National Institutes of Health grants R01 AI 111820, 2I01BX000624, U19 AI 095227-02, R01 HL 090664-04 and R56 AI076411 and US Department of Veterans Affairs grant 2I01BX000624.	Broere F, 2009, MUCOSAL IMMUNOL, V2, P254, DOI 10.1038/mi.2009.2; Carey MA, 2003, AM J RESP CRIT CARE, V167, P1509, DOI 10.1164/rccm.200211-1383OC; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Chinen T, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1181; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Gavett SH, 1999, J CLIN INVEST, V104, P721, DOI 10.1172/JCI6890; Gereke M, 2009, AM J RESP CRIT CARE, V179, P344, DOI 10.1164/rccm.200804-592OC; Hashimoto K, 2005, J IMMUNOL, V174, P525, DOI 10.4049/jimmunol.174.1.525; Hashimoto K, 2004, J VIROL, V78, P10303, DOI 10.1128/JVI.78.19.10303-10309.2004; Idzko M, 2007, J CLIN INVEST, V117, P464, DOI 10.1172/JCI28949; Jaffar Z, 2007, J IMMUNOL, V179, P6193, DOI 10.4049/jimmunol.179.9.6193; Jarvis D, 1998, BRIT MED J, V316, P607, DOI 10.1136/bmj.316.7131.607; Laouini D, 2005, J ALLERGY CLIN IMMUN, V116, P390, DOI 10.1016/j.jaci.2005.03.042; Marquis A, 2011, J ALLERGY CLIN IMMUN, V127, P270, DOI 10.1016/j.jaci.2010.08.044; MORROW JD, 1991, ANAL BIOCHEM, V193, P142, DOI 10.1016/0003-2697(91)90054-W; Nagao K, 2003, AM J RESP CELL MOL, V29, P314, DOI 10.1165/rcmb.2003-0035OC; Ostroukhova M, 2006, J CLIN INVEST, V116, P996, DOI 10.1172/JCI26490; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Peebles RS, 2000, AM J RESP CRIT CARE, V162, P676; Peebles RS, 2002, AM J RESP CRIT CARE, V165, P1154, DOI 10.1164/rccm.2106025; Shaheen SO, 2005, CLIN EXP ALLERGY, V35, P18, DOI 10.1111/j.1365-2222.2005.02151.x; Takahashi Y, 2002, BRIT J PHARMACOL, V137, P315, DOI 10.1038/sj.bjp.0704872; Thomsen SF, 2009, CLIN RESPIR J, V3, P82, DOI 10.1111/j.1752-699X.2008.00113.x; Wing K, 2010, NAT IMMUNOL, V11, P7, DOI 10.1038/ni.1818; Yaqub S, 2008, CANCER IMMUNOL IMMUN, V57, P813, DOI 10.1007/s00262-007-0417-x; Zhou WS, 2008, J IMMUNOL, V181, P5360, DOI 10.4049/jimmunol.181.8.5360; Zhou WS, 2007, J LEUKOCYTE BIOL, V81, P809, DOI 10.1189/jlb.0606375; Zhou WS, 2007, J IMMUNOL, V178, P702, DOI 10.4049/jimmunol.178.2.702	28	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					698	+		10.1016/j.jaci.2014.06.004	http://dx.doi.org/10.1016/j.jaci.2014.06.004			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	25042746	Green Accepted			2022-12-18	WOS:000341372400024
J	Lumia, M; Luukkainen, P; Takkinen, HM; Kaila, M; Nwaru, BI; Nevalainen, J; Salminen, I; Uusitalo, L; Niinisto, S; Tuokkola, J; Niemela, O; Haapala, AM; Ilonen, J; Simell, O; Knip, M; Veijola, R; Virtanen, SM				Lumia, Mirka; Luukkainen, Paivi; Takkinen, Hanna-Mari; Kaila, Minna; Nwaru, Bright I.; Nevalainen, Jaakko; Salminen, Irma; Uusitalo, Liisa; Niinisto, Sari; Tuokkola, Jetta; Niemela, Onni; Haapala, Anna-Maija; Ilonen, Jorma; Simell, Olli; Knip, Mikael; Veijola, Riitta; Virtanen, Suvi M.			Cow's milk allergy and the association between fatty acids and childhood asthma risk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HLA-CONFERRED SUSCEPTIBILITY; BETA-CELL AUTOIMMUNITY; RESPIRATORY SYMPTOMS; YOUNG-CHILDREN; CONSUMPTION; WORKERS; DISEASE; FEMALE; HEALTH; AGE		[Lumia, Mirka; Takkinen, Hanna-Mari; Uusitalo, Liisa; Niinisto, Sari; Tuokkola, Jetta; Virtanen, Suvi M.] Natl Inst Hlth & Welf, Dept Lifestyle & Participat, Nutr Unit, Helsinki, Finland; [Salminen, Irma] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Dis Risk Unit, Helsinki, Finland; [Lumia, Mirka; Takkinen, Hanna-Mari; Uusitalo, Liisa; Niinisto, Sari; Virtanen, Suvi M.] Univ Tampere, Sch Hlth Sci, FIN-33101 Tampere, Finland; [Lumia, Mirka; Luukkainen, Paivi; Tuokkola, Jetta; Knip, Mikael] Univ Helsinki, Childrens Hosp, Helsinki, Finland; [Lumia, Mirka; Luukkainen, Paivi; Tuokkola, Jetta; Knip, Mikael] Univ Helsinki, Cent Hosp, Helsinki, Finland; [Kaila, Minna] Univ Helsinki, Hjelt Inst, Helsinki, Finland; [Knip, Mikael] Univ Helsinki, Folkhalsan Res Inst, Helsinki, Finland; [Knip, Mikael] Univ Helsinki, Diabet & Obes Res Program, Helsinki, Finland; [Nwaru, Bright I.] Univ Edinburgh, Ctr Populat Hlth Sci, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland; [Nevalainen, Jaakko] Univ Turku, Dept Math & Stat, Turku, Finland; [Simell, Olli] Univ Turku, Dept Pediat, Turku, Finland; [Niemela, Onni] Seinajoki Cent Hosp, Dept Lab Med, Tampere, Finland; [Niemela, Onni] Seinajoki Cent Hosp, Med Res Unit, Tampere, Finland; [Niemela, Onni; Virtanen, Suvi M.] Univ Tampere, FIN-33101 Tampere, Finland; [Haapala, Anna-Maija] Pirkanmaa Hosp Dist, Ctr Lab Med, Tampere, Finland; [Ilonen, Jorma] Univ Turku, Immunogenet Lab, Turku, Finland; Univ Eastern Finland, Dept Clin Microbiol, Joensuu, Finland; [Knip, Mikael] Tampere Univ Hosp, Dept Pediat, Tampere, Finland; [Veijola, Riitta] Univ Oulu, Dept Pediat, SF-90100 Oulu, Finland; [Virtanen, Suvi M.] Tampere Univ Hosp, Pirkanmaa Hosp Dist, Res Ctr Child Hlth, Tampere, Finland; [Virtanen, Suvi M.] Tampere Univ Hosp, Pirkanmaa Hosp Dist, Ctr Sci, Tampere, Finland	Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; Tampere University; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Folkhalsan Research Center; University of Helsinki; University of Helsinki; University of Edinburgh; University of Turku; University of Turku; Seinajoki Central Hospital; Seinajoki Central Hospital; Pirkanmaa Hospital District; University of Turku; University of Eastern Finland; Tampere University; Tampere University Hospital; University of Oulu; Pirkanmaa Hospital District; Tampere University; Tampere University Hospital; Pirkanmaa Hospital District; Tampere University; Tampere University Hospital	Lumia, M (corresponding author), Natl Inst Hlth & Welf, Dept Lifestyle & Participat, Nutr Unit, Helsinki, Finland.	mirka.lumia@fimnet.fi	Virtanen, Suvi/AAP-1922-2021; Knip, Mikael/AAL-3773-2020; Nevalainen, Jaakko/X-1828-2019	Nevalainen, Jaakko/0000-0001-6295-0245; Virtanen, Suvi/0000-0001-8928-0878; Kaila, Minna/0000-0002-9645-4925; Nwaru, Bright/0000-0002-2876-6089; Knip, Mikael/0000-0003-0474-0033; Luukkainen, Paivi/0000-0002-3953-4312				[Anonymous], 1997, J ALLERGY CLIN IMMUN, V99, P583; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Calder PC, 2009, BIOCHIMIE, V91, P791, DOI 10.1016/j.biochi.2009.01.008; Craiu RV, 2008, BIOMETRICAL J, V50, P97, DOI 10.1002/bimj.200610379; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Dosman JA, 2009, J AGROMEDICINE, V14, P270, DOI 10.1080/10599240902772738; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Kupila A, 2001, DIABETOLOGIA, V44, P290, DOI 10.1007/s001250051616; Magnusson J, 2013, AM J CLIN NUTR, V97, P1324, DOI 10.3945/ajcn.112.045377; Nwaru BI, 2011, CLIN RESPIR J, V5, P211, DOI 10.1111/j.1752-699X.2010.00222.x; Pahwa Punam, 2012, BMC Res Notes, V5, P400, DOI 10.1186/1756-0500-5-400; Pahwa Punam, 2009, BMC Pulm Med, V9, P46, DOI 10.1186/1471-2466-9-46; Sala-Vila A, 2008, CLIN EXP ALLERGY, V38, P1432, DOI 10.1111/j.1365-2222.2008.03072.x; Senthilselvan A, 1997, CHEST, V111, P1733, DOI 10.1378/chest.111.6.1733; Senthilselvan A, 2007, CHEST, V131, P1197, DOI 10.1378/chest.06-2323; Senthilselvan A, 2009, J ALLERGY CLIN IMMUN, V123, P1034, DOI 10.1016/j.jaci.2009.02.019; Uusitalo L, 2013, MATERN CHILD NUTR, V9, P381, DOI 10.1111/j.1740-8709.2011.00374.x; Virtanen SM, 2006, DIABETOLOGIA, V49, P1512, DOI 10.1007/s00125-006-0236-1; Virtanen SM, 2012, AM J CLIN NUTR, V95, P471, DOI 10.3945/ajcn.111.018879; Xu H, 2005, BIOINFORMATICS, V21, P4181, DOI 10.1093/bioinformatics/bti682; ZEJDA JE, 1993, CHEST, V103, P702, DOI 10.1378/chest.103.3.702	22	13	14	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					488	490		10.1016/j.jaci.2014.04.012	http://dx.doi.org/10.1016/j.jaci.2014.04.012			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24875617				2022-12-18	WOS:000341370800035
J	Ruiz-Garcia, R; Lermo-Rojo, S; Martinez-Lostao, L; Mancebo, E; Mora-Diaz, S; Paz-Artal, E; Ruiz-Contreras, J; Anel, A; Gonzalez-Granado, LI; Allende, LM				Ruiz-Garcia, Raquel; Lermo-Rojo, Sara; Martinez-Lostao, Luis; Mancebo, Esther; Mora-Diaz, Sergio; Paz-Artal, Estela; Ruiz-Contreras, Jesus; Anel, Alberto; Gonzalez-Granado, Luis I.; Allende, Luis M.			A case of partial dedicator of cytokinesis 8 deficiency with altered effector phenotype and impaired CD8(+) and natural killer cell cytotoxicity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DOCK8		[Ruiz-Garcia, Raquel; Lermo-Rojo, Sara; Mancebo, Esther; Mora-Diaz, Sergio; Paz-Artal, Estela; Allende, Luis M.] Hosp Univ 12 Octubre, Serv Immunol, Madrid, Spain; [Martinez-Lostao, Luis; Anel, Alberto] Univ Zaragoza, Dept Bioquim Biol Mol & Cellular, Zaragoza, Spain; [Mancebo, Esther; Paz-Artal, Estela; Ruiz-Contreras, Jesus; Gonzalez-Granado, Luis I.; Allende, Luis M.] Inst Invest I 12, Madrid, Spain; [Ruiz-Contreras, Jesus; Gonzalez-Granado, Luis I.] Hosp Univ 12 Octubre, Unidad Inmunodeficiencias, Madrid, Spain	Hospital Universitario 12 de Octubre; University of Zaragoza; Hospital Universitario 12 de Octubre	Ruiz-Garcia, R (corresponding author), Hosp Univ 12 Octubre, Serv Immunol, Madrid, Spain.	lallende.hdoc@salud.madrid.org	Martinez-Lostao, Luis/AAI-3090-2021; Gonzalez-Granado, Luis Ignacio/ABG-4515-2020; Anel, Alberto/Z-3068-2019; Ruiz-García, Raquel/AAE-6659-2021; Gonzalez-Granado, Luis Ignacio/B-9257-2009	Gonzalez-Granado, Luis Ignacio/0000-0001-6917-8980; Gonzalez-Granado, Luis Ignacio/0000-0001-6917-8980; Martinez-Lostao, Luis/0000-0003-3043-147X; Paz-Artal, Estela/0000-0002-0646-2375; RUIZ-CONTRERAS, JESUS/0000-0002-2788-7524; Ruiz-Garcia, Raquel/0000-0002-8403-3613; /0000-0001-9586-8539; Mancebo, Esther/0000-0002-1535-9062				Appay V, 2008, CYTOM PART A, V73A, P975, DOI 10.1002/cyto.a.20643; Bernardo I, 2011, HAEMATOL-HEMATOL J, V96, P1195, DOI 10.3324/haematol.2011.041301; Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Ham H, 2013, J IMMUNOL, V190, P3661, DOI 10.4049/jimmunol.1202792; Mizesko MC, 2013, J ALLERGY CLIN IMMUN, V131, P840, DOI 10.1016/j.jaci.2012.12.1568; Randall KL, 2011, J EXP MED, V208, P2305, DOI 10.1084/jem.20110345; Renner ED, 2004, J PEDIATR-US, V144, P93, DOI 10.1016/S0022-3476(03)00449-9; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	9	13	13	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					218	221		10.1016/j.jaci.2014.01.023	http://dx.doi.org/10.1016/j.jaci.2014.01.023			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24636087				2022-12-18	WOS:000338930300028
J	Kenney, P; Hilberg, O; Pedersen, H; Nielsen, OB; Sigsgaard, T				Kenney, Peter; Hilberg, Ole; Pedersen, Henrik; Nielsen, Ole Bkgaard; Sigsgaard, Torben			Nasal filters for the treatment of allergic rhinitis: A randomized, double-blind, placebocontrolled crossover clinical trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXPOSURE; IMMUNOTHERAPY; EFFICACY; RAGWEED; IMPACT		[Kenney, Peter; Sigsgaard, Torben] Aarhus Univ, Dept Publ Hlth, Sect Environm Occupat & Hlth, Aarhus, Denmark; [Pedersen, Henrik] Aarhus Univ, Dept Engn, Aarhus, Denmark; [Nielsen, Ole Bkgaard] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Hilberg, Ole] Aarhus Univ Hosp, Dept Resp Dis & Allergol, DK-8000 Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University	Kenney, P (corresponding author), Aarhus Univ, Dept Publ Hlth, Sect Environm Occupat & Hlth, Aarhus, Denmark.	ts@mil.au.dk	Sigsgaard, Torben/AAC-1292-2020	Sigsgaard, Torben/0000-0002-2043-7571; Nielsen, Ole Baekgaard/0000-0003-3535-7862				Akerlund Anders, 2005, J Allergy Clin Immunol, V115, pS460, DOI 10.1016/j.jaci.2004.12.016; BACON JR, 1981, J ALLERGY CLIN IMMUN, V67, P111, DOI 10.1016/0091-6749(81)90005-1; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; D'Amato G, 2012, EUR ANN ALLERGY CLIN, V44, P83; Day J. H., 2006, Clinical and Experimental Allergy Reviews, V6, P31, DOI 10.1111/j.1365-2222.2005.00099.x; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Durham SR, 2008, CURR OPIN ALLERGY CL, V8, P577, DOI 10.1097/ACI.0b013e3283196764; Ellis AK, 2013, ANN ALLERG ASTHMA IM, V111, P323, DOI 10.1016/j.anai.2013.07.019; Greiner AN, 2011, LANCET, V378, P2112, DOI 10.1016/S0140-6736(11)60130-X; Hilberg O, 2002, ALLERGY, V57, P5, DOI 10.1046/j.0908-665x.2001.all.doc.x; LAINE MT, 1995, LARYNGOSCOPE, V105, P425, DOI 10.1288/00005537-199504000-00016; NIELSEN L, 1994, ALLERGY, V49, P630, DOI 10.1111/j.1398-9995.1994.tb00131.x; O'Meara TJ, 2005, ALLERGY, V60, P529, DOI 10.1111/j.1398-9995.2005.00741.x; Plaut M, 2005, NEW ENGL J MED, V353, P1934, DOI 10.1056/NEJMcp044141; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI [10.1186/1741-7015-8-18, 10.1136/bmj.c332]; Stokes JR, 2012, J ALLERGY CLIN IMMUN, V129, P409, DOI 10.1016/j.jaci.2011.11.026; UNITED STATES, 2000, GUID IND WAIV IN VIV, P1; WACHS M, 1989, J ALLERGY CLIN IMMUN, V84, P492, DOI 10.1016/0091-6749(89)90362-X; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003	21	13	13	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1477	U423		10.1016/j.jaci.2014.01.004	http://dx.doi.org/10.1016/j.jaci.2014.01.004			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24589343				2022-12-18	WOS:000335450700036
J	Mas, S; Torres, M; Garrido-Arandia, M; Salamanca, G; Castro, L; Barral, P; Purohit, A; Pauli, G; Rodriguez, R; Batanero, E; Barderas, R; Villalba, M				Mas, Salvador; Torres, Maria; Garrido-Arandia, Maria; Salamanca, Guillermo; Castro, Lourdes; Barral, Patricia; Purohit, Ashok; Pauli, Gabrielle; Rodriguez, Rosalia; Batanero, Eva; Barderas, Rodrigo; Villalba, Mayte			Ash pollen immunoproteomics: Identification, immunologic characterization, and sequencing of 6 new allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MAJOR ALLERGEN; IMMUNOTHERAPY; FRA-E-1		[Mas, Salvador; Torres, Maria; Garrido-Arandia, Maria; Salamanca, Guillermo; Castro, Lourdes; Barral, Patricia; Rodriguez, Rosalia; Batanero, Eva; Barderas, Rodrigo; Villalba, Mayte] Univ Complutense Madrid, Dpto Bioquim & Biol Mol 1, Madrid, Spain; [Garrido-Arandia, Maria] UPM, INIA, Ctr Biotecnol & Genom Plantas, Madrid, Spain; [Salamanca, Guillermo; Castro, Lourdes] ALK Abello, Madrid, Spain; [Barral, Patricia] Kings Coll London, Guys Hosp, Peter Gorer Dept Immunobiol, London, England; [Purohit, Ashok; Pauli, Gabrielle] Hop Univ Strasbourg, Hop Lyautey, Serv Pneumol, Strasbourg, France	Complutense University of Madrid; Universidad Politecnica de Madrid; ALK-Abello AS; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Mas, S (corresponding author), Univ Complutense Madrid, Dpto Bioquim & Biol Mol 1, Madrid, Spain.	rbarderas@quim.ucm.es	RODRIGUEZ, ROSALIA/K-4993-2014; Garrido-Arandia, Maria/ABG-9760-2020; Villalba, Mayte/K-5365-2014; Villalba, María Teresa/AAW-1067-2020; Torres, Maria/GVU-3391-2022; Barderas, Rodrigo/K-3560-2014	RODRIGUEZ, ROSALIA/0000-0002-4280-3691; Villalba, María Teresa/0000-0002-0042-9953; Barderas, Rodrigo/0000-0003-3539-7469; Barral, Patricia/0000-0003-4324-8973; Garrido Arandia, Maria/0000-0001-6114-5754				Barderas R, 2006, ANN ALLERG ASTHMA IM, V96, P557, DOI 10.1016/S1081-1206(10)63550-8; Barderas R, 2005, J ALLERGY CLIN IMMUN, V115, P351, DOI 10.1016/j.jaci.2004.10.001; Hemmer W, 2000, ALLERGY, V55, P923, DOI 10.1034/j.1398-9995.2000.00671.x; Metz-Favre C, 2010, REV FR ALLERGOL, V50, P568, DOI 10.1016/j.reval.2010.08.001; Poncet P, 2010, ALLERGY, V65, P571, DOI 10.1111/j.1398-9995.2009.02231.x; Rodriguez R, 2007, J INVEST ALLERG CLIN, V17, P4; Rodriguez R, 2001, INT ARCH ALLERGY IMM, V125, P185, DOI 10.1159/000053815; Schmid-Grendelmeier P, 2012, Ther Umsch, V69, P239, DOI 10.1024/0040-5930/a000280	8	13	13	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					923	926		10.1016/j.jaci.2013.10.061	http://dx.doi.org/10.1016/j.jaci.2013.10.061			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24418479	Green Accepted			2022-12-18	WOS:000332397600050
J	Krishnamurthy, P; Sherrill, JD; Parashette, K; Goenka, S; Rothenberg, ME; Gupta, S; Kaplan, MH				Krishnamurthy, Purna; Sherrill, Joseph D.; Parashette, Kalyan; Goenka, Shreevrat; Rothenberg, Marc E.; Gupta, Sandeep; Kaplan, Mark H.			Correlation of increased PARP14 and CCL26 expression in biopsies from children with eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Krishnamurthy, Purna; Parashette, Kalyan; Goenka, Shreevrat; Gupta, Sandeep; Kaplan, Mark H.] Indiana Univ Sch Med, Dept Pediat, Wells Ctr Pediat Res, Riley Hosp Children, Indianapolis, IN 46202 USA; [Rothenberg, Marc E.] Univ Cincinnati, Dept Pediat, Div Allergy & Immunol, Cincinnati Childrens Hosp,Med Ctr,Coll Med, Cincinnati, OH 45221 USA	Indiana University System; Indiana University Bloomington; James Whitcomb Riley Hospital Children; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Krishnamurthy, P (corresponding author), Indiana Univ Sch Med, Dept Pediat, Wells Ctr Pediat Res, Riley Hosp Children, Indianapolis, IN 46202 USA.	mkaplan2@iupui.edu	Parashette, Kalyan Ray/Y-7621-2019		NHLBI NIH HHS [R01 HL093105] Funding Source: Medline; NIAID NIH HHS [R01 AI095282, U19 AI070235] Funding Source: Medline; NIDDK NIH HHS [R01 DK076893, P30 DK090971] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL093105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070235, R01AI095282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076893, P30DK090971] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Goenka S, 2011, IMMUNOL RES, V50, P87, DOI 10.1007/s12026-011-8205-2; Goswami R, 2012, J IMMUNOL, V188, P968, DOI 10.4049/jimmunol.1102840; Gupta SK, 2006, J PEDIATR GASTR NUTR, V42, P22, DOI 10.1097/01.mpg.0000188740.38757.d2; Lim EJ, 2011, J BIOL CHEM, V286, P13193, DOI 10.1074/jbc.M110.210724; Lu TX, 2012, J ALLERGY CLIN IMMUN, V129, P1064, DOI 10.1016/j.jaci.2012.01.060; Mehrotra P, 2013, J ALLERGY CLIN IMMUN, V131, P521, DOI 10.1016/j.jaci.2012.06.015; Mehrotra P, 2011, J BIOL CHEM, V286, P1767, DOI 10.1074/jbc.M110.157768; Rosado MM, 2013, IMMUNOLOGY, V139, P428, DOI 10.1111/imm.12099	9	13	15	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					577	580		10.1016/j.jaci.2013.09.031	http://dx.doi.org/10.1016/j.jaci.2013.09.031			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24238647	Bronze, Green Accepted, Green Submitted			2022-12-18	WOS:000332397100036
J	Lukkarinen, H; Soderlund-Venermo, M; Vuorinen, T; Allander, T; Hedman, K; Simell, O; Ruuskanen, O; Jartti, T				Lukkarinen, Heikki; Soderlund-Venermo, Maria; Vuorinen, Tytti; Allander, Tobias; Hedman, Klaus; Simell, Olli; Ruuskanen, Olli; Jartti, Tuomas			Human bocavirus 1 may suppress rhinovirus-associated immune response in wheezing children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; BRONCHIOLITIS; RISK		[Lukkarinen, Heikki; Simell, Olli; Ruuskanen, Olli; Jartti, Tuomas] Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland; [Soderlund-Venermo, Maria; Hedman, Klaus] Univ Helsinki, Dept Virol, Haartman Inst, Helsinki, Finland; [Vuorinen, Tytti] Univ Turku, Dept Virol, Turku, Finland; [Allander, Tobias] Karolinska Univ Hosp, Dept Clin Microbiol, Stockholm, Sweden; [Hedman, Klaus] Univ Helsinki, Cent Hosp, Dept Virol & Immunol, Lab Div, Helsinki, Finland	University of Turku; University of Helsinki; University of Turku; Karolinska Institutet; Karolinska University Hospital; University of Helsinki; Helsinki University Central Hospital	Lukkarinen, H (corresponding author), Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland.	hepelu@utu.fi	Söderlund-Venermo, Maria/AAX-2112-2020; Hedman, Klaus/D-5379-2009	Hedman, Klaus/0000-0003-1779-7960				Baraldo S, 2012, J ALLERGY CLIN IMMUN, V130, P1307, DOI 10.1016/j.jaci.2012.08.005; Chung JY, 2008, J CLIN VIROL, V43, P223, DOI 10.1016/j.jcv.2008.06.008; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, P532, DOI 10.1016/j.jaci.2011.06.037; James KM, 2013, J ALLERGY CLIN IMMUN, V132, P227, DOI 10.1016/j.jaci.2013.01.009; Jartti T, 2012, REV MED VIROL, V22, P46, DOI 10.1002/rmv.720; Jartti T, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-85; Lukkarinen M, 2013, PEDIAT ALLERG IMM-UK, V24, P237, DOI 10.1111/pai.12046; Soderlund-Venermo M, 2009, EMERG INFECT DIS, V15, P1423, DOI 10.3201/eid1509.090204; Zhang ZF, 2012, J IMMUNOL, V189, P1144, DOI 10.4049/jimmunol.1200096	9	13	14	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					256	258		10.1016/j.jaci.2013.10.014	http://dx.doi.org/10.1016/j.jaci.2013.10.014			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24369801	Green Published, Bronze			2022-12-18	WOS:000329105700034
J	Bekkers, MB; Aalberse, RC; Gehring, U; Kerkhof, M; Koppelman, GH; de Jongste, JC; Smit, HA; Brunekreef, B; Wijga, AH				Bekkers, Marga B.; Aalberse, Rob C.; Gehring, Ulrike; Kerkhof, Marjan; Koppelman, Gerard H.; de Jongste, Johan C.; Smit, Henriette A.; Brunekreef, Bert; Wijga, Alet H.			Hen's egg, not cow's milk, sensitization in infancy is associated with asthma: 10-year follow-up of the PIAMA birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AGE; RISK		[Bekkers, Marga B.; Wijga, Alet H.] Natl Inst Publ Hlth & Environm RIVM, Ctr Nutr Prevent & Hlth Serv, Bilthoven, Netherlands; [Aalberse, Rob C.] Sanquin Res, Dept Immunopathol, Amsterdam, Netherlands; [Gehring, Ulrike; Brunekreef, Bert] Univ Utrecht, IRAS, Utrecht, Netherlands; [Kerkhof, Marjan] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol & Bioinformat, Groningen, Netherlands; [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol & Pediat Allergol, GRIAC Res Inst, Groningen, Netherlands; [de Jongste, Johan C.] Erasmus Univ, Sophia Childrens Hosp, Med Ctr, Dept Pediat, Rotterdam, Netherlands; [Smit, Henriette A.] Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	Netherlands National Institute for Public Health & the Environment; Utrecht University; University of Groningen; University of Groningen; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Utrecht University; Utrecht University Medical Center	Bekkers, MB (corresponding author), Natl Inst Publ Hlth & Environm RIVM, Ctr Nutr Prevent & Hlth Serv, Bilthoven, Netherlands.	m.bekkers@hotmail.com	Koppelman, Gerard/AAG-9187-2020	Gehring, Ulrike/0000-0003-3612-5780; brunekreef, bert/0000-0001-9908-0060; Koppelman, Gerard/0000-0001-8567-3252				BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Gehring U, 2012, ALLERGY, V67, P248, DOI 10.1111/j.1398-9995.2011.02739.x; Kotaniemi-Syrjanen A, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e255; Lazic N, 2013, ALLERGY, V68, P764, DOI 10.1111/all.12134; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Savenije OEM, 2012, J ALLERGY CLIN IMMUN, V130, P325, DOI 10.1016/j.jaci.2012.05.007; Tariq SM, 2000, PEDIATR ALLERGY IMMU, V11, P162, DOI 10.1034/j.1399-3038.2000.00077.x; Wijga AH, 2013, INT J EPIDEMIOL	9	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1427	1428		10.1016/j.jaci.2013.07.053	http://dx.doi.org/10.1016/j.jaci.2013.07.053			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	24131824				2022-12-18	WOS:000327538200022
J	Giancane, G; Ferrari, S; Carsetti, R; Papoff, P; Iacobini, M; Duse, M				Giancane, Gabriella; Ferrari, Simona; Carsetti, Rita; Papoff, Paola; Iacobini, Metello; Duse, Marzia			Anhidrotic ectodermal dysplasia: A new mutation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNODEFICIENCY; NEMO		[Giancane, Gabriella; Papoff, Paola; Iacobini, Metello; Duse, Marzia] Univ Roma La Sapienza, Dept Pediat, I-00185 Rome, Italy; [Ferrari, Simona] S Orsola Malpighi Univ Hosp, Med Genet Lab, Bologna, Italy; [Carsetti, Rita] Bambino Gesu Pediat Hosp, Cell Dev Lab B, Rome, Italy	Sapienza University Rome; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Bambino Gesu	Giancane, G (corresponding author), Univ Roma La Sapienza, Dept Pediat, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	marzia.duse@gmail.com	Carsetti, Rita/K-7616-2016; Giancane, Gabriella/AAB-3380-2019	Carsetti, Rita/0000-0002-2632-1078; Giancane, Gabriella/0000-0003-2558-3559				Casanova JL, 2011, ANNU REV IMMUNOL, V29, P447, DOI 10.1146/annurev-immunol-030409-101335; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Dupuis-Girod S, 2006, PEDIATRICS, V118, pE205, DOI 10.1542/peds.2005-2661; Granados EL, 2008, HUM MUTAT, V29, P861, DOI 10.1002/humu.20740; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Kawai T, 2012, ALLERGOL INT, V61, P207, DOI 10.2332/allergolint.12-RAI-0446; McDonald DR, 2007, J ALLERGY CLIN IMMUN, V120, P900, DOI 10.1016/j.jaci.2007.08.035; Orange JS, 2003, J CLIN INVEST, V112, P983, DOI 10.1172/JCI200319960; Schimke L, 2013, J CLIN IMMUNOL	10	13	14	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1451	1453		10.1016/j.jaci.2013.05.034	http://dx.doi.org/10.1016/j.jaci.2013.05.034			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	23870671				2022-12-18	WOS:000327538200032
J	Sprecher, E; Leung, DYM				Sprecher, Eli; Leung, Donald Y. M.			Atopic dermatitis: Scratching through the complexity of barrier dysfunction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Atopic dermatitis; eczema; skin	STRATUM-CORNEUM; FILAGGRIN; MUTATION; SECRETION; SKIN		[Sprecher, Eli] Tel Aviv Sourasky Med Ctr, Dept Dermatol, Tel Aviv, Israel; [Sprecher, Eli] Tel Aviv Univ, Sackler Fac Med, Dept Human Mol Genet & Biochem, Ramat Aviv, Israel; [Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA; [Leung, Donald Y. M.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus	Leung, DYM (corresponding author), Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA.	Leungd@njhealth.org						Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fartasch M, 1999, ARCH DERMATOL, V135, P823, DOI 10.1001/archderm.135.7.823; Hershkovitz D, 2008, ARCH DERMATOL, V144, P334, DOI 10.1001/archderm.144.3.334; Ishida-Yamamoto A, 2011, J DERMATOL, V38, P645, DOI 10.1111/j.1346-8138.2011.01227.x; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kezic S, 2012, J ALLERGY CLIN IMMUN, V129, P1031, DOI 10.1016/j.jaci.2011.12.989; Lee KH, 2011, EXP DERMATOL, V20, P149, DOI 10.1111/j.1600-0625.2010.01203.x; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Moniaga CS, 2010, AM J PATHOL, V176, P2385, DOI 10.2353/ajpath.2010.090957; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Samuelov L, 2013, NAT GENET; Sasaki T, 2013, J ALLERGY CLIN IMMUN, V132, P1111, DOI 10.1016/j.jaci.2013.08.027; Saunders SP, 2013, J ALLERGY CLIN IMMUN, V132, P1121, DOI 10.1016/j.jaci.2013.08.046; Sprecher E, 2005, AM J HUM GENET, V77, P242, DOI 10.1086/432556	14	13	14	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1130	1131		10.1016/j.jaci.2013.09.026	http://dx.doi.org/10.1016/j.jaci.2013.09.026			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	24176684	Bronze			2022-12-18	WOS:000326235600012
J	Jaramillo, R; Cohn, RD; Crockett, PW; Gowdy, KM; Zeldin, DC; Fessler, MB				Jaramillo, Renee; Cohn, Richard D.; Crockett, Patrick W.; Gowdy, Kymberly M.; Zeldin, Darryl C.; Fessler, Michael B.			Relation between objective measures of atopy and myocardial infarction in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Myocardial infarction; immune system; risk factors; atopy; immunoglobulin E	E-KNOCKOUT MICE; T-CELLS; RHEUMATOID-ARTHRITIS; ALLERGIC RHINITIS; IGE; ATHEROSCLEROSIS; DISEASE; GENDER; ASTHMA; SERUM	Background: Although rodent studies indicate that atherosclerosis is a T(H)1-mediated disease and that atopic T(H)2 immunity is atheroprotective, findings in humans are conflicting. Total IgE (tIgE) is associated with atherosclerotic disease but has limited specificity for atopy. Objective: Our aim was to determine the relation between atopy, as indicated by a broad panel of serum allergen-specific IgE (sIgE), and past myocardial infarction (MI) in a sample representative of the US population. Methods: Data were analyzed from 4002 participants aged >= 20 years from the 2005-2006 National Health and Nutrition Examination Survey. Results: Subjects reporting a history of MI had lower summed sIgE (5.51 vs 7.71 kU/L; P<.001) and were less likely to have >= 1 positive sIgE test (29.9% vs 44.6%; P=.02) or current hay fever (3.3% vs 7.6%; P=.002). After adjustment for age, sex, race/ethnicity, diabetes mellitus, hypertension, family history of MI, smoking, total/high-density lipoprotein cholesterol, body mass index, and C-reactive protein, the odds ratio (OR) for MI was 0.91 (95% CI, 0.85-0.97) per positive sIgE; 0.70 (95% CI, 0.57-0.85) per 2-fold increase in sum[sIgE]; and 0.82 (95% CI, 0.69-0.98) per 10% increase in the ratio of sum[sIgE] to tIgE. Analysis with 7 data-driven, prespecified allergen clusters found that house dust mite is the only allergen cluster for which sIgE is associated with reduced odds for MI (fully adjusted OR, 0.36; 95% CI, 0.20-0.64). Conclusion: Serum sIgE is inversely related to MI in the US population in a manner independent of multiple coronary risk factors. (J Allergy Clin Immunol 2013;131:405-11.)	[Jaramillo, Renee; Cohn, Richard D.; Crockett, Patrick W.] SRA Int, Durham, NC USA; [Gowdy, Kymberly M.; Zeldin, Darryl C.; Fessler, Michael B.] NIEHS, Lab Resp Biol, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA	SRA International; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Fessler, MB (corresponding author), NIEHS, 111 TW Alexander Dr,POB 12233,Maildrop D2-01, Res Triangle Pk, NC 27709 USA.	fesslerm@niehs.nih.gov	Zeldin, Darryl C/Y-7091-2018; Fessler, Michael B/C-6323-2019	Zeldin, Darryl C/0000-0002-2087-7307; Fessler, Michael B/0000-0002-8262-8613	National Institutes of Health, National Institute of Environmental Health Sciences [Z01 ES102005, Z01 ES025041]; NIEHS; National Institute of Environmental Health Sciences, National Institutes of Health; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES102005, ZIAES025034, ZIAES025041] Funding Source: NIH RePORTER	National Institutes of Health, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute of Environmental Health Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences grants Z01 ES102005 and Z01 ES025041.; R. Jaramillo has received fees for participation in review activities and payment for writing/reviewing the manuscript from the NIEHS. R. D. Cohn has received research support and has a contract with the SRA for statistical support from the National Institute of Environmental Health Sciences, National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	Barrenas F, 2008, CYTOKINE, V42, P325, DOI 10.1016/j.cyto.2008.03.004; Benagiano M, 2003, P NATL ACAD SCI USA, V100, P6658, DOI 10.1073/pnas.1135726100; Bergmann MM, 1998, AM J EPIDEMIOL, V147, P969; Binder CJ, 2004, J CLIN INVEST, V114, P427, DOI 10.1172/jci200420479; Calatroni A, 2009, J ALLERGY CLIN IMMUN, V123, pS193, DOI 10.1016/j.jaci.2008.12.732; Ciprandi G, 2009, INT J IMMUNOPATH PH, V22, P809, DOI 10.1177/039463200902200327; CRIQUI MH, 1987, AM J MED, V82, P964, DOI 10.1016/0002-9343(87)90159-8; Di Lorenzo G, 2009, J ALLERGY CLIN IMMUN, V123, P1103, DOI 10.1016/j.jaci.2009.02.012; Eckman JA, 2010, J ALLERGY CLIN IMMUN, V125, P889, DOI 10.1016/j.jaci.2009.09.012; Eid RE, 2009, CIRCULATION, V119, P1424, DOI 10.1161/CIRCULATIONAHA.108.827618; Falcone M, 1997, J EXP MED, V185, P901, DOI 10.1084/jem.185.5.901; Fredrikson GN, 2005, AUTOIMMUNITY, V38, P171, DOI 10.1080/08916930500050525; Gergen PJ, 2009, J ALLERGY CLIN IMMUN, V124, P447, DOI 10.1016/j.jaci.2009.06.011; Giron-Gonzalez JA, 2000, EUR J ENDOCRINOL, V143, P31, DOI 10.1530/eje.0.1430031; Gloria-Bottini F, 2007, INT ARCH ALLERGY IMM, V143, P170, DOI 10.1159/000099308; Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001; Hartung AD, 2003, CLIN EXP RHEUMATOL, V21, P481; Honda A, 2001, BIOSCI BIOTECH BIOCH, V65, P1063, DOI 10.1271/bbb.65.1063; Huber SA, 2001, CIRCULATION, V103, P2610; Hunninghake GM, 2008, AM J RESP CRIT CARE, V177, P830, DOI 10.1164/rccm.200711-1697OC; Hunninghake GM, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-17; Ichikawa S, 2005, J BIOCHEM, V137, P255, DOI 10.1093/jb/mvi039; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; Jackola DR, 2004, HUM IMMUNOL, V65, P20, DOI 10.1016/j.humimm.2003.10.012; JOSEPH M, 1986, EUR J IMMUNOL, V16, P306, DOI 10.1002/eji.1830160318; Khallou-Laschet J, 2006, ATHEROSCLEROSIS, V184, P330, DOI 10.1016/j.atherosclerosis.2005.04.021; Kim J, 2010, AM J CARDIOL, V106, P984, DOI 10.1016/j.amjcard.2010.05.029; Knoflach M, 2005, ARCH INTERN MED, V165, P2521, DOI 10.1001/archinte.165.21.2521; KORKMAZ ME, 1991, INT J CARDIOL, V31, P199, DOI 10.1016/0167-5273(91)90216-C; Kounis NG, 2006, INT J CARDIOL, V110, P7, DOI 10.1016/j.ijcard.2005.08.007; Langer RD, 1996, J CLIN EPIDEMIOL, V49, P203, DOI 10.1016/0895-4356(95)00548-X; Laurat E, 2001, CIRCULATION, V104, P197, DOI 10.1161/01.CIR.104.2.197; Loza MJ, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-103; McQueen MJ, 2008, LANCET, V372, P224, DOI 10.1016/S0140-6736(08)61076-4; Melgert BN, 2005, CLIN EXP ALLERGY, V35, P1496, DOI 10.1111/j.1365-2222.2005.02362.x; MERZ CNB, 2006, J AM COLL CARDIOL, V47, pS21, DOI [DOI 10.1016/J.JACC.2004.12.084, 10.1016/j.jacc.2004.12.084]; Methe H, 2005, J AM COLL CARDIOL, V45, P1939, DOI 10.1016/j.jacc.2005.03.040; Miller AM, 2008, J EXP MED, V205, P339, DOI 10.1084/jem.20071868; Mueller GA, 2010, J ALLERGY CLIN IMMUN, V125, P909, DOI 10.1016/j.jaci.2009.12.016; Okura Y, 2004, J CLIN EPIDEMIOL, V57, P1096, DOI 10.1016/j.jclinepi.2004.04.005; Okuyama K, 2008, CLIN EXP ALLERGY, V38, P1212, DOI 10.1111/j.1365-2222.2008.03015.x; Oro AS, 1996, J ALLERGY CLIN IMMUN, V97, P1402, DOI 10.1016/S0091-6749(96)70210-5; Salo PM, 2011, J ALLERGY CLIN IMMUN, V127, P1226, DOI 10.1016/j.jaci.2010.12.1106; Sampi M, 2008, J AM COLL CARDIOL, V52, P1370, DOI 10.1016/j.jacc.2008.06.047; Schlendorf KH, 2009, PREV MED, V48, P115, DOI 10.1016/j.ypmed.2008.12.002; Schulte S, 2008, AM J PATHOL, V172, P1500, DOI 10.2353/ajpath.2008.070776; Shaw LJ, 2009, J AM COLL CARDIOL, V54, P1561, DOI 10.1016/j.jacc.2009.04.098; Sinkiewicz Wladyslaw, 2008, Cardiol J, V15, P122; Verhoef CM, 1998, ANN RHEUM DIS, V57, P275, DOI 10.1136/ard.57.5.275; Wambre E, 2011, CLIN EXP ALLERGY, V41, P192, DOI 10.1111/j.1365-2222.2010.03641.x; Yang KD, 2004, CLIN EXP ALLERGY, V34, P32, DOI 10.1111/j.1365-2222.2004.01776.x; Zenovich AG, 2008, TRANSPL P, V40, P641, DOI 10.1016/j.transproceed.2008.01.040	52	13	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					405	+		10.1016/j.jaci.2012.06.033	http://dx.doi.org/10.1016/j.jaci.2012.06.033			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	22921873	Green Accepted			2022-12-18	WOS:000314661500018
J	Rachid, O; Rawas-Qalaji, MM; Simons, FER; Simons, KJ				Rachid, Ousama; Rawas-Qalaji, Mutasem M.; Simons, F. Estelle R.; Simons, Keith J.			Epinephrine (adrenaline) absorption from new-generation, taste-masked sublingual tablets: A preclinical study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANAPHYLAXIS; INJECTION; ADULTS		[Rachid, Ousama; Simons, Keith J.] Univ Manitoba, Fac Pharm, Winnipeg, MB R3T 2N2, Canada; [Simons, F. Estelle R.; Simons, Keith J.] Univ Manitoba, Fac Med, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Simons, F. Estelle R.] Univ Manitoba, Fac Med, Dept Immunol, Winnipeg, MB R3T 2N2, Canada; [Rawas-Qalaji, Mutasem M.] Nova SE Univ, Coll Pharm, Ft Lauderdale, FL 33314 USA	University of Manitoba; University of Manitoba; University of Manitoba; Nova Southeastern University	Rachid, O (corresponding author), Univ Manitoba, Fac Pharm, Winnipeg, MB R3T 2N2, Canada.	umrachid@cc.umanitoba.ca	Rachid, Ousama/AAO-9768-2020	RACHID, OUSAMA/0000-0002-2364-3848				Edwards ES, 2012, J ALLERGY CLIN IMMUN, V129, pAB179, DOI 10.1016/j.jaci.2011.12.234; Estelle F, 2001, J ALLERGY CLIN IMMUN, V108, P871, DOI 10.1067/mai.2001.119409; Rachid O, 2012, EUR J PHARM BIOPHARM; Rachid O, 2010, AAPS PHARMSCITECH, V11, P550, DOI 10.1208/s12249-010-9402-3; Rawas-Qalaji MM, 2006, J ALLERGY CLIN IMMUN, V117, P398, DOI 10.1016/j.jaci.2005.12.1310; Simons FER, 2009, J ALLERGY CLIN IMMUN, V124, P301, DOI 10.1016/j.jaci.2009.03.050; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3; Simons KJ, 2010, CURR OPIN ALLERGY CL, V10, P354, DOI 10.1097/ACI.0b013e32833bc670; Vadas P, 2012, J ALLERGY CLIN IMMUN, V129, P1329, DOI 10.1016/j.jaci.2012.02.027	9	13	19	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					236	238		10.1016/j.jaci.2012.10.016	http://dx.doi.org/10.1016/j.jaci.2012.10.016			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23177259				2022-12-18	WOS:000312961200038
J	Gerald, LB; Gerald, JK; Zhang, B; McClure, LA; Bailey, WC; Harrington, KF				Gerald, Lynn B.; Gerald, Joe K.; Zhang, Bin; McClure, Leslie A.; Bailey, William C.; Harrington, Kathy F.			Can a school-based hand hygiene program reduce asthma exacerbations among elementary school children?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; schools; children; hand hygiene; hand sanitizer	INFLUENZA-A H1N1; ILLNESS-RELATED ABSENTEEISM; PANDEMIC INFLUENZA; BENZALKONIUM CHLORIDE; CONTROLLED-TRIAL; VIRUS-INFECTION; SANITIZER; TRANSMISSION; INTERVENTIONS; OUTBREAK	Background: Viral upper respiratory tract infections have been implicated as a major cause of asthma exacerbations among school-aged children. Regular hand washing is the most effective method to prevent the spread of viral respiratory tract infections, but effective hand-washing practices are difficult to establish in schools. Objectives: This randomized controlled trial evaluated whether a standardized regimen of hand washing plus alcohol-based hand sanitizer could reduce asthma exacerbations more than schools' usual hand hygiene practices. Methods: This was a 2-year, community-based, randomized controlled crossover trial. Schools were randomized to usual care and then intervention (sequence 1) or intervention and then usual care (sequence 2). Intervention schools were provided with alcohol-based hand sanitizer, hand soap, and hand hygiene education. The primary outcome was the proportion of students experiencing an asthma exacerbation each month. Generalized estimating equations were used to model the difference in the marginal rate of exacerbations between sequences while controlling for individual demographic factors and the correlation within each student and between students within each school. Results: Five hundred twenty-seven students with asthma were enrolled among 31 schools. The hand hygiene intervention did not reduce the number of asthma exacerbations compared with the schools' usual hand hygiene practices (P = .132). There was a strong temporal trend because both sequences experienced fewer exacerbations during year 2 compared with year 1 (P < .001). Conclusions: Although the intervention was not found to be effective, the results were confounded by the H1N1 influenza pandemic that resulted in substantially increased hand hygiene behaviors and resources in usual-care schools. Therefore these results should be viewed cautiously. (J Allergy Clin Immunol 2012;130:1317-24.)	[Gerald, Lynn B.] Univ Arizona, Div Hlth Promot Sci, Mel & Enid Zuckerman Coll Publ Hlth, Arizona Resp Ctr, Tucson, AZ 85724 USA; [Gerald, Joe K.] Univ Arizona, Div Community Environm & Policy, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ 85724 USA; [Zhang, Bin] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [McClure, Leslie A.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA; [Bailey, William C.; Harrington, Kathy F.] Univ Alabama Birmingham, Sch Med, Lung Hlth Ctr, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA	University of Arizona; University of Arizona; Cincinnati Children's Hospital Medical Center; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Gerald, LB (corresponding author), Univ Arizona, Div Hlth Promot Sci, Mel & Enid Zuckerman Coll Publ Hlth, Arizona Resp Ctr, 1295 N Martin Ave,POB 245163, Tucson, AZ 85724 USA.	lgerald@email.arizona.edu	Zhang, Bin/P-7459-2015; McClure, Leslie/P-2929-2015	Harrington, Kathleen/0000-0002-4154-0631	National Heart, Lung, and Blood Institute [1 R01 HL086972]; BlueCross; BlueShield of Alabama; National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI); Health Resources and Services Administration; UpToDate; NIH/NHLBI; NHLBI; National Institute on Drug Abuse; Merck; Boehringer Ingelheim; GlaxoSmithKline; AstraZeneca; Health Resources and Services Association; National Institute of Nursing Research; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086972] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BlueCross; BlueShield of Alabama; National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Health Resources and Services Administration(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); UpToDate; NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Merck(Merck & Company); Boehringer Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); Health Resources and Services Association; National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by a grant from the National Heart, Lung, and Blood Institute (1 R01 HL086972). Quick-relief medication for in-school use was donated by Schering-Plough, which is now owned by Merck and Co, and data system support was provided by BlueCross and BlueShield of Alabama (registered at clinicaltrials.gov NCT00528814).; L. B. Gerald has received grants from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) and the Health Resources and Services Administration; and has received royalties from UpToDate. J. K. Gerald and L. A. McClure have received grants from the NIH/NHLBI. W. C. Bailey has received grants from the NHLBI, the National Institute on Drug Abuse, and Merck; has consultant arrangements with Boehringer Ingelheim, GlaxoSmithKline, and AstraZeneca; has provided expert testimony for Pfizer; has received payment for lectures from Boehringer Ingelheim, GlaxoSmithKline, and AstraZeneca; and has received royalties from UpToDate. K. F. Harrington has received grants from the NHLBI, the Health Resources and Services Association, the National Institute on Drug Abuse, and the National Institute of Nursing Research. B. Zhang declares no relevant conflicts of interest.	Aiello AE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029744; Akinbami Lara, 2006, Adv Data, P1; Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Aledort JE, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-208; Bateman ED, 2002, EUR RESPIR J, V20, P588, DOI 10.1183/09031936.02.00294702; Blaisdell CJ, 2002, J ASTHMA, V39, P567, DOI 10.1081/JAS-120014921; Boyce JM, 2002, INFECT CONT HOSP EP, V23, pS3, DOI 10.1086/503164; Centers for Disease Control and Prevention, HLTH SCH HLTH PEOPL; Centers for Disease Control and Prevention, CLEAN HANDS SAV LIV; Cowling BJ, 2009, ANN INTERN MED, V151, P437, DOI 10.7326/0003-4819-151-7-200910060-00142; Crowe A., SWINE FLU LEADING PU; Dales RE, 1996, EUR RESPIR J, V9, P72, DOI 10.1183/09031936.96.09010072; Dyer DL, 2000, FAM MED, V32, P633; Early E, 1998, AM J INFECT CONTROL, V26, P263, DOI 10.1016/S0196-6553(98)80011-4; Ferk F, 2007, MUTAGENESIS, V22, P363, DOI 10.1093/mutage/gem027; Freymuth F, 1999, J CLIN VIROL, V13, P131, DOI 10.1016/S1386-6532(99)00030-X; Gerald LB, 2011, CLIN TRIALS, V8, P311, DOI 10.1177/1740774511403513; Gerald LB, 2009, PEDIATRICS, V123, P466, DOI 10.1542/peds.2008-0499; Guinan M, 2002, AM J INFECT CONTROL, V30, P217, DOI 10.1067/mic.2002.120366; Hammond B, 2000, AM J INFECT CONTROL, V28, P340, DOI 10.1067/mic.2000.107276; Hann S, 2007, BRIT J DERMATOL, V157, P795, DOI 10.1111/j.1365-2133.2007.08134.x; Houari A, 2007, LETT APPL MICROBIOL, V45, P652, DOI 10.1111/j.1472-765X.2007.02249.x; Iuliano AD, 2011, CLIN INFECT DIS, V52, pS161, DOI 10.1093/cid/ciq032; Jefferson T, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006207.pub4; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Jones JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008032; LARSON E, 1995, J HOSP INFECT, V30, P88, DOI 10.1016/0195-6701(95)90010-1; Lau CH, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-52; Lee GM, 2005, PEDIATRICS, V115, P852, DOI 10.1542/peds.2004-0856; Marchbanks TL, 2011, CLIN INFECT DIS, V52, pS154, DOI 10.1093/cid/ciq058; Maskerine C, 2006, J CONTIN EDUC HEALTH, V26, P244, DOI 10.1002/chp.77; McClure LA, 2008, CLIN TRIALS, V5, P31, DOI 10.1177/1740774507086647; Meadows E, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-50; Mitchell T, 2011, CLIN INFECT DIS, V52, pS138, DOI 10.1093/cid/ciq056; Monto AS, 2002, CLIN THER, V24, P1987, DOI 10.1016/S0149-2918(02)80093-5; Morton Jennifer L, 2004, J Sch Nurs, V20, P161; Pittet D, 2002, INFECT CONT HOSP EP, V23, P118, DOI 10.1086/502019; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Ramos MM, 2010, J SCH NURS, V26, P393, DOI 10.1177/1059840510370328; Ritger K. A., 2009, Morbidity and Mortality Weekly Report, V58, P913; Robinson Judith, 2002, J Sch Nurs, VSuppl, P12; Rooney B., HAND SANITIZER SHORT; Rubin GJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2651; Sandora TJ, 2005, PEDIATRICS, V116, P587, DOI 10.1542/peds.2005-0199; Schmier JK, 2007, ANN ALLERG ASTHMA IM, V98, P245, DOI 10.1016/S1081-1206(10)60713-2; Silverman RA, 2005, ARCH PEDIAT ADOL MED, V159, P818, DOI 10.1001/archpedi.159.9.818; Stebbins S, 2011, PEDIATR INFECT DIS J, V30, P921, DOI 10.1097/INF.0b013e3182218656; Suess Thorsten, 2012, BMC Infect Dis, V12, P26, DOI 10.1186/1471-2334-12-26; Thumerelle C, 2003, PEDIATR PULM, V35, P75, DOI 10.1002/ppul.10191; Varani J, 2007, TOXICOL PATHOL, V35, P693, DOI 10.1080/01926230701481907; Vessey Judith A, 2007, Pediatr Nurs, V33, P368; Wang Li Yan, 2005, Prev Chronic Dis, V2, pA11; White C, 2003, AM J INFECT CONTROL, V31, P364, DOI 10.1016/S0196-6553(03)00041-5; White C G, 2001, J Sch Nurs, V17, P258; Zengerie P, OBAMA DECLARES SWINE	56	13	14	0	33	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1317	1324		10.1016/j.jaci.2012.08.031	http://dx.doi.org/10.1016/j.jaci.2012.08.031			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	23069487	Green Accepted			2022-12-18	WOS:000311641100011
J	Rudders, SA; Geyer, BC; Banerji, A; Phipatanakul, W; Clark, S; Camargo, CA				Rudders, Susan A.; Geyer, Brian C.; Banerji, Aleena; Phipatanakul, Wanda; Clark, Sunday; Camargo, Carlos A., Jr.			Obesity is not a risk factor for repeat epinephrine use in the treatment of anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOOD		[Rudders, Susan A.] Rhode Isl Hosp, Div Asthma & Allergy, Dept Pediat, Providence, RI 02903 USA; [Geyer, Brian C.] Massachusetts Gen Hosp, Harvard Affiliated Emergency Med Residency, Boston, MA 02114 USA; [Geyer, Brian C.; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Banerji, Aleena; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Phipatanakul, Wanda] Childrens Hosp Boston, Div Allergy & Immunol, Dept Pediat, Boston, MA USA; [Clark, Sunday] Weill Cornell Med Coll, Dept Emergency Med, New York, NY USA	Lifespan Health Rhode Island; Rhode Island Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Cornell University	Rudders, SA (corresponding author), Rhode Isl Hosp, Div Asthma & Allergy, Dept Pediat, Providence, RI 02903 USA.	srudders@lifespan.org	Clark, Sunday/AAA-5458-2021; Camargo, Carlos A./C-2145-2008; Banerji, Aleena/ABG-1245-2021	Camargo, Carlos A./0000-0002-5071-7654; 				[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Clark S, 2006, ANN EPIDEMIOL, V16, P696, DOI 10.1016/j.annepidem.2005.12.003; Estelle F, 2001, J ALLERGY CLIN IMMUN, V108, P871, DOI 10.1067/mai.2001.119409; Jarvinen KM, 2008, J ALLERGY CLIN IMMUN, V122, P133, DOI 10.1016/j.jaci.2008.04.031; Manivannan V, 2009, ANN ALLERG ASTHMA IM, V103, P395, DOI 10.1016/S1081-1206(10)60358-4; Rudders SA, 2010, ANN ALLERG ASTHMA IM, V105, P85, DOI 10.1016/j.anai.2010.05.004; Rudders SA, 2010, PEDIATRICS, V125, pE711, DOI 10.1542/peds.2009-2832; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, P587, DOI 10.1016/j.jaci.2011.01.038; Song TT, 2005, ANN ALLERG ASTHMA IM, V94, P539, DOI 10.1016/S1081-1206(10)61130-1	9	13	14	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1216	1218		10.1016/j.jaci.2012.08.029	http://dx.doi.org/10.1016/j.jaci.2012.08.029			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	23021879	Bronze			2022-12-18	WOS:000310571400031
J	Gouvis-Echraghi, R; Saint-Pierre, P; Besharaty, AA; Bernard, A; Just, J				Gouvis-Echraghi, Rahele; Saint-Pierre, Philippe; Besharaty, Amir-Abbas; Bernard, Agnes; Just, Jocelyne			Exhaled nitric oxide measurement confirms 2 severe wheeze phenotypes in young children from the Trousseau Asthma Program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Gouvis-Echraghi, Rahele; Besharaty, Amir-Abbas; Bernard, Agnes; Just, Jocelyne] Univ Paris 06, Hop Enfants Armand Trousseau, APHP, Ctr Asthme & Allergies, Paris, France; [Saint-Pierre, Philippe] Univ Paris 06, Lab Stat Theor & Appl, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite	Gouvis-Echraghi, R (corresponding author), Univ Paris 06, Hop Enfants Armand Trousseau, APHP, Ctr Asthme & Allergies, Paris, France.	jocelyne.just@trs.aphp.fr						ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Gabriele C, 2006, PEDIATR RES, V60, P461, DOI 10.1203/01.pdr.0000238242.39881.64; Ghdifan S, 2010, PEDIAT ALLERG IMM-UK, V21, P1015, DOI 10.1111/j.1399-3038.2010.01076.x; Just J, 2012, J ALLERGY CLIN IMMUN, V130, pe8; Just J, 2012, J ALLERGY CLIN IMMUN, V130, P103, DOI 10.1016/j.jaci.2012.02.041; Latzin P, 2006, AM J RESP CRIT CARE, V174, P1292, DOI 10.1164/rccm.200606-782OC; Moeller A, 2008, J ALLERGY CLIN IMMUN, V121, P705, DOI 10.1016/j.jaci.2007.11.008; Sonnappa S, 2010, J ALLERGY CLIN IMMUN, V126, P519, DOI 10.1016/j.jaci.2010.04.018; Stern G, 2011, J ALLERGY CLIN IMMUN, V128, P293, DOI 10.1016/j.jaci.2011.03.010; Yao TC, 2011, CLIN EXP ALLERGY, V41, P556, DOI 10.1111/j.1365-2222.2010.03687.x	10	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					1005	1007		10.1016/j.jaci.2012.07.007	http://dx.doi.org/10.1016/j.jaci.2012.07.007			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22920491				2022-12-18	WOS:000309594800030
J	Ballow, M; Akdis, CA; Casale, TB; Wardlaw, AJ; Wenzel, SE; Ballas, Z; Lotvall, J				Ballow, Mark; Akdis, Cezmi A.; Casale, Thomas B.; Wardlaw, Andrew J.; Wenzel, Sally E.; Ballas, Zuhair; Lotvall, Jan			Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immune response modifiers; monoclonal antibodies; asthma; allergic diseases	SEVERE PERSISTENT ASTHMA; AIRWAY INFLAMMATION; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; INCREASED EXPRESSION; ACTIVATED RECEPTORS; ATOPIC-DERMATITIS; BIOLOGICAL AGENTS; T-CELLS		[Ballow, Mark] SUNY Buffalo, Sch Med, Div Allergy Immunol & Pediat Rheumatol, Buffalo, NY 14260 USA; [Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, CH-8006 Zurich, Switzerland; [Casale, Thomas B.] Creighton Univ, Sch Med, Omaha, NE USA; [Wardlaw, Andrew J.] Glenfield Gen Hosp, Dept Infect Immun & Inflammat, Inst Lung Hlth, Leicester LE3 9QP, Leics, England; [Wenzel, Sally E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA; [Ballas, Zuhair] Univ Iowa, Div Immunol, Iowa City VA Med Ctr, Iowa City, IA USA; [Ballas, Zuhair] Univ Iowa, Carver Coll Med, Iowa City, IA USA; [Lotvall, Jan] Univ Gothenburg, Krefting Res Ctr, Gothenburg, Sweden	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Swiss Institute of Allergy & Asthma Research; University of Zurich; Creighton University; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; University of Gothenburg	Ballow, M (corresponding author), Women & Childrens Hosp Buffalo, Div Allergy Immunol & Pediat Rheumatol, 239 Bryant St, Buffalo, NY 14222 USA.	markbal.aird@gmail.com	Casale, Thomas B/K-4334-2013; Akdis, Cezmi/AAV-4844-2020	Casale, Thomas B/0000-0002-3149-7377; Akdis, Cezmi/0000-0001-8020-019X; Wardlaw, Andrew/0000-0001-6583-0791; Lotvall, Jan/0000-0001-9195-9249; Knaack, Aaron/0000-0001-7712-1415; Wenzel, Sally/0000-0002-4242-0164; Ballas, Zuhair/0000-0001-5569-1230	Grifols; Novartis; European Commission [260895, 261357]; Swiss National Science Foundation; Global Allergy and Asthma European Network; Christine Kuhne Center for Allergy Research and Education; MedImmune; Stallergenes; Roche; Genentech; Merck; AstraZeneca; GlaxoSmithKline; Pfizer; Cephalon-TEVA; Amgen; Sanofi Aventis; Array; Veterans Affairs Merit Review; National Institutes of Health; European Academy of Allergy and Clinical Immunology	Grifols; Novartis(Novartis); European Commission(European CommissionEuropean Commission Joint Research Centre); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Global Allergy and Asthma European Network; Christine Kuhne Center for Allergy Research and Education; MedImmune(AstraZenecaMedimmune); Stallergenes; Roche(Roche Holding); Genentech(Roche HoldingGenentech); Merck(Merck & Company); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Pfizer(Pfizer); Cephalon-TEVA(Teva Pharmaceutical Industries); Amgen(Amgen); Sanofi Aventis(Sanofi-Aventis); Array; Veterans Affairs Merit Review(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Academy of Allergy and Clinical Immunology	M. Ballow receives research support from Grifols; serves on advisory boards for Baxter, CSL Behring, and Grifols; serves on data safety monitoring boards for Green Cross; and is a paid lecturer for Baxter and CSL Behring. C. A. Akdis receives research support from Novartis, PREDICTA: European Commission's Seventh Framework programme No. 260895, the Swiss National Science Foundation, MeDALL: European Commission's Seventh Framework Programme No. 261357, the Global Allergy and Asthma European Network, and the Christine Kuhne Center for Allergy Research and Education; has provided legal consultation for Actellion, Aventis, Stallergenes, and Allergopharma; is President of the European Academy of Allergy and Clinical Immunology; is a fellow and research group member of the American Academy of Allergy, Asthma & Immunology; is an ex-committee member of the Global Allergy and Asthma European Network; and is director of the Christine Kuhne Center for Allergy Research and Education. T. B. Casale receives research support from MedImmune, Novartis, Stallergenes, Roche, Genentech, Merck, and AstraZeneca; has consultant arrangements with Novartis, Merck, MedImmune, Stallergenes, and Genentech; and serves as Executive Vice President of the American Academy of Allergy, Asthma & Immunology. A. J. Wardlaw has received grants from GlaxoSmithKline and Pfizer and has received fees for participating in a data monitoring board from Cephalon-TEVA. S. E. Wenzel receives research support from Amgen, GlaxoSmithKline, MedImmune, Sanofi Aventis, Array, and Genentech. Z. Ballas has received grant support from the Veterans Affairs Merit Review and the National Institutes of Health and has received royalties from UpToDate. J. Lotvall has received travel support from the European Academy of Allergy and Clinical Immunology; has consultant arrangements with GlaxoSmithKline, Novartis, AstraZeneca, and Merck; has received grant support from GlaxoSmithKline, Novartis, AstraZeneca, and Merck; is a paid lecturer for GlaxoSmithKline, Novartis, AstraZeneca, and Merck; has a patent on exosomes; and has received royalties from Wiley.	ABRAMOWICZ D, 1992, NEW ENGL J MED, V327, P736; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888; Barnes N, 2012, CLIN EXP ALLERGY, V42, P38, DOI 10.1111/j.1365-2222.2011.03813.x; Beck A, 2010, NAT REV IMMUNOL, V10, P345, DOI 10.1038/nri2747; Beeh KM, 2006, PULM PHARMACOL THER, V19, P233, DOI 10.1016/j.pupt.2005.07.004; Belvisi MG, 2008, CHEST, V134, P152, DOI 10.1378/chest.08-0019; Berger W, 2003, ANN ALLERG ASTHMA IM, V91, P182, DOI 10.1016/S1081-1206(10)62175-8; Bernstein DI, 2007, J ALLERGY CLIN IMMUN, V119, pS78, DOI 10.1016/j.jaci.2006.11.332; Berry M, 2007, THORAX, V62, P1043, DOI 10.1136/thx.2006.073429; Bieber J, 2004, RHEUM DIS CLIN N AM, V30, P257, DOI 10.1016/j.rdc.2004.01.003; Blaziene A, 2009, ANN ALLERG ASTHMA IM, V102, pA8; Bochner BS, 2004, J ALLERGY CLIN IMMUN, V113, P868, DOI 10.1016/j.jaci.2004.02.016; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Bousquet J, 2011, ALLERGY, V66, P671, DOI 10.1111/j.1398-9995.2010.02522.x; Brennan PJ, 2009, J ALLERGY CLIN IMMUN, V124, P1259, DOI 10.1016/j.jaci.2009.09.009; Brichtling CE, 2000, AM J RESP CRIT CARE, V162, P878, DOI 10.1164/ajrccm.162.3.9909064; Busse WW, 2008, AM J RESP CRIT CARE, V178, P1002, DOI 10.1164/rccm.200708-1200OC; Campi P, 2007, CURR OPIN ALLERGY CL, V7, P393, DOI 10.1097/ACI.0b013e3282ef96df; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; Chang HC, 2010, NAT IMMUNOL, V11, P527, DOI 10.1038/ni.1867; Chevalier E, 2005, J IMMUNOL, V175, P2056, DOI 10.4049/jimmunol.175.4.2056; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Commins SP, 2010, CURR ALLERGY ASTHM R, V10, P29, DOI 10.1007/s11882-009-0079-1; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Corrigan CJ, 2011, J ALLERGY CLIN IMMUN, V128, P116, DOI 10.1016/j.jaci.2011.03.043; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, P1373, DOI 10.1016/j.jaci.2007.09.032; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Cruz AA, 2007, CLIN EXP ALLERGY, V37, P197, DOI 10.1111/j.1365-2222.2007.02650.x; Davenpeck KL, 2000, J ALLERGY CLIN IMMUN, V105, P769, DOI 10.1067/mai.2000.105121; Denning GM, 2006, PEDIATR PULM, V41, P23, DOI 10.1002/ppul.20338; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Duechs MJ, 2011, PULM PHARMACOL THER, V24, P203, DOI 10.1016/j.pupt.2010.12.009; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Gallant M, 2011, BIOORG MED CHEM LETT, V21, P288, DOI 10.1016/j.bmcl.2010.11.015; Gauvreau GM, 2008, AM J RESP CRIT CARE, V177, P952, DOI 10.1164/rccm.200708-1251OC; Gauvreau GM, 2006, AM J RESP CRIT CARE, V174, P15, DOI 10.1164/rccm.200601-057OC; Gauvreau GM, 2011, AM J RESP CRIT CARE, V183, P1007, DOI 10.1164/rccm.201008-1210OC; Goswami R, 2011, J IMMUNOL, V186, P3283, DOI 10.4049/jimmunol.1003049; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Horak F, 2011, J ALLERGY CLIN IMMUN, V127, pAB199, DOI 10.1016/j.jaci.2010.12.790; Kawano T, 2004, J ALLERGY CLIN IMMUN, V114, P1278, DOI 10.1016/j.jaci.2004.09.003; Kearley J, 2011, AM J RESP CRIT CARE, V183, P865, DOI 10.1164/rccm.200909-1462OC; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Klimek L, 2011, CLIN EXP ALLERGY, V41, P1305, DOI 10.1111/j.1365-2222.2011.03783.x; Koivuniemi R, 2011, SCAND J RHEUMATOL, V40, P154, DOI 10.3109/03009742.2010.504188; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Lane JE, 2006, J AM ACAD DERMATOL, V54, P68, DOI 10.1016/j.jaad.2005.09.030; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee SJ, 2005, J ALLERGY CLIN IMMUN, V116, P900, DOI 10.1016/j.jaci.2005.03.028; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; Van LP, 2011, EUR J IMMUNOL, V41, P1992, DOI 10.1002/eji.201040914; Linke R, 2010, MABS-AUSTIN, V2, P129, DOI 10.4161/mabs.2.2.11221; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; MacGlashan D, 2009, J ALLERGY CLIN IMMUN, V123, P114, DOI 10.1016/j.jaci.2008.10.053; Magnano MD, 2004, CLIN EXP RHEUMATOL, V22, pS134; Meltzer EO, 2006, J ALLERGY CLIN IMMUN, V118, pS17, DOI 10.1016/j.jaci.2006.09.005; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Musarra A, 2010, EUR ANN ALLERGY CLIN, V42, P115; Mutalithas K, 2010, CLIN EXP ALLERGY, V40, P1175, DOI 10.1111/j.1365-2222.2010.03504.x; Mutalithas K, 2010, CLIN EXP IMMUNOL, V161, P34, DOI 10.1111/j.1365-2249.2010.04161.x; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nelson HS, 2005, J ALLERGY CLIN IMM S, V115, pS134; Nopp A, 2010, ALLERGY, V65, P56, DOI 10.1111/j.1398-9995.2009.02144.x; Ogbogu PU, 2009, J ALLERGY CLIN IMMUN, V124, P1319, DOI 10.1016/j.jaci.2009.09.022; Oliphant CJ, 2011, IMMUNOLOGY, V134, P378, DOI 10.1111/j.1365-2567.2011.03499.x; Parker JM, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-14; Parks KW, 2006, ALLERGY ASTHMA PROC, V27, pS33; Pavord ID, 2010, CLIN EXP ALLERGY, V40, P62, DOI 10.1111/j.1365-2222.2009.03410.x; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Pease JE, 2011, BIOCHEM J, V434, P11, DOI 10.1042/BJ20101132; Pettipher R, 2007, NAT REV DRUG DISCOV, V6, P313, DOI 10.1038/nrd2266; Pfaar O, 2011, INT ARCH ALLERGY IMM, V154, P336, DOI 10.1159/000321826; Price KS, 2007, ALLERGY ASTHMA PROC, V28, P313, DOI 10.2500/aap.2007.28.3003; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Reiser H, 1996, NEW ENGL J MED, V335, P1369, DOI 10.1056/NEJM199610313351807; Renner WA, 2011, AM J RESP CRIT CARE, V183; Rodrigo GJ, 2011, CHEST, V139, P28, DOI 10.1378/chest.10-1194; Rosewich M, 2010, CLIN EXP IMMUNOL, V160, P403, DOI 10.1111/j.1365-2249.2010.04106.x; Rosewich M, 2010, PEDIAT ALLERG IMM-UK, V21, pE185, DOI 10.1111/j.1399-3038.2009.00953.x; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sandhu MS, 2010, J ALLERGY CLIN IMMUN, V125, pAB66, DOI 10.1016/j.jaci.2009.12.258; Satoh T, 2006, J IMMUNOL, V177, P2621, DOI 10.4049/jimmunol.177.4.2621; Senti G, 2009, CLIN EXP ALLERGY, V39, P562, DOI 10.1111/j.1365-2222.2008.03191.x; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Shimbara A, 2000, J ALLERGY CLIN IMMUN, V105, P108, DOI 10.1016/S0091-6749(00)90185-4; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Slavin RG, 2009, J ALLERGY CLIN IMMUN, V123, P107, DOI 10.1016/j.jaci.2008.09.050; Smith DE, 2010, CLIN EXP ALLERGY, V40, P200, DOI 10.1111/j.1365-2222.2009.03384.x; Sornasse TR, 2005, J ALLERGY CLIN IMMUN, V115, pS73; Spears M, 2009, CLIN PHARMACOL THER, V86, P49, DOI 10.1038/clpt.2009.41; Springer TA, 2002, NAT IMMUNOL, V3, P501, DOI 10.1038/ni0602-501; Staudt V, 2010, IMMUNITY, V33, P192, DOI 10.1016/j.immuni.2010.07.014; Stevenson DD, 2005, J ALLERGY CLIN IMMUN, V116, P755, DOI 10.1016/j.jaci.2005.05.020; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Tan R, 2011, EXPERT REV RESP MED, V5, P747, DOI [10.1586/ers.11.73, 10.1586/ERS.11.73]; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Temann UA, 2007, INT IMMUNOL, V19, P1, DOI 10.1093/intimm/dxl117; Tian L, 2011, ALLERGY, V66, P287, DOI 10.1111/j.1398-9995.2010.02478.x; Ulven T, 2010, EXPERT OPIN THER PAT, V20, P1505, DOI 10.1517/13543776.2010.525506; van Vollenhoven RF, 2004, CLIN EXP RHEUMATOL, V22, pS122; Vijayanand P, 2010, J IMMUNOL, V184, P4568, DOI 10.4049/jimmunol.0901342; Virtanen H, 2007, J ALLERGY CLIN IMMUN, V120, P1464, DOI 10.1016/j.jaci.2007.08.021; WARDLAW AJ, 1987, ALLERGY, V42, P321, DOI 10.1111/j.1398-9995.1987.tb02218.x; Wardlaw AJ, 2005, CLIN EXP ALLERGY, V35, P1254, DOI 10.1111/j.1365-2222.2005.02344.x; Wardlaw AJ, 1999, J ALLERGY CLIN IMMUN, V104, P917, DOI 10.1016/S0091-6749(99)70069-2; Wardlaw AJ, 2002, CLIN SCI, V103, P201; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; Warrier P, 2009, ANN ALLERG ASTHMA IM, V102, P257, DOI 10.1016/S1081-1206(10)60091-9; Wasserman MJ, 2004, J RHEUMATOL, V31, P1912; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wenzel SE, 2009, NEW ENGL J MED, V360, P1026, DOI 10.1056/NEJMe0900334; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; Woerly G, 2003, J EXP MED, V198, P411, DOI 10.1084/jem.20021384; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Woodside DG, 2008, BIODRUGS, V22, P85, DOI 10.2165/00063030-200822020-00002; Wu CB, 2009, MABS, V1, P339, DOI 10.4161/mabs.1.4.8755; Xirakia C, 2010, AM J RESP CRIT CARE, V181, P1207, DOI 10.1164/rccm.200908-1255OC; Youdim A, 2004, INFLAMM BOWEL DIS, V10, P333, DOI 10.1097/00054725-200407000-00002; Zhu M, 2011, AM J RESP CELL MOL, V45, P111, DOI 10.1165/rcmb.2009-0445OC	130	13	13	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					311	324		10.1016/j.jaci.2012.04.046	http://dx.doi.org/10.1016/j.jaci.2012.04.046			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22713596	Green Submitted			2022-12-18	WOS:000307002200009
J	Ballow, M				Ballow, Mark			Vaccines in the assessment of patients for immune deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Intravenous immunoglobulin; subcutaneous immunoglobulin; pneumococcal vaccines immune response to vaccines; adverse reactions	INTRAVENOUS IMMUNOGLOBULIN; ADVERSE-REACTIONS; PNEUMOCOCCAL VACCINE; ANTIBODY-RESPONSE; CHILDREN; RISK		SUNY Buffalo, Women & Childrens Hosp Buffalo, Allergy Clin Immunol Div, Sch Med & Biomed Sci, Buffalo, NY 14222 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Women & Children's Hospital of Buffalo	Ballow, M (corresponding author), SUNY Buffalo, Women & Childrens Hosp Buffalo, Allergy Clin Immunol Div, Sch Med & Biomed Sci, 219 Bryant St, Buffalo, NY 14222 USA.	ballow@buffalo.edu			Grifols; Baxter; CSL Behring	Grifols; Baxter; CSL Behring	Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: M. Ballow receives research support from Grifols; serves on advisory boards for Baxter, CSL Behring, and Grifols; serves on the data safety monitoring board for GreenCross; has consultant arrangements with CSL Behring; and receives speaker's fees from Baxter and CSL Behring. J. T. Li has consulted for Abbott.	Ameratunga R, 2004, CLIN EXP IMMUNOL, V136, P111, DOI 10.1111/j.1365-2249.2004.02412.x; [Anonymous], RED BOOK 2009 REPORT; Ballow M, 2008, J ALLERGY CLIN IMMUN, V122, P1038, DOI 10.1016/j.jaci.2008.08.012; Berger M, 2004, CLIN IMMUNOL, V112, P1, DOI 10.1016/j.clim.2004.02.002; Bonilla FA, 2008, J ALLERGY CLIN IMMUN, V122, P1238, DOI 10.1016/j.jaci.2008.08.033; Brennan VM, 2003, CLIN EXP IMMUNOL, V133, P247, DOI 10.1046/j.1365-2249.2003.02199.x; Hare ND, 2009, J ALLERGY CLIN IMMUN, V123, P195, DOI 10.1016/j.jaci.2008.09.021; Immune Deficieny Foundation, 2008, TREATM EXP PREF PAT; LANDESMAN SH, 1981, REV INFECT DIS, V3, pS184; Orange JS, 2012, J ALLERGY C IN PRESS; Paris K, 2007, ANN ALLERG ASTHMA IM, V99, P462, DOI 10.1016/S1081-1206(10)60572-8; Rachid R, 2012, J ALLERGY CLIN IMMUN, V129, P628, DOI 10.1016/j.jaci.2011.06.047; Romero-Steiner S, 2006, CLIN VACCINE IMMUNOL, V13, P165, DOI 10.1128/CVI.13.2.165-169.2006; Rose MA, 2005, CLIN DIAGN LAB IMMUN, V12, P1216, DOI 10.1128/CDLI.12.10.1216-1222.2005; Sorensen RU, 1998, PEDIATR INFECT DIS J, V17, P685, DOI 10.1097/00006454-199808000-00005	15	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					283	+		10.1016/j.jaci.2012.04.028	http://dx.doi.org/10.1016/j.jaci.2012.04.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22742841				2022-12-18	WOS:000306644800050
J	Hsia, BJ; Ledford, JG; Potts-Kant, EN; Nikam, VS; Lugogo, NL; Foster, WM; Kraft, M; Abraham, SN; Wright, JR				Hsia, Bethany J.; Ledford, Julie G.; Potts-Kant, Erin N.; Nikam, Vinayak S.; Lugogo, Njira L.; Foster, W. Michael; Kraft, Monica; Abraham, Soman N.; Wright, Jo Rae			Mast cell TNF receptors regulate responses to Mycoplasma pneumoniae in surfactant protein A (SP-A)(-/-) mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; TNF; Mycoplasma species; airway hyperresponsiveness; mucus	NECROSIS-FACTOR-ALPHA; AIRWAY INFLAMMATION; CYTOKINE PRODUCTION; CHRONIC ASTHMA; MURINE MODEL; INFECTION; HYPERRESPONSIVENESS; MACROPHAGES; EXPRESSION; RELEASE	Background: Mycoplasma pneumoniae (Mp) frequently colonizes the airways of patients with chronic asthma and likely contributes to asthma exacerbations. We previously reported that mice lacking surfactant protein A (SP-A) have increased airway hyperresponsiveness (AHR) during M pneumoniae infection versus wild-type mice mediated by TNF-alpha. Mast cells (MCs) have been implicated in AHR in asthma models and produce and respond to TNF-alpha. Objective: Determine the contribution of MC/TNF interactions to AHR in airways lacking functional SP-A during Mp infection. Methods: Bronchoalveolar lavage fluid was collected from healthy and asthmatic subjects to examine TNF-alpha levels and M pneumoniae positivity. To determine how SP-A interactions with MCs regulate airway homeostasis, we generated mice lacking both SP-A and MCs (SP-A(-)/(-)Kit(W-sh/W-sh)) and infected them with M pneumoniae. Results: Our findings indicate that high TNF-alpha levels correlate with M pneumoniae positivity in human asthmatic patients and that human SP-A inhibits M pneumoniae-stimulated transcription and release of TNF-alpha by MCs, implicating a protective role for SP-A. MC numbers increase in M pneumoniae-infected lungs, and airway reactivity is dramatically attenuated when MCs are absent. Using SP-A(-/-)Kit(W-sh/W-sh) mice engrafted with TNF-alpha(-/-) or TNF receptor (TNF-R)(-/-) MCs, we found that TNF-alpha activation of MCs through the TNF-R, but not MC-derived TNF-alpha, leads to augmented AHR during M pneumoniae infection when SP-A is absent. Additionally, M pneumoniae-infected SP-A(-/-)Kit(W-sh/W-sh) mice engrafted with TNF-alpha(-/-) or TNF-R-/- MCs have decreased mucus production compared with that seen in mice engrafted with wild-type MCs, whereas burden was unaffected. Conclusion: Our data highlight a previously unappreciated but vital role for MCs as secondary responders to TNF-alpha during the host response to pathogen infection. (J Allergy Clin Immunol 2012; 130:205-14.)	[Ledford, Julie G.] Duke Univ, Med Ctr, Dept Cell Biol, DUMC, Durham, NC 27710 USA; [Ledford, Julie G.; Potts-Kant, Erin N.; Lugogo, Njira L.; Foster, W. Michael; Kraft, Monica] Duke Univ, Med Ctr, Dept Pulm Allergy & Crit Care Med, Durham, NC 27710 USA; [Abraham, Soman N.] Duke Univ, Med Ctr, Dept Pathol Immunol Mol Genet & Microbiol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Ledford, JG (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, DUMC, 261 MSRB 1,CB 2641, Durham, NC 27710 USA.	julie.ledford@dm.duke.edu			National Institutes of Health [F32-HL091642, PO1-AI81672]; National Institutes of Health; GlaxoSmithKline; Merck; Eumedics; Novartis; Genentech; Asthmatx (Boston Scientific); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL091642, K99HL111151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI081672] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Eumedics; Novartis(Novartis); Genentech(Roche HoldingGenentech); Asthmatx (Boston Scientific); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants F32-HL091642 (to J.G.L.) and PO1-AI81672 (to J.R.W., M.K., and W.M.F.).; Disclosure of potential conflict of interest: B. J. Hsia, J. G. Ledford, and N. L. Lugogo receive research support from the National Institutes of Health. M. Kraft receives research support from GlaxoSmithKline, Merck, Eumedics, Novartis, Genentech, and Asthmatx (Boston Scientific). The rest of the authors declare that they have no relevant conflicts of interest.	Alcorn JF, 2004, AM J PHYSIOL-LUNG C, V286, pL129, DOI 10.1152/ajplung.00427.2002; [Anonymous], 2007, J ALLERGY CLIN IMM S, V120, pS94; Baseman JB, 1997, EMERG INFECT DIS, V3, P21, DOI 10.3201/eid0301.970103; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Brinker KG, 2003, AM J PHYSIOL-LUNG C, V284, pL232, DOI 10.1152/ajplung.00187.2002; BRINKMAN GL, 1968, J ULTRA MOL STRUCT R, V23, P115, DOI 10.1016/S0022-5320(68)80035-8; Erin EM, 2006, AM J RESP CRIT CARE, V174, P753, DOI 10.1164/rccm.200601-072OC; Fifadara NH, 2009, INT IMMUNOL, V21, P991, DOI 10.1093/intimm/dxp066; Hart PH, 2001, IMMUNOL CELL BIOL, V79, P149, DOI 10.1046/j.1440-1711.2001.00983.x; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Hughes JM, 1995, PULM PHARMACOL, V8, P31, DOI 10.1006/pulp.1995.1004; Jin C, 2011, J CLIN INVEST, V121, P941, DOI 10.1172/JCI43584; Juremalm M, 2005, CHEM IMMUNOL ALLERGY, V87, P130, DOI 10.1159/000087640; Kannan TR, 2005, INFECT IMMUN, V73, P2828, DOI 10.1128/IAI.73.5.2828-2834.2005; Kim YS, 2007, EUR J IMMUNOL, V37, P1107, DOI 10.1002/eji.200636612; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092; Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782; Kraft M, 2006, J ALLERGY CLIN IMMUN, V117, P1197, DOI 10.1016/j.jaci.2006.03.001; Krause DC, 2004, MOL MICROBIOL, V51, P917, DOI 10.1046/j.1365-2958.2003.03899.x; Ledford JG, 2009, J IMMUNOL, V182, P7818, DOI 10.4049/jimmunol.0900452; Malherbe DC, 2005, AM J PHYSIOL-LUNG C, V289, pL856, DOI 10.1152/ajplung.00009.2005; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Martin RJ, 2001, AM J RESP CELL MOL, V24, P577, DOI 10.1165/ajrcmb.24.5.4315; Martin RJ, 2001, J ALLERGY CLIN IMMUN, V107, P595, DOI 10.1067/mai.2001.113563; McIntosh JC, 1996, AM J PHYSIOL-LUNG C, V271, pL310, DOI 10.1152/ajplung.1996.271.2.L310; McLachlan JB, 2003, NAT IMMUNOL, V4, P1199, DOI 10.1038/ni1005; Michels NM, 2010, CLIN EXP ALLERGY, V40, P1406, DOI 10.1111/j.1365-2222.2010.03488.x; Morjaria S, 2006, INT J IMMUNOPATH PH, V19, P525, DOI 10.1177/039463200601900308; Nakae S, 2007, J ALLERGY CLIN IMMUN, V120, P48, DOI 10.1016/j.jaci.2007.02.046; Piboonpocanun S, 2005, J BIOL CHEM, V280, P9, DOI 10.1074/jbc.M411570200; Pushparaj PN, 2009, J IMMUNOL, V183, P221, DOI 10.4049/jimmunol.0803430; Reuter S, 2010, YONSEI MED J, V51, P797, DOI 10.3349/ymj.2010.51.6.797; Rouhani FN, 2005, RESP MED, V99, P1175, DOI 10.1016/j.rmed.2005.02.031; Sano H, 1999, J IMMUNOL, V163, P387; Stamme C, 2000, AM J RESP CELL MOL, V23, P772, DOI 10.1165/ajrcmb.23.6.4083; VANOVERVELD FJ, 1991, CLIN EXP ALLERGY, V21, P711; Wang Y, 2011, AM J PHYSIOL-LUNG C, V301, pL598, DOI 10.1152/ajplung.00381.2010; Xu X, 2006, AM J RESP CRIT CARE, V173, P219, DOI 10.1164/rccm.200507-1034OC	39	13	18	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					205	+		10.1016/j.jaci.2012.03.002	http://dx.doi.org/10.1016/j.jaci.2012.03.002			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22502799	Green Accepted			2022-12-18	WOS:000306644800029
J	Seidel, MG				Seidel, Markus G.			CD27: A new player in the field of common variable immunodeficiency and EBV-associated lymphoproliferative disorder?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CELL-ACTIVATION ANTIGEN; FACTOR RECEPTOR FAMILY; MEMBER		[Seidel, Markus G.] St Anna Childrens Hosp, A-1090 Vienna, Austria; [Seidel, Markus G.] Med Univ Graz, Graz, Austria	Saint Anna Children's Hospital; Medical University of Graz	Seidel, MG (corresponding author), St Anna Childrens Hosp, A-1090 Vienna, Austria.	markus.seidel@medunigraz.at	Seidel, Markus G/N-9951-2017	Seidel, Markus G/0000-0003-0981-8661				BIGLER RD, 1988, J IMMUNOL, V141, P21; CAMERINI D, 1991, J IMMUNOL, V147, P3165; Gravestein LA, 1998, SEMIN IMMUNOL, V10, P423, DOI 10.1006/smim.1998.0144; Hendriks J, 2000, NAT IMMUNOL, V1, P433, DOI 10.1038/80877; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; van Montfrans JM, 2012, J ALLERGY CLIN IMMUN, V129, P787, DOI 10.1016/j.jaci.2011.11.013	6	13	13	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1175	1175		10.1016/j.jaci.2012.01.053	http://dx.doi.org/10.1016/j.jaci.2012.01.053			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22365582				2022-12-18	WOS:000302144600046
J	Lemiere, C; Miedinger, D; Jacob, V; Chaboillez, S; Tremblay, C; Brannan, JD				Lemiere, Catherine; Miedinger, David; Jacob, Veronique; Chaboillez, Simone; Tremblay, Caroline; Brannan, John D.			Comparison of methacholine and mannitol bronchial provocation tests in workers with occupational asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AIRWAY INFLAMMATION; DRY POWDER; RESPONSIVENESS; CHALLENGE		[Lemiere, Catherine; Miedinger, David; Jacob, Veronique; Chaboillez, Simone; Tremblay, Caroline] Univ Montreal, Hop Sacre Coeur Montreal, Montreal, PQ, Canada; [Miedinger, David] Univ Basel Hosp, CH-4031 Basel, Switzerland; [Brannan, John D.] Royal Prince Alfred Hosp, Dept Resp & Sleep Med, Sydney, NSW, Australia	Universite de Montreal; University of Basel; University of Sydney	Lemiere, C (corresponding author), Univ Montreal, Hop Sacre Coeur Montreal, Montreal, PQ, Canada.	catherine.lemiere@umontreal.ca		Brannan, John/0000-0001-7243-7998				Anderson SD, 1997, AM J RESP CRIT CARE, V156, P758, DOI 10.1164/ajrccm.156.3.9701113; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P912; Brannan JD, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-144; BURROWS B, 1992, J ALLERGY CLIN IMMUN, V90, P376, DOI 10.1016/S0091-6749(05)80018-1; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Juniper E, 1994, HISTAMINE METHACHOLI; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Wood LG, 2010, CLIN EXP ALLERGY, V40, P232, DOI 10.1111/j.1365-2222.2009.03371.x	9	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					555	556		10.1016/j.jaci.2011.09.012	http://dx.doi.org/10.1016/j.jaci.2011.09.012			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22019089				2022-12-18	WOS:000299951700037
J	Roujeau, JC; Bricard, G; Nicolas, JF				Roujeau, Jean-Claude; Bricard, Gabriel; Nicolas, Jean-Francois			Drug-induced epidermal necrolysis: Important new piece to end the puzzle	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Epidermal necrolysis	STEVENS-JOHNSON-SYNDROME; CELLS		[Roujeau, Jean-Claude] Univ Paris Est Creteil, Creteil, France; [Bricard, Gabriel; Nicolas, Jean-Francois] Univ Lyon 1, Ctr Hosp Lyon Sud, Drug Allergy Unit, INSERM,U851, F-69365 Lyon, France	Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Roujeau, JC (corresponding author), 19 Ave Alembert, F-92160 Antony, France.	jean-claude.roujeau@wanadoo.fr	Nicolas, Jean-François/AAW-9289-2020	NICOLAS, JEAN FRANCOIS/0000-0003-4204-803X				Auquier-Dunant A, 2002, ARCH DERMATOL, V138, P1019, DOI 10.1001/archderm.138.8.1019; Chen P, 2011, NEW ENGL J MED, V364, P1126, DOI 10.1056/NEJMoa1009717; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; CORREIA O, 1993, ARCH DERMATOL, V129, P466, DOI 10.1001/archderm.129.4.466; Hung SL, 2006, PHARMACOGENET GENOM, V16, P297, DOI 10.1097/01.fpc.0000199500.46842.4a; Kedzierska K, 2008, MOL IMMUNOL, V45, P607, DOI 10.1016/j.molimm.2006.05.017; Ko TM, 2011, J ALLERGY CLIN IMMUN, V128, P1266, DOI 10.1016/j.jaci.2011.08.013; Le Cleach L, 2000, CLIN EXP IMMUNOL, V119, P225, DOI 10.1046/j.1365-2249.2000.01119.x; Lonjou C, 2008, PHARMACOGENET GENOM, V18, P99, DOI 10.1097/FPC.0b013e3282f3ef9c; LYELL A, 1990, BRIT J DERMATOL, V122, P837, DOI 10.1111/j.1365-2133.1990.tb06275.x; McCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Pichler WJ, 2011, J ALLERGY CLIN IMMUN, V127, pS74, DOI 10.1016/j.jaci.2010.11.048; Rozieres A, 2009, CURR OPIN ALLERGY CL, V9, P305, DOI 10.1097/ACI.0b013e32832d565c; Yang CWO, 2007, J ALLERGY CLIN IMMUN, V120, P870, DOI 10.1016/j.jaci.2007.06.017	16	13	13	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1277	1278		10.1016/j.jaci.2011.10.015	http://dx.doi.org/10.1016/j.jaci.2011.10.015			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	22133320	Bronze			2022-12-18	WOS:000298342700017
J	Belpinati, F; Malerba, G; Trabetti, E; Galavotti, R; Xumerle, L; Pescollderungg, L; Boner, AL; Pignatti, PF				Belpinati, Francesca; Malerba, Giovanni; Trabetti, Elisabetta; Galavotti, Roberta; Xumerle, Luciano; Pescollderungg, Lydia; Boner, Attilio Loris; Pignatti, Pier Franco			Association of childhood allergic asthma with markers flanking the IL33 gene in Italian families	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LINKAGE; ATOPY		[Belpinati, Francesca; Malerba, Giovanni; Trabetti, Elisabetta; Galavotti, Roberta; Xumerle, Luciano; Boner, Attilio Loris; Pignatti, Pier Franco] Univ Verona, Dept Life & Reprod Sci, Sect Biol & Genet, I-37100 Verona, Italy; [Belpinati, Francesca; Malerba, Giovanni; Trabetti, Elisabetta; Galavotti, Roberta; Xumerle, Luciano; Boner, Attilio Loris; Pignatti, Pier Franco] Univ Verona, Sect Pedriat, I-37100 Verona, Italy; [Pescollderungg, Lydia] Hosp Bolzano, Inst Pediat, Bolzano, Italy	University of Verona; University of Verona; Krankenhaus Bozen	Belpinati, F (corresponding author), Univ Verona, Dept Life & Reprod Sci, Sect Biol & Genet, I-37100 Verona, Italy.	francesca.belpinati@univr.it	Malerba, Giovanni/T-3278-2019	Malerba, Giovanni/0000-0001-8705-8560; Xumerle, Luciano/0000-0003-4518-3958				Bouzigon E, 2010, EUR J HUM GENET, V18, P700, DOI 10.1038/ejhg.2009.224; Gorski Pawel, 2002, Int J Occup Med Environ Health, V15, P207; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Malerba G, 2002, 52 ANN M AM SOC HUM; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Purcell S, PACKAGE PLINK V1 07; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Venanzi S, 2001, CLIN EXP ALLERGY, V31, P1220, DOI 10.1046/j.1365-2222.2001.01132.x	10	13	13	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					667	668		10.1016/j.jaci.2011.05.004	http://dx.doi.org/10.1016/j.jaci.2011.05.004			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21802127				2022-12-18	WOS:000294283400029
J	Knight, DA; Stick, SM; Hackett, TL				Knight, Darryl A.; Stick, Stephen M.; Hackett, Tillie-Louise			Defective function at the epithelial junction: A novel therapeutic frontier in asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Epithelium; asthma; airways; adhesion; barrier	TIGHT JUNCTIONS; CELLS; INFLAMMATION; ADHESION; PROTEIN		[Knight, Darryl A.] St Pauls Hosp, UBC James Hogg Res Ctr, Inst Heart Lung Hlth, Vancouver, BC V6Z 1Y6, Canada; [Knight, Darryl A.; Hackett, Tillie-Louise] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada; [Stick, Stephen M.] Princess Margaret Hosp Children, Dept Resp Med, Perth, WA, Australia; [Stick, Stephen M.] Univ Western Australia, Sch Pediat & Child Hlth, Nedlands, WA 6009, Australia	St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of British Columbia; University of Western Australia; University of Western Australia	Knight, DA (corresponding author), St Pauls Hosp, UBC James Hogg Res Ctr, Inst Heart Lung Hlth, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	darryl.knight@hli.ubc.ca	Stick, Stephen/AAA-5945-2021; Stick, Stephen/GZG-7584-2022; Stick, Stephen/O-5683-2014	Stick, Stephen/0000-0002-5386-8482; 				Bates JHT, 2006, J APPL PHYSIOL, V100, P500, DOI 10.1152/japplphysiol.01013.2005; Coyne CB, 2002, MOL BIOL CELL, V13, P3218, DOI 10.1091/mbc.E02-03-0134; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI [10.1139/Y08-004, 10.1139/y08-004]; Hackett TL, 2011, AM J RESP CELL MOL B; Heijink IH, 2010, EUR RESPIR J, V36, P1016, DOI 10.1183/09031936.00125809; Ierodiakonou D, 2011, EUR RESP J; Morar N, 2007, J INVEST DERMATOL, V127, P1667, DOI 10.1038/sj.jid.5700739; Park SJ, 2007, EXP MOL MED, V39, P629, DOI 10.1038/emm.2007.69; Parker J, 2010, PEDIATR RES, V67, P17, DOI 10.1203/PDR.0b013e3181c0b200; Runswick S, 2007, RESPIROLOGY, V12, P834, DOI 10.1111/j.1440-1843.2007.01175.x; Sajjan U, 2008, AM J RESP CRIT CARE, V178, P1271, DOI 10.1164/rccm.200801-136OC; Shahana S, 2006, RESP MED, V100, P2018, DOI 10.1016/j.rmed.2006.02.012; Trautmann A, 2005, INT ARCH ALLERGY IMM, V138, P142, DOI 10.1159/000088436; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Zabner J, 2003, J APPL PHYSIOL, V95, P394, DOI 10.1152/japplphysiol.01134.2002	16	13	13	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					557	558		10.1016/j.jaci.2011.07.031	http://dx.doi.org/10.1016/j.jaci.2011.07.031			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21878242	Bronze			2022-12-18	WOS:000294283400014
J	Palomares, O; O'Mahony, L; Akdis, CA				Palomares, Oscar; O'Mahony, Liam; Akdis, Cezmi A.			The many routes of dendritic cells to ensure immune regulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Immune regulation; vitamin D3; skin; Langerhans cells; dermal dendritic cells; regulatory T cells; forkhead box protein 3; IL-10; TGF-beta	T-CELLS; MECHANISMS; PATHWAY		[Palomares, Oscar; O'Mahony, Liam; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, CH-7270 Davos, Switzerland; [Palomares, Oscar] Univ Complutense Madrid, Sch Chem, Dept Biochem & Mol Biol, E-28040 Madrid, Spain	Swiss Institute of Allergy & Asthma Research; University of Zurich; Complutense University of Madrid	Akdis, CA (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22,Davos Pl, CH-7270 Davos, Switzerland.	akdisac@siaf.uzh.ch	Palomares, Oscar/ABG-5229-2020; Akdis, Cezmi/AAV-4844-2020; O'Mahony, Liam/AAG-5838-2019	Akdis, Cezmi/0000-0001-8020-019X; O'Mahony, Liam/0000-0003-4705-3583; Palomares, Oscar/0000-0003-4516-0369				Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Belkaid Y, 2008, IMMUNITY, V29, P362, DOI 10.1016/j.immuni.2008.08.005; Chen W, 2008, J IMMUNOL, V181, P5396, DOI 10.4049/jimmunol.181.8.5396; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Klunker S, 2009, J EXP MED, V206, P2701, DOI 10.1084/jem.20090596; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Miyara M, 2009, J ALLERGY CLIN IMMUN, V123, P749, DOI 10.1016/j.jaci.2009.03.001; Mucida D, 2009, J ALLERGY CLIN IMMUN, V123, P997, DOI 10.1016/j.jaci.2009.03.016; Novak N, 2010, J ALLERGY CLIN IMMUN, V125, P50, DOI 10.1016/j.jaci.2009.11.019; Roncarolo MG, 2006, IMMUNOL REV, V212, P28; van der Aar AMG, 2011, J ALLERGY CLIN IMMUN, V127, P1532, DOI 10.1016/j.jaci.2011.01.068	16	13	14	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1541	1542		10.1016/j.jaci.2011.04.002	http://dx.doi.org/10.1016/j.jaci.2011.04.002			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21531017				2022-12-18	WOS:000291048500034
J	Custovic, A; Nicolaou, N				Custovic, Adnan; Nicolaou, Nicolaos			Peanut allergy: Overestimated in epidemiology or underdiagnosed in primary care?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Peanut; peanut allergy; food allergy; epidemiology	PREVALENCE; CHILDREN		[Custovic, Adnan; Nicolaou, Nicolaos] Univ Manchester, Univ Hosp S Manchester NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Translat Res Facil Resp Med, Manchester M23 9LT, Lancs, England	University of Manchester; Wythenshawe Hospital NHS Foundation Trust	Custovic, A (corresponding author), Univ Manchester, Univ Hosp S Manchester NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Translat Res Facil Resp Med, Manchester M23 9LT, Lancs, England.	adnan.custovic@manchester.ac.uk	Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071				[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Ben-Shoshan M, 2009, J ALLERGY CLIN IMMUN, V123, P783, DOI 10.1016/j.jaci.2009.02.004; Burney P, 2010, ALLERGY, V65, P1182, DOI 10.1111/j.1398-9995.2010.02346.x; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Keil T, 2010, ALLERGY, V65, P482, DOI 10.1111/j.1398-9995.2009.02171.x; Kotz D, 2011, J ALLERGY CLIN IMMUN, V127, P623, DOI 10.1016/j.jaci.2010.11.021; Mullins RJ, 2009, J ALLERGY CLIN IMMUN, V123, P689, DOI 10.1016/j.jaci.2008.12.1116; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Venter C, 2010, ALLERGY, V65, P103, DOI 10.1111/j.1398-9995.2009.02176.x; Zuidmeer L, 2008, J ALLERGY CLIN IMMUN, V121, P1210, DOI 10.1016/j.jaci.2008.02.019	15	13	13	2	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					631	632		10.1016/j.jaci.2011.01.026	http://dx.doi.org/10.1016/j.jaci.2011.01.026			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21377031	Bronze			2022-12-18	WOS:000288018400011
J	Horn, PC; Belohradsky, BH; Urban, C; Weber-Mzell, D; Meindl, A; Schuster, V				Horn, Peter C.; Belohradsky, Bernd H.; Urban, Christian; Weber-Mzell, Daniela; Meindl, Alfons; Schuster, Volker			Two new families with X-linked inhibitor of apoptosis deficiency and a review of all 26 published cases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC GRANULOMATOUS-DISEASE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; CARTILAGE-HAIR HYPOPLASIA; HODGKINS-DISEASE; ATAXIA-TELANGIECTASIA; XIAP DEFICIENCY; LYMPHOMA; PATIENT; MUTATION; GENE		[Horn, Peter C.] Tech Univ Munich, Dept Med, D-8000 Munich, Germany; [Meindl, Alfons] Tech Univ Munich, Dept Obstet & Gynecol, D-8000 Munich, Germany; [Horn, Peter C.] Univ Freiburg, Dept Ophthalmol, D-7800 Freiburg, Germany; [Belohradsky, Bernd H.] Univ Munich, Univ Childrens, D-80539 Munich, Germany; [Urban, Christian; Weber-Mzell, Daniela] Med Univ Graz, Dept Pediat & Adolescent Med, Div Pediat Hematol Oncol, Graz, Austria; [Schuster, Volker] Univ Leipzig, Hosp Children & Adolescents, Leipzig, Germany	Technical University of Munich; Technical University of Munich; University of Freiburg; University of Munich; Medical University of Graz; Leipzig University	Horn, PC (corresponding author), Tech Univ Munich, Dept Med, D-8000 Munich, Germany.	volker.schuster@medizin.uni-leipzig.de		Horn, Peter/0000-0002-4588-1433				Aguilera DG, 2009, J PEDIAT HEMATOL ONC, V31, P965, DOI 10.1097/MPH.0b013e3181b84751; BERNSTEIN R, 1981, CANCER GENET CYTOGEN, V4, P31, DOI 10.1016/0165-4608(81)90005-4; CHRISTOPOULOS C, 1995, J CLIN PATHOL, V48, P871, DOI 10.1136/jcp.48.9.871; Dugois P, 1967, Bull Soc Fr Dermatol Syphiligr, V74, P507; Filipovich A H, 1994, Immunodeficiency, V5, P91; Filipovich AH, 2010, BLOOD, V116, P3398, DOI 10.1182/blood-2010-03-275909; Geramizadeh B, 2010, IRAN RED CRESCENT ME, V12, P319; HARRIS VJ, 1973, CANCER, V32, P1415, DOI 10.1002/1097-0142(197312)32:6<1415::AID-CNCR2820320619>3.0.CO;2-Y; Jovanovic A, 2009, J PEDIAT HEMATOL ONC, V31, P49, DOI 10.1097/MPH.0b013e318190d72c; Kashef MA, 2006, PEDIATR HEMAT ONCOL, V23, P59, DOI 10.1080/08880010500313512; Lin SJ, 1998, PEDIATR HEMAT ONCOL, V15, P451, DOI 10.3109/08880019809016576; Marsh RA, 2010, BLOOD, V116, P1079, DOI 10.1182/blood-2010-01-256099; Niehues T, 2003, KLIN PADIATR, V215, P315; Notarangelo LD, 2009, J ALLERGY CLIN IMMUN, V124, P1161, DOI 10.1016/j.jaci.2009.10.013; Oliveira JB, 2010, J ALLERGY CLIN IMMUN, V125, pS297, DOI 10.1016/j.jaci.2009.08.043; PERIMAN P, 1980, CANCER, V45, P372, DOI 10.1002/1097-0142(19800115)45:2&lt;372::AID-CNCR2820450230&gt;3.0.CO;2-N; Peters AMJ, 1999, EXP HEMATOL, V27, P868, DOI 10.1016/S0301-472X(99)00033-8; Poppema S, 2004, LEUKEMIA LYMPHOMA, V45, P423, DOI 10.1080/10428190310001593166; Rigaud S, 2006, NATURE, V444, P110, DOI 10.1038/nature05257; ROBERTS MA, 1984, MIL MED, V149, P280; Sasahara Y, 2001, ACTA PAEDIATR, V90, P1348, DOI 10.1080/080352501317130461; Schuster V, 2007, PRIMARY IMMUNODEFICI, P470; Soucek P, 2003, EUR J HUM GENET, V11, P416, DOI 10.1038/sj.ejhg.5200972; Taskinen M, 2008, AM J MED GENET A, V146A, P2370, DOI 10.1002/ajmg.a.32478; van den Berg A, 2002, BLOOD, V99, P1492, DOI 10.1182/blood.V99.4.1492; Weel EAM, 1996, EUR J CANCER, V32A, P734, DOI 10.1016/0959-8049(95)00627-3; Wolach B, 2005, AM J HEMATOL, V80, P50, DOI 10.1002/ajh.20424; Yalcin B, 2002, PEDIATR PULM, V33, P399, DOI 10.1002/ppul.10057; Zenone T, 1996, J INTERN MED, V240, P99, DOI 10.1046/j.1365-2796.1996.514837000.x; Zenone T, 1996, J CLIN PATHOL, V49, P1021, DOI 10.1136/jcp.49.12.1021-a; Zhao M, 2009, HAEMATOLOGICA, V95, P688	31	13	14	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					544	546		10.1016/j.jaci.2010.11.040	http://dx.doi.org/10.1016/j.jaci.2010.11.040			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21281876				2022-12-18	WOS:000286808000039
J	Kim, JS; Nowak-Wegrzyn, A; Noone, SR; Bencharitiwong, R; Bloom, KA; Sampson, HA				Kim, J. S.; Nowak-Wegrzyn, A.; Noone, S. R.; Bencharitiwong, R.; Bloom, K. A.; Sampson, H. A.			Tolerance To Extensively Heated Milk (HM) In Children With Cow's Milk Allergy: A Follow Up	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	American-Academy-of-Allergy-Asthma-and-Immunology Annual Meeting	MAR 18-22, 2011	San Francisco, CA	Amer Acad Allergy Asthma & Immunol					[Kim, J. S.; Nowak-Wegrzyn, A.; Noone, S. R.; Bencharitiwong, R.; Bloom, K. A.; Sampson, H. A.] Mt Sinai Sch Med, New York, NY USA	Icahn School of Medicine at Mount Sinai									0	13	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2		S			AB27	AB27		10.1016/j.jaci.2010.12.118	http://dx.doi.org/10.1016/j.jaci.2010.12.118			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	832YI					2022-12-18	WOS:000295846400102
J	Barnes, KC				Barnes, Kathleen C.			Ancestry, ancestry-informative markers, asthma, and the quest for personalized medicine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Admixture mapping; ethnicity; ancestry-informative markers (AIMs)	GENETIC ANCESTRY; ALLERGY		Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Barnes, KC (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	kbarnes@jhmi.edu						Barnes KC, 2006, J ALLERGY CLIN IMMUN, V117, P243, DOI 10.1016/j.jaci.2005.11.030; Choudhry S, 2006, AM J RESP CRIT CARE, V174, P1086, DOI [10.1164/RCCM.200605-596OC, 10.1164/rccm.200605-596OC]; Corvol H, 2009, PHARMACOGENET GENOM, V19, P489, DOI 10.1097/FPC.0b013e32832c440e; Gould W, 2010, J ALLERGY CLIN IMMUN, V126, P1131, DOI 10.1016/j.jaci.2010.08.002; Hamburg MA, 2010, NEW ENGL J MED, V363, P301, DOI 10.1056/NEJMp1006304; Kittles RA, 2003, ANNU REV GENOM HUM G, V4, P33, DOI 10.1146/annurev.genom.4.070802.110356; Kumar R, 2010, NEW ENGL J MED, V363, P321, DOI 10.1056/NEJMoa0907897; Meyers DA, 2010, J ALLERGY CLIN IMMUN, V126, P439, DOI 10.1016/j.jaci.2010.07.012; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Murray T, 2010, GENET EPIDEMIOL, V34, P561, DOI 10.1002/gepi.20512; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Obeng BB, 2008, CURR OPIN ALLERGY CL, V8, P391, DOI 10.1097/ACI.0b013e32830ebb70; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Tian C, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040004; Vergara C, 2009, HUM GENET, V125, P565, DOI 10.1007/s00439-009-0649-2	15	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1139	1140		10.1016/j.jaci.2010.10.032	http://dx.doi.org/10.1016/j.jaci.2010.10.032			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21134571				2022-12-18	WOS:000284947800008
J	Bonner, K; Kariyawasam, HH; Ali, FR; Clark, P; Kay, AB				Bonner, Kandace; Kariyawasam, Harsha H.; Ali, F. Runa; Clark, Peter; Kay, A. Barry			Expression of functional receptor activity modifying protein 1 by airway epithelial cells with dysregulation in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RAMP1; CGRP; asthma; epithelial cells	GENE-RELATED PEPTIDE; CALCITONIN-RECEPTOR; HYPERRESPONSIVENESS; RAMPS; IMMUNOREACTIVITY; ADRENOMEDULLIN; ANGIOGENESIS; INFLAMMATION; RELEASE; LINE	Background: Epithelial cell expression of calcitonin generelated peptide (CGRP) is a feature of provoked asthma. Receptor activity modifying protein 1 (RAMP1) and the calcitonin receptor-like receptor combine to form the CGRP1 receptor. Objective: To determine whether functional RAMP1 is expressed by airway epithelial cells and whether there are alterations in asthma. Methods: BEAS-2B and A549 cells lines were studied by RTPCR, confocal microscopy, a quantitative immunofluorescence assay, and ELISA. Bronchial biopsies from normal subjects and subjects with asthma were examined by immunohistochemistry and in situ hybridization. Results: Inflammatory cytokines induced CGRP release and CGRP mRNA in BEAS-2B and A549 epithelial cell lines. RAMP1 was highly expressed by resting, unstimulated BEAS-2B and A549 cells. CGRP induced internalization of RAMP1 and IL-6 production, both of which were inhibited by the CGRP antagonist, CGRP8-37. Activation of BEAS-2B and A549 cells by inflammatory cytokines induced CGRP secretion, binding of CGRP to RAMP1, and RAMP1 internalization, which was blocked by CGRP 8-37. RAMP1 immunoreactivity and RAMP1 mRNA expression in bronchial biopsies from subjects with asthma were significantly lower than in normal subjects (P = .002 and P = .007, respectively). Inhalational challenge of atopic subjects with asthma with allergen-derived peptides produced a significant decrease in the numbers of RAMP1-positive epithelial cells in responders (P = .027) but not nonresponders. Conclusion: Receptor activity modifying protein 1 was expressed both by airway epithelial cells in culture and in bronchial biopsies from normal subjects and internalized after epithelial cell activation through autocrine feedback of CGRP. There is an apparent dysregulation of RAMP1 in asthmatic epithelium, suggesting continuous stimulation of pathways involving CGRP. (J Allergy Clin Immunol 2010;126:1277-83.)	[Bonner, Kandace; Kariyawasam, Harsha H.; Clark, Peter; Kay, A. Barry] Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, London SW7 2AZ, England; [Kariyawasam, Harsha H.; Ali, F. Runa] Univ London Imperial Coll Sci Technol & Med, Dept Allergy & Clin Immunol, London SW7 2AZ, England; [Bonner, Kandace; Kariyawasam, Harsha H.; Ali, F. Runa; Clark, Peter; Kay, A. Barry] Univ London Imperial Coll Sci Technol & Med, MRC, London SW7 2AZ, England; [Bonner, Kandace; Kariyawasam, Harsha H.; Ali, F. Runa; Clark, Peter; Kay, A. Barry] Univ London Imperial Coll Sci Technol & Med, Asthma UK Ctr Allerg Mech Asthma, Natl Heart & Lung Inst, Fac Med, London SW7 2AZ, England	Imperial College London; Imperial College London; Imperial College London; Imperial College London; University of London; King's College London	Kay, AB (corresponding author), Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Sir Alexander Fleming Bldg,S Kensington Campus, London SW7 2AZ, England.	a.b.kay@imperial.ac.uk			Asthma UK; National Heart and Lung Institute, Imperial College London	Asthma UK; National Heart and Lung Institute, Imperial College London	Supported by Asthma UK and the National Heart and Lung Institute, Imperial College London.	Ali FR, 2007, THORAX, V62, P750, DOI 10.1136/thx.2006.072041; Aoki-Nagase T, 2002, AM J PHYSIOL-LUNG C, V283, pL963, DOI 10.1152/ajplung.00130.2002; Armour SL, 1999, J PHARMACOL TOXICOL, V42, P217, DOI 10.1016/S1056-8719(00)00074-5; AVILA PC, 2008, ALLERGY ALLERGIC DIS, P336; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; CROMWELL O, 1992, IMMUNOLOGY, V77, P330; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; Hay DL, 2006, PHARMACOL THERAPEUT, V109, P173, DOI 10.1016/j.pharmthera.2005.06.015; Hoshino M, 2003, EUR RESPIR J, V21, P804, DOI 10.1183/09031936.03.00082002; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; Kariyawasam HH, 2008, AM J RESP CRIT CARE, V177, P1074, DOI 10.1164/rccm.200709-1376OC; Kariyawasam HH, 2007, AM J RESP CRIT CARE, V175, P896, DOI 10.1164/rccm.200609-1260OC; Kay AB, 2007, ALLERGY, V62, P495, DOI 10.1111/j.1398-9995.2007.01342.x; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; Kuwasako K, 2006, J BIOL CHEM, V281, P7205, DOI 10.1074/jbc.M511147200; Li WJ, 2004, FASEB J, V18, P1603, DOI 10.1096/fj.04-1737fje; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Motoyama S, 2004, SHOCK, V22, P234, DOI 10.1097/01.shk.0000132459.68561.f4; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233; Steiner S, 2002, BIOCHEMISTRY-US, V41, P11398, DOI 10.1021/bi020279r; Tanaka H, 2003, AM J RESP CRIT CARE, V168, P1495, DOI 10.1164/rccm.200306-727OC; Tavakoli S, 2001, AM J PHYSIOL-LUNG C, V280, pL127, DOI 10.1152/ajplung.2001.280.1.L127; Veronesi B, 1999, NEUROPEPTIDES, V33, P447, DOI 10.1054/npep.1999.0761	24	13	14	2	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1277	U314		10.1016/j.jaci.2010.08.013	http://dx.doi.org/10.1016/j.jaci.2010.08.013			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	20933260				2022-12-18	WOS:000284947800028
J	McDonald, DR; Goldman, F; Gomez-Duarte, OD; Issekutz, AC; Kumararatne, DS; Doffinger, R; Geha, RS				McDonald, Douglas R.; Goldman, Frederick; Gomez-Duarte, Oscar D.; Issekutz, Andrew C.; Kumararatne, Dinakantha S.; Doffinger, Rainer; Geha, Raif S.			Impaired T-cell receptor activation in IL-1 receptor-associated kinase-4-deficient patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-1 receptor-associated kinase 4; T cell; T-cell receptor; cytokines; TNF-alpha; IL-2; IL-6; IFN-gamma; CD25; CD69	IRAK4 KINASE-ACTIVITY; IMMUNE-RESPONSES; BACTERIAL-INFECTIONS; DIFFERENTIATION; INNATE; DEFICIENCY; SUPERFAMILY; LYMPHOCYTES; PATHWAYS	Background: IL-1 receptor-associated kinase 4 (IRAK-4) is an effector of the Toll-like receptor and IL-1 receptor pathways that plays a critical role in innate immune responses. The role of IRAK-4 in adaptive immune functions in human subjects is incompletely understood. Objective: We sought to evaluate T-cell function in IRAK-4 deficient patients. Methods: We compared upregulation of CD25 and CD69 on T cells and production of IL-2, IL-6, and IFN-gamma after stimulation of PBMCs from 4 IRAK-4-deficient patients and healthy control subjects with anti-CD3 and anti-CD28. Results: Upregulation of CD25 and CD69 on T cells and production of IL-6 and IFN-gamma, but not IL-2, was significantly reduced in IRAK-4-deficient patients. Conclusions: IRAK-4-deficient patients have defects in T-cell activation. (J Allergy Clin Immunol 2010;126:332-7.)	[McDonald, Douglas R.; Geha, Raif S.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [McDonald, Douglas R.; Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Goldman, Frederick] Childrens Hosp Alabama, Div Hematol & Oncol, Birmingham, AL USA; [Goldman, Frederick] Childrens Hosp Alabama, Dept Pediat, Birmingham, AL USA; [Gomez-Duarte, Oscar D.] Univ Iowa, Childrens Hosp, Dept Pediat, Iowa City, IA USA; [Issekutz, Andrew C.] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada; [Kumararatne, Dinakantha S.; Doffinger, Rainer] Addenbrookes Hosp, Dept Clin Biochem & Immunol, Cambridge, England	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Iowa; Dalhousie University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu			National Institutes of Health [5KO8AI76625, PO1AI035714]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI076625, P01AI035714] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant 5KO8AI76625 (D. R. M.) and National Institutes of Health grant PO1AI035714 (R. S. G.).	BIGBY M, 1990, J IMMUNOL, V144, P3111; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bouma G, 2009, BRIT J HAEMATOL, V147, P153, DOI 10.1111/j.1365-2141.2009.07838.x; BURDIN N, 1995, J IMMUNOL, V154, P2533; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; Gaffen SL, 2008, CYTOKINE, V43, P402, DOI 10.1016/j.cyto.2008.07.017; Goldman FD, 2002, CLIN IMMUNOL, V104, P31, DOI 10.1006/clim.2002.5249; Ivanov II, 2007, SEMIN IMMUNOL, V19, P409, DOI 10.1016/j.smim.2007.10.011; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; Kawagoe T, 2007, J EXP MED, V204, P1013, DOI 10.1084/jem.20061523; Kim TW, 2007, J EXP MED, V204, P1025, DOI 10.1084/jem.20061825; Ku CL, 2007, J EXP MED, V204, P2407, DOI 10.1084/jem.20070628; LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537; Lye E, 2008, EUR J IMMUNOL, V38, P870, DOI 10.1002/eji.200737429; McDonald DR, 2006, J ALLERGY CLIN IMMUN, V118, P1357, DOI 10.1016/j.jaci.2006.08.006; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Sen G, 2005, J IMMUNOL, V175, P3084, DOI 10.4049/jimmunol.175.5.3084; Sporri R, 2005, NAT IMMUNOL, V6, P163, DOI 10.1038/ni1162; Staschke KA, 2009, J IMMUNOL, V183, P568, DOI 10.4049/jimmunol.0802361; Suzuki N, 2006, SCIENCE, V311, P1927, DOI 10.1126/science.1124256; Takeuchi O, 2001, INT IMMUNOPHARMACOL, V1, P625, DOI 10.1016/S1567-5769(01)00010-8; vanderPoll T, 1997, J INFECT DIS, V176, P439, DOI 10.1086/514062; VANLIER RAW, 1989, IMMUNOLOGY, V68, P45; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; Zhang Z, 2009, J CLIN INVEST, V119, P1899, DOI 10.1172/JCI36731; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	27	13	16	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					332	U52		10.1016/j.jaci.2010.05.013	http://dx.doi.org/10.1016/j.jaci.2010.05.013			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20621347	Bronze, Green Accepted			2022-12-18	WOS:000281203800019
J	Leo, HL; Clark, SJ; Butchart, AT; Singer, DC; Clark, NM; Davis, MM				Leo, Harvey L.; Clark, Sarah J.; Butchart, Amy T.; Singer, Dianne C.; Clark, Noreen M.; Davis, Matthew M.			2009 Seasonal and H1N1 influenza vaccination compliance in asthmatic children and adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Leo, Harvey L.; Clark, Noreen M.] Univ Michigan, Sch Publ Hlth, Ctr Managing Chron Dis, Ann Arbor, MI 48109 USA; [Clark, Sarah J.; Butchart, Amy T.; Singer, Dianne C.; Davis, Matthew M.] Univ Michigan, Dept Pediat, Child Hlth Evaluat & Res Unit CHEAR, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Leo, HL (corresponding author), Univ Michigan, Sch Publ Hlth, Ctr Managing Chron Dis, Ann Arbor, MI 48109 USA.	hleo@med.umich.edu						Ampofo K, 2006, PEDIATRICS, V118, P2409, DOI 10.1542/peds.2006-1475; Brim S. N., 2007, Morbidity and Mortality Weekly Report, V56, P193; Dombkowski KJ, 2008, AMBUL PEDIATR, V8, P294, DOI 10.1016/j.ambp.2008.06.005; Hahn Robert, 2007, MMWR Recomm Rep, V56, P1; Hassan F, 2009, AM J PREV MED, V36, P292, DOI 10.1016/j.amepre.2008.11.016; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Ligon C. B., 2008, Morbidity and Mortality Weekly Report, V57, P653; Lu PJ, 2009, AM J PREV MED, V37, P109, DOI 10.1016/j.amepre.2009.03.021; Miller EK, 2008, PEDIATRICS, V121, P1, DOI 10.1542/peds.2007-1053	9	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					166	168		10.1016/j.jaci.2010.03.040	http://dx.doi.org/10.1016/j.jaci.2010.03.040			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20546882				2022-12-18	WOS:000280061800031
J	Caviglia, AG; Passalacqua, G; Senna, G				Caviglia, Antonio G.; Passalacqua, Giovanni; Senna, Gianenrico			Risk of severe anaphylaxis for patients with Hymenoptera venom allergy: Are angiotensin-receptor blockers comparable to angiotensin-converting enzyme inhibitors?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Caviglia, Antonio G.] Italian Natl Healthcare Syst, Saronno, Italy; [Passalacqua, Giovanni] Univ Genoa, DIMI, I-16126 Genoa, Italy; [Senna, Gianenrico] Verona Gen Hosp, Allergy Unit, Verona, Italy	University of Genoa	Caviglia, AG (corresponding author), Italian Natl Healthcare Syst, Saronno, Italy.	caviglia.ag@tin.it	Senna, Gianenrico/AAC-5201-2022	Senna, Gianenrico/0000-0003-4172-3216				Banerji A, 2008, ANN ALLERG ASTHMA IM, V100, P327, DOI 10.1016/S1081-1206(10)60594-7; Mancia G, 2007, EUR HEART J, V28, P1462, DOI [10.1093/eurheartj/ehm236, 10.1093/eurheartj/eht151]; RING J, 1977, LANCET, V1, P466; Rueff F, 2009, J ALLERGY CLIN IMMUN, V124, P1047, DOI 10.1016/j.jaci.2009.08.027	4	13	14	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1171	1171		10.1016/j.jaci.2010.01.045	http://dx.doi.org/10.1016/j.jaci.2010.01.045			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20347124				2022-12-18	WOS:000277686700034
J	FitzGerald, JM; Shahidi, N				FitzGerald, J. Mark; Shahidi, Neal			Achieving asthma control in patients with moderate disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma control; moderate disease; education; inhaled corticosteroids; long acting beta agonists	ACTING BETA-AGONISTS; INHALED CORTICOSTEROIDS; THEOPHYLLINE; SALMETEROL; EXACERBATIONS; SAFETY; METAANALYSIS; CROMOLYN; THERAPY; RISK	Patients with moderate asthma are symptomatic on an ongoing basis. They are usually treated initially with low-dose inhaled corticosteroids (ICSs) supplemented with a short-acting bronchodilator as a rescue medication. Most steroid-naive patients will achieve good control with this strategy. For patients in whom adherence, inhaler technique, environmental control, and comorbidities have been addressed but who still have uncontrolled symptoms, the addition of a long-acting beta-adrenergic agonist should be considered. Some patients might require a higher close of ICS. Leukotriene receptor antagonists might be considered as alternate initial therapy or as an add-on to maintenance therapy with an ICS. All patients should receive a structured education program emphasizing the need for ongoing maintenance treatment, even when control is achieved. Patients should also be provided with a written action plan that clearly explains which additional anti-inflammatory therapy should be taken if asthma symptoms worsen. The most effective strategy in this situation has been shown to be the quadrupling of the maintenance dose of ICS. (J Allergy Clin Immunol 2010;125:307-11.)	Univ British Columbia, Div Resp, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Ctr Lung Hlth, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; University of British Columbia	FitzGerald, JM (corresponding author), Vancouver Gen Hosp, Lung Ctr, 2775 Laurel St, Vancouver, BC V5Z 1M9, Canada.	markf@interchange.ubc.ca		Shahidi, Neal/0000-0002-4536-0515	National Sanitarium Association	National Sanitarium Association	J.M.F. is a Michael Smith Foundation for Health Research Distinguished Scholar and a Canadian Institute for Health Research and BC Lung Scientist and is funded in part by the National Sanitarium Association.	Adams N, 2001, Cochrane Database Syst Rev, pCD003271; Adams N, 1999, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002879; Adams NP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003534.pub3; Bahadori Katayoun, 2009, BMC Pulm Med, V9, P24, DOI 10.1186/1471-2466-9-24; BARNES PJ, 1999, ARCH INTERN MED, V159, P941; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bateman E, 2008, ANN INTERN MED, V149, P33, DOI 10.7326/0003-4819-149-1-200807010-00229; BRUMBACK RA, 1984, LANCET, V1, P958; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; CHROININ MN, 2005, COCHRANE DB SYST REV; CHROININ MN, 2004, COCHRANE DB SYST REV; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Ducharme FM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003137.pub3; Efthimiou J, 1998, EUR RESPIR J, V11, P1167, DOI 10.1183/09031936.98.11051167; Ernst P, 2006, ANN INTERN MED, V145, P692, DOI 10.7326/0003-4819-145-9-200611070-00012; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; FitzGerald JM, 2006, THORAX, V61, P992, DOI 10.1136/thx.2005.045195; FURUKAWA CT, 1984, PEDIATRICS, V74, P453; Gibson PG, 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001005, DOI 10.1002/14651858.CD001005]; Jaeschke R, 2008, AM J RESP CRIT CARE, V178, P1009, DOI 10.1164/rccm.200804-494OC; Kramer JM, 2009, NEW ENGL J MED, V360, P1592, DOI 10.1056/NEJMp0810561; Littner MR, 2005, CHEST, V128, P1128, DOI 10.1378/chest.128.3.1128; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Ng D, 2004, COCHRANE DATABASE SY, DOI [10.1002/14651858.CD002314.pub2, DOI 10.1002/14651858.CD002314.PUB2]; Oborne J, 2009, AM J RESP CRIT CARE, V180, P598, DOI 10.1164/rccm.200904-0616OC; Salpeter SR, 2006, ANN INTERN MED, V144, P904, DOI 10.7326/0003-4819-144-12-200606200-00126; Sears MR, 2009, CHEST, V136, P604, DOI 10.1378/chest.09-1214; SPRINGER C, 1985, J ALLERGY CLIN IMMUN, V76, P64, DOI 10.1016/0091-6749(85)90806-1; Walters JAE, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001288.pub3; Weinberger M, 1996, NEW ENGL J MED, V334, P1380, DOI 10.1056/NEJM199605233342107; Wijesinghe M, 2009, EUR RESPIR J, V34, P803, DOI 10.1183/09031936.00159708; WILLIAMSON IJ, 1995, EUR RESPIR J, V8, P590; Yurdakul AS, 2002, RESP MED, V96, P322, DOI 10.1053/rmed.2002.1282	34	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					307	311		10.1016/j.jaci.2009.12.978	http://dx.doi.org/10.1016/j.jaci.2009.12.978			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159239				2022-12-18	WOS:000274764000004
J	Greenberger, PA; Grammer, LC				Greenberger, Paul A.; Grammer, Leslie C.			Pulmonary disorders, including vocal cord dysfunction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate; acquired; hypersensitivity; eosinophilia; lymphocyte; tuberculosis; aspergillosis; bronchopulmonary; bronchiectasis; immunologic	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ACUTE LUNG INJURY; CHURG-STRAUSS-SYNDROME; DISEASE; SURVIVAL; IGE; FIREFIGHTERS; SALMETEROL; EXPRESSION; MANAGEMENT	The lung is a very complex immunologic organ and responds in a variety of ways to inhaled antigens, organic or inorganic materials, infectious or saprophytic agents, fumes, and irritants. There might be airways obstruction, restriction, neither, or both accompanied by inflammatory destruction of the pulmonary interstitium, alveoli, or bronchioles. This review focuses on diseases organized by their predominant immunologic responses, either innate or acquired. Pulmonary innate immune conditions include transfusion-related acute lung injury, World Trade Center cough, and acute respiratory distress syndrome. Adaptive immunity responses involve the systemic and mucosal immune systems, activated lymphocytes, cytokines, and antibodies that produce CD4+ T(H)1 phenotypes, such as for tuberculosis or acute forms of hypersensitivity pneumonitis, and CD4+ T(H)2 phenotypes, such as for asthma, Churg-Strauss syndrome, and allergic bronchopulmonary aspergillosis. (J Allergy Clin Immunol 2010;125:S248-54.)	[Greenberger, Paul A.; Grammer, Leslie C.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Dept Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Greenberger, PA (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Dept Med, 676 N St Clair St,14018, Chicago, IL 60611 USA.	p-greenberger@northwestern.edu	Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498; Grammer, Leslie/0000-0001-6860-2014	S&C Electric Company	S&C Electric Company	Supported by the Ernest S. Bazley Grant to Northwestern Memorial Hospital and Northwestern University; Disclosure of potential conflict of interest: P. A. Greenberger has served as an expert witness on the topics of immunotheraphy, remote practice, ABPA misdiagnosis, and anaphylaxis. L. Grammer has received research support from S&C Electric Company.	Aaron SD, 2007, ANN INTERN MED, V146, P545, DOI 10.7326/0003-4819-146-8-200704170-00152; Agostini C, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-20; Banauch GI, 2003, AM J RESP CRIT CARE, V168, P54, DOI 10.1164/rccm.200211-1329OC; Barrera L, 2008, AM J RESP CRIT CARE, V177, P44, DOI 10.1164/rccm.200701-093OC; Bastarache JA, 2007, THORAX, V62, P608, DOI 10.1136/thx.2006.063305; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; Calfee CS, 2007, CHEST, V131, P913, DOI 10.1378/chest.06-1743; Callejas-Rubio Jose Luis, 2008, Ther Clin Risk Manag, V4, P1305; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Chen BM, 2004, SARCOIDOSIS VASC DIF, V21, P199; Eder AF, 2007, TRANSFUSION, V47, P599, DOI 10.1111/j.1537-2995.2007.01102.x; Eder AF, 2009, J CLIN APHERESIS, V24, P122, DOI 10.1002/jca.20198; Eppinger TM, 1999, J ALLERGY CLIN IMMUN, V104, P1265, DOI 10.1016/S0091-6749(99)70023-0; Fabbri LM, 2006, AM J RESP CRIT CARE, V173, P1056, DOI 10.1164/rccm.2603005; Fink JN, 2005, AM J RESP CRIT CARE, V171, P792, DOI 10.1164/rccm.200409-1205WS; Glynn JR, 2008, AIDS, V22, P1859, DOI 10.1097/QAD.0b013e3283097cfa; Greenberger PA, 2002, J ALLERGY CLIN IMMUN, V110, P685, DOI 10.1067/mai.2002.130179; Greenberger PA, 2008, J ALLERGY CLIN IMMUN, V121, pS393, DOI 10.1016/j.jaci.2007.07.039; Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003; Guyot-Revol V, 2006, AM J RESP CRIT CARE, V173, P803, DOI 10.1164/rccm.200508-1294OC; HAMAGAMI S, 1999, AM J RESP CRIT CARE, V159, P1830; Higashi N, 2004, J ALLERGY CLIN IMMUN, V114, P1353, DOI 10.1016/j.jaci.2004.09.027; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Joshi AD, 2009, AM J RESP CRIT CARE, V179, P705, DOI 10.1164/rccm.200811-1700OC; Kieszko R, 2007, RESP MED, V101, P722, DOI 10.1016/j.rmed.2006.08.019; KITA H, 2003, MIDDLETONS ALLERGY P, P305; Klion AD, 2006, J ALLERGY CLIN IMMUN, V117, P1292, DOI 10.1016/j.jaci.2006.02.042; Knutsen Alan P, 2006, Clin Mol Allergy, V4, P3, DOI 10.1186/1476-7961-4-3; Kurup Viswanath P, 2006, Clin Mol Allergy, V4, P11, DOI 10.1186/1476-7961-4-11; Lee KS, 2008, RESP MED, V102, P464, DOI 10.1016/j.rmed.2007.10.001; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Menzies D, 2007, ANN INTERN MED, V146, P340, DOI 10.7326/0003-4819-146-5-200703060-00006; Moore WC, 2006, J ALLERGY CLIN IMMUN, V117, P487, DOI 10.1016/j.jaci.2006.01.033; Moss RB, 2006, MED MYCOL, V44, pS269, DOI 10.1080/13693780600835757; Papi A, 2006, AM J RESP CRIT CARE, V173, P1114, DOI 10.1164/rccm.200506-859OC; Perry LP, 1998, MODERN PATHOL, V11, P432; Prezant DJ, 2002, NEW ENGL J MED, V347, P806, DOI 10.1056/NEJMoa021300; Prussin C, 2006, J ALLERGY CLIN IMMUN, V117, pS450, DOI 10.1016/j.jaci.2005.11.016; Reade MC, 2009, CRIT CARE MED, V37, P1655, DOI 10.1097/CCM.0b013e31819da853; Richeldi L, 2006, AM J RESP CRIT CARE, V174, P736, DOI 10.1164/rccm.200509-1516PP; Selman M, 2006, AM J RESP CRIT CARE, V173, P188, DOI 10.1164/rccm.200504-644OC; Shorr AF, 2004, JAMA-J AM MED ASSOC, V292, P2997, DOI 10.1001/jama.292.24.2997; Sterner JB, 2009, RESP CARE, V54, P461; Stevens DA, 2003, CLIN INFECT DIS, V37, pS225, DOI 10.1086/376525; Tsao TCY, 2002, CHEST, V122, P1285, DOI 10.1378/chest.122.4.1285; Tsurikisawa N, 2008, J ALLERGY CLIN IMMUN, V122, P610, DOI 10.1016/j.jaci.2008.05.040; Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741; van der Ent CK, 2007, THORAX, V62, P276, DOI 10.1136/thx.2004.035519; Vemuri P, 2002, ANN ALLERG ASTHMA IM, V88, P640, DOI 10.1016/S1081-1206(10)61898-4; Wark PAB, 2003, J ALLERGY CLIN IMMUN, V111, P952, DOI 10.1067/mai.2003.1388; Wedzicha JA, 2008, AM J RESP CRIT CARE, V177, P19, DOI 10.1164/rccm.200707-973OC; Yuan FF, 2008, IMMUNOL CELL BIOL, V86, P268, DOI 10.1038/sj.icb.7100155	52	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S248	S254		10.1016/j.jaci.2009.09.020	http://dx.doi.org/10.1016/j.jaci.2009.09.020			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20176261				2022-12-18	WOS:000280170600022
J	Kelsay, K				Kelsay, Kimberly			Assessing risk: Data from montelukast clinical trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Montelukast; placebo; clinical trial; suicide; suicidality; adverse experiences; asthma; allergic rhinitis	ASTHMA		[Kelsay, Kimberly] Univ Colorado, Dept Pediat, Denver, CO 80206 USA; [Kelsay, Kimberly] Univ Colorado, Dept Psychiat, Denver, CO 80206 USA	University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Denver	Kelsay, K (corresponding author), Univ Colorado, Dept Pediat, 1400 Jackson St,Suite A206, Denver, CO 80206 USA.	kelsayk@njhealth.org						[Anonymous], 2009, LEUK INH MONT MARK S; Goodwin RD, 2005, AM J PUBLIC HEALTH, V95, P717, DOI 10.2105/AJPH.2003.019109; McQuaid EL, 2001, J DEV BEHAV PEDIATR, V22, P430, DOI 10.1097/00004703-200112000-00011; Nease DE, 2003, J FAM PRACTICE, V52, P469; Philip G, 2009, J ALLERGY CLIN IMMUN, V124, P699, DOI 10.1016/j.jaci.2009.08.011; Philip G, 2009, J ALLERGY CLIN IMMUN, V124, P691, DOI 10.1016/j.jaci.2009.08.010; Posner K, 2007, AM J PSYCHIAT, V164, P1035, DOI 10.1176/appi.ajp.164.7.1035	7	13	14	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					697	698		10.1016/j.jaci.2009.09.001	http://dx.doi.org/10.1016/j.jaci.2009.09.001			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	506UV	19815115				2022-12-18	WOS:000270802800011
J	Tilles, SA; Inglis, AF				Tilles, Stephen A.; Inglis, Andrew F.			Masqueraders of exercise-induced vocal cord dysfunction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Tilles, Stephen A.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; [Inglis, Andrew F.] Seattle Childrens Hosp & Reg Med Ctr, Dept Otolaryngol, Seattle, WA USA	University of Washington; University of Washington Seattle; Seattle Children's Hospital	Tilles, SA (corresponding author), Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.	stilles@nwasthma.com						Abu-Hasan M, 2005, ANN ALLERG ASTHMA IM, V94, P366, DOI 10.1016/S1081-1206(10)60989-1; Davis RS, 2007, J ALLERGY CLIN IMMUN, V119, P1329, DOI 10.1016/j.jaci.2007.04.007; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; NEWMAN KB, 1995, AM J RESP CRIT CARE, V152, P1382, DOI 10.1164/ajrccm.152.4.7551399; Patel NJ, 2004, OTOLARYNG HEAD NECK, V130, P686, DOI 10.1016/j.otohns.2004.01.003; Richter GT, 2008, ARCH OTOLARYNGOL, V134, P75, DOI 10.1001/archoto.2007.17; Weiler JM, 2007, J ALLERGY CLIN IMMUN, V119, P1349, DOI 10.1016/j.jaci.2007.02.041; Wood RP, 1996, J ALLERGY CLIN IMMUN, V98, P481, DOI 10.1016/S0091-6749(96)70079-9	8	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					377	378		10.1016/j.jaci.2009.03.026	http://dx.doi.org/10.1016/j.jaci.2009.03.026			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19477493				2022-12-18	WOS:000268860400028
J	Suzuki, Y; Hattori, S; Mashimo, Y; Funamizu, M; Kohno, Y; Okamoto, Y; Hata, A; Shimojo, N				Suzuki, Yoichi; Hattori, Satoshi; Mashimo, Yoichi; Funamizu, Makiko; Kohno, Yoichi; Okamoto, Yoshitaka; Hata, Akira; Shimojo, Naoki			CD14 and IL4R gene polymorphisms modify the effect of day care attendance on serum IgE levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; AGE		[Suzuki, Yoichi; Hattori, Satoshi; Mashimo, Yoichi; Funamizu, Makiko; Hata, Akira] Chiba Univ, Grad Sch Med, Dept Publ Hlth, Chiba, Japan; [Kohno, Yoichi; Shimojo, Naoki] Chiba Univ, Grad Sch Med, Dept Pediat, Chiba, Japan; [Okamoto, Yoshitaka] Chiba Univ, Grad Sch Med, Dept Otolaryngol, Chiba, Japan	Chiba University; Chiba University; Chiba University	Suzuki, Y (corresponding author), Chiba Univ, Grad Sch Med, Dept Publ Hlth, Chiba, Japan.	ysuzuki@faculty.chiba-u.jp						Celedon JC, 2002, ARCH PEDIAT ADOL MED, V156, P241, DOI 10.1001/archpedi.156.3.241; Fujii K, 2000, HUM MUTAT, V15, P189, DOI 10.1002/(SICI)1098-1004(200002)15:2<189::AID-HUMU8>3.3.CO;2-8; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; Inoue Y, 2007, J INFECT DIS, V195, P1618, DOI 10.1086/516790; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Nishima Sankei, 2009, Allergology International, V58, P37, DOI 10.2332/allergolint.O-08-550; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Rothers J, 2007, J ALLERGY CLIN IMMUN, V120, P1201, DOI 10.1016/j.jaci.2007.07.036; Yang IA, 2007, CURR OPIN ALLERGY CL, V7, P75, DOI 10.1097/ACI.0b013e328012ce39	9	13	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1408	1411		10.1016/j.jaci.2009.03.035	http://dx.doi.org/10.1016/j.jaci.2009.03.035			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19447482				2022-12-18	WOS:000266799100037
J	Wright, RJ				Wright, Rosalind J.			Stress and acquired glucocorticoid resistance: A relationship hanging in the balance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Glucocorticoid resistance; psychological stress; toll-like receptors; social disparities	ASTHMA; HYPERCORTISOLISM		[Wright, Rosalind J.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Channing Lab, Boston, MA 02115 USA; [Wright, Rosalind J.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Wright, RJ (corresponding author), Harvard Univ, Sch Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	rerjw@channing.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080674] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL080674] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adcock IM, 2008, CHEST, V134, P394, DOI 10.1378/chest.08-0440; Bailey MT, 2004, BRAIN BEHAV IMMUN, V18, P416, DOI 10.1016/j.bbi.2003.09.012; Corrigan Chris J, 2007, Ther Clin Risk Manag, V3, P771; Ito K, 2008, AM J RESP CELL MOL, V39, P543, DOI 10.1165/rcmb.2008-0028OC; Lee T, 1996, AM J RESP CRIT CARE, V154, pS1, DOI 10.1164/ajrccm/154.2_Pt_2.S1; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; Malarkey WB, 2007, BRAIN BEHAV IMMUN, V21, P161, DOI 10.1016/j.bbi.2006.10.008; Marwick JA, 2008, BIOCHEM BIOPH RES CO, V377, P797, DOI 10.1016/j.bbrc.2008.10.065; McEwen BS, 2002, METABOLISM, V51, P2, DOI 10.1053/meta.2002.33183; Miller GE, 2002, HEALTH PSYCHOL, V21, P531, DOI 10.1037//0278-6133.21.6.531; MILLER GE, 2009, J ALLERGY C IN PRESS; Myers HF, 2009, J BEHAV MED, V32, P9, DOI 10.1007/s10865-008-9181-4; Powell ND, 2009, BRAIN BEHAV IMMUN, V23, P225, DOI 10.1016/j.bbi.2008.09.010; Sapolsky RM, 1997, ARCH GEN PSYCHIAT, V54, P1137; SAPOLSKY RM, 1989, ARCH GEN PSYCHIAT, V46, P1047; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Wright RJ, 2007, PAEDIATR PERINAT EP, V21, P8, DOI 10.1111/j.1365-3016.2007.00879.x; Wright RJ, 2006, CLIN CHEST MED, V27, P413, DOI 10.1016/j.ccm.2006.04.003; Zhang Y, 2008, J NEUROIMMUNOL, V204, P13, DOI 10.1016/j.jneuroim.2008.08.011	20	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					831	832		10.1016/j.jaci.2009.02.017	http://dx.doi.org/10.1016/j.jaci.2009.02.017			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	431JW	19348921	Green Accepted			2022-12-18	WOS:000265058600007
J	Varshney, P; Jones, SM; Pons, L; Kulis, M; Steele, PH; Kemper, AR; Scurlock, AM; Perry, TT; Burks, AW				Varshney, P.; Jones, S. M.; Pons, L.; Kulis, M.; Steele, P. H.; Kemper, A. R.; Scurlock, A. M.; Perry, T. T.; Burks, A. W.			Oral Immunotherapy (OIT) Induces Clinical Tolerance in Peanut-Allergic Children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	65th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 13-17, 2009	Washington, DC	Amer Acad Allergy, Asthma & Immunol					[Varshney, P.; Pons, L.; Kulis, M.; Steele, P. H.; Kemper, A. R.; Burks, A. W.] Duke Univ, Med Ctr, Durham, NC USA; [Jones, S. M.; Scurlock, A. M.; Perry, T. T.] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Little Rock, AR 72205 USA	Duke University; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences									0	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2				665	S174	S174		10.1016/j.jaci.2008.12.656	http://dx.doi.org/10.1016/j.jaci.2008.12.656			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	410RR					2022-12-18	WOS:000263596301138
J	Winther, L; Poulsen, LK; Robin, B; Melac, M; Malling, H				Winther, L.; Poulsen, L. K.; Robin, B.; Melac, M.; Malling, H.			Safety and Tolerability of Recombinant Bet v 1 (rBet v 1) Tablets in Sublingual Immunotherapy (SLIT)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	65th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 13-17, 2009	Washington, DC	Amer Acad Allergy, Asthma & Immunol					[Winther, L.; Poulsen, L. K.; Malling, H.] Natl Univ Hosp, Copenhagen, Denmark; [Robin, B.; Melac, M.] Stallergenes SA, Antony, France	Stallergenes Greer			m, m/GZB-2153-2022; Poulsen, Lars K/J-3065-2019	Poulsen, Lars K/0000-0002-1730-847X					0	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2				828	S215	S215		10.1016/j.jaci.2008.12.822	http://dx.doi.org/10.1016/j.jaci.2008.12.822			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	410RR					2022-12-18	WOS:000263596301300
J	Adamko, DJ; Wu, YQ; Ajamian, F; Ilarraza, R; Moqbel, R; Gleieh, GJ				Adamko, Darryl J.; Wu, Yingqi; Ajamian, Farnam; Ilarraza, Ramses; Moqbel, Redwan; Gleieh, Gerald J.			The effect of cationic charge on release of eosinophil mediators	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; cationic charge; heparin; eosinophil peroxidase; eosinophil-derived neurotoxin; CD18	MAJOR BASIC-PROTEIN; NEUTROPHIL ADHESION; GRANULE PROTEINS; MAST-CELLS; IN-VIVO; DEPOSITION; HEPARIN; AIRWAY; KINASE; DEGRANULATION	Background: In patients with atopic diseases, cationic-charged eosinophil proteins are deposited in inflamed tissues. Although the role of cytokines in cell activation is well established, the presence of cationic-charged tissue can also be an important factor in inflammatory cell function. Objectives: We sought to determine whether increased cationic charge seen in an atopic microenvironment plays a role in the activation of eosinophils. Methods: Human eosinophils were incubated with Sepharose beads coated ith cationic or anionic compounds in the presence and absence of a cytokine cocktail (IL-3, IL-5, and GM-CSF) to simulate the milieu of inflammation. Eosinophil peroxidase and eosinophil-derived neurotoxin (EDN) release were compared with eosinophil morphology and expression of CD18, as determined by means of confocal microscopy. Results: Cytokines with positively charged beads caused greater eosinophil peroxidase release (lysine coated, 44.2 nmol/L; compound 48/80, 40.0 nmol/L; or EDN coated, 49.1 nmol/L) than cytokines alone (14.9 nmol/L). Beads coated with heparin, dextran sulfate, and aspartic acid did not show this effect. EDN release was also induced by lysine-coated beads with cytokines (67.1 ng/100 mu L) and blocked by heparin. Eosinophil incubation with wortmannin, genistein, and the src kinase inhibitor PP1 blocked cationic signaling. Eosinophils adherent to cationic-charged beads but not anionic-charged beads show polarization of CD18 expression toward the bead's surface. Conclusion: Cationic-charged surfaces induce increased eosinophil mediator release by increasing the density of CD18 expression available at the target surface.	[Adamko, Darryl J.] Univ Alberta, Fac Med & Dent, Pulm Res Grp, Div Pediat Pulm Med,Dept Pediat, Edmonton, AB T6G 2S2, Canada; [Ajamian, Farnam; Moqbel, Redwan] Univ Alberta, Pulm Res Grp, Dept Med, Edmonton, AB T6G 2S2, Canada; [Gleieh, Gerald J.] Univ Utah, Dept Dermatol, Salt Lake City, UT USA; [Gleieh, Gerald J.] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA	University of Alberta; University of Alberta; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Adamko, DJ (corresponding author), Univ Alberta, Fac Med & Dent, Pulm Res Grp, Div Pediat Pulm Med,Dept Pediat, 550A HMRC, Edmonton, AB T6G 2S2, Canada.	dadamko@ualberta.ca			Hospital for Sick Children Foundation; Alberta Heritage Foundation for Medical Research (AHFMR); National Institute of Allergy and Infectious Disease [A109728]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009728, R01AI009728] Funding Source: NIH RePORTER	Hospital for Sick Children Foundation; Alberta Heritage Foundation for Medical Research (AHFMR)(Alberta Heritage Foundation for Medical Research); National Institute of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Hospital for Sick Children Foundation, Alberta Heritage Foundation for Medical Research (AHFMR), and National Institute of Allergy and Infectious Disease grant no. A109728. D.J.A. is an Alberta Heritage Clinical Investigator, and R.M. is an Alberta Heritage Medical Scientist.	ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; Adamko D, 2004, CURR ALLERGY ASTHM R, V4, P149, DOI 10.1007/s11882-004-0061-x; Adamko Darryl, 2002, Curr Allergy Asthma Rep, V2, P107, DOI 10.1007/s11882-002-0005-2; Adamko DJ, 2004, J IMMUNOL METHODS, V291, P101, DOI 10.1016/j.jim.2004.05.003; BARR SE, 1960, J ALLERGY, V31, P406, DOI 10.1016/0021-8707(60)90003-4; Befus AD, 1999, J IMMUNOL, V163, P947; Berton G, 2005, TRENDS IMMUNOL, V26, P208, DOI 10.1016/j.it.2005.02.002; Bochner BS, 2001, IMMUNOL REV, V179, P5, DOI 10.1034/j.1600-065X.2001.790101.x; Bracke M, 2000, BLOOD, V95, P2037, DOI 10.1182/blood.V95.6.2037; BUTTERWORTH AE, 1979, J EXP MED, V150, P1456, DOI 10.1084/jem.150.6.1456; Chung HL, 1999, J ALLERGY CLIN IMMUN, V103, P1195, DOI 10.1016/S0091-6749(99)70199-5; Coffer PJ, 1998, BLOOD, V91, P2547, DOI 10.1182/blood.V91.7.2547.2547_2547_2557; Costello RW, 1997, AM J PHYSIOL-LUNG C, V273, pL93, DOI 10.1152/ajplung.1997.273.1.L93; COYLE AJ, 1993, AM REV RESPIR DIS, V147, P896, DOI 10.1164/ajrccm/147.4.896; DAHL S, 1962, Z Tuberk Erkr Thoraxorg, V118, P255; Diamant Z, 1996, AM J RESP CRIT CARE, V153, P1790, DOI 10.1164/ajrccm.153.6.8665036; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; Fal A M, 2001, Pol Arch Med Wewn, V106, P1121; Feistritzer C, 2005, EXP CELL RES, V305, P214, DOI 10.1016/j.yexcr.2005.01.001; FILLEY WV, 1982, LANCET, V2, P11; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; HAMANN KJ, 1990, J IMMUNOL, V144, P3166; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HAVERSTICK DM, 1992, AM J PHYSIOL, V262, pC916, DOI 10.1152/ajpcell.1992.262.4.C916; INASE N, 1993, AM J PHYSIOL, V264, pL387, DOI 10.1152/ajplung.1993.264.4.L387; Kato M, 1998, AM J RESP CELL MOL, V18, P675, DOI 10.1165/ajrcmb.18.5.2885; KEPHART GM, 1984, LAB INVEST, V50, P51; Khiabani KT, 2004, PLAST RECONSTR SURG, V114, P1846, DOI 10.1097/01.PRS.0000143580.45631.DD; KITA H, 1995, J IMMUNOL, V154, P4749; LEIFERMAN KM, 1990, LAB INVEST, V62, P579; Lynch OT, 1999, BRIT J PHARMACOL, V128, P1149, DOI 10.1038/sj.bjp.0702892; Motegi Y, 2000, INT ARCH ALLERGY IMM, V122, P25, DOI 10.1159/000053627; OTT NL, 1994, J ALLERGY CLIN IMMUN, V94, P120, DOI 10.1016/0091-6749(94)90078-7; Plager DA, 1999, J BIOL CHEM, V274, P14464, DOI 10.1074/jbc.274.20.14464; Rochon YP, 2000, J MICROSC-OXFORD, V197, P15, DOI 10.1046/j.1365-2818.2000.00645.x; SARMIENTO EU, 1995, J IMMUNOL, V155, P2211; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; SHALIT M, 1995, CELL IMMUNOL, V160, P50, DOI 10.1016/0008-8749(95)80008-7; Shenoy NG, 2003, J IMMUNOL, V171, P3734, DOI 10.4049/jimmunol.171.7.3734; Tachimoto H, 2002, INT ARCH ALLERGY IMM, V128, P18, DOI 10.1159/000059414; TALLEY NJ, 1992, GASTROENTEROLOGY, V103, P137, DOI 10.1016/0016-5085(92)91106-E; Tanaka Y, 1996, J EXP MED, V184, P1987, DOI 10.1084/jem.184.5.1987; Trocme SD, 2003, CURR EYE RES, V26, P319, DOI 10.1076/ceyr.26.5.319.15437; UCHIDA DA, 1993, AM REV RESPIR DIS, V147, P982, DOI 10.1164/ajrccm/147.4.982; VILLALTA F, 1987, J PROTOZOOL, V34, P285, DOI 10.1111/j.1550-7408.1987.tb03176.x; VLIAGOFTIS H, 1992, BIOCHEM PHARMACOL, V43, P2237, DOI 10.1016/0006-2952(92)90183-J; Wong CK, 2003, AM J RESP CELL MOL, V29, P133, DOI 10.1165/rcmb.2002-0289OC	48	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					383	390		10.1016/j.jaci.2008.03.020	http://dx.doi.org/10.1016/j.jaci.2008.03.020			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18455220	Bronze			2022-12-18	WOS:000258426300027
J	Bas, M; Kirchhartz, N; Hochfeld, J; Tullmann, C; Kumpf, S; Suvorava, T; Oppermann, M; Hafner, D; Bier, H; Hoffmann, TK; Balz, V; Kojda, G				Bas, Murat; Kirchhartz, Nadine; Hochfeld, Jessica; Tuellmann, Cornelia; Kumpf, Stephanie; Suvorava, Tatsiana; Oppermann, Marc; Hafner, Dieter; Bier, Henning; Hoffmann, Thomas K.; Balz, Vera; Kojda, Georg			Potential role of vasomotor effects of fibrinogen in bradykinin-induced angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						angioedema; angiotensin converting enzyme inhibitor; fibrinogen; acute-phase-protein; bradykinin	INHIBITOR-INDUCED ANGIOEDEMA; ACE-INHIBITORS; MYOCARDIAL-INFARCTION; NITRIC-OXIDE; PROTEIN; EDEMA; CONSTRICTION; PREVENTION; MANAGEMENT; ABCIXIMAB	Background: Although bradykinin is known to play a major role in the pathophysiology of hereditary and angiotensin-converting enzyme inhibitor (ACEi)-induced angioedema, other factors acting as triggers or enhancers are likely important as well. Objective: We hypothesized that fibrinogen might contribute to ACEi-induced angioedema (eg, through direct actions on vascular tone). Methods: Plasma levels of fibrinogen were determined in 59 patients with acute angioedema. Vascular activity of human and bovine fibrinogen and its effects on bradykinin-induced vasodilation and phosphorylation of vasodilator-stimulated phosphoprotein were investigated in small (0.8-1.4 mm in diameter) porcine coronary artery and human internal thoracic artery (ITA) segments. Results: In patients with ACEi-induced angioedema, fibrinogen levels (481 +/- 22 mg/dL, n = 39) were significantly higher than in patients with idiopathic angioedema (302 +/- 15 mg/dL, P < .001). Fibrinogen (1-15 mu mol/L) induced a concentration-dependent vasodilation in preconstricted small porcine coronary arteries (n = 13), reaching a maximum vasodilator effect of 70% +/- 4.7%. Likewise, fibrinogen induced a 52.1% +/- 9.1% (n = 7) vasodilation in ITA rings. Fibrinogen vasorelaxations were completely inhibited by abciximab and diminished by endothelial denudation and treatment with the nitric oxide synthase inhibitor L-nitroargininemethylester and glibenclamide (P <.01). Importantly, fibrinogen increased the vasodilator potency of bradykinin by 10-fold (P <.0001) and increased bradykinin-induced vasodilator-stimulated phosphoprotein phosphorylation (P <.01). Conclusion: The increase of plasma fibrinogen levels, its vasodilator activity in human ITAs, and the potentiation of bradykinin-induced vasodilation suggest that fibrinogen might contribute to the pathophysiology of ACEi-induced angioedema. Thus acute-phase proteins, such as fibrinogen, might be viewed as risk factors for bradykinin-induced angioedema.	[Kojda, Georg] Univ Dusseldorf, Inst Pharmakol & Klin Pharmakol, D-40225 Dusseldorf, Germany; [Bas, Murat; Bier, Henning] Univ Munich, Hals Nasen Ohrenklin & Poliklin, Klinikum Recht Isar Tech, Munich, Germany; [Hoffmann, Thomas K.; Balz, Vera] Univ Klinikum Dusseldorf, Hals Nasen Ohrenklin, Dusseldorf, Germany	Heinrich Heine University Dusseldorf; University of Munich; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital	Kojda, G (corresponding author), Univ Dusseldorf, Inst Pharmakol & Klin Pharmakol, Moorenstr 5, D-40225 Dusseldorf, Germany.	kojda@uni-duesseldorf.de						Adam A, 2002, LANCET, V359, P2088, DOI 10.1016/S0140-6736(02)08914-6; Agostoni A, 2001, DRUG SAFETY, V24, P599, DOI 10.2165/00002018-200124080-00004; Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Ajayi AAL, 2000, BRIT J CLIN PHARMACO, V50, P81, DOI 10.1046/j.1365-2125.2000.00207.x; Bas M, 2007, ALLERGY, V62, P842, DOI 10.1111/j.1398-9995.2007.01427.x; Bas M, 2005, BRIT J CLIN PHARMACO, V59, P233, DOI 10.1111/j.1365-2125.2004.02268.x; Bas M, 2004, HNO, V52, P886, DOI 10.1007/s00106-003-1017-5; Blais C, 1999, IMMUNOPHARMACOLOGY, V43, P293, DOI 10.1016/S0162-3109(99)00133-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Gainer JV, 1996, J ALLERGY CLIN IMMUN, V98, P283, DOI 10.1016/S0091-6749(96)70151-3; Gewaltig MT, 2002, CARDIOVASC RES, V55, P250, DOI 10.1016/S0008-6363(02)00327-9; Gibbs CR, 1999, BRIT J CLIN PHARMACO, V48, P861; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; HECKER M, 1993, J VASC RES, V30, P257, DOI 10.1159/000159004; Herrick S, 1999, INT J BIOCHEM CELL B, V31, P741, DOI 10.1016/S1357-2725(99)00032-1; Hicks RCJ, 1996, NATURE, V379, P818, DOI 10.1038/379818a0; Kojda G, 1999, CARDIOVASC RES, V42, P206, DOI 10.1016/S0008-6363(98)00315-0; Lefebvre J, 2002, HYPERTENSION, V39, P460, DOI 10.1161/hy0202.103054; Lominadze D, 2005, AM J PHYSIOL-HEART C, V288, pH1257, DOI 10.1152/ajpheart.00856.2004; Martinez-Lemus LA, 2005, AM J PHYSIOL-HEART C, V289, pH322, DOI 10.1152/ajpheart.00923.2003; McDowell SE, 2006, BMJ-BRIT MED J, V332, P1177, DOI 10.1136/bmj.38803.528113.55; Messerli FH, 2000, LANCET, V356, P608, DOI 10.1016/S0140-6736(00)02596-4; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Nussberger J, 2002, NEW ENGL J MED, V347, P621, DOI 10.1056/NEJM200208223470820; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Schror K, 2003, J THROMB THROMBOLYS, V15, P71, DOI 10.1023/B:THRO.0000003308.63022.8d; Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; Tam SH, 1998, CIRCULATION, V98, P1085, DOI 10.1161/01.CIR.98.11.1085; Topol EJ, 1999, LANCET, V353, P227, DOI 10.1016/S0140-6736(98)11086-3; Vleeming W, 1998, DRUG SAFETY, V18, P171, DOI 10.2165/00002018-199818030-00003	31	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					969	975		10.1016/j.jaci.2008.01.071	http://dx.doi.org/10.1016/j.jaci.2008.01.071			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18395553				2022-12-18	WOS:000254884000023
J	Matsuoka, H; Niimi, A; Matsumoto, H; Ueda, T; Takemura, M; Yamaguchi, M; Jinnai, M; Chang, L; Otsuka, K; Ogunia, T; Takeda, T; Chin, K; Mishima, M				Matsuoka, Hirofumi; Niimi, Akio; Matsumoto, Hisako; Ueda, Tetsuya; Takemura, Masaya; Yamaguchi, Mosafumi; Jinnai, Makiko; Chang, Liang; Otsuka, Kojiro; Ogunia, Tsuyoshi; Takeda, Tomoshi; Chin, Kazuo; Mishima, Michiaki			Patients' characteristics associated with unsuccessful sputum induction in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EOSINOPHIL CATIONIC PROTEIN; AIRWAY INFLAMMATION		[Matsuoka, Hirofumi; Niimi, Akio; Matsumoto, Hisako; Ueda, Tetsuya; Takemura, Masaya; Yamaguchi, Mosafumi; Jinnai, Makiko; Chang, Liang; Otsuka, Kojiro; Ogunia, Tsuyoshi; Takeda, Tomoshi; Chin, Kazuo; Mishima, Michiaki] Kyoto Univ, Sch Med, Dept Resp Med, Kyoto 6068501, Japan	Kyoto University	Niimi, A (corresponding author), Kyoto Univ, Sch Med, Dept Resp Med, Kyoto 6068501, Japan.	niimi@kuhp.kyoto-u.ac.jp		Matsuoka, Hirofumi/0000-0001-5219-7501				Matsumoto H, 2001, CLIN EXP ALLERGY, V31, P637, DOI 10.1046/j.1365-2222.2001.01034.x; Mayuzumi H, 2007, INT ARCH ALLERGY IMM, V143, P255, DOI 10.1159/000100570; Niimi A, 1998, CLIN EXP ALLERGY, V28, P233; Paggiaro PL, 2002, EUR RESPIR J, V20, p3S, DOI 10.1183/09031936.02.00000302; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; POPOV TA, 1995, EUR RESPIR J, V8, P559; Takemura M, 2004, CHEST, V125, P1352, DOI 10.1378/chest.125.4.1352; Takeyama K, 2001, AM J PHYSIOL-LUNG C, V280, pL165, DOI 10.1152/ajplung.2001.280.1.L165; Wong HH, 1997, AM J RESP CRIT CARE, V156, P299, DOI 10.1164/ajrccm.156.1.9610114; Wright JL, 2002, INHAL TOXICOL, V14, P1153, DOI 10.1080/08958370290084836	10	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					774	776		10.1016/j.jaci.2007.11.032	http://dx.doi.org/10.1016/j.jaci.2007.11.032			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18207226				2022-12-18	WOS:000253918900039
J	Spector, SL; Tan, RA				Spector, Sheldon L.; Tan, Ricardo A.			Omalizumab also successful in chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IGE		[Spector, Sheldon L.] Univ Calif Los Angeles, Med Ctr, Dept Med, Los Angeles, CA 90024 USA; [Spector, Sheldon L.; Tan, Ricardo A.] Calif Allergy & Asthma Med Grp, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Spector, SL (corresponding author), Univ Calif Los Angeles, Med Ctr, Dept Med, Los Angeles, CA 90024 USA.	rtantan@aol.com						Bousquet J, 2004, CHEST, V125, P1378, DOI 10.1378/chest.125.4.1378; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Sands MF, 2007, J ALLERGY CLIN IMMUN, V120, P979, DOI 10.1016/j.jaci.2007.07.041; Spector SL, 2007, ANN ALLERG ASTHMA IM, V99, P190, DOI 10.1016/S1081-1206(10)60644-8	5	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					784	784		10.1016/j.jaci.2007.12.1174	http://dx.doi.org/10.1016/j.jaci.2007.12.1174			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18328900				2022-12-18	WOS:000253918900048
J	Lanz, MJ; Prendes, S; Peyrou, N; Toledo, G; Ferrer, CM				Lanz, Miguel J.; Prendes, Stefunia; Peyrou, Natalia; Toledo, Grace; Ferrer, Cristina M.			Nasal nitric oxide as a noninvasive marker in the antibiotic treatment of acute bacterial sinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RHINOSINUSITIS		[Lanz, Miguel J.] Univ Miami, Miami, FL 33152 USA; [Prendes, Stefunia; Peyrou, Natalia; Toledo, Grace; Ferrer, Cristina M.] Allergy Asthma Sinusitis Clin Res Ctr, Coral Gables, FL USA	University of Miami	Lanz, MJ (corresponding author), Univ Miami, Miami, FL 33152 USA.	mjlanz@pol.net						[Anonymous], 2005, AM J CRIT CARE MED, V171, P912; Baraldi E, 1997, AM J RESP CRIT CARE, V155, P1680, DOI 10.1164/ajrccm.155.5.9154876; Deja M, 2003, AM J RESP CRIT CARE, V168, P281, DOI 10.1164/rccm.200207-640OC; Lanza DC, 1997, OTOLARYNG HEAD NECK, V117, pS1, DOI 10.1016/S0194-5998(97)70001-9; Maniscalco M, 2004, EUR J CLIN INVEST, V34, P555, DOI 10.1111/j.1365-2362.2004.01384.x; Meltzer EO, 2006, J ALLERGY CLIN IMMUN, V118, pS17, DOI 10.1016/j.jaci.2006.09.005; Weitzberg E, 2002, AM J RESP CRIT CARE, V166, P144, DOI 10.1164/rccm.200202-138BC	7	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					530	531		10.1016/j.jaci.2007.09.034	http://dx.doi.org/10.1016/j.jaci.2007.09.034			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18061652				2022-12-18	WOS:000253337800039
J	Vonakis, BM; Saini, SS				Vonakis, Becky M.; Saini, Sarhjit S.			Syk-deficient basophils from donors with chronic idiopathic urticaria exhibit a spectrum of releasability	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AFFINITY IGE RECEPTOR; HISTAMINE-RELEASE; TYROSINE KINASE; EXPRESSION		[Vonakis, Becky M.; Saini, Sarhjit S.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA	Johns Hopkins University	Vonakis, BM (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.	bvonaki@jhmi.edu	Vonakis, Becky/GSN-7958-2022	Vonakis, Becky/0000-0003-4174-6514				HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; Lavens-Phillips SE, 2000, AM J RESP CELL MOL, V23, P566, DOI 10.1165/ajrcmb.23.4.4123; MacGlashan D, 2004, J ALLERGY CLIN IMMUN, V114, P1317, DOI 10.1016/j.jaci.2004.08.037; MacGlashan DW, 2007, J ALLERGY CLIN IMMUN, V119, P626, DOI 10.1016/j.jaci.2006.09.040; Vonakis BM, 2007, J ALLERGY CLIN IMMUN, V119, P441, DOI 10.1016/j.jaci.2006.09.035; Vonakis BM, 2001, J ALLERGY CLIN IMMUN, V108, P822, DOI 10.1067/mai.2001.119159; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	9	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					262	264		10.1016/j.jaci.2007.10.010	http://dx.doi.org/10.1016/j.jaci.2007.10.010			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18206515				2022-12-18	WOS:000252372000045
J	Di Sabatino, A; Rosado, MM; Miele, L; Capolunghi, F; Cazzola, P; Biancheri, P; Carsetti, R; Gasbarrini, G; Corazza, GR				Di Sabatino, Antonio; Rosado, M. Manuela; Miele, Luca; Capolunghi, Federico; Cazzola, Paolo; Biancheri, Paolo; Carsetti, Rita; Gasbarrini, Giovanni; Corazza, Gino R.			Impairment of splenic IgM-memory but not switched-memory B cells in a patient with celiac disease and splenic atrophy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PNEUMOCOCCAL VACCINE; HYPOFUNCTION		[Di Sabatino, Antonio; Cazzola, Paolo; Biancheri, Paolo; Corazza, Gino R.] Univ Pavia, Dept Med 1, Policlin San Matteo, Fdn Ist Ricovero & Cura Carattere Sci, I-27100 Pavia, Italy; [Rosado, M. Manuela; Capolunghi, Federico; Carsetti, Rita] IRCCS Osped Pediat Bambino Gesu, Res Ctr, Rome, Italy; [Miele, Luca; Gasbarrini, Giovanni] Univ Cattolica Sacro Cuore, Dept Internal Med, Policlin Univ Gemelli, Rome, Italy	IRCCS Fondazione San Matteo; University of Pavia; IRCCS Bambino Gesu; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Di Sabatino, A (corresponding author), Univ Pavia, Dept Med 1, Policlin San Matteo, Fdn Ist Ricovero & Cura Carattere Sci, I-27100 Pavia, Italy.	a.disabatino@smatteo.pv.it	Rosado, Maria Manuela/AAX-6495-2020; Corazza, Gino Roberto/K-8500-2016; Biancheri, Paolo/AAC-2394-2022; Di Sabatino, Antonio/K-8015-2016; Miele, Luca/C-2255-2015; Carsetti, Rita/K-7616-2016	Corazza, Gino Roberto/0000-0001-9532-0573; Biancheri, Paolo/0000-0002-8163-9062; Di Sabatino, Antonio/0000-0002-0302-8645; Miele, Luca/0000-0003-3464-0068; Carsetti, Rita/0000-0002-2632-1078				Carsetti R, 2005, J ALLERGY CLIN IMMUN, V115, P412, DOI 10.1016/j.jaci.2004.10.048; CORAZZA GR, 1984, ITAL J GASTROENTEROL, V16, P300; Corazza GR, 1999, AM J GASTROENTEROL, V94, P391; Di Sabatino A, 2006, CLIN GASTROENTEROL H, V4, P179, DOI 10.1016/S1542-3565(05)00982-1; French N, 2003, J INFECTION, V46, P78, DOI 10.1053/jinf.2002.1113; HOSEA SW, 1981, LANCET, V1, P804; Kruetzmann S, 2003, J EXP MED, V197, P939, DOI 10.1084/jem.20022020; MATUCHANSKY C, 1984, GASTROENTEROLOGY, V87, P606; MCKINLEY M, 1995, J CLIN GASTROENTEROL, V20, P113, DOI 10.1097/00004836-199503000-00008; OGRADY JG, 1984, GASTROENTEROLOGY, V87, P1326	10	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1461	1463		10.1016/j.jaci.2007.07.054	http://dx.doi.org/10.1016/j.jaci.2007.07.054			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17889288	Bronze			2022-12-18	WOS:000251653800033
J	Yoo, KH; Johnson, SK; Voigt, RG; Campeau, LJ; Yawn, BP; Juhn, YL				Yoo, Kwang Ha; Johnson, Shirley K.; Voigt, Robert G.; Campeau, Lynnelle J.; Yawn, Barbara P.; Juhn, Young. L.			Characterization of asthma status by parent report and medical record review	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Yoo, Kwang Ha] KonKuk Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Yoo, Kwang Ha; Johnson, Shirley K.; Voigt, Robert G.; Campeau, Lynnelle J.; Juhn, Young. L.] Mayo Clin, Coll Med, Dept Pediat & Adolescent Med, Rochester, MN USA; [Yawn, Barbara P.] Olmsted Med Ctr, Dept Res, Rochester, MN USA	Konkuk University; Konkuk University Medical Center; Mayo Clinic; Olmsted Medical Center	Yoo, KH (corresponding author), KonKuk Univ, Coll Med, Dept Internal Med, Seoul, South Korea.	juhn.young@mayo.edu	Voigt, Robert/AAO-6336-2021					JESSOP DJ, 1995, ARCH PEDIAT ADOL MED, V149, P1105, DOI 10.1001/archpedi.1995.02170230059008; Joseph CLM, 1996, J PEDIATR-US, V129, P735, DOI 10.1016/S0022-3476(96)70158-0; Juhn YJ, 2005, J ALLERGY CLIN IMMUN, V116, P510, DOI 10.1016/j.jaci.2005.05.043; KAPPA RAF, PRINCIPLES MED STAT, P415; Landgraf J.M., 1996, CHILD HLTH QUESTIONN; MILLER JE, 2001, VITAL HLTH STAT, V2, P1; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Yawn BP, 1999, J ALLERGY CLIN IMMUN, V103, P54, DOI 10.1016/S0091-6749(99)70525-7; [No title captured]	9	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1468	1469		10.1016/j.jaci.2007.09.008	http://dx.doi.org/10.1016/j.jaci.2007.09.008			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17981319				2022-12-18	WOS:000251653800036
J	Hens, G; Bobic, S; Reekmans, K; Ceuppens, JL; Hellings, PW				Hens, Greet; Bobic, Sonja; Reekmans, Kristien; Ceuppens, Jan Louis; Hellings, Peter Wim			Rapid systemic uptake of allergens through the respiratory mucosa	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LOWER AIRWAY INFLAMMATION; RHINITIS; ABSORPTION		Catholic Univ Louvain, Clin Immunol, B-3000 Louvain, Belgium; Univ Hosp, Louvain, Belgium	Universite Catholique Louvain	Hens, G (corresponding author), Catholic Univ Louvain, Clin Immunol, B-3000 Louvain, Belgium.	Peter.Hellings@med.kuleuven.be	Hellings, Peter W/I-4068-2018	Hellings, Peter W/0000-0001-6898-688X; Ceuppens, Jan/0000-0003-4502-2679; Hens, Greet/0000-0001-9690-7376				Beeh KM, 2003, CLIN EXP ALLERGY, V33, P475, DOI 10.1046/j.1365-2222.2003.01632.x; Greiff L, 1999, ALLERGY, V54, P31, DOI 10.1111/j.1398-9995.1999.tb04404.x; Greiff L, 1997, AM J RESP CRIT CARE, V156, P783, DOI 10.1164/ajrccm.156.3.9607013; GREIFF L, 1993, THORAX, V48, P648, DOI 10.1136/thx.48.6.648; Hellings PW, 2001, CLIN EXP ALLERGY, V31, P782, DOI 10.1046/j.1365-2222.2001.01081.x; Li J, 2005, IMMUNOLOGY, V114, P386, DOI 10.1111/j.1365-2567.2005.02109.x; Passalacqua G, 2005, CLIN EXP ALLERGY, V35, P880, DOI 10.1111/j.1365-2222.2005.2226.x; SEAYUONG J, 1995, ANN OTO RHINOL LARYN, V104, P895; TOGIAS A, 2006, J ALLERGY CLIN IMM S, V2004, pS1	9	13	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					472	474		10.1016/j.jaci.2007.03.047	http://dx.doi.org/10.1016/j.jaci.2007.03.047			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17498792	Bronze			2022-12-18	WOS:000248654900039
J	Chung, HL; Kim, SY; Kim, SG				Chung, Hai Lee; Kim, So Yeon; Kim, Sang Gyung			Vascular endothelial growth factor and plasminogen activator inhibitor-1 in children with recurrent early wheeze	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; ANGIOGENIN; EXPRESSION; CELLS		Catholic Univ Taegu, Dept Pediat, Sch Med, Taegu, South Korea; Catholic Univ Taegu, Dept Clin Pathol, Sch Med, Taegu, South Korea	Catholic University of Daegu; Catholic University of Daegu	Chung, HL (corresponding author), Catholic Univ Taegu, Dept Pediat, Sch Med, Taegu, South Korea.	hlchung@cu.ac.kr						Abdel-Rahman AMO, 2006, CHEST, V129, P266, DOI 10.1378/chest.129.2.266; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Kucharewicz I, 2003, THROMB RES, V112, P1, DOI 10.1016/j.thromres.2003.10.011; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Piippo-Savolainen E, 2006, ALLERGY ASTHMA PROC, V27, P341, DOI 10.2500/aap.2006.27.2912; Suzaki Y, 2005, J ALLERGY CLIN IMMUN, V116, P1220, DOI 10.1016/j.jaci.2005.08.052; Tutluoglu B, 2005, CLIN APPL THROMB-HEM, V11, P77, DOI 10.1177/107602960501100109	9	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1541	1542		10.1016/j.jaci.2007.02.040	http://dx.doi.org/10.1016/j.jaci.2007.02.040			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17445877				2022-12-18	WOS:000247232800035
J	Davis, RS; Brugman, SM; Larsen, GL				Davis, Ray S.; Brugman, Susan M.; Larsen, Gary L.			Use of videography in the diagnosis of exercise-induced vocal cord dysfunction: A case report with video clips	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						vocal cord dysfunction; videography; exercise-induced asthma; exercise-induced vocal cord dysfunction	INDUCED ASTHMA		Washington Univ, St Louis Childrens Hosp, Div Allergy & Pulm Med, Sch Med, St Louis, MO 63110 USA; Natl Jewish Med & Res Ctr, Div Pediat Pulm Med, Denver, CO USA	St. Louis Children's Hospital; Washington University (WUSTL); National Jewish Health	Davis, RS (corresponding author), 456 N New Ballas Rd,Suite 129, St Louis, MO 63141 USA.	ahchu1@aol.com						Brugman SM, 1998, PHYSICIAN SPORTSMED, V26, P63, DOI 10.3810/psm.1998.05.1013; CHRISTOPHER KL, 1983, NEW ENGL J MED, V308, P1566, DOI 10.1056/NEJM198306303082605; Heimdal JH, 2006, LARYNGOSCOPE, V116, P52, DOI 10.1097/01.mlg.0000184528.16229.ba; Heinle Robert, 2003, Pediatric Asthma Allergy & Immunology, V16, P215, DOI 10.1089/088318703322751273; LAKIN RC, 1984, CHEST, V86, P499, DOI 10.1378/chest.86.3.499; Landwehr LP, 1996, PEDIATRICS, V98, P971; McFadden ER, 1996, AM J RESP CRIT CARE, V153, P942, DOI 10.1164/ajrccm.153.3.8630577; Morris MJ, 1999, CHEST, V116, P1676, DOI 10.1378/chest.116.6.1676; NEWMAN KB, 1995, AM J RESP CRIT CARE, V152, P1382, DOI 10.1164/ajrccm.152.4.7551399; Nixon Gillian M, 2002, Paediatr Respir Rev, V3, P18, DOI 10.1053/prrv.2002.0176	10	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1329	1331		10.1016/j.jaci.2007.04.007	http://dx.doi.org/10.1016/j.jaci.2007.04.007			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17556057	Bronze			2022-12-18	WOS:000247232800006
J	Chinchilli, VM				Chinchilli, Vernon M.			General principles for systematic reviews and meta-analyses and a critique of a recent systematic review of long-acting beta-agonists	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						overviews; literature search; publication bias; funnel plots; fixed-effects models; random-effects models	CLINICAL-TRIALS; QUALITY; ASTHMA	systematic review attempts to summarize the scientific evidence related to treatment, causation, diagnosis, or prognosis of a specific disease. Meta-analysis refers to that portion of the systematic review that involves the statistical analysis. This perspective describes the appropriate steps in a systematic review and meta-analysis and critiques the recent systematic review on the effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. The authors of this systematic review identified 19 relevant studies and applied most of the methodological steps appropriately, although there is some concern about publication bias. The authors uncovered statistically significantly increased risk for long-acting beta-agonists compared with placebo with respect to severe asthma exacerbations, life-threatening asthma exacerbations, and asthma-related deaths. Out of the 19 studies included in the systematic review, the Salmeterol Multicenter Asthma Research Trial provided 80% of the data and dominated the meta-analysis component, especially with respect to asthma-related deaths.	Penn State Coll Med, Dept Hlth Evaluat Sci, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Chinchilli, VM (corresponding author), Penn State Coll Med, Dept Hlth Evaluat Sci, A210,600 Centerview Dr,Suite 2200, Hershey, PA 17033 USA.	vchinchi@psu.edu						COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; Copas J, 2000, Biostatistics, V1, P247, DOI 10.1093/biostatistics/1.3.247; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Glassroth J, 2006, ANN INTERN MED, V144, P936, DOI 10.7326/0003-4819-144-12-200606200-00127; HOLT S, 2001, BRIT MED J, V323, P1, DOI DOI 10.1136/BMJ.323.7307.253; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Nelson HS, 2006, J ALLERGY CLIN IMMUN, V117, P3, DOI 10.1016/j.jaci.2005.10.013; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Pearlman DS, 2006, J ALLERGY CLIN IMMUN, V117, P30, DOI 10.1016/j.jaci.2005.09.030; Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676; Salpeter SR, 2006, ANN INTERN MED, V144, P904, DOI 10.7326/0003-4819-144-12-200606200-00126; Schmid J E, 1991, J Biopharm Stat, V1, P103; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Szefler SJ, 2006, J ALLERGY CLIN IMMUN, V117, P26, DOI 10.1016/j.jaci.2005.11.006	16	13	14	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					303	306		10.1016/j.jaci.2006.11.632	http://dx.doi.org/10.1016/j.jaci.2006.11.632			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17291850	Bronze			2022-12-18	WOS:000244327900005
J	Staley, KG; Stover, C; Strippoli, MPF; Spycher, BD; Silverman, M; Kuehni, CE				Staley, Kathryn G.; Stover, Cordula; Strippoli, Marie-Pierre F.; Spycher, Ben D.; Silverman, Michael; Kuehni, Claudia E.			Mannan-binding lectin in young children with asthma differs by level of severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							POLYMORPHISM; PREVALENCE; WHEEZE		Univ Leicester, Leicester LE1 7RH, Leics, England; Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland	University of Leicester; University of Bern	Staley, KG (corresponding author), Univ Leicester, Leicester LE1 7RH, Leics, England.	kuehni@ispm.unibe.ch	Spycher, Ben/B-3308-2008; Strippoli, Marie-Pierre/K-8164-2013	Spycher, Ben/0000-0002-1430-5695; Stover, Cordula/0000-0002-0125-4868; Strippoli, Marie-Pierre/0000-0003-3053-484X; Kuehni, Claudia E./0000-0001-8957-2002				Aittoniemi J, 2005, CLIN EXP IMMUNOL, V142, P120, DOI 10.1111/j.1365-2249.2005.02881.x; Cedzynski M, 2004, CLIN EXP IMMUNOL, V136, P304, DOI 10.1111/j.1365-2249.2004.02453.x; Kaur S, 2006, CLIN EXP IMMUNOL, V143, P414, DOI 10.1111/j.1365-2249.2006.03007.x; KOCH A, 2001, JAMA-J AM MED ASSOC, V285, P1216; Kuehni CE, 2001, LANCET, V357, P1821, DOI 10.1016/S0140-6736(00)04958-8; Kuehni CE, 2006, J ALLERGY CLIN IMMUN, V118, P528, DOI 10.1016/j.jaci.2006.04.019; Kurukulaaratchy RJ, 2004, THORAX, V59, P563, DOI 10.1136/thx.2003.010462; Michel G, 2006, EUR RESPIR J, V28, P1124, DOI 10.1183/09031936.06.00008406; Uguz A, 2005, PEDIAT ALLERG IMM-UK, V16, P231, DOI 10.1111/j.1399-3038.2005.00258.x; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1	10	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					503	505		10.1016/j.jaci.2006.09.028	http://dx.doi.org/10.1016/j.jaci.2006.09.028			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17125823				2022-12-18	WOS:000244327900034
J	da Costa, JCS; Olsen, PC; Siqueira, RDA; Carvalho, VDF; Serra, MF; Alves, LA; Faria, RX; Xisto, DG; Rocco, PRM; Cordeiro, RSB; Silva, PMRE; Martins, MA				Santos da Costa, Jorge Carlos; Olsen, Priscilla Christina; Siqueira, Rodrigo de Azeredo; Carvalho, Vinicius de Frias; Serra, Magda Fraguas; Alves, Luiz Anastacio; Faria, Robson Xavier; Xisto, Debora Goncalves; Macedo Rocco, Patricia Rieken; Balao Cordeiro, Renato Sergio; Rodrigues e Silva, Patricia Machado; Martins, Marco Auerlio			JMF2-1, a lidocaine derivative acting on airways spasm and lung allergic inflammation in rats	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; local anesthetics; lidocaine; rat model	LOCAL-ANESTHETICS; NEBULIZED LIDOCAINE; INDUCED BRONCHOCONSTRICTION; MAST-CELLS; REFLEX BRONCHOCONSTRICTION; INHALED LIDOCAINE; HISTAMINE-RELEASE; ASTHMA; ATTENUATION; ACTIVATION	Background: Prior reports show that nebulized lidocaine might be an effective treatment for asthma. Objective: We sought to determine the anti-inflammatory and spasmolytic effects of lidocaine and its analogue, JMF2-1, which we have synthesized for reduced local anesthetic activity. Methods: Blockade of Na+ currents was assayed in cultured GH(3) cells by using the patch-clamp technique, whereas anesthesia was assessed in a cutaneous pinching test in rats. Lidocaine and its analogue were nebulized into sensitized rats for evaluation of their effectiveness on airways spasm and inflammation induced by methacholine and allergen, respectively. Tissue histamine release and tracheal spasm triggered by allergen challenge in the absence and presence of these treatments were also examined in vitro. Results: The 50% inhibitory concentration values for blockade of Na+ currents after treatment with JMF2-1 (25.4 mM) was remarkably higher than that of lidocaine (0.18 mM), which is consistent with the weak anesthetic capacity of this analogue. In contrast, JMF2-1 was more potent than lidocaine in inhibiting allergen-induced histamine release and tracheal spasm. In in vivo settings methacholine-induced increase in lung resistance (145%) significantly reduced to 72% and 47% after lidocaine and JMF2-1 treatment, respectively. Both treatments inhibited by about 81% allergen-evoked eosinophil accumulation into the lung tissue. Conclusion: Replacement of the 2,6-dimethyl radicals by the 2-trifluormethyl group on the benzene ring of lidocaine significantly reduces anesthetic activity, preserving its ability to prevent key aspects of the allergic inflammatory response in the lung. Clinical implications: Nebulized JMF2-1 might be a means of achieving the antiasthmatic effects of lidocaine without the anesthetic effects.	Fiocruz MS, Oswaldo Cruz Fdn, Dept Physiol & Pharmacodynam, IOC, BR-926 Rio De Janeiro, Brazil; Fiocruz MS, Oswaldo Cruz Fdn, Dept Immunol, BR-926 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Pulm Invest, Rio De Janeiro, Brazil	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Universidade Federal do Rio de Janeiro	Martins, MA (corresponding author), Fiocruz MS, Oswaldo Cruz Fdn, Dept Physiol & Pharmacodynam, IOC, Av Brasil 4365, BR-926 Rio De Janeiro, Brazil.	mmartins@ioc.fiocruz.br	Rocco, Patricia/I-7460-2012; CORDEIRO, RENATO/B-4137-2009; SILVA, PATRICIA MACHADO RODRIGUES E/AAS-4906-2020; Carvalho, Vinicius F/M-4762-2016; Olsen, Priscilla C/I-8994-2012	Rocco, Patricia/0000-0003-1412-7136; Olsen, Priscilla C/0000-0002-8795-037X; SIQUEIRA, RODRIGO/0000-0002-2967-678X				Bankers-Fulbright JL, 1998, J IMMUNOL, V160, P5546; Barnes PJ, 2004, NAT REV DRUG DISCOV, V3, P831, DOI 10.1038/nrd1524; Barreto ED, 2003, INT ARCH ALLERGY IMM, V131, P212, DOI 10.1159/000071489; Bulut Y, 1996, ANESTHESIOLOGY, V85, P853, DOI 10.1097/00000542-199610000-00021; CAPLAN RA, 1990, ANESTHESIOLOGY, V72, P828, DOI 10.1097/00000542-199005000-00010; Decco ML, 1999, ANN ALLERG ASTHMA IM, V82, P29, DOI 10.1016/S1081-1206(10)62656-7; FISH JE, 1979, RESPIRATION, V37, P201, DOI 10.1159/000194028; Funao T, 2003, CAN J ANAESTH, V50, P805, DOI 10.1007/BF03019376; GOLDSTEIN IM, 1977, J EXP MED, V146, P483, DOI 10.1084/jem.146.2.483; Groeben H, 2002, ANESTHESIOLOGY, V97, P1445, DOI 10.1097/00000542-200212000-00016; Groeben H, 1999, AM J RESP CRIT CARE, V159, P530, DOI 10.1164/ajrccm.159.2.9806102; Groeben H, 2001, ANESTHESIOLOGY, V94, P423, DOI 10.1097/00000542-200103000-00010; Groeben H, 2000, EUR J ANAESTH, V17, P672; Harrison TW, 1998, RESP MED, V92, P1359, DOI 10.1016/S0954-6111(98)90142-1; Hollmann MW, 2000, ANESTHESIOLOGY, V93, P858, DOI 10.1097/00000542-200009000-00038; Hunt LW, 1996, MAYO CLIN PROC, V71, P361, DOI 10.4065/71.4.361; Hunt LW, 2004, J ALLERGY CLIN IMMUN, V113, P853, DOI 10.1016/j.jaci.2004.02.039; JOHNSON HG, 1979, AGENTS ACTIONS, V9, P239, DOI 10.1007/BF01966694; KAI T, 1993, ANESTHESIOLOGY, V78, P954, DOI 10.1097/00000542-199305000-00021; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; LOEHNING RW, 1976, ANESTHESIOLOGY, V44, P306, DOI 10.1097/00000542-197604000-00008; MAKKER HK, 1993, J ALLERGY CLIN IMMUN, V92, P82, DOI 10.1016/0091-6749(93)90041-D; MCALPINE LG, 1989, CHEST, V96, P1012, DOI 10.1378/chest.96.5.1012; MILLER WC, 1975, AM REV RESPIR DIS, V111, P739; NEHER E, 1992, SCI AM, V266, P44, DOI 10.1038/scientificamerican0392-44; Ohnishi T, 1996, CLIN EXP IMMUNOL, V104, P325, DOI 10.1046/j.1365-2249.1996.32737.x; Okada S, 1998, J IMMUNOL, V160, P4010; Rosario NA, 2000, ANN ALLERG ASTHMA IM, V85, P245, DOI 10.1016/S1081-1206(10)62475-1; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SINCLAIR R, 1993, ACTA ANAESTH SCAND, V37, P159, DOI 10.1111/j.1399-6576.1993.tb03693.x; SUZUKI T, 1984, EUR J PHARMACOL, V98, P347, DOI 10.1016/0014-2999(84)90283-8; TAKAGI H, 1966, JPN J PHARMACOL, V16, P287, DOI 10.1254/jjp.16.287; Tanaka A, 2002, J ALLERGY CLIN IMMUN, V109, P485, DOI 10.1067/mai.2002.122155; WEISS EB, 1977, CHEST, V72, P429, DOI 10.1378/chest.72.4.429; WEISS EB, 1978, AM REV RESPIR DIS, V117, P859; WEISS EB, 1975, AM REV RESPIR DIS, V112, P393; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Yanagi H, 1997, Masui, V46, P16; ZAMPONI GW, 1993, BIOPHYS J, V65, P2335, DOI 10.1016/S0006-3495(93)81292-X	39	13	17	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					219	225		10.1016/j.jaci.2006.08.037	http://dx.doi.org/10.1016/j.jaci.2006.08.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208605				2022-12-18	WOS:000243622200031
J	Wagner, F; Rosenkranz, B; Knolle, J				Wagner, F.; Rosenkranz, B.; Knolle, J.			Absolute bioavailability of subcutaneously administered icatibant, a selective and potent bradykinin B2 receptor antagonist	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	63rd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	FEB 23-27, 2007	San Diego, CA	Amer Acad Allergy, Asthma & Immunol					[Wagner, F.] Charite Res Org GmbH, Berlin, Germany; [Rosenkranz, B.; Knolle, J.] Jerini AG, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Shire Pharmaceuticals Limited									0	13	14	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1		1		1071	S274	S274		10.1016/j.jaci.2006.12.441	http://dx.doi.org/10.1016/j.jaci.2006.12.441			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	238PT					2022-12-18	WOS:000251460401454
J	Sacchetti, M; Lambiase, A; Aronni, S; Griggi, T; Ribatti, V; Bonini, S; Bonini, S				Sacchetti, Marta; Lambiase, Alessandro; Aronni, Silvia; Griggi, Tamara; Ribatti, Valentina; Bonini, Stefano; Bonini, Sergio			Hyperosmolar conjunctival provocation for the evaluation of nonspecific hyperreactivity in healthy patients and patients with allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						conjunctival hyperreactivity; conjunctival provocation test; ocular discomfort; nonspecific hyperreactivity; allergy	OCULAR ALLERGY; DOSE-RESPONSE; MITE ALLERGY; CHALLENGE; HYPERRESPONSIVENESS; ASTHMA; HISTAMINE; EYE; INFLAMMATION; CHILDREN	Background: Tissue hyperreactivity of target organs to nonspecific stimuli is known to be an important factor in influencing the clinical picture of allergic disease. Objective: To identify the sensitivity and specificity of a hyperosmolar conjunctival provocation test in predicting conjunctival hyperreactivity and to relate this reactivity to the presence of ocular discomfort in subjects with and without allergy. Methods: In 50 healthy patients and 19 patients with allergic conjunctivitis during remission phase, symptoms of ocular discomfort triggered by nonspecific stimuli were identified and graded with a discomfort score. Subjects were then challenged with a glucose solution at increasing concentrations (from 10% to 50%). The glucose concentration that elicited 2+ conjunctival hyperemia was considered the provoking dose. The response to this hyperosmolar provocation in subjects with ocular discomfort was compared with that of asymptomatic subjects. Sensitivity and specificity of the test in predicting conjunctival hyperreactivity were analyzed. Results: Six of 50 healthy subjects and 12 of 19 subjects with allergy complained of ocular discomfort after exposure to nonspecific stimuli. The hyperosmolar provocation test discriminated between subjects with and without ocular discomfort (mean provoking dose: 39.5%+/- 5% and 47.5%+/- 5% glucose, respectively; P <.001). Forty percent glucose was the optimal threshold dose that demonstrated the highest sensitivity and specificity for prediction of conjunctival hyperreactivity. Discomfort scores were significantly related to provoking dose values (P <.05). Conclusion: This study provides a standardized procedure to detect nonspecific conjunctival hyperreactivity independent of underlying atopy. Clinical implications: Hyperosmolar provocation test may be useful for identifying conjunctival hyperreactivity in subjects with and without allergy with a history of ocular discomfort.	Univ Rome, Dept Ophthalmol, Rome, Italy; Univ Naples 2, Naples, Italy; Italian Natl Res Council, Inst Neurobiol & Mol Med, Rome, Italy	Sapienza University Rome; Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR)	Bonini, S (corresponding author), Via E Longoni 86, I-00155 Rome, Italy.	s.bonini@unicampus.it	Bonini, Stefano/A-2250-2012; Lambiase, Alessandro/K-3902-2016; Bonini, Sergio/T-6594-2019; Sacchetti, Marta/AAB-8616-2021	Bonini, Stefano/0000-0002-7787-2144; Lambiase, Alessandro/0000-0002-8974-991X; Bonini, Sergio/0000-0003-0079-3031; sacchetti, marta/0000-0001-5569-778X				Abelson M B, 1981, Ann Ophthalmol, V13, P1225; Anderson S D, 1996, Respirology, V1, P175, DOI 10.1111/j.1440-1843.1996.tb00029.x; ANDERSON SD, 1975, BRIT J DIS CHEST, V69, P1; Bielory L, 2000, J ALLERGY CLIN IMMUN, V106, P1019, DOI 10.1067/mai.2000.111238; BONINI S, 1993, ANN ALLERGY, V71, P296; BONINI S, 1990, J ALLERGY CLIN IMMUN, V86, P869, DOI 10.1016/S0091-6749(05)80148-4; Bonini S, 1994, Ocul Immunol Inflamm, V2, P191, DOI 10.3109/09273949409057076; BONINI S, 1992, J ALLERGY CLIN IMMUN, V89, P103, DOI 10.1016/S0091-6749(05)80046-6; BONINI S, 1988, J ALLERGY CLIN IMMUN, V81, P173, DOI 10.1016/0091-6749(88)90254-0; BONINI S, 1989, INT ARCH ALLER A IMM, V88, P144, DOI 10.1159/000234769; Bonini S, 2000, OPHTHALMOLOGY, V107, P1157, DOI 10.1016/S0161-6420(00)00092-0; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P1227, DOI 10.1016/0091-6749(93)90327-C; CIPRANDI G, 1994, INT ARCH ALLERGY IMM, V104, P92, DOI 10.1159/000236713; Ciprandi G, 1995, J ALLERGY CLIN IMMUN, V96, P971, DOI 10.1016/S0091-6749(95)70235-0; Ciprandi G, 1999, J INVEST ALLERG CLIN, V9, P35; de Graaf-in't Veld C, 1997, THORAX, V52, P143; De Paiva CS, 2004, AM J OPHTHALMOL, V137, P109, DOI 10.1016/S0002-9394(03)00897-3; DEVRIES K, 1987, CLIN SIGNIFICANCE BR, P359; Gilbard J P, 1999, J Ophthalmic Nurs Technol, V18, P109; Hakonarson H, 2003, RESP PHYSIOL NEUROBI, V137, P263, DOI 10.1016/S1569-9048(03)00152-6; James A, 1997, Respirology, V2, P97, DOI 10.1111/j.1440-1843.1997.tb00061.x; KONNO A, 1987, J ALLERGY CLIN IMMUN, V79, P620, DOI 10.1016/S0091-6749(87)80158-6; KRAYENBUHL MC, 1989, ALLERGY, V44, P25, DOI 10.1111/j.1398-9995.1989.tb00441.x; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; MAGNUSSEN H, 1989, RESPIRATION, V55, P65; Nelson HS, 2005, J ALLERGY CLIN IMMUN, V115, P676, DOI 10.1016/j.jaci.2005.01.037; Nockher WA, 2006, J ALLERGY CLIN IMMUN, V117, P67, DOI 10.1016/j.jaci.2005.08.029; Ono SJ, 2005, J ALLERGY CLIN IMMUN, V115, P118, DOI 10.1016/j.jaci.2004.10.042; PROUD D, 1992, J ALLERGY CLIN IMMUN, V89, P1098, DOI 10.1016/0091-6749(92)90293-B; Rolando M, 2001, SURV OPHTHALMOL, V45, pS203, DOI 10.1016/S0039-6257(00)00203-4; Schiffman RM, 2000, ARCH OPHTHALMOL-CHIC, V118, P615, DOI 10.1001/archopht.118.5.615; Shapiro DE, 1999, STAT METHODS MED RES, V8, P113, DOI 10.1177/096228029900800203; SMITH L, 1995, ANN ALLERG ASTHMA IM, V74, P454; Tosca M, 1998, J INVEST ALLERG CLIN, V8, P23; Van Schoor J, 2000, EUR RESPIR J, V16, P514, DOI 10.1034/j.1399-3003.2000.016003514.x; van Wijk R. Gerth, 1999, Rhinology (Utrecht), V37, P50; Wojnarowski C, 1996, EUR RESPIR J, V9, P1896, DOI 10.1183/09031936.96.09091896	37	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					872	877		10.1016/j.jaci.2006.06.022	http://dx.doi.org/10.1016/j.jaci.2006.06.022			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030240	Bronze			2022-12-18	WOS:000241434200014
J	Higgins, D; Rodriguez, R; Milley, R; Marshall, J; Abbate, C; dela Cruz, T; Patton, K; Walker, F; Chichester, K; Eiden, J; Tuck, S; Van Nest, G				Higgins, Deborah; Rodriguez, Roberto; Milley, Robert; Marshall, Jason; Abbate, Christi; dela Cruz, Tracy; Patton, Kathryn; Walker, Fiona; Chichester, Kristin; Eiden, Joseph; Tuck, Stephen; Van Nest, Gary			Modulation of immunogenicity and allergenicity by controlling the number of immunostimulatory oligonucleotides linked to Amb a 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; immunostimulatory oligonucleotide; linked; immunogenicity; ragweed; Amb a 1; allergy vaccine	RAGWEED HAY-FEVER; CPG OLIGODEOXYNUCLEOTIDES; MURINE MODEL; AIRWAY HYPERRESPONSIVENESS; DNA; AMB; IMMUNOTHERAPY; INFLAMMATION; ASTHMA; CONJUGATION	Background: Immunostimulatory DNA sequences (ISS) are potent immunomodulators that can drive T(H)1 responses to antigens or allergens. This effect can be dramatically enhanced by direct linkage of ISS to the protein. Objective: Evaluate the effects of the number of ISS bound to the major ragweed allergen Amb a 1 on inummogenicity and allergenicity. Methods: Immunogenicity in mice and allergenicity using PBMC or sera from subjects with ragweed allergy were assayed. Results: Both antibody induction in vivo and antibody recognition in vitro were highly sensitive to the number of ISSs linked. IgE recognition of Amb a 1 in competitive ELISA or histamine release assays was inhibited by ISS linkage and showed an inverse relationship to the number of ISSs bound. Type and magnitude of antibody induction in mice was also highly dependent on the number of ISS bound. At the highest ISS to protein ratios, antibody induction was very low. Moderate ISS to protein ratios induced high antibody responses in which IgG(2a) generally predominated. Low ISS to protein ratios produced the highest overall antibody responses in which IgG(1) predominated. In contrast, varied ISS to protein ratios did not affect T-cell responses. In both in vivo mouse studies and in vitro human PBMC studies, all ISS to protein ratios evaluated induced similar responses represented by high levels of IFN-gamma and low levels of T(H)2 cytokines. Conclusion: Controlling the number of ISS bound to a protein allows manipulation of antibody recognition and induction while retaining the potent T(H)1 properties of an ISS-linked protein. Clinical implications: Immunostimulatory DNA sequence-linked Amb a 1 conjugate represents a safe, novel therapeutic approach for treating ragweed allergy.	Dynavax Technol Corp, Berkeley, CA 94710 USA; Johns Hopkins Univ, Ctr Asthma & Allergy, Baltimore, MD 21224 USA	Johns Hopkins University	Higgins, D (corresponding author), Dynavax Technol Corp, 2929 7th St,Suite 100, Berkeley, CA 94710 USA.	dhiggins@dvax.com	Marshall, Jason/ABA-2542-2020	Marshall, Jason/0000-0002-7864-803X				Broide D, 1998, J IMMUNOL, V161, P7054; Cho HJ, 2000, NAT BIOTECHNOL, V18, P509, DOI 10.1038/75365; Creticos PS, 2004, IMMUNOL ALLERGY CLIN, V24, P569, DOI 10.1016/j.iac.2004.06.012; HAYGLASS KT, 1991, IMMUNOLOGY, V73, P407; Horner AA, 2002, J ALLERGY CLIN IMMUN, V110, P413, DOI 10.1067/mai.2002.126660; Kline JN, 1999, J ALLERGY CLIN IMMUN, V104, P1258, DOI 10.1016/S0091-6749(99)70022-9; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 2004, IMMUNOL REV, V199, P201, DOI 10.1111/j.0105-2896.2004.00148.x; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; Marshall JD, 2001, J ALLERGY CLIN IMMUN, V108, P191, DOI 10.1067/mai.2001.116984; NORMAN PS, 1982, J ALLERGY CLIN IMMUN, V70, P248, DOI 10.1016/0091-6749(82)90061-6; Santeliz JV, 2002, J ALLERGY CLIN IMMUN, V109, P455, DOI 10.1067/mai.2002.122156; Shirota H, 2000, J IMMUNOL, V164, P5575, DOI 10.4049/jimmunol.164.11.5575; Shirota H, 2001, J IMMUNOL, V167, P66, DOI 10.4049/jimmunol.167.1.66; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Sur S, 1999, J IMMUNOL, V162, P6284; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Tighe H, 2000, EUR J IMMUNOL, V30, P1939, DOI 10.1002/1521-4141(200007)30:7<1939::AID-IMMU1939>3.0.CO;2-#; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001	19	13	14	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					504	510		10.1016/j.jaci.2006.05.001	http://dx.doi.org/10.1016/j.jaci.2006.05.001			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890778	Bronze			2022-12-18	WOS:000239877700029
J	Malo, JL; L'Archeveque, J; Lummus, Z; Bernstein, D				Malo, Jean-Luc; L'Archeveque, Jocelyne; Lummus, Zana; Bernstein, David			Changes in specific IgE and IgG and monocyte chemoattractant protein-1 in workers with occupational asthma caused by diisocyanates and removed from exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANTIBODIES; ISOCYANATES		Hop Sacre Coeur, Dept Chest Med, Montreal, PQ H4J 1C5, Canada; Univ Cincinnati, Dept Internal Med, Div Immunol & Allergy, Cincinnati, OH USA	Universite de Montreal; University System of Ohio; University of Cincinnati	Malo, JL (corresponding author), Hop Sacre Coeur, Dept Chest Med, Montreal, PQ H4J 1C5, Canada.							Bayer Edward A., 1996, P237, DOI 10.1016/B978-012214730-2/50012-1; Bernstein DI, 2002, AM J RESP CRIT CARE, V166, P445, DOI 10.1164/rccm.2109018; Bernstein IL, 1999, ASTHMA WORKPLACE; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; KAROL MH, 1979, J OCCUP ENVIRON MED, V21, P354; Lemiere C, 2000, AM J RESP CRIT CARE, V162, P976, DOI 10.1164/ajrccm.162.3.9910031; MALO JL, 1988, AM REV RESPIR DIS, V138, P807, DOI 10.1164/ajrccm/138.4.807; Park Hae Sim, 2002, Korean J Intern Med, V17, P249; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709, DOI 10.1016/S0091-6749(98)70181-2; VENABLES KM, 1987, J ALLERGY CLIN IMMUN, V80, P212, DOI 10.1016/0091-6749(87)90131-X	11	13	13	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					530	533		10.1016/j.jaci.2006.04.022	http://dx.doi.org/10.1016/j.jaci.2006.04.022			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890787				2022-12-18	WOS:000239877700038
J	Alexis, NE; Peden, DB				Alexis, NE; Peden, DB			Inflammatory response of the airway to inhaled endotoxin correlates with body mass index in atopic patients with asthma but not in normal volunteers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NEUTROPHIL RESPONSE; OBESITY; LPS; CHILDREN		Univ N Carolina, Dept Pediat, Ctr Environm Med Astham & Lung Biol, Div Pediat Immunol & Infect Dis, Chapel Hill, NC 27516 USA	University of North Carolina; University of North Carolina Chapel Hill	Alexis, NE (corresponding author), Univ N Carolina, Dept Pediat, Ctr Environm Med Astham & Lung Biol, Div Pediat Immunol & Infect Dis, 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27516 USA.			Peden, David/0000-0003-4526-4627	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066559, R01HL062624] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-000046] Funding Source: Medline; NHLBI NIH HHS [R01 HL062624-07, R01-HL66559, R01 HL062624, R01-HL62624] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexis N, 2001, J ALLERGY CLIN IMMUN, V107, P31, DOI 10.1067/mai.2001.111594; Alexis NE, 2005, J ALLERGY CLIN IMMUN, V115, P345, DOI 10.1016/j.jaci.2004.11.040; Alexis NE, 2001, J ALLERGY CLIN IMMUN, V108, P577; Bennett WD, 2004, J APPL PHYSIOL, V97, P821, DOI 10.1152/japplphysiol.01403.2003; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Boehlecke B, 2003, J ALLERGY CLIN IMMUN, V112, P1241, DOI 10.1016/j.jaci.2003.08.052; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; Rivera-Sanchez YM, 2004, J APPL PHYSIOL, V96, P2200, DOI 10.1152/japplphysiol.00960.2003; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P925, DOI 10.1016/j.jaci.2005.01.064; Weiss ST, 2005, NAT IMMUNOL, V6, P537, DOI 10.1038/ni0605-537	10	13	13	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1185	1186		10.1016/j.jaci.2005.12.1305	http://dx.doi.org/10.1016/j.jaci.2005.12.1305			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675350				2022-12-18	WOS:000237436300034
J	Saitoh, A; Singh, KK; Sandall, S; Powell, CA; Fenton, T; Fletcher, CV; Hsia, K; Spector, SA				Saitoh, A; Singh, KK; Sandall, S; Powell, CA; Fenton, T; Fletcher, CV; Hsia, K; Spector, SA			Association of CD4(+) T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	11th Conference on Retroviruses and Opportunistic Infections	FEB 08-11, 2004	San Francisco, CA			T-cell receptor excision circles; immune reconstitution; HIV-1 intracellular DNA; CD4(+) T lymphocytes; HAART; children	PERIPHERAL-BLOOD; HIV-1-INFECTED CHILDREN; IMMUNE RECONSTITUTION; COMBINATION THERAPY; TYPE-1 DNA; CIRCLES; CELLS; INTERLEUKIN-7; REPOPULATION; SUPPRESSION	Background: In a cohort of children receiving highly active antiretroviral therapy (HAART) with sustained plasma HIV-1 RNA < 50 copies/ml,, children who reached undetectable RNA after week 8 (slow responders, median: week 20) had higher HIV-1 intracellular DNA (HIA-1 DNA) and equal or greater CD4(+) T-lymphocyte counts compared with children who reached undetectable plasma HIV-1 RNA by week 8 (rapid responders) throughout HAART. Objective: To determine whether levels of T-cell receptor excision circles (TRECs) could explain the apparent inconsistency between the quantity of HIV-1 DNA and CD4(+) T-lymphocyte counts in HIV-1-infected children receiving HAART with sustained virologic suppression. Methods: T-cell receptor excision circles and HIV-1 DNA and plasma HIV-1 RNA were quantified longitudinally by PCR in 31 children (median age, 5.6 years) with sustained undetectable plasma HIV-1 RNA for >104 weeks of HAART. Results: There was,I positive correlation between TREC and HIV-1 DNA during HAART, notably at weeks 48 and 80 (P < .004). During the early stage of HAART, TREC levels positively correlated with CD4(+) T-lymphocyte percentages (P < .02) and naive CD4(+) T-lymphocyte counts (P < .001) and percentages (P = .05). Median TREC levels were consistently equal or higher in slow responders compared with rapid responders (P < .001) despite slow responders having consistently greater quantities of HIV-1 DNA. Conclusion: To maintain adequate levels of CD4(+) T-lymphocytes, children with high HIV-1 DNA maintain high levels of TREC while receiving HAART. Thus, a thymic control mechanism is required to maintain new CD4(+) T lymphocytes in the presence of persistent virus. Clinical implications: The TREC level is a useful marker of thymic function in HIV-infected children.	Univ Calif San Diego, Dept Pediat, Div Infect Dis, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr AIDS Res, La Jolla, CA 92093 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Univ Colorado, Hlth Sci Ctr, Dept Clin Pharm, Boulder, CO 80309 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University; Harvard T.H. Chan School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Spector, SA (corresponding author), Univ Calif San Diego, Dept Pediat, Div Infect Dis, Stein Clin Res Bldg,Room 428,9500 Gilman Dr, La Jolla, CA 92093 USA.	saspector@ucsd.edu			NCRR NIH HHS [M01 RR000827-30S21059, M01 RR000827] Funding Source: Medline; NIAID NIH HHS [AI-39004, R01 AI033835, AI-33835, AI-41110, AI-27563, U01 AI041110, P30 AI036214, AI-32921, U01 AI027563, U01 AI041089-08, U01 AI032921, R01 AI039004-10, R01 AI039004, U01 AI041089, U01 AI027563-17, AI-36214] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041089, P30AI036214, U01AI027563, R01AI033835, R01AI039004, U01AI032921, U01AI041110] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aladdin H, 2003, SCAND J IMMUNOL, V57, P485, DOI 10.1046/j.1365-3083.2003.01258.x; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Chavan S, 2001, J INFECT DIS, V183, P1445, DOI 10.1086/320197; Christopherson C, 2000, J CLIN MICROBIOL, V38, P630, DOI 10.1128/JCM.38.2.630-634.2000; Correa R, 2003, J CLIN IMMUNOL, V23, P401, DOI 10.1023/A:1025325718213; Correa R, 2002, AIDS, V16, P1181, DOI 10.1097/00002030-200205240-00013; De Rossi A, 2005, ANTIVIR THER, V10, P63; De Rossi A, 2002, J INFECT DIS, V186, P312, DOI 10.1086/341657; Delgado J, 2002, J INFECT DIS, V186, P410, DOI 10.1086/341561; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Franco JM, 2000, CLIN EXP IMMUNOL, V119, P493, DOI 10.1046/j.1365-2249.2000.01152.x; Franco JM, 2002, BLOOD, V99, P3702, DOI 10.1182/blood.V99.10.3702; Gibb DM, 2000, LANCET, V355, P1331, DOI 10.1016/S0140-6736(00)02117-6; Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157; Hazenberg MD, 2000, NAT MED, V6, P1036, DOI 10.1038/79549; Kong FK, 1998, IMMUNITY, V8, P97, DOI 10.1016/S1074-7613(00)80462-8; Kong FK, 1999, P NATL ACAD SCI USA, V96, P1536, DOI 10.1073/pnas.96.4.1536; Okamoto Y, 2002, BLOOD, V99, P2851, DOI 10.1182/blood.V99.8.2851; Ometto L, 2002, AIDS, V16, P839, DOI 10.1097/00002030-200204120-00003; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Ruiz-Mateos E, 2003, AIDS, V17, P947, DOI 10.1097/00002030-200305020-00002; Saitoh A, 2002, J INFECT DIS, V185, P1409, DOI 10.1086/340614; Sempowski GD, 2002, ANNU REV MED, V53, P269, DOI 10.1146/annurev.med.53.082901.104032; Sharland M, 1998, LANCET, V352, P577, DOI 10.1016/S0140-6736(05)79289-8; Starr SE, 1999, NEW ENGL J MED, V341, P1874, DOI 10.1056/NEJM199912163412502; Steffens CM, 2001, AIDS, V15, P1757, DOI 10.1097/00002030-200109280-00003; Wu HL, 2001, AIDS RES HUM RETROV, V17, P1231, DOI 10.1089/088922201750461285	29	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					909	915		10.1016/j.jaci.2006.01.013	http://dx.doi.org/10.1016/j.jaci.2006.01.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	033QB	16630951	Green Accepted, Bronze			2022-12-18	WOS:000236862800028
J	Beasley, R				Beasley, R			A historical perspective of the New Zealand asthma mortality epidemics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							PRESCRIBED FENOTEROL; BETA-AGONISTS; FATAL ASTHMA; DEATH		Med Res Inst New Zealand, Wellington, New Zealand	Medical Research Institute Of New Zealand	Beasley, R (corresponding author), Med Res Inst New Zealand, POB 10055, Wellington, New Zealand.	Richard.Beasley@mrinz.ac.nz	Beasley, Richard/AAH-3908-2019	Beasley, Richard/0000-0003-0337-406X				BEASLEY R, 1994, CLIN EXP ALLERGY, V24, P660, DOI 10.1111/j.1365-2222.1994.tb00970.x; Bremner P, 1996, CHEST, V109, P957, DOI 10.1378/chest.109.4.957; BUIST AS, 1989, LANCET, V1, P1071; CRANE J, 1989, THORAX, V44, P136, DOI 10.1136/thx.44.2.136; CRANE J, 1989, LANCET, V1, P917; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; HORWITZ RI, 1991, CHEST, V100, P1586, DOI 10.1378/chest.100.6.1586; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; ODONNELL TV, 1989, LANCET, V1, P1070; PEARCE N, 1995, LANCET, V345, P41, DOI 10.1016/S0140-6736(95)91159-6; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; PEARCE N, 1992, NEW ENGL J MED, V327, P355; PEARCE N, 1992, HLTH PROFIT MED PHAR, P75; PEARCE N, 2000, ASTHMA RHINITIS, P56; SACKETT DL, 1990, LANCET, V1, P46; SEARS MR, 1985, NEW ZEAL MED J, V98, P271; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P383, DOI 10.1016/0091-6749(87)90055-8; SEARS MR, 1987, BRIT MED J, V294, P477, DOI 10.1136/bmj.294.6570.477; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; VENNING GR, 1983, BRIT MED J, V286, P199, DOI 10.1136/bmj.286.6360.199; WILSON JD, 1981, LANCET, V1, P1235; 1972, BMJ, V2, P443	23	13	13	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					225	228		10.1016/j.jaci.2005.10.029	http://dx.doi.org/10.1016/j.jaci.2005.10.029			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16429618				2022-12-18	WOS:000235687100048
J	Szefler, SJ; Whelan, GJ; Leung, DYM				Szefler, SJ; Whelan, GJ; Leung, DYM			"Black box" warning: Wake-up call or overreaction?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									Natl Jewish Med & Res Ctr, Div Pediat Clin Pharmacol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Allergy & Immunol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	National Jewish Health; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Szefler, SJ (corresponding author), Natl Jewish Med & Res Ctr, Div Pediat Clin Pharmacol, 1400 Jackson St,Rm J313, Denver, CO 80206 USA.	szeflers@njc.org						Aaronson DW, 2006, J ALLERGY CLIN IMMUN, V117, P40, DOI 10.1016/j.jaci.2005.08.060; Beasley R, 2006, J ALLERGY CLIN IMMUN, V117, P225, DOI 10.1016/j.jaci.2005.10.029; Fonacier L, 2005, J ALLERGY CLIN IMMUN, V115, P1249, DOI 10.1016/j.jaci.2005.04.006; Johnson M, 2006, J ALLERGY CLIN IMMUN, V117, P18, DOI 10.1016/j.jaci.2005.11.012; Murphy S, 2006, J ALLERGY CLIN IMMUN, V117, P34, DOI 10.1016/j.jaci.2005.10.031; Nelson HS, 2006, J ALLERGY CLIN IMMUN, V117, P3, DOI 10.1016/j.jaci.2005.10.013; Pearlman DS, 2006, J ALLERGY CLIN IMMUN, V117, P30, DOI 10.1016/j.jaci.2005.09.030; *US FDA, 2005, MED OFF REV PROV M P	8	13	13	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					26	29		10.1016/j.jaci.2005.11.006	http://dx.doi.org/10.1016/j.jaci.2005.11.006			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387579				2022-12-18	WOS:000235687100003
J	Colice, GL; Stampone, P; Leung, DYM; Szefler, SJ				Colice, GL; Stampone, P; Leung, DYM; Szefler, SJ			Oral corticosteroids in poorly controlled asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HYDROFLUOROALKANE-134A BECLOMETHASONE DIPROPIONATE		Washington Hosp Ctr, Pulm Serv, Washington, DC 20010 USA; Washington Hosp Ctr, Crit Care Serv, Washington, DC 20010 USA; Washington Hosp Ctr, Resp Serv, Washington, DC 20010 USA; 3M Pharmaceut, Clin Res, St Paul, MN USA; Natl Jewish Med & Res Ctr, Denver, CO USA	MedStar Washington Hospital Center; MedStar Washington Hospital Center; MedStar Washington Hospital Center; 3M; National Jewish Health	Colice, GL (corresponding author), Washington Hosp Ctr, Pulm Serv, 110 Irving St NW, Washington, DC 20010 USA.							Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; Davies RJ, 1998, RESP MED, V92, P23, DOI 10.1016/S0954-6111(98)90214-1; Gross G, 1999, CHEST, V115, P343, DOI 10.1378/chest.115.2.343; *NAT ASTH ED PROGR, 1997, EXP PAN 2 REP GUID D; Szefler SJ, 1997, EUR RESPIR J, V10, P1640, DOI 10.1183/09031936.97.10071640	5	13	13	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					200	201		10.1016/j.jaci.2004.07.065	http://dx.doi.org/10.1016/j.jaci.2004.07.065			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637569				2022-12-18	WOS:000226267000029
J	Portnoy, J; Barnes, C				Portnoy, J; Barnes, C			The national allergy bureau: Pollen and spore reporting today	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Biographical-Item									Childrens Mercy Hosp, Sect Allergy & Immunol, Kansas City, MO USA	Children's Mercy Hospital	Portnoy, J (corresponding author), Childrens Mercy Hosp, Sect Allergy & Immunol, Kansas City, MO USA.							PUBLICATION LIST	1	13	14	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1235	1238		10.1016/j.jaci.2004.07.062	http://dx.doi.org/10.1016/j.jaci.2004.07.062			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536440				2022-12-18	WOS:000225047800039
J	Morgan, M; Bowers, DC; Gruchalla, RS; Khan, DA				Morgan, M; Bowers, DC; Gruchalla, RS; Khan, DA			Safety and efficacy of repeated monthly carboplatin desensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HYPERSENSITIVITY REACTIONS		Div Allergy & Immunol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Pediat Hematol & Oncol, Dallas, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Morgan, M (corresponding author), Div Allergy & Immunol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Bowers, Daniel/0000-0002-3947-2481				Broome CB, 1996, MED PEDIATR ONCOL, V26, P105; Kook H, 1998, BONE MARROW TRANSPL, V21, P727, DOI 10.1038/sj.bmt.1701161; Markman M, 1999, J CLIN ONCOL, V17, P1141, DOI 10.1200/JCO.1999.17.4.1141; Markman M, 2003, J CLIN ONCOL, V21, P4611, DOI 10.1200/JCO.2003.05.539; Markman M, 2002, GYNECOL ONCOL, V84, P353, DOI 10.1006/gyno.2001.6513; Markman M, 2003, GYNECOL ONCOL, V89, P514, DOI 10.1016/S0090-8258(03)00155-0; Robinson JB, 2001, GYNECOL ONCOL, V82, P550, DOI 10.1006/gyno.2001.6331; Rose PG, 2003, GYNECOL ONCOL, V89, P429, DOI 10.1016/S0090-8258(03)00178-1; WINDOM HH, 1992, J ALLERGY CLIN IMMUN, V90, P681, DOI 10.1016/0091-6749(92)90142-O	9	13	15	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					974	975		10.1016/j.jaci.2004.05.061	http://dx.doi.org/10.1016/j.jaci.2004.05.061			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480344	Bronze			2022-12-18	WOS:000224439100038
J	Stephan, M; Jaeger, B; Lamprecht, F; Kapp, A; Werfel, T; Schmid-Ott, G				Stephan, M; Jaeger, B; Lamprecht, F; Kapp, A; Werfel, T; Schmid-Ott, G			Alterations of stress-induced expression of membrane molecules and intracellular cytokine levels in patients with atopic dermatitis depend on serum IgE levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INTERFERON-GAMMA; LYMPHOCYTES; DISEASES; CELLS; SKIN		Hannover Med Sch, Dept Psychosomat Med, D-30625 Hannover, Germany; Hannover Med Sch, Dept Dermatol & Allergol, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School	Stephan, M (corresponding author), Hannover Med Sch, Dept Psychosomat Med, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Schmid-Ott.Gerhard@mh-hannover.de	Werfel, Thomas/B-6921-2012	Kapp, Alexander/0000-0002-1748-6276				Akdis M, 1997, J IMMUNOL, V159, P4611; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Leung DYM, 2001, J AM ACAD DERMATOL, V44, pS1, DOI 10.1067/mjd.2001.109815; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; REINHOLD U, 1988, INT ARCH ALLER A IMM, V87, P120, DOI 10.1159/000234661; Schmid-Ott G, 2001, J ALLERGY CLIN IMMUN, V107, P171, DOI 10.1067/mai.2001.111850; Schmid-Ott G, 2001, J ALLERGY CLIN IMMUN, V108, P455, DOI 10.1067/mai.2001.117800	9	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					977	978		10.1016/j.jaci.2004.06.041	http://dx.doi.org/10.1016/j.jaci.2004.06.041			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480346				2022-12-18	WOS:000224439100040
J	Poole, JA; Rosenwasser, LJ				Poole, JA; Rosenwasser, LJ			Chronic idiopathic urticaria exacerbated with progesterone therapy treated with a novel desensitization protocol	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AUTOIMMUNITY; ANGIOEDEMA; DERMATITIS		Natl Jewish Med & Res Ctr, Dept Med, Div Allergy Immunol, Denver, CO 80206 USA	National Jewish Health	Poole, JA (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Div Allergy Immunol, 1400 Jackson St, Denver, CO 80206 USA.							BORISH L, 1987, J ALLERGY CLIN IMMUN, V80, P314, DOI 10.1016/0091-6749(87)90037-6; FARAH FS, 1971, J ALLERGY CLIN IMMUN, V48, P257, DOI 10.1016/0091-6749(71)90025-X; GEBER H, 1921, DERMATOL Z, V32, P143; GUY WH, 1951, AMA ARCH DERM SYPH, V63, P377, DOI 10.1001/archderm.1951.01570030091012; HART R, 1977, ARCH DERMATOL, V113, P426, DOI 10.1001/archderm.113.4.426; Kaplan AP, 2002, NEW ENGL J MED, V346, P175, DOI 10.1056/NEJMcp011186; LEZNOFF A, 1989, J ALLERGY CLIN IMMUN, V84, P66, DOI 10.1016/0091-6749(89)90180-2; Snyder JL, 2003, ANN ALLERG ASTHMA IM, V90, P469, DOI 10.1016/S1081-1206(10)61838-8; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X	9	13	13	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					456	457		10.1016/j.jaci.2004.05.031	http://dx.doi.org/10.1016/j.jaci.2004.05.031			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15341029				2022-12-18	WOS:000223405600041
J	Crummy, F; Livingston, M; Ennis, M; Heaney, LG				Crummy, F; Livingston, M; Ennis, M; Heaney, LG			Mast cell mediator release in nonasthmatic subjects after endobronchial adenosine challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cell; adenosine; bronchoscopy; endobronchial challenge	INHALED ADENOSINE; HISTAMINE-RELEASE; SMOOTH-MUSCLE; BRONCHOCONSTRICTION; 5'-MONOPHOSPHATE; PROVOCATION	Background: Adenosine 5'-monophosphate (AMP) has been shown to cause bronchoconstriction in atopic subjects but to have no effect on nonatopic nonasthmatic subjects. Endobronchial AMP challenge has previously been shown to cause mast cell mediator release in asthmatic subjects, but it is unknown whether a similar response occurs in atopic nonasthmatic and nonatopic nonasthmatic control subjects who have no response to inhalation AMP challenge. Objective: This study examined the change in mast cell-derived products after endobronchial saline challenge and AMP challenge in subjects with and without a positive inhalation response to AMP. Methods: Inhalation challenge with AMP challenge was performed in normal, atopic nonasthmatic, and atopic asthmatic subjects. Levels of mast cell mediators were measured after endobronchial adenosine challenge and after placebo endobronchial saline challenge. Results: There were significant increases in histamine, tryptase, protein, and prostaglandin D-2 levels (P =.02, P =.02, P =.01, and P =.01, respectively) after AMP challenge compared with after saline challenge in nonatopic nonasthmatic subjects. There was no significant increase in any mediator in either of the other 2 groups. Conclusion: This study suggests dissociation between mediator release and bronchoconstriction in response to AMP.	Queens Univ Belfast, Resp Res Grp, Inflammat Res Ctr, Belfast, Antrim, North Ireland; Queens Univ Belfast, Dept Clin Biochem & Metab Med, Belfast, Antrim, North Ireland; Queens Univ Belfast, Dept Med, Belfast, Antrim, North Ireland	Queens University Belfast; Queens University Belfast; Queens University Belfast	Heaney, LG (corresponding author), Belfast City Hosp, Reg Resp Ctr, Level 8,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	liam.heaney@bch.n-i.nhs.uk	Ennis, Madeleine/GZG-4070-2022					Ammit AJ, 1997, AM J RESP CRIT CARE, V155, P1123, DOI 10.1164/ajrccm.155.3.9116997; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; Brichtling CE, 2000, AM J RESP CRIT CARE, V162, P878, DOI 10.1164/ajrccm.162.3.9909064; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; CANONICA GW, 1989, ALLERGY, V44, P1, DOI 10.1111/j.1398-9995.1989.tb00438.x; Church MK, 1997, J ALLERGY CLIN IMMUN, V99, P155, DOI 10.1016/S0091-6749(97)70089-7; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CRIMI N, 1992, EUR RESPIR J, V5, P560; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; DRIVER AG, 1993, AM REV RESPIR DIS, V148, P91, DOI 10.1164/ajrccm/148.1.91; Forsythe P, 1999, CLIN SCI, V96, P349, DOI 10.1042/CS19980228; HOLGATE ST, 1986, ARCH INT PHARMACOD T, V280, P240; Holgate ST, 1999, CLIN EXP ALLERGY, V29, P3; KOSHINO T, 1993, CLIN EXP ALLERGY, V23, P919, DOI 10.1111/j.1365-2222.1993.tb00276.x; MANN JS, 1986, J APPL PHYSIOL, V61, P1667, DOI 10.1152/jappl.1986.61.5.1667; PEACHELL PT, 1988, AM REV RESPIR DIS, V138, P1143, DOI 10.1164/ajrccm/138.5.1143; PHILLIPS GD, 1989, CLIN EXP ALLERGY, V19, P405, DOI 10.1111/j.1365-2222.1989.tb02406.x; Polosa R, 1999, THORAX, V54, P230, DOI 10.1136/thx.54.3.230; POLOSA R, 1995, AM J RESP CRIT CARE, V151, P624; Prieto L, 2001, EUR RESPIR J, V17, P64, DOI 10.1183/09031936.01.17100640; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; WATT AH, 1987, BRIT J CLIN PHARMACO, V24, P665, DOI 10.1111/j.1365-2125.1987.tb03227.x	22	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					34	39		10.1016/j.jaci.2004.03.006	http://dx.doi.org/10.1016/j.jaci.2004.03.006			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241341				2022-12-18	WOS:000222534300005
J	Inomata, N; Osuna, H; Ikezawa, Z				Inomata, N; Osuna, H; Ikezawa, Z			Late-onset anaphylaxis to Bacillus natto-fermented soybeans (natto)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LINKED-IMMUNOSORBENT-ASSAY		Yokohama City Univ, Sch Med, Dept Dermatol, Yokohama, Kanagawa 232, Japan	Yokohama City University	Inomata, N (corresponding author), Yokohama City Univ, Sch Med, Dept Dermatol, Yokohama, Kanagawa 232, Japan.		Inomata, Naoko/AAD-7025-2019; Inomata, Naoko/AFS-5909-2022	Inomata, Naoko/0000-0002-1989-9824				DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Drebotg S, 1989, ALLERGY S10, V44, P22; Richard A, 2003, BIOTECHNOL BIOENG, V82, P299, DOI 10.1002/bit.10568; SAKAGUCHI M, 1987, MICROBIOL IMMUNOL, V31, P711, DOI 10.1111/j.1348-0421.1987.tb03132.x; SHIBASAKI M, 1989, ANN ALLERGY, V63, P421; TSUJI H, 1995, BIOSCI BIOTECH BIOCH, V59, P150, DOI 10.1271/bbb.59.150	6	13	14	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					998	1000		10.1016/j.jaci.2004.02.037	http://dx.doi.org/10.1016/j.jaci.2004.02.037			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15148963				2022-12-18	WOS:000221269000028
J	Apter, AJ; Szefler, SJ				Apter, AJ; Szefler, SJ			Advances in adult and pediatric asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; adult asthma; pediatric asthma; adherence; disease management; epidemiology; drug therapy; medical economics; atopy; minorities; inhaled corticosteroids; health disparities; guidelines; alletgic bronchopulmonary aspergillosis; omalizumab; montelukast; clinical research	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; QUALITY-OF-LIFE; FLUTICASONE PROPIONATE; BRONCHIAL HYPERRESPONSIVENESS; INHALED CORTICOSTEROIDS; PERSISTENT ASTHMA; CHILDHOOD ASTHMA; CONTROLLED-TRIAL; ADAM33 GENE; CHILDREN	This review summarizes the highlights in the study of adult and pediatric asthma from October 2002 through October 2003. It is easiest to categorize this year's advances into physiologic, epidemiologic, therapeutic, and primarily pediatric developments. In physiology the identification of the ADAM33 gene as an asthma susceptibility gene has led to a new hypothesis concerning the pathogenesis of asthma. Understanding the integration of the upper and lower airways is likely to have important implications for patient management. Epidemiologic studies continue to show that asthma is a significant and costly disease, with medications comprising the most significant direct costs. Early intervention and improved management can significantly reduce the burden of illness. Research presented indicates there is an opportunity for allergist-immunologists to improve diagnostic and therapeutic approaches to asthma management. Our community has a strong commitment to health care quality, education, and delivery. The Journal will reflect this commitment with a new section devoted to these issues.	Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80202 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80202 USA	University of Pennsylvania; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Apter, AJ (corresponding author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.							Adams RJ, 2002, J ALLERGY CLIN IMMUN, V110, P58, DOI 10.1067/mai.2002.125489; Allen David B, 2003, J Allergy Clin Immunol, V112, pS1, DOI 10.1016/S0091-6749(03)01859-1; Anderson SD, 2003, J ALLERGY CLIN IMMUN, V111, P45, DOI 10.1067/mai.2003.1; [Anonymous], 1993, NIH PUBLICATION, V93-3352; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P938, DOI 10.1067/mai.2003.1417; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Apter Andrea J., 2003, Journal of Allergy and Clinical Immunology, V111, pS780, DOI 10.1067/mai.2003.153; Bager P, 2003, J ALLERGY CLIN IMMUN, V111, P1227, DOI 10.1067/mai.2003.1483; Bager P, 2003, J ALLERGY CLIN IMMUN, V111, P51, DOI 10.1067/mai.2003.34; Busse W, 2003, J ALLERGY CLIN IMMUN, V111, P57, DOI 10.1067/mai.2003.38; Calam R, 2003, J ALLERGY CLIN IMMUN, V112, P499, DOI 10.1067/mai.2003.1639; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Chulada PC, 2003, J ALLERGY CLIN IMMUN, V111, P328, DOI 10.1067/mai.2003.127; Cisternas MG, 2003, J ALLERGY CLIN IMMUN, V111, P1212, DOI 10.1067/mai.2003.1449; Corren J, 2003, J ALLERGY CLIN IMMUN, V111, P87, DOI 10.1067/mai.2003.49; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Drazen JM, 2002, NATURE, V418, P383, DOI 10.1038/418383a; Elmstahl S, 2003, J ALLERGY CLIN IMMUN, V111, P91, DOI 10.1067/mai.2003.4; Finn A, 2003, J ALLERGY CLIN IMMUN, V111, P278, DOI 10.1067/mai.2003.54; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; George M, 2003, J ALLERGY CLIN IMMUN, V111, P967, DOI 10.1067/mai.2003.1459; Gore C, 2003, J ALLERGY CLIN IMMUN, V112, P702, DOI 10.1016/S0091-6749(03)01886-4; Greenberger PA, 2002, J ALLERGY CLIN IMMUN, V110, P685, DOI 10.1067/mai.2002.130179; Ho J, 2003, J ALLERGY CLIN IMMUN, V111, P498, DOI 10.1067/mai.2003.160; Howard TD, 2000, J ALLERGY CLIN IMMUN, V105, pS477, DOI 10.1016/S0091-6749(00)90046-0; Howard TD, 2003, J ALLERGY CLIN IMMUN, V112, P717, DOI 10.1016/S0091-6749(03)01939-0; Hughes R, 2003, LANCET, V361, P2114, DOI 10.1016/S0140-6736(03)13721-X; Israel E, 2002, J ALLERGY CLIN IMMUN, V110, P847, DOI 10.1067/mai.2002.129413; Jenkins HA, 2003, CHEST, V124, P32, DOI 10.1378/chest.124.1.32; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; Kim CK, 2003, J ALLERGY CLIN IMMUN, V112, P64, DOI 10.1067/mai.2003.1618; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kurukulaaratchy RJ, 2003, J ALLERGY CLIN IMMUN, V112, P311, DOI 10.1067/mai.2003.1623; Lai CKW, 2003, J ALLERGY CLIN IMMUN, V111, P263, DOI 10.1067/mai.2003.30; Lind DL, 2003, AM J RESP CRIT CARE, V168, P1312, DOI 10.1164/rccm.200306-877OC; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Liu AH, 2003, J ALLERGY CLIN IMMUN, V111, P471, DOI 10.1067/mai.2003.172; Marotta A, 2003, J ALLERGY CLIN IMMUN, V112, P317, DOI 10.1067/mai.2003.1627; Medeiros M, 2003, J ALLERGY CLIN IMMUN, V111, P947, DOI 10.1067/mai.2003.1381; Melo RE, 2003, J ALLERGY CLIN IMMUN, V111, P301, DOI 10.1067/mai.2003.66; Meyer KA, 2003, J ALLERGY CLIN IMMUN, V111, P757, DOI 10.1067/mai.2003.1391; Nagy A, 2003, J ALLERGY CLIN IMMUN, V112, P729, DOI 10.1016/S0091-6749(03)02010-4; Nakano Y, 2003, J ALLERGY CLIN IMMUN, V112, P525, DOI 10.1067/mai.2003.1710; Nelson HS, 2003, J ALLERGY CLIN IMMUN, V112, P29, DOI 10.1067/mai.2003.1558; *NIH NAT HEART LUN, 1997, NIH NAT HEART LUNG B; Oddy WH, 2003, J ALLERGY CLIN IMMUN, V112, P723, DOI 10.1016/S0091-6749(03)01941-9; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Rasmussen F, 2002, J ALLERGY CLIN IMMUN, V110, P220, DOI 10.1067/mai.2002.125295; Roberts G, 2003, J ALLERGY CLIN IMMUN, V111, P491, DOI 10.1067/mai.2003.138; Rullo VEV, 2002, J ALLERGY CLIN IMMUN, V110, P582, DOI 10.1067/mai.2002.127511; Samee S, 2003, J ALLERGY CLIN IMMUN, V111, P1205, DOI 10.1067/mai.2003.1544; Sandrini A, 2003, J ALLERGY CLIN IMMUN, V111, P313, DOI 10.1067/mai.2003.64; Sano Y, 2003, J ALLERGY CLIN IMMUN, V111, P958, DOI 10.1067/mai.2003.1415; Schatz M, 2003, J ALLERGY CLIN IMMUN, V111, P503, DOI 10.1067/mai.2003.178; Schatz M, 2003, J ALLERGY CLIN IMMUN, V112, P283, DOI 10.1067/mai.2003.1516; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P534, DOI 10.1016/S0091-6749(99)70320-9; Stafford RS, 2003, J ALLERGY CLIN IMMUN, V111, P729, DOI 10.1067/mai.2003.177; Steinke JW, 2003, J ALLERGY CLIN IMMUN, V111, P342, DOI 10.1067/mai.2003.67; Stevens DA, 2000, NEW ENGL J MED, V342, P756, DOI 10.1056/NEJM200003163421102; Strunk RC, 2002, J ALLERGY CLIN IMMUN, V110, P596, DOI 10.1067/mai.2002.128803; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Sullivan SD, 2002, J ALLERGY CLIN IMMUN, V110, P576, DOI 10.1067/mai.2002.128009; Svanes C, 2003, J ALLERGY CLIN IMMUN, V112, P289, DOI 10.1067/mai.2003.1596; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Verlato G, 2003, J ALLERGY CLIN IMMUN, V111, P1232, DOI 10.1067/mai.2003.1484; Wark PAB, 2003, J ALLERGY CLIN IMMUN, V111, P952, DOI 10.1067/mai.2003.1388; Werner M, 2003, J ALLERGY CLIN IMMUN, V112, P323, DOI 10.1067/mai.2003.1648; Wong J, 2002, J ALLERGY CLIN IMMUN, V110, P721, DOI 10.1067/mai.2002.128858; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; 2002, J ALLERGY CLIN IMM S, V110, pS141	72	13	14	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					407	414		10.1016/j.jaci.2003.12.002	http://dx.doi.org/10.1016/j.jaci.2003.12.002			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007338	Bronze			2022-12-18	WOS:000220144200009
J	Frew, AJ				Frew, AJ			Mold allergy: Some progress made, more needed	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							ASTHMA		Southampton Gen Hosp, Sch Med, Infect Inflammat & Repair Res Div, Southampton SO16 6YD, Hants, England	University of Southampton	Frew, AJ (corresponding author), Southampton Gen Hosp, Sch Med, Infect Inflammat & Repair Res Div, Mailpoint 810, Southampton SO16 6YD, Hants, England.		Kelly, Frank J/C-6125-2009	Kelly, Frank J/0000-0003-2558-8392				AKIYAMA K, 1994, ALLERGY, V49, P778, DOI 10.1111/j.1398-9995.1994.tb02102.x; BLACKLEY C, 1873, EXPT RES CAUSES CATA; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; *CDCP, 2000, JAMA-J AM MED ASSOC, V283, P1951; CROFT WA, 1986, ATMOS ENVIRON, V20, P549, DOI 10.1016/0004-6981(86)90096-X; Esch RE, 2004, J ALLERGY CLIN IMMUN, V113, P210, DOI 10.1016/j.jaci.2003.11.024; Etzel RA, 1998, ARCH PEDIAT ADOL MED, V152, P757; Hossain MA, 2004, J ALLERGY CLIN IMMUN, V113, P200, DOI 10.1016/j.jaci.2003.12.018; Lacour M, 2002, INT J HYG ENVIR HEAL, V205, P257, DOI 10.1078/1438-4639-00159; Levetin E, 2004, J ALLERGY CLIN IMMUN, V113, P366, DOI 10.1016/j.jaci.2003.09.049; MALO JL, 1977, THORAX, V32, P269, DOI 10.1136/thx.32.3.269; Portnoy JM, 2004, J ALLERGY CLIN IMMUN, V113, P189, DOI 10.1016/j.jaci.2003.11.021; Terr AI, 2004, J ALLERGY CLIN IMMUN, V113, P221, DOI 10.1016/j.jaci.2003.11.014	14	13	13	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					216	218		10.1016/j.jaci.2003.12.038	http://dx.doi.org/10.1016/j.jaci.2003.12.038			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767432	Bronze			2022-12-18	WOS:000188885700004
J	Banwell, ME; Robinson, DS; Lloyd, CM				Banwell, ME; Robinson, DS; Lloyd, CM			Adenoid-derived T(H)2 cells reactive to allergen and recall antigen express CC chemokine receptor 4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; airway; T(H)2; CCR4; adenoid	T-CELLS; DIFFERENTIAL EXPRESSION; LUNG INFLAMMATION; PERIPHERAL-BLOOD; CANDIDA-ALBICANS; DENDRITIC CELLS; AIRWAY DISEASE; IN-VIVO; CHILDREN; LYMPHOCYTES	Background: Interrupting recruitment of allergen-specific T(H)2 cells to the airway is an attractive potential therapeutic strategy for allergic disease. CC chemokine receptor 4 (CCR4) is preferentially expressed on T(H)2 cells, and CCR4-expressing cells have been described at sites of allergic inflammation. However, whether selective recruitment of allergen-specific T(H)2 cells to the airways occurs through CCR4 or other chemokine receptors remains controversial. Objective: We investigated the expression of the T(H)2-associated chemokine receptors (CCR3, CCR4, and CCR8) by primary antigen-specific human airway T(H)2 cells. Methods: Children undergoing elective adenoidectomy were recruited, and their atopic status was determined. Adenoid cells were cultured with allergen or recall antigen. Flow cytometric analyses permitted identification of T-H cells proliferating in response to antigen and characterization of chemokine receptor and cytokine expression. Results: An increased proportion of airway CD4(+) T cells proliferated to allergen in atopic children (n = 6, of which 4 were given diagnoses of asthma or rhinitis) compared with nonatopic children (P = .0004). These cells were 44.7% (32.6% to 50.0%) IL-4(+) and only 2.5% (0.6% to 3.3%) IFN-gamma and showed a greater than 5-fold upregulation of CCR4 expression to 54.0% (40.7% to 67.8%) after culture, whereas CCR3 was expressed on 9.7% (7.4% to 18.9%) of allergen-reactive cells and CCR8 on less than 1%. Interestingly, increased expansion of recall antigen-specific cells was also seen in atopic children, and these cells were also predominantly of a T(H)2 CCR4(+) phenotype. Conclusion: We conclude that airway allergen-specific T(H)2 cells are CCR4(+), but in the atopic child CCR4 does not distinguish between recall antigen and allergen specificity.	Univ London Imperial Coll Sci Technol & Med, Biomed Sci Div, Fac Med, London SW7 2AZ, England; St Marys Hosp NHS Trust, Dept Otorhinolaryngol, London, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England	Imperial College London; Imperial College London	Lloyd, CM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Biomed Sci Div, Fac Med, Sir Alexander Fleming Bldg,Exhibit Rd, London SW7 2AZ, England.			Lloyd, Clare/0000-0001-8977-6726	Wellcome Trust [087618] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Biedermann T, 2002, EUR J IMMUNOL, V32, P3171, DOI 10.1002/1521-4141(200211)32:11<3171::AID-IMMU3171>3.0.CO;2-4; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Chung CD, 2003, J IMMUNOL, V170, P581, DOI 10.4049/jimmunol.170.1.581; Chvatchko Y, 2000, J EXP MED, V191, P1755, DOI 10.1084/jem.191.10.1755; D'Ambrosio D, 2003, J IMMUNOL METHODS, V273, P3, DOI 10.1016/S0022-1759(02)00414-3; Dunbar PR, 1998, CURR BIOL, V8, P413, DOI 10.1016/S0960-9822(98)70161-7; Fokkens WJ, 1998, CLIN EXP ALLERGY, V28, P187; Gonzalo JA, 1999, J IMMUNOL, V163, P403; Goya I, 2003, J IMMUNOL, V170, P2138, DOI 10.4049/jimmunol.170.4.2138; Huang SW, 2001, ANN ALLERG ASTHMA IM, V87, P350, DOI 10.1016/S1081-1206(10)62251-X; Julia V, 2002, IMMUNITY, V16, P271, DOI 10.1016/S1074-7613(02)00276-5; Kawasaki S, 2001, J IMMUNOL, V166, P2055, DOI 10.4049/jimmunol.166.3.2055; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kim CH, 2001, J CLIN INVEST, V108, P1331, DOI 10.1172/JCI200113543; Kleinegger CL, 1996, J CLIN MICROBIOL, V34, P2246, DOI 10.1128/JCM.34.9.2246-2254.1996; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Lilic D, 1996, CLIN EXP IMMUNOL, V105, P205, DOI 10.1046/j.1365-2249.1996.d01-764.x; Lloyd C, 2002, IMMUNOLOGY, V105, P144, DOI 10.1046/j.1365-2567.2002.01344.x; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Mori A, 2001, INT ARCH ALLERGY IMM, V125, P48, DOI 10.1159/000053853; Nouri-Aria KT, 2002, EUR J IMMUNOL, V32, P1933, DOI 10.1002/1521-4141(200207)32:7<1933::AID-IMMU1933>3.0.CO;2-R; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; Paganelli R, 1998, ALLERGY, V53, P763; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Papatziamos G, 1999, ALLERGY, V54, P916, DOI 10.1034/j.1398-9995.1999.00033.x; Perry M, 1998, IMMUNOL TODAY, V19, P414, DOI 10.1016/S0167-5699(98)01307-3; Robinson DS, 2000, BRIT MED BULL, V56, P956, DOI 10.1258/0007142001903625; Romani L, 1999, CURR OPIN MICROBIOL, V2, P363, DOI 10.1016/S1369-5274(99)80064-2; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Schuh JM, 2002, FASEB J, V16, P1313, DOI 10.1096/fj.02-0193fje; Soler D, 2003, BLOOD, V101, P1677, DOI 10.1182/blood-2002-07-2348; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Vogler RC, 2000, CLIN OTOLARYNGOL, V25, P392, DOI 10.1046/j.1365-2273.2000.00381.x; Zingoni A, 1998, J IMMUNOL, V161, P547	36	13	15	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1155	1161		10.1016/j.jaci.2003.08.029	http://dx.doi.org/10.1016/j.jaci.2003.08.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657875				2022-12-18	WOS:000187154200019
J	Plaut, M; Tinkle, SS				Plaut, M; Tinkle, SS			Risks of smallpox vaccination: 200 Years after Jenner	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						vaccination; smallpox; atopic dermatitis; eczema; immunity	COMPLICATIONS		NIAID, Allerg Mech Sect, Asthma Allergy & Inflammat Branch, Div Allergy Immunol & Transplantat,NIH,DHHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Plaut, M (corresponding author), NIAID, Allerg Mech Sect, Asthma Allergy & Inflammat Branch, Div Allergy Immunol & Transplantat,NIH,DHHS, 6610 Rockledge Dr,Room 3093,MSC 6601, Bethesda, MD 20892 USA.							Bray M, 2003, ANTIVIR RES, V58, P101, DOI 10.1016/S0166-3542(03)00008-1; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P639; COPEMAN PWM, 1964, BRIT MED J, V2, P906, DOI 10.1136/bmj.2.5414.906; Engler RJM, 2002, J ALLERGY CLIN IMMUN, V110, P357, DOI 10.1067/mai.2002.128052; Grabenstein JD, 2003, JAMA-J AM MED ASSOC, V289, P3278, DOI 10.1001/jama.289.24.3278; Gruchalla RS, 2003, J ALLERGY CLIN IMMUN, V112, P675, DOI 10.1016/j.jaci.2003.08.001; Hackett CJ, 2003, J ALLERGY CLIN IMMUN, V112, P686, DOI 10.1016/S0091-6749(03)02025-6; Halsell JS, 2003, JAMA-J AM MED ASSOC, V289, P3283, DOI 10.1001/jama.289.24.3283; KEMPE CH, 1960, PEDIATRICS, V26, P176; LANE JM, 1970, J INFECT DIS, V122, P303, DOI 10.1093/infdis/122.4.303; LANE JM, 1969, NEW ENGL J MED, V281, P1201, DOI 10.1056/NEJM196911272812201; LANE JM, 1970, J AMER MED ASSOC, V212, P441, DOI 10.1001/jama.212.3.441; Mullin D, 2003, J ALLERGY CLIN IMMUN, V112, P810; Naleway AL, 2003, ANN INTERN MED, V139, P1, DOI 10.7326/0003-4819-139-1-200307010-00006; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Stittelaar KJ, 2001, VACCINE, V19, P3700, DOI 10.1016/S0264-410X(01)00075-5; Urashima R, 1998, VIRCHOWS ARCH, V432, P363, DOI 10.1007/s004280050179; Wollenberg A, 2003, J ALLERGY CLIN IMMUN, V112, P667, DOI 10.1016/j.jaci.2003.07.001; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x; Wright ME, 2003, JAMA-J AM MED ASSOC, V289, P3306, DOI 10.1001/jama.289.24.3306	20	13	13	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					683	685		10.1016/j.jaci.2003.07.002	http://dx.doi.org/10.1016/j.jaci.2003.07.002			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564344	Bronze			2022-12-18	WOS:000185831200005
J	Leung, DYM; Bock, SA				Leung, DYM; Bock, SA			Progress in peanut allergy research: Are we closer to a cure?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						peanut allergy; food allergy	ANTI-IGE THERAPY; FOOD ALLERGY; ANAPHYLACTIC REACTIONS; CHILDREN; IMMUNOTHERAPY; PREVALENCE; MANAGEMENT; RESPONSES; ASTHMA		Natl Jewish Med & Res Ctr, Div Pediat Allergy Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Div Pediat Allergy Immunol, 1400 Jackson St,Room K926, Denver, CO 80206 USA.							Beyer K, 2003, J ALLERGY CLIN IMMUN, V112, P202, DOI 10.1067/mai.2003.1621; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Boushey HA, 2001, J ALLERGY CLIN IMMUN, V108, pS77, DOI 10.1067/mai.2001.116434; Busse PJ, 2002, NEW ENGL J MED, V347, P1535, DOI 10.1056/NEJM200211073471921; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Gold MS, 2000, J ALLERGY CLIN IMMUN, V106, P171, DOI 10.1067/mai.2000.106041; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Maleki SJ, 2003, J ALLERGY CLIN IMMUN, V112, P190, DOI 10.1067/mai.2003.1551; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Oettgen HC, 2001, J ALLERGY CLIN IMMUN, V107, P429, DOI 10.1067/mai.2001.113759; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Roberts G, 2003, J ALLERGY CLIN IMMUN, V112, P168, DOI 10.1067/mai.2003.1569; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Simonte SJ, 2003, J ALLERGY CLIN IMMUN, V112, P180, DOI 10.1067/mai.2003.1486; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Vadas P, 2003, J ALLERGY CLIN IMMUN, V112, P175, DOI 10.1067/mai.2003.1480	30	13	13	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					12	14		10.1067/mai.2003.1624	http://dx.doi.org/10.1067/mai.2003.1624			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847473				2022-12-18	WOS:000184010600003
J	Anand, MK; Nelson, HS; Dreskin, SC				Anand, MK; Nelson, HS; Dreskin, SC			A possible role for cyclooxygenase 2 inhibitors in the treatment of chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SKIN MAST-CELLS; COX-2 INHIBITORS; ANGIOEDEMA; CANCER		Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Div Allergy Immunol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Div Clin Immunol & Allergy, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Anand, MK (corresponding author), Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Div Allergy Immunol, 4200 E 9th Ave,Campus Box B164, Denver, CO 80262 USA.							AUSTEN KF, 1987, DRUGS, V33, P10, DOI 10.2165/00003495-198700331-00004; BENYON RC, 1989, BRIT J PHARMACOL, V97, P898, DOI 10.1111/j.1476-5381.1989.tb12030.x; Borges MS, 2001, ANN ALLERG ASTHMA IM, V87, P201, DOI 10.1016/S1081-1206(10)62226-0; Church MK, 1999, ANN ALLERG ASTHMA IM, V83, P471, DOI 10.1016/S1081-1206(10)62853-0; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Dang CT, 2002, ONCOLOGY-NY, V16, P30; Greaves M, 2000, J ALLERGY CLIN IMMUN, V105, P664, DOI 10.1067/mai.2000.105706; Grimm V, 2002, J ALLERGY CLIN IMMUN, V109, P370, DOI 10.1067/mai.2002.121315; KAPLAN AP, 2001, SAMTERS IMMUNOLOGIC, P865; KAWATA R, 1995, J IMMUNOL, V155, P818; Kelkar PS, 2001, J RHEUMATOL, V28, P2553; LINDELOF B, 1990, BRIT J DERMATOL, V123, P453; SCHEIMER RP, 1998, ALLERGY PRINCIPLES P, P638; Schellenberg RR, 2001, NEW ENGL J MED, V345, P1856, DOI 10.1056/NEJM200112203452518; Spector S, 1998, J ALLERGY CLIN IMMUN, V101, P572	15	13	13	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1133	1136		10.1067/mai.2003.1454	http://dx.doi.org/10.1067/mai.2003.1454			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743584	Bronze			2022-12-18	WOS:000182904500034
J	Fiset, PO; Soussi-Gounni, A; Christodoulopoulos, P; Tulic, M; Sobol, SE; Frenkiel, S; Lavigne, F; Lamkhioued, B; Hamid, Q				Fiset, PO; Soussi-Gounni, A; Christodoulopoulos, P; Tulic, M; Sobol, SE; Frenkiel, S; Lavigne, F; Lamkhioued, B; Hamid, Q			Modulation of allergic response in nasal mucosa by antisense oligodeoxynucleotides for IL-4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; nasal mucosa; cytokines; antisense oligonucleotides; immunomodulation	HUMAN B-CELLS; IFN-GAMMA; IN-VITRO; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; GENE TRANSCRIPTS; MESSENGER-RNA; BACTERIAL-DNA; CPG MOTIFS; EOTAXIN; EXPRESSION	Background: The cytokine IL-4 is highly involved in T(H)2 inflammation, such as that seen in allergic rhinitis. IL-4 can induce IgE synthesis and eotaxin. Recent studies have shown that stimulation of allergic nasal tissue with ragweed allergen can induce local IL-4 mRNA production. Objective: We set out to determine whether IL-4 antisense phosphorothioate-modified oligodeoxynucleotides (PS-ODNs) could inhibit IL-4 production and downstream events of IL-4. Methods: Nasal mucosa biopsy specimens were obtained from patients with seasonal ragweed allergic rhinitis out of season, incubated ex vivo with or without PS-ODNs, and challenged with ragweed. FITC-labeled oligonucleotides were used to determine tissue uptake. By using immunocytochemistry, IL4-, IL-13-, eotaxin 1-, and IFN-gamma-producing cells were enumerated, and by using in situ hybridization, epsilon germline transcript RNA- and IL-4 mRNA-positive cells were examined. Results: The antisense PS-ODN was taken up by the tissue, and preincubation of the tissue with the IL-4 antisense PS-OWN caused a decrease in allergen-induced IL-4 mRNA and a decrease in the amount of IL-4 immunoreactivity (n = 7, P <.001). PS-ODNs had inhibitory effects on allergen-induced E germline transcript RNA expression (n = 7, P <.001) and mucosa eotaxin 1 immunoreactivity (n = 7, P <.05). In contrast, the PS-ODNs increased the amount of IFN-gamma immunoreactivity (n = 7, P <.05), suggesting a nonspecific mechanism for reduced synthesis of IgE and eotaxin. Conclusions: Our results show that the IL-4 antisense PS-ODN effectively inhibits IL-4, IgE synthesis, and eotaxin, principal mediators of allergic inflammation, suggesting that PS-ODNs might offer a possible topical treatment for allergic rhinitis.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Sir Mortimer B Davis Jewish Hosp, Montreal, PQ, Canada; Notre Dame Hosp, Montreal, PQ, Canada	McGill University; McGill University; Universite de Montreal	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.		Gounni, Abdelilah Soussi/AAH-3456-2020; Tulic, Meri K/ABB-5138-2020; Tulic, Meri/P-6613-2016; LAMKHIOUED, Bouchaib/AAL-4201-2021	Tulic, Meri K/0000-0002-2661-2369; Tulic, Meri/0000-0002-2661-2369; Soussi Gounni, Abdelilah/0000-0002-7282-0388; Gounni, Abdelilah/0000-0003-1265-6560				ABEHSIRAAMAR O, 1992, J IMMUNOL, V148, P3820; Baek KH, 2001, J IMMUNOL, V167, P2847, DOI 10.4049/jimmunol.167.5.2847; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Cameron L, 2000, J ALLERGY CLIN IMMUN, V106, P46; Cameron L, 2000, J IMMUNOL, V164, P1538, DOI 10.4049/jimmunol.164.3.1538; Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538; Crooke ST, 1999, BBA-GENE STRUCT EXPR, V1489, P31, DOI 10.1016/S0167-4781(99)00148-7; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2000, VACCINE, V19, P618, DOI 10.1016/S0264-410X(00)00249-8; Li L, 1999, J IMMUNOL, V162, P2477; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Miyamasu M, 1999, INT IMMUNOL, V11, P1001, DOI 10.1093/intimm/11.6.1001; Mochizuki M, 1998, J IMMUNOL, V160, P60; Molet S, 1999, J ALLERGY CLIN IMMUN, V104, P205, DOI 10.1016/S0091-6749(99)70137-5; Nakamura Y, 2000, J ALLERGY CLIN IMMUN, V105, P1146, DOI 10.1067/mai.2000.107045; Oettgen HC, 2001, J ALLERGY CLIN IMMUN, V107, P429, DOI 10.1067/mai.2001.113759; Parronchi P, 1999, J IMMUNOL, V163, P5946; Shinkai A, 1999, J IMMUNOL, V163, P1602; Teran LM, 1999, AM J RESP CELL MOL, V20, P777, DOI 10.1165/ajrcmb.20.4.3508; Vinogradov SV, 2002, ADV DRUG DELIVER REV, V54, P135, DOI 10.1016/S0169-409X(01)00245-9; XU LX, 1993, P NATL ACAD SCI USA, V90, P3705, DOI 10.1073/pnas.90.8.3705; XU LX, 1994, INT IMMUNOL, V6, P515, DOI 10.1093/intimm/6.4.515; ZHANG K, 1991, J IMMUNOL, V146, P1836; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	29	13	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					580	586		10.1067/mai.2003.179	http://dx.doi.org/10.1067/mai.2003.179			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642840				2022-12-18	WOS:000181639500021
J	Melamed, J; Stahlman, JE				Melamed, J; Stahlman, JE			Rapid desensitization and rush immunotherapy to trastuzumab (Herceptin)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Allergy & Asthma Specialists, Chelmsford, MA USA; Ctr Asthma & Allergy, Atlanta, GA USA		Melamed, J (corresponding author), Allergy & Asthma Specialists, Chelmsford, MA USA.							Eiermann W, 2001, ANN ONCOL, V12, P57, DOI 10.1023/A:1011172125897; GEORGITIS JW, 1991, ANN ALLERGY, V66, P343; McKeage K, 2002, DRUGS, V62, P209, DOI 10.2165/00003495-200262010-00008	3	13	14	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2002	110	5					813	814		10.1067/mai.2002.128689	http://dx.doi.org/10.1067/mai.2002.128689			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	612NN	12417895				2022-12-18	WOS:000179082500021
J	Katial, RK; Grier, MJ; Hazelhurst, DM; Hershey, J; Engler, RJM				Katial, RK; Grier, MJ; Hazelhurst, DM; Hershey, J; Engler, RJM			Deleterious effects of electron beam radiation on allergen extracts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						electron beam radiation; ionizing radiation; allergen extracts		Background: The recent threat to the public posed by the dissemination of Bacillus anthracis through the US postal system has resulted in increased security measures, including electron beam irradiation for the sterilization of some mail. The deleterious effects of electron beam radiation on biological products are not fully understood. Objective: The purpose of this investigation was to assess the effect of electron beam radiation, as currently used to sterilize packages and mail in the United States, on several standardized or characterized allergen extracts. Methods: Selected irradiated extracts were analyzed for allergen content and potency by SDS-PAGE, immunoblot, and ELISA (including inhibition) and compared with untreated extracts. Results: The compositions and immunochemical potencies of these products were altered significantly by irradiation treatment. Physical changes to native protein structures observed after electrophoretic separations coincided with near-complete loss of allergenic and antigenic epitopes present on major and minor allergens, according to ELISA and immunoblot comparisons with untreated extracts. Conclusions: These results indicate that extracts subjected to electron beam sterilization conditions are likely to contain modified component structures and properties that might compromise the clinical effectiveness of these products.	Walter Reed Army Med Ctr, Allergy & Immunol Clin, Dept Allergy & Immunol, Washington, DC 20307 USA; Greer Labs, Lenoir, NC USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Katial, RK (corresponding author), Walter Reed Army Med Ctr, Allergy & Immunol Clin, Dept Allergy & Immunol, Bldg 2,Room 1J, Washington, DC 20307 USA.							*ASS ADV MED INSTR, 1997, 17 AAMITIR; Bowen JE, 1996, SALISBURY MED B S, V87, P70; Byun MW, 2000, J FOOD PROTECT, V63, P940, DOI 10.4315/0362-028X-63.7.940; CHRISTENSEN EA, 1992, PRINCIPLES PRACTICE, P528; Hansen J.M., 2001, DISINFECTION STERILI, V5, P729; MOREHOUSE K, 1998, FOOD TESTING ANAL, V4, P25; Morehouse K. M., 1998, FOOD TESTING ANAL, V4, P9; Morehouse K.M., 1998, FOOD TESTING ANAL, V4, P32; 2002, USPS IRRADIATION UPD	9	13	19	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					215	219	UNSP 1/10/126377	10.1067/mai.2002.126377	http://dx.doi.org/10.1067/mai.2002.126377			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170260				2022-12-18	WOS:000177509800004
J	Reuben, JM; Lee, BN; Paul, M; Kline, MW; Cron, SG; Abramson, S; Lewis, D; Kozinetz, CA; Shearer, WT				Reuben, JM; Lee, BN; Paul, M; Kline, MW; Cron, SG; Abramson, S; Lewis, D; Kozinetz, CA; Shearer, WT			Magnitude of IFN-gamma production in HIV-1-infected children is associated with virus suppression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pediatric HIV; highly active antiretroviral therapy; immune restoration; cytokine production; virus suppression	HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; INTERLEUKIN-2 PRODUCTION; WHOLE-BLOOD; TYPE-1; INFECTION; HAART; QUANTIFICATION; LYMPHOCYTES; INDIVIDUALS	Background: Little is known about the cytokine production by peripheral blood cells of pediatric patients who have suppressed HIV-1 replication after highly active antiretroviral therapy (HAART). Objective: We sought to determine the effect of HAART on the production of T(H)1 and T(H)2 cytokines by HIV-infected children who have suppressed HIV replication. Methods: At 3- to 6-month intervals over a 5-year period, CD4(+) T cells were enumerated, plasma HIV-1 RNA was measured, and levels of cytokine production by whole blood cultures were determined in 21 HIV-1-infected children. Results: Ten patients achieved an HIV-1 RNA level of less than 3000 copies/mL of plasma and maintained that level for at least 15 months (virus-suppressed [VS] group). Eleven patients had a mean HIV-1 RNA level of greater than 104 copies/mL of plasma and a mean CD4+ T-cell count of less than 500/muL of blood (active infection group). The median levels of anti-CD3-induced IL-2, IFN-gamma, and IL-10 in the active infection group were significantly lower than those in the VS group after suppression of the virus. The median slope of IFN-gamma production by means of PHA-stimulated culture after achieving VS status (4.04) was significantly higher than the level before VS status (-1.31, P = .004). The difference in the median slopes for IL-10 production by anti-CD3-stimulated cultures before (0.21) and after (-0.16) achieving VS status was statistically different (P = .027). Conclusion: The immune restoration of HIV-1-infected children receiving HAART might be related to an increase in IFN-gamma production and a decrease in the rate of IL-10 production after virus suppression.	Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine	Reuben, JM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, 1515 Holcombe Blvd,Box 54, Houston, TX 77030 USA.		Paul, Mary/AAA-2722-2021		NCRR NIH HHS [RR 00188] Funding Source: Medline; NIAID NIH HHS [AI 36211, AI 39131] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039131, P30AI036211] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1994, MMWR-MORBID MORTAL W, V43, P1; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BAROJA ML, 1987, J IMMUNOL METHODS, V98, P267, DOI 10.1016/0022-1759(87)90014-7; Benyoucef S, 1996, PATHOL BIOL, V44, P393; Carcelain G, 2001, J VIROL, V75, P234, DOI 10.1128/JVI.75.1.234-241.2001; COHEN SJ, 1998, AIDS, V12, P2155; David D, 1998, P NATL ACAD SCI USA, V95, P11348, DOI 10.1073/pnas.95.19.11348; Essajee SM, 1999, AIDS, V13, P2523, DOI 10.1097/00002030-199912240-00005; Gibb DM, 2000, LANCET, V355, P1331, DOI 10.1016/S0140-6736(00)02117-6; Goulder PJR, 2000, J EXP MED, V192, P1819, DOI 10.1084/jem.192.12.1819; Hodge G, 2000, CYTOKINE, V12, P1763, DOI 10.1006/cyto.2000.0790; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; Kostense S, 2001, EUR J IMMUNOL, V31, P677, DOI 10.1002/1521-4141(200103)31:3<677::AID-IMMU677>3.0.CO;2-M; Lee BN, 1996, CLIN DIAGN LAB IMMUN, V3, P493, DOI 10.1128/CDLI.3.5.493-499.1996; Lin HJ, 1996, J CLIN MICROBIOL, V34, P329, DOI 10.1128/JCM.34.2.329-333.1996; MOSSMAN TR, 1991, IMMUNOL TODAY, V12, pA48; Ostrowski MA, 2001, J INFECT DIS, V184, P1268, DOI 10.1086/324005; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Ross L, 2000, AIDS, V14, P813, DOI 10.1097/00002030-200005050-00007; Smith KY, 2000, J INFECT DIS, V181, P141, DOI 10.1086/315169; Weiss L, 1999, J INFECT DIS, V180, P1057, DOI 10.1086/315025; WEISSMAN D, 1994, AIDS RES HUM RETROV, V10, P1199, DOI 10.1089/aid.1994.10.1199	22	13	15	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					255	261	UNSP 1/84/125979	10.1067/mai.2002.125979	http://dx.doi.org/10.1067/mai.2002.125979			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170266				2022-12-18	WOS:000177509800010
J	Bacharier, LB				Bacharier, LB			"Step-down" therapy for asthma: Why, when, and how?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						asthma therapy; "step down"	RANDOMIZED CONTROLLED TRIAL; LONG-TERM TREATMENT; INHALED CORTICOSTEROIDS; AIRWAY INFLAMMATION; SALMETEROL; BUDESONIDE; REDUCTION; MONTELUKAST; ANTAGONIST; MODERATE		St Louis Childrens Hosp, Div Allergy & Pulm Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, St Louis, MO 63130 USA	St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL)	Bacharier, LB (corresponding author), St Louis Childrens Hosp, Div Allergy & Pulm Med, 1 Childrens Pl, St Louis, MO 63110 USA.			Bacharier, Leonard/0000-0003-0432-2704				Campbell LM, 1998, INT J CLIN PRACT, V52, P361; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; Fowler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P929, DOI 10.1067/mai.2002.123869; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Lofdahl CG, 1999, BMJ-BRIT MED J, V319, P87, DOI 10.1136/bmj.319.7202.87; Lonnkvist K, 2001, J ALLERGY CLIN IMMUN, V107, P812, DOI 10.1067/mai.2001.114246; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; *NAT ASTHM ED PREV, 1997, PUBL US DEP HHS; National cholesterol education program National heart lung and blood institute National institutes of health, 2002, 3 REP NAT CHOL ED PR; Nielsen LP, 1999, RESP MED, V93, P863, DOI 10.1016/S0954-6111(99)90051-3; Roberts JA, 1999, EUR RESPIR J, V14, P275, DOI 10.1034/j.1399-3003.1999.14b07.x; Self T, 1998, CURR THER RES CLIN E, V59, P803, DOI 10.1016/S0011-393X(98)85106-0; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Tamaoki J, 1997, AM J RESP CRIT CARE, V155, P1235, DOI 10.1164/ajrccm.155.4.9105060; Visser MJ, 2001, AM J RESP CRIT CARE, V164, P2073, DOI 10.1164/ajrccm.164.11.2103075; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252, DOI 10.1164/ajrccm/148.5.1252; Wilding P, 1997, BRIT MED J, V314, P1441, DOI 10.1136/bmj.314.7092.1441; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590	24	13	13	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					916	919		10.1067/mai.2002.124665	http://dx.doi.org/10.1067/mai.2002.124665			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063517	Bronze			2022-12-18	WOS:000176442700003
J	Srivastava, KD; Li, XM; King, N; Stanley, S; Bannon, GA; Burks, W; Sampson, HA				Srivastava, KD; Li, XM; King, N; Stanley, S; Bannon, GA; Burks, W; Sampson, HA			Immunotherapy with modified peanut allergens in a murine model of peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Univ Arkansas, Little Rock, AR 72204 USA; Mt Sinai Med Ctr, New York, NY 10029 USA	University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Icahn School of Medicine at Mount Sinai									0	13	15	1	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1		S		877	S287	S287		10.1016/S0091-6749(02)82012-7	http://dx.doi.org/10.1016/S0091-6749(02)82012-7			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519UX					2022-12-18	WOS:000173744800874
J	Irani, C; Gordon, ND; Zweiman, B; Levinson, AI				Irani, C; Gordon, ND; Zweiman, B; Levinson, AI			Chronic urticaria/angioedema and Graves' disease: Coexistence of 2 antireceptor antibody-mediated diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC IDIOPATHIC URTICARIA; FC-EPSILON-RI		Univ Penn, Allergy & Immunol Sect, Philadelphia, PA 19104 USA	University of Pennsylvania	Irani, C (corresponding author), Univ Penn, Allergy & Immunol Sect, 421 Curie Blvd,911 BRBII, Philadelphia, PA 19104 USA.							Hermes B, 1999, J ALLERGY CLIN IMMUN, V103, P307, DOI 10.1016/S0091-6749(99)70506-3; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; LEZNOFF A, 1989, J ALLERGY CLIN IMMUN, V84, P66, DOI 10.1016/0091-6749(89)90180-2; Sabroe RA, 1999, J ALLERGY CLIN IMMUN, V103, P484, DOI 10.1016/S0091-6749(99)70475-6; Weetman AP, 2000, NEW ENGL J MED, V343, P1236, DOI 10.1056/NEJM200010263431707; Zweiman B, 1996, J ALLERGY CLIN IMMUN, V98, P89, DOI 10.1016/S0091-6749(96)70230-0	6	13	13	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					874	874		10.1067/mai.2001.119161	http://dx.doi.org/10.1067/mai.2001.119161			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692119				2022-12-18	WOS:000172523800034
J	Homer, AA; Widhopf, GF; Burger, JA; Takabayashi, K; Cinman, N; Ronaghy, A; Spiegelberg, HL; Raz, E				Homer, AA; Widhopf, GF; Burger, JA; Takabayashi, K; Cinman, N; Ronaghy, A; Spiegelberg, HL; Raz, E			Immunostimulatory DNA inhibits IL-4-dependent IgE synthesis by human B cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; B lymphocytes; allergy; isotype switching; vaccination; IL-4 receptor; IFN-gamma receptor; CpG motif; immunostimulatory DNA	CPG MOTIFS; AIRWAY INFLAMMATION; GAMMA PRODUCTION; MURINE MODEL; IFN-GAMMA; IN-VITRO; OLIGODEOXYNUCLEOTIDES; LYMPHOCYTES; EXPRESSION; INTERLEUKIN-12	Background: Immunostimulatory sequence oligodeoxynucleotide (ISS-ODN) is a potent antiallergic immunomodulating agent in mice. However, few studies have addressed its antiallergic potential in human subjects. Objective: We sought to determine whether a phosphorothioate ISS-ODN could inhibit IL-4-dependent IgE synthesis by human B cells. Methods: Initially, nonatopic- and atopic-donor PBMCs were incubated with ISS-ODN or mutated oligodeoxynucleotide, and cytokine production and B-cell expression of IFN-gamma receptor and IL-4 receptor were measured by using ELISA and flow cytometry, respectively. In subsequent studies atopic-donor PBMCs were incubated with IL-4 alone or with ISS-ODN or mutated oligodeoxynucleotide. After 14 days, IgE production and IgM, IgG, and IWAL production were determined by using ELISA. In select IgE studies cytokines were neutralized with mAbs. Results: ISS-ODN induced IL-12, IFN-alpha, IFN-gamma, IL-10, and IL-6 production from both nonatopic- and atopic-donor PBMCs. ISS-ODN also increased IFN-gamma receptor and inhibited IL-4 receptor expression on B cells from both donor populations. Furthermore, ISS-ODN inhibited IL-4-dependent IgE production by atopic-donor PBMCs. Neutralization of IL-12, IFN-alpha, IFN-7, and IL-10, but not IL-6, attenuated the inhibitory activity of ISS-ODN on IgE production. In contrast to its inhibition of IgE synthesis, ISS-ODN stimulated the production of IgM, IgG, and IgA. Conclusion: These in vitro studies demonstrate that phosphorothioate ISS-ODN elicits an innate immune response by PBMCs, which inhibits IL-4-dependent IgE synthesis. In addition, these results provide further support for consideration of ISS-ODN therapy for the treatment of allergic disease in clinical practice.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Homer, AA (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI040682, K08AI001490] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40682, AI01490] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ballas ZK, 1996, J IMMUNOL, V157, P1840; Barnes PJ, 1998, MOL MED TODAY, V4, P452, DOI 10.1016/S1357-4310(98)01335-5; Bauer M, 1999, IMMUNOLOGY, V97, P699, DOI 10.1046/j.1365-2567.1999.00811.x; Bohle B, 1999, EUR J IMMUNOL, V29, P2344, DOI 10.1002/(SICI)1521-4141(199907)29:07<2344::AID-IMMU2344>3.0.CO;2-R; Borish L, 1998, J ALLERGY CLIN IMMUN, V101, P293, DOI 10.1016/S0091-6749(98)70238-6; Broide D, 1998, J IMMUNOL, V161, P7054; Creticos PS, 2001, J ALLERGY CLIN IMMUN, V107, pS216; CRETICOS PS, 2000, J ALLERGY CLIN IMMUN, V105, pA215; Davis HL, 1998, J IMMUNOL, V160, P870; Deichmann KA, 1998, CLIN EXP ALLERGY, V28, P151; Dickensheets HL, 1999, J LEUKOCYTE BIOL, V65, P307, DOI 10.1002/jlb.65.3.307; Fujieda S, 2000, AM J RESP CRIT CARE, V162, P232, DOI 10.1164/ajrccm.162.1.9906136; Halpern MD, 1996, CELL IMMUNOL, V167, P72, DOI 10.1006/cimm.1996.0009; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hartmann G, 2000, J IMMUNOL, V164, P1617, DOI 10.4049/jimmunol.164.3.1617; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; HOMER AA, 1998, CELL IMMUNOL, V190, P77; HOMER AA, 2000, J ALLERGY CLIN IMMUN, V106, P349; Kline JN, 1999, J ALLERGY CLIN IMMUN, V104, P1258, DOI 10.1016/S0091-6749(99)70022-9; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Liang H, 1996, J CLIN INVEST, V98, P1119, DOI 10.1172/JCI118894; Magone MT, 2000, EUR J IMMUNOL, V30, P1841, DOI 10.1002/1521-4141(200007)30:7<1841::AID-IMMU1841>3.0.CO;2-E; Martin-Orozco E, 1999, INT IMMUNOL, V11, P1111, DOI 10.1093/intimm/11.7.1111; MASHIBA H, 1988, JPN J MED SCI BIOL, V41, P197, DOI 10.7883/yoken1952.41.197; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Parronchi P, 1999, J IMMUNOL, V163, P5946; PUNNONEN J, 1993, ALLERGY, V48, P189, DOI 10.1111/j.1398-9995.1993.tb00712.x; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Ruzek MC, 1996, J IMMUNOL, V156, P2124; Sur S, 1999, J IMMUNOL, V162, P6284; Van Uden J, 1999, J ALLERGY CLIN IMMUN, V104, P902, DOI 10.1016/S0091-6749(99)70066-7; VERCELLI D, 1993, SPRINGER SEMIN IMMUN, V15, P5; YAMAMOTO T, 1994, JPN J CANCER RES, V85, P775, DOI 10.1111/j.1349-7006.1994.tb02947.x; ZOLA H, 1993, CELL IMMUNOL, V150, P149, DOI 10.1006/cimm.1993.1186	36	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					417	423		10.1067/mai.2001.117795	http://dx.doi.org/10.1067/mai.2001.117795			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544462				2022-12-18	WOS:000171215400014
J	Daser, A; Daheshia, M; De Sanctis, GT				Daser, A; Daheshia, M; De Sanctis, GT			Genetics of allergen-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						airway hyperresponsiveness; antigen; asthma; genetics; inflammation; linkage	INDUCED AIRWAY HYPERRESPONSIVENESS; GERMINAL-CENTER FORMATION; QUANTITATIVE TRAIT LOCI; RECEPTOR-ALPHA CHAIN; SERUM IGE LEVELS; MURINE MODEL; PULMONARY INFLAMMATION; SIGNAL-TRANSDUCTION; INBRED MICE; MUCUS PRODUCTION	Antigen-induced airway hyperresponsiveness and airway inflammation are features of both human asthma and animal models of this disease. The genesis of these key asthma phenotypes represents the summation of a complex cascade of immune responses. It is hypothesized that multiple cell types are involved in the induction, propagation, and maintenance of these immune processes. Several molecules have been reported to be essential for cell-cell interactions, inflammatory cell recruitment; and effector functions leading to the overall expression of the asthmatic phenotype. This review summarizes the genetic evidence supporting a role for these molecules in antigen-driven airway hyperresponsiveness and inflammation.	Charite, Inst Lab Med & Pathobiochem, Berlin, Germany; Brigham & Womens Hosp, Dept Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Pulm, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Crit Care Div, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	De Sanctis, GT (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.							Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Becker KG, 1998, P NATL ACAD SCI USA, V95, P9979, DOI 10.1073/pnas.95.17.9979; Beebe AM, 1997, IMMUNITY, V6, P551, DOI 10.1016/S1074-7613(00)80343-X; Bogdan CT, 2000, IMMUNOL REV, V173, P17, DOI 10.1034/j.1600-065X.2000.917307.x; Braun MC, 2000, J IMMUNOL, V164, P3009, DOI 10.4049/jimmunol.164.6.3009; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919, DOI 10.1164/ajrccm.160.3.9812024; Butterfield RJ, 1998, J IMMUNOL, V161, P1860; Cohn L, 1999, J IMMUNOL, V162, P6178; Conroy DM, 1997, MEM I OSWALDO CRUZ, V92, P183, DOI 10.1590/S0074-02761997000800024; Cookson WOC, 2000, HUM MOL GENET, V9, P2359, DOI 10.1093/hmg/9.16.2359; Corry DB, 1999, NATURE, V402, pB18; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; Daser A, 2000, IMMUNOGENETICS, V51, P632, DOI 10.1007/s002510000206; De Sanctis GT, 1999, AM J PHYSIOL-LUNG C, V277, pL1118, DOI 10.1152/ajplung.1999.277.6.L1118; De Sanctis GT, 1999, J EXP MED, V189, P1621, DOI 10.1084/jem.189.10.1621; Deng J, 2000, J IMMUNOL, V165, P5054, DOI 10.4049/jimmunol.165.9.5054; Dent AL, 1998, P NATL ACAD SCI USA, V95, P13823, DOI 10.1073/pnas.95.23.13823; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Denzler KL, 2000, J IMMUNOL, V165, P5509, DOI 10.4049/jimmunol.165.10.5509; Donovan CE, 1999, J IMMUNOL, V163, P6827; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; Ewart SL, 2000, AM J RESP CELL MOL, V23, P537, DOI 10.1165/ajrcmb.23.4.4199; Ewart SL, 1996, AM J RESP CELL MOL, V14, P487, DOI 10.1165/ajrcmb.14.5.8624254; Fleming TJ, 1997, J EXP MED, V186, P1307, DOI 10.1084/jem.186.8.1307; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gorham JD, 1996, P NATL ACAD SCI USA, V93, P12467, DOI 10.1073/pnas.93.22.12467; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Green JM, 2000, AM J RESP CELL MOL, V22, P261, DOI 10.1165/ajrcmb.22.3.f179; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guler ML, 1999, J IMMUNOL, V162, P1339; Haile S, 1999, AM J RESP CELL MOL, V20, P891, DOI 10.1165/ajrcmb.20.5.3446; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Holt PG, 1999, NATURE, V402, pB12; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Karp CL, 2000, NAT IMMUNOL, V1, P221, DOI 10.1038/79759; KeaneMyers A, 1997, J IMMUNOL, V158, P2042; Kodani M, 2000, IMMUNOPHARMACOLOGY, V49, P263, DOI 10.1016/S0162-3109(00)00240-X; Krinzman SJ, 1996, J CLIN INVEST, V98, P2693, DOI 10.1172/JCI119093; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; Mark DA, 2000, AM J RESP CELL MOL, V22, P265, DOI 10.1165/ajrcmb.22.3.3747; Mark DA, 1998, INT IMMUNOL, V10, P1647, DOI 10.1093/intimm/10.11.1647; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; Nickel R, 1997, GENOMICS, V46, P159, DOI 10.1006/geno.1997.5013; Nickel RG, 2000, J IMMUNOL, V164, P1612, DOI 10.4049/jimmunol.164.3.1612; Nilsson G, 1996, J IMMUNOL, V157, P1693; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390, DOI 10.1164/ajrccm.156.5.9702084; O'Sullivan S, 1999, ACTA PHYSIOL SCAND, V166, P1; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Osaka H, 1999, NEUROSCIENCE, V88, P1073, DOI 10.1016/S0306-4522(98)00372-8; Rosenwasser LJ, 1997, AM J RESP CRIT CARE, V156, pS152, DOI 10.1164/ajrccm.156.4.12tac-14; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Shirakawa T, 2000, IMMUNOL TODAY, V21, P60, DOI 10.1016/S0167-5699(99)01492-9; Tanaka H, 2000, CLIN EXP ALLERGY, V30, P874; Teran LM, 1997, CLIN EXP ALLERGY, V27, P396; Teuscher C, 1999, J IMMUNOL, V163, P2262; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; WETSEL RA, 1990, J BIOL CHEM, V265, P2435; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wittmann M, 1999, J IMMUNOL, V162, P6763; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Yang HT, 1999, J IMMUNOL, V163, P2916; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang YM, 1999, HUM MOL GENET, V8, P601, DOI 10.1093/hmg/8.4.601	80	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					167	174		10.1067/mai.2001.116987	http://dx.doi.org/10.1067/mai.2001.116987			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496230	Bronze			2022-12-18	WOS:000170584600002
J	Fiocchi, A; Restani, P; Ballabio, C; Bouygue, GR; Serra, A; Travaini, M; Terracciano, L				Fiocchi, A; Restani, P; Ballabio, C; Bouygue, GR; Serra, A; Travaini, M; Terracciano, L			Severe anaphylaxis induced by latex as a contaminant of plastic balls in play pits	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						natural rubber latex; anaphylaxis; children; ball pits		Background: Latex causes anaphylaxis in specific contexts among children. We present 2 cases that show that severe reactions may occur in everyday circumstances with latex as a contaminant. Objective: Because 2 cases of severe reactions to latex suggested similar circumstances of exposure, we investigated the immediate environment in which episodes occurred. Methods. A 5-year-old girt presented to our casualty department with anaphylaxis after playing in a ball pit filled with approximately 10-cm diameter plastic balls in an American-style fast-food outlet. Two months later, a 9-year-old boy had severe anaphylaxis followed by an asthma attack with loss of consciousness while playing in the playpen of a different outlet belonging to the same company. Latex sensitization was confirmed in both cases by means of skin prick testing, latex glove skin prick testing, and 1-glove finger testing. Immunoblotting of elutions from a ball, the natural rubber latex foam pit lining and its polyvinyl chloride sheet were performed. Results: In the girl's immunoblot high levels of IgE specific to Hey b 4, Hev b 7, and Hev b 2 were found. The boy's immunoblot showed positivity to Rev b 7. The polyvinyl chloride ball sample showed a high concentration of specific Hevea species allergen similar to that of the foam layer sample. Conclusion. Severe anaphylaxis can result from contact with latex proteins as a contaminant, rather than as a component, of play area ball pits and therefore outside the reported settings. Emergency health care workers should be aware of this kind of risk. A latex-reduced environment might prevent potentially severe reactions in young customers of fast-food outlets.	Melloni Hosp, Dept Child & Maternal Med, I-20134 Milan, Italy; San Paolo Hosp, Dept Paediat, Milan, Italy; Univ Milan, Dept Pharmacol Sci, Toxicol Lab, I-20122 Milan, Italy	San Paolo-Polo Universitaria Hospital; University of Milan	Fiocchi, A (corresponding author), Melloni Hosp, Dept Child & Maternal Med, Via Melloni 52, I-20134 Milan, Italy.		Terracciano, Luigi M./AAB-5335-2022; Fiocchi, Alessandro/K-9235-2016	Terracciano, Luigi M./0000-0002-9393-9660; Fiocchi, Alessandro/0000-0002-2549-0523				BEEZHOLD D, 1997, SURG SERV MANAGE, V3, P35; Eseverri J L, 1999, Allergol Immunopathol (Madr), V27, P133; Frankland AW, 1999, PEDIATR ALLERGY IMMU, V10, P152, DOI 10.1034/j.1399-3038.1999.00041.x; Franklin W, 1999, NEW ENGL J MED, V341, P1858, DOI 10.1056/NEJM199912093412419; Hamilton RG, 1997, ANN ALLERG ASTHMA IM, V79, P266, DOI 10.1016/S1081-1206(10)63013-X; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Poley GE, 2000, J ALLERGY CLIN IMMUN, V105, P1054, DOI 10.1067/mai.2000.106925; RESTANI P, 1995, CLIN EXP ALLERGY, V25, P651, DOI 10.1111/j.1365-2222.1995.tb01113.x; *US DEPT HHS, 1999, US DEP HLTH HUM SERV; WILLIAMS PB, 1995, J ALLERGY CLIN IMMUN, V95, P88, DOI 10.1016/S0091-6749(95)70156-7	10	13	14	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					298	300		10.1067/mai.2001.116985	http://dx.doi.org/10.1067/mai.2001.116985			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496251				2022-12-18	WOS:000170584600023
J	Tanaka, LG; El-Dahr, JM; Lehrer, SB				Tanaka, LG; El-Dahr, JM; Lehrer, SB			Double-blind, placebo-controlled corn challenge resulting in anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SURGICAL GLOVE POWDER; CONTACT URTICARIA		Tulane Univ, Sch Med, New Orleans, LA 70112 USA	Tulane University	Tanaka, LG (corresponding author), Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.							ASSALVE D, 1988, CONTACT DERMATITIS, V19, P61, DOI 10.1111/j.1600-0536.1988.tb02870.x; DAVID TJ, 1984, ARCH DIS CHILD, V59, P983, DOI 10.1136/adc.59.10.983; FISHER AA, 1987, CONTACT DERMATITIS, V16, P224, DOI 10.1111/j.1600-0536.1987.tb01430.x; Pauls JD, 1998, J ALLERGY CLIN IMMUN, V101, P853, DOI 10.1016/S0091-6749(98)70317-3; SEGGEV JS, 1990, ANN ALLERGY, V65, P152	5	13	13	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					744	744		10.1067/mai.2001.113765	http://dx.doi.org/10.1067/mai.2001.113765			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295671				2022-12-18	WOS:000168190100034
J	Columbo, M; Bochner, BS				Columbo, M; Bochner, BS			Human skin mast cells adhere to vitronectin via the alpha v beta(3) integrin receptor (CD51/CD61)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXTRACELLULAR-MATRIX; ADHESION; PROTEINS; EXPRESS		Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol & Allergy, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Columbo, M (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol & Allergy, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.							BIANCHINE PJ, 1992, J IMMUNOL, V149, P3665; COLUMBO M, 1995, J IMMUNOL, V154, P6058; KrugerKrasagakes S, 1996, J INVEST DERMATOL, V106, P538, DOI 10.1111/1523-1747.ep12343953; SHIMIZU Y, 1995, BLOOD, V86, P930; Trautmann A, 1997, ARCH DERMATOL RES, V289, P194, DOI 10.1007/s004030050180	5	13	13	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					554	554		10.1067/mai.2001.113238	http://dx.doi.org/10.1067/mai.2001.113238			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240961				2022-12-18	WOS:000167793300021
J	Edin, HM; Payne, E; Herrle, MR; Schoaf, L; Mather, DB; Scott, CA; Shah, TP				Edin, HM; Payne, E; Herrle, MR; Schoaf, L; Mather, DB; Scott, CA; Shah, TP			Salmeterol/fluticasane propionate combination via HFA MDI improves quality of life in asthma patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline									0	13	13	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2		S		806	S246	S246						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	405RE					2022-12-18	WOS:000167172300802
J	Sung, KLP; Yang, L; Kim, J; Ko, D; Stachnick, G; Castaneda, D; Nayar, J; Broide, DH				Sung, KLP; Yang, L; Kim, J; Ko, D; Stachnick, G; Castaneda, D; Nayar, J; Broide, DH			Eotaxin induces a sustained reduction in the functional adhesive state of very late antigen 4 for the connecting segment 1 region of fibronectin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; adhesion; integrin; eotaxin	CELL-ADHESION; EOSINOPHIL CHEMOATTRACTANT; GPIIB-IIIA; IN-VIVO; RECEPTOR; ACTIVATION; BINDING; CLONING; RECRUITMENT; EXPRESSION	Background: Eosinophils that have bound to extracellular matrix proteins, such as the connecting segment 1(CS-1) region of fibronectin, need to deadhere before undergoing chemotaxis through the extracellular matrix. Objective: We have investigated whether eotaxin can regulate the strength of eosinophil adhesion to the CS-I region of fibronectin. Methods: We have used a micropipette single-cell adhesion assay to determine the force of eosinophil adhesion to the CS-I region of fibronectin. Results: Eosinophils bound to CS-1 with high avidity, and this binding could be inhibited with neutralizing antibodies to alpha4 integrins expressed by eosinophils or with neutralizing antibodies to CS-l, Eosinophils incubated in the presence of eotaxin demonstrated a transient increase in the force of eosinophil adhesion to CS-1, which was followed by a more sustained reduction in the force of eosinophil adhesion to CS-1, as assessed in the micropipette single-cell adhesion assay. This decreased binding of eosinophils to CS-I was not due to alterations in very late antigen 4 (VLA-4) receptor number, as assessed with FACS analysis, or alterations in VLA-4 receptor distribution, as assessed with immunofluorescence microscopy. Conclusions: These studies suggest that eotaxin can cause a transient increase followed by a more sustained reduction in the functional force of VLA-4 adhesion to CS-I and thus promote deadhesion of CS-l adherent eosinophils in the extracellular matrix.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Broide, DH (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr,MC 0635, La Jolla, CA 92093 USA.			Broide, David/0000-0001-8405-9090	NCRR NIH HHS [MO1RR00827] Funding Source: Medline; NIAID NIH HHS [AI33977, AI38425] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI038425, R01AI033977, R01AI038425] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Boehme SA, 1999, J IMMUNOL, V163, P1611; Bonini JA, 1997, DNA CELL BIOL, V16, P1249, DOI 10.1089/dna.1997.16.1249; Broide DH, 1998, BLOOD, V91, P2847, DOI 10.1182/blood.V91.8.2847.2847_2847_2856; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DiScipio RG, 1999, J IMMUNOL, V162, P1127; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; Kitayama J, 1998, J CLIN INVEST, V101, P2017, DOI 10.1172/JCI2688; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; Lukacs NW, 1999, J CLIN INVEST, V104, P995, DOI 10.1172/JCI8125; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; Matsumoto K, 1997, J ALLERGY CLIN IMMUN, V99, P648, DOI 10.1016/S0091-6749(97)70027-7; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Rankin SM, 2000, MOL MED TODAY, V6, P20, DOI 10.1016/S1357-4310(99)01635-4; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; SRIRAMARAO P, 1994, J IMMUNOL, V153, P4238; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SUNG KLP, 1993, BLOOD, V81, P419; Sung KLP, 1997, J IMMUNOL, V158, P919; SUNG KLP, 1986, SCIENCE, V234, P1405, DOI 10.1126/science.3491426; SYMONS MH, 1992, J CELL BIOL, V118, P1235, DOI 10.1083/jcb.118.5.1235; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zimmermann N, 1999, J BIOL CHEM, V274, P12611, DOI 10.1074/jbc.274.18.12611	35	13	14	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					933	940		10.1067/mai.2000.110797	http://dx.doi.org/10.1067/mai.2000.110797			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080717				2022-12-18	WOS:000167865200019
J	Paronen, J; Bjorksten, B; Hattevig, G; Akerblom, HK; Vaarala, O				Paronen, J; Bjorksten, B; Hattevig, G; Akerblom, HK; Vaarala, O			Effect of maternal diet during lactation on development of bovine insulin-binding antibodies in children at risk for allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; cow's milk-free diet; lactation; insulin-binding antibodies	COWS MILK ALLERGY; DEPENDENT DIABETES-MELLITUS; BREAST-FED INFANTS; IMMUNE-RESPONSE; PROTEINS; EXPOSURE; AVOIDANCE; EGGS; FISH; IGE	Background: The role of exposure to dietary antigens through maternal milk is intriguing, because it may result either in immunization or in tolerance, Exposure to cow's milli proteins results in antibody formation against bovine insulin in infants at risk for type 1 diabetes, Objective: To study the appearance of IgG antibodies to bovine and human insulin in infants with an atopic family history whose mothers followed a cow's milk-free diet during the first 3 months of lactation. Methods: In a prospective cohort study on prevention of food allergies, 123 infants were exclusively breast-fed or received supplementation with a hydrolyzed casein-based formula (Nutramigen) until the age of 6 months. The mothers either avoided cow's milk during the first 3 months of lactation (diet group) or had an unrestricted diet (nondiet group). The levels of Ige antibodies to bovine and human insulin were determined by enzyme immunoassay at 3, 6, 12, and 18 months and at 4 years. In addition, cord blood was obtained at birth and a maternal sample at delivery Results: At 3 months, IgG antibodies to bovine insulin were low in both dietary groups (median levels 0.150 and 0.114 optical density units in the diet and nondiet groups). After exposure to dietary insulin, IgG antibodies to bovine insulin increased in both groups, reaching a peak at 12 months in the nondiet group and at 18 months in the diet group. At 18 months, Ige antibodies to bovine insulin were lower in infants in the nondiet group than in infants in the diet group (0.287 vs 0.500, P < .0001). At 4 years, the antibodies no longer differed between the groups. Conclusion: The exposure to fowls milli proteins through breast milk during the first 3 months of life resulted in decreased levels of antibodies to dietary bovine insulin at 18 months of age, suggesting a role for breast milk antigens in early tolerance induction.	Univ Helsinki, Hosp Children & Adolescents, Res Lab, FIN-00290 Helsinki, Finland; Natl Publ Hlth Inst, Helsinki, Finland; Linkoping Univ Hosp, Dept Pediat, S-58185 Linkoping, Sweden; Cent Hosp Skovde, Dept Pediat, S-54185 Skovde, Sweden	University of Helsinki; Finland National Institute for Health & Welfare; Linkoping University	Paronen, J (corresponding author), Univ Helsinki, Hosp Children & Adolescents, Res Lab, Stenbackinkatu 11, FIN-00290 Helsinki, Finland.							Akerblom HK, 1998, DIABETES METAB REV, V14, P31, DOI 10.1002/(SICI)1099-0895(199803)14:1&lt;31::AID-; BAILEY M, 1994, INT ARCH ALLERGY IMM, V103, P183, DOI 10.1159/000236625; Bjorksten B, 1999, J ALLERGY CLIN IMMUN, V104, P1119; DEBOISSIEU D, 1994, ALLERGY, V49, P882, DOI 10.1111/j.1398-9995.1994.tb00792.x; DUCHEN K, 1991, IMMUNOLOGY MILK NEON, P427; FAITHMAGNUSSON K, 1987, J ALLERGY CLIN IMMUN, V80, P869; GERRARD JW, 1979, ANN ALLERGY, V42, P69; GERSTEIN HC, 1994, DIABETES CARE, V17, P13, DOI 10.2337/diacare.17.1.13; GREENBAUM CJ, 1992, J CLIN ENDOCR METAB, V74, P1040, DOI 10.1210/jc.74.5.1040; GYORGY P, 1954, ARCH BIOCHEM BIOPHYS, V48, P193, DOI 10.1016/0003-9861(54)90323-9; HANSON LA, 1985, PEDIATRICS, V75, P172; HATTEVIG G, 1989, CLIN EXP ALLERGY, V19, P27, DOI 10.1111/j.1365-2222.1989.tb02339.x; HATTEVIG G, 1990, J ALLERGY CLIN IMMUN, V85, P108, DOI 10.1016/0091-6749(90)90231-R; Holt PG, 1996, J EXP MED, V183, P1297, DOI 10.1084/jem.183.4.1297; JAKOBSSON I, 1978, LANCET, V2, P437; Jenmalm MC, 1998, J ALLERGY CLIN IMMUN, V102, P671, DOI 10.1016/S0091-6749(98)70286-6; Kalliomaki M, 1999, J ALLERGY CLIN IMMUN, V104, P1251, DOI 10.1016/S0091-6749(99)70021-7; KILSHAW PJ, 1984, INT ARCH ALLER A IMM, V75, P8, DOI 10.1159/000233582; MACHTINGER S, 1986, J ALLERGY CLIN IMMUN, V77, P341, DOI 10.1016/S0091-6749(86)80115-4; NICKLIN S, 1987, J REPROD IMMUNOL, V10, P167, DOI 10.1016/0165-0378(87)90074-X; PATHIRANA C, 1991, INT ARCH ALLER A IMM, V66, P114; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P1093, DOI 10.1016/S0091-6749(99)70094-1; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; Shannon WR, 1921, AM J DIS CHILD, V22, P223; SHEARD NF, 1988, NUTR REV, V46, P1; SIGURS N, 1992, PEDIATRICS, V89, P735; TELEMO E, 1987, IMMUNOLOGY, V62, P35; TRONCONE R, 1987, ACTA PAEDIATR SCAND, V76, P453, DOI 10.1111/j.1651-2227.1987.tb10498.x; Vaarala O, 1999, DIABETES-METAB RES, V15, P353, DOI 10.1002/(SICI)1520-7560(199909/10)15:5<353::AID-DMRR59>3.0.CO;2-4; Vaarala O, 1999, DIABETES, V48, P1389, DOI 10.2337/diabetes.48.7.1389; Vaarala O, 1998, SCAND J IMMUNOL, V47, P131; Vaarala O, 1995, J ALLERGY CLIN IMMUN, V96, P917, DOI 10.1016/S0091-6749(95)70229-6; VIRTANEN SM, 1993, DIABETES, V42, P1786, DOI 10.2337/diabetes.42.12.1786; Wright AL, 1999, J ALLERGY CLIN IMMUN, V104, P589, DOI 10.1016/S0091-6749(99)70328-3	34	13	14	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					302	306						5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932074				2022-12-18	WOS:000088708100013
J	Zweiman, B; Haralabatos, IC; Pham, NC; David, M; von Allmen, C				Zweiman, B; Haralabatos, IC; Pham, NC; David, M; von Allmen, C			Sequential patterns of inflammatory events during developing and expressed skin late-phase reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						late-phase reaction; neutrophils; eosinophils; lymphocytes; adhesion molecules; mast cells	CUTANEOUS ALLERGIC REACTIONS; MESSENGER-RNA EXPRESSION; ATOPIC SUBJECTS; T-CELLS; ADHESION MOLECULE-1; GRANULE PROTEINS; HOMING RECEPTOR; IGE; RESPONSES; EOSINOPHILS	Background: Although there has been much study of the histologic features of the late-phase reactions (LPR) seen 6 to 24 hours after intradermal injection of allergens, much less is known about the events occurring during development of such LPR. Objective: Our purpose was to compare sequential gross and histologic inflammatory responses during developing skin LPR within 6 hours after challenge. Methods: Gross reactions were measured and biopsy specimens obtained at 20 minutes and 1, 2, and 6 hours after intradermal allergen (Ag) and buffer diluent control (B) injections in 7 atopic subjects with known immediate and LPR, Inflammatory cell responses were compared, as detected by immunohistochemistry in Ag and B sites. These endings were then compared with those at 24 hours. Results: Cross LPR evolved without a hiatus from the immediate wheal responses over the next 6 hours (P = .04 vs that in B sites) and then decreased by 24 hours. Prominent PMN accumulation started by 20 minutes, peaking at 1 hour (P < .01). Eosinophil accumulation was significant, starting at 1 hour (P < .001) and peaking at 6 hours (P < .001). Many eosinophils were activated (EG(2)(+)). T-cell accumulation started at 2 hours (P = .01) and was most prominent at 24 hours. The frequency of vessels expressing E-selectin increased at 1 hour (P < .005), correlating with the degree of local PMN accumulation. The frequency of vessels expressing vascular cell adhesion molecules started increasing at 6 hours (P = .02), well after eosinophil accumulation was prominent. Conclusions: Skin LPR is characterized by evolution of a gross indurated reaction from the immediate whealing response over the first 6 hours after intradermal Ag challenge, with an early accumulation of PMN and eosinophils, not directly attributable to lymphocyte entry or vascular cell adhesion molecule expression. Likely, multiple other factors may also play roles in the complex pathogenesis of LPR.	Univ Penn, Med Ctr, Dept Med, Allergy & Immunol Sect,Allergy & Crit Care Div, Philadelphia, PA 19104 USA	University of Pennsylvania	Zweiman, B (corresponding author), Hosp Univ Penn, Allergy & Immunol Clin, Silverstein 3-B, Philadelphia, PA 19104 USA.							ADKIS CA, 1998, ACI INT, V10, P116; Akdis M, 1997, J IMMUNOL, V159, P4611; ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; ATKINS PC, 1995, J ALLERGY CLIN IMMUN, V95, P742, DOI 10.1016/S0091-6749(95)70180-X; ATKINS PC, 1993, J ALLERGY CLIN IMMUN, V91, P956, DOI 10.1016/0091-6749(93)90354-I; AUNG UK, 1991, J IMMUNOL, V146, P521; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; Barata LT, 1998, J ALLERGY CLIN IMMUN, V101, P222, DOI 10.1016/S0091-6749(98)70387-2; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FREW AJ, 1991, SKIN PHARMACOL, V4, P71; FREW AJ, 1990, J ALLERGY CLIN IMMUN, V85, P533, DOI 10.1016/0091-6749(90)90090-Q; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KLINE B. S., 1932, JOUR ALLERGY, V3, P531, DOI 10.1016/S0021-8707(32)90148-8; LEIFERMAN KM, 1990, LAB INVEST, V62, P579; Lemanske RF, 1993, ALLERGY PRINCIPLES P, P320; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; Litchfield TM, 1996, BRIT J DERMATOL, V134, P997; Martin LB, 1996, INT ARCH ALLERGY IMM, V109, P207, DOI 10.1159/000237239; MURPHY G, 1994, J ALLERGY CLIN IMMUN, V93, P183; PICKER LJ, 1993, J IMMUNOL, V150, P1122; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TSICOPOULOS A, 1994, J ALLERGY CLIN IMMUN, V94, P764, DOI 10.1016/0091-6749(94)90185-6; VOWELS BR, 1995, J ALLERGY CLIN IMMUN, V96, P92, DOI 10.1016/S0091-6749(95)70037-4; Ying S, 1997, J IMMUNOL, V158, P5050; Ying S, 1999, J IMMUNOL, V163, P3976; ZENG L, 1997, J ALLERGY CLIN IMMUN, V99, pS37; Zweiman B, 1997, J ALLERGY CLIN IMMUN, V100, P104, DOI 10.1016/S0091-6749(97)70201-X; ZWEIMAN B, 1993, CURR OPIN IMMUNOL, V5, P950, DOI 10.1016/0952-7915(93)90111-5; ZWEIMAN B, 1991, J ALLERGY CLIN IMMUN, V87, P984, DOI 10.1016/0091-6749(91)90421-J; ZWEIMAN B, 1990, J IMMUNOL, V144, P3953; Zweiman B, 1997, J ALLERGY CLIN IMMUN, V100, P341, DOI 10.1016/S0091-6749(97)70247-1; ZWEIMAN B, 1999, CAN J ALERGY IMMUNOL, V4, P336	35	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					776	781		10.1067/mai.2000.105223	http://dx.doi.org/10.1067/mai.2000.105223			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756229				2022-12-18	WOS:000086604100017
J	Escalante, MT; Sanchez-Borges, M; Capriles-Hulett, A; Belfort, E; Di Biagio, E; Gonzalez-Aveledo, L				Escalante, MT; Sanchez-Borges, M; Capriles-Hulett, A; Belfort, E; Di Biagio, E; Gonzalez-Aveledo, L			Trichophyton-specific IgE in patients with dermatophytosis is not associated with aeroallergen sensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; dermatophytosis; Trichophyton; IgE; radioallergosorbent test	IMMUNE-RESPONSES; TINEA IMBRICATA; INFECTION; RHINITIS; RUBRUM; ASTHMA; ANTIBODIES	Background: It has been proposed that Trichophyton infection is associated with atopy and allergy. Objectives: Our purpose was (1) to confirm whether atopy predisposes to chronic dermatophytosis and (2) to investigate whether Trichophyton infection induces atopic disease. Methods: Patients attending dermatology clinics and suspected of having dermatomycosis underwent in a prospective manner fungal culture and Trichophyton and inhalent skin tests, and blood serum was collected fur total IgE and Trichophyton radioallergosorbent testing. Personal and family history of atopic diseases was also Investigated. Results: According to mycologic culture, atopic history, and inhalent skin test results, patients were classified into 4 groups: (1) atopy plus mycosis (n = 28), (2) atopy (n = 26), (3) mycosis (n = 35), and (4) no atopy, no mycosis (n = 33), Patients with active mycosis (groups 1 and 3) demonstrated significantly increased positivity of Trichophyton skin tests compared with patients without fungal infection (groups 2 and 4), regardless of their atopic status, whereas atopic patients (those in groups 1 and 2) had significantly increased levels of total serum IgE compared with nonatopic subjects. Trichophytosis was not more prevalent in atopic than in nonatopic subjects, and atopic diseases were not more frequent in culture-positive than in culture negative patients. Conclusions: Our results indicate that Trichophyton-specific IgE is observed in patients with trichophytosis regardless of atopy.	Minist Hlth, Inst Oncol & Hematol, Caracas, Venezuela; Cent Univ Venezuela, Caracas, Venezuela; Ctr Med Docente La Trinidad, Caracas, Venezuela; Ctr Med Dr Carlos Diez del Ciervo, Caracas, Venezuela; Hosp Dr Miguel Perez Carreno, Inst Venezolano Seguros Sociales, Caracas, Venezuela	University of Central Venezuela	Sanchez-Borges, M (corresponding author), POB Air Int 635, Miami, FL 33102 USA.							BORELLI D, 1993, MICROBIOLOGIA MEDICA, P560; DAVIES RR, 1983, CLIN ALLERGY, V13, P309, DOI 10.1111/j.1365-2222.1983.tb02605.x; GUMOWSKI P, 1987, ANN ALLERGY, V59, P48; HANIFIN JM, 1974, BRIT J DERMATOL, V90, P1, DOI 10.1111/j.1365-2133.1974.tb06355.x; HAY RJ, 1977, CLIN EXP DERMATOL, V2, P373, DOI 10.1111/j.1365-2230.1977.tb01578.x; HAY RJ, 1985, INT J DERMATOL, V24, P562, DOI 10.1111/j.1365-4362.1985.tb05850.x; HAY RJ, 1984, T ROY SOC TROP MED H, V78, P653, DOI 10.1016/0035-9203(84)90231-1; HAY RJ, 1983, BRIT J DERMATOL, V108, P581, DOI 10.1111/j.1365-2133.1983.tb01060.x; HONBO S, 1984, J INVEST DERMATOL, V82, P287, DOI 10.1111/1523-1747.ep12260385; JONES HE, 1974, ARCH DERMATOL, V110, P213, DOI 10.1001/archderm.110.2.213; JONES HE, 1973, ARCH DERMATOL, V108, P61, DOI 10.1001/archderm.108.1.61; JONES HE, 1980, ACTA DERM-VENEREOL, V92, P81; KAAMAN T, 1984, MYKOSEN, V28, P185; KIVITY S, 1992, CLIN EXP ALLERGY, V22, P498, DOI 10.1111/j.1365-2222.1992.tb00153.x; LOBITZ WC, 1972, BRIT J DERMATOL, V86, P317, DOI 10.1111/j.1365-2133.1972.tb05045.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P40, DOI 10.1016/S0091-6749(87)80014-3; PLATTSMILLS TAE, 1986, ANN ALLERGY, V56, P454; Slunt JB, 1997, CLIN EXP ALLERGY, V27, P1184, DOI 10.1111/j.1365-2222.1997.tb01156.x; SORENSEN GW, 1976, ARCH DERMATOL, V112, P40, DOI 10.1001/archderm.112.1.40; SULZBERGER MB, 1949, ANN NY ACAD SCI, V50, P767, DOI 10.1111/j.1749-6632.1949.tb39881.x; SVEJGAARD E, 1984, ACTA DERM-VENEREOL, V64, P493; SVEJGAARD E, 1989, ACTA DERM-VENEREOL S, V144, P140; WARD GW, 1989, LANCET, V1, P859; Ward GW, 1994, P 50 ANN M AM AC ALL; WEARY PE, 1967, ARCH DERMATOL, V95, P400, DOI 10.1001/archderm.95.4.400; WILSON BB, 1993, CUTIS, V51, P191; Wise F, 1930, J AMER MED ASSOC, V95, P1504, DOI 10.1001/jama.1930.27210200002011a; WOOD SR, 1962, BRIT J DERMATOL, V74, P329, DOI 10.1111/j.1365-2133.1962.tb13521.x	28	13	14	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					547	551		10.1067/mai.2000.104381	http://dx.doi.org/10.1067/mai.2000.104381			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719306				2022-12-18	WOS:000088946700022
J	Banfield, C; Padhi, D; Glue, P; Herron, JM; Statkevich, P; Affrime, MB				Banfield, C; Padhi, D; Glue, P; Herron, JM; Statkevich, P; Affrime, MB			Electrocardiographic effects of multiple high doses of desloratadine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Arkansas Res Med Testing Ctr, Little Rock, AR USA; Schering Plough Corp, Inst Res, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation									0	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	2	S		1119	S383	S383		10.1016/S0091-6749(00)91545-8	http://dx.doi.org/10.1016/S0091-6749(00)91545-8			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	287WR		Bronze			2022-12-18	WOS:000085530101113
J	Berlyne, GS; Efthimiadis, A; Hussack, P; Groves, D; Dolovich, J; Hargreave, FE				Berlyne, GS; Efthimiadis, A; Hussack, P; Groves, D; Dolovich, J; Hargreave, FE			Sputum in asthma: Color versus cell counts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INFLAMMATION		St Josephs Hosp, Dept Med, Fire Reg Chest & Allergy Unit, Asthma Res Grp, Hamilton, ON L8N 4A6, Canada; St Josephs Hosp, Serv Lab Med, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Hamilton, ON, Canada	McGill University; McMaster University; McGill University; McMaster University; McMaster University	Hargreave, FE (corresponding author), St Josephs Hosp, Dept Med, Fire Reg Chest & Allergy Unit, Asthma Res Grp, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.							BELDA J, 1999, IN PRESS AM J RESP C; ELMES PC, 1959, LANCET, V1, P1241; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; Hargreave F E, 1999, Can Respir J, V6, P169; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799	5	13	14	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				182	183		10.1016/S0091-6749(00)90195-7	http://dx.doi.org/10.1016/S0091-6749(00)90195-7			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629470				2022-12-18	WOS:000084992100025
J	Chen, Z; Rihs, HP; Slater, JE; Paupore, EJ; Schneider, EM; Baur, X				Chen, Z; Rihs, HP; Slater, JE; Paupore, EJ; Schneider, EM; Baur, X			The absence of Hev b 5 in capture antigen may cause false-negative results in serologic assays for latex-specific IgE antibodies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									BGFA, Bochum, Germany; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA	US Food & Drug Administration (FDA)									0	13	13	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	2	S		249	S83	S83		10.1016/S0091-6749(00)90679-1	http://dx.doi.org/10.1016/S0091-6749(00)90679-1			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	287WR					2022-12-18	WOS:000085530100247
J	Soldatova, LN; Bakst, JB; Hoffman, DR; Slater, JE				Soldatova, LN; Bakst, JB; Hoffman, DR; Slater, JE			Molecular cloning of a new honeybee venom allergen, acid phosphatase	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									E Carolina Univ, Sch Med, Greenville, NC USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD USA	University of North Carolina; East Carolina University; US Food & Drug Administration (FDA)									0	13	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	2	S		1105	S378	S378		10.1016/S0091-6749(00)91531-8	http://dx.doi.org/10.1016/S0091-6749(00)91531-8			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	287WR					2022-12-18	WOS:000085530101099
J	Forte, R; Dibble, C				Forte, R; Dibble, C			The role of international environmental agreements in metered dose inhaler technology changes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						metered dose inhalers; inhalers; ozone; chlorofluorocarbon; hydrofluorocarbon; hydrofluoroalkane; Kyoto Protocol; greenhouse gas; global warming		Introduced in the 1950s, metered dose inhalers (MDIs) became a revolutionary way to deliver medication directly to the lungs of patients with asthma and chronic obstructive pulmonary disease. Since their initial introduction, MDIs have used chlorofluorocarbons to propel the medication out of the canister into a patient's lungs. This article presents an overview of the global transition away from the use of chlorofluorocarbon propellants in MDIs to non-ozone-depleting substitutes including hydrofluoroalkane (outside of the pharmaceutical industry and in the context of Montreal Protocol and Kyoto Protocol discussions, these gases are referred to as hydrofluorocarbons; hydrofluoroalkane-134a, for example, is referred to as hydrofluorocarbon-134a) propellants, in accordance with the terms of the international environmental agreement the Montreal Protocol on substances that deplete the ozone layer (the Montreal Protocol). This article will also describe the environmental characteristics of chlorofluorocarbons and hydrofluoroalkanes when they are used as MDI propellants. Finally, the article will review key provisions of the pending Kyoto Protocol to the United Nations Framework Convention on Climate Change (the Kyoto Protocol) that may affect the future of hydrofluoroalkanes.	US EPA, Washington, DC 20460 USA	United States Environmental Protection Agency	Forte, R (corresponding author), US EPA, Washington, DC 20460 USA.							1999, M CHALLENGE GLOBAL C; 1998, WORLD METEOROLOGICAL; 1998, KYOTO PROTOCOL PRESI	3	13	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					S217	S220		10.1016/S0091-6749(99)70033-3	http://dx.doi.org/10.1016/S0091-6749(99)70033-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10588977				2022-12-18	WOS:000084289200033
J	Parameswaran, K				Parameswaran, K			Concocts of establishing clinical bioequivalence of chlorofluorocarbon and hydrofluoroalkane beta-agonists	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bioequivalence; inhaled beta-agonist	METERED-DOSE INHALER; SALBUTAMOL; ASTHMA; HFA	There are no established guidelines for judging equivalence between inhaled medications. The principles of establishing bioequivalence on the basis of bioavailability and pharmacokinetics mag. not be applicable to inhaled medications with predominantly topical and minimal systemic effects, For inhaled beta(2)-agonists, the most practical method of showing in vivo therapeutic equivalence is by comparing relative potencies (RPs) of pharmacodynamic effects (bronchodilation and bronchoprotection). A range of doses that includes placebo should be studied in an appropriate design with adequate sample size, and relative potency should be estimated. Hydrofluoroalkane and chlorofluorocarbon salbutamol are bioequivalent for both their bronchodilator (RP, 1.08; 90% confidence interval, 0.95%, 1.23%) and bronchoprotective effects (RP, 1.08; 90% confidence interval, 0.81%, 1.46%) with similar safety profile. Eighteen subjects are required in a crossover design to demonstrate bronchoprotective bioequivalence with a confidence interval of 67% to 150% for the relative potency (80% power), For salbutamol, this can be achieved with a comparison of 100 and 200 mu g doses. Twelve subjects would suffice for a cumulative dose-response study for bronchodilator bioequivalence. For both outcomes, repeatability and quality control of measurements have to be ensured for an accurate interpretation of the results.	McMaster Univ, Dept Med, Asthma Res Grp, Hamilton, ON, Canada	McMaster University	Parameswaran, K (corresponding author), St Josephs Hosp, Firestone Chest Clin, Hamilton, ON L8N 4A6, Canada.							AHRENS R, 1997, AM J RESP CRIT CARE, V155, pA667; AHRENS RC, 1987, J ALLERGY CLIN IMMUN, V79, P876, DOI 10.1016/0091-6749(87)90235-1; BRITTON J, 1988, THORAX, V43, P300, DOI 10.1136/thx.43.4.300; DOCKHORN R, 1995, J ALLERGY CLIN IMMUN, V96, P50, DOI 10.1016/S0091-6749(95)70032-3; Finney D. J., 1978, STAT METHODS BIOL AS; FOSTER RW, 1991, BRIT J CLIN PHARMACO, V31, P445, DOI 10.1111/j.1365-2125.1991.tb05561.x; HINDLE M, 1992, BRIT J CLIN PHARMACO, V34, P311, DOI 10.1111/j.1365-2125.1992.tb05921.x; JENKINS M, 1995, J AEROSOL MED, V8, pS41; Kleerup EC, 1996, CHEST, V109, P702, DOI 10.1378/chest.109.3.702; Parameswaran KN, 1999, AM J RESP CRIT CARE, V160, P354, DOI 10.1164/ajrccm.160.1.9812035; ROGERS DF, 1995, RESP MED, V89, P253, DOI 10.1016/0954-6111(95)90085-3; Tinkelman DC, 1998, CHEST, V113, P290, DOI 10.1378/chest.113.2.290; *UN ENV PROGR, 1997, MONTR PROT SUBST DEP, V1; *UN ENV PROGR, 1997, MONTR PROT SUBST DEP, V2; Wong A G, 1998, Can Respir J, V5, P119; WONG BJO, 1993, J ALLERGY CLIN IMMUN, V92, P373, DOI 10.1016/0091-6749(93)90115-V	16	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					S243	S245		10.1016/S0091-6749(99)70039-4	http://dx.doi.org/10.1016/S0091-6749(99)70039-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10588983				2022-12-18	WOS:000084289200039
J	Seroogy, CM; Wara, DW; Bluth, MH; Dorenbaum, A; White, C; Durkin, HG; Elder, ME				Seroogy, CM; Wara, DW; Bluth, MH; Dorenbaum, A; White, C; Durkin, HG; Elder, ME			Cytokine profile of a long-term pediatric HIV survivor with hyper-IgE syndrome and a normal CD4(+) T-cell count	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HIV; hyper-IgE syndrome; anti-HIV IgE; T-H1; T-H2; cytokine	HUMAN-IMMUNODEFICIENCY-VIRUS; DISEASE PROGRESSION; TYPE-1 INFECTION; SERUM IGE; IMMUNOLOGICAL CHARACTERIZATION; VIRAL LOAD; CHILDREN; RESPONSES; ELEVATION; INFANTS	Background: An elevated IgE level and increased production of T-H2 cytokines are factors associated with poor prognosis in HIV infection. We report a pediatric long-term survivor of vertically acquired HIV infection with a normal CD4 count and a lon viral burden despite the lack of antiretroviral therapy and a phenotype resembling hyper-IgE syndrome. Objective: We sought to characterize the patient's T-H1 versus T-H2 cytokine profile and anti-HIV-specific immune responses, Methods: Supernatants collected from cultures of peripheral blood T cells stimulated with phorbol myristate acetate plus ionomycin were assayed for T-H1 and T-H2 cytokines by means of ELISA. Specific IgE antibodies were determined by immunoblot, HIV-specific cytotoxic T-lymphocyte responses were measured from cell lysis by fresh T cells of autologous B-lymphoblastoid cells expressing recombinant AIV proteins. Results: Patient CD4(+) T cells secreted significantly more T-H2 cytokines. IL-4 (P < .003) and IL-5 (P < .03), than HIV-infected and seronegative control cells. No difference was noted in T-H1 cytokine production. IgE specific for HIV gp160, p24, p17, and p66 proteins and,Aspergillus fumigatus was detected in patient sera. Despite predominance of T-H2 cytokines, HIV-specific cytotoxic T-lymphocyte activity was vigorous, Conclusions: The patient demonstrated predominantly T-H2 cytokine production in vitro. Unlike other patients with HIV who have hyper-IgE and increased T-H2 cytokine production, our patient has maintained HIV-specific immune responses, a low viral load, and a normal CD4 count without antiretroviral therapy. These findings support a diagnosis of primary hyper-IgE syndrome. Presence of anti-HIV-specific IgE may represent a protective mechanism against HIV replication in our patient.	Univ Calif San Francisco, Dept Pediat, Div Rheumatol Allergy & Immunol, San Francisco, CA 94143 USA; SUNY Hlth Sci Ctr, Dept Pathol, Brooklyn, NY 11203 USA	University of California System; University of California San Francisco; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Seroogy, CM (corresponding author), Stanford Univ, Dept Med, Div Rheumatol & Immunol, 300 Pasteur Dr,Rm S021, Stanford, CA 94305 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027541] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR01271] Funding Source: Medline; NIAID NIH HHS [AI 27541] Funding Source: Medline; PHS HHS [5U01A13183407] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Agarwal SK, 1998, HUM IMMUNOL, V59, P99, DOI 10.1016/S0198-8859(97)00261-9; Bacot BK, 1997, J ALLERGY CLIN IMMUN, V100, P707, DOI 10.1016/S0091-6749(97)70177-5; BARKER E, 1995, P NATL ACAD SCI USA, V92, P11135, DOI 10.1073/pnas.92.24.11135; BUCKLEY R, 1988, IMMUNOLOGIC DISORDER; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CLERICI M, 1994, IMMUNOL TODAY, V15, P575, DOI 10.1016/0167-5699(94)90220-8; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; DULIEGE AM, 1992, PEDIATR INFECT DIS J, V11, P630; ELDER ME, 1995, CELL IMMUNOL, V165, P110, DOI 10.1006/cimm.1995.1193; ELLAURIE M, 1995, ANN ALLERG ASTHMA IM, V75, P332; HAANEN JBAG, 1991, J EXP MED, V174, P583, DOI 10.1084/jem.174.3.583; HYJEK E, 1995, J IMMUNOL, V155, P4060; ISRAELBIET D, 1992, J ALLERGY CLIN IMMUN, V89, P68, DOI 10.1016/S0091-6749(05)80042-9; Jourdan P, 1998, J IMMUNOL, V160, P4153; Kinter AL, 1996, P NATL ACAD SCI USA, V93, P14076, DOI 10.1073/pnas.93.24.14076; Koutsonikolis A, 1996, J ALLERGY CLIN IMMUN, V97, P692, DOI 10.1016/S0091-6749(96)70316-0; Lee B, 1998, J VIROL, V72, P7450, DOI 10.1128/JVI.72.9.7450-7458.1998; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LUCEY DR, 1990, AIDS RES HUM RETROV, V6, P427, DOI 10.1089/aid.1990.6.427; MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142; MARTIN NL, 1991, J PEDIATR-US, V118, P354, DOI 10.1016/S0022-3476(05)82146-8; McElrath MJ, 1997, AIDS RES HUM RETROV, V13, P211, DOI 10.1089/aid.1997.13.211; McMichael A, 1996, NEW ENGL J MED, V334, P801, DOI 10.1056/NEJM199603213341215; Mummidi S, 1998, NAT MED, V4, P786, DOI 10.1038/nm0798-786; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; Paganelli R, 1993, Immunodeficiency, V4, P149; PAGANELLI R, 1995, J EXP MED, V181, P423, DOI 10.1084/jem.181.1.423; Paganelli R, 1997, ALLERGY, V52, P110, DOI 10.1111/j.1398-9995.1997.tb02555.x; PAGANELLI R, 1995, J ALLERGY CLIN IMMUN, V95, P995, DOI 10.1016/S0091-6749(95)70100-1; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PELLEGRINO MG, 1996, 11 INT C AIDS VANC C; RICH R, 1996, CLIN IMMUNOLOGY PRIN, P615; Rodriguez MF, 1998, ANN ALLERG ASTHMA IM, V81, P443, DOI 10.1016/S1081-1206(10)63143-2; ROMAGNANI S, 1994, IMMUNOL REV, V140, P73, DOI 10.1111/j.1600-065X.1994.tb00865.x; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; Secord EA, 1996, J ALLERGY CLIN IMMUN, V98, P979, DOI 10.1016/S0091-6749(96)80015-7; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Small CB, 1998, ANN ALLERG ASTHMA IM, V81, P75, DOI 10.1016/S1081-1206(10)63112-2; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2; VIGANO A, 1995, J ALLERGY CLIN IMMUN, V95, P627, DOI 10.1016/S0091-6749(95)70326-8; VIGANO A, 1995, J PEDIATR-US, V126, P368, DOI 10.1016/S0022-3476(95)70450-7; Vigano A, 1997, PATHOBIOLOGY, V65, P169, DOI 10.1159/000164119; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P445, DOI 10.1016/0091-6749(90)90154-V; YSSEL H, 1991, J EXP MED, V174, P593, DOI 10.1084/jem.174.3.593	49	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					1045	1051		10.1016/S0091-6749(99)70087-4	http://dx.doi.org/10.1016/S0091-6749(99)70087-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550751				2022-12-18	WOS:000083778400029
J	Nelson, HS				Nelson, HS			Mechanisms of intranasal steroids in the management of upper respiratory allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						intranasal steroids; allergic rhinitis; mechanisms of action; cytokines; chemokines	CYTOKINE MESSENGER-RNA; NASAL-MUCOSA; TOPICAL CORTICOSTEROIDS; INDUCED RHINITIS; SEASONAL RHINITIS; POLLEN SEASON; EXPRESSION; CELLS; BECLOMETHASONE; INFLAMMATION	Intranasal steroids have proved to be the most effective class of drugs in reducing the symptoms of allergic rhinitis, This clinical response reflects the broad anti-inflammatory activity that has been demonstrated for corticosteroids. Single doses of topical corticosteroids administered before nasal allergen challenge block the late-phase reaction, whereas repealed dosing with intranasal steroids blocks both the early and the late response, as well as the priming phenomenon. Nasal inflammation is accomplished through a number of effector cells and mechanisms, which in turn are produced by director cells through the release of cytokines and chemokines, The antiinflammatory action of corticosteroids is largely effected through blocking the synthesis and release of these cytokines/chemokines.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nelson, HS (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.							ANDERSSON M, 1988, J ALLERGY CLIN IMMUN, V82, P1019, DOI 10.1016/0091-6749(88)90139-X; Baroody FM, 1998, AM J RESP CRIT CARE, V157, P899, DOI 10.1164/ajrccm.157.3.97-07060; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1900, DOI 10.1164/ajrccm.151.6.7767538; CALDERON MA, 1994, J ALLERGY CLIN IMMUN, V93, P635, DOI 10.1016/S0091-6749(94)70075-3; Cameron LA, 1998, J ALLERGY CLIN IMMUN, V101, P330, DOI 10.1016/S0091-6749(98)70244-1; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Fokkens WJ, 1997, ALLERGY, V52, P29, DOI 10.1111/j.1398-9995.1997.tb04819.x; Ghaffar O, 1997, AM J RESP CELL MOL, V17, P17, DOI 10.1165/ajrcmb.17.1.2696; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; HOLM AF, 1995, ALLERGY, V50, P204, DOI 10.1111/j.1398-9995.1995.tb01134.x; HOWARTH PH, 1995, ALLERGY, V50, P6, DOI 10.1111/j.1398-9995.1995.tb02734.x; KANAI N, 1994, AM J RESP CRIT CARE, V150, P1094, DOI 10.1164/ajrccm.150.4.7921442; Kim YK, 1997, J ALLERGY CLIN IMMUN, V100, P389, DOI 10.1016/S0091-6749(97)70254-9; KLEMENTSSON H, 1991, CLIN EXP ALLERGY, V21, P705, DOI 10.1111/j.1365-2222.1991.tb03199.x; Laberge S, 1997, J ALLERGY CLIN IMMUN, V100, P569, DOI 10.1016/S0091-6749(97)70152-0; LOZEWICZ S, 1992, J ALLERGY CLIN IMMUN, V89, P951, DOI 10.1016/0091-6749(92)90217-P; MALM L, 1981, ALLERGY, V36, P209, DOI 10.1111/j.1398-9995.1981.tb01836.x; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; MELTZER EO, 1995, ALLERGY, V50, P15, DOI 10.1111/j.1398-9995.1995.tb02736.x; Mygind N, 1996, CLIN EXP ALLERGY, V26, P2, DOI 10.1111/j.1365-2222.1996.tb00652.x; NACLERIO RM, 1993, J ALLERGY CLIN IMMUN, V92, P717, DOI 10.1016/0091-6749(93)90015-8; OKUDA M, 1983, ANN ALLERGY, V50, P116; PIPKORN U, 1983, ALLERGY, V38, P125, DOI 10.1111/j.1398-9995.1983.tb01596.x; Pullerits T, 1997, J ALLERGY CLIN IMMUN, V100, P601, DOI 10.1016/S0091-6749(97)70162-3; RocaFerrer J, 1997, EUR RESPIR J, V10, P1489, DOI 10.1183/09031936.97.10071489; SIM TC, 1995, AM J RESP CRIT CARE, V152, P927, DOI 10.1164/ajrccm.152.3.7545059; SMALL P, 1982, J ALLERGY CLIN IMMUN, V70, P178, DOI 10.1016/0091-6749(82)90039-2; SVENSSON C, 1994, ALLERGY, V49, P177, DOI 10.1111/j.1398-9995.1994.tb00822.x; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170	30	13	13	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				S138	S143		10.1016/S0091-6749(99)70309-X	http://dx.doi.org/10.1016/S0091-6749(99)70309-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518810				2022-12-18	WOS:000083281200030
J	Pacocha, SE; Oriente, A; Huang, SK; Essayan, DM				Pacocha, SE; Oriente, A; Huang, SK; Essayan, DM			Regulation of antigen-induced human T-lymphocyte responses by calcineurin antagonists	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; T lymphocyte; cyclosporine; tacrolimus; IL-4; IL-5; IL-13; IFN-gamma	NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS; BLOOD MONONUCLEAR-CELLS; IFN-GAMMA PRODUCTION; CYCLOSPORINE-A; IL-13 PRODUCTION; DIFFERENTIAL REGULATION; GENE-TRANSCRIPTION; INTERFERON-GAMMA; EXPRESSION; CYTOKINE	Background: Cyclosporin A (CS) and tacrolimus (FK506, FK) are calcineurin antagonists used widely as T-cell immunosuppressants: however, their relative efficacy on antigen-stimulated T-cell subsets remains undefined. Objective: We have examined the effects of CS and FK on antigen-driven proliferation and cytokine generation from human PBMCs and T-cell clones, Methods: Proliferation was assessed by tritiated thymidine incorporation. Cytokine generation was assessed by reverse transcription-PCR and ELISA, Results: Ragweed- and tetanus toroid-driven proliferation of PBMCs was down-regulated equally by CS or FK, Gene expression for proinflammatory cytokines (IL-I, IL-5, IL-13, and IFN-gamma) assessed by reverse transcription-PCR was down-regulated in a concentration-dependent manner by either drug. Antigen-induced proliferation of ragweed-specific Th0, Th1, or Th2 clones was inhibited by either CS or FK. Cytokine gene expression and protein secretion into culture supernatants (IL-4, IL-5, IL-13, and IFN-gamma) were down-regulated in a concentration-dependent manner by either CS or FK in all relevant T-cell subsets. Interestingly, down-regulation of IL-5 protein generation from Th0 and Th2 clones was consistently less sensitive to either drug than was the effect on either IL-4 or IL-13 protein generation, Conclusion: CS and FK promote equivalent down-regulation of Th0, Th1, and Th2 responses; how ever, IL-5 generation is relatively insensitive to the immunomodulatory effects of calcineurin antagonists.	Johns Hopkins Univ, Sch Med, Div Clin Immunol, Dept Med, Baltimore, MD USA	Johns Hopkins University	Essayan, DM (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Room 1A12, Baltimore, MD 21224 USA.		Huang, Shau-Ku/F-5509-2010; Preheim, Sarah P/B-3432-2010	Preheim, Sarah P/0000-0001-7365-2382	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034002] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07290, AI34002] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Batiuk TD, 1996, TRANSPLANTATION, V61, P158, DOI 10.1097/00007890-199601150-00031; BATIUK TD, 1995, J CLIN INVEST, V96, P1254, DOI 10.1172/JCI118159; Braun CM, 1997, J ALLERGY CLIN IMMUN, V100, P400, DOI 10.1016/S0091-6749(97)70255-0; Briscoe DM, 1997, J IMMUNOL, V159, P3247; Cardenas M E, 1995, Curr Opin Nephrol Hypertens, V4, P472, DOI 10.1097/00041552-199511000-00002; Dolganov G, 1996, BLOOD, V87, P3316, DOI 10.1182/blood.V87.8.3316.bloodjournal8783316; Dumont FJ, 1997, INT ARCH ALLERGY IMM, V114, P300, DOI 10.1159/000237684; ESSAYAN DM, 1994, J IMMUNOL, V153, P3408; Essayan DM, 1996, J ALLERGY CLIN IMMUN, V98, P1035, DOI 10.1016/S0091-6749(96)80188-6; Essayan DM, 1997, J PHARMACOL EXP THER, V282, P505; ESSAYAN DM, 1995, AM J RESP CELL MOL, V13, P692, DOI 10.1165/ajrcmb.13.6.7576707; Eum SY, 1997, BRIT J PHARMACOL, V120, P130, DOI 10.1038/sj.bjp.0700860; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; Homey B, 1998, J IMMUNOL, V160, P5331; HUANG SK, 1994, J IMMUNOL METHODS, V168, P167, DOI 10.1016/0022-1759(94)90052-3; Iacono A, 1997, TRANSPLANTATION, V64, P263, DOI 10.1097/00007890-199707270-00015; Kraan TCTMV, 1996, J IMMUNOL, V156, P1818; LANG T, 1995, TRANSPLANT P, V27, P1146; LITTLE RG, 1990, TRANSPLANTATION, V49, P937, DOI 10.1097/00007890-199005000-00021; Martinez OM, 1998, TRANSPLANTATION, V65, P1240, DOI 10.1097/00007890-199805150-00016; Mattila PS, 1996, BIOCHEM SOC T, V24, P45, DOI 10.1042/bst0240045; MORI A, 1995, INT ARCH ALLERGY IMM, V107, P366, DOI 10.1159/000237036; MORI A, 1995, INT IMMUNOL, V7, P449, DOI 10.1093/intimm/7.3.449; Pazderka F, 1996, Transpl Immunol, V4, P23, DOI 10.1016/S0966-3274(96)80029-3; Rafiq K, 1998, EUR J IMMUNOL, V28, P1481, DOI 10.1002/(SICI)1521-4141(199805)28:05<1481::AID-IMMU1481>3.0.CO;2-4; Redrup AC, 1998, J IMMUNOL, V160, P1957; Rolfe FG, 1997, AM J RESP CELL MOL, V17, P243, DOI 10.1165/ajrcmb.17.2.2819; Takamatsu Y, 1998, DERMATOLOGY, V196, P377, DOI 10.1159/000017928; Tian L, 1997, TRANSPL IMMUNOL, V5, P189, DOI 10.1016/S0966-3274(97)80037-8; Umland SP, 1998, AM J RESP CELL MOL, V18, P631, DOI 10.1165/ajrcmb.18.5.3046; Valentine JE, 1997, INT IMMUNOL, V9, P975, DOI 10.1093/intimm/9.7.975	32	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				828	835		10.1016/S0091-6749(99)70294-0	http://dx.doi.org/10.1016/S0091-6749(99)70294-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518828				2022-12-18	WOS:000083281200015
J	Huang, TJ; Newton, R; Haddad, EB; Chung, KF				Huang, TJ; Newton, R; Haddad, EB; Chung, KF			Differential regulation of cytokine expression after allergen exposure of sensitized rats by cyclosporin A and corticosteroids: Relationship to bronchial hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cyclosporin A; dexamethasone; bronchial hyperresponsiveness; IL-4; IL-5; IL-10; IFN-gamma; neutrophil	BROWN-NORWAY RATS; LATE ASTHMATIC RESPONSE; INTERFERON-GAMMA; T-CELLS; MESSENGER-RNA; AIRWAY HYPERRESPONSIVENESS; ATOPIC ASTHMA; GUINEA-PIGS; ANTIGEN; INTERLEUKIN-2	Background: Cyclosporin A and dexamethasone exhibit different effects on allergic airway eosinophilia and bronchial hyperresponsiveness (BHR). Objective: We determined whether these mere related to alteration of cytokine expression, particularly with regard to the profile of Th1- versus Th2-derived cytokines, Methods: Brown-Norway rats sensitized with ovalbumin were administered cyclosporine or dexamethasone before ovalbumin aerosol challenge. Bronchial responsiveness was measured 18 to 24 hours after aerosol exposure. Airway cellular influx was determined by bronchoalveolar lavage and tissue immunohistochemistry, The expression of Th1 and Th2 cytokine messenger RNA (mRNA) was analyzed by reverse transcriptase-PCR, Results: Ovalbumin exposure induced significant BHR, with increases in eosinophils, lymphocytes, and neutrophils in bronchoalveolar lavage fluid and an increase in eosinophils, CD2(+) and CD8(+), but not CD4(+) T cells, in the airway submucosa, IL-2, IFN-gamma, IL-4, and IL-5 mRNA expression in the lungs of sensitized ovalbumin-exposed rats was increased (P < .05) compared with controls, Cyclosporin A had no significant effect on BHR and neutrophil accumulation but reduced the number of bronchoalveolar lavage eosinophils (P < .002), airway submucosal eosinophils, and CD4(+) and CD8(+) T cells (P < .02), It also suppressed the induced mRNA expression of IL-2, IL-4, IL-5, and IFN-gamma, By contrast, the inflammatory cell influx and mRNA expression for IL-2, IL-4, and IL-5, as well as BHR, were suppressed by dexamethasone, However, an increase in IL-10 and IFN-gamma mRNA expression was found. Conclusion: The differential activities of cyclosporin A and dexamethasone on inflammatory cell influx, particularly neutrophils, or cytokine expression such as IL-10 and IFN-gamma may underlie their contrasting effects on BHR.	Natl Heart & Lung Inst, Dept Thorac Med, Imperial Coll, London SW3 6LY, England; Chang Gung Mem Hosp, Keelung Branch, Dept Thorac Med, Keelung, Taiwan	Imperial College London; Chang Gung Memorial Hospital	Chung, KF (corresponding author), Natl Heart & Lung Inst, Dept Thorac Med, Imperial Coll, Dovehouse St, London SW3 6LY, England.		Newton, Robert/C-6814-2012; Chung, Kian Fan/B-1872-2012; Chung, Kian Fan/I-8456-2019	Newton, Robert/0000-0002-4919-8498; Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARYA SK, 1984, J IMMUNOL, V133, P273; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; CALHOUN WJ, 1995, AM J RESP CRIT CARE, V151, pA778; CEMBRZYNSKANOWAK M, 1993, AM REV RESPIR DIS, V147, P291, DOI 10.1164/ajrccm/147.2.291; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; Cox G, 1996, AM J PHYSIOL-LUNG C, V271, pL566, DOI 10.1152/ajplung.1996.271.4.L566; DIPADOVA FE, 1989, PHARMACOL REV, V41, P373; Driscoll KE, 1998, AM J PHYSIOL-LUNG C, V275, pL887, DOI 10.1152/ajplung.1998.275.5.L887; ELWOOD W, 1992, AM REV RESPIR DIS, V145, P1289, DOI 10.1164/ajrccm/145.6.1289; ELWOOD W, 1991, J ALLERGY CLIN IMMUN, V88, P951, DOI 10.1016/0091-6749(91)90253-K; ERARD F, 1985, J IMMUNOL, V134, P1644; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FUKUDA T, 1991, INT ARCH ALLER A IMM, V94, P259, DOI 10.1159/000235377; FUKUDA T, 1995, ANN ALLERG ASTHMA IM, V75, P65; HACZKU A, 1995, IMMUNOLOGY, V85, P591; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hofstra CL, 1998, AM J RESP CELL MOL, V19, P826, DOI 10.1165/ajrcmb.19.5.3027; HOWARD M, 1983, J EXP MED, V158, P2024, DOI 10.1084/jem.158.6.2024; Huang TJ, 1999, IMMUNOLOGY, V96, P416; HUANG TJ, 1999, IN PRESS IMMUNOLOGY; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; KEANEMYERS A, 1997, J IMMUNOL, V158, P2040; Li XM, 1996, J IMMUNOL, V157, P3216; Lock SH, 1996, AM J RESP CRIT CARE, V153, P509, DOI 10.1164/ajrccm.153.2.8564089; MALEK TR, 1985, J EXP MED, V161, P1575, DOI 10.1084/jem.161.6.1575; MAUSER P J, 1992, American Review of Respiratory Disease, V145, pA859; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; Nagai H, 1997, CLIN EXP ALLERGY, V27, P218; NORRIS AA, 1992, CLIN EXP IMMUNOL, V89, P347; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P214; Pullerits T, 1997, INT ARCH ALLERGY IMM, V112, P279, DOI 10.1159/000237466; RAND TH, 1991, J CLIN INVEST, V88, P825, DOI 10.1172/JCI115383; RENZI PM, 1992, AM REV RESPIR DIS, V146, P163, DOI 10.1164/ajrccm/146.1.163; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rolfe FG, 1997, AM J RESP CELL MOL, V17, P243, DOI 10.1165/ajrcmb.17.2.2819; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SANO T, 1995, EUR RESPIR J, V8, P1473; SCHMIDT J, 1994, EUR J PHARMACOL, V260, P247, DOI 10.1016/0014-2999(94)90345-X; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SILVA JRLE, 1995, EUR RESPIR J, V8, P1321, DOI 10.1183/09031936.95.08081321; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	45	13	14	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				644	652		10.1016/S0091-6749(99)70337-4	http://dx.doi.org/10.1016/S0091-6749(99)70337-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482841				2022-12-18	WOS:000082870000029
J	Weiler, JM				Weiler, JM			Anaphylaxis in the general population: A frequent and occasionally fatal disorder that is underrecognized	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							EPIDEMIOLOGY		Univ Iowa Hosp & Clin, Dept Internal Med, Iowa City, IA 52242 USA	University of Iowa	Weiler, JM (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA.							BACAL E, 1978, CLIN ALLERGY, V8, P295, DOI 10.1111/j.1365-2222.1978.tb03227.x; BRESSER H, 1995, J ALLERGY CLIN IMMUN, V95, P368; Dibs S D, 1997, Pediatrics, V99, pE7, DOI 10.1542/peds.99.1.e7; ESSAYAN DM, 1994, ANN ALLERGY, V73, P297; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; KLEIN JS, 1995, J ALLERGY CLIN IMMUN, V95, P637, DOI 10.1016/S0091-6749(95)70329-2; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; PATTERSON R, 1995, ARCH INTERN MED, V155, P869, DOI 10.1001/archinte.155.8.869; Portier P, 1902, CR SEANC SOC BIOL, V54, P170; SORENSEN HT, 1989, ALLERGY, V44, P288, DOI 10.1111/j.1398-9995.1989.tb01071.x; STEINER DJ, 1995, J AM COLL SURGEONS, V180, P754; VANDERKLAUW MM, 1993, BRIT J CLIN PHARMACO, V35, P400; WITHINGTON DE, 1994, CAN J ANAESTH, V41, P1133, DOI 10.1007/BF03020649; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450; 1991, MMWR MORBID MORTAL W, V40, P443	15	13	15	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				271	273		10.1016/S0091-6749(99)70363-5	http://dx.doi.org/10.1016/S0091-6749(99)70363-5			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452741				2022-12-18	WOS:000082364800011
J	Magnan, A; Venemalm, L; Porri, F; Vervloet, D				Magnan, A; Venemalm, L; Porri, F; Vervloet, D			Anaphylactic reaction to rifamycin SV: Presence of specific IgE antibodies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CONTACT		Hop St Marguerite, UPRES 2050, Serv Pneumoallergol, F-13274 Marseille 09, France; Pharmacia & Upjohn SA Diagnost, Uppsala, Sweden	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Pfizer	Magnan, A (corresponding author), Hop St Marguerite, UPRES 2050, Serv Pneumoallergol, 270 Bd St Marguerite,BP 29, F-13274 Marseille 09, France.		Magnan, Antoine/D-4100-2015; MAGNAN, ANTOINE/GVT-4308-2022					BASSI L, 1976, INT ARCH ALLER A IMM, V51, P390, DOI 10.1159/000231612; BIRNBAUM J, 1994, CLIN EXP ALLERGY, V24, P915, DOI 10.1111/j.1365-2222.1994.tb02722.x; CARDOT E, 1995, J ALLERGY CLIN IMMUN, V95, P1, DOI 10.1016/S0091-6749(95)70145-1; GROB JJ, 1987, CONTACT DERMATITIS, V16, P284, DOI 10.1111/j.1600-0536.1987.tb01460.x; GUERRA L, 1991, CONTACT DERMATITIS, V25, P328, DOI 10.1111/j.1600-0536.1991.tb01886.x; PIAZZA I, 1989, ALLERGOLOGIE S, V12, P96	6	13	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				954	956		10.1016/S0091-6749(99)70446-X	http://dx.doi.org/10.1016/S0091-6749(99)70446-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329836				2022-12-18	WOS:000080470200037
J	Kim, KT; Safadi, GS				Kim, KT; Safadi, GS			Relation of latex-specific IgE titer and symptoms in patients allergic to latex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; in vitro IgE assay; asthma; AlaSTAT; CAP	NATURAL-RUBBER LATEX; OCCUPATIONAL ASTHMA; DIAGNOSIS; PROTEINS	Background: The relation between latex-specific IgE titer and the type or total number of latex-induced symptoms has not been previously investigated. Objective: We sought to determine the association of latex-IgE in vitro assay results with the type, number, or severity of symptoms in patients allergic to latex. Methods: Ninety-one patients with positive histories and positive skin test responses were identified as having type I allergy. Data was collected for reported symptoms after latex exposure. Symptom severity was quantitated by 2 scores: (1) the total number of symptoms to latex exposure and (2) a symptom severity score (3 = anaphylaxis, 2 = asthma, and I = rhinoconjunctivitis, urticaria, or both). All subjects underwent AlaSTAT and CAP tests. Results: AlaSTAT class was associated with total number of symptoms (r = 0.32, P <.001) and severity score (r = 0.33, P < .002), Similarly, CAP class was associated with both number of symptoms (r = 0.32, P <.001) and severity score (r = 0.31, P <.001), Among the symptoms reported, asthma had the strongest association with a positive in vitro IgE assay (odds ratio = 6.7 [95% confidence interval = 1.9, 25.6]), followed by urticaria (odds ratio = 1.9 [95% confidence interval = 0.8, 4.6]), Contact dermatitis had no statistical association with in vitro assays in this study. AlaSTAT and CAP class correlated together significantly (r = 0.58, P <.001). Conclusion: Patients allergic to latex with higher AlaSTAT or CAP class were more symptomatic, increasing class or titer also predicted more severe symptoms. Higher class of either the AlaSTAT or CAP assay to latex was strongly associated with latex-related asthma and urticaria and marginally associated with latex-related rhinoconjunctivitis.	Long Beach Mem Med Ctr, Long Beach, CA USA; Univ Jordan, Amman, Jordan	University of Jordan	Kim, KT (corresponding author), 2501 Cherry Ave 350, Long Beach, CA 90806 USA.							Aamir R, 1996, INT ARCH ALLERGY IMM, V111, P48, DOI 10.1159/000237345; ALENIUS H, 1994, J ALLERGY CLIN IMMUN, V93, P859, DOI 10.1016/0091-6749(94)90378-6; BEEBE R, 1997, ANN ALLERG ASTHMA IM, V78, P86; BRUGNAMI G, 1995, J ALLERGY CLIN IMMUN, V96, P457, DOI 10.1016/S0091-6749(95)70287-3; CORDER WT, 1995, ANN ALLERG ASTHMA IM, V75, P434; Hadjiliadis D, 1996, J ALLERGY CLIN IMMUN, V97, P1202, DOI 10.1016/S0091-6749(96)70185-9; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V93, P813, DOI 10.1016/0091-6749(94)90370-0; Kim K T, 1998, AORN J, V67, P615, DOI 10.1016/S0001-2092(06)62830-5; Kim KT, 1998, ANN ALLERG ASTHMA IM, V80, P66, DOI 10.1016/S1081-1206(10)62942-0; KUJALA VM, 1995, ALLERGY PROC, V16, P93, DOI 10.2500/108854195778771372; ODA KK, 1998, ANN ALLERGY, V80, P101; PISATI G, 1994, EUR RESPIR J, V7, P332, DOI 10.1183/09031936.94.07020332; SAFADI GS, 1996, ANN ALLERG ASTHMA IM, V74, P77; VANDENPLAS O, 1995, EUR RESPIR J, V8, P1957, DOI 10.1183/09031936.95.08111957; YASSIN MS, 1994, ANN ALLERGY, V72, P245	16	13	15	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					671	677		10.1016/S0091-6749(99)70241-1	http://dx.doi.org/10.1016/S0091-6749(99)70241-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200018	Bronze			2022-12-18	WOS:000079723900022
J	Lieberman, P				Lieberman, P			Management of allergic rhinitis with a combination antihistamine/antiflammatory agent	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							AZELASTINE NASAL SPRAY; INTRANASAL AZELASTINE; HISTAMINE-RELEASE; DOUBLE-BLIND; GUINEA-PIGS; EFFICACY; INHIBITION; SAFETY; NEUTROPHIL; SUPEROXIDE	Azelastine nasal spray is a topical antihistamine treatment for the symptoms of seasonal allergic rhinitis, Besides histamine antagonism, azelastine affects other chemical mediators of the inflammatory response including leukotrienes and kinins, This article reviews and discusses the antihistaminic and antiinflammatory properties of azelastine and the results of pharmacokinetic studies and controlled clinical trials.	Univ Tennessee, Sch Med, Div Allergy & Immunol, Knoxville, TN 37996 USA; Univ Tennessee, Sch Med, Dept Pediat, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Lieberman, P (corresponding author), 300 Walnut Bend Rd, Cordova, TN 38018 USA.							BAUMGARTEN CR, 1994, J PHARM U THER, V3, P43; BUSSE W, 1989, J ALLERGY CLIN IMMUN, V83, P400, DOI 10.1016/0091-6749(89)90125-5; Busse WW, 1996, AM J RESP CRIT CARE, V153, P122, DOI 10.1164/ajrccm.153.1.8542104; CASALE TB, 1989, J ALLERGY CLIN IMMUN, V83, P771, DOI 10.1016/0091-6749(89)90013-4; CHAND N, 1986, ALLERGY, V41, P473, DOI 10.1111/j.1398-9995.1986.tb00331.x; CHAND N, 1989, INT ARCH ALLER A IMM, V90, P67, DOI 10.1159/000235002; CHAND N, 1983, EUR J PHARMACOL, V96, P227, DOI 10.1016/0014-2999(83)90311-4; CHAND N, 1992, INT ARCH ALLERGY IMM, V97, P229, DOI 10.1159/000236124; Charpin D, 1995, EUR ARCH OTO-RHINO-L, V252, P455, DOI 10.1007/BF02114749; Ciprandi G, 1996, J ALLERGY CLIN IMMUN, V98, P1088, DOI 10.1016/S0091-6749(96)80196-5; GAMBARDELLA R, 1993, J INT MED RES, V21, P268, DOI 10.1177/030006059302100505; GASTPAR H, 1994, ALLERGY, V49, P152, DOI 10.1111/j.1398-9995.1994.tb00818.x; GROSSMAN J, 1994, ANN ALLERGY, V73, P141; Hamasaki Y, 1996, ANN ALLERG ASTHMA IM, V76, P469, DOI 10.1016/S1081-1206(10)63465-5; INOUE Y, 1983, NICHI IDAISHI, V50, P65; KONNO S, 1995, INT ARCH ALLERGY IMM, V108, P292, DOI 10.1159/000237167; LaForce C, 1996, ANN ALLERG ASTHMA IM, V76, P181, DOI 10.1016/S1081-1206(10)63420-5; LITTLE MM, 1989, J ALLERGY CLIN IMMUN, V83, P862, DOI 10.1016/0091-6749(89)90096-1; MATSUMURA M, 1990, RESP RES, V9, P206; *MED EC CO, 1998, PHYS DESK REF, P2952; MELTZER EO, 1994, ANN ALLERGY, V72, P354; MELTZER EO, 1994, AM J RHINOL, V8, P323, DOI 10.2500/105065894781874142; Morganroth J, 1997, J CLIN PHARMACOL, V37, P1065, DOI 10.1002/j.1552-4604.1997.tb04289.x; MORITA M, 1993, CURR MED RES OPIN, V13, P163, DOI 10.1185/03007999309111546; MULLER S, 1993, TOPICAL TREATMENT AL, P148; NAKAMURA T, 1988, EUR J PHARMACOL, V148, P35, DOI 10.1016/0014-2999(88)90451-7; NewsonSmith G, 1997, EUR ARCH OTO-RHINO-L, V254, P236, DOI 10.1007/BF00874095; PEARLMAN D, 1999, ANN ALLERG ASTHMA IM, V82, P90; RATNER PH, 1994, J ALLERGY CLIN IMMUN, V94, P818, DOI 10.1016/0091-6749(94)90148-1; RENESTO P, 1991, BRIT J PHARMACOL, V103, P1435, DOI 10.1111/j.1476-5381.1991.tb09807.x; SALE M, 1996, ANN ALLERG ASTHMA IM, V76, P91; SHIN MH, 1992, CLIN EXP ALLERGY, V22, P289, DOI 10.1111/j.1365-2222.1992.tb03085.x; Smits AJ, 1997, EXP THERM FLUID SCI, V14, P1, DOI 10.1016/S0894-1777(96)00189-6; Storms W W, 1994, Ear Nose Throat J, V73, P382; TANIGUCHI K, 1984, BIOCHEM PHARMACOL, V33, P3165, DOI 10.1016/0006-2952(84)90072-8; THOMAS KE, 1992, CLIN EXP ALLERGY, V22, P642, DOI 10.1111/j.1365-2222.1992.tb00182.x; UMEKI S, 1992, BIOCHEM PHARMACOL, V43, P1109, DOI 10.1016/0006-2952(92)90619-T; WEILER JM, 1994, J ALLERGY CLIN IMMUN, V94, P972, DOI 10.1016/0091-6749(94)90115-5; WERNER U, 1991, AGENT ACTION SUPPL, V32, P243	39	13	17	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	2	S			S400	S404		10.1016/S0091-6749(99)70220-4	http://dx.doi.org/10.1016/S0091-6749(99)70220-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	179CL	10069901				2022-12-18	WOS:000079305900007
J	Klein, RS; Flanigan, T; Schuman, P; Smith, D; Vlahov, D				Klein, RS; Flanigan, T; Schuman, P; Smith, D; Vlahov, D		HIV Epidemiologic Res Study Grp	Criteria for assessing cutaneous anergy in women with or at risk for HIV infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anergy; cellular immunity; delayed hypersensitivity; skin tests	DELAYED-TYPE HYPERSENSITIVITY; IMMUNODEFICIENCY-VIRUS-INFECTION; CELL-MEDIATED-IMMUNITY; SKIN-TEST ANERGY; DRUG-USERS; TUBERCULIN; PROGRESSION; PLASMA; AIDS; RNA	Background: Controversy exists about both the clinical utility of anergy testing and the optimal criteria for defining anergy. Objective: We sought to assess various definitions of cutaneous anergy for ability to distinguish HIV status, level of immunodeficiency, and ability to mount a tuberculin reaction among women with or at risk for HIV infection. Methods: HIV-seropositive (n = 721) and HIV-seronegative (n = 358) at-risk women at academic medical centers in Baltimore, Detroit, New York, and Providence had cutaneous testing with mumps, Candida, tetanus toroid, and tuberculin antigens. Associations with HIV status and CD4+ lymphocyte levels mere analyzed. Results: Candida, mumps, and tetanus antigens alone or in combination elicited reactions significantly less often in HIV-seropositive than in HIV-seronegative women and less often in seropositive women with lower CD4+ counts, regardless of induration cutpoint chosen to define a positive reaction. The best antigen combinations far distinguishing groups included tetanus and mumps. Some women nonreactive to the 3 antigens ("anergic") had positive tuberculin reactions among both seropositive subjects (range, 1.1% to 2.9% depending on induration cutpoint for defining anergy) and seronegative subjects (range, 8.9% to 14%). Conclusion: Absence of reactions to Candida, mumps, and tetanus antigens alone or in combination and at any induration cutpoint is associated with HIV status and with CD4+ level. Combinations, including tetanus and mumps antigens with an induration cutpoint of less than 2 mm, mag be the best for defining anergy.	Montefiore Med Ctr, AIDS Res Program, Div Infect Dis, Dept Med, Bronx, NY 10467 USA; Montefiore Med Ctr, Dept Epidemiol & Social Med, Bronx, NY 10467 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Miriam Hosp, Dept Med, Div Infect Dis, Providence, RI 02906 USA; Brown Univ, Sch Med, Providence, RI 02912 USA; Wayne State Univ, Sch Med, Dept Med, Div Infect Dis, Detroit, MI 48201 USA; Ctr Dis Control & Prevent, Atlanta, GA USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Lifespan Health Rhode Island; Miriam Hospital; Brown University; Wayne State University; Centers for Disease Control & Prevention - USA; Johns Hopkins University	Klein, RS (corresponding author), Montefiore Med Ctr, AIDS Res Program, Div Infect Dis, Dept Med, 111 E 210th St, Bronx, NY 10467 USA.				PHS HHS [U64/CCU206798, U64/CCU106795, U64/CCU306802] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHMED AR, 1983, ARCH DERMATOL, V119, P934, DOI 10.1001/archderm.119.11.934; BIRX DL, 1993, J ACQ IMMUN DEF SYND, V6, P1248; BLATT SP, 1993, ANN INTERN MED, V119, P177, DOI 10.7326/0003-4819-119-3-199308010-00001; BORLEFFS JCC, 1991, AIDS, V5, P110, DOI 10.1097/00002030-199101000-00020; CAIAFFA WT, 1995, ARCH INTERN MED, V155, P2111, DOI 10.1001/archinte.155.19.2111; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P27; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Chin DP, 1996, AM J RESP CRIT CARE, V153, P1982, DOI 10.1164/ajrccm.153.6.8665065; COLEBUNDERS RL, 1989, J ACQ IMMUN DEF SYND, V2, P576; FAIRSHTER RD, 1980, J ALLERGY CLIN IMMUN, V66, P452, DOI 10.1016/0091-6749(80)90005-6; FAUCI AS, 1984, ANN INTERN MED, V100, P92, DOI 10.7326/0003-4819-100-1-92; GORDIN FM, 1994, J INFECT DIS, V169, P893, DOI 10.1093/infdis/169.4.893; GORDON EH, 1983, J ALLERGY CLIN IMMUN, V72, P487, DOI 10.1016/0091-6749(83)90586-9; GOTTLIEB MS, 1983, ANN INTERN MED, V99, P208, DOI 10.7326/0003-4819-99-2-208; Gourevitch MN, 1996, AM J RESP CRIT CARE, V154, P1029, DOI 10.1164/ajrccm.154.4.8887602; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; GROSSMAN J, 1975, J ALLERGY CLIN IMMUN, V55, P268, DOI 10.1016/0091-6749(75)90146-3; HUEBNER RE, 1992, JAMA-J AM MED ASSOC, V267, P409, DOI 10.1001/jama.267.3.409; HUEBNER RE, 1994, CLIN INFECT DIS, V19, P26, DOI 10.1093/clinids/19.1.26; Janis EM, 1996, AM J MED, V100, P186, DOI 10.1016/S0002-9343(97)89457-0; KNIKER WT, 1979, ANN ALLERGY, V43, P73; MARKOWITZ N, 1993, ANN INTERN MED, V119, P185, DOI 10.7326/0003-4819-119-3-199308010-00002; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Miller WC, 1996, J ACQ IMMUN DEF SYND, V12, P303, DOI 10.1097/00042560-199607000-00012; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; PALMER DL, 1974, J INFECT DIS, V130, P132, DOI 10.1093/infdis/130.2.132; PESANTI EL, 1994, AM J RESP CRIT CARE, V149, P1699, DOI 10.1164/ajrccm.149.6.7710481; SEARS SD, 1987, CLIN IMMUNOL IMMUNOP, V45, P177, DOI 10.1016/0090-1229(87)90032-8; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; Smith DK, 1997, AM J EPIDEMIOL, V146, P459, DOI 10.1093/oxfordjournals.aje.a009299; SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013; STOMPSON PG, 1976, S MED J, V69, P424; ZEBALLOS RS, 1992, J CLIN LAB ANAL, V6, P119, DOI 10.1002/jcla.1860060303	36	13	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				93	98		10.1016/S0091-6749(99)70531-2	http://dx.doi.org/10.1016/S0091-6749(99)70531-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893191				2022-12-18	WOS:000078112300015
J	Weiss, SJ; Ahmed, AE; Bonagura, VR				Weiss, SJ; Ahmed, AE; Bonagura, VR			Complement factor D deficiency in an infant first seen with pneumococcal neonatal sepsis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Schneider Childrens Hosp, Div Allergy & Immunol, New Hyde Park, NY 11040 USA; Specialty Labs, Santa Monica, CA USA	Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Yeshiva University	Weiss, SJ (corresponding author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Schneider Childrens Hosp, Div Allergy & Immunol, Room 235,Clin Campus, New Hyde Park, NY 11040 USA.			Bonagura, Vincent/0000-0002-0681-2099				AHMED AEE, 1995, CLIN DIAGN LAB IMMUN, V2, P509, DOI 10.1128/CDLI.2.5.509-517.1995; HIEMSTRA PS, 1989, J CLIN INVEST, V84, P1957, DOI 10.1172/JCI114384; KLUINNELEMANS HC, 1984, CLIN EXP IMMUNOL, V58, P724; NILSSON UR, 1984, J IMMUNOL METHODS, V72, P49, DOI 10.1016/0022-1759(84)90432-0	4	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				1043	1044		10.1016/S0091-6749(98)70346-X	http://dx.doi.org/10.1016/S0091-6749(98)70346-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847449	Bronze			2022-12-18	WOS:000077690700026
J	Crocker, IC; Ohia, SE; Church, MK; Townley, RG				Crocker, IC; Ohia, SE; Church, MK; Townley, RG			Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic; cytokines; glucocorticoids; IL-10; phosphodiesterase inhibitors; TNF-alpha	NECROSIS-FACTOR-ALPHA; CAMP-SPECIFIC PHOSPHODIESTERASE; INTERFERON-GAMMA PRODUCTION; RECEPTOR-BINDING AFFINITY; DEPENDENT PROTEIN-KINASE; T-CELLS; GENE-EXPRESSION; DOWN-REGULATION; TNF-ALPHA; PROLIFERATION	Background: Both glucocorticosteroids and phosphodiesterase (PDE) type 4 inhibitors have modulatory effects on PBMC cytokine secretion, In this study se compared the effect of glucocorticoids and PDE inhibitors on IL-10 and TNF-alpha production by PBMCs from nonatopic versus atopic individuals. Methods: PBMCs were incubated with glucocorticoids (beclomethasone dipropionate and mometasone furoate) or media alone for 24 hours. PDE type 4 inhibitors (Ro20-1724 and rolipram) were then added to the cells preincubated with media. After stimulation with PHA, incubation was continued for 48 hours, The cytokine content of the cell supernatants was determined by ELISA. Results: PDE-4 inhibitors and glucocorticoids caused a concentration-dependent inhibition of the secretion of both TNF-alpha and IL-10. PDE-4 inhibitors were over 20 times more potent in suppressing cytokine secretion by PBMCs from atopic than nonatopic donors, and approximately 5 times more potent in preventing TNF-alpha than IL-10 secretion. In cells from nonatopic donors, glucocorticoids inhibited the production of TNF-alpha to a greater extent than IL-10, but these drugs were more potent in cells from nonatopic than atopic persons. Conclusion: In conclusion, both PDE-4 inhibitors and glucocorticoids suppress secretion of TNF-alpha and IL-10, However, because PDE-4 inhibitors are more potent in suppressing cytokine secretion by PBMCs from atopic individuals hut less potent in inhibiting production of IL-10, PDE-4 inhibitors may have greater therapeutic potential than glucocorticoids in allergic diseases.	Creighton Univ, Ctr Allerg Dis, Dept Med, Div Allergy, Omaha, NE 68178 USA; Creighton Univ, Ctr Allerg Dis, Dept Pharmaceut & Adm Sci, Omaha, NE 68178 USA; Southampton Gen Hosp, Immunopharmacol Grp, Southampton SO9 4XY, Hants, England	Creighton University; Creighton University; University of Southampton	Townley, RG (corresponding author), Creighton Univ, Ctr Allerg Dis, Dept Med, Div Allergy, 2500 Calif Plaza, Omaha, NE 68178 USA.							ABBAS AK, 1994, CELLULAR MOL IMMUNOL, P136; Banner KH, 1995, BRIT J PHARMACOL, V116, P3169, DOI 10.1111/j.1476-5381.1995.tb15120.x; BARNES PJ, 1995, EUR RESPIR J, V8, P457, DOI 10.1183/09031936.95.08030457; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, pS125, DOI 10.1164/ajrccm/152.6_Pt_2.S125; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; BRACKEEN MF, 1995, J MED CHEM, V38, P4848, DOI 10.1021/jm00024a012; BRINKMANN V, 1995, J IMMUNOL, V155, P3322; CHAN SC, 1993, J ALLERGY CLIN IMMUN, V91, P1179, DOI 10.1016/0091-6749(93)90321-6; CHANDUVI F, 1993, FAO WATER REP, V1, P11; Crocker I. C., 1997, Journal of Allergy and Clinical Immunology, V99, pS331; Crocker IC, 1997, ANN ALLERG ASTHMA IM, V78, P497, DOI 10.1016/S1081-1206(10)63238-3; Crocker IC, 1998, J ALLERGY CLIN IMMUN, V101, pS143; Crocker IC, 1996, IMMUNOPHARMACOLOGY, V31, P223, DOI 10.1016/0162-3109(95)00053-4; CROCKER IC, 1997, AM J RESP CRIT CARE, V155, pA751; CROCKER IC, 1998, IN PRESS ANN ALLERGY; DELPRETE G, 1993, J IMMUNOL, V150, P353; Dent G, 1996, THORAX, V51, P647, DOI 10.1136/thx.51.6.647; ESSAYAN DM, 1994, J IMMUNOL, V153, P3408; Essayan DM, 1997, J ALLERGY CLIN IMMUN, V99, P28, DOI 10.1016/S0091-6749(97)81041-X; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Hanifin JM, 1996, J INVEST DERMATOL, V107, P51, DOI 10.1111/1523-1747.ep12297888; HARTMAN DA, 1995, INFLAMM RES, V44, P269, DOI 10.1007/BF02032567; Jacobitz S, 1996, MOL PHARMACOL, V50, P891; KAM JC, 1993, J IMMUNOL, V151, P3460; KAMBAYASHI T, 1995, J IMMUNOL, V155, P4909; KUNICKA JE, 1993, CELL IMMUNOL, V149, P39, DOI 10.1006/cimm.1993.1134; MALEFYT RD, 1991, J EXP MED, V174, P915; MALEFYT RD, 1993, J IMMUNOL, V150, P4754; Nimmagadda SR, 1997, AM J RESP CRIT CARE, V155, P87, DOI 10.1164/ajrccm.155.1.9001294; PALIOGIANNI F, 1993, J CLIN INVEST, V91, P1481, DOI 10.1172/JCI116353; Pindolia KR, 1996, HEMATOPATHOL MOL HEM, V10, P171; PRABHAKAR U, 1994, INT J IMMUNOPHARMACO, V16, P805, DOI 10.1016/0192-0561(94)90054-X; RAVID A, 1990, J ALLERGY CLIN IMMUN, V86, P881, DOI 10.1016/S0091-6749(05)80150-2; Rieckmann P, 1996, J NEUROIMMUNOL, V64, P193, DOI 10.1016/0165-5728(95)00176-X; ROUSSET F, 1991, J ALLERGY CLIN IMMUN, V87, P58, DOI 10.1016/0091-6749(91)90213-8; SCHUMACHER JH, 1988, J IMMUNOL, V141, P1576; SELDON PM, 1995, MOL PHARMACOL, V48, P747; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P20806; SETTE C, 1994, J BIOL CHEM, V269, P18271; Spahn JD, 1996, J ALLERGY CLIN IMMUN, V98, P1073, DOI 10.1016/S0091-6749(96)80194-1; Tabardel Y, 1996, SURGERY, V119, P76, DOI 10.1016/S0039-6060(96)80217-0; TANIMOTO Y, 1994, J ALLERGY CLIN IMMUN, V93, pA570; Umland SP, 1997, J ALLERGY CLIN IMMUN, V100, P511, DOI 10.1016/S0091-6749(97)70144-1; vanderPoll T, 1996, J CLIN INVEST, V97, P713, DOI 10.1172/JCI118469; VANFURTH AM, 1995, CLIN DIAGN LAB IMMUN, V2, P689, DOI 10.1128/CDLI.2.6.689-692.1995; WANIDWORANUN C, 1993, J IMMUNOL, V151, P6853; YU XP, 1995, P NATL ACAD SCI USA, V92, P10990, DOI 10.1073/pnas.92.24.10990	48	13	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					797	804		10.1016/S0091-6749(98)70020-X	http://dx.doi.org/10.1016/S0091-6749(98)70020-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819297				2022-12-18	WOS:000077033400014
J	Demoly, P; Messaad, D; Trylesinski, A; Faucherre, V; Fabre, J; Reynes, J; Delmas, C; Dohin, E; Godard, P; Bousquet, J				Demoly, P; Messaad, D; Trylesinski, A; Faucherre, V; Fabre, J; Reynes, J; Delmas, C; Dohin, E; Godard, P; Bousquet, J			Nelfinavir-induced urticaria and successful desensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PROTEASE INHIBITORS		CHU Montpellier, Hop Arnaud de Villeneuve, INSERM, U454, F-34295 Montpellier 5, France; Hop St Eloi, Montpellier, France; Hop Guy de Chauliac, Montpellier, France; Prod Roche, Clin Dept, Neuilly Sur Seine, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Roche Holding	Demoly, P (corresponding author), CHU Montpellier, Hop Arnaud de Villeneuve, INSERM, U454, F-34295 Montpellier 5, France.		Demoly, Pascal/Y-9938-2019; Bousquet, Jean/O-4221-2019	Demoly, Pascal/0000-0001-7827-7964; 				Bonfanti P, 1997, AIDS, V11, P1301, DOI 10.1097/00002030-199710001-00008; CARR A, 1991, J CLIN IMMUNOL, V11, P52; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; SAAG M, 1997, INT C ANT AG CHEM SE; WEBBER S, 1996, 3 C RETR OPP INF JAN	5	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					875	876		10.1016/S0091-6749(98)70031-4	http://dx.doi.org/10.1016/S0091-6749(98)70031-4			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819308				2022-12-18	WOS:000077033400025
J	Wilson, AM; Brewster, HJA; Lipworth, BJ				Wilson, AM; Brewster, HJA; Lipworth, BJ			Dose-response comparison of systemic bioactivity with inhaled budesonide and triamcinolone acetonide in asthmatic adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adrenal suppression; asthma; corticosteroids; budesonide; triamcinolone acetonide; bone markers; eosinophils	PITUITARY-ADRENAL AXIS; FLUTICASONE PROPIONATE; BECLOMETHASONE DIPROPIONATE; CORTICOSTEROIDS; SUPPRESSION; PHARMACOKINETICS; TWICE	Background: Budesonide (BUD) has recently been licensed for treatment of asthma in the United States, whereas triamcinolone acetonide (TAA) has been used for many years. Objective: Ne sought to evaluate the dose-response effect of inhaled BUD and TAA in terms of adrenal, bone, and blood markers, Methods: Twelve asthmatic subjects (mean age, 32 Sears; mean FEV1, 91% of predicted value) were studied in a randomized design comparing 3 days of treatment with placebo and low (200 mu g twice daily), medium (400 mu g twice daily), and high (800 mu g twice daily) doses of BUD (Pulmicort Turbuhaler, 100 mu g) and TAA (Azmacort integrated actuator/spacer, 100 mu g) with a 7-day period at crossover, when patients received their usual inhaled corticosteroid therapy. Measurements were made at 8 AM for serum cortisol, osteocalcin, and blood eosinophils. Measurements were also made for overnight urinary cortisol/creatinine excretion. Results: For all measurements there were no significant differences between the 2 treatments at any dose level. Ratios between BUD and TAA (95% CI) at the highest dose levels were as follows: 8 AM serum cortisol, 1.08-fold (0.63 to 1.85); urinary cortisol, 1.09-fold (0.63 to 1.86); eosinophils, 0.98-fold (0.69 to 1.38); and osteocalcin 1.05-fold (0.78 to 1.41), There was no evidence of a significant overall dose-response effect for any parameter of hypothalamo-pituitary-adrenocortical axis activity, with neither drug being significantly different from placebo at any dose. For the 3 dose levels of both drugs, total abnormal low values for 8 AM serum cortisol (ie, <5.4 mu g/dL [<150 nmol/L]) showed 2 of 36 for BUD and 2 of 36 for TAA, There was also no significant overall dose-response effect for eosinophils or osteocalcin, although both drugs were significantly (P < .05) different from placebo at the highest dose: eosinophils (x 10(9) g/L), placebo: 0.36, TAA: 0.24, and BUD: 0.23; and osteocalcin (nmol/L), placebo: 1.04, TAA: 0.73, and BUD: 0.77. Conclusion: There were no significant differences in the systemic bioactivity profiles, in terms of adrenal, blood, and bone markers, between BUD administered by means of Turbuhaler and TAA administered by means of an integrated actuator/spacer in a dose range of 400 mu g to 1600 mu g/day. Both drugs exhibited a significant degree of detectable systemic bioactivity but only at the highest dose of 1600 mu g/day for effects on eosinophil count and osteocalcin.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland	University of Dundee	Lipworth, BJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland.							Aaronson D, 1998, J ALLERGY CLIN IMMUN, V101, P312, DOI 10.1016/S0091-6749(98)70241-6; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1996, Arthritis Rheum, V39, P1791; [Anonymous], PUBL NIH; BOOTSMA GP, 1995, THORAX, V50, P1044, DOI 10.1136/thx.50.10.1044; BROIDE J, 1995, J CLIN ENDOCR METAB, V80, P1243, DOI 10.1210/jc.80.4.1243; BROWN PH, 1991, RESP MED, V85, P511, DOI 10.1016/S0954-6111(06)80269-6; Clark DJ, 1997, THORAX, V52, P55, DOI 10.1136/thx.52.1.55; DERENDORF H, 1995, J CLIN PHARMACOL, V35, P302, DOI 10.1002/j.1552-4604.1995.tb04064.x; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; Grahnen A, 1997, EUR J CLIN PHARMACOL, V52, P261, DOI 10.1007/s002280050287; Grebe SKG, 1997, CLIN ENDOCRINOL, V47, P297, DOI 10.1046/j.1365-2265.1997.2391059.x; HEALD D, 1995, P JOINT M AM AC ALL, P14; HOGGER P, 1994, STEROIDS, V59, P597, DOI 10.1016/0039-128X(94)90054-X; Iula AK, 1997, CURR THER RES CLIN E, V58, P544, DOI 10.1016/S0011-393X(97)80046-X; JOHANSSON SA, 1982, EUR J CLIN PHARMACOL, V22, P523, DOI 10.1007/BF00609625; KNUTSSON U, 1995, J ENDOCRINOL, V144, P301, DOI 10.1677/joe.0.1440301; Lipworth BJ, 1996, BRIT J CLIN PHARMACO, V42, P697, DOI 10.1046/j.1365-2125.1996.00493.x; Lipworth BJ, 1996, PULM PHARMACOL THER, V9, P19, DOI 10.1006/pulp.1996.0002; Lipworth BJ, 1997, THORAX, V52, P476, DOI 10.1136/thx.52.5.476; MCINTYRE HD, 1995, THORAX, V50, P1280, DOI 10.1136/thx.50.12.1280; OLSSON B, 1995, J AEROSOL MED, V8, pS13; Pearson MG, 1997, THORAX, V52, pS1; RYRFELDT A, 1982, EUR J RESPIR DIS, V63, P86; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; Wilson A, 1997, THORAX, V52, pA57; Wilson AM, 1997, AM J RESP CRIT CARE, V156, P1274, DOI 10.1164/ajrccm.156.4.97-03029; WURTHWEIN G, 1992, PHARM ZELT WISSENSCH, V137, P161	29	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					751	756		10.1016/S0091-6749(98)70014-4	http://dx.doi.org/10.1016/S0091-6749(98)70014-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819291				2022-12-18	WOS:000077033400008
J	Huszar, E; Horvath, I; Barat, E; Herjavecz, I; Boszormenyi-Nagy, G; Kollai, M				Huszar, E; Horvath, I; Barat, E; Herjavecz, I; Boszormenyi-Nagy, G; Kollai, M			Elevated circulating adenosine level potentiates antigen induced immediate bronchospasm and bronchoconstrictor mediator release in sensitized guinea pigs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adenosine; antigen challenge; histamine; PGD(2); thromboxane B-2; prostaglandins; asthma; guinea pigs	BRONCHOALVEOLAR LAVAGE FLUID; DEPENDENT HISTAMINE-RELEASE; LUNG MAST-CELLS; SMOOTH-MUSCLE; RECEPTOR; ASTHMATICS; MECHANISM; CHALLENGE; CONTRACTION; RESPONSES	Background: Adenosine causes bronchoconstriction in asthmatic patients, and it is also accepted that adenosine influences histamine release from activated human mast cells and basophils in vitro. Objective: In this study we tested the hypothesis that adenosine potentiates both the airway narrowing and the release of bronchoconstrictor mediators induced by ovalbumin challenge in sensitized guinea pigs. Methods: After ovalbumin sensitization, 4 groups were studied: control group, adenosine group (ADO), ovalbumin group (OA), and adenosine plus ovalbumin group (ADO + GA). Changes in airway resistance were assessed from continuously recorded pulmonary insufflation pressure (PIP), The concentration of histamine, PGD(2), and thromboxane B-2 were determined from bronchoalveolar lavage fluids. Results: Adenosine alone (6 mg/kg intravenously) did not influence baseline values of PIP and the mediator concentrations; however, ovalbumin (10 mg/kg intravenously) increased both the PIP and the Levels of the measured mediators compared with the control and ADO groups, When ovalbumin challenge was preceded by adenosine administration, both PDP and mediator Levels were significantly enhanced compared with values obtained after simple ovalbumin provocation (ADO + OA vs OA: P < .05). Conclusion: These results suggest that adenosine potentiates the airway narrowing induced by ovalbumin challenge and that this effect may develop through facilitation of the release of bronchoconstrictor mediators during the immediate airway response.	Natl Koranyi Inst TB & Pulmonol, Dept Pathophysiol, H-1529 Budapest, Hungary; Semmelweis Univ Med, Dept Phys 2, H-1085 Budapest, Hungary	Semmelweis University	Huszar, E (corresponding author), Natl Koranyi Inst TB & Pulmonol, Dept Pathophysiol, Piheno 1, H-1529 Budapest, Hungary.		Horváth, Ildikó/GPP-6088-2022; Horvath, Ildiko/M-7874-2019	Horvath, Ildiko/0000-0001-6891-1044				ALI S, 1994, J PHARMACOL EXP THER, V268, P1328; BJORCK T, 1992, AM REV RESPIR DIS, V145, P1087; BRESCHI MC, 1994, PHARMACOLOGY, V49, P42, DOI 10.1159/000139215; BUTCHERS PR, 1980, INT ARCH ALLER A IMM, V62, P205, DOI 10.1159/000232513; CHURCH MK, 1983, BRIT J PHARMACOL, V80, P719, DOI 10.1111/j.1476-5381.1983.tb10063.x; CRIMI N, 1989, J ALLERGY CLIN IMMUN, V83, P921, DOI 10.1016/0091-6749(89)90106-1; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; CUSHLEY MJ, 1985, J ALLERGY CLIN IMMUN, V75, P272, DOI 10.1016/0091-6749(85)90057-0; DRIVER AG, 1993, AM REV RESPIR DIS, V148, P91, DOI 10.1164/ajrccm/148.1.91; FARMER SG, 1988, BRIT J PHARMACOL, V95, P371, DOI 10.1111/j.1476-5381.1988.tb11655.x; FINNEY MJB, 1985, BRIT J PHARMACOL, V85, P29, DOI 10.1111/j.1476-5381.1985.tb08827.x; FREDHOLM BB, 1981, ACTA PHYSIOL SCAND, V111, P507, DOI 10.1111/j.1748-1716.1981.tb06772.x; HOLGATE ST, 1986, ARCH INT PHARMACOD T, V280, P240; HUGHES PJ, 1984, BIOCHEM PHARMACOL, V33, P3847, DOI 10.1016/0006-2952(84)90050-9; INGENITO EP, 1991, AM REV RESPIR DIS, V143, P572, DOI 10.1164/ajrccm/143.3.572; LARSSON K, 1988, CHEST, V93, P280, DOI 10.1378/chest.93.2.280; LAWRENCE BP, 1990, EXP LUNG RES, V16, P617; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANN JS, 1986, J APPL PHYSIOL, V61, P1667, DOI 10.1152/jappl.1986.61.5.1667; MARQUARDT DL, 1994, J IMMUNOL, V152, P4508; MARQUARDT DL, 1984, P NATL ACAD SCI USA, V81, P192; NAMBU F, 1990, PROSTAGLANDINS, V39, P623, DOI 10.1016/0090-6980(90)90023-O; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; PETERS SP, 1982, AM REV RESPIR DIS, V126, P1034; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; RAMKUMAR V, 1995, J IMMUNOL, V154, P5436; TURNER NC, 1988, BRIT J PHARMACOL, V93, P751, DOI 10.1111/j.1476-5381.1988.tb11459.x; VanSchaick EA, 1996, EUR J PHARMACOL, V308, P311, DOI 10.1016/0014-2999(96)00373-1; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450	30	13	14	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				687	691		10.1016/S0091-6749(98)70288-X	http://dx.doi.org/10.1016/S0091-6749(98)70288-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802380				2022-12-18	WOS:000076600400022
J	Miller, RL; Eppinger, TM; McConnell, D; Cunningham-Rundles, C; Rothman, P				Miller, RL; Eppinger, TM; McConnell, D; Cunningham-Rundles, C; Rothman, P			Analysis of cytokine signaling in patients with extrinsic asthma and hyperimmunoglobulin E	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-4; IL-13; hyperimmunoglobulin E; extrinsic asthma; Stat6; switch recombination	HUMAN B-CELLS; INTERFERON-GAMMA; TYROSINE PHOSPHORYLATION; INTERLEUKIN-4 RECEPTOR; SWITCH RECOMBINATION; IGE PRODUCTION; BRONCHOALVEOLAR LAVAGE; EPSILON-TRANSCRIPTS; PERIPHERAL-BLOOD; BINDING SUBUNIT	Background: Recent data suggest that the regulation of class switching to IgE by cytokines is mediated by STAT transcription factors. The induction of IgE by IL-4 and IL-13 occurs through the activation of the intracellular signal-transducing protein Stat6, whereas the inhibition of IgE class switching by interferon-gamma (IFN-gamma occurs through the activation of Stat1. Objective: We hypothesized that in extrinsic asthma or in cases of markedly elevated IgE tie, hyperimmunoglobulin E [HIE]) increased levels of IgE may be associated with alterations in the cytokine levels or the activation of Stat6, Methods: PBMCs and sera from 8 patients with extrinsic asthma (mean IgE, 285 +/- 100 IU/mL), 3 patients with HIE (mean IgE, 7050 +/- 1122 IU/mL), and 14 nonatopic control subjects (mean IgE, 112 +/- 28 IU/mL) were analyzed. Results: The mean IL-4 level detected by ELISA was much greater in patients with HIE than control subjects (88.6 +/- 11.5 pg/mL vs 11.5 +/- 7.1 pg/mL, P =.005), and increased IL-4 levels among patients with both asthma and HIE correlated with the increased IgE levels, In contrast, IL-13 levels were not elevated. Levels of Stat6 protein present in PBMCs did not differ in the patients and control subjects. Examination of Stat6 DNA-binding activity demonstrated no activation of IL-4 signaling in patients with either HIE or acute asthma, Interestingly, evidence for the presence of B cells that have already switched to IgE was seen in PBMCs of several patients with asthma or HIE. Conclusion: These results indicate that (1) IgE production in asthma and HIE usually is associated with elevated levels of IL-4, but not IL-13, in the peripheral blood; (2) the increased sera IL-4 levels in asthma and HIE are not sufficient to induce Stat6 activation in PBMCs; and (3) evidence of switch recombination to E may be detected in isolated cases of elevated IgE, This implies that high levels of IgE in these patients either results from B cells that have already undergone class switching, from Ig class switching that is localized to target tissues, or both.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med & Microbiol, New York, NY 10032 USA; Mt Sinai Hosp, Dept Pediat & Biochem, New York, NY 10029 USA; Mt Sinai Hosp, Dept Med, New York, NY 10029 USA	Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Miller, RL (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P20ES006831] Funding Source: NIH RePORTER; NCRR NIH HHS [5M01 RR00645] Funding Source: Medline; NIEHS NIH HHS [P20 5 ESO6831-03] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BOTTARO A, 1994, EMBO J, V13, P665, DOI 10.1002/j.1460-2075.1994.tb06305.x; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADDING P, 1993, J IMMUNOL, V151, P3853; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; Chvatchko Y, 1996, J EXP MED, V184, P2353, DOI 10.1084/jem.184.6.2353; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; COFFMAN RL, 1986, J IMMUNOL, V136, P949; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; CORRIGAN CJ, 1995, AM J RESP CELL MOL, V12, P567, DOI 10.1165/ajrcmb.12.5.7742019; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; DELPRETE G, 1989, J CLIN INVEST, V84, P1830, DOI 10.1172/JCI114368; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; DONABEDIAN H, 1983, MEDICINE, V62, P195, DOI 10.1097/00005792-198307000-00001; GASCAN H, 1991, J IMMUNOL, V147, P8; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GERBLICH AA, 1991, AM REV RESPIR DIS, V143, P533, DOI 10.1164/ajrccm/143.3.533; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUANG SK, 1995, J IMMUNOL, V155, P2688; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JABARA HH, 1993, J IMMUNOL, V151, P4528; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KING CL, 1989, P NATL ACAD SCI USA, V86, P10085, DOI 10.1073/pnas.86.24.10085; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu BF, 1997, J IMMUNOL, V159, P1255; MATRICARDI PM, 1984, J CLIN IMMUNOL, V4, P388, DOI 10.1007/BF00917142; MATSUMOTO K, 1994, CHEST, V105, P681, DOI 10.1378/chest.105.3.681; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845, DOI 10.1164/ajrccm.155.3.9117015; Ohkawara Y, 1997, AM J RESP CELL MOL, V16, P510, DOI 10.1165/ajrcmb.16.5.9160833; PalmerCrocker RL, 1996, J CLIN INVEST, V98, P604, DOI 10.1172/JCI118829; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059, DOI 10.1164/ajrccm.152.6.8520776; PERNIS A, 1995, P NATL ACAD SCI USA, V92, P7971, DOI 10.1073/pnas.92.17.7971; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SHAPIRA SK, 1991, P NATL ACAD SCI USA, V88, P7528, DOI 10.1073/pnas.88.17.7528; SHAPIRA SK, 1992, J EXP MED, V175, P289, DOI 10.1084/jem.175.1.289; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; Takeda K, 1996, J IMMUNOL, V157, P3220; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TANG M, 1993, CLIN EXP IMMUNOL, V92, P120; VERCELLI D, 1990, J CLIN INVEST, V85, P1666, DOI 10.1172/JCI114618; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; XU LX, 1993, P NATL ACAD SCI USA, V90, P3705, DOI 10.1073/pnas.90.8.3705; XU LX, 1994, INT IMMUNOL, V6, P515, DOI 10.1093/intimm/6.4.515; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012; YSSEL H, 1992, J IMMUNOL, V148, P738; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	62	13	16	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					503	511		10.1016/S0091-6749(98)70141-1	http://dx.doi.org/10.1016/S0091-6749(98)70141-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768594	hybrid			2022-12-18	WOS:000076212800027
J	Codina, R; Lockey, RF				Codina, R; Lockey, RF			Possible role of molds as secondary etiologic agents of the asthma epidemics in Barcelona, Spain	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PURIFICATION; OUTBREAKS; ALLERGENS		Univ S Florida, Dept Internal Med, Div Allergy & Immunol, Tampa, FL 33612 USA; James A Haley VA Hosp, Tampa, FL USA	State University System of Florida; University of South Florida	Codina, R (corresponding author), Univ S Florida, Dept Internal Med, Div Allergy & Immunol, 13000 Bruce B Downs Blvd VAR 111D, Tampa, FL 33612 USA.							ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; Codina R, 1997, CLIN EXP ALLERGY, V27, P424, DOI 10.1046/j.1365-2222.1997.d01-514.x; Codina R, 1996, J ALLERGY CLIN IMMUN, V98, P236, DOI 10.1016/S0091-6749(96)70249-X; Codina RM, 1997, CHEST, V111, P75, DOI 10.1378/chest.111.1.75; GONZALEZ R, 1992, CLIN EXP ALLERGY, V22, P748, DOI 10.1111/j.1365-2222.1992.tb02814.x; Molina AM, 1996, J INVEST ALLERG CLIN, V6, P196; Soriano JB, 1997, AM J RESP CRIT CARE, V156, P1394, DOI 10.1164/ajrccm.156.5.9701064; SUNYER J, 1992, AM REV RESPIR DIS, V145, P1098, DOI 10.1164/ajrccm/145.5.1098	8	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					318	320		10.1016/S0091-6749(98)70102-2	http://dx.doi.org/10.1016/S0091-6749(98)70102-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723678				2022-12-18	WOS:000075537100027
J	Cuesta-Herranz, J; Lazaro, M; Martinez, A; Alvarez-Cuesta, E; Figueredo, E; Martinez, J; Cuesta, C; de-las-Heras, M				Cuesta-Herranz, J; Lazaro, M; Martinez, A; Alvarez-Cuesta, E; Figueredo, E; Martinez, J; Cuesta, C; de-las-Heras, M			A method for quantitation of food biologic activity: Results with peach allergen extracts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						biologic activity; food; standardization; peach; skin test; food allergy	SKIN-TEST EXTRACTS; CROSS-REACTIVITY; FRESH FOODS; STANDARDIZATION; HYPERSENSITIVITY; DIAGNOSIS; APPLE	Objective: The aim of this study was to develop a quantitative skin test assay for measurement of the biologic activity of food allergen extracts, as well as to report the results obtained with a peach extract labeled in food biological units (FBUs). Methods: me prepared a biologically quantified peach extract. The biologic activity was measured in FBUs by assigning 100 FBU/ml to the biologic activity of the extract that elicited a wheal area with a geometric mean equal to that produced by the prick-prick method by using the food itself in a population of 30 patients allergic to food. We evaluated 265 patients, including 70 patients allergic to peach and 195 control subjects (100 nonatopic subjects and 95 subjects allergic to pollen). The biologically quantified peach extract was used during the study and was compared with four commercial peach extracts, which were labeled in weight per volume. Results: The sensitivity of the nonstandardized commercial peach extracts varied from 4.3% to 74%, with biologic activity being very low in all of them. The sensitivity of the biologically quantified peach extract was 100%, with a 100% concordance between the prick-prick and the skin prick test results. Conclusion: These data demonstrate that if peach allergen preparations were biologically standardized in FBUs, the quality of these food extracts used for diagnosis would be improved.	Univ Autonoma Madrid, Fdn Jimenez Diaz, Serv Alergia, Dept Allergy, Madrid, Spain; Hosp Ramon & Cajal, E-28034 Madrid, Spain; ARISTEGUI, IFIDESA, Dept Res & Dev, Bilbao, Spain	Autonomous University of Madrid; Hospital Universitario Ramon y Cajal	Cuesta-Herranz, J (corresponding author), Univ Autonoma Madrid, Fdn Jimenez Diaz, Serv Alergia, Dept Allergy, C Reyes Catolicos 2, Madrid, Spain.			MARTINEZ, JORGE/0000-0001-7002-0056				AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; [Anonymous], 1997, J ALLERGY CLIN IMMUN, V99, P583; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; BACKMAN A, 1991, ALLERGY, V46, P81, DOI 10.1111/j.1398-9995.1991.tb00548.x; BERNHISELBROADBENT J, 1995, ANN ALLERG ASTHMA IM, V75, P295; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; BRIGHTON WD, 1979, CLIN ALLERGY, V9, P591, DOI 10.1111/j.1365-2222.1979.tb00484.x; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; DREBORG S, 1992, ALLERGY, V47, P418, DOI 10.1111/j.1398-9995.1992.tb02082.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; *EAACI SUBC SKIN T, 1989, ALLERGY S10, V44, P13; *EACCI, 1993, ALLERGY          S14, V48, P49; HEFLE SL, 1995, J ALLERGY CLIN IMMUN, V95, P837, DOI 10.1016/S0091-6749(95)70127-3; HERIAN AM, 1992, CLIN EXP ALLERGY, V22, P461, DOI 10.1111/j.1365-2222.1992.tb00148.x; Martinez A, 1997, ALLERGY, V52, P155, DOI 10.1111/j.1398-9995.1997.tb00969.x; MAY CD, 1985, J ALLERGY CLIN IMMUN, V75, P329, DOI 10.1016/0091-6749(85)90067-3; NORGAARD A, 1992, CLIN EXP ALLERGY, V22, P940, DOI 10.1111/j.1365-2222.1992.tb02068.x; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; PASTORELLO EA, 1995, ALLERGY, V50, P289, DOI 10.1111/j.1398-9995.1995.tb01150.x; PLATTSMILLS TAE, 1991, J ALLERGY CLIN IMMUN, V87, P621, DOI 10.1016/0091-6749(91)90379-3; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V82, P718, DOI 10.1016/0091-6749(88)90070-X; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9	24	13	14	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					275	280		10.1016/S0091-6749(98)70096-X	http://dx.doi.org/10.1016/S0091-6749(98)70096-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723672				2022-12-18	WOS:000075537100021
J	Dvorak, AM; Costa, JJ; Monahan-Earley, RA; Fox, P; Galli, SJ				Dvorak, AM; Costa, JJ; Monahan-Earley, RA; Fox, P; Galli, SJ			Ultrastructural analysis of human skin biopsy specimens from patients receiving recombinant human stem cell factor: Subcutaneous injection of rhSCF induces dermal mast cell degranulation and granulocyte recruitment at the injection site	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylactic degranulation; basophil; piecemeal degranulation; microvessels; eosinophil; neutrophil; secretion; granulogenesis	C-KIT LIGAND; CYTOPLASMIC LIPID BODIES; BLOOD MONONUCLEAR-CELLS; PIECEMEAL DEGRANULATION; MEDIATOR RELEASE; HUMAN INTERLEUKIN-5; HUMAN EOSINOPHILS; HUMAN BASOPHILS; ACTIVATION; APOPTOSIS	We performed an ultrastructural analysis of 10 skin biopsy specimens that had been obtained from three women who were undergoing daily subcutaneous dosing with recombinant methionyl-human stem cell factor (rhSCF) as part of a phase I clinical trial. The biopsy specimens were obtained at sites of subcutaneous administration of rhSCF, within approximately 1 to 2 hours of rhSCF injection, and, at the same time, at contralateral control sites that had not been directly injected with rhSCF, We previously reported that subcutaneous dosing with rhSCF in these subjects induced the local development of a wheal and flare response, which was associated with evidence of mast cell degranulation, as well as a systemic increase in numbers of cutaneous mast cells, The present electron microscopic analysis revealed that all biopsies of swollen, erythematous rhSCF-injected sites exhibited anaphylactic degranulation of both mature and immature mast cells, an acute inflammatory response characterized by the migration of neutrophils, basophils (some of which exhibited evidence of piecemeal degranulation), and eosinophils through blood vessel walls into the perivascular and extravascular spaces, and edema and fibrin deposition within the interstitium. By contrast, the control biopsies contained no evidence of mast cell degranulation or acute inflammation, However, both control and rhSCF-injected sites exhibited mast cells that were undergoing granule building and maturation. Thus at the doses tested in these subjects, subcutaneous injection of rhSCF induced anaphylactic-type degranulation of dermal mast cells at the injection site, with an acute inflammatory response that was associated with the recruitment of granulocytes. By contrast, mast cells at sites distant from those directly injected with rhSCF exhibited no evidence of enhanced secretion.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Dvorak, AM (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, East Campus,330 Brookline Ave, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA072074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023990, R01AI033372, R37AI023990] Funding Source: NIH RePORTER; NCI NIH HHS [CA/AI-72074] Funding Source: Medline; NIAID NIH HHS [AI-33372, AI/GM-23990] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; BROWN LF, 1993, AM J PATHOL, V142, P273; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; COLUMBO M, 1992, J IMMUNOL, V149, P599; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DVORAK AM, 1992, AM J PATHOL, V140, P795; DVORAK AM, 1991, AM J PATHOL, V138, P69; DVORAK AM, 1993, J LEUKOCYTE BIOL, V54, P465, DOI 10.1002/jlb.54.5.465; DVORAK AM, 1995, INT J CLIN LAB RES, V25, P7, DOI 10.1007/BF02592571; DVORAK AM, 1992, J LEUKOCYTE BIOL, V51, P557, DOI 10.1002/jlb.51.6.557; DVORAK AM, 1991, J LEUKOCYTE BIOL, V49, P197, DOI 10.1002/jlb.49.2.197; DVORAK AM, 1987, J ELECTRON MICR TECH, V6, P255, DOI 10.1002/jemt.1060060302; DVORAK AM, 1991, BLOOD, V77, P569; DVORAK AM, 1994, INT ARCH ALLERGY IMM, V105, P245; DVORAK AM, 1989, MAST CELL BASOPHIL D, P119; DVORAK AM, 1992, MAST CELL HLTH DISEA, V62, P1; DVORAK AM, 1991, BLOOD CELL BIOCH, V4; DVORAK HF, 1974, LAB INVEST, V31, P111; DVORAK HF, 1986, HUM PATHOL, V17, P122, DOI 10.1016/S0046-8177(86)80285-4; DVORAK HF, 1985, SCIENCE, V227, P1059, DOI 10.1126/science.3975602; Feng D, 1996, J EXP MED, V183, P1981, DOI 10.1084/jem.183.5.1981; FRIEDMAN MM, 1988, J ALLERGY CLIN IMMUN, V82, P998, DOI 10.1016/0091-6749(88)90136-4; FURITSU T, 1989, P NATL ACAD SCI USA, V86, P10039, DOI 10.1073/pnas.86.24.10039; Gagari E, 1997, BLOOD, V89, P2654, DOI 10.1182/blood.V89.8.2654; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GLOVSKY MM, 1987, J ALLERGY CLIN IMMUN, V79, P181; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; IEMURA A, 1994, AM J PATHOL, V144, P321; IRANI AMA, 1992, BLOOD, V80, P3009; ISHIZAKA T, 1993, CURR OPIN IMMUNOL, V5, P937, DOI 10.1016/0952-7915(93)90109-6; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; Kitamura Y., 1989, MAST CELL BASOPHIL D, P15; LEMANSKE RF, 1988, ALLERGY PRINCIPLES P, V1, P224; MAJNO G, 1969, J CELL BIOL, V42, P617; MEKORI YA, 1993, J IMMUNOL, V151, P3775; MITSUI H, 1993, P NATL ACAD SCI USA, V90, P735, DOI 10.1073/pnas.90.2.735; MORSTYN G, 1994, ONCOLOGY, V51, P205, DOI 10.1159/000227335; Rodewald HR, 1996, SCIENCE, V271, P818, DOI 10.1126/science.271.5250.818; SCHWARTZ L, 1993, ALLERGY PRINCIPLES P, P135; SUEKI H, 1993, LAB INVEST, V69, P160; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; TSAI M, 1991, J EXP MED, V174, P125, DOI 10.1084/jem.174.1.125; VALENT P, 1992, BLOOD, V80, P2237; WELLER PF, 1991, AM J PATHOL, V138, P141; WERSHIL BK, 1992, J EXP MED, V175, P245, DOI 10.1084/jem.175.1.245; YEE NS, 1994, J EXP MED, V179, P1777, DOI 10.1084/jem.179.6.1777	49	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				793	806		10.1016/S0091-6749(98)70404-X	http://dx.doi.org/10.1016/S0091-6749(98)70404-X			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648707				2022-12-18	WOS:000074414200014
J	Kelling, CK; Bartolo, RG; Ertel, KD; Smith, LA; Watson, DD; Sarlo, K				Kelling, CK; Bartolo, RG; Ertel, KD; Smith, LA; Watson, DD; Sarlo, K			Safety assessment of enzyme-containing personal cleansing products: Exposure characterization and development of IgE antibody to enzymes after a 6-month use test	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						enzyme; proteases; inhalation exposure; IgE-mediated hypersensitivity; allergy		Background: Enzyme-containing personal cleansing products were being considered for the consumer market. Although enzymes have been marketed safely for many years as ingredients in laundry products, their use in a personal cleansing application represented a new type of exposure for consumers that was not supported by the historical safety data. An exposure assessment and additional safety data would be needed before marketing to ensure consumer safety. Objective: The work in this paper was designed to evaluate the potential for inhalation exposure to the enzyme during use of this new product while showering. Then a clinical trial was conducted to determine whether or not the level, duration, and routes of exposure encountered during use of this product would induce a Type I sensitization response to the enzyme. Methods: Exposure was assessed during normal showering activities by collecting air samples with both high volume and personal samplers and quantitating enzyme levels with an ELISA. To assess the potential for sensitization, panelists were asked to use a prototype protease-containing bar product for all personal cleansing tasks and to keep a use diary reporting any associated symptoms. Physical and dermatologic examinations and skin prick tests with enzyme were conducted before the test commenced and at 2-month intervals. Results: Exposure assessment results showed that airborne enzyme levels were primarily dependent on the concentration of the enzyme in the personal cleansing product. Mean values for total airborne enzyme protein ranged from 5.7 to 11.8 ng/m(3) when enzyme concentration, time of use, and measurement technique remained constant. After 6 months of at-home product use, four of 61 test subjects using the enzyme-containing bar had positive skin prick test responses when tested with the enzyme. The skin prick test data were supplemented with serologic analyses, which detected IgE specific for the protease enzyme. None of these subjects showed any clinical symptoms indicative of allergic reaction. Conclusion: The ability of enzymes to induce development of allergic antibodies in this study led to the conclusion that this prototype enzyme-containing personal cleansing bar would represent an inappropriate use of enzymes in a consumer product application. The likelihood of both induction of an immunologic response and subsequent elicitation of allergy symptoms in a small but significant fraction of the user population was high. This finding resulted in the decision to halt further development of this prototype.	Procter & Gamble Co, Miami Valley Labs, Cincinnati, OH 45253 USA	Procter & Gamble	Sarlo, K (corresponding author), Procter & Gamble Co, Miami Valley Labs, POB 538707, Cincinnati, OH 45253 USA.							*AM C GOV IND HYG, 1995, THRESH LIM VAL CHEM, P32; BELIN L, 1970, LANCET, V2, P1153; BERNSTEIN DI, 1984, J ALLERGY CLIN IMMUN, V74, P258, DOI 10.1016/0091-6749(84)90255-0; Cormier E., 1997, Journal of Allergy and Clinical Immunology, V99, pS79; FALLERONI AE, 1971, LANCET, V1, P548; FISHER AA, 1985, CUTIS, V36, P209; FLINDT MLH, 1969, LANCET, V1, P1177; FLOOD DFS, 1985, BRIT J IND MED, V42, P43; GAINES WG, 1994, TOXICOLOGY FORUM, P143; HENDRICKS MH, 1970, J AM OIL CHEM SOC, V47, P207, DOI 10.1007/BF02638872; JUNIPER CP, 1984, J SOC OCCUP MED, V34, P127; KOOKIS D, 1985, STATISTICS, P191; LANGLEY R, 1971, PRACTICAL STATISTICS, P166; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; MILLER LS, 1994, CHEMOMETR INTELL LAB, V26, P79, DOI 10.1016/0169-7439(94)90049-3; NIINIMAKI A, 1993, J ALLERGY CLIN IMMUN, V92, P492, DOI 10.1016/0091-6749(93)90129-4; PEPYS J, 1969, LANCET, V1, P1181; Pepys J., 1975, BR J HOSP MED, V14, P412; Sarlo K, 1997, FUND APPL TOXICOL, V39, P44, DOI 10.1006/faat.1997.2356; SHAW A, 1995, SOAP COSMETICS CHEM, P64; Soap and Detergent Association, 1995, WORK PRACT HANDL ENZ, P20; ZETTERSTROM O, 1977, CLIN ALLERGY, V7, P355, DOI 10.1111/j.1365-2222.1977.tb01463.x; 1991, SOAP DETERGENT IND A, P7; 1995, AM C GOV IND HYG, P32	24	13	14	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				179	187		10.1016/S0091-6749(98)70382-3	http://dx.doi.org/10.1016/S0091-6749(98)70382-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500750				2022-12-18	WOS:000072244800006
J	Beyer, K; Wahn, U; Freidhoff, L; Nickel, R; Bjorksten, B; Huang, S; Barnes, KC; Beaty, T; Marsh, DG				Beyer, K; Wahn, U; Freidhoff, L; Nickel, R; Bjorksten, B; Huang, S; Barnes, KC; Beaty, T; Marsh, DG			Evidence for linkage of chromosome 5q31-q33 and 13q12-q14 markers to atopic dermatitis.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									JHAAC, Baltimore, MD USA; JHAAC, Berlin, Germany; JHAAC, Linkoping, Sweden										0	13	14	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	2			631	S152	S153						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YW339					2022-12-18	WOS:000071924800631
J	Nieto, A; Mazon, A; Estornell, F; Boquete, M; Carballada, F; Martinez, A; Asturias, JA; Aguirre, M; Martinez, J; Palacios, R				Nieto, A; Mazon, A; Estornell, F; Boquete, M; Carballada, F; Martinez, A; Asturias, JA; Aguirre, M; Martinez, J; Palacios, R			Profilin, a relevant allergen in latex allergy.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Compleixo Hosp Calde, Lugo, Spain; Hosp Infantil La Fe, Valencia, Spain; ARISTEGUI, IFIDESA, R&D Dept, Bilbao, Spain				Mazon, Angel/ABG-8016-2020	Mazon, Angel/0000-0001-5639-1037					0	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	2			856	S207	S207						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YW339					2022-12-18	WOS:000071924800855
J	van der Bruggen, T; Kanters, D; Tool, ATJ; Raaijmakers, JAM; Lammers, JWJ; Verhoeven, AJ; Koenderman, L				van der Bruggen, T; Kanters, D; Tool, ATJ; Raaijmakers, JAM; Lammers, JWJ; Verhoeven, AJ; Koenderman, L			Cytokine-induced protein tyrosine phosphorylation is essential for cytokine priming of human eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; IL-5; platelet activating factor; signal transduction; tyrosine phosphorylation; priming; serum-treated zymosan; herbimycin A; respiratory burst; binding	COLONY-STIMULATING FACTOR; PULMONARY IMMUNE CELLS; SIGNAL-TRANSDUCTION; OPSONIZED PARTICLES; COMPLEMENT RECEPTOR-TYPE-3; RESPIRATORY BURST; PERIPHERAL-BLOOD; GM-CSF; INTERLEUKIN-5; ACTIVATION	Background: Human eosinophils are strongly modulated by the eosinophilotrophic cytokines IL-5, IL-3, and granulocyte-macrophage colony-stimulating factor (GM-CSF), A clear intracellular effect of these cytokines is the induction of tyrosine phosphorylation of multiple cellular substrates. However, the relevance of tyrosine phosphorylation for eosinophil functioning has not been established. Objective: In this study we have investigated dose-response and time curves of IL-5-, IL-3-, and GM-CSF-induced tyrosine phosphorylation in eosinophils. Moreover, we have evaluated the importance of IL-5-induced tyrosine phosphorylation for priming of human eosinophils. Methods: Cytokine-induced tyrosine phosphorylation was monitored on western blot with an antiphosphotyrosine antibody (4G10). To probe the relevance of tyrosine phosphorylation for priming, eosinophils were primed with IL-5 in the presence of the tyrosine kinase inhibitor herbimycin A, Platelet activating factor (PAF) was used as a control priming agent. Subsequently, the eosinophils were incubated with serum-treated zymosan (STZ) to activate the respiratory burst, Binding of STZ was determined by FACS analysis. Results: IL-5-, IL-3-, and GM-CSF-induced tyrosine phosphorylation was found at concentrations that primed eosinophil effector mechanism (median effective dose values: congruent to 5.10(-11) mol/L, congruent to 5.10(-10) mol/L, and congruent to 5.10(-12) mol/L for IL-5, IL-3, and GM-CSF, respectively). Cytokine-induced tyrosine phosphorylation was transient with an optimum value at 15 minutes. IL-5 priming of STZ-induced activation of the respiratory burst was blocked by herbimycin A, whereas PAF still primed this response. In fact, herbimycin A inhibited IL-5 priming of STZ binding to human eosinophils. On the other hand, PAF priming of STZ binding was not affected by herbimycin A, Both IL-5-induced and PAF-induced tyrosine phosphorylation were inhibited by herbimycin A. Conclusion: These data demonstrate for the first time that IL-5 priming of opsonized particle-induced responses is mediated by tyrosine kinase activity in human eosinophils.	Univ Utrecht Hosp, Dept Pulm Dis, NL-3508 GA Utrecht, Netherlands; Univ Amsterdam, Netherlands Red Cross, Blood Transfus Serv,Cent Lab, Lab Expt & Clin Immunol, Amsterdam, Netherlands; Univ Amsterdam, Netherlands Red Cross, Blood Transfus Serv,Cent Lab, Dept Transfus Technol, Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; University of Amsterdam; University of Amsterdam	Koenderman, L (corresponding author), Univ Utrecht Hosp, Dept Pulm Dis, POB 85500, NL-3508 GA Utrecht, Netherlands.		Koenderman, Leo/AAE-7870-2020	Koenderman, Leo/0000-0002-5636-6453				BLOM M, 1992, J IMMUNOL, V149, P3672; BLOM M, 1994, BLOOD, V83, P2978, DOI 10.1182/blood.V83.10.2978.2978; BLOM M, 1995, J IMMUNOL METHODS, V178, P183, DOI 10.1016/0022-1759(94)00255-U; CAMBRONERO JG, 1989, P NATL ACAD SCI USA, V86, P3569; CARLSON M, 1993, ALLERGY, V48, P437; CHIHARA J, 1990, J EXP MED, V172, P1347, DOI 10.1084/jem.172.5.1347; ENOKIHARA H, 1990, BRIT J HAEMATOL, V75, P458, DOI 10.1111/j.1365-2141.1990.tb07782.x; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GOLDSTEIN IM, 1975, J CLIN INVEST, V56, P1155, DOI 10.1172/JCI108191; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; HARTNELL A, 1992, J IMMUNOL, V148, P1471; IDE M, 1994, J IMMUNOL METHODS, V168, P187, DOI 10.1016/0022-1759(94)90054-X; INGLEY E, 1991, BLOOD, V78, P339; KAPP A, 1995, CLIN EXP ALLERGY, V25, P210, DOI 10.1111/j.1365-2222.1995.tb01031.x; KOENDERMAN L, 1989, J IMMUNOL, V142, P623; KOENDERMAN L, 1988, J LEUKOCYTE BIOL, V44, P79, DOI 10.1002/jlb.44.2.79; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; KROEGEL C, 1994, EUR RESPIR J, V7, P743, DOI 10.1183/09031936.94.07040743; KROEGEL C, 1994, EUR RESPIR J, V7, P519, DOI 10.1183/09031936.94.07030519; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCCOLL SR, 1991, BLOOD, V78, P1842; MIYAJIMA A, 1993, BLOOD, V82, P1960; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MURATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1102, DOI 10.1016/S0006-291X(05)80899-X; OETH P, 1995, BLOOD, V86, P4144, DOI 10.1182/blood.V86.11.4144.bloodjournal86114144; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; PAZDRAK K, 1995, J IMMUNOL, V155, P397; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; RICHARD S, 1994, J IMMUNOL, V152, P2479; ROLLET E, 1994, J IMMUNOL, V153, P353; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SCHWEIZER RC, 1994, BLOOD, V83, P3697; TAI PC, 1990, CLIN EXP IMMUNOL, V80, P426; TAKAFUJI S, 1991, J IMMUNOL, V147, P3855; VANDERBRUGGEN T, 1994, J IMMUNOL, V153, P2729; VanderBruggen T, 1996, CLIN EXP ALLERGY, V26, P880, DOI 10.1046/j.1365-2222.1996.d01-391.x; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; VANDERBRUGGEN T, 1993, J LEUKOCYTE BIOL, V53, P347, DOI 10.1002/jlb.53.4.347; WARRINGA RAJ, 1991, BLOOD, V77, P2694; WARRINGA RAJ, 1992, AM J RESP CELL MOL, V7, P631, DOI 10.1165/ajrcmb/7.6.631; WARRINGA RAJ, 1992, BLOOD, V79, P1836; YAZDANBAKHSH M, 1985, J IMMUNOL, V135, P1378; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868	47	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				103	109		10.1016/S0091-6749(98)70200-3	http://dx.doi.org/10.1016/S0091-6749(98)70200-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449508				2022-12-18	WOS:000071539800016
J	Morgan, MS; Arlian, LG; Barnes, KC; FernandezCaldas, E				Morgan, MS; Arlian, LG; Barnes, KC; FernandezCaldas, E			Characterization of the allergens of the house dust mite Euroglyphus maynei	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Euroglyphus maynei; house dust mite; allergens; characterization	DERMATOPHAGOIDES-PTERONYSSINUS; CROSS-ANTIGENICITY; MONOCLONAL-ANTIBODIES; SARCOPTES-SCABIEI; FARINAE; PYROGLYPHIDAE; BINDING; ASTHMA; HOMES; ACARI	Background: The house dust mite Euroglyphus maynei inhabits homes in many parts of the world and is the source of many allergens. Objective: The purpose of this study was to biochemically and immunologically characterize the major allergens of E. maynei. Methods: Proteins in an extract of E. maynei were separated into 20 fractions by using preparative isoelectric focusing. Most proteins and allergens were contained in fractions 7 to 17 with pH of 4.8 to 8.0. The fractions were further characterized by nonreducing sodium dodecylsulfate-polyacrylamide gel electrophoresis and immunoblotting with the serum of 16 individuals sensitive to E. maynei. Results: Molecular weights and isoelectric points were assigned to 47 IgE-binding proteins in an E. maynei extract, and the frequency of IgE binding to each allergen was determined. Twenty-two of the allergens were recognized by more than 50% of the 16 sera, and all but one of the subjects had IgE that bound to more than 10 allergens (range, 0 to 32). One of the proteins was identified as the allergen fur m 2. Conclusion: E. maynei is the source of at least 47 individual allergens that have been characterized by molecular weight, isoelectric point, and IgE-binding properties.	WRIGHT STATE UNIV,DEPT BIOL SCI,DAYTON,OH 45435; JOHNS HOPKINS ASTHMA & ALLERGY CTR,DIV CLIN IMMUNOL & ALLERGY,BALTIMORE,MD; UNIV S FLORIDA,DIV CLIN IMMUNOL & ALLERGY,TAMPA,FL	University System of Ohio; Wright State University Dayton; Johns Hopkins University; Johns Hopkins Medicine; State University System of Florida; University of South Florida								ARLIAN LG, 1991, J INVEST DERMATOL, V96, P349, DOI 10.1111/1523-1747.ep12465257; ARLIAN LG, 1993, J ALLERGY CLIN IMMUN, V91, P1051, DOI 10.1016/0091-6749(93)90219-6; ARLIAN LG, 1988, J MED ENTOMOL, V25, P240, DOI 10.1093/jmedent/25.4.240; ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P457, DOI 10.1016/0091-6749(87)90363-0; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P467, DOI 10.1016/0091-6749(87)90364-2; ARRUDA LK, 1992, EXP APPL ACAROL, V16, P129, DOI 10.1007/BF01201496; BLYTHE ME, 1974, CLIN ALLERGY, V4, P25, DOI 10.1111/j.1365-2222.1974.tb01359.x; BLYTHE ME, 1976, BRIT J DIS CHEST, V70, P3, DOI 10.1016/0007-0971(76)90003-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLOFF MJ, 1991, CLIN EXP ALLERGY, V21, P225, DOI 10.1111/j.1365-2222.1991.tb00834.x; COLLOFF MJ, 1992, INT ARCH ALLERGY IMM, V97, P44, DOI 10.1159/000236094; COLLOFF MJ, 1991, EXP APPL ACAROL, V11, P177, DOI 10.1007/BF01246090; COLLOFF MJ, 1991, DUST MITE ALLERGENS, P102; FERNANDEZCALDAS E, 1990, ALLERGY PROC, V11, P263, DOI 10.2500/108854190778879710; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; HILL MR, 1993, CLIN EXP ALLERGY, V23, P110, DOI 10.1111/j.1365-2222.1993.tb00305.x; HILL MR, 1991, DUST MITE ALLERGENS, P65; KUROKI M, 1990, CANCER RES, V50, P4872; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Morgan MS, 1996, ANN ALLERG ASTHMA IM, V77, P386, DOI 10.1016/S1081-1206(10)63337-6; OVSYANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537, DOI 10.1016/0091-6749(94)90211-9; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; STEWART GA, 1995, CLIN REV ALLERG IMMU, V13, P135; STEWART GA, 1992, EXP APPL ACAROL, V16, P165, DOI 10.1007/BF01201499; WALSHAW MJ, 1987, CLIN ALLERGY, V17, P7, DOI 10.1111/j.1365-2222.1987.tb02314.x; YOUNG PR, 1989, J IMMUNOL METHODS, V121, P295, DOI 10.1016/0022-1759(89)90174-9	27	13	17	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					222	228		10.1016/S0091-6749(97)70228-8	http://dx.doi.org/10.1016/S0091-6749(97)70228-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275144	hybrid			2022-12-18	WOS:A1997XR35100013
J	Gonzalez, FJ; Carvajal, MJ; delPozo, V; Lahoz, C; Santamaria, L; Blanca, M; Juarez, C				Gonzalez, FJ; Carvajal, MJ; delPozo, V; Lahoz, C; Santamaria, L; Blanca, M; Juarez, C			Erythema multiforme to phenobarbital: Involvement of eosinophils and T cells expressing the skin homing receptor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ANTICONVULSANT HYPERSENSITIVITY SYNDROME	In general, adverse reactions to anticonvulsants are characterized by fever, rash, erythroderma, and hematologic complications including agranulocytosis, leukopenia, atypical lymphocytes, eosinophilia, and pseudolymphoma. Because of the variable presentation, diverse clinical features, and delayed onset (which can range from a few days to several weeks after initiation of drug therapy) this syndrome can be confused with other illnesses including viral infection, collagen vascular disease, lymphoma, Kawasaki syndrome, and porphyria.(1) The anticonvulsant hypersensitivity syndrome has an incidence of from 1 in 1000 to 1 in 10,000 exposures.(2) We report the case of a patient who had a severe desquamative skin reaction after the administration of phenobarbital. The involvement of different inflammatory cells and the potential mechanism causing the reaction were studied.	CARLOS HAYA HOSP,ALLERGY LAB,RES UNIT ALLERG DIS,MALAGA 29010,SPAIN; FDN JIMENEZ DIAZ,DEPT INMUNOL,E-28040 MADRID,SPAIN; CTR INVEST,LAB ALMIRALL,BARCELONA,SPAIN; CARLOS HAYA HOSP,DEPT INTERNAL MED,MALAGA,SPAIN	Hospital Carlos Haya; Almirall; Hospital Carlos Haya			Gonzalez-Sanchez, Francisco-Jesus/B-3715-2014	Santamaria Babi, Luis F/0000-0002-1674-6654				GENNIS MA, 1991, AM J MED, V91, P631, DOI 10.1016/0002-9343(91)90216-K; Gonzalez FJ, 1997, INT ARCH ALLERGY IMM, V113, P345, DOI 10.1159/000237597; Horie S, 1996, J ALLERGY CLIN IMMUN, V98, P371, DOI 10.1016/S0091-6749(96)70161-6; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; SHEAR NH, 1988, J CLIN INVEST, V82, P1826, DOI 10.1172/JCI113798; VITTORIO CC, 1995, ARCH INTERN MED, V155, P2285, DOI 10.1001/archinte.155.21.2285	6	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					135	137		10.1016/S0091-6749(97)70205-7	http://dx.doi.org/10.1016/S0091-6749(97)70205-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257798				2022-12-18	WOS:A1997XP42800020
J	Kamada, AK; Szefler, SJ				Kamada, AK; Szefler, SJ			How should inhaled glucocorticoids be compared?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							ASTHMATIC-CHILDREN; SHORT-TERM; GROWTH; BUDESONIDE; CORTICOSTEROIDS		NATL JEWISH MED & RES CTR, DEPT PEDIAT, DIV ALLERGY & IMMUNOL, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, SCH PHARM, DEPT PHARM PRACTICE, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, SCH MED, DEPT PEDIAT, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, SCH MED, DEPT PHARMACOL, DENVER, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kamada, AK (corresponding author), NATL JEWISH MED & RES CTR, DEPT PEDIAT, DIV CLIN PHARMACOL, 1400 JACKSON ST, K962, DENVER, CO 80206 USA.							AGERTOFT L, 1993, ARCH DIS CHILD, V69, P130, DOI 10.1136/adc.69.1.130; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; AGERTOFT L, 1997, RANDOMIZED DOUBLE BL, V99, P773; BISGAARD H, 1993, ACTA PAEDIATR, V82, P1066, DOI 10.1111/j.1651-2227.1993.tb12814.x; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HANANIA NA, 1995, AM J MED, V98, P196, DOI 10.1016/S0002-9343(99)80404-5; HINDLE M, 1995, CHEST, V107, P629, DOI 10.1378/chest.107.3.629; Kamada AK, 1995, PEDIAT ALLERG IMM-UK, V6, P145, DOI 10.1111/j.1399-3038.1995.tb00274.x; KARLBERG J, 1993, ACTA PAEDIATR, V82, P631, DOI 10.1111/j.1651-2227.1993.tb18029.x; LEMANSKE RF, 1993, ALLERGY PRINCIPLES P, P1; *NIH NAT HEART LUN, 1995, NIH PUBL; REID DM, 1993, RESP MED, V87, P9, DOI 10.1016/S0954-6111(05)80251-3; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839; WOLTHERS OD, 1993, ARCH DIS CHILD, V68, P673, DOI 10.1136/adc.68.5.673; WOLTHERS OD, 1992, PEDIATRICS, V89, P839; WOLTHERS OD, 1991, BMJ-BRIT MED J, V303, P163, DOI 10.1136/bmj.303.6795.163	17	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	1				735	737		10.1016/S0091-6749(97)80004-8	http://dx.doi.org/10.1016/S0091-6749(97)80004-8			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XH193	9215238	Bronze			2022-12-18	WOS:A1997XH19300003
J	Reisner, C; Nelson, HS				Reisner, C; Nelson, HS			Vocal cord dysfunction with nocturnal awakening	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	American-College-of-Allergy-Asthma-and-Immunology Meeting	NOV, 1995	DALLAS, TX	Amer Coll Allergy Asthma & Immunol			OBSTRUCTION; STRIDOR; MOTION		YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DENVER,CO	Yale University; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Reisner, C (corresponding author), BOEHRINGER INGELHEIM PHARMACEUT INC,PULM GRP,900 RIDGEBURY RD,RIDGEFIELD,CT 06877, USA.							KELLMAN RM, 1982, LARYNGOSCOPE, V92, P58; MYEARS DW, 1985, LARYNGOSCOPE, V95, P1235; NEWMAN KB, 1995, AM J RESP CRIT CARE, V152, P1382, DOI 10.1164/ajrccm.152.4.7551399; OCONNELL MA, 1995, ANN ALLERG ASTHMA IM, V74, P341; PATTERSON R, 1974, CLIN ALLERGY, V4, P307, DOI 10.1111/j.1365-2222.1974.tb01390.x; STARKMAN MN, 1984, PSYCHOSOMATICS, V25, P327, DOI 10.1016/S0033-3182(84)73049-0	6	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	1				843	846		10.1016/S0091-6749(97)80020-6	http://dx.doi.org/10.1016/S0091-6749(97)80020-6			4	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XH193	9215254				2022-12-18	WOS:A1997XH19300019
J	Beyer, K; Niggemann, B; Nasert, S; Renz, H; Wahn, U				Beyer, K; Niggemann, B; Nasert, S; Renz, H; Wahn, U			Severe allergic reactions to foods are predicted by increases of CD4+CD45RO+ T cells and loss of L-selectin expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; cow's milk; DBPCFC; food allergy; hen's egg; L-selectin lymphocyte function; oral provocation	SEVERE ATOPIC-DERMATITIS; INTERFERON-GAMMA; HELPER-INDUCER; CHILDREN; INFILTRATE; SKIN; IGE; HYPERSENSITIVITY; INTERLEUKIN-4; ANTIBODIES	Objective: The aim of the study was to determine whether the clinical outcome of double-blind, placebo-controlled food challenges of patients with atopic dermatitis would be associated with changes in lymphocyte functions. Methods: Peripheral blood mononuclear cells were prepared from 19 children with atopic dermatitis and stimulated in vitro with the suspected allergen (cow's milk, hen's egg), tetanus toxoid, and pokeweed mitogen. After 14 days in culture, quantitative and qualitative distribution of cell surface marker expression was assessed by Bon cytometry, and results were compared with the clinical outcome of a subsequent oral food challenge. Results: After stimulation with the allergen, a significant increase of CD4+CD45RO+ T cells (p < 0.05) was detected selectively for patients showing severe clinical reactions. This increase was not detected for patients with mild or no reactions or in six nonatopic control subjects. Increased expression of CD45RO was paralleled by a significant decrease in L-selectin expression (p < 0.05) for the same patient group. Conclusion: The combined assessment of CD4+CD45RO+ and CD4+L-selectin+ expression on T cells was more sensitive for the prediction of the clinical outcome of the food challenge (p < 0.01) than measurement of cytokines or immunoglobulins in cell culture supernatants. These data indicate that a shift in lymphocyte functions may predict the development of severe allergic reactions in food-sensitized children with atopic dermatitis.	CHILDRENS HOSP,BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,VIRCHOW CLIN,INST CLIN CHEM & BIOCHEM,BERLIN,GERMANY	Humboldt University of Berlin								ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; AXEN RE, 1988, NEW ENG REG ALLERGY, V9, P503; BERNHISELBROADBENT J, 1994, J ALLERGY CLIN IMMUN, V93, P1047, DOI 10.1016/S0091-6749(94)70054-0; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BOS JD, 1987, J INVEST DERMATOL, V88, P569, DOI 10.1111/1523-1747.ep12470172; BURKS AW, 1988, J PEDIATR-US, V113, P447, DOI 10.1016/S0022-3476(88)80626-7; BURKS AW, 1992, J PEDIATR, V121, P64; COSTA C, 1989, ACTA DERM-VENEREOL, V69, P41; DEVRIES JE, 1991, CURR OPIN IMMUNOL, V3, P851, DOI 10.1016/S0952-7915(05)80003-2; FREW AJ, 1991, CLIN EXP IMMUNOL, V84, P270; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; KOHNO Y, 1994, ANN ALLERGY, V73, P419; KONDO N, 1990, J ALLERGY CLIN IMMUN, V86, P253, DOI 10.1016/S0091-6749(05)80073-9; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MARKEY AC, 1990, BRIT J DERMATOL, V122, P325, DOI 10.1111/j.1365-2133.1990.tb08280.x; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; OR R, 1994, CLIN IMMUNOL IMMUNOP, V72, P141, DOI 10.1006/clin.1994.1118; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; REINHOLD U, 1988, INT ARCH ALLER A IMM, V87, P120, DOI 10.1159/000234661; REINHOLD U, 1989, ACTA DERM-VENEREOL, V69, P497; REMY N, 1991, EUR J PEDIATR, V150, P230, DOI 10.1007/BF01955518; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V81, P635, DOI 10.1016/0091-6749(88)91033-0; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SEYMOUR JL, 1987, J AM ACAD DERMATOL, V17, P988, DOI 10.1016/S0190-9622(87)70288-6; TAKAHASHI T, 1992, Journal of Dermatological Science, V3, P172, DOI 10.1016/0923-1811(92)90032-7; TANG M, 1994, CLIN EXP IMMUNOL, V95, P66	32	13	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					522	529		10.1016/S0091-6749(97)70080-0	http://dx.doi.org/10.1016/S0091-6749(97)70080-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111498	Bronze			2022-12-18	WOS:A1997WU27400016
J	Gupta, S; Aggarwal, S; Nguyen, T				Gupta, S; Aggarwal, S; Nguyen, T			Accelerated spontaneous programmed cell death in lymphocytes in DiGeorge syndrome.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									UNIV CALIF IRVINE,IRVINE,CA 92717	University of California System; University of California Irvine									0	13	13	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	2	S			11	11						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH142					2022-12-18	WOS:A1997WH14200011
J	Craig, TJ; Peralta, F; Boggavarapu, J				Craig, TJ; Peralta, F; Boggavarapu, J			Desensitization for fluconazole hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242	University of Iowa	Craig, TJ (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT MED,ALLERGY SECT,500 UNIV DR,HERSHEY,PA 17033, USA.							ABBOTT M, 1991, LANCET, V338, P633, DOI 10.1016/0140-6736(91)90643-4; ABSAR N, 1994, J ALLERGY CLIN IMMUN, V93, P1001, DOI 10.1016/S0091-6749(94)70048-6; GUSSENHOVEN MJE, 1991, LANCET, V338, P120, DOI 10.1016/0140-6736(91)90112-3; MUNOZ P, 1991, ARCH INTERN MED, V151, P1020, DOI 10.1001/archinte.151.5.1020; NEUHAUS G, 1991, BRIT MED J, V302, P1341, DOI 10.1136/bmj.302.6788.1341-b; SLAVIN MA, 1995, J INFECT DIS, V171, P1545, DOI 10.1093/infdis/171.6.1545	6	13	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1996	98	4					845	846		10.1016/S0091-6749(96)70136-7	http://dx.doi.org/10.1016/S0091-6749(96)70136-7			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VM665	8876563				2022-12-18	WOS:A1996VM66500020
J	Toogood, JH; Andreou, P; Baskerville, J				Toogood, JH; Andreou, P; Baskerville, J			A methodological assessment of diurnal variability of peak flow as a basis for comparing different inhaled steroid formulations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; glucocorticoids; antiinflammatory agents; steroids; respiratory therapy; peak expiratory flow rate; respiratory function tests; clinical pharmacology	AIRWAY INFLAMMATION; BRONCHIAL HYPERRESPONSIVENESS; ASTHMA; BUDESONIDE; BRONCHODILATOR; MANAGEMENT; HISTAMINE; SYMPTOMS; THERAPY	Background: A ''survival'' model offers certain ethical and practical advantages over alternative experimental designs if used to compare antiasthmatic inhaled steroid formulations. The model requires an objective daily measure of therapeutic effect (e.g., peak expiratory flow rate, which may be expressed as the lower of two daily measurements (LPF) or as diurnal variability (DVPF). The relative efficiency of these two measures is unknown. Objective: This study was conducted to determine the relative efficiency of LPF and DVPF. Methods: We analyzed data from a placebo-controlled comparison of an active inhaled formulation of budesonide versus an inactive oral formulation. The primary outcome measure in this design is the number of days from the time the test treatments start until a statistically significant deterioration occurs from an optimal asthma control value established at baseline. Results: DVPF proved less sensitive than LPF; that is, fewer patients relapsed during the 8-week trial period: 32 versus 41, respectively. Also, the median interval until relapse was longer: 24 versus 9 days. With LPF, inhaled budesonide proved more effective than placebo or oral budesonide (p = 0.03), whereas DVPF failed to discriminate among the test treatments (p = 0.38). LPF correlated with all three symptom indices (p greater than or equal to 0.003) and two of three spirometric indices measured concomitantly (p less than or equal to 0.04). DVPF did not correlate with any index (p greater than or equal to 0.10). Conclusion: In this experimental model, LPF proved more sensitive and valid than DVPF as an indicator of differences in antiasthmatic potency between two inhaled steroid formulations.	UNIV WESTERN ONTARIO,DEPT MED,LONDON,ON,CANADA; UNIV WESTERN ONTARIO,DEPT STAT & ACTUARIAL SCI,LONDON,ON,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario)	Toogood, JH (corresponding author), VICTORIA HOSP,ALLERGY CLIN,800 COMMISSIONERS RD E,LONDON,ON N6A 4G5,CANADA.							AMAROGALVEZ R, 1987, ANN ALLERGY, V59, P298; BOE J, 1989, ALLERGY, V44, P349, DOI 10.1111/j.1398-9995.1989.tb00457.x; BOSCHETTO P, 1991, AM REV RESPIR DIS, V143, P605, DOI 10.1164/ajrccm/143.3.605; BRATTSAND R, 1994, DRUGS LUNG, P101; BURKE C, 1992, EUR RESPIR J, V5, P73; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1990, AM REV RESPIR DIS, V142, P497, DOI 10.1164/ajrccm/142.3.497; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; NEWMAN SP, 1981, EUR J RESPIR DIS, V62, P3; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SAS Institute Inc, 1989, SAS STAT US GUID VER, P846; SHIMURA S, 1990, AM REV RESPIR DIS, V141, P1044, DOI 10.1164/ajrccm/141.4_Pt_1.1044; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723; TOOGOOD JH, 1990, J ALLERGY CLIN IMMUN, V85, P872, DOI 10.1016/0091-6749(90)90071-B; TOOGOOD JH, 1983, LANCET, V2, P790; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; WOOLCOCK AJ, 1988, CLIN ALLERGY, V18, P165, DOI 10.1111/j.1365-2222.1988.tb02856.x; 1992, EUR RESPIR J, V5, P601	25	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					555	562		10.1016/S0091-6749(96)70089-1	http://dx.doi.org/10.1016/S0091-6749(96)70089-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828533				2022-12-18	WOS:A1996VJ42800012
J	Vandenplas, O; Vandezande, LM; Halloy, JL; Delwiche, JP; Jamart, J; Looze, Y				Vandenplas, O; Vandezande, LM; Halloy, JL; Delwiche, JP; Jamart, J; Looze, Y			Association between sensitization to natural rubber latex and papain	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							OCCUPATIONAL ASTHMA; CHEMONUCLEOLYSIS; CHYMOPAPAIN; ALLERGY; AVOCADO		FONDS MALAD PROFESS,BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,FAC MED,PROT CHEM UNIT,B-1050 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Vandenplas, O (corresponding author), UNIV HOSP MT GODINNE,DEPT CHEST MED,B-5530 YVOIR,BELGIUM.							AHLROTH M, 1995, J ALLERGY CLIN IMMUN, V96, P167, DOI 10.1016/S0091-6749(95)70004-8; BERNSTEIN DI, 1985, J ALLERGY CLIN IMMUN, V76, P458, DOI 10.1016/0091-6749(85)90727-4; LAVAUD F, 1995, J ALLERGY CLIN IMMUN, V95, P557, DOI 10.1016/S0091-6749(95)70318-7; MONERETVAUTRIN DA, 1994, CLIN EXP ALLERGY, V24, P471, DOI 10.1111/j.1365-2222.1994.tb00936.x; PAUL C, 1994, PHYTOCHEMISTRY, V35, P1413, DOI 10.1016/S0031-9422(00)86866-1; QUARRE JP, 1995, J ALLERGY CLIN IMMUN, V95, P922, DOI 10.1016/S0091-6749(95)70144-3; TARLO SM, 1978, CLIN ALLERGY, V8, P207, DOI 10.1111/j.1365-2222.1978.tb03216.x; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P887	9	13	14	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1421	1424		10.1016/S0091-6749(96)70216-6	http://dx.doi.org/10.1016/S0091-6749(96)70216-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648044				2022-12-18	WOS:A1996VD60700036
J	Raud, J; Hallden, G; Roquet, A; vanHageHamsten, M; Alkner, U; Hed, J; Zetterstrom, O; Dahlen, SE; Hedqvist, P; Gronneberg, R				Raud, J; Hallden, G; Roquet, A; vanHageHamsten, M; Alkner, U; Hed, J; Zetterstrom, O; Dahlen, SE; Hedqvist, P; Gronneberg, R			Anti-IgE-induced accumulation of leukocytes, mediators, and albumin in skin chamber fluid from healthy and atopic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic skin reaction; atopy; anti-IgE; skin chamber; leukocytes; eosinophils; histamine; tryptase; leukotriene B-4; albumin extravasation	LATE CUTANEOUS REACTIONS; EOSINOPHIL CHEMOTACTIC FACTOR; LATE-PHASE RESPONSE; ALLERGIC INDIVIDUALS; MONOCLONAL-ANTIBODY; ADHESION MOLECULES; GRANULE PROTEINS; IMMUNOGLOBULIN-E; PLASMA LEAKAGE; MAST-CELLS	The aim of this study ws to examine potential differences between healthy and atopic subjects with regard to IgE-mediated cutaneous inflammation. For this purpose, we analyzed histamine, tryptase, leukotriene B-4, albumin, eosinophils, and total leukocytes in skin chamber fluid after challenge with anti-human IgE. We also measured gross skin reactivity (wheal, flare, and late-phase reactions), circulating IgE, and eosinophils, as well as the state of eosinophil activation. It was found that despite having more circulating IgE, the skin responsiveness of the atopic subjects did not differ significantly from that of the nonatopic subjects with respect to mediator release, albumin extravasation, or total recruitment of leukocytes. Moreover, the sizes of anti-IgE-induced wheal, flare, and late-phase reactions were very similar in the two groups. On the other hand, significant recruitment of eosinophils during the IgE-mediated reaction was more or less restricted to the atopic group. Yet the recruited eosinophils, of which the majority was in an early state of activation before degranulation, did not seem to contribute significantly to the IgE-mediated delayed skin edema. Furthermore, the eosinophil count in anti-IgE chambers of the atopic subjects did not correlate with any of the other parameters monitored. Thus because the anti-IgE-induced recruitment of eosinophils appeared to be unrelated to factors such as the number of peripheral blood eosinophils, the degree of mast cell activation, the intensity of inflammatory skin changes, and the level of circulating IgE, it is apparent that the mechanisms for and pathophysiologic role of IgE-mediated dermal eosinophil accumulation in atopic subjects require further investigation.	KAROLINSKA INST,DEPT LAB MED,DIV CLIN IMMUNOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,KAROLINSKA HOSP,SECT ALLERGOL,DIV PNEUMOL,DEPT MED,S-10401 STOCKHOLM,SWEDEN; ASTRO DRACO AB,DEPT BIOANALYT CHEM,LUND,SWEDEN; HUDDINGE UNIV HOSP,KAROLINSKA INST,DIV RESP & ALLERG DIS,DEPT MED,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Raud, J (corresponding author), KAROLINSKA INST,DEPT PHYSIOL & PHARMACOL,S-17177 STOCKHOLM,SWEDEN.		van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596				ARFORS KE, 1987, BLOOD, V69, P338; ATKINS PC, 1992, J ALLERGY CLIN IMMUN, V89, P552, DOI 10.1016/0091-6749(92)90322-S; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY MA, 1986, AGENTS ACTIONS, V19, P87, DOI 10.1007/BF01977263; BRUIJNZEEL PLB, 1993, J INVEST DERMATOL, V100, P137, DOI 10.1111/1523-1747.ep12462781; CAMP RDR, 1983, BRIT J PHARMACOL, V80, P497, DOI 10.1111/j.1476-5381.1983.tb10721.x; CHARLESWORTH EN, 1991, J IMMUNOL, V146, P671; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CZARNETZKI BM, 1989, DERMATOLOGICA, V179, P54, DOI 10.1159/000248450; DORSCH W, 1985, ARCH DERMATOL RES, V277, P400, DOI 10.1007/BF00509240; ERIKSSON NE, 1990, ALLERGY, V45, P285, DOI 10.1111/j.1398-9995.1990.tb00497.x; FLEEKOP PD, 1987, J ALLERGY CLIN IMMUN, V80, P140, DOI 10.1016/0091-6749(87)90122-9; FREW AJ, 1988, J IMMUNOL, V141, P4158; GLEICH GJ, 1990, CLIN EXP ALLERGY, V20, P245, DOI 10.1111/j.1365-2222.1990.tb02678.x; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GRONNEBERG R, 1990, J ALLERGY CLIN IMMUN, V85, P843, DOI 10.1016/0091-6749(90)90066-D; GRONNEBERG R, 1991, CLIN EXP ALLERGY, V21, P377, DOI 10.1111/j.1365-2222.1991.tb01672.x; HALLDEN G, 1989, J IMMUNOL METHODS, V124, P103, DOI 10.1016/0022-1759(89)90191-9; HALLDEN G, 1993, ACI NEWS, V5, P139; HANAHOE THP, 1984, AGENTS ACTIONS, V14, P468, DOI 10.1007/BF01973851; HED J, 1993, ALLERGY, V48, P87, DOI 10.1111/j.1398-9995.1993.tb04707.x; HENOCQ E, 1990, CLIN EXP ALLERGY, V20, P269, DOI 10.1111/j.1365-2222.1990.tb02682.x; HENOCQ E, 1986, LANCET, V1, P1378; HENOCQ E, 1988, J ALLERGY CLIN IMMUN, V81, P691, DOI 10.1016/0091-6749(88)91040-8; HOLGATE S, 1993, THORAX, V48, P103, DOI 10.1136/thx.48.2.103; IHRE E, 1993, PHYSL CHANGES EOSINO; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; LEIFERMAN KM, 1990, LAB INVEST, V62, P579; MONTEFORT S, 1993, EUR RESPIR J, V6, P1044; MOSER R, 1992, J IMMUNOL, V149, P1432; NISH WA, 1994, J ALLERGY CLIN IMMUN, V93, P484, DOI 10.1016/0091-6749(94)90358-1; OHTO H, 1987, LEUKOCYTE TYPING, V3, P731; RAUD J, 1992, ACTA PHYSIOL SCAND, V146, P545, DOI 10.1111/j.1748-1716.1992.tb09463.x; RAUD J, 1994, HDB IMMUNOPHARMACOLO, P127; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P67, DOI 10.1016/0091-6749(79)90085-X; RIHOUX JP, 1991, CLIN EXP ALLERGY, V21, P378, DOI 10.1111/j.1365-2222.1991.tb01673.x; ROQUET A, 1995, ALLERGY, V50, P414, DOI 10.1111/j.1398-9995.1995.tb01171.x; SEHMI R, 1991, J IMMUNOL, V147, P2276; SEHMI R, 1992, BLOOD, V79, P2952; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TADA T, 1975, PROG ALLERGY, V19, P122, DOI 10.1159/000313387; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; TOGIAS A, 1988, J ALLERGY CLIN IMMUN, V81, P782, DOI 10.1016/0091-6749(88)90932-3; WARRINGA RAJ, 1992, AM J RESP CELL MOL, V7, P631, DOI 10.1165/ajrcmb/7.6.631; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0; WEG VB, 1993, J EXP MED, V177, P561, DOI 10.1084/jem.177.2.561; WEISS ME, 1989, J ALLERGY CLIN IMMUN, V83, P1040, DOI 10.1016/0091-6749(89)90445-4; WILLIAMS TJ, 1983, BRIT MED BULL, V39, P239, DOI 10.1093/oxfordjournals.bmb.a071826; ZWEIMAN B, 1976, INT ARCH ALLER A IMM, V52, P48, DOI 10.1159/000231666; ZWEIMAN B, 1991, J ALLERGY CLIN IMMUN, V87, P984, DOI 10.1016/0091-6749(91)90421-J; ZWEIMAN B, 1988, CLIN ALLERGY, V18, P419, DOI 10.1111/j.1365-2222.1988.tb02892.x	54	13	13	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1151	1163		10.1016/S0091-6749(96)70270-1	http://dx.doi.org/10.1016/S0091-6749(96)70270-1			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626994				2022-12-18	WOS:A1996UL26100017
J	Miadonna, A; Milazzo, N; Lorini, M; Sala, A; Tedeschi, A				Miadonna, A; Milazzo, N; Lorini, M; Sala, A; Tedeschi, A			Nasal neutrophilia and release of myeloperoxidase induced by nasal challenge with platelet activating factor: Different degrees of responsiveness in atopic and nonatopic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						leukotriene B-4; lyso-PAF; myeloperoxidase; neutrophil; nasal lavage; PAF	HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PAF-ACETHER; RECEPTOR ANTAGONIST; ANTIGEN CHALLENGE; ALLERGIC RHINITIS; HUMAN EOSINOPHILS; INHALED PAF; GUINEA-PIG; LACTOFERRIN; AIRWAYS	Background: Nasal challenge with platelet activating factor (PAF) is able to induce local neutrophilia, with a different degree of responsiveness in atopic subjects and in nonatopic subjects. We investigated whether nasal accumulation of neutrophils induced by PAF is accompanied by the release of neutrophil-derived mediators. Methods: Nasal lavages were performed before and after challenge with PAF (500 nmol), lyso-PAF (500 nmol), and saline solution in 10 patients with allergic rhinitis and 10 normal subjects to evaluate changes in neutrophil counts and the release of myeloperoxidase (MPO) and immunoreactive leukotriene B-4. Results: PAF caused neutrophilia, which appeared after 30 minutes in atopic subjects and after 3 hours in nonatopic subjects. Furthermore, when compared with saline insufflation, PAF caused a significant release of MPO in the nasal lavage fluids collected 30 minutes, 3 hours, and 24 hours after challenge in atopic subjects and 3 hours after challenge in nonatopic subjects, with higher values in the former than in the latter. Neutrophil counts correlated with MPO levels in the nasal lavages collected after PAF challenge. A lower degree of neutrophilia was found 3 hours after stimulation with lyso-PAF in both groups of subjects, with a marginal release of MPO in atopic subjects only. No significant increase of immunoreactive leukotriene B-4 levels in nasal lavages was found after challenge with either PAF or lyso-PAF. Conclusion: These results indicate that PAF-induced neutrophilia in the nose is accompanied by the release of MPO, which appears earlier and is more marked in atopic subjects than in nonatopic subjects.	UNIV MILAN,CTR CARDIOPULM PHARMACOL,MILAN,ITALY	University of Milan	Miadonna, A (corresponding author), OSPED MAGGIORE POLICLIN,DEPT INTERNAL MED,RESP ALLERGY & IMMUNOL UNIT,VIA SFORZA 35,I-20122 MILAN,ITALY.		Sala, Angelo/H-5478-2019	Sala, Angelo/0000-0001-9290-0257				ANDERSON WH, 1983, BRIT J PHARMACOL, V78, P67, DOI 10.1111/j.1476-5381.1983.tb09363.x; ANDERSSON M, 1988, EUR J CLIN PHARMACOL, V35, P231, DOI 10.1007/BF00558258; ARNOUX B, 1988, AM REV RESPIR DIS, V137, P855, DOI 10.1164/ajrccm/137.4.855; BARNES PJ, 1988, J ALLERGY CLIN IMMUN, V81, P919, DOI 10.1016/0091-6749(88)90952-9; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BENVENISTE J, 1987, AM REV RESPIR DIS, V135, pS2; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRUIJNZEEL PLB, 1986, PHARMACOL RES COMMUN, V18, P61; CHANYEUNG M, 1991, J ALLERGY CLIN IMMUN, V87, P668; CUSS FM, 1986, LANCET, V2, P189; DENIZOT Y, 1989, BIOCHEM BIOPH RES CO, V161, P939, DOI 10.1016/0006-291X(89)92689-2; EWANS TW, 1987, J APPL PHYSIOL, V63, P479; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; HENOCQ E, 1986, LANCET, V1, P1378; KIDNEY JC, 1993, AM REV RESPIR DIS, V147, P215, DOI 10.1164/ajrccm/147.1.215; KROEGEL C, 1989, J IMMUNOL, V142, P3518; LEGGIERI E, 1991, ALLERGY, V46, P466, DOI 10.1111/j.1398-9995.1991.tb04363.x; LIN AH, 1982, J CLIN INVEST, V70, P1058, DOI 10.1172/JCI110693; LINDER A, 1987, ALLERGY, V42, P583, DOI 10.1111/j.1398-9995.1987.tb00388.x; MESLIER N, 1988, AM REV RESPIR DIS, V137, P617, DOI 10.1164/ajrccm/137.3.617; MIADONNA A, 1989, AM REV RESPIR DIS, V140, P142, DOI 10.1164/ajrccm/140.1.142; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; MURPHY RC, 1987, AM REV RESPIR DIS, V136, P207, DOI 10.1164/ajrccm/136.1.207; NIEMINEN MM, 1991, EUR RESPIR J, V4, P561; NINIO E, 1982, BIOCHIM BIOPHYS ACTA, V710, P23, DOI 10.1016/0005-2760(82)90185-0; OLOFSSON T, 1977, SCAND J HAEMATOL, V18, P73; RUBIN AHE, 1987, AM REV RESPIR DIS, V136, P1145, DOI 10.1164/ajrccm/136.5.1145; SAKAMOTO T, 1993, J APPL PHYSIOL, V74, P1117, DOI 10.1152/jappl.1993.74.3.1117; SHAW JO, 1981, J IMMUNOL, V127, P1250; SHIN MH, 1994, AM J RESP CRIT CARE, V149, P660, DOI 10.1164/ajrccm.149.3.8118633; SPENCER DA, 1991, THORAX, V46, P441, DOI 10.1136/thx.46.6.441; STENTON SC, 1990, CLIN EXP ALLERGY, V20, P311, DOI 10.1111/j.1365-2222.1990.tb02689.x; TAYLOR IK, 1991, J APPL PHYSIOL, V71, P1396, DOI 10.1152/jappl.1991.71.4.1396; TAYLOR MB, 1990, J ALLERGY CLIN IMMUN, V86, P740, DOI 10.1016/S0091-6749(05)80178-2; TEDESCHI A, 1994, J ALLERGY CLIN IMMUN, V93, P526, DOI 10.1016/0091-6749(94)90363-8; TEDESCHI A, 1994, EUR RESPIR J, V7, P1445, DOI 10.1183/09031936.94.07081445; TOUQUI L, 1994, J ALLERGY CLIN IMMUN, V94, P109, DOI 10.1016/0091-6749(94)90077-9; VALONE FH, 1983, IMMUNOLOGY, V48, P141; VENGE P, 1984, CLIN CHIM ACTA, V136, P121, DOI 10.1016/0009-8981(84)90283-3; VOELKEL NF, 1982, SCIENCE, V218, P286, DOI 10.1126/science.7123233; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WARDLAW AJ, 1990, AM REV RESPIR DIS, V41, P386	42	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1996	97	4					947	954		10.1016/S0091-6749(96)80069-8	http://dx.doi.org/10.1016/S0091-6749(96)80069-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UG086	8655890				2022-12-18	WOS:A1996UG08600009
J	Tsuruta, L; Lee, HJ; Masuda, ES; Yokota, T; Arai, N; Arai, K				Tsuruta, L; Lee, HJ; Masuda, ES; Yokota, T; Arai, N; Arai, K			Regulation of expression of the IL-2 and IL-5 genes and the role of proteins related to nuclear factor of activated T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1994 Conference	JUL   23, 1994	TOKYO, JAPAN	Sandoz Pharm Ltd		IL-2 gene; IL-5 gene; nuclear factor of activate T cells; helper T cells; cyclic adenosine monophosphate	INTERLEUKIN-2 GENE; ANTIGEN RECEPTOR; CYCLOSPORINE-A; LYMPHOCYTES-T; PROMOTER; CAMP; INDUCTION	Cyclic adenosine monophosphate (cAMP) inhibits phorbol 12-myristate 13-acetate (PMA)-induced IL-2 production while it inhibits IL-5 production at the transcriptional level in EL-4, a mouse lymphoma line. The -321 to $46 region of the mouse IL-2 promoter is required for activation by PMA and inhibition by cAMP. This promoter region contains several elements that interact with transcription factors, such as nuclear factor of activated T cells (NF-AT), NF-kappa B, AP-1, and octamer. With use of reporter plasmid carrying multiple copies of each element, we found that the construct that contained the NF-AT site was most effective for responding to PMA activation and cAMP inhibition. In electrophoretic mobility shift assay (EMSA), PMA-induced NF-AT binding complex was altered by cAMP. Furthermore, overexpression of the crytoplasmic component of NF-AT abrogated the inhibitory action of cAMP. These results indicate that the NF-AT site is a target of the inhibitory action of cAMP. We have previously reported that the -1200 to +33 region of the mouse IL-5 promoter can mediate transcriptional stimulation by PMA and cAMP in EL-4 cells. Here we identified the element IL-5P, which is required for maximal activation of the IL-5 promoter. We found that this element is homologous to the binding site for. NF-AT and interacted with NF-AT-related factors induced by PMA and cAMP. Thus it appears that an NF-AT factor is involved in the regulation of IL-5 gene transcription.	UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,MINATO KU,TOKYO 108,JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT CELL BIOL,PALO ALTO,CA 94304	University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Yokota, Takashi/J-8483-2015	Masuda, Esteban/0000-0002-3175-2868				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BETZ M, 1991, J IMMUNOL, V146, P108; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; LEE HJ, 1993, J IMMUNOL, V151, P6135; LEE JH, 1995, J BIOL CHEM, V270, P17541; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MASUDA ES, 1995, MOL CELL BIOL, V15, P2694; MASUDA ES, 1993, IMMUNOLOGIST, V1, P198; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSSMAN TR, 1991, IMMUNOL RES, V10, P183; MUNOZ E, 1990, J EXP MED, V172, P95, DOI 10.1084/jem.172.1.95; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; TSURUTA L, 1995, J IMMUNOL, V154, P5255; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788	26	13	13	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	2	S			1126	1135		10.1016/S0091-6749(95)70197-4	http://dx.doi.org/10.1016/S0091-6749(95)70197-4			10	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ509	8543769	Bronze			2022-12-18	WOS:A1995TQ50900008
J	Volovitz, B; Kauschansky, A; Nussinovitch, M; Harel, L; Varsano, I				Volovitz, B; Kauschansky, A; Nussinovitch, M; Harel, L; Varsano, I			Normal diurnal variation in serum cortisol concentration in asthmatic children treated with inhaled budesonide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						diurnal variation; serum cortisol; children; asthma inhaled corticosteroids; budesonide	BECLOMETHASONE DIPROPIONATE; SECRETION; GROWTH; CORTICOSTEROIDS; SUPPRESSION	Background: Twenty-four-hour serum cortisol secretion is a sensitive parameter for the assessment of the pituitary-adrenal function of asthmatic children treated with inhaled corticosteroids. This study was undertaken to determine Ae effect of the long-term administration of inhaled budesonide on 24-hour cortisol production in young children with asthma. Methods: We studied II children, aged 7 to 12 years, with severe perennial asthma. All had been receiving 100 mu g of inhaled budesonide twice daily, administered with a spacer device, for 3 to 5 years. Serum cortisol concentration was measured at 8:00 AM, 60 minutes after intravenous administration of 0.25 mg of corticotropin, and every 30 minutes for 24 hours in an open-design study. Urinary cortisol secretion was measured by 24-hour urine collection. All determinations were made with a radioimmunoassay kit. Results: The individual morning serum cortisol concentration and the serum cortisol concentration at 60 minutes after corticotropin stimulation were within normal limits in all children. The 24-hour urinary cortisol excretion was also normal. The individual 24-hour serum cortisol concentration showed a normal pattern in all children, with no evidence of nocturnal suppression of serum cortisol concentration. Conclusion: Prolonged (3 to 5 years) administration of 200 mu g/day of inhaled budesonide in young children with severe asthma does not impair pituitary-adrenal function, even according to the sensitive test for 24-hour serum cortisol secretion.	TEL AVIV UNIV,SACKLER SCH MED,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	Volovitz, B (corresponding author), SHENIEDER CHILDRENS MED CTR ISRAEL,DEPT PEDIAT C,14 KAPLAN ST,BEILINSON MED CAMPUS,IL-49202 PETAH TIQWA,ISRAEL.							AGERTOFT L, 1993, ARCH DIS CHILD, V69, P130, DOI 10.1136/adc.69.1.130; LACERDA LD, 1973, J CLIN ENDOCR METAB, V36, P227; LAW CM, 1986, LANCET, V1, P942; LITTLEWOOD JM, 1988, LANCET, V1, P115; MIGEON CJ, 1956, J CLIN ENDOCR METAB, V16, P622, DOI 10.1210/jcem-16-5-622; PEDERSEN S, 1988, EUR RESPIR J, V1, P433; PERKOFF GT, 1959, J CLIN ENDOCR METAB, V19, P432, DOI 10.1210/jcem-19-4-432; PHILLIP M, 1992, PEDIATR PULM, V12, P84, DOI 10.1002/ppul.1950120205; PRAHL P, 1991, CLIN EXP ALLERGY, V21, P145, DOI 10.1111/j.1365-2222.1991.tb00817.x; TABACHNIK E, 1991, J PEDIATR-US, V118, P294, DOI 10.1016/S0022-3476(05)80506-2; VARSANO I, 1990, J ALLERGY CLIN IMMUN, V85, P914, DOI 10.1016/0091-6749(90)90077-H; VOLOVITZ B, 1993, NEW ENGL J MED, V329, P1703, DOI 10.1056/NEJM199312023292305; WALLACE WHB, 1991, CLIN ENDOCRINOL, V34, P215, DOI 10.1111/j.1365-2265.1991.tb00297.x; WEITZMAN ED, 1971, J CLIN ENDOCR METAB, V33, P14, DOI 10.1210/jcem-33-1-14; WOLTHERS OD, 1992, PEDIATRICS, V89, P839	15	13	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				874	878		10.1016/S0091-6749(95)70222-9	http://dx.doi.org/10.1016/S0091-6749(95)70222-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543743				2022-12-18	WOS:A1995TN12400002
J	PITTMAN, T; KIBURZ, J; STEINHARDT, G; KROCK, J; GABRIEL, K				PITTMAN, T; KIBURZ, J; STEINHARDT, G; KROCK, J; GABRIEL, K			ETHYLENE-OXIDE ALLERGY IN CHILDREN WITH SPINA-BIFIDA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ETHYLENE OXIDE; LATEX; MYELOMENINGOCELE; ALLERGY	HEMODIALYSIS; GAS; ANTIBODIES	Background: Allergic reactions to ethylene oxide (EtO)-treated products have o Objective: The object of this study was to define the prevalence and significance of EtO-specific IgE among the children in our myelomeningocele clinic. Methods: The study population comprised three groups: children with myelomeningoceles, chronically ill controls (defined as children who had undergone at least three major operations), and well-child controls. Serum specimens were collected from each child and a commercially available ELISA designed to identify, IgE directed against both EtO and latex was performed on the specimens. Results: Seventeen of 75 (23%) children with myelomeningoceles had antibodies directed against EtO, as did 1 of 26 (4%) chronically ill controls. None of the 25 well controls had detectable levels of anti-EtO IgE. Children with antibodies directed against EtO were more likely to be atopic (p = 0.007) and to have a shunt (p = 0.021) and were markedly more likely to have antibodies directed against latex (p < 0.001). On average they had undergone more shunt revisions and other operations than had children without anti-EtO antibodies. Conclusion: During the period of study no child had anaphylaxis thought to have been due to EtO exposure.	CARDINAL GLENNON MEM HOSP CHILDREN, DIV PEDIAT ORTHOPED, ST LOUIS, MO 63104 USA; CARDINAL GLENNON MEM HOSP CHILDREN, DIV PEDIAT UROL, ST LOUIS, MO 63104 USA; CARDINAL GLENNON MEM HOSP CHILDREN, DIV PEDIAT ANESTHESIOL, ST LOUIS, MO 63104 USA		PITTMAN, T (corresponding author), CARDINAL GLENNON MEM HOSP CHILDREN, DIV NEUROL SURG, 1465 S GRAND BLVD, ST LOUIS, MO 63104 USA.							ANDERSEN SR, 1971, J LAB CLIN MED, V77, P346; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V81, P590, DOI 10.1016/0091-6749(88)90201-1; DOLOVICH J, 1984, ARTIF ORGANS, V8, P334, DOI 10.1111/j.1525-1594.1984.tb04301.x; JACKSON DW, 1990, AM J SPORT MED, V18, P1, DOI 10.1177/036354659001800101; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V94, P53, DOI 10.1016/0091-6749(94)90071-X; LEITMAN SF, 1986, NEW ENGL J MED, V315, P1192, DOI 10.1056/NEJM198611063151904; LEMKE HD, 1990, NEPHROL DIAL TRANSPL, V5, P264, DOI 10.1093/ndt/5.4.264; MARSHALL CP, 1985, J ALLERGY CLIN IMMUN, V75, P563, DOI 10.1016/0091-6749(85)90030-2; MONERETVAUTRIN DA, 1990, ANESTHESIOLOGY, V73, P556, DOI 10.1097/00000542-199009000-00032; PITTMAN T, 1994, BRIT J NEUROSURG, V8, P41, DOI 10.3109/02688699409002391; POOTHULLIL J, 1975, ANN INTERN MED, V82, P58, DOI 10.7326/0003-4819-82-1-58; RUMPF KW, 1985, LANCET, V2, P1385	12	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					486	488		10.1016/S0091-6749(95)70291-1	http://dx.doi.org/10.1016/S0091-6749(95)70291-1			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560659				2022-12-18	WOS:A1995TA09500008
J	COGAN, E; SCHANDENE, L; PAPADOPOULOS, T; CRUSIAUX, A; GOLDMAN, M				COGAN, E; SCHANDENE, L; PAPADOPOULOS, T; CRUSIAUX, A; GOLDMAN, M			INTERLEUKIN-5 PRODUCTION BY T-LYMPHOCYTES IN ATHEROEMBOLIC DISEASE WITH HYPEREOSINOPHILIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									FREE UNIV BRUSSELS,HOP ERASME,DEPT IMMUNOL,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,HOP UNIV BRUGMANN,DEPT MED INTERNE,B-1020 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	COGAN, E (corresponding author), FREE UNIV BRUSSELS,HOP ERASME,SERV MED INTERNE,808 ROUTE LENNIK,B-1070 BRUSSELS,BELGIUM.			Cogan, Elie/0000-0003-2890-766X				COGAN E, 1995, NEW ENGL J MED, V330, P535; KASINATH BS, 1987, ARCH INTERN MED, V147, P1384, DOI 10.1001/archinte.147.8.1384; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHANDENE L, 1993, CLIN EXP IMMUNOL, V93, P115	5	13	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1995	96	3					427	429		10.1016/S0091-6749(95)70065-X	http://dx.doi.org/10.1016/S0091-6749(95)70065-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RU660	7560648	Bronze			2022-12-18	WOS:A1995RU66000018
J	MOCHIZUKI, H; SHIMIZU, T; MAEDA, S; TOKUYAMA, K; MORIKAWA, A; KUROUME, T				MOCHIZUKI, H; SHIMIZU, T; MAEDA, S; TOKUYAMA, K; MORIKAWA, A; KUROUME, T			RELATIONSHIP BETWEEN ULTRASONICALLY NEBULIZED DISTILLED WATER-INDUCED BRONCHOCONSTRICTION AND ACETIC ACID-INDUCED COUGH IN ASTHMATIC-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ACETIC ACID INHALATION CHALLENGE; ASTHMATIC CHILDREN; BRONCHOCONSTRICTION; COUGH; FUROSEMIDE; HISTAMINE INHALATION CHALLENGE; ULTRASONICALLY NEBULIZED DISTILLED WATER-INHALATION CHALLENGE	INHALED FUROSEMIDE; TRACHEAL EPITHELIUM; BRONCHIAL-ASTHMA; ION-TRANSPORT; CAPSAICIN; INHALATION; HISTAMINE; CROMOGLYCATE; METHACHOLINE; OSMOLARITY	Background: Although wheezing and cough are the most common complaints in asthmatic persons, the mechanisms of hyperresponsiveness to bronchoconstriction and cough are nevertheless still unclear. Objective: To investigate the common mechanisms between them, we studied the relationship between ultrasonically nebulized distilled water (UNDW) inhalation challenge and acetic acid (AA) inhalation challenge In addition, we evaluated the effect of inhaled furosemide on both provocation tests by means of a placebo-controlled study. Method: In study 1 the UNDW; AA, and histamine inhalation challenges were performed in 40 asthmatic children (26 boys, aged from 7 to 16 years; mean +/- SD, 11.2 +/- 2.0 years). In study 2, 12 of the study 1 subjects (9 boys, 11.3 +/- 2.4 years) were subjected to each challenge test after inhalation of furosemide (10 mg/body square meters), or placebo (0.9% saline solution) on separate days. Results: There was a good correlation between the provocative dose causing a 20% fall in forced expiratory volume in 1 second in the UNDW inhalation challenge (UNDW-PD20) and threshold dose causing cough in the AA inhalation challenge (R = 0.527; p < 0.001). There was no relationship either between UNDW-PD20 and the provocative concentration causing a 20% fall in the histamine inhalation challenge (histamine-PC20)(R = 0.384; p > 0.1), or between histamine-PC20 and the cough threshold (R = 0.30S; p > 0.05). In study 2 neither bronchoconstriction nor bronchodilatation after inhalation of furosemide was observed. Inhaled furosemide everted a protective effect on UNDW-PD20 and cough threshold of the AA inhalation challenge (p < 0.01 and p < 0.01, respectively), but did not attenuate histamine-PC20 (p > 0.1). Conclusion: These data suggest that a common mechanism may cause hyperresponsiveness against both UNDW-induced bronchoconstriction and AA-induced cough in asthmatic children.			MOCHIZUKI, H (corresponding author), GUNMA UNIV,SCH MED,DEPT PEDIAT,3-39-15 SHOWA MACHI,MAEBASHI,GUMMA 371,JAPAN.							ALLEGRA L, 1980, EUR J RESPIR DIS, V61, P41; ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; BIANCO S, 1988, LANCET, V2, P252; BIANCO S, 1989, NEW ENGL J MED, V321, P1069, DOI 10.1056/NEJM198910193211602; BICKERMAN HA, 1954, AM J MED SCI, V228, P156, DOI 10.1097/00000441-195408000-00005; BIENENSTOCK J, 1988, AM REV RESPIR DIS, V138, pS31, DOI 10.1164/ajrccm/138.6_Pt_2.S31; BURG M, 1973, AM J PHYSIOL, V225, P119, DOI 10.1152/ajplegacy.1973.225.1.119; BUTT AG, 1990, AM J PHYSIOL, V258, pC630, DOI 10.1152/ajpcell.1990.258.4.C630; CHAUSOW AM, 1983, J APPL PHYSIOL, V55, P541, DOI 10.1152/jappl.1983.55.2.541; COLERIDGE JCG, 1984, REV PHYSIOL BIOCH P, V99, P1, DOI 10.1007/BFb0027715; COLLIER JG, 1984, BRIT J PHARMACOL, V81, P113, DOI 10.1111/j.1476-5381.1984.tb10750.x; ESCHENBACHER WL, 1984, AM REV RESPIR DIS, V129, P211; FABBRI LM, 1987, J ALLERGY CLIN IMMUN, V79, P85; FINE JM, 1987, AM REV RESPIR DIS, V135, P826, DOI 10.1164/arrd.1987.135.4.826; FULLER RW, 1991, RESP MED, V85, P31, DOI 10.1016/S0954-6111(06)80251-9; GODDEN DJ, 1986, CLIN SCI, V70, P301, DOI 10.1042/cs0700301; HOOK WA, 1981, IMMUNOLOGY, V43, P723; JACOBY DB, 1988, AM REV RESPIR DIS, V137, P13, DOI 10.1164/ajrccm/137.1.13; KARLSSON JA, 1988, J APPL PHYSIOL, V65, P1007, DOI 10.1152/jappl.1988.65.3.1007; MAGGI CA, 1988, GEN PHARMACOL-VASC S, V19, P1, DOI 10.1016/0306-3623(88)90002-X; MAKINO S, 1982, JPN J ALLERGOL, V31, P1074; MARIN MG, 1977, J APPL PHYSIOL, V42, P735, DOI 10.1152/jappl.1977.42.5.735; MCFADDEN ER, 1975, NEW ENGL J MED, V292, P555, DOI 10.1056/NEJM197503132921103; MITSUHASHI M, 1985, PEDIATRICS, V75, P855; MITSUHASHI M, 1984, LANCET, V1, P576; MOCHIZUKI H, 1988, Japanese Journal of Allergology, V37, P1016; NICHOL GM, 1990, AM REV RESPIR DIS, V142, P576, DOI 10.1164/ajrccm/142.3.576; ROBUSCHI M, 1987, PULM PHARMACOL, V1, P187; SALEM H, 1964, AM J MED SCI, V247, P585, DOI 10.1097/00000441-196405000-00009; SANTAMBROGIO G, 1987, B EUR PHYSIOPATH RES, V23, pS19; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285, DOI 10.1136/bmj.283.6302.1285; SHIMIZU T, 1993, CHEST, V104, P1723, DOI 10.1378/chest.104.6.1723; TOWNLEY RJ, 1987, J ALLERGY CLIN IMMUN, V80, P111, DOI 10.1016/0091-6749(87)90116-3; VAGHI A, 1988, EUR RESPIR J, V1, pS8; VENTRESCA PG, 1990, AM REV RESPIR DIS, V142, P143, DOI 10.1164/ajrccm/142.1.143; WIDDICOMBE JH, 1983, AM J PHYSIOL, V245, pC3388; YANAURA S, 1978, JPN J PHARMACOL, V28, P447, DOI 10.1254/jjp.28.447	37	13	14	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					193	199		10.1016/S0091-6749(95)70008-0	http://dx.doi.org/10.1016/S0091-6749(95)70008-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636057				2022-12-18	WOS:A1995RQ00100008
J	PRICE, GW; HOGAN, AD; FARRIS, AH; BURKS, AW; PLATTSMILLS, TAE; HEYMANN, PW				PRICE, GW; HOGAN, AD; FARRIS, AH; BURKS, AW; PLATTSMILLS, TAE; HEYMANN, PW			SENSITIZATION (IGE ANTIBODY) TO FOOD ALLERGENS IN WHEEZING INFANTS AND CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							INHALANT ALLERGENS; EARLY-CHILDHOOD; BRONCHIOLITIS; ATOPY; RISK		UNIV VIRGINIA,HLTH SCI CTR,DEPT PEDIAT,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908; UNIV ARKANSAS MED SCI HOSP,DEPT PEDIAT,LITTLE ROCK,AR 72205	University of Virginia; University of Virginia; University of Arkansas System; University of Arkansas Medical Sciences			Price, G/AAY-5410-2020	Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024261, R37AI020565, R01AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24261, AI-20565] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUFFUM WP, 1966, AM J DIS CHILD, V112, P214, DOI 10.1001/archpedi.1966.02090120082007; BURKS WA, 1992, J PEDIATR, V121, P564; DUFF AL, 1993, PEDIATRICS, V92, P535; DUFF AL, 1992, J ALLERGY CLIN IMMUN, V89, P315; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; KORPPI M, 1993, AM J DIS CHILD, V147, P628, DOI 10.1001/archpedi.1993.02160300034017; LANGELAND T, 1983, CLIN ALLERGY, V13, P371, DOI 10.1111/j.1365-2222.1983.tb02611.x; Lemanske R F Jr, 1988, Adv Pediatr, V35, P189; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; NAGAYAMA Y, 1987, J ASTHMA, V24, P9, DOI 10.3109/02770908709073188; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WELLIVER RC, 1986, J PEDIATR-US, V109, P776, DOI 10.1016/S0022-3476(86)80692-8; WILSON NM, 1992, ARCH DIS CHILD, V67, P491, DOI 10.1136/adc.67.4.491; ZEIGER RS, 1985, J ALLERGY CLIN IMMUN, V75, P633, DOI 10.1016/0091-6749(85)90086-7	15	13	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					266	270		10.1016/S0091-6749(95)70020-X	http://dx.doi.org/10.1016/S0091-6749(95)70020-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636067				2022-12-18	WOS:A1995RQ00100020
J	PARKKINEN, S; RYTKONEN, M; PENTIKAINEN, J; VIRTANEN, T; MANTYJARVI, R				PARKKINEN, S; RYTKONEN, M; PENTIKAINEN, J; VIRTANEN, T; MANTYJARVI, R			HOMOLOGY OF A BOVINE ALLERGEN AND THE OLIGOMYCIN SENSITIVITY-CONFERRING PROTEIN OF THE MITOCHONDRIAL ADENOSINE-TRIPHOSPHATE SYNTHASE COMPLEX	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BOVINE ALLERGEN; COMPLEMENTARY DNA CLONING; OLIGOMYCIN SENSITIVITY-CONFERRING; PROTEIN; IGE BINDING	ATP SYNTHASE; HEART-MITOCHONDRIA; INHIBITOR PROTEIN; SEQUENCE-ANALYSIS; MAJOR ALLERGEN; DOMESTIC CAT; IDENTIFICATION; PRECURSORS; SUBUNITS; EXTRACT	We have characterized bovine allergens by constructing and analyzing a complementary DNA library from bovine skin. Clones producing proteins that reacted with IgE antibodies from persons with allergy were purified and sequenced. One set of the allergen-coding clones showed an almost complete homology with the bovine oligomycin sensitivity-conferring protein of the mitochondrial adenosine triphosphate synthase complex. The IgE antibodies adsorbed with the recombinant allergen reacted with an II kd protein in the cow dander extract. Binding of the IgE from patients allergic to the recombinant allergen expressed in Escherichia coli confirmed the allergen-coding ability of the complementary DNA sequence. The prevalence of the IgE-positive sera among patients with cow allergy and control subjects suggests that the recombinant allergen represents one of the minor allergens in cow dander. This is the first time a mammalian allergen has been identified as a protein with a known function.	UNIV KUOPIO, DEPT CLIN MICROBIOL, SF-70211 KUOPIO, FINLAND	University of Eastern Finland				Rytkonen-Nissinen, Marja/0000-0002-2014-8315				ANDO T, 1991, INT ARCH ALLER A IMM, V96, P199, DOI 10.1159/000235495; ANSORGE W, 1987, NUCLEIC ACIDS RES, V15, P4593, DOI 10.1093/nar/15.11.4593; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; DONOVAN GR, 1990, MONOGR ALLERGY, V28, P52; GRIFFITH IJ, 1992, GENE, V113, P263, DOI 10.1016/0378-1119(92)90405-E; HEKMAN C, 1991, ARCH BIOCHEM BIOPHYS, V284, P90, DOI 10.1016/0003-9861(91)90268-N; HIGUTI T, 1993, BIOCHIM BIOPHYS ACTA, V1172, P311, DOI 10.1016/0167-4781(93)90219-4; JOSHI S, 1990, J BIOL CHEM, V265, P14518; KENT NA, 1992, INT ARCH ALLERGY IMM, V99, P150, DOI 10.1159/000236349; LAKE FR, 1991, J ALLERGY CLIN IMMUN, V87, P1035, DOI 10.1016/0091-6749(91)92147-S; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; PRAHL P, 1982, INT ARCH ALLER A IMM, V67, P293, DOI 10.1159/000233036; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEINER O, 1992, INT ARCH ALLERGY IMM, V98, P93, DOI 10.1159/000236170; SCHOU C, 1993, CLIN EXP ALLERGY, V23, P7, DOI 10.1111/j.1365-2222.1993.tb02477.x; SHANTI KN, 1993, J IMMUNOL, V151, P5354; STEWART GA, 1992, IMMUNOLOGY, V75, P29; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VIRTANEN T, 1988, INT ARCH ALLER A IMM, V87, P171, DOI 10.1159/000234668; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; WALKER JE, 1987, BIOCHEMISTRY-US, V26, P8613, DOI 10.1021/bi00400a018; YLONEN J, 1992, INT ARCH ALLERGY IMM, V99, P112, DOI 10.1159/000236343; YLONEN J, 1994, J ALLERGY CLIN IMMUN, V93, P851, DOI 10.1016/0091-6749(94)90377-8	23	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1995	95	6					1255	1260		10.1016/S0091-6749(95)70083-8	http://dx.doi.org/10.1016/S0091-6749(95)70083-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD309	7797794				2022-12-18	WOS:A1995RD30900014
J	HADJOKAS, NE; CROWLEY, JJ; BAYER, CR; NIELSON, CP				HADJOKAS, NE; CROWLEY, JJ; BAYER, CR; NIELSON, CP			BETA-ADRENERGIC REGULATION OF THE EOSINOPHIL RESPIRATORY BURST AS DETECTED BY LUCIGENIN-DEPENDENT LUMINESCENCE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ISOPROTERENOL; EOSINOPHIL; RESPIRATORY BURST	PLATELET-ACTIVATING-FACTOR; CHEMOATTRACTANT RECEPTORS; GUINEA-PIGS; ASTHMA; NEUTROPHILS; DEGRANULATION; TRANSDUCTION; FORMOTEROL; LEUKOCYTES; RESPONSES	Because beta-adrenoceptor agonists are commonly used in the treatment of disease states associated with eosinophil activation, beta-adrenergic regulation of the eosinophil respiratory burst (as monitored with lucigenin-dependent luminescence) was evaluated. Normodense, nonprimed eosinophils from healthy volunteer subjects were potently inhibited by very low concentrations of isoproterenol. The inhibitory concentration of 50% for isoproterenol was approximately 2 nmol/L. The beta-agonist was able to inhibit the eosinophil respiratory burst induced by receptor-mediated (chemotactic peptide) and nonreceptor-mediated (calcium ionophore and phorbol ester) stimuli. Thus beta-agonist inhibition was unlikely to be isolated to an effect at the receptor or G protein linkage. To determine whether cyclic adenosine 3',5' monophosphate (cAMP) may mediate beta-agonist effects, studies were performed with the type IV cAMP phosphodiesterase inhibitor Ro-201724. beta-agonist inhibition of the respiratory burst was clearly synergistic with effects of Ro-201724. We conclude that beta-adrenoceptor agonists can regulate the eosinophil respiratory burst at least partially through an effect mediated by cAMP. Because regulation of the eosinophil by isoproterenol was observed at very low concentrations, these results may be relevant to pharmacologic effects of beta-agonists in diseases states complicated by eosinophil activation during asthma.	IDAHO STATE UNIV, COLL PHARM, DEPT PHARMACEUT SCI, POCATELLO, ID 83209 USA; UNIV WASHINGTON, DEPT MED, DIV GERONTOL & GERIATR MED, SEATTLE, WA USA	Idaho; Idaho State University; University of Washington; University of Washington Seattle	HADJOKAS, NE (corresponding author), VET AFFAIRS MED CTR, RES SERV 151, RES UNIT, 500 W FORT ST, BOISE, ID 83702 USA.							BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BUSSE WW, 1992, ANN ALLERGY, V68, P286; CALHOUN WJ, 1991, ANN NY ACAD SCI, V629, P62; CHAN SC, 1993, J LAB CLIN MED, V121, P44; CHUNG KF, 1989, THORAX, V44, P102, DOI 10.1136/thx.44.2.102; CRONSTEIN BN, 1988, BIOCHEM J, V252, P709, DOI 10.1042/bj2520709; CRONSTEIN BN, 1992, BLOOD, V80, P1052; DENT G, 1991, BRIT J PHARMACOL, V103, P1339, DOI 10.1111/j.1476-5381.1991.tb09790.x; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; HOLGATE ST, 1991, AM REV RESPIR DIS, V143, pS66, DOI 10.1164/ajrccm/143.3_Pt_2.S66; HUSSEY EK, 1991, J CLIN PHARMACOL, V31, P561, DOI 10.1002/j.1552-4604.1991.tb03738.x; JANSON C, 1992, EUR RESPIR J, V5, P80; KERNEN P, 1991, J CLIN INVEST, V87, P2012, DOI 10.1172/JCI115230; KITA H, 1991, J IMMUNOL, V146, P2712; KITA H, 1991, J IMMUNOL, V147, P3466; KOENDERMAN L, 1990, J IMMUNOL, V145, P3883; KOOMEN CB, 1992, J ALLERGY CLIN IMMUN, V89, P52; LEE TC, 1984, J BIOL CHEM, V259, P5526; MASUYAMA K, 1985, INT ARCH ALLER A IMM, V78, P243, DOI 10.1159/000233893; MUELLER H, 1989, J CELL BIOCHEM, V40, P287, DOI 10.1002/jcb.240400305; MUNOZ NM, 1994, J PHARMACOL EXP THER, V268, P139; SANJAR S, 1990, BRIT J PHARMACOL, V99, P267, DOI 10.1111/j.1476-5381.1990.tb14692.x; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SMOLEN JE, 1981, BIOCHIM BIOPHYS ACTA, V672, P197, DOI 10.1016/0304-4165(81)90393-7; SUGIYAMA H, 1992, J ALLERGY CLIN IMMUN, V89, P858, DOI 10.1016/0091-6749(92)90442-5; VERGHESE MW, 1985, J BIOL CHEM, V260, P6769; WONG BJ, 1992, AM REV RESPIR DIS, V146, P1156, DOI 10.1164/ajrccm/146.5_Pt_1.1156; YUKAWA T, 1990, AM J RESP CELL MOL, V2, P341, DOI 10.1165/ajrcmb/2.4.341; YUKAWA T, 1990, AM REV RESPIR DIS, V141, P1446, DOI 10.1164/ajrccm/141.6.1446; ZORATTI EM, 1991, J ALLERGY CLIN IMMUN, V88, P749, DOI 10.1016/0091-6749(91)90182-N	30	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					735	741		10.1016/S0091-6749(95)70179-6	http://dx.doi.org/10.1016/S0091-6749(95)70179-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897157				2022-12-18	WOS:A1995QM01700014
J	DEMAIN, JG; GOETZ, DW				DEMAIN, JG; GOETZ, DW			IMMEDIATE, LATE, AND DELAYED SKIN-TEST RESPONSES TO CENTRUROIDES VITTATUS SCORPION-VENOM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									WILFORD HALL USAF MED CTR,DEPT ALLERGY IMMUNOL,LACKLAND AFB,TX 78236	United States Department of Defense; United States Air Force								GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; KEEGAN HL, 1971, AM J TROP MED HYG, V20, P770, DOI 10.4269/ajtmh.1971.20.770; Rochat H, 1979, Adv Cytopharmacol, V3, P325; YAHELNIV A, 1979, TOXICON, V17, P435, DOI 10.1016/0041-0101(79)90277-0	5	13	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				135	137		10.1016/S0091-6749(95)70163-X	http://dx.doi.org/10.1016/S0091-6749(95)70163-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7822656	Bronze			2022-12-18	WOS:A1995QC31200019
J	SOLDATOV, D; DEBLAY, F; GRIESS, P; CHARLES, P; CHARPENTIER, C; OTT, M; PAULI, G				SOLDATOV, D; DEBLAY, F; GRIESS, P; CHARLES, P; CHARPENTIER, C; OTT, M; PAULI, G			EFFECTS OF ENVIRONMENTAL-CONTROL MEASURES ON PATIENT STATUS AND AIRBORNE FEL-D-I LEVELS WITH A CAT IN-SITU	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																		ARRD, V143, P1334	1	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	2				263	263						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QE854					2022-12-18	WOS:A1995QE85400488
J	DVORAK, AM				DVORAK, AM			SIMILARITIES IN THE ULTRASTRUCTURAL MORPHOLOGY AND DEVELOPMENTAL AND SECRETORY MECHANISMS OF HUMAN BASOPHILS AND EOSINOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							LEYDEN CRYSTAL PROTEIN; CYTOPLASMIC LIPID BODIES; ENDOPEROXIDE SYNTHASE CYCLOOXYGENASE; RECOMBINANT HUMAN INTERLEUKIN-5; MONONUCLEAR CELL-CULTURES; MAJOR BASIC-PROTEIN; MAST-CELLS; HYPEREOSINOPHILIC SYNDROME; IMMUNOGOLD LOCALIZATION; PIECEMEAL DEGRANULATION		HARVARD UNIV,SCH MED,BOSTON,MA; BETH ISRAEL HOSP,CHARLES A DANA RES INST,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	DVORAK, AM (corresponding author), BETH ISRAEL HOSP,DEPT PATHOL,330 BROOKLINE AVE,BOSTON,MA 02215, USA.				NIAID NIH HHS [AI-33372] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033372] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEIL WJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1611, DOI 10.1177/41.11.8409368; DVORAK AM, 1992, AM J PATHOL, V140, P795; DVORAK AM, 1991, AM J PATHOL, V138, P69; DVORAK AM, 1976, J IMMUNOL, V116, P687; DVORAK AM, 1994, CLIN EXP ALLERGY, V24, P10, DOI 10.1111/j.1365-2222.1994.tb00910.x; DVORAK AM, 1993, J LEUKOCYTE BIOL, V54, P465, DOI 10.1002/jlb.54.5.465; DVORAK AM, 1989, LAB INVEST, V61, P116; DVORAK AM, 1990, LAB INVEST, V62, P590; DVORAK AM, 1984, CLIN IMMUNOL IMMUNOP, V32, P142, DOI 10.1016/0090-1229(84)90116-8; DVORAK AM, 1990, LAB INVEST, V62, P608; DVORAK AM, 1983, J IMMUNOL, V131, P2965; DVORAK AM, 1991, LAB INVEST, V64, P234; DVORAK AM, 1980, LAB INVEST, V43, P126; DVORAK AM, 1988, EOS-RIV IMMUNOL, V8, P50; DVORAK AM, 1992, J HISTOCHEM CYTOCHEM, V40, P759, DOI 10.1177/40.6.1316915; DVORAK AM, 1994, J HISTOCHEM CYTOCHEM, V42, P251, DOI 10.1177/42.2.7507143; DVORAK AM, 1985, LAB INVEST, V53, P57; DVORAK AM, 1989, LAB INVEST, V60, P557; DVORAK AM, 1993, J HISTOCHEM CYTOCHEM, V41, P787, DOI 10.1177/41.6.8315271; DVORAK AM, 1993, INT ARCH ALLERGY IMM, V101, P136, DOI 10.1159/000236511; DVORAK AM, 1992, AM J PATHOL, V141, P1309; DVORAK AM, 1992, INT ARCH ALLERGY IMM, V99, P208, DOI 10.1159/000236250; DVORAK AM, 1994, INT ARCH ALLERGY IMM, V105, P8, DOI 10.1159/000236796; DVORAK AM, 1993, INT ARCH ALLERGY IMM, V102, P33, DOI 10.1159/000236548; DVORAK AM, 1980, J IMMUNOL, V125, P460; DVORAK AM, 1988, BLOOD, V72, P150; DVORAK AM, 1981, J IMMUNOL, V126, P523; DVORAK AM, 1993, EOSINOPHILS ALLERGY, P159; DVORAK AM, 1994, IN PRESS HISTOCHEM C; DVORAK AM, 1993, HDB IMMUNOPHARMACOLO, P89; DVORAK AM, 1988, MAST CELLS MEDIATORS, P29; DVORAK AM, 1993, HDB IMMUNOPHARMACOLO, P153; DVORAK AM, 1991, BLOOD CELL BIOCH, V4, P1; Dvorak AM, 1992, GRANULOCYTE RESPONSE, P169; DVORAK AM, 1991, EFFECTS IMMUNE CELLS, P139; DVORAK AM, 1994, PATHOPHYSIOLOGY PULM; Dvorak Ann M., 1993, P13; DVORAK HF, 1974, LAB INVEST, V31, P111; DVORAK HF, 1975, CLIN HAEMATOL, V4, P651; EGESTEN A, 1986, J HISTOCHEM CYTOCHEM, V34, P1399, DOI 10.1177/34.11.3772075; FINDLAY SR, 1981, J CLIN INVEST, V67, P1604, DOI 10.1172/JCI110195; HASTIE R, 1974, LAB INVEST, V31, P223; ISHIZAKA T, 1985, J IMMUNOL, V134, P532; PETERS MS, 1986, LAB INVEST, V54, P656; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; WELLER PF, 1985, BLOOD, V65, P1269; WELLER PF, 1991, AM J PATHOL, V138, P141; WELLER PF, 1995, ASTHMA RHINITIS, P255; WELLER PF, 1994, J ALLERGY CLIN IMMUN, V94, P269; WELLER PF, 1991, PROSTAGLANDINS LEUKO, P353; [No title captured]	51	13	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1103	1134		10.1016/0091-6749(94)90320-4	http://dx.doi.org/10.1016/0091-6749(94)90320-4			32	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798550				2022-12-18	WOS:A1994QA02000001
J	SCHWARTZ, LB; KEPLEY, C				SCHWARTZ, LB; KEPLEY, C			DEVELOPMENT OF MARKERS FOR HUMAN BASOPHILS AND MAST-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							HISTAMINE-RELEASING FACTOR; MAJOR BASIC-PROTEIN; COLONY-STIMULATING FACTOR; KALLIKREIN-LIKE ACTIVITY; ACTIVATING PEPTIDE-III; CHONDROITIN SULFATE-E; TUMOR-NECROSIS-FACTOR; FC-GAMMA RECEPTORS; C-KIT LIGAND; NON-T CELLS		VIRGINIA COMMONWEALTH UNIV,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298	Virginia Commonwealth University	SCHWARTZ, LB (corresponding author), VIRGINIA COMMONWEALTH UNIV,DEPT INTERNAL MED,BOX 980263,RICHMOND,VA 23298, USA.							ACKERMAN SJ, 1983, J EXP MED, V158, P946, DOI 10.1084/jem.158.3.946; AGIS H, 1993, J IMMUNOL, V151, P4221; ALAM R, 1992, J CLIN INVEST, V89, P723, DOI 10.1172/JCI115648; ANSELMINO LM, 1989, J ALLERGY CLIN IMMUN, V84, P907, DOI 10.1016/0091-6749(89)90388-6; AROCK M, 1993, J IMMUNOL, V151, P1441; BAEZA ML, 1990, J CLIN INVEST, V85, P1516, DOI 10.1172/JCI114598; BECKER EL, 1966, J EXP MED, V124, P379, DOI 10.1084/jem.124.3.379; BENYON RC, 1989, BRIT J PHARMACOL, V97, P898, DOI 10.1111/j.1476-5381.1989.tb12030.x; BISCHOFF SC, 1990, P NATL ACAD SCI USA, V87, P6813, DOI 10.1073/pnas.87.17.6813; BISCHOFF SC, 1990, J EXP MED, V172, P1577, DOI 10.1084/jem.172.6.1577; BISCHOFF SC, 1992, J EXP MED, V175, P1271, DOI 10.1084/jem.175.5.1271; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; BRUNNER T, 1991, J IMMUNOL, V147, P237; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; BUTRUS SI, 1990, OPHTHALMOLOGY, V97, P1678; BUTTERFIELD JH, 1990, LAB INVEST, V62, P77; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; CASTELLS MC, 1987, J IMMUNOL, V138, P2174; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; COLEMAN JW, 1981, IMMUNOLOGY, V44, P859; CRAIG SS, 1993, LAB INVEST, V69, P552; CRAIG SS, 1989, LAB INVEST, V60, P147; CRAIG SS, 1988, LAB INVEST, V58, P682; CRAIG SS, 1990, LAB INVEST, V63, P581; DAHINDEN CA, 1991, INT ARCH ALLER A IMM, V94, P161, DOI 10.1159/000235350; DEPAULIS A, 1991, ARTHRITIS RHEUM-US, V34, P1289, DOI 10.1002/art.1780341013; DVORAK AM, 1989, LAB INVEST, V61, P116; DVORAK AM, 1988, MAST CELLS MEDIATORS, P29; Ehrlich P, 1878, THESIS U LEIPZIG; EHRLICH P, 1879, ARCH PHYSL, P571; FOREMAN JC, 1973, NATURE, V245, P249, DOI 10.1038/245249a0; FOX CC, 1985, J IMMUNOL, V135, P483; FURITSU T, 1989, P NATL ACAD SCI USA, V86, P10039, DOI 10.1073/pnas.86.24.10039; GOLIGHTLY LM, 1992, J LEUKOCYTE BIOL, V51, P386, DOI 10.1002/jlb.51.4.386; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GRUBER BL, 1988, ARTHRITIS RHEUM-US, V31, P1000, DOI 10.1002/art.1780310810; GRUBER BL, 1983, J INVEST DERMATOL, V90, P213; IRANI AA, 1990, NEUTRAL PROTEASES MA, P146; IRANI AMA, 1992, BLOOD, V80, P3009; ISHIZAKA K, 1970, J IMMUNOL, V105, P1459; ISHIZAKA T, 1979, J IMMUNOL, V123, P578; ISHIZAKA T, 1993, CURR OPIN IMMUNOL, V5, P937, DOI 10.1016/0952-7915(93)90109-6; JARJOUR NN, 1991, AM REV RESPIR DIS, V144, P83, DOI 10.1164/ajrccm/144.1.83; Kaplan A P, 1991, Clin Exp Allergy, V21 Suppl 1, P8, DOI 10.1111/j.1365-2222.1991.tb01699.x; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; KIRSHENBAUM AS, 1991, J IMMUNOL, V146, P1410; KOSHINO T, 1993, CLIN EXP ALLERGY, V23, P919, DOI 10.1111/j.1365-2222.1993.tb00276.x; KRISTENSEN KS, 1992, AGENTS ACTIONS, V36, pC260; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; KUNA P, 1992, J IMMUNOL, V149, P636; KUNA P, 1991, J IMMUNOL, V147, P1920; LAROCHE D, 1992, AGENTS ACTIONS, V36, pC199; LAVKER RM, 1987, DERMATOLOGICA, V175, P213, DOI 10.1159/000248906; LAVKER RM, 1986, BRIT J DERMATOL, V115, P101, DOI 10.1111/j.1365-2133.1986.tb02118.x; LAWRENCE ID, 1987, J IMMUNOL, V139, P3062; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; MACGLASHAN D, 1983, J IMMUNOL, V130, P2330; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MASSEY WA, 1989, J IMMUNOL, V143, P1875; METCALFE DD, 1984, J IMMUNOL, V132, P1943; MITSUI H, 1993, P NATL ACAD SCI USA, V90, P735, DOI 10.1073/pnas.90.2.735; NEWBALL HH, 1979, J CLIN INVEST, V64, P466, DOI 10.1172/JCI109484; NEWBALL HH, 1979, J CLIN INVEST, V64, P457, DOI 10.1172/JCI109483; NILSSON G, 1993, IMMUNOLOGY, V79, P325; OH C, 1988, IMMUNOLOGY, V65, P143; PETERS SP, 1984, J IMMUNOL, V132, P1972; PICCINNI MP, 1991, P NATL ACAD SCI USA, V88, P8656, DOI 10.1073/pnas.88.19.8656; RILEY JF, 1953, J PHYSIOL-LONDON, V120, P528, DOI 10.1113/jphysiol.1953.sp004915; ROBINSON C, 1988, MAST CELLS MEDIATORS, P149; ROTHENBERG ME, 1987, J IMMUNOL, V138, P2616; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHLEIMER RP, 1983, CLIN REV ALLERG, V1, P327; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SCHWARTZ L, 1993, ALLERGY PRINCIPLES P, P135; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; SCHWARTZ LB, 1990, MONOGRPAHS ALLERGY N, P1; SEDER RA, 1991, P NATL ACAD SCI USA, V88, P2835, DOI 10.1073/pnas.88.7.2835; SEDER RA, 1991, J IMMUNOL, V147, P903; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SHALIT M, 1988, J IMMUNOL, V141, P821; SHALIT M, 1990, J ALLERGY CLIN IMMUN, V86, P117, DOI 10.1016/S0091-6749(05)80131-9; STEFFEN M, 1989, IMMUNOLOGY, V66, P445; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; TAKEISHI T, 1991, J CLIN INVEST, V88, P598, DOI 10.1172/JCI115344; THOMAS LL, 1989, IMMUNOLOGY, V66, P611; THOMPSON HL, 1988, J IMMUNOL, V140, P2708; TOMIOKA H, 1971, J IMMUNOL, V107, P971; URADE Y, 1989, J IMMUNOL, V143, P2982; VALENT P, 1992, ADV IMMUNOL, V52, P333, DOI 10.1016/S0065-2776(08)60879-2; VALENT P, 1989, BLOOD, V73, P1763; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENT P, 1990, J IMMUNOL, V145, P3432; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; WALDEN SM, 1988, J ALLERGY CLIN IMMUN, V81, P940, DOI 10.1016/0091-6749(88)90157-1; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; WELLER PF, 1982, J IMMUNOL, V128, P1346; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WENZEL S, 1986, J IMMUNOL METHODS, V86, P139, DOI 10.1016/0022-1759(86)90277-2; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002; YAM LT, 1971, AM J CLIN PATHOL, V55, P283; YOUNG JDE, 1987, P NATL ACAD SCI USA, V84, P9175, DOI 10.1073/pnas.84.24.9175; YUNGINGER JW, 1991, J FORENSIC SCI, V36, P857	114	13	14	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1231	1240		10.1016/0091-6749(94)90337-9	http://dx.doi.org/10.1016/0091-6749(94)90337-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798565				2022-12-18	WOS:A1994QA02000017
J	PERIN, PV; WELDON, D; MCGEADY, SJ				PERIN, PV; WELDON, D; MCGEADY, SJ			OBJECTIVE INDICATORS OF SEVERITY OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							LONG-TERM TREATMENT; BETA-AGONISTS; AIRWAY HYPERRESPONSIVENESS; BRONCHIAL RESPONSIVENESS; INHALED CORTICOSTEROIDS; CHILDREN	Subjects with asthma who are intensively treated in residential care facilities frequently demonstrate marked clinical improvement in their disease, with fewer attacks and improved well being. Despite their improved status it is known that pulmonary function test results often remain abnormal in patients with asthma. This prospective study on children with asthma receiving residential care was carried out to determine which pulmonary function parameter best reflected clinical improvement through correlation with the duration of complete freedom from wheezing. Evaluated in 42 children were spirometry values including forced vital capacity forced expiratory volume in 1 second, peak expiratory pow rate, forced expiratory pow (between 25% and 75% of forced vital capacity), and lung volumes as reflected by residual volume/total lung capacity. Bronchial hyperreactivity as reflected by bimonthly provocative concentration causing a 20% fall in FEV(1) in response to methacholine inhalation was evaluated in 18 patients. All pulmonary function test results were correlated with days since last wheezing episode. Results indicate that only peak expiratory pow rate (r = 0.91; p < 0.001), forced expiratory volume in 1 second (r = 0.69; p < 0.01), and forced expiratory flow (r = 0.62; p < 0.05) demonstrated significant correlation with the number of days since last wheezing episode. Of particular interest was the failure of bronchial hyperreactivity to improve despite intensive therapy with bronchodilators and corticosteroids. Persistence of bronchial hyperreactivity despite intensive therapy with corticosteroids suggests that in at least some children with severe asthma, bronchial hyperreactivity may be especially long-lived may be perpetuated by inhaled beta(2) agonists, or may exist independently of airway inflammation.	THOMAS JEFFERSON UNIV,DIV CLIN IMMUNOL & ALLERGY,PHILADELPHIA,PA 19107; CHILDRENS REHABIL HOSP,PHILADELPHIA,PA	Jefferson University								BEL EH, 1991, AM REV RESPIR DIS, V143, P109, DOI 10.1164/ajrccm/143.1.109; BLACKHALL MI, 1970, ARCH DIS CHILD, V45, P363, DOI 10.1136/adc.45.241.363; CANNY J, 1988, J ALLERGY CLIN IMMUN, V82, P1; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, 1992, J ALLERGY CLIN IMMUN, V90, P739, DOI 10.1016/0091-6749(92)90096-K; ENGSTROM I, 1959, Acta Paediatr, V48, P114; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KERREBIJN KF, 1970, BRONCHITIS, V3, P38; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; MURRAY AB, 1983, PEDIATRICS, V71, P418; ODONNELL TV, 1989, LANCET, V2, P45; PEARCE N, 1991, CLIN EXP ALLERGY, V21, P401, DOI 10.1111/j.1365-2222.1991.tb01679.x; PLATTSMILLS TAE, 1982, LANCET, V2, P675; RACHELEFSKY GS, 1992, AM FAM PHYSICIAN, V45, P153; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SZEFLER SJ, 1991, J ALLERGY CLIN IMMUN, V88, P147, DOI 10.1016/0091-6749(91)90323-G; TOOLEY WH, 1965, J PEDIATR-US, V66, P517, DOI 10.1016/S0022-3476(65)80116-0; VATHENEN AS, 1988, LANCET, V1, P544	22	13	13	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	1				517	522		10.1016/0091-6749(94)90208-9	http://dx.doi.org/10.1016/0091-6749(94)90208-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG907	8083457				2022-12-18	WOS:A1994PG90700011
J	BROOKS, SM				BROOKS, SM			HOST SUSCEPTIBILITY TO INDOOR AIR-POLLUTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Symposium on Building-Related and Home-Related Complaints and Illnesses: Sick Building Syndrome	DEC 03-05, 1992	LAKE BUENA VISTA, FL				BRONCHIAL REACTIVITY; CIGARETTE SMOKERS; ADULT-POPULATION; TOBACCO-SMOKE; ASTHMA; OZONE; HYPERRESPONSIVENESS; DYSFUNCTION; PREVALENCE; COMMUNITY		UNIV S FLORIDA,COLL MED,DEPT INTERNAL MED & PULM CRIT CARE & OCCUPAT MED,DIV ALLERGY,TAMPA,FL; UNIV S FLORIDA,COLL MED,DEPT INTERNAL MED & PULM CRIT CARE & OCCUPAT MED,DIV CLIN IMMUNOL,TAMPA,FL	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	BROOKS, SM (corresponding author), UNIV S FLORIDA,COLL PUBL HLTH,DEPT ENVIRONM & OCCUPAT HLTH,13201 BRUCE B DOWNS BLVD,MDC BOX 56,TAMPA,FL 33612, USA.							BAKKE PS, 1991, AM REV RESPIR DIS, V143, P317, DOI 10.1164/ajrccm/143.2.317; BASCOM R, 1990, AM REV RESPIR DIS, V142, P594, DOI 10.1164/ajrccm/142.3.594; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BROOKS S, 1990, CHEST; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; BROOKS SM, 1993, AM REV RESPIR DIS, V147, pA378; BURNEY PGJ, 1987, THORAX, V42, P38, DOI 10.1136/thx.42.1.38; CASALE TB, 1987, J APPL PHYSIOL, V62, P1888, DOI 10.1152/jappl.1987.62.5.1888; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COWIE RL, 1989, BRIT J IND MED, V46, P873; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72, DOI 10.1165/ajrcmb/4.1.72; EMMONS KM, 1992, AM J PUBLIC HEALTH, V82, P24, DOI 10.2105/AJPH.82.1.24; GERRARD JW, 1980, AM REV RESPIR DIS, V122, P577; HOFFMAN RE, 1993, AM J PUBLIC HEALTH, V83, P89, DOI 10.2105/AJPH.83.1.89; HORSTMAN DH, 1990, AM REV RESPIR DIS, V142, P1158, DOI 10.1164/ajrccm/142.5.1158; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LEFF AR, 1988, AM REV RESPIR DIS, V137, P1198; MCCONNOCHIE KM, 1989, PEDIATR PULM, V6, P138, DOI 10.1002/ppul.1950060303; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; RICE S, 1985, ANN ALLERGY, V55, P7903; SCHACHTER EN, 1985, CHEST, V87, P51, DOI 10.1378/chest.87.1.51; SPENGLER J, 1992, PRINCIPLES PRACTICE, P21; TARLO SM, 1989, CHEST, V96, P297, DOI 10.1378/chest.96.2.297; VANDEGRAAF EA, 1991, AM REV RESPIR DIS, V143, P362, DOI 10.1164/ajrccm/143.2.362; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; WEILER JM, 1986, CHEST, V90, P23, DOI 10.1378/chest.90.1.23; WHITE JR, 1991, CHEST, V100, P39, DOI 10.1378/chest.100.1.39; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215; ZWICK H, 1990, LUNG, V168, P111, DOI 10.1007/BF02719681; 1981, BOARD TOXICOLOGY ENV	32	13	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2	2				344	351		10.1053/ai.1994.v94.a56013	http://dx.doi.org/10.1053/ai.1994.v94.a56013			8	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG770	8077588				2022-12-18	WOS:A1994PG77000010
J	GOLDBERG, A; CONFINOCOHEN, R; MEKORI, YA				GOLDBERG, A; CONFINOCOHEN, R; MEKORI, YA			DELIBERATE BEE STING CHALLENGE OF PATIENTS RECEIVING MAINTENANCE VENOM IMMUNOTHERAPY AT 3-MONTH INTERVALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BEE VENOM ALLERGY; LIVE CHALLENGE; MAINTENANCE INTERVAL; VENOM IMMUNOTHERAPY; YELLOW JACKET	NATURAL-HISTORY; INSECT STINGS; ALLERGY	Background: A large part of the cost and inconvenience associated with venom immunotherapy (VIT) is related to the need for monthly treatments. Since VIT is advocated for at least 3 to 5 years, and occasionally longer, reducing the number of venom injections may cut down significantly on both cost and inconvenience. Objective: We evaluated whether maintenance VIT given every 3 months is both safe and effective regarding reactions to treatment injections or field re-stings and lack of systemic reaction (SR) to deliberate challenge sting. Methods: The standard I-month interval was gradually extended to 3 months in 28 patients (mean age 26 years, range 7 to 76) allergic to bee venom (BV), yellow jacket venom, or both venoms. Nineteen patients allergic to BV were deliberately challenged by a live bee sting. In 15 patients the original SR in the field was moderate; in one patient it was mild; and in three patients it was severe. Results: Mean duration receiving standard maintenance VIT before extending the I-month interval was 17 months. No patient had an SR while receiving the 3-month VIT therapy. Two patients experienced four field re-stings while receiving the S-month therapy with no reaction. After the live challenge, there was mild urticaria ina single patient; no SR developed in the rest of the patients. Conclusion: For young patients allergic to BV whose initial SR is mild to moderate and who have already received I-month VIT for longer than 17 months the maintenance interval may safely be extended to 3 months while preserving its protective activity against re-stings.	TEL AVIV UNIV,SACKLER SCH MED,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	GOLDBERG, A (corresponding author), MEIR HOSP,ALLERGY & CLIN IMMUNOL UNIT,IL-44281 KEFAR SAVA,ISRAEL.							BOUSQUET J, 1987, ALLERGY, V42, P401, DOI 10.1111/j.1398-9995.1987.tb00355.x; GADDE J, 1985, ANN ALLERGY, V54, P348; GOLDBERG A, 1991, NEW ENGL J MED, V324, P1220; GOLDBERG A, 1988, ANN ALLERGY, V61, P177; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P482, DOI 10.1016/0091-6749(81)90102-0; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1991, J ALLERGY CLIN IMMUN, V87, P618, DOI 10.1016/0091-6749(91)90378-2; SAVLIWALA MN, 1987, J ALLERGY CLIN IMMUN, V80, P741, DOI 10.1016/0091-6749(87)90296-X; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; VALENTINE MD, 1993, ANN ALLERGY, V70, P427; YUNGINGER JW, 1993, ALLERGY PRINCIPLES P, V2, P1511	12	13	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1994	93	6					997	1001		10.1016/S0091-6749(94)70047-8	http://dx.doi.org/10.1016/S0091-6749(94)70047-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT172	8006322				2022-12-18	WOS:A1994NT17200007
J	BUSSE, W				BUSSE, W			DOSE-RELATED EFFICACY OF PULMICORT(R) (BUDESONIDE) TURBUHALER(R) IN MODERATE TO SEVERE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									PULMICORT TURBUHALER STUDY GRP,MADISON,WI										0	13	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	2				186	186						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MV317					2022-12-18	WOS:A1994MV31700143
J	DURHAM, SR; VARNEY, VA; SUN, Y; JACOBSON, MR; SUDDERICK, RM; MACKAY, IS; KAY, AB; HAMID, Q				DURHAM, SR; VARNEY, VA; SUN, Y; JACOBSON, MR; SUDDERICK, RM; MACKAY, IS; KAY, AB; HAMID, Q			EFFECT OF GRASS-POLLEN IMMUNOTHERAPY ON CELL INFILTRATION AND CYTOKINE MESSENGER-RNA EXPRESSION DURING ALLERGEN-INDUCED LATE NASAL RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									ROYAL BROMPTON NATL HEART & LUNG INST & HOSP,LONDON,ENGLAND	Royal Brompton Hospital								1993, J ALLERGY CLIN IMMUN, V91, P290	1	13	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	2				230	230						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MV317					2022-12-18	WOS:A1994MV31700405
J	SCHECKER, MH; WILSON, AF; MUKAI, DS; HAHN, M; CROOK, D; NOVEY, HS				SCHECKER, MH; WILSON, AF; MUKAI, DS; HAHN, M; CROOK, D; NOVEY, HS			A DEVICE FOR OVERCOMING DISCOORDINATION WITH METERED-DOSE INHALERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						METERED-DOSE INHALER; DISCOORDINATION; AUTOHALER; BREATH-ACTIVATED INHALER; SPACERS; PIRBUTEROL ACETATE	PRESSURIZED AEROSOL INHALERS; INHALATION TECHNIQUE; TUBE SPACER; BRONCHODILATOR; CHILDREN	Background: Despite widespread acceptance of metered-dose inhalers (MDIs) in the treatment of asthma, many patients fail to operate these devices correctly. Inability to properly coordinate activation with onset of inhalation is regarded as the major factor in suboptimal MDI therapy. Methods: We evaluated Autohaler Inhalation Device (3M Pharmaceuticals, St. Paul, Minn.), a breath-activated MDI that is typically activated at a triggering flow rate of approximately 0.5 L/sec. We compared bronchodilator effect of pirbuterol acetate (Maxair), inhaled from Autohaler and a standard MDI, under conditions that ensured optimal technique in 20 patients with asthma. Spirometric variables (forced expiratory volume in 1 second [FEV1], forced expiratory flow between 25% and 75% of vital capacity [FEF25-75], forced vital capacity [FVC]) were measured before and at 15, 30, 60, and 90 minutes after two inhalations of full inspiratory reserve volume for each device. Results: Both devices produced significant and similar bronchodilation. Mean FEV1 increased 32% above baseline 60 minutes after use of Autohaler and 31% after use of a standard MDI. Similar changes were noted in FEF25-75 and FVC for the two devices. Differences between devices for all spirometric variables were not statistically significant. Conclusion: Autohaler provides a promising alternative to the standard MDI by overcoming breath-hand discoordination.	UNIV CALIF IRVINE, DEPT MED, DIV BASIC & CLIN IMMUNOL, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, DEPT MED, DIV PULM & CRIT CARE MED, IRVINE, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine								[Anonymous], 1979, AM REV RESPIR DIS, V119, P831; BAUM EA, 1989, 3RD P AER SOC 3RD AN, P235; BAUM EA, 1988, J AEROSOL MED, V3, P219; BAUM EA, 1989, P MED PUBLISHING F S, V26, P20; BLOOMFIELD P, 1979, BRIT MED J, V2, P1479, DOI 10.1136/bmj.2.6203.1479; COADY TJ, 1976, CLIN ALLERGY, V6, P1, DOI 10.1111/j.1365-2222.1976.tb01406.x; CROMPTON G, 1989, PRACTITIONER, V233, P268; CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P101; DARCY PF, 1971, PHARM J, V206, P306; DOLOVICH M, 1981, CHEST, V80, P911; EPSTEIN SW, 1979, CAN MED ASSOC J, V120, P813; HIDINGER KG, 1981, EUR J CLIN PHARMACOL, V20, P109, DOI 10.1007/BF00607145; HOLGATE ST, 1977, THORAX, V32, P643; KELLING JS, 1983, CHEST, V83, P612, DOI 10.1378/chest.83.4.612; LARSSON S, 1977, AM REV RESPIR DIS, V116, P861; LINDGREN S, 1987, EUR J RESPIR DIS, V70, P93; LITTNER MR, 1982, ANN ALLERGY, V48, P14; MOLINA MJ, 1974, NATURE, V249, P810, DOI 10.1038/249810a0; MUNT PW, 1979, CAN MED ASSOC J, V120, P781; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; Newman S, 1983, PRACTICAL CARDIOL, V9, P157; NEWMAN SP, 1983, THORAX, V38, P233, DOI 10.1136/thx.38.12.881; NEWMAN SP, 1985, CHEST, V88, pS152, DOI 10.1378/chest.88.2.152S; NEWMAN SP, 1981, EUR J RESPIR DIS, V62, P3; NEWMAN SP, 1991, THORAX, V46, P712, DOI 10.1136/thx.46.10.712; OREHEK J, 1976, BRIT MED J, V1, P76, DOI 10.1136/bmj.1.6001.76; PEDERSEN S, 1983, NEW ENGL J MED, V308, P1328, DOI 10.1056/NEJM198306023082205; PEDERSEN S, 1986, ALLERGY, V41, P118, DOI 10.1111/j.1398-9995.1986.tb00287.x; SAUNDERS KB, 1965, BRIT MED J, V1, P1037, DOI 10.1136/bmj.1.5441.1037; SELF TH, 1982, IMMUNOL ALLERGY PRAC, V4, P40; SHIM C, 1976, BRIT MED J, V1, P76; WILSON AF, 1993, BRONCHIAL ASTHMA MEC	32	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1993	92	6					783	789		10.1016/0091-6749(93)90054-J	http://dx.doi.org/10.1016/0091-6749(93)90054-J			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML893	7794289	Bronze			2022-12-18	WOS:A1993ML89300002
J	DOOPER, MWSM; TIMMERMANS, A; AALBERS, R; DEMONCHY, JGR; KAUFFMAN, HF				DOOPER, MWSM; TIMMERMANS, A; AALBERS, R; DEMONCHY, JGR; KAUFFMAN, HF			DESENSITIZATION OF THE ADENYLYL-CYCLASE SYSTEM IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS FROM PATIENTS WITH ASTHMA 3 HOURS AFTER ALLERGEN CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; ADENYLYL CYCLASE; DESENSITIZATION; ALLERGEN CHALLENGE	PROTEIN-KINASE-C; BETA-ADRENERGIC RECEPTORS; CYCLIC-AMP; BRONCHIAL-ASTHMA; T-CELLS; RESPONSIVENESS; HISTAMINE; LYMPHOCYTES; ACTIVATION; MODULATION	Background: Bronchial hyperreactivity is a common characteristic of patients with asthma and is often associated with enhanced activities of peripheral blood cells. Signal transduction systems are important in regulating cellular activities and can be modified by allergen challenge. Methods: Patients with allergic asthma (n = 15) were challenged with house dust mite allergen, resulting in an asthmatic response. Adenylyl cyclase activity was measured in membranes from peripheral blood mononuclear cells before, 3 hours after, and 24 hours after challenge. Results: Allergen challenge proved to have opposite effects in two distinct subgroups of patients. In 10 patients (group I) a heterologous desensitization of the adenylyl cyclase system was observed after challenge, whereas in five patients (group II) an increase in adenylyl cyclase activity was found. Adenylyl cyclase activity before allergen challenge in group II was significantly lower than in group I and comparable to cyclase activity found in group I after allergen challenge. This suggests that in these five patients the adenylyl cyclase system was already desensitized before the start of the study, possibly as a result of natural allergen exposure. Heterologous desensitization in group I was found within 3 hours after allergen challenge, that is before the onset of the late bronchoconstrictive reaction. Conclusions: Because adenylyl cyclase is important in the regulation of cytokine production by mononuclear cells, alteration of cytokine production induced by desensitization of adenylyl cyclase could therefore play a role in the development of the late bronchoconstrictive reaction.	UNIV GRONINGEN HOSP, INTERNAL MED CLIN, DEPT ALLERGOL, OOSTERSINGEL 59, 9713 EZ GRONINGEN, NETHERLANDS	University of Groningen								AALBERS R, 1991, AM REV RESPIR DIS, V144, P352, DOI 10.1164/ajrccm/144.2.352; ALAM R, 1987, J ALLERGY CLIN IMMUN, V79, P103, DOI 10.1016/S0091-6749(87)80023-4; BACHELET M, 1991, J ALLERGY CLIN IMMUN, V88, P322, DOI 10.1016/0091-6749(91)90093-4; BECKNER SK, 1986, J BIOL CHEM, V261, P3043; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CARLSON M, 1991, J ALLERGY CLIN IMMUN, V87, P27, DOI 10.1016/0091-6749(91)90209-7; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V143, P538, DOI 10.1164/ajrccm/143.3.538; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DURHAM SR, 1988, J ALLERGY CLIN IMMUN, V82, P764, DOI 10.1016/0091-6749(88)90077-2; ENDRES S, 1991, IMMUNOLOGY, V72, P56; GADDY JN, 1986, AM REV RESPIR DIS, V134, P969, DOI 10.1164/arrd.1986.134.5.969; GAMBOA PM, 1990, ALLERGOL IMMUNOPATH, V18, P115; GUSOVSKY F, 1991, MOL PHARMACOL, V39, P124; IIZUKA K, 1991, ANN ALLERGY, V66, P167; KRAUSE DS, 1991, J IMMUNOL, V146, P2285; LEFKOWITZ RJ, 1983, ANNU REV BIOCHEM, V52, P159, DOI 10.1146/annurev.bi.52.070183.001111; MELTZER S, 1989, J ALLERGY CLIN IMMUN, V83, P960, DOI 10.1016/0091-6749(89)90112-7; MEURS H, 1980, CLIN CHIM ACTA, V106, P91, DOI 10.1016/0009-8981(80)90378-2; MEURS H, 1986, BIOCHEM PHARMACOL, V35, P4217, DOI 10.1016/0006-2952(86)90698-2; MEURS H, 1987, J ALLERGY CLIN IMMUN, V80, P326, DOI 10.1016/0091-6749(87)90039-X; MEURS H, 1985, INT ARCH ALLER A IMM, V76, P256, DOI 10.1159/000233701; MEURS H, 1982, J ALLERGY CLIN IMMUN, V70, P272, DOI 10.1016/0091-6749(82)90063-X; MEURS H, 1986, INT ARCH ALLER A IMM, V81, P224, DOI 10.1159/000234138; NEYENS HJ, 1980, CLIN ALLERGY, V10, P535; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; POSTMA DS, 1988, AM REV RESPIR DIS, V137, P57, DOI 10.1164/ajrccm/137.1.57; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SATO T, 1990, J ALLERGY CLIN IMMUN, V86, P839, DOI 10.1016/S0091-6749(05)80144-7; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; VANOOSTERHOUT AJM, 1992, J ALLERGY CLIN IMMUN, V90, P340, DOI 10.1016/S0091-6749(05)80013-2; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; YAGISAWA H, 1990, IMMUNOLOGY, V71, P242	36	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1993	92	4					559	566		10.1016/0091-6749(93)90080-Y	http://dx.doi.org/10.1016/0091-6749(93)90080-Y			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MC590	8409116	Bronze			2022-12-18	WOS:A1993MC59000008
J	PRAT, J; MULLOL, J; RAMIS, I; ROSELLOCATAFAU, J; XAUBET, A; NERIN, I; GELPI, E; PICADO, C				PRAT, J; MULLOL, J; RAMIS, I; ROSELLOCATAFAU, J; XAUBET, A; NERIN, I; GELPI, E; PICADO, C			RELEASE OF CHEMICAL MEDIATORS AND INFLAMMATORY CELL INFLUX DURING EARLY ALLERGIC REACTION IN THE NOSE - EFFECT OF FUROSEMIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FUROSEMIDE; DERMATOPHAGOIDES PTERONYSSINUS; NASAL MUCOSA; PERENNIAL RHINITIS; PGD2; PGE2; PEPTIDE LEUKOTRIENES; 15-HETE	INDUCED BRONCHOCONSTRICTION; INHALED FUROSEMIDE; NASAL SECRETIONS; ASTHMATIC SUBJECTS; ANTIGEN CHALLENGE; ARACHIDONIC-ACID; METABOLITES; FRUSEMIDE; AIRWAYS; LOOP	Background: We evaluated the effect of furosemide on allergen-induced rhinitis in a double-blind, crossover, placebo controlled experiment Methods: Fourteen patients with rhinitis who were allergic to house dust were nebulized with an intranasal dose of 20 mg of furosemide or placebo before allergen challenge with an extract of Dermatophagoides pteronyssinus (100 BU). Clinical evaluation and nasal lavages with normal saline solution were performed at baseline; after placebo-furosemide nebulization, and at 10, 30, and 60 minutes after allergen challenge. Number of sneezes and a composite symptom score were recorded to evaluate clinical response. Prostaglandin E2 (PGE2), PGD2, peptide leukotrienes and 15-hydroxy 5,8,11,13-eicosatetraenoic acid (15-HETE) were measured by radioimmunoassay in nasal lavages. Cells were counted and classified as epithelial cells, neutrophils, eosinopilds, and others. Results: No differences in either clinical symptoms or cell influx after allergen challenge were found between furosemide and placebo groups. PGE2 levels did not change after provocation, and furosemide had no effect on its production. Ten minutes after antigen challenge there was a marked increase of PGD2 (P < 0.01), peptide leukotrienes (p < 0.01), and 15-HETE (not significant) on both study days. However, no significant differences in the release of eicosanoids were found between furosemide and placebo groups. Conclusions: Our observations in the nasal mucosa suggest that furosemide has no effect on the release of proinflammatory and bronchoconstrictor metabolites (PGD2 peptide leukotrienes, and 15-HETE). In contrast to bronchial asthma, allergen-induced rhinitis was not effectively prevented by furosemide.	UNIV BARCELONA,FAC MED,HOSP CLIN,SERV PNEUMOL,VILLARROEL 170,E-08036 BARCELONA,SPAIN; CSIC,DEPT NEUROQUIM,BRANCA ECOSANOIDS,BARCELONA,SPAIN	University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC)			/AFX-9519-2022; /AAL-7347-2021	Rosello-Catafau, Joan/0000-0001-7127-4883				ANDERSON SD, 1991, NEW ENGL J MED, V324, P131; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BIANCO S, 1988, LANCET, V2, P252; BIANCO S, 1989, NEW ENGL J MED, V321, P1069, DOI 10.1056/NEJM198910193211602; BIANCO S, 1990, RESPIRATORY ALLERGY, P119; ELWOOD W, 1991, AM REV RESPIR DIS, V143, P1340, DOI 10.1164/ajrccm/143.6.1340; KNOX AJ, 1990, THORAX, V45, P856, DOI 10.1136/thx.45.11.856; MIYANOSHITA A, 1989, J PHARMACOL EXP THER, V251, P1155; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NICHOL GM, 1990, AM REV RESPIR DIS, V142, P576, DOI 10.1164/ajrccm/142.3.576; OCONNOR BJ, 1991, AM REV RESPIR DIS, V143, P1329, DOI 10.1164/ajrccm/143.6.1329; PAVORD ID, 1991, THORAX, V46, P663; POLOSA R, 1990, EUR RESPIR J, V3, P665; RAMIS I, 1989, J CHROMATOGR-BIOMED, V496, P416, DOI 10.1016/S0378-4347(00)82589-X; RAMIS I, 1990, J CHROMATOGR-BIOMED, V532, P217, DOI 10.1016/S0378-4347(00)83773-1; RAMIS I, 1991, PROSTAG OTH LIPID M, V42, P411, DOI 10.1016/0090-6980(91)90032-B; ROBUSCHI M, 1989, Pulmonary Pharmacology, V1, P187, DOI 10.1016/S0952-0600(89)80016-X; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112	20	13	13	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1993	92	2					248	254		10.1016/0091-6749(93)90168-F	http://dx.doi.org/10.1016/0091-6749(93)90168-F			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LT469	8349935	Bronze			2022-12-18	WOS:A1993LT46900005
J	BRUIJNZEEL, PLB; WARRINGA, RAJ; KOK, PTM; HAMELINK, ML; KREUKNIET, H; KOENDERMAN, L				BRUIJNZEEL, PLB; WARRINGA, RAJ; KOK, PTM; HAMELINK, ML; KREUKNIET, H; KOENDERMAN, L			EFFECTS OF NEDOCROMIL SODIUM ON IN-VITRO INDUCED MIGRATION, ACTIVATION, AND MEDIATOR RELEASE FROM HUMAN GRANULOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EOSINOPHIL CHEMOTAXIS; LEUKOTRIENE FORMATION; ASTHMATIC REACTIONS; HUMAN-NEUTROPHILS; INDIVIDUALS; CROMOGLYCATE; INHIBITION	Using the allergen-induced late-phase asthmatic reaction as a working model, we studied the activity of certain inflammatory cells and their reaction to nedocromil sodium. The processes that were examined in vitro included the following: the chemotaxis of purified neutrophils and eosinophils, the early steps of neutrophil and eosinophil activation, and the release of mediators from these cells. Nedocromil sodium strongly inhibited neutrophil mobilization caused by four chemotactic factors (zymosan activated serum, N-formyl-methionyl-leucyl-phenylalanine platelet-activating factor [PAF], and leukotriene B4 [LTB4] and eosinophil mobilization caused by two factors (PAF and LTB4). In vitro treatment of eosinophils from normal subjects with picomolar concentrations of interleukin-3, interleukin-5, or granulocyte-macrophage colony stimulating factor increased the chemotactic responsiveness toward PAF and LTB4 and induced a chemotactic responsiveness toward N-formyl-methionyl-leucyl-phenylalanine and neutrophil activating factor/interleukin-8. The zymosan activated serum-induced chemotactic responsiveness remained unaltered. Nedocromil sodium inhibited the cytokine-primed chemotactic responsiveness to the various chemotaxins, not the influence of the cytokines on the cells. Activation of granulocytes, as measured by Ca2+ influx, was not inhibited by nedocromil sodium. Mediator formation in eosinophils was modified only slightly. These results suggest that inhibiting the mobilization of inflammatory cells in the lung tissue may be an important action of nedocromil sodium. Therefore these effects may be relevant to the treatment of asthma given the role of airway inflammation in this disease process.	UNIV UTRECHT,DEPT PULM DIS,UTRECHT,NETHERLANDS	Utrecht University			Koenderman, Leo/AAE-7870-2020	Koenderman, Leo/0000-0002-5636-6453				BRUIJNZEEL PBL, UNPUB; BRUIJNZEEL PLB, 1990, BRIT J PHARMACOL, V99, P798, DOI 10.1111/j.1476-5381.1990.tb13009.x; BRUIJNZEEL PLB, 1989, BRIT J PHARMACOL, V96, P631, DOI 10.1111/j.1476-5381.1989.tb11862.x; BRUIJNZEEL PLB, 1989, BRIT J PHARMACOL, V97, P1251, DOI 10.1111/j.1476-5381.1989.tb12586.x; BRUIJNZEEL PLB, 1989, CLIN EXP ALLERGY S1, V19, P25; BRUIJNZEEL PLB, 1985, FEBS LETT, V189, P350; BRUIJNZEEL PLB, 1987, PROSTAGLANDINS, V34, P305; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1987, J ALLERGY CLIN IMMUN, V79, P256; KOENDERMAN L, 1989, IMMUNOLOGY, V67, P534; KOENDERMAN L, 1988, J LEUKOCYTE BIOL, V44, P79, DOI 10.1002/jlb.44.2.79; KOK PTM, 1988, BIOCHEM BIOPH RES CO, V153, P676, DOI 10.1016/S0006-291X(88)81148-3; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; ROTH M, 1989, EUR RESPIR J S8, V2, P738; VERHAGEN J, 1984, FEBS LETT, V168, P23, DOI 10.1016/0014-5793(84)80199-4; WARRINGA RAJ, 1991, BLOOD, V77, P2694; WARRINGA RAJ, 1992, BLOOD, V79, P1836; WARRINGA RAJ, 1993, IN PRESS J ALLERGY C	18	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	2				159	164		10.1016/0091-6749(93)90099-2	http://dx.doi.org/10.1016/0091-6749(93)90099-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ354	8393021				2022-12-18	WOS:A1993LQ35400005
J	LANZA, DC; KENNEDY, DW				LANZA, DC; KENNEDY, DW			CURRENT CONCEPTS IN THE SURGICAL-MANAGEMENT OF NASAL POLYPOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		NASAL; POLYPOSIS; ENDOSCOPY; SURGERY; SINUSITIS	ASTHMA	One of the most common and occasionally frustrating health care problems is that of nasal polyposis. Patient symptoms are debilitating and have a tendency to recur despite the treatment modality used. Nasal endoscopy is a significant advancement for the early diagnosis and objective assessment of treatment modalities used for nasal polyposis. Surgery used in conjunction with medical therapies offers a safe, thorough means of relieving patient symptoms. It is possible to monitor these patients closely for recurrence with nasal endoscopy as well as debride early recurrences before they become symptomatic.			LANZA, DC (corresponding author), HOSP UNIV PENN,DEPT OTORHINOLARYNGOL HEAD & NECK SURG,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.							ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; BROOK I, 1981, LARYNGOSCOPE, V91, P372; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; FRIEDMAN WH, 1981, OTOLARYNGOL HEAD HEC, V90, P171; MARAN AGD, 1990, CLIN RHINOLOGY, P95; SLAVIN RG, 1988, ALLERGY PRINCIPLES P, P1291; SUONPAA J, 1990, SCAND J INFECT DIS, V22, P563, DOI 10.3109/00365549009027097; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P	8	13	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			543	546		10.1016/0091-6749(92)90182-2	http://dx.doi.org/10.1016/0091-6749(92)90182-2			4	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527347				2022-12-18	WOS:A1992JP52100023
J	FREW, AJ; OHEHIR, RE				FREW, AJ; OHEHIR, RE			WHAT CAN WE LEARN FROM STUDIES OF LYMPHOCYTES PRESENT IN ALLERGIC-REACTION SITES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							HOUSE DUST MITE; T-CELL SUBSETS; LATE-PHASE; IFN-GAMMA; DISTINCT SUBPOPULATIONS; ADHESION MOLECULES; IMMUNE REGULATION; CD4+ LYMPHOCYTES; LANGERHANS CELLS; SKIN REACTION		ST MARYS HOSP,DEPT IMMUNOL,LONDON W2 1PG,ENGLAND	Imperial College London	FREW, AJ (corresponding author), CITY GEN HOSP,DEPT RESP MED,STOKE ON TRENT ST5 3NT,STAFFS,ENGLAND.		Kelly, Frank J/C-6125-2009; O'Hehir, Robyn E/H-3627-2011	Kelly, Frank J/0000-0003-2558-8392; O'Hehir, Robyn E/0000-0002-3489-7595				AKBAR AN, 1988, J IMMUNOL, V140, P2171; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BENTLEY A M, 1991, Journal of Allergy and Clinical Immunology, V87, P246, DOI 10.1016/0091-6749(91)91710-B; BYRNE JA, 1988, J IMMUNOL, V141, P3249; CHANG TL, 1990, J IMMUNOL, V145, P2803; CLEMENT LT, 1990, J IMMUNOL, V145, P102; CLEMENT LT, 1988, J IMMUNOL, V141, P1464; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; FERGUSON J, 1985, CONTACT DERMATITIS, V13, P166, DOI 10.1111/j.1600-0536.1985.tb02530.x; FIRESTEIN GS, 1989, J IMMUNOL, V143, P518; FREW AJ, 1990, AM REV RESPIR DIS, V141, P407, DOI 10.1164/ajrccm/141.2.407; FREW AJ, 1990, J ALLERGY CLIN IMMUN, V85, P533, DOI 10.1016/0091-6749(90)90090-Q; FREW AJ, 1988, J IMMUNOL, V141, P4158; FREW AJ, 1991, CLIN EXP IMMUNOL, V84, P270; GAJEWSKI TF, 1989, J IMMUNOL, V143, P15; GOCINSKI BL, 1990, J IMMUNOL, V144, P4121; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; INABA K, 1986, J EXP MED, V164, P605, DOI 10.1084/jem.164.2.605; KAPSENBERG ML, 1988, EUR J IMMUNOL, V18, P977, DOI 10.1002/eji.1830180702; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; KAPSENBERG ML, 1987, J INVEST DERMATOL, V87, P148; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; LANB JR, 1982, J IMMUNOL, V128, P233; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MAGGI E, 1991, J IMMUNOL, V146, P1169; MARKEY AC, 1990, BRIT J DERMATOL, V122, P325, DOI 10.1111/j.1365-2133.1990.tb08280.x; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X; OHEHIR RE, 1989, IMMUNOLOGY, V66, P499; OHEHIR RE, 1991, INT IMMUNOL, V3, P819, DOI 10.1093/intimm/3.8.819; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; OHEHIR RE, 1987, IMMUNOLOGY, V62, P635; OHEHIR RE, 1991, CLIN EXP ALLERGY, V21, P209, DOI 10.1111/j.1365-2222.1991.tb00832.x; OPPENHEIMERMARKS N, 1990, J IMMUNOL, V145, P140; OPPENHEIMERMARKS N, 1991, J IMMUNOL, V147, P2913; PALIARD X, 1988, J IMMUNOL, V141, P849; PICKER LJ, 1990, J IMMUNOL, V145, P3247; PITZALIS C, 1988, EUR J IMMUNOL, V18, P1397, DOI 10.1002/eji.1830180915; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P67, DOI 10.1016/0091-6749(79)90085-X; ROTHSTEIN DM, 1991, J IMMUNOL, V146, P1175; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SANDERSON CJ, 1988, IMMUNOL REV, V102, P29, DOI 10.1111/j.1600-065X.1988.tb00740.x; SCHALL TJ, 1991, IN PRESS J IMMUNOL; SHINOHARA N, 1991, EUR J IMMUNOL, V21, P23, DOI 10.1002/eji.1830210105; SILVENNOINENKAS.I, 1992, J INVEST DERMATOL, V89, P794; SINAGAGLIA F, 1985, J IMMUNOL, V135, P3929; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOULILLOU JP, 1987, IMMUNOL TODAY, V8, P285, DOI 10.1016/0167-5699(87)90012-0; STREET NE, 1990, J IMMUNOL, V144, P1629; SUNDAY ME, 1981, J IMMUNOL, V127, P766; WEYAND CM, 1987, J IMMUNOL, V138, P1351; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	55	13	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1992	89	4					783	788		10.1016/0091-6749(92)90431-Z	http://dx.doi.org/10.1016/0091-6749(92)90431-Z			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN860	1348514				2022-12-18	WOS:A1992HN86000001
J	FRANK, MM				FRANK, MM			DETECTION OF COMPLEMENT IN RELATION TO DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FRANK, MM (corresponding author), DUKE UNIV,MED CTR,DEPT PEDIAT,BOX 3352,DURHAM,NC 27710, USA.							FRANK MM, 1987, NEW ENGL J MED, V316, P1525, DOI 10.1056/NEJM198706113162407; FRANK MM, 1989, COMPLEMENT FUNDAMENT, P679; FRIES LF, 1987, MOL MECHANISMS COMPL	3	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1992	89	3					641	648		10.1016/0091-6749(92)90367-B	http://dx.doi.org/10.1016/0091-6749(92)90367-B			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HJ340	1545085				2022-12-18	WOS:A1992HJ34000001
J	MATHEW, SN; MELTON, A; WAGNER, W; BATTISTO, JR				MATHEW, SN; MELTON, A; WAGNER, W; BATTISTO, JR			LATEX HYPERSENSITIVITY - PREVALENCE AMONG CHILDREN WITH SPINA-BIFIDA AND IMMUNOBLOTTING IDENTIFICATION OF LATEX PROTEINS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	2				225	225						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HB760					2022-12-18	WOS:A1992HB76000273
J	YOUKELES, LH; SOLIMAN, MY; ROSENSTREICH, DL				YOUKELES, LH; SOLIMAN, MY; ROSENSTREICH, DL			USE OF STREPTOKINASE AS A RECALL ANTIGEN FOR LYMPHOCYTE-PROLIFERATION TESTING INVITRO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						STREPTOKINASE; LYMPHOCYTE PROLIFERATION; CELL-MEDIATED IMMUNITY; TETANUS TOXOID; ANTIGENS; MITOGENS; CORD BLOOD; LYMPHOCYTES	DELAYED-HYPERSENSITIVITY; STREPTODORNASE	The use of streptokinase (SK) as a recall antigen (Ag) for stimulation of human lymphocyte proliferation in vitro was evaluated. SK is a potent stimulant, inducing a greater response than three other Ags, tetanus toxoid, Candida albicans extract, or streptolysin. The optimum stimulatory concentration is 1000 U/ml, and peak stimulation occurs between days 6 and 8. Human cord-blood lymphocytes do not respond to SK, suggesting that it is an Ag and not a mitogen. The response rate in an adult population was 82%, higher than the rate of two other Ags tested (tetanus toxoid or Candida). These findings demonstrate the ability of SK to act as a potent recall Ag for human lymphocyte proliferation in vitro.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,1300 MORRIS PK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NCI NIH HHS [P30-CA-13330] Funding Source: Medline; NIAID NIH HHS [AI-29871-01] Funding Source: Medline; NIGMS NIH HHS [T32 GM-7288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COWLEY MJ, 1982, AM HEART J, V102, P1149; FRANCIS TC, 1970, CLIN EXP IMMUNOL, V6, P573; HAVERLY RW, 1984, J ALLERGY CLIN IMMUN, V74, P205, DOI 10.1016/0091-6749(84)90288-4; KNIKER WT, 1979, ANN ALLERGY, V43, P73; MASON DT, 1981, AM HEART J, V102, P1126, DOI 10.1016/0002-8703(81)90642-6; MCGRATH KG, 1985, J ALLERGY CLIN IMMUN, V76, P453, DOI 10.1016/0091-6749(85)90726-2; OPPENHEIM JJ, 1970, J IMMUNOL, V104, P835; PABST HF, 1989, AM REV RESPIR DIS, V140, P1007, DOI 10.1164/ajrccm/140.4.1007; PONTE CD, 1982, SOUTHERN MED J, V75, P1076, DOI 10.1097/00007611-198209000-00012; TOMAR RH, 1972, J IMMUNOL, V108, P231; TOMAR RH, 1976, INT ARCH ALLER A IMM, V50, P220, DOI 10.1159/000231499; TOMAR RH, 1976, FED PROC, V35, P511; TOTTY WG, 1982, AM J ROENTGENOL, V138, P143, DOI 10.2214/ajr.138.1.143; WEATHERBEE TC, 1984, CURR THER RES CLIN E, V35, P433; WEINSTEIN J, 1983, CIRCULATION, V68, P161; 1981, CLIN EXP IMMUNOL, V46, P662	16	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1991	88	2					166	171		10.1016/0091-6749(91)90324-H	http://dx.doi.org/10.1016/0091-6749(91)90324-H			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB225	1880316				2022-12-18	WOS:A1991GB22500003
J	WHITE, MV; PHILLIPS, RL; KALINER, MA				WHITE, MV; PHILLIPS, RL; KALINER, MA			NEUTROPHILS AND MAST-CELLS - NEDOCROMIL SODIUM INHIBITS THE GENERATION OF NEUTROPHIL-DERIVED HISTAMINE-RELEASING ACTIVITY (HRA-N)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							COLONY-STIMULATING FACTOR; EXERCISE-INDUCED ASTHMA; MONONUCLEAR-CELLS; BASOPHIL; SECRETION; CROMOGLYCATE; ACTIVATION; PLACEBO; TILADE; IL-3	The effect of nedocromil sodium on the generation of neutrophil-derived histamine-releasing activity (HRA-N) from human peripheral blood neutrophils and on the secretory effects of HRA-N and anti-IgE on rat basophil leukemia (RBL) cells was studied. Nedocromil sodium caused dose-related inhibition of HRA-N generation by human neutrophils (10(-7) to 10(-4) mol/L; inhibitory concentration of 50%, 1.5 x 10(-8) mol/L). In contrast, the presence of nedocromil sodium had no effect on HRA-N-mediated serotonin release from RBL cells. In five experiments, with one crude and four partially purified HRA-N preparations, serotonin release from RBL cells exposed to native HRA-N or HRA-N in the presence of nedocromil sodium (10(-4) mol/L) was 28% +/- 6% and 26% +/- 5%, respectively. Similar results were found with all concentrations of nedocromil sodium studied. Preincubation of RBL cells with nedocromil sodium (10(-4) mol/L) for 0 to 60 minutes also did not affect HRA-N-mediated serotonin release. Likewise, nedocromil sodium (10(-7) to 10(-4) mol/L) had no effect on anti-IgE-induced serotonin release from RBL cells. In 10 experiments, anti-IgE alone or in the presence of nedocromil sodium (10(-4) mol/L) induced 32% +/- 6% and 32% +/- 5% serotonin release, respectively. Preincubation of RBL cells with nedocromil sodium before anti-IgE exposure had no further effect. This is the first study of pharmacologic manipulation of the generation of a histamine-releasing factor. It is hypothesized that one possible mechanism whereby nedocromil sodium protects against asthma and allergic rhinitis is through inhibition of HRA-N generation.			WHITE, MV (corresponding author), NIAID, BLDG 10, ROOM 11C207, BETHESDA, MD 20892 USA.							ALAM R, 1989, J IMMUNOL, V142, P3431; ALAM R, 1987, J ALLERGY CLIN IMMUN, V79, P103, DOI 10.1016/S0091-6749(87)80023-4; BAEZA ML, 1990, J CLIN INVEST, V85, P1516, DOI 10.1172/JCI114598; DAHL R, 1985, 4TH P C EUR SOC PNEU, P65; FYANS PG, 1986, CLIN ALLERGY, V16, P505, DOI 10.1111/j.1365-2222.1986.tb01988.x; GONZALEZ JP, 1987, DRUGS, V34, P560, DOI 10.2165/00003495-198734050-00004; HAAKFRENDSCHO M, 1988, J CLIN INVEST, V82, P17, DOI 10.1172/JCI113567; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; LEBEL B, 1988, CLIN ALLERGY, V18, P605, DOI 10.1111/j.1365-2222.1988.tb02912.x; LEUNG KBP, 1988, THORAX, V43, P756, DOI 10.1136/thx.43.10.756; LIU MC, 1986, J IMMUNOL, V136, P2588; MACDONALD SM, 1989, J IMMUNOL, V142, P3527; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MOQBEL R, 1988, ALLERGY, V43, P268, DOI 10.1111/j.1398-9995.1988.tb00899.x; ORCHARD MA, 1986, J IMMUNOL, V136, P2240; PEARCE FL, 1989, DRUGS, V37, P37, DOI 10.2165/00003495-198900371-00009; ROBERTS JA, 1985, CLIN ALLERGY, V15, P377, DOI 10.1111/j.1365-2222.1985.tb03006.x; RUHNO J, 1988, J ALLERGY CLIN IMMUN, V81, P557, DOI 10.1016/0091-6749(88)90196-0; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SHAW RJ, 1985, BRIT J DIS CHEST, V79, P385, DOI 10.1016/0007-0971(85)90073-7; THEOHARIDES TC, 1982, NATURE, V297, P229, DOI 10.1038/297229a0; THUESON DO, 1979, J IMMUNOL, V123, P626; WELLS E, 1986, J IMMUNOL, V137, P3941; WHITE MV, 1989, IMMUNOL LETT, V22, P151, DOI 10.1016/0165-2478(89)90182-X; WHITE MV, 1987, J IMMUNOL, V139, P1624; WHITE MV, 1988, J IMMUNOL, V141, P3575; WHITE MV, 1989, J ALLERGY CLIN IMMUN, V84, P773, DOI 10.1016/0091-6749(89)90308-4; YOUNGCHAIYUD P, 1986, CLIN ALLERGY, V16, P129, DOI 10.1111/j.1365-2222.1986.tb00756.x; ZHEUTLIN LM, 1984, J IMMUNOL, V133, P2180	29	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					812	820		10.1016/0091-6749(91)90127-A	http://dx.doi.org/10.1016/0091-6749(91)90127-A			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	1707428				2022-12-18	WOS:A1991FG05900010
J	SPERBER, K; GOSWAMI, SK; GOLLUB, E; MAYER, L; MAROM, Z				SPERBER, K; GOSWAMI, SK; GOLLUB, E; MAYER, L; MAROM, Z			MUCUS SECRETAGOGUE PRODUCTION BY A HUMAN MACROPHAGE HYBRIDOMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HUMAN AIRWAYS INVITRO; MONOHYDROXYEICOSATETRAENOIC ACID; SECRETION; RELEASE	A pulmonary macrophage-monocyte-derived mucus secretagogue (MMS) oligopeptide has been previously reported to induce mucus secretion in an in vitro model system with human airway explants and secretory epithelial cells. To understand the possible role of macrophages in the regulation of secretion of mucus, our laboratory has used a series of human macrophage hybridomas that were generated by fusing an hypoxanthine guanine phosphoribosyl transferase-deficient promonocytic line, U937, with macrophages obtaining by maturing monocytes in Teflon bags. The cell lines were proven to be true hybridomas by acquisition of donor class I antigens, additional chromosomes, as well as macrophage specific (maximum velocity) not present on the U937 parent line. One clone, clone 63, produced large amounts of an oligopeptide with an approximate molecular weight of 2000, which was identified from culture supernatants by ultrafiltration, chromatography, isoelectric focusing, and Western blot. Processed clone 63 supernatant had biologic activity causing increased secretion of radiolabeled glycoconjugate in both cultured airways and secretory epithelial cells. Immunoblot analysis with a polyclonal rabbit antisera generated against MMS was positive, and Western blot analysis produced a band at approximately 2000 daltons, consistent with the previously described MMS. MMS secretion could be stimulated by zymosan and lipopolysaccharide and inhibited by both cycloheximide and erythromycin. Dexamethasone had a different effect, appearing to stimulate MMS production intracellularly but inhibiting its release once it was synthesized. The availability of cloned hybridomas allows for study of the regulation of mucus secretagogue production as well as purification of molecular species and provides a valuable tool for the study of mucus secretion.	MT SINAI MED CTR,DIV PULM & CRIT CARE MED,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai	SPERBER, K (corresponding author), MT SINAI MED CTR,DIV CLIN IMMUNOL,1 GUSTAVE LEVY PL,BOX 1089,NEW YORK,NY 10029, USA.				NATIONAL CANCER INSTITUTE [R01CA041583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024671, R01AI023504] Funding Source: NIH RePORTER; NCI NIH HHS [CA41583] Funding Source: Medline; NIAID NIH HHS [AI24671, AI23504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BURSTON BC, 1955, HISTOPATHOLOGIC TECH, P342; CHAPMAN RS, 1985, AM REV RESPIR DIS, V132, P261; DAVIS B, 1982, J APPL PHYSIOL, V53, P985, DOI 10.1152/jappl.1982.53.4.985; GOSWAMI S K, 1987, American Review of Respiratory Disease, V135, pA159; GOSWAMI SK, 1990, AM REV RESPIR DIS, V141, P72, DOI 10.1164/ajrccm/141.1.72; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HJELM H, 1972, FEBS LETT, V28, P73, DOI 10.1016/0014-5793(72)80680-X; KALINER M, 1984, J ALLERGY CLIN IMMUN, V73, P318, DOI 10.1016/0091-6749(84)90403-2; KEAL EE, 1975, NEW DIRECTIONS ASTHM, P223; LOGUN C, 1988, AM REV RESPIR DIS, V137, pA14; LUNDGREN JD, 1990, J ALLERGY CLIN IMMUN, V85, P399, DOI 10.1016/0091-6749(90)90147-V; LUNDGREN JD, 1988, AM REV RESPIR DIS, V137, pA11; LUNGREN JD, 1988, AM REV RESPIR DIS, V137, P353; MAROM Z, 1983, J CLIN INVEST, V72, P122, DOI 10.1172/JCI110949; MAROM Z, 1984, J EXP MED, V159, P844, DOI 10.1084/jem.159.3.844; MAROM Z, 1981, J CLIN INVEST, V67, P1695, DOI 10.1172/JCI110207; MAROM Z, 1984, AM REV RESPIR DIS, V129, P62; MAROM Z, 1985, J CLIN INVEST, V75, P191, DOI 10.1172/JCI111674; MAROM Z, 1986, AM REV RESPIR DIS, V133, pA211; MAROM Z, 1989, ANN ALLERGY, V300, pA53; MAROM Z, 1988, AM REV RESPIR DIS, V137, pA6; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MURLAS CG, 1985, AM REV RESPIR DIS, V131, P314; NILAS RM, 1986, J LAB CLIN MED, V108, P489; NISHIDA M, 1985, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V37, P1103; PEATFIELD AC, 1983, J PHYSIOL-LONDON, V342, P335, DOI 10.1113/jphysiol.1983.sp014854; RODGERS DF, 1988, AM REV RESPIR DIS, V137, pA12; SPERBER K, 1990, J IMMUNOL METHODS, V129, P31, DOI 10.1016/0022-1759(90)90417-T; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4	29	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					490	498		10.1016/0091-6749(91)90007-B	http://dx.doi.org/10.1016/0091-6749(91)90007-B			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1993809				2022-12-18	WOS:A1991EX98700006
J	PETERS, SP				PETERS, SP			MAST-CELLS AND HISTAMINE IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	MEETING ON HISTAMINE AND DISEASE : A FORUM ON CURRENT AND FUTURE MANAGEMENT	AUG 25-26, 1989	CARLSBAD, CA	MERRELL DOW PHARM					THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV PULM MED & CRIT CARE,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024509] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24509] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BARNES PJ, 1986, LANCET, V1, P242; BEWTRA AK, 1989, ANN ALLERGY, V62, P299; FINNERTY JP, 1989, AM REV RESPIR DIS, V140, P593, DOI 10.1164/ajrccm/140.3.593; HOLGATE ST, 1987, CLIN SCI, V73, P561, DOI 10.1042/cs0730561; HOLGATE ST, 1988, ALLERGY PRINCIPLES P, P135; JOSEPHS LK, 1989, AM REV RESPIR DIS, V140, P350, DOI 10.1164/ajrccm/140.2.350; KALINER M, 1984, J ALLERGY CLIN IMMUN, V73, P318, DOI 10.1016/0091-6749(84)90403-2; KAY AB, 1987, IMMUNOL ALLERGY PRAC, V9, P84; NACLERIO RM, 1988, ALLERGY PRINCIPLES P, P437; PETERS SP, 1989, HIGHLIGHTS ASTHMOLOG, P167; PETERS SP, 1990, IN PRESS LUNG BIOL H; PETERS SP, 1989, LUNG BIOL HLTH DISEA, V41, P345; PHILLIPS GD, 1989, AM REV RESPIR DIS, V139, P463, DOI 10.1164/ajrccm/139.2.463; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113; WOOLCOCK AJ, 1988, CLIN ALLERGY, V18, P165, DOI 10.1111/j.1365-2222.1988.tb02856.x; WOOLCOCK AJ, 1988, TXB RESPIRATORY MED, P1030	21	13	13	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	2	S			642	646		10.1016/S0091-6749(05)80230-1	http://dx.doi.org/10.1016/S0091-6749(05)80230-1			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH093	2229827				2022-12-18	WOS:A1990EH09300011
J	CZARNETZKI, BM				CZARNETZKI, BM			KETOTIFEN IN CHOLINERGIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter											CZARNETZKI, BM (corresponding author), FREE UNIV BERLIN,KLINIKUM RUDOLPH VIRCHOW,HAUTKLIN,AUGUSTENBURGERPL 1,W-1000 BERLIN 65,GERMANY.							CAP JP, 1985, HAUTARZT, V36, P509; MCCLEAN SP, 1989, J ALLERGY CLIN IMMUN, V83, P738, DOI 10.1016/0091-6749(89)90008-0	2	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					138	139		10.1016/S0091-6749(05)80136-8	http://dx.doi.org/10.1016/S0091-6749(05)80136-8			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	2370385	Bronze			2022-12-18	WOS:A1990DQ68800022
J	GRONNEBERG, R; DAHLEN, SE				GRONNEBERG, R; DAHLEN, SE			INTERACTIONS BETWEEN HISTAMINE AND PROSTANOIDS IN IGE-DEPENDENT, LATE CUTANEOUS REACTIONS IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									KAROLINSKA INST,DEPT PHYSIOL,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,INST ENVIRONM MED,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska Institutet	GRONNEBERG, R (corresponding author), HUDDINGE UNIV HOSP,DEPT LUNG MED,S-14186 HUDDINGE,SWEDEN.							AAS K, 1979, ALLERGY, V34, P121, DOI 10.1111/j.1398-9995.1979.tb01372.x; ABRAMSON S, 1985, P NATL ACAD SCI USA, V82, P7227, DOI 10.1073/pnas.82.21.7227; BACH MK, 1982, ANNU REV MICROBIOL, V36, P371, DOI 10.1146/annurev.mi.36.100182.002103; CARPENTER GB, 1980, J ALLERGY CLIN IMMUN, V65, P187; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CURZEN N, 1987, THORAX, V42, P946, DOI 10.1136/thx.42.12.946; DAHLEN SE, 1986, DERMATOLOGY GENERAL, P450; DOLOVICH J, 1972, J ALLERGY CLIN IMMUN, V49, P43, DOI 10.1016/0091-6749(72)90122-4; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DORSCH W, 1982, J ALLERGY CLIN IMMUN, V70, P236, DOI 10.1016/0091-6749(82)90059-8; DORSCH W, 1980, ALLERGY, V35, P503, DOI 10.1111/j.1398-9995.1980.tb01797.x; FOREMAN JC, 1981, ANNU REV PHARMACOL, V21, P63, DOI 10.1146/annurev.pa.21.040181.000431; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GRANSTROM E, 1976, ADV PROSTAG THROMB R, V1, P81; GRONNEBERG R, 1981, ALLERGY, V36, P201, DOI 10.1111/j.1398-9995.1981.tb01835.x; GRONNEBERG R, 1985, ALLERGY, V40, P36, DOI 10.1111/j.1398-9995.1985.tb04152.x; HANDLER AH, 1968, GOLDEN HAMSTER, P195; HAY DWP, 1987, J PHARMACOL EXP THER, V243, P474; HEDQVIST P, 1977, ANNU REV PHARMACOL, V17, P259, DOI 10.1146/annurev.pa.17.040177.001355; JONES TR, 1988, CAN J PHYSIOL PHARM, V66, P762, DOI 10.1139/y88-121; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; LICHTENSTEIN LM, 1971, BIOCH ACUTE ALLERGIC, P161; PIENKOWSKI MM, 1988, J ALLERGY CLIN IMMUN, V82, P95, DOI 10.1016/0091-6749(88)90057-7; RAUD J, 1988, P NATL ACAD SCI USA, V85, P2315, DOI 10.1073/pnas.85.7.2315; RAUD J, 1989, ACTA PHYSIOL SCAND, V135, P1; SHAIKH W, 1977, J ALLERGY CLIN IMMUN, V60, P242, DOI 10.1016/0091-6749(77)90138-5; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TALBOT SF, 1984, J ALLERGY CLIN IMMUN, V74, P819, DOI 10.1016/0091-6749(84)90185-4; TURNBULL LW, 1976, IMMUNOLOGY, V31, P797; VENGE P, 1987, INT ARCH ALLER A IMM, V82, P333, DOI 10.1159/000234219; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0; WEISS ME, 1989, J ALLERGY CLIN IMMUN, V83, P1040, DOI 10.1016/0091-6749(89)90445-4; WEST GB, 1957, INT ARCH ALLER A IMM, V10, P257, DOI 10.1159/000228384; WILLIAMS TJ, 1983, BRIT MED BULL, V39, P239, DOI 10.1093/oxfordjournals.bmb.a071826; ZETTERSTROM O, 1978, CLIN ALLERGY, V8, P77, DOI 10.1111/j.1365-2222.1978.tb00452.x; ZWEIMAN B, 1988, CLIN ALLERGY, V18, P419, DOI 10.1111/j.1365-2222.1988.tb02892.x	38	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					843	852		10.1016/0091-6749(90)90066-D	http://dx.doi.org/10.1016/0091-6749(90)90066-D			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	2110197				2022-12-18	WOS:A1990DD95900004
J	SCHNEIDER, LC; INSEL, RA; HOWIE, G; MADORE, DV; GEHA, RS				SCHNEIDER, LC; INSEL, RA; HOWIE, G; MADORE, DV; GEHA, RS			RESPONSE TO A HAEMOPHILUS-INFLUENZAE TYPE-B DIPHTHERIA CRM197 CONJUGATE VACCINE IN CHILDREN WITH A DEFECT OF ANTIBODY-PRODUCTION TO HAEMOPHILUS-INFLUENZAE TYPE-B POLYSACCHARIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									PRAXIS BIOL, ROCHESTER, NY USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT PEDIAT & MICROBIOL, ROCHESTER, NY 14642 USA	Harvard University; Harvard Medical School; University of Rochester	SCHNEIDER, LC (corresponding author), CHILDRENS HOSP MED CTR, DIV IMMUNOL, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.				NIAID NIH HHS [AI17217] Funding Source: Medline; NICHD NIH HHS [HD-07321] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017217] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBROSINO D, 1987, NEW ENGL J MED, V13, P790; AMBROSINO DM, 1988, J ALLERGY CLIN IMMUN, V81, P1175, DOI 10.1016/0091-6749(88)90887-1; ANDERSON P, 1985, J PEDIATR-US, V107, P346, DOI 10.1016/S0022-3476(85)80504-7; ANDERSON P, 1987, J PEDIATR-US, V111, P644, DOI 10.1016/S0022-3476(87)80237-8; ANDERSON P, 1978, J IMMUNOL, V120, P866; ANDERSON PW, 1986, J IMMUNOL, V137, P1181; CLAESSON BA, 1989, J PEDIATR-US, V114, P97, DOI 10.1016/S0022-3476(89)80611-0; ESKOLA J, 1985, LANCET, V1, P1184; ESKOLA J, 1987, NEW ENGL J MED, V317, P717, DOI 10.1056/NEJM198709173171201; GIGLIOTTI F, 1988, PEDIATR INFECT DIS J, V7, P417, DOI 10.1097/00006454-198806000-00010; GIGLIOTTI F, 1989, J PEDIATR-US, V114, P1006, DOI 10.1016/S0022-3476(89)80451-2; GRANOFF DM, 1989, J PEDIATR-US, V114, P925, DOI 10.1016/S0022-3476(89)80432-9; GRANOFF DM, 1986, NEW ENGL J MED, V315, P1584, DOI 10.1056/NEJM198612183152505; GRANOFF DM, 1988, PEDIATR RES, V24, P180, DOI 10.1203/00006450-198808000-00008; INSEL RA, 1986, NEW ENGL J MED, V315, P499, DOI 10.1056/NEJM198608213150807; INSEL RA, 1988, MONOGR ALLERGY, V23, P128; KNUTSEN AP, 1989, J ALLERGY CLIN IMMUN, V84, P640, DOI 10.1016/0091-6749(89)90203-0; LENOIR AA, 1987, PEDIATRICS, V80, P283; LEPOW ML, 1987, J INFECT DIS, V156, P591, DOI 10.1093/infdis/156.4.591; MADORE DV, 1990, PEDIATRICS, V85, P331; PELTOLA H, 1984, NEW ENGL J MED, V310, P1561, DOI 10.1056/NEJM198406143102404; PELTOLA H, 1977, PEDIATRICS, V60, P730; SCHUR PH, 1979, PEDIATR RES, V13, P181, DOI 10.1203/00006450-197903000-00010; SHACKELFORD PG, 1987, J IMMUNOL, V138, P587; SHACKELFORD PG, 1985, PEDIATR RES, V19, P846, DOI 10.1203/00006450-198508000-00014; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002	26	13	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					948	953		10.1016/0091-6749(90)90082-F	http://dx.doi.org/10.1016/0091-6749(90)90082-F			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	2332568				2022-12-18	WOS:A1990DD95900020
J	SIVAN, Y; ARCE, P; EIGEN, H; NICKERSON, BG; NEWTH, CJL				SIVAN, Y; ARCE, P; EIGEN, H; NICKERSON, BG; NEWTH, CJL			A DOUBLE-BLIND, RANDOMIZED STUDY OF SODIUM CROMOGLYCATE VERSUS PLACEBO IN PATIENTS WITH CYSTIC-FIBROSIS AND BRONCHIAL HYPERREACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; JAMES WHITCOMB RILEY HOSP CHILDREN,INDIANAPOLIS,IN 46202; CHILDRENS HOSP NO CALIF,OAKLAND,CA	University of California System; University of California San Francisco; James Whitcomb Riley Hospital Children								Allan J D, 1975, Clin Allergy, V5, P255, DOI 10.1111/j.1365-2222.1975.tb01860.x; BLACK JL, 1987, J ALLERGY CLIN IMMUN, V80, P39, DOI 10.1016/S0091-6749(87)80188-4; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DERBES VJ, 1957, J ALLERGY, V28, P287, DOI 10.1016/0021-8707(57)90038-2; DICKSON W, 1970, DISODIUM CROMOGLYCAT, P105; GODFREY S, 1975, J PEDIATR-US, V87, P465, DOI 10.1016/S0022-3476(75)80663-9; GRIFFIN MP, 1983, J ALLERGY CLIN IMMUN, V71, P331, DOI 10.1016/0091-6749(83)90088-X; HOLZER FJ, 1981, ARCH DIS CHILD, V56, P455, DOI 10.1136/adc.56.6.455; HORDVIK NL, 1985, AM REV RESPIR DIS, V131, P889; LANDAU LI, 1973, J PEDIATR-US, V82, P863, DOI 10.1016/S0022-3476(73)80085-X; MATTOLI S, 1986, ANN ALLERGY, V57, P295; MELLIS CM, 1978, PEDIATRICS, V61, P446; MITCHELL I, 1978, J PEDIATR-US, V93, P744, DOI 10.1016/S0022-3476(78)81070-1; MITCHELL I, 1985, ANN ALLERGY, V54, P233; MYERS DJ, 1986, AM REV RESPIR DIS, V133, P1150; NEWTH CJL, 1982, AUST NZ J MED, V12, P238; ORMEROD LP, 1980, THORAX, V35, P768, DOI 10.1136/thx.35.10.768; PATEL KR, 1982, THORAX, V37, P663, DOI 10.1136/thx.37.9.663; PATEL KR, 1984, CLIN ALLERGY, V14, P87, DOI 10.1111/j.1365-2222.1984.tb02195.x; PRICE JF, 1979, CLIN ALLERGY, V9, P563, DOI 10.1111/j.1365-2222.1979.tb00480.x; RUBENFELD AR, 1977, AM REV RESPIR DIS, V115, P381; SMITH CM, 1987, J ALLERGY CLIN IMMUN, V79, P85, DOI 10.1016/S0091-6749(87)80021-0; WARNER JO, 1976, ARCH DIS CHILD, V51, P507, DOI 10.1136/adc.51.7.507; WARREN C P W, 1975, Clinical Allergy, V5, P1, DOI 10.1111/j.1365-2222.1975.tb01831.x; WEINER P, 1988, AM REV RESPIR DIS, V137, P1309, DOI 10.1164/ajrccm/137.6.1309; WOENNE R, 1979, AM REV RESPIR DIS, V119, P927	26	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1990	85	3					649	654		10.1016/0091-6749(90)90106-E	http://dx.doi.org/10.1016/0091-6749(90)90106-E			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CU668	2107242				2022-12-18	WOS:A1990CU66800017
J	SEGAL, R; DAYAN, M; EPSTEIN, N; ZECLER, E; PELLER, S; MICHALEVITCH, R; BRAUTBAR, C; MOSES, E				SEGAL, R; DAYAN, M; EPSTEIN, N; ZECLER, E; PELLER, S; MICHALEVITCH, R; BRAUTBAR, C; MOSES, E			COMMON VARIABLE IMMUNODEFICIENCY - A FAMILY STUDY AND THERAPEUTIC TRIAL WITH CIMETIDINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,DEPT MED,DIV RESP,VANCOUVER V5Z 1M9,BC,CANADA	University of British Columbia								DOUGLAS SD, 1970, AM J MED, V48, P48, DOI 10.1016/0002-9343(70)90097-5; EIBL MM, 1982, NEW ENGL J MED, V307, P803, DOI 10.1056/NEJM198209233071307; ERSHLER WB, 1983, CLIN IMMUNOL IMMUNOP, V26, P10, DOI 10.1016/0090-1229(83)90168-X; FUCHS HB, 1984, CLIN EXP IMMUNOL, V56, P29; FUDENBERG HH, 1962, ARTHRITIS RHEUM, V5, P565, DOI 10.1002/art.1780050605; GEHA RS, 1974, NEW ENGL J MED, V291, P1, DOI 10.1056/NEJM197407042910101; GRISWOLD DE, 1984, J IMMUNOL, V132, P3054; HERMANS PE, 1976, AM J MED, V61, P221, DOI 10.1016/0002-9343(76)90173-X; KAMIN RM, 1968, P NATL ACAD SCI USA, V60, P881, DOI 10.1073/pnas.60.3.881; KATZ D, 1981, P NATL ACAD SCI-BIOL, V78, P4505, DOI 10.1073/pnas.78.7.4505; MAGE MG, 1977, J IMMUNOL METHODS, V15, P47, DOI 10.1016/0022-1759(77)90016-3; MITTAL KK, 1968, TRANSPLANTATION, V6, P913, DOI 10.1097/00007890-196811000-00006; MORITO T, 1980, J CLIN INVEST, V65, P422, DOI 10.1172/JCI109685; NAIR MPN, 1983, CELL IMMUNOL, V81, P45, DOI 10.1016/0008-8749(83)90210-1; PALACIOS R, 1981, IMMUNOL LETT, V3, P33, DOI 10.1016/0165-2478(81)90092-4; REINHERZ EL, 1979, NEW ENGL J MED, V301, P1018, DOI 10.1056/NEJM197911083011902; REINHERZ EL, 1981, NEW ENGL J MED, V304, P811, DOI 10.1056/NEJM198104023041403; REINHERZ EL, 1981, J CLIN INVEST, V68, P699, DOI 10.1172/JCI110305; SCHLESINGER M, 1986, ISRAEL J MED SCI, V21, P886; SEGAL R, 1986, CLIN EXP IMMUNOL, V66, P52; SHALEV Y, 1985, CLIN EXP IMMUNOL, V60, P355; SIEGAL FP, 1978, NEW ENGL J MED, V299, P172, DOI 10.1056/NEJM197807272990404; SIEGAL FP, 1976, J CLIN INVEST, V58, P109, DOI 10.1172/JCI108439; SUEZ D, 1985, HUM IMMUNOL, V13, P219, DOI 10.1016/0198-8859(85)90001-1; TERASAKI PI, 1978, AM J CLIN PATHOL, V69, P103; WALDMANN TA, 1974, LANCET, V2, P609; WHITE WB, 1985, NEW ENGL J MED, V312, P198, DOI 10.1056/NEJM198501243120402; WHITE WB, 1987, AM J MED, V83, P431, DOI 10.1016/0002-9343(87)90752-2; WOLLHEIM FA, 1964, ACTA MED SCAND, V176, P1	29	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	1				753	761		10.1016/0091-6749(89)90305-9	http://dx.doi.org/10.1016/0091-6749(89)90305-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA314	2530265				2022-12-18	WOS:A1989CA31400014
J	LORIA, RC; WILSON, P; WEDNER, HJ				LORIA, RC; WILSON, P; WEDNER, HJ			IDENTIFICATION OF POTENTIAL ALLERGENS IN WHITE OAK (QUERCUS-ALBA) POLLEN BY IMMUNOBLOTTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WASHINGTON UNIV,SCH MED,DEPT MED,DIV ALLERGY & IMMUNOL,BOX 8122,660 S EUCLID,ST LOUIS,MO 63110	Washington University (WUSTL)								BIRK HW, 1987, ANAL BIOCHEM, V164, P12, DOI 10.1016/0003-2697(87)90360-5; BLANCHARD GC, 1977, ANN ALLERGY, V39, P253; CORBI AL, 1984, INT ARCH ALLER A IMM, V74, P318, DOI 10.1159/000233567; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FEO S, 1984, MOL IMMUNOL, V21, P25, DOI 10.1016/0161-5890(84)90086-5; FLORVAAG E, 1984, INT ARCH ALLER A IMM, V75, P300, DOI 10.1159/000233638; FORD SA, 1987, J ALLERGY CLIN IMMUN, V79, P711, DOI 10.1016/0091-6749(87)90201-6; FORD SA, 1986, INT ARCH ALLER A IMM, V79, P120, DOI 10.1159/000233957; FORD SA, 1985, INT ARCH ALLER A IMM, V78, P15, DOI 10.1159/000233855; FORD SA, 1986, INT ARCH ALLER A IMM, V81, P193, DOI 10.1159/000234134; FREY J, 1983, BIOCHEM J, V214, P629, DOI 10.1042/bj2140629; GROSS GN, 1978, SCAND J IMMUNOL, V8, P437, DOI 10.1111/j.1365-3083.1978.tb00539.x; GUEVARA J, 1982, ELECTROPHORESIS, V3, P197, DOI 10.1002/elps.1150030404; HOFFMAN DR, 1987, J ALLERGY CLIN IMMUN, V80, P307, DOI 10.1016/0091-6749(87)90036-4; HOFFMAN DR, 1987, J ALLERGY CLIN IMMUN, V80, P300, DOI 10.1016/0091-6749(87)90035-2; IPSEN H, 1985, ALLERGY, V40, P289, DOI 10.1111/j.1398-9995.1985.tb00234.x; IPSEN H, 1985, ALLERGY, V40, P510, DOI 10.1111/j.1398-9995.1985.tb00259.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS WH, 1975, ANN ALLERGY, V35, P113; Lewis WH VP, 1983, AIRBORNE ALLERGENIC; LORIA RC, 1988, J ALLERGY CLIN IMMUN, V82, P834, DOI 10.1016/0091-6749(88)90086-3; MANDRELL RE, 1984, J IMMUNOL METHODS, V67, P1, DOI 10.1016/0022-1759(84)90080-2; MENARDO JL, 1982, ANN ALLERGY, V48, P235; Miller HA, 1985, OAKS N AM; NILSSON B, 1987, MOL IMMUNOL, V24, P487, DOI 10.1016/0161-5890(87)90023-X; PRAVDA J, 1986, J ALLERGY CLIN IMMUN, V77, P196; SOLOMON AM, 1983, AM J BOT, V70, P481, DOI 10.2307/2443159; STANALAND BE, 1986, INT ARCH ALLER A IMM, V80, P278, DOI 10.1159/000234066; STANDRING R, 1987, INT ARCH ALLER A IMM, V83, P96, DOI 10.1159/000234338; TOVEY ER, 1987, J BIOCHEM BIOPH METH, V14, P1, DOI 10.1016/0165-022X(87)90002-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRELEASE W, 1924, MEMORIS NATIONAL ACA, V20; WEDNER HJ, 1986, J IMMUNOL, V136, P4226; WEDNER HJ, 1987, CELL IMMUNOL, V104, P201, DOI 10.1016/0008-8749(87)90022-0; YASUEDA H, 1983, J ALLERGY CLIN IMMUN, V71, P77, DOI 10.1016/0091-6749(83)90550-X; YOUNG DB, 1986, IMMUNOLOGY, V59, P167; ZENGER VE, 1985, J ALLERGY CLIN IMMUN, V75, P175, DOI 10.1016/0091-6749(85)90416-6	37	13	13	1	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1989	84	1					9	18		10.1016/0091-6749(89)90172-3	http://dx.doi.org/10.1016/0091-6749(89)90172-3			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG120	2754148				2022-12-18	WOS:A1989AG12000003
J	MINUK, GY; BOYD, ND; MATHESON, DS; FRITZLER, MJ; GREEN, BJ				MINUK, GY; BOYD, ND; MATHESON, DS; FRITZLER, MJ; GREEN, BJ			SERUM IMMUNOGLOBULIN-E LEVELS IN PATIENTS WITH PRIMARY BILIARY-CIRRHOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALGARY,DEPT MED,CALGARY T2N 1N4,ALBERTA,CANADA; UNIV CALGARY,DEPT PAEDIAT,CALGARY T2N 1N4,ALBERTA,CANADA	University of Calgary; University of Calgary	MINUK, GY (corresponding author), HLTH SCI CTR,LIVER DIS UNIT,820 SHERBROOK ST,WINNIPEG R3A 1R9,MANITOBA,CANADA.							ALAGHBAR MNA, 1986, GUT, V27, P317, DOI 10.1136/gut.27.3.317; BESWICK DR, 1985, GASTROENTEROLOGY, V89, P267, DOI 10.1016/0016-5085(85)90325-7; CHARLESWORTH JA, 1978, AUST NZ J MED, V8, P43, DOI 10.1111/j.1445-5994.1978.tb02401.x; FRITZLER MJ, 1985, CLIN IMMUNOL IMMUNOP, V36, P120, DOI 10.1016/0090-1229(85)90045-5; HEINER DC, 1970, J ALLERGY, V45, P30, DOI 10.1016/0021-8707(70)90014-6; HOOFNAGLE JH, 1986, GASTROENTEROLOGY, V91, P1327, DOI 10.1016/0016-5085(86)90183-6; ISHIZAKA K, 1979, COMPREHENSIVE IMMUNO, V6, P153; IWARSON S, 1972, J INFECT DIS, V125, P178, DOI 10.1093/infdis/125.2.178; JAMES SP, 1980, GASTROENTEROLOGY, V79, P242; JOSKE RA, 1976, MED J AUSTRALIA, V2, P555, DOI 10.5694/j.1326-5377.1976.tb130385.x; LEVO Y, 1981, ANN ALLERGY, V47, P456; LINDGREN S, 1984, SCAND J GASTROENTERO, V19, P97, DOI 10.1080/00365521.1984.12005692; LINDGREN S, 1982, J LAB CLIN MED, V99, P636; MATHESON DS, 1987, J IMMUNOL, V138, P2469; MINUK GY, 1986, GUT, V27, P324, DOI 10.1136/gut.27.3.324; PETERS CJ, 1972, CLIN EXP IMMUNOL, V11, P381; VANEPPS E, 1976, CLIN EXP IMMUNOL, V23, P444	17	13	13	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	1				462	466		10.1016/0091-6749(89)90134-6	http://dx.doi.org/10.1016/0091-6749(89)90134-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4489	2918187	Bronze			2022-12-18	WOS:A1989T448900015
J	ENBERG, RN; MCCULLOUGH, J; OWNBY, DR				ENBERG, RN; MCCULLOUGH, J; OWNBY, DR			ANTIBODY-RESPONSES IN WATERMELON SENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HENRY FORD HOSP,DEPT PEDIAT,DIV ALLERGY & CLIN IMMUNOL,2799 W GRAND BLVD,DETROIT,MI 48202; HENRY FORD HOSP,DEPT MED,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital								DJURUP R, 1984, ALLERGY, V39, P433, DOI 10.1111/j.1398-9995.1984.tb01965.x; ENBERG RN, 1987, J ALLERGY CLIN IMMUN, V79, P867, DOI 10.1016/0091-6749(87)90234-X; FAGAN DL, 1982, J ALLERGY CLIN IMMUN, V70, P399, DOI 10.1016/0091-6749(82)90031-8; FORD SA, 1985, INT ARCH ALLER A IMM, V78, P15, DOI 10.1159/000233855; FOX DJ, 1976, DOCUMENTATIONS MIDAS; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERRETT J, 1983, CLIN ALLERGY, V13, P397, DOI 10.1111/j.1365-2222.1983.tb02615.x; NAKAGAWA T, 1986, ANN ALLERGY, V57, P359; NAKAGAWA T, 1981, CLIN ALLERGY, V11, P21, DOI 10.1111/j.1365-2222.1981.tb01561.x; PERELMUTTER L, 1984, ANN ALLERGY, V52, P64; ROWE MS, 1986, J ALLERGY CLIN IMMUN, V77, P714, DOI 10.1016/0091-6749(86)90416-1; SHAKIB F, 1984, INT ARCH ALLER A IMM, V75, P107, DOI 10.1159/000233599; SKOENS R, 1983, J CLIN IMMUNOL, V3, P65; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; TOVEY ER, 1985, INT ARCH ALLER A IMM, V76, P82, DOI 10.1159/000233667; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIJAY HM, 1977, INT ARCH ALLER A IMM, V53, P78, DOI 10.1159/000231734; WINTER A, 1975, PREPARATIVE FLATBED, P198; YOUNT WJ, 1968, J EXP MED, V127, P633, DOI 10.1084/jem.127.3.633; 1986, BIORAD IMMUNOBLOT GO	20	13	13	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				795	800		10.1016/0091-6749(88)90081-4	http://dx.doi.org/10.1016/0091-6749(88)90081-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	3192863				2022-12-18	WOS:A1988R170800013
J	IBANEZ, MD; HORNER, WE; LIENGSWANGSWONG, V; SASTRE, J; LEHRER, SB				IBANEZ, MD; HORNER, WE; LIENGSWANGSWONG, V; SASTRE, J; LEHRER, SB			IDENTIFICATION AND ANALYSIS OF BASIDIOSPORE ALLERGENS FROM PUFFBALLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,SCH MED,DEPT MED,CLIN IMMUNOL SECT,1700 PERDIDO ST,NEW ORLEANS,LA 70112	Tulane University					NHLBI NIH HHS [HL 07376] Funding Source: Medline; NIAID NIH HHS [AI 20331] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020331] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENGTSSON A, 1986, INT ARCH ALLER A IMM, V80, P383, DOI 10.1159/000234085; BUSH RK, 1987, CLIN REV ALLERG, V5, P3; BUTCHER BT, 1987, J ALLERGY CLIN IMMUN, V80, P803, DOI 10.1016/S0091-6749(87)80269-5; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; Coker W.C., 1928, GASTEROMYCETES E US; DAVIS WE, 1988, CLIN ALLERGY, V18, P261, DOI 10.1111/j.1365-2222.1988.tb02868.x; DEMEULEMESTER C, 1987, ELECTROPHORESIS, V8, P71, DOI 10.1002/elps.1150080113; GREGORY P, 1957, J GEN MICROBIOL, V7, P135; HASNAIN SM, 1985, NEW ZEAL MED J, V98, P393; HERXHEIMER M, 1969, LANCET, V2, P131; HORNER WE, IN PRESS J ALLERGY C; HYDE H. A., 1960, ACTA ALLERGOL, V15, P159; KARR RM, 1981, J ALLERGY CLIN IMMUN, V67, P194, DOI 10.1016/0091-6749(81)90061-0; KING TP, 1974, IMMUNOCHEMISTRY, V11, P83, DOI 10.1016/0019-2791(74)90321-8; LEHRER SB, 1986, J ALLERGY CLIN IMMUN, V78, P478, DOI 10.1016/0091-6749(86)90036-9; LIENGSWANGWONG V, 1987, CLIN ALLERGY, V17, P191, DOI 10.1111/j.1365-2222.1987.tb02003.x; LOPEZ M, 1976, J ALLERGY CLIN IMMUN, V57, P480, DOI 10.1016/0091-6749(76)90064-6; LOPEZ M, 1985, INT ARCH ALLER A IMM, V77, P169, DOI 10.1159/000233775; OCHOA JL, 1978, BIOCHIMIE, V60, P1, DOI 10.1016/S0300-9084(78)80193-X; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SANTILLI J, 1985, ANN ALLERGY, V55, P469; SCHONHEYDER H, 1984, INT ARCH ALLER A IMM, V73, P231, DOI 10.1159/000233473; SPRENGER JD, 1986, J ALLERGY CLIN IMMUN, V77, P200	23	13	14	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				787	795		10.1016/0091-6749(88)90080-2	http://dx.doi.org/10.1016/0091-6749(88)90080-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	2461403	Bronze			2022-12-18	WOS:A1988R170800012
J	FERRERI, NR; ZEIGER, RS; SPIEGELBERG, HL				FERRERI, NR; ZEIGER, RS; SPIEGELBERG, HL			IGG-INDUCED, IGA-INDUCED, AND IGE-INDUCED RELEASE OF LEUKOTRIENE C-4 BY MONOCYTES ISOLATED FROM PATIENTS WITH ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN,RES INST,DEPT IMMUNOL,10666 N TORREY PINES RD,LA JOLLA,CA 92037; KAISER PERMANENTE MED CTR,SAN DIEGO,CA	Scripps Research Institute; Kaiser Permanente				Zeiger, Robert/0000-0001-5788-5063	NCRR NIH HHS [RRO 5514, RR 00833] Funding Source: Medline; NIAID NIH HHS [AI-10386] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALY R, 1980, ACTA DERM-VENEREOL, V92, P16; BAUD L, 1987, J IMMUNOL, V138, P1190; BIGBY TD, 1987, J IMMUNOL, V138, P1546; CAPRON M, 1985, J IMMUNOL, V134, P3013; COLTON T, 1974, STAT MED, P207; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DU JT, 1983, BIOCHIM BIOPHYS ACTA, V753, P159, DOI 10.1016/0005-2760(83)90003-6; FANGER MW, 1980, P NATL ACAD SCI-BIOL, V77, P3640, DOI 10.1073/pnas.77.6.3640; FERRERI NR, 1986, J IMMUNOL, V136, P4188; FERRERI NR, 1986, CELL IMMUNOL, V98, P57, DOI 10.1016/0008-8749(86)90267-4; FRIES LF, 1984, J IMMUNOL, V132, P695; GOLDYNE ME, 1984, J BIOL CHEM, V259, P8815; GONZALEZMOLINA A, 1977, J CLIN INVEST, V59, P616, DOI 10.1172/JCI108679; GUREVITCH AW, 1973, ARCH DERMATOL, V107, P712, DOI 10.1001/archderm.107.5.712; GUYRE PM, 1983, J CLIN INVEST, V72, P393, DOI 10.1172/JCI110980; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; HENSON PM, 1972, J IMMUNOL, V109, P1182; HUBSCHER T, 1975, J IMMUNOL, V114, P1379; HUMES JL, 1980, J IMMUNOL, V124, P2110; JOHANSSON SGO, 1973, BIOL ROLE IMMUNOGLOB, P211; JOHNSON WD, 1977, J EXP MED, V146, P1613, DOI 10.1084/jem.146.6.1613; JONES HE, 1975, BRIT J DERMATOL, V92, P17; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; KENNEDY MS, 1980, PROSTAGLANDINS, V20, P135; KIKUTANI H, 1986, J EXP MED, V164, P1455, DOI 10.1084/jem.164.5.1455; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; LAWRENCE DA, 1975, J CLIN INVEST, V55, P368, DOI 10.1172/JCI107940; LOTEM J, 1977, J CELL PHYSIOL, V92, P97, DOI 10.1002/jcp.1040920112; MALISZEWSKI CR, 1985, J IMMUNOL, V135, P3878; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MELEWICZ FM, 1981, J IMMUNOL, V126, P1592; MELEWICZ FM, 1980, J IMMUNOL, V125, P1026; MIKHAIL GR, 1964, J INVEST DERMATOL, V43, P249, DOI 10.1038/jid.1964.152; NARAYFEJESTOTH A, 1984, J IMMUNOL, V133, P1914; NAWATA Y, 1985, J IMMUNOL, V135, P478; NEWMAN SL, 1982, J EXP MED, V156, P430, DOI 10.1084/jem.156.2.430; PAWLOWSKI NA, 1983, J EXP MED, V158, P393, DOI 10.1084/jem.158.2.393; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; SCHULMAN ES, 1983, J IMMUNOL, V131, P1936; SCOTT WA, 1982, J EXP MED, V155, P1148, DOI 10.1084/jem.155.4.1148; Spiegelberg H L, 1974, Adv Immunol, V19, P259, DOI 10.1016/S0065-2776(08)60254-0; SPIEGELBERG HL, 1983, J IMMUNOL, V131, P3001; STEVENS WJ, 1984, J ALLERGY CLIN IMMUN, V73, P276, DOI 10.1016/S0091-6749(84)80020-2; TAKEMURA R, 1984, AM J PHYSIOL, V246, pC1, DOI 10.1152/ajpcell.1984.246.1.C1; TALALAY P, 1946, J BIOL CHEM, V166, P757; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WILLIAMS JD, 1984, J IMMUNOL, V132, P3034; WILLIAMS RC, 1972, J CLIN INVEST, V51, P955, DOI 10.1172/JCI106890; WILLIAMS TJ, 1977, NATURE, V270, P530, DOI 10.1038/270530a0	49	13	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					556	567		10.1016/0091-6749(88)90965-7	http://dx.doi.org/10.1016/0091-6749(88)90965-7			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	2844875				2022-12-18	WOS:A1988Q639900005
J	SCHULMAN, ES; POST, TJ; VIGDERMAN, RJ				SCHULMAN, ES; POST, TJ; VIGDERMAN, RJ			DENSITY HETEROGENEITY OF HUMAN-LUNG MAST-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV PULM DIS,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI120634, R01AI020634, R23AI020634] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20634] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSTEN KF, 1975, AM REV RESPIR DIS, V112, P423; BARRETT KE, 1986, J IMMUNOL, V137, P2001; BEFUS AD, 1982, J IMMUNOL, V128, P2475; BIENENSTOCK J, 1982, J ALLERGY CLIN IMMUN, V70, P407, DOI 10.1016/0091-6749(82)90001-X; COUTTS SM, 1980, J IMMUNOL, V124, P2309; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P303, DOI 10.1111/apm.1966.66.3.303; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289, DOI 10.1111/apm.1966.66.3.289; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P313, DOI 10.1111/apm.1966.66.3.313; GILBERT HS, 1975, BLOOD, V46, P179; GUYGRAND D, 1984, J EXP MED, V160, P12, DOI 10.1084/jem.160.1.12; HASLETT C, 1985, AM J PATHOL, V119, P101; ISHIZAKA T, 1983, J IMMUNOL, V130, P2357; JOHNSON AR, 1970, J PHARMACOL EXP THER, V175, P632; LICHTENSTEIN LM, 1973, NATURE, V244, P287, DOI 10.1038/244287a0; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MARONE G, 1979, J IMMUNOL, V123, P1669; MAYRHOFER G, 1980, BLOOD, V55, P532; METCALFE DD, 1983, CLIN REV ALLERG, V1, P311; NAKANO T, 1987, J IMMUNOL, V138, P544; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; PATTERSON R, 1978, J CLIN INVEST, V62, P519, DOI 10.1172/JCI109155; PEARCE FL, 1982, J IMMUNOL, V128, P2481; PETERS SP, 1984, J IMMUNOL, V132, P1972; POLLACK RB, 1986, CLIN RES, V34, pA277; RAZIN E, 1984, J IMMUNOL, V133, P938; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; RAZIN E, 1984, J IMMUNOL, V132, P1479; RUITENBERG EJ, 1982, INT ARCH ALLER A IMM, V67, P233, DOI 10.1159/000233024; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHULMAN ES, 1982, J IMMUNOL, V129, P2662; SCHULMAN ES, 1981, AM REV RESPIR DIS, V124, P402; SCHULMAN ES, 1986, CHEST, V90, P578, DOI 10.1378/chest.90.4.578; SCHULMAN ES, 1982, J APPL PHYSIOL, V53, P589, DOI 10.1152/jappl.1982.53.3.589; SCHULMAN ES, 1983, J IMMUNOL, V131, P1936; SIRAGANIAN RP, 1977, J IMMUNOL, V119, P2078; SRENDI B, 1983, J IMMUNOL, V131, P915; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA; ULMER AJ, 1979, J IMMUNOL METHODS, V30, P1, DOI 10.1016/0022-1759(79)90268-0	38	13	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1988	82	1					78	86		10.1016/0091-6749(88)90055-3	http://dx.doi.org/10.1016/0091-6749(88)90055-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P4004	2455745				2022-12-18	WOS:A1988P400400014
J	KOENIG, JQ				KOENIG, JQ			INDOOR AND OUTDOOR POLLUTANTS AND THE UPPER RESPIRATORY-TRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KOENIG, JQ (corresponding author), UNIV WASHINGTON,DEPT ENVIRONM HLTH,SC-34,SEATTLE,WA 98195, USA.							BARROW C, 1986, TOXICOLOGY NASAL PAS; BERKEY CS, 1986, AM J EPIDEMIOL, V123, P250, DOI 10.1093/oxfordjournals.aje.a114233; BURCHFIEL CM, 1986, AM REV RESPIR DIS, V133, P966; COLE P, 1979, ACTA OTO-LARYNGOL, V88, P148, DOI 10.3109/00016487909137154; KOENIG JQ, 1984, CLIN REV ALLERG, V2, P255; KOENIG JQ, 1985, J ALLERGY CLIN IMMUN, V76, P813, DOI 10.1016/0091-6749(85)90754-7; KRAEMER MJ, 1983, JAMA-J AM MED ASSOC, V249, P1022, DOI 10.1001/jama.249.8.1022; MORGAN KT, 1986, TOXICOLOGY NASAL PAS; MORGAN MS, 1986, J OCCUP ENVIRON MED, V28, P415, DOI 10.1097/00043764-198606000-00007; MURRAY AB, 1986, J ALLERGY CLIN IMMUN, V77, P575, DOI 10.1016/0091-6749(86)90348-9; OCONNOR GT, 1987, AM REV RESPIR DIS, V135, P800, DOI 10.1164/arrd.1987.135.4.800; Proctor DF, 1982, NOSE UPPER AIRWAY PH; SOLOMON WR, 1965, J ALLERGY, V36, P62, DOI 10.1016/0021-8707(65)90033-X; 1987, ENV HLTH NEWSLE 0701	14	13	14	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	2	S			1055	1059		10.1016/0091-6749(88)90180-7	http://dx.doi.org/10.1016/0091-6749(88)90180-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7037	3286732				2022-12-18	WOS:A1988N703700025
J	MASSEY, KL; HILL, M; HARMAN, E; RUTLEDGE, DR; AHRENS, R; HENDELES, L				MASSEY, KL; HILL, M; HARMAN, E; RUTLEDGE, DR; AHRENS, R; HENDELES, L			DOSE-RESPONSE OF INHALED GALLOPAMIL (D600), A CALCIUM-CHANNEL BLOCKER, IN ATTENUATING AIRWAY REACTIVITY TO METHACHOLINE AND EXERCISE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV FLORIDA,COLL PHARM,DEPT PHARM PRACTICE,GAINESVILLE,FL 32611; UNIV FLORIDA,DEPT PEDIAT,DIV CLIN PHARMACOL TOXICOL,GAINESVILLE,FL 32611; UNIV FLORIDA,DEPT INTERNAL MED,DIV PULM MED,GAINESVILLE,FL 32611; UNIV IOWA,DIV PEDIAT ALLERGY & PULM,IOWA CITY,IA 52242; WAYNE STATE UNIV,DEPT PHARM PRACTICE,DETROIT,MI 48202	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Iowa; Wayne State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031489] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31489] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMED T, 1985, CHEST, V88, P176, DOI 10.1378/chest.88.2.176; AHMED T, 1986, CHEST, V89, pS535; AHRENS RC, 1987, J ALLERGY CLIN IMMUN, V79, P876, DOI 10.1016/0091-6749(87)90235-1; ANDERSON SD, 1976, AM REV RESPIR DIS, V114, P493; BENDOV I, 1986, AM REV RESPIR DIS, V133, P116, DOI 10.1164/arrd.1986.133.1.116; BRAUNWALD E, 1982, NEW ENGL J MED, V307, P1618; BUNDGAARD A, 1980, ALLERGY, V35, P639, DOI 10.1111/j.1398-9995.1980.tb02016.x; CARPENTER H, 1986, AM REV RESPIR DIS, V133, pA14; CHRISTOPHER M, 1987, J ALLERGY CLIN IMMUN, V79, P250; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COLBURN RF, 1979, AM J PHYSIOL, V236, pC177; CORRIS PA, 1983, AM REV RESPIR DIS, V128, P991; CROPP GJA, 1979, J ALLERGY CLIN IMMUN, V64, P627, DOI 10.1016/0091-6749(79)90026-5; CUSS FM, 1985, J ALLERGY CLIN IMMUN, V76, P718, DOI 10.1016/0091-6749(85)90677-3; FARLEY JM, 1978, J PHARMACOL EXP THER, V207, P340; HARTMANN V, 1985, CHEST, V87, P174, DOI 10.1378/chest.87.2.174; HILL M, 1985, DRUG INTEL CLIN PHAR, V19, P464; MALIK S, 1982, THORAX, V37, P230; MANNING P J, 1987, American Review of Respiratory Disease, V135, pA313; MCFADDEN ER, 1984, J ALLERGY CLIN IMMUN, V73, P413, DOI 10.1016/0091-6749(84)90347-6; MIDDLETON E, 1980, J PHARM SCI-US, V69, P243, DOI 10.1002/jps.2600690244; MOHANKUMAR T, 1984, RESPIRATION, V46, P291, DOI 10.1159/000194701; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; NAWARTH H, 1981, CALCIUM ANTAGONISM C, P52; PATEL KR, 1985, EUR J RESPIR DIS, V67, P269; PATEL KR, 1981, CLIN ALLERGY, V11, P441, DOI 10.1111/j.1365-2222.1981.tb01617.x; POLLOCK J, 1977, PEDIATRICS, V60, P840; POPA VT, 1984, AM REV RESPIR DIS, V130, P1006; RUTLEDGE DR, 1987, J CHROMATOGR-BIOMED, V421, P165, DOI 10.1016/0378-4347(87)80393-6	29	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	1				912	918		10.1016/0091-6749(88)90950-5	http://dx.doi.org/10.1016/0091-6749(88)90950-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7036	3286722				2022-12-18	WOS:A1988N703600022
J	WASS, U; PLASCHKE, P; BJORKANDER, J; BELIN, L				WASS, U; PLASCHKE, P; BJORKANDER, J; BELIN, L			ASSAY OF SPECIFIC IGE ANTIBODIES TO DISODIUM-CROMOGLYCATE IN SERUM FROM A PATIENT WITH AN IMMEDIATE HYPERSENSITIVITY REACTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											WASS, U (corresponding author), SAHLGRENS HOSP,DEPT MED 1,ASTHMA & ALLERGY RES CTR,S-41345 GOTHENBURG,SWEDEN.							AHMAD S, 1983, ANN INTERN MED, V99, P882, DOI 10.7326/0003-4819-99-6-882_2; BERNSTEIN IL, 1985, CHEST, V87, pS68, DOI 10.1378/chest.87.1_Supplement.68S; BIGGS DF, 1985, CAN J PHYSIOL PHARM, V63, P760, DOI 10.1139/y85-126; BROWN LA, 1981, J ALLERGY CLIN IMMUN, V68, P416, DOI 10.1016/0091-6749(81)90194-9; CACOUB P, 1986, PRESSE MED, V15, P803; CLARK B, 1978, J PHARM PHARMACOL, V30, P386, DOI 10.1111/j.2042-7158.1978.tb13266.x; COX JSG, 1977, PHARM BIOCH PROPERTI, V1, P277; DEWDNEY JM, 1978, DRUGS IMMUNE RESPONS, P161; KABAT EA, 1968, STRUCTURAL CONCEPTS, P25; KALLOS P, 1982, PAR PSEUDOALLERGIC R, V3, P122; Kus J, 1978, Pneumonol Pol, V46, P745; LEYNADIER F, 1985, ALLERGY, V40, P540, DOI 10.1111/j.1398-9995.1985.tb00264.x; MENON MPS, 1977, SCAND J RESPIR DIS, V58, P145; MULLER J, 1975, PNEUMONOLOGIE, V151, P323, DOI 10.1007/BF02095113; OSTLER HB, 1982, ARCH OPHTHALMOL-CHIC, V100, P412; PLASCHKE P, 1986, 13 C EUR AC ALL CLIN, P153; PRICE HV, 1982, LANCET, V2, P606; ROSENBERG JL, 1978, ARCH INTERN MED, V138, P989, DOI 10.1001/archinte.138.6.989; SALMON JA, 1982, PROSTAGLANDINS, V24, P225, DOI 10.1016/0090-6980(82)90148-4; SERUP J, 1979, ACTA MED SCAND, V205, P447; SETTIPANE GA, 1979, JAMA-J AM MED ASSOC, V241, P811, DOI 10.1001/jama.241.8.811; SHAPIRO GG, 1985, PHARMACOTHERAPY, V5, P156; SHEFFER AL, 1975, NEW ENGL J MED, V293, P1220, DOI 10.1056/NEJM197512112932402; SKARPAAS IJK, 1987, ALLERGY, V42, P318; TOMLINSON E, 1980, J COLLOID INTERF SCI, V74, P349, DOI 10.1016/0021-9797(80)90204-0	25	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1988	81	4					750	757		10.1016/0091-6749(88)91049-4	http://dx.doi.org/10.1016/0091-6749(88)91049-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N0650	3128591				2022-12-18	WOS:A1988N065000018
J	TAYLOR, ML; LONGBOTTOM, JL				TAYLOR, ML; LONGBOTTOM, JL			PARTIAL CHARACTERIZATION OF A RAPIDLY RELEASED ANTIGENIC ALLERGENIC COMPONENT (AG-5) OF ASPERGILLUS-FUMIGATUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP, INST CARDIOTHORAC, DEPT ALLERGY & CLIN IMMUNOL, FULHAM RD, LONDON SW3 6HP, ENGLAND	Royal Brompton Hospital								GORDON MA, 1977, J CLIN MICROBIOL, V6, P161; HARVEY C, 1987, J ALLERGY CLIN IMMUN, V79, P324, DOI 10.1016/0091-6749(87)90149-7; HARVEY C, 1986, CLIN EXP IMMUNOL, V65, P206; HARVEY C, 1987, CLIN EXP IMMUNOL, V70, P247; HORNSLETH A, 1980, J IMMUNOL METHODS, V39, P95, DOI 10.1016/0022-1759(80)90298-7; KAUFFMAN HF, 1984, J ALLERGY CLIN IMMUN, V73, P567, DOI 10.1016/0091-6749(84)90512-8; Longbottom J L, 1978, Mykosen Suppl, V1, P207; LONGBOTTOM JL, 1983, CLIN EXP IMMUNOL, V53, P354; LONGBOTTOM JL, 1986, J ALLERGY CLIN IMMUN, V78, P18, DOI 10.1016/0091-6749(86)90109-0; LONGBOTTOM JL, 1983, J ALLERGY CLIN IMMUN, V72, P668, DOI 10.1016/0091-6749(83)90627-9; LONGBOTTOM JL, 1986, J ALLERGY CLIN IMMUN, V78, P9, DOI 10.1016/0091-6749(86)90108-9; SCHOLER HJ, 1974, ASPERGILLOSIS FARMER, P45; SMITH CE, 1948, AM REV TUBERC PULM, V57, P330; THURSTON JR, 1986, AM J VET RES, V47, P919	14	13	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1988	81	3					537	541		10.1016/0091-6749(88)90193-5	http://dx.doi.org/10.1016/0091-6749(88)90193-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M6181					2022-12-18	WOS:A1988M618100009
J	LACHANCE, P; CARTIER, A; DOLOVICH, J; MALO, JL				LACHANCE, P; CARTIER, A; DOLOVICH, J; MALO, JL			OCCUPATIONAL ASTHMA FROM REACTIVITY TO AN ALKALINE-HYDROLYSIS DERIVATIVE OF GLUTEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV, MED CTR,FAC HLTH SCI,DEPT PEDIAT,ROOM 3V41, 1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA; HOP SACRE COEUR, DEPT CHEST MED, MONTREAL H4J 1C5, QUEBEC, CANADA	McMaster University; Universite de Montreal								[Anonymous], 1979, AM REV RESPIR DIS, V119, P831; BAHNA SL, 1980, ANN ALLERGY, V44, P146; BAHNA SL, 1980, ALLERGIES MILK, P17; BALDO BA, 1978, CLIN ALLERGY, V8, P109, DOI 10.1111/j.1365-2222.1978.tb00456.x; BLANDS J, 1976, INT ARCH ALLER A IMM, V52, P392, DOI 10.1159/000231706; BURGE PS, 1979, THORAX, V34, P308, DOI 10.1136/thx.34.3.308; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; HEINER DC, 1970, J ALLERGY, V45, P333, DOI 10.1016/0021-8707(70)90042-0; HERXHEIMER H, 1967, LANCET, V1, P83; HOFFMAN DR, 1975, IMMUNOCHEMISTRY, V12, P535, DOI 10.1016/0019-2791(75)90080-4; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PRAUSNITZ C, 1962, CLIN ASPECTS IMMUNOL, P808; RAWCLIFFE PM, 1985, CLIN ALLERGY, V15, P155, DOI 10.1111/j.1365-2222.1985.tb02268.x; SAVILAHTI E, 1983, LANCET, V1, P320; SHELDON JM, 1967, MANUAL CLIN ALLERGY, P202; WALSH BJ, 1985, J ALLERGY CLIN IMMUN, V76, P23, DOI 10.1016/0091-6749(85)90799-7; WILBUR RD, 1976, J ALLERGY CLIN IMMUN, V58, P366, DOI 10.1016/0091-6749(76)90116-0	21	13	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1988	81	2					385	390		10.1016/0091-6749(88)90906-2	http://dx.doi.org/10.1016/0091-6749(88)90906-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0993	3339195				2022-12-18	WOS:A1988M099300004
J	DECLERCK, LS; GIGASE, PL; BRIDTS, CH; STEVENS, WJ				DECLERCK, LS; GIGASE, PL; BRIDTS, CH; STEVENS, WJ			NEUTROPHIL ACTIVATION BY IGE-CONTAINING CIRCULATING IMMUNE-COMPLEXES OF PATIENTS WITH CONNECTIVE-TISSUE DISEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV INSTELLING ANTWERP,IMMUNOL SECT,UNIV PLEIN 1,B-2610 WILRIJK,BELGIUM	University of Antwerp			BRIDTS, Chris HM/M-7933-2016	BRIDTS, Chris HM/0000-0002-3324-7320				BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; DECLERCK LS, 1985, ANN RHEUM DIS, V44, P772, DOI 10.1136/ard.44.11.772; GALE R, 1983, ANN RHEUM DIS, V42, P158, DOI 10.1136/ard.42.2.158; HENSON PM, 1971, J IMMUNOL, V107, P1535; HENSON PM, 1971, J EXP MED, V133, P554, DOI 10.1084/jem.133.3.554; JOHNSON KJ, 1982, LAB INVEST, V47, P218; JOSEPH M, 1980, CLIN EXP IMMUNOL, V40, P416; LEUNG DYM, 1985, CLIN RES, V33, pA161; MERETEY K, 1982, ANN RHEUM DIS, V41, P405, DOI 10.1136/ard.41.4.405; MERETEY K, 1984, ANN RHEUM DIS, V43, P246, DOI 10.1136/ard.43.2.246; OHNO O, 1978, ARTHRITIS RHEUM, V21, P516, DOI 10.1002/art.1780210505; PERMIN H, 1978, ACTA PATH MICRO IM C, V86, P245; PERMIN H, 1984, ACTA PATH MICRO IM C, V92, P37; PERTOFT H, 1978, ANAL BIOCHEM, V88, P271, DOI 10.1016/0003-2697(78)90419-0; PESTEL J, 1984, CLIN EXP IMMUNOL, V57, P404; RANKIN JA, 1982, NATURE, V297, P329, DOI 10.1038/297329a0; ROPES M W, 1958, Bull Rheum Dis, V9, P175; ROUZER CA, 1982, P NATL ACAD SCI-BIOL, V79, P5656, DOI 10.1073/pnas.79.18.5656; Stevens W. J., 1983, Clinical and Experimental Immunology, V52, P142; STEVENS WJ, 1984, J ALLERGY CLIN IMMUN, V73, P276, DOI 10.1016/S0091-6749(84)80020-2; THOMSEN P, 1985, SCAND J RHEUMATOL, V14, P239, DOI 10.3109/03009748509100401; UGAI K, 1979, ARTHRITIS RHEUM, V22, P353, DOI 10.1002/art.1780220407; WALSH GM, 1986, CLIN EXP IMMUNOL, V63, P466; WEISS SJ, 1981, J CLIN INVEST, V68, P714, DOI 10.1172/JCI110307; WEISS SJ, 1982, J IMMUNOL, V129, P309; WEISSMANN G, 1982, J LAB CLIN MED, V100, P322; ZAIFLER NJ, 1983, AM J MED, V75, P3	27	13	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					95	99		10.1016/0091-6749(88)90226-6	http://dx.doi.org/10.1016/0091-6749(88)90226-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	2828451				2022-12-18	WOS:A1988M027400015
J	FELDMAN, CH				FELDMAN, CH			ASTHMA EDUCATION - GENERAL-ASPECTS OF CHILDHOOD PROGRAMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FELDMAN, CH (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DIV PEDIAT ALLERGY,630 W 168TH ST,NEW YORK,NY 10032, USA.							BLESSINGMOORE J, 1981, SELF MANAGEMENT ED P, V2, P257; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; CLARK NM, 1984, J SCHOOL HEALTH, V54, P143, DOI 10.1111/j.1746-1561.1984.tb08796.x; CLARK NM, 1986, PATIENT EDUC COUNS, V8, P27, DOI 10.1016/0738-3991(86)90024-8; CLARK NM, 1981, HEALTH EDUC QUART, V8, P166, DOI 10.1177/109019818100800203; CREER TL, 1981, SELF MANAGEMENT ED P, V2, P107; EVANS D, 1987, HEALTH EDUC QUART, V14, P267, DOI 10.1177/109019818701400302; FELDMAN CH, 1983, J ASTHMA, V20, P17, DOI 10.3109/02770908309070907; FIREMAN P, 1981, PEDIATRICS, V68, P341; GREEN LW, 1977, HEALTH EDUC QUART, V5, P161, DOI 10.1177/109019817700500206; HINDIALEXANDER MC, 1984, J ALLERGY CLIN IMMUN, V74, P505, DOI 10.1016/0091-6749(84)90386-5; KAPLAN DL, 1986, J SCHOOL HEALTH, V56, P267, DOI 10.1111/j.1746-1561.1986.tb05748.x; LEWIS CE, 1984, PEDIATRICS, V74, P478; MASCIA AV, 1964, ANN ALLERGY, V22, P191; MCNABB WL, 1985, AM J PUBLIC HEALTH, V75, P1219, DOI 10.2105/AJPH.75.10.1219; Parcel G S, 1980, J Dev Behav Pediatr, V1, P128; PARCEL GS, 1980, TEACHING MY PARENTS; RAKOS RF, 1985, J PSYCHOSOM RES, V29, P101, DOI 10.1016/0022-3999(85)90014-5; RICHARDS W, 1981, CLIN PEDIATR, V20, P453, DOI 10.1177/000992288102000705; RUBIN DH, 1986, PEDIATRICS, V77, P1; WEISS JH, 1981, SUPERSTUFF SELF MANA, V2, P273; WHITMAN N, 1985, HEALTH EDUC QUART, V12, P333, DOI 10.1177/109019818501200312; WILSONPESSANO SR, 1985, PREV MED, V14, P670, DOI 10.1016/0091-7435(85)90066-0	23	13	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			494	497		10.1016/0091-6749(87)90084-4	http://dx.doi.org/10.1016/0091-6749(87)90084-4			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	K1037	3624705				2022-12-18	WOS:A1987K103700031
J	SMITH, LJ; KERN, R; PATTERSON, R; KRELL, RD; BERNSTEIN, PR				SMITH, LJ; KERN, R; PATTERSON, R; KRELL, RD; BERNSTEIN, PR			MECHANISM OF LEUKOTRIENE-D4-INDUCED BRONCHOCONSTRICTION IN NORMAL SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM LAKESIDE MED CTR,CHICAGO,IL 60611; STUART PHARMACEUT,WILMINGTON,DE 19897		SMITH, LJ (corresponding author), NORTHWESTERN UNIV,MED CTR,SCH MED,DEPT MED,PULM SECT,WESLEY 456,250 E SUPERIOR ST,CHICAGO,IL 60611, USA.			Bernstein, Peter/0000-0003-0407-9150; Smith, Lewis J/0000-0002-4728-1562	NCRR NIH HHS [RR-00048] Funding Source: Medline; PHS HHS [A1-11403] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUSTEN KF, 1983, BRIT J PHARMACOL, V80, P47, DOI 10.1111/j.1476-5381.1983.tb11048.x; BANDOUVAKIS J, 1981, BRIT J DIS CHEST, V75, P295, DOI 10.1016/0007-0971(81)90009-7; BOULET LP, 1984, AM REV RESPIR DIS, V130, P368; CASTERLINE CL, 1976, J ALLERGY CLIN IMMUN, V58, P607, DOI 10.1016/0091-6749(76)90207-4; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHUNG KF, 1982, AM REV RESPIR DIS, V126, P849; CRESSE BR, 1984, EUR J PHARM, V102, P197; DAHLEN SE, 1983, ACTA PHYSIOL SCAND, V118, P415, DOI 10.1111/j.1748-1716.1983.tb07291.x; DAHLEN SE, 1983, ACTA PHYSIOL SCAND, V118, P393, DOI 10.1111/j.1748-1716.1983.tb07289.x; DAHLEN SE, 1983, ACTA PHYSL SCAND S, V512, P1; DAIN DS, 1975, J APPL PHYSIOL, V38, P1045, DOI 10.1152/jappl.1975.38.6.1045; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; EISER NM, 1982, B EUR PHYSIOPATH RES, V18, P449; GREENSPON LW, 1986, AM REV RESPIR DIS, V133, P735; HAMEL R, 1982, PROSTAGLANDINS, V24, P419, DOI 10.1016/0090-6980(82)90168-X; HIRSHMAN CA, 1983, PROSTAGLANDINS, V25, P481, DOI 10.1016/0090-6980(83)90020-5; JOHNSON HG, 1985, PROSTAGLANDINS, V29, P313, DOI 10.1016/0090-6980(85)90211-4; KERN R, 1986, AM REV RESPIR DIS, V133, P1127; KIRCHNER T, 1984, PROSTAGLANDINS, V27, P119, DOI 10.1016/0090-6980(84)90226-0; KRELL RD, 1983, PROSTAGLANDINS, V25, P171, DOI 10.1016/0090-6980(83)90102-8; LAUBE BL, 1986, AM REV RESPIR DIS, V133, P740; LEITCH AG, 1983, AM REV RESPIR DIS, V128, P639; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; MALO JL, 1985, AM REV RESPIR DIS, V132, P644; MILLMAN RP, 1982, J APPL PHYSIOL, V53, P690, DOI 10.1152/jappl.1982.53.3.690; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; NADEL JA, 1963, ANN NY ACAD SCI, V109, P712, DOI 10.1111/j.1749-6632.1963.tb13499.x; OBYRNE PM, 1985, J ALLERGY CLIN IMMUN, V76, P97, DOI 10.1016/0091-6749(85)90810-3; PIPER PJ, 1982, AGENTS ACTIONS S, V13, P173; PONG SS, 1983, P NATL ACAD SCI-BIOL, V80, P7415, DOI 10.1073/pnas.80.24.7415; RANE A, 1978, CLIN PHARMACOL THER, V23, P658; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SHEPPARD D, 1983, AM REV RESPIR DIS, V127, P691; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; STIMLER NP, 1984, BIOCHEM BIOPH RES CO, V125, P852, DOI 10.1016/0006-291X(84)91361-5; VINCENT JE, 1984, AGENTS ACTIONS S, V14, P69; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P2814, DOI 10.1001/jama.249.20.2814	39	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	1				340	347		10.1016/0091-6749(87)90040-6	http://dx.doi.org/10.1016/0091-6749(87)90040-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1036	3624684				2022-12-18	WOS:A1987K103600016
J	PLATTSMILLS, TAE				PLATTSMILLS, TAE			ORAL IMMUNOTHERAPY - A WAY FORWARD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											PLATTSMILLS, TAE (corresponding author), UNIV VIRGINIA,DEPT MED,DIV ALLERGY & IMMUNOL,CHARLOTTESVILLE,VA 22903, USA.							ASHERSON GL, 1980, IMMUNOL REV, V50, P3, DOI 10.1111/j.1600-065X.1980.tb00306.x; BJORKSTEN B, 1987, CLIN ALLERGY, V17, P91, DOI 10.1111/j.1365-2222.1987.tb02325.x; BLACK JH, 1939, ALLERGY, V10, P156; CHALLACOMBE SJ, 1980, J EXP MED, V152, P1459, DOI 10.1084/jem.152.6.1459; CHILLER JM, 1971, SCIENCE, V171, P813, DOI 10.1126/science.171.3973.813; COHEN SH, 1979, J ALLERGY CLIN IMMUN, V64, P270, DOI 10.1016/0091-6749(79)90143-X; COOPER PJ, 1984, CLIN ALLERGY, V14, P541, DOI 10.1111/j.1365-2222.1984.tb02242.x; GEORGITIS JW, 1983, J ALLERGY CLIN IMMUN, V71, P71, DOI 10.1016/0091-6749(83)90549-3; HARGREAVE FE, 1984, ASTHMA PHYSL IMMUNOP, P263; HASTIE R, 1979, LAB INVEST, V40, P554; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P189, DOI 10.1159/000227963; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; LOWENSTEIN H, 1978, ALLERGY, V33, P238, DOI 10.1111/j.1398-9995.1978.tb01543.x; MITCHELL EB, 1986, BRIT J DERMATOL, V114, P65, DOI 10.1111/j.1365-2133.1986.tb02780.x; MITCHELL EB, 1984, J INVEST DERMATOL, V83, P290, DOI 10.1111/1523-1747.ep12340423; MITCHELL EB, 1983, CLIN REV ALLERG, V1, P427; MOLLER C, 1986, ALLERGY, V41, P271, DOI 10.1111/j.1398-9995.1986.tb02028.x; NICKELSEN JA, 1979, J ALLERGY CLIN IMMUN, V63, P166; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1987, J ALLERGY CLIN IMMUN, V79, P572, DOI 10.1016/S0091-6749(87)80150-1; NORMAN PS, 1986, 12 P INT C ALL CLIN, P319; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PLATTSMILLS TAE, 1979, ADV ALLERGOLOGY APPL, P133; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROSENWASSER LJ, IN PRESS J ALLERGY C; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; TAMIR R, 1987, J ALLERGY CLIN IMMUN, V79, P591, DOI 10.1016/S0091-6749(87)80154-9; TAUDORF E, 1985, ALLERGY, V40, P321, DOI 10.1111/j.1398-9995.1985.tb00243.x; TAUDORF E, 1987, J ALLERGY CLIN IMMUN, V80	31	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1987	80	2					129	132		10.1016/0091-6749(87)90120-5	http://dx.doi.org/10.1016/0091-6749(87)90120-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J6575	2956315				2022-12-18	WOS:A1987J657500002
J	OSUR, SL; LILLIE, MA; CHEN, PB; AMBRUS, JL; WILSON, ME				OSUR, SL; LILLIE, MA; CHEN, PB; AMBRUS, JL; WILSON, ME			ELEVATION OF SERUM IGG LEVELS AND NORMALIZATION OF T4/T8 RATIO AFTER HEPATITIS IN A PATIENT WITH COMMON VARIABLE HYPOGAMMAGLOBULINEMIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,DEPT ORAL BIOL,3435 MAIN ST,FOSTER HALL,BUFFALO,NY 14214; SUNY BUFFALO,DIV ALLERGY & IMMUNOL,BUFFALO,NY 14214; SUNY BUFFALO,DEPT PEDIAT,BUFFALO,NY 14214; SUNY BUFFALO,DEPT MED,BUFFALO,NY 14214; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20205	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE006880, P50DE004898] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE04898, DE06880] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691; BARNABA V, 1985, GUT, V26, P739, DOI 10.1136/gut.26.7.739; DWYER JM, 1984, AM J MED, V76, P46; Eibl M, 1983, Birth Defects Orig Artic Ser, V19, P193; FIORILLI M, 1986, J CLIN IMMUNOL, V6, P21, DOI 10.1007/BF00915360; GEHA RS, 1974, NEW ENGL J MED, V291, P1, DOI 10.1056/NEJM197407042910101; GITNICK G, 1984, ANNU REV MED, V35, P265; HOOFNAGLE J, 1985, PRINCIPLES PRACTICE, P772; HORWITZ MA, 1982, REV INFECT DIS, V4, P104; KNODELL RG, 1975, GASTROENTEROLOGY, V69, P1278; KORETZ RL, 1980, GASTROENTEROLOGY, V79, P893; LEMON SM, 1985, NEW ENGL J MED, V313, P1059, DOI 10.1056/NEJM198510243131706; LEVER AML, 1984, LANCET, V2, P1062; OCKNER RK, 1985, CECIL TXB MED, P813; SIEGAL FP, 1978, NEW ENGL J MED, V299, P172, DOI 10.1056/NEJM197807272990404; ZHUANG H, 1982, GASTROENTEROLOGY, V82, P549; 1985, MMWR, V34, P245	17	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1987	79	6					969	975		10.1016/0091-6749(87)90249-1	http://dx.doi.org/10.1016/0091-6749(87)90249-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H9044	3108350	Bronze			2022-12-18	WOS:A1987H904400021
J	SIMONS, KJ; SIMONS, FER				SIMONS, KJ; SIMONS, FER			THE EFFECT OF CHRONIC ADMINISTRATION OF HYDROXYZINE ON HYDROXYZINE PHARMACOKINETICS IN DOGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC MED,DEPT PEDIAT & CHILD HLTH,ALLERGY & CLIN IMMUNOL SECT,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba	SIMONS, KJ (corresponding author), UNIV MANITOBA,FAC PHARM,WINNIPEG R3T 2N2,MANITOBA,CANADA.							[Anonymous], 1980, PRINCIPLES PROCEDURE; BANTZ FW, UNPUB J ALLERGY CLIN; BARAF CS, 1976, CURR THER RES CLIN E, V19, P32; BURNS JJ, 1963, ANN NY ACAD SCI, V104, P881, DOI 10.1111/j.1749-6632.1963.tb57090.x; BYE CE, 1977, EUR J CLIN PHARMACOL, V12, P181, DOI 10.1007/BF00609857; CONNEY AH, 1961, J PHARMACOL EXP THER, V132, P202; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; CROUTHAMEL W, 1983, ANIMAL MODELS ORAL D; DANNENBERG TB, 1951, J ALLERGY, V22, P330, DOI 10.1016/0021-8707(51)90033-0; FINDLAY JWA, 1984, J PHARM SCI, V73, P1339, DOI 10.1002/jps.2600731003; GENDREAUREID L, 1986, J ALLERGY CLIN IMMUN, V77, P335, DOI 10.1016/S0091-6749(86)80114-2; Gibaldi M, 1982, PHARMACOKINETICS; GOTH A, 1978, ALLERGY PRINCIPLES P, P454; KLEIN GL, 1980, ANN ALLERGY, V44, P142; LONG WF, 1985, J ALLERGY CLIN IMMUN, V76, P113, DOI 10.1016/0091-6749(85)90813-9; MATTHEWS CN, 1973, BRIT J DERMATOL, V88, P279; MONASH S, 1950, J INVEST DERMATOL, V15, P1, DOI 10.1038/jid.1950.61; MYGIND N, 1979, NASAL ALLERGY, P257; OSTERLOH JD, 1980, DRUG METAB DISPOS, V8, P12; PONG SF, 1974, J PHARM SCI, V63, P1527, DOI 10.1002/jps.2600631008; SCHAAF L, 1979, J ALLERGY CLIN IMMUN, V63, P129, DOI 10.1016/0091-6749(79)90203-3; SIMONS FER, 1984, J ALLERGY CLIN IMMUN, V73, P69, DOI 10.1016/0091-6749(84)90486-X; SIMONS FER, 1983, PEDIATR CLIN N AM, V30, P899; SIMONS FER, 1984, J PEDIATR-US, V104, P123; SIMONS KJ, 1984, J PHARM SCI, V73, P595, DOI 10.1002/jps.2600730505; TAYLOR RJ, 1985, J ALLERGY CLIN IMMUN, V76, P103, DOI 10.1016/0091-6749(85)90811-5; WONG L, 1981, J ALLERGY CLIN IMMUN, V67, P223, DOI 10.1016/0091-6749(81)90065-8	27	13	13	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1987	79	6					928	932		10.1016/0091-6749(87)90242-9	http://dx.doi.org/10.1016/0091-6749(87)90242-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H9044	2884246				2022-12-18	WOS:A1987H904400014
J	PATTERSON, R; DYKEWICZ, MS; GRAMMER, LC; PRUZANSKY, JJ; ZEISS, CR; HARRIS, KE				PATTERSON, R; DYKEWICZ, MS; GRAMMER, LC; PRUZANSKY, JJ; ZEISS, CR; HARRIS, KE			FORMALDEHYDE REACTIONS AND THE BURDEN OF PROOF	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											PATTERSON, R (corresponding author), NORTHWESTERN UNIV,SCH MED,ALLERGY IMMUNOL SECT,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.			Grammer, Leslie/0000-0001-6860-2014				FASSBINDER W, 1978, VOX SANG, V35, P41, DOI 10.1111/j.1423-0410.1978.tb02899.x; Horsfall FL, 1934, J IMMUNOL, V27, P569; Jacobs JL, 1939, J IMMUNOL, V36, P531; LANDSTEINER K, 1917, Z IMMUNOL, V26, P133; LANDSTEINER K, 1914, Z IMMUNITATSFORSCH, V20, P618; LYNEN R, 1983, VOX SANG, V44, P81, DOI 10.1111/j.1423-0410.1983.tb04106.x; MARSHALL E, 1986, SCIENCE, V234, P1490, DOI 10.1126/science.3787255; MAURICE F, 1986, J ALLERGY CLIN IMMUN, V77, P594, DOI 10.1016/0091-6749(86)90351-9; PATTERSON R, 1985, J LAB CLIN MED, V106, P93; PATTERSON R, 1982, J ALLERGY CLIN IMMUN, V70, P19, DOI 10.1016/0091-6749(82)90196-8; PATTERSON R, 1986, INT ARCH ALLER A IMM, V79, P53, DOI 10.1159/000233942; SANDLER SG, 1978, ISRAEL J MED SCI, V14, P1177; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0	13	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1987	79	5					705	706		10.1016/0091-6749(87)90199-0	http://dx.doi.org/10.1016/0091-6749(87)90199-0			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H4349	3571763				2022-12-18	WOS:A1987H434900002
J	TERR, AI				TERR, AI			CLINICAL ECOLOGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											TERR, AI (corresponding author), STANFORD UNIV,MED CTR,DIV IMMUNOL,STANFORD,CA 94305, USA.							ADLER G, 1981, NEW ENGL J MED, V304, P1394, DOI 10.1056/NEJM198106043042304; BASSLER A, 1930, INTESTINAL TOXEMIA A; Beard George Miller, 1881, AM NERVOUSNESS ITS C; BELL IR, 1982, CLIN ECOLOGY NEW MED; BOUCHARD C, 1906, LECTURES AUTOINTOXIC; BRODSKY CM, 1983, PSYCHOSOMATICS, V24, P731, DOI 10.1016/S0033-3182(83)73168-3; CROOK WG, 1984, YEAST CONNECTION MED; DICKEY LD, 1976, CLIN ECOLOGY, P152; JEWETT DL, 1985, J ALLERGY CLIN IMMUN, V75, P205, DOI 10.1016/0091-6749(85)90537-8; QUILL TE, 1985, JAMA-J AM MED ASSOC, V254, P3075, DOI 10.1001/jama.254.21.3075; Randolph T.G., 1962, HUMAN ECOLOGY SUSCEP; RANDOLPH TG, 1980, ALTERNATIVE APPROACH; TERR AI, 1986, ARCH INTERN MED, V146, P145; 1972, STUDY HLTH PRACTICES; 1980, DIAGNOSTIC STATISTIC, P241; 1981, J ALLERGY CLIN IMMUN, V67, P333; 1986, W J MED, V144, P239; 1985, M7A2C4 MIN HLTH PUBL; 1983, ALLERGY PRINCIPLES P, pR21	19	13	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1987	79	3					423	426		10.1016/0091-6749(87)90357-5	http://dx.doi.org/10.1016/0091-6749(87)90357-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G4795	3819224				2022-12-18	WOS:A1987G479500002
J	PRICE, LA; SAFKO, M				PRICE, LA; SAFKO, M			BEE VENOM ALLERGY IN A PATIENT WITH URTICARIA PIGMENTOSA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PRICE, LA (corresponding author), FAAAI,2320 BATH ST,SANTA BARBARA,CA 93105, USA.							LEWIS RA, 1984, J ALLERGY CLIN IMMUN, V74, P755, DOI 10.1016/0091-6749(84)90172-6; LEWIS RA, 1982, CECIL TXB MED, P1818; MULLER UR, 1983, J ALLERGY CLIN IMMUN, V72, P685, DOI 10.1016/0091-6749(83)90630-9	3	13	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1987	79	2					407	409		10.1016/0091-6749(87)90162-X	http://dx.doi.org/10.1016/0091-6749(87)90162-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G1791	3819222				2022-12-18	WOS:A1987G179100017
J	KING, TP				KING, TP			SENSITIVITY OF IMMUNOASSAYS FOR DETECTING CROSS-REACTIVITY OF HOMOLOGOUS VENOM PROTEINS OF YELLOW JACKETS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KING, TP (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.				NIAID NIH HHS [AI 17021] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017021] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berzofsky J., 1984, FUNDAMENTAL IMMUNOLO, P595; GIALLONGO A, 1982, J IMMUNOL METHODS, V52, P379, DOI 10.1016/0022-1759(82)90009-6; HIRAYAMA A, 1985, J IMMUNOL, V134, P3241; HOFFMAN DR, 1982, ANN ALLERGY, V48, P78; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P611, DOI 10.1016/0091-6749(85)90038-7; KARUSH F, 1978, COMPR IMMUNOL, V5, P85; KING TP, 1985, J ALLERGY CLIN IMMUN, V75, P621, DOI 10.1016/0091-6749(85)90040-5; KING TP, 1983, MOL IMMUNOL, V20, P297, DOI 10.1016/0161-5890(83)90069-X; KING TP, 1984, ARCH BIOCHEM BIOPHYS, V230, P1, DOI 10.1016/0003-9861(84)90080-8; KING TP, 1978, BIOCHEMISTRY, V17, P51615; LACY MJ, 1986, J IMMUNOL METHODS, V87, P169, DOI 10.1016/0022-1759(86)90527-2; PETERFY F, 1983, J IMMUNOL, V130, P1809; ROCK CO, 1975, J BIOL CHEM, V250, P6564; STEWARD MW, 1985, J IMMUNOL METHODS, V78, P173, DOI 10.1016/0022-1759(85)90074-2; THOMPSON RJ, 1984, TRENDS BIOCHEM SCI, V9, P1, DOI 10.1016/0968-0004(84)90033-1; TUNG AS, 1983, METHOD ENZYMOL, V93, P12; WICHER K, 1980, J ALLERGY CLIN IMMUN, V66, P244, DOI 10.1016/0091-6749(80)90047-0; [No title captured]	18	13	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					113	120		10.1016/S0091-6749(87)80025-8	http://dx.doi.org/10.1016/S0091-6749(87)80025-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810	2433322				2022-12-18	WOS:A1987F881000021
J	MALVEAUX, FJ				MALVEAUX, FJ			DEATHS FROM ASTHMA BY RACE, SEX, AND AGE, 1979-83	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					183	183						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810					2022-12-18	WOS:A1987F881000255
J	SILK, H; GEHA, RS				SILK, H; GEHA, RS			INTRAVENOUSGAMMAGLOBULIN (IVGG) PROPHYLAXIS IN CHILDREN WITH IGG2 DEFICIENCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					188	188						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810					2022-12-18	WOS:A1987F881000276
J	VALONE, F; SHALIT, M; ATKINS, P; GOETZEL, E; ZWEIMAN, B				VALONE, F; SHALIT, M; ATKINS, P; GOETZEL, E; ZWEIMAN, B			PLATELET-ACTIVATING-FACTOR RELEASE IN ALLERGIC SKIN SITES IN HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					248	248						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810					2022-12-18	WOS:A1987F881000516
J	PEDERSEN, S				PEDERSEN, S			EFFECTS OF FOOD ON THE ABSORPTION OF THEOPHYLLINE IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									AALBORG HOSP N,DEPT PEDIAT,AALBORG,DENMARK	Aalborg University; Aalborg University Hospital								BENZVI Z, 1981, NEW ENGL J MED, V304, P613; BIRKETT DJ, 1984, BR J CLIN PRACT S35, V38, P17; BIRKETT DT, 1983, SUSTAINED RELEASE TH, P147; DASTA J, 1979, AM J HOSP PHARM, V36, P613, DOI 10.1093/ajhp/36.5.613; HENDELES L, 1985, CHEST, V87, P758, DOI 10.1378/chest.87.6.758; HENDELES L, 1984, LANCET, V2, P1471; KARIM A, 1985, CLIN PHARMACOL THER, V38, P77, DOI 10.1038/clpt.1985.138; LAGAS M, 1983, EUR J CLIN PHARMACOL, V24, P761, DOI 10.1007/BF00607084; LAGAS M, 1985, PHARM WEEKBLAD, V7, P10, DOI 10.1007/BF01962863; LEEDS NH, 1982, J CLIN PHARMACOL, V22, P196, DOI 10.1002/j.1552-4604.1982.tb02162.x; LOTNER GZ, 1983, ANN ALLERGY, V50, P27; NERMINATHAN V, 1984, ARCH DIS CHILD, V59, P762, DOI 10.1136/adc.59.8.762; NEWMAN LJ, 1980, ANN ALLERGY, V45, P95; OSMAN MA, 1983, BIOPHARM DRUG DISPOS, V4, P63, DOI 10.1002/bdd.2510040109; OSMAN MA, 1983, SUSTAINED RELEASE TH, P47; PEDERSEN S, 1985, CLIN ALLERGY, V15, P253, DOI 10.1111/j.1365-2222.1985.tb02282.x; PEDERSEN S, 1982, ALLERGY, V37, P531, DOI 10.1111/j.1398-9995.1982.tb02336.x; PEDERSEN S, 1986, ALLERGY, V41, P46, DOI 10.1111/j.1398-9995.1986.tb00274.x; PEDERSEN S, 1984, PEDIATRICS, V74, P534; PEDERSEN S, 1981, BRIT J CLIN PHARMACO, V12, P904, DOI 10.1111/j.1365-2125.1981.tb01329.x; PEDERSEN S, ABSORPTION THEODUR S; PEDERSEN S, CHILDHOOD ASTHMA SUS; PEDERSEN S, 1984, BR J CLIN PRACT S35, V38, P37; ROGERS RJ, 1985, J PEDIATR-US, V106, P496, DOI 10.1016/S0022-3476(85)80690-9; SHENFIELD GM, 1984, MED J AUSTRALIA, V140, P477, DOI 10.5694/j.1326-5377.1984.tb108166.x; SIMONS FER, 1982, AM J DIS CHILD, V136, P790, DOI 10.1001/archpedi.1982.03970450032008; SIPS AP, 1984, EUR J CLIN PHARMACOL, V26, P405, DOI 10.1007/BF00548776; SOMMER B, 1981, ALLERGY, V36, P507, DOI 10.1111/j.1398-9995.1981.tb01863.x; SPECTOR SL, 1985, J ALLERGY CLIN IMMUN, V75, P105, DOI 10.1016/0091-6749(85)90139-3; STEFFENSEN G, FOOD INDUCED CHANGES; STEWART RB, 1972, CLIN PHARMACOL THER, V13, P463; TABACHNIK E, 1982, J PEDIATR-US, V100, P489, DOI 10.1016/S0022-3476(82)80467-8; THOMPSON PJ, 1983, BRIT J DIS CHEST, V77, P293; TINKELMAN DG, 1985, ANN ALLERGY, V54, P280; TINKELMAN DG, 1980, ANN ALLERGY, V44, P283; WEINBERGER M, 1981, J PEDIATR-US, V99, P145, DOI 10.1016/S0022-3476(81)80982-1; WHYTE KF, 1983, LANCET, V2, P618	37	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	2				704	709		10.1016/0091-6749(86)90049-7	http://dx.doi.org/10.1016/0091-6749(86)90049-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5684	3771960				2022-12-18	WOS:A1986E568400007
J	WAGNER, JG				WAGNER, JG			ESTIMATION OF THEOPHYLLINE ABSORPTION RATE BY MEANS OF THE WAGNER-NELSON EQUATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,SCH MED,UPJOHN CTR CLIN PHARMACOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	WAGNER, JG (corresponding author), UNIV MICHIGAN,COLL PHARM,ANN ARBOR,MI 48109, USA.							CABANNA BE, 1980, BETTER SAFETY DRUGS, P301; GONZALEZ MA, 1983, DRUG DEV IND PHARM, V9, P1379, DOI 10.3109/03639048309046324; HEIMLICH BN, 1978, 25TH NAT M AC PHARM, V8, P79; UPTON RA, 1982, J PHARMACOKINET BIOP, V10, P123, DOI 10.1007/BF01062330; Wagner J.G., 1984, PHARMACOKINETICS MOD, P173; WAGNER JG, 1983, J PHARM SCI, V72, P578, DOI 10.1002/jps.2600720531; WAGNER JG, 1983, BIOPHARM DRUG DISPOS, V4, P359, DOI 10.1002/bdd.2510040408; WAGNER JG, 1985, CLIN PHARMACOKINET, V10, P432, DOI 10.2165/00003088-198510050-00005; WAGNER JG, 1974, J PHARMACOKINET BIOP, V2, P469, DOI 10.1007/BF01070942; WAGNER JG, 1984, BIOPHARM DRUG DISPOS, V5, P75, DOI 10.1002/bdd.2510050110; WAGNER JG, 1963, J PHARM SCI, V52, P610, DOI 10.1002/jps.2600520629; WAGNER JG, 1975, FUNDAMENTALS CLIN PH, P181; WAGNER JG, 1984, SUSTAINED RELEASE TH, P113; WEINBERGER M, 1978, NEW ENGL J MED, V299, P852, DOI 10.1056/NEJM197810192991603; WILKINSON PK, 1976, CLIN PHARMACOL THER, V19, P213	15	13	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	2				681	688		10.1016/0091-6749(86)90046-1	http://dx.doi.org/10.1016/0091-6749(86)90046-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5684	3771958				2022-12-18	WOS:A1986E568400004
J	DUNNETTE, SL; HALL, MM; WASHINGTON, JA; KERN, EB; MCDONALD, TJ; FACER, GW; GLEICH, GJ				DUNNETTE, SL; HALL, MM; WASHINGTON, JA; KERN, EB; MCDONALD, TJ; FACER, GW; GLEICH, GJ			MICROBIOLOGIC ANALYSES OF NASAL POLYP TISSUE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,CLIN MICROBIOL SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT OTORHINOLARYNGOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic	DUNNETTE, SL (corresponding author), MAYO CLIN & MAYO FDN,DIV ALLERG DIS & INTERNAL MED,200 1ST ST SW,ROCHESTER,MN 55905, USA.				NIAID NIH HHS [AI 11483] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLOOM S M, 1969, Journal of Asthma Research, V6, P137, DOI 10.3109/02770906909104330; HEGGERS JP, 1969, T ROY SOC TROP MED H, V63, P532, DOI 10.1016/0035-9203(69)90043-1; KNIGHT A, 1968, CAN MED ASSOC J, V99, P116; KRIZEK TJ, 1975, AM J SURG, V130, P579, DOI 10.1016/0002-9610(75)90516-4; Lindberg R B, 1965, J Trauma, V5, P601; LOEBL EC, 1974, AM J CLIN PATHOL, V61, P20; MARSHALL KA, 1976, AM J SURG, V131, P730, DOI 10.1016/0002-9610(76)90190-2; ROBERTS GD, 1981, LABORATORY PROCEDURE, P69; SANDERS SH, 1966, ANN ALLERGY, V24, P535; Shuck J M, 1969, Curr Probl Surg, P3; SIEGAL S, 1956, ARCH INTERN MED, V97, P431, DOI 10.1001/archinte.1956.00250220051005; SMITH AG, 1978, INVASION NASAL POLYP, P319; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TEPLITZ C, 1964, J Surg Res, V4, P200, DOI 10.1016/S0022-4804(64)80026-3; WASHINGTON JA, 1981, LABORATORY PROCEDURE, P91; WEISSKOPF A, 1959, Ann Otol Rhinol Laryngol, V68, P509; WLADISLAVOSKYWASERMAN P, 1984, CLIN ALLERGY, V14, P241, DOI 10.1111/j.1365-2222.1984.tb02203.x	17	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	1				102	108		10.1016/0091-6749(86)90121-1	http://dx.doi.org/10.1016/0091-6749(86)90121-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2996	3722630				2022-12-18	WOS:A1986D299600016
J	CALVANICO, NJ				CALVANICO, NJ			A COMPONENT OF PIGEON DROPPING EXTRACT THAT REACTS SPECIFICALLY WITH SERA OF INDIVIDUALS WITH PIGEON-BREEDERS DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53226	Medical College of Wisconsin	CALVANICO, NJ (corresponding author), VET ADM MED CTR,RES SERV 151,WOOD,WI 53193, USA.				NHLBI NIH HHS [HL 29327] Funding Source: Medline; NIAID NIH HHS [AI 19104] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI019104] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AXELSEN NH, 1973, MANUAL QUANTITATIVE, P47; BARON C, 1975, BIOCHIM BIOPHYS ACTA, V382, P276, DOI 10.1016/0005-2736(75)90270-9; CALVANICO NJ, 1985, CLIN EXP IMMUNOL, V59, P336; CALVANICO NJ, 1984, IMMUNOLOGY LUNG UPPE, P365; CUATRECA.P, 1968, P NATL ACAD SCI USA, V61, P636, DOI 10.1073/pnas.61.2.636; FINK JN, 1969, J LAB CLIN MED, V74, P325; FINK JN, 1972, CHEST, V62, P277, DOI 10.1378/chest.62.3.277; FINK JN, MONOGRAPH RESPIRATOR; KARR RM, 1979, COMPREHENSIVE IMMUNO, V6, P469; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBIN P, 1978, ANAL BIOCHEM, V85, P114, DOI 10.1016/0003-2697(78)90281-6; MCCORMICK DJ, 1982, J IMMUNOL, V129, P1493; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; PATTERSON R, 1976, AM J MED, V60, P144, DOI 10.1016/0002-9343(76)90543-X; PEPYS J, 1978, IMMUNOLOGICAL DISEAS, P692; REYES CN, 1982, CHEST, V81, P142, DOI 10.1378/chest.81.2.142; ROSEN A, 1979, J IMMUNOL METHODS, V28, P1, DOI 10.1016/0022-1759(79)90322-3; SMITH JA, 1978, ANAL BIOCHEM, V87, P299, DOI 10.1016/0003-2697(78)90679-6; WARREN KS, 1967, AM J PATHOL, V51, P735; WEEKE B, 1973, MANUAL QUANTITATIVE, P71	20	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	1				80	86		10.1016/0091-6749(86)90327-1	http://dx.doi.org/10.1016/0091-6749(86)90327-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD36	3944376				2022-12-18	WOS:A1986AZD3600015
J	COCKCROFT, DW; MURDOCK, KY				COCKCROFT, DW; MURDOCK, KY			PROTECTIVE EFFECT OF INHALED ALBUTEROL, CROMOLYN, BECLOMETHASONE AND PLACEBO ON ALLERGEN-INDUCED EARLY ASTHMATIC RESPONSE (EAR), LATE ASTHMATIC RESPONSE (LAR), AND ALLERGEN-INDUCED INCREASE IN BRONCHIAL RESPONSIVENESS TO INHALED HISTAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	2	S			122	122						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD38					2022-12-18	WOS:A1986AZD3800008
J	AURITT, WA; MCGEADY, SJ; MANSMANN, HC				AURITT, WA; MCGEADY, SJ; MANSMANN, HC			THE RELATIONSHIP OF CEREBROSPINAL-FLUID AND PLASMA THEOPHYLLINE CONCENTRATIONS IN CHILDREN AND ADOLESCENTS TAKING THEOPHYLLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,1025 WALNUT ST,PHILADELPHIA,PA 19107; CHILDRENS HEART HOSP,PHILADELPHIA,PA	Jefferson University					NHLBI NIH HHS [R01-HL27578] Funding Source: Medline; CIT NIH HHS [MCT-009021] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); CIT NIH HHS		GANDREAULT P, 1983, J PEDIATR, V102, P474; JUSKO WJ, 1976, AM J HOSP PHARM, V33, P1193, DOI 10.1093/ajhp/33.11.1193; KADLEC GJ, 1978, ANN ALLERGY, V41, P337; KAPITULNIK J, 1975, J PEDIATRICS, V86, P422; LAWYER C, 1978, ANN INTERN MED, V88, P516, DOI 10.7326/0003-4819-88-4-516; NELLHAUS G, 1975, PEDIATR CLIN N AM, V22, P89; PETERS SG, 1984, MAYO CLIN PROC, V59, P568, DOI 10.1016/S0025-6196(12)61495-5; SHAW LM, 1982, CLIN PHARMACOL THER, V32, P490, DOI 10.1038/clpt.1982.193; SOMANI SM, 1980, J PEDIATR-US, V96, P1091, DOI 10.1016/S0022-3476(80)80652-4; TURMEN T, 1979, J PEDIATR-US, V95, P644, DOI 10.1016/S0022-3476(79)80788-X; 1981, ELECTROENCEPHALOGRAP, P287	11	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	6					731	735		10.1016/0091-6749(85)90102-2	http://dx.doi.org/10.1016/0091-6749(85)90102-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ALA84	4008802	Bronze			2022-12-18	WOS:A1985ALA8400017
J	HALWIG, JM; KURUP, VP; GREENBERGER, PA; PATTERSON, R				HALWIG, JM; KURUP, VP; GREENBERGER, PA; PATTERSON, R			A FAMILIAL OCCURRENCE OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS - A PROBABLE ENVIRONMENTAL SOURCE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY SECT,303 E CHICAGO AVE,CHICAGO,IL 60611; MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53226; VET ADM MED CTR,RES SERV,WOOD,WI 53193	Northwestern University; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403, P50AI019104] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-11403, AI-19104] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASICH JE, 1981, J ALLERGY CLIN IMMUN, V68, P98, DOI 10.1016/0091-6749(81)90165-2; FINK JN, 1976, MANUAL CLIN IMMUNOLO, P616; FLAHERTY DK, 1978, CLIN ALLERGY, V8, P73, DOI 10.1111/j.1365-2222.1978.tb00451.x; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GRAVES TS, 1979, ANN INTERN MED, V91, P378, DOI 10.7326/0003-4819-91-3-378; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; GREENBERGER PA, 1983, ARCH INTERN MED, V143, P2003, DOI 10.1001/archinte.143.10.2003; HENDERSON AH, 1968, THORAX, V23, P513, DOI 10.1136/thx.23.5.513; KURUP VP, 1978, AM J CLIN PATHOL, V69, P414; KURUP VP, 1978, MICROBIOS, V19, P191; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286; PATTERSON R, 1977, AM J MED, V63, P257, DOI 10.1016/0002-9343(77)90240-6; RICKETTI AJ, 1983, ARCH INTERN MED, V143, P1553, DOI 10.1001/archinte.143.8.1553; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSENBERG M, 1977, J CHRON DIS, V30, P193, DOI 10.1016/0021-9681(77)90039-X; SCADDING JG, 1967, SCAND J RESPIR DIS, V48, P372; SLAVIN RG, 1978, INT ARCH ALLER A IMM, V56, P325, DOI 10.1159/000232038; Vithayasai V, 1973, IMJ Ill Med J, V144, P564; WANG JLF, 1982, AM REV RESPIR DIS, V76, P286	20	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	1					55	59		10.1016/0091-6749(85)90804-8	http://dx.doi.org/10.1016/0091-6749(85)90804-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AMV84	4008814				2022-12-18	WOS:A1985AMV8400007
J	HEMADY, Z; GELLIS, S; CHAMBERS, M; ROCKLIN, RE				HEMADY, Z; GELLIS, S; CHAMBERS, M; ROCKLIN, RE			EFFECT OF DEXAMETHASONE ON DENOVO IGE SYNTHESIS BY HUMAN-BLOOD LYMPHOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TUFTS UNIV,NEW ENGLAND MED CTR,DEPT MED,DIV ALLERGY,171 HARRISON AVE,BOSTON,MA 02111; TUFTS UNIV,NEW ENGLAND MED CTR,DEPT DERMATOL,DIV ALLERGY,BOSTON,MA 02111	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University					NIAID NIH HHS [AI-15952] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON J, 1974, EUR J IMMUNOL, V4, P533, DOI 10.1002/eji.1830040803; BALARD P, 1979, GLUCOCORTICOID HORMO, P494; BAYLER JD, 1975, TRANSPLANT P, V7, P55; BUCKLEY RH, 1982, ANN ALLERGY, V49, P67; CHEN WY, 1981, J EXP MED, V153, P365, DOI 10.1084/jem.153.2.365; CLAMAN HN, 1972, NEW ENGL J MED, V287, P388, DOI 10.1056/NEJM197208242870806; ENGLEMAN EG, 1981, J IMMUNOL, V127, P2124; FAUCI AS, 1976, ANN INTERN MED, V84, P304, DOI 10.7326/0003-4819-84-3-304; FAUCI AS, 1974, J CLIN INVEST, V53, P240, DOI 10.1172/JCI107544; FAUCI AS, 1977, J IMMUNOL, V119, P598; FISER PM, 1979, J IMMUNOL, V123, P1788; FLOWER RJ, 1979, NATURE, V278, P456, DOI 10.1038/278456a0; GALANAUD P, 1981, CLIN IMMUNOL IMMUNOP, V18, P68, DOI 10.1016/0090-1229(81)90009-X; GRAYSON J, 1981, J CLIN INVEST, V68, P1539, DOI 10.1172/JCI110408; HEMADY Z, 1983, J ALLERGY CLIN IMMUN, V71, P324, DOI 10.1016/0091-6749(83)90087-8; HIRATA F, 1980, P NATL ACAD SCI-BIOL, V77, P2533, DOI 10.1073/pnas.77.5.2533; ILFELD DN, 1977, J IMMUNOL, V119, P428; ORSON FM, 1983, J EXP MED, V158, P1473, DOI 10.1084/jem.158.5.1473; SAXON A, 1978, J CLIN INVEST, V61, P922, DOI 10.1172/JCI109017; SETTIPANE GA, 1978, J ALLERGY CLIN IMMUN, V62, P162, DOI 10.1016/0091-6749(78)90101-X; SHERMAN NA, 1973, J ALLERGY CLIN IMMUN, V52, P13, DOI 10.1016/0091-6749(73)90116-4; SMITH RS, 1972, INT ARCH ALLER A IMM, V43, P859, DOI 10.1159/000230903; THIELE DL, 1982, J IMMUNOL, V129, P1033; THOMPSON EB, 1974, METABOLISM, V23, P159, DOI 10.1016/0026-0495(74)90113-9; TOSATO G, 1980, J CLIN INVEST, V66, P383, DOI 10.1172/JCI109867; WALDMANN TA, 1976, FED PROC, V35, P2067; YODI T, 1981, J IMMUNOL, V127, P476	27	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	2					304	312		10.1016/0091-6749(85)90062-4	http://dx.doi.org/10.1016/0091-6749(85)90062-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABZ05	3918092				2022-12-18	WOS:A1985ABZ0500012
J	HUMPHRIES, T; WEINBERGER, M; VAUGHAN, L; EKWO, E				HUMPHRIES, T; WEINBERGER, M; VAUGHAN, L; EKWO, E			DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF CHILDHOOD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					197	197		10.1016/0091-6749(85)90504-4	http://dx.doi.org/10.1016/0091-6749(85)90504-4			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	ACF22		Bronze			2022-12-18	WOS:A1985ACF2200369
J	FREY, MJ; CHESROWN, SE; REED, BR; GREENSPON, LW; SHIELDS, RL; BOURNE, HR; BROWN, JK; GOLD, WM				FREY, MJ; CHESROWN, SE; REED, BR; GREENSPON, LW; SHIELDS, RL; BOURNE, HR; BROWN, JK; GOLD, WM			IMMUNOLOGICAL RELEASE OF HISTAMINE FROM DOG LUNG - COMPARISON OF INVIVO AND INVITRO RESPONSES IN THE SAME ANIMAL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,DIV CLIN PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-19156, HL-24136, HL-07159] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASSEM ESK, 1969, NATURE, V224, P1028, DOI 10.1038/2241028a0; AUSTEN KF, 1975, AM REV RESPIR DIS, V112, P423; BOOTH BH, 1970, J LAB CLIN MED, V76, P181; FRICK OL, 1965, J IMMUNOL, V94, P890; GOLD WM, 1977, J APPL PHYSIOL, V43, P271, DOI 10.1152/jappl.1977.43.2.271; GOLD WM, 1972, J APPL PHYSIOL, V33, P496, DOI 10.1152/jappl.1972.33.4.496; GREENSPON L W, 1981, American Review of Respiratory Disease, V123, P52; HIRSHMAN CA, 1980, J APPL PHYSIOL, V49, P953, DOI 10.1152/jappl.1980.49.6.953; Hogg J. C., 1977, Asthma - physiology, immunopharmacology, and treatment. (Proc. 2nd Internat. Conf. on asthma, Augusta, Michigan, Sept. 20-22, 1976)., P1; KAGEYSOBOTKA A, 1982, FED PROC, V41, P12; KESSLER GF, 1974, INT ARCH ALLER A IMM, V47, P313, DOI 10.1159/000231225; KRELL RD, 1976, INT ARCH ALLER A IMM, V51, P641, DOI 10.1159/000231643; LAZARUS SC, 1979, J APPL PHYSIOL, V46, P919, DOI 10.1152/jappl.1979.46.5.919; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LICHTENSTEIN L M, 1973, P91; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MJORNDAL TO, 1983, J ALLERGY CLIN IMMUN, V71, P62, DOI 10.1016/0091-6749(83)90548-1; NISAM MR, 1978, J APPL PHYSIOL, V44, P455, DOI 10.1152/jappl.1978.44.3.455; Osler A G, 1968, Adv Immunol, V8, P183, DOI 10.1016/S0065-2776(08)60467-8; OSLER AG, 1957, J EXP MED, V106, P811, DOI 10.1084/jem.106.6.811; SNAPPER JR, 1980, AM REV RESPIR DIS, V122, P775, DOI 10.1164/arrd.1980.122.5.775; THOMPSON AR, 1972, BIOCHIM BIOPHYS ACTA, V261, P245, DOI 10.1016/0304-4165(72)90335-2; UVNAS B, 1967, ACTA PHYSIOL SCAND, V70, P269, DOI 10.1111/j.1748-1716.1967.tb03625.x; VANARSDEL PP, 1958, J ALLERGY, V29, P429, DOI 10.1016/0021-8707(58)90084-4; WANNER A, 1975, J APPL PHYSIOL, V39, P950, DOI 10.1152/jappl.1975.39.6.950	27	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	5					728	737		10.1016/0091-6749(84)90237-9	http://dx.doi.org/10.1016/0091-6749(84)90237-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TT169	6209322				2022-12-18	WOS:A1984TT16900012
J	GOLDYNE, ME				GOLDYNE, ME			HETEROGENEITY IN LEUKOCYTE PREPARATIONS - EFFECTS ON DEFINING EICOSANOID METABOLISM BY HUMAN-LYMPHOCYTES AND MONOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT DERMATOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	GOLDYNE, ME (corresponding author), SAN FRANCISCO GEN HOSP,ROSALIND RUSSELL ARTHRIT RES LABS,SAN FRANCISCO,CA 94110, USA.				NIADDK NIH HHS [AM-30803] Funding Source: Medline; NIAID NIH HHS [AI-14752] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM030803] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACH MK, 1978, J IMMUNOL, V120, P998; BAGGIOLINI M, 1982, IMMUNOBIOLOGY, V161, P369, DOI 10.1016/S0171-2985(82)80094-6; BANKHURST AD, 1981, J LAB CLIN MED, V97, P179; BRAY MA, 1981, INT J IMMUNOPHARMACO, V3, P377, DOI 10.1016/0192-0561(81)90033-3; CASALE TB, 1982, J IMMUNOL METHODS, V55, P347, DOI 10.1016/0022-1759(82)90094-1; COHEN AM, 1980, ACTA HAEMATOL-BASEL, V64, P61, DOI 10.1159/000207212; DEJANA E, 1983, BIOCHIM BIOPHYS ACTA, V750, P261, DOI 10.1016/0005-2760(83)90027-9; DOIG MV, 1980, PROSTAGLANDINS, V20, P1007, DOI 10.1016/0090-6980(80)90055-6; DY M, 1980, EUR J IMMUNOL, V10, P121, DOI 10.1002/eji.1830100210; FIELD EJ, 1963, BRIT MED J, V2, P388; FRIEDMAN SA, 1979, CELL IMMUNOL, V42, P213, DOI 10.1016/0008-8749(79)90237-5; GOETZL EJ, 1981, BIOCHEM BIOPH RES CO, V101, P344, DOI 10.1016/0006-291X(81)91266-3; Goldyne M E, 1980, Adv Prostaglandin Thromboxane Res, V8, P1655; GOLDYNE ME, 1979, PROSTAGLANDINS, V18, P687, DOI 10.1016/0090-6980(79)90089-3; GOLDYNE ME, 1982, PROSTAGLANDINS, V24, P623, DOI 10.1016/0090-6980(82)90032-6; GOLDYNE ME, J BIOL CHEM; GOLDYNE ME, 1983, RECENT ADV CLIN IMMU, V3, P9; KENNEDY MS, 1980, PROSTAGLANDINS, V20, P135; KURLAND JI, 1978, J EXP MED, V147, P952, DOI 10.1084/jem.147.3.952; KURLAND JI, 1979, P NATL ACAD SCI USA, V76, P2326, DOI 10.1073/pnas.76.5.2326; MORLEY J, 1979, PROSTAGLANDINS, V17, P729, DOI 10.1016/S0090-6980(79)80044-1; MYATT L, 1975, NATURE, V257, P227, DOI 10.1038/257227a0; PARKER CW, 1979, J IMMUNOL, V122, P1572; PARKER CW, 1979, J EXP MED, V149, P1487, DOI 10.1084/jem.149.6.1487; PASSWELL JH, 1979, J IMMUNOL, V123, P115; PAWLOWSKI NA, 1983, J EXP MED, V158, P393, DOI 10.1084/jem.158.2.393; PHILLIPS CA, 1978, FEBS LETT, V94, P115, DOI 10.1016/0014-5793(78)80919-3; POON MC, 1981, AM J HEMATOL, V10, P341, DOI 10.1002/ajh.2830100404; RAPOPORT B, 1977, BIOCHEM BIOPH RES CO, V77, P1245, DOI 10.1016/S0006-291X(77)80113-7; SCOTT WA, 1982, J EXP MED, V155, P535, DOI 10.1084/jem.155.2.535; SKINNIDER LF, 1978, AM J HEMATOL, V4, P179, DOI 10.1002/ajh.2830040210; STENSON WF, 1979, J CLIN INVEST, V64, P1457, DOI 10.1172/JCI109604; STOSSEL TP, 1974, J CLIN INVEST, V54, P638, DOI 10.1172/JCI107801; YAMAMOTO M, 1979, P NATL ACAD SCI USA, V76, P6627, DOI 10.1073/pnas.76.12.6627	34	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					331	337		10.1016/0091-6749(84)90125-8	http://dx.doi.org/10.1016/0091-6749(84)90125-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6088610	Bronze			2022-12-18	WOS:A1984TQ63300005
J	METZ, SA; FUJIMOTO, WY; ROBERTSON, RP				METZ, SA; FUJIMOTO, WY; ROBERTSON, RP			OXYGENATION PRODUCTS OF ARACHIDONIC-ACID - 3RD MESSENGERS FOR INSULIN RELEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,HLTH SCI CTR,DIV ENDOCRINOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; VET ADM MED CTR,DENVER,CO 80220; UNIV WASHINGTON,SEATTLE,WA 98195	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle	METZ, SA (corresponding author), UNIV COLORADO,HLTH SCI CTR,DIV CLIN PHARMACOL,DENVER,CO 80262, USA.		Roberston, R Paul/AAX-5613-2021		NIADDK NIH HHS [AM31112, AM17047, AM15312] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P30AM017047] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN D, 1976, NATURE, V261, P58, DOI 10.1038/261058a0; AXEN KV, 1983, J CLIN INVEST, V72, P13, DOI 10.1172/JCI110951; BAREIS DL, 1983, P NATL ACAD SCI-BIOL, V80, P2514, DOI 10.1073/pnas.80.9.2514; BEST L, 1983, BIOCHIM BIOPHYS ACTA, V750, P157, DOI 10.1016/0005-2760(83)90215-1; BREEN KJ, 1982, CLIN PHARMACOL THER, V31, P297, DOI 10.1038/clpt.1982.36; BRYANT RW, 1982, J BIOL CHEM, V257; CANONICO PL, 1983, NEUROENDOCRINOLOGY, V37, P212, DOI 10.1159/000123545; CAPDEVILA J, 1983, ENDOCRINOLOGY, V113, P421; CHACOS N, 1982, BIOCHEM BIOPH RES CO, V104, P916, DOI 10.1016/0006-291X(82)91336-5; CLEMENTS RS, 1976, J CLIN INVEST, V57, P684, DOI 10.1172/JCI108325; CLEMENTS RS, 1977, DIABETES, V26, P1109, DOI 10.2337/diabetes.26.12.1109; DUNLOP M, 1982, FEBS LETT, V144, P259, DOI 10.1016/0014-5793(82)80650-9; EVANS MH, 1983, DIABETES, V32, P509, DOI 10.2337/diabetes.32.6.509; FALCK JR, 1983, BIOCHEM BIOPH RES CO, V114, P743, DOI 10.1016/0006-291X(83)90843-4; FARESE RV, 1981, DIABETES, V30, P396, DOI 10.2337/diabetes.30.5.396; FEX G, 1972, FEBS LETT, V25, P287, DOI 10.1016/0014-5793(72)80505-2; FEX G, 1975, BIOCHIM BIOPHYS ACTA, V388, P1, DOI 10.1016/0005-2760(75)90055-7; FREINKEL N, 1975, EUR J BIOCHEM, V59, P245, DOI 10.1111/j.1432-1033.1975.tb02448.x; FRYE RA, 1983, MOL PHARMACOL, V23, P547; GERRARD JM, 1977, PROSTAGLANDINS, V14, P39, DOI 10.1016/0090-6980(77)90155-1; GORRAY KC, 1981, CLIN RES, V29, pA406; HALTER JB, 1982, J CLIN ENDOCR METAB, V54, P127, DOI 10.1210/jcem-54-1-127; HEANEY TP, 1981, DIABETES, V30, P824, DOI 10.2337/diab.30.10.824; HEISLER S, 1982, P NATL ACAD SCI-BIOL, V79, P6502, DOI 10.1073/pnas.79.21.6502; HEMLER ME, 1978, BIOCHEMISTRY-US, V17, P1772, DOI 10.1021/bi00602a031; HOKIN MR, 1953, J BIOL CHEM, V203, P967; ISAKSON PC, 1977, PROSTAG OTH LIPID M, V14, P853, DOI 10.1016/0090-6980(77)90302-1; KATO R, 1983, ADV PROSTAG THROMB L, V12, P265; KELLY KL, 1981, PROSTAG OTH LIPID M, V21, P759, DOI 10.1016/0090-6980(81)90233-1; LAYCHOCK SG, 1983, DIABETES, V32, pA141; LAYCHOCK SG, 1982, CELL CALCIUM, V3, P43, DOI 10.1016/0143-4160(82)90036-7; LAYCHOCK SG, 1983, DIABETES, V32, P6, DOI 10.2337/diabetes.32.1.6; LILAVIVATHANA U, 1980, J CLIN ENDOCR METAB, V50, P923, DOI 10.1210/jcem-50-5-923; LUCKNER G, 1975, Z NATURFORSCH C, V30, P429; MALAISSE WJ, 1979, DIABETOLOGIA, V16, P331, DOI 10.1007/BF01223623; MALAISSE WJ, 1982, P NATL ACAD SCI-BIOL, V79, P927, DOI 10.1073/pnas.79.3.927; MATO JM, 1983, BIOCHEM J, V213, P1; METZ S, 1983, J CLIN INVEST, V71, P1191, DOI 10.1172/JCI110868; METZ S, 1982, METABOLISM, V31, P1014, DOI 10.1016/0026-0495(82)90145-7; METZ S, 1984, CLIN RES, V32, pA403; METZ S, 1980, J CLIN ENDOCR METAB, V51, P93, DOI 10.1210/jcem-51-1-93; METZ SA, 1983, ADV PROSTAG THROMB L, V12, P271; METZ SA, 1982, ENDOCRINOLOGY, V111, P2141, DOI 10.1210/endo-111-6-2141; METZ SA, 1983, MED HYPOTHESES, V12, P341, DOI 10.1016/0306-9877(83)90106-8; METZ SA, 1981, DIABETES, V30, P551, DOI 10.2337/diabetes.30.7.551; METZ SA, 1980, AM J PHYSIOL, V239, pE490, DOI 10.1152/ajpendo.1980.239.6.E490; METZ SA, 1984, DIABETES, V33, P119, DOI 10.2337/diabetes.33.2.119; METZ SA, 1981, PROSTAG LEUKOTR ESS, V7, P581, DOI 10.1016/0161-4630(81)90048-3; METZ SA, 1983, LIFE SCI, V32, P903, DOI 10.1016/0024-3205(83)90228-X; MIURA Y, 1982, LIPIDS, V17, P864, DOI 10.1007/BF02534580; MORRISON AR, 1982, BIOCHEM BIOPH RES CO, V108, P1757, DOI 10.1016/S0006-291X(82)80115-0; NAOR Z, 1981, J BIOL CHEM, V256, P2226; NISHIBE S, 1983, LIFE SCI, V32, P1613, DOI 10.1016/0024-3205(83)90868-8; PETERFREUND RA, 1983, ENDOCRINOLOGY, V113, P200, DOI 10.1210/endo-113-1-200; PONTIROLI AE, 1982, HORM METAB RES, V14, P496, DOI 10.1055/s-2007-1019056; PRENTKI M, 1984, NATURE, V309, P562, DOI 10.1038/309562a0; PUTNEY JW, 1981, LIFE SCI, V29, P1183, DOI 10.1016/0024-3205(81)90221-6; Raz A, 1980, Adv Prostaglandin Thromboxane Res, V6, P255; ROBERTSON RP, 1983, DIABETES, V32, P231, DOI 10.2337/diabetes.32.3.231; ROBERTSON RP, 1979, DIABETES, V28, P943; RUBIN RP, 1982, FED PROC, V41, P2181; SCARPIGNATO C, 1981, HORM RES, V15, P228, DOI 10.1159/000179461; SERHAN C, 1981, J BIOL CHEM, V256, P2736; SERHAN CN, 1982, J BIOL CHEM, V257, P4746; SIEGEL MI, 1979, BIOCHEM BIOPH RES CO, V89, P1273, DOI 10.1016/0006-291X(79)92146-6; SIEGEL MI, 1979, P NATL ACAD SCI USA, V76, P3774, DOI 10.1073/pnas.76.8.3774; SNYDER GD, 1983, P NATL ACAD SCI-BIOL, V80, P3504, DOI 10.1073/pnas.80.11.3504; SUGDEN MC, 1978, DIABETOLOGIA, V15, P173, DOI 10.1007/BF00421235; SUSSMAN KE, 1982, ENDOCRINOLOGY, V111, P316, DOI 10.1210/endo-111-1-316; TAMARIT J, 1981, DIABETOLOGIA, V21, pA334; TANIGAWA K, 1982, FEBS LETT, V138, P183, DOI 10.1016/0014-5793(82)80436-5; TANIGAWA K, 1983, BIOCHEM BIOPH RES CO, V112, P419, DOI 10.1016/0006-291X(83)91480-8; TURK J, 1983, DIABETES, V32, pA139; UTHE JF, 1971, CAN J BIOCHEM CELL B, V49, P776, DOI 10.1139/o71-109; WADA A, 1983, BIOCHEM PHARMACOL, V32, P1175, DOI 10.1016/0006-2952(83)90267-8; WALSH MF, 1983, DIABETES, V32, pA7; YAMAMOTO S, 1982, EUR J PHARMACOL, V78, P225, DOI 10.1016/0014-2999(82)90240-0; YAMAMOTO S, 1982, BIOCHEM BIOPH RES CO, V105, P759, DOI 10.1016/0006-291X(82)91499-1; YAMAMOTO S, 1983, European Journal of Pharmacology, V86, P121; YAMANISHI J, 1983, BIOCHEM BIOPH RES CO, V112, P778, DOI 10.1016/0006-291X(83)91529-2	80	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					391	402		10.1016/0091-6749(84)90137-4	http://dx.doi.org/10.1016/0091-6749(84)90137-4			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6432880				2022-12-18	WOS:A1984TQ63300017
J	GOLDEN, DBK; KAGEYSOBOTKA, A; HAMILTON, RG; VALENTINE, MD; LICHTENSTEIN, LM				GOLDEN, DBK; KAGEYSOBOTKA, A; HAMILTON, RG; VALENTINE, MD; LICHTENSTEIN, LM			HUMAN IMMUNE-RESPONSE TO HYMENOPTERA VENOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	13	13	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					140	140		10.1016/0091-6749(83)90330-5	http://dx.doi.org/10.1016/0091-6749(83)90330-5			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ462		Bronze			2022-12-18	WOS:A1983PZ46200207
J	RAK, S; MILLQVIST, E; LOWHAGEN, O				RAK, S; MILLQVIST, E; LOWHAGEN, O			THERAPEUTIC MODIFICATION OF NON-SPECIFIC HYPERREACTIVITY BY SODIUM CROMOGLYCATE (SCG)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									GOTHENBURG UNIV,S-41124 GOTHENBURG,SWEDEN	University of Gothenburg									0	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					149	149		10.1016/0091-6749(83)90367-6	http://dx.doi.org/10.1016/0091-6749(83)90367-6			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ462					2022-12-18	WOS:A1983PZ46200244
J	SCHULLER, DE				SCHULLER, DE			ADVERSE-EFFECTS OF BROMPHENIRAMINE ON PULMONARY-FUNCTION IN A SUBSET OF ASTHMATIC-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SCHULLER, DE (corresponding author), GEISINGER MED CTR,DEPT PEDIAT CARDIOPULM ALLERG & INFECT DIS,DANVILLE,PA 17821, USA.							ARUNLAKSHANA O, 1953, J PHYSL, V119, P470; CASTERLINE CL, 1977, J ALLERGY CLIN IMMUN, V59, P420, DOI 10.1016/0091-6749(77)90004-5; CRIEP LH, 1948, J ALLERGY, V19, P215, DOI 10.1016/0021-8707(48)90057-4; CRIEP LH, 1948, J ALLERGY, V19, P304, DOI 10.1016/0021-8707(48)90110-5; ENGELSHER DL, 1947, NEW YORK STATE J MED, V47, P1696; EYERMANN CH, 1946, J ALLERGY, V17, P210, DOI 10.1016/0021-8707(46)90146-3; HAWKINS DF, 1955, BRIT J PHARM CHEMOTH, V10, P230, DOI 10.1111/j.1476-5381.1955.tb00088.x; HYDE JS, 1974, ANN ALLERGY, V32, P73; KARLIN JM, 1972, ANN ALLERGY, V30, P342; LEVIN SJ, 1946, J ALLERGY, V17, P145, DOI 10.1016/0021-8707(46)90004-4; LEVY L, 1947, J ALLERGY, V18, P244, DOI 10.1016/0021-8707(47)90048-8; MCELIN TW, 1945, MAYO CLIN P, V20, P417; NATHAN S P, 1979, Chest, V76, P384, DOI 10.1378/chest.76.4.384; POPA VT, 1980, CHEST, V78, P442, DOI 10.1378/chest.78.3.442; POPA VT, 1977, J ALLERGY CLIN IMMUN, V59, P54, DOI 10.1016/0091-6749(77)90177-4; RATNER B, 1947, J PEDIATR, V30, P583, DOI 10.1016/S0022-3476(47)80051-4; WALDBOTT GL, 1946, J ALLERGY, V17, P142, DOI 10.1016/0021-8707(46)90003-2; 1972, ANN ALLERGY, V30, P95; 1955, LANCET, P1182	19	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	2					175	179		10.1016/0091-6749(83)90526-2	http://dx.doi.org/10.1016/0091-6749(83)90526-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD959	6886255				2022-12-18	WOS:A1983RD95900011
J	WARREN, K; DYER, J; MERLIN, S; KALINER, M				WARREN, K; DYER, J; MERLIN, S; KALINER, M			MEASUREMENT OF URINARY HISTAMINE - COMPARISON OF FLUOROMETRIC AND RADIOISOTOPIC-ENZYMATIC ASSAY PROCEDURES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ADAM HM, 1950, Q J EXP PHYSIOL CMS, V35, P281, DOI 10.1113/expphysiol.1950.sp000954; ATACK C, 1978, ACTA PHARMACOL TOX, V42, P35; BEAVEN MA, 1977, HDB EXPT PHARM 2, V18, P151; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P92; DAVIS TP, 1978, CLIN CHEM, V24, P1317; DUNER H, 1956, SCAND J CLIN LAB INV, V8, P296, DOI 10.3109/00365515609049287; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; KAPELLERADLER R, 1956, CLIN CHIM ACTA, V1, P197, DOI 10.1016/0009-8981(56)90066-3; KAPELLERADLER R, 1957, BIOCHIM BIOPHYS ACTA, V25, P394, DOI 10.1016/0006-3002(57)90484-5; KOBAYASHI Y, 1972, ANAL BIOCHEM, V46, P85, DOI 10.1016/0003-2697(72)90397-1; MELL LD, 1979, J LIQ CHROMATOGR, V2, P1393, DOI 10.1080/01483917908060145; MEYERS G, 1981, J ALLERGY CLIN IMMUN, V67, P305; MITCHELL RG, 1956, BRIT J PHARM CHEMOTH, V11, P462, DOI 10.1111/j.1476-5381.1956.tb00018.x; OATES JA, 1962, CLIN CHIM ACTA, V7, P488; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; Shore PA, 1971, METHODS BIOCH ANAL S, P89, DOI [10.1002/9780470110409.ch3, DOI 10.1002/9780470110409.CH3]; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603	18	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	2					206	211		10.1016/0091-6749(83)90101-X	http://dx.doi.org/10.1016/0091-6749(83)90101-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC188	6401774	Bronze			2022-12-18	WOS:A1983QC18800006
J	GOODFRIEND, L; ROEBBER, M; LUNDKVIST, U; CHOUDHURY, AM				GOODFRIEND, L; ROEBBER, M; LUNDKVIST, U; CHOUDHURY, AM			2 VARIANTS OF RAGWEED ALLERGEN RA3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									PHARMACIA DIAGNOST AB,DEPT BIOCHEM,UPPSALA,SWEDEN	Pfizer; Pharmacia Corporation	GOODFRIEND, L (corresponding author), ROYAL VICTORIA HOSP,DIV CLIN IMMUNOL,MONTREAL H3A 1A1,QUEBEC,CANADA.							AAS K, 1973, CLIN ALLERGY, V3, P225; ADOLPHSON C, 1978, J ALLERGY CLIN IMMUN, V62, P197, DOI 10.1016/0091-6749(78)90208-7; BEAVEN GH, 1952, ADV PROTEIN CHEM, V7; BIAS WB, 1979, TRANSPLANT P, V11, P1853; CHOUDHURY AM, 1978, FED PROC, V37, P1553; Cohn E. J., 1943, PROTEINS AMINO ACIDS; GIBBONS RA, 1966, GLYCOPROTEINS; Kabat E., 1961, EXPT IMMUNOCHEMISTRY; KING TP, 1967, BIOCHEMISTRY-US, V6, P1992, DOI 10.1021/bi00859a017; KLAPPER DG, 1980, BIOCHEMISTRY-US, V19, P5729, DOI 10.1021/bi00566a010; KOENIG R, 1970, BIOCHIM BIOPHYS ACTA, V207, P184, DOI 10.1016/0005-2795(70)90150-9; LAPKOFF CB, 1974, INT ARCH ALLER A IMM, V46, P215, DOI 10.1159/000231125; MARSH DG, 1979, P NATL ACAD SCI USA, V76, P2903, DOI 10.1073/pnas.76.6.2903; MARSH DG, 1977, IMMUNOGENETICS, V5, P217, DOI 10.1007/BF01570478; MARSH DG, 1973, MECHANISMS ALLERGY R, P113; MOLE LE, 1975, BIOCHEMISTRY-US, V14, P1216, DOI 10.1021/bi00677a019; REISFELD RA, 1962, NATURE, V195, P281, DOI 10.1038/195281a0; ROEBBER MG, 1975, THESIS MCGILL U MONT; UNDERDOWN BJ, 1969, BIOCHEMISTRY-US, V8, P980, DOI 10.1021/bi00831a031	19	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	4					299	304		10.1016/0091-6749(81)90025-7	http://dx.doi.org/10.1016/0091-6749(81)90025-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LL697	6162874				2022-12-18	WOS:A1981LL69700008
J	MATHEWS, KP				MATHEWS, KP			CALCULATION OF SECRETORY ANTIBODIES AND IMMUNOGLOBULINS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,MONTGOMERY ALLERGY RES LAB,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIAID NIH HHS [5 P50 AI 10391] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLOW M, 1980, J ALLERGY CLIN IMMUN, V66, P112, DOI 10.1016/0091-6749(80)90057-3; COHEN AB, 1970, CLIN EXP IMMUNOL, V6, P753; DEUSCHL H, 1976, INT ARCH ALLER A IMM, V52, P376, DOI 10.1159/000231704; DONOVAN R, 1970, INT ARCH ALLER A IMM, V37, P154, DOI 10.1159/000230229; JOHANSSON SGO, 1976, INT ARCH ALLER A IMM, V52, P364, DOI 10.1159/000231703; MATHEWS KP, INT ARCH ALLERGY APP; MERRETT TG, 1976, CLIN ALLERGY, V6, P69, DOI 10.1111/j.1365-2222.1976.tb01413.x; NAKAJIMA S, 1975, CLIN EXP IMMUNOL, V21, P306; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; Soothill J F, 1967, Sci Basis Med Annu Rev, P276	11	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	1					46	50		10.1016/0091-6749(81)90122-6	http://dx.doi.org/10.1016/0091-6749(81)90122-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LY101	6972402				2022-12-18	WOS:A1981LY10100008
J	LAWYER, CH; BARDANA, EJ; RODGERS, R; GERBER, N				LAWYER, CH; BARDANA, EJ; RODGERS, R; GERBER, N			UTILIZATION OF INTRAVENOUS DIHYDROXYPROPYL THEOPHYLLINE (DYPHYLLINE) IN AN AMINOPHYLLINE-SENSITIVE PATIENT, AND ITS PHARMACOKINETIC COMPARISON WITH THEOPHYLLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV OREGON,HLTH SCI CTR,DEPT MED,PORTLAND,OR 97201; UNIV OREGON,HLTH SCI CTR,DEPT PHARMACOL,PORTLAND,OR 97201; VET ADM HOSP,PORTLAND,OR 97207	University of Oregon; University of Oregon								BAER RL, 1959, ARCH DERMATOL, V79, P647, DOI 10.1001/archderm.1959.01560180021006; FISHER A, 1973, CONTACT DERMATITIS, P41; Fisher A A, 1976, Cutis, V17, P839; GREENBLATT DJ, 1975, NEW ENGL J MED, V293, P702, DOI 10.1056/NEJM197510022931406; ISAKSSON B, 1962, ACTA MED SCAND, V171, P33; JENNE JW, 1976, CLIN PHARMACOL THER, V19, P375; LAWYER CH, 1977, P AM C ALLERGY IMMUN; LEVY G, 1976, J CLIN PHARMACOL, V16, P329, DOI 10.1002/j.1552-4604.1976.tb01528.x; MCKEE M, 1957, NEW ENGL J MED, V256, P956, DOI 10.1056/NEJM195705162562015; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; PIAFSKY KM, 1975, NEW ENGL J MED, V292, P1218, DOI 10.1056/NEJM197506052922305; SIMONS FER, 1975, J ALLERGY CLIN IMMUN, V56, P347, DOI 10.1016/0091-6749(75)90128-1; SIMONS FER, 1975, PEDIATRICS, V56, P916; SIMONS KJ, 1977, J CLIN PHARMACOL, V17, P237, DOI 10.1177/009127007701700408; SUURMOND D, 1966, DERMATOLOGICAL, V133, P505; TAS J., 1958, ACTA ALLERGOL, V12, P39, DOI 10.1111/j.1398-9995.1958.tb04018.x; WONG D, 1971, J ALLERGY CLIN IMMUN, V48, P165, DOI 10.1016/0091-6749(71)90012-1; ZWILLICH CW, 1975, ANN INTERN MED, V82, P784, DOI 10.7326/0003-4819-82-6-784	18	13	15	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	5					353	357		10.1016/0091-6749(80)90212-2	http://dx.doi.org/10.1016/0091-6749(80)90212-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV955	7372953				2022-12-18	WOS:A1980JV95500006
J	KARR, RM				KARR, RM			BRONCHOPROVOCATION STUDIES IN COFFEE WORKER ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KARR, RM (corresponding author), CLIN IMMUNOL LAB,3030 HOYT AVE,EVERETT,WA 98201, USA.							BERNTON HS, 1973, JAMA-J AM MED ASSOC, V223, P1146; COULSON EJ, 1950, J ALLERGY, V21, P554, DOI 10.1016/0021-8707(50)90107-9; FIGLEY KD, 1950, J ALLERGY, V21, P545, DOI 10.1016/0021-8707(50)90106-7; KARR RM, 1978, J ALLERGY CLIN IMMUN, V61, P54, DOI 10.1016/0091-6749(78)90474-8; KARR RM, 1978, J ALLERGY CLIN IMMUN, V62, P143, DOI 10.1016/0091-6749(78)90098-2; LAYTON LL, 1968, INT ARCH ALLER A IMM, V33, P417, DOI 10.1159/000230057; LEHRER SB, 1978, CLIN ALLERGY, V8, P217, DOI 10.1111/j.1365-2222.1978.tb03217.x	7	13	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					650	654		10.1016/0091-6749(79)90030-7	http://dx.doi.org/10.1016/0091-6749(79)90030-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX843	512261				2022-12-18	WOS:A1979HX84300018
J	SIMON, RA; GINSBERG, M; TIMMS, RM; STEVENSON, DD				SIMON, RA; GINSBERG, M; TIMMS, RM; STEVENSON, DD			EXERCISE-INDUCED BRONCHOSPASM - STUDY OF PLASMA MEDIATORS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	3					153	153						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GN274					2022-12-18	WOS:A1979GN27400062
J	FREDRICKS, W				FREDRICKS, W			ANTIGENS IN PIGEON DROPPING EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FREDRICKS, W (corresponding author), MARQUETTE UNIV,MILWAUKEE,WI 53233, USA.								0	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	4					221	223		10.1016/0091-6749(78)90186-0	http://dx.doi.org/10.1016/0091-6749(78)90186-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EV080	416061	Bronze			2022-12-18	WOS:A1978EV08000011
J	NEEDLEMAN, P				NEEDLEMAN, P			CHARACTERIZATION OF REACTION SEQUENCE INVOLVED IN PHOSPHOLIPID LABELING AND DEACYLATION AND PROSTAGLANDIN SYNTHESIS AND ACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NEEDLEMAN, P (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,ST LOUIS,MO 63110, USA.							AIKEN JW, 1973, J PHARMACOL EXP THER, V184, P678; BARTELS J, 1970, N-S ARCH PHARMAKOL, V266, P199, DOI 10.1007/BF00997282; BERGSTROM S, 1964, BIOCHIM BIOPHYS ACTA, V90, P207, DOI 10.1016/0304-4165(64)90145-X; BILLS TK, 1976, BIOCHIM BIOPHYS ACTA, V424, P303, DOI 10.1016/0005-2760(76)90198-3; BLACKWELL GJ, 1977, BRIT J PHARMACOL, V59, P353, DOI 10.1111/j.1476-5381.1977.tb07500.x; CHRIST EJ, 1972, ADV BIOSCI, V9, P35; DAWSON W, 1976, NATURE, V262, P699, DOI 10.1038/262699a0; DUSTING GJ, 1977, PROSTAGLANDINS, V13, P3, DOI 10.1016/0090-6980(77)90037-5; FERREIRA SH, 1967, NATURE, V216, P868, DOI 10.1038/216868a0; FLOWER RJ, 1976, BIOCHEM PHARMACOL, V25, P285, DOI 10.1016/0006-2952(76)90216-1; FREDHOLM B, 1969, Acta Physiologica Scandinavica, V76, P446, DOI 10.1111/j.1748-1716.1969.tb04491.x; GILMORE N, 1968, NATURE, V218, P1135, DOI 10.1038/2181135a0; GORMAN RR, 1977, P NATL ACAD SCI USA, V74, P4007, DOI 10.1073/pnas.74.9.4007; GRYGLEWSKI RJ, 1975, PROSTAGLANDINS, V10, P343, DOI 10.1016/S0090-6980(75)80087-6; GRYGLEWSKI RJ, 1976, PROSTAG OTH LIPID M, V12, P685, DOI 10.1016/0090-6980(76)90047-2; HAMBERG M, 1975, LIFE SCI, V16, P451, DOI 10.1016/0024-3205(75)90266-0; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HAMBERG M, 1974, P NATN ACAD SCI US, V71, P3823; HILL E, 1970, LIPID METABOLISM, P258; HONG SCL, 1976, J BIOL CHEM, V251, P5814; HONG SL, 1976, P NATL ACAD SCI USA, V73, P1730, DOI 10.1073/pnas.73.5.1730; HSEUH W, 1977, PROSTAGLANDINS, V13, P1073; ISAKSON PC, 1976, PROSTAGLANDINS, V12, P739, DOI 10.1016/0090-6980(76)90049-6; ISAKSON PC, 1977, PROSTAG OTH LIPID M, V14, P853, DOI 10.1016/0090-6980(77)90302-1; ISAKSON PC, 1977, P NATL ACAD SCI USA, V74, P101, DOI 10.1073/pnas.74.1.101; JAKSCHIK BA, 1977, P NATL ACAD SCI USA, V74, P4577, DOI 10.1073/pnas.74.10.4577; JESSE RL, 1976, BIOCHEM J, V158, P283, DOI 10.1042/bj1580283; KANTROWITZ F, 1975, NATURE, V258, P737, DOI 10.1038/258737a0; KULKARNI PS, 1976, PROSTAGLANDINS, V12, P337, DOI 10.1016/0090-6980(76)90015-0; LANDS WEM, 1968, BIOCHIM BIOPHYS ACTA, V164, P426, DOI 10.1016/0005-2760(68)90168-9; MCGIFF JC, 1973, CIRC RES, V33, P479, DOI 10.1161/01.RES.33.5.479; MCGIFF JC, 1975, CHEM BIOL KALLIKREIN, P267; MONCADA S, 1977, PROSTAGLANDINS, V13, P611, DOI 10.1016/0090-6980(77)90232-5; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; MONCADA S, 1976, PROSTAGLANDINS, V12, P715, DOI 10.1016/0090-6980(76)90048-4; MORRISON AR, 1977, NATURE, V267, P259, DOI 10.1038/267259a0; NEEDLEMAN P, 1977, SCIENCE, V195, P409, DOI 10.1126/science.831285; NEEDLEMAN P, 1976, FED PROC, V35, P2376; NEEDLEMAN P, 1975, CIRC RES, V37, P802, DOI 10.1161/01.RES.37.6.802; NEEDLEMAN P, 1978, J CLIN INVEST, V61, P839, DOI 10.1172/JCI108998; NEEDLEMAN P, 1975, P NATL ACAD SCI USA, V72, P2060, DOI 10.1073/pnas.72.6.2060; NEEDLEMAN P, 1977, P NATL ACAD SCI USA, V74, P1716, DOI 10.1073/pnas.74.4.1716; NEEDLEMAN P, 1977, BIOCH ASPECTS PROSTA, P199; NIHSIKAWA K, 1977, J CLIN INVEST, V59, P1143; PACEASCIAK C, 1971, BIOCHEMISTRY-US, V10, P3657, DOI 10.1021/bi00796a004; PIPER P, 1971, ANN NY ACAD SCI, V180, P363, DOI 10.1111/j.1749-6632.1971.tb53205.x; PIPER PJ, 1969, NATURE, V223, P29, DOI 10.1038/223029a0; POSSMAYE.F, 1969, BIOCHIM BIOPHYS ACTA, V176, P95, DOI 10.1016/0005-2760(69)90078-2; RAMWELL PW, 1966, NATURE, V210, P273, DOI 10.1038/210273a0; RAZ A, 1977, J BIOL CHEM, V252, P1123; SAMUELSS.B, 1965, J AM CHEM SOC, V87, P3011, DOI 10.1021/ja01091a043; TASHJIAN AH, 1975, NATURE, V258, P739, DOI 10.1038/258739a0; VANDORP DA, 1964, NATURE, V203, P839, DOI 10.1038/203839a0; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VARGAFTIG BB, 1972, J PHARM PHARMACOL, V24, P159, DOI 10.1111/j.2042-7158.1972.tb08953.x; VOGT W, 1969, N-S ARCH PHARMAKOL, V262, P124, DOI 10.1007/BF00536823; VOGT W., 1966, MEM SOC ENDOCRINOL, V14, P137; VONKEMAN H, 1968, BIOCHIM BIOPHYS ACTA, V164, P430, DOI 10.1016/0005-2760(68)90169-0; WILLIS AL, 1974, SCIENCE, V183, P327, DOI 10.1126/science.183.4122.327; ZUSMAN RM, 1977, J BIOL CHEM, V252, P2069	61	13	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	2					96	102		10.1016/0091-6749(78)90085-4	http://dx.doi.org/10.1016/0091-6749(78)90085-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL835	97337				2022-12-18	WOS:A1978FL83500005
J	SEHON, AH				SEHON, AH			SPECIFIC SUPPRESSION OF IGE ANTIBODIES - IMMUNOTHERAPEUTIC GOAL ACHIEVABLE IN FORESEEABLE FUTURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											SEHON, AH (corresponding author), UNIV MANITOBA,MRC,DEPT IMMUNOL,ALLERGY RES GRP,WINNIPEG R3E OW3,MANITOBA,CANADA.							BENNICH H, 1967, GAMMA GLOBULINS STRU, P192; BOREL Y, 1976, NATURE, V261, P50; CHIORAZZI N, 1976, P NATL ACAD SCI USA, V73, P2091, DOI 10.1073/pnas.73.6.2091; CHIORAZZI N, 1977, J IMMUNOL, V118, P48; FILION LG, 1977, FED PROC, V36, P1184; HUBER B, 1976, J EXP MED, V144, P1128, DOI 10.1084/jem.144.4.1128; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; ISHIZAKA K, 1978, LUNG, V155, P3, DOI 10.1007/BF02730676; ISHIZAKA K, 1966, J IMMUNOL, V97, P84; KATZ DH, 1978, J ALLERGY CLIN IMMUN, V62, P44, DOI 10.1016/0091-6749(78)90072-6; KATZ DH, 1977, LYMPHOCYTE DIFFERENT; KISHIMOTO T, J EXP MED; LEE WY, 1977, NATURE, V267, P618, DOI 10.1038/267618a0; LEE WY, 1976, J IMMUNOL, V117, P927; LEE WY, 1978, INT ARCH ALLER A IMM, V56, P193, DOI 10.1159/000232023; LEE WY, 1978, INT ARCH ALLER A IMM, V56, P159, DOI 10.1159/000232019; LESSOF MH, 1976, J ALLERGY CLIN IMMUN, V57, P247; LOOR F, 1977, B T CELLS IMMUNE REC; MICHAEL JG, 1973, J IMMUNOL, V111, P1600; MOLLER G, 1975, TRANSPLANT REV, V26; MOLLER G, 1977, IMMUNOL REV, V33; MOLLER G, 1978, IMMUNOL REV, V40; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P281, DOI 10.1016/0091-6749(78)90047-7; PEETERS SH, J IMMUNOL; SEHON AH, 1974, ALLERGOLOGIA IMMUN S, V1, P19; URBAN JF, 1977, J IMMUNOL, V118, P1982; WATANABE N, 1976, J EXP MED, V143, P833, DOI 10.1084/jem.143.4.833	27	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	5					257	260		10.1016/0091-6749(78)90155-0	http://dx.doi.org/10.1016/0091-6749(78)90155-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FW432	701660				2022-12-18	WOS:A1978FW43200001
J	TSE, KS; KEPRON, W; SEHON, A				TSE, KS; KEPRON, W; SEHON, A			EFFECTS OF TOLEROGENIC CONJUGATES IN A CANINE MODEL FOR REAGINIC HYPERSENSITIVITY .1. SUPPRESSION OF HAPTEN-SPECIFIC IGE ANTIBODY-RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC MED,DEPT MED,WINNIPEG R3E OW3,MANITOBA,CANADA; HLTH SCI CTR,CLIN INVEST UNIT,WINNIPEG R3E 0W1,MANITOBA,CANADA	University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba	TSE, KS (corresponding author), UNIV MANITOBA,FAC MED,DEPT IMMUNOL,MRC,ALLERGY RES GRP,WINNIPEG R3E OW3,MANITOBA,CANADA.							ALDOBENSON M, 1974, J IMMUNOL, V112, P1793; ALDOBENSON M, 1976, J IMMUNOL, V116, P223; AULT KA, 1974, P NATL ACAD SCI USA, V71, P3111, DOI 10.1073/pnas.71.8.3111; BOREL Y, 1976, NATURE, V261, P49, DOI 10.1038/261049a0; BOREL Y, 1975, J EXP MED, V142, P1254, DOI 10.1084/jem.142.5.1254; BOREL Y, 1976, TRANSPLANTATION REV, V31, P1; CHIORAZZI N, 1976, P NATL ACAD SCI USA, V73, P2091, DOI 10.1073/pnas.73.6.2091; DAVIE JM, 1972, J EXP MED, V136, P426, DOI 10.1084/jem.136.3.426; DESAYMARD C, 1975, EUR J IMMUNOL, V5, P537, DOI 10.1002/eji.1830050806; HAMAOKA T, 1975, J EXP MED, V141, P1308, DOI 10.1084/jem.141.6.1308; HAMILTON JA, 1974, EUR J IMMUNOL, V4, P261, DOI 10.1002/eji.1830040407; HAVAS HF, 1969, IMMUNOLOGY, V17, P189; KATZ DH, 1975, J ALLERGY CLIN IMMUN, V55, P403, DOI 10.1016/0091-6749(75)90079-2; KATZ DH, 1973, P NATL ACAD SCI USA, V70, P2776, DOI 10.1073/pnas.70.10.2776; KATZ DH, 1971, J EXP MED, V134, P201, DOI 10.1084/jem.134.1.201; KEPRON W, 1977, J ALLERGY CLIN IMMUN, V59, P64, DOI 10.1016/0091-6749(77)90178-6; KESSLER GF, 1974, INT ARCH ALLER A IMM, V47, P313, DOI 10.1159/000231225; LEE WY, 1975, J IMMUNOL, V114, P829; LEE WY, 1976, J IMMUNOL, V117, P927; LEE WY, 1975, J IMMUNOL, V114, P837; MCMASTER PRB, 1975, CELL IMMUNOL, V20, P42, DOI 10.1016/0008-8749(75)90082-9; MILLER SD, 1977, EUR J IMMUNOL, V7, P165, DOI 10.1002/eji.1830070310; NOSSAL GJV, 1973, J EXP MED, V138, P312, DOI 10.1084/jem.138.1.312; PAN D, 1976, FED PROC, V35, P433; PATTERSON R, 1969, PROG ALLERGY, V13, P332, DOI 10.1159/000287510; SZEWCZUK MR, 1977, J EXP MED, V145, P968, DOI 10.1084/jem.145.4.968; VENKATARAMAN M, 1977, J IMMUNOL, V119, P1006; WATANABE N, 1977, J IMMUNOL, V118, P251	28	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	5					303	309		10.1016/0091-6749(78)90051-9	http://dx.doi.org/10.1016/0091-6749(78)90051-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EY714	641265				2022-12-18	WOS:A1978EY71400005
J	BRASHER, GW				BRASHER, GW			C1Q LEVELS IN HEREDITARY ANGIOEDEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCOTT & WHITE MEM HOSP,TEMPLE,TX 76501	Scott & White Medical Center								BRASHER GW, 1975, ARCH DERMATOL, V111, P1140, DOI 10.1001/archderm.111.9.1140; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; CARPENTER CB, 1969, J CLIN INVEST, V48, P1495, DOI 10.1172/JCI106116; DONALDSON VH, 1964, J CLIN INVEST, V43, P2204, DOI 10.1172/JCI105094; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; KOHLER PF, 1972, J CLIN INVEST, V51, P868, DOI 10.1172/JCI106881; KOHLER PF, 1967, J IMMUNOL, V99, P1211; Laurell A B, 1966, Clin Exp Immunol, V1, P13; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; PICKERING R. J., 1968, CLIN EXP IMMUNOL, V3, P423; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; ROSENFELD SI, 1976, J ALLERGY CLIN IMMUN, V55, P104; RUDDY S, 1972, N ENGL J MED, V287, P89; RUDDY S, 1968, EXCERPTA MEDICA FDN, P351	15	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	3					263	265		10.1016/0091-6749(77)90160-9	http://dx.doi.org/10.1016/0091-6749(77)90160-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CZ249	838995				2022-12-18	WOS:A1977CZ24900013
J	DUNAND, P; CROPP, JA; MIDDLETON, E				DUNAND, P; CROPP, JA; MIDDLETON, E			SEVERE OBSTRUCTIVE LUNG-DISEASE IN A 14-YEAR-OLD GIRL WITH ALPHA-1 ANTITRYPSIN DEFICIENCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									CHILDRENS ASTHMA RES INST & HOSP NATL ASTHMA CTR,DEPT MED,DENVER,CO 80204									BLACK LF, 1972, AM REV RESPIR DIS, V105, P891; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; ERIKSSON S, 1964, ACTA MED SCAND, V175, P197; FAGERHOL MK, 1969, ACTA ALLERGOL, V24, P107, DOI 10.1111/j.1398-9995.1969.tb03760.x; FAGERHOL MK, 1967, CLIN CHIM ACTA, V16, P199, DOI 10.1016/0009-8981(67)90181-7; HOUSTEK J, 1973, CHEST, V64, P773, DOI 10.1378/chest.64.6.773; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; LIEBERMA.J, 1969, NEW ENGL J MED, V281, P279, DOI 10.1056/NEJM196908072810601; MAKINO S, 1970, J ALLERGY, V46, P40, DOI 10.1016/0021-8707(70)90060-2; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MORSE JO, 1975, NEW ENGL J MED, V292, P278, DOI 10.1056/NEJM197502062920602; OSTROW DN, 1972, AM REV RESPIR DIS, V106, P377, DOI 10.1164/arrd.1972.106.3.377; SZCZEKLIK A, 1973, AM REV RESPIR DIS, V107, P289; TALAMO RC, 1971, J PEDIATR-US, V79, P20, DOI 10.1016/S0022-3476(71)80053-7; TARKOFF MP, 1968, AM J MED, V45, P220, DOI 10.1016/0002-9343(68)90040-5; WITTMAN C, 1971, CHEST, V60, P214; 1971, BRIT MED J, V3, P655	18	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	6					615	622		10.1016/0091-6749(76)90014-2	http://dx.doi.org/10.1016/0091-6749(76)90014-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BV054	1084359				2022-12-18	WOS:A1976BV05400014
J	MCDOUGALL, JC; GLEICH, GJ				MCDOUGALL, JC; GLEICH, GJ			TOBACCO ALLERGY - FACT OR FANCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	3					237	237						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BJ240					2022-12-18	WOS:A1976BJ24000117
J	RUBINSTEIN, E; FUJITA, Y; OKAZAKI, T; TRIPODI, D; REISMAN, RE; ARBESMAN, CE				RUBINSTEIN, E; FUJITA, Y; OKAZAKI, T; TRIPODI, D; REISMAN, RE; ARBESMAN, CE			EFFECT OF RAGWEED HYPERIMMUNE HUMAN GAMMA-GLOBULIN ON INVIVO AND INVITRO PARAMETERS OF RAGWEED SENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203; BUFFALO GEN HOSP,BUFFALO,NY 14203; SUNY BUFFALO,DEPT MED,BUFFALO,NY; SUNY BUFFALO,DEPT MICROBIOL,BUFFALO,NY	Buffalo General Medical Center; Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								ARBESMAN CE, 1972, J ALLERGY CLIN IMMUN, V49, P72, DOI 10.1016/0091-6749(72)90058-9; ARBESMAN CE, 1974, J ALLERGY CLIN IMMUN, V53, P81; ARBESMAN CE, 1960, J ALLERGY, V31, P4; ASSEM E S K, 1973, Clinical Allergy, V3, P161, DOI 10.1111/j.1365-2222.1973.tb01319.x; ASSEM ESK, 1970, INT ARCH ALLER A IMM, V38, P68, DOI 10.1159/000230260; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CONNELL JT, 1970, J ALLERGY, V45, P115; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; FUJITA Y, 1975, INT ARCH ALLER A IMM, V49, P724, DOI 10.1159/000231456; GOLDFARB AR, 1961, J IMMUNOL, V86, P83; HOURI M, 1972, Clinical Allergy, V2, P285, DOI 10.1111/j.1365-2222.1972.tb01292.x; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; Noon L, 1911, LANCET, V1, P1572; OKAZAKI T, 1975, J ALLERGY CLIN IMMUN, V56, P27, DOI 10.1016/0091-6749(75)90031-7; PATTERSON R, 1971, INT ARCH ALLER A IMM, V41, P592, DOI 10.1159/000230552; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SEHON AH, 1971, IMMUNOLOGICAL DISEAS	19	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	4					335	341		10.1016/0091-6749(76)90090-7	http://dx.doi.org/10.1016/0091-6749(76)90090-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BM689	57128	Bronze			2022-12-18	WOS:A1976BM68900007
J	RUSSELL, AS; KAISER, JT				RUSSELL, AS; KAISER, JT			CELL-MEDIATED-IMMUNITY TO HERPES-SIMPLEX VIRUS IN MAN .5. ANTIBODY-MEDIATED CELL-DEPENDENT IMMUNE LYSIS OF HERPES VIRUS-INFECTED TARGET-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV ALBERTA,DEPT MED,EDMONTON,ALBERTA,CANADA	University of Alberta								ALLISON AC, 1972, ANN I PASTEUR PARIS, V123, P585; CESARIO TC, 1969, AM J EPIDEMIOL, V90, P416, DOI 10.1093/oxfordjournals.aje.a121087; DENNERT G, 1972, NATURE-NEW BIOL, V238, P114, DOI 10.1038/newbio238114a0; DOUGLAS R G JR, 1970, Journal of Immunology, V104, P289; EISEN SA, 1972, IMMUNOL COMMUN, V1, P571, DOI 10.3109/08820137209022965; FAKHRI O, 1972, NATURE-NEW BIOL, V235, P177, DOI 10.1038/newbio235177a0; FORMAN J, 1973, TRANSPLANT REV, V17, P108; GREENBERG AH, 1973, NATURE-NEW BIOL, V242, P111, DOI 10.1038/newbio242111a0; HARRIS R, 1969, LANCET, V2, P327; KOVITHAVONGS T, 1974, J IMMUNOL, V113, P1178; KURTZ JB, 1974, J MED MICROBIOL, V7, P333, DOI 10.1099/00222615-7-3-333; MCDONALD AD, 1974, AM J EPIDEMIOL, V100, P124, DOI 10.1093/oxfordjournals.aje.a112014; NAHMIAS AJ, 1973, NEW ENGL J MED, V289, P781, DOI 10.1056/NEJM197310112891505; PERLMANN P, 1972, TRANSPLANT REV, V13, P91; Perlmann P, 1970, Cell Immunol, V1, P300, DOI 10.1016/0008-8749(70)90051-1; RUSSELL AS, 1974, J INFECT DIS, V129, P142, DOI 10.1093/infdis/129.2.142; RUSSELL AS, 1976, J IMMUNOL METHODS, V9, P273, DOI 10.1016/0022-1759(76)90202-7; RUSSELL AS, 1975, INFECT IMMUN, V11, P355, DOI 10.1128/IAI.11.2.355-359.1975; SHORE SL, 1976, J IMMUNOL, V116, P194; SMITH IW, 1967, J HYG-CAMB, V65, P395, DOI 10.1017/S0022172400045915; WEINER MS, 1973, BLOOD, V42, P939, DOI 10.1182/blood.V42.6.939.939; WISLOFF F, 1973, SCAND J IMMUNOL, V2, P151, DOI 10.1111/j.1365-3083.1973.tb02026.x	22	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	5					539	545		10.1016/0091-6749(76)90199-8	http://dx.doi.org/10.1016/0091-6749(76)90199-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CL088	185242				2022-12-18	WOS:A1976CL08800001
J	SCHUMACHER, MJ; FARR, RS; MCCLATCHY, JK; MINDEN, P				SCHUMACHER, MJ; FARR, RS; MCCLATCHY, JK; MINDEN, P			PRIMARY INTERACTION BETWEEN ANTIBODY AND COMPONENTS OF ALTERNARIA .2. ANTIBODIES IN SERA FROM NORMAL, ALLERGIC, AND IMMUNOGLOBULIN-DEFICIENT CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,DEPT ALLERGY & CLIN IMMUNOL,DENVER,CO	National Jewish Health								BAILEY NTJ, 1959, STATISTICAL METHODS, P51; BARDANA EJ, 1973, CLIN EXP IMMUNOL, V13, P65; BARDANA EJ, 1974, ANN NY ACAD SCI, V221, P64, DOI 10.1111/j.1749-6632.1974.tb28200.x; BARDANA EJ, 1972, J ALLERGY CLIN IMMUN, V50, P222, DOI 10.1016/0091-6749(72)90016-4; BARDANA EJ, COMMUNICATION; BODEY GP, 1966, J CHRON DIS, V19, P667, DOI 10.1016/0021-9681(66)90066-X; BONIL.O, 1961, J ALLERGY, V32, P246, DOI 10.1016/0021-8707(61)90055-7; BRADSHAW MW, 1971, LANCET, V1, P1095; CHMELIK F, 1974, J ALLERGY CLIN IMMUN, V53, P86; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; FARR RS, 1958, J INFECT DIS, V103, P239, DOI 10.1093/infdis/103.3.239; FEINBERG SM, 1935, WISC MED J, V34, P254; FREY D., 1963, MYCOPATHOL ET MYCOL APPL, V19, P83, DOI 10.1007/BF02049016; FUDENBERG H, 1971, PEDIATRICS, V47, P927; GILMAN JC, 1957, MANUAL SOIL FUNGI, P347; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327; HAYWARD B. J., 1960, ACTA ALLERGOL, V15, P87; Hopkins JG, 1930, J AMER MED ASSOC, V94, P6, DOI 10.1001/jama.1930.02710270008002; ISHIZAKA T, 1967, J IMMUNOL, V99, P82; JONES HE, 1973, J ALLERGY CLIN IMMUN, V52, P346, DOI 10.1016/0091-6749(73)90093-6; JULIAN A J, 1970, Infection and Immunity, V1, P555; KAWAI T, 1973, CHEST, V64, P420, DOI 10.1378/chest.64.4.420; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P169; LOVELESS M, 1944, J ALLERGY, V15, P311; MAY CD, 1972, J ALLERGY CLIN IMMUN, V49, P54, DOI 10.1016/0091-6749(72)90123-6; MINDEN P, 1969, J EXP MED, V130, P931, DOI 10.1084/jem.130.5.931; MINDEN P, 1971, INFECT IMMUN, V3, P524, DOI 10.1128/IAI.3.4.524-529.1971; MINDEN P, 1969, J IMMUNOL, V102, P832; MINDEN P, 1973, HDB EXPTL IMMUNOLOGY, V2, P1; MINDEN P, 1971, IMMUNOLOGICAL DISEAS, P179; NETER E, 1959, AM J PUBLIC HEALTH N, V49, P1050, DOI 10.2105/AJPH.49.8.1050; ORIE NGM, 1960, AM REV RESPIR DIS, V82, P649; PEPYS J, 1969, MONOGRAPHS ALLERGY, V4; REED CE, 1973, J ALLERGY CLIN IMMUN, V51, P84, DOI 10.1016/S0091-6749(73)80017-X; RIDDLE HFV, 1968, THORAX, V23, P271, DOI 10.1136/thx.23.3.271; ROWLEY MJ, 1970, AUST J EXP BIOL MED, V48, P249, DOI 10.1038/icb.1970.26; SALVAGGIO JE, 1964, J ALLERGY, V35, P62, DOI 10.1016/0021-8707(64)90050-4; SCHLUETER DP, 1972, ANN INTERN MED, V77, P907, DOI 10.7326/0003-4819-77-6-907; SCHONWALD PHILIPP, 1938, JOUR ALLERGY, V9, P175, DOI 10.1016/S0021-8707(38)90512-X; Schumacher M J, 1972, Clin Allergy, V2, P345, DOI 10.1111/j.1365-2222.1972.tb01299.x; SCHUMACHER MJ, 1975, J ALLERGY CLIN IMMUN, V56, P39, DOI 10.1016/0091-6749(75)90033-0; SEELIGER H. P. R., 1960, TRANS BRIT MYCOL SOC, V43, P543; SNEDECOR GW, 1956, STATISTICAL METHODS, pCH4; SOLOMON WR, 1974, J ALLERGY CLIN IMMUN, V53, P71; SOSMAN JA, 1974, J ALLERGY CLIN IMMUN, V53, P71; STEIHM ER, 1966, PEDIATRICS SPRINGFIE, V37, P715; VANSELOW NA, 1967, MANUAL CLIN ALLERGY, P55; YOUNG RC, 1970, MEDICINE, V49, P147, DOI 10.1097/00005792-197003000-00002; 1972, AM ACADEMY ALLERGY S	50	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	1					54	63		10.1016/0091-6749(75)90034-2	http://dx.doi.org/10.1016/0091-6749(75)90034-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AH615	1094055				2022-12-18	WOS:A1975AH61500006
J	BLOCK, SH				BLOCK, SH			NASAL CONGESTION AS A SIDE-EFFECT OF CROMOLYN SODIUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note																		BRUCE RA, 1968, PRACTITIONER, V201, P915; DAVIES SE, 1968, BRIT MED J, V3, P593, DOI 10.1136/bmj.3.5618.593; JOSEPH M, 1969, MED J AUSTRALIA, V2, P533, DOI 10.5694/j.1326-5377.1969.tb107254.x; KINDER PH, 1968, LANCET, V2, P655; MAWDSLEY P, 1973, PRIVATE COMMUNICATIO	5	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	4					243	244		10.1016/0091-6749(74)90087-6	http://dx.doi.org/10.1016/0091-6749(74)90087-6			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S6732	4209469				2022-12-18	WOS:A1974S673200008
J	MALLEY, A; BAECHER, L				MALLEY, A; BAECHER, L			HYPERSENSITIVITY TO BACTERIAL ENZYMES .1. ATOPIC HYPERSENSITIVITY INDUCED IN RHESUS-MONKEYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BELIN L, 1970, LANCET, V2, P1153; CAMPBELL DH, 1963, METHOD IMMUNOL, P141; FLINDT MLH, 1969, LANCET, V1, P1177; FRANZ T, 1971, J ALLERGY, V47, P170, DOI 10.1016/S0091-6749(71)80295-6; ISHIZAKA K, 1968, J ALLERGY, V41, P96; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MALLEY A, 1969, J ALLERGY, V43, P59, DOI 10.1016/0021-8707(69)90126-9; MALLEY A, 1968, J IMMUNOL, V100, P915; MALLEY A, 1968, J IMMUNOL, V101, P292; MALLEY A, 1967, J IMMUNOL, V99, P825; PEPYS J, 1969, LANCET, V1, P1181; SHAPIRO RS, 1971, J ALLERGY, V47, P76, DOI 10.1016/S0091-6749(71)80373-1; TOWNLEY RG, 1967, J ALLERGY, V39, P177, DOI 10.1016/0021-8707(67)90036-6; WUTHRICH B, 1969, SCHWEIZ MED WSCHR, V99, P1584	14	13	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	1					36	&		10.1016/0091-6749(72)90121-2	http://dx.doi.org/10.1016/0091-6749(72)90121-2			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L3388	4108808				2022-12-18	WOS:A1972L338800005
J	Altrichter, S; Staubach, P; Pasha, M; Singh, B; Chang, AT; Bernstein, JA; Rasmussen, HS; Siebenhaar, F; Maurer, M				Altrichter, Sabine; Staubach, Petra; Pasha, Malika; Singh, Bhupinder; Chang, Alan T.; Bernstein, Jonathan A.; Rasmussen, Henrik S.; Siebenhaar, Frank; Maurer, Marcus			An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AK002; Siglec-8; cholinergic urticaria; symptomatic dermographism	EOSINOPHILS; VALIDATION; OMALIZUMAB; INSTRUMENT	Background: Chronic urticaria (CU) is a debilitating mast celldriven disease, often refractory to standard therapy (ie, antihistamines). Lirentelimab, an anti-sialic acid-binding immunoglobulin-like lectin 8 mAb, selectively inhibits mast cells and depletes eosinophils. Objective: We sought to determine safety and efficacy of lirentelimab in patients with CU. Methods: This phase 2a study enrolled patients with CU refractory to up to 4-fold H1-antihistamine doses. Patients received 6 monthly intravenous doses of lirentelimab (0.3, 1, and up to 3 mg/kg). Primary efficacy end point was change in Urticaria Control Test score at week 22. Urticaria Activity Score weekly average (UAS7) was assessed in patients with chronic spontaneous urticaria (CSU), and Cholinergic UAS7 was used for patients with cholinergic urticaria (CholU). Results: A total of 45 patients were enrolled in 4 cohorts (n = 13 omalizumab-naive CSU, n = 11 omalizumab-refractory CSU, n = 11 CholU, n = 10 symptomatic dermographism). Urticaria Control Test scores increased with lirentelimab across cohorts, with mean changes at week 22 of 11.1 +/- 4.1, 4.8 +/- 7.0, 6.5 +/- 6.2, and 3.4 +/- 4.1 and complete response rates (Urticaria Control Test score >= 12) of 92%, 36%, 82%, and 40%, respectively. In omalizumab-naive and omalizumab-refractory patients with CSU, disease activity decreased at week 22 (mean UAS7 change, -73% and -47%, respectively), with UAS7 response rates (>= 50% reduction) of 77% and 45%, respectively. In patients with symptomatic dermographism, 50% (5 of 10) and 40% (4 of 10) had complete itch and hive resolution by FricTest, respectively, and 100% (7 of 7) evaluable patients with CholU had negative responses to Pulse-Controlled Ergometry exercise test. Most common adverse events included infusion-related reactions (43%; all mild/moderate and transient), nasopharyngitis (21%), and headache (19%). No treatment-related serious adverse events occurred. Conclusions: Lirentelimab demonstrated activity across 3 forms of antihistamine-refractory CU.	[Altrichter, Sabine; Siebenhaar, Frank; Maurer, Marcus] Charite Univ Med Berlin, Dermatol Allergol, Dept Dermatol & Allergy, Charitepl 1, Berlin, Germany; [Altrichter, Sabine; Siebenhaar, Frank; Maurer, Marcus] Humboldt Univ, Freie Univ Berlin, Berlin, Germany; [Altrichter, Sabine; Siebenhaar, Frank; Maurer, Marcus] Berlin Inst Hlth, Berlin, Germany; [Staubach, Petra] Univ Med Hosp Mainz, Dept Dermatol, Mainz, Germany; [Pasha, Malika; Singh, Bhupinder; Chang, Alan T.; Rasmussen, Henrik S.] Allakos Inc, Redwood City, CA USA; [Bernstein, Jonathan A.] Univ Cincinnati, Cincinnati, OH USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; University System of Ohio; University of Cincinnati	Maurer, M (corresponding author), Charite Univ Med Berlin, Dermatol Allergol, Allergie Ctr Charite, Dept Dermatol & Allergy, Charitepl 1, D-10117 Berlin, Germany.	marcus.maurer@charite.de	Maurer, Marcus/ABG-2174-2020	Maurer, Marcus/0000-0002-4121-481X; Siebenhaar, Frank/0000-0003-4532-1644	Allakos Inc (Allakos)	Allakos Inc (Allakos)	This study was sponsored by Allakos Inc (Allakos). The study sponsor was involved in the study design, in the collection, analysis, and interpretation of data, and in the writing of the report.	Altrichter S, 2020, J ALLERGY CLIN IMMUN, V145, P1510, DOI 10.1016/j.jaci.2020.03.005; Altrichter S, 2014, J DERMATOL SCI, V75, P88, DOI 10.1016/j.jdermsci.2014.04.007; Asero R, 2009, WORLD ALLERGY ORGAN, V2, P213, DOI 10.1097/WOX.0b013e3181bb965f; Bernstein JA, 2020, NEW ENGL J MED, V383, P1389, DOI 10.1056/NEJMc2016395; Can PK, 2019, INT ARCH ALLERGY IMM, V178, P76, DOI 10.1159/000492970; Dellon ES, 2020, NEW ENGL J MED, V383, P1624, DOI 10.1056/NEJMoa2012047; Ertas R, 2020, J ALLER CL IMM-PRACT, V8, P1074, DOI 10.1016/j.jaip.2019.10.046; Fricke J, 2020, ALLERGY, V75, P423, DOI 10.1111/all.14037; Gastaminza G, 2019, J ALLER CL IMM-PRACT, V7, P1599, DOI 10.1016/j.jaip.2018.12.025; Kaplan A, 2013, J ALLERGY CLIN IMMUN, V132, P101, DOI 10.1016/j.jaci.2013.05.013; Kaplan AP, 2008, J ALLERGY CLIN IMMUN, V122, P569, DOI 10.1016/j.jaci.2008.07.006; Kiwamoto T, 2012, PHARMACOL THERAPEUT, V135, P327, DOI 10.1016/j.pharmthera.2012.06.005; Koch K, 2016, J ALLERGY CLIN IMMUN, V138, P1483, DOI 10.1016/j.jaci.2016.05.026; Maurer M, 2011, ALLERGY, V66, P317, DOI 10.1111/j.1398-9995.2010.02496.x; Maurer M, 2019, NEW ENGL J MED, V381, P1321, DOI 10.1056/NEJMoa1900408; Maurer M, 2019, ALLERGY, V74, P2550, DOI 10.1111/all.13878; Maurer M, 2017, J ALLERGY CLIN IMMUN, V140, P870, DOI 10.1016/j.jaci.2017.01.042; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Mlynek A, 2009, ALLERGY, V64, P927, DOI 10.1111/j.1398-9995.2008.01920.x; Saini SS, 2015, J INVEST DERMATOL, V135, P925, DOI [10.1038/jid.2014.512, 10.1038/jid.2014.306]; Salman A, 2019, DERMATOL THER, V32, DOI 10.1111/dth.12975; Schoepke N, 2015, CLIN EXP DERMATOL, V40, P399, DOI 10.1111/ced.12547; Weller K, 2014, J ALLERGY CLIN IMMUN, V133, P1365, DOI 10.1016/j.jaci.2013.12.1076; Youngblood BA, 2019, INT ARCH ALLERGY IMM, V180, P91, DOI 10.1159/000501637; Youngblood BA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126219; Zuberbier T, 2018, ALLERGY, V73, P1393, DOI 10.1111/all.13397	26	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2022	149	5					1683	+		10.1016/j.jaci.2021.12.772	http://dx.doi.org/10.1016/j.jaci.2021.12.772			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	3W0TR	34954198	hybrid			2022-12-18	WOS:000842068800018
J	Trier, AM; Mack, MR; Fredman, A; Tamari, M; Ver Heul, AM; Zhao, YH; Guo, CJ; Avraham, O; Ford, ZK; Oetjen, LK; Feng, J; Dehner, C; Coble, D; Badic, A; Joshita, S; Kubo, M; Gereau, RW; Alexander-Brett, J; Cavalli, V; Davidson, S; Hu, HZ; Liu, Q; Kim, BS				Trier, Anna M.; Mack, Madison R.; Fredman, Avery; Tamari, Masato; Ver Heul, Aaron M.; Zhao, Yonghui; Guo, Changxiong J.; Avraham, Oshri; Ford, Zachary K.; Oetjen, Landon K.; Feng, Jing; Dehner, Carina; Coble, Dean; Badic, Asima; Joshita, Satoru; Kubo, Masato; Gereau, Robert W.; Alexander-Brett, Jennifer; Cavalli, Valeria; Davidson, Steve; Hu, Hongzhen; Liu, Qin; Kim, Brian S.			IL-33 signaling in sensory neurons promotes dry skin itch	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; chronic pruritus of unknown origin; dry skin; IL-33; itch; neuroimmunology; pruriceptor; pruritogen	MOUSE MODEL; CELL; CHLOROQUINE	Background: Chronic pruritus, or itch, is common and debilitating, but the neuroimmune mechanisms that drive chronic itch are only starting to be elucidated. Recent studies demonstrate that the IL-33 receptor (IL-33R) is expressed by sensory neurons. However, whether sensory neuron-restricted activity of IL-33 is necessary for chronic itch remains poorly understood. Objectives: We sought to determine if IL-33 signaling in sensory neurons is critical for the development of chronic itch in 2 divergent pruritic disease models. Methods: Plasma levels of IL-33 were assessed in patients with atopic dermatitis (AD) and chronic pruritus of unknown origin (CPUO). Mice were generated to conditionally delete IL-33R from sensory neurons. The contribution of neuronal IL-33R signaling to chronic itch development was tested in mouse models that recapitulate key pathologic features of AD and CPUO, respectively. Results: IL-33 was elevated in both AD and CPUO as well as their respective mouse models. While neuron-restricted IL-33R signaling was dispensable for itch in AD-like disease, it was required for the development of dry skin itch in a mouse model that mirrors key aspects of CPUO pathology. Conclusions: These data highlight how IL-33 may be a predominant mediator of itch in certain contexts, depending on the tissue microenvironment. Further, this study provides insight into future therapeutic strategies targeting the IL-33 pathway for chronic itch.	[Trier, Anna M.; Mack, Madison R.; Fredman, Avery; Tamari, Masato; Ver Heul, Aaron M.; Zhao, Yonghui; Guo, Changxiong J.; Oetjen, Landon K.; Feng, Jing; Badic, Asima; Hu, Hongzhen; Liu, Qin; Kim, Brian S.] Washington Univ, Sch Med, Ctr Study Itch & Sensory Disorders, St Louis, MO USA; [Trier, Anna M.; Mack, Madison R.; Fredman, Avery; Tamari, Masato; Oetjen, Landon K.; Dehner, Carina; Badic, Asima; Kim, Brian S.] Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA; [Ver Heul, Aaron M.] Washington Univ, Sch Med, Dept Med, Div Allergy & Immunol, St Louis, MO 63110 USA; [Zhao, Yonghui; Guo, Changxiong J.; Feng, Jing; Gereau, Robert W.; Hu, Hongzhen; Liu, Qin; Kim, Brian S.] Washington Univ, Sch Med, Dept Med, Dept Anesthesiol, St Louis, MO 63110 USA; [Avraham, Oshri; Gereau, Robert W.; Cavalli, Valeria] Washington Univ, Sch Med, Dept Neurosci, St Louis, MO USA; [Coble, Dean] Washington Univ, Sch Med, Div Biostat, St Louis, MO USA; [Gereau, Robert W.] Washington Univ, Sch Med, Washington Univ Pain Ctr, St Louis, MO USA; [Alexander-Brett, Jennifer] Washington Univ, Sch Med, Dept Med, Div Pulm & Crit Care, St Louis, MO 63110 USA; [Kim, Brian S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Ford, Zachary K.; Davidson, Steve] Univ Cincinnati, Coll Med, Dept Anesthesiol, Cincinnati, OH USA; [Ford, Zachary K.; Davidson, Steve] Univ Cincinnati, Coll Med, Neurosci Program, Cincinnati, OH USA; [Joshita, Satoru] Shinshu Univ, Sch Med, Dept Med, Div Gastroenterol, Nagano, Japan; [Kubo, Masato] RIKEN Yokohama Inst, Ctr Integrat Med Sci IMS, Lab Cytokine Regulat, Yokohama, Kanagawa, Japan; [Kubo, Masato] Tokyo Univ Sci, Res Inst Biomed Sci, Div Mol Pathol, Tokyo, Japan	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Shinshu University; RIKEN; Tokyo University of Science	Kim, BS (corresponding author), 660 S Euclid Ave,Box 8123, St Louis, MO 63110 USA.	briankim@wustl.edu		Trier, Anna/0000-0001-7957-2180; Hu, Hongzhen/0000-0002-8967-7522; Avraham, Oshri/0000-0002-5826-0134	Celgene Corporation; Doris Duke Charitable Foundation; LEO Pharma; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [K08AR065577, R01AR070116, R01AR077007, R21AI167047]; National Institute of Allergy and Infectious Diseases (NIAID) [T32AI007163]; National Heart, Lung, and Blood Institute (NHLBI) [T32HL007317]; NIAID [R01AI125743, F30AI154912]; National Institute of Neurological Disorders and Strokes (NINDS) [R01NS042595]; NHLBI [R01HL152245]; Burroughs Welcome Fund [1014685]; McDonnell Center for Cellular and Molecular Neurobiology; NINDS [RF1NS113881, R01NS111719]; National Institute for Alcohol Abuse and Alcoholism (NIAAA) [R01AA027065]; NIAMS [R01AR077183]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01DK103901]; Washington University School of Medicine Digestive Disease Research Core Center (NIDDK) [P30DK052574]; Brain Research Foundation Fay/Frank Seed Grant; Pew Scholar Award; National Cancer Institute [P30CA091842]	Celgene Corporation(Bristol-Myers SquibbCelgene Corporation); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); LEO Pharma(LEO Pharma); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Neurological Disorders and Strokes (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Burroughs Welcome Fund(Burroughs Wellcome Fund); McDonnell Center for Cellular and Molecular Neurobiology; NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute for Alcohol Abuse and Alcoholism (NIAAA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Washington University School of Medicine Digestive Disease Research Core Center (NIDDK); Brain Research Foundation Fay/Frank Seed Grant; Pew Scholar Award; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research in the Kim laboratory is supported by the Celgene Corporation, Doris Duke Charitable Foundation, LEO Pharma, and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (K08AR065577, R01AR070116, R01AR077007, and R21AI167047) (to B.S.K.). A.M.T. and M.R.M. are supported by National Institute of Allergy and Infectious Diseases (NIAID) (T32AI007163). A.M.T. and L.K.O. are supported by National Heart, Lung, and Blood Institute (NHLBI) (T32HL007317). A.M.T. is supported by NIAID (F30AI154912). Research in the Gereau laboratory involving human dorsal root ganglia research is supported by National Institute of Neurological Disorders and Strokes (NINDS) (R01NS042595) (to R.W.G.). Research in the Alexander-Brett laboratory is supported by NHLBI (R01HL152245) and the Burroughs Welcome Fund (1014685) (to J.A.B). Research in the Cavalli laboratory is supported by the McDonnell Center for Cellular and Molecular Neurobiology and NINDS (R01NS111719) (to V.C.). O.A. is supported by the postdoctoral fellowship from the McDonnell Center for Cellular and Molecular Neurobiology. Research in the Davidson laboratory is supported by NINDS (RF1NS113881) (to S.D.). Research in the Hu laboratory is supported by National Institute for Alcohol Abuse and Alcoholism (NIAAA) (R01AA027065), NIAMS (R01AR077183), and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01DK103901) (to H.H.). Additional support was provided by the Washington University School of Medicine Digestive Disease Research Core Center (NIDDK, P30DK052574). Research in the Liu laboratory is supported by NIAID (R01AI125743), Brain Research Foundation Fay/Frank Seed Grant, and Pew Scholar Award (to Q.L.). Support with flow cytometry and Luminex was provided by the Bursky Center for Human Immunology & Immunotherapy Programs at Washington University, Immunomonitoring Laboratory (IML). The IML is a shared resource of the Alvin J. Siteman Cancer Center (Washington University School of Medicine and Barnes-Jewish Hospital in St Louis), which is supported in part by the National Cancer Institute (P30CA091842).	Agarwal N, 2004, GENESIS, V38, P122, DOI 10.1002/gene.20010; Avraham O, 2020, BIORXIV; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Chan BCL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00364; Du LX, 2019, GLIA, V67, P1680, DOI 10.1002/glia.23639; E. E.Ewan, 2020, bioRxiv, DOI 10.1101/2020.11.25.398537; Feng J, 2018, SCIENCE, V360, P530, DOI 10.1126/science.aar5703; Huang JT, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108233; Hulsen T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-488; Imai Y, 2019, J DERMATOL SCI, V96, P2, DOI 10.1016/j.jdermsci.2019.08.006; Kim BS, 2019, J AM ACAD DERMATOL, V81, P1223, DOI 10.1016/j.jaad.2019.06.038; Kim BS, 2014, J IMMUNOL, V193, P3717, DOI 10.4049/jimmunol.1401307; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kini SP, 2011, ARCH DERMATOL, V147, P1153, DOI 10.1001/archdermatol.2011.178; Liu BY, 2016, P NATL ACAD SCI USA, V113, pE7572, DOI 10.1073/pnas.1606608113; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mack MR, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay1005; Meixiong J, 2019, IMMUNITY, V50, P1163, DOI 10.1016/j.immuni.2019.03.013; Miyamoto T, 2002, JPN J PHARMACOL, V88, P285, DOI 10.1254/jjp.88.285; Nakamura N, 2019, CLIN IMMUNOL, V201, P1, DOI 10.1016/j.clim.2019.02.006; Oetjen LK, 2017, CELL, V171, P217, DOI 10.1016/j.cell.2017.08.006; Otsuka A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025538; Peng G, 2018, INFLAMMATION, V41, P154, DOI 10.1007/s10753-017-0673-7; Pietka W, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63410-z; Shi H, 2017, NEUROREPORT, V28, P1127, DOI 10.1097/WNR.0000000000000877; Sidbury R, 2014, J AM ACAD DERMATOL, V71, P1218, DOI 10.1016/j.jaad.2014.08.038; Solinski HJ, 2019, CELL REP, V26, P3561, DOI 10.1016/j.celrep.2019.02.089; Tamagawa-Mineoka R, 2014, J AM ACAD DERMATOL, V70, P882, DOI 10.1016/j.jaad.2014.01.867; Thakur M, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00087; Valtcheva MV, 2015, J PAIN, V16, P346, DOI 10.1016/j.jpain.2015.01.005; Wang F, 2021, CELL, V184, P422, DOI 10.1016/j.cell.2020.12.033; Wang F, 2020, IMMUNITY, V52, P753, DOI 10.1016/j.immuni.2020.04.008; Weisshaar E, 2009, ACTA DERM-VENEREOL, V89, P339, DOI 10.2340/00015555-0662; Wilson SR, 2013, J NEUROSCI, V33, P9283, DOI 10.1523/JNEUROSCI.5318-12.2013	34	12	12	6	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2022	149	4					1473	+		10.1016/j.jaci.2021.09.014	http://dx.doi.org/10.1016/j.jaci.2021.09.014			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	2R0DI		Green Accepted, hybrid			2022-12-18	WOS:000820784100014
J	Pham, MN; Murugesan, K; Banaei, N; Pinsky, BA; Tang, M; Hoyte, E; Lewis, DB; Gernez, Y				Pham, Michele N.; Murugesan, Kanagavel; Banaei, Niaz; Pinsky, Benjamin A.; Tang, Monica; Hoyte, Elisabeth; Lewis, David B.; Gernez, Yael			Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SARS-CoV-2; SARS-CoV-2 vaccination; primary immu-nodeficiency; ACE2 blocking antibody; SARS-CoV-2 spike protein antibody; antibody deficiency; common variable immunodeficiency; Good syndrome; mAb; SARS-CoV-2 IFN-gamma release assay	SARS-COV-2	Background: Data on the safety and efficacy of coronavirus disease 2019 (COVID-19) vaccination in people with a range of primary immunodeficiencies (PIDs) are lacking because these patients were excluded from COVID-19 vaccine trials. This information may help in clinical management of this vulnerable patient group. Objective: We assessed humoral and T-cell immune responses after 2 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients with PID and functional B-cell defects. Methods: A double-center retrospective review was performed of patients with PID who completed COVID-19 mRNA vaccination and who had humoral responses assessed through SARS-CoV-2 spike protein receptor binding domain (RBD) IgG antibody levels with reflex assessment of the antibody to block RBD binding to angiotensin-converting enzyme 2 (ACE2; hereafter referred to as ACE2 receptor blocking activity, as a surrogate test for neutralization) and T-cell response evaluated by an IFN-gamma release assay. Immunization reactogenicity was also reviewed. Results: A total of 33 patients with humoral defect were evaluated; 69.6% received BNT162b2 vaccine (Pfizer-BioNTech) and 30.3% received mRNA-1273 (Moderna). The mRNA vaccines were generally well tolerated without severe reactions. The IFN-gamma release assay result was positive in 24 (77.4%) of 31 patients. Sixteen of 33 subjects had detectable RBD-specific IgG responses, but only 2 of these 16 subjects had an ACE2 receptor blocking activity level of >= 50%. Conclusion: Vaccination of this cohort of patients with PID with COVID-19 mRNAvaccines was safe, and cellular immunity was stimulated in most subjects. However, antibody responses to the spike protein RBD were less consistent, and, when detected, were not effective at ACE2 blocking.	[Pham, Michele N.; Tang, Monica] Univ Calif San Francisco, Dept Internal Med, Div Pulm Crit Care Allergy & Sleep Med, San Francisco, CA 94143 USA; [Murugesan, Kanagavel; Banaei, Niaz; Pinsky, Benjamin A.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Banaei, Niaz; Pinsky, Benjamin A.] Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Dept Med, Stanford, CA 94305 USA; [Hoyte, Elisabeth; Lewis, David B.; Gernez, Yael] Stanford Univ, Sch Med, Div Allergy Immunol & Rheumatol, Dept Pediat, 269 Campus Dr,CCSR Ste 3215, Stanford, CA 94305 USA; [Banaei, Niaz] Stanford Hlth Care, Clin Microbiol Lab, Stanford, CA USA; [Pinsky, Benjamin A.] Stanford Hlth Care, Clin Virol Lab, Stanford, CA USA	University of California System; University of California San Francisco; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University	Gernez, Y (corresponding author), Stanford Univ, Sch Med, Div Allergy Immunol & Rheumatol, Dept Pediat, 269 Campus Dr,CCSR Ste 3215, Stanford, CA 94305 USA.	yaelg@stanford.edu	Murugesan, Kanagavel/K-2006-2019	Murugesan, Kanagavel/0000-0003-3334-5358; Banaei, Niaz/0000-0001-8501-3000				Amirthalingam G, 2021, EMERG INFECT DIS, V27, P1795, DOI 10.3201/eid2707.203167; Banaei Niaz, 2016, J Clin Microbiol, V54, P845, DOI 10.1128/JCM.02803-15; Bradley T, 2021, NEW ENGL J MED, V384, P1959, DOI 10.1056/NEJMc2102051; Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9; Dalakas MC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.627285; Delmonte OM, 2021, J ALLERGY CLIN IMMUN, V148, P1192, DOI 10.1016/j.jaci.2021.08.016; Farcet MR, J INFECT DIS; Hagin D, 2021, J ALLERGY CLIN IMMUN, V148, P739, DOI 10.1016/j.jaci.2021.05.029; Jin DK, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250319; Murugesan K, 2021, CLIN INFECT DIS, V73, pE3130, DOI 10.1093/cid/ciaa1537; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Roltgen K, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe0240; Romero C, 2021, LANCET INFECT DIS, V21, P765, DOI 10.1016/S1473-3099(21)00059-1; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Shields AM, 2021, J ALLERGY CLIN IMMUN, V147, P870, DOI 10.1016/j.jaci.2020.12.620; Squire Jacqueline, 2021, Ann Allergy Asthma Immunol, V127, P383, DOI 10.1016/j.anai.2021.05.015; US Centers for Disease Control and Prevention, 2021, COVID 19 VACC MOD SE; Walker SN, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01533-20	19	12	12	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2022	149	3					907	+		10.1016/j.jaci.2021.11.022	http://dx.doi.org/10.1016/j.jaci.2021.11.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZO7WJ	34952033	Green Published, Bronze			2022-12-18	WOS:000765938100020
J	Chollet, MB; Akin, C				Chollet, Madeleine B.; Akin, Cem			Hereditary alpha tryptasemia is not associated with specific clinical phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hereditary alpha tryptasemia; mastocytosis	CLASSIFICATION; MASTOCYTOSIS	Background: Hereditary alpha tryptasemia (H alpha T) is found in approximately 7% of the population. Associations with a variety of clinical symptoms including gastric reflux, joint hypermobility, dysautonomia, flushing and pruritus, and hymenoptera allergy have variably been described in prior reports. However, our understanding of this genetic trait is limited by a paucity of published studies, referral bias, and conflicting findings at clinical presentation. Objective: The purpose of this study was to assess the clinical phenotype of H alpha T in a random biorepository population and in patients with and without mastocytosis referred to the allergy clinic. Methods: Tryptase copy number allele was assessed using digital droplet PCR. Participants with or without H alpha T were interviewed and examined by a clinician and surveyed regarding their medical history and symptomology. Results: H alpha T was identified in 7.5% of the random biorepository samples and in 18% of patients with mastocytosis. There was no difference in the clinical symptomology or medical history of individuals with H alpha T compared to controls. Average baseline serum tryptase was higher in individuals with H alpha T compared to controls, but there was no difference in urinary mast cell activation products. Conclusions: Elevated baseline serum tryptase was the only consistent phenotypic marker for H alpha T in this study. There was a higher frequency of H alpha T in patients with mastocytosis than in the general population.	[Chollet, Madeleine B.; Akin, Cem] Univ Michigan, Div Allergy, 24 Frank Lloyd Wright Dr,Suite H-2100, Ann Arbor, MI 48106 USA	University of Michigan System; University of Michigan	Akin, C (corresponding author), Univ Michigan, Div Allergy, 24 Frank Lloyd Wright Dr,Suite H-2100, Ann Arbor, MI 48106 USA.	cemakin@med.umich.edu			University of Michigan	University of Michigan(University of Michigan System)	This study was funded by the University of Michigan.	Caughey GH, 2006, J ALLERGY CLIN IMMUN, V117, P1411, DOI 10.1016/j.jaci.2006.02.026; Giannetti MP, 2021, ANN ALLERG ASTHMA IM, V126, P655, DOI 10.1016/j.anai.2021.01.016; Greiner G, 2021, BLOOD, V137, P238, DOI 10.1182/blood.2020006157; Lyons JJ, 2021, J ALLERGY CLIN IMMUN, V147, P622, DOI 10.1016/j.jaci.2020.06.035; Lyons JJ, 2016, NAT GENET, V48, P1564, DOI 10.1038/ng.3696; Lyons JJ, 2014, J ALLERGY CLIN IMMUN, V133, P1471, DOI 10.1016/j.jaci.2013.11.039; Palsson OS, 2016, GASTROENTEROLOGY, V150, P1481, DOI 10.1053/j.gastro.2016.02.014; Robey RC, 2020, J ALLER CL IMM-PRACT, V8, P3549, DOI 10.1016/j.jaip.2020.05.057; Sabato V, 2018, J CLIN IMMUNOL, V38, P457, DOI 10.1007/s10875-018-0506-y; Sabato V, 2014, J ALLERGY CLIN IMMUN, V134, P1448, DOI 10.1016/j.jaci.2014.06.007; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Sletten DM, 2012, MAYO CLIN PROC, V87, P1196, DOI 10.1016/j.mayocp.2012.10.013; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Valent P, 2017, BLOOD, V129, P1420, DOI 10.1182/blood-2016-09-731893	14	12	12	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2022	149	2					728	+		10.1016/j.jaci.2021.06.017	http://dx.doi.org/10.1016/j.jaci.2021.06.017			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YV3IA					2022-12-18	WOS:000752623200030
J	Egg, D; Rump, IC; Mitsuiki, N; Rojas-Restrepo, J; Maccari, ME; Schwab, C; Gabrysch, A; Warnatz, K; Goldacker, S; Patino, V; Wolff, D; Okada, S; Hayakawa, S; Shikama, Y; Kanda, K; Imai, K; Sotomatsu, M; Kuwashima, M; Kamiya, T; Morio, T; Matsumoto, K; Mori, T; Yoshimoto, Y; Dybedal, I; Kanariou, M; Kucuk, ZY; Chapdelaine, H; Petruzelkova, L; Lorenz, HM; Sullivan, KE; Heimall, J; Moutschen, M; Litzman, J; Recher, M; Albert, MH; Hauck, F; Seneviratne, S; Schmid, JP; Kolios, A; Unglik, G; Klemann, C; Snapper, S; Giulino-Roth, L; Svaton, M; Platt, CD; Hambleton, S; Neth, O; Gosse, G; Reinsch, S; Holzinger, D; Kim, YJ; Bakhtiar, S; Atschekzei, F; Schmidt, R; Sogkas, G; Chandrakasan, S; Rae, W; Derfalvi, B; Marquart, HV; Ozen, A; Kiykim, A; Karakoc-Aydiner, E; Kralickova, P; De Bree, G; Kiritsi, D; Seidel, MG; Kobbe, R; Dantzer, J; Alsina, L; Armangue, T; Lougaris, V; Agyeman, P; Nystrom, S; Buchbinder, D; Arkwright, PD; Grimbacher, B				Egg, David; Rump, Ina Caroline; Mitsuiki, Noriko; Rojas-Restrepo, Jessica; Maccari, Maria-Elena; Schwab, Charlotte; Gabrysch, Annemarie; Warnatz, Klaus; Goldacker, Sigune; Patino, Virginia; Wolff, Daniel; Okada, Satoshi; Hayakawa, Seiichi; Shikama, Yoshiaki; Kanda, Kenji; Imai, Kohsuke; Sotomatsu, Manabu; Kuwashima, Makoto; Kamiya, Takahiro; Morio, Tomohiro; Matsumoto, Kazuaki; Mori, Takeshi; Yoshimoto, Yuri; Dybedal, Ingunn; Kanariou, Maria; Kucuk, Zeynep Yesim; Chapdelaine, Hugo; Petruzelkova, Lenka; Lorenz, Hanns-Martin; Sullivan, Kathleen E.; Heimall, Jennifer; Moutschen, Michel; Litzman, Jiri; Recher, Mike; Albert, Michael H.; Hauck, Fabian; Seneviratne, Suranjith; Schmid, Jana Pachlopnik; Kolios, Antonios; Unglik, Gary; Klemann, Christian; Snapper, Scott; Giulino-Roth, Lisa; Svaton, Michael; Platt, Craig D.; Hambleton, Sophie; Neth, Olaf; Gosse, Geraldine; Reinsch, Steffen; Holzinger, Dirk; Kim, Yae-Jean; Bakhtiar, Shahrzad; Atschekzei, Faranaz; Schmidt, Reinhold; Sogkas, Georgios; Chandrakasan, Shanmuganathan; Rae, William; Derfalvi, Beata; Marquart, Hanne Vibeke; Ozen, Ahmet; Kiykim, Ayca; Karakoc-Aydiner, Elif; Kralickova, Pavlina; de Bree, Godelieve; Kiritsi, Dimitra; Seidel, Markus G.; Kobbe, Robin; Dantzer, Jennifer; Alsina, Laia; Armangue, Thais; Lougaris, Vassilios; Agyeman, Philipp; Nystrom, Sofia; Buchbinder, David; Arkwright, Peter D.; Grimbacher, Bodo			Therapeutic options for CTLA-4 insufficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CTLA-4; common variable immunodeficiency; primary immunodeficiency; diagnosis; treatment; abatacept; sirolimus; LRBA; rituximab; HSCT	IMMUNE DYSREGULATION; MANAGEMENT; RITUXIMAB; DEFICIENCY; MUTATIONS; DISEASE	Background: Heterozygous germline mutations in cytotoxic T lymphocyte-associated antigen-4 (CTLA4) impair the immunomodulatory function of regulatory T cells. Affected individuals are prone to life-threatening autoimmune and lymphoproliferative complications. A number of therapeutic options are currently being used with variable effectiveness. Objective: Our aim was to characterize the responsiveness of patients with CTLA-4 insufficiency to specific therapies and provide recommendations for the diagnostic workup and therapy at an organ-specific level. Methods: Clinical features, laboratory findings, and response to treatment were reviewed retrospectively in an international cohort of 173 carriers of CTLA4 mutation. Patients were followed between 2014 and 2020 for a total of 2624 months from diagnosis. Clinical manifestations were grouped on the basis of organ-specific involvement. Medication use and response were recorded and evaluated. Results: Among the 173 CTLA4 mutation carriers, 123 (71%) had been treated for immune complications. Abatacept, rituximab, sirolimus, and corticosteroids ameliorated disease severity, especially in cases of cytopenias and lymphocytic organ infiltration of the gut, lungs, and central nervous system. Immunoglobulin replacement was effective in prevention of infection. Only 4 of 16 patients (25%) with cytopenia who underwent splenectomy had a sustained clinical response. Cure was achieved with stem cell transplantation in 13 of 18 patients (72%). As a result of the aforementioned methods, organ-specific treatment pathways were developed. Conclusion: Systemic immunosuppressants and abatacept may provide partial control but require ongoing administration. Allogeneic hematopoietic stem cell transplantation offers a possible cure for patients with CTLA-4 insufficiency.	[Egg, David; Rump, Ina Caroline; Mitsuiki, Noriko; Rojas-Restrepo, Jessica; Maccari, Maria-Elena; Schwab, Charlotte; Gabrysch, Annemarie; Warnatz, Klaus; Goldacker, Sigune; Klemann, Christian; Grimbacher, Bodo] Albert Ludwig Univ Freiburg, Fac Med, Ctr Chron Immunodeficiency, Med Ctr,Inst Immunodeficiency, Freiburg, Germany; [Maccari, Maria-Elena; Klemann, Christian] Albert Ludwig Univ Freiburg, Fac Med, Med Ctr, Dept Pediat & Adolescent Med,Div Pediat Hematol &, Freiburg, Germany; [Warnatz, Klaus; Goldacker, Sigune; Grimbacher, Bodo] Albert Ludwig Univ Freiburg, Fac Med, Med Ctr, Dept Rheumatol & Clin Immunol, Freiburg, Germany; [Kiritsi, Dimitra] Albert Ludwig Univ Freiburg, Fac Med, Med Ctr, Dept Dermatol, Freiburg, Germany; [Grimbacher, Bodo] Albert Ludwig Univ Freiburg, Ctr Integrat Biol Signaling Studies, Med Ctr, Fac Med, Freiburg, Germany; [Patino, Virginia] Amer Insurance, Immunol Team, Montevideo, Uruguay; [Wolff, Daniel] Univ Hosp Regensburg, Dept Internal Med 3, Regensburg, Germany; [Okada, Satoshi; Hayakawa, Seiichi] Hiroshima Univ, Dept Pediat, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan; [Shikama, Yoshiaki] Kanagawa Childrens Med Ctr, Div Infect Immunol & Infect, Yokohama, Kanagawa, Japan; [Kanda, Kenji] Hikone Municipal Hosp, Dept Pediat, Hikone, Shiga, Japan; [Imai, Kohsuke] Tokyo Med & Dent Univ, Dept Community Pediat Perinatal & Maternal Med, Tokyo, Japan; [Sotomatsu, Manabu; Matsumoto, Kazuaki] Gunma Childrens Med Ctr, Dept Hematol Oncol, Shibukawa, Japan; [Kuwashima, Makoto] Kiryu Kosei Gen Hosp, Dept Pediat, Kiry, Japan; [Kamiya, Takahiro] Tokyo Med & Dent Univ, Dept Lifetime Clin Immunol, Tokyo, Japan; [Morio, Tomohiro] Tokyo Med & Dent Univ, Dept Pediat & Dev Biol, Tokyo, Japan; [Mori, Takeshi] Hyogo Prefectural Kobe Childrens Hosp, Dept Hematol & Oncol, Kobe, Hyogo, Japan; [Yoshimoto, Yuri] Ctr Hosp Natl Ctr Global Hlth & Med, Dept Pediat, Tokyo, Japan; [Dybedal, Ingunn] Oslo Univ Hosp, Dept Hematol, Oslo, Norway; [Kanariou, Maria] Aghia Sophia Childrens Hosp, Ctr Primary Immunodeficiencies Paediat Immunol, Dept Immunol & Histocompatibil, Athens, Greece; [Kucuk, Zeynep Yesim] Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH USA; [Chapdelaine, Hugo] Montreal Clin Res Inst, Div Clin Immunol, Montreal, PQ, Canada; [Petruzelkova, Lenka] Charles Univ Prague, Motol Univ Hosp, Med Fac Prague 2, Dept Paediat, Prague, Czech Republic; [Lorenz, Hanns-Martin] Heidelberg Univ, Dept Internal Med 5, Div Rheumatol, Heidelberg, Germany; [Sullivan, Kathleen E.; Heimall, Jennifer] Univ Penn, Perelman Sch Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Moutschen, Michel] Univ Hosp Liege, Dept Infect Dis & Gen Internal Med, Liege, Belgium; [Litzman, Jiri] Masaryk Univ, Med Fac, Dept Clin Immunol & Allergol, Brno, Czech Republic; [Litzman, Jiri] St Annes Univ Hosp, Dept Clin Immunol & Allergol, Brno, Czech Republic; [Recher, Mike] Univ Hosp, Dept Biomed, Med Outpatient Unit, Immunodeficiency Clin, Basel, Switzerland; [Recher, Mike] Univ Hosp, Dept Biomed, Immunodeficiency Lab, Basel, Switzerland; [Albert, Michael H.; Hauck, Fabian] Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Dept Pediat, Univ Hosp, Munich, Germany; [Seneviratne, Suranjith; Grimbacher, Bodo] UCL, Royal Free Hosp, Inst Immunol & Transplantat, London, England; [Schmid, Jana Pachlopnik] Univ Zurich, Univ Childrens Hosp Zurich, Div Immunol, Zurich, Switzerland; [Kolios, Antonios] Univ Zurich, Univ Hosp Zurich, Dept Immunol, Zurich, Switzerland; [Unglik, Gary] Royal Melbourne Hosp, Dept Clin Immunol & Allergy, Melbourne, Vic, Australia; [Snapper, Scott] Harvard Med Sch, Boston Childrens Hosp, Div Pediat Gastroenterol, Boston, MA USA; [Platt, Craig D.] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Platt, Craig D.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Giulino-Roth, Lisa] Weill Cornell Med, Div Pediat Hematol Oncol, Dept Pediat, New York, NY USA; [Svaton, Michael] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Childhood Leukaemia Invest Prague, Prague, Czech Republic; [Svaton, Michael] Univ Hosp Motol, Prague, Czech Republic; [Hambleton, Sophie] Newcastle Upon Tyne Hosp NHS Fdn Trust, Great North Childrens Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Hambleton, Sophie] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Neth, Olaf] Hosp Virgen del Roc, Inst Biomed Sevilla, RECLIP, Pediat Infect Dis Rheumatol & Immunol Unit, Seville, Spain; [Gosse, Geraldine] Univ Montreal, Montreal Clin Res Inst, Montreal, PQ, Canada; [Reinsch, Steffen] Jena Univ Hosp, Pediat Gastroenterol, Jena, Germany; [Holzinger, Dirk] Univ Duisburg Essen, Dept Pediat Hematol Oncol, Essen, Germany; [Kim, Yae-Jean] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pediat, Div Infect Dis & Immunodeficiency,Sch Med, Seoul, South Korea; [Bakhtiar, Shahrzad] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Children & Adolescents, Div Stem Cell Transplantat & Immunol, Frankfurt, Germany; [Atschekzei, Faranaz; Schmidt, Reinhold; Sogkas, Georgios] Hannover Med Sch, Dept Clin Rheumatol & Immunol, Hannover, Germany; [Chandrakasan, Shanmuganathan] Emory Univ, Sch Med, Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr,Div Bone Marrow, Atlanta, GA USA; [Rae, William] Univ Hosp Southampton NHSFT, Dept Immunol, Southampton, Hants, England; [Rae, William] Univ Hosp Southampton NHSFT, Southampton Natl Inst Hlth Res, Clin Res Facil, Southampton, Hants, England; [Derfalvi, Beata] IWK Hlth Ctr, Div Immunol, Halifax, NS, Canada; [Derfalvi, Beata] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada; [Marquart, Hanne Vibeke] Univ Copenhagen, Rigshosp, Dept Clin Immunol, Copenhagen, Denmark; [Ozen, Ahmet; Kiykim, Ayca; Karakoc-Aydiner, Elif] Marmara Univ, Div Pediat Allergy & Immunol, Sch Med, Istanbul, Turkey; [Kralickova, Pavlina] Charles Univ Prague, Univ Hosp Hradec Kralove, Fac Med Hradec Kralove, Inst Clin Immunol & Allergy, Hradec Kralove, Czech Republic; [de Bree, Godelieve] Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam Inst Infect & Immun, Dept Internal Med, Amsterdam, Netherlands; [Seidel, Markus G.] Med Univ Graz, Dept Pediat & Adolescent Med, Div Pediat Hematooncol, Res Unit Pediat Hematol & Immunol, Graz, Austria; [Kobbe, Robin] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Div Infect Dis, Hamburg, Germany; [Dantzer, Jennifer] Johns Hopkins Univ, Dept Pediat, Div Pediat Allergy & Immunol & Rheumatol, Sch Med, Baltimore, MD USA; [Alsina, Laia] Hosp St Joan de Deu, Pediat Allergy & Clin Immunol Dept, Clin Immunol & Primary Immunodeficiencies Unit, Barcelona, Spain; [Alsina, Laia] Inst Recerca St Joan de Deu, Barcelona, Spain; [Alsina, Laia] Univ Barcelona, Hosp Clin Barcelona, Hosp St Joan de Deu, Barcelona, Spain; [Armangue, Thais] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi & Sunyer, Neuroimmunol Program, Barcelona, Spain; [Lougaris, Vassilios] Univ Barcelona, Neurol Dept, Pediat Neuroimmunol Unit, St Joan de Deu Childrens Hosp, Barcelona, Spain; [Agyeman, Philipp] Univ Brescia, Pediat Clin, Dept Clin & Expt Sci, ASST Spedali Civili Brescia, Brescia, Italy; [Agyeman, Philipp] Univ Brescia, ASST Spedali Civili Brescia, Dept Clin & Expt Sci, Inst Mol Med A Nocivelli, Brescia, Italy; [Nystrom, Sofia] Univ Bern, Bern Univ Hosp, Dept Pediat, Inselspital, Bern, Switzerland; [Buchbinder, David] Linkoping Univ, Dept Clin Immunol & Transfus Med, Linkoping, Sweden; [Buchbinder, David] Linkoping Univ, Dept Biomed & Clin Sci, Linkoping, Sweden; [Arkwright, Peter D.] Childrens Hosp Orange Cty, Div Pediat Hematol, Orange, CA USA; [Grimbacher, Bodo] Univ Manchester, Royal Manchester Childrens Hosp, Lydia Becker Inst Immunol & Inflammat, Manchester, Lancs, England; [Grimbacher, Bodo] German Ctr Infect Res, Satellite Ctr Freiburg, Freiburg, Germany; [Grimbacher, Bodo] Hannover Med Sch, RESIST Cluster Excellence 2155, Satellite Ctr Freiburg, Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Regensburg; Hiroshima University; Tokyo Medical & Dental University (TMDU); Gunma Children's Medical Centre; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); University of Oslo; The Aghia Sophia Children's Hospital; Cincinnati Children's Hospital Medical Center; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Charles University Prague; Motol University Hospital; Ruprecht Karls University Heidelberg; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Liege; Masaryk University Brno; St Anne's University Hospital Brno (FNUSA-ICRC); University of Munich; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University Children's Hospital Zurich; University of Zurich; University of Zurich; University Zurich Hospital; Royal Melbourne Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Cornell University; Charles University Prague; Motol University Hospital; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Friedrich Schiller University of Jena; University of Duisburg Essen; Sungkyunkwan University (SKKU); Samsung Medical Center; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Hannover Medical School; Children's Healthcare of Atlanta (CHOA); Emory University; Dalhousie University; Dalhousie University; Rigshospitalet; University of Copenhagen; Marmara University; Charles University Prague; University Hospital Hradec Kralove; University of Amsterdam; Medical University of Graz; University of Hamburg; University Medical Center Hamburg-Eppendorf; Johns Hopkins University; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Spedali Civili Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Brescia; University of Bern; University Hospital of Bern; Linkoping University; Linkoping University; Childrens Hospital of Orange County; Royal Manchester Children's Hospital; University of Manchester; German Center for Infection Research; Hannover Medical School	Grimbacher, B (corresponding author), Univ Klinikum Freiburg, Ctr Chron Immunodeficiency, Breisacher Str 115, D-79106 Freiburg, Germany.	bodo.grimbacher@uniklinik-freiburg.de	KIYKIM, Ayca/J-6400-2017; NystrÃm, Sofia/GYQ-5893-2022; Rae, William/AGX-6005-2022; Ba, Sha/HGB-9711-2022; Alsina, Laia/AID-4372-2022; Svaton, Michael/AAB-3869-2019; Okada, Satoshi/B-8901-2011	KIYKIM, Ayca/0000-0001-5821-3963; Okada, Satoshi/0000-0002-4622-5657	Deutsche Forschungsgemeinschaft [SFB1160/2_B5, CIBSS-EXC-2189, 390939984, RESIST-EXC 2155, 39087428]; E-Rare Program of the European Union [GR1617/14-1/iPAD]; Netzwerke Seltener Erkrankungen of the German Ministry of Education and Research [GAIN 01GM1910A]; Ministry of Health of the Czech Republic [NV19-05-00332]; Else Kroner-Fresenius-Stiftung (EKFS) [2017_A110]; German Federal Ministry of Education and Research (BMBF) [01GM1910C]; Cancer Research Center Funding Program (CRC, C3Z) of the University of Zurich, Zurich, Switzerland; Torrons Vicens Foundation [PFNR0144]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); E-Rare Program of the European Union; Netzwerke Seltener Erkrankungen of the German Ministry of Education and Research; Ministry of Health of the Czech Republic(Ministry of Health, Czech Republic); Else Kroner-Fresenius-Stiftung (EKFS); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Cancer Research Center Funding Program (CRC, C3Z) of the University of Zurich, Zurich, Switzerland; Torrons Vicens Foundation	Supported by the Deutsche Forschungsgemeinschaft (grant SFB1160/2_B5), under Germany's Excellence Strategy (CIBSS-EXC-2189 [project identifier 390939984] and RESIST-EXC 2155 [project identifier 39087428] [to B.D.]); the E-Rare Program of the European Union, managed by the Deutsche Forschungsgemeinschaft (grant code GR1617/14-1/iPAD [to B.D.]); the Netzwerke Seltener Erkrankungen of the German Ministry of Education and Research (grant code GAIN 01GM1910A [to B.D.]); the Ministry of Health of the Czech Republic (grant code NV19-05-00332 [to M.S.]); the Torrons Vicens Foundation (grant code PFNR0144 [to L.A. and T.A.]); the Else Kr_oner-Fresenius-Stiftung (EKFS, 2017_A110 [to F.H.]), and the German Federal Ministry of Education and Research (BMBF, 01GM1910C [to F.H.]); and the Cancer Research Center Funding Program (CRC, C3Z) of the University of Zurich, Zurich, Switzerland (to J.P.S.).	Arnold DM, 2017, BRIT J HAEMATOL, V178, P302, DOI 10.1111/bjh.14664; Birgens H, 2013, BRIT J HAEMATOL, V163, P393, DOI 10.1111/bjh.12541; Deya-Martinez A, 2018, PEDIAT ALLERG IMM-UK, V29, P425, DOI 10.1111/pai.12890; Egg D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02012; Gangemi S, 2015, LEUKEMIA RES, V39, P389, DOI 10.1016/j.leukres.2015.02.002; Gobert D, 2011, BRIT J HAEMATOL, V155, P498, DOI 10.1111/j.1365-2141.2011.08880.x; Gupta NK, 2014, J CLIN GASTROENTEROL, V48, P55, DOI 10.1097/MCG.0b013e3182a4e0ec; Hurst JR, 2017, J ALLER CL IMM-PRACT, V5, P938, DOI 10.1016/j.jaip.2017.01.021; Jamee M, 2020, J ALLER CL IMM-PRACT, V8, P2747, DOI 10.1016/j.jaip.2020.04.070; Kiykim A, 2019, J ALLER CL IMM-PRACT, V7, P2790, DOI 10.1016/j.jaip.2019.06.011; Klemann C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00297; Krivan G, 2017, AM J CLIN EXP IMMUNO, V6, P76; Kucuk ZY, 2017, J ALLERGY CLIN IMMUN, V140, P862, DOI 10.1016/j.jaci.2017.02.032; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Lee S, 2016, J ALLERGY CLIN IMMUN, V137, P327, DOI 10.1016/j.jaci.2015.08.036; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Matson DR, 2020, ARCH PATHOL LAB MED, V144, P245, DOI 10.5858/arpa.2018-0190-RS; Michel M, 2009, BLOOD, V114, P3167, DOI 10.1182/blood-2009-04-215368; Neunert C, 2011, BLOOD, V117, P4190, DOI 10.1182/blood-2010-08-302984; Pan PCW, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0859-2; Rae W, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.38; Ramanathan S, 2016, AUTOIMMUN REV, V15, P307, DOI 10.1016/j.autrev.2015.12.004; Scheuerlein P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01656; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Schwab C, 2018, J ALLERGY CLIN IMMUN, V142, P1932, DOI 10.1016/j.jaci.2018.02.055; Serwas NK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10812-x; Sewell WAC, 2014, EUR J IMMUNOL, V44, P2207, DOI 10.1002/eji.201444700; Shivaj UN, 2019, THER ADV GASTROENTER, V12, DOI 10.1177/1756284819884196; Slatter MA, 2016, J ALLERGY CLIN IMMUN, V138, P615, DOI 10.1016/j.jaci.2016.01.045; Stingl Cory, 2018, Curr Treatm Opt Rheumatol, V4, P14, DOI 10.1007/s40674-018-0089-z; Tesch VK, 2020, J ALLERGY CLIN IMMUN, V145, P1452, DOI 10.1016/j.jaci.2019.12.896; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; van Leeuwen EM, 2018, J CLIN IMMUNOL, V38, P464, DOI 10.1007/s10875-018-0511-1; Varley J, 2018, NEUROPHARMACOLOGY, V132, P71, DOI 10.1016/j.neuropharm.2017.04.046; von Spee-Mayer C, 2021, J ALLER CL IMM-PRACT, V9, P760, DOI 10.1016/j.jaip.2020.10.028; Walter JE, 2016, J ALLER CL IMM-PRACT, V4, P1089, DOI 10.1016/j.jaip.2016.08.004; Wang J, 2005, J AUTOIMMUN, V25, P57, DOI 10.1016/j.jaut.2005.04.006; Wong GK, 2013, CLIN EXP IMMUNOL, V172, P63, DOI 10.1111/cei.12039; Zeissig S, 2015, GUT, V64, P1889, DOI 10.1136/gutjnl-2014-308541	39	12	12	4	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2022	149	2					736	746		10.1016/j.jaci.2021.04.039	http://dx.doi.org/10.1016/j.jaci.2021.04.039			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YV3IA					2022-12-18	WOS:000752623200031
J	Hou, HY; Zhang, YD; Tang, GX; Luo, Y; Liu, W; Cheng, C; Jiang, YH; Xiong, ZG; Wu, SJ; Sun, ZY; Xu, SB; Fan, XL; Wang, F				Hou, Hongyan; Zhang, Yandi; Tang, Guoxing; Luo, Ying; Liu, Wei; Cheng, Chang; Jiang, Yuhuan; Xiong, Zhigang; Wu, Shiji; Sun, Ziyong; Xu, Shabei; Fan, Xionglin; Wang, Feng			Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SARS-CoV-2; COVID-19; neutralizing antibodies; CD4(+) T-cell responses; immune memory	CD4(+) T-CELLS; ANTIBODIES; IMMUNITY	Background: Understanding the complexities of immune memory to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is key to gain insights into the durability of protective immunity against reinfection. Objective: We sought to evaluate the immune memory to SARSCoV-2 in convalescent patients with longer follow-up time. Methods: SARS-CoV-2-specific humoral and cellular responses were assessed in convalescent patients with coronavirus disease 2019 (COVID-19) at 1 year postinfection. Results: A total of 78 convalescent patients with COVID-19 (26 moderate, 43 severe, and 9 critical) were recruited after 1 year of recovery. The positive rates of both anti-receptor-binding domain and antinucleocapsid antibodies were 100%, whereas we did not observe a statistical difference in antibody levels among different severity groups. Accordingly, the prevalence of neutralizing antibodies (nAbs) reached 93.59% in convalescent patients. Although nAb titers displayed an increasing trend in convalescent patients with increased severity, the difference failed to achieve statistical significance. Notably, there was a significant correlation between nAb titers and anti-receptorbinding domain levels. Interestingly, SARS-CoV-2-specific T cells could be robustly maintained in convalescent patients, and their number was positively correlated with both nAb titers and anti-receptor-binding domain levels. Amplified SARS-CoV-2- specific CD4+ T cells mainly produced a single cytokine, accompanying with increased expression of exhaustion markers including PD-1, Tim-3, TIGIT, CTLA-4, and CD39, while the proportion of multifunctional cells was low. Conclusions: Robust SARS-CoV-2-specific humoral and cellular responses are maintained in convalescent patients with COVID-19 at 1 year postinfection. However, the dysfunction of SARS-CoV-2-specific CD4+ T cells supports the notion that vaccination is needed in convalescent patients for preventing reinfection.	[Hou, Hongyan; Tang, Guoxing; Luo, Ying; Liu, Wei; Xiong, Zhigang; Wu, Shiji; Sun, Ziyong; Wang, Feng] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Lab Med, Wuhan 430030, Peoples R China; [Zhang, Yandi; Fan, Xionglin] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Pathogen Biol,Sch Basic Med, Wuhan, Peoples R China; [Cheng, Chang; Xu, Shabei] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Neurol, Wuhan 430030, Peoples R China; [Jiang, Yuhuan] Nanchang Univ, Dept Clin Lab, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Nanchang University	Wu, SJ; Sun, ZY; Wang, F (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Lab Med, Wuhan 430030, Peoples R China.; Xu, SB (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Neurol, Wuhan 430030, Peoples R China.; Fan, XL (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Pathogen Biol, Wuhan, Peoples R China.	wilson547@163.com; zysun@tjh.tjmu.edu.cn; xushabei@126.com; xlfan@hust.edu.cn; fengwang@tjh.tjmu.edu.cn	Fan, Xionglin/E-2747-2015	Fan, Xionglin/0000-0001-9754-372X; Luo, Ying/0000-0002-1325-2296	National Mega Project on Major Infectious Disease Prevention [2017ZX10103005-007]; COVID-19 Emergency Project from Wuhan Science and Technology Bureau [2020020401010096]	National Mega Project on Major Infectious Disease Prevention; COVID-19 Emergency Project from Wuhan Science and Technology Bureau	This study was supported by the National Mega Project on Major Infectious Disease Prevention (grant no. 2017ZX10103005-007) and COVID-19 Emergency Project from Wuhan Science and Technology Bureau (grant no. 2020020401010096).	Amanat F, 2020, NAT MED, V26, P1033, DOI [10.1038/s41591-020-0913-5, 10.1101/2020.03.17.20037713]; [Anonymous], 2020, LANCET, V395, P311, DOI 10.1016/S0140-6736(20)30186-0; Bastard P, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abl4340; CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036; Chen XY, 2020, CELL MOL IMMUNOL, V17, P647, DOI 10.1038/s41423-020-0426-7; Chen XY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00301-9; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116; He ZY, 2021, LANCET, V397, P1075, DOI 10.1016/S0140-6736(21)00238-5; Hou HY, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1136; Huang AT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18450-4; Huber SR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00171; Kared H, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI145476; Kroemer M, 2021, J INFECTION, V82, P314, DOI 10.1016/j.jinf.2020.08.036; Liu CM, 2021, J MED VIROL, V93, P2227, DOI 10.1002/jmv.26646; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Luchsinger LL, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.02005-20; Mousset CM, 2019, CYTOM PART A, V95A, P647, DOI 10.1002/cyto.a.23724; Murin CD, 2019, NAT MICROBIOL, V4, P734, DOI 10.1038/s41564-019-0392-y; Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x; Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468; Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008; Schulien I, 2021, NAT MED, V27, P78, DOI 10.1038/s41591-020-01143-2; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; Swain SL, 2012, NAT REV IMMUNOL, V12, P136, DOI 10.1038/nri3152; Tan Y, 2020, FRONT MED-PRC, V14, P746, DOI 10.1007/s11684-020-0822-5; To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; Wang F, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137799; Xiao AT, 2020, J INFECTION, V81, P174, DOI 10.1016/j.jinf.2020.03.012; Zeng C, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.143213; Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	39	12	12	3	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2021	148	6					1481	+		10.1016/j.jaci.2021.09.008	http://dx.doi.org/10.1016/j.jaci.2021.09.008		DEC 2021	14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XM1ZO	34536418	Green Published			2022-12-18	WOS:000728634000015
J	Ali, GB; Bui, DS; Lodge, CJ; Waidyatillake, NT; Perret, JL; Sun, C; Walters, EH; Abramson, MJ; Lowe, AJ; Dharmage, SC				Ali, Gulshan Bano; Bui, Dinh Son; Lodge, Caroline Jane; Waidyatillake, Nilakshi T.; Perret, Jennifer L.; Sun, Cong; Walters, Eugene Haydn; Abramson, Michael John; Lowe, Adrian J.; Dharmage, Shyamali Chandrika			Infant body mass index trajectories and asthma and lung function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Infant body mass index; early rapid growth; body mass index trajectories; early growth pattern; group-based trajectory modeling; infant growth trajectories; growth developmental trajec-tories; asthma; lung function	OBESITY; CHILDREN; ALLERGY; HEALTH; RISK	Background: The impact of early rapid increase in body mass index (BMI) on asthma risk and subsequent lung function remains contentious, with limited prospective studies during a critical window for lung growth. Objective: Our aim was to investigate the associations between BMI trajectories in the first 2 years of life and adolescent asthma and lung function. Methods: Anthropometric data on 620 infants from the Melbourne Atopy Cohort Study were collected up to 18 times in the first 24 months of the study. BMI trajectories were developed by using group-based trajectory modeling. Associations between these trajectories and spirometry, fractional exhaled nitric oxide level, and current asthma status at 12 and/or 18 years of age were modeled by using multiple linear and logistic regression. Results: A total of 5 BMI trajectories were identified. Compared with those children with the "average"trajectory, the children belonging to the "early-low and catch-up"and "persistently high"BMI trajectories were at higher risk of asthma at the age of 18 years (odds ratios = 2.2 [95% CI = 1.0-4.8] and 2.4 [95% CI = 1.1-5.3], respectively). These trajectories were also associated with a lower ratio of FEV1 to forced vital capacity and a higher fractional exhaled nitric oxide levels at age 18 years. In addition, children belonging to the persistently low trajectory had lower FEV1 (13 = -183.9 mL [95% CI = -340.9 to -26.9]) and forced vital capacity (13 = -207.8 mL [95% CI = -393.6 to -22.0]) values at the age of 18 years. Conclusion: In this cohort, the early-low and catch-up and persistently high trajectories were associated with asthma and obstructive lung function pattern in adolescence. Having a persistently low BMI at an early age was associated with a restrictive pattern. Thus, maintenance of normal growth patterns may lead to improved adolescent respiratory health.	[Ali, Gulshan Bano; Bui, Dinh Son; Lodge, Caroline Jane; Waidyatillake, Nilakshi T.; Perret, Jennifer L.; Lowe, Adrian J.; Dharmage, Shyamali Chandrika] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Melbourne, Vic, Australia; [Perret, Jennifer L.] Inst Breathing & Sleep, Melbourne, Vic, Australia; [Sun, Cong] Murdoch Childrens Res Inst, Royal Childrens Hosp, Melbourne, Vic, Australia; [Walters, Eugene Haydn] Univ Tasmania, Sch Med, Hobart, Tas, Australia; [Abramson, Michael John] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Dharmage, Shyamali Chandrika] Murdoch Childrens Res Inst, Royal Childrens Hosp, Melbourne, Vic, Australia	University of Melbourne; Institute for Breathing & Sleep (IBAS); Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Tasmania; Monash University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Dharmage, SC (corresponding author), Sch Populat & Global Hlth, Ctr Epidemiol & Biostatist, Level 3,207 Bouverie St, Victoria 3010, Australia.	s.dharmage@unimelb.edu.au		Bui, Dinh/0000-0002-4388-784X; Lodge, Caroline/0000-0002-2342-3888	Nestec, a branch of Nestle Australia; Asthma Foundation of Victoria; National Health and Medical Council of Australia	Nestec, a branch of Nestle Australia; Asthma Foundation of Victoria; National Health and Medical Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	The initial 6 years of funding for the Melbourne Atopy Cohort Study (MACS) was granted by Nestec, a branch of Nestle Australia. The Asthma Foundation of Victoria provided funds for the 12-year follow-up. The National Health and Medical Council of Australia funded the 18-year follow-up. The current follow-up of the MACS study has been funded by the National Health and Medical Council of Australia. None of the funding bodies supporting the establishment and ongoing follow-ups of theMACS had any role in the study design, collection, analysis, interpretation of the data, or writing of this article. The study design, results, conclusion, and implications reported in this article are those of the authors involved in the study.	Ali Z, 2013, RESP MED, V107, P1287, DOI 10.1016/j.rmed.2013.03.019; Andruff H, 2009, TUTOR QUANT METHODS, V5, P11, DOI 10.20982/tqmp.05.1.p011; Asher I, 2014, INT J TUBERC LUNG D, V18, P1269, DOI 10.5588/ijtld.14.0170; Chen YC, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00741-2016; DeVries A, 2015, CURR OPIN ALLERGY CL, V15, P435, DOI 10.1097/ACI.0000000000000201; Do JG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50488-3; Elliot JG, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00857-2019; Inokuchi M, 2011, ANN HUM BIOL, V38, P747, DOI 10.3109/03014460.2011.620625; Jeon YK, 2015, OSTEOPOROSIS INT, V26, P2423, DOI 10.1007/s00198-015-3152-8; Jones BL, 2013, SOCIOL METHOD RES, V42, P608, DOI 10.1177/0049124113503141; Litonjua AA, 2008, J ALLERGY CLIN IMMUN, V121, P1075, DOI 10.1016/j.jaci.2008.03.005; Lowe AJ, 2017, INT J EPIDEMIOL, V46, P25, DOI 10.1093/ije/dyw011; Miele CH, 2016, COPD, V13, P186, DOI 10.3109/15412555.2015.1067765; Myung J, 2018, J ASTHMA, V55, P741, DOI 10.1080/02770903.2017.1362701; Nagin DS., 2012, STATA PLUGIN ESTIMAT; Peralta GP, 2019, AM J RESP CRIT CARE, V200, P75, DOI 10.1164/rccm.201806-1168OC; Peters U, 2018, J ALLERGY CLIN IMMUN, V141, P1169, DOI 10.1016/j.jaci.2018.02.004; Poulos Leanne M, 2005, Paediatr Respir Rev, V6, P20, DOI 10.1016/j.prrv.2004.11.004; Rastogi D, 2012, CHEST, V141, P895, DOI 10.1378/chest.11-0930; Rodriguez A, 2015, ENVIRON HEALTH-GLOB, V14, DOI 10.1186/1476-069X-14-15; Rzehak P, 2013, J ALLERGY CLIN IMMUN, V131, P1528, DOI 10.1016/j.jaci.2013.01.001; Smego A, 2017, J PEDIATR-US, V183, P87, DOI 10.1016/j.jpeds.2016.11.020; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; Tantisira KG, 2001, THORAX, V56, P64; To T, 2004, J PEDIATR-US, V144, P162, DOI 10.1016/j.jpeds.2003.09.047; Tsai HJ, 2018, ANN AM THORAC SOC, V15, P1197, DOI 10.1513/AnnalsATS.201712-921OC; van der Gugten AC, 2012, EUR RESPIR J, V39, P403, DOI 10.1183/09031936.00188310; Vidmar SI, 2013, STATA J, V13, P366, DOI 10.1177/1536867X1301300211; Wadden D, 2018, INT J PEDIAT, V2018, DOI 10.1155/2018/9057435; Williamson EJ, 2014, RESPIROLOGY, V19, P303, DOI 10.1111/resp.12238; Ziyab AH, 2014, J EPIDEMIOL COMMUN H, V68, P934, DOI 10.1136/jech-2014-203808	31	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2021	148	3					763	770		10.1016/j.jaci.2021.02.020	http://dx.doi.org/10.1016/j.jaci.2021.02.020		SEP 2021	8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UP2VR	33662371				2022-12-18	WOS:000695242900025
J	Nihira, H; Izawa, K; Ito, M; Umebayashi, H; Okano, T; Kajikawa, S; Nanishi, E; Keino, D; Murakami, K; Isa-Nishitani, M; Shiba, T; Honda, Y; Hijikata, A; Yasu, T; Kubota, T; Hasegawa, Y; Kawashima, Y; Nakano, N; Takada, H; Ohga, S; Heike, T; Takita, J; Ohara, O; Takei, S; Takahashi, M; Kanegane, H; Morio, T; Iwaki-Egawa, S; Sasahara, Y; Nishikomori, R; Yasumi, T				Nihira, Hiroshi; Izawa, Kazushi; Ito, Moeko; Umebayashi, Hiroaki; Okano, Tsubasa; Kajikawa, Shunsuke; Nanishi, Etsuro; Keino, Dai; Murakami, Kosaku; Isa-Nishitani, Masahiko; Shiba, Takeshi; Honda, Yoshitaka; Hijikata, Atsushi; Yasu, Tadateru; Kubota, Tomohiro; Hasegawa, Yoshinori; Kawashima, Yusuke; Nakano, Naoko; Takada, Hidetoshi; Ohga, Shouichi; Heike, Toshio; Takita, Junko; Ohara, Osamu; Takei, Syuji; Takahashi, Makio; Kanegane, Hirokazu; Morio, Tomohiro; Iwaki-Egawa, Sachiko; Sasahara, Yoji; Nishikomori, Ryuta; Yasumi, Takahiro			Detailed analysis of Japanese patients with adenosine deaminase 2 deficiency reveals characteristic elevation of type II interferon signature and STAT1 hyperactivation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ADA2 deficiency; DADA2; adenosine deaminase 2; cat eye syndrome critical region protein 1; anti-TNF-alpha; vasculitis; omics; proteome; transcriptome; STAT1; IFN-gamma	POLYARTERITIS-NODOSA; DISEASE-ACTIVITY; GENES; TNF; ASSOCIATION; ACTIVATION; MUTATIONS; PHENOTYPE	Background: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive inflammatory disease caused by loss-of-function mutations in both alleles of the ADA2 gene. Most patients with DADA2 exhibit systemic vasculopathy consistent with polyarteritis nodosa, but large phenotypic variability has been reported, and the pathogenesis of DADA2 remains unclear. Objectives: This study sought to assess the clinical and genetic characteristics of Japanese patients with DADA2 and to gain insight into the pathogenesis of DADA2 by multi-omics analysis. Methods: Clinical and genetic data were collected from 8 Japanese patients with DADA2 diagnosed between 2016 and 2019. ADA2 variants in this cohort were functionally analyzed by in vitro overexpression analysis. PBMCs from 4 patients with DADA2 were subjected to transcriptome and proteome analyses. Patient samples were collected before and after introduction of anti-TNF-alpha therapies. Transcriptome data were compared with those of normal controls and patients with other autoinflammatory diseases. Results: Five novel ADA2 variants were identified in these 8 patients and were confirmed pathogenic by in vitro analysis. Anti-TNF-alpha therapy controlled inflammation in all 8 patients. Transcriptome and proteome analyses showed that upregulation of type II interferon signaling was characteristic of DADA2. Network analysis identified STAT1 as a key regulator and a hub molecule in DADA2 pathogenesis, a finding supported by the hyperactivation of STAT1 in patients' monocytes and B cells after IFN-gamma stimulation. Conclusions: Type II interferon signaling and STAT1 are associated with the pathogenesis of DADA2.	[Nihira, Hiroshi; Izawa, Kazushi; Isa-Nishitani, Masahiko; Honda, Yoshitaka; Takita, Junko; Yasumi, Takahiro] Kyoto Univ, Dept Pediat, Kyoto, Japan; [Kajikawa, Shunsuke] Kyoto Univ, Dept Neurol, Kyoto, Japan; [Murakami, Kosaku] Kyoto Univ, Dept Rheumatol & Clin Immunol, Kyoto, Japan; [Ito, Moeko; Iwaki-Egawa, Sachiko] Hokkaido Univ Sci, Dept Pharm, Sapporo, Hokkaido, Japan; [Umebayashi, Hiroaki] Miyagi Childrens Hosp, Dept Rheumatol, Sendai, Miyagi, Japan; [Okano, Tsubasa; Morio, Tomohiro] Tokyo Med & Dent Univ, Dept Pediat & Dev Biol, Tokyo, Japan; [Kanegane, Hirokazu] Tokyo Med & Dent Univ, Dept Child Hlth & Dev, Tokyo, Japan; [Nanishi, Etsuro; Ohga, Shouichi] Kyushu Univ, Grad Sch Med Sci, Dept Pediat, Fukuoka, Japan; [Keino, Dai] Kanagawa Childrens Med Ctr, Div Hematol Oncol, Yokohama, Kanagawa, Japan; [Shiba, Takeshi; Kubota, Tomohiro] Tenri Hosp, Dept Pediat, Tenri, Nara, Japan; [Hijikata, Atsushi] Nagahama Inst Biosci & Technol, Dept Biosci, Nagahama, Japan; [Yasu, Tadateru] Nagasaki Med Ctr, Dept Pediat, Omura, Japan; [Takei, Syuji] Kagoshima Univ, Dept Pediat, Kagoshima, Japan; [Hasegawa, Yoshinori; Kawashima, Yusuke; Ohara, Osamu] Kazusa DNA Res Inst, Dept Appl Genom, Kisarazu, Japan; [Nakano, Naoko] Ehime Univ, Dept Pediat, Toon, Japan; [Takada, Hidetoshi] Univ Tsukuba, Fac Med, Dept Child Hlth, Tsukuba, Ibaraki, Japan; [Heike, Toshio] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Pediat, Amagasaki, Hyogo, Japan; [Takahashi, Makio] Osaka Red Cross Hosp, Dept Neurol, Osaka, Japan; [Sasahara, Yoji] Tohoku Univ, Dept Pediat, Sendai, Miyagi, Japan; [Nishikomori, Ryuta] Kurume Univ, Dept Pediat & Child Hlth, Sch Med, Kurume, Fukuoka, Japan	Kyoto University; Kyoto University; Kyoto University; Hokkaido University of Science; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Kyushu University; Tenri Hospital; Kagoshima University; Kazusa DNA Research Institute; Ehime University; University of Tsukuba; Osaka Red Cross Hospital; Tohoku University; Kurume University	Izawa, K (corresponding author), Kyoto Univ, Fac Med, Dept Pediat, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	kizawa@kuhp.kyoto-u.ac.jp	Ohara, Osamu/G-5448-2015; Nishikomori, Ryuta/AAM-5771-2020	Ohara, Osamu/0000-0002-3328-9571; Nishikomori, Ryuta/0000-0002-9407-6158; Hasegawa, Yoshinori/0000-0003-2904-6611; Izawa, Kazushi/0000-0003-1080-0936	Health Labor Sciences Research Grants for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan [H29-Nanchi-Ippan-020, JPMH20317089]; Japan Agency for Medical Research and Development [JP19ek0109200, JP20ek0109477, JP20am0101111]; Morinaga Hoshikai	Health Labor Sciences Research Grants for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan; Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); Morinaga Hoshikai	This research was partially supported by the following grants: Health Labor Sciences Research Grants for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan (H29-Nanchi-Ippan-020 and JPMH20317089); the Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development (JP19ek0109200, JP20ek0109477); the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research) from Japan Agency for Medical Research and Development (JP20am0101111); and a research grant from the Morinaga Hoshikai.	Belot A, 2014, PEDIATR RHEUMATOL, V12, DOI 10.1186/1546-0096-12-44; Carmona-Rivera C, 2019, BLOOD, V134, P395, DOI 10.1182/blood.2018892752; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Jesus AA, 2020, J CLIN INVEST, V130, P1669, DOI 10.1172/JCI129301; Elkan PN, 2014, NEW ENGL J MED, V370, P921, DOI 10.1056/NEJMoa1307362; Feng XB, 2006, ARTHRITIS RHEUM, V54, P2951, DOI 10.1002/art.22044; Haider AS, 2008, J INVEST DERMATOL, V128, P655, DOI 10.1038/sj.jid.5701064; Hashem H, 2017, BLOOD, V130, P2682, DOI 10.1182/blood-2017-07-798660; Honda-Ozaki F, 2018, STEM CELL REP, V10, P1835, DOI 10.1016/j.stemcr.2018.04.004; Hu XY, 2002, NAT IMMUNOL, V3, P859, DOI 10.1038/ni828; Insalaco A, 2019, J RHEUMATOL, V46, P523, DOI 10.3899/jrheum.180045; Ivashkiv LB, 2018, NAT REV IMMUNOL, V18, P545, DOI 10.1038/s41577-018-0029-z; Iwaki-Egawa S, 2004, COMP BIOCHEM PHYS B, V137, P247, DOI 10.1016/j.cbpc.2003.11.010; Kaljas Y, 2017, CELL MOL LIFE SCI, V74, P555, DOI 10.1007/s00018-016-2357-0; Kawashima Y, 2019, J PROTEOME RES, V18, P301, DOI 10.1021/acs.jproteome.8b00609; Keer N, 2016, RHEUMATOLOGY, V55, P1145, DOI 10.1093/rheumatology/kew050; Keino D, 2021, SCAND J RHEUMATOL, V50, P243, DOI 10.1080/03009742.2020.1772868; Kim H, 2018, J INTERF CYTOK RES, V38, P171, DOI 10.1089/jir.2017.0127; Kirou KA, 2004, ARTHRITIS RHEUM, V50, P3958, DOI 10.1002/art.20798; Landolt-Marticorena C, 2009, ANN RHEUM DIS, V68, P1440, DOI 10.1136/ard.2008.093146; Lee PY, 2020, J ALLERGY CLIN IMMUN, V145, P1664, DOI [10.1016/j.jaci.2019.12908, 10.1016/j.jaci.2019.12.908]; Lieberman OJ, 2020, ELIFE, V9, DOI 10.7554/eLife.50843; Liu MM, 2018, CLIN RHEUMATOL, V37, P2675, DOI 10.1007/s10067-018-4138-7; Mehta NN, 2017, SCI REP-UK, V7, P1; Meyts I, 2018, J CLIN IMMUNOL, V38, P569, DOI 10.1007/s10875-018-0525-8; Nadkarni S, 2007, J EXP MED, V204, P33, DOI 10.1084/jem.20061531; Nihira H, 2018, SCAND J RHEUMATOL, V47, P170, DOI 10.1080/03009742.2017.1324912; Ombrello AK, 2019, NEW ENGL J MED, V380, P1582, DOI 10.1056/NEJMc1801927; Prencipe G, 2018, J ALLERGY CLIN IMMUN, V141, P1439, DOI 10.1016/j.jaci.2017.07.021; Qiao Y, 2013, IMMUNITY, V39, P454, DOI 10.1016/j.immuni.2013.08.009; Rama M, 2018, EUR J HUM GENET, V26, P960, DOI 10.1038/s41431-018-0130-6; Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963; Rice GI, 2017, J CLIN IMMUNOL, V37, P123, DOI 10.1007/s10875-016-0359-1; Rice GI, 2013, LANCET NEUROL, V12, P1159, DOI 10.1016/S1474-4422(13)70258-8; Rodero MP, 2016, J EXP MED, V213, P2527, DOI 10.1084/jem.20161596; Sanchez GAM, 2018, J CLIN INVEST, V128, P3041, DOI 10.1172/JCI98814; Skrabl-Baumgartner A, 2017, PEDIATR RHEUMATOL, V15, DOI 10.1186/s12969-017-0193-x; Thibaudeau TA, 2019, PHARMACOL REV, V71, P170, DOI 10.1124/pr.117.015370; Van Montfrans JM, 2016, RHEUMATOLOGY, V55, P902, DOI 10.1093/rheumatology/kev439; Zhou Q, 2014, NEW ENGL J MED, V370, P911, DOI 10.1056/NEJMoa1307361	40	12	12	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2021	148	2					550	562		10.1016/j.jaci.2021.01.018	http://dx.doi.org/10.1016/j.jaci.2021.01.018		AUG 2021	13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UD3IW	33529688	Green Published			2022-12-18	WOS:000687104900007
J	Wu, D; Yan, B; Wang, Y; Wang, CS; Zhang, L				Wu, Di; Yan, Bing; Wang, Yang; Wang, Chengshuo; Zhang, Luo			Prognostic and pharmacologic value of cystatin SN for chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis with nasal polyps; CRSwNP; cystatin SN; cytokines; endotype; management	MEDICAL-MANAGEMENT; CHRONIC SINUSITIS; EXPRESSION; PERIOSTIN; CORTICOSTEROIDS; ENDOTYPES; INFLAMMATION; BIOMARKERS; INHIBITORS; ROLES	Background: Integrated care pathways improve the management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The application of integrated care pathways requires development of endotype-based biomarkers to stratifypatients. The value of cytokines and markers induced by cytokines for the management of CRSwNP is largely unknown. Objectives: Our aim was to determine the prognostic and pharmacologic value of type 2, non-type 2 cytokines, and markers associated with type 2 inflammation, including CCL26, periostin, and cystatin SN, in nasal secretions for CRSwNP. Methods: This retrospective study assigned 151 patients with CRSwNP to the discovery and validation phases. Concentrations of cytokines, CCL26, periostin, and cystatin SN in nasal secretions were determined by using Luminex and ELISA. Predictive significance was assessed with receiver operating characteristic curves. Survival analysis was performed by using Kaplan-Meier curves and Cox regression models. Results: Cystatin SN was an independent predictor of the uncontrolled status of CRSwNP over a 2-year follow-up after adjustment for other risk factors (hazard ratio = 1.168 and 1.132 in the discovery and validation phases, respectively; both P < .001). Patients with high cystatin SN concentrations presented with a faster onset and higher rate of uncontrolled status than did those with low levels (P < .001). Enhanced medical treatment for patients with high cystatin SN levels postponed the uncontrolled status in the discovery (P = .016) and validation (P = .002) phases but did not completely abolish it by the end of the follow-up. Conclusion: Cystatin SN levels in nasal secretions hold strong prognostic value and can facilitate medical instructions for managing CRSwNP.	[Wu, Di; Yan, Bing; Wang, Yang; Wang, Chengshuo; Zhang, Luo] Capital Med Univ, Dept Otolaryngol Head & Neck Surg, Beijing TongRen Hosp, Beijing, Peoples R China; [Zhang, Luo] Capital Med Univ, Dept Allergy, Beijing TongRen Hosp, Beijing, Peoples R China; [Yan, Bing; Wang, Yang; Wang, Chengshuo; Zhang, Luo] Chinese Acad Med Sci, Beijing Key Lab Nasal Dis, Beijing Inst Otolaryngol, Beijing, Peoples R China; [Yan, Bing; Wang, Yang; Wang, Chengshuo; Zhang, Luo] Chinese Acad Med Sci, Res Unit Diag & Treatment Chron Nasal Dis, Beijing, Peoples R China	Capital Medical University; Capital Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College	Wang, CS; Zhang, L (corresponding author), Capital Med Univ, Beijing TongRen Hosp, 1 DongJiaoMinXiang, Beijing, Peoples R China.	wangcs830@126.com; dr.luozhang@139.com		Zhang, Luo/0000-0002-0910-9884	National Natural Science Foundation of China [81900917, 81630023, 81870698, 82025010]; Beijing Natural Science Foundation [7194247]; Beijing Municipal Administration of Hospitals incubating Program [PX2019007]; CAMS Innovation Fund for Medical Sciences [2019I2M5022]; Program for Changjiang Scholars and Innovative Research Team [IRT13082]; National Key R&D Program of China [2018YFC0116800, 2016YFC20160905200]; Research of Capital Health Security and Cultivation [Z18110700160000]; Beijing Municipal Administration of Hospitals' Mission Plan [SML20150203]; Beijing Municipal Administration of Hospitals' Innovation Program of Clinical Techniques [XMLX201816]; Priming Scientific Research Foundation for the Senior Researcher in Beijing TongRen Hospital, Capital MedicalUniversity [2017YJJGGL005]; Beijing Municipal Administration of Hospitals' Youth Programme [QML20150202]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Beijing Municipal Administration of Hospitals incubating Program; CAMS Innovation Fund for Medical Sciences; Program for Changjiang Scholars and Innovative Research Team(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); National Key R&D Program of China; Research of Capital Health Security and Cultivation; Beijing Municipal Administration of Hospitals' Mission Plan; Beijing Municipal Administration of Hospitals' Innovation Program of Clinical Techniques; Priming Scientific Research Foundation for the Senior Researcher in Beijing TongRen Hospital, Capital MedicalUniversity; Beijing Municipal Administration of Hospitals' Youth Programme	Supported by the National Natural Science Foundation of China (grants 81900917, 81630023, 81870698, and 82025010) ; the Beijing Natural Science Foundation (grant 7194247) ; the Beijing Municipal Administration of Hospitals incubating Program (grant PX2019007) ; the CAMS Innovation Fund for Medical Sciences (grant 2019I2M5022) ; the Program for Changjiang Scholars and Innovative Research Team (grant IRT13082) ; the National Key R&D Program of China (grants 2018YFC0116800 and 2016YFC20160905200) ; the Research of Capital Health Security and Cultivation (grant Z18110700160000) ; the Beijing Municipal Administration of Hospitals' Mission Plan (grant SML20150203) ; the Beijing Municipal Administration of Hospitals' Innovation Program of Clinical Techniques (grant XMLX201816) ; the Priming Scientific Research Foundation for the Senior Researcher in Beijing TongRen Hospital, Capital MedicalUniversity (grant 2017YJJGGL005) ; and the Beijing Municipal Administration of Hospitals' Youth Programme (grant QML20150202) .	Agache I, 2019, J CLIN INVEST, V129, P1493, DOI 10.1172/JCI124611; Akdis M, 2016, J ALLERGY CLIN IMMUN, V138, P984, DOI 10.1016/j.jaci.2016.06.033; Alsharif S, 2019, LARYNGOSCOPE, V129, P1286, DOI 10.1002/lary.27815; Avdeeva K, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0776-8; Bachert C, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-00218-1; Bachert C, 2020, J ALLERGY CLIN IMMUN, V145, P725, DOI 10.1016/j.jaci.2020.01.020; Bachert C, 2018, J ALLERGY CLIN IMMUN, V141, P1543, DOI 10.1016/j.jaci.2018.03.004; Calus L, 2019, CLIN TRANSL ALLERGY, V9, DOI 10.1186/s13601-019-0269-4; Cao PP, 2019, ANN ALLERG ASTHMA IM, V122, P33, DOI 10.1016/j.anai.2018.10.014; Cardell LO, 2020, J ALLERGY CLIN IMMUN, V145, P752, DOI 10.1016/j.jaci.2020.01.019; Chen FH, 2017, ANN ALLERG ASTHMA IM, V119, P310, DOI 10.1016/j.anai.2017.07.012; Cho SH, 2020, J ALLER CL IMM-PRACT, V8, P1559, DOI 10.1016/j.jaip.2020.02.020; Chung YW, 2020, AM J RESP CELL MOL, V62, P23, DOI 10.1165/rcmb.2018-0248OC; Davide R, 2020, AM J OTOLARYNG, V41, DOI 10.1016/j.amjoto.2019.102286; De Greve G, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0157-8; De Schryver E, 2017, RHINOLOGY, V55, P152, DOI 10.4193/Rhino16.314; Ebenezer JA, 2017, RHINOLOGY, V55, P234, DOI [10.4193/Rhino16215, 10.4193/Rhino16.215]; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Giovannini-Chami L, 2012, EUR RESPIR J, V39, P1197, DOI 10.1183/09031936.00070511; Gurrola J, 2017, J ALLERGY CLIN IMMUN, V140, P1499, DOI 10.1016/j.jaci.2017.10.006; Hissaria P, 2006, J ALLERGY CLIN IMMUN, V118, P128, DOI 10.1016/j.jaci.2006.03.012; Ho J, 2020, CURR OPIN ALLERGY CL, V20, P23, DOI 10.1097/ACI.0000000000000602; Hoggard M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02065; Hong HY, 2018, J ALLERGY CLIN IMMUN, V141, P1890, DOI 10.1016/j.jaci.2017.10.050; Imoto Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067057; Javanbakht M, 2020, PHARMACOECON-OPEN, V4, P679, DOI 10.1007/s41669-020-00198-8; Kanemitsu Y, 2020, INT ARCH ALLERGY IMM, V181, P862, DOI 10.1159/000509253; Kanemitsu Y, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2019.100094; Kato A, 2019, CHEST, V156, P141, DOI 10.1016/j.chest.2019.04.101; Kato Y, 2018, AM J RESP CELL MOL, V59, P448, DOI 10.1165/rcmb.2017-0325OC; Kern RC, 2018, INT FORUM ALLERGY RH, V8, P471, DOI 10.1002/alr.22084; Kim DK, 2020, ALLERGY ASTHMA IMMUN, V12, P42, DOI 10.4168/aair.2020.12.1.42; Kouzaki H, 2017, AM J RESP CRIT CARE, V195, P737, DOI 10.1164/rccm.201603-0529OC; Kuznik A, 2017, DERMATOLOGY THER, V7, P493, DOI 10.1007/s13555-017-0201-6; Li ZP, 2019, J ALLERGY CLIN IMMUN, V144, P1228, DOI 10.1016/j.jaci.2019.06.037; Liao B, 2018, ALLERGY, V73, P1459, DOI 10.1111/all.13411; Lou HF, 2019, EXPERT REV CLIN IMMU, V15, P1171, DOI 10.1080/1744666X.2020.1679626; Lou HF, 2016, RHINOLOGY, V54, P150, DOI [10.4193/Rhin15.271, 10.4193/Rhino15.271]; Matsuwaki Y, 2008, INT ARCH ALLERGY IMM, V146, P77, DOI 10.1159/000126066; McHugh T, 2018, INT FORUM ALLERGY RH, V8, P1421, DOI 10.1002/alr.22194; Min JY, 2017, J ALLERGY CLIN IMMUN, V139, P130, DOI 10.1016/j.jaci.2016.07.020; Miyake MM, 2019, INT FORUM ALLERGY RH, V9, P1069, DOI 10.1002/alr.22380; Mueller SK, 2019, INT FORUM ALLERGY RH, V9, P1212, DOI 10.1002/alr.22407; Mueller SK, 2019, INT FORUM ALLERGY RH, V9, P177, DOI 10.1002/alr.22226; Nakayama T, 2019, AURIS NASUS LARYNX, V46, P374, DOI 10.1016/j.anl.2018.09.004; Ninomiya T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29612-2; Plager DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011450; Qin Z, 2016, B-ENT, V12, P305; Ren L, 2019, WORLD ALLERGY ORGAN, V12, DOI 10.1016/j.waojou.2019.100050; Riechelmann H, 2003, EUR RESPIR J, V21, P600, DOI 10.1183/09031936.03.00072003; Roan F, 2019, J CLIN INVEST, V129, P1441, DOI 10.1172/JCI124606; Rudmik L, 2015, JAMA-J AM MED ASSOC, V314, P926, DOI 10.1001/jama.2015.7544; Schwartz JS, 2017, EXPERT OPIN INV DRUG, V26, P1123, DOI 10.1080/13543784.2017.1371699; She WY, 2018, AM J RHINOL ALLERGY, V32, P181, DOI 10.1177/1945892418768581; Sozener ZC, 2020, J ALLERGY CLIN IMMUN, V145, P1517, DOI 10.1016/j.jaci.2020.04.024; Stevens WW, 2019, J ALLER CL IMM-PRACT, V7, P2812, DOI 10.1016/j.jaip.2019.05.009; Tajudeen BA, 2019, LARYNGOSCOPE, V129, P794, DOI 10.1002/lary.27693; Takabayashi T, 2020, J ALLERGY CLIN IMMUN, V145, P740, DOI 10.1016/j.jaci.2020.01.027; Tokunaga T, 2015, ALLERGY, V70, P995, DOI 10.1111/all.12644; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Turner JH, 2018, F1000 FACULTY REV, V7; Turner JH, 2018, J ALLERGY CLIN IMMUN, V141, P1895, DOI 10.1016/j.jaci.2018.02.002; Vennik J, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022643; Wang CS, 2020, EXPERT REV CLIN IMMU, V16, P293, DOI 10.1080/1744666X.2020.1723417; Wang CS, 2019, CURR OPIN ALLERGY CL, V19, P365, DOI 10.1097/ACI.0000000000000540; Wang CS, 2015, J ALLERGY CLIN IMMUN, V135, P922, DOI 10.1016/j.jaci.2014.10.018; Wang M, 2019, J ALLERGY CLIN IMMUN, V144, P1254, DOI 10.1016/j.jaci.2019.06.023; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; Watelet JB, 2004, EUR ARCH OTO-RHINO-L, V261, P242, DOI 10.1007/s00405-003-0691-y; Wei B, 2018, RHINOLOGY, V56, P216, DOI 10.4193/Rhin17.240; Workman AD, 2018, IMMUNOL ALLERGY CLIN, V38, P679, DOI 10.1016/j.iac.2018.06.006; Wu DP, 2021, IEEE J SEL AREA COMM, V39, P479, DOI 10.1109/JSAC.2020.3020677; Xu M, 2018, ACTA OTO-LARYNGOL, V138, P387, DOI 10.1080/00016489.2017.1388540; Xu XN, 2020, ALLERGY, V75, P769, DOI 10.1111/all.14044; Xu ZF, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2020.100131; Yamada T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00074; Yan B, 2019, J ALLERGY CLIN IMMUN, V144, P455, DOI 10.1016/j.jaci.2019.03.026; Yao Y, 2017, EUR ARCH OTO-RHINO-L, V274, P3559, DOI 10.1007/s00405-017-4547-2; Yip J, 2019, CURR OPIN OTOLARYNGO, V27, P14, DOI 10.1097/MOO.0000000000000503; Zhang L, 2020, RHINOLOGY, V58, P126, DOI 10.4193/Rhin19.184; Zhang Y, 2017, J ALLERGY CLIN IMMUN, V140, P1230, DOI 10.1016/j.jaci.2017.09.009; Zhang YY, 2019, ALLERGY ASTHMA IMMUN, V11, P482, DOI 10.4168/aair.2019.11.4.482; Zhang YY, 2019, AM J RHINOL ALLERGY, V33, P567, DOI 10.1177/1945892419851312	83	12	15	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2021	148	2					450	460		10.1016/j.jaci.2021.01.036	http://dx.doi.org/10.1016/j.jaci.2021.01.036		AUG 2021	11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TZ7BX	33675819				2022-12-18	WOS:000684625700022
J	Laberko, A; Burlakov, V; Maier, S; Abinun, M; Skinner, R; Kozlova, A; Suri, D; Lehmberg, K; Muller, I; Balashov, D; Novichkova, G; Holzinger, D; Gennery, AR; Shcherbina, A				Laberko, Alexandra; Burlakov, Vasiliy; Maier, Sarah; Abinun, Mario; Skinner, Roderick; Kozlova, Anna; Suri, Deepti; Lehmberg, Kai; Mueller, Ingo; Balashov, Dmitry; Novichkova, Galina; Holzinger, Dirk; Gennery, Andrew R.; Shcherbina, Anna			HSCT is effective in patients with PSTPIP1-associated myeloid-related proteinemia inflammatory (PAMI) syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hematopoietic stem cell transplantation; PSTPIP1; autoinflammatory disorder; hypercalprotectinemia and hyperzincemia; macrophage activation syndrome	TRANSPLANTATION; HYPERCALPROTECTINAEMIA; HYPERZINCAEMIA; MUTATIONS; DISORDER	Background: Proline-serine-threonine phosphatase-interacting protein 1 associated myeloid-related proteinemia inflammatory (PAMI) syndrome is a novel genetic disorder, causing hypercalprotectinemia and hyperzincemia with inflammatory complications accompanied by cytopenia. Immunosuppressive and/or anticytokine therapy is of limited effect. Objectives: Because of cytokine production in nonhematopoietic tissues, the potential therapeutic effect of allogeneic hematopoietic stem cell transplantation (HSCT) in autoinflammatory disorders, including PAMI syndrome, has remained uncertain. Methods: Five patients with PAMI syndrome underwent allogeneic HSCT with myeloablative (4) or reduced-intensity (1) conditioning regimens. Lack of PAMI disease control served as indication for the HSCT in 4 patients and myelodysplastic syndrome development in 1. Results: All 5 patients engrafted; however, 1 patient at day +13 developed hemophagocytic syndrome, followed by graft rejection at day +17. After 5.5 months, a second HSCT was performed from an alternative donor. A further patient at day +116 developed an intense inflammatory syndrome with significant serositis and severe mitral and aortic valve regurgitation, controlled with adalimumab, tacrolimus, and prednisone. No other noninfectious inflammatory episodes, or acute or chronic graft-versus-host disease, occurred in any patient. At the last follow-up (median, 2.2 years), all 5 patients have predominantly or complete donor chimerism and adequate immune recovery and are free of any PAMI symptoms. Conclusions: Allogeneic HSCT seems to be an effective option to cure cytopenia and severe autoinflammation in PAMI syndrome and may be a curative option for other proline-serine-threonine phosphatase-interacting protein 1 associated inflammatory disorders with poor therapeutic control.	[Laberko, Alexandra; Burlakov, Vasiliy; Kozlova, Anna; Shcherbina, Anna] Dmitry Rogachev Natl Med Res Ctr Pediat Hematol, Dept Immunol Oncol & Immunol, Moscow, Russia; [Laberko, Alexandra; Abinun, Mario; Skinner, Roderick; Gennery, Andrew R.] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Maier, Sarah; Lehmberg, Kai; Mueller, Ingo] Univ Med Ctr Eppendorf, Dept Pediat Hematol & Oncol, Div Pediat Stem Cell Transplantat & Immunol, Hamburg, Germany; [Abinun, Mario; Skinner, Roderick; Suri, Deepti; Gennery, Andrew R.] Newcastle Univ, Great North Childrens Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Balashov, Dmitry] Natl Med Ctr Pediat Hematol Oncol & Immunol, Dept Hematopoiet Stem Cell Transplantat, Moscow, Russia; [Novichkova, Galina] Natl Med Ctr Pediat Hematol Oncol & Immunol, Dept Hematol, Moscow, Russia; [Holzinger, Dirk] Univ Duisburg Essen, Dept Pediat Hematol Oncol, Essen, Germany	Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology & Immunology; Newcastle University - UK; University of Hamburg; University Medical Center Hamburg-Eppendorf; Newcastle University - UK; University of Duisburg Essen	Laberko, A (corresponding author), Dmitry Rogachev Natl Ctr Pediat Hematol Oncol & I, Dept Immunol, 1 Samory Mashela St, Moscow 117997, Russia.	alexandra.laberko@gmail.com	Müller, Ingo/AAW-9025-2021	Müller, Ingo/0000-0002-7477-6632				Arkwright PD, 2007, NEW ENGL J MED, V357, P1350, DOI 10.1056/NEJMc072018; Bagal B, 2016, INDIAN J HEMATOL BLO, V32, pS189, DOI 10.1007/s12288-014-0477-y; Belelli Elena, 2017, Clin Exp Rheumatol, V35 Suppl 108, P113; Chaudhury S, 2012, AM J TRANSPLANT, V12, P1627, DOI 10.1111/j.1600-6143.2011.03989.x; Cugno M, 2017, AM J CLIN DERMATOL, V18, P555, DOI 10.1007/s40257-017-0265-1; Dai P, 2019, J CLIN IMMUNOL, V39, P519, DOI 10.1007/s10875-019-00646-z; Giardino S, 2015, PEDIATRICS, V135, pE211, DOI 10.1542/peds.2014-2553; Gustafsson D, 2012, SCAND J CLIN LAB INV, V72, P34, DOI 10.3109/00365513.2011.623177; Hashem H, 2017, BLOOD, V130, P2682, DOI 10.1182/blood-2017-07-798660; Hashmi SK, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27439; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Holzinger D, 2019, AUTOINFLAMMATORY SYN, P39, DOI [10.1007/978-3-319-96929-9_4, DOI 10.1007/978-3-319-96929-9_4]; Holzinger D, 2015, J ALLERGY CLIN IMMUN, V136, P1337, DOI 10.1016/j.jaci.2015.04.016; Klotgen HW, 2018, BRIT J DERMATOL, V178, P982, DOI 10.1111/bjd.16136; Laberko A, 2019, BLOOD, V134, P1755, DOI 10.1182/blood.2019001757; Link DC, 2019, CURR OPIN HEMATOL, V26, P34, DOI 10.1097/MOH.0000000000000479; Nesterovitch AB, 2011, CLIN EXP DERMATOL, V36, P889, DOI 10.1111/j.1365-2230.2011.04137.x; Neven B, 2007, NEW ENGL J MED, V356, P2700, DOI 10.1056/NEJMoa070715; Saito Y, 2002, J PEDIATR-US, V140, P267, DOI 10.1067/mpd.2002.121699; Sampson B, 2002, LANCET, V360, P1742, DOI 10.1016/S0140-6736(02)11683-7; Schaffler H, 2019, HAUTARZT, V70, P116, DOI 10.1007/s00105-018-4312-5; Szymanski AM, 2020, PEDIATR TRANSPLANT, V24, DOI 10.1111/petr.13604; Takagi S, 2009, BRIT J HAEMATOL, V147, P543, DOI 10.1111/j.1365-2141.2009.07863.x; Tsuchida Y, 2017, MOD RHEUMATOL, V27, P556, DOI 10.1080/14397595.2016.1221875; Vatsayan A, 2018, PEDIATR TRANSPLANT, V22, DOI 10.1111/petr.13174; Yokota S, 2016, ANN RHEUM DIS, V75, P1654, DOI 10.1136/annrheumdis-2015-207818; Zeeli T, 2015, CLIN EXP DERMATOL, V40, P367, DOI 10.1111/ced.12585	27	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2021	148	1					250	+		10.1016/j.jaci.2020.11.043	http://dx.doi.org/10.1016/j.jaci.2020.11.043		JUL 2021	7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE3IW	33338535				2022-12-18	WOS:000669908500007
J	Leyva-Castillo, JM; Das, M; Artru, E; Yoon, J; Galand, C; Geha, RS				Leyva-Castillo, Juan Manuel; Das, Mrinmoy; Artru, Emilie; Yoon, Juhan; Galand, Claire; Geha, Raif S.			Mast cell-derived IL-13 downregulates IL-12 production by skin dendritic cells to inhibit the T(H)1 cell response to cutaneous antigen exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; IL-13; dendritic cells; T(H)1 cells	THYMIC STROMAL LYMPHOPOIETIN; CD8(+) T-CELLS; CONTACT HYPERSENSITIVITY; ATOPIC-DERMATITIS; INTERLEUKIN-13; INTERFERON; MIGRATION; MICE; EXPRESSION; CYTOKINE	Background: Atopic dermatitis (AD) is characterized by a skin barrier defect aggravated by mechanical injury inflicted by scratching, a T(H)2 cell-dominated immune response, and susceptibility to viral skin infections that are normally restrained by a T(H)1 cell response. The signals leading to a T(H)2 cell-dominated immune response in AD are not completely understood. Objective: Our aim was to determine the role of IL-13 in initiation of the T-H cell response to cutaneously encountered antigens. Methods: Wild-type, Il13(-/-), Il1rl1(-/-), and Il4ra(-/-) mice, as well as mice with selective deficiency of IL-13 in mast cells (MCs) were studied; in addition, dendritic cells (DCs) purified from the draining lymph nodes of tape-stripped and ovalbumin (OVA)-sensitized skin were examined for their ability to polarize naive OVA-TCR transgenic CD4(+) T cells. Cytokine expression was examined by reverse-transcriptase quantitative PCR, intracellular flow cytometry, and ELISA. Contact hypersensitivity to dinitrofluorobenzene was examined. Results: Tape stripping caused IL-33-driven upregulation of Il13 expression by skin MCs. MC-derived IL-13 acted on DCs from draining lymph nodes of OVA-sensitized skin to selectively suppress their ability to polarize naive OVA-TCR transgenic CD4(+) T cells into IFN-gamma-secreting cells. MC-derived IL-13 inhibited the T(H)1 cell response in contact hypersensitivity to dinitrofluorobenzene. IL-13 suppressed IL-12 production by mouse skin-derived DCs in vitro and in vivo. Scratching upregulated IL13 expression in human skin, and IL-13 suppressed the capacity of LPS-stimulated human skin DCs to express IL-12 and promote IFN-gamma secretion by CD4(+) T cells. Conclusion: Release of IL-13 by cutaneous MCs in response to mechanical skin injury inhibits the T(H)1 cell response to cutaneous antigen exposure in AD.	[Leyva-Castillo, Juan Manuel; Das, Mrinmoy; Artru, Emilie; Yoon, Juhan; Galand, Claire; Geha, Raif S.] Harvard Med Sch, Boston Childrens Hosp, Dept Pediat, Div Immunol, Boston, MA 02115 USA; [Yoon, Juhan] MirimGENE Co Ltd, Yeonsugu, South Korea; [Galand, Claire] Agenus Inc, Lexington, MA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Agenus Inc	Leyva-Castillo, JM; Geha, RS (corresponding author), Boston Childrens Hosp, Div Immunol, One Blackfan Circle, Boston, MA 02115 USA.	Manuel.LeyvaCastillo@childrens.harvard.edu; raif.geha@childrens.harvard.edu	Das, Mrinmoy/AAS-5750-2021	Das, Mrinmoy/0000-0002-5785-5697; Geha, Raif/0000-0002-6019-3751	National Institutes of Health/National Institute of Allergy and Infectious Diseases Atopic Dermatitis Research Network [U19AI117673]; National Institutes of Health [AI11329401A1]; National Institute of Allergy and Infectious Diseases T32 training grant [5T32AI00751232]; Consejo Nacional de Ciencia y Tecnologia (CONACYT), Mexico; Boston Children's Hospital Office of Faculty Development/Basic/Translation Research Executive Committee and the Clinical and Translational Research Executive Committee (OFD/BTREC/CTREC) Faculty Career Development Fellowship	National Institutes of Health/National Institute of Allergy and Infectious Diseases Atopic Dermatitis Research Network; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases T32 training grant; Consejo Nacional de Ciencia y Tecnologia (CONACYT), Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Boston Children's Hospital Office of Faculty Development/Basic/Translation Research Executive Committee and the Clinical and Translational Research Executive Committee (OFD/BTREC/CTREC) Faculty Career Development Fellowship	This work was funded by the National Institutes of Health/National Institute of Allergy and Infectious Diseases Atopic Dermatitis Research Network grant U19AI117673, National Institutes of Health grant AI11329401A1, and National Institute of Allergy and Infectious Diseases T32 training grant 5T32AI00751232. J.M. LeyvaCastillo was supported by a postdoctoral fellowship from Consejo Nacional de Ciencia y Tecnologia (CONACYT) , Mexico, and Boston Children's Hospital Office of Faculty Development/Basic/Translation Research Executive Committee and the Clinical and Translational Research Executive Committee (OFD/BTREC/CTREC) Faculty Career Development Fellowship.	Angelova-Fischer I, 2010, J INVEST DERMATOL, V130, P2505, DOI 10.1038/jid.2010.143; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Bieber T, 2020, ALLERGY, V75, P54, DOI 10.1111/all.13954; Bonnelykke K, 2015, CURR OPIN IMMUNOL, V36, P115, DOI 10.1016/j.coi.2015.08.002; BOUR H, 1995, EUR J IMMUNOL, V25, P3006, DOI 10.1002/eji.1830251103; Cihakova D, 2008, AM J PATHOL, V172, P1195, DOI 10.2353/ajpath.2008.070207; DANDREA A, 1995, J EXP MED, V181, P537, DOI 10.1084/jem.181.2.537; Davidson C, 2007, TRANSPL IMMUNOL, V17, P178, DOI 10.1016/j.trim.2006.09.035; Dobbs ME, 2005, J VIROL, V79, P14546, DOI 10.1128/JVI.79.23.14546-14554.2005; Galand C, 2016, J ALLERGY CLIN IMMUN, V138, P1356, DOI 10.1016/j.jaci.2016.03.056; Gorczynski RM, 1996, TRANSPLANTATION, V62, P1592, DOI 10.1097/00007890-199612150-00012; Herrick CA, 2003, J IMMUNOL, V170, P2488, DOI 10.4049/jimmunol.170.5.2488; Heufler C, 1996, EUR J IMMUNOL, V26, P659, DOI 10.1002/eji.1830260323; Ho LH, 2007, J LEUKOCYTE BIOL, V82, P1481, DOI 10.1189/jlb.0407200; Honzke S, 2016, J INVEST DERMATOL, V136, P631, DOI 10.1016/j.jid.2015.11.007; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Jawdat DM, 2004, J IMMUNOL, V173, P5275, DOI 10.4049/jimmunol.173.8.5275; Kamijo S, 2013, J IMMUNOL, V190, P4489, DOI 10.4049/jimmunol.1201212; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Katz HR, 2011, IMMUNITY, V35, P668, DOI 10.1016/j.immuni.2011.11.004; Kim TG, 2015, J ALLERGY CLIN IMMUN, V136, P713, DOI 10.1016/j.jaci.2015.03.033; Kondo S, 1996, J INVEST DERMATOL, V106, P993, DOI 10.1111/1523-1747.ep12338505; Krasteva M, 1999, EUR J DERMATOL, V9, P65; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Lewkowich IP, 2013, MUCOSAL IMMUNOL, V6, P728, DOI 10.1038/mi.2012.111; Leyva-Castillo JM, 2013, J INVEST DERMATOL, V133, P154, DOI 10.1038/jid.2012.239; Leyva-Castillo JM, 2019, IMMUNITY, V50, P1262, DOI 10.1016/j.immuni.2019.03.023; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Malissen B, 2014, NAT REV IMMUNOL, V14, P417, DOI 10.1038/nri3683; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; MELKOVA Z, 1994, VIROLOGY, V198, P731, DOI 10.1006/viro.1994.1087; Ong PY, 2016, CLIN REV ALLERG IMMU, V51, P329, DOI 10.1007/s12016-016-8548-5; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, P976, DOI 10.1016/j.jaci.2010.08.041; Purwar R, 2006, J INVEST DERMATOL, V126, P1043, DOI 10.1038/sj.jid.5700085; Saint-Mezard P, 2005, J INVEST DERMATOL, V124, P562, DOI 10.1111/j.0022-202X.2005.23567.x; Scholten J, 2008, TRANSGENIC RES, V17, P307, DOI 10.1007/s11248-007-9153-4; Suto H, 2006, J IMMUNOL, V176, P4102, DOI 10.4049/jimmunol.176.7.4102; Tomura M, 2014, SCI REP-UK, V4, DOI 10.1038/srep06030; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Wang BH, 2000, J IMMUNOL, V165, P6783, DOI 10.4049/jimmunol.165.12.6783; Webb DC, 2007, J IMMUNOL, V178, P219, DOI 10.4049/jimmunol.178.1.219; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142; Zaccone P, 1999, DIABETES, V48, P1522, DOI 10.2337/diabetes.48.8.1522; Zheng T, 2009, J INVEST DERMATOL, V129, P742, DOI 10.1038/jid.2008.295	46	12	13	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2021	147	6					2305	+		10.1016/j.jaci.2020.11.036	http://dx.doi.org/10.1016/j.jaci.2020.11.036		JUN 2021	14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM7MD	33316284	Green Accepted			2022-12-18	WOS:000657783800010
J	Li, XK; Yang, HF; Han, YW; Yin, SJ; Shen, BZ; Wu, YL; Li, WX; Cao, ZJ				Li, Xueke; Yang, Haifeng; Han, Yuewen; Yin, Shijin; Shen, Bingzheng; Wu, Yingliang; Li, Wenxin; Cao, Zhijian			Tick peptides evoke itch by activating MrgprC77/MRGPRX7 to sensitize TRPV7 in pruriceptors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Tick; peptide; itch; Mrgprs; TRP channel	PROTEIN-COUPLED RECEPTORS; DEFENSIN; CHANNEL; MECHANISMS; RESPONSES; ISOFORMS; TARGETS; TRPA1; GENE	Background: Tick bites severely threaten human health because they allow the transmission of many deadly pathogens, including viruses, bacteria, protozoa, and helminths. Pruritus is a leading symptom of tick bites, but its molecular and neural bases remain elusive. Objectives: This study sought to discover potent drugs and targets for the specific prevention and treatment of tick bite-induced pruritus and arthropod-related itch. Methods: We used live-cell calcium imaging, patch-clamp recordings, and genetic ablation and evaluated mouse behavior to investigate the molecular and neural bases of tick bite-induced pruritus. Results: We found that 2 tick salivary peptides, IP defensin 1 (IPDef1) and IR defensin 2 (IRDef2), induced itch in mice. IPDef1 was further revealed to have a stronger pruritogenic potential than IRDef2 and to induce pruritus in ahistamine-independent manner. IPDef1 evoked itch by activating mouse MrgprC11 and human MRGPRX1 on dorsal root ganglion neurons. IPDef1-activated MrgprC11/X1 signaling sensitized downstream ion channel TRPV1 on dorsal root ganglion neurons. Moreover, IPDef1 also activated mouse MrgprB2 and its ortholog human MRGPRX2 selectively expressed on mast cells, inducing the release of inflammatory cytokines and driving acute inflammation in mice, although mast cell activation did not contribute to oxidated IPDef1-induced itch. Conclusions: Our study identifies tick salivary peptides as a new class of pruritogens that initiate itch through MrgprC11/ X1-TRPV1 signaling in pruritoceptors. Our work will provide potential drug targets for the prevention and treatment of pruritus induced by the bites or stings of tick and maybe other arthropods. (J Allergy Clin Immunol 2021;147:2236-48.)	[Li, Xueke; Yang, Haifeng; Han, Yuewen; Shen, Bingzheng; Wu, Yingliang; Li, Wenxin; Cao, Zhijian] Wuhan Univ, State Key Lab Virol, Coll Life Sci, Wuhan 430072, Peoples R China; [Cao, Zhijian] Wuhan Univ, Biodrug Res Ctr, Wuhan, Peoples R China; [Cao, Zhijian] Wuhan Univ, Hubei Prov Engn & Technol Res, Ctr Fluorinated Pharmaceut, Wuhan, Peoples R China; [Yin, Shijin] South Cent Univ Nationalities, Sch Pharmaceut Sci, Wuhan, Peoples R China	Wuhan University; Wuhan University; Wuhan University; South Central Minzu University	Cao, ZJ (corresponding author), Wuhan Univ, State Key Lab Virol, Coll Life Sci, Wuhan 430072, Peoples R China.	zjcao@whu.edu.cn			National Science Fund of China [32070525, 31872239, 81630091]; Hubei Science Fund for Excellent Scholars [2020CFA015]; Open Research Program of the State Key Laboratory of Virology of China [2020KF002]	National Science Fund of China(National Natural Science Foundation of China (NSFC)); Hubei Science Fund for Excellent Scholars; Open Research Program of the State Key Laboratory of Virology of China	Supported by grants from National Science Fund of China (32070525, 31872239, and 81630091), Hubei Science Fund for Excellent Scholars (2020CFA015), and the Open Research Program of the State Key Laboratory of Virology of China (2020KF002).	Akahoshi M, 2011, J CLIN INVEST, V121, P4180, DOI 10.1172/JCI46139; Cao ZJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3602; Casewell NR, 2013, TRENDS ECOL EVOL, V28, P219, DOI 10.1016/j.tree.2012.10.020; Cevikbas F, 2020, PHYSIOL REV, V100, P945, DOI 10.1152/physrev.00017.2019; Chrudimska T, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-63; Cyranoski D, 2018, NATURE, V556, P282, DOI 10.1038/d41586-018-04486-6; Feng J, 2018, SCIENCE, V360, P530, DOI 10.1126/science.aar5703; Feng J, 2017, J ALLERGY CLIN IMMUN, V140, P885, DOI 10.1016/j.jaci.2017.03.035; Fisher EJ, 2006, ARCH DERMATOL, V142, P491, DOI 10.1001/archderm.142.4.491; Grazzini E, 2004, P NATL ACAD SCI USA, V101, P7175, DOI 10.1073/pnas.0307185101; Han SK, 2002, P NATL ACAD SCI USA, V99, P14740, DOI 10.1073/pnas.192565799; Holding M, 2020, LANCET, V395, P411, DOI 10.1016/S0140-6736(20)30040-4; HOOGSTRAAL H, 1982, LANCET, V2, P288; Ikoma A, 2006, NAT REV NEUROSCI, V7, P535, DOI 10.1038/nrn1950; Imamachi N, 2009, P NATL ACAD SCI USA, V106, P11330, DOI 10.1073/pnas.0905605106; Immke DC, 2006, SEMIN CELL DEV BIOL, V17, P582, DOI 10.1016/j.semcdb.2006.09.004; Jones AV, 2017, HUM MOL GENET, V26, P1391, DOI 10.1093/hmg/ddx036; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; King JVL, 2019, CELL, V178, P1362, DOI 10.1016/j.cell.2019.07.014; Lay M, 2020, ANNU REV NEUROSCI, V43, P187, DOI 10.1146/annurev-neuro-083019-024537; Liu Q, 2009, CELL, V139, P1353, DOI 10.1016/j.cell.2009.11.034; Liu YueHua, 2002, Journal of Clinical Dermatology, V31, P720; Luo L, 2018, P NATL ACAD SCI USA, V115, P1646, DOI 10.1073/pnas.1714760115; McNamara CR, 2007, P NATL ACAD SCI USA, V104, P13525, DOI 10.1073/pnas.0705924104; Meixiong J, 2017, ANNU REV GENET, V51, P103, DOI 10.1146/annurev-genet-120116-024723; Meng LX, 2016, J BIOL CHEM, V291, P7097, DOI 10.1074/jbc.M115.680611; Metz M, 2006, SCIENCE, V313, P526, DOI 10.1126/science.1128877; Osteen JD, 2016, NATURE, V534, P494, DOI 10.1038/nature17976; Reck J, 2011, VET CLIN PATH, V40, P356, DOI 10.1111/j.1939-165X.2011.00338.x; Ru F, 2017, J PHYSIOL-LONDON, V595, P3651, DOI 10.1113/JP273795; Rudenko N, 2007, INSECT MOL BIOL, V16, P501, DOI 10.1111/j.1365-2583.2007.00745.x; Schneider T, 2010, SCIENCE, V328, P1168, DOI 10.1126/science.1185723; Sikand P, 2011, J NEUROSCI, V31, P7563, DOI 10.1523/JNEUROSCI.1192-11.2011; Thangamani S, 2009, PARASITE VECTOR, V2, DOI 10.1186/1756-3305-2-34; Thurmond RL, 2015, HANDB EXP PHARMACOL, V226, P257, DOI 10.1007/978-3-662-44605-8_15; Undheim EAB, 2014, MOL BIOL EVOL, V31, P2124, DOI 10.1093/molbev/msu162; Valtcheva MV, 2015, MOL PAIN, V11, DOI 10.1186/1744-8069-11-1; Wilson SR, 2011, NAT NEUROSCI, V14, P595, DOI 10.1038/nn.2789; Wooten M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5122; Yang SL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9297; Yin SJ, 2013, J CLIN INVEST, V123, P3941, DOI 10.1172/JCI66413; Zhang L, 2019, J ALLERGY CLIN IMMUN, V143, P1960, DOI 10.1016/j.jaci.2019.01.013	43	12	12	7	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2021	147	6					2236	+		10.1016/j.jaci.2020.12.626	http://dx.doi.org/10.1016/j.jaci.2020.12.626		JUN 2021	29	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM7MD	33358893	hybrid			2022-12-18	WOS:000657783800004
J	Patel, N; Adelman, DC; Anagnostou, K; Baumert, JL; Blom, WM; Campbell, DE; Chinthrajah, RS; Mills, ENC; Javed, B; Purington, N; Remington, BC; Sampson, HA; Smith, AD; Yarham, RAR; Turner, PJ				Patel, Nandinee; Adelman, Daniel C.; Anagnostou, Katherine; Baumert, Joseph L.; Blom, W. Marty; Campbell, Dianne E.; Chinthrajah, R. Sharon; Mills, E. N. Clare; Javed, Bushra; Purington, Natasha; Remington, Benjamin C.; Sampson, Hugh A.; Smith, Alexander D.; Yarham, Ross A. R.; Turner, Paul J.			Using data from food challenges to inform management of consumers with food allergy: A systematic review with individual participant data meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eliciting dose; peanut allergy; thresholds; oral food challenge; precautionary allergen labeling	THRESHOLD DOSE DISTRIBUTIONS; DOUBLE-BLIND; PEANUT ALLERGY; ORAL IMMUNOTHERAPY; PLACEBO; CHILDREN; RISK; SAFETY; ANAPHYLAXIS; EFFICACY	Background: Eliciting doses (EDs) (eg, EDoi or ED05 values, which are the amounts of allergen expected to cause objective symptoms in 1% and 5% of the population with an allergy, respectively) are increasingly being used to inform allergen labeling and clinical management. These values are generated from food challenge, but the frequency of anaphylaxis in response to these low levels of allergen exposure and their reproducibility are unknown. Objective: Our aim was to determine (1) the rate of anaphylaxis in response to low-level peanut exposure and (2) the reproducibility of reaction thresholds (and anaphylaxis) at food challenge. Methods: We conducted a systematic review and individual participant data meta-analysis of studies that reported at least 50 individuals with peanut allergy reacting to peanut at double-blind, placebo-controlled food challenge (DBPCFC) and were published between January 2010 and September 2020. Risk of bias was assessed by using National Institute for Clinical Excellence methodologic checklists. Results: A total of 19 studies were included (covering a total of 3151 participants, 534 of whom subsequently underwent further peanut challenge). At individual participant data meta-analysis, 4.5% (95% CI, 1.9% to 10.1%) of individuals reacted to 5 mg or less of peanut protein with anaphylaxis (moderate heterogeneity [I-2 = 57 %]). Intraindividual thresholds varied by up to 3 logs, although this variation was limited to a half-log change in 71.2% (95% CI, 56.2% to 82.6%) of individuals. In all, 2.4% (95% CI, 1.1% to 5.0%) of patients initially tolerated 5 mg of peanut protein but then reacted to this dose at subsequent challenge (low heterogeneity [I-2 = 16%]); none developed anaphylaxis. Conclusion: Around 5% of individuals reacting to an ED01 or ED05 level of exposure to peanut might develop anaphylaxis in response to that dose. This equates to 1 and 6 anaphylaxis events per 2500 patients exposed to an EDoi or ED05 dose, respectively, in the broader population of individuals with peanut allergy.	[Patel, Nandinee; Turner, Paul J.] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Adelman, Daniel C.; Smith, Alexander D.] Aimmune Therapeut, Brisbane, Qld, Australia; [Anagnostou, Katherine] Baylor Coll Med, Sect Allergy & Immunol, Houston, TX 77030 USA; [Anagnostou, Katherine] Texas Childrens Hosp, Dept Pediat, Sect Allergy & Immunol, Houston, TX 77030 USA; [Baumert, Joseph L.; Remington, Benjamin C.] Univ Nebraska, Food Allergy Res & Resource Program, Lincoln, NE USA; [Blom, W. Marty] Netherlands Org Appl Sci Res, Utrecht, Netherlands; [Campbell, Dianne E.] Childrens Hosp Westmead, Dept Allergy & Immunol, Sydney, NSW, Australia; [Campbell, Dianne E.; Sampson, Hugh A.] DBV Technol, Montrouge, France; [Chinthrajah, R. Sharon] Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA USA; [Chinthrajah, R. Sharon] Stanford Univ, Div Pulm Allergy & Crit Care Med, Stanford, CA 94305 USA; [Mills, E. N. Clare; Javed, Bushra] Univ Manchester, Manchester Inst Biotechnol, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Purington, Natasha] Stanford Univ, Dept Med, Quantitat Sci Unit, Sch Med, Stanford, CA 94305 USA; [Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Div Pediat Allergy & Immunol, New York, NY 10029 USA; [Yarham, Ross A. R.] Food Stand Agcy, London, England	Imperial College London; Baylor College of Medicine; Baylor College of Medicine; University of Nebraska System; University of Nebraska Lincoln; Netherlands Organization Applied Science Research; University of Sydney; Stanford University; University of Manchester; Stanford University; Icahn School of Medicine at Mount Sinai	Turner, PJ (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, Sect Inflammat Repair & Dev, Norfolk Pl, London W2 1PG, England.	p.turner@imperial.ac.uk	Turner, Paul/ABE-2261-2021	Turner, Paul/0000-0003-4504-2338; Anagnostou, Aikaterini/0000-0001-6240-7437; Campbell, Dianne/0000-0002-0907-6963; Turner, Paul/0000-0001-9862-5161; Patel, Nandinee/0000-0002-4997-9411; Blom, W.M./0000-0002-6853-0900	UK Medical Research Council Clinician Scientist award [MR/K010468/1]; National Institute for Health Research Biomedical Research Centre based at Imperial College Healthcare National Health Service Trust; Imperial College London	UK Medical Research Council Clinician Scientist award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research Biomedical Research Centre based at Imperial College Healthcare National Health Service Trust; Imperial College London(General Electric)	Funded in part by a UK Medical Research Council Clinician Scientist award to P.J.T. (reference MR/K010468/1). N.P. and P.J.T. are supported through the National Institute for Health Research Biomedical Research Centre based at Imperial College Healthcare National Health Service Trust and Imperial College London. The views expressed in this article are those of the authors and do not necessarily reflect those of the National Health Service, National Institute for Health Research, the Department of Health, or the Food Standards Agency.	Allen KJ, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-10; Allen KJ, 2014, J ALLERGY CLIN IMMUN, V133, P156, DOI 10.1016/j.jaci.2013.06.042; Anagnostou K, 2014, LANCET, V383, P1297, DOI 10.1016/S0140-6736(13)62301-6; Ballmer-Weber BK, 2015, J ALLERGY CLIN IMMUN, V135, P964, DOI 10.1016/j.jaci.2014.10.047; Bird JA, 2018, J ALLER CL IMM-PRACT, V6, P476, DOI 10.1016/j.jaip.2017.09.016; Blom WM, 2019, FOOD CHEM TOXICOL, V125, P413, DOI 10.1016/j.fct.2019.01.025; Blom WM, 2013, J ALLERGY CLIN IMMUN, V131, P172, DOI 10.1016/j.jaci.2012.10.034; Blumchen K, 2014, J ALLERGY CLIN IMMUN, V134, P390, DOI 10.1016/j.jaci.2014.03.035; Cardona V, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2020.100472; Chastell, PAEDIAT ALLERGY IMMU, DOI [10.22541/au.160221621.11001222/v1, DOI 10.22541/AU.160221621.11001222/V1]; Chinthrajah RS, 2019, LANCET, V394, P1437, DOI 10.1016/S0140-6736(19)31793-3; Dua S, 2019, J ALLERGY CLIN IMMUN, V144, P1584, DOI 10.1016/j.jaci.2019.06.038; Dubois AEJ, 2018, ALLERGY, V73, P1383, DOI 10.1111/all.13405; DunnGalvin A, 2015, ALLERGY, V70, P1039, DOI 10.1111/all.12614; DunnGalvin A, 2019, CLIN EXP ALLERGY, V49, P1191, DOI 10.1111/cea.13464; Fleischer DM, 2019, JAMA-J AM MED ASSOC, V321, P946, DOI 10.1001/jama.2019.1113; Graham F, 2020, PEDIAT ALLERG IMM-UK, V31, P601, DOI 10.1111/pai.13244; Houben GF, 2020, FOOD CHEM TOXICOL, V146, DOI 10.1016/j.fct.2020.111831; Hourihane JO, 2005, CLIN EXP ALLERGY, V35, P1227, DOI 10.1111/j.1365-2222.2005.02312.x; Hourihane JO, 2017, J ALLERGY CLIN IMMUN, V139, P1583, DOI 10.1016/j.jaci.2017.01.030; Klemans RJB, 2015, CLIN EXP ALLERGY, V45, P1237, DOI 10.1111/cea.12558; Kukkonen AK, 2015, ALLERGY, V70, P1239, DOI 10.1111/all.12671; Lin LF, 2020, HEALTH SCI REP-US, V3, DOI 10.1002/hsr2.178; Madsen CB, 2012, CLIN EXP ALLERGY, V42, P30, DOI 10.1111/j.1365-2222.2011.03868.x; Madsen CB, 2020, REGUL TOXICOL PHARM, V117, DOI 10.1016/j.yrtph.2020.104751; National Institute for Health and Care Excellence, SOCIAL CARE GUIDANCE; O'BHourihane J, 2020, LANCET CHILD ADOLESC, V4, P728, DOI 10.1016/S2352-4642(20)30234-0; Patel N, 2018, ALLERGY, V73, P1348, DOI 10.1111/all.13442; Pettersson ME, 2018, ALLERGY, V73, P1532, DOI 10.1111/all.13423; Purington N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02057; Reier-Nilsen T, 2018, CLIN EXP ALLERGY, V48, P415, DOI 10.1111/cea.13078; Remington BC, 2020, FOOD CHEM TOXICOL, V139, DOI 10.1016/j.fct.2020.111259; Rolinck-Werninghaus C, 2012, ALLERGY, V67, P951, DOI 10.1111/j.1398-9995.2012.02838.x; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sampson HA, 2017, JAMA-J AM MED ASSOC, V318, P1798, DOI 10.1001/jama.2017.16591; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Santos AF, 2020, J ALLERGY CLIN IMMUN, V146, P344, DOI 10.1016/j.jaci.2020.03.035; Schwarzer G, 2019, RES SYNTH METHODS, V10, P476, DOI 10.1002/jrsm.1348; Stewart LA, 2015, JAMA-J AM MED ASSOC, V313, P1657, DOI 10.1001/jama.2015.3656; Taylor SL, 2014, FOOD CHEM TOXICOL, V63, P9, DOI 10.1016/j.fct.2013.10.032; Taylor SL, 2010, FOOD CHEM TOXICOL, V48, P814, DOI 10.1016/j.fct.2009.12.013; Turner PJ, 2017, ALLERGY, V72, P9, DOI 10.1111/all.12997; Turner PJ, 2016, ALLERGY, V71, P1241, DOI 10.1111/all.12924; Turner PJ, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6180; van Erp FC, 2013, PEDIAT ALLERG IMM-UK, V24, P596, DOI 10.1111/pai.12107; Vickery BP, 2018, NEW ENGL J MED, V379, P1991, DOI 10.1056/NEJMoa1812856; Wang J, 2015, J ALLERGY CLIN IMMUN, V136, P962, DOI 10.1016/j.jaci.2015.04.029; Westerhout J, 2019, J ALLERGY CLIN IMMUN, V144, P1290, DOI 10.1016/j.jaci.2019.07.046	49	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2021	147	6					2249	+		10.1016/j.jaci.2021.01.025	http://dx.doi.org/10.1016/j.jaci.2021.01.025		JUN 2021	21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM7MD	33571537	Green Published, hybrid			2022-12-18	WOS:000657783800005
J	Boonpiyathad, T; Tantilipikorn, P; Ruxrungtham, K; Pradubpongsa, P; Mitthamsiri, W; Piedvache, A; Thantiworasit, P; Sirivichayakul, S; Jacquet, A; Suratannon, N; Chatchatee, P; Morisaki, N; Saito, H; Sangasapaviriya, A; Matsumoto, K; Morita, H				Boonpiyathad, Tadech; Tantilipikorn, Pongsakokorn; Ruxrungtham, Kiat; Pradubpongsa, Panitan; Mitthamsiri, Wat; Piedvache, Aurelie; Thantiworasit, Pattarawat; Sirivichayakul, Sunee; Jacquet, Alain; Suratannon, Narissara; Chatchatee, Pantipa; Morisaki, Naho; Saito, Hirohisa; Sangasapaviriya, Atik; Matsumoto, Kenji; Morita, Hideaki			IL-10-producing innate lymphoid cells increased in patients with house dust mite allergic rhinitis following immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Boonpiyathad, Tadech; Pradubpongsa, Panitan; Mitthamsiri, Wat; Sangasapaviriya, Atik] Phramongkutklao Hosp, Dept Med, Bangkok, Thailand; [Tantilipikorn, Pongsakokorn] Mahidol Univ, Siriraj Hosp, Dept Otorhinolaryngol, Fac Med, Bangkok, Thailand; [Ruxrungtham, Kiat; Thantiworasit, Pattarawat; Sirivichayakul, Sunee] Chulalongkorn Univ, King Chulalongkorn Mem Hosp, Thai Red Cross Soc, Dept Med,Fac Med, Bangkok, Thailand; [Ruxrungtham, Kiat; Sirivichayakul, Sunee; Jacquet, Alain] Chulalongkorn Univ, King Chulalongkorn Mem Hosp, Thai Red Cross Soc, Ctr Excellence Vaccine Res & Dev, Bangkok, Thailand; [Suratannon, Narissara; Chatchatee, Pantipa] Chulalongkorn Univ, King Chulalongkorn Mem Hosp, Thai Red Cross Soc,Div Allergy & Immunol,Dept Ped, Pediat Allergy & Clin Immunol Res Unit,Fac Med, Bangkok, Thailand; [Piedvache, Aurelie; Morisaki, Naho] Natl Res Inst Child Hlth & Dev, Dept Social Med, Tokyo, Japan; [Saito, Hirohisa; Matsumoto, Kenji; Morita, Hideaki] Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan	Phramongkutklao Hospital; Mahidol University; Chulalongkorn University; Thai Red Cross Society; Chulalongkorn University; Thai Red Cross Society; Chulalongkorn University; Thai Red Cross Society; National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan	Morita, H (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan.	morita-hi@ncchd.go.jp	Morita, Hideaki/ADL-2008-2022; Morita, Hideaki/S-2214-2016; Jacquet, Alain/GQI-0546-2022	Morita, Hideaki/0000-0003-0928-8322; Jacquet, Alain/0000-0002-0980-9741; Saito, Hirohisa/0000-0002-6630-8337; Ruxrungtham, Kiat/0000-0001-7348-2352; Boonpiyathad, Tadech/0000-0001-8690-7647; PIEDVACHE, AURELIE/0000-0002-2737-0461	Health System Research Institute in Thailand; Nipponham Foundation for the Future of Food; National Center for Child Health and Development [29-2]; Chulalongkorn Academic Advancement (2nd Century Project-CUAASC)	Health System Research Institute in Thailand; Nipponham Foundation for the Future of Food; National Center for Child Health and Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Chulalongkorn Academic Advancement (2nd Century Project-CUAASC)	The MITAR study is supported by the Health System Research Institute in Thailand. This research was supported by a Grants-in-Aid for Young Scientists grant (to H.M.), a grant from the Nipponham Foundation for the Future of Food (to H.M.), a grant from the National Center for Child Health and Development (grant 29-2 [to H.M.]), and a grant from Chulalongkorn Academic Advancement (2nd Century Project-CUAASC to [A.J.]).	Boonpiyathad T, 2019, J ALLERGY CLIN IMMUN, V143, P1077, DOI 10.1016/j.jaci.2018.10.061; Boonpiyathad T, 2019, ALLERGY, V74, P976, DOI 10.1111/all.13684; Guilliams M, 2010, BLOOD, V115, P1958, DOI 10.1182/blood-2009-09-245274; Lao-Araya M, 2014, J ALLERGY CLIN IMMUN, V134, P1193, DOI 10.1016/j.jaci.2014.07.029; Mitthamsiri W, 2018, ALLERGY ASTHMA IMMUN, V10, P662, DOI 10.4168/aair.2018.10.6.662; Miyamoto C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08365-0; Morita H, 2019, J ALLERGY CLIN IMMUN, V143, P2190, DOI 10.1016/j.jaci.2018.12.1018; Morita H, 2016, J ALLERGY CLIN IMMUN, V138, P1253, DOI 10.1016/j.jaci.2016.09.011; Sokolowska M, 2019, ALLERGY, V74, P2061, DOI 10.1111/all.13973	9	12	12	2	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1507	1510		10.1016/j.jaci.2020.10.029	http://dx.doi.org/10.1016/j.jaci.2020.10.029		APR 2021	4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UU3GE	33137358				2022-12-18	WOS:000698687100001
J	Abdel-Aziz, MI; Brinkman, P; Vijverberg, SJH; Neerincx, AH; de Vries, R; Dagelet, YWF; Riley, JH; Hashimoto, S; Montuschi, P; Chung, KF; Djukanovic, R; Fleming, LJ; Murray, CS; Frey, U; Bush, A; Singer, F; Hedlin, G; Roberts, G; Dahlen, SE; Adcock, IM; Fowler, SJ; Knipping, K; Sterk, PJ; Kraneveld, AD; Maitland-van Der Zee, AH				Abdel-Aziz, Mahmoud I.; Brinkman, Paul; Vijverberg, Susanne J. H.; Neerincx, Anne H.; de Vries, Rianne; Dagelet, Yennece W. F.; Riley, John H.; Hashimoto, Simone; Montuschi, Paolo; Chung, Kian Fan; Djukanovic, Ratko; Fleming, Louise J.; Murray, Clare S.; Frey, Urs; Bush, Andrew; Singer, Florian; Hedlin, Gunilla; Roberts, Graham; Dahlen, Sven-Erik; Adcock, Ian M.; Fowler, Stephen J.; Knipping, Karen; Sterk, Peter J.; Kraneveld, Aletta D.; Maitland-van Der Zee, Anke H.		U-BIOPRED Study Grp; Amsterdam UMC Breath Res Grp	eNose breath prints as a surrogate biomarker for classifying patients with asthma by atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						VOCs; eNose; asthma; atopy; discrimination; machine learning	LATENT CLASS ANALYSIS; CLUSTER-ANALYSIS; PHENOTYPES; METABOLOMICS; PREVALENCE; SELECTION	Background: Electronic noses (eNoses) are emerging point-of-care tools that may help in the subphenotyping of chronic respiratory diseases such as asthma. Objective: We aimed to investigate whether eNoses can classify atopy in pediatric and adult patients with asthma. Methods: Participants with asthma and/or wheezing from 4 independent cohorts were included; BreathCloud participants (n 5 429), Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes adults (n 5 96), Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes pediatric participants (n 5 100), and Pharmacogenetics of Asthma Medication in Children: Medication with Anti-Inflammatory Effects 2 participants (n 5 30). Atopy was defined as a positive skin prick test result (>3 mm) and/or a positive specific IgE level (>0.35 kU/L) for common allergens. Exhaled breath profiles were measured by using either an integrated eNose platform or the SpiroNose. Data were divided into 2 training and 2 validation sets according to the technology used. Supervised data analysis involved the use of 3 different machine learning algorithms to classify patients with atopic versus nonatopic asthma with reporting of areas under the receiver operating characteristic curves as a measure of model performance. In addition, an unsupervised approach was performed by using a bayesian network to reveal data-driven relationships between eNose volatile organic compound profiles and asthma characteristics. Results: Breath profiles of 655 participants (n 5 601 adults and school-aged children with asthma and 54 preschool children with wheezing [68.2% of whom were atopic]) were included in this study. Machine learning models utilizing volatile organic compound profiles discriminated between atopic and nonatopic participants with areas under the receiver operating characteristic curves of at least 0.84 and 0.72 in the training and validation sets, respectively. The unsupervised approach revealed that breath profiles classifying atopy are not confounded by other patient characteristics. Conclusion: eNoses accurately detect atopy in individuals with asthma and wheezing in cohorts with different age groups and could be used in asthma phenotyping.	[Abdel-Aziz, Mahmoud I.; Brinkman, Paul; Vijverberg, Susanne J. H.; Neerincx, Anne H.; de Vries, Rianne; Dagelet, Yennece W. F.; Hashimoto, Simone; Sterk, Peter J.; Maitland-van Der Zee, Anke H.] Univ Amsterdam, Emma Childrens Hosp, Amsterdam UMC, Dept Resp Med, Amsterdam, Netherlands; [Hashimoto, Simone; Maitland-van Der Zee, Anke H.] Univ Amsterdam, Emma Childrens Hosp, Amsterdam UMC, Dept Paediat Resp Med, Amsterdam, Netherlands; [Abdel-Aziz, Mahmoud I.] Assiut Univ, Fac Pharm, Dept Clin Pharm, Assiut, Egypt; [Vijverberg, Susanne J. H.; Maitland-van Der Zee, Anke H.] Univ Utrecht, Fac Sci, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands; [Knipping, Karen; Kraneveld, Aletta D.] Univ Utrecht, Fac Sci, Utrecht Inst Pharmaceut Sci, Div Pharmacol, Utrecht, Netherlands; [Kraneveld, Aletta D.] Univ Utrecht, Fac Vet Med, Inst Risk Assessment Sci, Utrecht, Netherlands; [de Vries, Rianne] Breathomix BV, Reeuwijk, Netherlands; [Riley, John H.] GlaxoSmithKline, Resp Therapeut Unit, Stockley Pk, Uxbridge, Middx, England; [Montuschi, Paolo] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli, IRCCS, Dept Pharmacol,Fac Med, Rome, Italy; [Chung, Kian Fan; Fleming, Louise J.; Bush, Andrew; Adcock, Ian M.] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Chung, Kian Fan; Fleming, Louise J.; Bush, Andrew; Adcock, Ian M.] Royal Brompton & Harefield NHS Trust, London, England; [Djukanovic, Ratko; Roberts, Graham] Univ Southampton, NIHR Southampton Resp Biomed Res Unit, Clin & Expt Sci & Human Dev & Hlth, Southampton, Hants, England; [Murray, Clare S.; Fowler, Stephen J.] Univ Manchester, Fac Biol Med & Hlth, Sch Biol Sci, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Murray, Clare S.; Fowler, Stephen J.] Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Murray, Clare S.; Fowler, Stephen J.] Manchester Univ Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, Manchester, Lancs, England; [Frey, Urs] Univ Basel, Univ Childrens Hosp Basel, Basel, Switzerland; [Singer, Florian] Univ Childrens Hosp Bern, Bern, Switzerland; [Hedlin, Gunilla] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Hedlin, Gunilla] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Dahlen, Sven-Erik] Karolinska Inst, Ctr Allergy Res, Inst Environm Med, Stockholm, Sweden; [Knipping, Karen] Danone Nutricia Res, Utrecht, Netherlands	Emma Children's Hospital; University of Amsterdam; Emma Children's Hospital; University of Amsterdam; Egyptian Knowledge Bank (EKB); Assiut University; Utrecht University; Utrecht University; Utrecht University; GlaxoSmithKline; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; University of Southampton; University of Manchester; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital NHS Foundation Trust; University of Basel; University of Bern; University Hospital of Bern; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Danone Nutricia	Maitland-van Der Zee, AH (corresponding author), Univ Amsterdam, Amsterdam UMC, Dept Resp Med, Meibergdreef 9, Amsterdam, Netherlands.; Maitland-van Der Zee, AH (corresponding author), Univ Amsterdam, Amsterdam UMC, Dept Paediat Resp Med, Meibergdreef 9, Amsterdam, Netherlands.	a.h.maitland@amsterdamumc.nl	Brinkman, Paul/AAV-5110-2021; Singer, Florian/AAO-1460-2021; Maitland-van der Zee, Anke/I-9572-2016	Singer, Florian/0000-0003-3471-5664; Roberts, Graham/0000-0003-2252-1248; Murray, Clare/0000-0002-8961-8055; Brinkman, Paul/0000-0003-4546-8478; Djukanovic, Ratko/0000-0001-6039-5612; Frey, Urs/0000-0003-3773-2822; Maitland-van der Zee, Anke/0000-0002-0414-3442; Adcock, Ian/0000-0003-2101-8843; Hashimoto, Simone/0000-0001-8995-3817	Innovative Medicines Initiative Joint Undertaking [115010]; European Union; GlaxoSmithKline; public charity Dutch Vriendenloterij; Egyptian Government	Innovative Medicines Initiative Joint Undertaking; European Union(European Commission); GlaxoSmithKline(GlaxoSmithKline); public charity Dutch Vriendenloterij; Egyptian Government	U-BIOPRED has received funding from the Innovative Medicines Initiative Joint Undertaking (under grant agreement no. 115010), the resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007-2013) and in-kind contributions of companies belonging to the European Federation of Pharmaceutical Industries and Associations (www.imi.europa.eu). The PACMAN study was funded by an unrestricted GlaxoSmithKline grant. BreathCloud was sponsored by the public charity Dutch Vriendenloterij. The salary of M.I.A. was sponsored by Egyptian Government PhD Research Scholarships.	Abramson MJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001186.pub2; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Boots AW, 2015, TRENDS MOL MED, V21, P633, DOI 10.1016/j.molmed.2015.08.001; Bossuyt PM, 2015, BMJ-BRIT MED J, V351, DOI [10.1148/radiol.2015151516, 10.1136/bmj.h5527, 10.1373/clinchem.2015.246280]; Bouwmeester R, 2019, ANAL CHEM, V91, P3694, DOI 10.1021/acs.analchem.8b05820; Brinkman P, 2019, J ALLERGY CLIN IMMUN, V143, P1811, DOI 10.1016/j.jaci.2018.10.058; Brinkman P, 2019, CURR OPIN PULM MED, V25, P94, DOI 10.1097/MCP.0000000000000534; Broadhurst DI, 2006, METABOLOMICS, V2, P171, DOI 10.1007/s11306-006-0037-z; Cao KAL, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-253; Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F; Cuperlovic-Culf M, 2018, METABOLITES, V8, DOI 10.3390/metabo8010004; de Vries R, 2019, ANN ONCOL, V30, P1660, DOI 10.1093/annonc/mdz279; de Vries R, 2015, J BREATH RES, V9, DOI 10.1088/1752-7155/9/4/046001; de Vries R, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01817-2017; de Vries R, 2014, EUR RESPIR J, V44; DETERMAN CE, 2015, INT J BIOL, V7, P100, DOI DOI 10.5539/ijb.v7n1p100; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Fleming L, 2015, EUR RESPIR J, V46, P1322, DOI 10.1183/13993003.00780-2015; Friedman JH, 2001, ANN STAT, V29, P1189, DOI 10.1214/aos/1013203451; Fuglsbjerg MG, 2018, ERJ OPEN RES, V4, DOI 10.1183/23120541.00026-2018; Gautier C, 2017, J ASTHMA ALLERGY, V10, P47, DOI 10.2147/JAA.S121276; Haggstrom J, 2018, BIOMETRICS, V74, P389, DOI 10.1111/biom.12788; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Heinzerling Lucie, 2013, Clin Transl Allergy, V3, P3, DOI 10.1186/2045-7022-3-3; Hose AJ, 2017, J ALLERGY CLIN IMMUN, V139, P1935, DOI 10.1016/j.jaci.2016.08.046; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Lawal O, 2018, J BREATH RES, V12, DOI 10.1088/1752-7163/aa8efc; Lefaudeux D, 2017, J ALLERGY CLIN IMMUN, V139, P1797, DOI 10.1016/j.jaci.2016.08.048; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Neerincx AH, 2017, PEDIATR PULM, V52, P1616, DOI 10.1002/ppul.23785; Normansell R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub4; Norrman G, 2009, PEDIAT ALLERG IMM-UK, V20, P273, DOI 10.1111/j.1399-3038.2008.00761.x; RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Romero KM, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-48; Schatz M, 2014, J ALLERGY CLIN IMMUN, V133, P1549, DOI 10.1016/j.jaci.2013.10.006; Schleich FN, 2019, AM J RESP CRIT CARE, V200, P444, DOI 10.1164/rccm.201811-2210OC; Sellaturay P, 2015, ANN ALLERG ASTHMA IM, V115, P229, DOI 10.1016/j.anai.2015.07.005; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015; Silverberg JI, 2013, J ALLERGY CLIN IMMUN, V132, P1132, DOI 10.1016/j.jaci.2013.08.031; Unsworth J, 2011, CLIN MED, V11, P376, DOI 10.7861/clinmedicine.11-4-376; Venkatraman ES, 2000, BIOMETRICS, V56, P1134, DOI 10.1111/j.0006-341X.2000.01134.x; Vijverberg SJH, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-94; Weinmayr G, 2013, CLIN EXP ALLERGY, V43, P223, DOI 10.1111/cea.12035; Wilkinson M, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.01068-2019; Wilson AD, 2015, METABOLITES, V5, P140, DOI 10.3390/metabo5010140; Wilson Andrew M, 2006, Treat Respir Med, V5, P149, DOI 10.2165/00151829-200605030-00001; Zou H, 2006, J AM STAT ASSOC, V101, P1418, DOI 10.1198/016214506000000735	49	12	12	4	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2020	146	5					1045	1055		10.1016/j.jaci.2020.05.038	http://dx.doi.org/10.1016/j.jaci.2020.05.038			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OP5VH	32531371	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000588153700009
J	Gann, PH; Deaton, RJ; McMahon, N; Collins, MH; Dellon, ES; Hirano, I; Hua, SY; Rodriguez, C; Harris, S				Gann, Peter H.; Deaton, Ryan J.; McMahon, Nathan; Collins, Margaret H.; Dellon, Evan S.; Hirano, Ikuo; Hua, Steven Ye; Rodriguez, Cristian; Harris, Sarah			An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial results	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; epithelial-mesenchymal transition; IL-13 antibody	PULMONARY-FIBROSIS; GENE-EXPRESSION; IL-13; FEATURES; INTERLEUKIN-13; VALIDATION; ENDOSCOPY; PLACEBO; RPC4046	Background: Fibrostenosis, the most serious eosinophilic esophagitis (EoE) complication, is mediated by epithelial-mesenchymal transition (EMT). Transitioned cells contribute to pathogenesis by overproducing extracellular matrix. Objective: Our aim was to determine whether RPC4046 (anti-IL-13 mAb) modulates EMT biomarkers in biopsy samples from adults with active EoE in a substudy of a double-blind, placebo-controlled phase 2 trial. Methods: Baseline and week 16 esophageal biopsy samples were taken from 69 patients who were randomized to weekly treatment with subcutaneous RPC4046, 180 mg (n = 19), 360 mg (n = 26), or placebo (n = 24). Duplex immunofluorescence slides stained for E-cadherin and vimentin were digitally analyzed by mapping each epithelial cell and recording fluorescence intensities. End points included change from baseline to week 16 in percentage of vimentin-positive epithelial cells (primary), total E-cadherin expression, and vimentin-to E-cadherin ratio per cell (an average of 47,000 cells per biopsy sample analyzed). Results: The mean percentage of vimentin-positive cells decreased by 0.94%, 2.75%, and 4.24% in the placebo, low-dose, and high-dose groups, respectively (P =.032 for the high-dose vs placebo group). Mean E-cadherin expression per cell increased 5.6-fold in both dose groups versus in the placebo group (high-dose group P =.047). The increases in E-cadherin expression per cell from baseline to week 16 were correlated with improvements in histology, eosinophil counts, endoscopic findings, and symptoms. Conclusion: RPC4046 significantly reduced EMT markers in adults with active EoE, with greater effects at 360 mg. Together with results for eosinophil density and clinical end points from the main trial, these data support the hypothesis that pharmacologic IL-13 inhibition ameliorates both inflammatory and remodeling pathways and could potentially reduce the risk of fibrostenotic complications.	[Gann, Peter H.; Deaton, Ryan J.; McMahon, Nathan] Univ Illinois, Coll Med, Dept Pathol, Chicago, IL 60612 USA; [Collins, Margaret H.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Pathol & Lab Med, Cincinnati, OH USA; [Dellon, Evan S.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27515 USA; [Hirano, Ikuo] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Hua, Steven Ye; Rodriguez, Cristian; Harris, Sarah] Celgene Corp, Summit, NJ USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Northwestern University; Feinberg School of Medicine; Bristol-Myers Squibb; Celgene Corporation	Gann, PH (corresponding author), 840 S Wood St,MC847, Chicago, IL 60612 USA.	pgann@uic.edu			Celgene; Celgene Corporation	Celgene(Bristol-Myers SquibbCelgene Corporation); Celgene Corporation(Bristol-Myers SquibbCelgene Corporation)	This study was sponsored by Celgene. Support for third-party writing assistance for this article was provided by CodonMedical (an Ashfield Company that is part of UDG Healthcare and Peloton Advantage, an OPEN Health Company) and was funded by Celgene Corporation.	Aceves SS, 2010, ALLERGY, V65, P109, DOI 10.1111/j.1398-9995.2009.02142.x; Armbruster-Lee J, 2018, J LEUKOCYTE BIOL, V104, P31, DOI 10.1002/JLB.5MR1017-395R; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Brightling CE, 2010, CLIN EXP ALLERGY, V40, P42, DOI 10.1111/j.1365-2222.2009.03383.x; Collins MH, 2017, DIS ESOPHAGUS, V30, DOI 10.1111/dote.12470; Dellon ES, 2019, J ALLERGY CLIN IMMUN, V143, pAB208, DOI 10.1016/j.jaci.2018.12.635; Dellon ES, 2017, GASTROENTEROLOGY, V152, P776, DOI 10.1053/j.gastro.2016.11.021; Dellon ES, 2014, GASTROINTEST ENDOSC, V79, P577, DOI 10.1016/j.gie.2013.10.027; Dougherty M, 2017, GASTROINTEST ENDOSC, V86, P581, DOI 10.1016/j.gie.2017.04.028; Fichtner-Feigl S, 2007, J IMMUNOL, V178, P5859, DOI 10.4049/jimmunol.178.9.5859; Fulkerson PC, 2006, AM J RESP CELL MOL, V35, P337, DOI 10.1165/rcmb.2005-0474OC; Furuta GT, 2015, NEW ENGL J MED, V373, P1640, DOI 10.1056/NEJMra1502863; Gentile N, 2014, ALIMENT PHARM THER, V40, P1333, DOI 10.1111/apt.12977; Hirano I, 2019, GASTROENTEROLOGY, V156, P592, DOI 10.1053/j.gastro.2018.10.051; Hirano I, 2014, GASTROENTEROL CLIN N, V43, P297, DOI 10.1016/j.gtc.2014.02.015; Hirano I, 2013, GUT, V62, P489, DOI 10.1136/gutjnl-2011-301817; Jensen ET, 2015, AM J GASTROENTEROL, V110, P626, DOI 10.1038/ajg.2014.316; Kagalwalla AF, 2012, J ALLERGY CLIN IMMUN, V129, P1387, DOI 10.1016/j.jaci.2012.03.005; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; Li YJ, 2003, J CLIN INVEST, V112, P503, DOI 10.1172/JCI200317913; Lucendo AJ, 2011, J ALLERGY CLIN IMMUN, V128, P1037, DOI 10.1016/j.jaci.2011.08.007; Moawad FJ, 2016, CLIN GASTROENTEROL H, V14, P23, DOI 10.1016/j.cgh.2015.08.034; Muir AB, 2019, J GASTROENTEROL, V54, P10, DOI 10.1007/s00535-018-1498-3; Muir AB, 2015, EXP CELL RES, V330, P102, DOI 10.1016/j.yexcr.2014.08.026; Muir AB, 2013, EXP CELL RES, V319, P850, DOI 10.1016/j.yexcr.2012.12.002; Murray LA, 2014, AM J RESP CELL MOL, V50, P985, DOI 10.1165/rcmb.2013-0342OC; Schoepfer AM, 2018, AM J GASTROENTEROL, V113, P348, DOI 10.1038/ajg.2017.493; Schoepfer AM, 2014, GASTROENTEROLOGY, V147, P1255, DOI 10.1053/j.gastro.2014.08.028; Schoepfer AM, 2013, GASTROENTEROLOGY, V145, P1230, DOI 10.1053/j.gastro.2013.08.015; Sherrill JD, 2014, MUCOSAL IMMUNOL, V7, P718, DOI 10.1038/mi.2013.90; Singla MB, 2015, CLIN TRANSL GASTROEN, V6, DOI 10.1038/ctg.2015.62; Tripp CS, 2017, ADV THER, V34, P1364, DOI 10.1007/s12325-017-0525-8; Zeisberg M, 2007, J BIOL CHEM, V282, P23337, DOI 10.1074/jbc.M700194200; Zuo L, 2010, J IMMUNOL, V185, P660, DOI 10.4049/jimmunol.1000471	35	12	13	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2020	146	2					367	+		10.1016/j.jaci.2020.03.045	http://dx.doi.org/10.1016/j.jaci.2020.03.045			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ0TA	32407835	hybrid			2022-12-18	WOS:000558835000027
J	Hultberg, J; Ernerudh, J; Larsson, M; Nilsdotter-Augustinsson, A; Nystrom, S				Hultberg, Jonas; Ernerudh, Jan; Larsson, Marie; Nilsdotter-Augustinsson, Asa; Nystrom, Sofia			Plasma protein profiling reflects T(H)1-driven immune dysregulation in common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						plasma proteomics; proximity extension immunoassay; immune dysregulation; lymphoproliferation; immunodeficiency; CVID	B-CELLS; INTERNATIONAL UNION; T-CELLS; DEFICIENCY; SUBGROUPS; PHENOTYPE; COMMITTEE; DISEASES; RECEPTOR	Background: Common variable immunodeficiency (CVID) is a disorder characterized by antibody deficiency. A significant fraction of the patients suffer from immune dysregulation, which leads to increased morbidity and mortality. The pathogenesis of this condition is poorly understood. Objective: Our aim was to find out whether the plasma protein signature in CVID is associated with clinical characteristics and lymphocyte aberrations. Methods: A highly sensitive proximity extension assay was used for targeted profiling of 145 plasma proteins in 29 patients with CVID. Phenotyping of peripheral lymphocytes was done by flow cytometry. The findings were correlated with the burden of immune dysregulation. Results: Unsupervised clustering of plasma protein profiles identified 2 distinct groups of patients with CVID that differed significantly in terms of the degree of complications due to immune dysregulation and in terms of the frequency of activated B- and T-cell subpopulations. Pathway analysis identified IFN-gamma and IL-1 beta as the top enriched upstream regulators associated with higher grade of immune dysregulation. In addition, CVID was found to be associated with increased plasma levels of the B-cell attracting chemokine CXCL13. Conclusion: Clustering based on plasma protein profiles delineated a subgroup of patients with CVID with activated T cells and clinical complications due to immune dysregulation. Thus, data indicate that CVID-associated immune dysregulation is a T(H)1-mediated inflammatory process driven by the IFN-gamma pathway.	[Hultberg, Jonas; Larsson, Marie; Nystrom, Sofia] Linkoping Univ, Div Mol Virol, Linkoping, Sweden; [Hultberg, Jonas; Ernerudh, Jan; Nystrom, Sofia] Linkoping Univ, Dept Clin Immunol & Transfus Med, Linkoping, Sweden; [Nilsdotter-Augustinsson, Asa] Linkoping Univ, Dept Infect Dis, Linkoping, Sweden; [Nilsdotter-Augustinsson, Asa] Linkoping Univ, Dept Biomed & Clin Sci, Linkoping, Sweden	Linkoping University; Linkoping University; Linkoping University; Linkoping University	Nystrom, S (corresponding author), Univ Hosp, Clin Immunol & Transfus Med, S-58185 Linkoping, Sweden.; Nystrom, S (corresponding author), Univ Hosp, Dept Biomed & Clin Sci, S-58185 Linkoping, Sweden.	sofia.c.nystrom@liu.se	NystrÃm, Sofia/GYQ-5893-2022	Nystrom, Sofia/0000-0002-0145-4966; Larsson, Marie/0000-0002-4524-0177	ALF Grants, Region Ostergotland	ALF Grants, Region Ostergotland	We would like to acknowledge the support of the Clinical Biomarker Facility at SciLifeLab Sweden for providing assistance in protein analyses. The study was financially supported by ALF Grants, Region Ostergotland.	Ameratunga R, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00415; Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; Assarsson E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095192; Babicki S, 2016, NUCLEIC ACIDS RES, V44, pW147, DOI 10.1093/nar/gkw419; Buchan SL, 2018, BLOOD, V131, P39, DOI 10.1182/blood-2017-07-741025; Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310; Cols M, 2016, J ALLERGY CLIN IMMUN, V137, P1206, DOI 10.1016/j.jaci.2015.09.013; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; De Carvalho VP, 2019, TRANSL RES, V206, P71, DOI 10.1016/j.trsl.2018.11.001; Feldreich T, 2019, J NEPHROL, V32, P111, DOI 10.1007/s40620-018-0556-5; Fliegauf M, 2015, AM J HUM GENET, V97, P389, DOI 10.1016/j.ajhg.2015.07.008; Giovannetti A, 2007, J IMMUNOL, V178, P3932, DOI 10.4049/jimmunol.178.6.3932; Havenar-Daughton C, 2016, P NATL ACAD SCI USA, V113, P2702, DOI 10.1073/pnas.1520112113; Hel Z, 2014, J CLIN IMMUNOL, V34, P971, DOI 10.1007/s10875-014-0099-z; Hennig C, 2014, J ALLERGY CLIN IMMUN, V133, P172; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Jensen LE, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan3589; Karnell JL, 2017, CELL IMMUNOL, V321, P40, DOI 10.1016/j.cellimm.2017.05.008; Klemann C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00297; Kroenke MA, 2012, J IMMUNOL, V188, P3734, DOI 10.4049/jimmunol.1103246; Lee SW, 2009, ADV EXP MED BIOL, V647, P120, DOI 10.1007/978-0-387-89520-8_8; Lundberg M, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr424; Malphettes M, 2009, CLIN INFECT DIS, V49, P1329, DOI 10.1086/606059; Mouillot G, 2010, J CLIN IMMUNOL, V30, P746, DOI 10.1007/s10875-010-9424-3; Orange JS, 2011, J ALLERGY CLIN IMMUN, V127, P1360, DOI 10.1016/j.jaci.2011.02.039; Park J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074893; Perreau M, 2014, J EXP MED, V211, P2033, DOI 10.1084/jem.20140039; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Rakhmanov M, 2009, P NATL ACAD SCI USA, V106, P13451, DOI 10.1073/pnas.0901984106; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Romberg N, 2019, J ALLERGY CLIN IMMUN, V143, P258, DOI 10.1016/j.jaci.2018.06.012; Schreeder DM, 2010, J IMMUNOL, V185, P23, DOI 10.4049/jimmunol.1000832; SEIDEL MG, 2019, J ALLERGY CLIN IMMUN; Stuchly J, 2017, SCI REP-UK, V7, DOI 10.1038/srep39710; Tasaki S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05044-4; Toribio M, 2018, EBIOMEDICINE, V35, P58, DOI 10.1016/j.ebiom.2018.08.039; Tuijnenburg P, 2018, J ALLERGY CLIN IMMUN, V142, P1285, DOI 10.1016/j.jaci.2018.01.039; Unger S, 2018, J ALLERGY CLIN IMMUN, V141, P730, DOI 10.1016/j.jaci.2017.04.041; van Schouwenburg PA, 2015, CLIN IMMUNOL, V160, P301, DOI 10.1016/j.clim.2015.05.020; Wang S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0894-1; Wang XM, 2011, J EXP MED, V208, P2497, DOI 10.1084/jem.20111449; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Wilson TJ, 2007, BLOOD, V109, P3786, DOI 10.1182/blood-2006-06-030023; Yellin M, 2012, ARTHRITIS RHEUM-US, V64, P1730, DOI 10.1002/art.34330; Zhong HQ, 2017, SCI REP-UK, V7, DOI [10.1038/s41598-017-18195-Z, 10.1038/s41598-017-18195-z]; Zumaquero E, 2019, ELIFE, V8, DOI 10.7554/eLife.41641	49	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2020	146	2					417	428		10.1016/j.jaci.2020.01.046	http://dx.doi.org/10.1016/j.jaci.2020.01.046			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ0TA	32057767	Green Published			2022-12-18	WOS:000558835000031
J	Glickman, JW; Dubin, C; Han, J; Dahabreh, D; Garcet, S; Krueger, JG; Pavel, AB; Guttman-Yassky, E				Glickman, Jacob W.; Dubin, Celina; Han, Joseph; Dahabreh, Dante; Garcet, Sandra; Krueger, James G.; Pavel, Ana B.; Guttman-Yassky, Emma			Comparing cutaneous molecular improvement with different treatments in atopic dermatitis patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Glickman, Jacob W.; Dubin, Celina; Han, Joseph; Dahabreh, Dante; Pavel, Ana B.; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Glickman, Jacob W.; Dubin, Celina; Han, Joseph; Dahabreh, Dante; Pavel, Ana B.; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, New York, NY 10029 USA; [Garcet, Sandra; Krueger, James G.] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rockefeller University	Pavel, AB (corresponding author), Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA.; Pavel, AB (corresponding author), Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, New York, NY 10029 USA.	ana.pavel@mssm.edu; emma.guttman@mountsinai.org		, Ana Brandusa/0000-0002-8155-8553; Garcet, Sandra/0000-0002-4465-8547				Bissonnette R, 2019, J ALLERGY CLIN IMMUN, V144, P1274, DOI 10.1016/j.jaci.2019.06.047; Brunner PM, 2019, J ALLERGY CLIN IMMUN, V143, P142, DOI 10.1016/j.jaci.2018.07.028; Brunner PM, 2016, J ALLERGY CLIN IMMUN, V138, P169, DOI 10.1016/j.jaci.2015.12.1323; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V143, P155, DOI 10.1016/j.jaci.2018.08.022; Khattri S, 2017, EXP DERMATOL, V26, P28, DOI 10.1111/exd.13112; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Pavel AB, 2019, J ALLERGY CLIN IMMUN, V144, P1011, DOI 10.1016/j.jaci.2019.07.013; Sawyer LM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220868; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042	9	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2020	145	4					1285	1288		10.1016/j.jaci.2020.01.005	http://dx.doi.org/10.1016/j.jaci.2020.01.005			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LA0FR	31954776	Bronze			2022-12-18	WOS:000523633400024
J	Mobus, L; Weidinger, S; Emmert, H				Moebus, Lena; Weidinger, Stephan; Emmert, Hila			Epigenetic factors involved in the pathophysiology of inflammatory skin diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Inflammatory skin disease; psoriasis; atopic dermatitis; methylation; epigenetics; cutaneous lupus erythematosus; oral lichen planus; urticaria	THYMIC STROMAL LYMPHOPOIETIN; CHILDHOOD ATOPIC-DERMATITIS; GENOME-WIDE ASSOCIATION; ORAL LICHEN-PLANUS; CD4+ T-CELLS; DNA METHYLATION; S100 PROTEINS; PROMOTER DEMETHYLATION; PSORIATIC EPIDERMIS; HLA-C	Epigenetics has been discussed as a potential factor influencing the pathophysiology and severity of inflammatory skin diseases. In recent years, emerging evidence suggests that epigenetic mechanisms are involved in the pathophysiology of not only atopic dermatitis (AD) and psoriasis (PSO) but also lupus erythematosus and oral lichen. A systematic review of the literature was undertaken to provide an unbiased and comprehensive update on the involvement of methylation patterns in inflammatory skin disease. In addition to reviewing the contribution of epigenetic mechanisms regulating the development of inflammatory skin diseases, this review aimed to discern the overlap of epigenetic risk factors of the 2 most common inflammatory skin diseases, AD and PSO. Although AD and PSO are both inflammatory skin diseases, both show a distinct genetic profile. Herein, we give evidence that both AD and PSO share epigenetic risk factors that might contribute to disease characteristics. We identify a core subset of inflammation-associated differentially methylated genes in both AD and PSO and discuss the association in other inflammatory diseases.	[Moebus, Lena; Weidinger, Stephan; Emmert, Hila] Univ Hosp Schleswig Holstein, Dept Dermatol & Allergy, Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Emmert, H (corresponding author), Christian Albrechts Univ Kiel, Dermatol, Arnold Heller Str 3, D-24105 Kiel, Germany.	hemmert@dermatology.uni-kiel.de	Emmert, Hila/AAT-1086-2020	Emmert, Hila/0000-0002-7051-7350; Mobus, Lena/0000-0003-0685-0893	Deutsche Forschungsgemeinschaft (DFG) [GE 2879/2-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	L. Mobus received a Deutsche Forschungsgemeinschaft (DFG) grant (grant no. GE 2879/2-1). S. Weidinger is co-principal investigator of the German Atopic Eczema Registry TREATgermany; has received institutional research grants from Novartis, Pfizer, and L'Oreal; has performed consultancies for Sanofi-Genzyme, Regeneron, LEO Pharma, Incyte, and Novartis; has also lectured at educational events sponsored by Sanofi-Genzyme, Regeneron, LEO Pharma, AbbVie, and Galderma; and is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic eczema. H. Emmert received grants from LEO Pharma.	Bai J, 2015, J IMMUNOL, V194, P4185, DOI 10.4049/jimmunol.1403196; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P30; Barrea L, 2016, INT J ENV RES PUB HE, V13; Bartsch S, 2017, CAMBRIDGE COMPANION TO THE AGE OF NERO, P1, DOI 10.1111/cea.12988; Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10; Bernstein JA, 2014, J ALLERGY CLIN IMMUN, V133, P1270, DOI 10.1016/j.jaci.2014.02.036; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Boothe WD, 2017, ADV EXP MED BIOL, V1027, P21, DOI 10.1007/978-3-319-64804-0_3; Carvalho-Silva D, 2019, NUCLEIC ACIDS RES, V47, pD1056, DOI 10.1093/nar/gky1133; Chandra A, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0541-9; Chen M, 2008, BRIT J DERMATOL, V158, P987, DOI 10.1111/j.1365-2133.2008.08505.x; Chen M, 2016, J DERMATOL SCI, V83, P10, DOI 10.1016/j.jdermsci.2016.04.003; Chen W, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.190; Cho HJ, 2019, J ALLERGY CLIN IMMUN, V143, P1215, DOI 10.1016/j.jaci.2018.10.010; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Cruz AF, 2018, J ORAL PATHOL MED, V47, P91, DOI 10.1111/jop.12645; Dand N, 2017, HUM MOL GENET, V26, P4301, DOI 10.1093/hmg/ddx328; Dang J, 2013, J ORAL PATHOL MED, V42, P315, DOI 10.1111/jop.12012; Deng YX, 2016, CLIN REV ALLERG IMMU, V50, P377, DOI 10.1007/s12016-016-8535-x; Desai A, 2016, J ALLERGY CLIN IMMUN, V137, P1863, DOI 10.1016/j.jaci.2015.09.059; Di Meglio P, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a015354; Eckert RL, 2004, J INVEST DERMATOL, V123, P23, DOI 10.1111/j.0022-202X.2004.22719.x; Emberley ED, 2004, BIOCHEM CELL BIOL, V82, P508, DOI 10.1139/O04-052; Ferreira MA, 2017, NAT GENET, V49, P1752, DOI 10.1038/ng.3985; Fujita H, 2011, J ALLERGY CLIN IMMUN, V128, P574, DOI 10.1016/j.jaci.2011.05.016; Gao MH, 2018, EXP DERMATOL, V27, P1112, DOI 10.1111/exd.13745; Gervin K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002454; Gu XL, 2016, SCI REP-UK, V6, DOI 10.1038/srep32579; Gu XL, 2015, J INVEST DERMATOL, V135, P2077, DOI 10.1038/jid.2015.128; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Han J, 2012, BIOCHEM BIOPH RES CO, V422, P157, DOI 10.1016/j.bbrc.2012.04.128; Hinz D, 2012, ALLERGY, V67, P380, DOI 10.1111/j.1398-9995.2011.02767.x; Hou RX, 2013, J DERMATOL SCI, V72, P103, DOI 10.1016/j.jdermsci.2013.07.002; Jang HS, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060148; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kim TH, 2010, INT IMMUNOPHARMACOL, V10, P1310, DOI 10.1016/j.intimp.2010.08.004; Kolkhir P, 2017, J ALLERGY CLIN IMMUN, V139, P1772, DOI 10.1016/j.jaci.2016.08.050; Li QW, 2018, J AUTOIMMUN, V93, P1, DOI 10.1016/j.jaut.2018.07.007; Liang Y, 2012, ALLERGY, V67, P424, DOI 10.1111/j.1398-9995.2011.02760.x; Lima XT, 2013, J EUR ACAD DERMATOL, V27, P680, DOI 10.1111/j.1468-3083.2012.04531.x; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Luo Y, 2008, BRIT J DERMATOL, V159, P827, DOI 10.1111/j.1365-2133.2008.08758.x; Luo Y, 2014, CLIN EXP DERMATOL, V39, P48, DOI 10.1111/ced.12206; Luo Y, 2010, CLIN EXP DERMATOL, V35, P425, DOI 10.1111/j.1365-2230.2009.03611.x; Luo YQ, 2009, J DERMATOL SCI, V56, P33, DOI 10.1016/j.jdermsci.2009.06.010; Mathur AN, 2007, J IMMUNOL, V178, P4901, DOI 10.4049/jimmunol.178.8.4901; Minskaia E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02540; Misery L, 2014, M S-MED SCI, V30, P142, DOI 10.1051/medsci/20143002009; Miyagaki T, 2015, J DERMATOL SCI, V78, P89, DOI 10.1016/j.jdermsci.2015.02.010; Mollanazar NK, 2016, CLIN REV ALLERG IMMU, V51, P263, DOI 10.1007/s12016-015-8488-5; Moran Timothy P, 2014, Pediatrics, V134 Suppl 3, pS160, DOI 10.1542/peds.2014-1817VV; Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311; Nair RP, 2006, AM J HUM GENET, V78, P827, DOI 10.1086/503821; Nakamura T, 2006, ARCH DERMATOL RES, V298, P253, DOI 10.1007/s00403-006-0682-0; Nemeth CG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215055; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Noh YH, 2018, ANIM CELLS SYST, V22, P172, DOI 10.1080/19768354.2018.1458652; Nutten S, 2015, ANN NUTR METAB, V66, P8, DOI 10.1159/000370220; Ogasawara H, 2003, CLIN EXP RHEUMATOL, V21, P733; Park GT, 2014, ARCH DERMATOL RES, V306, P259, DOI 10.1007/s00403-013-1432-8; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Pollock RA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212043; Pollock RA, 2017, J AUTOIMMUN, V78, P29, DOI 10.1016/j.jaut.2016.12.002; Quraishi BM, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0108-y; Rangel SM, 2018, CLIN DERMATOL, V36, P641, DOI 10.1016/j.clindermatol.2018.05.005; Renauer P, 2015, LUPUS SCI MED, V2, DOI 10.1136/lupus-2015-000101; Roberson EDO, 2012, J INVEST DERMATOL, V132, P583, DOI 10.1038/jid.2011.348; Rodriguez E, 2014, J INVEST DERMATOL, V134, P1873, DOI 10.1038/jid.2014.87; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Roopashree MR, 2010, J ORAL PATHOL MED, V39, P729, DOI 10.1111/j.1600-0714.2010.00946.x; Roth J, 2003, TRENDS IMMUNOL, V24, P155, DOI 10.1016/S1471-4906(03)00062-0; Ruchusatsawat K, 2006, J MOL MED, V84, P175, DOI 10.1007/s00109-005-0020-6; Ruchusatsawat K, 2017, ASIAN PAC J ALLERGY, V35, P86, DOI 10.12932/AP0818; Ruchusatsawat K, 2011, HUM PATHOL, V42, P1878, DOI 10.1016/j.humpath.2011.02.005; SCOTT IR, 1986, DEV BIOL, V115, P84, DOI 10.1016/0012-1606(86)90230-7; Sekigawa I, 2003, LUPUS, V12, P79, DOI 10.1191/0961203303lu321oa; Shabani F, 2018, INFLAMM RES, V67, P801, DOI 10.1007/s00011-018-1173-4; Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354; Stannard JN, 2016, CURR OPIN RHEUMATOL, V28, P453, DOI 10.1097/BOR.0000000000000308; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Tang LL, 2018, J DERMATOL SCI, V91, P285, DOI 10.1016/j.jdermsci.2018.06.001; Thurmann L, 2018, J ALLERGY CLIN IMMUN, V141, P1482, DOI 10.1016/j.jaci.2017.11.018; Tsakok T, 2019, BRIT J DERMATOL, V180, P464, DOI 10.1111/bjd.16934; Uysal P, 2017, CLIN LAB, V63, P1071, DOI 10.7754/Clin.Lab.2017.161107; Verma D, 2018, J INVEST DERMATOL, V138, P1088, DOI 10.1016/j.jid.2017.11.036; Wang IJ, 2013, CLIN EXP ALLERGY, V43, P535, DOI 10.1111/cea.12108; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Weidinger S, 2013, HUM MOL GENET, V22, P4841, DOI 10.1093/hmg/ddt317; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Wilsmann-Theis D, 2016, J EUR ACAD DERMATOL, V30, P1165, DOI 10.1111/jdv.13269; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Yooyongsatit S, 2015, J HUM GENET, V60, P349, DOI 10.1038/jhg.2015.33; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang P, 2013, J AUTOIMMUN, V41, P17, DOI 10.1016/j.jaut.2013.01.001; Zhang P, 2010, J DERMATOL SCI, V60, P40, DOI 10.1016/j.jdermsci.2010.07.011; Zhou FS, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0297-z; ZHOU Z, 1995, IMMUNOL LETT, V45, P67, DOI 10.1016/0165-2478(94)00227-I; Ziyab AH, 2013, J EUR ACAD DERMATOL, V27, pe420, DOI 10.1111/jdv.12000; Zong WK, 2017, ONCOTARGET, V8, P12323, DOI 10.18632/oncotarget.12468	104	12	12	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2020	145	4					1049	1060		10.1016/j.jaci.2019.10.015	http://dx.doi.org/10.1016/j.jaci.2019.10.015			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LA0FR	32272981	Bronze			2022-12-18	WOS:000523633400002
J	Sordillo, JE; Coull, BA; Rifas-Shiman, SL; Wu, AC; Lutz, SM; Hivert, MF; Oken, E; Gold, DR				Sordillo, Joanne E.; Coull, Brent A.; Rifas-Shiman, Sheryl L.; Wu, Ann Chen; Lutz, Sharon M.; Hivert, Marie-France; Oken, Emily; Gold, Diane R.			Characterization of longitudinal wheeze phenotypes from infancy to adolescence in Project Viva, a prebirth cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHILDHOOD WHEEZE		[Sordillo, Joanne E.; Rifas-Shiman, Sheryl L.; Hivert, Marie-France; Oken, Emily] Harvard Med Sch, Div Chron Dis Res Lifecourse CoRAL, Boston, MA 02115 USA; [Wu, Ann Chen; Lutz, Sharon M.] Harvard Med Sch, Precis Med Translat Res PROMoTeR Ctr, Dept Populat Med, Boston, MA 02115 USA; Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Coull, Brent A.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Gold, Diane R.] Harvard T H Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Gold, Diane R.] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sordillo, JE (corresponding author), Harvard Med Sch, Div Chron Dis Res Lifecourse CoRAL, Boston, MA 02115 USA.	redrg@channing.harvard.edu	Wu, Ann/AAY-4293-2020; Hivert, Marie-France/GWN-0455-2022	Wu, Ann/0000-0003-0599-9063; 	National Institutes of Health (NIH) [R01AI102960, UH3OD023286, R01HD085993, R01HD034568]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by National Institutes of Health (NIH) grants R01AI102960, UH3OD023286, R01HD085993, and R01HD034568.	Bonnelykke K, 2018, AM J RESP CRIT CARE, V197, P589, DOI 10.1164/rccm.201705-1021OC; Chen QX, 2012, ANN ALLERG ASTHMA IM, V108, P311, DOI 10.1016/j.anai.2012.02.016; Neuman A, 2014, PEDIAT ALLERG IMM-UK, V25, P380, DOI 10.1111/pai.12223; Oken E, 2015, INT J EPIDEMIOL, V44, P37, DOI 10.1093/ije/dyu008; Oksel C, 2019, ANN AM THORAC SOC, V16, P868, DOI 10.1513/AnnalsATS.201811-837OC; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Schmiedel BJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13426; Tse SM, 2016, J ALLERGY CLIN IMMUN, V138, P1561, DOI 10.1016/j.jaci.2016.04.005; Vicente CT, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.54	9	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2020	145	2					716	+		10.1016/j.jaci.2019.10.026	http://dx.doi.org/10.1016/j.jaci.2019.10.026			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK6ZG	31705908	Green Accepted, Bronze			2022-12-18	WOS:000512887400036
J	Santos, AF; James, LK; Kwok, M; McKendry, RT; Anagnostou, K; Clark, AT; Lack, G				Santos, Alexandra F.; James, Louisa K.; Kwok, Matthew; McKendry, Richard T.; Anagnostou, Katherine; Clark, Andrew T.; Lack, Gideon			Peanut oral immunotherapy induces blocking antibodies but does not change the functional characteristics of peanut-specific IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BASOPHIL; ALLERGY; CELLS		[Santos, Alexandra F.; Kwok, Matthew; McKendry, Richard T.; Lack, Gideon] Kings Coll London, Sch Life Course Sci, Dept Women & Childrens Hlth Paediat Allergy, London, England; [Santos, Alexandra F.; Kwok, Matthew; McKendry, Richard T.; Lack, Gideon] Kings Coll London, Sch Immunol & Microbial Sci, Peter Gorer Dept Immunobiol, London, England; [Santos, Alexandra F.; Lack, Gideon] Guys & St Thomas Hosp, Evelina London Childrens Hosp, Childrens Allergy Serv, London, England; [Santos, Alexandra F.; Kwok, Matthew; McKendry, Richard T.] Asthma UK Ctr Allerg Mech Asthma, London, England; [James, Louisa K.] Queen Mary Univ London, Blizard Inst, London, England; [Anagnostou, Katherine] Baylor Coll Med, Sect Pediat Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [Anagnostou, Katherine] Texas Childrens Hosp, Dept Pediat, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [Clark, Andrew T.] Addenbrookes Hosp, Cambridge Univ Hosp NHS Fdn Trust, Dept Allergy, Cambridge, England	University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; Queen Mary University London; Baylor College of Medicine; Baylor College of Medicine; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Santos, AF (corresponding author), Kings Coll London, Sch Life Course Sci, Dept Women & Childrens Hlth Paediat Allergy, London, England.; Santos, AF (corresponding author), Kings Coll London, Sch Immunol & Microbial Sci, Peter Gorer Dept Immunobiol, London, England.; Santos, AF (corresponding author), Guys & St Thomas Hosp, Evelina London Childrens Hosp, Childrens Allergy Serv, London, England.; Santos, AF (corresponding author), Asthma UK Ctr Allerg Mech Asthma, London, England.	alexandra.santos@kcl.ac.uk	James, Louisa/C-9831-2010	James, Louisa/0000-0002-2252-4636; Santos, Alexandra/0000-0002-7805-1436; Anagnostou, Aikaterini/0000-0001-6240-7437; Lack, Gideon/0000-0001-7350-4021	Medical Research Council (MRC Clinical Research Training Fellowship) [G090218]; Medical Research Council (MRC Clinician Scientist Fellowship) [MR/M008517/1]; Medical Research Council (MRC Centenary Early Career Award); Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award; King's College London; King's College Hospital NHS Foundation Trust; MRC [G0902018, MR/M008517/1] Funding Source: UKRI	Medical Research Council (MRC Clinical Research Training Fellowship)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council (MRC Clinician Scientist Fellowship)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council (MRC Centenary Early Career Award)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award; King's College London; King's College Hospital NHS Foundation Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Medical Research Council (MRC Clinical Research Training Fellowship G090218, MRC Clinician Scientist Fellowship MR/M008517/1, and MRC Centenary Early Career Award awarded to A.F.S.) and the Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust.	Anagnostou K, 2011, CLIN EXP ALLERGY, V41, P1273, DOI 10.1111/j.1365-2222.2011.03699.x; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Chu DK, 2019, LANCET, V393, P2222, DOI 10.1016/S0140-6736(19)30420-9; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Nurmatov U, 2017, ALLERGY, V72, P1133, DOI 10.1111/all.13124; Ogasawara N, 2018, J ALLERGY CLIN IMMUN, V141, P1147, DOI 10.1016/j.jaci.2017.09.025; Orgel K, 2019, CLIN EXP ALLERGY, V49, P461, DOI 10.1111/cea.13305; Orlandi RR, 2016, INT FORUM ALLERGY RH, V6, pS22, DOI 10.1002/alr.21695; Poposki JA, 2015, CLIN EXP ALLERGY, V45, P384, DOI 10.1111/cea.12471; Poposki JA, 2017, IMMUN INFLAMM DIS, V5, P233, DOI 10.1002/iid3.161; Santos AF, 2018, J ALLERGY CLIN IMMUN, V142, P689, DOI 10.1016/j.jaci.2018.03.011; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Thyagarajan A, 2012, CLIN EXP ALLERGY, V42, P1197, DOI 10.1111/j.1365-2222.2012.04028.x; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007	17	12	12	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					440	+		10.1016/j.jaci.2019.09.005	http://dx.doi.org/10.1016/j.jaci.2019.09.005			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31676085				2022-12-18	WOS:000505590800049
J	Blumenthal, KG; Huebner, EM; Banerji, A; Long, AA; Gross, N; Kapoor, N; Blumenthal, DM				Blumenthal, Kimberly G.; Huebner, Emily M.; Banerji, Aleena; Long, Aidan A.; Gross, Nate; Kapoor, Neena; Blumenthal, Daniel M.			Sex differences in academic rank in allergy/immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; promotion; professor; disparity; sex; women; advancement	GENDER-DIFFERENCES; UNITED-STATES; FACULTY RANK; RESPONSIBILITIES; PHYSICIANS; SALARY; TRENDS; WOMEN	Background: Female physicians are significantly less likely than male physicians to be full professors, even after accounting for age, experience, specialty, and measures of research and clinical productivity. Objective: We sought to evaluate sex differences in academic rank in the allergy and immunology workforce. Methods: We used a cross-sectional physician data set containing the allergist's sex, age, years since residency, faculty appointment, authored publications, National Institutes of Health (NIH) funding, clinical trial investigation, and Medicare reimbursement to investigate sex differences in the academic allergy and immunology workforce using multilevel logistic regression models. Results: Among 507 academic allergists (9.3% of practicing US allergists in 2014), 323 (63.7%) were men, and 184 (36.3%) were women. Female allergists were younger (47.9 vs 56.9 years, P < .001), had fewer total (12.5 vs 28.7, P < .001) and first/last author (8.0 vs 21.5, P < .001) average publications, were less likely to have NIH funding (13.0% vs 23.5%, P = .004), were less frequently a clinical trial investigator (10.3% vs 16.1%, P = .07), and generated less average annual Medicare revenue ($44,000 vs $23,000, P = .10). Of 152 (30.0%) full professors, 126 (82.9%) were male, and 26 (17.0%) were female. After multivariable adjustment, rates of full professorship among female and male allergists were not significantly different (absolute adjusted difference for female vs male allergists, 6.0%; 95% CI, 28.3% to 20.2%). Conclusions: Among allergists with US medical school faculty appointments, men and women were similarly likely to be full professors after accounting for factors influencing promotion. Underlying differences in research productivity and NIH funding not explained by age differences alone warrant additional investigation.	[Blumenthal, Kimberly G.; Huebner, Emily M.; Banerji, Aleena; Long, Aidan A.] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA USA; [Blumenthal, Daniel M.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA USA; [Blumenthal, Kimberly G.; Banerji, Aleena; Kapoor, Neena; Blumenthal, Daniel M.] Harvard Med Sch, Boston, MA USA; [Huebner, Emily M.] Boston Univ, Div Grad Med Sci, Boston, MA USA; [Gross, Nate] Doximity, San Francisco, CA USA; [Kapoor, Neena] Brigham & Womens Hosp, Dept Radiol, Boston, MA USA; [Blumenthal, Daniel M.] Devoted Hlth, Waltham, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Boston University; Harvard University; Brigham & Women's Hospital	Blumenthal, KG (corresponding author), Massachusetts Gen Hosp, Mongan Inst, 100 Cambridge St,16th Floor, Boston, MA 02114 USA.	kblumenthal@mgh.harvard.edu	Blumenthal, Kimberly/AAG-8290-2019; Banerji, Aleena/ABG-1245-2021	Blumenthal, Kimberly/0000-0003-4773-9817; 				[Anonymous], 2019, UCSOM FUND RET CLIN; [Anonymous], 2018, EQ PAY COMP DISCR; [Anonymous], 2019, CLAFL DIST SCHOL AW; [Anonymous], 2019, EL MIL SHOR 50 ANN; [Anonymous], 2018, MED PROV UT PAYM DAT; [Anonymous], 2019, PIP PATHW LEAD 2015; [Anonymous], 2018, MEDSCAPE ALLERGIST C; Bennett CL, 2019, ACAD EMERG MED, V26, P281, DOI 10.1111/acem.13685; Blumenthal DM, 2018, ANN SURG, V268, P193, DOI 10.1097/SLA.0000000000002662; Blumenthal DM, 2017, CIRCULATION, V135, P506, DOI 10.1161/CIRCULATIONAHA.116.023520; Carr PL, 1998, ANN INTERN MED, V129, P532, DOI 10.7326/0003-4819-129-7-199810010-00004; CARR PL, 1993, ANN INTERN MED, V119, P908, DOI 10.7326/0003-4819-119-9-199311010-00008; Dorsey ER, 2003, JAMA-J AM MED ASSOC, V290, P1173, DOI 10.1001/jama.290.9.1173; Holliday E, 2015, J GEN INTERN MED, V30, P401, DOI 10.1007/s11606-014-2988-5; Jagsi R, 2013, ACAD MED, V88, P1689, DOI 10.1097/ACM.0b013e3182a71519; Jagsi R, 2012, JAMA-J AM MED ASSOC, V307, P2410, DOI 10.1001/jama.2012.6183; Jena AB, 2016, JAMA INTERN MED, V176, P1294, DOI 10.1001/jamainternmed.2016.3284; Jena AB, 2015, JAMA-J AM MED ASSOC, V314, P1149, DOI 10.1001/jama.2015.10680; Jolly S, 2014, ANN INTERN MED, V160, P344, DOI 10.7326/M13-0974; Kaplan SH, 1996, NEW ENGL J MED, V335, P1282, DOI 10.1056/NEJM199610243351706; Kapoor N, 2017, RADIOLOGY, V283, P140, DOI 10.1148/radiol.2016160950; Ly DP, 2018, MAYO CLIN PROC, V93, P1484, DOI 10.1016/j.mayocp.2018.02.018; Marshall GD, 2007, J ALLERGY CLIN IMMUN, V119, P802, DOI 10.1016/j.jaci.2007.01.040; Nonnemaker L, 2000, NEW ENGL J MED, V342, P399, DOI 10.1056/NEJM200002103420606; Oliveira DFM, 2019, JAMA-J AM MED ASSOC, V321, P898, DOI 10.1001/jama.2018.21944; Reed DA, 2011, ACAD MED, V86, P43, DOI 10.1097/ACM.0b013e3181ff9ff2; Seabury SA, 2013, JAMA INTERN MED, V173, P1748; Sege R, 2015, JAMA-J AM MED ASSOC, V314, P1175, DOI 10.1001/jama.2015.8517; Shen Y, 2018, P INT C LEARNING REP, P1, DOI DOI 10.1101/275362; Shishkova E, 2017, J AM SOC MASS SPECTR, V28, P2523, DOI 10.1007/s13361-017-1803-z; Witteman HO, 2019, LANCET, V393, P531, DOI 10.1016/S0140-6736(18)32611-4	31	12	12	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2019	144	6					1697	+		10.1016/j.jaci.2019.06.026	http://dx.doi.org/10.1016/j.jaci.2019.06.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT0NR	31279008	Green Accepted, Bronze			2022-12-18	WOS:000500694900026
J	Noguchi, E; Akiyama, M; Yagami, A; Hirota, T; Okada, Y; Kato, Z; Kishikawa, R; Fukutomi, Y; Hide, M; Morita, E; Aihara, M; Hiragun, M; Chinuki, Y; Okabe, T; Ito, A; Adachi, A; Fukunaga, A; Kubota, Y; Aoki, T; Aoki, Y; Nishioka, K; Adachi, T; Kanazawa, N; Miyazawa, H; Sakai, H; Kozuka, T; Kitamura, H; Hashizume, H; Kanegane, C; Masuda, K; Sugiyama, K; Tokuda, R; Furuta, J; Higashimoto, I; Kato, A; Seishima, M; Tajiri, A; Tomura, A; Taniguchi, H; Kojima, H; Tanaka, H; Sakai, A; Morii, W; Nakamura, M; Kamatani, Y; Takahashi, A; Kubo, M; Tamari, M; Saito, H; Matsunaga, K				Noguchi, Emiko; Akiyama, Masato; Yagami, Akiko; Hirota, Tomomitsu; Okada, Yukinori; Kato, Zenichiro; Kishikawa, Reiko; Fukutomi, Yuma; Hide, Michihiro; Morita, Eishin; Aihara, Michiko; Hiragun, Makiko; Chinuki, Yuko; Okabe, Takahiro; Ito, Akiko; Adachi, Atsuko; Fukunaga, Atsushi; Kubota, Yumiko; Aoki, Toshiyuki; Aoki, Youko; Nishioka, Kazue; Adachi, Tetsuya; Kanazawa, Nobuo; Miyazawa, Hitoshi; Sakai, Hiroyuki; Kozuka, Takehito; Kitamura, Hideo; Hashizume, Hideo; Kanegane, Chiharu; Masuda, Koji; Sugiyama, Kumiya; Tokuda, Reiko; Furuta, Junichi; Higashimoto, Ikkou; Kato, Atsuko; Seishima, Mariko; Tajiri, Akihiko; Tomura, Atsuko; Taniguchi, Hiroko; Kojima, Hiroto; Tanaka, Hidenori; Sakai, Aiko; Morii, Wataru; Nakamura, Masashi; Kamatani, Yoichiro; Takahashi, Atsushi; Kubo, Michiaki; Tamari, Mayumi; Saito, Hirohisa; Matsunaga, Kayoko			HLA-DQ and RBFOX1 as susceptibility genes for an outbreak of hydrolyzed wheat allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hydrolyzed wheat protein; allergy; percutaneous; genome-wide association study; HLA; RBFOX1	PEANUT ALLERGY; FOOD ALLERGY; DISEASE; PROTEIN; ASSOCIATION; RISK; SENSITIZATION; VARIANTS; LOCI; SKIN	Background: Food allergy is a growing health problem worldwide because of its increasing prevalence, life-threatening potential, and shortage of effective preventive treatments. In an outbreak of wheat allergy in Japan, thousands of patients had allergic reactions to wheat after using soap containing hydrolyzed wheat protein (HWP). Objectives: The aim of the present study was to investigate genetic variation that can contribute to susceptibility to HWP allergy. Methods: We conducted a genome-wide association study of HWP allergy in 452 cases and 2700 control subjects using 6.6 million genotyped or imputed single nucleotide polymorphisms. Replication was assessed by genotyping single nucleotide polymorphisms in independent samples comprising 45 patients with HWP allergy and 326 control subjects. Results: Through the genome-wide association study, we identified significant associations with the class II HLA region on 6p21 (P = 2.16 X 10(-24) for rs9271588 and P = 2.96 X 10(-24) for HLA-DQ alpha 1 amino acid position 34) and with the RBFOX1 locus at 16p13 (rs74575857, P = 8.4 X 10(-9)). The associations were also confirmed in the replication data set. Both amino acid polymorphisms (HLA-DQ beta 1 amino acid positions 13 and 26) located in the P4 binding pockets on the HLA-DQ molecule achieved the genome-wide significance level (P < 5.0 X 10(-8) ). Conclusions: Our data provide the first demonstration of genetic risk for HWP allergy and show that this genetic risk is mainly represented by multiple combinations of HLA variants.	[Noguchi, Emiko; Morii, Wataru] Univ Tsukuba, Fac Med, Dept Med Genet, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan; [Akiyama, Masato; Kamatani, Yoichiro; Takahashi, Atsushi] RIKEN Ctr Integrat Med Sci, Lab Stat Anal, Yokohama, Kanagawa, Japan; [Akiyama, Masato] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Fukuoka, Japan; [Yagami, Akiko] Fujita Hlth Univ, Sch Med, Dept Allergol, Nagoya, Aichi, Japan; [Hirota, Tomomitsu; Tamari, Mayumi] RIKEN Ctr Integrat Med Sci, Lab Resp & Allerg Dis, Yokohama, Kanagawa, Japan; [Hirota, Tomomitsu; Tamari, Mayumi] Jikei Univ, Sch Med, Res Ctr Med Sci, Core Res Facil Basic Sci Mol Genet, Tokyo, Japan; [Okada, Yukinori] Osaka Univ, Grad Sch Med, Dept Stat Genet, Osaka, Japan; [Okada, Yukinori] Osaka Univ, Immunol Frontier Res Ctr WPI IFReC, Lab Stat Immunol, Osaka, Japan; [Kato, Zenichiro] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Struct Med, Gifu, Japan; [Kato, Zenichiro] Gifu Univ, Grad Sch Med, Dept Pediat, Gifu, Japan; [Kishikawa, Reiko] Natl Hosp Org Fukuoka Natl Hosp, Dept Allergol, Fukuoka, Fukuoka, Japan; [Fukutomi, Yuma] Natl Hosp Org Sagamihara Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan; [Hide, Michihiro; Hiragun, Makiko] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Dermatol, Hiroshima, Japan; [Morita, Eishin; Chinuki, Yuko] Shimane Univ, Fac Med, Dept Dermatol, Izumo, Shimane, Japan; [Aihara, Michiko] Yokohama City Univ, Sch Med, Dept Dermatol, Yokohama, Kanagawa, Japan; [Okabe, Takahiro] Okabe Allergy Clin, Fukuoka, Fukuoka, Japan; [Ito, Akiko] Niigata Univ, Med & Dent Hosp, Dept Dermatol, Niigata, Japan; [Adachi, Atsuko] Hyogo Prefectural Kakogawa Hosp, Dept Dermatol, Kakogawa, Hyogo, Japan; [Fukunaga, Atsushi] Kobe Univ, Grad Sch Med, Dept Internal Related, Div Dermatol, Kobe, Hyogo, Japan; [Kubota, Yumiko] Fukuoka Sanno Hosp, Dept Dermatol, Fukuoka, Fukuoka, Japan; [Aoki, Toshiyuki] Aoki Skin & Allergy Clin Itchy Skin Dis, Osaka, Japan; [Aoki, Youko] Aoki Dermatol, Miyazaki, Japan; [Nishioka, Kazue] Joy Dermatol Clin, Sanyo Onoda, Japan; [Adachi, Tetsuya] Musashino Allergy Clin, Tokyo, Japan; [Kanazawa, Nobuo] Wakayama Med Univ, Dept Dermatol, Wakayama, Japan; [Miyazawa, Hitoshi] Nishi Sapporo Skin & Allergy Clin, Sapporo, Hokkaido, Japan; [Sakai, Hiroyuki] Asahikawa City Hosp, Dept Dermatol, Asahikawa, Hokkaido, Japan; [Kozuka, Takehito] Hino Clin, Dermatol Sect, Sakai, Osaka, Japan; [Kitamura, Hideo] Aomori Prefectural Cent Hosp, Dept Dermatol, Aomori, Japan; [Hashizume, Hideo] Shimada Municipal Hosp, Dept Dermatol, Shimada, Japan; [Kanegane, Chiharu] Natl Hosp Org Toyama Hosp, Dept Allergy, Toyama, Japan; [Masuda, Koji] Kyoto Prefectural Univ Med, Dept Dermatol, Kyoto, Japan; [Sugiyama, Kumiya] Dokkyo Med Univ, Saitama Med Ctr, Dept Resp Med & Clin Immunol, Koshigaya, Japan; [Tokuda, Reiko] Natl Mie Hosp, Tsu, Mie, Japan; [Furuta, Junichi] Univ Tsukuba, Fac Med, Dept Dermatol, Tsukuba, Ibaraki, Japan; [Higashimoto, Ikkou] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Pulm Med, Kagoshima, Japan; [Kato, Atsuko] Osaka Kaisei Hosp, Dept Dermatol, Osaka, Japan; [Seishima, Mariko] Gifu Univ, Grad Sch Med, Dept Dermatol, Gifu, Japan; [Tajiri, Akihiko] Tajiri Dermatol Clin, Miyazaki, Japan; [Tomura, Atsuko] Tomura Clin Dermatol, Akita, Japan; [Taniguchi, Hiroko] Kudanzaka Hosp, Dept Dermatol, Tokyo, Japan; [Kojima, Hiroto; Tanaka, Hidenori] HLA Fdn Lab, Kyoto, Japan; [Sakai, Aiko] Univ Tsukuba, Fac Med, Dept Child Hlth, Tsukuba, Ibaraki, Japan; [Nakamura, Masashi; Matsunaga, Kayoko] Fujita Hlth Univ, Sch Med, Dept Integrat Med Sci Allerg Dis, Nagoya, Aichi, Japan; [Kamatani, Yoichiro] Kyoto Univ, Grad Sch Med, Kyoto McGill Int Collaborat Sch Genom Med, Kyoto, Japan; [Takahashi, Atsushi] Natl Cerebral & Cardiovas Ctr, Dept Genom Med, Res Inst, Osaka, Japan; [Kubo, Michiaki] RIKEN Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan; [Saito, Hirohisa] Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan	University of Tsukuba; RIKEN; Kyushu University; Fujita Health University; RIKEN; Jikei University; Osaka University; Osaka University; Gifu University; Gifu University; Hiroshima University; Shimane University; Yokohama City University; Niigata University; Kobe University; Wakayama Medical University; Kyoto Prefectural University of Medicine; Dokkyo Medical University; University of Tsukuba; Kagoshima University; Gifu University; University of Tsukuba; Fujita Health University; Kyoto University; RIKEN; National Center for Child Health & Development - Japan	Noguchi, E (corresponding author), Univ Tsukuba, Fac Med, Dept Med Genet, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan.; Matsunaga, K (corresponding author), Fujita Hlth Univ, Sch Med, Dept Integrat Med Sci Allerg Dis, Nakagawa Ku, 3-6-10 Otobashi, Nagoya, Aichi 4548509, Japan.; Saito, H (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Setagaya Ku, 2-10-1 Taishido, Tokyo 1578535, Japan.	enoguchi@md.tsukuba.ac.jp; saito-hr@ncchd.go.jp; kamatsu@fujita-hu.ac.jp	Hashizume, Hideo/AAL-9490-2020; Akiyama, Masato/AHC-2589-2022; Kanazawa, Nobuo/AAM-7353-2021; Fukutomi, Yuma/AFQ-4306-2022	Hashizume, Hideo/0000-0002-5809-0040; Kanazawa, Nobuo/0000-0003-3000-9711; Saito, Hirohisa/0000-0002-6630-8337; Ito, Akiko/0000-0002-6967-0710	AMED [15ek0410010h0002]; JSPS KAKENHI of the Japan Society for the Promotion of Science [17H05786]; BioBank Japan project by the Ministry of Education, Culture, Sports, Sciences and Technology of the Japanese government; BioBank Japan project by the Ministry of Education, Culture, Sports, Sciences and Technology of the Japan Agency for Medical Research and Development	AMED; JSPS KAKENHI of the Japan Society for the Promotion of Science; BioBank Japan project by the Ministry of Education, Culture, Sports, Sciences and Technology of the Japanese government(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); BioBank Japan project by the Ministry of Education, Culture, Sports, Sciences and Technology of the Japan Agency for Medical Research and Development	Supported in part by AMED grant number 15ek0410010h0002, JSPS KAKENHI grant number 17H05786 for a Grant-in-Aid for Scientific Research on Innovative Areas of the Japan Society for the Promotion of Science, and the BioBank Japan project by the Ministry of Education, Culture, Sports, Sciences and Technology of the Japanese government and the Japan Agency for Medical Research and Development.	Asai Y, 2018, J ALLERGY CLIN IMMUN, V141, P1513, DOI 10.1016/j.jaci.2017.10.047; Asai Y, 2018, J ALLERGY CLIN IMMUN, V141, P991, DOI 10.1016/j.jaci.2017.09.015; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Burnett C, 2018, INT J TOXICOL, V37, p55S, DOI 10.1177/1091581818776013; Catassi C, 2015, DIGEST DIS, V33, P141, DOI 10.1159/000369518; Christensen MJ, 2018, J ALLERGY CLIN IMMUN, V141, P802, DOI 10.1016/j.jaci.2017.09.016; Conboy JG, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1398; DeLano W. L, 2002, PYMOL MOL GENETICS G; Dubois PCA, 2010, NAT GENET, V42, P295, DOI 10.1038/ng.543; Ebisawa M, 2017, ALLERGOL INT, V66, P248, DOI 10.1016/j.alit.2017.02.001; Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003; Fukunaga M, 2018, J GASTROENTEROL, V53, P208, DOI 10.1007/s00535-017-1339-9; Fukutomi Y, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Fukutomi Y, 2011, J ALLERGY CLIN IMMUN, V127, P531, DOI 10.1016/j.jaci.2010.09.035; Gupta RS, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-1235; Gutierrez-Achury J, 2015, NAT GENET, V47, P577, DOI 10.1038/ng.3268; Henderson KN, 2007, IMMUNITY, V27, P23, DOI 10.1016/j.immuni.2007.05.015; Hirata J, 2018, J INVEST DERMATOL, V138, P542, DOI 10.1016/j.jid.2017.10.001; Hirata M, 2017, J EPIDEMIOL, V27, pS9, DOI 10.1016/j.je.2016.12.003; Hirota T, 2017, J ALLERGY CLIN IMMUN, V140, P1713, DOI 10.1016/j.jaci.2017.05.034; Ho MHK, 2014, CLIN REV ALLERG IMMU, V46, P225, DOI 10.1007/s12016-012-8339-6; Hong XM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7304; Ikeda N, 2015, TISSUE ANTIGENS, V85, P252, DOI 10.1111/tan.12536; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jia X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057858; Jin Y, 2003, EMBO J, V22, P905, DOI 10.1093/emboj/cdg089; Jones EY, 2006, NAT REV IMMUNOL, V6, P271, DOI 10.1038/nri1805; Kelleher MM, 2016, J ALLERGY CLIN IMMUN, V137, P1111, DOI 10.1016/j.jaci.2015.12.1312; Khor SS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18241-w; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Li J, 2015, J IMMUNOL, V195, P1599, DOI 10.4049/jimmunol.1402310; Marenholz I, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01220-0; Martino DJ, 2017, CLIN EXP ALLERGY, V47, P217, DOI 10.1111/cea.12863; Morii W, 2018, ALLERGOL INT, V67, P61, DOI 10.1016/j.alit.2017.04.004; Nagai A, 2017, J EPIDEMIOL, V27, pS2, DOI 10.1016/j.je.2016.12.005; Nakamura M, 2014, ALLERGOL INT, V63, P243, DOI 10.2332/allergolint.13-OA-0618; Okada Y, 2015, NAT GENET, V47, P798, DOI 10.1038/ng.3310; Sapone A, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-13; Solberg OD, 2008, HUM IMMUNOL, V69, P443, DOI 10.1016/j.humimm.2008.05.001; Valenti S, 2017, ANN MED, V49, P569, DOI 10.1080/07853890.2017.1325968; Venkataraman D, 2018, CLIN EXP ALLERGY, V48, P394, DOI 10.1111/cea.13088; Yagami A, 2017, J ALLERGY CLIN IMMUN, V140, P879, DOI 10.1016/j.jaci.2017.03.019	42	12	12	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1354	1363		10.1016/j.jaci.2019.06.034	http://dx.doi.org/10.1016/j.jaci.2019.06.034			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31301374	Bronze			2022-12-18	WOS:000495004700026
J	Shiba, T; Tanaka, T; Ida, H; Watanabe, M; Nakaseko, H; Osawa, M; Shibata, H; Izawa, K; Yasumi, T; Kawasaki, Y; Saito, MK; Takita, J; Heike, T; Nishikomori, R				Shiba, Takeshi; Tanaka, Takayuki; Ida, Hiroaki; Watanabe, Misa; Nakaseko, Haruna; Osawa, Mitsujiro; Shibata, Hirofumi; Izawa, Kazushi; Yasumi, Takahiro; Kawasaki, Yuri; Saito, Megumu K.; Takita, Junko; Heike, Toshio; Nishikomori, Ryuta			Functional evaluation of the pathological significance of MEFV variants using induced pluripotent stem cell-derived macrophages	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							FAMILIAL MEDITERRANEAN FEVER; MUTATIONS; ACTIVATION		[Shiba, Takeshi; Tanaka, Takayuki; Shibata, Hirofumi; Izawa, Kazushi; Yasumi, Takahiro; Takita, Junko; Heike, Toshio; Nishikomori, Ryuta] Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan; [Ida, Hiroaki] Kurume Univ, Sch Med, Dept Resp Neurol & Rheumatol, Fukuoka, Fukuoka, Japan; [Watanabe, Misa] Toho Univ, Sch Med, Dept Pediat, Tokyo, Japan; [Nakaseko, Haruna] Aichi Childrens Hlth & Med Ctr, Dept Infect & Immunol, Obu, Aichi, Japan; [Osawa, Mitsujiro; Kawasaki, Yuri; Saito, Megumu K.] Kyoto Univ, Dept Clin Applicat, Ctr iPS Cell Res & Applicat, Kyoto, Japan; [Heike, Toshio] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Pediat, Amagasaki, Hyogo, Japan	Kyoto University; Kurume University; Toho University; Kyoto University	Tanaka, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan.	tatanaka@kuhp.kyoto-u.ac.jp	Nishikomori, Ryuta/AAM-5771-2020	Nishikomori, Ryuta/0000-0002-9407-6158; Izawa, Kazushi/0000-0003-1080-0936; Yasumi, Takahiro/0000-0003-3257-5071	Japan Society for the Promotion of Science (JSPS) [17K16255, 15H04876, 17K10243]; Health Labor Sciences Research Grant for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan [H29-Nanchi-Ippan-020]; Core Center for iPS Cell Research of the Research Center Network for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development (AMED); Program for Intractable Diseases Research Utilizing Disease-Specific iPS Cells at AMED [17935423, 17935400, 15652065]; Practical Research Project for Rare/Intractable Diseases at AMED [17930095, 17929899]; iPS Cell Research Fund	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Health Labor Sciences Research Grant for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan; Core Center for iPS Cell Research of the Research Center Network for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Program for Intractable Diseases Research Utilizing Disease-Specific iPS Cells at AMED; Practical Research Project for Rare/Intractable Diseases at AMED; iPS Cell Research Fund	Supported by a Grant-in-Aid for Young Scientists (17K16255 to T.T.) and a Grant-in-Aid for Scientific Research (15H04876 to R.N. and 17K10243 to Y.K. and M.K.S.) from the Japan Society for the Promotion of Science (JSPS); a Health Labor Sciences Research Grant for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan (H29-Nanchi-Ippan-020 to R.N.); a grant from the Core Center for iPS Cell Research of the Research Center Network for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development (AMED; to M.K.S.); a grant from the Program for Intractable Diseases Research Utilizing Disease-Specific iPS Cells at AMED (17935423 and 17935400 to M.O. and M.K.S. and 15652065 to M.K.S.); a grant from the Practical Research Project for Rare/Intractable Diseases at AMED (17930095 and 17929899 to M.K.S.); and a grant from the iPS Cell Research Fund (to M.K.S.).	Chae JJ, 2011, IMMUNITY, V34, P755, DOI 10.1016/j.immuni.2011.02.020; De Benedetti F, 2018, NEW ENGL J MED, V378, P1908, DOI 10.1056/NEJMoa1706314; Gaidt MM, 2016, IMMUNITY, V44, P833, DOI 10.1016/j.immuni.2016.01.012; Gangemi S, 2018, CLIN GENET, V94, P81, DOI 10.1111/cge.13223; Jamilloux Y, 2018, RHEUMATOLOGY, V57, P100, DOI 10.1093/rheumatology/kex373; Kishida D, 2018, RHEUMATOL INT, V38, P105, DOI 10.1007/s00296-017-3886-z; Park YH, 2016, NAT IMMUNOL, V17, P914, DOI 10.1038/ni.3457; Stoffels M, 2014, ANN RHEUM DIS, V73, P455, DOI 10.1136/annrheumdis-2012-202580; Van Gorp H, 2016, P NATL ACAD SCI USA, V113, P14384, DOI 10.1073/pnas.1613156113	9	12	12	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1438	+		10.1016/j.jaci.2019.07.039	http://dx.doi.org/10.1016/j.jaci.2019.07.039			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31542286	Green Submitted, Bronze			2022-12-18	WOS:000495004700040
J	Yanez, DC; Lau, CI; Chawda, MM; Ross, S; Furmanski, AL; Crompton, T				Yanez, Diana C.; Lau, Ching-In; Chawda, Mira Manilal; Ross, Susan; Furmanski, Anna L.; Crompton, Tessa			Hedgehog signaling promotes T(H)2 differentiation in naive human CD4 T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ACTIVATION		[Yanez, Diana C.; Lau, Ching-In; Chawda, Mira Manilal; Ross, Susan; Furmanski, Anna L.; Crompton, Tessa] UCL Great Ormond St Inst Child Hlth, London, England; [Yanez, Diana C.] Univ San Francisco Quito, Sch Med, Quito, Ecuador; [Furmanski, Anna L.] Univ Bedfordshire, Sch Life Sci, Luton, Beds, England	University of London; University College London; University of Bedfordshire	Crompton, T (corresponding author), UCL Great Ormond St Inst Child Hlth, London, England.	t.crompton@ucl.ac.uk		Furmanski, Anna/0000-0001-6126-8770; Crompton, Tessa/0000-0002-8973-4021	MRC; Wellcome Trust; Great Ormond Street Children's Charity; Pfizer; SENESCYT; Asthma UK; NIHR BRC at Great Ormond Street Hospital; MRC [MR/P000843/1] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Great Ormond Street Children's Charity; Pfizer(Pfizer); SENESCYT; Asthma UK; NIHR BRC at Great Ormond Street Hospital; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This research was funded by grants from the MRC, Wellcome Trust, Great Ormond Street Children's Charity, and an investigator-initiated grant from Pfizer. D.C.Y. received a fellowship from SENESCYT, and A.L.F. received a fellowship from Asthma UK. Research at the UCL Great Ormond Street Institute of Child Health is supported by the NIHR BRC at Great Ormond Street Hospital.	Furmanski AL, 2013, J IMMUNOL, V190, P2641, DOI 10.4049/jimmunol.1202541; Gutierrez-Frias C, 2004, J IMMUNOL, V173, P5046, DOI 10.4049/jimmunol.173.8.5046; Li XN, 2011, J ALLERGY CLIN IMMUN, V127, P1457, DOI 10.1016/j.jaci.2011.01.056; Munchhof MJ, 2012, ACS MED CHEM LETT, V3, P106, DOI 10.1021/ml2002423; Rowbotham NJ, 2007, BLOOD, V109, P3757, DOI 10.1182/blood-2006-07-037655; Standing ASI, 2017, J LEUKOCYTE BIOL, V102, P965, DOI 10.1189/jlb.3HI1016-438RR; Stewart GA, 2002, J IMMUNOL, V169, P5451, DOI 10.4049/jimmunol.169.10.5451; Xu CY, 2018, MUCOSAL IMMUNOL, V11, P1306, DOI 10.1038/s41385-018-0033-4; Yanez DC, 2019, EUR J IMMUNOL, V49, P66, DOI 10.1002/eji.201847692	9	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1419	+		10.1016/j.jaci.2019.07.011	http://dx.doi.org/10.1016/j.jaci.2019.07.011			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31351102	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000495004700034
J	Kim, HJ; Ahn, HS; Kang, T; Bachert, C; Song, WJ				Kim, Hyun Jung; Ahn, Hyeong Sik; Kang, Taeuk; Bachert, Claus; Song, Woo-Jung			Nasal polyps and future risk of head and neck cancer: A nationwide population-based cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nasal polyps; head and neck cancer; paranasal sinus neoplasms; nasopharyngeal neoplasms; cancer risk	CHRONIC RHINOSINUSITIS; NASOPHARYNGEAL CARCINOMA; PREVALENCE; MORTALITY; CAVITY	Background: Nasal polyps are a common condition with a significant effect on quality of life. The association between nasal polyps and future risk of head and neck cancer is unknown. Objective: We sought to investigate the relative risk of nasal cavity and paranasal sinus (NCPS) and nasopharyngeal cancers in a nationwide, population-based, longitudinal retrospective cohort of patients with nasal polyps and matched comparators. Methods: The 2005-2017 National Health Insurance claims and National Health Screening program databases were used to construct a cohort of patients with nasal polyps and matched comparators in Korea. The relative risk of NCPS and nasopharyngeal cancer in patients with nasal polyps was examined. Results: The study consisted of 453,892 patients with nasal polyps and 4,583,938 matched comparators. The mean duration of follow-up was 6.2 years (range, 2-13 years). The incidence rate ratios of patients with nasal polyps compared with the comparators was 7.00 (95% CI, 5.28-9.25) for NCPS cancer and 1.78 (95% CI, 1.28-2.42) for nasopharyngeal cancer. Increased risks of these cancers were only evident in older subjects (age >= 50 years). There were trends toward weaker associations of nasal polyps with these cancers in younger subjects with comorbid asthma or allergic rhinitis (<50 years). Conclusion: Although the absolute cancer incidence is very low, the relative risk of NCPS or nasopharyngeal cancers was significantly greater in older patients with nasal polyps. Given the regional and pathologic heterogeneity of nasal polyps, further studies are needed to explore the underlying mechanisms and validate the relationships.	[Kim, Hyun Jung; Ahn, Hyeong Sik] Korea Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; [Kang, Taeuk] Natl Hlth Insurance Policy Res Inst, Seoul, South Korea; [Bachert, Claus] Ghent Univ Hosp, Upper Airways Res Lab, Ghent, Belgium; [Song, Woo-Jung] Univ Ulsan, Asan Med Ctr, Dept Internal Med, Div Allergy & Clin Immunol,Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea	Korea University; Korea University Medicine (KU Medicine); Ghent University; Ghent University Hospital; University of Ulsan	Song, WJ (corresponding author), Univ Ulsan, Asan Med Ctr, Dept Internal Med, Div Allergy & Clin Immunol,Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea.	swj0126@amc.seoul.kr	Bachert, Claus/J-8825-2012	Song, Woo-Jung/0000-0002-4630-9922; kang, taeuk/0000-0003-1467-2281				Bachert C, 2015, J ALLERGY CLIN IMMUN, V136, P1431, DOI 10.1016/j.jaci.2015.10.010; Beachler DC, 2017, JAMA OTOLARYNGOL, V143, P25, DOI 10.1001/jamaoto.2016.2624; Bossi P, 2016, CRIT REV ONCOL HEMAT, V98, P45, DOI 10.1016/j.critrevonc.2015.09.009; BRINTON LA, 1984, AM J EPIDEMIOL, V119, P896, DOI 10.1093/oxfordjournals.aje.a113812; Chua MLK, 2016, LANCET, V387, P1012, DOI 10.1016/S0140-6736(15)00055-0; FUKUDA K, 1988, CANCER RES, V48, P1651; Ho J, 2018, AM J RHINOL ALLERGY, V32, P252, DOI 10.1177/1945892418779451; Jensen-Jarolim E, 2017, ALLERGY, V72, P866, DOI 10.1111/all.13119; Johansson L, 2003, ANN OTO RHINOL LARYN, V112, P625, DOI 10.1177/000348940311200709; Klossek JM, 2005, ALLERGY, V60, P233, DOI 10.1111/j.1398-9995.2005.00688.x; Pourang D, 2018, ANN ALLERG ASTHMA IM, V120, P439, DOI 10.1016/j.anai.2018.01.007; Shin SH, 2017, AM J RHINOL ALLERGY, V31, P168, DOI 10.2500/ajra.2017.31.4423; Slavin RG, 1997, JAMA-J AM MED ASSOC, V278, P1849, DOI 10.1001/jama.278.22.1849; Tang LL, 2016, CANCER LETT, V374, P22, DOI 10.1016/j.canlet.2016.01.040; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Tsou YA, 2014, AM J RHINOL ALLERGY, V28, pE168, DOI 10.2500/ajra.2014.28.4083; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; Won HK, 2018, ANN ALLERG ASTHMA IM, V120, P389, DOI 10.1016/j.anai.2018.02.005; Wu EL, 2017, INT FORUM ALLERGY RH, V7, P786, DOI 10.1002/alr.21956; Xiao XL, 2018, AM J EPIDEMIOL, V187, P2117, DOI 10.1093/aje/kwy095; Youlden DR, 2013, CANCER EPIDEMIOL, V37, P770, DOI 10.1016/j.canep.2013.09.014; YU MC, 1990, INT J CANCER, V45, P1033, DOI 10.1002/ijc.2910450609; Zhang Y, 2017, J ALLERGY CLIN IMMUN, V140, P1230, DOI 10.1016/j.jaci.2017.09.009; ZHENG W, 1992, INT J CANCER, V52, P557, DOI 10.1002/ijc.2910520410	24	12	12	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2019	144	4					1004	+		10.1016/j.jaci.2019.06.024	http://dx.doi.org/10.1016/j.jaci.2019.06.024			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB8FZ	31279013				2022-12-18	WOS:000488803900016
J	Apter, AJ; Localio, AR; Morales, KH; Han, XY; Perez, L; Mullen, AN; Rogers, M; Klusaritz, H; Howell, JT; Canales, MN; Bryant-Stephens, T				Apter, Andrea J.; Localio, A. Russell; Morales, Knashawn H.; Han, Xiaoyan; Perez, Luzmercy; Mullen, Alyssa N.; Rogers, Marisa; Klusaritz, Heather; Howell, John T.; Canales, Maryori N.; Bryant-Stephens, Tyra			Home visits for uncontrolled asthma among low-income adults with patient portal access	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; patient portal; community health worker; electronic health record; information technology; health disparities	COMMUNITY-HEALTH WORKERS; QUESTIONNAIRE; VALIDATION; DISPARITIES; LITERACY; BARRIERS; OUTCOMES; VIOLENCE	Background: Asthma disproportionately affects low-income and minority adults. In an era of electronic records and Internet-based digital devices, it is unknown whether portals for patient-provider communication can improve asthma outcomes. Objective: We sought to estimate the effect on asthma outcomes of an intervention using home visits (HVs) by community health workers (CHWs) plus training in patient portals compared with usual care and portal training only. Methods: Three hundred one predominantly African American and Hispanic/Latino adults with uncontrolled asthma were recruited from primary care and asthma specialty practices serving low-income urban neighborhoods, directed to Internet access, and given portal training. Half were randomized to HVs over 6 months by CHWs to facilitate competency in portal use and promote care coordination. Results: One hundred seventy (56%) patients used the portal independently. Rates of portal activity did not differ between randomized groups. Asthma control and asthma-related quality of life improved in both groups over 1 year. Differences in improvements over time were greater for the HV group for all outcomes but reached conventional levels of statistical significance only for the yearly hospitalization rate (-0.53; 95% CI, -1.08 to -0.024). Poor neighborhoods and living conditions plus limited Internet access were barriers for patients to complete the protocol and for CHWs to make HVs. Conclusion: For low-income adults with uncontrolled asthma, portal access and CHWs produced small incremental benefits. HVs with emphasis on self-management education might be necessary to facilitate patient-clinician communication and to improve asthma outcomes.	[Apter, Andrea J.; Perez, Luzmercy] Univ Penn, Perelman Sch Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA; [Apter, Andrea J.; Rogers, Marisa] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA; [Localio, A. Russell; Morales, Knashawn H.; Han, Xiaoyan] Univ Penn, Perelman Sch Med, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA; [Klusaritz, Heather] Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA; [Apter, Andrea J.; Rogers, Marisa; Klusaritz, Heather; Howell, John T.] Univ Penn Hlth Syst, Philadelphia, PA USA; [Mullen, Alyssa N.] Temple Univ Hlth Syst, Temple Phys, Philadelphia, PA USA; [Canales, Maryori N.; Bryant-Stephens, Tyra] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Apter, AJ (corresponding author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.	andrea.apter@uphs.upenn.edu	han, xiao/HDN-9782-2022	Perez, Luzmercy/0000-0002-1423-7901	Patient-Centered Outcomes Research Institute (PCORI) [AS 1307-05218]; National Heart, Lung, and Blood Institute/National Institutes of Health [R18 HL116285]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R18HL116285, R01HL143364] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR065577] Funding Source: NIH RePORTER	Patient-Centered Outcomes Research Institute (PCORI)(Patient-Centered Outcomes Research Institute - PCORI); National Heart, Lung, and Blood Institute/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Research reported in this article was funded through a Patient-Centered Outcomes Research Institute (PCORI) award (AS 1307-05218) as a response to its funding announcement "Treatment Options for African Americans and Hispanic/Latinos with Uncontrolled Asthma.'' A.J.A., K.H.M., X.H., L.P., and H.K. also have received support from the National Heart, Lung, and Blood Institute/National Institutes of Health (R18 HL116285).	Akinbami Lara J, 2012, NCHS Data Brief, P1; Alosh M, 2017, STAT MED, V36, P1334, DOI 10.1002/sim.7167; Apter AJ, 2006, J ASTHMA, V43, P705, DOI 10.1080/02770900600925585; Apter AJ, 2015, CONTEMP CLIN TRIALS, V44, P119, DOI 10.1016/j.cct.2015.08.001; Apter AJ, 2013, J ASTHMA, V50, P850, DOI 10.3109/02770903.2013.812655; Apter AJ, 2010, J ALLERGY CLIN IMMUN, V126, P552, DOI 10.1016/j.jaci.2010.07.014; Baker DW, 1999, PATIENT EDUC COUNS, V38, P33, DOI 10.1016/S0738-3991(98)00116-5; Black H, 2015, AM J MANAG CARE, V21, pE329; Black HL, 2010, J ASTHMA, V47, P913, DOI 10.3109/02770903.2010.506681; Bryant-Stephens T, 2009, AM J PUBLIC HEALTH, V99, pS657, DOI [DOI 10.2105/AJPH.2009.165423, 10.2105/AJPH.2009.165423]; Bryant-Stephens T, 2016, J ALLERGY CLIN IMMUN, V138, P1526, DOI 10.1016/j.jaci.2016.10.006; Busse WW, 2012, J ALLERGY CLIN IMMUN, V129, pS1, DOI 10.1016/j.jaci.2011.12.985; Carrasquillo O, 2017, JAMA INTERN MED, V177, P948, DOI 10.1001/jamainternmed.2017.0926; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DOLCE JJ, 1991, CHEST, V99, P837, DOI 10.1378/chest.99.4.837; EFRON B, 1975, J AM STAT ASSOC, V70, P311, DOI 10.2307/2285814; Fitzmaurice GM, 2011, APPL LONGITUDINAL AN; Goel MS, 2011, J AM MED INFORM ASSN, V18, pI8, DOI 10.1136/amiajnl-2011-000473; Goel MS, 2011, J GEN INTERN MED, V26, P1112, DOI 10.1007/s11606-011-1728-3; Goldzweig CL, 2013, ANN INTERN MED, V159, P677, DOI 10.7326/0003-4819-159-10-201311190-00006; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Holmbeck GN, 1997, J CONSULT CLIN PSYCH, V65, P599, DOI 10.1037/0022-006X.65.4.599; Howe LD, 2016, STAT METHODS MED RES, V25, P1854, DOI 10.1177/0962280213503925; Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, 2003, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330, DOI 10.1164/ajrccm.162.4.9912138; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Juniper EF, 2001, RESP MED, V95, P319, DOI 10.1053/rmed.2001.1034; Kangovi S, 2018, JAMA INTERN MED, V178, P1635, DOI 10.1001/jamainternmed.2018.4630; Krieger J, 2015, JAMA INTERN MED, V175, P109, DOI 10.1001/jamainternmed.2014.6353; Krieger JW, 2011, AM J PREV MED, V41, pS48, DOI 10.1016/j.amepre.2011.05.010; Leidy NK, 1998, AM J RESP CRIT CARE, V158, P1082, DOI 10.1164/ajrccm.158.4.9708130; Lo YT, 2001, BIOMETRIKA, V88, P767, DOI 10.1093/biomet/88.3.767; Lyles CR, 2017, AM J PUBLIC HEALTH, V107, P1608, DOI 10.2105/AJPH.2017.303933; McCutcheon AL, 1987, LATENT CLASS ANAL; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; National Institutes of Health. National Heart Lung and Blood Institute, 2007, 3 NAT I HLTH NAT HEA; National Research Council, 2010, PREV TREATM MISS DAT, P106; Nelson K, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/pcd14.160344; Norman CD, 2006, J MED INTERNET RES, V8, DOI 10.2196/jmir.8.2.e9; Office of Minority Health, 2012, ASTHM HISP AM; Postma J, 2009, J ASTHMA, V46, P564, DOI 10.1080/02770900902912638; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Sarkar U, 2010, J HEALTH COMMUN, V15, P183, DOI 10.1080/10810730.2010.499988; Seidman J, 2011, ROLE HLTH LITERACY H, P23; Shah M, 2013, CURR DIABETES REP, V13, P163, DOI 10.1007/s11892-012-0359-3; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; Singh P, 2013, NEW ENGL J MED, V369, P894, DOI 10.1056/NEJMp1305636; Standardization of Spirometry, 1994, AM J RESP CRIT CARE, V152, P1107; Tieu L, 2017, J AM MED INFORM ASSN, V24, pE47, DOI 10.1093/jamia/ocw098; VanderWeele TJ, 2015, EXPLANATION CAUSAL I; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Zvarova J, 2005, Rocz Akad Med Bialymst, V50, P138	57	12	12	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					846	+		10.1016/j.jaci.2019.05.030	http://dx.doi.org/10.1016/j.jaci.2019.05.030			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	IW8CV	31181221	Bronze, Green Accepted			2022-12-18	WOS:000485222300028
J	Almeida, CA; van Miert, P; O'Driscoll, K; Zoet, YM; Chopra, A; Witt, C; John, M; Claas, FHJ; D'Orsogna, LJ				Almeida, Coral-Ann; van Miert, Paula; O'Driscoll, Kane; Zoet, Yvonne M.; Chopra, Abha; Witt, Campbell; John, Mina; Claas, Frans H. J.; D'Orsogna, Lloyd J.			Virus-specific T-cell clonotypes might contribute to drug hypersensitivity reactions through heterologous immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							REACTIVITY		[Almeida, Coral-Ann; O'Driscoll, Kane; D'Orsogna, Lloyd J.] Fiona Stanley Hosp, Dept Clin Immunol & Pathwest, Perth, WA, Australia; [Almeida, Coral-Ann; O'Driscoll, Kane; D'Orsogna, Lloyd J.] Univ Western Australia, Pathol & Lab Med, Perth, WA, Australia; [van Miert, Paula; Zoet, Yvonne M.; Claas, Frans H. J.] Leiden Univ, Med Ctr, Dept Immunohaematol & Blood Transfus, Leiden, Netherlands; [Chopra, Abha; John, Mina] Murdoch Univ, Inst Immunol & Infect Dis, Perth, WA, Australia; [Witt, Campbell; John, Mina] Royal Perth Hosp, Dept Clin Immunol & Pathwest, Perth, WA, Australia	University of Western Australia; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Murdoch University; Royal Perth Hospital	D'Orsogna, LJ (corresponding author), Fiona Stanley Hosp, Dept Clin Immunol & Pathwest, Perth, WA, Australia.; D'Orsogna, LJ (corresponding author), Univ Western Australia, Pathol & Lab Med, Perth, WA, Australia.	Lloyd.dorsogna@health.wa.gov.au	D'Orsogna, Lloyd/ABE-9573-2021	D'Orsogna, Lloyd/0000-0002-6824-4189; Chopra, Abha/0000-0001-5008-9080	National Health and Medical Research Council (NHMRC), Australian Government [APP1034858]	National Health and Medical Research Council (NHMRC), Australian Government(National Health and Medical Research Council (NHMRC) of Australia)	This study is funded by National Health and Medical Research Council (NHMRC), Australian Government grant number APP1034858.	Almeida CA, 2017, CELL IMMUNOL, V316, P32, DOI 10.1016/j.cellimm.2017.03.004; Amir AL, 2010, BLOOD, V115, P3146, DOI 10.1182/blood-2009-07-234906; D'Orsogna LJA, 2011, TRANSPLANTATION, V91, P494, DOI 10.1097/TP.0b013e318207944c; Han A, 2014, NAT BIOTECHNOL, V32, P684, DOI 10.1038/nbt.2938; Illing PT, 2012, NATURE, V486, P554, DOI 10.1038/nature11147; Lucas A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117160; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Mueller SN, 2013, ANNU REV IMMUNOL, V31, P137, DOI 10.1146/annurev-immunol-032712-095954	8	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					608	+		10.1016/j.jaci.2019.05.009	http://dx.doi.org/10.1016/j.jaci.2019.05.009			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	31102700	Bronze			2022-12-18	WOS:000478789300031
J	Elias, MS; Wright, SC; Remenyi, J; Abbott, JC; Bray, SE; Cole, C; Edwards, S; Gierlinski, M; Glok, M; McGrath, JA; Nicholson, WV; Paternoster, L; Prescott, AR; Ten Have, S; Whitfield, PD; Lamond, AI; Brown, SJ				Elias, Martina S.; Wright, Sheila C.; Remenyi, Judit; Abbott, James C.; Bray, Susan E.; Cole, Christian; Edwards, Sharon; Gierlinski, Marek; Glok, Mateusz; McGrath, John A.; Nicholson, William V.; Paternoster, Lavinia; Prescott, Alan R.; Ten Have, Sara; Whitfield, Phillip D.; Lamond, Angus I.; Brown, Sara J.			EMSY expression affects multiple components of the skin barrier with relevance to atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; atopic eczema; EMSY; filaggrin; genetics; genomics; organotypic; lipidomics; proteomics; siRNA knockdown	GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; RISK LOCI; FILAGGRIN; ECZEMA; DIFFERENTIATION; MECHANISMS; VARIANTS; MUTATIONS; LINKS	Background: Atopic dermatitis (AD) is a common, complex, and highly heritable inflammatory skin disease. Genome-wide association studies offer opportunities to identify molecular targets for drug development. A risk locus on chromosome 11q13.5 lies between 2 candidate genes, EMSY and LRRC32 (leucine-rich repeat-containing 32) but the functional mechanisms affecting risk of AD remain unclear. Objectives: We sought to apply a combination of genomic and molecular analytic techniques to investigate which genes are responsible for genetic risk at this locus and to define mechanisms contributing to atopic skin disease. Methods: We used interrogation of available genomic and chromosome conformation data in keratinocytes, small interfering RNA (siRNA)-mediated knockdown in skin organotypic culture and functional assessment of barrier parameters, mass spectrometric global proteomic analysis and quantitative lipid analysis, electron microscopy of organotypic skin, and immunohistochemistry of human skin samples. Results: Genomic data indicate active promoters in the genome-wide association study locus and upstream of EMSY; EMSY, LRRC32, and intergenic variants all appear to be within a single topologically associating domain. siRNA-knockdown of EMSY in organotypic culture leads to enhanced development of barrier function, reflecting increased expression of structural and functional proteins, including filaggrin and filaggrin-2, as well as long-chain ceramides. Conversely, overexpression of EMSY in keratinocytes leads to a reduction in markers of barrier formation. Skin biopsy samples from patients with AD show greater EMSY staining in the nucleus, which is consistent with an increased functional effect of this transcriptional control protein. Conclusion: Our findings demonstrate an important role for EMSY in transcriptional regulation and skin barrier formation, supporting EMSY inhibition as a therapeutic approach.	[Elias, Martina S.; Wright, Sheila C.; Remenyi, Judit; Glok, Mateusz; Nicholson, William V.; Brown, Sara J.] Univ Dundee, Sch Med, Div Mol & Clin Med, Skin Res Grp, Dundee DD1 9SY, Scotland; [Abbott, James C.; Cole, Christian; Gierlinski, Marek] Univ Dundee, Data Anal Bioinformat Grp, Dundee, Scotland; [Prescott, Alan R.] Univ Dundee, Dundee Imaging Facil, Dundee, Scotland; [Ten Have, Sara; Lamond, Angus I.] Univ Dundee, Sch Life Sci, Ctr Gene Regulat & Express, Dundee, Scotland; [Bray, Susan E.] Univ Dundee, Ninewells Hosp & Med Sch, NHS Res Scotland Biorepository Tayside, Dundee, Scotland; [Edwards, Sharon] Ninewells Hosp & Med Sch, Dept Pathol, Dundee, Scotland; [McGrath, John A.] Kings Coll London, St Johns Inst Dermatol, Guys Campus, London, England; [Paternoster, Lavinia] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, MRC Integrat Epidemiol Unit, Bristol, Avon, England; [Whitfield, Phillip D.] Univ Highlands & Islands, Div Biomed Sci, Lipid Res Facil, Inverness, Scotland; [Brown, Sara J.] Ninewells Hosp, Dept Dermatol, Dundee, Scotland	University of Dundee; University of Dundee; University of Dundee; University of Dundee; University of Dundee; University of Dundee; University of London; King's College London; University of Bristol; UHI Millennium Institute; University of Dundee	Elias, MS; Brown, SJ (corresponding author), Univ Dundee, Sch Med, Div Mol & Clin Med, Skin Res Grp, Dundee DD1 9SY, Scotland.	m.elias@dundee.ac.uk; s.j.brown@dundee.ac.uk	McGrath, John/D-6824-2012	McGrath, John/0000-0002-3708-9964; Cole, Christian/0000-0002-2560-2484; Abbott, James/0000-0001-7701-4249; Nicholson, William/0000-0001-6614-0194	Wellcome Trust Senior Research Fellowship in Clinical Science [106865/Z/15/Z]; Manknell Charitable Trust; Tayside Dermatology Research Charity; Academy of Medical Sciences Springboard award - Wellcome Trust; Government Department for Business, Energy and Industrial Strategy; Global Challenges Research Fund; British Heart Foundation [SBF003/1094]; UK Medical Research Council [MC_UU_00011/1]; Wellcome Trust Technology Platform award [097945/B/11/Z]; European Regional Development Fund; Scottish Funding Council; Highlands and Islands Enterprise; Wellcome Trust [105024/Z/14/Z, 108058/Z/15/Z]	Wellcome Trust Senior Research Fellowship in Clinical Science(Wellcome Trust); Manknell Charitable Trust; Tayside Dermatology Research Charity; Academy of Medical Sciences Springboard award - Wellcome Trust; Government Department for Business, Energy and Industrial Strategy; Global Challenges Research Fund; British Heart Foundation(British Heart Foundation); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust Technology Platform award(Wellcome Trust); European Regional Development Fund(European Commission); Scottish Funding Council; Highlands and Islands Enterprise; Wellcome Trust(Wellcome TrustEuropean Commission)	Supported by a Wellcome Trust Senior Research Fellowship in Clinical Science, awarded to S.J.B. (reference 106865/Z/15/Z). The Brown laboratory has also received financial support from the Manknell Charitable Trust and the Tayside Dermatology Research Charity. L.P. is supported by an Academy of Medical Sciences Springboard award, which is supported by the Wellcome Trust; the Government Department for Business, Energy and Industrial Strategy; the Global Challenges Research Fund; and the British Heart Foundation (SBF003/1094). L.P. works in the MRC Integrative Epidemiology Unit, which receives funding from the UK Medical Research Council (MC_UU_00011/1). The mass spectrometry proteomic analysis was supported by grants to AIL from the Wellcome Trust (105024/Z/14/Z, 108058/Z/15/Z). The Dundee Imaging Facility is supported by a Wellcome Trust Technology Platform award (097945/B/11/Z). The UHI Lipidomics Research Facility acknowledges the support of the European Regional Development Fund, Scottish Funding Council, and Highlands and Islands Enterprise.	Amaral AFS, 2015, ALLERGY, V70, P328, DOI 10.1111/all.12557; Asai Y, 2018, J ALLERGY CLIN IMMUN, V141, P991, DOI 10.1016/j.jaci.2017.09.015; Astle WJ, 2016, CELL, V167, P1415, DOI 10.1016/j.cell.2016.10.042; Blunder S, 2017, J INVEST DERMATOL, V137, P706, DOI 10.1016/j.jid.2016.09.034; Bonder MJ, 2016, NAT GENET, V48, P1407, DOI 10.1038/ng.3663; Brown SJ, 2017, J PATHOL, V241, P140, DOI 10.1002/path.4810; Brown SJ, 2012, J INVEST DERMATOL, V132, P98, DOI 10.1038/jid.2011.342; Bulger M, 2011, CELL, V144, P327, DOI 10.1016/j.cell.2011.01.024; Cevikbas F, 2014, J ALLERGY CLIN IMMUN, V133, P448, DOI 10.1016/j.jaci.2013.10.048; CHRISTIANO AM, 1993, NAT GENET, V4, P62, DOI 10.1038/ng0593-62; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Davies JOJ, 2016, NAT METHODS, V13, P74, DOI [10.1038/NMETH.3664, 10.1038/nmeth.3664]; de Lange KM, 2017, NAT GENET, V49, P256, DOI 10.1038/ng.3760; Demenais F, 2018, NAT GENET, V50, P42, DOI 10.1038/s41588-017-0014-7; Ellinghaus D, 2013, NAT GENET, V45, P808, DOI 10.1038/ng.2642; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Ezella SA, 2012, P NATL ACAD SCI USA, V109, pE613, DOI 10.1073/pnas.1115029109; Ferreira MA, 2017, NAT GENET, V49, P1752, DOI 10.1038/ng.3985; Finan C, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag1166; Franke L, 2009, METHODS MOL BIOL, V573, P311, DOI 10.1007/978-1-60761-247-6_17; Gruber F., 2019, FREE RADIC BIOL MED; Hendricks AJ, 2018, J DERMATOL SCI, V89, P105, DOI 10.1016/j.jdermsci.2017.11.005; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Javierre BM, 2016, CELL, V167, P1369, DOI 10.1016/j.cell.2016.09.037; Jobard F, 2002, HUM MOL GENET, V11, P107, DOI 10.1093/hmg/11.1.107; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kogame T, 2014, J DERMATOL, V41, P1095, DOI 10.1111/1346-8138.12682; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Larcher F, 2007, MOL THER, V15, P1670, DOI 10.1038/sj.mt.6300238; Lee UH, 2017, BRIT J DERMATOL, V176, P537, DOI 10.1111/bjd.15010; Liu BX, 2019, NAT GENET, V51, P768, DOI 10.1038/s41588-019-0404-0; Manz J, 2016, J INVEST DERMATOL, V136, P2380, DOI 10.1016/j.jid.2016.07.009; Marenholz I, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01220-0; Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794; Meana A, 1998, BURNS, V24, P621, DOI 10.1016/S0305-4179(98)00107-7; Mildner M, 2010, J INVEST DERMATOL, V130, P2286, DOI 10.1038/jid.2010.115; O'Regan GM, 2010, J ALLERGY CLIN IMMUN, V125, P170, DOI 10.1016/j.jaci.2009.10.046; Oji V, 2010, AM J HUM GENET, V87, P274, DOI 10.1016/j.ajhg.2010.07.005; Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Paternoster L, 2018, J ALLERGY CLIN IMMUN, V141, P964, DOI 10.1016/j.jaci.2017.09.044; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Patil VS, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aan8664; Pennisi E, 2012, SCIENCE, V337, P1159, DOI 10.1126/science.337.6099.1159; Potaczek DP, 2017, EPIGENOMICS-UK, V9, P539, DOI 10.2217/epi-2016-0162; Purdie KJ, 2011, METHODS MOL BIOL, V731, P151, DOI 10.1007/978-1-61779-080-5_14; Raguz J, 2016, ELIFE, V5, DOI 10.7554/eLife.14012; Ramasamy A, 2011, J ALLERGY CLIN IMMUN, V128, P996, DOI 10.1016/j.jaci.2011.08.030; Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rubin AJ, 2017, NAT GENET, V49, P1522, DOI 10.1038/ng.3935; Tanikawa DYS, 2010, ACTA CIR BRAS, V25, P541, DOI 10.1590/S0102-86502010000600015; Schaarschmidt H, 2015, J ALLERGY CLIN IMMUN, V136, P802, DOI 10.1016/j.jaci.2015.01.047; Sen GL, 2010, NATURE, V463, P563, DOI 10.1038/nature08683; Simpson EL, 2017, J AM ACAD DERMATOL, V77, P623, DOI 10.1016/j.jaad.2017.06.042; Sleiman PMA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6593; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Smith FJD, 1998, J INVEST DERMATOL, V111, P817, DOI 10.1046/j.1523-1747.1998.00371.x; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Sud A, 2017, NAT REV CANCER, V17, P692, DOI 10.1038/nrc.2017.82; Sullivan PF, 2018, AM J PSYCHIAT, V175, P15, DOI 10.1176/appi.ajp.2017.17030283; Totsuka A, 2017, EUR J DERMATOL, V27, P247, DOI 10.1684/ejd.2017.2985; Tran DQ, 2009, P NATL ACAD SCI USA, V106, P13445, DOI 10.1073/pnas.0901944106; Trynka G, 2017, NAT GENET, V49, P1564, DOI 10.1038/ng.3982; van Smeden J, 2014, EXP DERMATOL, V23, P45, DOI 10.1111/exd.12293; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Winge MCG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028254; WIRTH B, 1988, HUM GENET, V80, P191, DOI 10.1007/BF00702868; Zhu ZZ, 2018, NAT GENET, V50, P857, DOI 10.1038/s41588-018-0121-0	72	12	12	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					470	481		10.1016/j.jaci.2019.05.024	http://dx.doi.org/10.1016/j.jaci.2019.05.024			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	31158401	Green Published, hybrid			2022-12-18	WOS:000478789300015
J	Heddle, R; Smith, A; Woodman, R; Hissaria, P; Petrovsky, N				Heddle, Robert; Smith, Anthony; Woodman, Richard; Hissaria, Pravin; Petrovsky, Nikolai			Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hymenoptera; anaphylaxis; immunotherapy; IgG(4); inulin; adjuvant; allergy	HYMENOPTERA VENOM; INFLUENZA VACCINE; HONEYBEE VENOM; B-CELLS; PROTECTION; ADVAX(TM); SAFETY; ANTIBODIES; IGE; ANTIGEN	Background: Allergic reactions to Hymenoptera insect stings remain a major global clinical problem. Although effective, parenteral desensitization regimens require use of costly venom extracts and require frequent visits over extended periods of time. Objective: Adjuvants are commonly used to enhance the efficacy of infectious disease vaccines, and this study asked whether Advax (Vaxine Pty Ltd, Adelaide, Australia), a novel noninflammatory polysaccharide adjuvant, might provide similar benefits for allergy desensitization. Methods: A randomized, controlled phase 1/2 trial was undertaken in 27 adults with a history of rapid-onset systemic allergic reactions to honeybee stings and positive specific IgE levels to evaluate the safety and efficacy of honeybee venom immunotherapy (HBVIT) combined with Advax adjuvant. Venom immunotherapy (VIT) was administered monthly for 30 months after achievement of maintenance doses. Results: Advax-adjuvanted HBVIT was well tolerated. Around week 14 of VIT, specific IgG(4) responses peaked in both groups but increased earlier, peaked higher, and were better maintained through the end of the study in the Advax-adjuvanted arm. Several different patterns of serologic response to VIT were seen; some subjects had a dominant IgG(4) response, some had a combined IgG(4) and IgG(1) response, and some had an exclusively IgG(1) response. In some subjects specific IgE levels increased during the induction phase and then decreased, whereas in others specific IgE levels progressively decreased from the start of VIT. Conclusion: Advax adjuvant favorably enhanced the immunogenicity of HBVIT, with an early and prolonged switch to specific IgG(4) production. The ability of Advax adjuvant to enhance VIT efficacy warrants further study.	[Heddle, Robert] Univ Adelaide, North Terrace, Adelaide, SA, Australia; [Heddle, Robert; Hissaria, Pravin] Royal Adelaide Hosp, North Terrace, Adelaide, SA, Australia; [Smith, Anthony] Flinders Med Ctr, Allergy & Clin Immunol Dept, Bedford Pk, SA, Australia; [Woodman, Richard] Flinders Univ S Australia, Flinders Ctr Epidemiol & Biostat, Bedford Pk, SA, Australia; [Heddle, Robert; Petrovsky, Nikolai] Flinders Univ S Australia, Bedford Pk, SA 5042, Australia; [Petrovsky, Nikolai] Vaxine, Bedford Pk, SA, Australia	University of Adelaide; Royal Adelaide Hospital; Flinders Medical Centre; Flinders University South Australia; Flinders University South Australia	Petrovsky, N (corresponding author), Flinders Univ S Australia, Bedford Pk, SA 5042, Australia.	nikolai.petrovsky@flinders.edu.au	Petrovsky, Nikolai/P-1912-2017	Petrovsky, Nikolai/0000-0002-1580-5245; Woodman, Richard/0000-0002-4094-1222	Australian Respiratory and Sleep Medicine Institute; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [HHSN272200800039C, U01 AI061142, HHSN272201400053C]	Australian Respiratory and Sleep Medicine Institute; National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The study was supported by a grant from the Australian Respiratory and Sleep Medicine Institute. Development of Advax adjuvant was supported by funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, under contracts HHSN272200800039C and U01 AI061142, and N.P. is currently supported by contract HHSN272201400053C.	Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Barclay TG, 2016, CARBOHYD POLYM, V143, P108, DOI 10.1016/j.carbpol.2016.01.062; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Brown SGA, 2003, LANCET, V361, P1001, DOI 10.1016/S0140-6736(03)12827-9; Cadario G, 2004, J INVEST ALLERG CLIN, V14, P127; COOPER PD, 1986, MOL IMMUNOL, V23, P895, DOI 10.1016/0161-5890(86)90075-1; Cooper PD, 2015, CARBOHYD POLYM, V117, P964, DOI 10.1016/j.carbpol.2014.10.022; Cooper PD, 2013, GLYCOBIOLOGY, V23, P1164, DOI 10.1093/glycob/cwt053; Cooper PD, 2011, GLYCOBIOLOGY, V21, P595, DOI 10.1093/glycob/cwq201; Counoupas C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09119-y; Denepoux S, 2000, FEBS LETT, V465, P39, DOI 10.1016/S0014-5793(99)01703-2; Dodev TS, 2015, ALLERGY, V70, P720, DOI 10.1111/all.12607; Dugas-Breit S, 2010, CLIN EXP ALLERGY, V40, P643, DOI 10.1111/j.1365-2222.2009.03436.x; Feinen B, 2014, CLIN VACCINE IMMUNOL, V21, P580, DOI 10.1128/CVI.00019-14; FERRANTE A, 1986, INT ARCH ALLER A IMM, V81, P284, DOI 10.1159/000234148; Golden DBK, 2017, ANN ALLERG ASTHMA IM, V118, P28, DOI 10.1016/j.anai.2016.10.031; Golden DBK, 2010, CURR OPIN ALLERGY CL, V10, P337, DOI 10.1097/ACI.0b013e32833bc0ba; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; Gordon D, 2014, VACCINE, V32, P6469, DOI 10.1016/j.vaccine.2014.09.034; Gordon DL, 2016, VACCINE, V34, P3780, DOI 10.1016/j.vaccine.2016.05.071; Gordon DL, 2012, VACCINE, V30, P5407, DOI 10.1016/j.vaccine.2012.06.009; Hess JA, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004797; Honda-Okubo Y, 2017, HUM VACC IMMUNOTHER, V13, P1261, DOI 10.1080/21645515.2017.1279765; Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14; Honda-Okubo Y, 2014, VACCINE, V32, P4651, DOI 10.1016/j.vaccine.2014.06.057; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Incorvaia C, 2011, EXPERT OPIN PHARMACO, V12, P2527, DOI 10.1517/14656566.2011.616494; Keselman A, 2017, J IMMUNOL, V199, P1573, DOI 10.4049/jimmunol.1601975; Layton RC, 2011, VACCINE, V29, P6242, DOI 10.1016/j.vaccine.2011.06.078; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; LOCKEY RF, 1989, J ALLERGY CLIN IMMUN, V84, P967, DOI 10.1016/0091-6749(89)90396-5; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; Menon V, 2017, J GEN VIROL, V98, P2143, DOI 10.1099/jgv.0.000863; MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; Santos BDO, 2017, HUM VACC IMMUNOTHER, V13, P2967, DOI 10.1080/21645515.2017.1368598; Ozdemir C, 2011, CLIN EXP ALLERGY, V41, P1226, DOI 10.1111/j.1365-2222.2011.03812.x; Petrovsky N, 2015, VACCINE, V33, P5920, DOI 10.1016/j.vaccine.2015.09.030; Petrovsky N, 2015, DRUG SAFETY, V38, P1059, DOI 10.1007/s40264-015-0350-4; Petrovsky N, 2013, J VIROL, V87, P10324, DOI 10.1128/JVI.00480-13; Quercia O, 2001, J INVEST ALLERG CLIN, V11, P27; Rodriguez-Del Rio E, 2015, VACCINE, V33, P1465, DOI 10.1016/j.vaccine.2015.01.062; Rueff F, 2004, ALLERGY, V59, P589, DOI 10.1111/j.1398-9995.2004.00505.x; Rueff F, 2010, J ALLERGY CLIN IMMUN, V126, P105, DOI 10.1016/j.jaci.2010.04.025; Seibert SM, 2011, ALLERGY ASTHMA PROC, V32, P203, DOI 10.2500/aap.2011.32.3436; Shamji MH, 2017, ALLERGY, V72, P1156, DOI 10.1111/all.13138; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Sturm G, 2002, J ALLERGY CLIN IMMUN, V110, P928, DOI 10.1067/mai.2002.129124; URBANEK R, 1983, CLIN ALLERGY, V13, P229, DOI 10.1111/j.1365-2222.1983.tb02592.x; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; Varga EM, 2009, CLIN EXP ALLERGY, V39, P1353, DOI 10.1111/j.1365-2222.2009.03303.x; Varga EM, 2013, J ALLERGY CLIN IMMUN, V131, P1419, DOI 10.1016/j.jaci.2012.08.037; Wang LX, 2017, VACCINE, V35, P4382, DOI 10.1016/j.vaccine.2017.06.045	55	12	12	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					504	+		10.1016/j.jaci.2019.03.035	http://dx.doi.org/10.1016/j.jaci.2019.03.035			26	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	31300280	Green Published, Bronze			2022-12-18	WOS:000478789300018
J	Leroy, E; Balligand, T; Pecquet, C; Mouton, C; Colau, D; Shiau, AK; Dusa, A; Constantinescu, SN				Leroy, Emilie; Balligand, Thomas; Pecquet, Christian; Mouton, Celine; Colau, Didier; Shiau, Andrew K.; Dusa, Alexandra; Constantinescu, Stefan N.			Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						JAK2 V617F; Janus kinases; myeloproliferative disorders; cytokine receptor signaling; IFN-gamma receptor; Janus kinase 1; kinases	TYROSINE KINASE JAK2; PSEUDOKINASE-DOMAIN; ERYTHROPOIETIN RECEPTOR; POLYCYTHEMIA-VERA; ATP-BINDING; CONSTITUTIVE ACTIVATION; BCR-ABL; MUTATION; INTERFERON; TRANSMEMBRANE	Background: Janus kinase (JAK) 2 plays pivotal roles in signaling by several cytokine receptors. The mutant JAK2 V617F is the most common molecular event associated with myeloproliferative neoplasms. Selective targeting of the mutant would be ideal for treating these pathologies by sparing essential JAK2 functions. Objective: We characterize inhibitory strategies for JAK2 V617F and assess their effect on physiologic signaling by distinct cytokine receptors. Methods: Through structure-guided mutagenesis, we assessed the role of key residues around F617 and used a combination of cellular and biochemical assays to measure the activity of JAKs in reconstituted cells. We also assessed the effect of several specific JAK2 V617F inhibitory mutations on receptor dimerization using the NanoBiT protein complementation approach. Results: We identified a novel Janus kinase homology 2 (JH2) alpha C mutation, A598F, which is suggested to inhibit the aromatic stacking between F617 with F594 and F595. Like other JAK2 V617F inhibitory mutations, A598F decreased oncogenic activation and spared cytokine activation while preventing JAK2 V617F-promoted erythropoietin receptor dimerization. Surprisingly, A598F and other V617F-inhibiting mutations (F595A, E596R, and F537A) significantly impaired IFN-gamma signaling. This was specific for IFN-gamma because the inhibitory mutations preserved responses to ligands of a series of receptor complexes. Similarly, homologous mutations in JAK1 prevented signaling by IFN-gamma. Conclusions: The JH2 alpha C region, which is required for JAK2 V617F hyperactivation, is crucial for relaying cytokine-induced signaling of the IFN-gamma receptor. We discuss how strategies aiming to inhibit JAK2 V617F could be used for identifying inhibitors of IFN-gamma signaling.	[Leroy, Emilie; Balligand, Thomas; Pecquet, Christian; Mouton, Celine; Colau, Didier; Dusa, Alexandra; Constantinescu, Stefan N.] Ludwig Inst Canc Res, Brussels, Belgium; [Leroy, Emilie; Balligand, Thomas; Pecquet, Christian; Mouton, Celine; Colau, Didier; Dusa, Alexandra; Constantinescu, Stefan N.] Catholic Univ Louvain, de Duve Inst, Brussels, Belgium; [Leroy, Emilie; Constantinescu, Stefan N.] WELBIO Walloon Excellence Life Sci & Biotechnol, Brussels, Belgium; [Shiau, Andrew K.] Ludwig Inst Canc Res, Small Discovery Program, La Jolla, CA USA; [Dusa, Alexandra] IMEC, Life Sci & Imaging Dept, Kapeldreef 75, B-3001 Leuven, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain; WELBIO; Ludwig Institute for Cancer Research; IMEC	Dusa, A; Constantinescu, SN (corresponding author), Ludwig Inst Canc Res, Ave Hippocrate 74-B1-75-07, B-1200 Brussels, Belgium.	Alexandra.Dusa@bru.licr.org; Stefan.Constantinescu@bru.licr.org		Balligand, Thomas/0000-0003-0156-8936; Christian, Pecquet/0000-0002-8623-3483; Leroy, Emilie/0000-0001-5897-1713	FRS-FNRS postdoctoral fellowship; WelBio [F 44/8/5-MCF/UIG-10955]; PhD Televie fellowship; Ludwig Institute for Cancer Research; FRS-FNRS fellowship; Duve Institute; Fondation contre le cancer; Salus Sanguinis; Fondation "Les avions de Sebastien'', project Action de recherche concertee (ARC) [16/21-073]; Fondation "Les avions de Sebastien'', project WelBio [F 44/8/5-MCF/UIG-10955]	FRS-FNRS postdoctoral fellowship(Fonds de la Recherche Scientifique - FNRS); WelBio(WELBIO); PhD Televie fellowship; Ludwig Institute for Cancer Research; FRS-FNRS fellowship(Fonds de la Recherche Scientifique - FNRS); Duve Institute; Fondation contre le cancer; Salus Sanguinis; Fondation "Les avions de Sebastien'', project Action de recherche concertee (ARC); Fondation "Les avions de Sebastien'', project WelBio	E.L. was funded by a FRS-FNRS postdoctoral fellowship and WelBio F 44/8/5-MCF/UIG-10955. T.B. was supported by a PhD Televie fellowship. C.P., D.C., and A.K.S. were funded by the Ludwig Institute for Cancer Research. C.M. was supported by a FRS-FNRS fellowship. A.D. was supported by a grant from de Duve Institute. S.N.C. is Honorary Research Director at FRS and is a Professor at UC Louvain, Belgium. Funding to S.N.C. is acknowledged from Ludwig Institute for Cancer Research, Fondation contre le cancer, Salus Sanguinis and Fondation "Les avions de Sebastien,'' projects Action de recherche concertee (ARC) 16/21-073, andWelBio F 44/8/5-MCF/UIG-10955.	Adrian FJ, 2006, NAT CHEM BIOL, V2, P95, DOI 10.1038/nchembio760; Bandaranayake RM, 2012, NAT STRUCT MOL BIOL, V19, P754, DOI 10.1038/nsmb.2348; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Brooks AJ, 2014, SCIENCE, V344, P710, DOI 10.1126/science.1249783; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; Constantinescu SN, 2013, BIOCHEM SOC T, V41, P1048, DOI 10.1042/BST20130084; Defour JP, 2013, P NATL ACAD SCI USA, V110, P2540, DOI 10.1073/pnas.1211560110; Dixon AS, 2016, ACS CHEM BIOL, V11, P400, DOI 10.1021/acschembio.5b00753; Dumoutier L, 2000, P NATL ACAD SCI USA, V97, P10144, DOI 10.1073/pnas.170291697; Dusa A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011157; Flex E, 2008, J EXP MED, V205, P751, DOI 10.1084/jem.20072182; Gnanasambandan K, 2010, BIOCHEMISTRY-US, V49, P9972, DOI 10.1021/bi1014858; Hammaren HM, 2015, P NATL ACAD SCI USA, V112, P4642, DOI 10.1073/pnas.1423201112; Heine A, 2013, BLOOD, V122, P3843, DOI 10.1182/blood-2013-10-531103; Hu JC, 2011, P NATL ACAD SCI USA, V108, P6067, DOI 10.1073/pnas.1102554108; Hubbard SR, 2018, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00361; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jaster R, 1997, MOL CELL BIOL, V17, P3364, DOI 10.1128/MCB.17.6.3364; Jeong EG, 2008, CLIN CANCER RES, V14, P3716, DOI 10.1158/1078-0432.CCR-07-4839; Keil E, 2014, BLOOD, V123, P520, DOI 10.1182/blood-2013-03-492157; Khateb M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-563; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Leroy E, 2017, LEUKEMIA, V31, P2853, DOI 10.1038/leu.2017.158; Leroy E, 2016, BIOCHEM J, V473, P1579, DOI 10.1042/BCJ20160085; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Lu XH, 2008, J BIOL CHEM, V283, P5258, DOI 10.1074/jbc.M707125200; Lupardus PJ, 2014, P NATL ACAD SCI USA, V111, P8025, DOI 10.1073/pnas.1401180111; Malka Y, 2008, J BIOL CHEM, V283, P33569, DOI 10.1074/jbc.M803125200; MARSTERS SA, 1995, P NATL ACAD SCI USA, V92, P5401, DOI 10.1073/pnas.92.12.5401; Mercher T, 2006, BLOOD, V108, P2770, DOI 10.1182/blood-2006-04-014712; Moraga I, 2015, CELL, V160, P1196, DOI 10.1016/j.cell.2015.02.011; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Mullighan CG, 2009, P NATL ACAD SCI USA, V106, P9414, DOI 10.1073/pnas.0811761106; Murphy JM, 2014, BIOCHEM J, V457, P323, DOI 10.1042/BJ20131174; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Patel AB, 2016, CLIN CANCER RES, V22, P1037, DOI 10.1158/1078-0432.CCR-15-0905; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Puleo DE, 2017, ACS MED CHEM LETT, V8, P618, DOI 10.1021/acsmedchemlett.7b00153; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Scott LM, 2007, NEW ENGL J MED, V356, P459, DOI 10.1056/NEJMoa065202; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Shan YB, 2014, NAT STRUCT MOL BIOL, V21, P579, DOI 10.1038/nsmb.2849; SLIVA D, 1994, J BIOL CHEM, V269, P26208; Staerk J, 2005, J BIOL CHEM, V280, P41893, DOI 10.1074/jbc.C500358200; Toms AV, 2013, NAT STRUCT MOL BIOL, V20, P1221, DOI 10.1038/nsmb.2673; Walters DK, 2006, CANCER CELL, V10, P65, DOI 10.1016/j.ccr.2006.06.002; Zhang JM, 2010, NATURE, V463, P501, DOI 10.1038/nature08675	51	12	12	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					224	235		10.1016/j.jaci.2018.12.1023	http://dx.doi.org/10.1016/j.jaci.2018.12.1023			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30707971	Bronze			2022-12-18	WOS:000473432800025
J	Ning, FK; Takeda, K; Schedel, M; Domenico, J; Joetham, A; Gelfand, EW				Ning, Fangkun; Takeda, Katsuyuki; Schedel, Michaela; Domenico, Joanne; Joetham, Anthony; Gelfand, Erwin W.			Hypoxia enhances CD8(+) T(C)2 cell-dependent airway hyperresponsiveness and inflammation through hypoxia-inducible factor 1 alpha	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; CD8(+) T cells; hypoxia; IL-13; hypoxia-inducible factor 1 alpha	LUNG-FUNCTION DECLINE; T-CELLS; INTERFERON-GAMMA; BRONCHIAL CD8; T(H)17 CELLS; ASTHMA; HIF-1-ALPHA; INHIBITION; GENE; EOSINOPHILIA	Background: CD8(+) type 2 cytotoxic T (T(C)2) cells undergo transcriptional reprogramming to IL-13 production in the presence of IL-4 to become potent, steroid-insensitive, pathogenic effector cells in asthmatic patients and in mice in a model of experimental asthma. However, no studies have described the effects of hypoxia exposure on T(C)2 cell differentiation. Objective: We determined the effects of hypoxia exposure on IL-13-producing CD8(+) T(C)2 cells. Methods: CD8(+) transgenic OT-1 cells differentiated with IL-2 and IL-4 (T(C)2 cells) were exposed to normoxia (21% oxygen) or hypoxia (3% oxygen), and IL-13 production in vitro was monitored. After differentiation under these conditions, cells were adoptively transferred into CD8-deficient mice, and lung allergic responses, including airway hyperresponsiveness to inhaled methacholine, were assessed. The effects of pharmacologic inhibitors of hypoxia-inducible factor (HIF) 1 alpha and HIF-2 alpha were determined, as were responses in HIF-1 alpha-deficient OT-1 cells. Results: Under hypoxic conditioning, CD8(+) T(C)2 cell differentiation was significantly enhanced, with increased numbers of IL-13(+) T cells and increased production of IL-13 in vitro. Adoptive transfer of T(C)2 cells differentiated under hypoxic conditioning restored lung allergic responses in sensitized and challenged CD8-deficient recipients to a greater degree than seen in recipients of T(C)2 cells differentiated under normoxic conditioning. Pharmacologic inhibition of HIF-1 alpha or genetic manipulation to reduce HIF-1 alpha expression reduced the hypoxia-enhanced differentiation of T(C)2 cells, IL-13 production, and the capacity of transferred cells to restore lung allergic responses in vivo. IL-4-dependent, hypoxia-mediated increases in HIF-1 alpha and T(C)2 cell differentiation were shown to be mediated through activation of Janus kinase 1/3 and GATA-3. Conclusions: Hypoxia enhances CD8(+) T(C)2 cell-dependent airway hyperresponsiveness and inflammation through HIF-1 alpha activation. These findings coupled with the known insensitivity of CD8(+) T cells to corticosteroids suggests that activation of the IL-4-HIF-1 alpha-IL-13 axis might play a role in the development of steroid-refractory asthma.	[Ning, Fangkun; Takeda, Katsuyuki; Schedel, Michaela; Domenico, Joanne; Joetham, Anthony; Gelfand, Erwin W.] Natl Jewish Hlth, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA	National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Hlth, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	erwin3460@gmail.com	Schedel, Michaela/B-3065-2019	Schedel, Michaela/0000-0001-8465-2986	National Institutes of Health (NIH) [HL-36577, AI-77609]; Joanne Siegel Fund; Eugene F. and Easton M. Crawford Charitable Lead Unitrust fund; Eugene F. and Easton M. Crawford Charitable Pohs fund; Eugene F. and Easton M. Crawford Charitable Dreizzesun fund	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Joanne Siegel Fund; Eugene F. and Easton M. Crawford Charitable Lead Unitrust fund; Eugene F. and Easton M. Crawford Charitable Pohs fund; Eugene F. and Easton M. Crawford Charitable Dreizzesun fund	Supported by National Institutes of Health (NIH) grants HL-36577 and AI-77609 (to E.W.G.) and the Joanne Siegel Fund. F.N. and M.S. were supported by the Eugene F. and Easton M. Crawford Charitable Lead Unitrust, Pohs, and Dreizzesun funds. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the NIH.	Pinheiro AAD, 2007, J LEUKOCYTE BIOL, V81, P1102, DOI 10.1189/jlb.0906583; Ahmad T, 2012, AM J RESP CELL MOL, V47, P1, DOI 10.1165/rcmb.2011-0203OC; Alcorn JF, 2010, ANNU REV PHYSIOL, V72, P495, DOI 10.1146/annurev-physiol-021909-135926; Alexander LEC, 2013, J MOL MED, V91, P637, DOI 10.1007/s00109-012-0986-9; Alonso AM, 2017, EXPERT REV RESP MED, V11, P867, DOI 10.1080/17476348.2017.1368391; Ashino S, 2014, J ALLERGY CLIN IMMUN, V133, P1162, DOI 10.1016/j.jaci.2013.10.036; Baek KJ, 2013, CLIN IMMUNOL, V147, P27, DOI 10.1016/j.clim.2013.02.004; Bel EH, 2011, THORAX, V66, P910, DOI 10.1136/thx.2010.153643; Belvisi Maria G, 2004, Proc Am Thorac Soc, V1, P207, DOI 10.1513/pats.200402-002MS; Bhakta NR, 2014, J ALLERGY CLIN IMMUN, V134, P1187, DOI 10.1016/j.jaci.2014.07.034; Brusselle Guy, 2014, Ann Am Thorac Soc, V11 Suppl 5, pS322, DOI 10.1513/AnnalsATS.201403-118AW; Bush A, 2011, CURR OPIN ALLERGY CL, V11, P115, DOI 10.1097/ACI.0b013e32834487ae; Cagnoni EF, 2015, J ALLERGY CLIN IMMUN, V135, P1352, DOI 10.1016/j.jaci.2014.08.021; Cho SH, 2005, AM J RESP CRIT CARE, V171, P224, DOI 10.1164/rccm.200310-1416OC; Cho SH, 2016, NATURE, V537, P234, DOI 10.1038/nature19334; Clambey ET, 2012, P NATL ACAD SCI USA, V109, pE2784, DOI 10.1073/pnas.1202366109; Dakhama A, 2013, ALLERGY, V68, P666, DOI 10.1111/all.12135; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; de Silly RV, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1232236; de Silly RV, 2015, EUR J IMMUNOL, V45, P2263, DOI 10.1002/eji.201445284; Dehne N, 2014, J LEUKOCYTE BIOL, V95, P129, DOI 10.1189/jlb.0113045; den Otter I, 2016, EUR RESPIR J, V48, P393, DOI 10.1183/13993003.01525-2015; Doedens AL, 2013, NAT IMMUNOL, V14, P1173, DOI 10.1038/ni.2714; Ellinghaus P, 2013, CANCER MED-US, V2, P611, DOI 10.1002/cam4.112; Fajardo I, 2004, AM J RESP CRIT CARE, V170, P477, DOI 10.1164/rccm.200402-178OC; Finlay DK, 2012, J EXP MED, V209, P2441, DOI 10.1084/jem.20112607; Guo J, 2009, INT ARCH ALLERGY IMM, V149, P98, DOI 10.1159/000189191; Hansbro PM, 2017, IMMUNOL REV, V278, P41, DOI 10.1111/imr.12543; Hilvering B, 2018, MUCOSAL IMMUNOL, V11, P1408, DOI 10.1038/s41385-018-0049-9; Huerta-Yepez S, 2008, CLIN IMMUNOL, V129, P313, DOI 10.1016/j.clim.2008.07.023; Jia Y, 2013, J IMMUNOL, V190, P4056, DOI 10.4049/jimmunol.1202640; Kanehiro A, 2001, AM J RESP CRIT CARE, V163, P173, DOI 10.1164/ajrccm.163.1.2001118; Kim HY, 2016, EUR J IMMUNOL, V46, P795, DOI 10.1002/eji.201444557; Kim SR, 2012, ALLERGY, V67, P869, DOI 10.1111/j.1398-9995.2012.02837.x; Kumar V, 2014, IMMUNOLOGY, V143, P512, DOI 10.1111/imm.12380; Larsen H, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3934; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Maier H, 2003, MOL CELL BIOL, V23, P1946, DOI 10.1128/MCB.23.6.1946-1960.2003; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Miyahara N, 2005, J IMMUNOL, V174, P4979, DOI 10.4049/jimmunol.174.8.4979; Miyahara N, 2004, NAT MED, V10, P865, DOI 10.1038/nm1081; Miyahara N, 2004, J IMMUNOL, V172, P2549, DOI 10.4049/jimmunol.172.4.2549; Nakamura H, 2005, J IMMUNOL, V174, P7592, DOI 10.4049/jimmunol.174.12.7592; Oda H, 2014, ANN ALLERG ASTHMA IM, V112, P23, DOI 10.1016/j.anai.2013.09.004; Ohnishi H, 2008, J ALLERGY CLIN IMMUN, V121, P864, DOI 10.1016/j.jaci.2008.01.035; Palazon A, 2014, IMMUNITY, V41, P518, DOI 10.1016/j.immuni.2014.09.008; Pollizzi KN, 2014, NAT REV IMMUNOL, V14, P435, DOI 10.1038/nri3701; Rogers JL, 2013, J MED CHEM, V56, P1739, DOI 10.1021/jm301847z; Saffar AS, 2011, CURR DRUG TARGETS, V12, P556; Scheuermann TH, 2013, NAT CHEM BIOL, V9, P271, DOI [10.1038/NCHEMBIO.1185, 10.1038/nchembio.1185]; Takeda K, 2001, AM J PHYSIOL-LUNG C, V281, pL394, DOI 10.1152/ajplung.2001.281.2.L394; Tomkinson A, 2001, AM J RESP CRIT CARE, V163, P721, DOI 10.1164/ajrccm.163.3.2005010; van Rensen ELJ, 2005, AM J RESP CRIT CARE, V172, P837, DOI 10.1164/rccm.200504-619OC; Wang MJ, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0462-0	54	12	12	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2026	+		10.1016/j.jaci.2018.11.049	http://dx.doi.org/10.1016/j.jaci.2018.11.049			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30660639				2022-12-18	WOS:000470113200009
J	Deak, PE; Kim, B; Adnan, A; Labella, M; De las Vecillas, L; Castells, M; Bilgicer, B				Deak, Peter E.; Kim, Baksun; Adnan, Ather; Labella, Marina; De las Vecillas, Leticia; Castells, Mariana; Bilgicer, Basar			Nanoallergen platform for detection of platin drug allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PEPTIDE HYDROPHILICITY; CELLULAR UPTAKE; LINKER LENGTH; OXALIPLATIN		[Deak, Peter E.; Kim, Baksun; Bilgicer, Basar] Univ Notre Dame, Dept Chem & Biomol Engn, Notre Dame, IN 46556 USA; [Bilgicer, Basar] Univ Notre Dame, Adv Diagnost & Therapeut, Notre Dame, IN 46556 USA; [Bilgicer, Basar] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; [Adnan, Ather; Labella, Marina; De las Vecillas, Leticia; Castells, Mariana] Harvard Med Sch, Div Rheumatol Immunol & Allergy, Dept Med, Brigham & Womens Hosp, Boston, MA 02115 USA; [De las Vecillas, Leticia] Marques Valdecilla Univ Hosp IDIVAL, Dept Allergy, Santander, Spain	University of Notre Dame; University of Notre Dame; University of Notre Dame; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Hospital Universitario Marques de Valdecilla (HUMV)	Bilgicer, B (corresponding author), Univ Notre Dame, Dept Chem & Biomol Engn, Notre Dame, IN 46556 USA.; Bilgicer, B (corresponding author), Univ Notre Dame, Adv Diagnost & Therapeut, Notre Dame, IN 46556 USA.; Bilgicer, B (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	bbilgicer@nd.edu	de las Vecillas Sanchez, Leticia/ABF-5180-2021; Labella, Marina/AAV-3223-2021; Kim, Baksun/AAL-6656-2020	de las Vecillas Sanchez, Leticia/0000-0003-4969-5678; Deak, Peter/0000-0002-2208-0174; Adnan, Ather/0000-0001-9640-9916	National Institutes of Health [R01AI108884]; Ovations for the Cure Fund; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI108884] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ovations for the Cure Fund; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported private donors (Mr Douglas Zych and Mr Jim and Mrs Annette Lecinski) and the National Institutes of Health (R01AI108884, B.B.) and Ovations for the Cure Fund (M.C.).	AUDERA C, 1991, CLIN EXP ALLERGY, V21, P139, DOI 10.1111/j.1365-2222.1991.tb00816.x; Caiado J, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0515-3; Caiado J, 2013, J ALLER CL IMM-PRACT, V1, P494, DOI 10.1016/j.jaip.2013.06.002; Castells M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01472; Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044; Sanchez LD, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061316; Deak PE, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04268-6; Deak PE, 2016, EXP BIOL MED, V241, P996, DOI 10.1177/1535370216644533; Ladics GS, 2008, REGUL TOXICOL PHARM, V51, P288, DOI 10.1016/j.yrtph.2008.04.012; Parel M, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-1; Sandlin RD, 2012, INORG CHIM ACTA, V391, P135, DOI 10.1016/j.ica.2012.05.008; Sloane D, 2016, J ALLER CL IMM-PRACT, V4, P497, DOI 10.1016/j.jaip.2015.12.019; Stefanick JF, 2015, J BIOMED NANOTECHNOL, V11, P1418, DOI 10.1166/jbn.2015.2087; Stefanick JF, 2013, ACS NANO, V7, P8115, DOI 10.1021/nn4033954; Stefanick JF, 2013, ACS NANO, V7, P2935, DOI 10.1021/nn305663e; Wong JT, 2014, J ALLER CL IMM-PRACT, V2, P40, DOI 10.1016/j.jaip.2013.08.011	16	12	12	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1957	+		10.1016/j.jaci.2019.01.010	http://dx.doi.org/10.1016/j.jaci.2019.01.010			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30682456	Green Accepted, Bronze			2022-12-18	WOS:000466784600038
J	Zhang, L; McNeil, BD				Zhang, Li; McNeil, Benjamin D.			Beta-defensins are proinflammatory pruritogens that activate Mrgprs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Zhang, Li; McNeil, Benjamin D.] Northwestern Univ, Dept Med, Div Allergy & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	McNeil, BD (corresponding author), Northwestern Univ, Dept Med, Div Allergy & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA.	benjamin.mcneil@northwestern.edu		McNeil, Benjamin/0000-0001-7545-3598	Bazley Foundation, USA	Bazley Foundation, USA	L.Z. and B.M. were supported by the Bazley Foundation, USA.	Fruitwala S, 2019, SEMIN CELL DEV BIOL, V88, P163, DOI 10.1016/j.semcdb.2018.02.023; Gaudenzio N, 2016, J CLIN INVEST, V126, P3981, DOI 10.1172/JCI85538; Han L, 2013, NAT NEUROSCI, V16, P174, DOI 10.1038/nn.3289; Kopfnagel V, 2013, CURR OPIN ALLERGY CL, V13, P531, DOI 10.1097/ACI.0b013e328364ddfd; Liu Q, 2009, CELL, V139, P1353, DOI 10.1016/j.cell.2009.11.034; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Roehrl J, 2008, J BIOL CHEM, V283, P5414, DOI 10.1074/jbc.M709103200; SOWUNMI A, 1989, LANCET, V2, P213; Subramanian H, 2013, J IMMUNOL, V191, P345, DOI 10.4049/jimmunol.1300023	9	12	12	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1960	+		10.1016/j.jaci.2019.01.013	http://dx.doi.org/10.1016/j.jaci.2019.01.013			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30682457				2022-12-18	WOS:000466784600039
J	Tang, XZ; Jung, JB; Allen, CDC				Tang, Xin-Zi; Jung, James B.; Allen, Christopher D. C.			A case of mistaken identity: The MAR-1 antibody to mouse Fc epsilon RI alpha cross-reacts with Fc gamma RI and Fc gamma RIV	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							AFFINITY IGE RECEPTOR; DENDRITIC CELLS; BASOPHILS; INDUCTION		[Tang, Xin-Zi; Jung, James B.; Allen, Christopher D. C.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA; [Tang, Xin-Zi; Jung, James B.; Allen, Christopher D. C.] Univ Calif San Francisco, Sandler Asthma Basic Res Ctr, San Francisco, CA 94143 USA; [Tang, Xin-Zi; Jung, James B.] Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94143 USA; [Allen, Christopher D. C.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Allen, CDC (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA.; Allen, CDC (corresponding author), Univ Calif San Francisco, Sandler Asthma Basic Res Ctr, San Francisco, CA 94143 USA.; Allen, CDC (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	Chris.Allen@ucsf.edu		Allen, Christopher/0000-0002-1879-9047	National Heart, Lung, and Blood Institute of the National Institutes of Health [DP2HL117752]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI103146, R21AI130495]; Cardiovascular Research Institute; Sandler Asthma Basic Research Center at the University of California, San Francisco; National Science Scholarship - Agency for Science, Technology and Research, Singapore; Pew Charitable Trusts; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI103146, R21AI130495, T32AI007334] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Cardiovascular Research Institute; Sandler Asthma Basic Research Center at the University of California, San Francisco(University of California System); National Science Scholarship - Agency for Science, Technology and Research, Singapore; Pew Charitable Trusts; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Heart, Lung, and Blood Institute (award no. DP2HL117752) and the National Institute of Allergy and Infectious Diseases (award nos. R01AI103146 and R21AI130495) of the National Institutes of Health, as well as the Cardiovascular Research Institute and the Sandler Asthma Basic Research Center at the University of California, San Francisco. X.-Z. Tang was partially funded by the National Science Scholarship awarded by the Agency for Science, Technology and Research, Singapore. C.D.C.A. is a Pew Scholar in the Biomedical Sciences supported by the Pew Charitable Trusts. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.	Allen CDC, 2004, NAT IMMUNOL, V5, P943, DOI 10.1038/ni1100; Denzel A, 2008, NAT IMMUNOL, V9, P733, DOI 10.1038/ni.1621; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Khodoun MV, 2013, J ALLERGY CLIN IMMUN, V131, P1555, DOI 10.1016/j.jaci.2013.02.043; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Mancardi DA, 2008, J CLIN INVEST, V118, P3738, DOI 10.1172/JCI36452; Platzer B, 2015, MUCOSAL IMMUNOL, V8, P516, DOI 10.1038/mi.2014.85; Porcherie A, 2011, J EXP MED, V208, P2225, DOI 10.1084/jem.20110845; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Voehringer D, 2011, CURR OPIN IMMUNOL, V23, P789, DOI 10.1016/j.coi.2011.09.005; Yang Z, 2018, METHODS MOL BIOL; Yang ZY, 2016, ELIFE, V5, DOI 10.7554/eLife.21238; Yang ZY, 2012, IMMUNITY, V36, P857, DOI 10.1016/j.immuni.2012.02.009	17	12	12	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1643	+		10.1016/j.jaci.2018.11.045	http://dx.doi.org/10.1016/j.jaci.2018.11.045			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30639345	Green Accepted, Bronze			2022-12-18	WOS:000463348900045
J	Berin, MC				Berin, M. Cecilia			Mechanisms that define transient versus persistent food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Tolerance; food allergy; anaphylaxis; natural history; IgE; components; epitopes; innate immunity; regulatory T cells; microbiome; memory B cells	NATURAL-HISTORY; MILK ALLERGY; EGG ALLERGY; TOLERANCE; CHILDREN; EPITOPES; IGE; SENSITIZATION; SPECIFICITY; MICROBIOTA	Currently, we have a poor understanding of why some food allergies are outgrown and others are not. Deciphering the immune basis of the natural resolution of food allergy will likely provide critical information for developing new therapies for the treatment of persistent food allergies. There are limited cohort studies that have followed children with food allergy over time, but information generated from such cohorts points to features of innate and adaptive immunity, as well as environmental differences (microbiome) that discriminate those with persistent versus transient food allergy. Studies from mouse models highlight the importance of novel subsets of memory B cells rather than plasma cells combined with antigen re-exposure and T-cell help in the maintenance of IgE. In this review we discuss these findings from human cohorts and experimental systems and discuss existing gaps in our knowledge.	[Berin, M. Cecilia] Icahn Sch Med Mt Sinai, Jaffe Food Allergy Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Berin, MC (corresponding author), One Gustave L Levy Pl,Box 1198, New York, NY 10029 USA.	cecilia.berin@mssm.edu		berin, cecilia/0000-0002-9051-9249	NIAID NIH HHS [U19 AI136053, U24 AI118644] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI136053, U24AI118644] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Azad MB, 2015, CLIN EXP ALLERGY, V45, P632, DOI 10.1111/cea.12487; Bunyavanich S, 2016, J ALLERGY CLIN IMMUN, V138, P1122, DOI 10.1016/j.jaci.2016.03.041; Caubet JC, 2017, ALLERGY, V72, P1677, DOI 10.1111/all.13167; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; Dang TD, 2019, ALLERGY, V74, P318, DOI 10.1111/all.13572; Fazlollahi M, 2018, ALLERGY, V73, P1515, DOI 10.1111/all.13389; Fishbein AB, 2014, ANN ALLERG ASTHMA IM, V113, P667, DOI 10.1016/j.anai.2014.09.002; Fleischer DM, 2005, J ALLERGY CLIN IMMUN, V116, P1087, DOI 10.1016/j.jaci.2005.09.002; Frischmeyer-Guerrerio PA, 2011, CLIN EXP ALLERGY, V41, P61, DOI 10.1111/j.1365-2222.2010.03606.x; He JS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00723-0; Jaervinen KM, 2007, ALLERGY, V62, P758, DOI 10.1111/j.1398-9995.2007.01332.x; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jimenez-Saiz R, 2017, J ALLERGY CLIN IMMUN, V140, P1604, DOI 10.1016/j.jaci.2017.01.018; Mitson-Salazar A, 2016, J ALLERGY CLIN IMMUN, V137, P907, DOI 10.1016/j.jaci.2015.08.007; Neeland MR, 2018, J ALLERGY CLIN IMMUN, V142, P857, DOI 10.1016/j.jaci.2017.10.024; Peters RL, 2017, J ALLERGY CLIN IMMUN, V140, P145, DOI 10.1016/j.jaci.2017.02.019; Peters RL, 2014, J ALLERGY CLIN IMMUN, V133, P485, DOI 10.1016/j.jaci.2013.11.032; Peters RL, 2015, J ALLERGY CLIN IMMUN, V135; Qamar N, 2015, CLIN EXP ALLERGY, V45, P1663, DOI 10.1111/cea.12570; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Savage JH, 2018, ALLERGY, V73, P145, DOI 10.1111/all.13232; Schoemaker AA, 2015, ALLERGY, V70, P963, DOI 10.1111/all.12630; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P492, DOI 10.1016/j.jaci.2013.12.1041; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1077, DOI 10.1016/j.jaci.2010.02.038; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Tan J, 2016, CELL REP, V15, P2809, DOI 10.1016/j.celrep.2016.05.047; Tang MLK, 2015, J ALLERGY CLIN IMMUN, V135, P737, DOI 10.1016/j.jaci.2014.11.034; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Vila L, 2001, CLIN EXP ALLERGY, V31, P1599, DOI 10.1046/j.1365-2222.2001.01218.x; Wood RA, 2013, J ALLERGY CLIN IMMUN, V131, P805, DOI 10.1016/j.jaci.2012.10.060; Xiong HZ, 2012, J EXP MED, V209, P353, DOI 10.1084/jem.20111941; Zhang YX, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad4322	35	12	12	6	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					453	457		10.1016/j.jaci.2018.12.991	http://dx.doi.org/10.1016/j.jaci.2018.12.991			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	30736894	Bronze, Green Accepted			2022-12-18	WOS:000457718700001
J	Zenarruzabeitia, O; Vitalle, J; Terren, I; Orrantia, A; Astigarraga, I; Dopazo, L; Gonzalez, C; Santos-Diez, L; Tutau, C; Gamboa, PM; Bilbao, A; Borrego, F				Zenarruzabeitia, Olatz; Vitalle, Joana; Terren, Inigo; Orrantia, Ane; Astigarraga, Itziar; Dopazo, Leire; Gonzalez, Carlos; Santos-Diez, Laura; Tutau, Carlos; Gamboa, Pedro M.; Bilbao, Agurtzane; Borrego, Francisco			CD300c costimulates IgE-mediated basophil activation, and its expression is increased in patients with cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Basophils; CD300; CD300a; CD300c; allergy; IgE-mediated activation; IL-3; activation threshold	RECEPTOR IRP60 CD300A; INHIBITORY RECEPTOR; MAST-CELLS; DIFFERENTIAL REGULATION; FOOD ALLERGY; PHOSPHATIDYLSERINE; LINKING; IDENTIFICATION; RESPONSES; DEGRANULATION	Background: Basophils express high-affinity IgE receptors (Fc epsilon RI), which play an essential role in allergic diseases. It is important to characterize new cell-surface receptors that modulate IgE-mediated basophil activation threshold to design promising immunomodulatory therapies. Objectives: We sought to analyze the expression of CD300 receptors on human basophils and their implication in IgE-mediated basophil activation processes. Methods: Blood samples from healthy subjects and patients with cow's milk allergy were collected through the Basque Biobank under an institutional review board-approved protocol. PBMCs were obtained by means of density centrifugation, basophils were purified with a specific isolation kit, and phenotypic and functional studies were performed by using flow cytometry. Results: We demonstrate that basophils express the activating receptor CD300c, which is specifically upregulated in response to IL-3. CD300c works as a costimulatory molecule during IgE-mediated basophil activation, as shown by a significant increase in degranulation and cytokine production when basophils are activated in the presence of CD300c cross-linking compared with activation through the IgE/Fc epsilon RI axis alone. Coligation of Fc epsilon RI and CD300c increased intracellular calcium mobilization and phosphorylation of signaling intermediates evoked only by Fc epsilon RI ligation. We show that the natural ligands of CD300c, phosphatidylserine and phosphatidylethanolamine, modulate IgE-mediated basophil activation. Furthermore, we have observed that CD300c expression in children with cow's milk allergy is increased compared with that in healthy control subjects and that the intensity of expression correlates with the severity of the hypersensitivity symptoms. Conclusion: CD300c could be considered a biomarker and therapeutic target in patients with IgE-mediated allergic diseases because it seems to be involved in the modulation of IgE-mediated basophil activation.	[Zenarruzabeitia, Olatz; Vitalle, Joana; Terren, Inigo; Orrantia, Ane; Dopazo, Leire; Santos-Diez, Laura; Gamboa, Pedro M.; Bilbao, Agurtzane; Borrego, Francisco] Biocruces Bizkaia Hlth Res Inst, Immunopathol Grp, Baracaldo, Spain; [Astigarraga, Itziar] Biocruces Bizkaia Hlth Res Inst, Pediat Oncol Grp, Baracaldo, Spain; [Astigarraga, Itziar; Dopazo, Leire; Santos-Diez, Laura; Tutau, Carlos; Bilbao, Agurtzane] Cruces Univ Hosp, Pediat Serv, Baracaldo, Spain; [Gamboa, Pedro M.] Cruces Univ Hosp, Allergol Serv, Baracaldo, Spain; [Astigarraga, Itziar; Gonzalez, Carlos] Univ Basque Country, Fac Med & Nursing, Dept Pediat, Leioa, Spain; [Gonzalez, Carlos] Basurto Univ Hosp, Pediat Serv, Bilbao, Spain; [Borrego, Francisco] Ikerbasque, Basque Fdn Sci, Bilbao, Spain; [Borrego, Francisco] Basque Ctr Transfus & Human Tissues, Galdakao, Spain	Hospital Universitario Cruces; Hospital Universitario Cruces; University of Basque Country; Basurto Hospital; Basque Foundation for Science	Zenarruzabeitia, O; Borrego, F (corresponding author), Biocruces Hlth Res Inst, Immunopathol Grp, Baracaldo 48903, Spain.	olatz.zenarruzabeitiabelaustegui@osakidetza.eus	Zenarruzabeitia, Olatz/AAD-6772-2019; Astigarraga, I/I-1215-2014; Borrego, Francisco/ABI-1391-2020; Terrén, Iñigo/AAX-3541-2021; Vitallé, Joana/AAP-3953-2020	Zenarruzabeitia, Olatz/0000-0002-0869-9034; Astigarraga, I/0000-0002-5012-0137; Borrego, Francisco/0000-0002-3105-981X; Terrén, Iñigo/0000-0002-8099-3916; Orrantia Robles, Ane/0000-0002-9016-3799	Instituto de Salud Carlos III [PI16/01223, CD17/00128]; European Regional Development Fund "Away to make Europe"; Department of Education, Language Policy and Culture, Basque Government [PRE_2017_2_0242]; Jesus de Gangoiti Barrera Foundation [FJGB17/003]; European Social Fund (ESF)-The ESF invests in your future	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); European Regional Development Fund "Away to make Europe"; Department of Education, Language Policy and Culture, Basque Government; Jesus de Gangoiti Barrera Foundation; European Social Fund (ESF)-The ESF invests in your future(European Social Fund (ESF))	Supported by a grant from "Instituto de Salud Carlos III" through the project PI16/01223 (cofunded by European Regional Development Fund "Away to make Europe"). J.V. is a recipient of a predoctoral contract funded by the Department of Education, Language Policy and Culture, Basque Government (PRE_2017_2_0242). I.T. is recipient of a fellowship from the Jesus de Gangoiti Barrera Foundation (FJGB17/003). O.Z. is recipient of a postdoctoral contract funded by "Instituto de Salud Carlos III-Contratos Sara Borrell 2017 (CD17/00128)" and the European Social Fund (ESF)-The ESF invests in your future. F.B. is an Ikerbasque Research Professor, Ikerbaque, Basque Foundation for Science.	Akdis M, 2016, J ALLERGY CLIN IMMUN, V138, P984, DOI 10.1016/j.jaci.2016.06.033; Alvarez Y, 2008, MOL IMMUNOL, V45, P253, DOI 10.1016/j.molimm.2007.05.006; Alvarez-Errico D, 2007, J IMMUNOL, V178, P808, DOI 10.4049/jimmunol.178.2.808; Bachelet I, 2005, J IMMUNOL, V175, P7989, DOI 10.4049/jimmunol.175.12.7989; Bachelet I, 2008, J IMMUNOL, V180, P6064, DOI 10.4049/jimmunol.180.9.6064; Bachelet I, 2006, J ALLERGY CLIN IMMUN, V117, P1314, DOI 10.1016/j.jaci.2006.04.031; Borrego F, 2002, MOL IMMUNOL, V38, P637, DOI 10.1016/S0161-5890(01)00107-9; Borrego F, 2013, BLOOD, V121, P1951, DOI 10.1182/blood-2012-09-435057; Bulfone-Paus S, 2017, TRENDS IMMUNOL, V38, P657, DOI 10.1016/j.it.2017.01.008; Bussmann C, 2010, ALLERGY, V65, P1558, DOI 10.1111/j.1398-9995.2010.02430.x; Choi SC, 2011, J IMMUNOL, V187, P3483, DOI 10.4049/jimmunol.1101549; Clark GJ, 2009, TRENDS IMMUNOL, V30, P209, DOI 10.1016/j.it.2009.02.003; Didichenko SA, 2008, BLOOD, V112, P3949, DOI 10.1182/blood-2008-04-149419; Dimitrova M, 2016, SCI REP-UK, V6, DOI 10.1038/srep23942; Falcone FH, 2006, EXP DERMATOL, V15, P855, DOI 10.1111/j.1600-0625.2006.00477.x; Frischmeyer-Guerrerio PA, 2017, J ALLERGY CLIN IMMUN, V140, pe8; Galli SJ, 2000, CURR OPIN HEMATOL, V7, P32, DOI 10.1097/00062752-200001000-00007; Gibbs BF, 2012, EXP DERMATOL, V21, P884, DOI 10.1111/exd.12018; Harvima IT, 2014, J ALLERGY CLIN IMMUN, V134, P530, DOI 10.1016/j.jaci.2014.03.007; Heine A, 2013, BLOOD, V122, P1192, DOI 10.1182/blood-2013-03-484642; Isobe M, 2018, J BIOL CHEM, V293, P3793, DOI 10.1074/jbc.RA117.000696; Izawa K, 2007, J BIOL CHEM, V282, P17997, DOI 10.1074/jbc.M701100200; Izawa K, 2014, J ALLERGY CLIN IMMUN, V133, P270, DOI 10.1016/j.jaci.2013.08.008; Izawa K, 2012, IMMUNITY, V37, P827, DOI 10.1016/j.immuni.2012.08.018; Kampfer SS, 2017, J LEUKOCYTE BIOL, V101, P227, DOI 10.1189/jlb.2A0715-292RR; Kepley CL, 1998, J LEUKOCYTE BIOL, V64, P474, DOI 10.1002/jlb.64.4.474; Lieberman JA, 2013, CURR ALLERGY ASTHM R, V13, P78, DOI 10.1007/s11882-012-0316-x; Long EO, 2013, ANNU REV IMMUNOL, V31, P227, DOI 10.1146/annurev-immunol-020711-075005; MacGlashan D, 2010, CLIN EXP ALLERGY, V40, P1365, DOI 10.1111/j.1365-2222.2010.03572.x; MacGlashan D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126435; Moshkovits I, 2014, MUCOSAL IMMUNOL, V7, P292, DOI 10.1038/mi.2013.47; Munitz A, 2006, BLOOD, V107, P1996, DOI 10.1182/blood-2005-07-2926; Munitz A, 2006, J ALLERGY CLIN IMMUN, V118, P1082, DOI 10.1016/j.jaci.2006.07.041; Murakami Y, 2014, CELL DEATH DIFFER, V21, P1746, DOI 10.1038/cdd.2014.86; Nakahashi-Oda C, 2012, BIOCHEM BIOPH RES CO, V417, P646, DOI 10.1016/j.bbrc.2011.12.025; Niggemann B, 2016, ALLERGY, V71, P135, DOI 10.1111/all.12765; Niizuma K, 2015, J BIOL CHEM, V290, P22298, DOI 10.1074/jbc.M115.643361; Oettgen HC, 2015, CURR OPIN IMMUNOL, V36, P109, DOI 10.1016/j.coi.2015.07.007; OFarrell AM, 1996, BLOOD, V87, P3655, DOI 10.1182/blood.V87.9.3655.bloodjournal8793655; Quintas-Cardama A, 2010, BLOOD, V115, P3109, DOI 10.1182/blood-2009-04-214957; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Rivera J, 2002, CURR OPIN IMMUNOL, V14, P688, DOI 10.1016/S0952-7915(02)00396-5; Ryu SD, 2009, CELL CALCIUM, V45, P99, DOI 10.1016/j.ceca.2008.07.002; Sabato V, 2014, J ALLERGY CLIN IMMUN, V134, P734, DOI 10.1016/j.jaci.2014.03.029; Sabato V, 2012, CYTOM PART B-CLIN CY, V82B, P132, DOI 10.1002/cyto.b.21003; SCHROEDER JT, 1995, ALLERGY, V50, P463, DOI 10.1111/j.1398-9995.1995.tb01180.x; Schroeder JT, 2001, ADV IMMUNOL, V77, P93, DOI 10.1016/S0065-2776(01)77015-0; Shik D, 2014, ALLERGY, V69, P719, DOI 10.1111/all.12388; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Simhadri VR, 2013, J INNATE IMMUN, V5, P389, DOI 10.1159/000350523; Simhadri VR, 2012, BLOOD, V119, P2799, DOI 10.1182/blood-2011-08-372425; Siracusa MC, 2010, IMMUNOL CELL BIOL, V88, P275, DOI 10.1038/icb.2010.1; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; Takahashi M, 2013, J BIOL CHEM, V288, P7662, DOI 10.1074/jbc.M112.434746; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Valent P, 2010, CURR OPIN HEMATOL, V17, P60, DOI 10.1097/MOH.0b013e328331fae9; Voehringer D, 2013, NAT REV IMMUNOL, V13, P362, DOI 10.1038/nri3427; Wang MQ, 2010, J ALLERGY CLIN IMMUN, V126, P306, DOI 10.1016/j.jaci.2010.05.017; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P1103, DOI 10.1016/j.jaci.2015.10.005; Yamanishi Y, 2008, BLOOD, V111, P688, DOI 10.1182/blood-2007-04-085787; Yamanishi Y, 2017, IMMUNOL REV, V278, P237, DOI 10.1111/imr.12548; Zenarruzabeitia O, 2016, SCI REP-UK, V6, DOI 10.1038/srep32693; Zenarruzabeitia O, 2015, J IMMUNOL, V194, P5053, DOI 10.4049/jimmunol.1500304	63	12	12	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					700	+		10.1016/j.jaci.2018.05.022	http://dx.doi.org/10.1016/j.jaci.2018.05.022			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	29906528	Bronze			2022-12-18	WOS:000457718700029
J	Garib, V; Rigler, E; Gastager, F; Campana, R; Dorofeeva, Y; Gattinger, P; Zhernov, Y; Khaitov, M; Valenta, R				Garib, Victoria; Rigler, Eva; Gastager, Felix; Campana, Raffaela; Dorofeeva, Yulia; Gattinger, Pia; Zhernov, Yury; Khaitov, Musa; Valenta, Rudolf			Determination of IgE and IgG reactivity to more than 170 allergen molecules in paper-dried blood spots	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MICROARRAY		[Garib, Victoria; Rigler, Eva; Campana, Raffaela; Dorofeeva, Yulia; Gattinger, Pia; Valenta, Rudolf] Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Gastager, Felix] HVD Vertriebs Gesell mbH, Vienna, Austria; [Zhernov, Yury; Khaitov, Musa; Valenta, Rudolf] Sechenov First Moscow State Med Univ, NRC Inst Immunol FMBA Russia, Moscow, Russia; [Valenta, Rudolf] Sechenov First Moscow State Med Univ, Lab Immunopathol, Dept Clin Immunol & Allergy, Moscow, Russia	Medical University of Vienna; NRC Institute of Immunology FMBA of Russia; Sechenov First Moscow State Medical University; Sechenov First Moscow State Medical University	Valenta, R (corresponding author), Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria.; Valenta, R (corresponding author), Sechenov First Moscow State Med Univ, NRC Inst Immunol FMBA Russia, Moscow, Russia.; Valenta, R (corresponding author), Sechenov First Moscow State Med Univ, Lab Immunopathol, Dept Clin Immunol & Allergy, Moscow, Russia.	Rudolf.valenta@meduniwien.ac.at	Garib, Victoria/ABD-9932-2020; Khaitov, Musa R/L-3369-2017; Zhernov, Yury/K-8219-2014; Khaitov, Musa/AAC-1516-2021	Khaitov, Musa R/0000-0003-4961-9640; Zhernov, Yury/0000-0001-8734-5527; Khaitov, Musa/0000-0003-4961-9640; Valenta, Rudolf/0000-0001-5944-3365; Gattinger, Pia/0000-0001-6724-8543; Campana, Raffaela/0000-0001-9309-9908	Austrian Science Fund (Fonds zur Forderung der wissenschaftlichen Forschung [FWF]) [F4605]; FWF; Government of the Russian Federation [14.W03.31.0024]	Austrian Science Fund (Fonds zur Forderung der wissenschaftlichen Forschung [FWF])(Austrian Science Fund (FWF)); FWF(Austrian Science Fund (FWF)); Government of the Russian Federation	This study was supported by the Austrian Science Fund (Fonds zur Forderung der wissenschaftlichen Forschung [FWF]) via grant number F4605 and the FWF-funded PhD programs Inflammation and Immunity (IAI) and Molecular, Cellular and Clinical Allergology (MCCA). R.V. is recipient of a megagrant of the Government of the Russian Federation (grant no. 14.W03.31.0024).	Canonica GW, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-17; Fedenko E, 2016, PEDIAT ALLERG IMM-UK, V27, P645, DOI 10.1111/pai.12572; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Matricardi PM, 2016, PEDIAT ALLERG IMM-UK, V27, P1, DOI 10.1111/pai.12563; Siroux V, 2017, J ALLERGY CLIN IMMUN, V139, P643, DOI 10.1016/j.jaci.2016.05.023; Thomas WR, 2011, J ALLERGY CLIN IMMUN, V127, P855, DOI 10.1016/j.jaci.2010.12.1084; Valenta R, 2010, ANNU REV IMMUNOL, V28, P211, DOI 10.1146/annurev-immunol-030409-101218; van Hage M, 2017, J ALLERGY CLIN IMMUN, V140, P974, DOI 10.1016/j.jaci.2017.05.008; Wollmann E, 2015, J ALLERGY CLIN IMMUN, V136, P806, DOI 10.1016/j.jaci.2015.02.034	9	12	12	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					437	440		10.1016/j.jaci.2018.08.047	http://dx.doi.org/10.1016/j.jaci.2018.08.047			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30392720	hybrid, Green Accepted			2022-12-18	WOS:000454918300056
J	Shakya, AK; Lee, CH; Gill, HS				Shakya, Akhilesh Kumar; Lee, Chang Hyun; Gill, Harvinder Singh			Coated microneedle-based cutaneous immunotherapy prevents Der p 1-induced airway allergy in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ASTHMA; INFLAMMATION		[Shakya, Akhilesh Kumar; Lee, Chang Hyun; Gill, Harvinder Singh] Texas Tech Univ, Dept Chem Engn, Lubbock, TX 79409 USA	Texas Tech University System; Texas Tech University	Gill, HS (corresponding author), Texas Tech Univ, Dept Chem Engn, Lubbock, TX 79409 USA.	harvinder.gill@ttu.edu	Gill, Harvinder Singh/D-8252-2014; Shakya, Akhilesh/AAL-2142-2021	Gill, Harvinder Singh/0000-0003-0832-5291; Shakya, Akhilesh K/0000-0002-8907-7009	National Institutes of Health [R01AI121322]; Texas Tech University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI121322] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Texas Tech University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health (grant no. R01AI121322) and by funding from Texas Tech University.	Akinbami LJ, 2016, J ASTHMA, V53, P356, DOI 10.3109/02770903.2015.1126848; Ano S, 2013, J IMMUNOL, V190, P1056, DOI 10.4049/jimmunol.1202386; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Gill HS, 2008, CLIN J PAIN, V24, P585, DOI 10.1097/AJP.0b013e31816778f9; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; Larsen JN, 2016, DRUG DISCOV TODAY, V21, P26, DOI 10.1016/j.drudis.2015.07.010; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Ray A, 2017, TRENDS IMMUNOL, V38, P942, DOI 10.1016/j.it.2017.07.003; Shakya AK, 2017, J CONTROL RELEASE, V265, P75, DOI 10.1016/j.jconrel.2017.08.012	9	12	13	2	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					2007	+		10.1016/j.jaci.2018.08.017	http://dx.doi.org/10.1016/j.jaci.2018.08.017			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	30171871	Green Accepted, Bronze			2022-12-18	WOS:000452315800044
J	Hubers, SA; Kohm, K; Wei, SZ; Yu, C; Nian, H; Grabert, R; Sexton, DJ; Brown, NJ				Hubers, Scott A.; Kohm, Kevin; Wei, Shouzuo; Yu, Chang; Nian, Hui; Grabert, Ryan; Sexton, Daniel J.; Brown, Nancy J.			Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RANDOMIZED-TRIAL; ICATIBANT		[Hubers, Scott A.; Kohm, Kevin; Wei, Shouzuo; Brown, Nancy J.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; [Yu, Chang; Nian, Hui] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Grabert, Ryan; Sexton, Daniel J.] Shire, Global Nonclin Dev, Lexington, MA USA	Vanderbilt University; Vanderbilt University; Shire Pharmaceuticals Limited	Brown, NJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA.	Nancy.j.brown@vanderbilt.edu			National Institutes of Health [R01-HL-125426]; Shire HGT; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL125426, R01HL079184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM108554] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Shire HGT; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by grants from the National Institutes of Health (R01-HL-125426) and by a grant from Shire HGT. Kininogen measurements were performed at Shire.	Bas M, 2015, NEW ENGL J MED, V372, P418, DOI 10.1056/NEJMoa1312524; Cicardi M, 2010, NEW ENGL J MED, V363, P532, DOI 10.1056/NEJMoa0906393; Lewis LM, 2015, ANN EMERG MED, V65, P204, DOI 10.1016/j.annemergmed.2014.07.014; Maeda S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17798-w; Murphey LJ, 2001, ANAL BIOCHEM, V292, P87, DOI 10.1006/abio.2001.5073; Nussberger J, 2002, NEW ENGL J MED, V347, P621, DOI 10.1056/NEJM200208223470820; Pare G, 2013, PHARMACOGENET GENOM, V23, P470, DOI 10.1097/FPC.0b013e328363c137; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Sinert R, 2017, J ALLER CL IMM-PRACT, V5, P1402, DOI 10.1016/j.jaip.2017.03.003; Straka BT, 2017, J ALLERGY CLIN IMMUN, V140, P242, DOI 10.1016/j.jaci.2016.09.051; Suffritti C, 2014, CLIN EXP ALLERGY, V44, P1503, DOI 10.1111/cea.12293	12	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1636	+		10.1016/j.jaci.2018.06.037	http://dx.doi.org/10.1016/j.jaci.2018.06.037			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	30036596	Green Accepted, Bronze			2022-12-18	WOS:000449429800027
J	Martorana, D; Marquez, A; Carmona, FD; Bonatti, F; Adorni, A; Urban, ML; Maritati, F; Buttini, EA; Marvisi, C; Palmisano, A; Rossi, GM; Trivioli, G; Fenaroli, P; Manenti, L; Nicastro, M; Incerti, M; Gianfreda, D; Bani, S; Ferretti, S; Corradi, D; Alberici, F; Emmi, G; Di Scala, G; Moroni, G; Percesepe, A; Scheel, PJ; Vermeer, E; van Bommel, EF; Martin, J; Vaglio, A				Martorana, Davide; Marquez, Ana; Carmona, F. David; Bonatti, Francesco; Adorni, Alessia; Urban, Maria L.; Maritati, Federica; Buttini, Eugenia Accorsi; Marvisi, Chiara; Palmisano, Alessandra; Rossi, Giovanni M.; Trivioli, Giorgio; Fenaroli, Paride; Manenti, Lucio; Nicastro, Maria; Incerti, Monia; Gianfreda, Davide; Bani, Stefano; Ferretti, Stefania; Corradi, Domenico; Alberici, Federico; Emmi, Giacomo; Di Scala, Gerardo; Moroni, Gabriella; Percesepe, Antonio; Scheel, Paul J., Jr.; Vermeer, Eric; van Bommel, Eric F.; Martin, Javier; Vaglio, Augusto			A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							SYSTEM		[Martorana, Davide; Bonatti, Francesco; Adorni, Alessia; Percesepe, Antonio] Parma Univ Hosp, Med Genet Unit, Parma, Italy; [Urban, Maria L.; Maritati, Federica; Buttini, Eugenia Accorsi; Marvisi, Chiara; Palmisano, Alessandra; Rossi, Giovanni M.; Trivioli, Giorgio; Fenaroli, Paride; Manenti, Lucio; Nicastro, Maria; Incerti, Monia; Gianfreda, Davide; Bani, Stefano; Vaglio, Augusto] Parma Univ Hosp, Nephrol Unit, Parma, Italy; [Ferretti, Stefania] Parma Univ Hosp, Urol Unit, Parma, Italy; [Corradi, Domenico] Parma Univ Hosp, Pathol Unit, Parma, Italy; [Marquez, Ana; Martin, Javier] CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada, Spain; [Carmona, F. David] Univ Granada, Dept Genet, Granada, Spain; [Carmona, F. David] Univ Granada, Inst Biotecnol, Granada, Spain; [Alberici, Federico] San Carlo Borromeo Hosp, Nephrol Unit, Milan, Italy; [Emmi, Giacomo; Di Scala, Gerardo] Univ Firenze, Internal Med, Florence, Italy; [Moroni, Gabriella] Fdn Ca Granda IRCCS Osped Maggiore, Nephrol Unit, Milan, Italy; [Scheel, Paul J., Jr.] Washington Univ, Dept Med, St Louis, MO USA; [Vermeer, Eric; van Bommel, Eric F.] Albert Schweitzer Hosp, Dutch Natl Ctr Expertise Retroperitoneal Fibrosis, Dept Internal Med, Dordrecht, Netherlands	University of Parma; University Hospital of Parma; University of Parma; University Hospital of Parma; University of Parma; University Hospital of Parma; University of Parma; University Hospital of Parma; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); University of Granada; University of Granada; San Carlo Borromeo Hospital; University of Florence; Washington University (WUSTL); Albert Schweitzer Ziekenhuis	Vaglio, A (corresponding author), Parma Univ Hosp, Nephrol Unit, Parma, Italy.	augusto.vaglio@virgilio.it	Vaglio, Augusto/AHE-8117-2022; Martín, Javier/AAV-5209-2021; Martín, María/HDL-9512-2022; Emmi, Giacomo/J-6913-2016; Manenti, Lucio/AAF-6437-2020; Alberici, Federico/AAC-5289-2022; Trivioli, Giorgio/AAT-8056-2021; Martorana, Davide/K-6374-2016; Di Scala, Gerardo/AAM-1633-2021; Martin, Javier/B-8141-2008; Maritati, Federica/AFV-5907-2022; Carmona, F. David/F-9953-2016; Bonatti, Francesco/K-6362-2016	Vaglio, Augusto/0000-0002-3814-9172; Alberici, Federico/0000-0002-1686-5709; Trivioli, Giorgio/0000-0003-1578-4402; Martorana, Davide/0000-0002-7572-7031; Di Scala, Gerardo/0000-0002-2245-5589; Martin, Javier/0000-0002-2202-0622; Carmona, F. David/0000-0002-1427-7639; Bonatti, Francesco/0000-0002-5067-5423; Ferretti, Stefania/0000-0002-2292-5632; Marquez, Ana/0000-0001-9913-7688; Rossi, Giovanni M./0000-0001-8886-4329; Emmi, Giacomo/0000-0001-9575-8321; Urban, Maria Letizia/0000-0003-1334-9538	"A tailored approach to the immune-monitoring and clinical management of viral and autoimmune diseases"; Regione Emilia-Romagna within the Programma di Ricerca Regione-Universita; "Tailoring Rituximab treatment in ANCA-associated vasculitis; a genetic and an immunological approach"; Regione Emilia-Romagna within the Programma di ricerca Regione-Universita Giovani Ricercatori "Alessandro Liberati''; Fondazione Emma ed Ernesto Rulfo per la Genetica Medica; "Juan de la Cierva'' fellowship from the Spanish Ministry of Economy and Competitiveness [IJCI-2014-20322]; "Ramon y Cajal'' programme from the Spanish Ministry of Economy, Industry and Competitiveness [RYC-2014-16458]	"A tailored approach to the immune-monitoring and clinical management of viral and autoimmune diseases"; Regione Emilia-Romagna within the Programma di Ricerca Regione-Universita(Regione Emilia Romagna); "Tailoring Rituximab treatment in ANCA-associated vasculitis; a genetic and an immunological approach"; Regione Emilia-Romagna within the Programma di ricerca Regione-Universita Giovani Ricercatori "Alessandro Liberati''; Fondazione Emma ed Ernesto Rulfo per la Genetica Medica; "Juan de la Cierva'' fellowship from the Spanish Ministry of Economy and Competitiveness; "Ramon y Cajal'' programme from the Spanish Ministry of Economy, Industry and Competitiveness	Supported in part by "A tailored approach to the immune-monitoring and clinical management of viral and autoimmune diseases,'' which was funded by the Regione Emilia-Romagna within the Programma di Ricerca Regione-Universita 2010-2012, and "Tailoring Rituximab treatment in ANCA-associated vasculitis; a genetic and an immunological approach,'' which was funded by the Regione Emilia-Romagna within the Programma di ricerca Regione-Universita Giovani Ricercatori "Alessandro Liberati'' 2013, Fondazione Emma ed Ernesto Rulfo per la Genetica Medica. A.M. is recipient of a "Juan de la Cierva'' fellowship (IJCI-2014-20322) from the Spanish Ministry of Economy and Competitiveness. F.D.C. is recipient of a grant from the "Ramon y Cajal'' programme (RYC-2014-16458) from the Spanish Ministry of Economy, Industry and Competitiveness.	Cortes A, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3204; Farahi N, 2012, BLOOD, V120, P4068, DOI 10.1182/blood-2012-07-443424; Gonem S, 2016, LANCET RESP MED, V4, P699, DOI 10.1016/S2213-2600(16)30179-5; Hamilton G, 2008, EMBO J, V27, P499, DOI 10.1038/sj.emboj.7601979; Jacobson EM, 2008, J AUTOIMMUN, V30, P58, DOI 10.1016/j.jaut.2007.11.010; Jones HA, 2002, J NUCL MED, V43, P652; Klein J, 2000, NEW ENGL J MED, V343, P782, DOI 10.1056/NEJM200009143431106; Martorana D, 2006, ARTHRIT RHEUM-ARTHR, V55, P126, DOI 10.1002/art.21698; Menconi F, 2010, P NATL ACAD SCI USA, V107, P16899, DOI 10.1073/pnas.1009511107; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; QUANJER PH, 1994, REV MAL RESPIR, V11, P5; Rossi GM, 2017, INTERN EMERG MED, V12, P287, DOI 10.1007/s11739-016-1599-z; Ruparelia P, 2011, EUR J NUCL MED MOL I, V38, P911, DOI 10.1007/s00259-010-1715-7; Summers C, 2014, THORAX, V69, P623, DOI 10.1136/thoraxjnl-2013-204742; Vaglio A, 2016, J AM SOC NEPHROL, V27, P1880, DOI 10.1681/ASN.2015101110; Vaglio A, 2011, LANCET, V378, P338, DOI 10.1016/S0140-6736(11)60934-3; Wright AKA, 2017, ALLERGY, V72, P645, DOI 10.1111/all.13061	18	12	14	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1662	+		10.1016/j.jaci.2018.06.045	http://dx.doi.org/10.1016/j.jaci.2018.06.045			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	30081155	Bronze			2022-12-18	WOS:000449429800036
J	Fliegauf, M; Grimbacher, B				Fliegauf, Manfred; Grimbacher, Bodo			Nuclear factor kappa B mutations in human subjects: The devil is in the details	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						NFKB1; nuclear factor kappa B signaling; primary immunodeficiency disease; common variable immunodeficiency	ANHIDROTIC ECTODERMAL DYSPLASIA; IMMUNODEFICIENCY; DEFICIENCY		[Fliegauf, Manfred; Grimbacher, Bodo] Univ Freiburg, Fac Med, Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany	University of Freiburg	Grimbacher, B (corresponding author), Univ Freiburg, Med Ctr, Ctr Chron Immunodeficiency, Breisacherstr 115, D-79106 Freiburg, Germany.	bodo.grimbacher@uniklinik-freiburg.de			German Ministry of Education and Research [01E01303, 01ZX1306F]; E-rare program of the European Commission EURO-CMC [01GM1502]; German Center for Infection Research DZIF; Deutsche Forschungsgemeinschaft [SFB1160-IMPATH]; Bristol-Myers Squibb; CSL Behring; Novartis; Baxalta	German Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); E-rare program of the European Commission EURO-CMC; German Center for Infection Research DZIF; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bristol-Myers Squibb(Bristol-Myers Squibb); CSL Behring; Novartis(Novartis); Baxalta	B. Grimbacher has received research funding from the German Ministry of Education and Research (grant no. 01E01303 and E:med/sysINFLAME grant no. 01ZX1306F), the E-rare program of the European Commission EURO-CMC (01GM1502), the German Center for Infection Research DZIF, the Deutsche Forschungsgemeinschaft (SFB1160-IMPATH), Bristol-Myers Squibb, CSL Behring, Novartis, and Baxalta, and over the last 3 years, he has received lecture honoraria from CSL-Behring, Baxalta, and Biotest. M. Fliegauf declares that he has no relevant conflicts of interest.	Badran YR, 2017, J EXP MED, V214, P1937, DOI 10.1084/jem.20160724; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Hoeger B, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01978; Jost PJ, 2007, BLOOD, V109, P2700, DOI 10.1182/blood-2006-07-025809; Kaustio M, 2017, J ALLERGY CLIN IMMUN, V140, P782, DOI 10.1016/j.jaci.2016.10.054; Lahtela J, 2010, NEW ENGL J MED, V363, P1631, DOI 10.1056/NEJMoa0911698; Pannicke U, 2013, NEW ENGL J MED, V369, P2504, DOI 10.1056/NEJMoa1309199; Tuijnenburg P, 2018, J ALLERGY CLIN IMMUN, V142, P1285, DOI 10.1016/j.jaci.2018.01.039; Zhou Q, 2016, NAT GENET, V48, P67, DOI 10.1038/ng.3459; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	11	12	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1062	1065		10.1016/j.jaci.2018.06.050	http://dx.doi.org/10.1016/j.jaci.2018.06.050			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	30165054	Bronze			2022-12-18	WOS:000446327300007
J	Mishra, A; Yao, XL; Saxena, A; Gordon, EM; Kaler, M; Cuento, RA; Barochia, AV; Dagur, PK; McCoy, JP; Keeran, KJ; Jeffries, KR; Qu, X; Yu, ZX; Levine, SJ				Mishra, Amarjit; Yao, Xianglan; Saxena, Ankit; Gordon, Elizabeth M.; Kaler, Maryann; Cuento, Rosemarie A.; Barochia, Amisha V.; Dagur, Pradeep K.; McCoy, J. Philip; Keeran, Karen J.; Jeffries, Kenneth R.; Qu, Xuan; Yu, Zu-Xi; Levine, Stewart J.			Low-density lipoprotein receptor-related protein 1 attenuates house dust mite-induced eosinophilic airway inflammation by suppressing dendritic cell-mediated adaptive immune responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Low-density lipoprotein receptor-related protein 1; dendritic cells; eosinophilic airway inflammation; house dust mite; type 2-high asthma	NF-KAPPA-B; HEAT-SHOCK PROTEINS; T-CELLS; ALLERGIC INFLAMMATION; IN-VIVO; CROSS-PRESENTATION; LECTIN RECEPTORS; ASTHMA; LUNG; HYPERRESPONSIVENESS	Background: Low-density lipoprotein receptor-related protein 1 (LRP-1) is a scavenger receptor that regulates adaptive immunity and inflammation. LRP-1 is not known to modulate the pathogenesis of allergic asthma. Objective: We sought to assess whether LRP-1 expression by dendritic cells (DCs) modulates adaptive immune responses in patients with house dust mite (HDM)-induced airways disease. Methods: LRP-1 expression on peripheral blood DCs was quantified by using flow cytometry. The role of LRP-1 in modulating HDM-induced airways disease was assessed in mice with deletion of LRP-1 in CD11c(+) cells (Lrp1(fl/fl); CD11c-Cre) and by adoptive transfer of HDM-pulsed CD11b(+) DCs from Lrp1(fl/fl); CD11c-Cre mice to wild-type (WT) mice. Results: Human peripheral blood myeloid DC subsets from patients with eosinophilic asthma have lower LRP-1 expression than cells from healthy nonasthmatic subjects. Similarly, LRP-1 expression by CD11b(+) lung DCs was significantly reduced in HDM-challenged WT mice. HDM-challenged Lrp1(fl/fl); CD11c-Cre mice have a phenotype of increased eosinophilic airway inflammation, allergic sensitization, T(H)2 cytokine production, and mucous cell metaplasia. The adoptive transfer of HDM-pulsed LRP-1-deficient CD11b(+) DCs into WT mice generated a similar phenotype of enhanced eosinophilic inflammation and allergic sensitization. Furthermore, CD11b(+) DCs in the lungs of Lrp1(fl/fl); CD11c-Cre mice have an increased ability to take up HDM antigen, whereas bone marrow-derived DCs display enhanced antigen presentation capabilities. Conclusion: This identifies a novel role for LRP-1 as a negative regulator of DC-mediated adaptive immune responses in the setting of HDM-induced eosinophilic airway inflammation. Furthermore, the reduced LRP-1 expression by circulating myeloid DCs in patients with eosinophilic asthma suggests a possible role for LRP-1 in modulating type 2-high asthma.	[Mishra, Amarjit; Yao, Xianglan; Gordon, Elizabeth M.; Kaler, Maryann; Cuento, Rosemarie A.; Barochia, Amisha V.; Levine, Stewart J.] NHLBI, Lab Asthma & Lung Inflammat, NIH, Bldg 10, Bethesda, MD 20892 USA; [Saxena, Ankit; Dagur, Pradeep K.; McCoy, J. Philip] NHLBI, Flow Cytometry Core Facil, NIH, Bldg 10, Bethesda, MD 20892 USA; [Keeran, Karen J.; Jeffries, Kenneth R.] NHLBI, Anim Surg & Resources Core Facil, NIH, Bldg 10, Bethesda, MD 20892 USA; [Qu, Xuan; Yu, Zu-Xi] NHLBI, Pathol Core Facil, Div Intramural Res, NIH, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Levine, SJ (corresponding author), NHLBI, Lab Asthma & Lung Inflammat, Cardiovasc & Pulm Branch, NIH, Bldg 10,Room 6D03,MSC 1590, Bethesda, MD 20892 USA.	levines@nhlbi.nih.gov	mccoy, john philip/ABD-9348-2021; MISHRA, AMARJIT/I-4928-2019; Barochia, Amisha/R-6964-2019	MISHRA, AMARJIT/0000-0002-3777-0338; 	Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIGHL006020, ZICHL005905, ZIAHL006055, ZICHL005904] Funding Source: NIH RePORTER	Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.	Arron JR, 2015, THORAX, V70, P105, DOI 10.1136/thoraxjnl-2014-206069; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Boucher P, 2011, BIOCHEM PHARMACOL, V81, P1, DOI 10.1016/j.bcp.2010.09.018; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Casciano J, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0263-8; CHU CT, 1994, J IMMUNOL, V152, P1538; Cianciolo GJ, 2001, VACCINE, V20, P554, DOI 10.1016/S0264-410X(01)00361-9; Clarke DL, 2014, MUCOSAL IMMUNOL, V7, P558, DOI 10.1038/mi.2013.74; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; D'Alise AM, 2008, P NATL ACAD SCI USA, V105, P19857, DOI 10.1073/pnas.0810713105; De Filippo A, 2008, J IMMUNOL, V181, P6525, DOI 10.4049/jimmunol.181.9.6525; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Foster B, 2003, J ALLERGY CLIN IMMUN, V112, P1132, DOI 10.1016/j.jaci.2003.09.011; Fredriksson K, 2014, J IMMUNOL, V192, P4497, DOI 10.4049/jimmunol.1301234; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; Gaultier A, 2008, BLOOD, V111, P5316, DOI 10.1182/blood-2007-12-127613; Gaultier A, 2010, MATRIX BIOL, V29, P22, DOI 10.1016/j.matbio.2009.08.003; Geijtenbeek TBH, 2016, NAT REV IMMUNOL, V16, P433, DOI 10.1038/nri.2016.55; Gonias SL, 2014, AM J PATHOL, V184, P18, DOI 10.1016/j.ajpath.2013.08.029; Hadeiba H, 2003, J IMMUNOL, V170, P5502, DOI 10.4049/jimmunol.170.11.5502; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hammad H, 2002, J IMMUNOL, V169, P1524, DOI 10.4049/jimmunol.169.3.1524; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Hancock DB, 2012, J ALLERGY CLIN IMMUN, V129, P1673, DOI 10.1016/j.jaci.2012.03.012; Hart JP, 2004, J IMMUNOL, V172, P70, DOI 10.4049/jimmunol.172.1.70; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI13992; Hodge S, 2007, AM J RESP CELL MOL, V37, P748, DOI 10.1165/rcmb.2007-0025OC; Ishii S, 2004, J IMMUNOL, V172, P7095, DOI 10.4049/jimmunol.172.11.7095; Ito T, 2017, J IMMUNOL, V198, P61, DOI 10.4049/jimmunol.1502393; Jaffar Z, 2004, J IMMUNOL, V172, P3842, DOI 10.4049/jimmunol.172.6.3842; Julia V, 2002, IMMUNITY, V16, P271, DOI 10.1016/S1074-7613(02)00276-5; Kanekiyo T, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00093; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAMARRE J, 1993, J CLIN INVEST, V91, P1219, DOI 10.1172/JCI116283; Lambrecht Bart N, 2014, Ann Am Thorac Soc, V11 Suppl 5, pS236, DOI 10.1513/AnnalsATS.201405-218AW; Lillis AP, 2008, PHYSIOL REV, V88, P887, DOI 10.1152/physrev.00033.2007; Makela MJ, 2000, P NATL ACAD SCI USA, V97, P6007, DOI 10.1073/pnas.100118997; Mantuano E, 2016, P NATL ACAD SCI USA, V113, P1369, DOI 10.1073/pnas.1515480113; Masten BJ, 1997, AM J RESP CELL MOL, V16, P335, DOI 10.1165/ajrcmb.16.3.9070619; May P, 2013, CELL TISSUE RES, V354, P887, DOI 10.1007/s00441-013-1699-2; May P, 2013, CURR OPIN LIPIDOL, V24, P134, DOI 10.1097/MOL.0b013e32835e809c; Medoff BD, 2009, J IMMUNOL, V182, P623, DOI 10.4049/jimmunol.182.1.623; Mesnil C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053242; Mishra A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7224; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Overton CD, 2007, CIRC RES, V100, P670, DOI 10.1161/01.RES.0000260204.40510.aa; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pawaria S, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1524; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Pope SM, 2005, J BIOL CHEM, V280, P13952, DOI 10.1074/jbc.M406037200; Pope SM, 2001, J ALLERGY CLIN IMMUN, V108, P594, DOI 10.1067/mai.2001.118600; Poynter ME, 2004, J IMMUNOL, V173, P7003, DOI 10.4049/jimmunol.173.11.7003; Song H, 2009, CANCER RES, V69, P879, DOI 10.1158/0008-5472.CAN-08-3379; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Subramanian M, 2014, J CLIN INVEST, V124, P1296, DOI 10.1172/JCI72051; Takayama Y, 2005, J BIOL CHEM, V280, P18504, DOI 10.1074/jbc.M410265200; Tobian AAR, 2004, J IMMUNOL, V172, P5277, DOI 10.4049/jimmunol.172.9.5277; Tucker TA, 2012, AM J RESP CELL MOL, V46, P196, DOI 10.1165/rcmb.2011-0071OC; Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Weckbach LT, 2014, BLOOD, V123, P1887, DOI 10.1182/blood-2013-06-510875; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wilson RH, 2012, NAT MED, V18, P1705, DOI 10.1038/nm.2920; Yang LY, 2017, NAT PROD RES, V31, P487, DOI 10.1080/14786419.2016.1190719; Yao XL, 2013, AM J RESP CELL MOL, V49, P902, DOI 10.1165/rcmb.2013-0001OC; Yao XL, 2010, AM J RESP CRIT CARE, V182, P1228, DOI 10.1164/rccm.201002-0308OC; Zhang XY, 2014, CLIN EXP ALLERGY, V44, P1137, DOI 10.1111/cea.12345; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	75	12	13	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1066	+		10.1016/j.jaci.2017.10.044	http://dx.doi.org/10.1016/j.jaci.2017.10.044			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29274414	Green Accepted, Bronze			2022-12-18	WOS:000446327300008
J	Sohn, S; Wi, CI; Wu, ST; Liu, HF; Ryu, E; Krusemark, E; Seabright, A; Voge, GA; Juhn, YJ				Sohn, Sunghwan; Wi, Chung-Il; Wu, Stephen T.; Liu, Hongfang; Ryu, Euijung; Krusemark, Elizabeth; Seabright, Alicia; Voge, Gretchen A.; Juhn, Young J.			Ascertainment of asthma prognosis using natural language processing from electronic medical records	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ALPHA; THERAPY; DISEASE; SERUM		[Sohn, Sunghwan; Liu, Hongfang; Ryu, Euijung] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA; [Wi, Chung-Il; Krusemark, Elizabeth; Juhn, Young J.] Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN 55902 USA; [Wi, Chung-Il; Krusemark, Elizabeth; Seabright, Alicia; Juhn, Young J.] Mayo Clin, Asthma Epidemiol Res Unit, Rochester, MN 55902 USA; [Wu, Stephen T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Voge, Gretchen A.] Childrens Hosp & Clin Minnesota, Div Neonatol, Minneapolis, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Oregon Health & Science University; Children's Hospitals & Clinics of Minnesota	Juhn, YJ (corresponding author), Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN 55902 USA.; Juhn, YJ (corresponding author), Mayo Clin, Asthma Epidemiol Res Unit, Rochester, MN 55902 USA.	Juhn.young@mayo.edu			National Institutes of Health (NIH) [R21AI116839-01]; Rochester Epidemiology Project from the National Institute on Aging and Center for Translational Science Activities (CTSA) grant from the National Center for Advancing Translational Sciences [R01-AG34676, UL1 TR000135]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000135] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL126667] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI116839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG034676] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rochester Epidemiology Project from the National Institute on Aging and Center for Translational Science Activities (CTSA) grant from the National Center for Advancing Translational Sciences; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by the National Institutes of Health (NIH; grant no. R21AI116839-01). It was made possible by Rochester Epidemiology Project (grant no. R01-AG34676) from the National Institute on Aging and Center for Translational Science Activities (CTSA) grant (grant no. UL1 TR000135) from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the NIH.	Covar RA, 2010, J ALLERGY CLIN IMMUN, V125, P359, DOI 10.1016/j.jaci.2009.10.037; DESNICK RJ, 1973, J LAB CLIN MED, V81, P157; Lenders M, 2017, J INTERN MED, V282, P241, DOI 10.1111/joim.12647; Lenders M, 2016, J AM SOC NEPHROL, V27, P256, DOI 10.1681/ASN.2014121226; Linthorst GE, 2004, KIDNEY INT, V66, P1589, DOI 10.1111/j.1523-1755.2004.00924.x; Liu Hongfang, 2013, AMIA Jt Summits Transl Sci Proc, V2013, P149; MAYES JS, 1981, CLIN CHIM ACTA, V112, P247, DOI 10.1016/0009-8981(81)90384-3; National Asthma Education and Prevention Program, 2008, J ALLERGY CLIN IMMUN, V121, P1330; Rombach SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047805; Sears MR, 2015, J ALLERGY CLIN IMMUN, V136, P829, DOI 10.1016/j.jaci.2015.04.048; Tai A, 2014, J ALLERGY CLIN IMMUN, V133, P1572, DOI 10.1016/j.jaci.2013.12.1033; Voge GA, 2017, ALLERGY ASTHMA PROC, V38, P152, DOI 10.2500/aap.2017.38.4021; Wi CI, 2018, J ALLER CL IMM-PRACT, V6, P126, DOI 10.1016/j.jaip.2017.04.041; Wu S., 2016, P 10 INT C LANGUAGE, P426; Wu ST, 2013, ANN ALLERG ASTHMA IM, V111, P364, DOI 10.1016/j.anai.2013.07.022	15	12	12	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2292	2294		10.1016/j.jaci.2017.12.1003	http://dx.doi.org/10.1016/j.jaci.2017.12.1003			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29438770	Green Accepted, Bronze			2022-12-18	WOS:000434701600039
J	de Wit, J; Emmelot, ME; Poelen, MCM; van Binnendijk, RS; van der Lee, S; van Baarle, D; Han, WGH; van Els, CACM; Kaaijk, P				de Wit, Jelle; Emmelot, Maarten E.; Poelen, Martien C. M.; van Binnendijk, Rob S.; van der Lee, Saskia; van Baarle, Debbie; Han, Wanda G. H.; van Els, Cecile A. C. M.; Kaaijk, Patricia			Mumps infection but not childhood vaccination induces persistent polyfunctional CD8(+) T-cell memory	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ADULTS		[de Wit, Jelle; Emmelot, Maarten E.; Poelen, Martien C. M.; van Binnendijk, Rob S.; van der Lee, Saskia; van Baarle, Debbie; Han, Wanda G. H.; van Els, Cecile A. C. M.; Kaaijk, Patricia] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands	Netherlands National Institute for Public Health & the Environment	de Wit, J (corresponding author), Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands.	jelle.de.wit@rivm.nl	de Wit, Jelle/W-7035-2019	de Wit, Jelle/0000-0003-2444-6050; Kaaijk, Patricia/0000-0001-9165-1703; Emmelot, Maarten/0000-0002-4930-6268	Dutch Ministry of Health, Welfare and Sport	Dutch Ministry of Health, Welfare and Sport	This study was funded by the Dutch Ministry of Health, Welfare and Sport.	Dayan GH, 2008, NEW ENGL J MED, V358, P1580, DOI 10.1056/NEJMoa0706589; Han WDGH, 2016, J IMMUNOL METHODS, V431, P52, DOI 10.1016/j.jim.2016.02.010; Hanna-Wakim R, 2008, J INFECT DIS, V197, P1669, DOI 10.1086/588195; Jokinen S, 2007, J INFECT DIS, V196, P861, DOI 10.1086/521029; Kaaijk P, 2008, EURO SURVEILL, V13; Kaaijk P, 2015, HUM VACC IMMUNOTHER, V11, P1754, DOI 10.1080/21645515.2015.1040967; Kontio M, 2012, J INFECT DIS, V206, P1542, DOI 10.1093/infdis/jis568; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; VANDERLEE S, 2018, FRONT IMMUNOL, V0009; Wolfl M, 2007, BLOOD, V110, P201, DOI 10.1182/blood-2006-11-056168	10	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1908	+		10.1016/j.jaci.2017.11.047	http://dx.doi.org/10.1016/j.jaci.2017.11.047			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29339261	Green Submitted, hybrid			2022-12-18	WOS:000432148200041
J	Retterer, MKC; Workman, LJ; Bacon, JR; Platts-Mills, TAE				Retterer, Maya K. C.; Workman, Lisa J.; Bacon, John R.; Platts-Mills, Thomas A. E.			Specific IgE to gelatin as a cause of anaphylaxis to zoster vaccine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGY		[Retterer, Maya K. C.; Workman, Lisa J.; Platts-Mills, Thomas A. E.] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Carter Immunol Ctr, Dept Med, Charlottesville, VA 22903 USA; [Bacon, John R.] Univ Maryland, St Joseph Med Ctr, Towson, MD USA; [Bacon, John R.] Greater Baltimore Med Ctr, Baltimore, MD USA	University of Virginia; Greater Baltimore Medical Center	Platts-Mills, TAE (corresponding author), Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Carter Immunol Ctr, Dept Med, Charlottesville, VA 22903 USA.	tap2z@virginia.edu		Platts-Mills, Thomas/0000-0002-1263-329X	National Institutes of Health; National Institutes of Health/National Institute of Allergy and Infectious Disease and Phadia/ThermoFisher Scientific; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020565] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health/National Institute of Allergy and Infectious Disease and Phadia/ThermoFisher Scientific; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	L. J. Workman has received a grant and travel support from the National Institutes of Health and is employed by the University of Virginia. T. A. E. Platts-Mills has received grants from the National Institutes of Health/National Institute of Allergy and Infectious Disease and Phadia/ThermoFisher Scientific; has received travel support from Phadia/ThermoFisher Scientific; and has a patent on the use of the assay for IgE to alpha-gal to screen monoclonal antibodies. The rest of the authors declare that they have no relevant conflicts of interest.	Burks W, 2003, J CLIN INVEST, V111, P950, DOI 10.1172/JCI200318233; Commins SP, 2013, CURR OPIN ALLERGY CL, V13, P354, DOI 10.1097/ACI.0b013e3283624560; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Minnesota Department of Health Tickborne diseases, BLACKL TICKS DEER TI; Pinson ML, 2015, VACCINE, V33, P1231, DOI 10.1016/j.vaccine.2015.01.020; Posthumus J, 2013, J ALLERGY CLIN IMMUN, V131, P923, DOI 10.1016/j.jaci.2012.12.665; Stone CA, 2017, J ALLERGY CLIN IMMUN, V139, P1710, DOI 10.1016/j.jaci.2016.10.037	7	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1956	1957		10.1016/j.jaci.2017.08.047	http://dx.doi.org/10.1016/j.jaci.2017.08.047			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29361333	Green Accepted, Bronze			2022-12-18	WOS:000432148200061
J	Sikora, KA; Bennett, JR; Vyncke, L; Deng, ZM; Tsai, WL; Pauwels, E; Layh-Schmitt, G; Brundidge, A; Navid, F; Zaal, KJM; Hanson, E; Gadina, M; Staudt, LM; Griffin, TA; Tavernier, J; Peelman, F; Colbert, RA				Sikora, Keith A.; Bennett, Joshua R.; Vyncke, Laurens; Deng, Zuoming; Tsai, Wanxia Li; Pauwels, Ewald; layh-Schmitt, GerlinDe; Brundidge, April; Navid, Fatemeh; Zaal, Kristien J. M.; Hanson, Eric; Gadina, Massimo; Staudt, Louis M.; Griffin, Thomas A.; Tavernier, Jan; Peelman, Frank; Colbert, Robert A.			Germline gain-of-function myeloid differentiation primary response gene-88 (MYD88) mutation in a child with severe arthritis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							SOMATIC MUTATION; KAPPA-B; CELL		[Sikora, Keith A.; Bennett, Joshua R.; layh-Schmitt, GerlinDe; Navid, Fatemeh; Colbert, Robert A.] NIAMSD, Pediat Translat Res Branch, NIH, Bethesda, MD 20892 USA; [Deng, Zuoming; Tsai, Wanxia Li; Zaal, Kristien J. M.; Gadina, Massimo] NIAMSD, Off Sci & Technol, NIH, Bethesda, MD 20892 USA; [Brundidge, April] NIAMSD, Off Clin Director, NIH, Bethesda, MD 20892 USA; [Hanson, Eric] NIAMSD, Autoimmun Branch, NIH, Bethesda, MD 20892 USA; [Vyncke, Laurens; Tavernier, Jan; Peelman, Frank] VIB Med Biotechnol Ctr, Ghent, Belgium; [Vyncke, Laurens; Tavernier, Jan; Peelman, Frank] Univ Ghent, Dept Biochem, Ghent, Belgium; [Pauwels, Ewald] Univ Ghent, Ctr Mol Modeling, Zwijnaarde, Belgium; [Staudt, Louis M.] NCI, Lymphoid Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Griffin, Thomas A.] Carolinas Med Ctr, Levine Childrens Hosp, Charlotte, NC 28203 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Carolinas Medical Center	Sikora, KA (corresponding author), NIAMSD, Pediat Translat Res Branch, NIH, Bethesda, MD 20892 USA.	keith.sikora@nih.gov	Gadina, Massimo/R-4195-2019; Staudt, Louis/AAC-5324-2019; Tavernier, Jan/AAG-3636-2019; Hanson, Eric/AAE-5511-2022		Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, Pediatric Translational Research Branch, of the National Institutes of Health [Z01-AR041184]; NATIONAL CANCER INSTITUTE [ZIABC011010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZICAR041181, ZIHAR041173, ZIAAR041184, ZIAAR041187, ZIDAR041180, ZIAAR041208, ZICAR041169, ZICAR041186] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, Pediatric Translational Research Branch, of the National Institutes of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (Z01-AR041184), Pediatric Translational Research Branch, of the National Institutes of Health.	Abdollahi-Roodsaz S, 2012, ARTHRITIS RHEUM-US, V64, P1838, DOI 10.1002/art.34328; Avbelj M, 2014, BLOOD, V124, P3896, DOI 10.1182/blood-2014-05-573188; Choe JY, 2003, J EXP MED, V197, P537, DOI 10.1084/jem.20021850; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Coornaert B, 2009, J BIOL CHEM, V284, P8217, DOI 10.1074/jbc.R800032200; Elshabrawy HA, 2017, AUTOIMMUN REV, V16, P103, DOI 10.1016/j.autrev.2016.12.003; Guven-Maiorov E, 2015, SCI REP-UK, V5, DOI 10.1038/srep13128; Joosten LAB, 2003, J IMMUNOL, V171, P6145, DOI 10.4049/jimmunol.171.11.6145; Lam LT, 2008, BLOOD, V111, P3701, DOI 10.1182/blood-2007-09-111948; Matmati M, 2011, NAT GENET, V43, P908, DOI 10.1038/ng.874; Motshwene PG, 2009, J BIOL CHEM, V284, P25404, DOI 10.1074/jbc.M109.022392; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Picozza M, 2013, BLOOD, V122, P456, DOI 10.1182/blood-2013-05-500058; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710; von Bernuth H, 2008, SCIENCE, V321, P691, DOI 10.1126/science.1158298; Vyncke L, 2016, STRUCTURE, V24, P437, DOI 10.1016/j.str.2015.12.018; Wang JQ, 2014, J EXP MED, V211, P413, DOI 10.1084/jem.20131424	18	12	13	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1943	+		10.1016/j.jaci.2018.01.027	http://dx.doi.org/10.1016/j.jaci.2018.01.027			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29427642	Green Accepted, Bronze			2022-12-18	WOS:000432148200054
J	Crescioli, S; Chiaruttini, G; Mele, S; Ilieva, KM; Pellizzari, G; Spencer, DIR; Gardner, RA; Lacy, KE; Spicer, JF; Tutt, ANJ; Wagner, GK; Karagiannis, SN				Crescioli, Silvia; Chiaruttini, Giulia; Mele, Silvia; Ilieva, Kristina M.; Pellizzari, Giulia; Spencer, Daniel I. R.; Gardner, Richard A.; Lacy, Katie E.; Spicer, James F.; Tutt, Andrew N. J.; Wagner, Gerd K.; Karagiannis, Sophia N.			Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ANTIBODY; AFFINITY; ALLERGY; BINDING; IMPACT		[Crescioli, Silvia; Chiaruttini, Giulia; Mele, Silvia; Ilieva, Kristina M.; Pellizzari, Giulia; Lacy, Katie E.; Karagiannis, Sophia N.] Kings Coll London, Sch Basic & Med Biosci, St Johns Inst Dermatol, London, England; [Crescioli, Silvia; Karagiannis, Sophia N.] Guys & St Thomas Hosp, NIHR Biomed Res Ctr, London, England; [Crescioli, Silvia; Karagiannis, Sophia N.] Kings Coll London, London, England; [Ilieva, Kristina M.; Tutt, Andrew N. J.; Karagiannis, Sophia N.] Kings Coll London, Guys Canc Ctr, Sch Canc & Pharmaceut Sci, Breast Canc Now Unit, London, England; [Spencer, Daniel I. R.; Gardner, Richard A.] Ludger, Culham Sci Ctr, Abingdon, Oxon, England; [Spicer, James F.] Kings Coll London, Guys Hosp, Sch Canc & Pharmaceut Sci, London, England; [Tutt, Andrew N. J.] Breast Canc Now Toby Robins Res Ctr, Inst Canc Res, London, England; [Wagner, Gerd K.] Kings Coll London, Fac Nat & Math Sci, Dept Chem, London, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London; Culham Science Centre; UK Atomic Energy Authority; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; King's College London	Karagiannis, SN (corresponding author), Kings Coll London, Sch Basic & Med Biosci, St Johns Inst Dermatol, London, England.; Karagiannis, SN (corresponding author), Guys & St Thomas Hosp, NIHR Biomed Res Ctr, London, England.; Karagiannis, SN (corresponding author), Kings Coll London, London, England.; Karagiannis, SN (corresponding author), Kings Coll London, Guys Canc Ctr, Sch Canc & Pharmaceut Sci, Breast Canc Now Unit, London, England.	sophia.karagiannis@kcl.ac.uk	Wagner, Gerd/D-4759-2013; Karagiannis, Sophia/H-1097-2011	Wagner, Gerd/0000-0003-1086-2301; Karagiannis, Sophia/0000-0002-4100-7810; Mele, Silvia/0000-0003-3709-5739; Pellizzari, Giulia/0000-0003-0387-1912; Crescioli, Silvia/0000-0002-1909-5957	National Institute for Health Research (NIHR) BRC based at Guy's and St Thomas' NHS Foundation Trust and King's College London [IS-BRC-1215-20006]; Medical Research Council [MR/L023091/1]; Breast Cancer Now [147]; British Skin Foundation [S633]; Dermatrust; Guy's and St Thomas's Charity Melanoma Special Fund; Cancer Research UK [C30122/A11527, C30122/A157745]; Academy of Medical Sciences; CR UK/EPSRC/MRC/NIHR KCL/UCL Comprehensive Cancer Imaging Centre [C1519/A10331]; CR UK/NIHR in England/DoH for Scotland, Wales, and Northern Ireland Experimental Cancer Medicine Centre [C10355/A15587]; BBSRC IBCarb Network [IBCarb-PoC-0616-040]; MRC [MR/L023091/1] Funding Source: UKRI	National Institute for Health Research (NIHR) BRC based at Guy's and St Thomas' NHS Foundation Trust and King's College London; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Breast Cancer Now; British Skin Foundation; Dermatrust; Guy's and St Thomas's Charity Melanoma Special Fund; Cancer Research UK(Cancer Research UK); Academy of Medical Sciences(Academy of Medical Sciences (AMS)); CR UK/EPSRC/MRC/NIHR KCL/UCL Comprehensive Cancer Imaging Centre(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)Cancer Research UKEngineering & Physical Sciences Research Council (EPSRC)); CR UK/NIHR in England/DoH for Scotland, Wales, and Northern Ireland Experimental Cancer Medicine Centre; BBSRC IBCarb Network(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the National Institute for Health Research (NIHR) BRC based at Guy's and St Thomas' NHS Foundation Trust and King's College London (IS-BRC-1215-20006). The views expressed are those of the author(s) and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health. The authors acknowledge support by the Medical Research Council (MR/L023091/1); Breast Cancer Now (147), working in partnership with Walk the Walk; the British Skin Foundation (S633); Dermatrust; Guy's and St Thomas's Charity Melanoma Special Fund; Cancer Research UK (C30122/A11527; C30122/A157745); the Academy of Medical Sciences; CR UK/EPSRC/MRC/NIHR KCL/UCL Comprehensive Cancer Imaging Centre (C1519/A10331); CR UK/NIHR in England/DoH for Scotland, Wales, and Northern Ireland Experimental Cancer Medicine Centre (C10355/A15587); and the BBSRC IBCarb Network (Proof-of-Concept award IBCarb-PoC-0616-040).	Bantleona F, 2016, MOL IMMUNOL, V72, P49, DOI 10.1016/j.molimm.2016.02.013; Chusainow J, 2009, BIOTECHNOL BIOENG, V102, P1182, DOI 10.1002/bit.22158; Dibbern DA, 2003, J IMMUNOL METHODS, V274, P37, DOI 10.1016/S0022-1759(02)00369-1; Dodev TS, 2014, SCI REP-UK, V4, DOI 10.1038/srep05885; Hunt J, 2005, J BIOL CHEM, V280, P16808, DOI 10.1074/jbc.M500965200; Ivarsson M, 2014, J BIOTECHNOL, V188, P88, DOI 10.1016/j.jbiotec.2014.08.026; Jensen-Jarolim E, 2017, ALLERGY, V72, P866, DOI 10.1111/all.13119; Jensen-Jarolim E, 2017, J ALLERGY CLIN IMMUN, V140, P982, DOI 10.1016/j.jaci.2017.04.034; Josephs DH, 2017, CANCER RES, V77, P1127, DOI 10.1158/0008-5472.CAN-16-1829; Karagiannis P, 2009, CANCER IMMUNOL IMMUN, V58, P915, DOI 10.1007/s00262-008-0607-1; Kozak RP, 2015, ANAL BIOCHEM, V486, P38, DOI 10.1016/j.ab.2015.06.006; Montero-Morales L, 2017, J PROTEOMICS, V161, P81, DOI 10.1016/j.jprot.2017.04.002; Neville JJ, 2017, BIOTECHNOL ADV, V35, P557, DOI 10.1016/j.biotechadv.2017.05.004; Shade K-TC, 2015, J EXP MED; Ventham NT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123028; Wiegand TW, 1996, J IMMUNOL, V157, P221	16	12	12	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1519	+		10.1016/j.jaci.2017.12.986	http://dx.doi.org/10.1016/j.jaci.2017.12.986			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29360527	Green Published, hybrid, Green Submitted			2022-12-18	WOS:000429197800047
J	Simons, L; Ma, KY; de Chappedelaine, C; Moiranghtem, RD; Elkaim, E; Olivre, J; Susini, S; Appourchaux, K; Reimann, C; Sadek, H; Pelle, O; Cagnard, N; Magrin, E; Lagresle-Peyrou, C; Taghon, T; Rausell, A; Cavazzana, M; Andre-Schmutz, I				Simons, Laura; Ma, Kuiying; de Chappedelaine, Corinne; Moiranghtem, Ranjita Devi; Elkaim, Elodie; Olivre, Juliette; Susini, Sandrine; Appourchaux, Kevin; Reimann, Christian; Sadek, Hanem; Pelle, Olivier; Cagnard, Nicolas; Magrin, Elisa; Lagresle-Peyrou, Chantal; Taghon, Tom; Rausell, Antonio; Cavazzana, Marina; Andre-Schmutz, Isabelle			Generation of adult human T-cell progenitors for immunotherapeutic applications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IMMUNE RECONSTITUTION; TRANSPLANTATION; DELTA-LIKE-4; SYSTEM		[Simons, Laura; Ma, Kuiying; de Chappedelaine, Corinne; Moiranghtem, Ranjita Devi; Elkaim, Elodie; Olivre, Juliette; Susini, Sandrine; Appourchaux, Kevin; Reimann, Christian; Sadek, Hanem; Lagresle-Peyrou, Chantal; Cavazzana, Marina; Andre-Schmutz, Isabelle] INSERM, Human Lymphohaematopoiesis Lab, U1163, Paris, France; [Simons, Laura; Ma, Kuiying; de Chappedelaine, Corinne; Moiranghtem, Ranjita Devi; Elkaim, Elodie; Olivre, Juliette; Susini, Sandrine; Appourchaux, Kevin; Reimann, Christian; Sadek, Hanem; Lagresle-Peyrou, Chantal; Rausell, Antonio; Cavazzana, Marina; Andre-Schmutz, Isabelle] Univ Paris 05, Sorbonne Paris Cite, IMAGINE Inst, Paris, France; [Reimann, Christian] Cantonal Hosp Lucerne, Childrens Hosp, Dept Oncol Hematol, Luzern, Switzerland; [Pelle, Olivier] CNRS, INSERM, Cytometry Platform SFR Necker, US24,UMS 3633, Paris, France; [Cagnard, Nicolas] Univ Paris 05, Sorbonne Paris Cite, Bioinformat Plateform, INSERM,CNRS,US24,UMS3633, Paris, France; [Magrin, Elisa; Lagresle-Peyrou, Chantal; Cavazzana, Marina; Andre-Schmutz, Isabelle] Necker Childrens Hosp, Biotherapy Clin Invest Ctr, Paris, France; [Taghon, Tom] Univ Ghent, Fac Med & Hlth Sci, Dept Clin Chem Microbiol & Immunol, Ghent, Belgium; [Rausell, Antonio] IMAGINE Inst, Clin Bioinformat Lab, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Lucerne Cantonal Hospital; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Ghent University; UDICE-French Research Universities; Universite Paris Cite	Andre-Schmutz, I (corresponding author), INSERM, Human Lymphohaematopoiesis Lab, U1163, Paris, France.; Andre-Schmutz, I (corresponding author), Univ Paris 05, Sorbonne Paris Cite, IMAGINE Inst, Paris, France.; Andre-Schmutz, I (corresponding author), Necker Childrens Hosp, Biotherapy Clin Invest Ctr, Paris, France.	isabelle.andre-schmutz@inserm.fr	Andre, Isabelle/F-6263-2013; Taghon, Tom/M-9111-2018; Andre-Schmutz, Isabelle/M-1279-2016; Peyrou, Chantal Lagresle/H-2911-2017; Rausell, Antonio/I-9071-2017; Moirangthem, Ranjita Devi/H-7911-2017; Cagnard, Nicolas/K-2754-2014; MA, Kuiying/H-7941-2017; Olivre, Juliette/H-7146-2017	Andre, Isabelle/0000-0002-3905-9910; Peyrou, Chantal Lagresle/0000-0002-2216-6453; Rausell, Antonio/0000-0002-4832-6101; Cavazzana, Marina/0000-0002-0264-0891; Taghon, Tom/0000-0002-5781-0288; Moirangthem, Ranjita Devi/0000-0003-2182-0959; Cagnard, Nicolas/0000-0002-9051-1896; MA, Kuiying/0000-0002-6971-0954; Olivre, Juliette/0000-0001-8286-8601	French National Institute of Health and Medical Research (INSERM); European Research Council grant (ERC Regenerative Therapy) [269037]; European Union FP7 grant (CELL-PID) [261387]; European Union H grant (SCIDNet) [666908]; Imagine Institute; INCA-Plan Cancer grant; French National Research Agency (ANR) as part of the program "Investissements d'Avenir'' [ANR-10-IAHU-01]; China Scholarship Council (CSC); INSERM-Plan Cancer fellowship; Deutsche Forschungsgemeinschaft (DFG); Fund for Scientific Research Flanders (FWO Vlaanderen research projects) [G0B2913N]	French National Institute of Health and Medical Research (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); European Research Council grant (ERC Regenerative Therapy); European Union FP7 grant (CELL-PID); European Union H grant (SCIDNet); Imagine Institute; INCA-Plan Cancer grant; French National Research Agency (ANR) as part of the program "Investissements d'Avenir''(French National Research Agency (ANR)); China Scholarship Council (CSC)(China Scholarship Council); INSERM-Plan Cancer fellowship; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Fund for Scientific Research Flanders (FWO Vlaanderen research projects)	Supported by the French National Institute of Health and Medical Research (INSERM), a European Research Council grant (ERC Regenerative Therapy, 269037), a European Union FP7 grant (CELL-PID, 261387), a European Union H2020 grant (SCIDNet, 666908), the Imagine Institute, an INCA-Plan Cancer grant (2009-2013), and a public grant overseen by the French National Research Agency (ANR) as part of the program "Investissements d'Avenir'' (reference: ANR-10-IAHU-01). K.M. was funded by a China Scholarship Council (CSC). E.E. was funded by an INSERM-Plan Cancer fellowship. C.R. was funded by postdoctoral scholarships from the Deutsche Forschungsgemeinschaft (DFG). T.T. was funded by the Fund for Scientific Research Flanders (FWO Vlaanderen research projects G0B2913N). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cavazzana-Calvo M, 2013, BRIT J HAEMATOL, V160, P146, DOI 10.1111/bjh.12119; Jacobson CA, 2012, BIOL BLOOD MARROW TR, V18, P565, DOI 10.1016/j.bbmt.2011.08.018; Koch U, 2008, J EXP MED, V205, P2515, DOI 10.1084/jem.20080829; Krenger W, 2011, BLOOD, V117, P6768, DOI 10.1182/blood-2011-02-334623; Kueh HY, 2016, NAT IMMUNOL, V17, P956, DOI 10.1038/ni.3514; Reimann C, 2012, STEM CELLS, V30, P1771, DOI 10.1002/stem.1145; Shukla S, 2017, NAT METHODS, V14, P531, DOI 10.1038/nmeth.4258; Six EM, 2007, J EXP MED, V204, P3085, DOI 10.1084/jem.20071003; Storek J, 2008, SEMIN IMMUNOPATHOL, V30, P425, DOI 10.1007/s00281-008-0132-5; Toubert A, 2012, TISSUE ANTIGENS, V79, P83, DOI 10.1111/j.1399-0039.2011.01820.x	10	12	12	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1491	+		10.1016/j.jaci.2017.10.034	http://dx.doi.org/10.1016/j.jaci.2017.10.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29208547	Green Published, hybrid			2022-12-18	WOS:000429197800038
J	Thurmann, L; Grutzmann, K; Klos, M; Bieg, M; Winter, M; Polte, T; Bauer, T; Schick, M; Bewerunge-Hudler, M; Roder, S; Bauer, M; Wissenbach, DK; Sack, U; Weichenhan, D; Mucke, O; Plass, C; Borte, M; von Bergen, M; Lehmann, I; Eils, R; Trump, S				Thuermann, Loreen; Gruetzmann, Konrad; Kloes, Matthias; Bieg, Matthias; Winter, Marcus; Polte, Tobias; Bauer, Tobias; Schick, Matthias; Bewerunge-Hudler, Melanie; Roeder, Stefan; Bauer, Mario; Wissenbach, Dirk K.; Sack, Ulrich; Weichenhan, Dieter; Muecke, Oliver; Plass, Christoph; Borte, Michael; von Bergen, Martin; Lehmann, Irina; Eils, Roland; Trump, Saskia			Early-onset childhood atopic dermatitis is related to NLRP2 repression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EXPRESSION; RISK		[Thuermann, Loreen; Gruetzmann, Konrad; Kloes, Matthias; Winter, Marcus; Polte, Tobias; Roeder, Stefan; Bauer, Mario; Lehmann, Irina; Trump, Saskia] Helmholtz Ctr Environm Res Leipzig, Dept Environm Immunol, Leipzig, Germany; [Wissenbach, Dirk K.; von Bergen, Martin] Helmholtz Ctr Environm Res Leipzig, Dept Mol Syst Biol, Leipzig, Germany; [Gruetzmann, Konrad] Natl Ctr Tumor Dis, Ctr Mol Tumor Diagnost, Partner Site Dresden, Dresden, Germany; [Bieg, Matthias; Bauer, Tobias; Eils, Roland] Div Theoret Bioinformat, Heidelberg, Germany; [Bieg, Matthias; Eils, Roland] Heidelberg Ctr Personalized Oncol DKFZ HIPO, Heidelberg, Germany; [Schick, Matthias; Bewerunge-Hudler, Melanie] German Canc Res Ctr, Genom & Prote Core Facil, Heidelberg, Germany; [Weichenhan, Dieter; Muecke, Oliver; Plass, Christoph] German Canc Res Ctr, Div Epigen & Canc Risk Factors, Heidelberg, Germany; [Wissenbach, Dirk K.] Univ Hosp Jena, Inst Forens Med, Jena, Germany; [Sack, Ulrich] Univ Hosp Leipzig, Inst Clin Immunol, Leipzig, Germany; [Borte, Michael] St Georg Childrens Hosp, Municipal Hosp, Leipzig, Germany; [von Bergen, Martin] Univ Leipzig, Fac Biosci Pharm & Psychol, Dept Biochem, Leipzig, Germany; [Eils, Roland] Heidelberg Univ, Inst Pharm & Mol Biotechnol, Heidelberg, Germany; [Eils, Roland] Heidelberg Univ, Bioquant Ctr, Heidelberg, Germany; [Eils, Roland] Heidelberg Univ, Translat Lung Res Ctr Heidelberg, German Ctr Lung Res, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Friedrich Schiller University of Jena; Leipzig University; Leipzig University; Leipzig University; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Lehmann, I (corresponding author), Helmholtz Ctr Environm Res Leipzig, Dept Environm Immunol, Leipzig, Germany.	irina.lehmann@ufz.de; saskia.trump@ufz.de	Trump, Saskia/ABG-5182-2021; Eils, Roland/B-6121-2009; Thürmann, Loreen/AAD-4716-2022; Bauer, Mario/AAZ-7540-2021; Sack, Ulrich/J-6301-2015	Eils, Roland/0000-0002-0034-4036; Thürmann, Loreen/0000-0003-1109-1924; Sack, Ulrich/0000-0002-7813-0492; Klos, Matthias/0000-0002-9620-1506; Bauer, Tobias/0000-0002-4961-3639; Lehmann, Irina/0000-0001-8875-5587; Trump, Saskia/0000-0002-9894-1807	Helmholtz Initiative on Personalized Medicine (iMed); Helmholtz Interdisciplinary Graduate School for Environmental Research (HIGRADE); Federal Ministry of Education and Research (BMBF) [01ZX1402D]	Helmholtz Initiative on Personalized Medicine (iMed); Helmholtz Interdisciplinary Graduate School for Environmental Research (HIGRADE); Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	This work was supported by the Helmholtz Initiative on Personalized Medicine (iMed) and the Helmholtz Interdisciplinary Graduate School for Environmental Research (HIGRADE). S. Trump was supported by the Federal Ministry of Education and Research (BMBF) grant 01ZX1402D.	Bauer T, 2016, MOL SYST BIOL, V12, DOI 10.15252/msb.20156520; Bock C, 2016, NAT BIOTECHNOL, V34, P726, DOI 10.1038/nbt.3605; Carlsten C, 2013, ANN ALLERG ASTHMA IM, V110, P24, DOI 10.1016/j.anai.2012.10.005; Englich B, 2017, INT J OBESITY, V41, P1440, DOI 10.1038/ijo.2017.113; Fontalba A, 2007, J IMMUNOL, V179, P8519, DOI 10.4049/jimmunol.179.12.8519; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hayes A. F., 2018, INTRO MEDIATION; Ji S, 2009, INFECT IMMUN, V77, P1044, DOI 10.1128/IAI.00449-08; Niebuhr M, 2014, ALLERGY, V69, P1058, DOI 10.1111/all.12428; OHMEN JD, 1995, J IMMUNOL, V154, P1956; R Development Core Team, 2018, R LANG ENV STAT COMP; Ricci G., 2008, OPEN DERMATOLOGY J, V2, P18; Saulyte J, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001611; Suchiman HED, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00287; Thompson RF, 2009, BIOINFORMATICS, V25, P2164, DOI 10.1093/bioinformatics/btp382; Trump S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28616; Winter M, 2017, J ALLERGY CLIN IMMUN, V140, P603, DOI 10.1016/j.jaci.2017.01.034; Yoshikawa Y, 2013, INT J MOL SCI, V14, P3215, DOI 10.3390/ijms14023215	19	12	12	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1482	+		10.1016/j.jaci.2017.11.018	http://dx.doi.org/10.1016/j.jaci.2017.11.018			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29233739	hybrid			2022-12-18	WOS:000429197800035
J	Huff, RD; Rider, CF; Yan, D; Newton, R; Giembycz, MA; Carlsten, C; Hirota, JA				Huff, Ryan D.; Rider, Christopher F.; Yan, Dong; Newton, Robert; Giembycz, Mark A.; Carlsten, Chris; Hirota, Jeremy A.			Inhibition of ABCC4 potentiates combination beta agonist and glucocorticoid responses in human airway epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Huff, Ryan D.; Rider, Christopher F.; Carlsten, Chris] Univ British Columbia, Dept Med, Div Resp Med, Vancouver, BC, Canada; [Yan, Dong; Giembycz, Mark A.] Univ Calgary, Sch Med, Snyder Inst Chron Dis, Dept Physiol & Pharmacol, Calgary, AB, Canada; [Newton, Robert] Univ Calgary, Sch Med, Snyder Inst Chron Dis, Dept Cell Biol & Anat, Calgary, AB, Canada; [Hirota, Jeremy A.] McMaster Univ, Dept Med, Firestone Inst Resp Hlth, Div Respirol, Hamilton, ON, Canada	University of British Columbia; University of Calgary; University of Calgary; McMaster University	Hirota, JA (corresponding author), McMaster Univ, Dept Med, Firestone Inst Resp Hlth, Div Respirol, Hamilton, ON, Canada.	hirotaja@mcmaster.ca	Rider, Christopher F/H-7073-2019; Newton, Robert/C-6814-2012	Rider, Christopher F/0000-0003-0399-5931; Newton, Robert/0000-0002-4919-8498; Huff, Ryan/0000-0002-6038-8217				Ahmadi S, 2017, NPJ GENOM MED, V2, DOI 10.1038/s41525-017-0015-6; Bittner S, 2014, J NEUROIMMUNE PHARM, V9, P293, DOI 10.1007/s11481-014-9530-8; Bittner S, 2013, NAT MED, V19, P1161, DOI 10.1038/nm.3303; Blidberg K, 2012, RESPIROLOGY, V17, P854, DOI 10.1111/j.1440-1843.2012.02181.x; Conner GE, 2013, AM J RESP CELL MOL, V49, P672, DOI 10.1165/rcmb.2013-0156OC; Garry A, 2007, EMBO REP, V8, P354, DOI 10.1038/sj.embor.7400916; Giembycz Mark A, 2015, F1000Prime Rep, V7, P16, DOI 10.12703/P7-16; Gold MJ, 2016, MUCOSAL IMMUNOL, V9, P809, DOI 10.1038/mi.2015.104; Johnson M, 2006, J ALLERGY CLIN IMMUN, V117, P18, DOI 10.1016/j.jaci.2005.11.012; Newton R, 2007, MOL PHARMACOL, V72, P799, DOI 10.1124/mol.107.038794; Reddel HK, 2015, EUR RESPIR J, V46, P622, DOI 10.1183/13993003.00853-2015; Rius M, 2008, J PHARMACOL EXP THER, V324, P86, DOI 10.1124/jpet.107.131342; Tieu DD, 2009, J ALLERGY CLIN IMMUN, V124, P37, DOI 10.1016/j.jaci.2009.04.045; Xie M, 2011, MOL PHARMACOL, V80, P281, DOI 10.1124/mol.111.071134	14	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1127	+		10.1016/j.jaci.2017.10.011	http://dx.doi.org/10.1016/j.jaci.2017.10.011			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29103996	Bronze			2022-12-18	WOS:000426974800035
J	Semitekolou, M; Morianos, I; Banos, A; Konstantopoulos, D; Adamou-Tzani, M; Sparwasser, T; Xanthou, G				Semitekolou, Maria; Morianos, Ioannis; Banos, Aggelos; Konstantopoulos, Dimitris; Adamou-Tzani, Marina; Sparwasser, Tim; Xanthou, Georgina			Dendritic cells conditioned by activin A-induced regulatory T cells exhibit enhanced tolerogenic properties and protect against experimental asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Activin-A; allergic asthma; regulatory T cells; tolerogenic dendritic cells; immune regulation	AIRWAY HYPERRESPONSIVENESS; IMMUNE-RESPONSES; ALLERGIC-ASTHMA; EXPRESSION; TOLERANCE; INDUCTION; AUTOIMMUNITY; INFLAMMATION; MECHANISMS; SUPPRESS	Background: Previously, we demonstrated that regulatory T (Treg) cells induced by the cytokine activin-A suppress T(H)2-mediated allergic responses and linked airway disease. Still, the effects of activin-A-induced regulatory T (Act-A-iTreg) cells on the regulation of dendritic cell (DC)-driven allergic inflammation remain elusive. Objective: Here we investigated whether Act-A-iTreg cells can modulate DC responses and endow them with enhanced tolerogenic functions. Methods: Using adoptive cell transfer studies in mouse models of allergic airway disease, we examined the effects of Act-A-iTreg cells on DC phenotype, maturation status, and T(H)2 cell priming potential. Genome-wide gene expression profiling characterized the transcriptional networks induced in tolerogenic DCs by Act-A-iTreg cells. The ability of DCs conditioned by Act-A-iTreg cells (Act-A-iTreg cell-modified DCs) to protect against experimental asthma, and the mechanisms involved were also explored. Results: Act-A-iTreg cell-modified DCs exhibited a significantly impaired capacity to uptake allergen and stimulate naive and T(H)2 effector responses on allergen stimulation in vivo accompanied by markedly attenuated inflammatory cytokine release in response to LPS. Gene-profiling studies revealed that Act-A-iTreg cells dampened crucial T(H)2-skewing transcriptional networks in DCs. Administration of Act-A-iTreg cell-modified DCs ameliorated cardinal asthma manifestations in preventive and therapeutic protocols through generation of strongly suppressive forkhead box P3(+) Treg cells. Finally, programed death protein 1/programmed death ligand 1 signaling pathways were essential in potentiating the generation of DCs with tolerogenic properties by Act-A-iTreg cells. Conclusion: Our studies reveal that Act-A-iTreg cells instruct the generation of a highly effective immunoregulatory circuit encompassing tolerogenic DCs and forkhead box P3(+) Treg cells that could be targeted for the design of novel immunotherapies for allergic disorders.	[Semitekolou, Maria; Morianos, Ioannis; Adamou-Tzani, Marina; Xanthou, Georgina] Acad Athens, Biomed Res Fdn, Ctr Basic Res, Cellular Immunol Lab, 4 Soranou Efessiou St, Athens 11527, Greece; [Banos, Aggelos] Acad Athens, Biomed Res Fdn, Ctr Basic Res, Mol Biol Lab, Athens, Greece; [Konstantopoulos, Dimitris] BSRC Alexander Fleming, Dept Mol Biol & Genet, Athens, Greece; [Sparwasser, Tim] TWINCORE, Ctr Expt & Clin Infect Res, Inst Infect Immunol, Hannover, Germany	Academy of Athens; Academy of Athens; Alexander Fleming Biomedical Sciences Research Center; Helmholtz Association; Helmholtz-Center for Infection Research	Xanthou, G (corresponding author), Acad Athens, Biomed Res Fdn, Ctr Basic Res, Cellular Immunol Lab, 4 Soranou Efessiou St, Athens 11527, Greece.	gxanthou@bioacademy.gr	Xanthou, Georgina/AAH-8682-2019; Sparwasser, Tim/AAF-7085-2019; Sparwasser, Tim D/AAA-4306-2022	Sparwasser, Tim/0000-0001-5645-902X; Konstantopoulos, Dimitris/0000-0003-2142-3021; Semitekolou, Maria/0000-0002-0318-6774; Morianos, Ioannis/0000-0001-5207-0869	Academia-Industry Co-Operation Program grant [09-12-1074]; "Research Excellence" Grant - General Secretariat for Research and Technology [5035]; European Respiratory Society "Romain Pauwels" Research Excellence Award; European Respiratory Society Fellowship; Academia-Industry Co-Operation Program grant - General Secretariat for Research and Technology [09-12-1074]	Academia-Industry Co-Operation Program grant; "Research Excellence" Grant - General Secretariat for Research and Technology; European Respiratory Society "Romain Pauwels" Research Excellence Award; European Respiratory Society Fellowship; Academia-Industry Co-Operation Program grant - General Secretariat for Research and Technology	G.X. is supported by an Academia-Industry Co-Operation Program grant (09-12-1074), a "Research Excellence" Grant (no. 5035) funded by the General Secretariat for Research and Technology, and the European Respiratory Society "Romain Pauwels" Research Excellence Award. M.S. is supported by a "Research Excellence" Grant (no. 5035) funded by the General Secretariat for Research and Technology and a European Respiratory Society Fellowship. I. M. is supported by an Academia-Industry Co-Operation Program grant funded by General Secretariat for Research and Technology (09-12-1074).	Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Awasthi A, 2007, NAT IMMUNOL, V8, P1380, DOI 10.1038/ni1541; Belkaid Y, 2010, NAT IMMUNOL, V11, P1077, DOI 10.1038/ni1210-1077; Chae WJ, 2016, IMMUNITY, V44, P246, DOI 10.1016/j.immuni.2016.01.008; Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483; Chattopadhyay G, 2013, J IMMUNOL, V191, P5875, DOI 10.4049/jimmunol.1301693; de Lafaille MAC, 2010, CURR OPIN IMMUNOL, V22, P616, DOI 10.1016/j.coi.2010.08.014; DiPaolo RJ, 2007, J IMMUNOL, V179, P4685, DOI 10.4049/jimmunol.179.7.4685; Gao Y, 2013, IMMUNITY, V39, P722, DOI 10.1016/j.immuni.2013.08.028; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; Hammad H, 2007, J EXP MED, V204, P357, DOI 10.1084/jem.20061196; Hardy CL, 2015, CLIN EXP ALLERGY, V45, P1510, DOI 10.1111/cea.12561; Hebenstreit D, 2008, J BIOL CHEM, V283, P22490, DOI 10.1074/jbc.M804096200; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Huang H, 2013, ALLERGY, V68, P1126, DOI 10.1111/all.12203; Ivanov S, 2016, J CLIN INVEST, V126, P1581, DOI 10.1172/JCI84518; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim J, 2009, J IMMUNOL, V183, P7631, DOI 10.4049/jimmunol.0804308; Koya T, 2007, J ALLERGY CLIN IMMUN, V119, P1241, DOI 10.1016/j.jaci.2007.01.039; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu M, 2011, ALLERGY, V66, P612, DOI 10.1111/j.1398-9995.2010.02526.x; Lugt BV, 2014, NAT IMMUNOL, V15, P161, DOI 10.1038/ni.2795; Maazi H, 2012, CLIN EXP ALLERGY, V42, P1519, DOI 10.1111/j.1365-2222.2012.04064.x; Maldonado RA, 2010, ADV IMMUNOL, V108, P111, DOI [10.1016/B978-0-12-380995-7.00004-5, 10.1016/S0065-2776(10)08004_1]; Mascanfroni ID, 2013, NAT IMMUNOL, V14, P1054, DOI 10.1038/ni.2695; Moulos P, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1273; Nayyar A, 2012, J IMMUNOL, V189, P72, DOI 10.4049/jimmunol.1103286; Nguyen KD, 2009, AM J RESP CRIT CARE, V180, P823, DOI 10.1164/rccm.200905-0761OC; Oertli M, 2012, J CLIN INVEST, V122, P1082, DOI 10.1172/JCI61029; Onishi Y, 2008, P NATL ACAD SCI USA, V105, P10113, DOI 10.1073/pnas.0711106105; Semitekolou M, 2009, J EXP MED, V206, P1769, DOI 10.1084/jem.20082603; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Singh AK, 2011, ALLERGY, V66, P155, DOI 10.1111/j.1398-9995.2010.02458.x; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Tarazona S, 2011, GENOME RES, V21, P2213, DOI 10.1101/gr.124321.111; Tussiwand R, 2015, IMMUNITY, V42, P916, DOI 10.1016/j.immuni.2015.04.017; Williams JW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3990; Wynn TA, 2015, NAT REV IMMUNOL, V15, P271, DOI 10.1038/nri3831; Xanthou G, 2007, NAT MED, V13, P570, DOI 10.1038/nm1580; Xiao YP, 2014, J EXP MED, V211, P943, DOI 10.1084/jem.20130790	41	12	13	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					671	+		10.1016/j.jaci.2017.03.047	http://dx.doi.org/10.1016/j.jaci.2017.03.047			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28579377	Bronze			2022-12-18	WOS:000424410800024
J	Azzu, V; Kennard, L; Morillo-Gutierrez, B; Slatter, M; Edgar, JDM; Kumararatne, DS; Griffiths, WJH				Azzu, Vian; Kennard, Lucinda; Morillo-Gutierrez, Beatriz; Slatter, Mary; Edgar, J. David M.; Kumararatne, Dinakantha S.; Griffiths, William J. H.			Liver disease predicts mortality in patients with X-linked immunodeficiency with hyper-IgM but can be prevented by early hematopoietic stem cell transplantation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; CD40 LIGAND DEFICIENCY; INNER-CITY ADOLESCENTS; NITRIC-OXIDE; ENTEROTOXIN; EXPOSURE; HOME; SENSITIZATION; INFLAMMATION; ASSOCIATION		[Azzu, Vian; Griffiths, William J. H.] Cambridge Univ Hosp NHS Fdn, Liver Unit, Cambridge, England; [Kennard, Lucinda] Cambridge Univ Hosp NHS Fdn, Dept Allergy, Cambridge, England; [Morillo-Gutierrez, Beatriz; Slatter, Mary] Great North Childrens Hosp, Dept Paediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England; [Edgar, J. David M.] Belfast Hlth & Social Care Trust, Royal Victoria Hosp, Reg Immunol Serv, Belfast, Antrim, North Ireland; [Kumararatne, Dinakantha S.] Cambridge Univ Hosp NHS Fdn, Dept Immunol, Cambridge, England		Griffiths, WJH (corresponding author), Cambridge Univ Hosp NHS Fdn, Liver Unit, Cambridge, England.	bill.griffiths@addenbrookes.nhs.uk		Morillo Gutierrez, Beatriz/0000-0001-5160-3627; Edgar, John David Moore/0000-0003-2969-4475	Primary Immunodeficiency Association	Primary Immunodeficiency Association	This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The UK Primary Immunodeficiency Network is supported by the Primary Immunodeficiency Association.	Breuer K, 2000, ALLERGY, V55, P551, DOI 10.1034/j.1398-9995.2000.00432.x; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; Davis MF, 2016, J ALLERGY CLIN IMMUN, V137, pAB391, DOI 10.1016/j.jaci.2015.12.1212; Davis MF, 2012, LANCET INFECT DIS, V12, P703, DOI 10.1016/S1473-3099(12)70156-1; de la Morena MT, 2017, J ALLERGY CLIN IMMUN, V139, P1282, DOI 10.1016/j.jaci.2016.07.039; Etzioni A, 2004, PEDIATR RES, V56, P519, DOI 10.1203/01.PDR.0000139318.65842.4A; Hayward AR, 1997, J IMMUNOL, V158, P977; Heaton T, 2003, ALLERGY, V58, P252, DOI 10.1034/j.1398-9995.2003.00088.x; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; Iverson SA, 2015, VET MICROBIOL, V176, P202, DOI 10.1016/j.vetmic.2015.01.003; Khawaja K, 2001, ARCH DIS CHILD, V84, P508, DOI 10.1136/adc.84.6.508; Klotz M, 2003, J CLIN MICROBIOL, V41, P4683, DOI 10.1128/JCM.41.10.4683-4687.2003; Knox J, 2016, JAMA INTERN MED, V176, P807, DOI 10.1001/jamainternmed.2016.1500; Krakauer T, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00023; Leven EA, 2016, J CLIN IMMUNOL, V36, P490, DOI 10.1007/s10875-016-0291-4; Levy J, 1997, J PEDIATR-US, V131, P47, DOI 10.1016/S0022-3476(97)70123-9; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P267, DOI 10.1016/j.jaci.2010.05.031; Ludwig S, 2017, SCI TOTAL ENVIRON, V581, P750, DOI 10.1016/j.scitotenv.2017.01.003; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Matsui EC, 2010, ALLERGY, V65, P1414, DOI 10.1111/j.1398-9995.2010.02412.x; Mitsui-Sekinaka K, 2015, J ALLERGY CLIN IMMUN, V136, P1018, DOI 10.1016/j.jaci.2015.02.020; Monecke S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017936; Muralimohan G, 2008, J IMMUNOL, V181, P3698, DOI 10.4049/jimmunol.181.5.3698; Pai HH, 2013, ACTA TROP, V125, P18, DOI 10.1016/j.actatropica.2012.08.016; Rajagopalan G, 2006, INFECT IMMUN, V74, P1284, DOI 10.1128/IAI.74.2.1284-1296.2006; Reddy P, 2014, J IMMUNOL METHODS, V408, P114, DOI 10.1016/j.jim.2014.05.012; Rene-Trouillefou M, 2010, BBA-PROTEINS PROTEOM, V1804, P1322, DOI 10.1016/j.bbapap.2010.01.014; ROSEN FS, 1961, PEDIATRICS, V28, P182; Rusnak JM, 2004, EMERG INFECT DIS, V10, P1544, DOI 10.3201/eid1009.040250; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Sorensen M, 2017, ALLERGY; Strange P, 1996, ARCH DERMATOL, V132, P27, DOI 10.1001/archderm.132.1.27; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Tanaka A, 2015, ANN ALLERG ASTHMA IM, V115, P191, DOI 10.1016/j.anai.2015.06.017; Tang XY, 2011, AM J RHINOL ALLERGY, V25, P176, DOI 10.2500/ajra.2011.25.3609; Taubel M, 2009, J ALLERGY CLIN IMMUN, V124, P834, DOI 10.1016/j.jaci.2009.07.045; Winkelstein JA, 2003, MEDICINE, V82, P373, DOI 10.1097/01.md.0000100046.06009.b0; Xu SX, 2015, TOXINS, V7, P1821, DOI 10.3390/toxins7051821; Zeng WP, 2017, J ALLERGY CLIN IMMUN, V139, P508, DOI 10.1016/j.jaci.2016.04.033; 1995, AM REV RESP DIS, V152, P1107	41	12	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					405	+		10.1016/j.jaci.2017.06.036	http://dx.doi.org/10.1016/j.jaci.2017.06.036			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28756297	Bronze			2022-12-18	WOS:000419312200047
J	Davis, MF; Ludwig, S; Brigham, EP; McCormack, MC; Matsui, EC				Davis, Meghan F.; Ludwig, Shanna; Brigham, Emily P.; McCormack, Meredith C.; Matsui, Elizabeth C.			Effect of home exposure to Staphylococcus aureus on asthma in adolescents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							FC-GAMMA-RIII; ANTIINFLAMMATORY ACTIVITY; IMMUNOGLOBULIN-G; CELL ACTIVATION; IGG ANTIBODIES; INNER-CITY; IMMUNOTHERAPY; ANAPHYLAXIS; MECHANISMS; ASSOCIATION		[Davis, Meghan F.; Ludwig, Shanna; McCormack, Meredith C.; Matsui, Elizabeth C.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Davis, Meghan F.; Brigham, Emily P.; McCormack, Meredith C.; Matsui, Elizabeth C.] Johns Hopkins Sch Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine	Davis, MF (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.; Davis, MF (corresponding author), Johns Hopkins Sch Med, Baltimore, MD 21205 USA.	mdavis65@jhu.edu	Davis, Meghan F./C-1494-2013	Davis, Meghan F./0000-0002-3475-4578; Koehl, Rachelle/0000-0002-7797-7456; Ayers, Andrew/0000-0001-5305-7156; McCormack, Meredith/0000-0003-1702-3201; Matsui, Elizabeth/0000-0001-8134-5593; Pham, Hewlett/0000-0003-0330-6104	Johns Hopkins Fisher Center Discovery Program [004MAT2014]; National Institutes of Health (NIH)/National Institute of Environmental Health Sciences NIEHS [R01ES023447, P50ES018176]; NIH/National Center for Advancing Translational Sciences [4KL2TR001077]; NIH/National Institute of Allergy and Infectious Diseases [K24AI114769]; NIH/Office of the Director [K01OD019918]; US Environmental Protection Agency [83451001, 83615201]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001077] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [F05AT002014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI114769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P50ES018176, R01ES023447] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [K01OD019918] Funding Source: NIH RePORTER	Johns Hopkins Fisher Center Discovery Program; National Institutes of Health (NIH)/National Institute of Environmental Health Sciences NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIH/National Center for Advancing Translational Sciences; NIH/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/Office of the Director(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Environmental Protection Agency(United States Environmental Protection Agency); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by the Johns Hopkins Fisher Center Discovery Program (004MAT2014). Investigators were supported by the National Institutes of Health (NIH)/National Institute of Environmental Health Sciences NIEHS (R01ES023447 to E.C.M. and P50ES018176 to M.C.M.), NIH/National Center for Advancing Translational Sciences (4KL2TR001077 to E.P.B.), NIH/National Institute of Allergy and Infectious Diseases (K24AI114769 to E.C.M.), and NIH/Office of the Director (K01OD019918 to M.F.D.). This publication was developed under Assistance Agreement Number 83451001 and 83615201 awarded by the US Environmental Protection Agency to MCM. It has not been formally reviewed by EPA. The views expressed in this document are solely those of the authors and do not necessarily reflect those of the Agency. EPA does not endorse any products or commercial services mentioned in this publication.	AALBERSE RC, 1983, J IMMUNOL, V130, P722; Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134; Anthony RM, 2008, P NATL ACAD SCI USA, V105, P19571, DOI 10.1073/pnas.0810163105; Bachert C, 2012, J INTERN MED, V272, P133, DOI 10.1111/j.1365-2796.2012.02559.x; Barb AW, 2012, BIOCHEMISTRY-US, V51, P4618, DOI 10.1021/bi300319q; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; Bondt A, 2013, J PROTEOME RES, V12, P4522, DOI 10.1021/pr400589m; Bruhns P, 2015, IMMUNOL REV, V268, P25, DOI 10.1111/imr.12350; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Collin M, 2001, INFECT IMMUN, V69, P7187, DOI 10.1128/IAI.69.11.7187-7189.2001; Davis MF, 2015, J ALLERGY CLIN IMMUN, V135, P811, DOI 10.1016/j.jaci.2014.10.052; Davis MF, 2012, LANCET INFECT DIS, V12, P703, DOI 10.1016/S1473-3099(12)70156-1; Davis MF, 2012, APPL ENVIRON MICROB, V78, P2474, DOI 10.1128/AEM.06886-11; de Haan N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00608; Esmann L, 2010, J IMMUNOL, V184, P391, DOI 10.4049/jimmunol.0900564; Gepp B, 2016, J ALLERGY CLIN IMMUN, V137, P1600, DOI 10.1016/j.jaci.2015.10.022; Gillis CM, 2017, J ALLERGY CLIN IMMUN, V139, P1253, DOI 10.1016/j.jaci.2016.06.058; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; Hess C, 2013, J CLIN INVEST, V123, P3788, DOI 10.1172/JCI65938; Jun SH, 2017, CLIN EXP ALLERGY, V47, P85, DOI 10.1111/cea.12851; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Karsten CM, 2012, NAT MED, V18, P1401, DOI 10.1038/nm.2862; Khodoun MV, 2011, P NATL ACAD SCI USA, V108, P12413, DOI 10.1073/pnas.1105695108; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Ludwig S, 2017, SCI TOTAL ENVIRON, V581, P750, DOI 10.1016/j.scitotenv.2017.01.003; Mahan AE, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005456; Matsui EC, 2008, IMMUNOL ALLERGY CLIN, V28, P665, DOI 10.1016/j.iac.2008.03.004; Meng L, 2013, J BIOL CHEM, V288, P34680, DOI 10.1074/jbc.M113.519041; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Mobs C, 2012, J ALLERGY CLIN IMMUN, V130, P1108, DOI 10.1016/j.jaci.2012.07.056; Mobs C, 2010, J IMMUNOL, V184, P2194, DOI 10.4049/jimmunol.0901379; Oefner CM, 2012, J ALLERGY CLIN IMMUN, V129, P1647, DOI 10.1016/j.jaci.2012.02.037; Ohmi Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11205; Packer NH, 1998, GLYCOCONJUGATE J, V15, P737, DOI 10.1023/A:1006983125913; Patel P, 2014, J ALLERGY CLIN IMMUN, V133, P121, DOI 10.1016/j.jaci.2013.05.032; Pezer M, 2016, SCI REP-UK, V6, DOI 10.1038/srep33198; Pfaar O, 2012, CURR OPIN ALLERGY CL, V12, P648, DOI 10.1097/ACI.0b013e32835a11d6; Quakkelaar ED, 2014, J IMMUNOL, V192, P5813, DOI 10.4049/jimmunol.1302337; RUDOLPH AK, 1981, EUR J IMMUNOL, V11, P527, DOI 10.1002/eji.1830110617; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Scherer HU, 2010, ARTHRITIS RHEUM-US, V62, P1620, DOI 10.1002/art.27414; Shade KTC, 2015, J EXP MED, V212, P457, DOI 10.1084/jem.20142182; Sonneveld ME, 2017, BRIT J HAEMATOL, V176, P651, DOI 10.1111/bjh.14438; Strait RT, 2015, NATURE, V517, P501, DOI 10.1038/nature13868; Subbarayal B, 2015, J ALLERGY CLIN IMMUN, V136, P1680, DOI 10.1016/j.jaci.2015.05.025; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Totte JEE, 2016, BRIT J DERMATOL, V175, P687, DOI 10.1111/bjd.14566; Valenta R, 2016, J ALLERGY CLIN IMMUN, V137, P351, DOI 10.1016/j.jaci.2015.12.1299; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Wawrzyniak P, 2016, J ALLERGY CLIN IMMUN, V137, P1681, DOI 10.1016/j.jaci.2016.02.010; WEISS ME, 1989, NEW ENGL J MED, V320, P886, DOI 10.1056/NEJM198904063201402; Wernersson S, 1999, J IMMUNOL, V163, P618; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	54	12	12	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					402	+		10.1016/j.jaci.2017.06.031	http://dx.doi.org/10.1016/j.jaci.2017.06.031			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28739287	Green Accepted, Bronze			2022-12-18	WOS:000419312200046
J	Kaspi, E; Heim, X; Granel, B; Guillet, B; Stalin, J; Nollet, M; Bertaud-Foucault, A; Robaglia-Schlupp, A; Roll, P; Cau, P; Leroyer, A; Bachelier, R; Benyamine, A; Dignat-George, F; Blot-Chabaud, M; Bardin, N				Kaspi, Elise; Heim, Xavier; Granel, Brigitte; Guillet, Benjamin; Stalin, Jimmy; Nollet, Marie; Bertaud-Foucault, Alexandrine; Robaglia-Schlupp, Andree; Roll, Patrice; Cau, Pierre; Leroyer, Aurelie; Bachelier, Richard; Benyamine, Audrey; Dignat-George, Francoise; Blot-Chabaud, Marcel; Bardin, Nathalie			Identification of CD146 as a novel molecular actor involved in systemic sclerosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SOLUBLE CD146; CLASSIFICATION; SCLERODERMA; MECHANISMS; CRITERIA		[Kaspi, Elise; Robaglia-Schlupp, Andree; Roll, Patrice; Cau, Pierre] Aix Marseille Univ, INSERM, GMGF, Marseille, France; [Kaspi, Elise; Robaglia-Schlupp, Andree; Roll, Patrice] Hop La Timone, AP HM, Serv Biol Cellulaire, Marseille, France; [Heim, Xavier; Granel, Brigitte; Guillet, Benjamin; Stalin, Jimmy; Nollet, Marie; Leroyer, Aurelie; Bachelier, Richard; Dignat-George, Francoise; Blot-Chabaud, Marcel; Bardin, Nathalie] Aix Marseille Univ, INSERM, VRCM, Marseille, France; [Granel, Brigitte; Benyamine, Audrey] Hop Nord Marseille, AP HM, Med Interne, Marseille, France; [Guillet, Benjamin] Hop Nord Marseille, AP HM, Serv Radiopharm, Marseille, France; [Guillet, Benjamin] Aix Marseille Univ, CERIMED, Marseille, France; [Dignat-George, Francoise; Bardin, Nathalie] Hop Conception, AP HM, Lab Hematol, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Bardin, N (corresponding author), Aix Marseille Univ, INSERM, VRCM, Marseille, France.; Bardin, N (corresponding author), Hop Conception, AP HM, Lab Hematol, Marseille, France.	nathalie.bardin@ap-hm.fr	Blot-Chabaud, Marcel/D-4064-2017; Heim, Xavier/GPT-3365-2022; ROLL, Patrice/I-4355-2016; NOLLET, MARIE/M-2752-2017; DIGNAT-GEORGE, Françoise/R-1129-2016; ROLL, Patrice/GLS-4467-2022; Leroyer, Aurelie S./M-4400-2016; Kaspi, Elise/I-4936-2016; Bardin, Nathalie/AAL-3663-2020	ROLL, Patrice/0000-0002-0045-5641; NOLLET, MARIE/0000-0002-9667-8216; DIGNAT-GEORGE, Françoise/0000-0001-7006-4462; ROLL, Patrice/0000-0002-0045-5641; Leroyer, Aurelie S./0000-0002-8079-7122; Kaspi, Elise/0000-0003-0458-5109; Bardin, Nathalie/0000-0003-3680-082X; Stalin, Jimmy/0000-0001-8092-7057				Bardin N, 2003, THROMB HAEMOSTASIS, V90, P915, DOI 10.1160/TH02-11-0285; Bardin N, 2009, ARTERIOSCL THROM VAS, V29, P746, DOI 10.1161/ATVBAHA.108.183251; Bilechele Travis L., 2008, V468, P99, DOI 10.1007/978-1-59745-249-6_8; Bompais H, 2004, BLOOD, V103, P2577, DOI 10.1182/blood-2003-08-2770; Gabrielli A, 2009, NEW ENGL J MED, V360, P1989, DOI 10.1056/NEJMra0806188; Harhouri K, 2010, BLOOD, V115, P3843, DOI 10.1182/blood-2009-06-229591; Jouve N, 2015, INT J CANCER, V137, P50, DOI 10.1002/ijc.29370; LeRoy EC, 2001, J RHEUMATOL, V28, P1573; Massacrier A, 1988, Brain Res, V468, P161; Ould-Ali D, 2013, J CLIN EXP DERMATOL; Reumaux D, 2007, INFLAMM BOWEL DIS, V13, P1315, DOI 10.1002/ibd.20166; Shi J, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/9392132; van Bon L, 2014, NEW ENGL J MED, V370, P433, DOI 10.1056/NEJMoa1114576; van den Hoogen F, 2013, ARTHRITIS RHEUM-US, V65, P2737, DOI 10.1002/art.38098; WEIBEL ER, 1979, STEREOLOGICAL METHOD, V1, P415; Xu Jianming, 2005, Curr Protoc Mol Biol, VChapter 28, DOI 10.1002/0471142727.mb2801s70; Yamamoto T, 2005, EXP DERMATOL, V14, P81, DOI 10.1111/j.0906-6705.2005.00280.x; Ye ZD, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3803	18	12	14	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1448	+		10.1016/j.jaci.2017.04.046	http://dx.doi.org/10.1016/j.jaci.2017.04.046			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28606586	Green Submitted, Bronze			2022-12-18	WOS:000414304300029
J	Yu, CJ; Fitzpatrick, A; Cong, DD; Yao, CC; Yoo, J; Turnbull, A; Schwarze, J; Norval, M; Howie, SEM; Weller, RB; Astier, AL				Yu, Cunjing; Fitzpatrick, Amanda; Cong, Duanduan; Yao, Chengcan; Yoo, Jinah; Turnbull, Andrew; Schwarze, Juergen; Norval, Mary; Howie, Sarah E. M.; Weller, Richard B.; Astier, Anne L.			Nitric oxide induces human CLA(+)CD25(+)Foxp3(+) regulatory T cells with skin-homing potential	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							UV-RADIATION		[Yu, Cunjing; Fitzpatrick, Amanda; Cong, Duanduan; Yao, Chengcan; Yoo, Jinah; Turnbull, Andrew; Schwarze, Juergen; Howie, Sarah E. M.; Weller, Richard B.; Astier, Anne L.] Univ Edinburgh, Queens Med Res Inst, MRC Ctr Inflammat Res, Edinburgh, Midlothian, Scotland; [Norval, Mary] Univ Edinburgh, Med Sch, Biomed Sci, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Astier, AL (corresponding author), Univ Edinburgh, Queens Med Res Inst, MRC Ctr Inflammat Res, Edinburgh, Midlothian, Scotland.	a.astier@ed.ac.uk	Astier, Anne L/A-1641-2008; Fitzpatrick, Amanda/AAJ-8670-2020; Weller, Richard/B-4954-2010; Schwarze, Jürgen/F-7396-2011	Astier, Anne L/0000-0002-0144-3431; Fitzpatrick, Amanda/0000-0001-9201-3797; Weller, Richard/0000-0003-2550-9586; Yao, Chengcan/0000-0003-3754-2842	Research Council UK (RCUK); China Scholarship Council; University of Edinburgh; Psoriasis Association UK; Medical Research Council [MR/P001564/1] Funding Source: researchfish; Psoriasis Association [RG1/15] Funding Source: researchfish; MRC [MR/P001564/1] Funding Source: UKRI	Research Council UK (RCUK)(UK Research & Innovation (UKRI)); China Scholarship Council(China Scholarship Council); University of Edinburgh; Psoriasis Association UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Psoriasis Association; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Fiona Rossi, Shonna Johnston, and Will Ramsay for their help with the flow cytometer, as well as the volunteers who participated in this study. A.L.A. is a detached member of CNRS, France, and holds an Research Council UK (RCUK) fellowship. These studies were supported by China Scholarship Council and University of Edinburgh studentships to C.Y. and D.C., and the Psoriasis Association UK (to R.B.W., S.E.M.H., C.Y., and A.L.A.).; These studies were supported by China Scholarship Council and University of Edinburgh studentships to C.Y. and D.C., and the Psoriasis Association UK (to R.B.W., S.E.M.H., C.Y., and A.L.A.).	Clark RA, 2007, BLOOD, V109, P194, DOI 10.1182/blood-2006-02-002873; Devenney I, 2010, PEDIAT ALLERG IMM-UK, V21, pE229, DOI 10.1111/j.1399-3038.2009.00892.x; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; Hart PH, 2011, NAT REV IMMUNOL, V11, P584, DOI 10.1038/nri3045; Jayaraman P, 2014, CLIN CANCER RES, V20, P6439, DOI 10.1158/1078-0432.CCR-13-3409; Kuchel JM, 2003, J INVEST DERMATOL, V121, P587, DOI 10.1046/j.1523-1747.2003.12415.x; Loser K, 2012, J INVEST DERMATOL, V132, P864, DOI 10.1038/jid.2011.375; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Mowbray M, 2009, J INVEST DERMATOL, V129, P834, DOI 10.1038/jid.2008.296; Niedbala W, 2007, P NATL ACAD SCI USA, V104, P15478, DOI 10.1073/pnas.0703725104	10	12	12	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1441	+		10.1016/j.jaci.2017.05.023	http://dx.doi.org/10.1016/j.jaci.2017.05.023			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28601680	Green Submitted, Bronze			2022-12-18	WOS:000414304300027
J	Fritzsching, B; Hagner, M; Dai, L; Christochowitz, S; Agrawal, R; van Bodegom, C; Schmidt, S; Schatterny, J; Hirtz, S; Brown, R; Goritzka, M; Duerr, J; Zhou-Suckow, Z; Mall, MA				Fritzsching, Benedikt; Hagner, Matthias; Dai, Lu; Christochowitz, Sandra; Agrawal, Raman; van Bodegom, Charlotte; Schmidt, Simone; Schatterny, Jolanthe; Hirtz, Stephanie; Brown, Ryan; Goritzka, Michelle; Duerr, Julia; Zhou-Suckow, Zhe; Mall, Marcus A.			Impaired mucus clearance exacerbates allergen-induced type 2 airway inflammation in juvenile mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Type 2 inflammation; airway epithelium; mucociliary clearance; IL-13; IL-33	CHANNEL-OVEREXPRESSING MICE; CYSTIC-FIBROSIS; LUNG-DISEASE; MUCOCILIARY CLEARANCE; EPITHELIAL-CELLS; SURFACE DEHYDRATION; CHRONIC-BRONCHITIS; OSMOTIC-PRESSURE; CYTOKINE PROFILE; GENE-EXPRESSION	Background: Type 2 airway inflammation plays a central role in the pathogenesis of allergen-induced asthma, but the underlying mechanisms remain poorly understood. Recently, we demonstrated that reduced mucociliary clearance, a characteristic feature of asthma, produces spontaneous type 2 airway inflammation in juvenile beta-epithelial Na+ channel (Scnn1b)-transgenic (Tg) mice. Objective: We sought to determine the role of impaired mucus clearance in the pathogenesis of allergen-induced type 2 airway inflammation and identify cellular sources of the signature cytokine IL-13. Methods: We challenged juvenile Scnn1b-Tg and wild-type mice with Aspergillus fumigatus and house dust mite allergen and compared the effects on airway eosinophilia, type 2 cytokine levels, goblet cell metaplasia, and airway hyperresponsiveness. Furthermore, we determined cellular sources of IL-13 and effects of genetic deletion of the key type 2 signal-transducing molecule signal transducer and activator of transcription 6 (STAT6) and evaluated the effects of therapeutic improvement of mucus clearance. Results: Reduced mucociliary allergen clearance exacerbated Stat6-dependent secretion of type 2 cytokines, airway eosinophilia, and airway hyperresponsiveness in juvenile Scnn1b-Tg mice. IL-13 levels were increased in airway epithelial cells, macrophages, type 2 innate lymphoid cells, and T(H)2 cells along with increased Il33 expression in the airway epithelium of Scnn1b-Tg mice. Treatment with the epithelial Na+ channel blocker amiloride, improving airway surface hydration and mucus clearance, reduced allergen-induced inflammation in Scnn1b-Tg mice. Conclusion: Our data support that impaired clearance of inhaled allergens triggering IL-13 production by multiple cell types in the airways plays an important role in the pathogenesis of type 2 airway inflammation and suggests therapeutic improvement of mucociliary clearance as a novel treatment strategy for children with allergen-induced asthma.	[Mall, Marcus A.] Heidelberg Univ, Dept Translat Pulmonol, Translat Lung Res Ctr Heidelberg TLRC, Neuenheimer Feld 156, D-69120 Heidelberg, Germany; Heidelberg Univ, German Ctr Lung Res DZL, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Mall, MA (corresponding author), Heidelberg Univ, Dept Translat Pulmonol, Translat Lung Res Ctr Heidelberg TLRC, Neuenheimer Feld 156, D-69120 Heidelberg, Germany.	Marcus.Mall@med.uni-heidelberg.de	Mall, Marcus A./AAA-1498-2022	Mall, Marcus A./0000-0002-4057-2199; Duerr, Julia/0000-0002-4862-9487; Paulsen, Michelle/0000-0002-8090-0118; Brown, Ryan/0000-0002-4735-3271	German Research Foundation [MA 2081/3-2, MA 2081/4-1]; German Federal Ministry of Education and Research [82DZL00401, 82DZL004A1]	German Research Foundation(German Research Foundation (DFG)); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	Supported by grants from the German Research Foundation (MA 2081/3-2 and MA 2081/4-1) and the German Federal Ministry of Education and Research (82DZL00401 and 82DZL004A1).	Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394; Agache I, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0529-x; Anagnostopoulou P, 2010, EUR RESPIR J, V36, P1436, DOI 10.1183/09031936.00181209; Anagnostopoulou P, 2012, J CLIN INVEST, V122, P3629, DOI 10.1172/JCI60429; Anderson WH, 2015, AM J RESP CRIT CARE, V192, P182, DOI 10.1164/rccm.201412-2230OC; BATEMAN JRM, 1983, THORAX, V38, P463, DOI 10.1136/thx.38.6.463; Bentley JK, 2014, J ALLERGY CLIN IMMUN, V134, P1433, DOI 10.1016/j.jaci.2014.05.029; Boucher RC, 2007, ANNU REV MED, V58, P157, DOI 10.1146/annurev.med.58.071905.105316; Button B, 2012, SCIENCE, V337, P937, DOI 10.1126/science.1223012; Byers DE, 2013, J CLIN INVEST, V123, P3967, DOI 10.1172/JCI65570; Byers DE, 2011, CHEST, V140, P768, DOI 10.1378/chest.10-2132; Byrne AJ, 2015, THORAX, V70, P1189, DOI 10.1136/thoraxjnl-2015-207020; Christenson SA, 2015, AM J RESP CRIT CARE, V191, P758, DOI 10.1164/rccm.201408-1458OC; Coote K, 2004, EXP LUNG RES, V30, P59, DOI 10.1080/01902140490252885; Darcan-Nicolaisen Y, 2009, J IMMUNOL, V182, P7501, DOI 10.4049/jimmunol.0713433; Daviskas E, 1996, EUR RESPIR J, V9, P725, DOI 10.1183/09031936.96.09040725; Duerr J, 2011, AM J RESP CELL MOL, V44, P244, DOI 10.1165/rcmb.2009-0115OC; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Gehrig S, 2014, AM J RESP CRIT CARE, V189, P1082, DOI 10.1164/rccm.201311-1932OC; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Henderson AG, 2014, J CLIN INVEST, V124, P3047, DOI 10.1172/JCI73469; Hiemstra PS, 2015, EUR RESPIR J, V45, P1150, DOI 10.1183/09031936.00141514; Holtzman MJ, 2014, NAT REV IMMUNOL, V14, P686, DOI 10.1038/nri3739; Houtmeyers E, 1999, EUR RESPIR J, V14, P452, DOI 10.1034/j.1399-3003.1999.14b35.x; KOHLER D, 1986, EUR J RESPIR DIS, V69, P319; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lauzon-Joset JF, 2014, MUCOSAL IMMUNOL, V7, P155, DOI 10.1038/mi.2013.34; Lewis Christina C, 2009, J Allergy Clin Immunol, V123, P795, DOI 10.1016/j.jaci.2009.01.003; Livraghi A, 2009, J IMMUNOL, V182, P4357, DOI 10.4049/jimmunol.0802557; Lloyd CM, 2015, CURR OPIN IMMUNOL, V34, P52, DOI 10.1016/j.coi.2015.02.001; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Mall MA, 2008, AM J RESP CRIT CARE, V177, P730, DOI 10.1164/rccm.200708-1233OC; Mall MA, 2015, J CYST FIBROS, V14, P561, DOI 10.1016/j.jcf.2015.06.002; Mall MA, 2014, EUR RESPIR J, V44, P1042, DOI 10.1183/09031936.00228013; Mall MA, 2010, J BIOL CHEM, V285, P26945, DOI 10.1074/jbc.M110.151803; MESSINA MS, 1991, AM REV RESPIR DIS, V143, P993, DOI 10.1164/ajrccm/143.5_Pt_1.993; Misharin AV, 2013, AM J RESP CELL MOL, V49, P503, DOI 10.1165/rcmb.2013-0086MA; Prescott SL, 1998, J IMMUNOL, V160, P4730; Roy MG, 2014, NATURE, V505, P412, DOI 10.1038/nature12807; Saglani S, 2009, AM J RESP CELL MOL, V41, P281, DOI 10.1165/rcmb.2008-0396OC; Saini Y, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-726; Sauer KA, 2006, NAT PROTOC, V1, P2870, DOI 10.1038/nprot.2006.435; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shalaby KH, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-82; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Soroosh P, 2013, J EXP MED, V210, P775, DOI 10.1084/jem.20121849; Tiringer K, 2013, AM J RESP CRIT CARE, V187, P621, DOI 10.1164/rccm.201206-1150OC; Trojanek JB, 2014, AM J RESP CELL MOL, V51, P709, DOI 10.1165/rcmb.2013-0407OC; Walford Hannah H, 2013, JAKSTAT, V2, pe25301, DOI 10.4161/jkst.25301; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yang ZH, 2013, AM J PHYSIOL-GASTR L, V304, pG381, DOI 10.1152/ajpgi.00357.2012; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhou Z, 2008, AM J RESP CRIT CARE, V178, P1245, DOI 10.1164/rccm.200803-442OC	56	12	13	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					190	+		10.1016/j.jaci.2016.09.045	http://dx.doi.org/10.1016/j.jaci.2016.09.045			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	27865862				2022-12-18	WOS:000404542000019
J	Ballow, M; Conaway, MR; Sriaroon, P; Rachid, RA; Seeborg, FO; Duff, CM; Bonilla, FA; Younger, MEM; Shapiro, R; Burns, TM				Ballow, Mark; Conaway, Mark R.; Sriaroon, Panida; Rachid, Rima A.; Seeborg, Filiz O.; Duff, Carla M.; Bonilla, Francisco A.; Younger, M. Elizabeth M.; Shapiro, Ralph; Burns, Ted M.			Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNOGLOBULIN REPLACEMENT THERAPY; PRIMARY IMMUNODEFICIENCY; TREATMENT SATISFACTION; INFUSIONS		[Ballow, Mark; Sriaroon, Panida; Duff, Carla M.] Univ S Florida, Johns Hopkins All Childrens Hosp, Div Allergy & Immunol, Dept Pediat, St Petersburg, FL 33701 USA; [Conaway, Mark R.] Univ Virginia, Sch Med, Publ Hlth Sci, Charlottesville, VA 22908 USA; [Rachid, Rima A.; Bonilla, Francisco A.] Harvard Med Sch, Boston Childrens Hosp, Div Immunol Allergy & Rheumatol, Dept Pediat, Boston, MA USA; [Seeborg, Filiz O.; Bonilla, Francisco A.] Texas Childrens Hosp, Baylor Coll Med, Div Allergy & Immunol, Houston, TX 77030 USA; [Younger, M. Elizabeth M.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Allergy & Immunol, Baltimore, MD 21205 USA; [Shapiro, Ralph] Midwest Immunol Clin, Plymouth, MN USA; [Burns, Ted M.] Univ Virginia Hlth Syst, Dept Neurol, Charlottesville, VA USA	Johns Hopkins University; Johns Hopkins Medicine; State University System of Florida; University of South Florida; University of Virginia; Harvard University; Boston Children's Hospital; Harvard Medical School; Baylor College of Medicine; Johns Hopkins University; University of Virginia	Ballow, M (corresponding author), Univ S Florida, Johns Hopkins All Childrens Hosp, Div Allergy & Immunol, Dept Pediat, St Petersburg, FL 33701 USA.	mballow@health.usf.edu		Sriaroon, Panida/0000-0002-6937-7303	CSL Behring [NCT02542228]	CSL Behring	This work was supported by an investigator-initiated grant from CSL Behring ClinicalTrials.Gov (NCT02542228).	Atkinson MJ, 2005, VALUE HEALTH, V8, pS9, DOI 10.1111/j.1524-4733.2005.00066.x; Ballow M, 2002, J ALLERGY CLIN IMMUN, V109, P581, DOI 10.1067/mai.2002.122466; Ballow M, 2013, J ALLERGY CLIN IMMUN, V131, pAB156, DOI 10.1016/j.jaci.2012.12.1218; Bond T. G, 2015, APPLYING RASCH MODEL, V3rd, DOI DOI 10.4324/9781315814698; Boone W.J., 2013, RASCH ANAL HUMAN SCI; GARDULF A, 1993, CLIN EXP IMMUNOL, V92, P200; Nicolay U, 2006, J CLIN IMMUNOL, V26, P65, DOI 10.1007/s10875-006-8905-x; Nicolay U, 2005, QUAL LIFE RES, V14, P1683, DOI 10.1007/s11136-005-1746-x; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Sriaroon P, 2015, IMMUNOL ALLERGY CLIN, V35, P713, DOI 10.1016/j.iac.2015.07.006; U. S. Food and Drug Administration, GUID IND PAT REP OUT, P65132; United States Department of Health Human Services Food Drug Administration, GUID IND PAT REP OUT	12	12	12	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					2007	+		10.1016/j.jaci.2016.11.029	http://dx.doi.org/10.1016/j.jaci.2016.11.029			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	28065678				2022-12-18	WOS:000402724600039
J	Chang, EH; Willis, AL; McCrary, HC; Noutsios, GT; Le, CH; Chiu, AG; Mansfield, CJ; Reed, DR; Brooks, SG; Adappa, ND; Palmer, JN; Cohen, NG; Stern, DA; Guerra, S; Martinez, FD				Chang, Eugene H.; Willis, Amanda L.; McCrary, Hilary C.; Noutsios, George T.; Le, Christopher H.; Chiu, Alexander G.; Mansfield, Corrine J.; Reed, Danielle R.; Brooks, Steven G.; Adappa, Nithin D.; Palmer, James N.; Cohen, Noam G.; Stern, Debra A.; Guerra, Stefano; Martinez, Fernando D.			Association between the CDHR3 rs6967330 risk allele and chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA		[Chang, Eugene H.; Willis, Amanda L.; McCrary, Hilary C.; Noutsios, George T.; Le, Christopher H.; Chiu, Alexander G.] Univ Arizona, Dept Otolaryngol, Tucson, AZ 85721 USA; [Mansfield, Corrine J.; Reed, Danielle R.; Cohen, Noam G.] Univ Penn, Monell Chem Senses Ctr, Philadelphia, PA 19104 USA; [Brooks, Steven G.; Adappa, Nithin D.; Palmer, James N.; Cohen, Noam G.] Univ Penn, Dept Otolaryngol, Philadelphia, PA 19104 USA; [Cohen, Noam G.] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA; [Stern, Debra A.; Guerra, Stefano; Martinez, Fernando D.] Univ Arizona, Asthma & Airway Dis Res Ctr, Tucson, AZ USA	University of Arizona; Monell Chemical Senses Center; University of Pennsylvania; University of Pennsylvania; University of Arizona	Chang, EH (corresponding author), Univ Arizona, Dept Otolaryngol, Tucson, AZ 85721 USA.	echang@oto.arizona.edu		Le, Christopher/0000-0002-7580-3030	National Institutes of Health [K08 DE021413, P30 DC011735, R01DC013588, R01 HL132523]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL132523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K08DE021413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P30DC011735, R01DC013588] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This study was supported by the National Institutes of Health (grant no. K08 DE021413 to E.H.C., grant no. P30 DC011735 to D.R.R., grant no. R01DC013588 to N.G.C., and grant no. R01 HL132523 to E.H.C., S.G., and F.D.M.).	BARDIN PG, 1994, AM J RESP CELL MOL, V10, P207, DOI 10.1165/ajrcmb.10.2.8110476; Bochkov YA, 2015, P NATL ACAD SCI USA, V112, P5485, DOI 10.1073/pnas.1421178112; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Cho GS, 2013, J CLIN MICROBIOL, V51, P979, DOI 10.1128/JCM.02806-12; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gern JE, 2010, J VIROL, V84, P7418, DOI 10.1128/JVI.02290-09; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Lamson D, 2006, J INFECT DIS, V194, P1398, DOI 10.1086/508551; Rosenfeld RM, 2015, OTOLARYNG HEAD NECK, V152, pS1, DOI 10.1177/0194599815572097	10	12	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1990	+		10.1016/j.jaci.2016.10.027	http://dx.doi.org/10.1016/j.jaci.2016.10.027			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27923563	Green Accepted, Bronze			2022-12-18	WOS:000402724600032
J	Huang, B; Wang, L; Cao, YN; Zhang, Y; Zhang, J; Xiao, HL; Zhang, QH; Wang, WD; Sun, ZX; Chen, Y; Hu, ZG; Sheng, HM				Huang, Biao; Wang, Liang; Cao, Ya-nan; Zhang, Yi; Zhang, Jue; Xiao, Hualong; Zhang, Qiuhua; Wang, Weidong; Sun, Zhuxing; Chen, Yu; Hu, Zhigang; Sheng, Huiming			Improvement of idiopathic membranous nephropathy diagnosis with ultrasensitive quantitative detection of anti-phospholipase A2 receptor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Huang, Biao; Zhang, Yi; Zhang, Jue] Jiangsu Inst Nucl Med, Wuxi, Peoples R China; [Wang, Liang; Xiao, Hualong; Zhang, Qiuhua; Wang, Weidong; Sun, Zhuxing; Hu, Zhigang] Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Dept Lab Med, Wuxi, Peoples R China; [Cao, Ya-nan; Sheng, Huiming] Shanghai Jiao Tong Univ, Sch Med, Tong Ren Hosp, Shanghai, Peoples R China; [Chen, Yu; Hu, Zhigang] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Lab Med, Hangzhou, Zhejiang, Peoples R China	Nanjing Medical University; Shanghai Jiao Tong University; Zhejiang University	Hu, ZG (corresponding author), Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Dept Lab Med, Wuxi, Peoples R China.; Hu, ZG (corresponding author), Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Lab Med, Hangzhou, Zhejiang, Peoples R China.	jswxhzg@163.com; polosheng@alumni.sjtu.edu.cn	Chen, Yu/Y-3292-2019; sheng, huiming/T-8439-2019; sheng, huiming/GQZ-8569-2022; zhang, qiu/GXG-5600-2022	sheng, huiming/0000-0001-9382-3687	Clinical Medical Science fund of Jiangsu Province [BL2014022]; Science and Technology Commission of Shanghai Municipality [15ZR1437900]; Directive Planning Project of Wuxi Science and Technology Bureau [CSE31N1302]; Key Subject of Wuxi's hospital administration center [YGZXM14013]	Clinical Medical Science fund of Jiangsu Province; Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Directive Planning Project of Wuxi Science and Technology Bureau; Key Subject of Wuxi's hospital administration center	Funding was provided by Clinical Medical Science fund of Jiangsu Province (No. BL2014022), Science and Technology Commission of Shanghai Municipality (No. 15ZR1437900), Directive Planning Project of Wuxi Science and Technology Bureau (No. CSE31N1302), Key Subject of Wuxi's hospital administration center (No. YGZXM14013).	Beck LH, 2009, NEW ENGL J MED, V361, P11, DOI 10.1056/NEJMoa0810457; Hanko JB, 2009, NEPHROL DIAL TRANSPL, V24, P3050, DOI 10.1093/ndt/gfp254; Hofstra JM, 2012, NETH J MED, V70, P109; Qin WS, 2011, J AM SOC NEPHROL, V22, P1137, DOI 10.1681/ASN.2010090967; Stanescu HC, 2011, NEW ENGL J MED, V364, P616, DOI 10.1056/NEJMoa1009742; Svobodova B, 2013, NEPHROL DIAL TRANSPL, V28, P1839, DOI 10.1093/ndt/gfs439	6	12	13	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1988	+		10.1016/j.jaci.2016.10.020	http://dx.doi.org/10.1016/j.jaci.2016.10.020			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27876629				2022-12-18	WOS:000402724600031
J	Iribarren, C; Rothman, KJ; Bradley, MS; Carrigan, G; Eisner, MD; Chen, H				Iribarren, Carlos; Rothman, Kenneth J.; Bradley, Mary S.; Carrigan, Gillis; Eisner, Mark D.; Chen, Hubert			Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Iribarren, Carlos] Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA; [Rothman, Kenneth J.] RTI Hlth Solut, Res Triangle Pk, NC USA; [Bradley, Mary S.; Carrigan, Gillis; Eisner, Mark D.; Chen, Hubert] Genentech Inc, San Francisco, CA 94080 USA	Kaiser Permanente; Research Triangle Institute; Roche Holding; Genentech	Chen, H (corresponding author), Genentech Inc, San Francisco, CA 94080 USA.	chen.hubert@gene.com		Chen, Hubert/0000-0002-6630-239X	EXCELS Advisory Board from Genentech; RTI International	EXCELS Advisory Board from Genentech; RTI International	C. Iribarren has received fees as a member of the EXCELS Advisory Board from Genentech. K. J. Rothman has received payment for writing or reviewing the manuscript from RTI International. M. S. Bradley was employed by Genentech at the time of the study and holds stock options from Roche. G. Carrigan and H. Chen are employed by Genentech and receive stock options from Roche. M. D. Eisner is employed by Genentech/Roche.	Iribarren C, 2016, J ALLERGY CLIN IMMUN; Long A, 2014, J ALLERGY CLIN IMMUN, V134, P560, DOI 10.1016/j.jaci.2014.02.007	2	12	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1678	1680		10.1016/j.jaci.2016.12.953	http://dx.doi.org/10.1016/j.jaci.2016.12.953			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	28108337	hybrid			2022-12-18	WOS:000400465300029
J	Yin, YZ; Mitson-Salazar, A; Wansley, DL; Singh, SP; Prussin, C				Yin, Yuzhi; Mitson-Salazar, Alyssa; Wansley, Daniel L.; Singh, Satya P.; Prussin, Calman			Rapamycin preferentially inhibits human IL-5(+) T(H)2-cell proliferation via an mTORC1/S6 kinase-1-dependent pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							T-CELLS; SUBPOPULATION; DEFINES; MTOR		[Yin, Yuzhi; Mitson-Salazar, Alyssa; Wansley, Daniel L.; Prussin, Calman] NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Singh, Satya P.] NIAID, Lab Mol Immunol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Prussin, C (corresponding author), NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	cprussin@niaid.nih.gov		Mitson-Salazar, Alyssa/0000-0003-0359-437X; Prussin, Calman/0000-0002-3917-3326	Intramural Research Program of the National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000725] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases.	Delgoffe GM, 2011, NAT IMMUNOL, V12, P295, DOI 10.1038/ni.2005; Endo Y, 2014, TRENDS IMMUNOL, V35, P69, DOI 10.1016/j.it.2013.11.003; Endo Y, 2011, IMMUNITY, V35, P733, DOI 10.1016/j.immuni.2011.08.017; Foster Barbara, 2011, Clin Mol Allergy, V9, P7, DOI 10.1186/1476-7961-9-7; Givan AL, 1999, J IMMUNOL METHODS, V230, P99, DOI 10.1016/S0022-1759(99)00136-2; Lamoreaux L, 2006, NAT PROTOC, V1, P1507, DOI 10.1038/nprot.2006.268; Li J, 2014, CELL METAB, V19, P373, DOI 10.1016/j.cmet.2014.01.001; Mitson-Salazar A, 2016, J ALLERGY CLIN IMMUN, V137, P907, DOI 10.1016/j.jaci.2015.08.007; Pollizzi KN, 2015, TRENDS IMMUNOL, V36, P13, DOI 10.1016/j.it.2014.11.005; Powell JD, 2012, ANNU REV IMMUNOL, V30, P39, DOI 10.1146/annurev-immunol-020711-075024; Powell N, 2001, J ALLERGY CLIN IMMUN, V108, P915, DOI 10.1067/mai.2001.119742; Prussin C, 2009, J ALLERGY CLIN IMMUN, V124, P1326, DOI 10.1016/j.jaci.2009.09.048; Singh SP, 2015, J IMMUNOL, V194, P4350, DOI 10.4049/jimmunol.1401093; Upadhyaya B, 2011, J IMMUNOL, V187, P3111, DOI 10.4049/jimmunol.1101283; Wansley Daniel L, 2013, Clin Mol Allergy, V11, P4, DOI 10.1186/1476-7961-11-4; Yin Y, 2015, CURR PROTOC IMMUNOL, V110	16	12	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1701	+		10.1016/j.jaci.2016.10.029	http://dx.doi.org/10.1016/j.jaci.2016.10.029			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27923564	Bronze			2022-12-18	WOS:000400465300038
J	Kawakami, Y; Ando, T; Lee, JR; Kim, G; Kawakami, Y; Nakasaki, T; Nakasaki, M; Matsumoto, K; Choi, YS; Kawakami, T				Kawakami, Yuko; Ando, Tomoaki; Lee, Jong-Rok; Kim, Gisen; Kawakami, Yu; Nakasaki, Tae; Nakasaki, Manando; Matsumoto, Kenji; Choi, Youn Soo; Kawakami, Toshiaki			Defective natural killer cell activity in a mouse model of eczema herpeticum	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; eczema herpeticum; herpes simplex virus; animal model; natural killer cell	REGULATORY T-CELLS; ATOPIC-DERMATITIS; NK CELLS; IN-VIVO; IMMUNE DYSREGULATION; GENOME SEQUENCE; VIRUS; DISEASE; PROTEIN; FOXP3	Background: Patients with atopic dermatitis (AD) are susceptible to several viruses, including herpes simplex virus (HSV). Some patients experience 1 or more episodes of a severe skin infection caused by HSV termed eczema herpeticum (EH). There are numerous mouse models of AD, but no established model exists for EH. Objective: We sought to establish and characterize a mouse model of EH. Methods: We infected AD-like skin lesions with HSV1 to induce severe skin lesions in a dermatitis-prone mouse strain of NC/Nga. Gene expression was investigated by using a microarray and quantitative PCR; antibody titers were measured by means of ELISA; and natural killer (NK) cell, cytotoxic T-cell, regulatory T-cell, and follicular helper T-cell populations were evaluated by using flow cytometry. The role of NK cells in HSV1-induced development of severe skin lesions was examined by means of depletion and adoptive transfer. Results: InoculationofHSV1inducedsevereerosiveskinlesionsin eczematousmice, which had an impaired skinbarrier, butmilder lesionsinsmallnumbersofnormalmice. Eczematousmiceexhibited lowerNKcellactivitybutsimilarcytotoxicT-cellactivityand humoralimmuneresponsescomparedwithnormalmice. Theroleof NKcellsincontrollingHSV1-inducedskinlesionswasdemonstrated byexperimentsdepletingortransferringNKcells. Conclusion: A murine model of EH with an impaired skin barrier was established in this study. We demonstrated a critical role of defective NK activities in the development of HSV1induced severe skin lesions in eczematous mice.	[Kawakami, Yuko; Ando, Tomoaki; Lee, Jong-Rok; Kawakami, Yu; Nakasaki, Tae; Nakasaki, Manando; Kawakami, Toshiaki] La Jolla Inst Allergy & Immunol, Div Cell Biol, 9420 Athena Circle, La Jolla, CA 92037 USA; [Kim, Gisen] La Jolla Inst Allergy & Immunol, Div Dev Immunol, La Jolla, CA USA; [Choi, Youn Soo] La Jolla Inst Allergy & Immunol, Div Vaccine Dev, La Jolla, CA USA; [Choi, Youn Soo] La Jolla Inst Allergy & Immunol, Ctr Infect Dis, La Jolla, CA USA; [Ando, Tomoaki; Kawakami, Toshiaki] RIKEN, Ctr Integrat Med Sci IMS, Lab Allerg Dis, Yokohama, Kanagawa, Japan; [Matsumoto, Kenji] Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan; [Lee, Jong-Rok] Gachon Univ, Gil Med Ctr, Dept Dermatol, Incheon, South Korea; [Choi, Youn Soo] Seoul Natl Univ, Coll Med, Dept Med, Seoul, South Korea	La Jolla Institute for Immunology; La Jolla Institute for Immunology; La Jolla Institute for Immunology; La Jolla Institute for Immunology; RIKEN; National Center for Child Health & Development - Japan; Gachon University; Seoul National University (SNU)	Kawakami, T (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, 9420 Athena Circle, La Jolla, CA 92037 USA.	toshi@lji.org			National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH) [HHSN272201000020C]; NIH [5R01AR064418, 5R01HL124283, 1R21AI115534]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL124283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI115534] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR064418] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This study was conducted as part of the Atopic Dermatitis Research Network funded by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH; HHSN272201000020C). T.K. is also supported by NIH grants 5R01AR064418, 5R01HL124283, and 1R21AI115534.	Ando T, 2013, J INVEST DERMATOL, V133, P2695, DOI 10.1038/jid.2013.250; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bin LH, 2014, J ALLERGY CLIN IMMUN, V134, P848, DOI 10.1016/j.jaci.2014.07.018; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Brans R, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-163; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Bussmann Caroline, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000756; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chiossone L, 2009, BLOOD, V113, P5488, DOI 10.1182/blood-2008-10-187179; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Desai P, 1998, J VIROL, V72, P7563, DOI 10.1128/JVI.72.9.7563-7568.1998; DIX RD, 1983, INFECT IMMUN, V40, P103, DOI 10.1128/IAI.40.1.103-112.1983; Engler RJM, 2002, J ALLERGY CLIN IMMUN, V110, P357, DOI 10.1067/mai.2002.128052; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fyhrquist N, 2012, J INVEST DERMATOL, V132, P1672, DOI 10.1038/jid.2012.40; Gaspar K, 2015, ACTA DERM-VENEREOL, V95, P151, DOI 10.2340/00015555-1882; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Ito Y, 2009, ANN ALLERG ASTHMA IM, V103, P160, DOI 10.1016/S1081-1206(10)60170-6; JENSEN JR, 1984, J INVEST DERMATOL, V82, P30, DOI 10.1111/1523-1747.ep12259055; Jin HL, 2009, J INVEST DERMATOL, V129, P31, DOI 10.1038/jid.2008.106; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; Kataoka S, 2004, DNA CELL BIOL, V23, P549, DOI 10.1089/dna.2004.23.549; Katsuta M, 2006, J IMMUNOL, V176, P7736, DOI 10.4049/jimmunol.176.12.7736; Kawakami T, 2009, CURR OPIN IMMUNOL, V21, P666, DOI 10.1016/j.coi.2009.09.006; Kawakami Yuko, 2007, Allergol Int, V56, P403, DOI 10.2332/allergolint.O-07-486; Kawakami Y, 2009, J EXP MED, V206, P1219, DOI 10.1084/jem.20082835; Kim S, 2002, NAT IMMUNOL, V3, P523, DOI 10.1038/ni796; Lanier LL, 2008, NAT REV IMMUNOL, V8, P259, DOI 10.1038/nri2276; Lee SH, 2007, TRENDS IMMUNOL, V28, P252, DOI 10.1016/j.it.2007.04.001; LEVER RS, 1984, CLIN ALLERGY, V14, P483, DOI 10.1111/j.1365-2222.1984.tb02232.x; Macdonald SJ, 2012, J VIROL, V86, P9540, DOI 10.1128/JVI.01469-12; Macdonald SJ, 2012, J VIROL, V86, P6371, DOI 10.1128/JVI.00646-12; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; Mott KR, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-56; Mueller SN, 2002, J EXP MED, V195, P651, DOI 10.1084/jem.20012023; Nishikado H, 2011, J IMMUNOL, V186, P5766, DOI 10.4049/jimmunol.1100370; Orihara K, 2007, J ALLERGY CLIN IMMUN, V120, P960, DOI 10.1016/j.jaci.2007.05.036; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Peng WM, 2007, J INVEST DERMATOL, V127, P1261, DOI 10.1038/sj.jid.5700657; Perng GC, 2002, J GEN VIROL, V83, P2933, DOI 10.1099/0022-1317-83-12-2933; Reefer AJ, 2008, J ALLERGY CLIN IMMUN, V121, P415, DOI 10.1016/j.jaci.2007.11.003; Shiohara T, 2011, CURR PROBL DERMATOL, V41, P125, DOI 10.1159/000323306; Slifka MK, 2000, J IMMUNOL, V164, P2009, DOI 10.4049/jimmunol.164.4.2009; Sloan DD, 2003, J IMMUNOL, V171, P6733, DOI 10.4049/jimmunol.171.12.6733; Souza-Fonseca-Guimaraes F, 2015, P NATL ACAD SCI USA, V112, pE2376, DOI 10.1073/pnas.1424241112; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Takahashi R, 2014, J IMMUNOL, V192, P969, DOI 10.4049/jimmunol.1300102; Tomimori Y, 2011, ANTIVIR THER, V16, P67, DOI 10.3851/IMP1717; Vosshenrich CAJ, 2005, CURR OPIN IMMUNOL, V17, P151, DOI 10.1016/j.coi.2005.01.005; WILTROUT RH, 1985, J LEUKOCYTE BIOL, V37, P597, DOI 10.1002/jlb.37.5.597; Wollenberg A, 2003, J AM ACAD DERMATOL, V49, P198, DOI 10.1067/S0190-9622(03)00896-X; Zhou L, 2011, J NEUROVIROL, V17, P212, DOI 10.1007/s13365-011-0031-8	54	12	12	3	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					997	+		10.1016/j.jaci.2016.06.034	http://dx.doi.org/10.1016/j.jaci.2016.06.034			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27476888	Green Accepted, Bronze			2022-12-18	WOS:000397295800031
J	Bindslev-Jensen, C; de Kam, PJ; van Twuijver, E; Boot, DB; El Galta, R; Mose, AP; Tannert, LK; Opstelten, DJ				Bindslev-Jensen, Carsten; de Kam, Pieter-Jan; van Twuijver, Esther; Boot, Diderik Boot; El Galta, Rachid; Mose, Anja Pahlow; Tannert, Line Kring; Opstelten, Dirk-Jan			SCIT-treatment With a Chemically Modified, Aluminum Hydroxide Adsorbed Peanut Extract (HAL-MPE1) Was Generally Safe And Well Tolerated And Showed Immunological Changes In Peanut Allergic Patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI)	MAR 03-16, 2017	Atlanta, GA	Amer Acad Allergy, Asthma & Immunol					[Bindslev-Jensen, Carsten; Mose, Anja Pahlow; Tannert, Line Kring] Odense Univ Hosp, Odense Res Ctr Anaphylaxis, Odense, Denmark; [de Kam, Pieter-Jan; van Twuijver, Esther; Boot, Diderik Boot; El Galta, Rachid; Opstelten, Dirk-Jan] HAL Allergy BV, Leiden, Netherlands	University of Southern Denmark; Odense University Hospital; HAL Allergy Group			Bindslev-Jensen, Carsten/H-1877-2011	Bindslev-Jensen, Carsten/0000-0002-8940-038X					0	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2		S		607	AB191	AB191		10.1016/j.jaci.2016.12.623	http://dx.doi.org/10.1016/j.jaci.2016.12.623			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	EV4AF		Bronze			2022-12-18	WOS:000401699800507
J	Hansen, CS; Dufva, M; Bogh, KL; Sullivan, E; Patel, J; Eiwegger, T; Szepfalusi, Z; Nielsen, M; Christiansen, A				Hansen, Christian S.; Dufva, Martin; Bogh, Katrine L.; Sullivan, Eric; Patel, Jigar; Eiwegger, Thomas; Szepfalusi, Zsolt; Nielsen, Morten; Christiansen, Anders			Linear epitope mapping of peanut allergens demonstrates individualized and persistent antibody-binding patterns	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MICROARRAY IMMUNOASSAY; IGE		[Hansen, Christian S.; Nielsen, Morten] Tech Univ Denmark, Ctr Biol Sequence Anal, Lyngby, Denmark; [Dufva, Martin; Christiansen, Anders] Tech Univ Denmark, Dept Micro & Nanotechnol, Lyngby, Denmark; [Bogh, Katrine L.] Tech Univ Denmark, Natl Food Inst, Soborg, Denmark; [Sullivan, Eric; Patel, Jigar] Roche NimbleGen, Madison, WI USA; [Eiwegger, Thomas; Szepfalusi, Zsolt] Med Univ Vienna, Dept Pediat, Vienna, Austria; [Eiwegger, Thomas] Univ Toronto, Hosp Sick Children, Food Allergy & Anaphylaxis Program, Div Immunol & Allergy, Toronto, ON, Canada; [Eiwegger, Thomas] Univ Toronto, Hosp Sick Children, Physiol & Expt Med, Dept Paediat,Res Inst, Toronto, ON, Canada; [Nielsen, Morten] Univ Nacl San Martin, Inst Invest Biotecnol, Buenos Aires, DF, Argentina	Technical University of Denmark; Technical University of Denmark; Technical University of Denmark; Roche Holding; Medical University of Vienna; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Dufva, M (corresponding author), Tech Univ Denmark, Dept Micro & Nanotechnol, Lyngby, Denmark.	Dufva@nanotech.dtu.dk	Dufva, Martin/V-9469-2019; Dufva, Martin/D-1873-2012	Dufva, Martin/0000-0001-5449-0189; Bogh, Katrine Lindholm/0000-0002-5266-0372; Szepfalusi, Zsolt/0000-0003-4852-3102; Eiwegger, Thomas/0000-0002-2914-7829				Burks AW, 2008, LANCET, V371, P1538, DOI 10.1016/S0140-6736(08)60659-5; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Knol EF, 2006, MOL NUTR FOOD RES, V50, P620, DOI 10.1002/mnfr.200500272; Lin J, 2012, J ALLERGY CLIN IMMUN, V129, P1321, DOI 10.1016/j.jaci.2012.02.012; Shreffler WG, 2005, J ALLERGY CLIN IMMUN, V116, P893, DOI 10.1016/j.jaci.2005.06.033; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048	9	12	13	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1728	1730		10.1016/j.jaci.2016.06.019	http://dx.doi.org/10.1016/j.jaci.2016.06.019			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27523433	Bronze			2022-12-18	WOS:000390019300035
J	Miller, M; Esnault, S; Kurten, RC; Kelly, EA; Beppu, A; Das, S; Rosenthal, P; Ramsdell, J; Croft, M; Zuraw, B; Jarjour, N; Hamid, Q; Broide, DH				Miller, Marina; Esnault, Stephane; Kurten, Richard C.; Kelly, Elizabeth A.; Beppu, Andrew; Das, Sudipta; Rosenthal, Peter; Ramsdell, Joe; Croft, Michael; Zuraw, Bruce; Jarjour, Nizar; Hamid, Qutayba; Broide, David H.			Segmental allergen challenge increases levels of airway follistatin-like 1 in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MATRIX-METALLOPROTEINASE-9; INFLAMMATION		[Miller, Marina; Beppu, Andrew; Das, Sudipta; Rosenthal, Peter; Ramsdell, Joe; Zuraw, Bruce; Broide, David H.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Esnault, Stephane; Kelly, Elizabeth A.; Jarjour, Nizar] Univ Wisconsin, Dept Med, Allergy Pulm & Crit Care Med Div, Sch Med & Publ Hlth, Madison, WI USA; [Kurten, Richard C.] Univ Arkansas Med Sci, Dept Physiol & Biophys, Arkansas Childrens Hosp, Res Inst, Little Rock, AR 72205 USA; [Croft, Michael] La Jolla Inst Allergy & Immunol, Div Immune Regulat, La Jolla, CA USA; [Hamid, Qutayba] McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada; [Hamid, Qutayba] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada	University of California System; University of California San Diego; University of Wisconsin System; University of Wisconsin Madison; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; La Jolla Institute for Immunology; McGill University; McGill University	Broide, DH (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	dbroide@ucsd.edu	Esnault, Stephane/AAJ-4511-2020; Esnault, Stephane/AAO-4712-2020	Esnault, Stephane/0000-0001-7238-8671; Kelly, Elizabeth/0000-0001-7335-6698; Zuraw, Bruce/0000-0003-0640-6768; Broide, David/0000-0001-8405-9090; Das, Sudipta/0000-0001-9380-2907	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL088594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI107779, R37AI038425, T32AI007535, R01AI038425, U19AI070535] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR000427] Funding Source: Medline; NCRR NIH HHS [UL1 RR025011] Funding Source: Medline; NHLBI NIH HHS [P01 HL088594] Funding Source: Medline; NIAID NIH HHS [R01 AI107779, U19 AI070535, T32 AI007535, R37 AI038425, R01 AI038425] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Broide DH, 2008, J ALLERGY CLIN IMMUN, V121, P560, DOI 10.1016/j.jaci.2008.01.031; Cataldo DD, 2002, AM J PATHOL, V161, P491, DOI 10.1016/S0002-9440(10)64205-8; Chaly Y, 2014, IMMUNOL RES, V59, P266, DOI 10.1007/s12026-014-8526-z; Gavala ML, 2013, CLIN EXP ALLERGY, V43, P187, DOI 10.1111/cea.12032; Graham JG, 2013, CELL MICROBIOL, V15, P1012, DOI 10.1111/cmi.12096; Kelly EAB, 2000, AM J RESP CRIT CARE, V162, P1157; Lim DH, 2006, AM J PHYSIOL-LUNG C, V291, pL265, DOI 10.1152/ajplung.00305.2005; Miller M, 2015, J IMMUNOL, V195, P3546, DOI 10.4049/jimmunol.1501105; Sylva M, 2013, BIRTH DEFECTS RES C, V99, P61, DOI 10.1002/bdrc.21030	9	12	12	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					596	599		10.1016/j.jaci.2016.01.019	http://dx.doi.org/10.1016/j.jaci.2016.01.019			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27001159	Green Accepted, Bronze			2022-12-18	WOS:000380835800035
J	Shoda, T; Matsuda, A; Arai, K; Shimizu, H; Morita, H; Orihara, K; Okada, N; Narita, M; Ohya, Y; Saito, H; Matsumoto, K; Nomura, I				Shoda, Tetsuo; Matsuda, Akio; Arai, Katsuhiro; Shimizu, Hirotaka; Morita, Hideaki; Orihara, Kanami; Okada, Naoko; Narita, Masami; Ohya, Yukihiro; Saito, Hirohisa; Matsumoto, Kenji; Nomura, Ichiro			Sera of patients with infantile eosinophilic gastroenteritis showed a specific increase in both thymic stromal lymphopoietin and IL-33 levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ESOPHAGITIS; CYTOKINES		[Shoda, Tetsuo; Matsuda, Akio; Morita, Hideaki; Orihara, Kanami; Okada, Naoko; Saito, Hirohisa; Matsumoto, Kenji; Nomura, Ichiro] Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan; [Shoda, Tetsuo; Narita, Masami; Ohya, Yukihiro; Nomura, Ichiro] Natl Ctr Child Hlth & Dev, Div Allergy, Tokyo, Japan; [Arai, Katsuhiro; Shimizu, Hirotaka] Natl Ctr Child Hlth & Dev, Div Gastroenterol, Tokyo, Japan; [Orihara, Kanami] Waseda Univ, Waseda Inst Adv Study, Tokyo, Japan	National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan; Waseda University	Nomura, I (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan.; Nomura, I (corresponding author), Natl Ctr Child Hlth & Dev, Div Allergy, Tokyo, Japan.	matsumoto-k@ncchd.go.jp; nomura-i@ncchd.go.jp	岡田, 直子/GRI-9555-2022; Morita, Hideaki/S-2214-2016; Narita, Masami/AAF-1079-2019	岡田, 直子/0000-0002-3378-5778; Morita, Hideaki/0000-0003-0928-8322; Narita, Masami/0000-0002-5862-679X; Saito, Hirohisa/0000-0002-6630-8337; Orihara, Kanami/0000-0002-2652-4529; Shoda, Tetsuo/0000-0001-8337-5438	Grants-in-Aid for Scientific Research [15H04866] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		DeBrosse CW, 2006, PEDIATR DEVEL PATHOL, V9, P210, DOI 10.2350/11-05-0130.1; Divekar R, 2015, CURR OPIN ALLERGY CL, V15, P98, DOI 10.1097/ACI.0000000000000133; Kinoshita Y, 2012, DIGESTION, V86, P238, DOI 10.1159/000341421; Nomura I, 2011, J ALLERGY CLIN IMMUN, V127, P685, DOI 10.1016/j.jaci.2011.01.019; Nowak-Wegrzyn A, 2015, J ALLERGY CLIN IMMUN, V135, P1114, DOI 10.1016/j.jaci.2015.03.025; Pastorelli L, 2010, P NATL ACAD SCI USA, V107, P8017, DOI 10.1073/pnas.0912678107; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Sherrill JD, 2011, J ALLERGY CLIN IMMUN, V128, P23, DOI 10.1016/j.jaci.2011.03.046; Tamagawa-Mineoka R, 2014, J AM ACAD DERMATOL, V70, P882, DOI 10.1016/j.jaad.2014.01.867	9	12	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					299	303		10.1016/j.jaci.2015.11.042	http://dx.doi.org/10.1016/j.jaci.2015.11.042			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26948075	Bronze			2022-12-18	WOS:000379659100038
J	Elling, R; Keller, B; Weidinger, C; Haffner, M; Deshmukh, SD; Zee, I; Speckmann, C; Ehl, S; Schwarz, K; Feske, S; Henneke, P				Elling, Roland; Keller, Baerbel; Weidinger, Carl; Haeffner, Monika; Deshmukh, Sachin D.; Zee, Isabelle; Speckmann, Carsten; Ehl, Stephan; Schwarz, Klaus; Feske, Stefan; Henneke, Philipp			Preserved effector functions of human ORAI1-and STIM1-deficient neutrophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							OPERATED CALCIUM-ENTRY; ALLERGIC-ASTHMA; OMALIZUMAB; ACTIVATION; MUTATION		[Elling, Roland; Keller, Baerbel; Haeffner, Monika; Deshmukh, Sachin D.; Speckmann, Carsten; Ehl, Stephan; Henneke, Philipp] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Henneke, Philipp] Univ Med Ctr Freiburg, Ctr Pediat & Adolescent Med, Freiburg, Germany; [Elling, Roland] Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Worcester, MA USA; [Weidinger, Carl; Zee, Isabelle; Feske, Stefan] NYU, Sch Med, Dept Pathol, New York, NY USA; [Schwarz, Klaus] Univ Ulm, German Red Cross Blood Serv Baden Wuerttemberg He, Inst Clin Transfus Med & Immunogenet Ulm, D-89069 Ulm, Germany; [Schwarz, Klaus] Univ Ulm, Inst Transfus Med, D-89069 Ulm, Germany	University of Freiburg; University of Freiburg; University of Massachusetts System; University of Massachusetts Worcester; New York University; Ulm University; Ulm University	Elling, R; Henneke, P (corresponding author), Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany.; Henneke, P (corresponding author), Univ Med Ctr Freiburg, Ctr Pediat & Adolescent Med, Freiburg, Germany.; Elling, R (corresponding author), Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Worcester, MA USA.	roland.elling@umassmed.edu; philipp.henneke@uniklinik-freiburg.de	Ehl, Stephan/AAM-6006-2020; Feske, stefan/ABB-3554-2021	Feske, stefan/0000-0001-5431-8178; Ehl, Stephan/0000-0002-9265-2721; Speckmann, Carsten/0000-0002-6217-1556	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI097302] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI097302] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Braunstahl GJ, 2013, RESP MED, V107, P1141, DOI 10.1016/j.rmed.2013.04.017; Brechard S, 2009, BIOCHEM PHARMACOL, V78, P504, DOI 10.1016/j.bcp.2009.05.006; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Clemens RA, 2015, J LEUKOCYTE BIOL, V98, P497, DOI 10.1189/jlb.2MR1114-573R; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Feske S, 2011, ANN NY ACAD SCI, V1238, P74, DOI 10.1111/j.1749-6632.2011.06240.x; Hoek KL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118528; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Kenzel S, 2012, J IMMUNOL, V189, P4582, DOI 10.4049/jimmunol.1200205; Maus M, 2015, P NATL ACAD SCI USA, V112, P6206, DOI 10.1073/pnas.1418852112; Salmon MD, 2011, INT IMMUNOPHARMACOL, V11, P145, DOI 10.1016/j.intimp.2010.11.006; Steinckwich N, 2011, J IMMUNOL, V186, P2182, DOI 10.4049/jimmunol.1001338; Zhang H, 2014, BLOOD, V123, P2238, DOI 10.1182/blood-2012-08-450403	13	12	12	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1587	+		10.1016/j.jaci.2015.09.047	http://dx.doi.org/10.1016/j.jaci.2015.09.047			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26670474	Green Accepted, Bronze			2022-12-18	WOS:000376180200036
J	Tkachenko, E; Rawson, R; La, E; Doherty, TA; Baum, R; Cavagnero, K; Miyanohara, A; Dohil, R; Kurten, RC; Aceves, SS				Tkachenko, Eugene; Rawson, Renee; La, Elizabeth; Doherty, Taylor A.; Baum, Rachel; Cavagnero, Kellen; Miyanohara, Atsushi; Dohil, Ranjan; Kurten, Richard C.; Aceves, Seema S.			Rigid substrate induces esophageal smooth muscle hypertrophy and eosinophilic esophagitis fibrotic gene expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MEDICATION USE; GLIOMA RISK; ANTIHISTAMINE; PHOSPHOLAMBAN		[Tkachenko, Eugene; Miyanohara, Atsushi; Aceves, Seema S.] Univ Calif San Diego, Dept Med, Ctr Infect Immun & Inflammat, La Jolla, CA 92093 USA; [Rawson, Renee; La, Elizabeth; Aceves, Seema S.] Univ Calif San Diego, Ctr Infect Immun & Inflammat, Div Allergy & Immunol, La Jolla, CA 92093 USA; [Doherty, Taylor A.; Baum, Rachel; Cavagnero, Kellen] Univ Calif San Diego, Dept Med, Div Allergy & Immunol, La Jolla, CA 92093 USA; [Miyanohara, Atsushi] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; [Dohil, Ranjan] Univ Calif San Diego, Dept Pediat, Div Gastroenterol & Nutr, La Jolla, CA 92093 USA; [Dohil, Ranjan; Aceves, Seema S.] Rady Childrens Hosp, San Diego, CA USA; [Kurten, Richard C.] Univ Arkansas Med Sci, Dept Physiol & Biophys, Arkansas Childrens Hosp, Res Inst, Little Rock, AR 72205 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences	Aceves, SS (corresponding author), Univ Calif San Diego, Dept Med, Ctr Infect Immun & Inflammat, La Jolla, CA 92093 USA.; Aceves, SS (corresponding author), Univ Calif San Diego, Ctr Infect Immun & Inflammat, Div Allergy & Immunol, La Jolla, CA 92093 USA.; Aceves, SS (corresponding author), Rady Childrens Hosp, San Diego, CA USA.	saceves@ucsd.edu		Cavagnero, Kellen J/0000-0003-4160-6394; Baum, Rachel/0000-0002-8227-7462; Miyanohara, Atsushi/0000-0002-7695-8798; Doherty, Taylor/0000-0003-3256-0398	FIC NIH HHS [D43 TW000237] Funding Source: Medline; NCATS NIH HHS [UL1TR000039, UL1 TR000039] Funding Source: Medline; NIAID NIH HHS [U54 AI117804, R01 AI092135, AI114585, R01 AI114585, AI092135, P30 AI036214] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000237] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, R01AI114585, U54AI117804, R01AI092135] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Amirian ES, 2013, CANCER EPIDEMIOL, V37, P908, DOI 10.1016/j.canep.2013.08.004; Beppu LY, 2014, J ALLERGY CLIN IMMUN, V134, P1100, DOI 10.1016/j.jaci.2014.04.004; Cavanaugh DJ, 2011, J NEUROSCI, V31, P5067, DOI 10.1523/JNEUROSCI.6451-10.2011; CIPRANDI G, 1992, DRUGS, V43, P154, DOI 10.2165/00003495-199243020-00003; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Fox VL, 2003, GASTROINTEST ENDOSC, V57, P30, DOI 10.1067/mge.2003.33; Friedlaender MH, 2011, CURR OPIN ALLERGY CL, V11, P477, DOI 10.1097/ACI.0b013e32834a9652; Indra I, 2011, PHYS BIOL, V8, DOI 10.1088/1478-3975/8/1/015015; Klein EA, 2009, CURR BIOL, V19, P1511, DOI 10.1016/j.cub.2009.07.069; Nicodeme F, 2013, CLIN GASTROENTEROL H, V11, P1101, DOI 10.1016/j.cgh.2013.03.020; Scheurer ME, 2008, CANCER EPIDEM BIOMAR, V17, P1277, DOI 10.1158/1055-9965.EPI-07-2621; Scheurer ME, 2011, INT J CANCER, V129, P2290, DOI 10.1002/ijc.25883; Schmitt JP, 2003, SCIENCE, V299, P1410, DOI 10.1126/science.1081578; Straumann A, 2010, GASTROENTEROLOGY, V139, P1526, DOI 10.1053/j.gastro.2010.07.048	15	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1270	+		10.1016/j.jaci.2015.09.020	http://dx.doi.org/10.1016/j.jaci.2015.09.020			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26542032	Bronze, Green Accepted			2022-12-18	WOS:000373351200043
J	Manoharan, A; von Wilamowitz-Moellendorff, A; Morrison, A; Lipworth, BJ				Manoharan, Arvind; von Wilamowitz-Moellendorff, Alexander; Morrison, Ashley; Lipworth, Brian J.			Effects of formoterol or salmeterol on impulse oscillometry in patients with persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; small airways; spirometry; impulse oscillometry; long-acting beta-agonist; formoterol; salmeterol	SMALL AIRWAY DYSFUNCTION; EXHALED NITRIC-OXIDE; DRY-POWDER INHALER; CONTROL QUESTIONNAIRE; CLINICAL-PRACTICE; BECLOMETHASONE/FORMOTEROL; HYDROFLUOROALKANE; DIPROPIONATE; SPIROMETRY; DEPOSITION	Background: Effects of small-particle long-acting beta-agonists on the small airways have been poorly documented. Objective: We used impulse oscillometry (IOS) to compare single and repeated dosing effects of small-and large-particle long-acting beta-agonists. Methods: After a 1- to 2-week run-in period, patients received either 12 mu g of small-particle hydrofluoroalkane 134a-formoterol solution or 50 mg of large-particle salmeterol dry powder twice daily plus inhaled corticosteroid for 1 to 2 weeks with a 1-to 2-week washout period in between. Measurements were made over 60 minutes after the first and last doses. Results: Sixteen patients completed the study as follows: mean age, 43 years; FEV1, 80%; forced midexpiratory flow between 25% and 75% of forced vital capacity (FEF25-75), 48%; total airway resistance at 5 Hz, 177%; peripheral airway resistance as the difference between 5 and 20 Hz, 0.18 kPa.L-1.s; Asthma Control Questionnaire score, 0.76; and inhaled corticosteroid dosage, 550 mu g/d. There were significantly greater improvements with formoterol versus salmeterol in all IOS outcomes and FEF25-75, but not FEV1, at 5 minutes after the first dose, which were not sustained over 60 minutes. After the last dose, all IOS outcomes, but not FEV1 or FEF25-75, were significantly better with formoterol over the entire 60 minutes: mean difference at 60 minutes between formoterol and salmeterol in total airway resistance at 5 Hz, 7.50% (95% CI, 1.56% to 13.43%, P = .02); central airway resistance at 20 Hz, 5.37% (95% CI, 0.13% to 10.62%, P = .045); peripheral airway resistance as the difference between 5 and 20 Hz, 12.76% (95% CI, 1.28% to 24.24%, P = .03); reactance area under the curve, 19.46% (95% CI, 7.56% to 31.36%, P = .003); reactance at 5 Hz, 11.19% (95% CI, 4.62% to 17.76%, P = .002); and resonant frequency, 9.34% (95% CI, 3.21% to 15.47%, P = .005). Peak expiratory flow significantly improved to a similar degree with both drugs. Conclusion: Significant improvements in IOS outcomes but not spirometry results occurred after chronic dosing with formoterol compared with salmeterol. This might reflect better deposition to the entire lung, including the small airways.	[Manoharan, Arvind; von Wilamowitz-Moellendorff, Alexander; Morrison, Ashley; Lipworth, Brian J.] Univ Dundee, Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Dundee DD1 9SY, Scotland	University of Dundee	Lipworth, BJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Dundee DD1 9SY, Scotland.	b.j.lipworth@dundee.ac.uk			Chiesi UK	Chiesi UK(Chiesi Pharmaceuticals Inc)	Supported by an unrestricted educational grant from Chiesi UK. B. J. L. has received funding from Chiesi UK for attending advisory boards. A. M. has received support from Chiesi UK to attend the 2014 European Respiratory Society Congress. Also, this study was supported by an unrestricted educational grant from Chiesi UK, who also supplied the small-particle formoterol and large-particle beclomethasone inhalers for the study.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Anderson WJ, 2012, CHEST, V142, P1553, DOI 10.1378/chest.12-1310; Boudewijn IM, 2013, ALLERGY, V68, P1419, DOI 10.1111/all.12242; Colice G, 2013, J ALLERGY CLIN IMMUN, V132, P45, DOI 10.1016/j.jaci.2013.02.008; Corda L, 2011, ALLERGY ASTHMA PROC, V32, pE29, DOI 10.2500/aap.2011.32.3477; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Ganderton D, 2002, RESP MED, V96, pS3, DOI 10.1016/S0954-6111(02)80018-X; Goldin JG, 1999, J ALLERGY CLIN IMMUN, V104, pS258, DOI 10.1016/S0091-6749(99)70043-6; Haussermann S, 2007, J AEROSOL MED, V20, P331, DOI 10.1089/jam.2007.0613; HAMID QA, 1991, EUR J PHARM-MOLEC PH, V206, P133, DOI 10.1016/0922-4106(91)90021-9; Houghton CM, 2005, BRIT J CLIN PHARMACO, V59, P152, DOI 10.1111/j.1365-2125.2004.2262.x; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; LANDSER FJ, 1976, J APPL PHYSIOL, V41, P101, DOI 10.1152/jappl.1976.41.1.101; Larsen GL, 2009, J ALLERGY CLIN IMMUN, V123, P861, DOI 10.1016/j.jaci.2008.10.036; Lipworth B, 2014, LANCET RESP MED, V2, P497, DOI 10.1016/S2213-2600(14)70103-1; Manoharan A, 2014, EUR RESPIR J, V44, P1353, DOI 10.1183/09031936.00082314; Nicolini G, 2010, ALLERGY ASTHMA PROC, V31, pE85, DOI 10.2500/aap.2010.31.3367; Oostveen E, 2003, EUR RESPIR J, V22, P1026, DOI 10.1183/09031936.03.00089403; Palmqvist M, 1997, EUR RESPIR J, V10, P2484, DOI 10.1183/09031936.97.10112489; Papi A, 2013, LANCET RESP MED, V1, P23, DOI 10.1016/S2213-2600(13)70012-2; Price D, 2013, RESP MED, V107, P987, DOI 10.1016/j.rmed.2013.03.009; Price D, 2010, J ALLERGY CLIN IMMUN, V126, P511, DOI 10.1016/j.jaci.2010.06.040; Scichilone N, 2010, ALLERGY, V65, P897, DOI 10.1111/j.1398-9995.2009.02306.x; Short PM, 2012, ANN ALLERG ASTHMA IM, V109, P412, DOI 10.1016/j.anai.2012.09.010; Takeda T, 2010, RESPIRATION, V80, P120, DOI 10.1159/000242113; Taki M, 2011, EUR J PHARM SCI, V43, P225, DOI 10.1016/j.ejps.2011.04.014; vanNoord JA, 1996, EUR RESPIR J, V9, P1684, DOI 10.1183/09031936.96.09081684; Yamaguchi M, 2009, PULM PHARMACOL THER, V22, P326, DOI 10.1016/j.pupt.2009.01.005	29	12	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					727	+		10.1016/j.jaci.2015.06.012	http://dx.doi.org/10.1016/j.jaci.2015.06.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26220533	hybrid, Green Published			2022-12-18	WOS:000371897500014
J	Naessens, T; Schepens, B; Smet, M; Pollard, C; Van Hoecke, L; De Beuckelaer, A; Willart, M; Lambrecht, B; De Koker, S; Saelens, X; Grooten, J				Naessens, Thomas; Schepens, Bert; Smet, Muriel; Pollard, Charlotte; Van Hoecke, Lien; De Beuckelaer, Ans; Willart, Monique; Lambrecht, Bart; De Koker, Stefaan; Saelens, Xavier; Grooten, Johan			GM-CSF treatment prevents respiratory syncytial virus-induced pulmonary exacerbation responses in postallergic mice by stimulating alveolar macrophage maturation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic asthma; respiratory syncytial virus-induced exacerbation; alveolar macrophage; GM-CSF	ALLERGIC AIRWAY INFLAMMATION; MUCOSAL SENSITIZATION; CYTOKINE SECRETION; LUNG INFLAMMATION; MURINE MODEL; INFECTION; ASTHMA; CELLS; IMMUNE; INTERLEUKIN-4	Background: Human respiratory syncytial virus (RSV) is a frequent cause of asthma exacerbations, yet the susceptibility of asthmatic patients to RSV is poorly understood. Objective: We sought to address the contribution of resident alveolar macrophages (rAMs) to susceptibility to RSV infection in mice that recovered from allergic airway eosinophilia. Methods: Mice were infected with RSV virus after clearance of allergic airway inflammation (AAI). The contribution of post-AAI rAMs was studied in vivo by means of clodronate liposome-mediated depletion, adoptive transfer, and treatment with recombinant cytokines before RSV infection. Results: After clearing the allergic bronchial inflammation, post-AAI mice had bronchial hyperreactivity and increased inflammatory cell influx when infected with RSV compared with nonallergic mice, whereas viral clearance was comparable in both mouse groups. Post-AAI rAMs were necessary and sufficient for mediating these proinflammatory effects. In post-AAI mice the residing CD11c hi autofluorescent rAM population did not upregulate the terminal differentiation marker sialic acid-binding immunoglobulin-like lectin F and overproduced TNF and IL-6 through increased nuclear factor kappa B nuclear translocation. In line with these results, post-AAI lungs had reduced levels of the rAM maturation cytokine GM-CSF. Intratracheal administration of GM-CSF induced final rAM maturation in post-AAI mice and prevented the increased susceptibility to RSV-induced hyperreactivity and inflammation. Conclusion: Defective production of GM-CSF leads to insufficient post-AAI rAM maturation in mice that recovered from an AAI, causing increased susceptibility to RSV-induced immunopathology. Promoting the differentiation of post-AAI rAMs might be a therapeutic option for preventing RSV-induced exacerbations in human asthmatic patients.	[Naessens, Thomas; Schepens, Bert; Smet, Muriel; Pollard, Charlotte; Van Hoecke, Lien; De Beuckelaer, Ans; De Koker, Stefaan; Saelens, Xavier; Grooten, Johan] Univ Ghent, Dept Biomed Mol Biol, Technol Pk 927, B-9052 Ghent, Belgium; [Willart, Monique; Lambrecht, Bart] Univ Ghent, Dept Pulm Med, B-9052 Ghent, Belgium; [Schepens, Bert; Willart, Monique; Lambrecht, Bart; Saelens, Xavier] Univ Ghent VIB, Inflammat Res Ctr, Ghent, Belgium	Ghent University; Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University	Grooten, J (corresponding author), Univ Ghent, Dept Biomed Mol Biol, Technol Pk 927, B-9052 Ghent, Belgium.	Johan.Grooten@ugent.be	Saelens, Xavier/N-5728-2015; Lambrecht, Bart N/K-2484-2014	Lambrecht, Bart N/0000-0003-4376-6834; Van Hoecke, Lien/0000-0001-8602-4211; , Xavier/0000-0002-3861-6965	UGhent Concerted Research Consortium [BOF12/GOA-B/12424/01]; Interuniversitary Attraction Pole consortium [IUAPVII/63-120C07812W-B/12917/01]; King Baudouin Foundation [365R9113U-B/13761/01]; FWO-Vlaanderen grants; IWT grant	UGhent Concerted Research Consortium; Interuniversitary Attraction Pole consortium; King Baudouin Foundation; FWO-Vlaanderen grants; IWT grant	Supported by the UGhent Concerted Research Consortium BOF12/GOA-B/12424/01, the Interuniversitary Attraction Pole consortium IUAPVII/63-120C07812W-B/12917/01, and the Maro Fund from the King Baudouin Foundation 365R9113U-B/13761/01. B. S. and S. D. K. are supported by FWO-Vlaanderen grants. A. D. B. is supported by an IWT grant.	Bang BR, 2011, EXP MOL MED, V43, P275, DOI 10.3858/emm.2011.43.5.028; Bartlett NW, 2012, EMBO MOL MED, V4, P1244, DOI 10.1002/emmm.201201650; Careau E, 2004, AM J RESP CELL MOL, V31, P22, DOI 10.1165/rcmb.2003-0229OC; Cates EC, 2003, J ALLERGY CLIN IMMUN, V111, P1076, DOI 10.1067/mai.2003.1460; CHERRIE AH, 1992, J VIROL, V66, P2102, DOI 10.1128/JVI.66.4.2102-2110.1992; Durbin JE, 2004, VIRAL IMMUNOL, V17, P370, DOI 10.1089/0882824041857120; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Guilliams M, 2013, J EXP MED, V210, P1977, DOI 10.1084/jem.20131199; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; Hussell T, 2014, NAT REV IMMUNOL, V14, P81, DOI 10.1038/nri3600; Jacobs PP, 2010, MICROB CELL FACT, V9, DOI 10.1186/1475-2859-9-93; Kumagai Y, 2007, IMMUNITY, V27, P240, DOI 10.1016/j.immuni.2007.07.013; Lei XF, 1998, CLIN EXP IMMUNOL, V113, P157; Mathias LJ, 2013, J IMMUNOL, V191, P5914, DOI 10.4049/jimmunol.1300667; Naessens T, 2012, AM J PATHOL, V181, P174, DOI 10.1016/j.ajpath.2012.03.015; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Pichlmair A, 2007, IMMUNITY, V27, P370, DOI 10.1016/j.immuni.2007.08.012; Pribul PK, 2008, J VIROL, V82, P4441, DOI 10.1128/JVI.02541-07; Reed JL, 2008, J INFECT DIS, V198, P1783, DOI 10.1086/593173; Ritz SA, 2002, AM J RESP CELL MOL, V27, P428, DOI 10.1165/rcmb.4824; Sanfilippo AM, 2015, INFECT IMMUN, V83, P2976, DOI 10.1128/IAI.00142-15; SAWADA KI, 1995, LEUKEMIA LYMPHOMA, V19, P33, DOI 10.3109/10428199509059661; Simpson JL, 2003, J CLIN VIROL, V26, P339, DOI 10.1016/S1386-6532(02)00084-7; Su YC, 2008, J IMMUNOL, V180, P2600, DOI 10.4049/jimmunol.180.4.2600; Tang CB, 2001, J IMMUNOL, V166, P1471, DOI 10.4049/jimmunol.166.3.1471; THEPEN T, 1989, J EXP MED, V170, P499, DOI 10.1084/jem.170.2.499; UPHAM JW, 1995, IMMUNOLOGY, V84, P142; Varin A, 2010, BLOOD, V115, P353, DOI 10.1182/blood-2009-08-236711; WAGNER DK, 1989, J CLIN MICROBIOL, V27, P589, DOI 10.1128/JCM.27.3.589-592.1989; WELLIVER RC, 1980, J PEDIATR-US, V96, P808, DOI 10.1016/S0022-3476(80)80547-6; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Willinger T, 2011, P NATL ACAD SCI USA, V108, P2390, DOI 10.1073/pnas.1019682108; Zaslona Z, 2014, J IMMUNOL, V193, P4245, DOI 10.4049/jimmunol.1400580; Zhao J, 2002, PEDIATR ALLERGY IMMU, V13, P47, DOI 10.1034/j.1399-3038.2002.00051.x; Zhou Q, 2014, J IMMUNOL, V193, P496, DOI 10.4049/jimmunol.1303138	36	12	12	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					700	+		10.1016/j.jaci.2015.09.031	http://dx.doi.org/10.1016/j.jaci.2015.09.031			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26560044	Bronze			2022-12-18	WOS:000371897500011
J	Silverberg, JI				Silverberg, Jonathan I.			Atopic disease and cardiovascular risk factors in US children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; POPULATION; OBESITY		[Silverberg, Jonathan I.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; [Silverberg, Jonathan I.] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA; [Silverberg, Jonathan I.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; [Silverberg, Jonathan I.] Northwestern Multidisciplinary Eczema Ctr, Chicago, IL USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Silverberg, JI (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.; Silverberg, JI (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA.; Silverberg, JI (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA.; Silverberg, JI (corresponding author), Northwestern Multidisciplinary Eczema Ctr, Chicago, IL USA.	JonathanISilverberg@Gmail.com	silverberg, jonathan/ABH-2765-2021	silverberg, jonathan/0000-0003-3686-7805	AHRQ HHS [K12 HS023011, K12HS023011] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K12HS023011] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bibi H, 2004, J ASTHMA, V41, P403, DOI 10.1081/JAS-120026097; Broide DH, 2001, J ALLERGY CLIN IMMUN, V108, pS65, DOI 10.1067/mai.2001.116436; Cockcroft DW, 1985, AIRWAY RESPONSIVENES, P22; Granell R, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001669; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; Ross KR, 2009, PEDIATR PULM, V44, P877, DOI 10.1002/ppul.21065; Salter BM, 2015, J ALLERGY CLIN IMMUN, V136, P1636, DOI 10.1016/j.jaci.2015.03.039; SENTHILSELVAN A, 1993, J ASTHMA, V30, P185, DOI 10.3109/02770909309054516; Silverberg JI, 2015, BRIT J DERMATOL, V173, P1400, DOI 10.1111/bjd.14031; Silverberg JI, 2015, J ALLERGY CLIN IMMUN, V135, P721, DOI 10.1016/j.jaci.2014.11.023; Silverberg JI, 2015, JAMA DERMATOL, V151, P144, DOI 10.1001/jamadermatol.2014.3059; Thomsen SF, 2011, ALLERGY, V66, P645, DOI 10.1111/j.1398-9995.2010.02517.x	12	12	12	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					938	940		10.1016/j.jaci.2015.09.012	http://dx.doi.org/10.1016/j.jaci.2015.09.012			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26679356	Bronze, Green Accepted			2022-12-18	WOS:000371897500042
J	Sugai, K; Kimura, H; Miyaji, Y; Tsukagoshi, H; Yoshizumi, M; Sasaki-Sakamoto, T; Matsunaga, S; Yamada, Y; Kashiwakura, J; Noda, M; Ikeda, M; Kozawa, K; Ryo, A; Yoshihara, S; Ogata, H; Okayama, Y				Sugai, Kazuko; Kimura, Hirokazu; Miyaji, Yumiko; Tsukagoshi, Hiroyuki; Yoshizumi, Masakazu; Sasaki-Sakamoto, Tomomi; Matsunaga, Satoko; Yamada, Yumi; Kashiwakura, Jun-ichi; Noda, Masahiro; Ikeda, Masanori; Kozawa, Kunihisa; Ryo, Akihide; Yoshihara, Shigemi; Ogata, Hiromitsu; Okayama, Yoshimichi			MIP-1 alpha level in nasopharyngeal aspirates at the first wheezing episode predicts recurrent wheezing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Acute lower respiratory tract illness; biomarkers; human rhinovirus; recurrent wheezing; IFN-gamma; MIP-1 alpha; MIP-1 beta; nasopharyngeal aspirates; respiratory syncytial virus	RESPIRATORY SYNCYTIAL VIRUS; ALLERGIC SENSITIZATION; EARLY-LIFE; AIRWAY HYPERREACTIVITY; RHINOVIRUS ILLNESSES; CYTOKINE RESPONSES; VIRAL-INFECTIONS; DISEASE SEVERITY; GAMMA PRODUCTION; ASTHMA	Background: Respiratory virus-induced wheezing, such as that induced by respiratory syncytial virus (RSV) and human rhinovirus, is an important risk factor for recurrent wheezing and childhood asthma. However, no biomarkers for predicting recurrent wheezing have been identified. Objective: We searched for predictors of recurrent wheezing using nasopharyngeal aspirates obtained from patients during the first wheezing episode who were hospitalized with an acute lower respiratory tract illness. Methods: We enrolled 82 infants during the first wheezing episode (median age, 5.0 months) who were hospitalized for acute lower respiratory tract illness between August 2009 and June 2012 and followed these patients for 2.5 years. Nasopharyngeal aspirates and blood samples were obtained on the first day of hospitalization. Viral genomes were identified by using RT-PCR and sequencing. Levels of 33 cytokines, tryptase, IgE, anti-RSV IgE, and anti-RSV IgG were measured by using ELISAs or the Bio-Plex multiplex assay. Predictors of recurrent wheezing were examined by using a stepwise logistic regression model with backward elimination. Results: Sixty percent of the patients experienced recurrent wheezing episodes. One or more viruses were detected in the nasopharynxes of 93% of the patients during the first wheezing episode. IFN-gamma, IL-2, IL-9, MIP-1 alpha, and MIP-1 beta levels were significantly higher among patients with recurrent wheezing than among those without recurrent wheezing (P < .05 or .01). The stepwise model demonstrated that the MIP-1a level (odds ratio, 7.72; 95% CI, 1.50-39.77; P = .015) was the strongest independent predictor of the occurrence of recurrent wheezing. Conclusion: An increased MIP-1 alpha level in nasopharyngeal aspirates from patients with acute respiratory symptoms during the first wheezing episode caused by viral infections might predict recurrent wheezing.	[Sugai, Kazuko; Ikeda, Masanori] Natl Hosp Org, Fukuyama Med Ctr, Dept Pediat, Hiroshima, Japan; [Kimura, Hirokazu; Noda, Masahiro] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo, Japan; [Miyaji, Yumiko] Natl Hosp Org, Yokohama Med Ctr, Dept Pediat, Yokohama, Kanagawa, Japan; [Tsukagoshi, Hiroyuki; Yoshizumi, Masakazu; Kozawa, Kunihisa] Gunma Prefectural Inst Publ Hlth & Environm Sci, Dept Hlth Sci, Maebashi, Gunma, Japan; [Sasaki-Sakamoto, Tomomi; Okayama, Yoshimichi] Nihon Univ, Sch Med, Div Med Educ Planning & Dev, Allergy & Immunol Grp,Res Inst Med Sci, Tokyo 1738610, Japan; [Matsunaga, Satoko; Ryo, Akihide] Yokohama City Univ, Grad Sch Med, Dept Mol Biodef Res, Yokohama, Kanagawa 232, Japan; [Yamada, Yumi] Yamada Gastroenterol Pediat Clin, Utsunomiya, Tochigi, Japan; [Kashiwakura, Jun-ichi] RIKEN Ctr Integrat Med Sci IMS RCAI, RCAI, Lab Allerg Dis, Yokohama, Kanagawa, Japan; [Yoshihara, Shigemi] Dokkyo Med Univ, Dept Pediat, Mibu, Tochigi, Japan; [Ogata, Hiromitsu] Natl Inst Publ Hlth, Ctr Informat Res, Tokyo, Japan	National Institute of Infectious Diseases (NIID); Nihon University; Yokohama City University; RIKEN; Dokkyo Medical University; National Institute of Public Health - Japan	Okayama, Y (corresponding author), Nihon Univ, Sch Med, Div Med Educ Planning & Dev, Allergy & Immunol Grp,Res Inst Med Sci,Itabashi K, 30-1 Oyaguchikami Machi, Tokyo 1738610, Japan.	okayama.yoshimichi@nihon-u.ac.jp	Okayama, Yoshimichi/AAG-4352-2021	SUGAI, Kazuko/0000-0002-1037-5063	Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of the Japanese Government [[C] 15K09558]; Nihon University; MEXT	Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of the Japanese Government(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Nihon University; MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of the Japanese Government (Project no. [C] 15K09558, awarded to Y.O.), the Nihon University Multidisciplinary Research Grant for 2015 (awarded to Y.O.), and the MEXT-Supported Program for the Strategic Research Foundation at Private Universities, 2015-2019 (awarded to Y.O.).	Aberle JH, 1999, AM J RESP CRIT CARE, V160, P1263, DOI 10.1164/ajrccm.160.4.9812025; Baraldo S, 2012, J ALLERGY CLIN IMMUN, V130, P1307, DOI 10.1016/j.jaci.2012.08.005; Bedke N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044580; Bennett BL, 2007, J INFECT DIS, V195, P1532, DOI 10.1086/515575; Bisset LR, 2005, CURR OPIN PULM MED, V11, P35, DOI 10.1097/01.mcp.0000144502.50149.e0; Bonnelykke K, 2015, J ALLERGY CLIN IMMUN, V136, P81, DOI 10.1016/j.jaci.2015.02.024; Bont L, 1999, EUR RESPIR J, V14, P144, DOI 10.1034/j.1399-3003.1999.14a24.x; Bont L, 2004, THORAX, V59, P512, DOI 10.1136/thx.2003.013391; Bont L, 2001, J INFECT DIS, V184, P355, DOI 10.1086/322035; Bullens DMA, 2008, CLIN EXP ALLERGY, V38, P1459, DOI 10.1111/j.1365-2222.2008.03045.x; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Campbell EM, 1998, J IMMUNOL, V161, P7047; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Dakhama A, 2009, J ALLERGY CLIN IMMUN, V123, P138, DOI 10.1016/j.jaci.2008.10.012; Foronjy RF, 2014, BMC IMMUNOL, V15, DOI 10.1186/s12865-014-0041-4; Fujitsuka A, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-168; Garcia C, 2012, PEDIATR INFECT DIS J, V31, P86, DOI 10.1097/INF.0b013e31822dc8c1; Halwani R, 2011, J IMMUNOL, V186, P4156, DOI 10.4049/jimmunol.1001210; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Holgate ST, 1997, AM J RESP CRIT CARE, V156, P1377, DOI 10.1164/ajrccm.156.5.9610064; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Ishioka T, 2013, INT ARCH ALLERGY IMM, V161, P129, DOI 10.1159/000350427; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Jartti T, 2010, PEDIAT ALLERG IMM-UK, V21, P1008, DOI 10.1111/j.1399-3038.2010.01059.x; Jartti T, 2015, J ALLERGY CLIN IMMUN, V135, P691, DOI 10.1016/j.jaci.2014.07.001; Kim CK, 2010, J PEDIATR-US, V156, P749, DOI 10.1016/j.jpeds.2009.12.001; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lee YM, 2008, AM J RESP CRIT CARE, V177, P208, DOI 10.1164/rccm.200612-1890OC; Legg JP, 2003, AM J RESP CRIT CARE, V168, P633, DOI 10.1164/rccm.200210-1148OC; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lim S, 2000, ALLERGY, V55, P489; Lloyd CM, 2015, CURR OPIN IMMUNOL, V34, P52, DOI 10.1016/j.coi.2015.02.001; Lukacs NW, 1996, J LEUKOCYTE BIOL, V60, P573, DOI 10.1002/jlb.60.5.573; Lukacs NW, 1997, J IMMUNOL, V158, P4398; Matsuse H, 2000, J IMMUNOL, V164, P6583, DOI 10.4049/jimmunol.164.12.6583; Maurer M, 2004, INT J BIOCHEM CELL B, V36, P1882, DOI 10.1016/j.biocel.2003.10.019; McCann KL, 2007, J VIROL, V81, P2880, DOI 10.1128/JVI.02583-06; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Miller EK, 2012, AM J RESP CRIT CARE, V185, P508, DOI 10.1164/rccm.201108-1462OC; Mizuta K, 2010, VIRUS RES, V147, P265, DOI 10.1016/j.virusres.2009.11.011; Okazaki K, 2008, PEDIATRICS, V121, pE748, DOI 10.1542/peds.2007-1697; Rajan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114322; Renzi PM, 1999, AM J RESP CRIT CARE, V159, P1417, DOI 10.1164/ajrccm.159.5.9805080; Schauer U, 2002, EUR RESPIR J, V20, P1277, DOI 10.1183/09031936.02.00019902; Schuurhof A, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-121; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Simoes EAF, 2010, J ALLERGY CLIN IMMUN, V126, P256, DOI 10.1016/j.jaci.2010.05.026; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Tregoning JS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009381; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Yoshihara S, 2013, PEDIATRICS, V132, P811, DOI 10.1542/peds.2013-0982; Yoshizumi M, 2008, CELL BIOL INT, V32, P1405, DOI 10.1016/j.cellbi.2008.08.011	55	12	15	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					774	781		10.1016/j.jaci.2015.08.032	http://dx.doi.org/10.1016/j.jaci.2015.08.032			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26494023	Bronze			2022-12-18	WOS:000371897500020
J	Weinstein, SF; Germinaro, M; Bardin, P; Korn, S; Bateman, ED				Weinstein, Steven F.; Germinaro, Matthew; Bardin, Philip; Korn, Stephanie; Bateman, Eric Donn			Efficacy of Reslizumab with Asthma, Chronic Sinusitis with Nasal Polyps and Elevated Blood Eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI)	MAR 04-07, 2016	Los Angeles, CA	Amer Acad Allergy, Asthma & Immunol					[Weinstein, Steven F.] Allergy & Asthma Specialists Med Grp & Res Ctr, Huntington Beach, CA USA; [Germinaro, Matthew] Teva Pharmaceut, N Wales, PA USA; [Bardin, Philip] Monash Univ, Clayton, Vic 3800, Australia; [Korn, Stephanie] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Mainz, Germany; [Bateman, Eric Donn] Univ Cape Town, ZA-7700 Rondebosch, South Africa	Monash University; Johannes Gutenberg University of Mainz; University of Cape Town									0	12	12	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2		S		283	AB86	AB86		10.1016/j.jaci.2015.12.409	http://dx.doi.org/10.1016/j.jaci.2015.12.409			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	DK6BI		Bronze			2022-12-18	WOS:000375005401220
J	Rosenberg, JM; Price, JV; Barcenas-Morales, G; Ceron-Gutierrez, L; Davies, S; Kumararatne, DS; Doffinger, R; Utz, PJ				Rosenberg, Jacob M.; Price, Jordan V.; Barcenas-Morales, Gabriela; Ceron-Gutierrez, Lourdes; Davies, Sophie; Kumararatne, Dinakantha S.; Doeffinger, Rainer; Utz, Paul J.			Protein microarrays identify disease-specific anti-cytokine autoantibody profiles in the landscape of immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anti-cytokine autoantibodies; immunodeficiency; autoimmune polyendocrine syndrome type I; pulmonary alveolar proteinosis; thymoma; protein microarray	PULMONARY ALVEOLAR PROTEINOSIS; COLONY-STIMULATING FACTOR; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CHRONIC MUCOCUTANEOUS CANDIDIASIS; IFN-GAMMA AUTOANTIBODY; GM-CSF AUTOANTIBODIES; SYNDROME TYPE-I; RITUXIMAB THERAPY; MYCOBACTERIAL INFECTION; IMMUNE-RESPONSE	Background: Anti-cytokine autoantibodies (ACAAs) are pathogenic in a handful of rare immunodeficiencies. However, the prevalence and significance of other ACAAs across immunodeficiencies have not yet been described. Objective: We profiled ACAAs in a diverse cohort of serum samples from patients with immunodeficiency and assessed the sensitivity and specificity of protein microarrays for ACAA identification and discovery. Methods: Highly multiplexed protein microarrays were designed and fabricated. Blinded serum samples from a cohort of 58 immunodeficiency patients and healthy control subjects were used to probe microarrays. Unsupervised hierarchical clustering was used to identify clusters of reactivity, and after unblinding, significance analysis of microarrays was used to identify disease-specific autoantibodies. A bead-based assay was used to validate protein microarray results. Blocking activity of serum containing ACAAs was measured in vitro. Results: Protein microarrays were highly sensitive and specific for the detection of ACAAs in patients with autoimmune polyendocrine syndrome type I and pulmonary alveolar proteinosis, detecting ACAA levels consistent with those reported in the published literature. Protein microarray results were validated by using an independent bead-based assay. To confirm the functional significance of these ACAAs, we tested and confirmed the blocking activity of select ACAAs in vitro. Conclusion: Protein microarrays are a powerful tool for ACAA detection and discovery, and they hold promise as a diagnostic for the evaluation and monitoring of clinical immunodeficiency.	[Rosenberg, Jacob M.; Price, Jordan V.; Utz, Paul J.] Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA; [Utz, Paul J.] Stanford Univ, Sch Med, Inst Immun Transplantat & Infect, Stanford, CA 94305 USA; [Barcenas-Morales, Gabriela; Ceron-Gutierrez, Lourdes; Davies, Sophie; Kumararatne, Dinakantha S.; Doeffinger, Rainer] Addenbrookes Hosp, Dept Clin Biochem & Immunol, Cambridge, England; [Barcenas-Morales, Gabriela] UNAM, Lab Inmunol, Fes Cuautitlan, Cuautitlan Izca, Mexico; [Doeffinger, Rainer] Cambridge Biomed Res Ctr, NIHR, Cambridge, England	Stanford University; Stanford University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Universidad Nacional Autonoma de Mexico; University of Cambridge	Rosenberg, JM (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, CCSR Room 2250,269 Campus Dr, Stanford, CA 94305 USA.	JakeRos@stanford.edu; PJUtz@stanford.edu		Barcenas Morales, Gabriela/0000-0003-0063-8795; Doffinger, R/0000-0002-9841-3617	National Institutes of Health (NIH) [T32GM007365]; Donald E. and Delia B. Baxter Foundation Career Development Award; National Heart, Lung, and Blood Institute (NHLBI) [N01-HV-00242, HSN268201000034C]; NIH [1 U19-AI110491, 1 U19-AI090019, 1 UH2 AR067676, 1 UM2 AR067678, 1 UM1AI110498]; Alliance for Lupus Research [21858]; FP grant [261]; European Union [261382]; UNAM-DGAPA-PAPIIT [IN217312-3, IN220815]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI090019, UM1AI110498, R01AI051614, U19AI110491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [UM2AR067678, UH2AR067676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK061934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Donald E. and Delia B. Baxter Foundation Career Development Award; National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alliance for Lupus Research; FP grant; European Union(European Commission); UNAM-DGAPA-PAPIIT(Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)Universidad Nacional Autonoma de Mexico); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Research reported in this publication was supported by the National Institutes of Health (NIH) under award number T32GM007365. P.J.U. is the recipient of a Donald E. and Delia B. Baxter Foundation Career Development Award, a gift from the Floren Family Trust, and a gift from the Ben May Charitable Trust (Mobile, Alabama) and is supported by National Heart, Lung, and Blood Institute (NHLBI) Proteomics contract N01-HV-00242, HSN268201000034C, NIH grants (1 U19-AI110491, 1 U19-AI090019, 1 UH2 AR067676, 1 UM2 AR067678, and 1 UM1AI110498), the Alliance for Lupus Research (grant no. 21858), and FP grant no. 261. The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 261382. G.B.-M. was supported by grants from UNAM-DGAPA-PAPIIT (grants IN217312-3 and IN220815). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933; Borie R, 2009, EUR RESPIR J, V33, P1503, DOI 10.1183/09031936.00160908; Browne SK, 2014, ANNU REV IMMUNOL, V32, P635, DOI 10.1146/annurev-immunol-032713-120222; Browne SK, 2012, NEW ENGL J MED, V367, P725, DOI 10.1056/NEJMoa1111160; Browne SK, 2012, BLOOD, V119, P3933, DOI 10.1182/blood-2011-12-395707; Browne SK, 2010, LANCET INFECT DIS, V10, P875, DOI 10.1016/S1473-3099(10)70196-1; Burbelo PD, 2010, BLOOD, V116, P4848, DOI 10.1182/blood-2010-05-286161; Burbelo Peter D, 2009, J Vis Exp, DOI 10.3791/1549; Bussone G, 2009, AUTOIMMUN REV, V8, P332, DOI 10.1016/j.autrev.2008.11.004; Casanova JL, 2013, ANNU REV GENOM HUM G, V14, P215, DOI 10.1146/annurev-genom-091212-153448; Dirksen U, 1997, J CLIN INVEST, V100, P2211, DOI 10.1172/JCI119758; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Doffinger R, 2004, CLIN INFECT DIS, V38, pE10, DOI 10.1086/380453; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; Duffy D, 2014, IMMUNITY, V40, P436, DOI 10.1016/j.immuni.2014.03.002; Ghillani P, 2011, AUTOIMMUN REV, V10, P509, DOI 10.1016/j.autrev.2011.03.004; Griffiths CEM, 2010, NEW ENGL J MED, V362, P118, DOI 10.1056/NEJMoa0810652; Hellmich B, 2002, ARTHRITIS RHEUM, V46, P2384, DOI 10.1002/art.10497; Hoflich C, 2004, BLOOD, V103, P673, DOI 10.1182/blood-2003-04-1065; Husebye ES, 2009, J INTERN MED, V265, P514, DOI 10.1111/j.1365-2796.2009.02090.x; Kisand K, 2010, J EXP MED, V207, P299, DOI 10.1084/jem.20091669; Kitamura T, 1999, J EXP MED, V190, P875, DOI 10.1084/jem.190.6.875; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P28; Maecker HT, 2012, NAT REV RHEUMATOL, V8, P317, DOI 10.1038/nrrheum.2012.66; Malur A, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-46; Meager A, 2003, CLIN EXP IMMUNOL, V132, P128, DOI 10.1046/j.1365-2249.2003.02113.x; Meager A, 2006, PLOS MED, V3, P1152, DOI 10.1371/journal.pmed.0030289; Meager A, 2014, EXPERT REV CLIN IMMU, V10, P1029, DOI 10.1586/1744666X.2014.918848; Mohammadi M, 2005, CYTOKINE GROWTH F R, V16, P107, DOI 10.1016/j.cytogfr.2005.01.008; NISHINAKAMURA R, 1995, IMMUNITY, V2, P211, DOI 10.1016/1074-7613(95)90046-2; Patel SY, 2005, J IMMUNOL, V175, P4769, DOI 10.4049/jimmunol.175.7.4769; Price JV, 2013, J CLIN INVEST, V123, P5135, DOI 10.1172/JCI70231; Puel A, 2010, J EXP MED, V207, P291, DOI 10.1084/jem.20091983; Robinson WH, 2002, NAT MED, V8, P295, DOI 10.1038/nm0302-295; Rosenberg JM, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00138; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sakagami T, 2009, NEW ENGL J MED, V361, P2679, DOI 10.1056/NEJMc0904077; Sandborn WJ, 2012, NEW ENGL J MED, V367, P1519, DOI 10.1056/NEJMoa1203572; Sim BTT, 2013, J CLIN IMMUNOL, V33, P1057, DOI 10.1007/s10875-013-9908-z; STANLEY E, 1994, P NATL ACAD SCI USA, V91, P5592, DOI 10.1073/pnas.91.12.5592; Todoric K, 2013, CURR ALLERGY ASTHM R, V13, P361, DOI 10.1007/s11882-013-0350-3; Trapnell BC, 2003, NEW ENGL J MED, V349, P2527, DOI 10.1056/NEJMra023226; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uchida K, 2007, NEW ENGL J MED, V356, P567, DOI 10.1056/NEJMoa062505; Watanabe M, 2007, FEBS LETT, V581, P2017, DOI 10.1016/j.febslet.2007.04.029	45	12	12	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					204	+		10.1016/j.jaci.2015.07.032	http://dx.doi.org/10.1016/j.jaci.2015.07.032			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26365387	Green Accepted, Bronze			2022-12-18	WOS:000367724300012
J	Visness, CM; Sandel, MT; O'Connor, G; Gern, JE; Jaffee, KF; Wood, RA; Kattan, M; Bloomberg, GR; Dresen, A; Gergen, PJ; Gold, DR; Lemanske, RF; Rajamanickam, V; Camargo, CA; Jackson, DJ				Visness, Cynthia M.; Sandel, Megan T.; O'Connor, George; Gern, James E.; Jaffee, Katy F.; Wood, Robert A.; Kattan, Meyer; Bloomberg, Gordon R.; Dresen, Amy; Gergen, Peter J.; Gold, Diane R.; Lemanske, Robert F.; Rajamanickam, Victoria; Camargo, Carlos A.; Jackson, Daniel J.			Cord blood vitamin D concentrations are unrelated to atopy and wheeze in 2 diverse birth cohort studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							25-HYDROXYVITAMIN D LEVELS; ASTHMA; SENSITIZATION; PREGNANCY; CHILDREN		[Visness, Cynthia M.; Jaffee, Katy F.] Rho Fed Syst Div Inc, Chapel Hill, NC 27515 USA; [Sandel, Megan T.; O'Connor, George] Boston Univ, Sch Med, Boston, MA 02118 USA; [Gern, James E.; Dresen, Amy; Lemanske, Robert F.; Rajamanickam, Victoria; Jackson, Daniel J.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Kattan, Meyer] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Bloomberg, Gordon R.] Washington Univ, Sch Med, St Louis, MO USA; [Gergen, Peter J.] NIH, Div Allergy Immunol & Transplantat, Bethesda, MD 20892 USA; [Gold, Diane R.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Camargo, Carlos A.] Massachusetts Gen Hosp, Boston, MA 02114 USA	Boston University; University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University; Columbia University; Washington University (WUSTL); National Institutes of Health (NIH) - USA; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	Visness, CM (corresponding author), Rho Fed Syst Div Inc, Chapel Hill, NC 27515 USA.	djj@medicine.wisc.edu	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	NCATS NIH HHS [UL1 TR000427, UL1 TR000448] Funding Source: Medline; NCRR NIH HHS [M01 RR03186, 1UL1RR025771, 5UL1RR024992-02, M01RR00533, 1UL1RR024156, M01RR00071, RR00052] Funding Source: Medline; NHLBI NIH HHS [R01 HL61879, P01 HL070831, P01 HL70831] Funding Source: Medline; NIAID NIH HHS [HHSN272200900052C, N01-AI-25482, UM1 AI114271, N01-AI-25496] Funding Source: Medline; PHS HHS [HHSN272200900052C, HHSN272201000052I] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427, UL1TR000448] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071, M01RR003186, M01RR000533, UL1RR024992, UL1RR024156, UL1RR025771] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061879, P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI114271, N01AI025496] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bird JA, 2014, J ALLERGY CLIN IMMUN, V134, P490, DOI 10.1016/j.jaci.2014.05.002; Camargo CA, 2011, PEDIATRICS, V127, pE180, DOI 10.1542/peds.2010-0442; Devereux G, 2007, AM J CLIN NUTR, V85, P853, DOI 10.1093/ajcn/85.3.853; Gergen PJ, 2013, AM J CLIN NUTR, V97, P1228, DOI 10.3945/ajcn.112.046961; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Harvey NC, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18450; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Powe CE, 2013, NEW ENGL J MED, V369, P1991, DOI 10.1056/NEJMoa1306357; Rothers J, 2011, J ALLERGY CLIN IMMUN, V128, P1093, DOI 10.1016/j.jaci.2011.07.015	10	12	12	4	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1108	1110		10.1016/j.jaci.2015.03.046	http://dx.doi.org/10.1016/j.jaci.2015.03.046			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25979524	Green Accepted, Bronze			2022-12-18	WOS:000362976300035
J	Rabinovitch, N; Shah, D; Lanser, BJ				Rabinovitch, Nathan; Shah, Dimple; Lanser, Bruce J.			Look before you LEAP: Risk of anaphylaxis in high-risk infants with early introduction of peanut	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGY		[Rabinovitch, Nathan; Lanser, Bruce J.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA; [Shah, Dimple] Natl Jewish Hlth, Dept Med, Denver, CO USA	National Jewish Health; National Jewish Health	Rabinovitch, N (corresponding author), Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA.	rabinovitchn@njhealth.org		Rabinovitch, Nathan/0000-0001-9735-6748; Lanser, Bruce J./0000-0002-3422-8658				Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Fleischer DM, 2015, J ALLERGY CLIN IMMUN, V136, P258, DOI 10.1016/j.jaci.2015.06.001	2	12	12	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					822	822		10.1016/j.jaci.2015.07.002	http://dx.doi.org/10.1016/j.jaci.2015.07.002			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	26253342				2022-12-18	WOS:000360913300043
J	Janikashvili, N; Trad, M; Gautheron, A; Samson, M; Lamarthee, B; Bonnefoy, F; Lemaire-Ewing, S; Ciudad, M; Rekhviashvili, K; Seaphanh, F; Gaugler, B; Perruche, S; Bateman, A; Martin, L; Audia, S; Saas, P; Larmonier, N; Bonnotte, B				Janikashvili, Nona; Trad, Malika; Gautheron, Alexandrine; Samson, Maxime; Lamarthee, Baptiste; Bonnefoy, Francis; Lemaire-Ewing, Stephanie; Ciudad, Marion; Rekhviashvili, Khatuna; Seaphanh, Famky; Gaugler, Beatrice; Perruche, Sylvain; Bateman, Andrew; Martin, Laurent; Audia, Sylvain; Saas, Philippe; Larmonier, Nicolas; Bonnotte, Bernard			Human monocyte-derived suppressor cells control graft-versus-host disease by inducing regulatory forkhead box protein 3-positive CD8(+) T lymphocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human monocyte-derived suppressor cells; T lymphocytes; regulatory T cells; signal transducer and activator of transcription 3; graft-versus-host disease; inflammation	SKIN ALLOGRAFTS; DENDRITIC CELLS; IN-VITRO; TRANSPLANTATION; ALLOANTIGEN; PREVENTION; INDUCTION; EXPANSION; GVHD; GENERATION	Background: Adoptive transfer of immunosuppressive cells has emerged as a promising strategy for the treatment of immune-mediated disorders. However, only a limited number of such cells can be isolated from in vivo specimens. Therefore efficient ex vivo differentiation and expansion procedures are critically needed to produce a clinically relevant amount of these suppressive cells. Objective: We sought to develop a novel, clinically relevant, and feasible approach to generate ex vivo a subpopulation of human suppressor cells of monocytic origin, referred to as human monocyte-derived suppressive cells (HuMoSCs), which can be used as an efficient therapeutic tool to treat inflammatory disorders. Methods: HuMoSCs were generated from human monocytes cultured for 7 days with GM-CSF and IL-6. The immuneregulatory properties of HuMoSCs were investigated in vitro and in vivo. The therapeutic efficacy of HuMoSCs was evaluated by using a graft-versus-host disease (GvHD) model of humanized mice (NOD/SCID/IL-2R gamma(-/-)(c) [NSG] mice). Results: CD33(+) HuMoSCs are highly potent at inhibiting the proliferation and activation of autologous and allogeneic effector T lymphocytes in vitro and in vivo. The suppressive activity of these cells depends on signal transducer and activator of transcription 3 activation. Of therapeutic relevance, HuMoSCs induce long-lasting memory forkhead box protein 3-positive CD8 1 regulatory T lymphocytes and significantly reduce GvHD induced with human PBMCs in NSG mice. Conclusion: Ex vivo-generated HuMoSCs inhibit effector T lymphocytes, promote the expansion of immunosuppressive forkhead box protein 3-positive CD8(+) regulatory T cells, and can be used as an efficient therapeutic tool to prevent GvHD.	[Janikashvili, Nona; Trad, Malika; Gautheron, Alexandrine; Samson, Maxime; Lamarthee, Baptiste; Bonnefoy, Francis; Ciudad, Marion; Rekhviashvili, Khatuna; Seaphanh, Famky; Gaugler, Beatrice; Perruche, Sylvain; Martin, Laurent; Audia, Sylvain; Saas, Philippe; Bonnotte, Bernard] Univ Bourgogne Franche Comte, EFS Bourgogne Franche Comte, INSERM, UMR 1098,LabEX LipSTIC,ANR LABX 0021 11, Besancon, France; [Samson, Maxime; Audia, Sylvain; Bonnotte, Bernard] Univ Hosp, Dept Internal Med, Dijon, France; [Lemaire-Ewing, Stephanie] Univ Bourgogne, INSERM, UMR866, Dijon, France; [Bateman, Andrew] Univ Southampton, Canc Sci, Southampton SO9 5NH, Hants, England; [Martin, Laurent] Univ Hosp, Dept Pathol & Cytol, Dijon, France; [Saas, Philippe] CHU Besancon, CIC BT506, FHU INCREASE, F-25030 Besancon, France; [Larmonier, Nicolas] Univ Arizona, BIO5 Inst, Dept Immunobiol, Steele Childrens Res Ctr,Dept Pediat, Tucson, AZ USA; [Larmonier, Nicolas] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; University of Southampton; CHU Dijon Bourgogne; Universite de Franche-Comte; CHU Besancon; University of Arizona; Arizona Center Cancer Care; University of Arizona	Janikashvili, N (corresponding author), Univ Bourgogne Franche Comte, Fac Med, INSERM, UMR 1098, 2 Bd Mal Lattre de Tassigny, F-21079 Dijon, France.	Nona.Janikashvili@u-bourgogne.fr	Audia, Sylvain/H-3366-2019; perruche, sylvain/N-4813-2017; Samson, Maxime/ABE-1461-2021; Lamarthée, Baptiste/ABF-9179-2020; SAAS, Philippe/M-3550-2015; Lamarthée, Baptiste/AGQ-8880-2022; Saas, Philippe/M-9605-2019; Gaugler-Verjus, Beatrice/M-3528-2018; perruche, sylvain/T-2109-2019; Bonnotte, Bernard/ABA-2525-2021	Audia, Sylvain/0000-0003-1772-1392; perruche, sylvain/0000-0002-2334-3116; Samson, Maxime/0000-0002-6547-232X; Lamarthée, Baptiste/0000-0002-8417-1661; Lamarthée, Baptiste/0000-0002-8417-1661; Saas, Philippe/0000-0002-8857-9939; Gaugler-Verjus, Beatrice/0000-0001-9434-7176; Bonnotte, Bernard/0000-0002-1098-4598; CIUDAD, Marion/0000-0002-2675-1780; Janikashvili, Nona/0000-0002-6997-5004	Conseil Regional de Bourgogne; Agence Nationale de la Recherche (Labex LipSTIC) [ANR-11-LABX-0021]; Conseil Regional de Franche-Comte ("soutien au LabEX LipSTIC")	Conseil Regional de Bourgogne(Region Bourgogne-Franche-Comte); Agence Nationale de la Recherche (Labex LipSTIC)(French National Research Agency (ANR)); Conseil Regional de Franche-Comte ("soutien au LabEX LipSTIC")(Region Bourgogne-Franche-Comte)	Supported by the Conseil Regional de Bourgogne 2011-2012, the Agence Nationale de la Recherche (Labex LipSTIC, ANR-11-LABX-0021), and the Conseil Regional de Franche-Comte ("soutien au LabEX LipSTIC" to P.S.).	Ali N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044219; Audia S, 2011, BLOOD, V118, P4394, DOI 10.1182/blood-2011-03-344051; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Beres AJ, 2012, J IMMUNOL, V189, P464, DOI 10.4049/jimmunol.1200886; Bisikirska B, 2005, J CLIN INVEST, V115, P2904, DOI 10.1172/JCI23961; Boros P, 2010, HUM IMMUNOL, V71, P1061, DOI 10.1016/j.humimm.2010.08.001; Brunstein CG, 2011, BLOOD, V117, P1061, DOI 10.1182/blood-2010-07-293795; Chess L, 2004, NAT IMMUNOL, V5, P469, DOI 10.1038/ni0504-469; Cohen JL, 2002, J EXP MED, V196, P401, DOI 10.1084/jem.20020090; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Di Ianni M, 2009, CLIN EXP IMMUNOL, V156, P246, DOI 10.1111/j.1365-2249.2009.03901.x; DIIANNI M, 2011, BLOOD, V117, P3921, DOI [DOI 10.1182/blood-2010-10-311894, DOI 10.1182/BLOOD-2010-10-311894]; Dilek N, 2012, J IMMUNOL, V188, P4209, DOI 10.4049/jimmunol.1101512; Dugast AS, 2009, CLIN EXP IMMUNOL, V156, P25, DOI 10.1111/j.1365-2249.2009.03877.x; Edinger M, 2003, NAT MED, V9, P1144, DOI 10.1038/nm915; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Golshayan D, 2007, BLOOD, V109, P827, DOI 10.1182/blood-2006-05-025460; Gregoire-Gauthier J, 2012, BONE MARROW TRANSPL, V47, P439, DOI 10.1038/bmt.2011.93; Gregori S, 2001, J IMMUNOL, V167, P1945, DOI 10.4049/jimmunol.167.4.1945; Highfill SL, 2010, BLOOD, V116, P5738, DOI 10.1182/blood-2010-06-287839; Hippen KL, 2011, AM J TRANSPLANT, V11, P1148, DOI 10.1111/j.1600-6143.2011.03558.x; Hippen KL, 2012, BLOOD, V119, P619, DOI 10.1182/blood-2011-07-368027; Hippen KL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001809; Ho VT, 2001, BLOOD, V98, P3192, DOI 10.1182/blood.V98.12.3192; Hoffmann P, 2002, J EXP MED, V196, P389, DOI 10.1084/jem.20020399; Issa F, 2010, TRANSPLANTATION, V90, P1321, DOI 10.1097/TP.0b013e3181ff8772; Janikashvili N, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/430394; Janikashvili N, 2011, BLOOD, V117, P1555, DOI 10.1182/blood-2010-06-288621; King MA, 2009, CLIN EXP IMMUNOL, V157, P104, DOI 10.1111/j.1365-2249.2009.03933.x; Krampera M, 2006, STEM CELLS, V24, P386, DOI 10.1634/stemcells.2005-0008; Lakomy D, 2011, J IMMUNOL, V187, P2775, DOI 10.4049/jimmunol.1004146; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; Lechner MG, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-90; Lechner MG, 2010, J IMMUNOL, V185, P2273, DOI 10.4049/jimmunol.1000901; Lees JR, 2011, CURR OPIN IMMUNOL, V23, P692, DOI 10.1016/j.coi.2011.07.004; Lerret NM, 2012, AM J TRANSPLANT, V12, P2335, DOI 10.1111/j.1600-6143.2012.04120.x; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; Luan Y, 2013, AM J TRANSPLANT, V13, P3123, DOI 10.1111/ajt.12461; Nadig SN, 2010, NAT MED, V16, P809, DOI 10.1038/nm.2154; Natarajan S, 2010, IMMUNOBIOLOGY, V215, P698, DOI 10.1016/j.imbio.2010.05.024; Nguyen VH, 2008, BLOOD, V111, P945, DOI 10.1182/blood-2007-07-103895; Putnam AL, 2013, AM J TRANSPLANT, V13, P3010, DOI 10.1111/ajt.12433; Robb RJ, 2012, BLOOD, V119, P5898, DOI 10.1182/blood-2011-12-396119; Sagoo P, 2008, CURR OPIN ORGAN TRAN, V13, P645, DOI 10.1097/MOT.0b013e328317a476; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Schlecker E, 2012, J IMMUNOL, V189, P5602, DOI 10.4049/jimmunol.1201018; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; Stenger EO, 2012, BLOOD, V119, P5088, DOI 10.1182/blood-2011-11-364091; Tang QZ, 2012, J MOL CELL BIOL, V4, P11, DOI 10.1093/jmcb/mjr047; Taylor PA, 2001, J EXP MED, V193, P1311, DOI 10.1084/jem.193.11.1311; Taylor PA, 2002, BLOOD, V99, P3493, DOI 10.1182/blood.V99.10.3493; Van Kaer L, 2010, J CLIN INVEST, V120, P3432, DOI 10.1172/JCI44395; Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027; Zheng J, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004943; Zheng J, 2009, J IMMUNOL, V183, P3742, DOI 10.4049/jimmunol.0901329	59	12	12	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1614	U334		10.1016/j.jaci.2014.12.1868	http://dx.doi.org/10.1016/j.jaci.2014.12.1868			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25630940	Bronze			2022-12-18	WOS:000355933400025
J	Fox, EM; Torrero, MN; Evans, H; Mitre, E				Fox, Ellen Mueller; Torrero, Marina N.; Evans, Holly; Mitre, Edward			Immunologic characterization of 3 murine regimens of allergen-specific immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Type I hypersensitivity; allergen-specific immunotherapy; mouse models; mast cells; basophils	GRASS-POLLEN IMMUNOTHERAPY; REGULATORY T-CELLS; IFN-GAMMA PRODUCTION; MAST-CELL; HISTAMINE-RELEASE; INOSITOL PHOSPHATASE; IGG ANTIBODIES; DOSE-RESPONSE; IN-VITRO; MECHANISMS	Background: Allergen-specific immunotherapy (ASIT) is used to treat the symptoms of immediate type I hypersensitivity. The mechanisms driving establishment of allergen tolerance are not yet fully understood. Objective: The goal of this study was to develop and immunologically characterize 3 murine models of ASIT to simulate protocols currently used to treat patients with type I hypersensitivities. Methods: Ovalbumin (OVA)-sensitized mice were desensitized to OVA by means of repeated injections of OVA with a rapid, intermediate, or gradual protocol. After desensitization, mice were assessed for clinical sensitivity to OVA, and immunologic parameters were assessed. Results: Mice in all treatment protocols displayed decreased vascular permeability in response to OVA challenge after desensitization. Circulating OVA-specific IgE levels, as well as basophil activation in response to OVA stimulation and IgE cross-linking, were significantly decreased in all treatment groups. Intermediate and gradual protocols, but not rapid desensitization, suppressed splenocyte proliferation and production of IL-4, IL-5, and IFN-gamma in response to OVA and polyclonal activation. Similarly, significant increases in IL-10 production, numbers of CD4(+) CD25(+) forkhead box protein 3-positive regulatory T cells, andOVA-specific IgG1 antibody levels were only observed in mice undergoing prolonged ASIT regimens. Conclusion: Suppression of IgE-mediated activation is a common feature of all desensitization schedules. Induction of immunoregulatory networks requires prolonged desensitization schedules.	[Fox, Ellen Mueller; Torrero, Marina N.; Evans, Holly; Mitre, Edward] Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Mitre, E (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	edward.mitre@usuhs.edu			National Institutes of Health/National Institute of Allergy and Infectious Diseases [R01AI076522]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI076522] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grant R01AI076522 from the National Institutes of Health/National Institute of Allergy and Infectious Diseases.	Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Alexander C, 2005, CLIN EXP ALLERGY, V35, P52, DOI 10.1111/j.1365-2222.2005.02143.x; Boghdadi G, 2012, INFLAMM RES, V61, P719, DOI 10.1007/s00011-012-0464-4; Calabria CW, 2013, CURR ALLERGY ASTHM R, V13, P389, DOI 10.1007/s11882-013-0356-x; Ciprandi G, 2008, INT IMMUNOPHARMACOL, V8, P1622, DOI 10.1016/j.intimp.2008.07.007; Cox L, 2008, DRUG BENEFIT TRENDS, V20, P1; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Faith A, 2003, CLIN EXP ALLERGY, V33, P1209, DOI 10.1046/j.1365-2222.2003.01748.x; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Frew AJ, 2010, J ALLERGY CLIN IMMUN, V125, pS306, DOI 10.1016/j.jaci.2009.10.064; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; Gibbs BF, 2006, J ALLERGY CLIN IMMUN, V118, P1060, DOI 10.1016/j.jaci.2006.07.022; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; Gratz IK, 2013, ANN NY ACAD SCI, V1283, P8, DOI 10.1111/nyas.12011; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; Hubner MP, 2009, IMMUNOLOGY, V127, P512, DOI 10.1111/j.1365-2567.2008.02958.x; Jacobsen Lars, 2012, Clin Transl Allergy, V2, P8, DOI 10.1186/2045-7022-2-8; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2011, ALLERGY, V66, P725, DOI 10.1111/j.1398-9995.2011.02589.x; Kojima T, 2007, J IMMUNOL, V179, P7093, DOI 10.4049/jimmunol.179.10.7093; Langdon JM, 2008, J LEUKOCYTE BIOL, V84, P1151, DOI 10.1189/jlb.0308172; Larson D, 2012, J IMMUNOL, V188, P4188, DOI 10.4049/jimmunol.1101859; Larson D, 2012, J IMMUNOL METHODS, V379, P15, DOI 10.1016/j.jim.2012.02.014; Magpantay Gil, 2011, Hawaii Med J, V70, P266; MAGRO AM, 1974, J IMMUNOL, V112, P1762; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; Mukai K, 2005, IMMUNITY, V23, P191, DOI 10.1016/j.immuni.2005.06.011; Obata K, 2007, BLOOD, V110, P913, DOI 10.1182/blood-2007-01-068718; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Pierkes M, 1999, J ALLERGY CLIN IMMUN, V103, P326, DOI 10.1016/S0091-6749(99)70509-9; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; Roth K, 2008, ARCH IMMUNOL THER EX, V56, P385, DOI 10.1007/s00005-008-0041-2; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Soyer OU, 2013, ALLERGY, V68, P161, DOI 10.1111/all.12085; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; TAGA K, 1992, J IMMUNOL, V148, P1143; Tarzi M, 2006, CLIN EXP ALLERGY, V36, P465, DOI 10.1111/j.1365-2222.2006.02469.x; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Torrero MN, 2009, CLIN EXP ALLERGY, V39, P361, DOI 10.1111/j.1365-2222.2008.03154.x; Torrero MN, 2013, VACCINE, V31, P3675, DOI 10.1016/j.vaccine.2013.06.010; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; VanRee R, 1997, CLIN EXP ALLERGY, V27, P68, DOI 10.1046/j.1365-2222.1997.d01-416.x; Verhagen J, 2006, IMMUNOL ALLERGY CLIN, V26, P207, DOI 10.1016/j.iac.2006.02.008; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x	47	12	13	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1341	U384		10.1016/j.jaci.2014.07.052	http://dx.doi.org/10.1016/j.jaci.2014.07.052			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25282017				2022-12-18	WOS:000353980700028
J	Hradetzky, S; Roesner, LM; Heratizadeh, A; Crameri, R; Garbani, M; Scheynius, A; Werfel, T				Hradetzky, Susanne; Roesner, Lennart Matthias; Heratizadeh, Annice; Crameri, Reto; Garbani, Mattia; Scheynius, Annika; Werfel, Thomas			Differential cytokine induction by the human skin-associated autoallergen thioredoxin in sensitized patients with atopic dermatitis and healthy control subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FC-EPSILON-RI; T-CELLS; IGE; MONOCYTES; RECEPTORS; EXPRESSION; BASOPHILS; IL-10		[Hradetzky, Susanne; Roesner, Lennart Matthias; Heratizadeh, Annice; Werfel, Thomas] Hannover Med Sch, Div Immunodermatol & Allergy Res, Dept Dermatol & Allergy, Hannover, Germany; [Crameri, Reto; Garbani, Mattia] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Scheynius, Annika] Karolinska Inst, Dept Med Solna, Translat Immunol Unit, Stockholm, Sweden; [Scheynius, Annika] Univ Hosp, Stockholm, Sweden	Hannover Medical School; Swiss Institute of Allergy & Asthma Research; University of Zurich; Karolinska Institutet	Hradetzky, S (corresponding author), Hannover Med Sch, Div Immunodermatol & Allergy Res, Dept Dermatol & Allergy, Hannover, Germany.	Hradetzky.Susanne@mh-hannover.de	Roesner, Lennart/K-1074-2019; Werfel, Thomas/B-6921-2012	Roesner, Lennart/0000-0001-6651-0458; 				Balaji H, 2011, J ALLERGY CLIN IMMUN, V128, P92, DOI 10.1016/j.jaci.2011.02.043; Gaitanis G, 2012, CLIN MICROBIOL REV, V25, P106, DOI 10.1128/CMR.00021-11; Hradetzky S, 2014, J INVEST DERMATOL, V134, P1570, DOI 10.1038/jid.2014.25; Hradetzky S, 2013, J INVEST DERMATOL, V133, P2289, DOI 10.1038/jid.2013.161; Limacher A, 2007, J IMMUNOL, V178, P389, DOI 10.4049/jimmunol.178.1.389; MAURER D, 1995, J IMMUNOL, V154, P6285; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; Mittermann I, 2008, J INVEST DERMATOL, V128, P1451, DOI 10.1038/sj.jid.5701195; Novak N, 2001, J IMMUNOL, V167, P797, DOI 10.4049/jimmunol.167.2.797; Palomares O, 2014, GENES IMMUN, V15, P511, DOI 10.1038/gene.2014.45; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Pyle DM, 2013, J ALLERGY CLIN IMMUN, V131, P491, DOI 10.1016/j.jaci.2012.11.037; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; Valenta R, 2009, TRENDS IMMUNOL, V30, P109, DOI 10.1016/j.it.2008.12.004	14	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1378	+		10.1016/j.jaci.2014.10.038	http://dx.doi.org/10.1016/j.jaci.2014.10.038			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25488692				2022-12-18	WOS:000353980700033
J	Niss, O; Sholl, A; Bleesing, JJ; Hildeman, DA				Niss, Omar; Sholl, Allyson; Bleesing, Jack J.; Hildeman, David A.			IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALPS; Bim; Bcl-2 pathway; IL-10; BH3 mimetic; ABT-737; T cell homeostasis; double negative T cells; apoptosis	APOPTOSIS REGULATORS FAS; CD4(-)CD8(-) T-CELLS; NF-KAPPA-B; BCL-2 PROTEINS; UP-REGULATION; BH3 MIMETICS; INTERLEUKIN-10; IL-10; LYMPHOCYTE; RECEPTOR	Background: Autoimmune lymphoproliferative syndrome (ALPS) is a human disorder of T cell homeostasis caused by mutations that impair FAS-mediated apoptosis. A defining characteristic of ALPS is the expansion of double negative T cells (DNTC). Relatively little is known about how defective FAS-driven cell death and the Bcl-2 apoptotic pathway intersect in ALPS patients. Objective: We studied changes in Bcl-2 family member expression in ALPS to determine whether the Bcl-2 pathway might provide a therapeutic target. Methods: We used flow cytometry to analyze the expression of pro-and anti-apoptotic Bcl-2 family members in T cells from 12 ALPS patients and determined the in vitro sensitivity of ALPS DNTC to the pro-apoptotic BH3 mimetic, ABT-737. Results: The pro-apoptoticmolecule, Bim, was significantly elevated in DNTC. Although no general pattern of individual anti-apoptotic Bcl-2 family members emerged, increased expression of Bim was always accompanied by increased expression of at least 1 anti-apoptotic Bcl-2 family member. Strikingly, Bim levels in DNTC correlated significantly with serum IL-10 in ALPS patients, and IL-10 was sufficient to mildly induce Bim in normal and ALPS T cells via a Janus kinase/signal transducer and activator of transcription 3-dependent mechanism. Finally, ABT-737 preferentially killed ALPS DNTC in vitro. Conclusion: Combined, these data show that an IL-10/Janus kinase/signal transducer and activator of transcription 3 pathway drives Bim expression in ALPS DNTC, which renders them sensitive to BH3 mimetics, uncovering a potentially novel therapeutic approach to ALPS.	[Niss, Omar; Bleesing, Jack J.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA; [Sholl, Allyson; Hildeman, David A.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Cellular & Mol Immunol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Hildeman, DA (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Cellular & Mol Immunol, S5 Room 214,MLC7038,3333 Burnet Ave, Cincinnati, OH 45229 USA.	david.hildeman@cchmc.org	Hildeman, David/AAA-1757-2020; Hildeman, David/I-4884-2015	Hildeman, David/0000-0002-0421-8483; Hildeman, David/0000-0002-0421-8483; Niss, Omar/0000-0003-4157-4644	Primary Immune Deficiency Treatment Consortium from NIH/NIAID [U54 AI082973]; United States National Institutes of Health (NIH) [AI057753, DK081175]; NIH of the Digestive Research Core Center at Cincinnati Children's Hospital [AR 47363, P30 DK078392]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057753, R56AI057753, U54AI082973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081175, P30DK090971, P30DK078392] Funding Source: NIH RePORTER	Primary Immune Deficiency Treatment Consortium from NIH/NIAID; United States National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH of the Digestive Research Core Center at Cincinnati Children's Hospital; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This project was supported by a grant from the Primary Immune Deficiency Treatment Consortium (a subaward from NIH/NIAID grant U54 AI082973), the United States National Institutes of Health (NIH) grants AI057753 and DK081175 (to D.A.H.), and by NIH grants AR 47363 and P30 DK078392 (of the Digestive Research Core Center at Cincinnati Children's Hospital) which support the research flow cytometry core.	ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; Andre N, 2004, HEPATOLOGY, V39, P864, DOI 10.1002/hep.20100; Asadullah K, 2003, PHARMACOL REV, V55, P241, DOI 10.1124/pr.55.2.4; Bajwa N, 2012, EXPERT OPIN THER PAT, V22, P37, DOI 10.1517/13543776.2012.644274; Bardwell PD, 2009, J IMMUNOL, V182, P7482, DOI 10.4049/jimmunol.0802813; Bidere N, 2006, ANNU REV IMMUNOL, V24, P321, DOI 10.1146/annurev.immunol.24.021605.090513; Billard C, 2013, MOL CANCER THER, V12, P1691, DOI 10.1158/1535-7163.MCT-13-0058; Bittker J.A., 2010, PROBE REPORTS NIH MO; Bleesing JJH, 2002, CLIN IMMUNOL, V104, P21, DOI 10.1006/clim.2002.5225; Bleesing JJH, 2001, SEMIN HEMATOL, V38, P100, DOI 10.1053/shem.2001.21922; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bristeau-Leprince A, 2008, J IMMUNOL, V181, P440, DOI 10.4049/jimmunol.181.1.440; Caminha I, 2010, J ALLERGY CLIN IMMUN, V125, P946, DOI 10.1016/j.jaci.2009.12.983; Carrington EM, 2010, P NATL ACAD SCI USA, V107, P10967, DOI 10.1073/pnas.1005256107; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Crepaldi L, 2001, J IMMUNOL, V167, P2312, DOI 10.4049/jimmunol.167.4.2312; Deisseroth A, 2012, CLIN CANCER RES, V18, P3212, DOI 10.1158/1078-0432.CCR-12-0653; Del-Rey M, 2006, BLOOD, V108, P1306, DOI 10.1182/blood-2006-04-015776; Dong J, 2007, LUPUS, V16, P101, DOI 10.1177/0961203306075383; Dowdell KC, 2010, BLOOD, V115, P5164, DOI 10.1182/blood-2010-01-263145; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Fleisher TA, 2012, CURR OPIN ALLERGY CL, V12, P609, DOI 10.1097/ACI.0b013e3283588da0; Fortner KA, 2010, EUR J IMMUNOL, V40, P3043, DOI 10.1002/eji.201040577; Furukawa H, 2008, TRANSPLANTATION, V85, P437, DOI 10.1097/TP.0b013e31816026e7; Georgescu L, 1997, J CLIN INVEST, V100, P2622, DOI 10.1172/JCI119806; Haas JP, 1998, CELL DEATH DIFFER, V5, P751, DOI 10.1038/sj.cdd.4400426; Herman MD, 2008, FEBS LETT, V582, P3590, DOI 10.1016/j.febslet.2008.09.028; Hillhouse EE, 2010, IMMUNOL CELL BIOL, V88, P771, DOI 10.1038/icb.2010.84; Holzelova E, 2004, NEW ENGL J MED, V351, P1409, DOI 10.1056/NEJMoa040036; Hughes PD, 2008, IMMUNITY, V28, P197, DOI 10.1016/j.immuni.2007.12.017; Hutcheson J, 2008, IMMUNITY, V28, P206, DOI 10.1016/j.immuni.2007.12.015; Jackson CE, 1999, AM J HUM GENET, V64, P1002, DOI 10.1086/302333; Kang MH, 2009, CLIN CANCER RES, V15, P1126, DOI 10.1158/1078-0432.CCR-08-0144; Khoshnan A, 2000, J IMMUNOL, V165, P1743, DOI 10.4049/jimmunol.165.4.1743; Kurtulus S, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00404; Kurtulus S, 2011, J IMMUNOL, V186, P5729, DOI 10.4049/jimmunol.1100102; Kyttaris VC, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/861028; LIU Y, 1994, J IMMUNOL, V152, P1821; Lopatin U, 2001, BLOOD, V97, P3161, DOI 10.1182/blood.V97.10.3161; Magerus-Chatinet A, 2009, BLOOD, V113, P3027, DOI 10.1182/blood-2008-09-179630; MALDONADO MA, 1995, J EXP MED, V181, P641, DOI 10.1084/jem.181.2.641; Marra LE, 2004, J IMMUNOL, V172, P1028, DOI 10.4049/jimmunol.172.2.1028; Mitchell T, 1999, J IMMUNOL, V162, P4527; MIXTER PF, 1995, J IMMUNOL, V154, P2063; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; O'Reilly LA, 2009, J IMMUNOL, V183, P261, DOI 10.4049/jimmunol.0803853; Ohga S, 2002, BRIT J HAEMATOL, V119, P535, DOI 10.1046/j.1365-2141.2002.03848.x; OHTEKI T, 1995, EUR J IMMUNOL, V25, P37, DOI 10.1002/eji.1830250108; Oliveira JB, 2007, P NATL ACAD SCI USA, V104, P8953, DOI 10.1073/pnas.0702975104; Oliveira JB, 2010, BLOOD, V116, pE35, DOI 10.1182/blood-2010-04-280347; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Oshima K, 2002, TRANSPLANTATION, V73, P1019, DOI 10.1097/00007890-200204150-00002; Price S, 2014, BLOOD, V123, P1989, DOI 10.1182/blood-2013-10-535393; Sadanaga A, 2005, ARTHRITIS RHEUM-US, V52, P3987, DOI 10.1002/art.21424; Salmena L, 2005, J EXP MED, V202, P727, DOI 10.1084/jem.20050683; Sandalova E, 2004, P NATL ACAD SCI USA, V101, P3011, DOI 10.1073/pnas.0400005101; Schoenwaelder SM, 2011, BLOOD, V118, P1663, DOI 10.1182/blood-2011-04-347849; SNELLER MC, 1992, J CLIN INVEST, V90, P334, DOI 10.1172/JCI115867; Sneller MC, 1997, BLOOD, V89, P1341, DOI 10.1182/blood.V89.4.1341; Snow AL, 2008, BIOL DIRECT, V3, DOI 10.1186/1745-6150-3-34; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Takagi M, 2011, BLOOD, V117, P2887, DOI 10.1182/blood-2010-08-301515; Tung TC, 2003, AM J PHYSIOL-HEART C, V285, pH964, DOI 10.1152/ajpheart.00976.2002; Vandenberg CJ, 2013, BLOOD, V121, P2285, DOI 10.1182/blood-2013-01-475855; Wan CK, 2013, IMMUNITY, V38, P514, DOI 10.1016/j.immuni.2013.02.011; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang S, 2010, LUPUS, V19, P1171, DOI 10.1177/0961203310367660; Weant AE, 2008, IMMUNITY, V28, P218, DOI 10.1016/j.immuni.2007.12.014; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Wojciechowski S, 2007, J EXP MED, V204, P1665, DOI 10.1084/jem.20070618; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	74	12	12	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					762	770		10.1016/j.jaci.2014.07.020	http://dx.doi.org/10.1016/j.jaci.2014.07.020			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25174872	Green Accepted			2022-12-18	WOS:000351065000024
J	Meazza, R; Tuberosa, C; Cetica, V; Falco, M; Parolini, S; Grieve, S; Griffiths, GM; Sieni, E; Marcenaro, S; Micalizzi, C; Montin, D; Fagioli, F; Moretta, A; Mingari, MC; Moretta, L; Notarangelo, LD; Bottino, C; Arico, M; Pende, D				Meazza, Raffaella; Tuberosa, Claudia; Cetica, Valentina; Falco, Michela; Parolini, Silvia; Grieve, Sam; Griffiths, Gillian M.; Sieni, Elena; Marcenaro, Stefania; Micalizzi, Concetta; Montin, Davide; Fagioli, Franca; Moretta, Alessandro; Mingari, Maria C.; Moretta, Lorenzo; Notarangelo, Luigi D.; Bottino, Cristina; Arico, Maurizio; Pende, Daniela			Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HLH; XLP1; SAP expression; 2B4 function; NK cells	LINKED LYMPHOPROLIFERATIVE-DISEASE; NKT CELL-DEVELOPMENT; CD8(+) T-CELLS; SAP; SH2D1A; MUTATIONS; GENE; DEFICIENCY; INFECTION; IMMUNODEFICIENCY	Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening, heterogeneous, hyperinflammmatory disorder. Prompt identification of inherited forms resulting from mutation in genes involved in cellular cytotoxicity can be crucial. X-linked lymphoproliferative disease 1 (XLP1), due to mutations in SH2D1A (Xq25) encoding signaling lymphocyte activation molecule-associated protein (SAP), may present with HLH. Defective SAP induces paradoxical inhibitory function of the 2B4 coreceptor and impaired natural killer (NK) (and T) cell response against EBV-infected cells. Objective: To characterize a cohort of patients with HLH and XLP1 for SAP expression and 2B4 function in lymphocytes, proposing a rapid diagnostic screening to direct mutation analysis. Methods: We set up rapid assays for 2B4 function (degranulation or 51 Cr-release) to be combined with intracellular SAP expression in peripheral blood NK cells. We studied 12 patients with confirmed mutation in SH2D1A and some family members. Results: The combined phenotypic/functional assays allowed efficient and complete diagnostic evaluation of all patients with XLP1, thus directing mutation analysis and treatment. Nine cases were SAP 2, 2 expressed SAP with mean relative fluorescence intensity values below the range of healthy controls (SAP dull), and 1, carrying the R55L mutation, was SAP 1. NK cells from all patients showed inhibitory 2B4 function and defective killing of B-EBV cells. Carriers with SH2D1A mutations abolishing SAP expression and low percentage of SAP 1 cells showed neutral 2B4 function at the polyclonal NK cell level. Three novel SH2D1A mutations have been identified. Conclusions: Study of SAP expression is specific but may have insufficient sensitivity for screening XLP1 as a single tool. Combination with 2B4 functional assay allows identification of all cases.	[Meazza, Raffaella; Tuberosa, Claudia; Mingari, Maria C.; Pende, Daniela] Univ San Martino, Azienda Osped, Ist Nazl Ric Cancro, Ist Ricovero & Cura Carattere Sci, Genoa, Italy; [Tuberosa, Claudia; Moretta, Alessandro; Mingari, Maria C.; Bottino, Cristina] Univ Genoa, Dipartimento Med Sperimentale, Genoa, Italy; [Cetica, Valentina; Arico, Maurizio] Univ Meyer, Azienda Osped, Dipartimento Oncol Pediat, Florence, Italy; [Cetica, Valentina; Arico, Maurizio] ITT, Pediat Oncol Network, I-50139 Florence, Italy; [Falco, Michela; Marcenaro, Stefania; Micalizzi, Concetta; Moretta, Lorenzo; Bottino, Cristina] Ist Giannina Gaslini, I-16148 Genoa, Italy; [Parolini, Silvia] Univ Brescia, Dipartimento Med Mol & Traslaz, Brescia, Italy; [Grieve, Sam; Griffiths, Gillian M.] Cambridge Inst Med Res, Dept Med, Cambridge, England; [Montin, Davide] Univ Turin, Dipartimento Sci Sanita Publ & Pediat, Turin, Italy; [Fagioli, Franca] Osped Infantile Regina Margherita, Oncoematol Pediat & Ctr Trapianti, Turin, Italy; [Notarangelo, Luigi D.] Boston Childrens Hosp, Div Immunol, Boston, MA USA	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Brescia; University of Cambridge; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; Harvard University; Boston Children's Hospital	Arico, M (corresponding author), ITT, ITT Bldg 27-B Cubo 3,Viale G Pieraccini 6, I-50139 Florence, Italy.	maurizio.arico@ittumori.it	Moretta, Lorenzo/AAA-7239-2020; Fagioli, Franca/AAC-2181-2022; Arico, Maurizio/ABI-2155-2020; Sieni, Elena/J-8729-2018; Micalizzi, Concetta/ABF-6300-2020; Falco, Michela/K-1574-2016; Notarangelo, Luigi D/F-9718-2016; Arico, Maurizio/S-3039-2019; Pende, Daniela/J-7429-2016; Mingari, Maria Cristina/AAB-1315-2019; Cetica, Valentina/J-2885-2018; Meazza, Raffaella/AAC-2425-2019; Bottino, Cristina/J-9977-2016	Moretta, Lorenzo/0000-0003-4658-1747; Sieni, Elena/0000-0002-6192-9812; Falco, Michela/0000-0002-0317-9830; Notarangelo, Luigi D/0000-0002-8335-0262; Arico, Maurizio/0000-0002-1908-6671; Pende, Daniela/0000-0003-1565-451X; Cetica, Valentina/0000-0001-8549-4158; Meazza, Raffaella/0000-0003-0242-3157; Montin, Davide/0000-0001-8953-2182; Bottino, Cristina/0000-0001-6695-1739; Marcenaro, Stefania/0000-0002-5232-0220; Griffiths, Gillian/0000-0003-0434-5842; FAGIOLI, FRANCA/0000-0002-9257-900X; PAROLINI, Silvia/0000-0003-1968-7765	Associazione Italiana Ricerca Istiocitosi (AIRI) O.N.L.U.S.; Associazione Ciemmeesse-Girotondo per il Meyer O.N.L.U.S.; Ministero della Salute [RF-TOS-2008-1219488, RF-2010-2316606]; Seventh Framework Programme (FP7-HEALTH-INNOVATION-1) of the European Commission ("FIGHT-HLH") [306124]; Associazione Italiana per la Ricerca sul Cancro [IG-10643, IG-10225, 531000-9962]; Ministero dell'Istruzione, dell'Universita e della Ricerca [20103FMJEN, 2009NREAT2]; Wellcome Trust [075880]	Associazione Italiana Ricerca Istiocitosi (AIRI) O.N.L.U.S.; Associazione Ciemmeesse-Girotondo per il Meyer O.N.L.U.S.; Ministero della Salute(Ministry of Health, Italy); Seventh Framework Programme (FP7-HEALTH-INNOVATION-1) of the European Commission ("FIGHT-HLH"); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Istruzione, dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); Wellcome Trust(Wellcome TrustEuropean Commission)	This work was partly supported by grants from Associazione Italiana Ricerca Istiocitosi (AIRI) O.N.L.U.S., Associazione Ciemmeesse-Girotondo per il Meyer O.N.L.U.S., Ministero della Salute (grant no. RF-TOS-2008-1219488), Seventh Framework Programme (FP7-HEALTH-2012-INNOVATION-1 #306124) of the European Commission ("FIGHT-HLH" Project no. 306124) (to M.A.); Associazione Italiana per la Ricerca sul Cancro (grant no. IG-10643 to A.M., grant no. IG-10225 to L.M., and special project 531000-9962 to A.M. and L.M.); Ministero dell'Istruzione, dell'Universita e della Ricerca (grant no. 20103FMJEN to A.M. and grant no. 2009NREAT2 to C.B.); Ministero della Salute (grant no. RF-2010-2316606 to D.P.); and the Wellcome Trust (Principal Research Fellowships 075880 to G.M.G.).	Arico M, 1996, LEUKEMIA, V10, P197; Arico M, 2001, BRIT J HAEMATOL, V114, P761, DOI 10.1046/j.1365-2141.2001.02936.x; Arico M, 2001, BLOOD, V97, P1131, DOI 10.1182/blood.V97.4.1131; Booth C, 2011, BLOOD, V117, P53, DOI 10.1182/blood-2010-06-284935; Bryceson YT, 2012, BLOOD, V119, P2754, DOI 10.1182/blood-2011-08-374199; Cannons JL, 2011, ANNU REV IMMUNOL, V29, P665, DOI 10.1146/annurev-immunol-030409-101302; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; de Saint Basile G, 2010, NAT REV IMMUNOL, V10, P568, DOI 10.1038/nri2803; Dupre L, 2005, BLOOD, V105, P4383, DOI 10.1182/blood-2004-08-3269; Dutz JP, 2001, BLOOD, V97, P95, DOI 10.1182/blood.V97.1.95; Filipovich AH, 2010, BLOOD, V116, P3398, DOI 10.1182/blood-2010-03-275909; HAMILTON JK, 1980, J PEDIATR-US, V96, P669, DOI 10.1016/S0022-3476(80)80735-9; Hislop AD, 2010, BLOOD, V116, P3249, DOI 10.1182/blood-2009-09-238832; Marcenaro S, 2006, BLOOD, V108, P2316, DOI 10.1182/blood-2006-04-015693; Marsh RA, 2010, J IMMUNOL METHODS, V362, P1, DOI 10.1016/j.jim.2010.08.010; Marsh RA, 2010, BLOOD, V116, P1079, DOI 10.1182/blood-2010-01-256099; Meazza R, 2014, EUR J IMMUNOL, V44, P1526, DOI 10.1002/eji.201344312; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Nichols KE, 2005, IMMUNOL REV, V203, P180, DOI 10.1111/j.0105-2896.2005.00230.x; Nichols KE, 2005, NAT MED, V11, P340, DOI 10.1038/nm1189; Palendira U, 2012, J EXP MED, V209, P911, DOI 10.1084/jem.20112391; Palendira U, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001187; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; Pasquier B, 2005, J EXP MED, V201, P695, DOI 10.1084/jem.20042432; Recher M, 2013, CLIN IMMUNOL, V146, P84, DOI 10.1016/j.clim.2012.11.007; Rezaei N, 2011, J ALLERGY CLIN IMMUN, V127, P1329, DOI 10.1016/j.jaci.2011.02.047; Rezaei N, 2011, BRIT J HAEMATOL, V152, P13, DOI 10.1111/j.1365-2141.2010.08442.x; Rivat C, 2013, BLOOD, V121, P1073, DOI 10.1182/blood-2012-07-445858; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; SCHUSTER V, 1993, AM J DIS CHILD, V147, P1303, DOI 10.1001/archpedi.1993.02160360045015; Schuster V, 2007, PRIMARY IMMUNODEFICI, P470; Sieni E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044649; Sieni E, 2012, CELL MOL LIFE SCI, V69, P29, DOI 10.1007/s00018-011-0835-y; Soresina A, 2002, EUR J PEDIATR, V161, P656, DOI 10.1007/s00431-002-1083-9; Sumegi J, 2000, BLOOD, V96, P3118; Sumegi J, 2002, LEUKEMIA LYMPHOMA, V43, P1189, DOI 10.1080/10428190290026240; Tabata Y, 2005, BLOOD, V105, P3066, DOI 10.1182/blood-2004-09-3651; Trottestam H, 2011, BLOOD, V118, P4577, DOI 10.1182/blood-2011-06-356261	38	12	12	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1381	+		10.1016/j.jaci.2014.04.043	http://dx.doi.org/10.1016/j.jaci.2014.04.043			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	24985396	Green Accepted			2022-12-18	WOS:000346075400021
J	Simhadri, VR; Mariano, JL; Zenarruzabeitia, O; Seroogy, CM; Holland, SM; Kuehn, HS; Rosenzweig, SD; Borrego, F				Simhadri, Venkateswara R.; Mariano, John L.; Zenarruzabeitia, Olatz; Seroogy, Christine M.; Holland, Steven M.; Kuehn, Hye Sun; Rosenzweig, Sergio D.; Borrego, Francisco			Intact IL-12 signaling is necessary for the generation of human natural killer cells with enhanced effector function after restimulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NK CELLS; MEMORY		[Simhadri, Venkateswara R.; Mariano, John L.; Borrego, Francisco] Food & Drug Adm, Ctr Drug Evaluat & Res, Lab Mol & Dev Immunol, Div Monoclonal Antibodies, Bethesda, MD 20993 USA; [Zenarruzabeitia, Olatz; Borrego, Francisco] BioCruces Hlth Res Inst, Baracaldo, Spain; [Seroogy, Christine M.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Holland, Steven M.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Rosenzweig, Sergio D.] NIAID, Primary Immuno Deficiency Clin, NIH, Bethesda, MD 20892 USA; [Kuehn, Hye Sun] Ctr Clin, Serv Immunol, Dept Lab Med, NIH, Bethesda, MD USA; [Borrego, Francisco] Basque Fdn Sci, Ikerbasque, Bilbao, Spain	US Food & Drug Administration (FDA); University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Basque Foundation for Science	Simhadri, VR (corresponding author), Food & Drug Adm, Ctr Drug Evaluat & Res, Lab Mol & Dev Immunol, Div Monoclonal Antibodies, Bethesda, MD 20993 USA.	francisco.borregorabasco@osakidetza.net	Zenarruzabeitia, Olatz/AAD-6772-2019; Borrego, Francisco/ABI-1391-2020	Zenarruzabeitia, Olatz/0000-0002-0869-9034; Borrego, Francisco/0000-0002-3105-981X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000646, ZIAAI000647, ZIAAI001122] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 CL999999] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Cooper MA, 2009, P NATL ACAD SCI USA, V106, P1915, DOI 10.1073/pnas.0813192106; Gruenberg DA, 2010, J ALLERGY CLIN IMMUN, V125, P264, DOI 10.1016/j.jaci.2009.07.061; Guia S, 2008, BLOOD, V111, P5008, DOI 10.1182/blood-2007-11-122259; Ni J, 2012, J EXP MED, V209, P2351, DOI 10.1084/jem.20120944; O'Leary JG, 2006, NAT IMMUNOL, V7, P507, DOI 10.1038/ni1332; Paust S, 2011, NAT IMMUNOL, V12, P500, DOI 10.1038/ni.2032; Paust S, 2010, NAT IMMUNOL, V11, P1127, DOI 10.1038/ni.1953; Romee R, 2012, BLOOD, V120, P4751, DOI 10.1182/blood-2012-04-419283; Sun JC, 2012, J EXP MED, V209, P947, DOI 10.1084/jem.20111760; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665	10	12	12	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1190	1193		10.1016/j.jaci.2014.06.006	http://dx.doi.org/10.1016/j.jaci.2014.06.006			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	25065718	hybrid, Green Accepted			2022-12-18	WOS:000344938900026
J	Hedayat, M; Massaad, MJ; Lee, YN; Conley, ME; Orange, JS; Ohsumi, TK; Al-Herz, W; Notarangelo, LD; Geha, RS; Chou, J				Hedayat, Mona; Massaad, Michel J.; Lee, Yu Nee; Conley, Mary Ellen; Orange, Jordan S.; Ohsumi, Toshiro K.; Al-Herz, Waleed; Notarangelo, Luigi D.; Geha, Raif S.; Chou, Janet			Lessons in gene hunting: A RAG1 mutation presenting with agammaglobulinemia and absence of B cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SEVERE COMBINED IMMUNODEFICIENCY; RECOMBINATION; IGM		[Hedayat, Mona; Massaad, Michel J.; Lee, Yu Nee; Notarangelo, Luigi D.; Geha, Raif S.; Chou, Janet] Harvard Univ, Sch Med, Childrens Hosp, Div Immunol, Boston, MA 02163 USA; [Hedayat, Mona; Massaad, Michel J.; Lee, Yu Nee; Notarangelo, Luigi D.; Geha, Raif S.; Chou, Janet] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Conley, Mary Ellen] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, New York, NY 10021 USA; [Orange, Jordan S.] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA; [Ohsumi, Toshiro K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; [Al-Herz, Waleed] Kuwait Univ, Dept Pediat, Fac Med, Kuwait, Kuwait	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Rockefeller University; Baylor College of Medicine; Harvard University; Massachusetts General Hospital; Kuwait University	Hedayat, M (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Div Immunol, Boston, MA 02163 USA.	Janet.Chou@childrens.harvard.edu	Notarangelo, Luigi D/F-9718-2016; Lee, Yu Nee/T-2360-2017	Notarangelo, Luigi D/0000-0002-8335-0262; Lee, Yu Nee/0000-0001-8648-5253; orange, jordan/0000-0001-7117-7725	NIAID NIH HHS [AI-094017, P01AI-076210, P01 AI076210, R03 AI094017] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI094017, P01AI076210] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Borte S, 2012, BLOOD, V119, P2552, DOI 10.1182/blood-2011-08-371021; Chou J, 2012, J ALLERGY CLIN IMMUN, V130, P1414, DOI 10.1016/j.jaci.2012.06.012; JOLLIFF CR, 1982, CLIN CHEM, V28, P126; Kirch SA, 1996, EUR J IMMUNOL, V26, P886, DOI 10.1002/eji.1830260425; Lee YN, 2014, J ALLERGY CLIN IMMUN, V133, P1099, DOI 10.1016/j.jaci.2013.10.007; Niehues T, 2010, CLIN IMMUNOL, V135, P183, DOI 10.1016/j.clim.2010.01.013; Notarangelo LD, 1999, CURR OPIN IMMUNOL, V11, P435, DOI 10.1016/S0952-7915(99)80073-9; Puck JM, 2012, J ALLERGY CLIN IMMUN, V129, P607, DOI 10.1016/j.jaci.2012.01.032; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Sobacchi C, 2006, HUM MUTAT, V27, P1174, DOI 10.1002/humu.20408; Tietz N.W., 1995, CLIN GUIDE LAB TESTS, V3rd; Zhang JY, 2005, PEDIATRICS, V116, pE445, DOI 10.1542/peds.2005-0369	12	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					983	985		10.1016/j.jaci.2014.04.037	http://dx.doi.org/10.1016/j.jaci.2014.04.037			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	24985406	Green Accepted			2022-12-18	WOS:000343155700036
J	Akhabir, L; Berube, JC; Bosse, Y; Laviolette, M; Hao, K; Nickle, DC; Timens, W; Sin, DD; Pare, PD; Postma, DS; Sandford, AJ				Akhabir, Loubna; Berube, Jean-Christophe; Bosse, Yohan; Laviolette, Michel; Hao, Ke; Nickle, David C.; Timens, Wim; Sin, Don D.; Pare, Peter D.; Postma, Dirkje S.; Sandford, Andrew J.			Lung expression quantitative trait loci data set identifies important functional polymorphisms in the asthma-associated IL1RL1 region	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Akhabir, Loubna; Sin, Don D.; Pare, Peter D.; Sandford, Andrew J.] Univ British Columbia, St Pauls Hosp, Heart Lung Inst, James Hogg Res Ctr, Vancouver, BC, Canada; [Akhabir, Loubna; Sin, Don D.; Pare, Peter D.; Sandford, Andrew J.] Univ British Columbia, Dept Med, Div Resp, Vancouver, BC, Canada; [Bosse, Yohan] Univ Laval, Dept Mol Med, Quebec City, PQ, Canada; [Berube, Jean-Christophe; Bosse, Yohan; Laviolette, Michel] Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada; [Hao, Ke; Nickle, David C.] Merck Res Labs, Boston, MA USA; [Hao, Ke; Nickle, David C.] Merck, Rahway, NJ USA; [Hao, Ke; Nickle, David C.] Merck, Genet Rosetta Inpharmat, Seattle, WA USA; [Timens, Wim] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Dept Pathol & Med Biol, Groningen, Netherlands; [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Med & TB, Groningen, Netherlands	St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of British Columbia; Laval University; Laval University; Merck & Company; Merck & Company; Merck & Company; University of Groningen; University of Groningen	Akhabir, L (corresponding author), Univ British Columbia, St Pauls Hosp, Heart Lung Inst, James Hogg Res Ctr, Vancouver, BC, Canada.	loubna.akhabir@hli.ubc.ca	Nickle, David/ABF-2727-2020; Pare, Peter D/C-7425-2011; Timens, Wim/K-5570-2013; Sin, Don/AAC-2219-2021	Timens, Wim/0000-0002-4146-6363; Berube, Jean-Christophe/0000-0002-7634-5270				Akhabir L, 2010, CURR GENOMICS, V11, P591, DOI 10.2174/138920210793360907; Bosse Y, 2012, CANCER RES, V72, P3753, DOI 10.1158/0008-5472.CAN-12-1160; Grotenboer NS, 2013, J ALLERGY CLIN IMMUN, V131, P856, DOI 10.1016/j.jaci.2012.11.028; Hao K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003029; Iwahana H, 1999, EUR J BIOCHEM, V264, P397, DOI 10.1046/j.1432-1327.1999.00615.x	5	12	14	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					729	731		10.1016/j.jaci.2014.02.039	http://dx.doi.org/10.1016/j.jaci.2014.02.039			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24746754				2022-12-18	WOS:000341372400029
J	Pike-Overzet, K; Baum, C; Bredius, RGM; Cavazzana, M; Driessen, GJ; Fibbe, WE; Gaspar, HB; Hoeben, RC; Lagresle-Peyrou, C; Lankester, A; Meij, P; Schambach, A; Thrasher, A; Van Dongen, JJM; Zwaginga, JJ; Staal, FJT				Pike-Overzet, Karin; Baum, Christopher; Bredius, Robbert G. M.; Cavazzana, Marina; Driessen, Gert-Jan; Fibbe, Willem E.; Gaspar, H. Bobby; Hoeben, Rob C.; Lagresle-Peyrou, Chantal; Lankester, Arjan; Meij, Pauline; Schambach, Axel; Thrasher, Adrian; Van Dongen, Jacques J. M.; Zwaginga, Jaap-Jan; Staal, Frank J. T.			Successful RAG1-SCID gene therapy depends on the level of RAG1 expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INSIGHTS; MICE		[Pike-Overzet, Karin; Zwaginga, Jaap-Jan; Staal, Frank J. T.] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands; [Bredius, Robbert G. M.; Lankester, Arjan] Leiden Univ, Dept Pediat, Med Ctr, Leiden, Netherlands; [Hoeben, Rob C.] Leiden Univ, Dept Mol Cell Biol, Med Ctr, Leiden, Netherlands; [Meij, Pauline] Leiden Univ, Dept Pharm, Med Ctr, Leiden, Netherlands; [Baum, Christopher; Schambach, Axel] Hannover Med Sch, Inst Expt Hematol, Hannover, Germany; [Cavazzana, Marina; Lagresle-Peyrou, Chantal] Hop Necker Enfants Malad, Dept Biotherapie, Paris, France; [Driessen, Gert-Jan] Erasmus MC, Dept Pediat, Rotterdam, Netherlands; [Gaspar, H. Bobby; Thrasher, Adrian] UCL Inst Child Hlth, Mol Immunol Unit, London, England; [Van Dongen, Jacques J. M.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Hannover Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Erasmus University Rotterdam; Erasmus MC; University of London; University College London; Erasmus University Rotterdam; Erasmus MC	Pike-Overzet, K (corresponding author), Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands.	f.j.t.staal@lumc.nl	Driessen, Gertjan/AAI-9711-2020; Bredius, Robbert/AAF-2592-2019; Pike-Overzet, Karin/AAT-3716-2021; Peyrou, Chantal Lagresle/H-2911-2017; Peyrou, Chantal Lagresle/AAK-9689-2020; Hoeben, Rob C./A-5771-2008; Schambach, Axel/C-5491-2011; van Dongen, Jacques J.M./F-8537-2015	Pike-Overzet, Karin/0000-0002-8827-246X; Peyrou, Chantal Lagresle/0000-0002-2216-6453; Peyrou, Chantal Lagresle/0000-0002-2216-6453; Hoeben, Rob C./0000-0001-9443-8377; van Dongen, Jacques J.M./0000-0001-7686-0021; Bredius, Robbert/0000-0001-8151-1539; van Dongen, Jacques J.M./0000-0002-3650-7087; Cavazzana, Marina/0000-0002-0264-0891	Great Ormond Street Hospital Childrens Charity [V1242] Funding Source: researchfish	Great Ormond Street Hospital Childrens Charity		Cassani B, 2010, J EXP MED, V207, P1525, DOI 10.1084/jem.20091928; Dik WA, 2005, J EXP MED, V201, P1715, DOI 10.1084/jem.20042524; IJspeert H, 2014, J ALLERGY CLIN IMMUN, V133, P1124, DOI 10.1016/j.jaci.2013.11.028; Lagresle-Peyrou C, 2006, BLOOD, V107, P63, DOI 10.1182/blood-2005-05-2032; Pike-Overzet K, 2011, LEUKEMIA, V25, P1471, DOI 10.1038/leu.2011.106; Pike-Overzet K, 2007, MOL THER, V15, P1910, DOI 10.1038/sj.mt.6300297; van Til NP, 2014, J ALLERGY CLIN IMMUN, V133, P1116, DOI 10.1016/j.jaci.2013.10.009	7	12	13	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					242	243		10.1016/j.jaci.2014.04.033	http://dx.doi.org/10.1016/j.jaci.2014.04.033			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	25117803				2022-12-18	WOS:000338930300039
